,nct_id,primaryOutcomes,secondaryOutcomes,otherOutcomes,startDate,status,study_type,phases
0,NCT00759109,Number of Participants With the Development of Hepatocellular Carcinoma (HCC),Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI),Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1,NCT04806243,os（overall survival）,DoR,,2021-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2,NCT01674309,Tumor control rate of the primary tumor and metastasis,metastasis response rate,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3,NCT05626309,1-year disease-free survival rate,Percentage of Participants With Adverse Events,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
4,NCT03979131,Pathological complete response (pCR) rate,Surgical complete resection rate (R0),,2019-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5,NCT00890188,Overall response(CR+PR) and Clinical benefit (CR+PR+SD),"To determine the progression free survival, overall survival (OS)and assess the safety profile",,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6,NCT04745390,Treated lesion progression,"Comparison of Quality of Life (QOL) Using a Standardly-Used Validated Instrument. Specifically, measures of physical, social/family, and functional well being. Overall symptoms, function, global health status will also be compared.",,2021-08-01,RECRUITING,INTERVENTIONAL,['NA']
7,NCT04249739,ORR (objective response rate) per RECIST 1.1,Genomic analysis,,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8,NCT00003046,Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9,NCT03789162,Blood-based biomarkers associated with genetic and epigenetic alterations,,,2018-12-20,RECRUITING,OBSERVATIONAL,['NA']
10,NCT01749865,Time to recurrence,Disease Free Survival,Adverse Events,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11,NCT05523271,Adenoma detection rate,Non-neoplastic detection rate,,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
12,NCT05201885,The positive rate of oncological contamination of peritoneal washings,Disease free survival,,2022-01-15,RECRUITING,OBSERVATIONAL,['NA']
13,NCT02527824,overall response rate,toxicity profiles - the number of participants and grade of intensity of treatment related adverse events,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14,NCT05134532,Progression-free survival (PFS) by RECIST v 1.1,Safety profiles by NCI-CTCAE version 5,,2021-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15,NCT03982641,Cost relate to HCRU,Rate of preoperative chemo-radiation therapy in patients with rectal cancer,,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA']
16,NCT04556344,Change in patient emotional skills from baseline to 15 days after the end of intervention,Patient satisfaction,,2020-10-26,RECRUITING,INTERVENTIONAL,['NA']
17,NCT03418584,radical rate,operation time,,2017-12-05,UNKNOWN,INTERVENTIONAL,['NA']
18,NCT01979549,Adverse events,,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
19,NCT00811447,Time to progression,Laboratory toxicities/symptomatology,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
20,NCT01830907,Infectious complication,Length of hospital stay,,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
21,NCT02017509,Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response,,,2014-01-24,COMPLETED,OBSERVATIONAL,['NA']
22,NCT03110068,Presence of microvascular invasion,,,2017-04-10,UNKNOWN,OBSERVATIONAL,['NA']
23,NCT03714555,CA19-9 Plasma Level,Incidence of Toxicities,Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC),2019-10-17,TERMINATED,INTERVENTIONAL,['PHASE2']
24,NCT03730558,Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment,,,2017-11-08,UNKNOWN,OBSERVATIONAL,['NA']
25,NCT04731428,Use of analgesic (See Table 1)(postoperative 3rd day),Postoperative serum cortisol levels (3rd. assessment),,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
26,NCT04964297,Hydrogen (H2) gas,Response time of the Perf-AlertTM device.,,2021-08-09,RECRUITING,INTERVENTIONAL,['NA']
27,NCT02270554,Incidence of pancreatic fistula grade B/C,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
28,NCT03204201,Number of urethras identified under white light and fluorescence,Number of adverse events related to trial intervention,,2017-07-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
29,NCT02324023,T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage,Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
30,NCT00066430,,,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
31,NCT05999162,Onset time,Re-admission,,2023-08-04,COMPLETED,OBSERVATIONAL,['NA']
32,NCT03199989,3-year disease free survival,Major adverse events,,2017-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
33,NCT02643173,Recurrence of HCC,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
34,NCT00359333,Tumor response,Time to tumor progression Overall survival Quality of life,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
35,NCT03170115,Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin,Overall survival,,2017-11-30,TERMINATED,INTERVENTIONAL,['PHASE2']
36,NCT04083365,Pathological complete response (pCR) rate after durvalumab treatment,Disease-free survival (DSF),,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
37,NCT06285097,Objective response rate (ORR) in Part 2 Expansion,AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2,,2024-02-08,RECRUITING,INTERVENTIONAL,['PHASE1']
38,NCT00553683,Overall tolerability,"Overall survival at 6, 12, and 24 months",,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
39,NCT01479465,Progression Free Survival (PFS),Objective Response Rate (ORR),,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2']
40,NCT04695782,1-year local control,Patient reported outcomes,,2020-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
41,NCT02934464,Progression-Free Survival (PFS),Quality of life EuroQol EQ-5D,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
42,NCT02901600,Determination of the histological localisation of DMBT1,,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
43,NCT01394939,Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study,,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
44,NCT03785743,5-year overall survival,intraoperative indicators,,2019-03-01,RECRUITING,INTERVENTIONAL,['NA']
45,NCT02504983,Complete remission,Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
46,NCT04609410,Total intra-operative blood loss,Surgery and hepatic resection time,90-day quality of life,2020-10-30,RECRUITING,INTERVENTIONAL,['NA']
47,NCT00576498,Proportion of patients with biopsy confirmed intestinal metaplasia,Inter observer variability in reading of mucosal and vascular patterns,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
48,NCT05609370,Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C,"Number of Participants with anti-drug antibodies (ADAs) to Tislelizumab, and Bevacizumab in Arm A, Arm B and Arm D",,2023-01-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
49,NCT04666688,Part 2: PFS or ORR [Preliminary Efficacy],Part 1: Pharmacodynamics (PD) of LYT- 200,,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
50,NCT05438797,incidence of adverse events( AE )and Serious adverse events(SAE),Progression-free survival (PFS),,2021-04-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
51,NCT05000554,pCR rate,operative mortality,,2021-07-02,RECRUITING,INTERVENTIONAL,['PHASE2']
52,NCT05640726,progression free survival,objective response rate,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
53,NCT05273931,Changes in adherence to the lifestyle recommendations between baseline and the 4 week follow-up,,,2022-03-16,COMPLETED,INTERVENTIONAL,['NA']
54,NCT00527891,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
55,NCT01791322,Correct identification of tumor mutant genes,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
56,NCT00493402,Overall survival,Time to progression,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
57,NCT04685525,PRO-CTCAE questionnaire scores,,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
58,NCT01445327,"Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment",Number of Participants With Chronic Gastrointestinal Injury After Radiotherapy,Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC) v3.0.,2007-02-20,TERMINATED,OBSERVATIONAL,['NA']
59,NCT05570279,Complete clinical response,Incidence of pelvis fractures,,2016-04-01,RECRUITING,OBSERVATIONAL,['NA']
60,NCT04542837,ORR,OS,,2020-09-11,COMPLETED,INTERVENTIONAL,['PHASE2']
61,NCT03575806,Recurrence-free Survival (RFS) Time,Overall Survival (OS) Rate at 24 Months,,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE2']
62,NCT05566834,To determine any increase of treatment emergent adverse events when Minnelide capsules are given in combination with paclitaxel.,Plasma levels of Minnelide when given with paclitaxel,,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE1']
63,NCT02188901,False referral rate of HCC,,,2014-10-15,COMPLETED,INTERVENTIONAL,['NA']
64,NCT00000764,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
65,NCT05095714,Incremental cost / QALY ratio,Compliance,,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
66,NCT05386056,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
67,NCT05534087,3-year disease-free survival rate,EORTC QLQ-C30 scale,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE3']
68,NCT00001428,,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2']
69,NCT00072748,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
70,NCT01871363,Pathological complete remission rate (pCR),Acute and late toxicity,Disease-free survival,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
71,NCT00467922,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay",1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
72,NCT03620643,Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1,Assessment of overall survival in each cohort,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
73,NCT02311361,Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),,2015-03-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
74,NCT05868317,Pathologic complete response,objective response rate to induction chemotherapy,,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
75,NCT06056336,2-year disease-free survival in non-pCR patients,overall survival,,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE2']
76,NCT03493880,Pathological response,yp TNM Stage,,2015-09-01,RECRUITING,OBSERVATIONAL,['NA']
77,NCT04384601,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,Disease free survival (DFS),,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
78,NCT04455932,HCC detection with US surveillance versus aNC-MRI surveillance,,,2022-01,RECRUITING,INTERVENTIONAL,['NA']
79,NCT00313872,Second progress-free survival,"Toxicity, overall survival",,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
80,NCT05473156,Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1),,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
81,NCT01759238,Progression free survival rate,Toxicity,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE2']
82,NCT05342636,Objective Response Rate (ORR),Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase,,2022-07-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
83,NCT02577393,Superiority of EGCG in reducing Grade II esophagitis as assessed by RTOG scores in patients with lung cancer receiving radiation,Improved quality of life with usage of EGCG for treatment of radiation-esophagitis in patient with lung cancer.,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
84,NCT03992664,Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.,Assessing the quality of life in relation to the rash through the QLQI questionnaire.,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
85,NCT00201747,Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas,"Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity.",,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
86,NCT00747292,Length of hospital stay,"Pain, time till flatus, time till bowels open, incidence of nausea and vomiting, quality of life",,2007-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
87,NCT04099901,Reduction of the incidence of fever during neutropenia,Tumor response evaluation,,2019-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
88,NCT01265979,WB-DWI as early predictor for regorafenib treatment response,Evaluation WB-DWI parameters in correlation with progression free survival (PFS),,2011-01,COMPLETED,OBSERVATIONAL,['NA']
89,NCT01016639,,,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
90,NCT04770896,Overall Survival (OS),Serum Concentration of Atezolizumab,,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE3']
91,NCT02550769,Evaluate the effectiveness of the T-TME versus L-LAR with the LARS score in patients with rectal cancer.,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
92,NCT00478634,Dose Limiting Toxicities,Objective Response Rate,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
93,NCT02607072,3-year disease free survival,,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
94,NCT00377936,Overall survival,Number of clinically significant abnormal laboratory values,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
95,NCT05484908,Mortality rate,Model for end-stage liver disease (MELD) score variation,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
96,NCT04550663,The occurrence of AEs and SAEs during the study treatment,Overall survival (OS),,2020-09-25,UNKNOWN,INTERVENTIONAL,['PHASE1']
97,NCT00593723,The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.,Evaluate overall survival rates,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
98,NCT01970748,Bleeding,Complication survival,,2009-08,RECRUITING,INTERVENTIONAL,['PHASE4']
99,NCT03256994,Description of the clinical context in which SIR-Spheres are applied,Diagnosis- and treatment-related considerations,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
100,NCT02588781,overall response rate,Number of subjects with Adverse Events as a measure of safety and Tolerability,,2015-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
101,NCT05035914,Objective response rate,Score of quality of Life,,2021-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
102,NCT06017661,IL-8 level,Patients' quality of life,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
103,NCT04857684,Proportion of patients with grade 3-4 treatment-related adverse events as assessed by CTCAE v5.0,Recurrence-free survival (RFS) after resection,,2021-06-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
104,NCT02327819,time until a new liver tumor is found,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
105,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",,,2018-07-26,RECRUITING,OBSERVATIONAL,['NA']
106,NCT02050503,Pain Intensity Difference,number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication,safety of intranasal transmucosal fentanyl,2012-12,COMPLETED,OBSERVATIONAL,['NA']
107,NCT00989469,disease control,overall survival,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
108,NCT01627080,Evaluation of Cardiac Biomarker Elevation with Radiation Therapy,Incidence of Adverse Cardiac Outcomes,,2014-04,WITHDRAWN,OBSERVATIONAL,['NA']
109,NCT00403624,Tumour response,Disease free and Overall survival ; Adverse events,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
110,NCT00700258,"Efficacy: best response, progression-free survival, overall survival",Safety: absolute and relative incidence of therapy interruption,,2008-02-13,COMPLETED,OBSERVATIONAL,['NA']
111,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes,,2018-01-19,RECRUITING,OBSERVATIONAL,['NA']
112,NCT03167112,Time to Progression (TTP).,Overall survival (OS),,2017-07-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
113,NCT00492999,Resectability rate,Survival,,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
114,NCT00991614,Patency of the stent,"Procedural success, implant duration, symptom resolution",,2009-12,COMPLETED,OBSERVATIONAL,['NA']
115,NCT02003339,Modifications of functional MRI parameters,Change of VEGF (vascular endothelial growth factor) release,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
116,NCT06015022,Change in Prognostic Liver Secretome signature (PLSec) score,Change in quality of life measured by the chronic liver disease questionnaire,HCC incidence,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
117,NCT02401815,Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation,Part 2: To determine the progression-free survival of PLX9486 treatment in combination with PLX3397 or sunitinib.,,2015-03-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
118,NCT03175146,Response rate within the treated liver lesion,Overall survival,,2017-09,UNKNOWN,INTERVENTIONAL,['NA']
119,NCT01692873,Biomarkers,Histology,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
120,NCT01100814,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
121,NCT00497224,Objective Response Rate,Tolerability of Erlotinib Dose Escalation,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
122,NCT00659113,Response rate,Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival,,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
123,NCT05705219,Diagnostic yield of the 3D-MPUS data acquisition,Relationship between baseline and one-month 3D-MPUS measurements and treatment response after three-months,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
124,NCT00072033,Feasibility of successful study therapy completion and survival after surgery,Feasibility in Switzerland after surgery,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
125,NCT00564694,Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29),,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
126,NCT00922896,"To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer",,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
127,NCT03790111,Project Overall Survival Rate at Month 6,Change From Baseline in Serum Albumin,,2019-03-13,TERMINATED,INTERVENTIONAL,['PHASE2']
128,NCT02112240,Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.,Feasibility,,2013-05,WITHDRAWN,INTERVENTIONAL,['NA']
129,NCT05911789,Response rate after surgery,Margins for clinical target volume(CTV) and gross tumor volume (GTV),,2023-08-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
130,NCT04208724,Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention,,,2020-11-18,COMPLETED,INTERVENTIONAL,['NA']
131,NCT04304001,Rate of Colorectal Cancer Screening,Colorectal Cancer Screening Self-Efficacy Scale,,2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
132,NCT03577665,2-year local control ratio of the treated liver area,5-year disease-free survival rate of treated patients,,2018-05-21,RECRUITING,INTERVENTIONAL,['NA']
133,NCT04048421,Postoperative complications,Overall survival,,2019-12-20,RECRUITING,INTERVENTIONAL,['NA']
134,NCT03026881,"DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.",Plasma Clearance (CL/F),,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
135,NCT03821909,The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases,The difference of the exosomes between portal venous and peripheral blood,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
136,NCT04024917,Cardiac Coherence Program Adherence Rate,Duration of cardiac coherence sessions in minutes,,2021-09-21,RECRUITING,INTERVENTIONAL,['NA']
137,NCT03347292,Dose Limiting Toxicities(DLTs),Duration of stable disease,,2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE1']
138,NCT00017212,,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
139,NCT05643417,ORR,OS,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
140,NCT01937715,Progression-Free Survival (PFS),Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C) (Phase 2),,2014-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
141,NCT05320497,"Intubation rates of bile duct ends, cystic duct openings, and left and right hepatic duct bifurcations",Biopsy accuracy,,2022-04-14,UNKNOWN,INTERVENTIONAL,['NA']
142,NCT04387071,Objective response rate (CR + PR),Overall survival,Immune cell populations,2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
143,NCT06102759,Progression Free Survival,Overall survival,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
144,NCT00073736,Safety and tolerability,Determine effect of MB07133 on tumor size,,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
145,NCT03695250,Objective Response Rate (ORR),Overall Survival (OS),,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
146,NCT00039403,Recommended phase II doses,"Frequency, extent, and duration of any tumor responses",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1']
147,NCT04646928,5-year Cumulative hepatocellular carcinoma incidence,Incidence of cirrhosis regression,,2017-03-17,UNKNOWN,OBSERVATIONAL,['NA']
148,NCT01836991,the overall survival time,,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
149,NCT04269083,"R0, number of patients achieving R0 resection.",safety profile,,2020-05-24,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
150,NCT05084859,Part 2 - Objective response rate,Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite,,2021-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
151,NCT01671449,Progression-free survival,Number of Adverse Events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
152,NCT00687778,Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
153,NCT05056116,Objective response rate(ORR),Overall survival (OS),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
154,NCT03746353,perioperative complications,Measure quality of life,,2018-09-05,TERMINATED,INTERVENTIONAL,['NA']
155,NCT00622674,Maximum tolerated dose (MTD) of bortezomib,Disease response as measured by RECIST criteria,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
156,NCT04014101,Objective response rate(ORR),Overall survival (OS),,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
157,NCT01403402,Congenital Muscle Disease Patient and Proxy Reported Outcomes,,,2009-09,RECRUITING,OBSERVATIONAL,['NA']
158,NCT01110668,To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.,To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
159,NCT02331641,"Number of postoperative complications after MH or MMH, graded based on the Dindo's classification (Dindo et al. Ann Surg 2004;240:205-13)",Long-term outcome (overall and disease-free survival),,2005-01,COMPLETED,OBSERVATIONAL,['NA']
160,NCT05253053,Dose limiting toxicity (DLT),Volume of Distribution,changes of main circulating metabolites of TT-00420 in plasma,2022-04-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
161,NCT02750657,The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.,Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.,,2015-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
162,NCT06182865,Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy.,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
163,NCT00016965,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
164,NCT04864054,To determine the Recommended Phase II Dose (RP2D) of ECT204,"To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population",,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2']
165,NCT00081315,- Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.,- Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
166,NCT05657743,Safety - Adverse events,Efficacy-Alpha DaRT seeds,Urine radioactivity measurements,2023-08-16,RECRUITING,INTERVENTIONAL,['NA']
167,NCT04422249,Survival rate,intraoperative parameters,Incidence of postoperative complications,2019-12-23,RECRUITING,INTERVENTIONAL,['NA']
168,NCT02752360,Anastomotic Stenosis Rate,The time of reconstruction in the surgery of Intestinal Anastomosis,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
169,NCT02050737,Disease free survival or progression free survival,To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.,,2013-10,TERMINATED,OBSERVATIONAL,['NA']
170,NCT01212887,Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose),Long-term follow up for insertional mutagenesis,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1']
171,NCT02869269,Circulating helper T cell activity,Cytotoxic T cell and natural killer cell activity,CD4 and Treg cell activity and change of percentage of CD39 and CD73,2015-10,COMPLETED,OBSERVATIONAL,['NA']
172,NCT02324127,Hsp90α Concentration of plasma,,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
173,NCT02663427,detection rate of gastric cancer among all group,,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
174,NCT02041481,DLT defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the combination of MEK inhibitor MEK162 and FOLFOX graded according to NCI CTCAE v4.03,Survival,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
175,NCT04602299,focal lesion detection rate,rate of procedures reaching the minimal time,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
176,NCT02139488,To quantify motion of the esophageal tumor over the course of chemoradiation,,,2014-04-18,COMPLETED,OBSERVATIONAL,['NA']
177,NCT04767503,Metabolomics,I-FEED scoring,,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA']
178,NCT03569488,validation of the French version of the LARS score,,,2020-01-24,RECRUITING,OBSERVATIONAL,['NA']
179,NCT05631613,Deposition of of lipiodol-idarubicin emulsion,Visibility of lipiodol-idarubicin emulsion under X-ray: image quality,,2022-12-28,RECRUITING,OBSERVATIONAL,['NA']
180,NCT01285102,Overall Survival,,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
181,NCT04491955,Objective Response Rate (ORR) for Quadruple Therapy,Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
182,NCT03777943,Immunohistochemistry (IHC) analysis,Laser capture microdisssection (LCM) followed by gene expression analysis,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
183,NCT03867409,Interpersonal Distance,,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
184,NCT01633411,Esophageal Stricture,Presence of Residual Barrett's Esophagus,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
185,NCT00733889,• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab,• To determine EGFR expression in the tumour and attempt to correlate it with efficacy,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
186,NCT00270543,high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.,Overall survival.,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
187,NCT05566899,Acceptability and feasibility of EGD-SC measured by Linear Scale,Number of participants with AE's will be measured by the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0,Acceptability and feasibility of EGD-SC measured by Linear Scale,2023-02-08,RECRUITING,INTERVENTIONAL,['NA']
188,NCT06085365,the incidence of chemotherapy related adverse reactions,changes in immune microenvironment,,2023-07-24,RECRUITING,INTERVENTIONAL,['PHASE3']
189,NCT02207465,Number of Adverse Events,,,2014-07,RECRUITING,INTERVENTIONAL,['PHASE1']
190,NCT01674374,Proportion of patients with severe mucositis (WHO score 3 or 4),Quality of Life as assessed by EORTC QLQ Head and Neck Cancer-Specific Module function and symptom sub-scores between groups (with 1 being not at all and 4 being very much),,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
191,NCT02305758,Progression-Free Survival (PFS): Time to Event,Objective Response Rate (ORR),,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2']
192,NCT04834505,To construct a diagnosis model for distinguishing FAIP from PC and further validate its efficacy,Compare the efficacy of EUS based on the model with that of CT/MRI/PET-CT in differentiating between FAIP and PC,,2021-05-11,RECRUITING,OBSERVATIONAL,['NA']
193,NCT00666991,Determine maximum tolerated dose and to assess qualitative and quantitative toxicities,Determine pharmacokinetics of intraperitoneal administration,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
194,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,Number of subjects with abnormal oral glucose tolerance test (OGTT),,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
195,NCT00001431,,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE1']
196,NCT02326727,Plasma concentration of cytokines,,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
197,NCT00394433,10-month Progression-Free Survival Rate,Progression-Free Survival,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
198,NCT05930860,Recurrence rate,,,2021-12-12,RECRUITING,OBSERVATIONAL,['NA']
199,NCT02551250,sensitivity for detecting HCC,false referral rate for HCC,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
200,NCT01102088,Maximum Tolerated Dose (MTD) of Simultaneous Integrated Boost (SIB),Pathologic Response,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
201,NCT05045976,Change of Functional Assessment of Cancer Therapy- Colorectal,M.D. Anderson Symptom Inventory,,2021-09-19,RECRUITING,INTERVENTIONAL,['NA']
202,NCT02185768,Rate of patients in objective response (complete or partial response),Treatment tolerance,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
203,NCT04150705,Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans,Percentage of Scans With Changes in Perceived Disease Status as Measured by PET/MRI Tumor Regression Grade Relative to the Conventional MRI Only Tumor Regression Grade,,2020-06-01,TERMINATED,INTERVENTIONAL,['NA']
204,NCT00865709,Progression-Free Survival (PFS),Duration of Response,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
205,NCT05280210,pathological complete response rate(pCR),prediction accuracy of PTC,,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
206,NCT02004262,"2nd-line Cohort: OS (All Data, FAS)",Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen,,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2']
207,NCT01404156,treatment response,EORTC QOL,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
208,NCT05246839,Impact of Brief Videos,,,2022-04-28,RECRUITING,OBSERVATIONAL,['NA']
209,NCT05286086,Comprehension Complication Index (CCI),Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale,,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
210,NCT04487704,Assess Safety as defined by the NCI CTCAE v5.0,overall survival,,2020-04-07,RECRUITING,INTERVENTIONAL,['NA']
211,NCT03073226,Sensitivity,Endoscopists confidence,,2016-02-06,COMPLETED,INTERVENTIONAL,['NA']
212,NCT00782457,"Lymph nodes isolated, circumferential margin involved, rate of complications and length of stay",,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3']
213,NCT00489671,Risk of pancreatic cancer as determined by urine cadmium levels,"Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer",,2003-06,COMPLETED,OBSERVATIONAL,['NA']
214,NCT00500188,Disease-free survival (DFS) time,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
215,NCT04380480,Percentage of Recent Weight Loss,"Changes of participants' intestinal flora assessed by blood, urine and stool test",,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
216,NCT04077372,Difference in proportions of patients with documented goals of care,Overall comparison of QOL survey,,2019-09-16,TERMINATED,INTERVENTIONAL,['NA']
217,NCT04563416,the diagnosis efficiency of the computer-assist diagnosis tool,,,2020-07-10,UNKNOWN,OBSERVATIONAL,['NA']
218,NCT05381792,Serial gut microbiome changes after endoscopic resection of colorectal advanced neoplasia.,"The differences in the bacterial gene markers (Fn, m3, Bc and Ch) between advanced adenoma and CRC",,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
219,NCT04427527,CRC screening - clinic level,CRC screening - community level,,2020-08-19,RECRUITING,INTERVENTIONAL,['NA']
220,NCT00878215,The Number of Participants Who Have Complete Ablation According to Early Post-ablative Imaging Studies as Well as no Recurrence of the Tumor Within 6 Months (Phase 4 Portion of the Study),,,2002-10-24,TERMINATED,INTERVENTIONAL,['PHASE2']
221,NCT00871169,Overall Response Rate (ORR),Toxicity,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
222,NCT05381636,Progression free survival (PFS),Overall survival (OS),,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
223,NCT05994001,Incidence of Treatment-Emergent Adverse Events(Phase I),OS,,2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
224,NCT04940286,Incidence of adverse events,,Change in circulating tumor deoxyribonucleic acid (ctDNA) levels,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2']
225,NCT03355443,Adenoma miss rate in the proximal colon (AMR),Adenoma Detection Rate in the proximal colon (ADR),,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
226,NCT00392899,Disease-free survival,Types and severities of adverse events,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
227,NCT00003810,,,,1999-08-11,COMPLETED,INTERVENTIONAL,['PHASE2']
228,NCT05312216,Objective response rate (ORR),Adverse events (AEs),,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
229,NCT01790035,Safety (phase I safety lead-in),Serum citrulline,,2014-08-19,TERMINATED,INTERVENTIONAL,['PHASE1']
230,NCT02534961,Infection after radiofrequency ablation,,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
231,NCT02143115,"Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post Colorectal cancer resection using optical colonoscopy as the reference standard",Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
232,NCT01336049,Objective response rate,adverse events,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
233,NCT03158610,Progression Free Survival 2 (PFS2),Number of participants with quality of life (QoL) as assessed by CTCAE v4.0,,2018-01-29,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
234,NCT01927146,Overall survival,,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
235,NCT02014025,survival rate,intraoperative parameters,postoperative complications,2013-03,COMPLETED,INTERVENTIONAL,['NA']
236,NCT03283540,Average intra-balloon pressure,Low Anterior Resection Syndrome score (LARS),,2017-09-25,RECRUITING,OBSERVATIONAL,['NA']
237,NCT04221893,Overall response rate (ORR),Time to new systemic therapy,,2020-08-07,RECRUITING,INTERVENTIONAL,['NA']
238,NCT06041425,Pain intensity at 24hours after the end of TACE.,Nausea and vomiting scale,,2023-08-07,COMPLETED,INTERVENTIONAL,['PHASE4']
239,NCT06226857,progression-free survival,progression-free survival based (per protocol),,2024-01-17,RECRUITING,INTERVENTIONAL,['PHASE3']
240,NCT04130854,Pathological Complete Response Rate,Disease free survival,Exploratory Immunological Response,2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
241,NCT01071941,Characterize rRp450 pharmacokinetics and viral shedding.,Correlate radiographic and pathologic assessments of tumor response.,,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
242,NCT00109031,Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4),Number of Participants With WHO Grade 4 Oral Mucositis,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
243,NCT04576572,Tumor recurrence,The Best Criteria,,2020-06-15,COMPLETED,OBSERVATIONAL,['NA']
244,NCT01929902,Placement of Aquamantys Device,Device Complications,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
245,NCT00005843,,,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
246,NCT03250273,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),Progression Free Survival (PFS) at 24 Months,,2017-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
247,NCT05889949,Progression-Free Survival (PFS),Adverse events,,2019-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
248,NCT06144853,The number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 one lesion after PIPAC 3,The number of patients where FDG-PET/CT evaluated by PERCIST one lesion agrees with histological response according to PRGS after PIPAC 1 and 3,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
249,NCT00380055,"Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.",Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
250,NCT00376909,"Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy",,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
251,NCT03878472,Immunotherapy-related biomarkers,R0 resection rate,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
252,NCT04401709,Two-year disease free survival (DFS),Overall Survival (OS),,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
253,NCT00057382,,,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
254,NCT06259149,VTE events within 28 days after surgery,Any bleeding event within 28 days after surgery,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
255,NCT04638036,Feasibility of molecular fluorescence-guided surgery using Cetuximab-800CW,Evaluation of the distribution of Cetuximab-IRDye800CW,,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
256,NCT05540483,AEs,Overal Survival,,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
257,NCT01499576,Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy,Number of Participants With Adverse Events,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
258,NCT03403101,progression free survival (PFS),Toxicity evaluated according to the Common Terminology Criteria Adverse Events,,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
259,NCT00795301,,,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
260,NCT01892527,Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS,Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
261,NCT04898504,Overall survival at 2 years,Quality of life using EQ-5D-5L,,2021-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
262,NCT02813967,Overall survival,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,the oesophagus-specific quality-of-life,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
263,NCT05087459,Comparison of total amount of postoperative drainage fluid between treatment group and control group,The change of platelet count from baseline at different time points,,2021-06-30,UNKNOWN,OBSERVATIONAL,['NA']
264,NCT00003332,,,,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
265,NCT06268379,RFS,,,2010-02-15,COMPLETED,OBSERVATIONAL,['NA']
266,NCT02119676,Overall Survival (OS),Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
267,NCT01435525,Number of Adverse Drug Reactions,Rate of H.Pylori eradication,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
268,NCT01558583,Participant-reported most important attribute from survey,Unlabeled screening test options,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
269,NCT01271504,Phase 2: Number of Participants With Markedly Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters,Phase 2: Percentage of Participants With Overall Response,,2011-07-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
270,NCT06283576,Cancer detection,Overall survival,,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
271,NCT05495685,The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm,Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.,,2022-03-24,RECRUITING,OBSERVATIONAL,['NA']
272,NCT02066701,to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue (and presence of dysplasia) from esophageal squamous and gastric cardia tissue.,Assess the accuracy of candidate markers in stool for detection of Barrett's Esophagus,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
273,NCT05688761,Gastric adenocarcinoma,Esophageal cancer,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
274,NCT05519410,1-year DFS%,2-year DFS%,,2022-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
275,NCT04821765,Locoregional control rate,Radiomics analysis,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
276,NCT00923897,To determine the change in index symptom(s) using an 11 point numerical rating scale for patients with locally advanced hepatocellular cancer or hepatic metastases treated with 8Gy,To determine serum marker and radiographic response with 8Gy,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
277,NCT04476082,Prevalence of Malnutrition According to the Global Leadership Initiative on Malnutrition criteria (GLIM criteria),Intestinal Microbiome,,2020-06-25,COMPLETED,OBSERVATIONAL,['NA']
278,NCT04127864,Cytokines in R848 stimulated blood,Cytokines in unstimulated blood,,2019-10-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
279,NCT00003596,,,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
280,NCT04980287,metastasis rate,3-year DFS,,2021-01-12,RECRUITING,OBSERVATIONAL,['NA']
281,NCT02378948,Functional recovery,Quality of life,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
282,NCT04611711,Overall response rate (ORR),Overall survival (OS),,2020-11-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
283,NCT04432870,Interest in colon cancer screening,Risk perception on COVID-19,,2020-06-09,COMPLETED,OBSERVATIONAL,['NA']
284,NCT00914615,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.",Cytokine response to radiation and association with complications,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
285,NCT05023928,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,Disease-free Survival,,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
286,NCT04961918,PFS,OS,,2021-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
287,NCT04797624,Comparison of the clinical staging and pathologic TNM staging of the patients,Comparison of the demographic data,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
288,NCT01034189,"To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).","Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery.",,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
289,NCT02150447,Time-to-bleeding event,Overall survival,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE3']
290,NCT01580631,Determine the inter-observer agreement of a consensus driven NBI classification system in Barrett's esophagus.,Negative predictive value of the newer NBI classification in identifying dysplasia in Barrett's esophagus.,,2012-10,SUSPENDED,OBSERVATIONAL,['NA']
291,NCT04246710,Reliability of PDAC molecular subtyping on biopsy samples,Overall survival,,2018-01-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
292,NCT03492164,Number of Adverse Events,,,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
293,NCT04207944,Percent of patients with IPMN progression as measured by a composite of several indicators,Percent of patients with cyst progression as measured by radiographic images,Percent of patients with Inflammatory Marker Progression,2020-07-10,RECRUITING,INTERVENTIONAL,['PHASE2']
294,NCT00409994,Phase II: Tumour blood flow assessed CT-PET + CTp,"Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0",,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
295,NCT02584998,The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months,The Number of Participants Who Received Any Colorectal Cancer Screening Test in the 6-month Period After Enrollment Into the Study.,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
296,NCT00526617,Pharmacokinetic Profile,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
297,NCT04501887,Progression-free survival,Positive rate,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
298,NCT04796818,Absolute change in the true diffusion coefficient (D),Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging,,2020-08-12,RECRUITING,INTERVENTIONAL,['NA']
299,NCT04007640,fibroinflammatory lesions at histology in obese patients,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,,2019-06-18,RECRUITING,INTERVENTIONAL,['NA']
300,NCT02785263,The fraction of enrolled patients choosing the lower radiation dose,Response evaluation assessed by diffusion weighted imaging,,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
301,NCT03977220,Recommended dose for Phase II study,,,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
302,NCT02418052,Incidence of post-operative cervical esophagogastric anastomotic leakage,,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
303,NCT00091312,Disease-free survival at 5 years,"Correlation of clinical, histological, and biological prognostic factors with outcome",,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
304,NCT03670134,Determine association between thickness of neosquamous epithelium measured with volumetric laser endomicroscopy and recurrence of Barrett's esophagus following endoscopic therapy,Develop a volumetric laser endomicrosopy feature scoring index to stratify the risk of disease recurrence in patients with Barrett's esophagus following treatment,,2018-08-06,WITHDRAWN,INTERVENTIONAL,['NA']
305,NCT02452021,Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT,Assessment of early cardiac toxicity after CRT using cardiac MRI,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
306,NCT02744729,Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan,Contrast-enhanced CT,,2015-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
307,NCT03620877,Evaluation of coordinated transmission,Adherence to personalized intervention,,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA']
308,NCT00898781,"Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers",,,2007-11,TERMINATED,OBSERVATIONAL,['NA']
309,NCT03208283,The mean independently performed flexible sigmoidoscopy completion rate in each study group,Patients' satisfaction,,2014-10-28,COMPLETED,INTERVENTIONAL,['NA']
310,NCT05844865,Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT),Overall Survival (OS),,2023-05-04,RECRUITING,INTERVENTIONAL,['NA']
311,NCT06281886,Progression free survival rate,Distant metastasis-free survival,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
312,NCT05339581,PVTT RR/NR,Duration of response (DOR),,2022-05-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
313,NCT05713994,Number of Patients Amendable to Curative Surgical Interventions,Quality of Life (QoL) after treatment,,2020-05-19,RECRUITING,OBSERVATIONAL,['NA']
314,NCT03152565,Progression Free Survival,Immunophenotype signature in tumor biopsies before and during treatment.,,2018-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
315,NCT00728078,morbility,recurrence rate,,2008-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
316,NCT01775267,Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ],Postoperative liver and renal function,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
317,NCT03884179,Accuracy of EUS-FNA vs Radiology,Accuracy of EUS FNA vs CEA,,2007-02-01,UNKNOWN,OBSERVATIONAL,['NA']
318,NCT05741255,Montreal Cognitive Assessment,,,2022-01-05,COMPLETED,INTERVENTIONAL,['NA']
319,NCT05048524,The percentage of subjects with R0 resection after surgery,Biomarkers of treatment response by single cell RNA sequencing and whole exome sequencing,,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2']
320,NCT03854890,The positive number of lymph nodes retrieved,Detection rate of indocyanine green-positive para-aortic lymph node,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
321,NCT04714814,recurrence or metastasis provened by imageologic diagnosis (PFS),,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
322,NCT02971956,Overall Response Rate (ORR),Number of Patients Experiencing Grade 3-4 Treatment-Related Toxicity,,2017-01-18,COMPLETED,INTERVENTIONAL,['PHASE2']
323,NCT02741401,Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire,Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
324,NCT05770882,Progression-free survival (PFS),Time to progression (TTP),,2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
325,NCT01384708,to determine whether or not tissue is neoplastic or non-neoplastic,,,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
326,NCT04540081,Overall Adherence to CLOVER Metrics,Hepatitis C screening,,2020-10-05,COMPLETED,INTERVENTIONAL,['NA']
327,NCT04538404,New surgical score using preoperative parameters to predict 30-day mortality after colon cancer surgery in the elderly population,,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
328,NCT00593060,To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.,To document objective response rate and progression-free survival in patients treated with the combination.,,2007-11-01,COMPLETED,INTERVENTIONAL,['PHASE1']
329,NCT01482299,4-month progression-free survival,Biomarker assessment,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
330,NCT01075048,Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,Treatment-Emergent Infection and Infestation Adverse Events Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,,2010-01-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
331,NCT01829035,The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects,Evaluation of adverse events,,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
332,NCT03619759,Length of stay,Time to first successful oral intake,,2018-03-22,COMPLETED,OBSERVATIONAL,['NA']
333,NCT00586235,"Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images.",Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm.,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
334,NCT05275985,Overall Survival (OS),,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
335,NCT01512407,1-year recurrence rate,Health-related quality of life assessment,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
336,NCT01395030,Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes,,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
337,NCT04609176,Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment,Number of Participants Experiencing an Adverse Event (AE),,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2']
338,NCT05592886,The incidence of metachronous recurrent colorectal adenoma at year 1 (local or at other sites),Changes in the levels of bacterial gene markers,,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
339,NCT03638141,Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.,Number of participants experiencing study drug-related toxicities,,2019-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
340,NCT03613389,Clinical assessment of Oral Mucositis,,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
341,NCT00624182,Safety (toxicities as assessed by NCI CTCAE version 3),Survival rate,,2008-02,SUSPENDED,INTERVENTIONAL,['PHASE1']
342,NCT04813913,Difference in carotid stiffness between baseline and at 4 months of bevacizumab treatment.,Progression-free survival at 12 months.,,2019-05-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
343,NCT03958435,Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer,,,2018-11-09,UNKNOWN,OBSERVATIONAL,['NA']
344,NCT01464151,low- or high grade dysplasia or colorectal cancer during follow-up,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
345,NCT02391038,Phase 2- Overall Response Rate,Phase 2- Number of Participants With ATA in Serum,,2014-12,TERMINATED,INTERVENTIONAL,['PHASE1']
346,NCT04597710,Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.,Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS.,,2021-02-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
347,NCT01355302,Time to Maximum Concentration (Tmax) of Golvatinib,Time to Progression (TTP),,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
348,NCT03930368,the change of glycated albumin,the change of uric acid,,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA']
349,NCT00554892,Overall morbidity including infectious and non infectious complications,Evaluate the postoperative complications classified according to the DINDO classification.,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
350,NCT04260191,Number of Participants Who Experienced a Treatment-emergent AE (TEAE),Overall Survival,,2020-06-29,TERMINATED,INTERVENTIONAL,['PHASE1']
351,NCT06222619,Overall survival,Recurrence free survival,,2020-01-30,COMPLETED,OBSERVATIONAL,['NA']
352,NCT02289053,Prevalence of advanced adenomas among 40-49 year old individuals with and without a family history of colorectal cancer,Absolute prevalence of advanced adenomas in 40-49 year old individuals with a family history of colorectal polyps,Risk factors associated with the presence of advanced adenomas,2006-04-01,COMPLETED,OBSERVATIONAL,['NA']
353,NCT06147492,urinary retention,,,2016-01-30,COMPLETED,INTERVENTIONAL,['NA']
354,NCT03439085,Objective response rate (ORR),Overall survival,,2018-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
355,NCT02968069,Accuracy of the diagnostic model in histological prediction of gastric cancerous lesions,,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
356,NCT01253837,Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR),Investigation of early signs of anti-tumor activity of L19TNFα,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
357,NCT05934643,Average daily energy expenditure in MET.h,30-day complication rate,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
358,NCT05339984,Estimation of the intraoperative portocaval post-procedural gradient.,Prediction of the evolution of hepatic artery and portal vein flows after surgery,,2023-01-03,RECRUITING,INTERVENTIONAL,['NA']
359,NCT02301338,acute healthcare utilization (AHCU) rates,,,2014-11,TERMINATED,OBSERVATIONAL,['NA']
360,NCT01256034,Postoperative Infectious Complication,"Plasma IL-6, CRP, Th1/Th2 Balance",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
361,NCT05012397,"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1 criteria",Overall Survival (OS),,2021-11-01,TERMINATED,INTERVENTIONAL,['PHASE2']
362,NCT05585580,Objective response rate （ORR),Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
363,NCT04709445,anastomotic leak,Length of hospital stay,,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
364,NCT02266849,Output weight,Gastrointestinal transit time,Patient evaluation,2014-10,TERMINATED,INTERVENTIONAL,['PHASE3']
365,NCT02479217,Number of Participants with Adverse Events,Disease free survival (DFS),,2006-07,COMPLETED,OBSERVATIONAL,['NA']
366,NCT02267343,Overall survival,Safety will be analyzed through the incidence of laboratory abnormalities,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
367,NCT05587556,The survial rate of the patients,,,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
368,NCT02464618,Compliance with scheduled upper endoscopy and colonoscopy,Bowel preparation quality,Social contact's activity,2014-06-26,COMPLETED,INTERVENTIONAL,['NA']
369,NCT02535117,Overall survival,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
370,NCT02926716,Accuracy for identifying the status of resection margin,Microvessel density,,2015-12-14,COMPLETED,OBSERVATIONAL,['NA']
371,NCT05210049,Sensitivity and Specificity of Esocheck/Esoguard in a Veteran population,Cost of two screening strategies,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
372,NCT04913480,Progression-free survival at 1 year,Changes in PD-L1 and PD-1 positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab,,2020-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
373,NCT06090994,3-year disease-free survival rate (DFS),"The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)",Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
374,NCT00033241,,,,2001-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
375,NCT00004256,,,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2']
376,NCT03008499,Relief degree of tumors,Overall survival（OS）,,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
377,NCT01015118,"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).",Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.,,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE3']
378,NCT02657044,Recurrence rate at follow-up colonoscopy after 6 months,R0-resection rate,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
379,NCT04612712,Phase II part - Objective response rate(ORR),Progression-Free Survival (PFS),,2021-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
380,NCT04931420,Progression Free Survival,The Effect of Interventions on Circulating Tumor DNA (ctDNA),,2025-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
381,NCT05359406,Early Tumor Shrinkage,Acute toxicity associated with immunotherapy,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
382,NCT00719199,• The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).,• To investigate potential markers of IMO 2055 immune activation and effect on cellular immunity.,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
383,NCT01914744,Incidence rate of HBV reactivation,Incidence rate and median time of HBV DNA level normalization,Incidence of drug resistance of viral variants,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
384,NCT05656326,Successful implementation,Satisfaction of the patient-led home-based follow-up,,2021-08-23,RECRUITING,OBSERVATIONAL,['NA']
385,NCT04588025,Measure change in blood flow within the pancreatic cancer as measured by the P4.,,,2020-10-14,RECRUITING,INTERVENTIONAL,['NA']
386,NCT03791398,Progression Free Survival,,,2019-11-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
387,NCT05168527,ORR,DOR,,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2']
388,NCT01413295,Progression Free Survival,Overall Survival,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
389,NCT02751086,Rate of patients alive,Rate of complications after discharge,,2016-04,RECRUITING,OBSERVATIONAL,['NA']
390,NCT03730948,Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC),Percentage of CD8+ cells in primary tumor tissue,,2019-03-12,TERMINATED,INTERVENTIONAL,['PHASE1']
391,NCT02439086,Accuracy of Texture analysis PET-CT,Accuracy of Texture analysis MRI,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
392,NCT00718211,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
393,NCT03344614,PFS,DCR,,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
394,NCT06111872,To evaluate the efficacy of Ketamine- Midazolam as a sedative agent in ERCP in terms of sedation failure rate.,To compare the depth of sedation,,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2']
395,NCT02797197,"number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures",to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic),,2016-05-18,COMPLETED,INTERVENTIONAL,['NA']
396,NCT03744962,Frequency of microsatellite instability,,,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA']
397,NCT00746161,The %body weight ratio,"preoperative complication, PNI and QOL score",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
398,NCT04074447,The proportion of ctDNA content decreased in patients with good therapeutic effect,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
399,NCT01718808,Progression free survival in week 12,"Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)",,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
400,NCT05385692,Phase Ib: Recommended Phase II Dose (RP2D),Progression-free Survival (PFS),,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE1']
401,NCT04233840,"Phase II portion - Recurrence-free survival (defined as the time from randomization to HCC recurrence or death from any cause, whichever occured first)",HBsAg level,,2019-02-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
402,NCT05434520,30-day Readmission,Histological Specimen,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
403,NCT06189560,Video fluoroscopic swallowing study,Rosenbek penetration-aspiration scale,,2022-06-21,TERMINATED,INTERVENTIONAL,['NA']
404,NCT04868149,Amount of future liver remnant volume increment by percentage after stage I ALPPS,Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS,,2020-09-02,RECRUITING,INTERVENTIONAL,['NA']
405,NCT03377842,Progression-free survival (PFS),Overall survival (OS),,2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
406,NCT05641922,Safety,Assessment Module (1),Assessment Module (2),2023-07,WITHDRAWN,INTERVENTIONAL,['NA']
407,NCT00529984,determine the safety of immunization with CEA(6D) VRP,evaluate CEA-specific immune response to immunizations,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
408,NCT00197405,,,,1999-08,UNKNOWN,OBSERVATIONAL,['NA']
409,NCT00696345,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
410,NCT04764240,OS,,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
411,NCT03881501,PFS,Safety as measured by number and grade of adverse events,,2019-03-05,UNKNOWN,OBSERVATIONAL,['NA']
412,NCT02571036,Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases,Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
413,NCT05988372,R0 Surgical Resection Rate,Quality of Life (QOL),,2023-10-23,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
414,NCT01465464,Overall Survival(OS),Time to Transcatheter Arterial Chemoembolization (TACE) Failure,,2010-12,TERMINATED,INTERVENTIONAL,['PHASE3']
415,NCT05895942,Degree of tumor regression,,,2021-09-10,RECRUITING,OBSERVATIONAL,['NA']
416,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,Re-hospitalization and Emergency Department Visits,,2020-04-16,COMPLETED,INTERVENTIONAL,['NA']
417,NCT03130166,Postoperative recovery,Whole blood gene expression profiling,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
418,NCT03233711,Disease free survival,Incidence of toxicities,,2018-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
419,NCT03172416,Tolerability of PIPAC with oxaliplatin in combination with IV nivolumab by monitoring dose limiting toxicities,Area under the curve (AUC) of oxaliplatin and in combination with IV nivolumab administered via PIPAC using blood drawn from patient.,,2017-04-12,RECRUITING,INTERVENTIONAL,['PHASE1']
420,NCT01386346,Evaluation of dose limiting toxicity (DLT),,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
421,NCT02646514,Patency of metal stent,Complication rate,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
422,NCT05400681,Relative frequency of ctDNA in peritoneal lavage and peripheral blood,Prognostic value of ctDNA in peritoneal lavage and peripheral blood,,2020-08-01,RECRUITING,OBSERVATIONAL,['NA']
423,NCT04780789,Interobserver variability of the methods used for assessing tumor response to the treatment,"Response to the treatment, as assessed by volumetric analysis",,2015-02-01,COMPLETED,OBSERVATIONAL,['NA']
424,NCT00667641,Maximum tolerated dose of paclitaxel in combination with bortezomib,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
425,NCT03407495,The Sensitivity and specificity of IOP-enhanced MRI,The size of lesions detected in liver,,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2']
426,NCT05052801,Overall Survival,Number of Participants with an Anti-bemarituzumab Antibody Formation,,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3']
427,NCT03236051,Numeric rating scales (NRS) score with 24 hours after the surgery,Prealbumin,,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA']
428,NCT06162468,The proportion of patients in whom EUS-PCA was completed as planned.,The IPMN complete response rate in the injected lesion(s) on imaging 3 months post-EUS-PCA.,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
429,NCT03613142,Rate of reflux esophagitis after operation,postoperative quality of life,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
430,NCT03113214,Maximum Tolerated Dose,Time to Local Failure,,2017-02-02,COMPLETED,INTERVENTIONAL,['NA']
431,NCT01932918,lung injury score,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
432,NCT00134069,Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues,,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
433,NCT01545544,"presentation of NHL and HCV infection, and treatments of NHL and HCV infection",haematological response,,2006-11,UNKNOWN,OBSERVATIONAL,['NA']
434,NCT02438839,Proportion of patients with locoregional tumor control with chemoradiation alone two years after end of treatment,"Response and tumor control on MRI scans compared to clinical observations, including rectoscopic examination",,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
435,NCT05667298,Safety (proportion of patients developing Grade 3 or above adverse events),Progression-free survival,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
436,NCT02423811,Progression-free survival,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
437,NCT06143722,Progression-Free Survival (PFS),Adverse events,,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
438,NCT06006286,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-08-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
439,NCT02836925,SVR12,Toxicity - Incidence of Adverse Events,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
440,NCT04576208,Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ≥Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing,Health-Related Quality of Life (HRQoL) as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Score,,2020-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
441,NCT06015035,Primary Endpoints: pCR,,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE2']
442,NCT05622825,Image Assessment,Quality of life assessment.,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
443,NCT00153881,To determine the maximum tolerated dose of oral capecitabine in combination with fixed doses of weekly docetaxel and concurrent radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.,"To investigate the feasibility of assaying thymidine phosphorylase, cyclin B, MPM-2, and perturbations in cell cycle as potential markers of efficacy.",,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1']
444,NCT01733628,Progression Free Survival (PFS),"Number of Participants With ""White Coat"" AHT With 24 Hours Ambulatory BP Measure",,2012-10-23,COMPLETED,OBSERVATIONAL,['NA']
445,NCT00829595,"Response, defined by postvaccination antibody titers",,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
446,NCT03385018,3 year relapse-free survival,Quality of life(EORTC QLC STO22),,2018-04-05,RECRUITING,INTERVENTIONAL,['NA']
447,NCT00005616,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1']
448,NCT05214820,Tumor uptake of 68Ga-PSMA,Radiation dose (mGy),,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE2']
449,NCT05659381,Progression-free survival,Residual Disease,,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
450,NCT05407584,Confirmed ORR,second objective disease progression,,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2']
451,NCT05495217,Operative time,Tumor size,,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
452,NCT04126733,Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5,,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE2']
453,NCT03057288,Success rate evaluation of the placement of two fiducial markers,The presence of the markers at the end of the radiotherapy,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
454,NCT02907385,Incidence of overall anastomotic leak,Incidence of post operative anastomotic leaks,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
455,NCT05443087,Trough concentration (Ctrough),Safety: drug toxicity,,2022-08-29,RECRUITING,INTERVENTIONAL,['NA']
456,NCT00819208,Disease-free survival,Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire,,2009-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
457,NCT03753659,Objective response rate (ORR) according to RECIST 1.1,Identification of molecular biomarkers in tumor tissue and blood samples by immunohistochemical and molecular analyses in a central lab,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
458,NCT05436275,Nasal Congestion Score (NCS),Anti-drug antibodies (ADA),,2022-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
459,NCT06105515,Severe complication,Health-related quality of life,,2023-12,RECRUITING,INTERVENTIONAL,['NA']
460,NCT05431244,Objective Response Rate (ORR),Best Overall Response Rate (BOR),,2022-07-01,WITHDRAWN,INTERVENTIONAL,['NA']
461,NCT04510935,mean percentage change from post- to pre-operative values of invasion of HepG2 cells cultured in patients' serum,serum IL-2 level,,2020-08-20,COMPLETED,INTERVENTIONAL,['NA']
462,NCT02893982,maximum tolerated dose,local control,,2017-11-09,TERMINATED,INTERVENTIONAL,['PHASE1']
463,NCT03233555,Use of preventive services,,,2013-09-03,COMPLETED,INTERVENTIONAL,['NA']
464,NCT03742453,Diagnostic performance of CEUS for diagnosing HCC,Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018,,2018-10-16,UNKNOWN,INTERVENTIONAL,['NA']
465,NCT00332280,Improvement in clinical benefit response,Safety and tolerability,,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
466,NCT01324284,Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with Lubiprostone,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
467,NCT05304481,Relapse-free survival rate,Changes in respiratory rate,,2022-05-14,RECRUITING,INTERVENTIONAL,['PHASE2']
468,NCT05585437,patient complication rate,,,2021-11-11,COMPLETED,OBSERVATIONAL,['NA']
469,NCT00584597,The specific aim will be to determine the safety of TRAUMEEL S for mucositis in head and neck cancer patients undergoing radiation therapy,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
470,NCT03879395,Overall survival,Complications according to Clavien-Dindo within 90 days.,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
471,NCT03589443,Validate the binding of the peptides using the SFE,Use of the SFE to detect QRH and KSP via contrast,,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
472,NCT05282433,Progression-free survival,,,2022-04-16,RECRUITING,INTERVENTIONAL,['PHASE2']
473,NCT02873598,The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant Progression After Induction Chemotherapies.,Quality of Life (QOL),,2016-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
474,NCT05251038,Objective Response Rate (ORR),Overall Survival (OS),,2022-09-13,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
475,NCT00103142,Recurrence-free Survival at 2 Years,Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
476,NCT00639522,Dose limiting toxicity,Pharmacokinetics,,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
477,NCT04634357,The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT,Determine the pharmacokinetics of ET140203 T cells after infusion.,,2022-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
478,NCT05431621,Establish and evaluate the non-invasive early detection model for hepatocellular carcinoma,,,2020-11-15,RECRUITING,OBSERVATIONAL,['NA']
479,NCT02976142,Overall 2-year survival,Quality of life,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
480,NCT05032027,grade 3 entiritis,Changes in intestinal flora,,2021-08-27,RECRUITING,INTERVENTIONAL,['NA']
481,NCT00003018,Overall Survival,Resectability of patents who respond to this regimen,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2']
482,NCT04133155,Progression-free survival,Toxicity profile,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
483,NCT00827684,Objective response rates,Translational Research,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
484,NCT04587310,endoscopy performed on patients,,,2008-10-01,COMPLETED,OBSERVATIONAL,['NA']
485,NCT01429038,"Incidence of infections (bacterial, viral, fungal, parasitic) and cancers",Anti-MSC donor HLA antibodies.,,2012-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
486,NCT00352638,Colorectal cancer screening compliance,Cost,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
487,NCT01762293,Progression Free Survival(PFS),Number of Participants with Adverse Events as a Measure of Safety,"body vitals, laboratory parameters",2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
488,NCT04418739,Overall Complications,Ease of surgery,,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE2']
489,NCT02375958,Incidence rate of dose limiting toxicities,Pharmacokinetic paramater Tmax,,2015-04-15,COMPLETED,INTERVENTIONAL,['PHASE1']
490,NCT00026273,,,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
491,NCT03937830,"To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab","To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC",,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE2']
492,NCT00737646,Changes in colorectal cancer screening rates (4 modalities),"Changes in measures of attitudes, beliefs, opinions, and social influence surrounding CRC screening among patients, clinicians, and clinical staff.",,2009-07,COMPLETED,INTERVENTIONAL,['NA']
493,NCT04493632,Resection Rates,,,2022-04-12,RECRUITING,OBSERVATIONAL,['NA']
494,NCT01831245,Pathological Anatomic diagnosis (PAD) on a tumor biopsy,C - reactive protein,Leakage of anastomosis,2011-01,COMPLETED,OBSERVATIONAL,['NA']
495,NCT06318793,Concentration of C-reactive protein (CRP),,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
496,NCT05573282,Progress Free Survival,Tumor Response,,2022-10-16,RECRUITING,OBSERVATIONAL,['NA']
497,NCT05999396,Safety 3-Hematology-White Blood Cells,,,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE1']
498,NCT04151355,incidence of mucositis,serum levels of tumor necrosis factor α (TNF-α),,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
499,NCT06298916,Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression,Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer,Exploratory Part 1 and Part 2,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
500,NCT05578287,Feasibility,Overall Survival (OS),,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2']
501,NCT04704661,Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase),PD markers,"Association of TP53, ATM, and RAS mutations with ORR",2021-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
502,NCT04581876,progression free survival,adverse events,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
503,NCT01575574,hepatocellular carcinoma diagnosed,magnetic resonance imaging sensitivity,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
504,NCT04481828,Tumor stage (American Joint Committee on Cancer 8th Edition),,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
505,NCT06191185,Colonoscopy completion,Scheduled by GI for colonoscopy,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
506,NCT00815113,"Characterization of the high-rik individual for gastric cancer - ""Gastric Cancer Phenotype""",Establish a screen plan for high-risk population for gastric cancer,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
507,NCT03187028,Feasibility - Participant satisfaction,Wearable activity monitor (weekly minutes of physical activity),,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
508,NCT01341210,The influencing factors of behavior intentions towards participating in clinical trials,The subjective norm and behavior intentions towards clinical trials in cancer patients,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
509,NCT01227772,Optimal dosing schedule,Induction of specific cytotoxic T-lymphocyte (CTL) response,,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
510,NCT04951804,Change in Likert pain scores,Difference in Global Rating Scale of Change at T3 vs all other follow-up time points,,2021-10-07,RECRUITING,INTERVENTIONAL,['NA']
511,NCT02908204,Overall survival,Long-term complications incidence rate,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
512,NCT05851534,Time to functional recovery,Evaluation of quality of life for cancer patients,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
513,NCT01278537,Quality of life,Stress,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
514,NCT00288444,Determine the molecular interaction,Determine safety and efficacy,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1']
515,NCT04794465,Time to treatment,Time to symptoms,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
516,NCT00060502,"Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).","Change in 6-minute walk test distance from baseline to the end of the first cycle; Safety, Karnofsky performance status; Survival.",,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
517,NCT00066846,,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2']
518,NCT00729677,Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
519,NCT04108494,3 years relapse-free survival,5 years overall survival,Postoperative morbidity,2019-01-01,RECRUITING,INTERVENTIONAL,['NA']
520,NCT04624217,ORR,OS,,2020-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
521,NCT02154737,Rate of dose limiting toxicities of each subject,Adverse events related to pulse dose erlotinib and gemcitabine,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
522,NCT03833700,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Overall Survival (OS),,2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
523,NCT01380262,number of patients with a severe skin toxicity,quality of life assessed with DLQI,,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
524,NCT03433703,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),Time to Progression (TTP),,2018-04-26,TERMINATED,INTERVENTIONAL,['PHASE2']
525,NCT04135690,Progression free survival rate at 6 months,Adverse events,,2019-10-20,RECRUITING,INTERVENTIONAL,['PHASE2']
526,NCT04569799,No Viable Disease on CT/MRI Imaging.,Lesions Missed or Miscategorized on CT/MRI Imaging.,,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE4']
527,NCT00316745,PFS of 1st line treatment,safety,,2006-04,SUSPENDED,INTERVENTIONAL,['PHASE3']
528,NCT05327517,Overall Survival,Laryngo-esophageal dysfunction free survival,,2022-04-10,RECRUITING,INTERVENTIONAL,['NA']
529,NCT02600949,Incidence of adverse events (AEs),Levels of intracellular cytokine staining of T cells,,2016-05-11,RECRUITING,INTERVENTIONAL,['PHASE1']
530,NCT01756183,radical resection rate,overall survival time,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
531,NCT01127425,primary: Length of stay,"secondary: Nursing hours, pain and recovery",,2006-07,TERMINATED,INTERVENTIONAL,['NA']
532,NCT02547480,Area Under the Curve (AUC),Technical success - total dose delivered,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
533,NCT05015296,1-year recurrence-free survival after surgery,,,2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
534,NCT03579836,DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II),Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II),,2018-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
535,NCT00444041,The primary objective of this study is the Resectability (R0) rate after neoadjuvant Bevacizumab in potentially resectable mCRC.,Overall Survival (OS),,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
536,NCT05227378,Objective Response Rate (ORR),Lymphocyte,,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
537,NCT04263948,Rates and grades toxicity and early tumor responses,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
538,NCT02658019,Number of Participants With Treatment-Related Adverse Events,Duration of Response (DoR),,2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2']
539,NCT02319018,"Maximum tolerated dose and the recommended phase II doses of mFOLFOX given in combination with alisertib, defined as the dose level at which the probability of dose limiting toxicities is 30%","Anti-tumor activity associated with this treatment, evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors version 1.1",Tumor expression by immunohistochemistry,2015-08-27,COMPLETED,INTERVENTIONAL,['PHASE1']
540,NCT02423785,Changes in retinal surface before and after therapy as measured by optical coherence tomography,,,2014-05,TERMINATED,OBSERVATIONAL,['NA']
541,NCT02605044,Overall survival,Progression Free Survival (PFS),,2014-01,TERMINATED,INTERVENTIONAL,['PHASE3']
542,NCT05588388,6- month Progression Free Survival (PFS) rate,Incidence of adverse events,Tissue and blood based biomarkers,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
543,NCT04425564,Peak and trough levels of capecitabine and relation to dosing,Overall survival,,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
544,NCT03771508,Prospective collection of PillCam SB3 videos,,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA']
545,NCT02092519,diagnostic accuracy,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
546,NCT01808417,Feasibility of real-time intraoperative NIR lymphatic mapping,Identification of sentinel lymph nodes,,2013-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
547,NCT02333188,"DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0",Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
548,NCT04567069,Health-related quality of life (QoL): 36-Item Short Form (SF-36),Health-related quality of life (QoL): 36-Item Short Form (SF-36),,2020-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
549,NCT00416351,Response Rate for Participants With Non-Hodgkin's Lymphoma,Participants Evaluated for Toxicity,,2006-06-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
550,NCT03983174,fecal incontinence,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
551,NCT03795311,Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability,,,2018-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
552,NCT04741308,Change from baseline immune function at follow-up.,Change from baseline chemotherapy response at follow-up.,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
553,NCT06252142,International Prostate Symptom Score (IPSS),Treatment-related toxicities,,2024-02-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
554,NCT05694949,All-cause mortality at 30 days after operation,Major Adverse Cardiovascular Events (MACE),,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
555,NCT03172403,Correlation between skeletal muscle and degree myostatin,Analysis level of myostatin muscular expression and blood samples results,,2018-08-02,TERMINATED,INTERVENTIONAL,['NA']
556,NCT06301386,objective response rate (ORR),advert events,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
557,NCT03803254,Overall Survival (OS),Adverse Events,,2019-01-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
558,NCT01411176,The proportion of patients had no or mild peristalsis during the therapeutic procedures,Adverse events and adverse drug reactions,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
559,NCT00250822,"Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.",,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
560,NCT03253536,Quality of life,correlation Qol with late toxicity,,2017-07-10,RECRUITING,OBSERVATIONAL,['NA']
561,NCT01769248,Diagnostic Yield of EUS-FNB and EUS-FNA,Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
562,NCT04540146,cytokine levels,,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
563,NCT04761172,Primary tumor detection,Tumor to background ratio,,2020-06-17,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
564,NCT05730595,Overall survival,Function score,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
565,NCT01617382,To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.,,,2012-05,RECRUITING,OBSERVATIONAL,['NA']
566,NCT00814086,Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks,Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
567,NCT00954174,Overall Survival,Patient-reported Peripheral Neuropathy Symptoms - Post Baseline,,2009-08-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
568,NCT06266832,Organ retention rate,QoL,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
569,NCT00689364,The recurrence and metastasis rates for 1、2、3、4 and 5-year.,Survival index: the survival rate for1、2、3、4 and 5-year.,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
570,NCT03595540,Quantification of FMD-emergent adverse events,,,2017-11-22,COMPLETED,INTERVENTIONAL,['NA']
571,NCT02788214,Bacterial DNA sequence,,,2016-07-27,TERMINATED,OBSERVATIONAL,['NA']
572,NCT00896467,Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires,,,2007-09,TERMINATED,OBSERVATIONAL,['NA']
573,NCT00002470,,,,1990-09,COMPLETED,INTERVENTIONAL,['PHASE2']
574,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,All-cause Mortality at 1 Year (Safety Outcome),,2020-04-23,COMPLETED,INTERVENTIONAL,['NA']
575,NCT01288625,Incidence and duration of oral mucositis,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
576,NCT03682289,Objective response rate (ORR) for endometrial cohort,Overall percent change in tumor size,,2019-01-17,RECRUITING,INTERVENTIONAL,['PHASE2']
577,NCT01564810,the rate of patients converted to resection for liver metastases,tumor response,,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
578,NCT03843749,Objective Response Rate(ORR),,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
579,NCT04599179,Quality of life (QoL) after endoscopic or surgical treatment,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
580,NCT02470533,Time to progression,Quality of life,,2015-04-30,TERMINATED,INTERVENTIONAL,['PHASE2']
581,NCT04440930,Incidence of oral mucositis grade 2 or higher as measured by the Revised Oral Assessment Guide.,Date of onset of oral mucositis grade 2 or higher as measured by Revised Oral Assessment Guide.,,2020-09-02,COMPLETED,INTERVENTIONAL,['NA']
582,NCT02560974,Disease-free survival rate,Incidence of adverse events,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
583,NCT04650451,Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE),Antitumor activity of BPX-603,,2020-12-07,SUSPENDED,INTERVENTIONAL,['PHASE1']
584,NCT01860144,Objective response rate,resection rate,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
585,NCT04391933,Is MRI usefull in colon cancer patients,,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
586,NCT04823793,Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening,,,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA']
587,NCT01443481,Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258,Pharmacokinetics and Hepatic Function Abnormalities,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
588,NCT01524848,Disease control rate,Overall response rate,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
589,NCT04303429,Disease Free Survival (DFS),Overall Survival (OS),Cost Utility Analysis,2020-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
590,NCT06205706,"identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety",Duration of response (DoR).,,2023-12-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
591,NCT02699047,Serum albumin,,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
592,NCT02046278,Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.,Performance Rate of anastomotic leak (both radiological and clinical leaks),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
593,NCT05734105,Progression-free Survival (PFS),Overall Survival (OS),,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE3']
594,NCT03174444,Colorectal Cancer Screening,,,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
595,NCT00636883,"Response rate (partial and complete response, stable disease, and progressive disease)",Overall survival,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
596,NCT01239095,Number of patients with adverse events or complications,,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1']
597,NCT00379782,subject satisfaction with navigation,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
598,NCT04606914,Radiographic tumor assessment per RECIST v1.1 criteria,Safety profile of treatment with carboplatin-mirvetuximab soravtansine according to CTCAE v4.03,,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2']
599,NCT02188342,VO2 peak,Quality of life,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
600,NCT00275951,Confirmed objective response rates,"Progression-free survival (PFS), overall survival (OS), treatment-related toxicity",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
601,NCT04045236,Distant recurrence,Quality of life Scale (QOLS),,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
602,NCT04532515,Proportion of surgeries with full sealant coverage - successful application,Hospital length of stay,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
603,NCT05821582,Primary Objective- Intestinal side effects of chemotherapy,,,2023-03-27,WITHDRAWN,OBSERVATIONAL,['NA']
604,NCT02473003,Change in Fatigue,Treatment completion rate,,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
605,NCT03958890,OS,Duration of response,,2019-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
606,NCT04804696,Pathologic complete response rate,Adverse events,,2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2']
607,NCT01245816,Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.,Presence of high grade dysplasia or villous adenoma in any polyp resected.,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
608,NCT00915863,the incidence of pancreatic fistula,"the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess",,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
609,NCT04840056,Gastric cancer and gastric dysplasia,Area under the receiver operating characteristic curve of machine learning model,,2021-04-15,RECRUITING,OBSERVATIONAL,['NA']
610,NCT04251403,Correlation of pathologic diagnosis from gastric aspirate compared with diagnosis from standard endoscopic inspection and biopsies.,,,2020-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
611,NCT04357158,Diagnostic accuracy in distinguishing colorectal carcinoma from healthy controls,Acceptance rate,,2020-05-25,COMPLETED,INTERVENTIONAL,['NA']
612,NCT05298020,PFS,AEs,,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
613,NCT00478946,maximum tolerated dose,safety and efficacy,,2006-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
614,NCT05156463,Use of Actigraph to measure changes in activity and sedentary behavior,Exercise Self-Efficacy Scale This scale assesses an individual's beliefs in their ability to continue exercising on a 3 time/week basis at moderate intensities for 40+ min. per session in the future.,,2022-04-12,WITHDRAWN,INTERVENTIONAL,['NA']
615,NCT04896684,Biological collection associated with clinical data,Optimize treatment success rates for IBD,,2021-04-29,RECRUITING,OBSERVATIONAL,['NA']
616,NCT03869034,Progression Free Survival (PFS) assessed by RECIST 1.1,Recurrence-free survival (RFS),Biomarkers of treatment response by single-cell RNA sequencing,2019-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
617,NCT01068327,Maximally tolerated dose (MTD) of stereotactic radiotherapy and concurrent nelfinavir mesylate,Pharmacogenomic status of CYP2C19*2 (G681A) (correlative),,2007-11-05,COMPLETED,INTERVENTIONAL,['PHASE1']
618,NCT01437007,"To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.",To evaluate the potential conversion rate from unresectable to resectable disease.,,2011-08-26,COMPLETED,INTERVENTIONAL,['PHASE1']
619,NCT03829462,Overall survival,Time to Deterioration,,2019-03-28,RECRUITING,INTERVENTIONAL,['PHASE3']
620,NCT05911243,Acceptability (feasibility),Change in body weight (kg),,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
621,NCT03690921,Acute Toxicity,Complete Response at 24 Weeks,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
622,NCT02534233,Number of patients with treatment-related adverse events (pain and dysphagia),Histological evaluation of treatment zone for intestinal metaplasia (BE patients),,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
623,NCT04961138,1-year disease free survival,objective response rate,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
624,NCT03774680,Measurement of pharmacokinetics parameters of Cetuximab for targeted colon cancer,,,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
625,NCT02989922,6-month Overall Survival Rate,Overall Survival,,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
626,NCT03428958,"Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations",Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1,,2018-10-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
627,NCT05426135,"Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).",,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
628,NCT03750786,Overall Response Rate,Duration of Response,,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE3']
629,NCT05959395,"Safety of the VectRx treatment evaluated by incidence of Adverse events (AEs) such as first and second-degree burns, edema and abdominal pain, will be assessed [safety and tolerability].",,,2023-08-15,RECRUITING,INTERVENTIONAL,['NA']
630,NCT03297996,Prevalence and relative abundance of selected fecal microbial taxa,,,2011-11-23,COMPLETED,OBSERVATIONAL,['NA']
631,NCT05391477,Comparison of the AIOD and HOD negative predictive value (NPV) for adenoma in rectosigmoid polyps ≤ 5 mm with respect to histology,Proportion of patients accepting to have their polyps diagnosed by the AI system or human optical diagnosis (designed questionnaire),,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
632,NCT04687163,Overall survival,Adverse Events,,2020-12-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
633,NCT02728921,Change in plasma volume,Incidence of postoperative complications,"Change in heart rate, change in central venous oxygen saturation, change in haemoglobin concentration in blood, change in blood pressure, change in central venous pressure, change in plasma lactate and diuresis.",2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
634,NCT06001268,Participant Rating on Ease of Use the Mobile Application - Usability,Malnutrition -Nutritional Status,,2023-08-14,RECRUITING,INTERVENTIONAL,['NA']
635,NCT04915807,Progression-free survival,Adverse events of special interest,,2021-06,UNKNOWN,OBSERVATIONAL,['NA']
636,NCT06325891,Microbiome analysis using gastric mucosal brushing,Microbiome analysis using gastric mucosal biopsy,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
637,NCT00780494,Progression-Free Survival (PFS),Vascular Endothelial Growth Factor Tumor Response Biomarker,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
638,NCT02753127,Overall Survival (OS),Number of Patients With Adverse Events in the General Population,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
639,NCT04827485,Left colon distension score,Left colon sessile serrated lesion detection rate,,2022-01-13,TERMINATED,INTERVENTIONAL,['NA']
640,NCT05338866,3-year progression free survival rate,Patients' quality of life scale,,2022-01-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
641,NCT03784417,Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor,Overall survival,,2019-10-15,TERMINATED,INTERVENTIONAL,['NA']
642,NCT05443321,Total clinician-reported medical errors,Time between transferred patient arrival and entry of admission orders,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
643,NCT00543777,Overall Image Quality of Magnetic Resonance Elastography (MRE),Hepatic Steatosis,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
644,NCT01641458,Predefined fluoropyrimidine-related (index) toxicity,Progression-free survival,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
645,NCT03154983,progress-free survival time,disease control rate,,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
646,NCT03095703,Number of participants with treatment-related adverse events,Immunohistochemistry of mTOR targets,,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2']
647,NCT05458986,Intent to complete a colonoscopy,Incidence of completed colonoscopies,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
648,NCT02670746,Adverse Event (AE),Evaluate the resources utilized for treatment of pancreatic adenocarcinoma with the combination nab-paclitaxel/gemcitabine in routine clinical practice,,2015-10-01,TERMINATED,OBSERVATIONAL,['NA']
649,NCT00252564,Progression-free Survival (PFS) Rate at 1 Year.,Objective Response Rate,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
650,NCT02042430,Number of participants with an increase in CD8+ T cells,Changes in IDO1 expression by IHC,,2014-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
651,NCT00142038,Response Rate,Quality of Life,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
652,NCT03993626,Immune Disease Control Rate (iDCR),Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2018-05-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
653,NCT05735912,Rate of adverse events,Pancreatic insufficiency,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
654,NCT00577538,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
655,NCT01904890,Receipt of CRC Screening,CRC screening Intention,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
656,NCT04548765,Colonoscopy Ordered at 6 months,Colonoscopy Result,,2020-07-24,COMPLETED,INTERVENTIONAL,['NA']
657,NCT00079365,,,,2001-05,UNKNOWN,INTERVENTIONAL,['NA']
658,NCT04269369,The frequency of severe ﬂuoropyrimidine-related toxicity,,,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
659,NCT04466631,Utilization of specific competences by participants,Number of participants maintaining their social activities,,2020-06-15,UNKNOWN,OBSERVATIONAL,['NA']
660,NCT05639972,Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC,2-year and 5-year disease free survival (DFS),,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
661,NCT04902352,SMA margin status,Disease free survival,,2021-04-06,RECRUITING,INTERVENTIONAL,['NA']
662,NCT04013347,number of patient with surgical complications,number of patient with anastomotic dehiscence,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
663,NCT04593407,Percentage of surgical referral after treatment,Cumulative complications rate after treatment,,2020-11-03,RECRUITING,INTERVENTIONAL,['NA']
664,NCT03176485,Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease,Modulatory effect of Ras inhibition in Epidermal Growth Factor Receptor (EGFR) and Activating Protein-1 (AP1) signaling pathways (IHC and RPPA).,,2014-10-17,COMPLETED,INTERVENTIONAL,['NA']
665,NCT04578444,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
666,NCT01801085,"Composite preparation, dispensing and administration time",Capital item utilization (hospital bed and infusion pump),,2011-10,TERMINATED,OBSERVATIONAL,['NA']
667,NCT01995591,number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
668,NCT05252390,Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868,,,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
669,NCT03069508,Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth),Overall survival associated with clemizole hydrochloride,,2017-02-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
670,NCT02125396,Overall survivals,Recurrence rates,,2019-05-01,RECRUITING,INTERVENTIONAL,['PHASE3']
671,NCT01765582,Progression-Free Survival During First-Line Therapy (PFS1),Percentage of Participants With Adverse Events,,2013-01-23,TERMINATED,INTERVENTIONAL,['PHASE2']
672,NCT04722120,Quantitative image quality analysis,,,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
673,NCT02900248,Time to Treatment Progression,To determine rate of enrollment into existing and future therapeutic clinical trials.,,2017-10-02,TERMINATED,OBSERVATIONAL,['NA']
674,NCT00008047,,,,1999-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
675,NCT03551470,Operative time,,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
676,NCT04404673,Urinary and sexual outcomes after rectal resection,,,2020-02-21,UNKNOWN,OBSERVATIONAL,['NA']
677,NCT02729948,Incidence of adverse events associated with TCE use,,,2016-07-28,COMPLETED,INTERVENTIONAL,['NA']
678,NCT04592913,Event-free survival (EFS),To compare Arm A relative to Arm B on pathological complete response (pCR) rate,,2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
679,NCT01056913,Anastomotic Leakage,Clinical Relevant Stenosis,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
680,NCT00131911,Confirmed Response Rate,Duration of Response,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
681,NCT00041197,Recurrence-free survival (RFS),Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
682,NCT04808466,overall survival,The positive rate of cancer cells of participants by exfoliative cytology examination,,2021-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
683,NCT01497964,Objective Response Rate,Pharmacokinetic parameter Vss,,2011-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
684,NCT00047112,overal survival,recurrence free survival,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
685,NCT00470782,,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
686,NCT02527967,Hospital length of stay (days),Readmission rate (%),,2013-01,COMPLETED,OBSERVATIONAL,['NA']
687,NCT03233360,Time to treatment recurrence,,,2017-04-17,COMPLETED,OBSERVATIONAL,['NA']
688,NCT01762514,Effect on improving mucositis,Incidence and severity of Hypocalcemia,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
689,NCT02503150,"Progression Free Survival, PFS",Adverse Events,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
690,NCT02330536,Respiratory change,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
691,NCT03776370,The five-year survival rates of rectal cancer between the two groups were compared.,,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
692,NCT03387774,Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ≥ 3),The Adverse events Related to Ulinastatin,,2018-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
693,NCT03652467,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer,Number of Participants With Drug-Related Treatment-Emergent Adverse Events,,2018-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
694,NCT00293462,Comparison of the Mean Number of Days for Mucositis to Heal Across by Group,Comparison of Combined Mean Score on the Pain Questionnaire by Group,,2005-06-07,COMPLETED,INTERVENTIONAL,['PHASE3']
695,NCT01269970,early metabolic response to predict pathological response and outcome,"to study correlations between early metabolic response, late metabolic response, histopathological response and outcome.",,2004-01,COMPLETED,OBSERVATIONAL,['NA']
696,NCT01726309,Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.,Correlation between the SNP profile(s) and disease response,,2011-05,TERMINATED,OBSERVATIONAL,['NA']
697,NCT01896869,Overall Survival (OS),Tumor Marker Kinetics as Assessed by Median Carbohydrate Antigen 19-9 (CA19-9) Levels,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
698,NCT01854255,Clinical Benefit Rate,Observed Survival,median time ot progression,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
699,NCT04004650,Perineal wound healing rate 30 days,Female sexual distress,,2019-06-28,UNKNOWN,INTERVENTIONAL,['NA']
700,NCT03474822,Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0,Immunological index,,2018-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
701,NCT03322969,disease free survival,,,2017-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
702,NCT04172402,Overall response rate (ORR),,,2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
703,NCT05661643,Objective respone rate in SDH deficiency wild type GIST,,,2023-06-28,RECRUITING,INTERVENTIONAL,['PHASE2']
704,NCT02524119,Progression Free Survival,Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1,,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2']
705,NCT00836303,Completion of Colorectal cancer screening,Patient adherence to physician recommended colorectal cancer screening test,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
706,NCT00813163,Survival Rate,pharmacogenetics,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
707,NCT03639792,Postoperative Morbidity and mortality,Overall survival,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
708,NCT03756051,Psychosocial Harms,Physical Harms,,2018-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
709,NCT04131426,Recruitment and Retention,Porportion of subjects with improved cachexia-related symptoms 3 months,,2020-04-24,COMPLETED,INTERVENTIONAL,['PHASE1']
710,NCT02408406,Functional Assessment of Cancer Therapy-General (FACT-G) scores,Change in health resource utilization,Individual patient changes in Functional Assessment of Cancer Therapy-General (FACT-G) total scores,2015-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
711,NCT06090656,progression free survival，PFS,"Patient-reported outcomes, PRO",,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2']
712,NCT04533490,DFS（disease-free survival）,OS（overall survival rate）,Exploratory analysis of biomarkers for predicting efficacy,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
713,NCT01696630,Variation of intraoperative Mean Arterial Pressure (MAP),Delay to intestinal transit recovery,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
714,NCT04718402,adverse events (AEs),overall survival (OS),,2021-03-30,TERMINATED,INTERVENTIONAL,['PHASE1']
715,NCT01514110,to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin,Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction,,2008-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
716,NCT03822130,Successful conversion rate of operation,PFS,,2019-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
717,NCT05221957,Complications,Mortality,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
718,NCT05800106,Relative bioavailability (F),Proportion of subjects with abnormal 12-lead electrocardiogram (ECG),,2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
719,NCT06184841,Adverse Events,The overall survival (OS),,2020-06-18,COMPLETED,INTERVENTIONAL,['PHASE1']
720,NCT05905887,Disease control rate,,,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE2']
721,NCT00355355,Overall survival,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3']
722,NCT05959356,Progression free survival,Quality-adjusted time without symptoms or toxicity,"Treatment-emergent genetic mutations (e.g., KRAS, NRAS, BRAF, SMAD4, HER2, Etc.)",2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
723,NCT03404661,Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume,,,2018-01-11,COMPLETED,OBSERVATIONAL,['NA']
724,NCT00337545,,,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
725,NCT02738359,"Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)",Rate of colorectal cancer identified by each screening strategy,Quality assessment of colonoscopy and capsule endoscopy,2017-11-03,RECRUITING,OBSERVATIONAL,['NA']
726,NCT04548752,Progression-free survival (PFS),Duration of response (DoR),,2021-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
727,NCT03009461,Overall survival,,,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
728,NCT01768104,En bloc resection,Quality of life,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
729,NCT01211210,3-year disease free survival,quality of life,,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
730,NCT01836653,Progression-free survival,Response rate,Progression-free survival among the RAS wild type subpopulation,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
731,NCT02108782,Progression-free survival,Incidence of adverse events graded according to National Cancer Institute (NCI) CTCAE version 4.0,Plasma levels of circulating angiogenic factors and soluble receptors,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
732,NCT05965466,Number of gallstone patients,Number of patients with bile duct stones,,2023-07-21,RECRUITING,INTERVENTIONAL,['NA']
733,NCT02202317,Number of Subjects Whose Y-90 Based PET/CT (Positron Emission Tomography/Computed Tomography)Scans Detected Extrahepatic Non-target Embolization.,Comparison of Y-90 PET/CT to Y90 SPECT,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
734,NCT02502630,Overall Survival (OS),Treatment related adverse events,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
735,NCT03712943,Maximum Tolerated Dose,Frequency and Severity of Adverse Events,,2018-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
736,NCT06084299,Maximum tolerated dose [Safety and Tolerability],Overall Survival (OS),,2020-05-27,RECRUITING,INTERVENTIONAL,['PHASE1']
737,NCT02814461,The maximal tolerated dose (MTD),,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
738,NCT00860860,Toxicity defined by NCI Common Terminology Criteria for Adverse Events version 3.0,"pharmacokinetics and biodistribution of TF2 and Lu-177-labeled IMP-288, sensitivity of pretargeted imaging with In-111-labeled IMP-288, and tumor response using RECIST criteria",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
739,NCT04458740,Assess how the patients and their family members face the disease,,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
740,NCT01739894,Overall survival (OS) rate,Number of participants with adverse events,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
741,NCT01224652,progression-free survival,Overall survival,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
742,NCT01678027,Gastric cancer incidence,All-cause mortality,,2004-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
743,NCT04739696,Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD),Caregiver: Job Satisfaction,,2021-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
744,NCT04858334,Improvement in relapse-free survival (RFS),OS in those who received any platinum-based perioperative chemotherapy versus no platinum-based perioperative chemotherapy,RFS and OS differences with those who had resectable disease at diagnosis,2021-06-22,RECRUITING,INTERVENTIONAL,['PHASE2']
745,NCT05578677,"Size of biopsy specimen, as assessed by a blinded study investigator","The percentage biopsies with the presence of dysplasia, as assessed by a blinded upper GI pathologist",,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
746,NCT01386502,To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.,To determine the clinical efficacy of this combination.,,2011-06-15,WITHDRAWN,INTERVENTIONAL,['PHASE1']
747,NCT04605731,Overall response,Overall survival,Gene expression signatures,2021-08-03,RECRUITING,INTERVENTIONAL,['PHASE1']
748,NCT05512260,Feasibility regarding iDA format,Self-reported lifestyle behaviors,Satisfaction with the iDA and the decision,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
749,NCT02355353,Tumor regression grade (TRG),"Histopathological measurements of tumor tissue cellularity /density, Necrosis, Proliferation (ki-67)",,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
750,NCT06280105,objective response rate (ORR) per RECIST1.1,Occurence of AE and SAE,,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
751,NCT01374451,Progression-free Survival (PFS) Per Local Radiological Review,Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
752,NCT04247958,Number of SureForm™ Stapler fires and reload colors,Incidence of peri-operative and short term outcomes,,2020-01-30,COMPLETED,OBSERVATIONAL,['NA']
753,NCT00747097,Progression-free survival,"overall survival, objective response, safety",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
754,NCT04930315,1-year tumor recurrence-free rate,Adverse events,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
755,NCT04192565,Complication rate (%),,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
756,NCT05775900,Pharmacokinetic (PK) characteristics 2,Quality of Life (QOL),Treatment-emergent genetic mutations,2023-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
757,NCT02643498,maximum tolerated dose (MTD) of SBRT,,,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
758,NCT00333788,Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks),Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
759,NCT00217711,"Efficacy of Oxaliplatin, Irinotecan, and Capecitabine",Overall survival,,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
760,NCT05449873,Local tumor progression rate,Complication rate,,2021-10-18,RECRUITING,INTERVENTIONAL,['NA']
761,NCT01984580,Changes in zinc-regulated cellular proteins within Barrett's tissue,Changes in cellular microRNA profile; changes in protein cancer biomarkers,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
762,NCT05163665,Cost of each closure,Successful Tissue approximation,,2022-08-23,COMPLETED,INTERVENTIONAL,['NA']
763,NCT02311439,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine,Tumor response,Number of Cases will have radical surgery,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
764,NCT01608646,Objective tumor response,Adverse event incidence,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
765,NCT05231382,Two-years progression-free survival rate,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30.",,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3']
766,NCT02169908,Thermal thresholds,Tactile sensitivity,Characterization of pain neuropathy,2014-05,COMPLETED,INTERVENTIONAL,['NA']
767,NCT02537158,recurrence-free survival,overall survival,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
768,NCT03715517,Cumulative 72-hour opioid consumption (OC_0-72h),Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score,Cumulative incidence (proportion) of postoperative vasopressor and/or inotrope dependency (%),2018-10-04,RECRUITING,INTERVENTIONAL,['NA']
769,NCT00920803,To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.,To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.,,2008-08-19,COMPLETED,INTERVENTIONAL,['PHASE1']
770,NCT06267378,"The sensitivity & specificity of blood based biomarkers for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events",Overall survival at 3 months and 5 years (the latter via cancer registry returns),,2023-08-30,RECRUITING,OBSERVATIONAL,['NA']
771,NCT04871204,Weight change in percent (%),Number of patients completing treatment,,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2']
772,NCT04942626,Identification of the maximum tolerated dose for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c,Quality of life based on treatment arm and surgical procedures/organ preservation,,2021-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
773,NCT00675194,response rate,Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
774,NCT04813432,time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma,,,2018-09-10,UNKNOWN,OBSERVATIONAL,['NA']
775,NCT01408407,Maximum skin toxicity,,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2']
776,NCT02869802,Number of days between biopsy and return of comprehensive genomic results.,Overall Survival,Targetable mutations,2016-10-06,RECRUITING,OBSERVATIONAL,['NA']
777,NCT01238965,To assess the safety of this regimen,Overall survival,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
778,NCT04466696,Postoperative length of stay,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
779,NCT02110953,"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",Time to progression,,2016-01-29,TERMINATED,INTERVENTIONAL,['PHASE1']
780,NCT01274962,Compliance to chemotherapy - patients receiving at least 85% of planned full-dose of chemotherapy prescribed at each cycle for the 12 cycles,Overall survival rate,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
781,NCT01287130,"To assess for evidence of anti-tumor activity with this combination, per tumor measurements",To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer,,2011-01-07,COMPLETED,INTERVENTIONAL,['PHASE1']
782,NCT01143922,,,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
783,NCT05775419,5-years overall survival (OS),5-year progression-free survival (PFS),,2021-06-30,RECRUITING,INTERVENTIONAL,['NA']
784,NCT01431599,downstaging effect of tumor,bladder and small bowel toxicity after chemoradiation,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
785,NCT04777604,Overall survival rate,,,2021-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
786,NCT00632515,Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information,,,2008-01-29,COMPLETED,OBSERVATIONAL,['NA']
787,NCT01585727,Urogenital function,Fecal incontinence,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
788,NCT00332865,Objective swallowing using videofluoroscopy and endoscopic evaluation of swallowing,Swallowing scale of EORTC HN 35,,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
789,NCT02173080,Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score,Total kidney volume,,2014-06,RECRUITING,OBSERVATIONAL,['NA']
790,NCT03977233,Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype,proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX,,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
791,NCT00234416,Incidence of DLT,"Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)",,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
792,NCT02032485,fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.,,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
793,NCT01652079,Progression Free Survival,Analysis of biopsies,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
794,NCT05351983,Feasibility of the process,Chemosensitivity testing,,2022-09-22,RECRUITING,INTERVENTIONAL,['NA']
795,NCT00729482,Progression-free Survival Rate at 4-month (16 Weeks),Number of Participants With Adverse Events,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
796,NCT04931394,Disease free time,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
797,NCT02628093,Versatility Score,Operative Procedure Time,,2016-02-17,COMPLETED,INTERVENTIONAL,['NA']
798,NCT02402036,Serum microRNA Quantification,,,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2']
799,NCT06209970,Numerical Rating Scale,,,2024-01-20,RECRUITING,INTERVENTIONAL,['NA']
800,NCT06216405,"Comparing the percentage of patients with at least one right colon polyp detected according to the randomization group, and adjusted for Boston Bowel preparation scale, for the operator, for the endoscope and for stratification factors.",,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA']
801,NCT03165591,Effect of V3-P on tumor burden,Effect of V3-P on sugar and bilirubin levels,,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
802,NCT05029869,The specificity of MRD detection using ctDNA as the biomarker,Mutation profile of gastric cancer,,2021-10-04,RECRUITING,OBSERVATIONAL,['NA']
803,NCT04125849,Postoperative respiratory complications,30-day mortality after surgery,,2020-04,UNKNOWN,INTERVENTIONAL,['NA']
804,NCT05367687,"Recurrence-Free Survival (RFS), as Determined by the investigator",The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
805,NCT03053167,Progression Free Survival [PFS],Disease Control Rate [DCR],Quality of Life [WHO-QOL],2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
806,NCT01442974,"Effect of nab-paclitaxel on pancreatic cancer stroma, new vessel formation and tumor cell metabolism.",Activity of nab-paclitaxel in combination with gemcitabine against PDA in relation with changes in tumor stroma and tumor metabolic activity.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
807,NCT04287400,K-RAS Mutation,Radiomics - MR image findings,,2019-03-05,RECRUITING,OBSERVATIONAL,['NA']
808,NCT00551057,,,,2007-10,UNKNOWN,OBSERVATIONAL,['NA']
809,NCT00425425,Response rate (histological remission) (Phase II),Metabolic response rate,,2006-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
810,NCT01721785,Diagnostic performance of the techniques under investigation,To determine the inter-observer agreement for the imaging techniques under investigation,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
811,NCT01817205,dose limiting toxicity,treatment response by alphafetoprotein,,2013-03,TERMINATED,INTERVENTIONAL,['NA']
812,NCT01289288,Receipt of CRC screening,,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
813,NCT02335151,Peak of CTC in the postoperative phase after curative tumor removal,Number of surviving patients,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
814,NCT01320683,Progression-free Survival,Overall Survival,,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
815,NCT04621370,Complete response,Euro Qol-5 dimensions 3 levels (EQ5D-3L),,2020-12-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
816,NCT06052332,Grade ≥3 toxicities during treatment,,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
817,NCT01083875,Evaluation of mucositis using the Oral Mucositis Assessment Score,"Frequency of treatment-emergent, drug-related Serious Adverse Events",,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
818,NCT01470586,Comparison of Oxidative stress markers in patients with colorectal cancer and controls,Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
819,NCT02229136,Incidence of Grade ≥ 2 stomatitis,Reduction in pain score on questionnaires,Time to Disease Progression of next anti-cancer therapy,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE2']
820,NCT00557557,Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.,Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
821,NCT01742806,Time to drain removal,total amount of exudate drainage,Time to discharge after surgery and postoperative complication,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
822,NCT06006338,R0 resection rate,Blood loss,,2023-09-15,RECRUITING,INTERVENTIONAL,['PHASE1']
823,NCT01488552,Complete Response Rate,Observing toxicity outcomes,,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
824,NCT00005590,,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3']
825,NCT05603065,Pathological complete response rate (pCR),Quality of life measurement and evaluation 2,,2022-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
826,NCT01018381,Patient survival,Disease recurrence,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
827,NCT01172860,treatment safety,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
828,NCT02969681,Progression Free Survival,Assessment of treatment-related adverse events,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE3']
829,NCT00037089,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
830,NCT03329534,Ratio of non-acidic to acidic reflux events,Gastroesophageal reflux disease-health related quality of life instrument,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
831,NCT04107324,Liver Function,Resection rate,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
832,NCT00996333,To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer,Toxicity Assessment,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
833,NCT01297998,Maximum tolerated dose,Number of Participants with dose limiting toxicity,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
834,NCT02713529,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST),AMG 820 Pharmacokinetic Parameter by Dose Group: Accumulation Ratio (AR),,2016-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
835,NCT01283217,3-year disease free survival(DFS),,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
836,NCT00003424,,,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3']
837,NCT03803241,Liver volume,Liver volume,,2019-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
838,NCT00005094,"Percentage of patients with adenomas, aspirin use at baseline, and covariates",Adverse events coded using the MedRA dictionary,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3']
839,NCT05230771,2-year overall survival rate,,,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
840,NCT01516216,Median Progression-free Survival (PFS),Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS,,2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2']
841,NCT00634751,Overall Response Rate,Overall Survival,,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
842,NCT00712751,"To investigate the feasibility, tolerability, acceptability (including adherence) and efficacy of CSI-SH, a psycho-educational intervention, on the primary outcome of sexual functioning among RC survivors.","To explore baseline variables that may influence the effectiveness of CSI-SH (i.e., moderators such as socio-demographic and medical variables).",,2008-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
843,NCT01171482,Progression free survival (PFS),Overall survival,,2015-11,TERMINATED,INTERVENTIONAL,['PHASE2']
844,NCT02288507,Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events,"Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS)",,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
845,NCT00591123,"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.","Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
846,NCT02239900,Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),,2014-08-26,COMPLETED,INTERVENTIONAL,['PHASE1']
847,NCT06092944,Heart rate (HR),Analgesia satisfaction,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
848,NCT04245865,The rate of progression free patients at six months,Overall survival,,2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE2']
849,NCT05060471,cCR rate,overall sruvival,,2021-09-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
850,NCT06124378,pCR,Gene mutation signatures of colon cancer,,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2']
851,NCT04823403,Maximum Tolerated Dose (MTD),,,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE1']
852,NCT03802097,Incidence of surgical site infections within 30 days,Incidence of remote non-surgical site infections,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA']
853,NCT02741856,Primary endpoint in adenocarcinoma when switching chemotherapy,Health economics,,2016-11-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
854,NCT03793335,Colorectal cancer prevention,,,2019-04-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
855,NCT06304545,Pathological Complete Response rate,3-years Overall Survival rate,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
856,NCT06069960,Overall survival（OS）,Disease-free survival，DFS,,2023-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
857,NCT02923622,Overall survival,Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
858,NCT03882866,Objective Response Rate (ORR),Quality of life of two treatment regimens in patients,,2019-03-28,UNKNOWN,INTERVENTIONAL,['NA']
859,NCT03428321,Thermal ablations,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
860,NCT00459108,Four Month Progression-free Survival (PFS),Safety and Tolerability,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2']
861,NCT02795429,Phase II: Overall Response Rate (ORR) Per RECIST v1.1,Phase Ib and Phase II: PD-L1 Percent Positive Tumor,,2016-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
862,NCT05663203,Attentional Function Index,Short Form Health Survey,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
863,NCT04005690,Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline,Incidence of >= grade 3 toxicities for each assigned window treatment (as described in sub-protocol),,2019-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
864,NCT00302094,Program to fuse 3D ultrasound and PET/CT data,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
865,NCT00407654,Progression-free Survival (Bevacizumab-treated Group),Number of Participants With Response (Bevacizumab-treated Group),,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
866,NCT05360420,Time benefits based on US and immediate CEUS with current routine,The economic benefit based on US and immediate CEUS with current routine,,2022-10-26,RECRUITING,INTERVENTIONAL,['NA']
867,NCT04714190,Overall survival (OS),Tumor progression time (TTP),,2021-03-24,RECRUITING,INTERVENTIONAL,['PHASE3']
868,NCT02638909,"Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment",Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria,,2015-12,TERMINATED,INTERVENTIONAL,['PHASE2']
869,NCT03368963,Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,Response rate,,2018-01-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
870,NCT01689376,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
871,NCT00199654,Time to colorectal cancer relapse,Comparison of the medical cost in the two detection strategies,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
872,NCT00733850,Progression-free survival,Survival,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
873,NCT00677443,To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma.,To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
874,NCT05631041,The change between groups in response rate (RECIST),Changes in serum levels of the measured biological marker serum permeability glycoprotein in ng/ml,,2022-12-31,RECRUITING,INTERVENTIONAL,['PHASE3']
875,NCT03707444,Change in Average pain as assessed by Brief Pain Inventory Question 3,Change in opioid use,,2018-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
876,NCT00656123,Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity,Percent Fold change in amount of interferon gamma-producing Ep-CAM-specific CD8 T cells after vaccination,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
877,NCT00753441,Serum bilirubin,Procedure-related complications,,2009-02-01,TERMINATED,INTERVENTIONAL,['NA']
878,NCT03956641,evolution of exercise tolerance,measurement of parameters reflecting the physical condition,,2019-09-17,UNKNOWN,INTERVENTIONAL,['NA']
879,NCT04906733,Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes,,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA']
880,NCT01970254,"Rate of a positive result (hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]) before first chemotherapy",,,2013-06-24,COMPLETED,OBSERVATIONAL,['NA']
881,NCT02738697,Overall survival,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
882,NCT05696002,Quality of life (survey),,,2023-01-14,RECRUITING,OBSERVATIONAL,['NA']
883,NCT03891472,Improvement of the overall survival.,,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
884,NCT01379807,Objective response rate,Exploratory Objectives,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
885,NCT02029326,To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform,3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab,,2010-02-01,COMPLETED,OBSERVATIONAL,['NA']
886,NCT05365256,Level of psychological well-being,,,2022-04-15,RECRUITING,INTERVENTIONAL,['NA']
887,NCT00388700,"Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.",Explore progression-free survival (PFS) and survival,,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
888,NCT04042831,Progression-free survival (PFS) at first scan,Incidence of adverse events,The number of patients that had biomarkers related to tumor evaluation and resistance,2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2']
889,NCT00513539,Overall survival,"Quality of life as assessed by EORTC QLQ 30 and PAN 26 at baseline and 1, 3, and 6 months after completion of study treatment",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
890,NCT04098796,Objective response rate (ORR),"Exploration of biomarkers (PD-L1 expression, TMB at the baseline, changes of AFP and T lymphocyte in peripheral blood)",,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
891,NCT05700188,Overall survival (OS),Progression-free survival (PFS),,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
892,NCT00004210,"Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members",,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
893,NCT05926726,RP2D of JWATM214 in HCC patients,overall survival (OS),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
894,NCT05208762,Number of participants with DLTs by dose level,Incidence of anti-drug antibodies (ADAs),,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1']
895,NCT01533311,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
896,NCT02565667,anastomotic leak rate,30-day mortality rate,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
897,NCT02951390,Adenoma detection rate,Total procedure time,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
898,NCT01438385,Establishing a database that contains all Interventional Endoscopies,,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
899,NCT04811703,Dose-limiting toxicities,Rates of adverse events and operative complications,,2021-07-30,RECRUITING,INTERVENTIONAL,['PHASE1']
900,NCT01949870,The Number of Dose-limiting Toxicities,,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1']
901,NCT05182762,Clavien-Dindo Grade,Age comparison,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
902,NCT03086291,maximum tolerated dose,,,2018-01-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
903,NCT05783076,Overall survival will be determined,Quality of life will be determined,,2023-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
904,NCT00003923,,,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2']
905,NCT00227734,Objective response (complete response [CR] and partial response [PR]) measured after completion of study treatment,Adverse drug reactions measured after completion of study treatment,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
906,NCT05826743,Study Success Case(Avoidance of ostomy),,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
907,NCT04457297,Disease-free survival 1 (DFS1),Treatment Completion Rate,,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE3']
908,NCT06084689,Disease control rate (DCR),Safety and tolerability of the combination,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
909,NCT04947371,Adverse events rate,Overall survival,,2018-12-15,WITHDRAWN,INTERVENTIONAL,['PHASE2']
910,NCT00844727,,,,2003-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
911,NCT04094675,Change in colon polyp burden by staging,Change in well-being assessment,,2019-09-16,RECRUITING,INTERVENTIONAL,['PHASE2']
912,NCT03636308,Objective response rate,The incidence of treatment related emergent adverse events（Safety and Tolerance）,,2018-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
913,NCT06005974,To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR),To assess the anti-tumor activity of REC-4881 as measured by to other efficacy endpoints,,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE2']
914,NCT05585073,surgery complicated,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
915,NCT05931445,HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score,Communication between patients and healthcare providers (EORTC QLQ-COMU26 score),,2021-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
916,NCT05334836,Prevalence of pancreatic steatosis determined by fat quantitation on MRI,Risk factors for pancreatic steatosis in patients with presumed IPMN or MCN,,2022-04-06,RECRUITING,INTERVENTIONAL,['NA']
917,NCT02695966,T lymphocyte changes,T lymphocyte localisation,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
918,NCT00330915,Feasibility of Pemetrexed Prior to Surgery,Number of Participants Receiving Sphincter Saving Surgery,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
919,NCT03980704,Infectious complications,Length of stay,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
920,NCT04977596,CT value of lesion portal phase,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
921,NCT01296984,3-year local recurrence,Stoma function,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
922,NCT00506844,Pathologic stage Tumor regression grade,Disease-free survival,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
923,NCT02785146,Disease-free survival (DFS),Metastasis-free survival (MFS),The effects of Huaier Granule on adverse events of adjuvant chemotherapy.,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
924,NCT00003799,MTD of oxaliplatin when combined with radiation therapy and fluorouracil based on the incidence of DLT as assessed by CTC version 2.0,,,1999-05,COMPLETED,INTERVENTIONAL,['PHASE1']
925,NCT02941562,Pathological Response,3-year Overall Survival,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
926,NCT02895464,Adverse events,Discharge destination,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
927,NCT05185947,"Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde...",Assess clinicopathologic response to therapy,,2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE2']
928,NCT04089150,Locoregional control (Locoregional Response Rate LRR),Overall Survival (OS),ePRO Acceptability,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
929,NCT01957241,BIOMARKER PANEL SELECTION AND MODELING,SURVIVAL AND RT-RELATED TOXICITY ANALYSIS AND MODELING,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
930,NCT06257264,Part 2: Objective Response Rate,Part 2: Plasma concentrations for BG-68501,,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
931,NCT00383149,Percentage of Participants Surviving at 6 Months,Change From Baseline in FHSI-8 Total Score by Time-point,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
932,NCT01718821,"Changes in pain, assessed by BPI-SF.","Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.",,2012-09,COMPLETED,OBSERVATIONAL,['NA']
933,NCT03822936,Progression free survival,intra and perioperatory complications,,2018-02-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
934,NCT05731947,Phase 2: Progression Free Survival (PFS),Phase 2: DOR as Assessed by the Investigator,,2023-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
935,NCT02424864,The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET,"Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes",,2014-08,COMPLETED,INTERVENTIONAL,['NA']
936,NCT02671890,Maximum tolerated dose (MTD) (Cohort I),Changes in fist-grip strength as measured by hand dynamometer (Cohort II),Changes in muscle messenger ribonucleic acid (mRNA) levels via real-time polymerase chain reaction,2016-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
937,NCT03206125,Esophageal squamous cell carcinoma,,,2017-08-01,TERMINATED,OBSERVATIONAL,['NA']
938,NCT03958500,Rate of anastomotic leakage,Timing of anastomosis leakage,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
939,NCT05669807,Objective Response Rate,Quality of life assessment,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
940,NCT03624725,Effects of quality of life,,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
941,NCT06023121,Detection of levels of an exosome-based liquid biopsy signature,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
942,NCT01405638,Colorectal Cancer Screening,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
943,NCT00216788,Urine sucrose level falls below 90 mg after 8 weeks of therapy,Reduction of patient symptoms consistent with GERD,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
944,NCT04459754,Disease-free Survival,,,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE2']
945,NCT05043688,pCR,AE,PD-L1 expression,2021-09-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
946,NCT00152087,- Adverse experience,,,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
947,NCT04534543,Change in PME/PDE (ΔPME/PDE): predictive,Response to treatment,,2021-12-15,RECRUITING,INTERVENTIONAL,['NA']
948,NCT02066259,"Number of participants in each of the clinicaly defined groups (0,1 and 2).",,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
949,NCT05771480,Number of participants with Grade 3 or 4 possibly related adverse event (PRAE),EORTC QLQ-BIL21 Score,,2023-08-16,RECRUITING,INTERVENTIONAL,['PHASE3']
950,NCT01088581,2-year recurrence rate and adverse events,overall survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
951,NCT01881932,Proportion of Colorectal and Breast Cancer Patients in Each Arm Who Require Dose Reduction or Discontinuation Due to Chemotherapy-induced Peripheral Neuropathy.,,,2013-02,TERMINATED,INTERVENTIONAL,['NA']
952,NCT05286320,objective response rate,Progression-free survival and overall survival,Immune biomarkers,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
953,NCT00997958,Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1']
954,NCT05913583,Graft rejection,Early allograft dysfunction (EAD),pDC to mDC ratio,2023-04-01,RECRUITING,OBSERVATIONAL,['NA']
955,NCT03044613,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Recurrence-Free Survival,,2017-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
956,NCT06250166,Change from baseline in mean platelet-lymphocyte ratio at 12 weeks,Change in mean daily energy and protein intake at 12 weeks,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
957,NCT03723720,correlation between ADR and PDR for all and screening colonoscopies,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
958,NCT01836432,Overall Survival,Immune Response,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
959,NCT04957511,"Microbiome change through analysis of biological samples (fecal specimen, blood, vaginal swab, oral mucosal swab).",,,2021-06-29,RECRUITING,OBSERVATIONAL,['NA']
960,NCT00808379,Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.,Comparison of pathological downstaging between the two groups who undergo surgery.,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
961,NCT01360892,Cumulative incidence of carcinogenesis of hepatocellular carcinoma,The cumulative incidence and severity of decompensated cirrhosis,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
962,NCT00681499,Quality of Life,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
963,NCT05650918,Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0,Radiological response rate as defined by RECIST version 1.1 and iRECIST,,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
964,NCT00003139,Acute salivary gland toxicity,Effects of continuing pilocarpine out to 6 months from the start of treatment,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3']
965,NCT02580253,Desease free Survival,Overall Survival,,2017-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
966,NCT00004193,"Determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with ISIS 2503, an antisense inhibitor of H-ras",Determine the safety profile of this regimen in these patients.,,1999-01,TERMINATED,INTERVENTIONAL,['PHASE2']
967,NCT06111105,Collection of clinical plasma samples at relevant time points,Prognostic value of ctDNA analysis at relevant time points,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
968,NCT01674959,feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
969,NCT00100945,1-year overall survival rate,Quality of life,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
970,NCT06161818,Disease-free survival,Future ctDNA analysis,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
971,NCT06034977,Overall survival,,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
972,NCT02606994,Oral mucositis changes,Quality of life changes,,2018-05-29,TERMINATED,INTERVENTIONAL,['PHASE2']
973,NCT04087889,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
974,NCT03642561,overall survival,objective response rate,,2019-09-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
975,NCT03829098,90 day mortality,Hospital based costs,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
976,NCT04557969,Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years,Characterize genomic and clinicopathologic features of GISTs,,2020-12-18,RECRUITING,OBSERVATIONAL,['NA']
977,NCT01523431,"Incidence of toxicity, especially neutropenia and diarrhea","Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G.",,2012-03-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
978,NCT01885702,Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients,"Clinical responses, e.g. disease-free survival, determined according to the standard protocol.",,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
979,NCT01448655,Disease-free survival time (DFS).,"Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).",,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
980,NCT02842047,Repeated Measures ANCOVA Model (F-Statistic),Change in FAMCARE Scale,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
981,NCT03306901,3-year overall survival,Treatment-related complications or adverse events,,2017-10-20,RECRUITING,INTERVENTIONAL,['NA']
982,NCT00128622,Safety as measured by rate of adverse events during study drug treatment,Rate of immune response as measured by ELISPot at week 10,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
983,NCT03109041,Safety & Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale,,,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
984,NCT00532909,"Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab",Dose limiting toxicities associated with the combination,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
985,NCT04426669,Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events,Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes,,2020-05-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
986,NCT01859182,"Proportion of patients who have a response (PR or CR), assessed by the RECIST v1.1",Changes in QOL evaluated using the Functional Assessment of Cancer Therapy - General (FACT-G),,2013-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
987,NCT00005878,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
988,NCT06055010,Subproject dependent,,,2014-01-01,RECRUITING,OBSERVATIONAL,['NA']
989,NCT04094454,incidence and grade of vaginal fibrosis,assessment of quality of life,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
990,NCT03546660,Feasibility of imaging of the Esophagus using a SECM Capsule,,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
991,NCT01770132,Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site,Overall survival,,2013-04-19,COMPLETED,INTERVENTIONAL,['PHASE1']
992,NCT01903018,Number of severe Radiation Induced Mucositis (WHO grade >=3),Overall Survival (OS),,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
993,NCT00423150,Tumor Responses (Complete and Partial Response),,,2007-01-26,TERMINATED,INTERVENTIONAL,['PHASE2']
994,NCT04781413,3-year relapse-free survival (RFS),Peritoneal metastasis rate,,2021-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
995,NCT02653521,Toxicity of treatment,Overall Survival（OS）,Dosimetric Parameters,2015-12-30,UNKNOWN,INTERVENTIONAL,['NA']
996,NCT01271582,Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment,Progression-free survival,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
997,NCT02866045,Proportion of patients receiving a definitive histologic diagnosis for gastrointestinal SELs by single incision needle-knife biopsy (SINK biopsy) vs. EUS-guided fine needle biopsy (EUS-FNB).,Proportion of patients for whom a mitotic rate may be calculated for gastrointestinal stromal tumors (GISTs) using SINK biopsy vs. EUS-FNB,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
998,NCT02178358,Overall Survival (OS): Number of Events,Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score,,2014-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
999,NCT03013010,Disease free survival,Proportion of patients with surgery-related complication,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
1000,NCT04539769,Diabetes remission rate,,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1001,NCT01033578,Overall Survival,Time to Recurrence,,1999-10,UNKNOWN,INTERVENTIONAL,['NA']
1002,NCT01108107,The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.,Overall survival,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1003,NCT02935764,progression free survival,quality of life questionnaire,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
1004,NCT05896787,pCR,AE,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1005,NCT05359393,NED rate,Acute toxicity associated with immunotherapy,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1006,NCT05987709,Assess colorectal cancer screening completion,Assess the proportion who completed follow-up testing.,,2022-03-17,COMPLETED,INTERVENTIONAL,['NA']
1007,NCT06223022,Patients' reported Quality of life,Patients' experiences of prostata cancer related to symptoms and side effects of treatment and diagnosis.,Sick-leave,2024-01-20,RECRUITING,INTERVENTIONAL,['NA']
1008,NCT03579732,Number of subjects with gastric cancer,Number of fatal cases due to colorectal cancer,,2018-06-29,COMPLETED,OBSERVATIONAL,['NA']
1009,NCT01926769,Disease Control Rate,Progression Free Survival,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
1010,NCT03511170,time to failure of strategy（TFS）,time to failure of strategy（TFS）,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1011,NCT02164916,Progression-free Survival,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,Overall Response Rate in Patients Who Register to Arm 3 (Crossover) After Disease Progression on Arm 1,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1012,NCT02812186,Peak Airway Pressures,Surgical Rating Scale,,2016-12-27,COMPLETED,INTERVENTIONAL,['PHASE4']
1013,NCT02115373,Phase 2: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,Phase 1b: Accumulation Ratio of AUC (Racc (AUC),,2014-05-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1014,NCT03800953,overall radiographic response,New metastasis-free survival,,2019-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
1015,NCT04940546,Adverse events,Overall Survival,,2021-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1016,NCT03887702,"Time until adverse liver outcome, assessed by incidence of adverse liver outcome",Death due to any cause,,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE3']
1017,NCT03366012,Patient Tolerability determined by Score on Likert Scale,Number of Serious Adverse Events (SAEs),,2018-08-01,SUSPENDED,INTERVENTIONAL,['NA']
1018,NCT00107536,Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST,Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1019,NCT02702089,morbidity,Reintervention rate,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
1020,NCT03604237,pathologic diagnosis,,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1021,NCT02804737,Effectiveness of Web-based instructions,Benefit of web-based instructions,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
1022,NCT04037241,Assess efficacy by overall survival,Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire,Assess the persistence of CAR-T cells in liver tumor biopsies over time.,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1023,NCT05056051,To assess the additive diagnostic yield as assessed by proportion of patients with recurrence be use of WATS-3D,To assess if the order by which tissue is sampled affects the diagnostic yield of WATS-3D by comparing the proportion of patients with recurrence between groups.,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
1024,NCT05081687,cCR + PathCR,Overall toxicity,,2020-02-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1025,NCT03176264,Overall Response Rate (ORR) per investigator assessment using RECIST v1.1,Antidrug antibodies (ADA),,2017-09-25,TERMINATED,INTERVENTIONAL,['PHASE1']
1026,NCT00019747,Time to Progression,,,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1027,NCT00079833,Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery,"The following safety variables will be assessed at Month 6 and Month 12: adverse events, clinical laboratory results (ie, chemistry, hematology, urinalysis), physical examinations, and EGDs.",,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1028,NCT01108705,Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,"Assess serious and nonserious adverse events, laboratory evaluations, significant physical examination findings and ECG results",,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3']
1029,NCT00354224,Response Rate as Determined by RECIST.,Progression-free Survival,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1030,NCT00997633,Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses,"The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables",,1991-05,COMPLETED,OBSERVATIONAL,['NA']
1031,NCT00622999,Complication rate,Mortality,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
1032,NCT03783936,Best Objective Response Rate (bORR),Number of Participants With Grade 3-4 Treatment Related Adverse Events,,2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2']
1033,NCT05909995,"Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs",Duration of Response,,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1']
1034,NCT00006269,,,,1999-12,TERMINATED,INTERVENTIONAL,['PHASE3']
1035,NCT00077987,Anti-tumor efficacy,Tumor control survival safety,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1036,NCT03804203,Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale,Quality of Life (QoL): EORTC questionnaire C15-PAL,,2017-11-08,UNKNOWN,INTERVENTIONAL,['NA']
1037,NCT04832763,Change in health-related quality of life (HRQoL),Biomarker analysis - C-Reactive Protein,,2019-09-27,TERMINATED,INTERVENTIONAL,['NA']
1038,NCT00086567,Create a multi-institutional repository from which investigations of serum proteomic signature profiles of epithelial ovarian cancer and relapse will be developed and validated,,,2005-12-12,COMPLETED,OBSERVATIONAL,['NA']
1039,NCT01028495,Survival,"Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1040,NCT00341484,Genetic determinants,,,1998-06-01,COMPLETED,OBSERVATIONAL,['NA']
1041,NCT04264702,Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™,Examine the number of Stage I CRC patients that have recurrent disease detected post-surgery based on SIGNATERA™ test results,,2020-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1042,NCT05980221,Metabolome,Response of the fed and fasted metabolome to PERT,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
1043,NCT03346980,Inter-observer agreement of the Spigelman Score evaluated by expert endoscopists.,Inter- and intra-observer agreement of the Spigelman Score and the endoscopic sub-scores evaluated by novices.,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
1044,NCT05353127,Influence of different CPET data averaging intervals on the numerical values of CPET-,High- or Low-risk for postoperative complications,,2022-04-12,COMPLETED,OBSERVATIONAL,['NA']
1045,NCT00358566,Overall survival time,Progression Free Survival,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
1046,NCT05729867,Technical success rate,Stent dysfunction rate,,2020-04-27,RECRUITING,INTERVENTIONAL,['NA']
1047,NCT05275075,Proportion of African American pancreatic cancer patients with weight loss and cachexia.,"Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.",,2022-12-07,RECRUITING,OBSERVATIONAL,['NA']
1048,NCT01558648,short -term quality of life (QOL),Complications,predict EUS T3/T4/stricture or earlier EUS disease,2012-03-14,COMPLETED,OBSERVATIONAL,['NA']
1049,NCT03811379,Objective Response Rates (ORR),Adverse Events (AEs),,2018-11-21,UNKNOWN,INTERVENTIONAL,['PHASE2']
1050,NCT04819516,Number of Participants With Abnormal Laboratory Values,Numeric rating scale,,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
1051,NCT00268333,Response rate,Quality of life,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1052,NCT02390947,Overall Survival(OS),The severity of Adverse Events,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1053,NCT04044859,To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with either nivolumab or pembrolizumab,Overall Survival (OS),,2019-08-20,RECRUITING,INTERVENTIONAL,['PHASE1']
1054,NCT01526590,Lesion Margin,Degree of venous washout,,2012-07,WITHDRAWN,INTERVENTIONAL,['NA']
1055,NCT02938195,Percentage of patients completing adjuvant chemoradiotherapy and surgery,Percentage of pathological complete response,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1056,NCT01323166,Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure,Impact of rectal cancer surgery and the level of intrusive thoughts,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
1057,NCT06100003,Specificity,,,2023-10-18,RECRUITING,OBSERVATIONAL,['NA']
1058,NCT01603004,Progression free survival,best response,,2012-05-14,COMPLETED,OBSERVATIONAL,['NA']
1059,NCT03167970,The overall diagnostic accuracy of capsule endoscopy in predicting the presence and extent of Barrett's esophagus in comparison to standard esophagogastroduodenoscopy,Incidence of Treatment related adverse events of capsule endoscopy in comparison to standard esophagogastroduodenoscopy,,2017-05-03,COMPLETED,OBSERVATIONAL,['NA']
1060,NCT04705194,Correlation coefficient between preoperative FLR-GC and post-operative ICG R15,Correlation coefficient between growth in FLR volume and growth in FLR-GC after the first stage,,2019-07-08,UNKNOWN,OBSERVATIONAL,['NA']
1061,NCT00049712,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1062,NCT06048146,3 year disease free survival,,,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1063,NCT03910699,Anastomotic leakage rate,Serious adverse events rate,,2019-04-10,UNKNOWN,INTERVENTIONAL,['NA']
1064,NCT00277303,Safety and tolerability,Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters,,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2']
1065,NCT05468892,PFS,"Safety and tolerability analysis: defined as the evaluation of incidence and severity of AEs, graded according to NCI- CTCAE, version 5.0 (v. 5.0).",,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE2']
1066,NCT04715321,Predictive performance of CT perfusion,Disease-free survival (DFS),,2013-02-15,UNKNOWN,OBSERVATIONAL,['NA']
1067,NCT04594772,Measuring the proportion of patients undergoing surgical resection using historical data compared to 32 patients in current study.,"Measuring the safety of neoadjuvant therapy will be determined using CTCAE v5, reported as proportions of patients experiencing toxicities, graded using CTCAE v. 5.0.",,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE2']
1068,NCT01007617,Mucositis scale - World Health Organization (WHO),Psychological impact,,2009-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1069,NCT04147078,Disease-free Survival (DFS),Incidence of Treatment-Related Adverse Events [Safety and Tolerability],,2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE1']
1070,NCT04296019,PFS,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1071,NCT00069108,Progression Free Survival,Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1072,NCT03825887,Total opioid consumptions,Assess serious adverse events,,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1073,NCT04707482,Difference of protein expression,,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
1074,NCT01043835,Disease free survival,"Complications, recurrence, quality of life measured by EORTC QLQ-C30 V 3.0 and EORTC QLQ-STO22",,2010-02,UNKNOWN,INTERVENTIONAL,['NA']
1075,NCT05699278,Rate of patients who remain in a gastric cancer clinical trial to trial completion,,,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1076,NCT05697107,PFS,OS,,2021-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1077,NCT00004252,,,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1078,NCT01032850,Number of Participants Experiencing Adverse Events,Progression Free Survival (PFS),,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
1079,NCT06152783,Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.,"Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated.",,2023-11-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1080,NCT02394795,Overall Survival (OS) in All Participants,Number of Participants With Treatment-emergent Adverse Events (TEAE),,2015-05-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1081,NCT00591461,The primary outcome will be the interobserver variability in the presence of columnar epithelium as well as the measured lengths.,variables that predict endoscopic interobserver agreement and path-confirmation,,2007-12,TERMINATED,OBSERVATIONAL,['NA']
1082,NCT04481659,The damage degree of anal function,Local recurrence,,2020-07-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1083,NCT05253716,3-year disease free survival after discharge,"toxicity of chemotherapy graded according to the CTCAE, version 5.0",,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
1084,NCT05494060,Disease Free Survival (DFS),Disease Free Survival (DFS) rate at 3 years,Toxicity by CTCAE v5.0 criteria,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2']
1085,NCT05245786,Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging.,Count of Adverse Events.,,2022-08-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1086,NCT06333665,Disease-free survival,perioperative 90-day mortality,,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1087,NCT06187103,Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.,Patient experience of HyperSight imaging,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1088,NCT00830778,Reduction of clinical postoperative pancreatic fistula (POPF) rate,Reduction of the severity of postoperative complications,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1089,NCT04428437,Response rate (RR),Adverse Events,,2022-07-02,TERMINATED,OBSERVATIONAL,['NA']
1090,NCT05054959,complete remission rate,local control,,2021-06-24,RECRUITING,INTERVENTIONAL,['PHASE2']
1091,NCT03410030,Phase II: Disease control rate (CR+PR+SD x18 weeks),Changes in patient's self-reported pain levels,Changes in circulating tumor stem cells,2017-12-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1092,NCT01136031,response rate (phase II part),toxicities,,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1093,NCT04745988,Major pathological response (MPR) rate,The incidence of adverse events,,2021-11-11,RECRUITING,INTERVENTIONAL,['PHASE2']
1094,NCT01025882,Tumor samples for RNA and protein harvesting (when possible) from pretreatment biopsies and surgical specimens,,,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1']
1095,NCT03944421,Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn,Changes in MicroRNA Expression,Blood Glucose,2019-07-03,COMPLETED,INTERVENTIONAL,['NA']
1096,NCT02409472,Health Related Quality of Life,Disease free survival (DFS),,1998-04,COMPLETED,INTERVENTIONAL,['NA']
1097,NCT05687474,Feasibility - reliability,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
1098,NCT03403634,Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions,Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1,Overall Survival,2018-04-19,COMPLETED,INTERVENTIONAL,['PHASE2']
1099,NCT01252628,"The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.",,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1100,NCT01442155,Disease-Free Survival (Time to Event),Safety: Percentage of Participants With Adverse Events,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
1101,NCT04965311,Rate of clinically relevant postoperative pancreatic fistula (POPF),Rate of any POPF,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1102,NCT06040541,Dose Limiting Toxicities,Progression-Free Survival (PFS),,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1']
1103,NCT05908786,Major Pathologic Response (MPR) Rate,Post-Operative Mortality,,2023-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1104,NCT04420026,"Evaluation of the primary success rate of percutaneous ablation treatment with IRE of hepatic tumors, as a function of the ultrasound visibility of the tumor, when using automatic CT cone-beam fusion and ultrasound",Evaluate the global survival at 12 months,,2020-07-06,COMPLETED,INTERVENTIONAL,['NA']
1105,NCT06313047,CYP2B6,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
1106,NCT00831493,Maximum Tolerated Dose (MTD) of Vorinostat + Chemoradiation,,,2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1107,NCT00467129,Progressive disease-free survival,,,2002-07,UNKNOWN,OBSERVATIONAL,['NA']
1108,NCT03305913,Maximum Tolerated Dose (MTD),Incidence of Treatment-Emergent Adverse Events,,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE1']
1109,NCT05453851,Proportion of patients that are free of metastatic disease to the liver from a pancreatic primary,Time to overall survival (OS),Incidence of adverse events (AEs),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1110,NCT03033186,Everolimus TDM to predict long-term toxicity,Everolimus TDM to predict dose reductions,,2017-05-16,UNKNOWN,OBSERVATIONAL,['NA']
1111,NCT03626350,Adverse Events,Submucosal endoscopy technique and device used,,2018-06-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1112,NCT04791176,MST,Rate of III-IV grade adverse events,,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1113,NCT03613168,Adverse events,Overall survival,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1114,NCT01226719,Overall Response Rate (ORR),Overall Survival (OS),,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1115,NCT00386516,Stable disease (SD) rate and progression-free survival (PFS) times,"Safety, tolerability and Quality of Life (QoL)",,2006-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1116,NCT04239781,HCC patients' willingness and expectation for post-operative treatment.,,,2020-01,UNKNOWN,OBSERVATIONAL,['NA']
1117,NCT05606081,Rates of colorectal neoplasia per number of colonoscopies performed,,,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
1118,NCT02884154,diagnostic sufficiency,complications,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1119,NCT05493683,Objective response rate(ORR),Duration of Response (DOR),,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1120,NCT03734627,Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus,EORTC health related quality of life,Duodenal enteroendocrine cell mRNA expression profile,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
1121,NCT04278222,objective response rate,adverse events,,2020-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1122,NCT04460937,Incidence of adverse events,Biomarkers,,2021-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1123,NCT00767234,Identify Biomarkers,,,2008-08,TERMINATED,OBSERVATIONAL,['NA']
1124,NCT04510064,margin-free-(R0) resection rate,overall survival (OS),,2020-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
1125,NCT01806675,Change From Baseline in Maximum Standard Uptake Values (SUVmax),Progression-free Survival (PFS),,2013-03-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1126,NCT03290937,Objective response rate (Dose expansion),Duration of response,,2017-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1127,NCT05164848,Incidence of Treatment-related Adverse Events，afety and Tolerability,The incidence of neutralizing antibody (Nab),The correlation of biomarkers with efficacy,2021-12-25,UNKNOWN,INTERVENTIONAL,['PHASE1']
1128,NCT00021398,tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1129,NCT00345761,Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0),concentrations of anti-bevacizumab antibody,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1130,NCT00699569,,,,2008-07,UNKNOWN,INTERVENTIONAL,['NA']
1131,NCT01030042,Overall Survival,Progression free survival,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1132,NCT03215459,Survival at 6 months (followed up for 12mths),Time-to-event endpoints,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
1133,NCT03662204,Biomarker Evaluation,,,2018-08-23,COMPLETED,OBSERVATIONAL,['NA']
1134,NCT00725712,Number of Participants Who Required Concomitant Medications,Median Duration of Overall Survival (OS)of GSK1363089,,2007-03-31,COMPLETED,INTERVENTIONAL,['PHASE2']
1135,NCT00436501,Median Progression-Free Survival (PFS) (Phase II),Number of Participants With PFS (Phase II),,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1136,NCT00844454,Local treatment responses,Disease-free survivals and overall survivals,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1137,NCT04246684,organ preservation,Translational / biomarker studies,,2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1138,NCT01774019,"Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last",All-cause Mortality,,2013-02-20,COMPLETED,INTERVENTIONAL,['NA']
1139,NCT02056041,Safety of surgery for HCC,Score systems HCC,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
1140,NCT00440934,Response rate,To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients.,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2']
1141,NCT05213195,Maximal Tolerable Dose#MTD#,Antitumor efficacy-Overall survival (OS),,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE1']
1142,NCT00374985,maximum tolerable dose and safety,,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1143,NCT00002551,Survival and Relapse-free survival,,,1994-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1144,NCT06291779,Urine,,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
1145,NCT04878692,Measurement of the percentage of Onco-Rash failure by counting the number of patients with a rash grade ≥ 2 (NCI-CTCAE scale).,Percentage of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been introduced,,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA']
1146,NCT04683965,Objective response rate(ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1147,NCT05183958,Progression-free survival (PFS),Adverse Events (AEs),Duration of Response (DoR),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1148,NCT01500993,Overall survival,Local recurrence rate,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1149,NCT04452266,Correlation between endometrial cancer and predictif factors,Correlation between endometrial cancer and predictif factors in post menopausal woman,,2020-08-14,COMPLETED,OBSERVATIONAL,['NA']
1150,NCT06017284,Rate of nausea/vomiting,Overall survival (OS),,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1151,NCT01767857,Overall Survival (OS),Percentage of Participants With Disease Control,,2013-03-31,TERMINATED,INTERVENTIONAL,['PHASE3']
1152,NCT02017704,Number of Patients With Pathologic Complete Response,Time to Local Disease Recurrence,,2014-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1153,NCT03723447,Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent),Postoperative Complications,,2018-10-23,COMPLETED,INTERVENTIONAL,['PHASE4']
1154,NCT01928290,Number of Participants With an Objective Response,Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events,,2013-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1155,NCT00445549,Number of Participants With Clinical Efficacy,The Number of Participants With Adverse Events,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1156,NCT02387138,Dose limiting toxicities,,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1157,NCT02102789,Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms,"Number of participants with surgical complications, AES and SAEs as a measure of safety",,2014-03,RECRUITING,INTERVENTIONAL,['PHASE3']
1158,NCT04005521,Swallowing ability,Maximal Interincisal opening (MIO),Incremental Cost Effectiveness Ratio (ICER),2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1159,NCT05671809,ARP,MASCP and Wexner,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1160,NCT04591028,Number of lymph nodes removed for each lymphatic station of gastrectomy,,,2022-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1161,NCT05903885,Fecal Immunochemical Test (FIT) kite return rate,Fecal Immunochemical Test (FIT) kit positive rate,,2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
1162,NCT03601234,operation time,hospitalization expenses,,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA']
1163,NCT06307938,Inflammatory bowel disease,Treatment response,,2025-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1164,NCT04888546,Overall response rate (ORR),The incidence and severity of SAE,,2021-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1165,NCT00839332,Phase 2: Overall Survival (OS),Phase 2: Electrocardiogram QTc Prolongation,Number of Deaths During the Phase 1 Post-study Period,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1166,NCT01044420,adverse events,response rate,,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
1167,NCT05706974,Rate of bile duct cancer patients who remain in a clinical study to completion,,,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1168,NCT01208194,Evaluation of median progression-free survival (PFS) in both treatment groups,Assessment of the safety profile of MGN1703,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1169,NCT00544700,Time to progression (TTP),Long-term bevacizumab treatment costs,,2007-11-26,TERMINATED,INTERVENTIONAL,['PHASE3']
1170,NCT06225609,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,Total hospitalization costs,The number of patients with complications after total mesorectal excision for rectal cancer,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1171,NCT04883450,Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group,,,2021-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1172,NCT05202600,NNT of IA for the appendiceal neoplasm,NNT of IA for the death due to appendicits in elderly,Definition of the elderly group for the complicated appendicitis or death,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA']
1173,NCT01662739,"Collection of life-style, familiar, clinical, histological and biomolecular data",Collection of biological samples (blood and cancer tissue samples),"Analysis of epidemiology, risk factors, family history and unidentified susceptibility genes and proteins",2010-01,UNKNOWN,OBSERVATIONAL,['NA']
1174,NCT04524871,Objective Response Rate (ORR),Percentage of Participants With Adverse Events During Stage 2,,2020-11-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1175,NCT01234701,Inter-observer agreement among expert radiologists in diagnosing primary liver tumors by Magnetic Resonance Imaging (MRI).,Investigate the diagnostic efficacy of radiologists' certainty of diagnosis (CoD) in accurately predicting primary liver tumors assessed by Magnetic Resonant Imaging (MRI),,2010-10,COMPLETED,OBSERVATIONAL,['NA']
1176,NCT00734513,Patient's psychological adjustment,Gender and marital satisfaction as moderators of the effects of partner-assisted ED.,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
1177,NCT01693432,Objective response rate,Disease control rate,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1178,NCT04145297,"Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies",Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR),,2020-03-17,COMPLETED,INTERVENTIONAL,['PHASE1']
1179,NCT04714957,"genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )",,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
1180,NCT03855800,High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group,High grade dysplasia (HGD) or cancer diagnosis in clinical follow up group,,2018-05-11,RECRUITING,INTERVENTIONAL,['NA']
1181,NCT02860546,Immune-Related Overall Response Rate (irORR),Overall Survival (OS),,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2']
1182,NCT05820906,Overall response rate ( ORR) per RECIST 1.1,Disease control rate (DCR) per RECIST 1.1,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1183,NCT01402180,Local control,Adverse Events,,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1184,NCT01035229,Overall Survival (OS),Pharmacokinetics Assessments - Cmax,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1185,NCT03178383,Integration of health-relation practices assessed via church survey,Implementation: Extent to which intervention is implemented as intended as assessed by a fidelity checklist completed by staff,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
1186,NCT02905968,anastomotic leak rate,Time Frame: Reoperation rate after anastomotic leak,,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1187,NCT04738214,Pathologic response rate,Disease free survival,,2021-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1188,NCT00529113,Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.,"Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F]).",,2007-09-30,TERMINATED,INTERVENTIONAL,['PHASE1']
1189,NCT05285358,Incidence of adverse events,Functional status,,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1']
1190,NCT01147991,"Demonstration by ELIspot assays of the frequency of T-lymphocytes recognizing major histocompatibility complex (MHC) class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...",Measurement of EBV-genome levels in plasma,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1191,NCT04333927,Overall Survival,Adverse Events,,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1192,NCT00604409,"To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.",Efficacy,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1193,NCT02143869,body composition,perioperative complications,comparison of the body composition obtained by BIA and anthropometric measurements.,2013-12,COMPLETED,OBSERVATIONAL,['NA']
1194,NCT03531320,"Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug",Part 2: PK- AUC,,2018-08-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1195,NCT00467142,Percentage of Participants in Objective Response (Partial or Complete Responses),Median Duration of Response,,2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1196,NCT02851004,ORR,Pharmacokinetic,safety according to immune status,2016-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1197,NCT02132858,Tumor response measured using the tumor regression grading system,Tumor heterogeneity in patients with partial response to radiation,PET-computed tomography parameters,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1198,NCT02943603,number of adverse events related to toxicity,PD-L1 expression in tumor cells,,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1199,NCT03714490,R0(microscopically margin-negative) resection rate,QoL by QLO-CR29,"circulating tumor DNA, and other potential biomarkers such as T-cell receptor",2018-10-23,RECRUITING,INTERVENTIONAL,['PHASE2']
1200,NCT03199274,Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses,,,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1201,NCT01634126,FIT Kit adherence,,,2012-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1202,NCT03628248,Colonic perfusion in the marginal artery after inferior mesenteric artery ligation between groups,Presence of post-surgery complications,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
1203,NCT00190541,Relapse-free survival,Incidence of sexual and urinary dysfunction,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1204,NCT01793805,To characterize common genetic/molecular profiles associated with colorectal cancer (CRC),To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
1205,NCT02575313,Measurement of Tolerability,Treatment Break Measurement,,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1206,NCT05223816,PFS,anti-HSV-1 antibody,,2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2']
1207,NCT01457846,Median Progression Free Survival,Percentage of Patients Without Progressive Disease at 8 Weeks,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
1208,NCT00846482,Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin,Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
1209,NCT05573776,Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups,Overall Survival (OS),,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
1210,NCT01773785,Progression free survival,Safety of SPI-1620 when administered in combination with docetaxel,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
1211,NCT00482365,Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US,Serum repository for registry patients,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
1212,NCT01357486,Time to radiologic progression,Quality of life,,2011-11-14,COMPLETED,INTERVENTIONAL,['PHASE2']
1213,NCT01459965,Documented change in Quality Of Life,Documented change in symptoms and concerns specific for patients with MBDO,,1993-07,COMPLETED,INTERVENTIONAL,['NA']
1214,NCT03768375,Progression Free Survival,,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1215,NCT00099294,Overall Survival,Performance Status,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1216,NCT04889820,3-year overall survival,circulating tumor DNA,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1217,NCT03672305,The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC,The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time,,2018-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1218,NCT04389502,Correct Answers (60% group),Correct Answers (80% group),,2020-05-15,UNKNOWN,INTERVENTIONAL,['NA']
1219,NCT00289445,activity,,,1999-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1220,NCT04525326,Conversion liver resection rate,overall survival,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1221,NCT00976508,Number of Participants With Dose Limiting Toxicities (DLT),Number of Participants With Objective Response,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE1']
1222,NCT02182687,Freedom From Progression Over Time,Quality of Life - Questionnaires Include PIQ-6 and SF-36v2 Health Survey,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1223,NCT00857545,Progression-free Survival (PFS),Overall Survival,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1224,NCT00027833,,,,2001-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
1225,NCT00536523,Alterations in serotonin levels associated with increased constipation,,,2007-04,TERMINATED,OBSERVATIONAL,['NA']
1226,NCT05988918,Progression Free Survival,Median Progression- Free Survival (PFS) within each cancer subtype,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1227,NCT01713244,Recurrence-free Survival,Overall Survival,Number of participants with adverse events,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
1228,NCT04316975,Correlation of Mean Mutational Load (ML) and Treatment Resistance,Correlation of Mutational Load and Stricture Formation,,2020-04-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1229,NCT03037437,Time to tumor progression evaluated via tumor imaging,,,2017-02-16,RECRUITING,INTERVENTIONAL,['PHASE2']
1230,NCT02272504,Biomarker assays exceeding threshold,Surveillance until HCC development and detection,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
1231,NCT02149784,Overall survival,Number of Participants with Adverse Events both in surgery group and chemotherapy group,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
1232,NCT03791905,clinical complete response,Chemoradiotherapy-related toxicity,,2019-01-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1233,NCT00788281,operation mortality,fee,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
1234,NCT05461664,Duration Of Response,serious adverse events,,2022-07-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1235,NCT00994526,"Urinary biomarker (DHN-MA:dihydroxynonene mercapturic acid), will be measured before and after every interventional period",Fecal biomarkers,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1236,NCT04674267,Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants,,,2022-01-18,RECRUITING,INTERVENTIONAL,['NA']
1237,NCT05323890,Pathologic complete response rate,Incidence of Treatment-related Adverse Events,,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
1238,NCT00220181,,,,2003-04,COMPLETED,OBSERVATIONAL,['NA']
1239,NCT00515866,To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine,To identify the dose-limiting toxicity of the combination therapy,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1240,NCT02496273,ELISPOT assays,overall survival (OS),,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1241,NCT04354064,Freedom from progression,Distant-metastasis-free survival,,2019-05-29,RECRUITING,OBSERVATIONAL,['NA']
1242,NCT00903396,Complete Response (no Episodes of Nausea or Vomiting),Average Level of Nausea Reported and the Proportion of Patients Experiencing a Complete Response Independent of Treatment Arm,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
1243,NCT01204177,Disease Control Rate (DCR),Biomarkers,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1244,NCT00666107,"Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit",,,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
1245,NCT02251782,Comparison of Adherence to Screening for Each Group,Diagnostic yield of colonoscopy:,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1246,NCT00555295,,,,2007-12,UNKNOWN,OBSERVATIONAL,['NA']
1247,NCT03902678,Percentage of patients with portal vein thrombosis who underwent EUS guided FNA and had complications as a result of the invasive maneuver,,,2017-05-11,UNKNOWN,INTERVENTIONAL,['NA']
1248,NCT04561336,overall survival,,,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1249,NCT04145193,ctDNA clearance,Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6,,2020-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1250,NCT05766605,The one-year DFS rate,Adverse events,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1251,NCT02487225,Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1252,NCT06104267,Adherence rates,self-rating depression scale（SDS）,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1253,NCT03957733,3-year disease free survival (DFS) rate.,Surgical complications.,,2017-11-23,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1254,NCT01867892,"the response rate, disease control rate, overall survival, and patients' quality of life.",,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
1255,NCT00637637,Progression-free survival at 6 months,Duration of use of anticonvulsive drugs,,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
1256,NCT03570684,ratio of patients with 2 or more reloads,complication rate,,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA']
1257,NCT03569137,difference in microbiome biomarkers between patients developing colitis after exposure to targeted therapy and those not developing colitis,"Creation of a predictive score of the occurrence of diarrhea in patients treated with Ibrutinib for malignant hemopathy B, including the biomarkers of the intestinal microbiome and the clinical characteristics of the patient",,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1258,NCT04511559,Analysis ctDNA methylation status and its Correlation to early diagnosis and prognostic evaluation of gastric cancer.,,,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1259,NCT01178944,Overall Response Rate,Time to Progression (TTP),MicroRNA Expression - miR-215-5p,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1260,NCT03816774,Adequate bowel preparation rate,Tolerability to the bowel cleansing regimen:questionnaire,Patients characteristics questionnaire,2019-06-15,COMPLETED,INTERVENTIONAL,['NA']
1261,NCT04956107,Development of ´fear of cancer recurrence' after PE or CRS+HIPEC for colorectal cancer,Risk factors associated with developing psychological distress,,2021-01-25,RECRUITING,OBSERVATIONAL,['NA']
1262,NCT00003296,,,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1263,NCT00522405,Survival rate- calculated from the start of TACE,"a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C",,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1264,NCT03037034,Complete resection rate,Tumor status after endoscopic resection,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
1265,NCT03735589,Persistence of nCTLs after their adoptive transfer,T cell populations and higher anti-tumor responses,Overall survival assessed by irRECIST,2023-12-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1266,NCT04044430,Incidence of treatment-related grade 3 or higher adverse events (AEs),Disease control rate (DCR),,2020-08-31,TERMINATED,INTERVENTIONAL,['PHASE1']
1267,NCT01917552,recurrence-free survival,Safety profiles,,2013-08-19,RECRUITING,INTERVENTIONAL,['PHASE3']
1268,NCT02127359,Describe Impact of Information Derived from Exome Sequencing,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
1269,NCT00002523,,,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1270,NCT02213692,Blood loss,Postoperative complications,,2014-05,TERMINATED,OBSERVATIONAL,['NA']
1271,NCT04802876,Overall Response rate (ORR) (Cohort 3),"Incidence, seriousness, treatment-related and intensity of Treatment Emergent Adverse Events",,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2']
1272,NCT01116635,Histopathological correlation with surgically resected tumor,maximum tolerated dose,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1273,NCT00026104,Overall survival,Progression-free survival,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1274,NCT03906565,Tumor response to utidelone treatment,Safety profile associated with utidelone injection,,2019-04-12,SUSPENDED,INTERVENTIONAL,['PHASE2']
1275,NCT02273206,"Changes From Baseline in Number of Participants With Colorectal, Breast, and/or Cervical Cancer Screening",Self-efficacy and Behavior Towards Cancer Screening/Mental Health Utilization,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1276,NCT06306755,Detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions,Quality of life Scale Score,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1277,NCT00332696,Number of Participants With Treatment Success From Day 10 to Day 13,Participant's Quality of Life Using the Edmonton Scale,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1278,NCT03418558,Objective Response Rate according to RECIST 1.1 criteria,Progression Free Survival,,2015-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
1279,NCT04110977,Rate of radiation dermatitis grade ≥2,Rate of radiation-induced oral mucositis grade ≥3,,2020-10-10,UNKNOWN,INTERVENTIONAL,['NA']
1280,NCT04701853,Parastomal hernia verified by computer tomography,Back pain,,2021-05-01,RECRUITING,INTERVENTIONAL,['NA']
1281,NCT04541173,Progression free survival (PFS) by RECIST 1.1,Subject function,,2020-11-30,TERMINATED,INTERVENTIONAL,['PHASE2']
1282,NCT04275557,Radiogenomic Analyses,Progression Free Survival,,2020-02-18,RECRUITING,OBSERVATIONAL,['NA']
1283,NCT03079596,Afebrile status without major complications,Time to first bowel motion,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
1284,NCT06031584,Phase II: Objective response rate (ORR),Phase Ib/II: Anti-drug antibody (ADA),,2024-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1285,NCT00003025,,,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1286,NCT06177288,converted resection rate,Adverse events,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1287,NCT05007145,Pathologic complete response (pCR) rate,Disease Free Survival (DFS),,2021-08-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1288,NCT03803436,Overall Survival,Complications rate,,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2']
1289,NCT02319200,rate of HCC occurrence and liver related-death or transplantation.,"occurrence of liver-related complications (Ascites , gastrointestinal bleeding, encephalopathy)",,2015-06,TERMINATED,INTERVENTIONAL,['PHASE3']
1290,NCT02022553,tumor reduction,,,2006-02,UNKNOWN,INTERVENTIONAL,['NA']
1291,NCT05842317,Overall response rate (ORR),Conversion surgery rate,,2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1292,NCT04530981,AUC from time 0 and extrapolated to infinity (AUC0-∞),Incidence of Adverse Events,,2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE1']
1293,NCT03264404,Progression-Free Survival (PFS),Disease Control Rate (DCR),,2017-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1294,NCT00004257,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1295,NCT06215677,the rate of R0 resection,Safety and tolerability of Camrelizumab administered,,2024-02-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1296,NCT04424043,"Progression-free survival, PFS","Overall survival, OS",,2020-07-08,RECRUITING,INTERVENTIONAL,['NA']
1297,NCT02098291,Pharmacodynamic,Number of Participants with Serious and Non-Serious Adverse Events,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1298,NCT01653171,Visibility at upper endoscopy,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1299,NCT04837885,Standardized uptake value (SUVmax) on liver metastases,177Lu-DOTA-peptide dosimetry,,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2']
1300,NCT06271980,Recurrence Free Survival,Overall Survival,,2023-04-15,COMPLETED,OBSERVATIONAL,['NA']
1301,NCT00401570,"The proportion of patients, in each dose cohort, with a confirmed tumor response",To evaluate the immunogenicity of M200,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1302,NCT06010901,Objective response rate (ORR),Neutralizing antibodies (NaB),,2024-01-13,RECRUITING,INTERVENTIONAL,['PHASE1']
1303,NCT03333486,Relapse Rate,Transplant Related Mortality,Myeloid Chimerism Expressed as a Percentage of Donor Cells,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1304,NCT03401957,Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure.,Overall survival from the start of 1st line treatment with cetuximab.,,2018-01,UNKNOWN,OBSERVATIONAL,['NA']
1305,NCT05835960,Establish the feasibility of immune analysis and NGS in informing patient treatment decisions.,,,2019-04-01,RECRUITING,OBSERVATIONAL,['NA']
1306,NCT06169202,Progression-free Survival (PFS),Disease Control Rate (DCR),,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
1307,NCT01300143,Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).,overall survival,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1308,NCT00193141,"To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer",To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1309,NCT03211416,Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors,Time to tumor progression,Change in levels of immunosuppressive cells,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1310,NCT02921256,Neoadjuvant Rectal Cancer (NAR) Score,Rate of Sphincter Preservation,Relationship Between Radiographic Findings and Pathologic Outcomes,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1311,NCT01549418,Clinically significant bleeding after colorectal polypectomy,Proportion of clinically significant delayed bleeding in both groups,,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1312,NCT05913570,Pathological complete response (pCR) rates,Number of participants with any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative Cadonilimab dose,,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1313,NCT00757965,Exploration of mutations at other loci that may predispose to endometrial cancer,,,2008-02,UNKNOWN,OBSERVATIONAL,['NA']
1314,NCT01256203,Skin erythema responses of control (unprotected) and Solar Protection Formula® SPF 60-protected sites to light exposure,Proportion of subjects with adverse events as a measure of safety,,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1315,NCT00731445,Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria,Phase II: Determine the PFS,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1316,NCT06332274,Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival),Cost effectiveness analysis: ICER,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1317,NCT04512729,Colonic Adenoma,Risk factors for Colonic adenoma,,2020-08-04,UNKNOWN,OBSERVATIONAL,['NA']
1318,NCT00465842,Number of participants with presence of serum protein markers,Number of participants with presence of serum protein markers with resectable and unrsectable HCC.,,2006-06-20,TERMINATED,OBSERVATIONAL,['NA']
1319,NCT05734430,Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents,"Association of germline genetic variants with clinical, pathologic and molecular features of appendix tumors",,2022-11-11,RECRUITING,OBSERVATIONAL,['NA']
1320,NCT00311610,Objective response rate,Overall survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1321,NCT01567631,Number of participants with operation complication,Number of participants with abnormal liver function or discomfort symptoms induced by the operation,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
1322,NCT03635619,MRI TN staging in Esophageal Cancer,MRI prediction of prognosis in esophageal cancer,,2018-09-02,UNKNOWN,OBSERVATIONAL,['NA']
1323,NCT00431756,early predictors of esophageal cancer,,,2002-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1324,NCT06128798,Physiology Return of Bowel Function,Length of Hospital Stay,,2023-09-26,RECRUITING,INTERVENTIONAL,['NA']
1325,NCT03469479,Overall survival,Adverse Events,,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
1326,NCT00189345,Selection of better dose level based on the confirmed tumor response.,Effects of removab(TM),,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1327,NCT00455559,To determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.,"To determine whether inhibition of Akt phosphorylation correlates with survival, time to disease progression, or response rate in patients with advanced GIST treated with imatinib mesylate plus perifosine.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1328,NCT00951496,Median Progression-free Survival,Patient Reported Nausea,,2009-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1329,NCT03958669,To prospectively evaluate molecular fingerprint analysis of HCC tumor tissue to predict therapy responses,Changes of ultrasound elastography under treatment with Sorafenib,,2019-11-01,TERMINATED,OBSERVATIONAL,['NA']
1330,NCT01646593,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
1331,NCT01121562,Clinical Benefit Response Rate (CBR),"Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662).",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1332,NCT00003524,,,,1996-10-04,TERMINATED,INTERVENTIONAL,['PHASE2']
1333,NCT01504256,Rate of macroscopic complete remissions of peritoneal carcinomatosis,Detection of disseminated tumor cells via PCR,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1334,NCT01751516,"Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology",Overall survival,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
1335,NCT04390399,Progression Free Survival (PFS),Quality of Life (QoL),,2020-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1336,NCT05360732,To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria.,To assess the Delayed Toxicity Rate,,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2']
1337,NCT02315625,Median Amount of Time Subject Survives Without Disease Progression After Treatment,Number of Participants With Serious and Non-Serious Adverse Events,,2015-04-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1338,NCT04803019,Time to progression,,,2019-12-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
1339,NCT04670588,Mean serum ctDNA concentration,Response based on standard clinical assessments,,2021-03-31,WITHDRAWN,OBSERVATIONAL,['NA']
1340,NCT00938470,Percentage of Participants With Pathologic Complete Response (PCR),Percentage of Participants With Overall Clinical Tumor Response (CR or PR),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1341,NCT00058487,Toxic effects,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1342,NCT00455091,Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).,"Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy.",,2007-05,TERMINATED,OBSERVATIONAL,['NA']
1343,NCT05756725,Number of open orders for mammography screening,Appropriateness of Implementation Strategies,,2023-07-25,COMPLETED,INTERVENTIONAL,['NA']
1344,NCT03642652,Follow-up colonoscopy 120 days after a positive fecal occult blood test,,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
1345,NCT06010303,Overall Response Rate (ORR),Number of Participants with Adverse Events (AEs),,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
1346,NCT05838768,Frequency of dose reductions as a measure of tolerability,Number of participants with anti tislelizumab antibodies,,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE1']
1347,NCT05927844,severity of TEAE and SAE,,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1348,NCT05709886,Effectiveness analysis,Alpha-fetoprotein levels,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1349,NCT01888978,Timing of biopsy and treatment,Progression-free survival,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1350,NCT04345783,OS,,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1351,NCT01502410,Objective Response by RECIST Criteria v 1.1,Presence of BRAF Mutation or RET/PTC Rearrangement,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1352,NCT01037049,"The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].",Radiotherapy related toxicity rates.,,2009-10-16,UNKNOWN,INTERVENTIONAL,['PHASE2']
1353,NCT00836407,Percent of Patients Experiencing an Unacceptable Toxicity,Progression Free Survival (PFS),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1354,NCT00208260,Response,Secondary resection,,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1355,NCT06254300,Aerobic capacity,Length of hospital stay,,2022-03-23,RECRUITING,INTERVENTIONAL,['NA']
1356,NCT02427269,Collaboration with other investigators,,,2015-04-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1357,NCT01032746,"Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record",Distribution of risk-status among participants who complete the web-based risk-assessment tool,,2005-03,UNKNOWN,INTERVENTIONAL,['NA']
1358,NCT04057274,Cell viability (%),Concentration of Insulin-like growth factor 1 (ng/ml),,2019-09-23,UNKNOWN,INTERVENTIONAL,['NA']
1359,NCT05493878,Expression levels of ITGA2b and SELP on Tumor Educated PLatelets for diagnosis of pancreatic and biliary cancer,Correlation between expression levels of ITGA2b and SELP on TEPs and the commonly used tumour marker CEA and CA 19-9 in the diagnosis of pancreatic and biliary cancer.,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1360,NCT02762474,Progress free survival,CTCAE 4.0 toxicity,,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1361,NCT05871892,Metabolic function of the liver evaluated by the PET tracer 18F-FDGal,,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
1362,NCT04961125,germline variant detection rate in the polyposis population,,,2021-08-02,RECRUITING,OBSERVATIONAL,['NA']
1363,NCT01126112,Progression-free survival rate at 6 months,Evaluation of molecular predictive markers for response.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1364,NCT02267707,Pharmacokinetics - CL,Gemcitabine PK profile,,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE1']
1365,NCT01821248,Curative resection rate,Response rate and toxicity,,2013-07-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
1366,NCT05595811,overall survival,adjuvant oncologic treatment,,1999-01-01,COMPLETED,OBSERVATIONAL,['NA']
1367,NCT04268888,Time to TACE Progression (TTTP) - phase II primary outcome,QOL: EORTC QLQ-C30,,2019-05-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1368,NCT05203120,Number of participants with Radiation-induced liver disease (RILD),Reduction in mean liver dose,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
1369,NCT02873520,Quality of life,,,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1370,NCT05570942,Changes of irritable bowel symptoms,The presence of bacteremia,,2021-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1371,NCT04541381,Grade 3 or Higher Toxicity (Co-Primary Endpoint),Overall Survival,,2022-02-07,RECRUITING,INTERVENTIONAL,['NA']
1372,NCT03110939,local recurrent rate,mortality rate after treatment,,2017-03-21,WITHDRAWN,INTERVENTIONAL,['NA']
1373,NCT01861912,Time to Progression,Safety,Recurrence Rate,2013-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1374,NCT04460456,"Duration of response, defined as the time from date of first response (CR or PR)",Progression free survival,,2020-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1375,NCT04049357,CCE detection rate of polyps compared to OC,,,2020-04-01,RECRUITING,INTERVENTIONAL,['NA']
1376,NCT01439724,Incidence and / or Severity of Oral Mucositis,"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy.",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1377,NCT00003049,,,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1378,NCT03828227,"Health-related quality of life (HRQoL) at 6 months in the ""candidate group"".",Performance status geriatric (PSG) score.,,2019-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1379,NCT05444478,Over-all survival (OS) rate at 36 months,Complication rate,,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
1380,NCT01237990,The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data.,Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy.,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
1381,NCT01191385,"Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)",To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases),,2010-11,WITHDRAWN,OBSERVATIONAL,['NA']
1382,NCT05733598,Overall Response Rate per modified RECIST 1.1,Overall Survival,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1383,NCT02168426,ileus rate,adverse effect rate,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1384,NCT04743102,pathological complete remission,Overall Survival,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
1385,NCT05300945,OS,Adverse Events,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1386,NCT01526486,Nodal yield,Oncologic outcomes--survival,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
1387,NCT01298011,Grade III/IV histological response in tumor specimen rate after induction therapy.,Overall Survival,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1388,NCT04843943,Events Free Survival (EFS) Assessed by RECIST1.1,Overall survival (OS),,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1389,NCT03209336,The basic information and medical history achieved (questionnaire),The short-term complications,,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA']
1390,NCT00767468,Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate,Median overall survival,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1']
1391,NCT01100372,Remission rates (complete response and partial response),Toxicity,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1392,NCT02709213,Determination of the aetiologies of colitis using microbiological examination of the stools +/- colonoscopy,"Identification of anamnestic, clinical and biological predicting factors for patients requiring diagnostic colonoscopy",,2016-11,COMPLETED,OBSERVATIONAL,['NA']
1393,NCT02645981,Overall Survival,Percentage of adverse events,,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1394,NCT00294203,"Post-operative hemoglobin, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte fraction measured on post-operative days 1, 4, 8, and between days 20 and 30",Post-operative quality of life related to anemia measured by Functional Assessment of Cancer Therapy - Anemia (FACT-An) between post-operative day 20 and 30 and post-operative transfusion requirement,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1395,NCT04954339,Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by flow cytometry (and/or CyTOF),Dynamic changes in T-cell receptor (TCR) repertoire of peripheral mononuclear cells,,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1396,NCT02102893,"To establish the database for GEP-NET by register the clinical presentation, diagnosis, stages, treatment and clinical outcome of GEP-NET patients.",,,2014-02-13,COMPLETED,OBSERVATIONAL,['NA']
1397,NCT01346280,,,,2011-04-16,COMPLETED,OBSERVATIONAL,['NA']
1398,NCT01129310,Overall Response Rate and dose limiting toxicity,"Progression Free Survival, overall survival, death, alterations in quality of life outcomes",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1399,NCT00673504,Time to Progression,Safety,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1400,NCT01589419,Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD),Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1401,NCT02873442,Progress-free survival,Quality of life,,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1402,NCT00870961,Rate of accrual,"Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)",,2009-02,TERMINATED,INTERVENTIONAL,['NA']
1403,NCT02386618,Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination),,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
1404,NCT02454686,Accuracy of Fibroscan in predicting complication after hepatectomy,,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
1405,NCT00897754,VEGF165b protein expression as measured by ELISA,,,2007-07-24,COMPLETED,OBSERVATIONAL,['NA']
1406,NCT02759588,Overall Response Rate (ORR) by RECIST 1.1 (Phase 2),Clinical Benefit Rate,,2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1407,NCT02551471,Clinical resection rates in both countries,Analyses of semi-structured interviews,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA']
1408,NCT05587725,Prevalence of type-specific HPV types,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
1409,NCT02175654,Progression free survival rate at 6 months,Changes in ECOG performance status over time from baseline,Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2']
1410,NCT04571489,Progression free survival (PFS),Patient-reported outcome (PRO),,2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1411,NCT04220242,Validation of predictive accuracy biophysics-visualisation model,Realtime delineation display of tumour area including margins,,2019-12-30,UNKNOWN,OBSERVATIONAL,['NA']
1412,NCT03612531,Incidence of adverse events,Improvement in tongue innervation on Electromyography (EMG) findings,,2018-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1413,NCT04032392,Overall survival (OS),Patients-based Quality of Life Evaluation,,2019-07-23,UNKNOWN,INTERVENTIONAL,['PHASE1']
1414,NCT01976494,"Efficacy: Analgesic effect, Accuracy of bolus 2 mL administration",Safety: Frequency of complications occurring after bolus,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
1415,NCT00068003,"Bank of autologous blood, stem cells, and/or tumor tissue from patients currently with cancer",Long-term storage of data and biospecimens,,2003-09-08,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1416,NCT02489838,Lung dose measured with actual lung mass vs Lung dose measured with conventional method.,,,2012-02-03,COMPLETED,OBSERVATIONAL,['NA']
1417,NCT01589471,Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score,Safety of intra-rectal Botox-A injections as documented with adverse events monitoring,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1418,NCT01236443,Toxicity of HPPH at different doses,"Determine optimal PDT parameters using HPPH in HGD, CIS and Barrett's esophagus",,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1419,NCT01458353,Peritoneal contamination after finishing the ileocolonic anastomosis,,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
1420,NCT01118897,To assess the feasibility of concurrent chemo-radiation with dose escalated IMRT in locally advanced inoperable gallbladder and pancreatic cancers,Overall survival,,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1421,NCT01446874,Adherence to the Pre-operative Toothbrushing Regimen,Incidence of Fever,,2011-09-22,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1422,NCT05767697,Number of subjects who still survive at 1 year,,,2020-04-15,RECRUITING,OBSERVATIONAL,['NA']
1423,NCT06324825,Recovery rate of Low-grade Intraepithelial Neoplasia,Adverse event rate,,2022-10-24,RECRUITING,INTERVENTIONAL,['NA']
1424,NCT02641691,Complete Response Rate,Quality of Anorectal Function as Measured by the FACT-C Questionnaire,,2016-05-27,COMPLETED,INTERVENTIONAL,['PHASE2']
1425,NCT05763277,progression free survival,Overall survival,,2022-07-22,RECRUITING,OBSERVATIONAL,['NA']
1426,NCT05733000,Overall response rate (ORR),Incidence of adverse events,,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
1427,NCT01283204,progression free survival(PFS),,,2010-03-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1428,NCT03662035,Progression Free Survival,Disease Control Rate,,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1429,NCT01103479,Colorectal Cancer (CRC) Screening Completion,Provider Recommendation of CRC Screening,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1430,NCT06287749,3-year Disease-free survival (DFS),Time to molecular recurrence,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1431,NCT05453292,Disease-free survival,Re-treatment rate,,2024-01-15,RECRUITING,INTERVENTIONAL,['NA']
1432,NCT04029857,Patient well-being improvement,,,2019-03-14,WITHDRAWN,INTERVENTIONAL,['PHASE3']
1433,NCT02316340,Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib,Median Overall Survival (mOS),,2015-02-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1434,NCT05776875,Grade 3 or higher Treatment Related Adverse Events,Time to untaceable progression,,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE2']
1435,NCT01483027,Hepatic Progression-Free Survival (HPFS),Overall Survival,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
1436,NCT00575562,The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.,"The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD).",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1437,NCT05167448,Phase 2: The anti-tumor activity of ES104,Phase 2: The immunogenicity of ES104,,2022-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1438,NCT05597384,Autogenous blood marker localization was not inferior to intraoperative colonoscopy localization,Adverse events related to endoscopic tattooing,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
1439,NCT00006387,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1440,NCT05327582,Object response rate (ORR),Number of participants with laboratory test abnormalities,,2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1441,NCT00089362,"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level",,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1442,NCT06084780,Overall Rate of Survival,Overall Rate of Mortality,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1443,NCT01012362,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT),Number of Participants With Treatment-Related Adverse Events,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1']
1444,NCT05480891,community education,,,2023-04-05,RECRUITING,OBSERVATIONAL,['NA']
1445,NCT04108481,Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC),Determine duration of response,Abscopal effects,2020-10-05,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1446,NCT01649271,Dose Limiting Toxicities During cycle1,Clinical Benefit,,2012-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
1447,NCT02309632,Detection rate of PC and precancerous lesion,,,2015-11,WITHDRAWN,INTERVENTIONAL,['NA']
1448,NCT00699816,Recurrence Free Survival(RFS) Rate,Cancer-specific Survival Rate,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1449,NCT03504618,Prognostic factor of progression free survival,Overall survival after 24 months,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
1450,NCT00003118,Overall survival,,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1451,NCT03799731,Progression Free Survival (PFS) at 6 months,AMHRII (Anti-Mullerian Hormone type II receptor) expression,,2018-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1452,NCT00038701,Patient Survival Rate,,,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1453,NCT00003029,,,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1454,NCT05040815,Disease free survival (DFS),Exercise Behavior and Physical Fitness,Relationship between radiotherapy treatment planning variables and acute toxicity.,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2']
1455,NCT05653934,Anxiety assessment,Morbidity,,2023-05,RECRUITING,INTERVENTIONAL,['NA']
1456,NCT02112357,The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.,The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.,Duration of response for patients who received a targeted treatment as a result of genetic sequencing.,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
1457,NCT00667082,To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat,To evaluate the anti-tumor activity of NPI-0052 and vorinostat,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1458,NCT04615806,Sensitivity and specificity of lymph node dissection,The mapping of sentinel lymph nodes in esophageal cancer,,2020-09-22,UNKNOWN,INTERVENTIONAL,['NA']
1459,NCT03271073,Progression-free survival (PFS),Quality of life(QoL),,2016-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1460,NCT00660582,,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1461,NCT03697564,Progression Free Survival (PFS),Overall Survival (OS),,2019-10-31,SUSPENDED,INTERVENTIONAL,['PHASE2']
1462,NCT02381249,Progressive ratio task breakpoint for a sweet-fat reward,Subjective symptom score,Sigstad score,2015-03,COMPLETED,INTERVENTIONAL,['NA']
1463,NCT03092128,Progression free survival,Number of patients with objective response and adverse events,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
1464,NCT01531595,Efficacy,Response,,2012-02,RECRUITING,INTERVENTIONAL,['PHASE2']
1465,NCT04905147,Postoperative time to the first passage of flatus.,Length of postoperative hospital stay,,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA']
1466,NCT02379039,Loco regional control,Site specific toxicity,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
1467,NCT06005493,Objective Response Rate (ORR),Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863,,2023-07-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1468,NCT00152607,"The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made.",,,2000-04,TERMINATED,INTERVENTIONAL,['PHASE4']
1469,NCT01197612,Olfaction,Sinonasal Health,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1470,NCT02229071,Adverse events,Time to progression(TTP),Time to symptomatic progression(TTSP),2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1471,NCT01336881,Biomarkers associated with hepatoblastoma subtypes and cancer stages,Exome sequencing,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
1472,NCT02065765,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
1473,NCT05748145,Impact of metronidazole on F.n. loads in CRC tissues.,Potential effects of metronidazole on the intestinal metabolic profile,,2023-09-11,RECRUITING,INTERVENTIONAL,['PHASE2']
1474,NCT00533533,To define the dose-limiting toxicity and maximum tolerated dose in phase I study To evaluate the overall response rate in phase II study,1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate overall survival. 3) To estimate the time to progression and the duration of overall response.,,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1475,NCT05833594,Disease Control Rate,"1-, 2-, 3-year Progression-free survival rate (PFS).",,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
1476,NCT00273585,Colorectal cancer screening self-efficacy,Colorectal cancer screening decisional conflict,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1477,NCT03426397,2-year non-regrowth disease-free survival,Quality of life,,2017-05-10,RECRUITING,OBSERVATIONAL,['NA']
1478,NCT05204173,1-year survival rate,3-year progressive free survival (PFS),,2021-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
1479,NCT01129167,Frequency of local invasion modalities in surgical population,,,2009-09-15,COMPLETED,OBSERVATIONAL,['NA']
1480,NCT04370925,Peritoneal recurrence free survival,Number of participants with adverse events,,2020-06-04,RECRUITING,INTERVENTIONAL,['PHASE3']
1481,NCT06003218,Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.,Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.,Incidence of postoperative complications during hospital stay.,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
1482,NCT02013830,Percentage of Participants With Objective Response (OR),Overall Survival - Percentage of Participants Event Free at 12 Months,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1483,NCT03573791,Comparing gene expression differences between poor response group and complete response group by using RNA sequencing.,Progression Free Survival(PFS),,2018-05-21,RECRUITING,OBSERVATIONAL,['NA']
1484,NCT01737827,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,Plasma pharmacokinetic parameter: Racc,,2013-03-25,TERMINATED,INTERVENTIONAL,['PHASE2']
1485,NCT00920751,Primary outcome - success of cecal intubation without sedation,"Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications.",,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
1486,NCT04080843,Objective response rate(ORR),Safety: NCI CTC AE Version 4.0.3,,2019-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1487,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
1488,NCT01303159,Change From Baseline in Bile Duct Stricture Diameter,Number of Participants With Adverse Events,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
1489,NCT02292641,To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.,To map original radiotherapy volumes (including integrated boosts) against types of recurrence,,2014-09-25,RECRUITING,INTERVENTIONAL,['NA']
1490,NCT01758341,Number of RFA-procedures with technical failures,Number of patients with interventional complications,Mortality,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1491,NCT03316222,Dose-Limiting Toxicity,,,2018-04-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1492,NCT05923450,Disease-free Survival,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
1493,NCT03756636,Rate of adverse events (according to the lexiconA ASGE).,,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1494,NCT02574013,Length of hospital stay,Postoperative complications,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
1495,NCT04200131,"Obtaining histological diagnosis by using ""The Moray"" micro forceps.",Quality of the sample,,2020-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1496,NCT02365480,Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0,Severity of Histologic Inflammation,,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1497,NCT00220116,Objective response rates,Number undergoing liver resections/curative resection (Ro) rate,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1498,NCT02420678,"Reliability of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18",Death rates,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1499,NCT00584402,Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography,"Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth",,2007-04,COMPLETED,INTERVENTIONAL,['NA']
1500,NCT00829413,Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard',Inter-reader Agreement,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1501,NCT03853278,Functional Assessment of Cancer Therapy- Colorectal,The Functional Assessment of Chronic Illness Therapy-Fatigue,,2018-01-15,COMPLETED,INTERVENTIONAL,['NA']
1502,NCT03923309,3-year overall survival,,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
1503,NCT04927780,Overall survival,Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire,,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3']
1504,NCT03095781,Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,Response duration as assessed by RECIST 1.1,Immune profile effects of pembrolizumab and Hsp90 inhibitor XL888 assessed in serum and tumor biopsies,2017-07-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1505,NCT03718624,Conversion to negative rate,Adverse events,,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
1506,NCT04781192,Progressin Free Survival (PFS),Overall Survival (OS),,2022-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1507,NCT00202774,Determine time to disease progression,"Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1508,NCT05024539,Regorafenib in combination with other drugs,Survival differences among the patients with different clinical phenotypes and genotypes,,2021-06-20,UNKNOWN,OBSERVATIONAL,['NA']
1509,NCT04141449,Incidence of curative-intent treatment,Patients treated for cancer,,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2']
1510,NCT02571725,Phase 2: Objective response rate (ORR),Phase 2: Progression free survival (PFS),,2016-02-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1511,NCT04814043,conversion rate to resection,,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
1512,NCT02233205,Number of Participants with Serious and Non-Serious Adverse Events,Time to Disease Progression,,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1513,NCT04751396,Decisional conflict scale,Patient's perception of usefulness of the tool,,2022-04-20,RECRUITING,OBSERVATIONAL,['NA']
1514,NCT03314935,Phase 2: Objective Response Rate (ORR),Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration,,2017-11-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1515,NCT06304350,Pathological complete remission (pCR),Safety (incidence of adverse drug reactions),,2024-02-17,RECRUITING,INTERVENTIONAL,['PHASE2']
1516,NCT01084460,,,,1997-01,COMPLETED,OBSERVATIONAL,['NA']
1517,NCT02353052,Number of participants with tumor metastasis,,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
1518,NCT05060770,IBD associated CRC oncogenesis,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
1519,NCT01094626,Difference in lesion conspicuity between S-MRI and N-MRI,Concordance of tumor measurements between S-MRI images and tumor specimens post-resection vs. concordance of tumor measurements between N-MRI and tumor specimens post-resection,,2010-04,WITHDRAWN,INTERVENTIONAL,['NA']
1520,NCT02885142,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,,,2016-11,TERMINATED,INTERVENTIONAL,['NA']
1521,NCT01048320,The primary outcome measure for the study is to establish the Maximum Tolerated Dose of the drug regimen based on the endpoint of dose-limiting toxicity,Characterise safety profile of Gemcitabine Plus Oxaliplatin in Combination with imatinib mesylate (Glivec) in Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1522,NCT01403883,Evolution of Psychological anxiety score (STAI/Beck),Specific stoma related morbidity,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
1523,NCT04811833,Comparison of anastomosis leakage rate at different timepoints in postoperative course,Assessment of suture material handling parameters,,2022-07,WITHDRAWN,OBSERVATIONAL,['NA']
1524,NCT04879979,Symbol Digit Modalities Test (SDMT),PROMIS Short Form: Pain 3a.,,2021-01-12,RECRUITING,INTERVENTIONAL,['NA']
1525,NCT04498689,Progression Free Survival,adverse events,,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1526,NCT00369460,"Collection of information on weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count",,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
1527,NCT02992886,2-year disease-free survival probability (%),QOL,Exploratory endpoints,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1528,NCT04886193,TRG grade,the incidence and severity of adverse events,,2021-04-16,UNKNOWN,INTERVENTIONAL,['NA']
1529,NCT03468712,Postoperative overall morbidity rate,Completion rate of laparoscopic surgery,,2018-03-31,UNKNOWN,INTERVENTIONAL,['NA']
1530,NCT02838186,number of additional identified polyps with right colon scope retroflexion,Rate of retroflexion-related adverse events.,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
1531,NCT05725200,"Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.",Main study: Patient-reported outcome measures.,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2']
1532,NCT00853931,Response rate,Overall survival,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1533,NCT04496765,Local recurrence,,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
1534,NCT06190639,Disease-free survival (DFS),Overall survival (OS),,2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1535,NCT05113134,Patient and Observer Scar Assessment Scale (POSAS),Female Sexual Function Index (FSFI) questionnaire,,2015-03-02,COMPLETED,INTERVENTIONAL,['NA']
1536,NCT02345460,Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy,Number of Participants Experiencing Perioperative (30-day) Mortality,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2']
1537,NCT00300521,overall recurrence-free survival rate at three year,hazard rate of vascular invasion on survival rate and recurrence-free survival rate,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1538,NCT02138981,overall survival time,Number of Adverse Events,,2014-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1539,NCT04660929,Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only),Estimate progression-free survival (PFS).,,2021-02-02,RECRUITING,INTERVENTIONAL,['PHASE1']
1540,NCT02283372,Maximum tolerated dose (MTD),Frequency of RT adaptation based on MR guidance,,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
1541,NCT06331273,Tumor recurrence rate,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1542,NCT06108596,cCR,Disease-free survival (DFS) and overall survival (OS),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1543,NCT03485209,Confirmed ORR per blinded independent central review (BICR) (Part E),Incidence of anti-therapeutic antibodies (ATAs),,2018-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1544,NCT00437424,The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations,To assess efficacy of BMS-582664 in subjects with advanced solid tumor malignancies and subjects with HCC by CT or MRI,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1545,NCT04593134,Quality of Life (EORTC QLQ-STO22),Circadian rhythms(using Actigraph),,2020-11-10,RECRUITING,INTERVENTIONAL,['NA']
1546,NCT05019534,Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D),Preliminary efficacy,,2021-08-15,RECRUITING,INTERVENTIONAL,['PHASE1']
1547,NCT06216561,Drug concentration in tumor,Adverse Events (AEs),,2023-11-30,RECRUITING,INTERVENTIONAL,['PHASE1']
1548,NCT02114164,Intraoperative Pneumoperitoneal Pressure (mmHg),Smoke Evacuation Quality,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1549,NCT03469596,presence of nodal status,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
1550,NCT04795661,Rate of complete pathological response (pCR) after surgery,The prognostic value of lung immune prognostic index (LIPI),,2021-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1551,NCT04715633,Clinical complete response or pathological complete response,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1552,NCT02267213,Disease Control Rate (DCR),"PK parameters, including AUC, Cmax and Tmax of S,S-TLC388, S,R-TLC388, metabolites TLC-U1, TLC-U2, and topotecan",,2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2']
1553,NCT02036008,Reader diagnostic accuracy using Gdfos vs. EcGd compared to gold standard,Reader diagnostic accuracy of EcGd-enhanced imaging vs. Gdfos-enhanced imaging compared to gold standard (subgroup analysis for small lesions less than or equal to 1cm),,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
1554,NCT04512937,Rate of patients with R0 resection,Progression-free survivial (PFS),,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1555,NCT05092113,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,Overall incidence of grade 3/4 gastrointestinal adverse events,Changes of fecal flora and enteritis-associated inflammatory factors,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
1556,NCT00652054,Overall tumor response rate (ORR - the proportion of patients with objective evidence of PR or CR),To investigate the relationship of S-1 plasma levels (components and metabolites) with safety and efficacy parameters,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1557,NCT01284231,Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.,Immunogenicity of MED-565,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1558,NCT04405206,OPR(organ preservation rate),SFS(stoma-free survival),,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
1559,NCT00003001,,,,1997-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1560,NCT05224596,Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.,"Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively.",Sensitivity and specificity of a blood miRNA-based model in detecting gastric cancer.,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA']
1561,NCT00425360,Survival at 1 year,Survival and response as assessed by delayed-type hypersensitivity,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1562,NCT03763266,Bowel preparation,Withdrawal time,,2018-12-06,COMPLETED,INTERVENTIONAL,['NA']
1563,NCT04539808,Proportion of participants with R0 resection,Incidence of grade >= 3 toxicities,Proportion of LAPC participants who die within 30 days of surgery,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2']
1564,NCT05111444,Objective Response Rate (ORR),Overall Survival (OS),,2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1565,NCT00014651,,,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE3']
1566,NCT01694966,To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1567,NCT04084496,Disease free survival,Overall survival,,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1568,NCT01127555,Response rate,To estimate overall survival,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1569,NCT03609151,Progression free survival,Overall survival,,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA']
1570,NCT06260111,Level of Pain,Triceps skinfold,,2024-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1571,NCT03223662,BH3 Profiling of Pre-neoadjuvant Tumor Biopsy and Outcome of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Adenocarcinoma or Squamous Cell Carcinoma,Overall Survival (OS) in Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) Patients Undergoing Neoadjuvant Chemoradiotherapy (nCRT) and Esophagectomy,,2017-10-31,TERMINATED,INTERVENTIONAL,['PHASE2']
1572,NCT04182724,ORR(phase II),PFS(phase I/II),,2019-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1573,NCT06322147,R0 resection rate,Early Tumor Shrinkage,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
1574,NCT04697394,Continuous retention of patients completing electronic data.,Symptom cluster identification,,2022-03-15,RECRUITING,OBSERVATIONAL,['NA']
1575,NCT06241703,urinary dysfunction,International Prostate Symptom Score,,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1576,NCT02210559,Number of Participants Who Had Surgical Complications Post-Resection,Median Progression-Free Survival,,2014-07-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1577,NCT04481100,Objective response rate (ORR),Overall survival (OS),,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1578,NCT04215861,Raman spectra,objective response rate,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1579,NCT04440332,Postoperative pulmonary infection rate and its relationship between peripheral blood of lymphocyte and immunocyte.,,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
1580,NCT00384176,Progression Free Survival,Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI),,2006-08-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1581,NCT03124498,Phase II: Disease Control Rate,,,2017-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1582,NCT03166436,Survival,Augmentation of antitumor immunity,,2017-06-08,UNKNOWN,INTERVENTIONAL,['NA']
1583,NCT01160926,To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.,To explore biological and radiological markers of response or toxicity,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1']
1584,NCT00259532,,,,2005-02,UNKNOWN,INTERVENTIONAL,['NA']
1585,NCT02891083,Disease free survival,side effect of adjuvant therapy,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1586,NCT06320080,Progression-free survival (PFS),Immunogenicity,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1587,NCT04863144,plasma concentrations of 3'-p-hydroxypaclitaxel,Incidence of adverse effects,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1588,NCT06251115,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),Efficacy: antitumor activity of QY-1-T in subjects with HBV-related HCC,Efficacy: antiviral activity of QY-1-T,2024-01-26,RECRUITING,INTERVENTIONAL,['NA']
1589,NCT04104334,Clinical examination and laboratory tests show no evidence of complications or untreated medical problems,Rate of hospital readmission and mortality postoperative,,2019-05-08,TERMINATED,INTERVENTIONAL,['NA']
1590,NCT00309179,"Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.","Pharmacokinetics: Blood samples will be taken on Days 1, 2, and 15 during Cycle 1 and Day 1. Pharmacodynamics: Blood will be taken prior to dosing on Day 1, Days 1, 2, and 15 during Cycle 1 and Day 1.",,2007-09-24,COMPLETED,INTERVENTIONAL,['PHASE2']
1591,NCT00841191,Percentage of Participants With Clinical Benefit Response (CBR),Percent Change From Baseline in Hepcidin Level,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1592,NCT01227746,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
1593,NCT00003147,,,,1998-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1594,NCT03017690,The total time for product preparation and administration,Patient satisfaction,,2017-04-12,COMPLETED,OBSERVATIONAL,['NA']
1595,NCT02230176,To determine the 12 months PFS,Best response,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
1596,NCT02578459,Visual Analog Scale Pain Scores,Adverse Events,,2016-04,WITHDRAWN,INTERVENTIONAL,['NA']
1597,NCT02667925,Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity,Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity,,2016-03,WITHDRAWN,INTERVENTIONAL,['NA']
1598,NCT00907543,Quality of life as assessed by FACT-E,Safety and morbidity,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
1599,NCT01452295,Gather data,,,2010-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1600,NCT00580359,To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer,"the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1",,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
1601,NCT00442507,Time to Progression (TTP),Incidence and Severity of Toxicities,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
1602,NCT00094978,,,,2004-10-25,TERMINATED,INTERVENTIONAL,['PHASE1']
1603,NCT01726452,Overall survival,,,2013-01-24,COMPLETED,INTERVENTIONAL,['PHASE3']
1604,NCT05880992,Adherence rate,Major complications,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
1605,NCT01543607,Safety: Number of Bile Leak After RFA Procedure,Effectiveness: Change From Baseline in Bile Duct Diameter.,,2012-02,TERMINATED,INTERVENTIONAL,['NA']
1606,NCT01995942,The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.,"Measurement of the change in mrEMVI from pre to post pre-operative therapy, will be based on a new proposed EMVI-TRG classification (EMVI TRG 1-5).",,2013-06-07,UNKNOWN,OBSERVATIONAL,['NA']
1607,NCT04278287,Local control rate,ctDNA analysis,,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1608,NCT05508737,Objective response rate (ORR),Number of participants with Adverse Events that are related to treatment,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1609,NCT00202800,To evaluate the response rate,To describe the toxicity profile,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1610,NCT04476537,Number of participants assigned therapy with OncoTreat,,,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1611,NCT02302794,3-year disease free survival rate,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
1612,NCT05983133,Number of participants with DLTs by dose level,Overall survival (OS),,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1']
1613,NCT04385147,procedure related complications,Effect of COVID-19 precautions on staff number,,2020-05-18,COMPLETED,OBSERVATIONAL,['NA']
1614,NCT00710697,ECG interval change,Safety/Efficacy,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
1615,NCT04528745,Thrombocytopenia,Hospitalization,Other adverse event(s) added by patient,2020-05-04,COMPLETED,OBSERVATIONAL,['NA']
1616,NCT01526239,Communication with primary care physicians about CRC screening,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1617,NCT06316908,Pain Score using the Visual Analog Scale,Incidence of Vomiting,,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE4']
1618,NCT05473325,Signal to Noise,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1619,NCT00555672,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),Progression-Free Survival (PFS),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1620,NCT05604378,EBV positive gastric cancer is associated with increased Ki-67 and decreased EGFR.,,,2022-08-03,COMPLETED,OBSERVATIONAL,['NA']
1621,NCT03735407,Number of Incidence of Device and Procedure Related Serious Adverse Events (SAE),To Evaluate Subject's Satisfaction,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
1622,NCT03000374,Pathologic complete response (pCR),Overall survival,,2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1623,NCT02572141,Disease-free survival,Postoperative complications,,2015-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1624,NCT01506687,Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks,Screening preferences; predictors of CRC screening and screening preference.,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1625,NCT02248519,Post-operative hospital stay,Oncologic outcomes (R0-resection rate and lymph node yield),Time to return to daily activity,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
1626,NCT01135056,Overall Survival,Disease control rate,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
1627,NCT03076502,Pathological diagnosis,Tumor status（worse/ maintain/ better）,,2017-04,UNKNOWN,OBSERVATIONAL,['NA']
1628,NCT06261138,Progression Free Survival (PFS) per mRECIST,Adverse events (AEs),,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
1629,NCT02343835,Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers,Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum,Overall survival and (local and distant) progression-free survival.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
1630,NCT03405909,Diagnostic value of standardised CEUS-based algorithms for the non-invasive diagnosis of HCC in high-risk patients,Influence of histological grading on contrast enhancement behaviour,,2018-04-21,COMPLETED,OBSERVATIONAL,['NA']
1631,NCT02637596,Quality of life after RFA of pancreatic cancer,3- months perioperative morbidity and mortality,Overall Survival,2013-02,COMPLETED,INTERVENTIONAL,['NA']
1632,NCT01080521,Cognitive function as measured by the HeadMinder Customized Research Tool (CRT),Patient-reported cognitive function as measured by Patient Assessment Own Functioning scale and web CRT,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
1633,NCT00601406,"Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity","PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability",,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
1634,NCT03165344,Esophageal stenosis rate,Side effect of drugs,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
1635,NCT01811277,Objective response rate for SOX sequential S-1,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1636,NCT05191940,Locoregional tumor control,"Incidence of CTCAE v5.0 Grade 2 - Grade 5 acute, subacute and late toxicities",,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
1637,NCT03677960,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.,Histopathology of areas with biopsy-proven disease following multiple doses of ABI-1968 Topical Cream.,2018-12-17,TERMINATED,INTERVENTIONAL,['PHASE1']
1638,NCT02944539,Relative copy number of mitochondrial DNA,,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
1639,NCT00785122,Safety assessment,Non-Cellular immunomonitoring,,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1640,NCT05967143,Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Hepatocellular Carcinoma module (EORTC QLQ-HCC18),Healthcare Resource Utilization summarized at follow-up timepoints,,2023-06-19,RECRUITING,OBSERVATIONAL,['NA']
1641,NCT02282111,Diagnostic Accuracy,Percent Sample Contribution to Immunohistochemistry Diagnosis,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
1642,NCT03273647,Disease-free survival time,overall survival time,,2017-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1643,NCT02795156,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,,2016-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
1644,NCT03253302,Positive rate of circumferential resection margin (CRM) of the specimens,the rate of postoperative complications,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1645,NCT02715492,Number of patients with portal vein thrombosis,,,2018-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
1646,NCT02602249,Reduced size of the tumor.,"Safety, as measured by the rate of adverse events and serious adverse events",,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
1647,NCT00005809,,,,2000-07,COMPLETED,INTERVENTIONAL,['NA']
1648,NCT02805829,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Number of Participants with tumor recurrence metastasis as a Measure of effectiveness,T cell subsets figures,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1649,NCT03470350,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,Baseline molecular status of potential predictive markers of tumor response,,2018-08-24,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1650,NCT00313794,"To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .","To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics.",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1651,NCT06313801,Complications from polychemotherapy.,Аssessment of the quality of life,,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2']
1652,NCT00174616,MRI staging and TME surgery,Measure safety - NCI-CTC version 2,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1653,NCT02719782,Safety of the TCR-T treatment,Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline,"1-year PFS (progression free survival) which is measured by the number of patients with stable disease after 1 year, using mRECIST",2015-07-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1654,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",,,2007-04-27,COMPLETED,OBSERVATIONAL,['NA']
1655,NCT05445245,Self-report Questionnaire,,,2022-04-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1656,NCT02199236,maximum tolerated dose (MTD),tumor response,,2014-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1657,NCT04442581,Number of Participants With Objective Response (Complete or Partial Response),Number of Participants With Adverse Events,,2021-04-20,TERMINATED,INTERVENTIONAL,['PHASE2']
1658,NCT00164879,The stoma rate in the two groups of patients,Hospital stay,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1659,NCT04475640,Impact of germline genetic testing on both therapeutic management and targeted cancer prevention,,,2019-12-13,RECRUITING,INTERVENTIONAL,['NA']
1660,NCT03706742,Hepatitis C Screening,Cost: Cost per-HCV diagnosis,,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
1661,NCT00639509,Best Overall Response Rate (ORR),Median Overall Survival,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1662,NCT01303029,Progression free survival,Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1663,NCT00923299,Objective response rate as assessed by RECIST criteria (Phase II),Overall survival,,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1664,NCT05915351,Overall Response Rate (ORR),Overall Survival (OS),,2023-06-30,RECRUITING,INTERVENTIONAL,['PHASE2']
1665,NCT05867901,Drug retreatment response rate,MRD versus imaging examination,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
1666,NCT06061328,Maintenance as assessed by maintenance of other measures,Feasibility of Intervention Measure (FIM),,2024-02-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1667,NCT06173310,To measure the reproducibility of qDCE-MRI measurement of BRPC.,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1668,NCT04409340,Detection of focal HCC lesions,,,2020-10-05,RECRUITING,OBSERVATIONAL,['NA']
1669,NCT03508180,Evaluation of nausea and vomiting,Body image,,2018-06-14,COMPLETED,INTERVENTIONAL,['NA']
1670,NCT03082833,Objective response rate (ORR) by RECIST 1.1,,,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1671,NCT02033213,Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.,Total Volume of Administered Intraoperative Fluid,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1672,NCT01904955,data concerning evolving relapse,,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
1673,NCT01871571,Rate of CPR in the pathology specimen,Incidence and nature of AEs of special interest for bevacizumab (grades) according to NCI CTCAE v4.0,,2013-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1674,NCT00450424,Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing,Patient Satisfaction With the Preparation to Make a Decision,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
1675,NCT02313688,3-year disease free survival,The positive rate of proximal resection margin,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
1676,NCT04298320,Incidence of Treatment-Emergent Adverse Events,PFS,,2020-03-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1677,NCT01896310,The diagnostic accuracy of the new classification system,,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
1678,NCT02047188,NBI prediction for lesion histology and invasion,immunohistochemical outcome of microvessel count and MMP-7,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
1679,NCT03448302,Blood flow of tumor,Permeability surface of the tumor,,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA']
1680,NCT06161207,3-year disease free survival rate,Postoperative quality of life (measured by EQ-5D),,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1681,NCT05600608,"To determine the diagnostic accuracy of the augmented exhaled breath test, in the prediction of oesophago-gastric cancer (OGC).",To identify the mechanistic pathways and origins of the production of breath Volatile compounds by investigating the tumour lipidome.,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1682,NCT01002443,Histological grading improvement rate,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1683,NCT01583361,disease free survival,safety,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
1684,NCT03942900,Peripheral CD4 anti-telomerase immunity and MDSC (Myeloid-Derived Suppressor Cells) analysis,,,2020-04-01,WITHDRAWN,OBSERVATIONAL,['NA']
1685,NCT01606098,Overall survival,Overall survival in patients in whom treatment according to protocol was initiated,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1686,NCT02162641,The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients,Delays in receiving radiotherapy treatment,,2014-09,WITHDRAWN,OBSERVATIONAL,['NA']
1687,NCT04529668,histopathology,,,2015-10-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
1688,NCT00615056,Progression Free Survival (PFS),"Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1689,NCT01835041,Maximum Tolerated Dose,,Number of Participants with a Clinical Response,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1690,NCT04809025,Diagnostic accuracy,Procedure duration,,2021-05-24,UNKNOWN,OBSERVATIONAL,['NA']
1691,NCT01256047,postoperative infectious complication,"plasma IL-6, CRP, Th1/Th2 balance",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1692,NCT03630640,Local recurrence-free survival during a 1-year follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure,Frequency of discontinuations treatment due to AEs,,2018-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1693,NCT04850027,Disease free survival,Postoperative complications,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
1694,NCT01613053,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
1695,NCT04224779,Area under the Receiver Operating Characteristic (ROC) curve of total cfDNA (defined as circulating cell-free DNA in plasma) percent change between the baseline sample (T1) and the sample at the end of the neo-adjuvant treatment (T3),Tumoral response assessed by Magnetic resonance Imaging (MRI),,2021-02-18,RECRUITING,INTERVENTIONAL,['NA']
1696,NCT05666271,Adjacent organ thermal injury rate,,,2022-08-29,RECRUITING,OBSERVATIONAL,['NA']
1697,NCT01109615,Response rate,Overall survival,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2']
1698,NCT06320990,"Feasibility, by retention rate",Objective response rate (ORR) of pancreatic MCN,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1699,NCT00727441,"Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",Disease Free Survival,,2008-07-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1700,NCT01975064,Over all survival,Over all survival,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1701,NCT01816659,Comparison of Ki-67 in Tumor Samples,,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1']
1702,NCT05482529,disease free survival rate,R0 resection rate,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
1703,NCT05550025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,The median overall survival time (mOS),,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2']
1704,NCT03587532,An ICGA based cutoff point to predict anastomotic leakage and graft necrosis after esophageal reconstructive surgery.,pulse pressure,,2021-12-13,RECRUITING,INTERVENTIONAL,['NA']
1705,NCT05965999,"Agreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy)","Agreement between negative EsoGuard test results and upper endoscopy diagnosis (i.e., subjects determined not to have BE/EAC on upper endoscopy)",,2023-04-11,RECRUITING,OBSERVATIONAL,['NA']
1706,NCT05210283,To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).,To assess time from positive ctDNA to clinical recurrence,,2021-12-15,RECRUITING,OBSERVATIONAL,['NA']
1707,NCT03122509,Overall Response Rate,,,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
1708,NCT05912075,Dose-limiting toxicities (DLTs),Distant metastasis-free survival,,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE1']
1709,NCT03718897,Overall survival rate,,,2018-09-14,UNKNOWN,OBSERVATIONAL,['NA']
1710,NCT06115499,Overall Survival (OS) (Phase III),Incidence of adverse events,,2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1711,NCT03396029,A questionnaire-based lifestyle score,Body weight,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
1712,NCT02494791,Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing,Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome),,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1713,NCT03109886,Overall Safety Profile,Duration of overall Response (DoR),,2017-07-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1714,NCT00934882,"Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)",Tumor response,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1715,NCT06177496,overall survival,Progression-free survival,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1716,NCT00251862,Patient Adherence (Test Completion),Screening Intentions,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
1717,NCT04888806,12-month progression-free survival (PFS),Overall Survival(OS),,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1718,NCT04536077,Amount of intratumoral conventional dendritic cells (cDCs),,,2021-08-13,TERMINATED,INTERVENTIONAL,['PHASE2']
1719,NCT01569672,"Amount of time from abnormal evaluation of the breast, cervix, and colon or rectum to needed tests and treatment",Number of barriers and effect of barriers on receiving needed tests and treatment,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
1720,NCT04612530,Safety of the combination treatment IRE + immunotherapy based on adverse events,Pain based on the Visual Analog Score (VAS),,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE1']
1721,NCT04751370,Pathological complete response,Incidence of adverse events,,2022-02-08,SUSPENDED,INTERVENTIONAL,['PHASE2']
1722,NCT00816634,Response rates of both regimens,a) progression-free survival b) quality of life c) toxicity d) overall survival e) predictive markers,,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1723,NCT05721885,Degree of radiation-induced oral mucositis (RTOG criteria),,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1724,NCT00507143,SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38,"SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival",,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
1725,NCT04617821,overall survival,postoperative complications,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1726,NCT03804372,Percentage of patients presenting hepatitis B virus reactivation,Number of patients experiencing adverse events.,,2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE2']
1727,NCT05997056,Efficacy of nab-sirolimus,Overall survival,,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE2']
1728,NCT03825328,OS,,,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
1729,NCT05990959,Disease free survival,,,2022-04-22,RECRUITING,OBSERVATIONAL,['NA']
1730,NCT04677504,Progression Free Survival (PFS),Incidence of ADAs to Atezolizumab,,2021-02-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1731,NCT05099848,Surgical conversion rate,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1732,NCT05554367,ORR (Cohort 4),Incidence of adverse events (AE) (All Cohorts),Plasma RAS allelic burden in in relation to response (Cohorts 3 and 4),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2']
1733,NCT06324097,negative predictive value,intra-observer agreement,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1734,NCT01111838,To Determine Overall Objective Response.,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1735,NCT04791735,The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.,Overall and disease free survivals.,,2021-05-21,RECRUITING,INTERVENTIONAL,['NA']
1736,NCT00021138,,,,2001-04,COMPLETED,INTERVENTIONAL,['NA']
1737,NCT05233358,Progression Free Survival,The incidence of adverse events and serious adverse events,,2022-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1738,NCT01147380,Side Effect of Cadaveric Donor Liver NK Cell Infusion,Anti-HCV Effect of This Treatment (If Applicable),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1739,NCT00191646,Progression Free Survival (PFS),Overall Survival,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1740,NCT02448056,Patient survival,,,2015-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1741,NCT05301699,postoperative complications during hospitalization,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
1742,NCT01523639,Reduction in the chemotherapy-associated steatosis,Reduction in chemo-therapy associated steatohepatitis (CASH),,2012-04,TERMINATED,INTERVENTIONAL,['PHASE2']
1743,NCT01107639,Progression-free survival (PFS),Time to progression (TTP),,2010-05-27,COMPLETED,INTERVENTIONAL,['PHASE3']
1744,NCT04967495,Overall survival (OS),Duration of portal patency,,2021-07-09,RECRUITING,INTERVENTIONAL,['NA']
1745,NCT00191568,"To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study",To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation),,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1746,NCT03232814,Adherence rates,Participants' Overall Experiences: Qualitative Interviews,,2017-10-05,WITHDRAWN,INTERVENTIONAL,['NA']
1747,NCT01938027,Total Mesorectal Excision(TME) quality,"30-day postoperative complications, No. of harvested LN","Oncologic outcome(2-year local recurrence free survival, 5-year survival)",2013-09,COMPLETED,INTERVENTIONAL,['NA']
1748,NCT04253249,Treatment pancreatic cyst without surgery,,,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA']
1749,NCT06073483,The rate of postoperative complications,Intraoperative instrument operation error rate,,2023-10-15,RECRUITING,INTERVENTIONAL,['NA']
1750,NCT00814619,Pathological complete or near-complete response (Dworak grade 3 and 4),Adverse events,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1751,NCT03099486,Progression Free Survival (PFS) at 2 Months,Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy,,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE2']
1752,NCT01350206,overall survival,Time to progression,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1753,NCT02009631,To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF),Tumor Assessment,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1754,NCT01534546,3 year Disease Free Survival,Adverse Event,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
1755,NCT02396745,Safety: Long-term (Study Related Adverse Events),Additional Interventions (Number of Subsequent Follow up Treatment Interventions),,2016-01-25,TERMINATED,INTERVENTIONAL,['NA']
1756,NCT04181645,ORR：Objective Response Rate by IRC,OS: overall survival,,2019-06-29,UNKNOWN,INTERVENTIONAL,['NA']
1757,NCT04550260,Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,Adverse events (AEs),2020-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1758,NCT06242418,change in value of ctDNA concentration,quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).,,2024-03-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1759,NCT03880721,Specificity,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1760,NCT05659290,Progression-free Survival (PFS),Overall Survival (OS),,2023-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1761,NCT02626312,Maximum dose constraint,Overall survival,Tumor biomarker expression in serum,2016-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1762,NCT02363218,Overall survival rate,Progression-free survival,,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
1763,NCT01675934,Percentage of cases in which right-sided retroflexion is successful with the adult and pediatric colonoscopes.,Reasons for failure of retroflexion.,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
1764,NCT00354887,Number of Participants With Overall Response,,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1765,NCT04698915,Median Overall Survival after SBRT completion,Median Progression Free Survival after SBRT Completion per RESIST 1.1,,2021-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
1766,NCT00891930,Part 2: Objective Response Rate (ORR),Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1767,NCT05284864,Determine and compare morbidity and mortality rates in patients with early and late stoma closure,Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure,"Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale.",2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
1768,NCT00682786,Rate of Tumor Downstaging Compared With Historical Controls.,Determine Patient Fears and Expectations of Pharmacogenetics.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1769,NCT01740648,Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.,Frequency of patients undergoing sphincter preserving surgery,,2012-11-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1770,NCT00120939,"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.","Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks",,na,COMPLETED,INTERVENTIONAL,['PHASE1']
1771,NCT00216437,Dose-limiting toxicity.,,,2004-12,TERMINATED,INTERVENTIONAL,['PHASE1']
1772,NCT05687318,PMR,AMR,,2022-09-20,COMPLETED,INTERVENTIONAL,['NA']
1773,NCT00020501,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1774,NCT00098579,MTD of alvocidib when given every three weeks in conjunction with doxorubicin hydrochloride,Therapeutic activity of alvocidib in combination with doxorubicin hydrochloride in patients with advanced solid tumors,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1775,NCT00844168,Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1776,NCT03627559,Pyruvate concentration postoperatively,,,2013-10-01,COMPLETED,OBSERVATIONAL,['NA']
1777,NCT03125980,3-year disease free survival,Relapse-free survival (RFS),,2017-05,RECRUITING,INTERVENTIONAL,['PHASE3']
1778,NCT05698992,General Quality of life,Rehabilitation process,Discharge destination,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
1779,NCT02780284,Percentage of participants retained at the end of study,"Percentage of participants with collected, processed, and analyzed stool samples",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
1780,NCT02204306,disease control rate,median overall survival,drug toxicities,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1781,NCT02745483,Cumulative 3-year LTP rate,3-year Recurrence free survival rate,Technical success rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1782,NCT01549756,,,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
1783,NCT06199973,Progressive free survive assessed by Independent Review Committee,Effectiveness: overall survive assessed by the researchers,,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1784,NCT04046133,Safety and tolerability- 12 months post CRT,Patient reported outcome - 12 months follow up,,2020-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
1785,NCT05466565,recurrence-free survival time,Dynamic changes of cccDNA,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
1786,NCT05356585,Detectable ctDNA at the Completion of TNT,Correlation of Complete Response TNT,The correlation of ctDNA at end of TNT with relapse-free survival,2023-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1787,NCT03821948,Blood-based biomarkers associated with genetic and epigenetic alterations.,,,2019-01-03,COMPLETED,OBSERVATIONAL,['NA']
1788,NCT01847794,HER2 positive CTC,clinical significance of HER 2 positive CTC,,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
1789,NCT05131958,Perception measure,,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
1790,NCT03493152,,,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA']
1791,NCT01785537,Change from baseline in the number of traditional cigarette smoked,Traditional and electronic smoking (overall smoking) cessation,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
1792,NCT03750669,Disease-free survival,Serious adverse events incidence,,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2']
1793,NCT02426762,freedom from surgical site infection,Pain Scores on the Visual Analog Scale,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
1794,NCT02845973,differences in abundance of gut microbiota,evidence of colorectal neoplasia,diet difference in patients with different clinical outcomes,2012-01,COMPLETED,OBSERVATIONAL,['NA']
1795,NCT03111368,Diagnostic yield,,,2015-04-27,COMPLETED,INTERVENTIONAL,['NA']
1796,NCT02042859,"Improvement in size(patency of bile duct) measured by cholangiography or cholangioscopy, immediately post ablation",,,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1797,NCT00063427,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
1798,NCT02459041,Strain histogram and contrast enhancement during EUS in pancreatic masses and lymph nodes,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
1799,NCT00176787,"e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response",,,2000-10,TERMINATED,INTERVENTIONAL,['PHASE2']
1800,NCT03878524,Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose),Time to decline (TTD),,2020-04-01,TERMINATED,INTERVENTIONAL,['PHASE1']
1801,NCT04592029,Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).,DOR assessed by investigators according to mRECIST.,,2020-09-27,UNKNOWN,INTERVENTIONAL,['PHASE1']
1802,NCT05582018,Safety,Assessment Module (1),Precision,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1803,NCT05669521,Mucositis,Secondary efficacy/outcome mucositis,,2022-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1804,NCT05453630,Number of participants who complete colonoscopy within 1 year of the colonoscopy referral,Number of participants who have colonoscopies with cecal intubation,,2022-06-16,RECRUITING,INTERVENTIONAL,['NA']
1805,NCT01073046,Influence of Naso-Gastric/Jejunal Tube on Postoperative complications,Influence of Naso-Gastric/Jejunal Tube on Postoperative Patient's Comfort,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
1806,NCT01563133,Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes,Feasibility and safety data on nCLE during EUS-FNA procedure,,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
1807,NCT03261947,Disease Control Rate (DCR) in Tumor-Specific Cohorts,"Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements, Reported as Adverse Events in Tumor-Specific Cohorts",,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2']
1808,NCT03382600,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),Number of Participants Discontinuing From Study Treatment Due to AE(s),,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1809,NCT06018857,Overall Survival,,,2017-05-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1810,NCT04885283,Time to Start Postoperative Chemotherapy,,,2021-01-20,COMPLETED,OBSERVATIONAL,['NA']
1811,NCT01876901,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA,,2010-08-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1812,NCT05634720,Feasibility of HA Chemotherapy for PDAC,Overall Survival,,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4']
1813,NCT00667628,Time to Appearance of New Lesions (TTNL),Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),,2008-04-24,TERMINATED,INTERVENTIONAL,['PHASE2']
1814,NCT03286738,percentage of use FOLFIRI regimen and target agents,,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
1815,NCT03631173,Total hospital stay,Risk factors of postoperative pancreatic fistula at 90 days after surgery,Number of patients expired at an average of 10 days,2019-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1816,NCT05445401,DMSM score,Postoperative complication rate of grade IIIa or above.,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1817,NCT03908788,Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy,Evaluation of the following criterion: frequency of mutated alleles,,2018-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1818,NCT05563766,Rate of pathological complete response with itraconazole,Determine the utility of ctDNA and exosome characterization as a prognostic marker,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1819,NCT05215379,The rate of cCR,quality of life,,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1820,NCT00423293,Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events),Five-Year Rate of Colostomy-free Survival,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1821,NCT02461043,3 year relapse free survival,3 year overall survival,5 year overall survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
1822,NCT00262990,To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer,To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1823,NCT06184152,Early HCC Detection,Early HCC Detection,,2023-11-28,RECRUITING,OBSERVATIONAL,['NA']
1824,NCT03150706,"Serum CEA, TSH, T3, free T4, EKG,CT (or MRI) scans of evaluable/measurable lesions by RECIST 1.1.",,,2017-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
1825,NCT04974047,pCR Rate,Number Of Participants Experiencing Treatment-Emergent Adverse Events,,2021-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1826,NCT00056992,,,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1827,NCT01470404,germline polymorphisms in xenobiotic metabolism genes in toxicity profile,,,2008-07-10,COMPLETED,OBSERVATIONAL,['NA']
1828,NCT04138381,Clinical benefit rate (CBR) for the use of selinexor in monotherapy,Clinical benefit rate (CBR),,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1829,NCT05303818,Deep venous thrombosis and embolic pulmonary disease,Safety of rivaroxaban,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1830,NCT05604573,detection sensitivity of genetic mutation by mmADPS,correlation of genetic mutation and prognosis,,2022-02-09,RECRUITING,OBSERVATIONAL,['NA']
1831,NCT01104129,Positive mutation rate in tumors/IPMN lesions vs. control,Percentage of patients with genetic abnormalities correctly detected in stool samples,,2009-07-09,COMPLETED,OBSERVATIONAL,['NA']
1832,NCT00005926,,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1833,NCT01104077,Percentage of IPMN patients with relatives with pancreatic cancer or IPMN,Percentage of IPMN patients exhibiting higher malignant potential or recurrence following surgical resection,,2008-11-17,COMPLETED,OBSERVATIONAL,['NA']
1834,NCT05533541,Primary End point,Secondary End point 4,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
1835,NCT04806464,Part2:ORR,"Part 2:PD-L1, PD-1",,2021-03-16,UNKNOWN,INTERVENTIONAL,['PHASE1']
1836,NCT03647839,Objective response per iRECIST,Overall survival,,2018-09-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1837,NCT02268435,Maximal tolerated dose and recommended dose,"Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters",,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1838,NCT01196390,Disease-free Survival (DFS),Number of Participants With Any Cardiac Adverse Events Regardless of Attribution,,2011-02-14,COMPLETED,INTERVENTIONAL,['PHASE3']
1839,NCT05214339,Objective response rate (ORR) by RECIST 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2']
1840,NCT00637364,"Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE)",,,2008-03,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1841,NCT00005077,,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1842,NCT02316834,Change in ribonucleic acid (RNA) protein expression,Change in RNA protein expression,,2015-06-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1843,NCT03396614,The cardiopulmonary (dys)function in EC survivors treated with neo-CRT followed by surgical resection will be compared to cardiopulmonary (dys)function in EC survivors treated with surgical resection alone.,,,2017-10-21,COMPLETED,OBSERVATIONAL,['NA']
1844,NCT04627142,Objective Response (OR) according to RECIST version 1.1,Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period,,2020-11-23,TERMINATED,INTERVENTIONAL,['PHASE1']
1845,NCT03301454,Estimate the overall survival for patients suffering from Esophageal cancer,Estimate the consequences of pursuing chemotherapy,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
1846,NCT00005640,Number of Procedures Resulting in Improved Detection,,,1999-06,COMPLETED,INTERVENTIONAL,['NA']
1847,NCT06060990,Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
1848,NCT01194206,Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy,Survival rate,,2010-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1849,NCT02597465,"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
1850,NCT05983367,Overall Response Rate,Disease Control Rate,,2023-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1851,NCT05664178,Participant Treatment Outcome,,,2023-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1852,NCT02358395,Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.,Overall Survival,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1853,NCT01310699,Number of Participants With Nonpolypoid (Flat and Depressed) Colorectal Neoplasm,Percentage of Nonpolypoid (Flat) Missed Lesions,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
1854,NCT05378867,AUCtau，Area under the curve over the dosing interval,DOR，Duration of response,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1855,NCT03245346,Overall survival (OS),Plasma levels of ropivacaine and sufentanil,,2017-12-19,UNKNOWN,INTERVENTIONAL,['NA']
1856,NCT05328960,Yearly incidence of rectal cancer,Treatment changes,,2022-02-15,RECRUITING,OBSERVATIONAL,['NA']
1857,NCT02689284,Duration of Response,Terminal Half-life,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1858,NCT04390243,Objective Response Rate (ORR) at 24 Weeks,Number of Patients With Grade 3+ Adverse Events,,2020-11-16,TERMINATED,INTERVENTIONAL,['PHASE2']
1859,NCT03812796,Main Phase IIB (efficacy) phase: Objective response rate using RECIST 1.1 criteria,Duration of objective response according to RECIST 1.1,,2019-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1860,NCT02931890,Event-Free survival,Toxicity,,2017-12-21,RECRUITING,INTERVENTIONAL,['PHASE2']
1861,NCT00003137,response rate,survival,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1862,NCT03026452,Tumor size assessed by MRI,Alpha Fetoprotein (AFP) level assessed by ELISA,,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1863,NCT04362449,Nausea according to the Common Terminology Criteria for Adverse Events (CTCAE) V4.03,Health economics in the context of duration of hospital attendance,,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2']
1864,NCT04289792,Kaplan-Meier Estimate of Progression-Free Survival (PFS),Participants With Treatment Emergent Adverse Events (TEAEs),,2020-05-09,RECRUITING,INTERVENTIONAL,['PHASE2']
1865,NCT06202066,PFS (Part 2),Incidence of adverse events (Part 2),,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1866,NCT03198546,Number of Patients with Dose Limiting Toxicity,Median CAR-T cell persistence,,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
1867,NCT02584400,"Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT",Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient,,2016-05,TERMINATED,INTERVENTIONAL,['PHASE2']
1868,NCT05293496,Number of participants with AEs leading to study treatment discontinuation,Duration of PSA response for mCRPC,,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
1869,NCT03679910,Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1870,NCT01425996,Adverse Event/Serious Adverse Event,Change from baseline in tumor marker/biomarkers,,2011-10-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1871,NCT05610163,Clincal Complete Response (cCR) Rates,Incidence of adverse events (AEs),,2022-12-08,RECRUITING,INTERVENTIONAL,['PHASE2']
1872,NCT03869294,Overall survival,adverse events,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
1873,NCT02654288,The dynamic change patterns of sera IgG4 and IL-10 of pancreatic cancer after gemcitabine-based chemotherapy will be recorded.,The correlation of the changes of IgG4 and IL-10 with the overall survival after chemotherapy will be analyzed.,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
1874,NCT04157140,Time To Progression(TTP),Incidence of Treatment-Emergent Adverse Events,,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
1875,NCT01184482,Maximum tolerated dose,Genetic variations and activation status for EGFR and ErbB2 pathways,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1876,NCT05720676,To use PDX and PDO to evaluate the efficacy of various treatments.,,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1877,NCT00155103,,,,2004-08,UNKNOWN,OBSERVATIONAL,['NA']
1878,NCT03768414,Overall survival (OS),Changes in carbohydrate antigen 19-9 (CA 19-9) levels,,2019-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1879,NCT05650216,pCR,OS,,2022-12-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1880,NCT06257030,LPFS,Post-treatment dosimetry analysis,,2024-02-05,RECRUITING,OBSERVATIONAL,['NA']
1881,NCT04124991,TTP,Number of participants with treatment-related adverse events,,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1882,NCT02989870,Occurrence of Treatment Related Adverse Events,Overall Survival (OS),,2017-03-27,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1883,NCT00367861,Progression free survival,Toxicity,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1884,NCT06239870,pCR,TRG,,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1885,NCT04042805,Objective Response Rate (ORR),Tumor mutation burden in association with ORR and survival.,,2019-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1886,NCT03752086,pancreatic fistula,major complications (Clavien-Dindo ≥III),,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
1887,NCT03185988,Response Rate(RR) for each cohort in intent to treat (ITT) population,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1888,NCT02885753,progression-free survival,,,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3']
1889,NCT00372944,Median time to death (TTD),To assess the safety and tolerability of AZD6244 in the treatment of advanced or metastatic pancreatic cancer by review of adverse events (AEs) and laboratory parameters.,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1890,NCT01735955,Number of Participants With Adverse Events and Serious Adverse Events,Number of Participants With Clinical Benefit From Nilotinib,,2013-03-29,COMPLETED,INTERVENTIONAL,['PHASE4']
1891,NCT00937248,Comparing the use of a prone pillow and simple ankle fixation device vs. the use of a CVID for immobilization rectal patients during the course of preoperative radiation therapy using KV CBCT for IGRT.,quantify interfractional set-up displacements using either of the two devices;determine a standard planning target volume margin; evaluate the role of soft-tissue image matching for IGRT using CBCT.,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
1892,NCT05688020,Postprocedural bleeding,Side effects,,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
1893,NCT03778879,Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone,Mean time to death,,2019-08-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1894,NCT03518489,Change from Baseline Numeric Rating Scale for Pain(NRS scale) at 7 weeks,The Adverse events Related to lappaconitine,,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA']
1895,NCT02944188,incidence of postoperative complications,operative mortality,postoperative hospital stay,2014-12-01,COMPLETED,INTERVENTIONAL,['NA']
1896,NCT06128551,Dose Limiting Toxicities,Progression-Free Survival (PFS),,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1']
1897,NCT05712356,Incidence of adverse events,,,2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2']
1898,NCT00154804,Clinical and pathological response rates,Toxicity,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1899,NCT02610218,Correlation of HER2 status on CTCs and cfDNA with clinical outcomes,Gene variations associated with resistance in HER2-targeted therapy,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
1900,NCT01071655,progression-free survival,Evaluation of KRAS status as a molecular marker,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1901,NCT02309177,Grade 3 or 4 TEAE,Duration of Response,,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1902,NCT02435953,Overall survival rate,Adverse event rate,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1903,NCT05379595,Cohorts D and E: Number of Participants with Vital Signs Abnormalities,Cohorts D and E: Progression Free Survival (PFS),,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1904,NCT01736410,Overall Response Rate (ORR),Time to Treatment Failure (TTF),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1905,NCT05599932,Pharmacokinetics (PK): AUCinf,,,2022-12-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1906,NCT02094625,Target Serum Level NAC,Glutathione serum level,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1907,NCT00001254,To determine an approach to the localization and management of tumor in patients with ZES.,,,1991-10-29,COMPLETED,OBSERVATIONAL,['NA']
1908,NCT04933669,Progression free survival（PFS）,R0 resection rate,,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE2']
1909,NCT04638868,Number of circulating tumor cells,,,2020-11-17,UNKNOWN,INTERVENTIONAL,['NA']
1910,NCT03285906,progression-free survival,median Overall Survival,,2017-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1911,NCT05925413,Objective response rate (ORR),Adverse events (safety),,2023-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1912,NCT03400592,Objective response rate,Potential predictive biomarkers of nimotuzumab,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
1913,NCT03825705,Overall Response Rate(ORR),,,2019-04-23,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1914,NCT05743049,"To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.",To integrate the data and specimens to permit the most informative clinical-biologic research platform.,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
1915,NCT00622440,Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL),Response With >75% Adherence,,2008-05-14,COMPLETED,INTERVENTIONAL,['PHASE2']
1916,NCT00068692,3-year Overall Survival Rate,Failure Pattern,,2003-10-15,COMPLETED,INTERVENTIONAL,['PHASE3']
1917,NCT05361954,Incidence of immune-related adverse events (IrAEs),Assess immunoglobulin levels,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1918,NCT00004187,,,,1999-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1919,NCT01048216,To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety,Set up verification with cone-beam CT (OBI on Boar Imager),,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
1920,NCT02404363,Response to treatment based on RECIST 1.1 criterion,Bleedings,,2016-01-11,TERMINATED,INTERVENTIONAL,['PHASE3']
1921,NCT00533975,,,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
1922,NCT00005060,Event-free survival,Rate of complete resection (RO) and postoperative mortality as measured after surgery,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1923,NCT05902988,Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells,,2023-10-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1924,NCT00006472,,,,2000-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1925,NCT01845467,Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy,Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial,,2013-02,WITHDRAWN,OBSERVATIONAL,['NA']
1926,NCT03783442,Overall Survival (OS),Number of Participants Experiencing Adverse Events (AEs),,2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1927,NCT05718492,Progress Free Survival (PFS),Adverse Events (AEs),,2022-10-18,RECRUITING,INTERVENTIONAL,['NA']
1928,NCT01372202,Pathological Complete Response,Esophageal Tumor CHFR Methylation and Detection in Plasma,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
1929,NCT04229355,Progression-free survival,Overall survival,,2021-02-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
1930,NCT04880772,Inflammatory cytokines,Quality of life measure (Mental Adjustment to Cancer Scale),,2021-07-15,COMPLETED,INTERVENTIONAL,['NA']
1931,NCT06053996,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Overall survival (OS),,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1932,NCT03888859,Frequency of ARTEMIS T cell treatment-related adverse events,"Time to baseline for serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ",,2017-12-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1933,NCT03517852,"Tumor blood flow (velocity, mm/sec)",Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.,,2018-08-15,COMPLETED,INTERVENTIONAL,['NA']
1934,NCT06271291,Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes,,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1935,NCT00427310,Survival,,,1984-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1936,NCT03566797,Incidence of SC-CIP in patients at risk,NOD2 polymorphisms,,2018-07-20,RECRUITING,OBSERVATIONAL,['NA']
1937,NCT00349817,skill in discussing these issues with patients,,,2005-10,UNKNOWN,INTERVENTIONAL,['NA']
1938,NCT00640692,,,,2007-12,WITHDRAWN,OBSERVATIONAL,['NA']
1939,NCT03364114,Rate of device- and procedure-related serious adverse events (SAEs),Post Procedure Pain,,2018-02-09,RECRUITING,INTERVENTIONAL,['NA']
1940,NCT03178812,Prediction of malignant potential of pancreatic cyst by measuring TNF levels,,,2017-06,UNKNOWN,INTERVENTIONAL,['NA']
1941,NCT05111795,Lung shunt prediction,Number of patients downstaged to liver resection or liver transplantation,,2022-01-17,COMPLETED,OBSERVATIONAL,['NA']
1942,NCT03464968,6 months overall survival rate,Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0,,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE2']
1943,NCT00081237,Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0,Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1944,NCT02400398,Weight,Changes in microbiome analysis,,2015-04-27,COMPLETED,OBSERVATIONAL,['NA']
1945,NCT05984589,To compare the difference in WCRF/AICR score between the intervention (RISE-PSMT) and control (SSMT) groups.,To assess percent change across the various component scores on the WCRF/AICR (e.g. grams of fiber) to better understand what might be driving any changes in the overall WCRF/AICR composite score.,,2024-01-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1946,NCT05665348,Overall survival (Phase III),Objective response rate (OR) under treatment (Phase III),,2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1947,NCT02705105,Number of Subjects Experiencing Dose-limiting Toxicity,Objective Tumor Response Rate According to RECIST,,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1948,NCT00825955,To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,"To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review",,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE3']
1949,NCT00448760,Pathologic Complete Response,Overall Survival,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1950,NCT02073500,Overall survival (OS),Disease-free survival (DFS),,2009-09,RECRUITING,OBSERVATIONAL,['NA']
1951,NCT00062374,Histological Response Determined by FDG Uptake Correlates,,Disease Free Survival (DFS),2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1952,NCT02639026,Number of Adverse Events,,,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1953,NCT04256226,Overall survival,Recurrence-free survival,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
1954,NCT05334849,Levels of circulating exosomal lncRNA-GC1,Survival outcomes of circulating exosomal lncRNA-GC1,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
1955,NCT02597712,Change in Ki67 Biomarker Expression,Abundance of Biomarkers of ECL Cell Hyperplasia,,2013-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1956,NCT04224636,24-months survival rate,Adverse Events,,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1957,NCT01998230,Postoperative complication,Length of postoperative stay,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1958,NCT01220999,Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008,Number of Subjects With Best Overall Metabolic Response,,2010-10-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1959,NCT01716949,Number of hyperthermia applications by patient,Rate of acute and late toxicity,,2012-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1960,NCT02564666,Drug compliance for patients with HCC who is taking Sorafenib compliance,Duration of dosing period,The satisfaction with Information about Medicines Scale (SIMS) score,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
1961,NCT02936856,Detection of numbers of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,Detection of distribution of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
1962,NCT03104283,Progression-free survival (PFS),Overall survival (OS),,2017-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1963,NCT02715882,"Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings",Blood leukocytes by FACS,,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1964,NCT00768157,Overall survivals,Recurrence rate,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1965,NCT05650151,Infection rate,,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1966,NCT04906434,vital signs changes from baseline,PFS,,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1']
1967,NCT05099237,Cohort 3 - Primary outcome measure: feasibility of monitoring for the daily weights:,"Cohorts 1,2 and 3 Device acceptability",,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
1968,NCT00910572,Time to progression (TTP),Time-to-symptomatic progression (TTSP),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1969,NCT04575922,Overall response rate for unirradiated lesions (ORR),Overall survival (OS),,2020-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1970,NCT00625651,Progression-free survival,The incidence of anti-AMG 655 antibody formation,,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1971,NCT03727633,Percentage of participants presenting a disease control at 4 months,Quality of life questionnaire (QLQ) QLQ-C30,,2018-07-19,RECRUITING,INTERVENTIONAL,['PHASE2']
1972,NCT05241249,R0 resection rate,Ki-67 expression in tumor cells,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1973,NCT02677038,Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1,Incidence of unacceptable toxicity,,2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1974,NCT00808145,Safety of the combination of gemcitabine/cisplatin/sorafenib,Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease,,2009-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1975,NCT02494687,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
1976,NCT01298570,Progression Free Survival (PFS),Percentage of Patients With Severe Adverse Events,,2011-04-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1977,NCT04083651,Overall Survival,,,2020-01-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1978,NCT02564614,Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue,Plasma Decay Half-Life (t1/2),,2016-05-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1979,NCT05659251,Pathological Complete Response (PCR),The changes in the peripheral blood immunoprofile and tumor tissue sample among non-PCR (NPCR) and PCR patients,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1980,NCT03200691,Pathologic Complete Response Rate,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,,2017-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1981,NCT02184195,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1),Number of Participants With Adverse Events (AEs),,2014-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
1982,NCT05897268,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
1983,NCT01923155,Adenoma detection rate,Cecal intubation TIME,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1984,NCT03163992,Overall Response Rate,Progression-free Survival (PFS) and Overall Survival (OS),,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1985,NCT04733963,Progression Free Survival,QoL,Exploratory Endpoint,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1986,NCT02871804,the incidence of pancreatic fsitula grade B/C,the incidence of conversion from laparoscopic surgery to open surgery,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
1987,NCT03096717,incidence of dysplasia in relation to therapy performed,,,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1988,NCT05475613,For patients with liver transplantation: The 2-year event-free survival rate,For all patients with HCC downstaging: Rate of successful tumor downstaging,,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1989,NCT03306966,Number of patients with adverse events related to the index-procedure.,Number of patients with colectomy related re-interventions.,,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA']
1990,NCT04716257,Ovarian specific overall survival,Quality of life questionnaire,,2021-01-14,UNKNOWN,OBSERVATIONAL,['NA']
1991,NCT02034968,Progression free survival(PFS),Objective Response Rate,Adverse events,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1992,NCT05458115,Adverse effect,,,2022-09-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1993,NCT01268384,R0 resection rate,Overall survival,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1994,NCT04000802,MODE-MDT scores,Decision factors,,2019-05-23,COMPLETED,OBSERVATIONAL,['NA']
1995,NCT02531620,Number of participants recruiting,Bowel Function Assessment,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
1996,NCT05008809,Progression-free survival (PFS) time,Quality of life (QoL),,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE3']
1997,NCT00576680,Response Rate,To Determine the Safety and Tolerability of This Drug Combination.,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1998,NCT05144854,Overall survival (OS),Adverse event,,2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1999,NCT00560560,Estimate of the 6 Month Survival Probability,Counts of Circulating Tumor Cells (CTCs),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2000,NCT01857141,Heart rate variability analysis,Epidural injection,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
2001,NCT04993846,Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients,Qualitative analysis of OM and periodontal status between the various stages of PC,,2021-07-26,UNKNOWN,OBSERVATIONAL,['NA']
2002,NCT04065984,Mean muscle attenuation pre and postoperatively,Sequential CT changes in body composition,,2019-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2003,NCT01924624,disease-free survival,Overall survival,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
2004,NCT03693378,Validation of IMMray™ PanCan-d test,Evaluation of the IMMray™ PanCan-d test performance,,2016-01-19,COMPLETED,OBSERVATIONAL,['NA']
2005,NCT05213637,Recurrence-free survival (RFS),Adverse events (AE),,2018-04-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
2006,NCT05745909,Ileus,Quality of life in patients with ostomy,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
2007,NCT02888743,Overall response rate,Prognostic effect of T-cell infiltration,Patient reported symptomatic adverse events(AEs),2017-08-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2008,NCT03208777,presence of telomeric abnormalities,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
2009,NCT01832467,overall response of re-treatment with cetuximab-based chemotherapy,progression-free survival,,2013-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
2010,NCT00361309,Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.,Overall Survival,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2011,NCT02062632,Change in Mouth Pain as Measured by Average Area Under the Curve Per Assessment,Patient Preference for Continued Therapy at Initial Dose and Crossover,Quality of Life Using European Organization for Research and Treatment of Cancer Quality of Life-Lung Cancer 13 and Functional Assessment of Cancer Therapy-Lung,2014-04-14,TERMINATED,INTERVENTIONAL,['PHASE2']
2012,NCT06304987,AE rate,immune-related adverse event rate,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2013,NCT03146637,OS,SRR,,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2014,NCT05191498,Feasibility of intratumoral implantation of QuiremSpheres® by SPECT imaging,Tumor response by RECIST 1.1,,2021-12-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2015,NCT02781285,The influences of traditional Chinese medicine standardized treatment on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,The influences of Western Medicine treatment mainly by chemotherapy on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,,2014-12,RECRUITING,OBSERVATIONAL,['NA']
2016,NCT06232434,increased survival,blood chemistry,,2024-02-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2017,NCT00855634,Overall survival,Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival,,2009-08,TERMINATED,INTERVENTIONAL,['NA']
2018,NCT02555501,Lesion size,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2019,NCT05559229,To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer.,,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
2020,NCT02422147,This study will evaluate the clinical outcomes (effectiveness) of all patients with pancreatic cyst lesions undergoing EUS-guided ethanol ablation. This will include complete resolution of the pancreatic cyst lesion at the end of the treatment period.,,,2016-06-01,RECRUITING,OBSERVATIONAL,['NA']
2021,NCT05777707,Disease-free survival (DFS),Overall survival (OS),,2020-10-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2022,NCT05514769,Gastroesophagus reflux disease apprised by questionnaire,Long-term outcome,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
2023,NCT04299048,Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities,Serum Total Ctrough of PF-06946860,,2020-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2024,NCT02723578,Progression-free survival,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2025,NCT02008656,disease-free survival (DFS),major adverse events,,2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2026,NCT04862793,Feedback from CoPS results in change in patient discomfort.,Make an immediate measure to assess the quality of individual colonoscopy performance.,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
2027,NCT01691391,The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months,Grade of skin toxicity,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
2028,NCT01751763,"Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.",Time to recurrence (TTR),,2013-07-09,COMPLETED,OBSERVATIONAL,['NA']
2029,NCT00094965,Adverse events.,Tumor evaluations for response or progressive disease.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2030,NCT04932187,Rate of adverse events as assessed by CTCAE v5.0,Duration of response,,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2031,NCT02662465,Oral mucositis WHO classification,Visual analog scale,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
2032,NCT04354246,Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).,To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).,Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
2033,NCT00658593,Overall survival,Toxicity,,2008-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
2034,NCT02437136,Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated),Time to Response (TTR),,2015-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2035,NCT05114148,Rate of unacceptable toxicity.,Assessment of regional liver function,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
2036,NCT05222854,proportion of patients with genomic alterations,The proportion of patients with actionable genomic alterations in all patients,,2017-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2037,NCT05927298,Precision-Matched Treatment Utilization Rate,Correlation of Immune Phenotypes and Molecular Profiles,Genetic and Environmental Factors in Pancreatic Cancer,2023-03-06,RECRUITING,OBSERVATIONAL,['NA']
2038,NCT01575990,Appropriate colorectal cancer screening,Appropriate screening for stool cards,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2039,NCT01952210,General nutritional status,Treatment tolerance,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2040,NCT03213054,Incidence rate of adverse event,Tumor response,,2017-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
2041,NCT00508001,Tumour Stabilisation Rate,Overall Survival,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2042,NCT01106261,Feasibility of recruitment,Survival,,2010-12-02,COMPLETED,INTERVENTIONAL,['NA']
2043,NCT02833246,objective pill count,,,2016-06-28,COMPLETED,INTERVENTIONAL,['NA']
2044,NCT04979611,Standard uptake value (SUV),,,2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2045,NCT01707121,Length of hospital stay,Health economic analysis,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
2046,NCT05702684,Patient experience,,,2023-07-31,RECRUITING,OBSERVATIONAL,['NA']
2047,NCT03407716,Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF),Perceived treatment efficacy as measured by the Subject Global Impression of Change,"Change in inflammation biomarkers (adiponectin, cortisol, IL-6)",2019-03-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2048,NCT02926040,Change from baseline in HRQol measured by health questionnaire,,,2016-10,TERMINATED,OBSERVATIONAL,['NA']
2049,NCT01945177,Detection rate of intestinal metaplasia,Aggregate detection rate of focal gastric lesions,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2050,NCT00580021,The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.,,,2006-01,WITHDRAWN,OBSERVATIONAL,['NA']
2051,NCT03233776,"Establish the maximum tolerated dose of anakinra (MTD, 100, 200 or 300 mg).",Short term overall survival,,2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2']
2052,NCT03513705,1-year overall survival,Use of smartphone application,Quality of life with Area Under the Curve (AUC) up to 1 year after diagnosis,2018-05-22,COMPLETED,INTERVENTIONAL,['NA']
2053,NCT00639314,delayed gastric empty after pancreaticoduodenectomy,"evaluation of quality of life, early and late complications after pancreaticoduodenectomy",,2005-10,COMPLETED,INTERVENTIONAL,['NA']
2054,NCT00198081,"Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months",Number of Participants With Clinical Changes in IPMN Progression.,,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2']
2055,NCT04307901,Complete mucosal visualization combining incomplete investigations,Patient preference,,2020-05-01,RECRUITING,OBSERVATIONAL,['NA']
2056,NCT03696472,5-years overall survival rate,Recovery time after surgery,,2018-12,UNKNOWN,INTERVENTIONAL,['NA']
2057,NCT00546065,recurrence-free survival,,,2006-08,TERMINATED,INTERVENTIONAL,['NA']
2058,NCT01439633,Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies.,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
2059,NCT02465983,Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria,,,2015-05,TERMINATED,INTERVENTIONAL,['PHASE1']
2060,NCT05017207,Risk factors relate to pancreatic fistula,Short-term result in treatment of post-operative pancreatic fistula,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
2061,NCT03969576,Objective response rate,Duration of response,,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA']
2062,NCT03178409,Survival analysis,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
2063,NCT02178956,Overall Survival,Number of Patients With Adverse Events,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2064,NCT00263029,Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).,Adverse events collection,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2065,NCT05819099,Accuracy,,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2066,NCT01630239,MR Images,,,2012-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2067,NCT03077334,Clinical PET type assessed by surgeons from preoperatively preformed PET imaging,Number of patients with recurrence of cancer or mortality from cancer following operation,,2014-10-07,COMPLETED,OBSERVATIONAL,['NA']
2068,NCT02991196,Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST]),Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood,,2016-12-01,TERMINATED,INTERVENTIONAL,['PHASE1']
2069,NCT01493713,Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.,Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival,,2011-11-16,COMPLETED,INTERVENTIONAL,['PHASE4']
2070,NCT03048266,Relationship of Serum Global Metabolic Profiles with Subsequent Development of Aggressive PNET,Prospectively Identify Potential miRNA Biomarkers of Serum with miRNA Sequencing in MEN1 Patients Who Have Developed Aggressive PNETs (Cases) and MEN1 Patients Who Have Developed Non-Aggressive PNETs (Controls),,2015-11-05,RECRUITING,OBSERVATIONAL,['NA']
2071,NCT03448835,Incidence of adverse events following treatment (safety),pathological tumor regression grade,,2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2072,NCT04654403,DOR,ORR,,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2073,NCT00255827,"To assess the side effects, dose-limiting toxicity and maximum tolerated dose.",To assess the rate of recurrence after treatment.,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2074,NCT01586611,The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.,Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms.,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
2075,NCT00679913,Survival,Morbidity,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2076,NCT01322152,Rate of Diarrhea,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2077,NCT03511222,Recommended phase II dose (RP2D) of vorolanib plus nivolumab,Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant,,2018-09-11,TERMINATED,INTERVENTIONAL,['PHASE1']
2078,NCT03594929,"serum AST (unit/L) following liver resection, measured at 24 hours",Mortality,,2016-08-15,UNKNOWN,INTERVENTIONAL,['NA']
2079,NCT01422993,Number of Screened Patients Who Participate and Complete the Study,Number of Participants With Measured Improvement,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
2080,NCT03099382,Overall Survival (OS),,,2017-05-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2081,NCT00593008,To determine the dosing regimen appropriate for Phase 2 studies of the combination,To document objective response rate and progression-free survival in patients treated with this combination,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1']
2082,NCT03614910,Tumor response,Cancer related pain,,2018-05-15,COMPLETED,OBSERVATIONAL,['NA']
2083,NCT04270500,"Sleep quality by an Actigraphy: ""change"" is being assessed","Hospital Anxiety and Depression Scale (HADS): ""change"" is being assessed","Weight: ""change"" is being assessed",2020-09-15,UNKNOWN,INTERVENTIONAL,['NA']
2084,NCT01860222,overall survival,local tumor progression,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
2085,NCT03413904,Conversion to open,Long-term postoperative complications,,2018-03-27,UNKNOWN,INTERVENTIONAL,['NA']
2086,NCT03510871,the percentage of subjects with tumor shrinkage after study drug treatment,,,2019-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
2087,NCT06098898,Maximal Tolerable Dose,Overall response rate (ORR),,2023-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
2088,NCT04718909,Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST),DCR assessed by investigators according to mRECIST.,,2021-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2089,NCT05358704,Positron emission tomography (PET),Magnetic resonance imaging (MRI),Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE2']
2090,NCT03790059,Tumor-free survival,Overall survival,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
2091,NCT03861702,Disease Control Rate (DCR),Quality of Life Assessment,,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2092,NCT01131689,MTD,,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2093,NCT03198338,opioid consumption up to 24 hours,sedation score,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
2094,NCT05213221,Objective reponse rate (ORR),Safety of treatment,,2022-03-14,COMPLETED,INTERVENTIONAL,['PHASE2']
2095,NCT03418428,Intestinal microbiome composition,Serum DAO,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
2096,NCT05183776,Safety of a fractional administration device for holmium radioembolization,Accurate dosimetry based on MRI and SPECT imaging of holmium-166.,,2022-07-12,COMPLETED,INTERVENTIONAL,['NA']
2097,NCT02428101,"Correlation of single nucleotide polymorphisms of ABCG2 gene (G34A - rs2231137 and A/A -rs3114018 genotypes) with peripheral neuropathy grades, using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE)",,,2014-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2098,NCT03941873,Phase 2: Objective response rate (ORR),,,2019-02-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2099,NCT01775254,Change in Quality of Life,Change in Demands of Illness,Psychometric analysis of a modified version of the Neurotoxicity Sub-scale.,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2100,NCT01291407,"To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.","To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2101,NCT00503737,"Increase the knowledge of providers as it pertains to current guidelines and strategies about CRCS; assist offices design a CRCS policy, assist offices adopt a CRC reminder system and increase the screening rates of CRC.","synthesize information about the strengths and weaknesses of the toolbox from the primary care physician's (PCP) point of view to aid in future development of an interactive, web-based version of the Toolbox.",,2007-09,COMPLETED,INTERVENTIONAL,['NA']
2102,NCT04949646,"Change in the quality of life of the patient at 3 months postoperatively, based on the SF-36 questionnaire","Difference in the low anterior syndrome symptoms of the patient, based on the LARS questionnaire",,2021-09-19,RECRUITING,INTERVENTIONAL,['NA']
2103,NCT00366457,Time to Tumor Progression,Overall Survival,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2104,NCT06009029,Overall survival (OS),Adverse Events,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2105,NCT00077259,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2106,NCT05661110,"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.",Genomic changes of ctDNA and see if they are predictive of relapse-Free Survival.,Genetic and transcriptional profiling results.,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2107,NCT05937295,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the peptide vaccine in combination with anti-PD-L1 immune checkpoint inhibition,,,2023-09-26,RECRUITING,INTERVENTIONAL,['PHASE1']
2108,NCT03071198,Disease Free Survival (DFS),Predictor efficacy of neoadjuvant chemotherapy for DFS,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2109,NCT00683358,PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST),"Tumor regression(Imaging study, tumor marker, etc.)",,2008-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2110,NCT04689594,Proportion of subjects without stenosis,,,2021-02-04,TERMINATED,INTERVENTIONAL,['PHASE3']
2111,NCT01934829,Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib,The percentage of patients discontinuing treatment,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2112,NCT01668381,"variation of serum IL-10,TGF-β1,IFN-γ concentration of HCC patients before and 1,4 weeks after radiofrequency ablation therapy","variation of suppression ability of CD4+CD25+ T cells of HCC patients on cytokine secretion before and 1,4 weeks after radiofrequency ablation therapy",,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
2113,NCT03641118,Skeletal muscle radiation attenuation at L3,oxygen uptake at lactate threshold,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
2114,NCT03383367,participation rate at future colonoscopy,Cost-utility analysis of the reminder letter for surveillance colonoscopy,,2017-08-24,UNKNOWN,INTERVENTIONAL,['NA']
2115,NCT06135558,DFS,,,2016-01-30,COMPLETED,OBSERVATIONAL,['NA']
2116,NCT01851941,"clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy",overall survival,Pharmacologic Genetic Marker,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2117,NCT01086683,psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF),self-efficacy as measured with the General Self-Efficacy Scale (GSE),,2004-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2118,NCT00624260,Percentage of patients with a non removable recurrence,Cost of the strategy,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2119,NCT04920955,Specificity for relapse detection,Sensitivity for CRC detection,,2021-02-10,COMPLETED,OBSERVATIONAL,['NA']
2120,NCT04202523,DFS,OS,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2121,NCT00126256,"Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up",Costs,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2122,NCT01398449,Overall survival,Failure pattern,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
2123,NCT00002475,Survival (patients without evaluable disease),,,1991-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2124,NCT03694522,Progression-Free Survival (PFS),Number of Participants With Treatment-emergent Adverse Events (TEAEs),,2018-09-14,COMPLETED,INTERVENTIONAL,['PHASE2']
2125,NCT04780802,The change in the perfusion pattern of HCC tumors,Tumor response,,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
2126,NCT02871115,Rates of study enrollment,Rates Of Appropriate Influenza Vaccinations,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
2127,NCT05412589,ORR,TRAE,,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2']
2128,NCT03794440,Progression-free survival (PFS),EORTC QLQ-HCC18,,2019-02-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2129,NCT00052507,,,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2130,NCT02024217,R0 resection rate,safety and tolerability of the treatment regimen,over-all survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2131,NCT05234177,Recurrence-Free Survival,Positive Predictive Value,Lead Time,2022-06-21,RECRUITING,OBSERVATIONAL,['NA']
2132,NCT03332433,Incidence of hypoxia,Other adverse events,,2017-11-10,COMPLETED,INTERVENTIONAL,['NA']
2133,NCT04193696,Objective response rate,Abscopal effects rate,,2020-01-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2134,NCT02159898,Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment,GERD-HRQL,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
2135,NCT03988556,Rate of discontinuation due to AEs,Oral mucosa lesions assessment - Time until resolution,Use of the device - Cumulative dose,2019-07-04,COMPLETED,INTERVENTIONAL,['NA']
2136,NCT01322178,Resection rate (R0),Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
2137,NCT00068380,"Baseline Gene Expression Levels of the Target Genes (PDGF-R and PDGF), Genes Associated With Induction of Apoptosis (Bcl-2, Bax), and Cell Cycle Regulatory Genes (p53, p21, p27",,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2138,NCT01943786,To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA,Number of each adverse event per cycle,,2013-04,UNKNOWN,OBSERVATIONAL,['NA']
2139,NCT02344810,Progression-free survival (Phase II),Evaluation of MET amplification and MET expression as determined by DAKO IHC (Phase II),,2015-03-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2140,NCT02981524,Objective Response Rate (ORR),Duration of Response (DOR),,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE2']
2141,NCT00002716,Time to progression,,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2142,NCT00589030,,,,2007-04,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
2143,NCT00614653,"Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation",Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2144,NCT00508443,Patient Response (Pain Relief),,,2002-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2145,NCT02964455,Maximum tolerated dose,Dynamic plasma concentration of docetaxel and nedaplatin,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2146,NCT02449135,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
2147,NCT05451849,Phase 2 - Disease Control Rate (DCR),,,2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2148,NCT01909856,Complete Response(CR) within 24-120 hours after chemotherapy,Incidence of Adverse events,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2149,NCT00154531,,,,2004-08,UNKNOWN,OBSERVATIONAL,['NA']
2150,NCT04121273,Number of patient with dose limiting toxicity,Number of Peripheral CAR-T cell,,2019-10-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
2151,NCT05352165,Pathologic Complete Response,anus-saving rate,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2152,NCT01955837,Overall Survival（OS）,Progression-free Survival (PFS) (Mutant Type KRAS),,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2153,NCT00025168,,,,2001-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2154,NCT00971841,Number of Adverse Events (AEs) Per Participant,Number of Participants With Complete Response to Tumor,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2155,NCT02774447,Number of patients who were able to return home after day-case closure of loop-ileostomy,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
2156,NCT04262609,faecal incontinence after prostate radiation therapy,Quality of life after prostate radiation therapy,,2019-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2157,NCT05672524,Clinical complete response of study participants,,,2022-12-30,RECRUITING,INTERVENTIONAL,['PHASE2']
2158,NCT04693754,"Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever)",,,2020-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2159,NCT00602602,Progression-free survival,Percentage of potentially resectable patients who are able to proceed to successful resection,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2160,NCT04104074,Incidence of treatment-emergent adverse events,Overall Survival (OS),,2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE1']
2161,NCT00819780,Progression-free Survival (PFS),Number of Participants With Adverse Events (AEs),,2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
2162,NCT03375281,1 year local tumor progression,,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
2163,NCT03156777,Number of circulating tumor cell (CTC),Overall survival,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
2164,NCT00699881,time to progression,toxicity,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2165,NCT02852525,Sensitivity and Specificity of probe based endomicroscopy as compared to histopathology in diagnosing Barrett's metaplasia,Tissue and blood Biomarker evaluation in targeted biopsies obtained at endomicroscopy in patients diagnosed to have Barrett's metaplasia and dysplasia,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
2166,NCT01318447,Local recurrence-free survival,Local recurrence-free survival,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2167,NCT01003808,"To evaluate the maximum tolerated dose, dose-limiting toxicities, type/frequency/degree of adverse events and NY-ESO-1 antigen-specific immune response of IMF-001 alone in patients with esophageal cancer.",To evaluate clinical activity (tumor response and time to progression).,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2168,NCT03413436,overall survival,toxicities of adjuvant chemotherapy,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE4']
2169,NCT01416688,Psychometric properties of the FACT-EGFRI 18,"Feasibility as measured by accrual, time to specified accrual, time to complete forms",,2011-11-15,COMPLETED,OBSERVATIONAL,['NA']
2170,NCT05727852,Indicators of arterial stiffness,Composite of clinical records,,2023-01-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2171,NCT05092373,"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).","To assess the objective response rate, progression-free survival and overall survival",,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE1']
2172,NCT01178801,the relationship between the clinical data and the decision of treatment strategies,,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
2173,NCT01790633,Accessibility of Testing Results,Access to Care,Proportion of Rapid Test Failures,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2174,NCT03147768,PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss,SECONDARY SAFETY: Surgical space abscess,SECONDARY EFFICACY: Total hospital stay (Duration and cost Metric ),2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2175,NCT01434147,occurence of toxicity,post-surgery morbidity,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2176,NCT04780256,recurrence rate,costs,,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA']
2177,NCT03444051,pancreatic mass anatomopathological characterization,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
2178,NCT03255343,size of tumor,HPFS,,2017-03-13,UNKNOWN,INTERVENTIONAL,['NA']
2179,NCT01869088,Overall survival time,Tumor response,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2180,NCT01374425,PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels,Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2181,NCT00422877,Response Rate,Survival,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2182,NCT05215574,Incidence of Adverse Events,Number of Patients with Objective Responses,,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
2183,NCT03415919,confirmation of diagnosis by pathologist,,,2018-07-13,UNKNOWN,OBSERVATIONAL,['NA']
2184,NCT04129177,Surgical site infection rate,,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
2185,NCT05379985,Number of Participants with Dose-Limiting Toxicity (DLT),Progression-Free Survival (PFS),,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE1']
2186,NCT00040599,,,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2187,NCT01516489,FOBT completion and return,FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2188,NCT06034964,OS,Safety and Tolerability,,2020-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2189,NCT04992143,1-year survival rate,Disease control rate,,2021-08-20,RECRUITING,INTERVENTIONAL,['PHASE2']
2190,NCT06308328,The AUC of the predictive model,The important predictors of severe oropharyngeal mucositis in the predictive model,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
2191,NCT01444495,local and systemic recurrence rate,downstaging of rectal cancer,,1999-01,COMPLETED,INTERVENTIONAL,['NA']
2192,NCT03279289,Progression-free survival,VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration,Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2']
2193,NCT00004931,DFS rate,Survival rate,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2194,NCT04941300,Colonoscopy after abnormal FIT (primary),Follow-up process,Repeat screening (exploratory outcome),2021-06-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
2195,NCT03928652,Tumor regression grade,Overall survival,,2019-04-24,UNKNOWN,OBSERVATIONAL,['NA']
2196,NCT06201065,Overall Survival (OS),Adverse Events,,2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE3']
2197,NCT03190941,Frequency and severity of treatment-related adverse events,,,2017-09-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2198,NCT02242786,oral morphine equivalent doseresponse criteria,Quality of Life,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
2199,NCT05448677,Progression-Free Survival (PFS),Objective response rate (ORR),,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
2200,NCT02213497,Number of Adverse Events,,,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2201,NCT03192618,Disease-free survival (DFS),Overall survival (OS),,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
2202,NCT01739465,stent patency,overall survival rate,,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2203,NCT01217060,Pathologic Complete Response (PCR) Rate,Disease-free Survival (DFS) Time,,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2204,NCT04602026,Health-related quality of life (composite measure),,,2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2205,NCT05154474,Rate of patients with sarcopenia diagnosed with metastatic cancer.,Rate of patients with sarcopenia at diagnosis across the inclusive population,,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2206,NCT02962063,pathologic complete response rate,overall survival (OS),,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2207,NCT01192971,TTP (Time to Progression),QoL (quality of life): EORTC QLQ-C30,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2208,NCT05704192,Overall Survival(OS),Progression free survival(PFS) per mRECIST,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA']
2209,NCT01418729,Overall survival,time to symptomatic progression (TTSP).,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2210,NCT02840331,Peritoneal metastases in terms of location,Histological evidence of apoptosis,,2017-07-31,UNKNOWN,INTERVENTIONAL,['PHASE3']
2211,NCT00510692,Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.,Number of Subjects With Adverse Events.,,2006-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2212,NCT03577535,Oral mucositis grade in patients during chemotherapy and radiotherapy treatments,Nutritional status of the patients during Chemotherapy and radiotherapy treatments,,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2213,NCT00158886,To determine the MTD of oral topotecan in combination with pelvic radiation,To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.,,2001-11-08,TERMINATED,INTERVENTIONAL,['PHASE1']
2214,NCT01560533,Body representations,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
2215,NCT01141478,Overall Survival Rate Between Time of Consent and Time of Death,,,2010-09-08,TERMINATED,INTERVENTIONAL,['NA']
2216,NCT04522908,Treatment discontinuation rate due to treatment-related adverse events,"Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR)",,2020-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2217,NCT00284258,Progression free survival,"Over all survival, Response rate, Adverse event, Medical economy",,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2218,NCT02524925,"Analyzing Neuropeptide Y, Cortisol and Adrenocorticotropic hormones levels in blood samples",Evaluating postoperative pain between the two protocols with scale,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2219,NCT02580422,"The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests",Change in levels of cytokines,,2015-10-01,TERMINATED,OBSERVATIONAL,['NA']
2220,NCT02426034,"Safety, which was assessed by recording the incidence and severity of adverse events","Quality of life, measured by the questionnaire of EORTC QLQ-C30",,2015-05-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2221,NCT04280640,Correlation between treatment response in CTCs and in vivo,"Sensitivity, specificity, and predictive values of CTC cultures' treatment response",,2021-06,WITHDRAWN,OBSERVATIONAL,['NA']
2222,NCT03107650,Evaluation of the circumferential margin status in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin),Survival,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
2223,NCT04729855,HOTTIP gene expression,EIF4EBP,,2022-04-15,UNKNOWN,OBSERVATIONAL,['NA']
2224,NCT03753789,Percentage of Lesions Where Re-ablation is Suggested,Hospital Resource Utilization,,2019-11-05,TERMINATED,INTERVENTIONAL,['NA']
2225,NCT04755452,Surgical rating scale,"Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin",,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
2226,NCT05039060,The change of gut microbiota diversity,The change of gut microbiota metabolite,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
2227,NCT01868139,Response Rate to Therapy,Safety of Spray Cryotherapy in This Setting;,,2013-06,TERMINATED,INTERVENTIONAL,['NA']
2228,NCT00025246,Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls,"Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria",,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2229,NCT00470184,Complete Response,Quality of Life Improved Rate,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2230,NCT04717947,Quality of the specimen,,,2020-02-25,UNKNOWN,OBSERVATIONAL,['NA']
2231,NCT02538341,GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks,Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI),,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2232,NCT00336856,Response Rate (RR),Overall Survival,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2233,NCT05607186,Correlation between mrTRG and pTRG,Prognostic value of mrTRG on survival outcomes of rectal cancer patients,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
2234,NCT06003673,recurrence-free survival (RFS),Overall Survival (OS),,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2235,NCT01289821,Objective Response (OR),Duration of Stable Disease (DOSD),,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2236,NCT00004087,maximum tolerated dose,,,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2237,NCT05109130,Change of circulating tumor cells during laparoscopic or transanal endoscopic surgery,Disease free survival,,2021-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2238,NCT06335654,high confidence diagnosis rate,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2239,NCT02698462,Diagnostic yield,Positive predictive value,Comparison of diagnostic yield in detecting advanced neoplasia of FIT with the national CRC screening yield,2016-04,COMPLETED,INTERVENTIONAL,['NA']
2240,NCT01046487,For safety: NCI-CTCAE scale version 3.0,For anti tumoral efficiency : RECIST criteria,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2241,NCT00003307,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2242,NCT03852238,exposure to Viral hepatitis B,exposure to viral hepatitis C,fats,2010-08-18,COMPLETED,OBSERVATIONAL,['NA']
2243,NCT01313416,"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)",Disease Response: Evaluated Using the Revised Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines (v1.1),,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2']
2244,NCT01333709,Ro resection rate,Incidence of metastases,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2245,NCT00741481,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
2246,NCT00453323,To evaluate the response rate,To estimate the overall survival,,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2247,NCT03013153,5-years overall survival rate,Sexual function scoring,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
2248,NCT05984576,Local control,,,2023-06-21,RECRUITING,OBSERVATIONAL,['NA']
2249,NCT05646355,Number of Participants who Completed Colonoscopy at 6 Months,Number of Participants with Positive FIT Test who Complete Colonoscopy at 6 Months,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
2250,NCT03978078,Number of biological risk factors for metastatic digestive cancer,,,2016-09-12,RECRUITING,INTERVENTIONAL,['NA']
2251,NCT05964543,Objective response rate (ORR),Progression-free survival (PFS),,2023-06-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2252,NCT05873972,response rate,overall survival,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2253,NCT04694521,intestinal function,the overall postoperative morbidities,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
2254,NCT02802124,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Number of participants with tumor response as assessed by RECIST 1.1,,2015-06,TERMINATED,INTERVENTIONAL,['NA']
2255,NCT02514525,percentage of all treated patients who have complete eradication of all dysplasia (CE-D),Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
2256,NCT02728219,overall survival,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
2257,NCT04924075,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR),Time to Surgery (TTS),,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2']
2258,NCT02325232,Identification of celiac patients at higher risk of developing small bowel neoplasia and evaluation of the the usefulness of VCE and DBE,The diagnostic yeld of DBE and VCE in this setting of patients,A flowchart for early diagnosis of small bowel tumors in CD patients,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
2259,NCT01031628,Evaluation of Lesions for Progression or Response Via RECIST Criteria,,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
2260,NCT00003076,,,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2261,NCT00515931,Target tumor response rate,Adverse effects of radiation therapy,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2262,NCT00350142,Rate of Local Control,Median Overall Survival Time,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2263,NCT04898426,Bowel preparation quality,Polyp detection rate,,2021-08-13,UNKNOWN,INTERVENTIONAL,['NA']
2264,NCT04360577,Total AUC of FACT-Gastric TOI,Average trajectory of Modified Edmonton Symptom Assessment Scale,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2020-05-27,RECRUITING,INTERVENTIONAL,['NA']
2265,NCT04401787,oncological outcome,early locoregional recurrence,,2016-12-11,COMPLETED,INTERVENTIONAL,['NA']
2266,NCT03174405,Progression Free Survival Rate (PFS) @ 12 months,Translational research,,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE2']
2267,NCT01763125,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,,,2003-11,RECRUITING,OBSERVATIONAL,['NA']
2268,NCT03659292,Overall survival (OS),Blood levels of ropivacaine and sufentanil,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
2269,NCT05568316,Biochemical Measurements,Lenght of Hospital Stay of Participants,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
2270,NCT03116152,Overall Survival,Duration of Response,,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2271,NCT04585919,Conditional Odds Ratio of Patients Screened for Social Needs During Intervention Compared to Patients Screened During Usual Care,Number of Reminders Per FIT Return,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
2272,NCT04535492,"Rate of successful completion of colorectal cancer screening noted via electronic health record having colonoscopy, fecal occult blood, or non invasive screening option result for the patient.",Average score of clinician experience and satisfaction as assessed via Likert scale survey.,,2022-01-04,WITHDRAWN,INTERVENTIONAL,['NA']
2273,NCT05059665,Evaluate the performance (sensitivity/specificity) of the HelioLiver Test for all stage HCCs,,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
2274,NCT04053231,Overall Survival,Number of redo-surgery,,2019-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2275,NCT02316028,toxicity of escalating doses of decitabine administered by HAI,measuring Global DNA methylation of cell free DNA,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2276,NCT01939223,Disease Free Survival (DFS) as Assessed by the Investigator,Overall Survival (OS),,2013-12-02,TERMINATED,INTERVENTIONAL,['PHASE3']
2277,NCT05035381,Objective response rate,Adverse Events,,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2278,NCT05174845,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Sub-analyzes of the primary and secondary outcomes,,2021-10-01,COMPLETED,OBSERVATIONAL,['NA']
2279,NCT00179751,"Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.",Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.,,2005-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2280,NCT05662813,Objective response rate,Overall survival,,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
2281,NCT06190652,PFS,RP,,2018-10-13,COMPLETED,OBSERVATIONAL,['NA']
2282,NCT03977272,Overall survival,EORTC QLQ - PAN26 score,,2019-03-27,COMPLETED,INTERVENTIONAL,['PHASE2']
2283,NCT04178759,Volume of regenerated liver after liver resection,Evaluation of short term surgical outcomes,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
2284,NCT01248299,Overall survival,Cost analysis,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2285,NCT05634525,Overall survival (OS),,,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1']
2286,NCT05176834,Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.,The proportion of the patients that will experience severe oral mucositis,,2022-01-31,UNKNOWN,INTERVENTIONAL,['NA']
2287,NCT02916511,Local control rate,overall survival,,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2288,NCT03275974,Change in tumor size,Overall survival,,2021-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2289,NCT01189227,Recurrence-free Survival (RFS),Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE3']
2290,NCT01054274,Overall survival and Median Survival,Successful rate of stent placement,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2291,NCT04288661,POD of intra-abdominal complication detection,Readmissions,,2020-02-28,RECRUITING,INTERVENTIONAL,['NA']
2292,NCT01590147,"Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)","Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
2293,NCT01930383,Numbers of circulating tumor cells,Clinical characteristics,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
2294,NCT02535988,The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.,"The proportion of patients alive with abscopal responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2295,NCT00513461,Change in Serum AFP Levels,Changes in Quality of Life - Mental Score,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2296,NCT01804179,Rate of Test Kit Completion,Time to Kit Return,,2011-02-11,COMPLETED,INTERVENTIONAL,['NA']
2297,NCT00069121,Disease-Free Survival (DFS) [Time to Event],Number of Participants With at Least One Adverse Event by Most Severe Intensity,,2003-04-18,COMPLETED,INTERVENTIONAL,['PHASE3']
2298,NCT00168987,improvement of quality of life at two months,"improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2299,NCT06328738,Incidence of electrocardiogram abnormalities,Brain metastases response (Phase 1b only),,2024-06-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2300,NCT02009423,Recurrence Free Survival (RFS),Overall Survival (OS),,2015-07,TERMINATED,INTERVENTIONAL,['PHASE3']
2301,NCT04523493,Overall survival (OS),Immunogenicity,Tumor mutation burden (TMB),2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2302,NCT03093870,Progression-free Survival (PFS) - Part 1,ECOG Performance Status - Part 1,,2017-07-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2303,NCT01839773,Progression Free Survival (PFS),Safety,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2304,NCT01097265,Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2),Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2),,2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2305,NCT04168931,Frequency of HER2 expression,,,2020-01-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2306,NCT03197155,Hepatocellular recurrence event,,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
2307,NCT04430179,Change in Lund-Mackay sinus computed tomography (LMK-CT) score,Change in biomarkers concentrations in nasal secretion measured by enzyme-linked immunosorbent assay (ELISA),,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2']
2308,NCT04517448,Change in the response scores to the standardized questionnaire Quality of life questionnaire in cancer patient,Change in the Activity of daily living score,,2020-10-16,UNKNOWN,OBSERVATIONAL,['NA']
2309,NCT02515344,Patient participation rate to colorectal cancer screening,Number of cancers screened in (versus diagnosed outside) the screening procedure.,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2310,NCT01434069,Maximum Tolerated Dose (MTD),Number of Participants With Tumor Response,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2311,NCT04131062,MyCode enrollment decision,,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
2312,NCT05771584,Immunologic efficacy of AST-301 immunization,Change in central memory T-cell populations between Arm 1 and Arm 2,,2023-07-04,RECRUITING,INTERVENTIONAL,['PHASE2']
2313,NCT05116917,Objective response rate (ORR),Treatment-related adverse events as assessed by CTCAE v5.0,,2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2314,NCT01652833,Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
2315,NCT00087074,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",Time to treatment failure,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2316,NCT00183885,Tumor Response,Number of participants with grade 3 or higher toxicity,,2004-10-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
2317,NCT01086618,Overall survival for ≥ 2 years (phase III),Economic evaluation (phase III),,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2318,NCT05262855,"Performance [sensitivity, specificity, accuracy] of [68Ga]FAPI-46 PET imaging to detect FAP-expressing cells, using histopathology as truth standard.",[68Ga]FAPI-46 accumulation observed by (PET)/ (CT) pre and post in patients undergoing Neoadjuvant treatment.,,2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2']
2319,NCT05220722,Phase 2: To Assess Overall Response Rate (ORR),Phase 2: To Assess Overall Survival (OS),,2022-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2320,NCT03259828,Interfraction sigmoid colon organ motion,Setup errors,,2017-12-06,COMPLETED,INTERVENTIONAL,['NA']
2321,NCT05861505,Overall survival (OS) per patient,Cost-effectiveness ratio (ICER),,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE3']
2322,NCT00598546,"Instrument: EORTC QLQ-C30, QLQ-STO22, and MSK-10. The intent of this study is to assess QOL in long-term survivors of all surgical procedures performed for the treatment of gastric cancer.",,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
2323,NCT00002783,,,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2324,NCT03015675,Progression Free Survival,Response Rate,,2017-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2325,NCT03045770,Adverse Event（AE）,Quality of Life (QoL),,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA']
2326,NCT00795977,To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432,To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells,,2003-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2327,NCT00132704,apoptotic response,,,2004-08,COMPLETED,OBSERVATIONAL,['NA']
2328,NCT02850783,Identification rate of SLNM with preoperative PET/CT imaging and intraoperative NIR fluorescence imaging in patients with colon carcinoma.,,,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2329,NCT01774786,Overall Survival,Cmin of Trastuzumab,,2013-06-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2330,NCT06193356,Performance of detecting a recurrence at an endoscopic resection scar.,Performance of a learning tool in improving detection of recurrence at an endoscopic resection scar compared between endoscopists with different experience level,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2331,NCT06202716,Progression-free Survival (PFS),Safety,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2332,NCT03804255,"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand",Proportion of pathology practices testing for novel biomarkers using a standard reflexive testing protocol,,2019-01-08,WITHDRAWN,OBSERVATIONAL,['NA']
2333,NCT01416038,Number of reported adverse events,Levels of cell mediated immunity targeting the survivin epitopes,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2334,NCT02013089,Overall survival,Response rate,Disease control rate,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
2335,NCT01048892,Recommended phase II dose of Seneca Valley virus-001 (NTX-010),Development of antibodies to NTX-010,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2336,NCT00155272,The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.,The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.,,2005-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2337,NCT04387903,Tumor recurrence,Risk factors for surgical reoperation,,2000-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2338,NCT01008917,Maximum tolerated dose,"Incidence of progression-free survival, overall survival, and disease control rate",,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2339,NCT02507765,"Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures",Progression-free survival,Change in plateau signal intensity calculated from the DCE curve,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2340,NCT05103631,Number of Patients with Dose Limiting Toxicity,Median T cell persistence,,2021-06-17,RECRUITING,INTERVENTIONAL,['PHASE1']
2341,NCT00873600,"Chemotherapy tolerability as measured by dose reduction, treatment delay, and incidence of grade 3-5 toxicities",3-year disease-free survival,,2007-10,WITHDRAWN,OBSERVATIONAL,['NA']
2342,NCT04288999,Locally recurrent free survival,QOL,,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
2343,NCT03461354,AUC for the Oral Mucositis Daily Questionnaire mouth and throat soreness question #2,Oral mucositis grade,Drug-related adverse events,2018-04-09,RECRUITING,INTERVENTIONAL,['NA']
2344,NCT00343408,,,,2005-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
2345,NCT03110510,Overall Overall Response Rate,Overall survival,,2019-09-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2346,NCT03239184,Relief degree of tumors,Overall survival（OS）,,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2347,NCT05400408,identification of Volatile Organic Compounds that can be related to Colorectal malignancy.,Test Sensitivity and specificity for pancreatic cancer.,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2348,NCT05065515,Degree of tumor regression,The relative abundance of species,Species richness,2021-10-01,RECRUITING,OBSERVATIONAL,['NA']
2349,NCT01379872,"Synthesise the data obtained for objectives 1-3 together with information from previous studies and expert opinion to estimate the safety, clinical efficacy and cost-effectiveness of new technologies compared to conventional standards",,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
2350,NCT01774643,"Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)",,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2351,NCT00002575,Overall survival,Compare the differences in quality of life of patients treated with these regimens,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2352,NCT04546802,Viral eradication,Adverse events,Overall survival,2019-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2353,NCT04907643,Patient-Reported Outcomes Measurement Information System Gastrointestinal Belly Pain over 30 days from the baseline,Opioid prescriptions of Morphine Milligram Equivalents (MME),Dosage of VR (minutes per week),2021-10-05,RECRUITING,INTERVENTIONAL,['NA']
2354,NCT03193216,Percentage of Patients With Successful Eradication,Number of Treatments (Mean),,2017-08-25,COMPLETED,INTERVENTIONAL,['PHASE2']
2355,NCT00427570,,,,1977-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2356,NCT01112046,Short-term morbidity,Local recurrence,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
2357,NCT00550836,Overall Survival,Frequency and Severity of Observed Adverse Effects,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2358,NCT00138060,tumor response rate,pharmacokinetics,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2359,NCT01661972,Median Progression Free Survival (PFS),Median Survival,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2360,NCT01298999,Number of Participants That Experienced Change in Any Biomarker Expression,Number of Participants That Experienced Adverse Events,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2361,NCT05848154,Objective response rate (ORR) of neoadjuvant therapy in patients with non-metastatic pancreatic cancer,The mechanisms of drug resistance to neoadjuvant chemotherapy,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2362,NCT01376453,Maximum Tolerated Dose (MTD),Number of Participants With Serious Adverse Events (SAEs),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2363,NCT06019702,Dose-limiting Toxicity (DLT),Cytokines Level [immunogenicity],,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1']
2364,NCT05410535,The survival rate of gastric cancer,,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4']
2365,NCT04316182,Rate of AEs leading to treatment discontinuation,Rate of patients who develop new extra-hepatic spread,,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
2366,NCT05248750,Overall survival,,,2021-07-22,RECRUITING,OBSERVATIONAL,['NA']
2367,NCT00767936,identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer,,,2008-03,TERMINATED,OBSERVATIONAL,['NA']
2368,NCT05446558,Overall survival,Cost of tests during hospitalization,,2022-02-28,RECRUITING,INTERVENTIONAL,['NA']
2369,NCT02729493,Disease control rates,,,2015-11-14,UNKNOWN,INTERVENTIONAL,['NA']
2370,NCT04525807,Objective response rate,Overall survival,,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA']
2371,NCT02298959,Recommended combination dose of ziv-aflibercept and pembrolizumab,Time-to-progression,Effects on tumor vasculature and vascular active molecules,2015-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2372,NCT05380414,"Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.",Duration of response (DoR),,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
2373,NCT01675258,,,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
2374,NCT03896646,Tumor objective response rate (ORR),Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging,,2019-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2375,NCT05962723,"sensitivity, specificity and accuracy",,,2023-08-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2376,NCT02293811,Analysis of expression of P2RX7,Five isoforms of the P2RX7 protein,,2015-02-09,TERMINATED,INTERVENTIONAL,['NA']
2377,NCT01197118,overall survival,,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2378,NCT04410601,Evaluation of Dysphagia- Esophago-gastro-duodenoscopy (EGD),Evaluation of Standard Dysphagia Rehabilitation,,2020-05-14,UNKNOWN,INTERVENTIONAL,['NA']
2379,NCT00815087,The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months,Questionnaire of Life Quality,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2380,NCT03960021,Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET).,Change from baseline metastatic disease at 12 months,,2019-03-04,COMPLETED,INTERVENTIONAL,['NA']
2381,NCT01483040,The primary endpoint is reaching the cecum of the colon with PeerScope B S,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
2382,NCT06189482,Body Mass Index,Penetration-Aspiration Scale,,2022-06-01,TERMINATED,INTERVENTIONAL,['NA']
2383,NCT02150733,Composite of plasma pharmacokinetic parameters of Tivantinib,Composite of plasma pharmacokinetic parameters of Tivantinib metabolites,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2384,NCT06155383,Pathological complete response (pCR) rate,Adverse events,,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE2']
2385,NCT02368236,"Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).",Testing difference in receipt of any type of colorectal cancer testing.,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2386,NCT00828594,Time to disease progression assessed when 60 events have been observed,Pharmokinetics of RAD001 at pre-dose and 1 hour and 2 hours post-dose,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE1']
2387,NCT05074589,Overall Survival(OS),Quality of life（QoL）,,2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3']
2388,NCT01771146,Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer,• R0 resection as defined as microscopically negative margins,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
2389,NCT00147134,Overall survival,The proportion of completion of LAP,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2390,NCT02908451,Adverse events (AEs) graded according to CTCAE v4.03.,Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST),,2017-04-24,TERMINATED,INTERVENTIONAL,['PHASE1']
2391,NCT03641313,Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria,Overall survival (OS),Presence of other deoxyribonucleic acid (DNA) damage response defects (DDRD),2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2392,NCT01085617,Event-free survival,Mucositis score in patients treated with palifermin,,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2393,NCT03393416,Incidence of Treatment-Emergent Adverse Events（Safety）,,,2018-04-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
2394,NCT00005050,,,,1999-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2395,NCT02503111,Anal dysplasia treatment on a per-patient basis,Acceptability of treatment,,2015-11,TERMINATED,INTERVENTIONAL,['NA']
2396,NCT02845479,Feasibility of study protocol,Feasibility of recruitment,Natural kill cell activation,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2397,NCT05723718,Tumor Regression Grade,Quality of Life score,,2022-12-20,RECRUITING,OBSERVATIONAL,['NA']
2398,NCT00897403,Collection of blood and tissue,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
2399,NCT00491855,Maximum Tolerated Dose (MTD),,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2400,NCT03400072,M6 Health-Related quality of life (HRQoL),,,2018-08-03,RECRUITING,INTERVENTIONAL,['NA']
2401,NCT02024438,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,quality of life,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2402,NCT01468688,Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy,"Clinical benefit rate (CBR) defined as the rate of confirmed complete response (CR) or partial response (PR), or stable disease (SD) which lasts for at least 16 weeks.",,2012-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
2403,NCT01830270,curative resection rate,global survival,,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2']
2404,NCT04067960,"Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing",Provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients,,2019-06-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2405,NCT03286244,Percentage of patients who suffer at least one adverse event,Progression-free survival,,2018-03-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
2406,NCT05564338,Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D,Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18,,2023-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2407,NCT01524094,Overall survival,Side effects of treatment,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2408,NCT03592641,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),Months of Progression-Free Survival (PFS),,2019-07-25,TERMINATED,INTERVENTIONAL,['PHASE2']
2409,NCT06045975,local recurrence-free survival,Safety of Durvalumab/Tremelimumab infusions,"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2410,NCT02450656,Progression Free Survival (Phase II),"Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)",Pharmacogenetics profiling to assess predictors of response and resistance- inducing mutations,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2411,NCT06116136,Objective Response Rate (ORR),Objective Response Rate (ORR),,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2412,NCT01352728,Two-year survival rate,Tissue and Serum Biomarkers,,2011-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
2413,NCT05361538,Comparison of progression-free survival between MSA and traditional MWA in HCC,Comparison of the complications rate of MSA and traditional MWA in HCC,,2022-06-22,RECRUITING,INTERVENTIONAL,['NA']
2414,NCT05128032,Radiotracer distribution,Technical success of radiotracer delivery as measured by ability to deliver radiotracer,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
2415,NCT00192088,The primary objective of this study is to determine the response rate of Pemetrexed plus oxaliplatin as first-line therapy in patients with advanced gastric carcinoma.,"Determinants of efficacy and toxicity of the treatment with pemetrexed and oxaliplatin in the patient population by means of pharmacogenomic and pharmacogenetics investigations: Quantitative analysis of TS, DHFR, GARFT, RFC, MRP5, DPD, TP, FPGS and ERCC1",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2416,NCT02877368,sarcopenia,Imatinib-induced toxicities,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
2417,NCT00041808,,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2418,NCT05422547,Tumour recurrence,Possible economic impact,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
2419,NCT02348229,Compartition of postoperative hospital stay,Change from baseline in C-Reactive Protein( CRP) and visceral proteins level,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
2420,NCT01373164,Phase 2: Overall Survival (OS),Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2421,NCT01274624,Pharmacokinetic parameters for irinotecan and 5-FU when combined with REOLYSIN®,"In vitro studies in human-derived colorectal cancer cells including the isogenic cell lines, to study the mechanism and scientific basis of synergy between irinotecan and reovirus",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2422,NCT05681234,Evaluation of tissue distribution of 18F-RD2,,,2022-08-24,COMPLETED,INTERVENTIONAL,['NA']
2423,NCT03981510,Children with NF1 and gastrointestinal symptoms has a longer transit time through the colon and fewer fast bowel movements than healthy children.,,,2019-06-13,UNKNOWN,INTERVENTIONAL,['NA']
2424,NCT02911974,The total area of procured tissue between the FNA and FNB needles,Diagnostic adequacy between the FNA and FNB needles,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
2425,NCT05530343,Diagnostic yield of intestinal metaplasia (Screening population only),Diagnostic yield of dysplasia (Screening population only),,2022-10-03,RECRUITING,INTERVENTIONAL,['NA']
2426,NCT01266564,Progression-free survival in a real life setting assessed by computer tomography,Safety: incidence of adverse events,,2010-09-03,COMPLETED,OBSERVATIONAL,['NA']
2427,NCT00121745,To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G,To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE1']
2428,NCT05379790,Maximum-tolerated dose,Area Under the Curve (AUC) ratio intraperitoneal/systemic irinotecan,,2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1']
2429,NCT01381913,,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
2430,NCT03871790,Identification of tumor specific mutations on the genomic level,Identification of neo-antigens epitopes at protein level,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
2431,NCT00364078,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
2432,NCT00027495,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2433,NCT05679674,Median Progression Free Survival (PFS),Chemotherapy-Free Interval,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
2434,NCT02994888,Track and validate specific known mechanisms of resistance/response to anti-EGFR therapies through,Identify novel biomarkers of resistance to anti-EGFR therapies through whole exome sequencing,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
2435,NCT05668910,The performance of each single feature and the ensemble model with integrated features for early GC detection in each clinical stage,"The performance of the ensemble model in combination of possible GC related biomarkers such as PG, G17, and/or Hp levels for early GC detection",,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
2436,NCT00262847,Progression-free Survival,Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI),,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2437,NCT05724992,Presence - absence of predisposing mutations,Correlation of genetic mutations with familial oncological history,,2022-12-20,RECRUITING,INTERVENTIONAL,['NA']
2438,NCT01630174,,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
2439,NCT00424827,"Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.",Toxicity Associated With This Regimen.,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2440,NCT03950908,Identification of signet ring cell carcinoma (SRCC) foci.,Dose of sedation.,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA']
2441,NCT01433016,PDR Peak,,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2442,NCT04988945,Downstaging for hepatectomy,Pathological response,,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2443,NCT04550897,Adverse Events related to BM7PE,Radiological response to BM7PE,,2020-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2444,NCT01171924,Number of Participants With Adverse Events,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2445,NCT03349398,the incidence of Roux stasis syndrome,the quility of life according to the RGB standards,,2017-11-10,UNKNOWN,INTERVENTIONAL,['NA']
2446,NCT06281145,Primary endpoint - Working memory,Secondary endpoint - Serious Adverse Events (SAE),,2024-03-15,RECRUITING,INTERVENTIONAL,['NA']
2447,NCT00695201,Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.,"To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels.",,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2448,NCT06087263,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2449,NCT03083951,Total number of lymph nodes and lymph node ratio.,Survival,Defecatory dysfunction assessed by FSFI and erectile dysfunction questionnaires,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
2450,NCT04347772,Length of hospital stay,Nutritional status - Dietary Intake,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
2451,NCT05817370,Change in HSIL treatment,Change in Maintenance of HSIL screening and treatment,,2023-05-02,RECRUITING,INTERVENTIONAL,['NA']
2452,NCT03002064,Progression free survival,Quality of life--Score of the questionnaire,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2453,NCT05948826,Recommended Phase 2 Dose (RP2D),Accumulation ratio (Rac) of TORL-3-600,,2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE1']
2454,NCT00971399,complete response of RINV (no vomiting and no rescue medication),,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2455,NCT05208047,Part 2 - Progression Free Survival (PFS),Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30),,2022-04-14,RECRUITING,INTERVENTIONAL,['PHASE3']
2456,NCT03904667,Operative outcomes,Postoperative survival,Disease-free survival,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2457,NCT02082886,Overall survival rate,Rates of complications,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2458,NCT03427684,Maximum tolerated dose AND Dose limited toxicity,2-year disease-free survival,,2016-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2459,NCT01950572,sample aquisition,,,2013-09-09,RECRUITING,OBSERVATIONAL,['NA']
2460,NCT05398380,Five years overall survival,Changes in quality of life assessed by EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30),Percentage of patients with circulating tumor DNA (ctDNA),2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
2461,NCT00888797,Rate of recurrent and metastatic cancer,Early postoperative morbidity and mortality,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2462,NCT03690323,Overall survival,Quality of Life questionnaire,,2015-04-07,UNKNOWN,INTERVENTIONAL,['NA']
2463,NCT02102022,Objective response rate (ORR),AFP (alpha feto-protein) changes,,2014-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2464,NCT01324141,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE),Number of Participants With Human Immunodeficiency Virus (HIV) in Biopsy Tissue From Rectal Mucosa,,2011-03-18,TERMINATED,INTERVENTIONAL,['PHASE1']
2465,NCT03671252,3-year disease free survival rate,Long term quality of life,,2018-11-16,RECRUITING,INTERVENTIONAL,['PHASE3']
2466,NCT06266871,pCR rate,2-year OS rate,,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2467,NCT04258072,Progression-Free Survival (PFS),,,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
2468,NCT01669044,Cardiac output,Stroke Volume,Systemic Venous Resistance Index,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
2469,NCT03663062,Risk model of colorectal adenomas and CRC,The incidence of colorectal adenomas or CRC in patients who are smokers or who have high alcohol intake,,2017-12-27,COMPLETED,OBSERVATIONAL,['NA']
2470,NCT01529827,Transplant Related Mortality (TRM),Median Time to Neutrophil Engraftment,,2012-02-28,COMPLETED,INTERVENTIONAL,['PHASE2']
2471,NCT02598687,Dose Limiting Toxicity (DLT ),metabolic response,,2015-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2472,NCT00125034,Best Overall Response Rate - Independent Review Committee (IRC),Safety - Number of Patients Experiencing Any Adverse Event,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2473,NCT01347333,Local Tumor Recurrence Rate,Late Complication Rates,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
2474,NCT01310478,Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6,Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
2475,NCT03730675,Overall survival,"Treatment Safety in terms of type, incidence, severity timing, seriousness, and relatedness of adverse events and laboratory abnormalities",,2018-11-10,UNKNOWN,INTERVENTIONAL,['NA']
2476,NCT01770275,Overall survival,Survival distinction,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
2477,NCT06284746,Objective Response Rate（ORR）,The incidence of adverse events during treatment,,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2478,NCT04744831,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer,Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd,,2021-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2479,NCT04294784,objective response rate(ORR),patient-reported outcomes (PROs),,2020-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2480,NCT02864849,Major adverse events,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29),,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2481,NCT03931304,Evaluation of 3-years disease free survival,,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
2482,NCT04724239,The progression-free survival (PFS) rates at 18 weeks,Duration of response (DoR),,2021-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2483,NCT05385900,"Pathological complete response, pCR","major pathologic response, MPR",,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2484,NCT03723915,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers,,2018-11-14,TERMINATED,INTERVENTIONAL,['PHASE2']
2485,NCT01123876,Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors,"To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2486,NCT01749722,Number of adverse events,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
2487,NCT05630937,Objective Response Rate (ORR) (Phase II),Overall survival (OS),,2020-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2488,NCT03597204,"Number of subjects diagnosed colonic adenoma, advanced adenoma or cancer",,,2015-10-07,COMPLETED,INTERVENTIONAL,['NA']
2489,NCT05578820,Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine),,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2490,NCT01651832,proportion of eligible patients undergoing adjuvant chemo therapy,Quality of inpatient care,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
2491,NCT04487717,Prognostic group's 5-yr Overall Survival(OS) rate,Subgroup analysis,,2020-07-29,RECRUITING,OBSERVATIONAL,['NA']
2492,NCT05391321,"Preference ranking of 4 validated sexual QOL questionnaires in French, FSFI, PISQ-IR, PISQ-12, BISF assessed on the collection of questionnaire returns by patients",,,2023-05-12,RECRUITING,INTERVENTIONAL,['NA']
2493,NCT02371135,"association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)",,,2015-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2494,NCT03207724,"Maximum Tolerated Dose (MTD) of onivyde, 5-fluorouracil/folinic acid in combination with Xilonix",Mean change in global score of patient-reported response to therapy (FAACT questionnaire- Functional Assessment of Anorexia/Cachexia Therapy),,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
2495,NCT04425876,R0 resection rate,Minimum concentration (Cmin),,2020-12-17,UNKNOWN,INTERVENTIONAL,['PHASE1']
2496,NCT00921661,Dose-limiting toxicity (DLT) combination with FOLFIRI,Immunogenicity,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2497,NCT04170257,"Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus",Discrimination of visualized abnormal features,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
2498,NCT04822103,Feasibility of immunochemotherapy defined as at least 80% of the patients completed all planned courses,Major pathological response,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
2499,NCT05157451,Feasibility of enrollment (enrollment rate),Time to next treatment,,2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2500,NCT04844385,progression-free survival rate,Quality of life assessed by QLQ-C30,,2021-02-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2501,NCT03841110,The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.,Duration of FT500 persistence,,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE1']
2502,NCT03974542,rescreening of CRC,,,2019-10,UNKNOWN,INTERVENTIONAL,['NA']
2503,NCT04443322,Recurrence-Free Survival (RFS),Percentage of Participants who Experience an Adverse Event (AE),,2020-09-19,RECRUITING,INTERVENTIONAL,['NA']
2504,NCT00949312,Disease-free survival (time to local or distant recurrence after resection),Overall survival (time to death from colorectal cancer),,2009-05,UNKNOWN,OBSERVATIONAL,['NA']
2505,NCT04134897,2-year local recurrence rate,Preoperative tumor-associated complications rate,,2019-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
2506,NCT03517488,Determine the safety and tolerability profile of XmAb20717,,,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2507,NCT03744624,Operative time,Mortality,,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2508,NCT00193128,"Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery",Overall Survival (OS),,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2509,NCT04394585,Eating restriction score (XEatR) at 3 months postoperatively,seum hemoglobin,,2020-04-20,RECRUITING,INTERVENTIONAL,['NA']
2510,NCT03492151,Accuracy of risk-stratification of IPMNs,Imaging quality,,2018-10-01,RECRUITING,OBSERVATIONAL,['NA']
2511,NCT02613260,Completion of FIT- one year,Cost,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
2512,NCT00769405,Overall survival,"Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2513,NCT06029010,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥5 months","Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥4 months",,2023-08-31,COMPLETED,OBSERVATIONAL,['NA']
2514,NCT01210235,Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
2515,NCT02576509,Overall Survival (OS),Efficacy Based on PD-L1 Expression - ORR,,2015-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2516,NCT04017455,clinical complete and near-complete response rate,local recurrence rate at 1 year follow-up,,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE2']
2517,NCT03493763,Time of hepatocellular carcinoma recurrence,Adverse effect of 5hmC blood test,,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA']
2518,NCT01944137,Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,"Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline",,2013-09,COMPLETED,INTERVENTIONAL,['NA']
2519,NCT00030862,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2520,NCT06239155,Progress free survival (PFS),,,2019-09-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2521,NCT02392143,Colorectal Cancer Screening,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2522,NCT04031625,Patient survival,Collection of patient and treatment characteristics,,2012-11-26,UNKNOWN,OBSERVATIONAL,['NA']
2523,NCT02465112,relapse-free survival (RFS),Impact of the therapy on 5-year RFS in treatment and control group,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE3']
2524,NCT00897429,Cancer-specific mortality (B6),Evaluation of up to 768 new genes for their relationship with colon cancer recurrence (B4,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
2525,NCT05511116,Inter-observer reproducibility,Tumor response on morphological imaging vs. tumor response grade on pathology,,2022-07-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2526,NCT00534131,Oncological safety assessment - where appropriate,,,2004-04-01,COMPLETED,INTERVENTIONAL,['NA']
2527,NCT03416699,The grade score of the specimens integrity,the grade of anastomotic leakage,,2017-11-15,UNKNOWN,OBSERVATIONAL,['NA']
2528,NCT02028845,The cannulation success rate,"The duration of the cannulation, immediate and late complications.",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2529,NCT02402699,Identify and describe observed adverse events (AEs) based on liver function abnormalities and changes in hepatitis viral load,,,2015-12-15,COMPLETED,OBSERVATIONAL,['NA']
2530,NCT03439462,"Progression-free Survival at 6 Months (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)","Overall Response Rate (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)",,2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2531,NCT02035072,Proportion of resectable patients,Progression free survival (PFS/local PFS),,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2532,NCT00155727,,,,2000-01,UNKNOWN,OBSERVATIONAL,['NA']
2533,NCT02301481,R0 resection rate,Overall survival,Comparison of dosimetric differences between radiation techniques,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2534,NCT05604560,Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response,Disease Free Survival (DFS),,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2535,NCT03158779,Overall survival,Progression free-survival of treated patients,,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2536,NCT05897138,Objective response rate (ORR),Overall survival(OS),,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2537,NCT01351194,overall survival,disease-free survival,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
2538,NCT00632333,Safety(toxicities as assessed by NCI CTCAE version3),survival,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
2539,NCT05178524,Species composition and differential analysis of gut microbiota,,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
2540,NCT02400996,Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
2541,NCT04713332,Matrix metalloproteinases(MMPs),,,2019-07-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
2542,NCT02442583,Change in number of minutes per day of bouts of sedentary behaviors.,"Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors",,2015-05,COMPLETED,INTERVENTIONAL,['NA']
2543,NCT05431530,Frequency of major LARS after surgery,EOTC QLQ-C30,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA']
2544,NCT00721916,Progression free survival (PFS),Safety,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2545,NCT00474097,"to assess if follow-up telephone calls after surgery affects patient satisfaction, surgical outcomes and quality of life in the early post-operative phase after colorectal surgery","to track readmissions, complications and emergency room visits via telephone calls to ensure communication between the patients and the surgical office is optimal.",,2006-02,COMPLETED,OBSERVATIONAL,['NA']
2546,NCT05281783,The efficacy,Incidence of Treatment-Emergent Adverse Events [Safety],,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
2547,NCT00096967,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2548,NCT04462354,Postoperative pancreatic fistula rate (PPF),Other complications.,,2020-06-04,UNKNOWN,INTERVENTIONAL,['NA']
2549,NCT00005870,,,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
2550,NCT01005225,Solid tumor biological insights,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
2551,NCT06157216,3-year Disease-Free Survival (DFS) rate,3-year Overall Survival (OS) Rate,Association between prognosis with multi-omic sequences,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
2552,NCT01236989,the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival,the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
2553,NCT06184698,Objective Response Rate,Incidence of adverse events,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2554,NCT01401699,Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening,,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
2555,NCT02538562,Incidence of HER2 positivity among gastric and gastroesophageal junction tumor samples,Correlation between HER2 status and gender,,2011-10-11,COMPLETED,OBSERVATIONAL,['NA']
2556,NCT04780529,Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ],Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria,,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2557,NCT04140318,ORR,OS,,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
2558,NCT05447923,Colorectal cancer disparities seen in people of color and minority populations,,,2022-05-22,RECRUITING,INTERVENTIONAL,['NA']
2559,NCT02448693,Number of residual neoplastic tissue detected with both techniques (NBI versus WLE),Number of missed lesions on basal colonoscopy,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
2560,NCT04548531,Shared Decision Making (SDM) Process Scale Score,Colon Cancer Screening Rate,,2020-09-10,COMPLETED,INTERVENTIONAL,['NA']
2561,NCT02280811,Duration of Response,Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells,,2014-10-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2562,NCT00145314,"To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer","To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups.",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2563,NCT01675505,,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
2564,NCT05622357,Sphincter saving surgery,Disease free survival,,2018-03-18,COMPLETED,INTERVENTIONAL,['PHASE2']
2565,NCT02157246,Group B Percentage change in FMISO-PET SUVmax and uptake volume,Comparison of changes in T1/T2* MRI,Radiotherapy planning feasibility study,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2566,NCT00563316,Number of Participants With Clinically Significant Adverse Events (AEs),,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2567,NCT01459757,Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
2568,NCT06104215,Dose-limiting toxicity（DLT）,PFS,,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2569,NCT00341705,,,,2001-04-27,COMPLETED,OBSERVATIONAL,['NA']
2570,NCT00262951,Number of Patients in Whom Tumor Was Resectable,Overall Survival,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2571,NCT06168786,Progression-free survival (PFS),AEs,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
2572,NCT02337465,Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe,,,2015-09-22,COMPLETED,INTERVENTIONAL,['NA']
2573,NCT03717519,Overall survival,Clinic-pathological variables,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
2574,NCT04050345,TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study):,"Relationship between ctDNA detection before, during and after treatment",,2016-12-05,RECRUITING,OBSERVATIONAL,['NA']
2575,NCT05452382,Overall survival,Positive resection margins,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
2576,NCT05807984,local control,progression free survival,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2577,NCT02538913,Anal incontinence,In-hospital time,,2015-09,TERMINATED,INTERVENTIONAL,['NA']
2578,NCT02526134,Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.,Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure),,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2579,NCT05451719,Progression-free Survival (PFS),The incidence of adverse events,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2580,NCT03544736,Incidence of Treatment-Emergent Adverse Events,Health Related Quality of Life (EORTC QLQ-OG25),,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2581,NCT06068127,GCSI score,Pyloric distensibility,,2023-10-12,RECRUITING,OBSERVATIONAL,['NA']
2582,NCT00987935,Time to Progression (TTP) in Phase II,"fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2583,NCT01726010,diagnostic yield,,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
2584,NCT02109146,DFS(Disease free survival),,,2014-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2585,NCT00017537,Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer,Document any clinical responses to this drug in these patients.,,2000-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2586,NCT03273686,postoperative complication,Length of postoperative stay,,2017-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
2587,NCT03254836,Actigraphy,"Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)",,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA']
2588,NCT02811666,muscle strength using a hand gauge,,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
2589,NCT02871336,Optimization of the surgical care of the patients,,,2014-11,RECRUITING,OBSERVATIONAL,['NA']
2590,NCT04221347,Detection of spectroscopic markers differences among specified groups,Measure of sensitivity and specificity of identified biomarkers for surveillance of HCC,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
2591,NCT05165264,Overall Survival (OS),OS measured by Programmed Death-Ligand 1 (PD-L1) combined positive score (CPS),,2022-02-16,RECRUITING,OBSERVATIONAL,['NA']
2592,NCT04936750,overall survival,,,2021-06-17,RECRUITING,OBSERVATIONAL,['NA']
2593,NCT06282484,corelation between the gastric xanthoma and gastric mucosa diseases,,,2022-09-01,COMPLETED,OBSERVATIONAL,['NA']
2594,NCT03416582,Percentage of patients using Intervention materials,Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management,,2018-11-29,COMPLETED,INTERVENTIONAL,['NA']
2595,NCT00876148,,,,na,COMPLETED,OBSERVATIONAL,['NA']
2596,NCT04994236,Objective response of intrahepatic lesions,The rate of adverse events,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2597,NCT04502082,The recommended phase 2 dose (RP2D) regimen of ET140203 T-cell therapy primarily based on DLT,Determine the pharmacokinetics of ET140203 T cells after infusion.,,2021-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2598,NCT01311232,Hepatitis B virus reactivation,,,2010-11-01,COMPLETED,OBSERVATIONAL,['NA']
2599,NCT04081168,One-year local tumor progression-free survival,Mortality,,2020-12-15,RECRUITING,INTERVENTIONAL,['NA']
2600,NCT01567488,Percentage of patients with progression-free survival (PFS),Percentage of patients with Adverse Events,,2011-06-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2601,NCT05317819,Overall Survival (OS),Progression free survival,,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3']
2602,NCT06070740,Objective Response Rate,Adverse events,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2603,NCT01095432,Study samples of rectal mucosa (the moist lining of the rectum) using PWS.,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
2604,NCT06144762,the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring,Correlate MRI results with hematological molecular biology results.,,2023-12-19,RECRUITING,INTERVENTIONAL,['NA']
2605,NCT01251536,PFS Probability Rate at 9 Months in the Dose Escalation Arm,Deaths Till 30 Days From Last Cetuximab Administration,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2606,NCT02642978,Surgical Complication,locoregional recurrence rate,liver function,2015-09-01,UNKNOWN,INTERVENTIONAL,['NA']
2607,NCT01661829,Incidence of anterior resection syndrome after stoma closure,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
2608,NCT03693248,Progression free survival,days of management in intensive care unit,,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE3']
2609,NCT00455247,,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2610,NCT02702414,Objective Response Rate (ORR),Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE),,2016-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
2611,NCT01978249,Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection,Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.,To compare the quality of life between the two groups using the Korean version of EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)-C30.,2013-09,TERMINATED,INTERVENTIONAL,['NA']
2612,NCT05673512,Progression-Free-Survival（PFS）,,,2023-05-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2613,NCT01394497,Graft survival,Primary graft dysfunction,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2614,NCT05021263,Quality of Recovery 40 Questionnaire,,,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE3']
2615,NCT01617876,Diagnostic accuracy of enhanced ME (combining ME-NBI and ME-AIM),The relationships between the microsurface patterns and the histopathological findings,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
2616,NCT05643833,Overall survival,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
2617,NCT01505842,Prevalence of dysplastic lesions,Number and rate of targeted and non-targeted biopsies detecting dysplasia and non-dysplasia,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
2618,NCT04110769,The rate of genetic mutation,oncologic outcome,,2019-07-17,RECRUITING,INTERVENTIONAL,['NA']
2619,NCT05401045,Fatigue state using the Revised Piper Fatigue Scale (RPFS),Quality of life using the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-C30),,2023-01-20,COMPLETED,INTERVENTIONAL,['NA']
2620,NCT03055130,The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test,Find drugs relating to HPV infection of IBD patients,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
2621,NCT02508883,mortality,"Finding the cut-off value of highest sensitivity and specificity of Rockall, Glasgow-Blatchford and AIMS65 scores employing the receiver operating curve (ROC).",,2015-04,COMPLETED,OBSERVATIONAL,['NA']
2622,NCT00965861,To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases,,,2010-05,TERMINATED,OBSERVATIONAL,['NA']
2623,NCT02839109,Tumor response,Disease free survival (DFS),,2015-02,COMPLETED,OBSERVATIONAL,['NA']
2624,NCT05096715,Dose Limiting Toxicity Rate,Out of field response rate,,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
2625,NCT03317483,Treatment response,Adverse events (AEs),,2015-11-12,COMPLETED,OBSERVATIONAL,['NA']
2626,NCT03180437,OS,CA 19-9,,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2627,NCT01064999,toxicity,overall survival,,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2628,NCT05216133,36-Item Short Form Survey Instrument (SF-36),,,2023-03-22,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2629,NCT05659576,Reduce opioid use,,,2022-12-13,RECRUITING,INTERVENTIONAL,['PHASE2']
2630,NCT01216644,median overall survival,R0-Resection rate,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2631,NCT00582296,"To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.","To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations.",,2004-12,RECRUITING,OBSERVATIONAL,['NA']
2632,NCT06277531,Patient is diagnosed with malignant disease from biliary system,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2633,NCT02579460,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days,change in HIF expression from baseline to 14 days,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
2634,NCT02534337,Progression-Free-Survival,Time-to-Progression,,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2635,NCT00397384,MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3,Antitumor effect observed,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2636,NCT05620498,Objective response rate (ORR),AE,,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2637,NCT05619614,Mean gaze time per area of influence,,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
2638,NCT00844064,To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.,"To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers.",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2639,NCT00642746,Response Rates of Radiographically Measurable Disease,Time to Second Progression (From Start of First-Line Regimen),,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2']
2640,NCT00600522,"The primary outcome measure was the rate of failure of conservative resection, i.e. the rate of patients who received TSs or MHs despite they fitted in the eligibility criteria.","The secondary outcome measure was the safety of the procedure. For that, we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests.",,2004-01,COMPLETED,OBSERVATIONAL,['NA']
2641,NCT01369329,Number of Participants With Clinical Response at Week 6,Number of Participants With CDAI 70-point Response at Week 3,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2642,NCT02568787,Change from baseline in immunological markers,Change from Baseline in Quality of Life,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
2643,NCT05331040,Model,,,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2644,NCT00004891,Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan,Determine the accuracy of FDG-PET,,1999-09,COMPLETED,INTERVENTIONAL,['NA']
2645,NCT05441254,Progression Free Survival(PFS),Peritoneal Cancer Index (PCI) assessed on preoperative CT (CT-PCI),"Adverse event (AE) rate, serious adverse event (SAE) rate, etc",2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2646,NCT04324294,"The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",Quantitative Parameters of Pancreas Lesions,,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1']
2647,NCT05220800,Changes in T-cell function - mRNA expression analysis,5 year cancer free survival,,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2648,NCT00343239,"To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.",,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2649,NCT00305643,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on the CTC 3.0 Criteria.,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on WHO Criteria.,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
2650,NCT02219529,Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy,Adverse events of both procedures,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2651,NCT02586987,"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)",MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma,,2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE1']
2652,NCT01941173,"Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0","Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0",Time on protocol therapy,2014-01,WITHDRAWN,INTERVENTIONAL,['NA']
2653,NCT00313560,Recurrence Free Survival,Time to Death as Assessed by Median Overall Survival (Months),,2006-03-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2654,NCT02644863,Overall survival,Phenotypic analysis of T cells,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
2655,NCT03276091,Participation to the colonoscopy,cancer and adenoma detected,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
2656,NCT03277235,Self-report Questionnaire,Self-report Questionnaire,Self-report Questionnaire,2017-09,UNKNOWN,INTERVENTIONAL,['NA']
2657,NCT01023412,Rate of post-operative complications,Rate of post-operative infectious complications,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3']
2658,NCT01157052,The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.,,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
2659,NCT02650986,Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells,Tumor Response (Complete and Partial Response),,2017-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2660,NCT03396354,Number of retrieved LN,,,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA']
2661,NCT02036112,The perioperative morbidity,Three years survival postoperatively,Three years local recurrence postoperatively,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
2662,NCT04006769,Adverse Events (AE) And Serious Adverse Events(SAE),Quality of Life(QOL),,2020-10-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2663,NCT00197444,Response rate,Survival rate,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2664,NCT03164486,Assessment of safe administration of 18F-αvβ6-BP,Level of αvβ6-BP expression in tumors,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2665,NCT01163305,Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy,RECIST-based tumor response at 10 weeks after chemotherapy,,2010-06-30,COMPLETED,OBSERVATIONAL,['NA']
2666,NCT00408681,Functional Recovery,Causes of Death,Agents Added to Treat GVHD More Than 3 Days After Enrollment,2006-06,COMPLETED,INTERVENTIONAL,['NA']
2667,NCT03940417,"Docking time,min",cost,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
2668,NCT04835246,Sensitivity of Spectra IMDx system,Accuracy of Spectra IMDx system,,2019-10-07,UNKNOWN,INTERVENTIONAL,['NA']
2669,NCT03976999,Proportion of patients who gave their consent to participate in the study,,,2017-07-05,RECRUITING,INTERVENTIONAL,['NA']
2670,NCT02649790,Part H: 2- Year Progression-free Survival (PFS),Part H: Overall Survival (OS),,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2671,NCT02510001,Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066,Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2672,NCT00331682,Objective Response Rate as Measured by RECIST Criteria,Overall Survival,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2673,NCT03117348,Morbidity of infection,Mortality,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
2674,NCT00075218,Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study,Change From Baseline in EQ-5D Health State Profile Index,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2675,NCT01426646,Relapse-free survival,Overall survival,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2676,NCT05636085,Specificity,Positive predictive value and negative predictive value,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2677,NCT00553696,Number of Participants With First Cycle Dose-limiting Toxicities (DLTs),Time to Progression (TTP),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2678,NCT06331260,Tumor recurrence rate,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2679,NCT00941967,Progression-free survival,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2680,NCT06022770,Nutritional risk screening（NRS） 2002 scale,quality of life of patients with esophageal and gastric cancer before and after chemotherapy,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2681,NCT03415763,Disease free survival,The quality of life postoperatively,,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3']
2682,NCT03541629,Data accuracy,,,2018-07-26,COMPLETED,OBSERVATIONAL,['NA']
2683,NCT03961776,Predictive value of Apparent Diffusion Coefficient measured using MRgRT system,,,2020-06-08,RECRUITING,OBSERVATIONAL,['NA']
2684,NCT05524155,Overall response rate ( ORR),Overall survival (OS),,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2685,NCT00320294,Safety,Quality of life,,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
2686,NCT00012922,,,,na,COMPLETED,INTERVENTIONAL,['NA']
2687,NCT00366509,"procure and analyze gastrointestinal, oropharyngeal, lung and/or blood specimens from healthy research volunteers and subjects with lung disease",,,2006-09-18,COMPLETED,OBSERVATIONAL,['NA']
2688,NCT00524706,"Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II",Phase II - Safety - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS),,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2689,NCT05586516,Incidence of treatment-emergent adverse events [Safety and Tolerability],Overall survival [OS],,2022-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2690,NCT00030524,,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2691,NCT01155440,Restoration of bowel function,Pain intensity,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2692,NCT00747448,"Primary objectives of the study are to enable analysis of patient outcomes 2 years after final treatment and report on the effectiveness of the device in eradicating, decreasing or downgrading of the lesions.",,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
2693,NCT02748161,Objective tumor response,Number of repeat DEB-TACE procedures per lesion,,2015-08,TERMINATED,INTERVENTIONAL,['NA']
2694,NCT01082419,The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.,Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
2695,NCT06194786,Dietary target-red meat,Disease free survival,,2023-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2696,NCT05493956,Overall survival,Hepatobiliary symptom index,,2019-04-01,RECRUITING,INTERVENTIONAL,['NA']
2697,NCT03208621,Change in treatment strategy,Mortality,,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2698,NCT00637390,safety & maximally tolerated dose,Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.,,2008-03,TERMINATED,INTERVENTIONAL,['PHASE1']
2699,NCT01396148,Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Post Dose AUC(0-8) for Sunitinib and Its Metabolite,"Estimated Sunitinib Plasma Concentration at Which 50% of the Maximum Effect (EC50) for Each Selected Safety Endpoint (e.g., Absolute Neutrophil Count) Was Observed",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2700,NCT05528367,the rate of resectable patients with negative incisal margin R0 resection rate,,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2701,NCT02037646,Time to diagnosis of advanced colorectal neoplasms,Patient anxiety levels,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2702,NCT02647099,Time To Recurrence (TTR),Frequency and severity of adverse events (AE),,2016-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2703,NCT03292289,"Quality of life 1 year after the second intervention, using LARS score","Quality of life of patients with a second stoma placement, using LARS score",,2018-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2704,NCT02813278,Length of hospital stay,,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2705,NCT01880658,Disease-free Survival rate(DFS),"Over all survival,genetic patterns, quality of life, toxic effects, convenience",,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2706,NCT06024356,pathologic complete response,overall survival (OS),The expression of PD-1,2023-09-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2707,NCT05435313,objective response rate (ORR),Adverse events as assessed by NCI CTCAE v5.0,,2022-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2708,NCT02062749,Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy,Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients,"Time to Recurrence After HIPEC in Pediatric, Adolescent and Young Adult Age Colon Cancer Patients",2014-05-19,COMPLETED,INTERVENTIONAL,['PHASE1']
2709,NCT01394159,Compare the Median Number of Passes Required to Establish a Diagnosis,Technical Failure,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
2710,NCT03321396,Number of Patients With Postpolypectomy Electrocoagulation Syndrome,Number of Patients With Late Tissue Injury,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
2711,NCT04233866,Overall survival (OS),Instrumental Activities of Daily Living (IADL),Geriatric assessment scores and biomarkers of aging (CRP and IL-6),2020-08-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2712,NCT02395224,survival,Health related quality of life,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
2713,NCT05109468,Change in Sexual quality of life score,,,2021-06-06,RECRUITING,OBSERVATIONAL,['NA']
2714,NCT03581435,The expression of protein A in the circulating exosomes from patients,,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2715,NCT03146377,Objective response rate,Overall survival,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2716,NCT00020579,Pharmacology and pharmacokinetics,Tumor response by CT scan every 12 weeks,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2717,NCT00002951,Locoregional control rate,,,1996-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2718,NCT02562716,Overall Survival (OS),Disease-free Survival From the Time of R0 or R1 Resection.,,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2719,NCT03898921,3-year overall survival rate,Safety profile: incidence of complications,Radiation-induced liver injury,2019-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
2720,NCT06046794,Percentage of alive GemCore+ patients treated with Gemcitabine,Progression-free survival,Overall survival of GemCore- patients,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2721,NCT01585805,Response rate of single-agent veliparib (Part II),Overall survival (Parts I and II),Differentially expressed genes found,2012-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2722,NCT05298722,Prediciton of surgical resectability,Measurement of quality of life in patients with pancreatic cancer,,2022-12-12,RECRUITING,INTERVENTIONAL,['NA']
2723,NCT02673177,Incidence of sexual and urinary dysfunction,Anus preservation rate,,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
2724,NCT01468389,Progression free survival,adverse events,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
2725,NCT01544790,Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher,Costs (euro),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2726,NCT04400357,Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively,Comparison of perioperative inflammatory response (Interleukin-6),,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA']
2727,NCT05903456,Objective Response Rate,adverse event,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2728,NCT00827047,Overall survival and disease free survival,"Bleeding and blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2729,NCT03827967,Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment,Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment,,2019-07-20,COMPLETED,INTERVENTIONAL,['PHASE1']
2730,NCT01215838,Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.,,,2010-08,TERMINATED,OBSERVATIONAL,['NA']
2731,NCT04090645,Evaluate SAE's associated with TheraSphere® treatment,,,2014-05-22,COMPLETED,INTERVENTIONAL,['NA']
2732,NCT02102984,Relief of malignant biliary obstruction,cost/effecacy,gallbladder in situ,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2733,NCT03017326,Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria,Adherence to surgical guidelines,,2017-08-24,RECRUITING,INTERVENTIONAL,['PHASE3']
2734,NCT05568667,Assessment of the programme feasability,Assessment of the evolution on CRC risk factors knowledge,,2022-10-17,COMPLETED,INTERVENTIONAL,['NA']
2735,NCT01048281,NER activity by routine pathologic analysis,,,2002-08,RECRUITING,OBSERVATIONAL,['NA']
2736,NCT01885884,perceived effectiveness,patient quality of life,caregiver depressive symptoms,2013-07,COMPLETED,INTERVENTIONAL,['NA']
2737,NCT04155242,Diagnostic accuracy of methylation panel for diffuse IM at the GOJ,Safety of Cytosponge,,2020-09-01,RECRUITING,INTERVENTIONAL,['NA']
2738,NCT05840341,Overall survival (OS),Disease Free Survival,,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE3']
2739,NCT02052050,Abdominal isometric endurance,Lower back muscle strength,Muscle structure,2012-09,COMPLETED,INTERVENTIONAL,['NA']
2740,NCT02419677,Recurrence-free survival,Adverse events,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2741,NCT00433927,Objective response rate,Safety and toxicity (according to NCI-CTCAE),,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2742,NCT05843955,Non-alcoholic fatty liver disease (NAFLD) grade,,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
2743,NCT05917431,PFS,Recurrence pattern,,2023-06,RECRUITING,INTERVENTIONAL,['PHASE2']
2744,NCT00003994,Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2745,NCT05993234,Real-World Time to Next Treatment (rwTTNT1) in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Stomach (EORTC QLQ-STO22) Score in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,,2023-12-05,RECRUITING,OBSERVATIONAL,['NA']
2746,NCT04135781,3 years Diseases-free Survival rate(3 years-DFS),Safety as measured by number and grade of adverse events,,2020-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
2747,NCT00005634,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2748,NCT01825824,Local control rate,Treatment related toxicity,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2749,NCT03472365,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,Number of Subjects With Treatment-related Adverse Events (AEs),,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2750,NCT05034692,The incidence of early complications,pain score,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
2751,NCT05747716,Progression free survival,Toxicities,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2752,NCT01942083,To investigate the maximum tolerated dose (MTD) of OPB-111077,Biomarker of OPB-111077,,2013-05-29,TERMINATED,INTERVENTIONAL,['PHASE1']
2753,NCT05532319,Progression-free survival,objective response rate,,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2754,NCT05111314,Intraindividual intralesional difference in maximum standardized uptake value (SUVmax),Incidence of adverse events,,2022-02-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
2755,NCT05523245,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of models in prediction tumor response,The negative predictive value of models in prediction tumor response,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
2756,NCT05701488,Number of Participants with Adverse Events,Number of Participants with Surgical Complications,,2023-04-21,RECRUITING,INTERVENTIONAL,['PHASE1']
2757,NCT01292681,Correlation early changes in imaging and treatment outcome,Correlation pretreatment imaging values and treatment outcome,,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
2758,NCT04727996,Disease control rate,overall survival,,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2759,NCT01714622,the changes of metabolic syndrome,the changes of insulin resistance after gastrectomy,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA']
2760,NCT05517343,Proportion of definite depression cases,Depression score,,2022-08-20,RECRUITING,INTERVENTIONAL,['NA']
2761,NCT00977613,Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater,Overall Survival,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
2762,NCT02199912,biological and radiological markers,loss of fat body mass and/or lean body mass,,2013-10-07,COMPLETED,INTERVENTIONAL,['NA']
2763,NCT02323464,Prevalence of sleep apnea,Sex differences,,2015-01-07,COMPLETED,OBSERVATIONAL,['NA']
2764,NCT00782886,"The overall purpose of this NIH-funded study is to evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.",,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
2765,NCT02100696,"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS",Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE3']
2766,NCT01360853,Survival,Full Pharmacokinetics,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2767,NCT03595722,Complications,Radiological changes,,2019-07-11,UNKNOWN,INTERVENTIONAL,['NA']
2768,NCT00040092,,,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2769,NCT05946226,Incidence and severity of dose-limiting toxicity (DLTs) within 28 days after IMC002 infusion,CAR-positive cell counts in peripheral blood,long-term safety,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1']
2770,NCT00030732,Gemcitabine + Capecitabine vs. Gemcitabine alone,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2771,NCT06050317,AE,Duration of response,,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE2']
2772,NCT05873829,Chemotherapy Induced Peripheral Neuropathy Symptoms Assessment,,,2022-04-25,COMPLETED,INTERVENTIONAL,['NA']
2773,NCT03421912,Overall patient satisfaction after 30 days treatment,Use rate of dermocorticoids,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
2774,NCT03777540,Post-operative mortality In-hospital mortality was defined that occurred during hospitalization up to 90 days excluded post-operative mortality. Postoperative mortality,Overall survival,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2775,NCT01882868,Percentage of Participants With Overall Response,Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2776,NCT04884581,Negative Predictive Value (NPV),,Performance metrics of the endoscopist with the aid of GI Genius CADx,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
2777,NCT05771181,objective response rate (ORR),advert events,,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2778,NCT05064059,Overall Survival (OS),TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,,2021-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2779,NCT04768660,Length of hospital stay,,,2021-02-14,UNKNOWN,INTERVENTIONAL,['NA']
2780,NCT03943043,maximum tolerated dose,"Number of responder (in term of CR, PR, SD) to GEMOX plus nab-paclitaxel as assessed by RECIST 1.1",,2017-07-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2781,NCT00786643,Best Response (BR),Time to Progression,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2782,NCT03669237,Postoperative bowel function of 1 year after surgery,Postoperative bowel function of the long stable result,,2018-10-12,COMPLETED,INTERVENTIONAL,['NA']
2783,NCT02079623,Tumor response,Overall survival,Pain registration,2013-11,COMPLETED,OBSERVATIONAL,['NA']
2784,NCT04201717,surgical site infection，SSI,hospital stay,,2020-06-12,RECRUITING,INTERVENTIONAL,['NA']
2785,NCT02784028,Maximum tolerated dose (MTD),,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
2786,NCT03299036,Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria,Serum Level of AFP,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
2787,NCT05198609,Overall survival,Disease control rate,,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE3']
2788,NCT02591667,Percentage of viable cells within the resected peritoneal deposits after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.,Overall survival (OS),,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2789,NCT06024837,Comparison of peritoneal and hepatic lesion mapping between spectral scanning and conventional scanning,Comparison of evaluation of response to chemotherapy (if indicated) in RECIST 1.1 and Radiomics,,2023-06-07,RECRUITING,OBSERVATIONAL,['NA']
2790,NCT00587600,The primary assessment for our first specific aim will be to determine the effect of photodynamic therapy on biomarkers after photodynamic therapy.,The primary assessment for our second specific aim will be to assess if specific biomarkers can be correlated with the confirmed histological elimination of their Barrett's esophagus.,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2791,NCT02030769,Detection rate of high grade dysplasia and carcinoma in iodine void lesion,overall detection rate of iodine void lesion,observation time for esophagus,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2792,NCT01396681,recurrence/metastasis free survival,Safety and tolerability,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2793,NCT05245331,LARS score,Adverse effects related to both treatments.,,2022-08-04,RECRUITING,INTERVENTIONAL,['NA']
2794,NCT00727376,Clinical benefit of the Polyflex Esophageal Stent as a means to maintain oral nutrition during chemotherapy and/or radiation,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
2795,NCT06136949,Frequency of overexpression of STARD3 in both early and advanced CRC patients,Concordance between the presence of selected molecular alterations on primary tumour tissues and organoids,,2023-05-22,RECRUITING,OBSERVATIONAL,['NA']
2796,NCT05797883,Objective response rate (ORR),Disease control rate (DCR),,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2797,NCT01366183,"Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays",Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events,"Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L",2011-08-15,UNKNOWN,OBSERVATIONAL,['NA']
2798,NCT00900016,Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression,Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
2799,NCT04521153,The rate of subjects of major pathological response (MPR),Safety and toleraty,,2021-03-25,RECRUITING,INTERVENTIONAL,['NA']
2800,NCT00233623,Time to progression (6 months after Last patient in),"Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)",,2004-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2801,NCT01765231,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,"the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis",,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2802,NCT03546985,Area under the curve (AUC) of pain score of oral mucositis,Incidence of adverse events,,2017-12-26,COMPLETED,INTERVENTIONAL,['NA']
2803,NCT05513716,Proportion of genetic mutations,Association with molecular subtypes and categorical variables,,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2804,NCT00510354,Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).,Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional),,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2805,NCT02863783,Relative Ease of Detection of the Tumor with Fiducial,"Pancreatitis, abdominal pain, infection, bleeding following placement.",,2016-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2806,NCT05724563,Objective Response rate of combination zimberelimab and domvanalimab.,Number of participants with Adverse Events (AEs) (serious / non-serious) as defined by CTCAE v5.0,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2807,NCT04735900,Optimize cutoff value,Determine progression free and 9-month survival,Exploratory objective 3,2020-09-14,UNKNOWN,INTERVENTIONAL,['NA']
2808,NCT04850040,Major Pathological Response(MPR) 10%,Intraoperative and postoperative complications,,2021-05-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2809,NCT06310590,Localized Objective response rates (ORR),"Radioactivity of Yttrium-90 for 9 participants, assessed by liquid scintillation counter",,2023-08-08,RECRUITING,INTERVENTIONAL,['PHASE1']
2810,NCT04008030,"PFS by BICR (arm B vs C, 1L, centrally confirmed)","ORR by BICR (crossover cohort, centrally confirmed)",,2019-08-05,RECRUITING,INTERVENTIONAL,['PHASE3']
2811,NCT00466505,Progression-free Survival (PFS),Serum TGF-alpha: Treatment Cycle 2,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2812,NCT03775473,progastrin rate,,,2019-02-07,TERMINATED,INTERVENTIONAL,['NA']
2813,NCT00006379,Evaluation of Donor Engraftment,Event free and overall survival,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2814,NCT03417921,Emergent Adverse Events,,,2021-04-26,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2815,NCT00541021,Progression-free survival,Biomarkers of response,,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2816,NCT03782831,Progression Free Survival (PFS),Adverse Events,,2018-12-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2817,NCT05675462,Serious adverse event (SAE).,Detection of systemic and local immune activation in tumors and peripheral blood mononuclear cell will be assessed by single cell RNA seq and/or bulk RNA seq.,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2818,NCT05510908,Number of cancers in people with HIV (PWH) who present for care at domestic AMC sites,Proportion of participants eligible for AMC trials who are successfully enrolled,3. State of planned cancer therapy for cancer patients with HIV initiating therapy or currently under treatment,2023-07-25,RECRUITING,OBSERVATIONAL,['NA']
2819,NCT00390364,Response Rate: The Total Number of Participants With Progression of Disease,,,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
2820,NCT04404491,PFS,OS Qol,,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2821,NCT05596760,EHR documentation of Goals of Care discussions,Anxiety and depression (HADS),,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
2822,NCT00145665,correlation FLT-uptake in colorectal liver metastases and the histologically determined proliferation,correlation FLT and recurrence rate,,2005-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2823,NCT03096899,Overall Survival,,,2016-01,WITHDRAWN,OBSERVATIONAL,['NA']
2824,NCT02934984,Rates of recurrence in pancreatic cancer patients,Rates of death in pancreatic cancer patients,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
2825,NCT00538954,Recovery of gastrointestinal function: Time to pass flatus/stool (hours following the end of surgery),Patient activity level: measured by activPAL® activity meter,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
2826,NCT03045952,overall survival,disease free survival,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
2827,NCT01472601,disease-free survival,,,2011-05-24,UNKNOWN,OBSERVATIONAL,['NA']
2828,NCT06005883,Recurrence of tumor,,,2021-04-10,COMPLETED,OBSERVATIONAL,['NA']
2829,NCT03221608,Incidence of endoperitoneal recurrence at 36 months,HIPEC toxicity rate,,2017-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2830,NCT04888299,Feasibility of Raman spectroscopy to identify mucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,Diagnostic performance of Raman spectroscopy for assessment of mmucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,,2021-04-14,UNKNOWN,INTERVENTIONAL,['NA']
2831,NCT03254394,Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time,The Cumulative Dose of Oxaliplatin,,2017-09-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2832,NCT00690300,tumor response,toxicity / safety,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2833,NCT04407416,Breath analysis sensitivity,,,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA']
2834,NCT03481296,Colorectal cancer screening test-specific adherence at 12 months (Colonoscopy),Change in knowledge about colorectal cancer and colorectal cancer screening between baseline and 6 months,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
2835,NCT06206278,Overall survival (OS),,,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2836,NCT01932125,Safety: Incidence of adverse events,Clinical benefit rate (complete response + partial response + stable disease),,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
2837,NCT00448136,PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months,EORTC QLQ-C30 Functional and Symptom Scale Scores,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2838,NCT04661046,Progression Free Survival,,,2020-11-30,UNKNOWN,INTERVENTIONAL,['NA']
2839,NCT04620538,"Determine the diagnostic accuracy of breath test for detection of fibrosis, cirrhosis or hepatocellular carcinoma.",,,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
2840,NCT03658772,Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab,Observed accumulation ratio,,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE1']
2841,NCT02132403,Maximum Tolerated Dose (MTD),Disease Response based on RECIST Criteria,,2014-08,TERMINATED,INTERVENTIONAL,['PHASE1']
2842,NCT00052897,,,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2843,NCT05843877,"Duration between surgery and time ""fit for adjuvant treatment"" (postoperative day X)",Comparison of long-term oncological course (24 months) in both arms: occurence of metastases,,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2844,NCT00079872,The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer,to characterize the quantitative and qualitative toxicities of both treatment arms in this patient population,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2845,NCT05488522,Primary Objective,Progression Free survival,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2846,NCT01196247,Determine the percent of patients who are alive at one year,,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2847,NCT01418391,amount of post-operative morphine consumption,evaluation of post-operative pain status using visual analog scale (VAS) and superimposed face pain severity scale,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
2848,NCT03273920,3-year relapse-free survival,Immune response,,2017-09-25,UNKNOWN,INTERVENTIONAL,['NA']
2849,NCT03287453,Self-reported intentions to engage in behavior change to reduce risk of colorectal cancer,,,2017-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2850,NCT00683631,,,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
2851,NCT05913661,Objective Response Rate,Overall Survival,,2023-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2852,NCT05184946,3 years disease free survival rate,overall survival time,,2021-10-09,RECRUITING,INTERVENTIONAL,['PHASE2']
2853,NCT03986294,Progression free survival of NaI-IRI with S1,Quality of life QoL (QLQ-C30),ctDNA,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2854,NCT00851084,Progression Free Survival (PFS) Rate at 12 Months,Immunogenicity of Intravenous (IV) Aflibercept,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2855,NCT00192842,time to tumor progression,toxicity,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2856,NCT02581423,Incidence of treatment discontinuation due to AEs,Incidence of toxocity-related dose reductions,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2857,NCT00976612,nilotinib pharmacokinetics,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
2858,NCT00956072,Progression-free survival,Quality of life as measured by EORTC QLQ-C30,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3']
2859,NCT00925015,Number of Participants With an Adverse Event (AE),"AUC0-24 of Irinotecan Following Administration of Cetuximab / Irinotecan Alone, or in Combination With 10 mg/kg Dalotuzumab",,2009-06-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2860,NCT03412799,Recommended dose of SBP-101,Peak plasma concentration (Cmax) for all three drugs,,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2861,NCT00005842,,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2862,NCT03862885,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
2863,NCT04492033,P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC,P2: Overall survival (OS),,2020-06-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2864,NCT05617378,Risk factor,,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
2865,NCT02349594,Change of TNF-α production in pg/ml,(anti-) Oxidant status and oxidative damage,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2866,NCT04447443,Therapeutic effect on the chemotherapy-related grade 2 to 4 diarrhea,Gut microbiota changes in response to intervention,,2020-06-30,WITHDRAWN,INTERVENTIONAL,['NA']
2867,NCT03430778,difference between SpHb value and SaHb value (SpHb - SaHb),,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
2868,NCT06189664,Detection of adenocarcinoma,,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
2869,NCT00684229,cancer recurrence,length of post operative hospitalization,,2007-12,WITHDRAWN,INTERVENTIONAL,['NA']
2870,NCT02457390,Detection of synchronous liver metastases with CE-LUS,CE-LUS feasibility,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
2871,NCT03891953,Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.,Time to Progression (TTP),,2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2872,NCT00318370,Serologic Response (Change in Cancer Antigen [CA-125] Level),Percentage of Participants Who Had a Prolongation of Remission,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2873,NCT05807542,Pathological complete response,Objective Response Rate (ORR),,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2874,NCT01571284,Number of Participants With Cycle Delay and/or Dose Modification,Change From Baseline in HRQL EQ-5D-3L VAS Score,,2012-05-30,COMPLETED,INTERVENTIONAL,['PHASE3']
2875,NCT04490668,Comparison of the rate of anastomotic leakage,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
2876,NCT03949231,Overall survival,Adverse event rate,,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
2877,NCT04310176,progression-free survival (PFS),metastases resection rate (R0/R1/R2),,2019-05-24,RECRUITING,INTERVENTIONAL,['PHASE2']
2878,NCT05541783,Scores on the physical function and pain symptom scales of EORTC QLQ-C30 questionnaire,Scores on ST22 questionnaire,,2022-09-15,RECRUITING,INTERVENTIONAL,['NA']
2879,NCT02123381,changes of serum vascular endothelial growth factor（VEGF）level before and after radiotherapy,grade 3-5 adverse events,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2880,NCT02456051,Pancreatic cancer diagnosis,Mortality,,2015-04,TERMINATED,OBSERVATIONAL,['NA']
2881,NCT02764944,En bloc resection,successful closure of resection site,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
2882,NCT03391687,Incidence of Pancreatic Fistula,The mortality of Grade B and C Pancreatic Fistula,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
2883,NCT04790227,Secondary outcome after chemo-radiotherapy,,,2022-01,UNKNOWN,OBSERVATIONAL,['NA']
2884,NCT03515941,Number of Participants Who Complete the Recommended Therapy From Each Arm,Median Time to Recurrence,,2018-06-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
2885,NCT01446458,Maximum tolerated total dose of stereotactic body radiation to patients with resectable or borderline resectable pancreas cancer following FOLFIRINOX chemotherapy,Clinical and pathologic objective response rate as measured by MRI (clinical response) and histopathology and rate of complete resection (R0) (pathologic response),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2886,NCT02676349,To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate,Evaluate the progression-free survival,,2016-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2887,NCT02448979,Long term survival,Postoperative complications,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2888,NCT05524974,Objective response rate,"The prediction performance of Exosome contents (including proteins, nucleic acids)",,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2889,NCT05616390,Overall survival (OS),Quality of Life (QoL),,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
2890,NCT03203304,Number of participants with adverse events,Rate of local control of the SBRT treated lesion,,2017-08-25,TERMINATED,INTERVENTIONAL,['PHASE1']
2891,NCT02110498,To develop and prospectively validate a panel of molecular markers to differentiate benign pancreatic cysts from those with malignant potential using surgical pathology as the gold standard,"To determine the sensitivity, specificity, and overall accuracy of imaging (CT, MRI and EUS) in patients with pancreatic cysts",To determine the proportion of patients with malignancy in operable pancreatic cysts,2014-03,RECRUITING,OBSERVATIONAL,['NA']
2892,NCT05853692,Oral Mucositis,Severity of Oral Mucositis,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
2893,NCT01797224,Major malformations,Infant follow-up,,2012-03,RECRUITING,OBSERVATIONAL,['NA']
2894,NCT01807156,Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression,Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2']
2895,NCT04266548,surgical benefit rate of fluorescent image,Post operative Mortality,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
2896,NCT04118114,Treatment related adverse events rate,,,2019-09-03,RECRUITING,INTERVENTIONAL,['PHASE2']
2897,NCT05354388,1-year Progression free survival rate,Duration of continuous medication before surgery,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
2898,NCT02934529,Overall Survival,Safety and tolerance as measured by the NCI-CTCAE version 4.03 criteria,,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2899,NCT03745326,Frequency and severity of treatment-related adverse events,,,2019-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2900,NCT03331406,Number of participants that adhered to physical activity program,Number of participants with adverse events,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
2901,NCT01276405,Disease-free survival,Safety (Incidence of adverse events),,2010-03,TERMINATED,OBSERVATIONAL,['NA']
2902,NCT04764006,Objective response rate (ORR),Assess the anti-tumor activity:DCR,,2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
2903,NCT06037954,Attrition rates,Treatment satisfaction,,2023-09-07,RECRUITING,INTERVENTIONAL,['NA']
2904,NCT03271255,Progression-free Survival (PFS) Time,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate),,2018-05-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
2905,NCT03325361,Anastomotic leakage,,,2017-10,UNKNOWN,INTERVENTIONAL,['NA']
2906,NCT01821729,Number of Participants With R0 Resection,To Measure Utilization of Health Services,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2907,NCT01912586,Changes in sexual function based on the (IIEF)-5 score and NPT,Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2908,NCT00579891,establish a serum and tissue bank,,,1989-03-28,COMPLETED,OBSERVATIONAL,['NA']
2909,NCT03722511,Effect of amino acids in tightening the intestinal barrier and protecting from antigenic translocation by evaluating plasma circulating cytokine levels in peripheral blood sample.,Evaluation of increased bacterial translocation and systemic inflammation.,,2018-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2910,NCT06185374,National Annie Colonoscopy Survey Score,Percentage of Participants who Had Adequate Bowel Preparation at Colonoscopy Appointment,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2911,NCT05319639,The maximum dose tolerated,Overall survival,,2023-02-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2912,NCT04712292,Rate of radical surgery,Mortality,,2020-09-08,UNKNOWN,OBSERVATIONAL,['NA']
2913,NCT00833508,Change of Anaerobic threshold of 1.5ml/min/kg or more,Operative outcome,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2914,NCT05710406,Disease free survival (DFS) (Phase III),Alternative disease free survival,"• Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events for symptoms of rash, diarrhea, and fatigue",2023-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2915,NCT03838406,Objective response rate,Overall survival,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2916,NCT03231176,Objective Response Rate (ORR),Safety and tolerability of varlitinib when combined with capecitabine,,2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2']
2917,NCT01853644,Overall Response Rate (ORR),Overall Survival (OS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib,,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2918,NCT02375581,all cause mortality,incidence rates of radiation-related pneumonitis and esophagitis,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2919,NCT01782690,Overall Survival Stratified by Rash,Score in Participant Questionnaire: Quality of Life,,2012-03-31,COMPLETED,OBSERVATIONAL,['NA']
2920,NCT02507882,"Specific miRNA levels and their association with degree of fibrosis, cirrhosis and HCC",,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
2921,NCT02323776,Postoperative complications,,,2014-12,TERMINATED,OBSERVATIONAL,['NA']
2922,NCT01342354,Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas,Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.,,2009-04-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2923,NCT00036400,Number of red blood cell transfusions,"Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2924,NCT03217773,Short-term morbidity,Local recurrence,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
2925,NCT02917759,Number of successful xenografts established,,,2014-02,RECRUITING,OBSERVATIONAL,['NA']
2926,NCT04597151,Categorical responses to program evaluation survey,Frequency of responses to the baseline socio-demographics survey,Change in Lifestyle Score on the National Institute of Health (NIH)/ National Cancer Institute (NCI) Automated Self- Administered 24-hour Dietary Assessment Tool (ASA24),2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
2927,NCT06085677,"Serologic concentrations of ghrelin, gastrin, pepsinogens and vitamin B12",,,2023-11-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2928,NCT03775798,Incidence of hepatocellular carcinoma after direct-acting antivirals for HCV,Adverse events after direct-acting antivirals for HCV,,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2929,NCT03462524,Global health-related quality of life (HR-QL) score as assessed by Eastern Co-operative Oncology Group QLQ-C30 questionnaire,Overall survival,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2930,NCT02159248,Evaluate safety and toxicity,Assess the anti-tumor response.,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2931,NCT03564405,Objective Response Rate,,,2016-12-05,COMPLETED,INTERVENTIONAL,['NA']
2932,NCT03948958,TIVAD function,Catheter tip and port chamber culture,Patient-reported outcome measure,2019-06-28,COMPLETED,INTERVENTIONAL,['NA']
2933,NCT01641276,Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response,Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2934,NCT00336700,2-year Recurrence Free Survival (RFS),KRAS Mutational Status,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2935,NCT00641615,Safety (toxicities as assessed by NCI CTCAE version 3),"Specific CTL induction in vitro, Objective rate as assessed by RECST criteria",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2936,NCT02195232,Percent Change in D-dimer Value,Cumulative Incidence of VTE at 56 Days,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2937,NCT00165594,Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST),Adverse drug reaction.,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2938,NCT00004895,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2939,NCT01904630,Data on association between sequence variants in exons and CRC risk,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
2940,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,Post transplant surgical complications,,2011-05-01,TERMINATED,OBSERVATIONAL,['NA']
2941,NCT03699111,Stratification Tools,,,2018-09-19,COMPLETED,OBSERVATIONAL,['NA']
2942,NCT00027274,Risk of Cancer with Specific Mutations,,,2001-11-28,RECRUITING,OBSERVATIONAL,['NA']
2943,NCT04868773,Recommended Phase 2 Dose [RP2D],Number of Participants with Objective Response Rate,,2021-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2944,NCT04906954,"Step 2 : Number of patients with improvement of 10 points between baseline and week 8, assessed using the EORTC QLQ-C30 physical functioning scale",Overall Survival (OS),,2021-06-29,UNKNOWN,INTERVENTIONAL,['NA']
2945,NCT05962450,Progression-Free Survival (PFS),Time to Quality of Life (QoL) Deterioration,,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2']
2946,NCT02545309,bile acid transporter genes,upper gastrointestinal bleeding episodes,,2015-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2947,NCT00035100,Tumor response rate,pharmacogenetic analyses with blood and tumor samples from these patients,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2948,NCT05376423,Recurrence-free survival rate,,,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2']
2949,NCT04003792,conversion rate to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.,,,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2950,NCT03516994,Proportion of Whites who complete advance care planning,Patient Quality of Life,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2951,NCT03899428,Time to decline to ≥ 2 log10 IU/mL of serum HBsAg,"Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",,2019-05-02,RECRUITING,INTERVENTIONAL,['PHASE2']
2952,NCT06190782,Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone,local control rate,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3']
2953,NCT01030757,Tumor Response Rate (Complete Response + Partial Response).,"Toxicity, Progression Free Survival, Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease), Median Duration of Clinical Benefit, and Median Overall Survival of Subjects.",,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2954,NCT00881816,maximum tolerated dose,dose limiting toxicity,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
2955,NCT01167712,Progression-Free Survival,Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI),Changes in the Tumor Perfusion Parameters as Quantified by Vascularity or Blood Volume; Perfusion or Blood Flow; Mean Transit Time; and Microvascular Permeability or Permeability Surface Area Product,2010-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2956,NCT01131078,Time to Progression (TTP),Duration of Overall Complete Response,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2957,NCT04926324,Determination of the clinical complete response rate,Determination of the organ preservation rate,,2022-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2958,NCT00651742,Overall Tumor Response Rate (ORR),Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE),,2006-01-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2959,NCT01465308,Change from baseline in oral mucositis grades,Change in baseline weight in one month,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2960,NCT04011033,Disease Control Rate (DCR),Alpha-fetoprotein (AFP),,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2961,NCT02955069,Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC).,PDR001 ADA Incidence On-treatment,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2']
2962,NCT00548236,"To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.","To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer.",,2007-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2963,NCT04293835,the height of sigmoid take-off,"The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge.",,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
2964,NCT01095523,To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.,To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.,,2010-01-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2965,NCT01779583,"• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.",,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
2966,NCT05750290,Best objective response rate,,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2967,NCT04666090,Pathological Complete Response (PCR),The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients,,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2968,NCT02148406,Changes in fatigue (recalled),Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory,Changes in circadian disruption (daily and recalled) as assessed by actigraphy and the Godin's Leisure Score Index,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2969,NCT03300921,Number of Adverse Events,,,2017-09-28,TERMINATED,INTERVENTIONAL,['PHASE1']
2970,NCT00103324,Confirmed response probability (complete and partial),Overall survival,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2971,NCT00444795,"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected SAEs/SADRs","Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors (RECIST)",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
2972,NCT03302637,Presence or absence of bacterial taxa will be compared in oral and pancreatic samples.,,,1992-12-01,COMPLETED,OBSERVATIONAL,['NA']
2973,NCT03179540,Rate of macroscopically positive resection margin,Bowel Function,,2018-03-16,RECRUITING,INTERVENTIONAL,['NA']
2974,NCT02730702,Whether rectal LEBS readings can predict the presence of advanced adenomas in the colon.,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
2975,NCT04452396,study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia,assessing concordance between CGMS and lab/finger prick glucose testing,,2019-12-01,TERMINATED,INTERVENTIONAL,['NA']
2976,NCT03397654,Incidence of treatment-emergent adverse events (safety and tolerability),Improvement of progression-free survival rate (PFSR; efficacy),,2018-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2977,NCT01043523,Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure,"Sensitivity, Specificity and Accuracy of Blinded Read of Precontrast and Combined Precontrast/Postcontrast Images Based on Final Diagnosis.",Change in Information About Lesion Characterization Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images,2009-12,COMPLETED,OBSERVATIONAL,['NA']
2978,NCT01387555,Survival,Time-to-symptomatic-progression,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2979,NCT00801294,PFS,Effectiveness of dose reduction guidelines in managing adverse events,,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2980,NCT00416494,Response Rate (Percentage of Participants With Partial or Complete Response),Safety and Tolerability,Effect on Wound Angiogenesis,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2981,NCT06194981,Overall Survival,Adverse Events,,2024-01-11,RECRUITING,OBSERVATIONAL,['NA']
2982,NCT02485119,"tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me",Immunogenicity evaluation based on anti-BAY94-9343 antibody count,,2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE1']
2983,NCT05201430,3-year disease free survival,adverse event,,2021-08-27,RECRUITING,INTERVENTIONAL,['PHASE3']
2984,NCT00663819,Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak,"Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses.",,2008-04,TERMINATED,INTERVENTIONAL,['NA']
2985,NCT02284529,To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2986,NCT02991638,Adverse events and severe adverse events,,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2987,NCT02151448,"Adverse Events Possibly, Probably or Definitely Related to Study Treatment",Tumor Necrosis Factor (TFNα) Cytokine Levels,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2988,NCT03329495,number of lymph nodes retrieved,operative time,,2018-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2989,NCT06102785,Progression Free Survival,Overall survival,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
2990,NCT00427349,Four-month Progression-free Survival Rate,Objective Response Rate,,2008-11-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2991,NCT01972490,the rate of patients converted to resection for liver metastases,tumor response,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2992,NCT02842203,ctDNA assessment and relation to clinical outcome,ctDNA versus CEA,,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2993,NCT06076265,Positive detection rate of CEA,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
2994,NCT00074867,"At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.","Given the outcome of the primary objective, analysis of secondary objectives were not formalized.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2995,NCT04184960,Operative links on gastric intestinal metaplasia (OLGIM),,,2019-12-05,RECRUITING,OBSERVATIONAL,['NA']
2996,NCT02041897,Rate of change of diagnosis,Number of Participants with Adverse Events,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
2997,NCT01439594,Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions,,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
2998,NCT01058655,Progression-Free Survival (PFS) [Phase II],Overall Survival (OS) [Phase II],,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2999,NCT05996276,Overall survival (OS),Progression-free survival (PFS).,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
3000,NCT00822718,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
3001,NCT00388037,Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3002,NCT00578071,Number of Participants With Dose-limiting Toxicities (DLTs),Pathological Complete Response Rates Associated With This Regimen.,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3003,NCT02817425,Overall Survial (OS),Dose intensity,,2013-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3004,NCT05944237,Number AEs Related to Atezolizumab (Dose Escalation and Expansion Phase),Assess change in tumour T cell infiltration in baseline and on-treatment biopsies,,2023-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3005,NCT00081848,,,,2004-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
3006,NCT04127734,1-year stomafree survival,1 year mortality,Hospital related costs,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
3007,NCT03699332,Fluorescent signal at time of surgery,Optimal dose of the dual-labeled antibody preparation,,2018-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3008,NCT05128708,detection of post operative wound infection in both groups,,,2020-08-07,COMPLETED,INTERVENTIONAL,['NA']
3009,NCT05704530,To observe the ctDNA MRD dynamics during adjuvant immunotherapy .,,,2023-03-29,RECRUITING,INTERVENTIONAL,['NA']
3010,NCT04777942,"Progression-free survival, PFS","Overall survival, OS",,2021-02-20,RECRUITING,INTERVENTIONAL,['NA']
3011,NCT05982184,Patient reported anxiety measured by the 6-item Spielberger State-trait Anxiety (STAI-6) inventory at admission.,Quality of recovery is a comprehensive 40-item questionnaire (QoR-40) used to assess the rate of recovery after surgery.,Rate and type of complications during surgery as recorded in the EHR,2023-10-03,RECRUITING,INTERVENTIONAL,['NA']
3012,NCT05304936,Determine the maximum tolerated dose (MTD),Duration of Response,,2022-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3013,NCT05445570,Specificity of the InterVenn test,,,2022-05-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3014,NCT04519138,Proportion of patients with pre-specified adverse events,Amount of visible biopsy material over or under 5 mm at endoscopy examination,,2020-09-30,COMPLETED,INTERVENTIONAL,['NA']
3015,NCT05669339,Maximally tolerated dose,Change in the biomarker TGF-B,,2024-04,RECRUITING,INTERVENTIONAL,['PHASE1']
3016,NCT04624555,Participant acceptance of mt-sDNA as a follow up strategy compared to colonoscopy as measured by the Stool Test Satisfaction Survey.,,,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3017,NCT03792854,Qol (EORTC QLQCR29) absolute values and change over time,late toxicity,,2018-12-01,RECRUITING,OBSERVATIONAL,['NA']
3018,NCT00974389,Disease-control rate,Safety,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
3019,NCT05506943,Best Overall Response,Exposure Response by Pharmacokinetic (PK) Sampling,,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3020,NCT05407519,RFS rate,AEs,,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
3021,NCT05967429,Assess the quality of life,,,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3022,NCT00185081,"Pharmacokinetics, biodistribution and dosimetry of In-IMP-205",,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3023,NCT00066651,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3024,NCT01853059,Functional quality of life after chemoradiotherapy for anal cancer,Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
3025,NCT01156142,Total Pain Reduction (Mouth and Throat),Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3026,NCT04154748,Complete ablation rate 6 weeks after APC treatment.,Complete ablation rate at the end of follow-up,,2002-06-04,COMPLETED,INTERVENTIONAL,['NA']
3027,NCT00812864,"Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.","Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6.",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3028,NCT03406299,6-month progression-free survival rate,Biomarker study,,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3029,NCT03957902,Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues,Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis,,2019-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3030,NCT04729322,Objective response rate,,,2021-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3031,NCT06137170,Overall Survival (OS),"Proportion of patients in the sequential treatment groups who received myelopoiesis supporting therapy, differentiating between prophylactic and for therapeutic purpose",,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3032,NCT00454519,overall survival time,perioperative morbidity and mortality,,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
3033,NCT05038397,Recurrence free survival (RFS) after resection,Rate of post operative hepatic decompensation,,2018-01-30,COMPLETED,INTERVENTIONAL,['NA']
3034,NCT01205711,Progression-free survival,Overall survival,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3035,NCT03702309,Collection and annotation of biospecimens,Correlative Studies Questionnaire,,2017-08-03,RECRUITING,OBSERVATIONAL,['NA']
3036,NCT03041532,Proximal retroflexion improve adenoma detection rate in colorectal cancer screening,Pre-procedure factors,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
3037,NCT00763646,To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.,,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3038,NCT02548910,Trial Feasibility,Change in Physiologic Parameters (Cardiac Index),,2016-04,COMPLETED,INTERVENTIONAL,['NA']
3039,NCT05254327,Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic Toxicities,,,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE2']
3040,NCT02547064,Time to Intubation,Airway Injury,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
3041,NCT00115765,Objective Tumor Response Through Week 12 (Irinotecan),Time to Treatment Failure (Irinotecan),,2005-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3042,NCT02528110,overall survival,complication rate,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3043,NCT01563991,Morbidity,,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
3044,NCT00416858,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3045,NCT01915693,patient-reported dysphagia,cost,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3046,NCT05601388,evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.,,,2022-10-01,RECRUITING,OBSERVATIONAL,['NA']
3047,NCT04771715,Overall Survival,Incidence of treatment-related adverse events (TRAE),,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
3048,NCT03362684,Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS),Prognostic and predictive value of miR-31-3p expression on SAR,Distribution of miR-31-5p expression,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3049,NCT02340949,Number of Patients Achieving Pathologic Complete Response (pCR).,Disease Free Survival (DFS) Rate at 3 Years,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3050,NCT00020345,,,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3051,NCT02754180,Disease free survival,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
3052,NCT00588575,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
3053,NCT02361320,Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT),,,2015-03-09,RECRUITING,INTERVENTIONAL,['NA']
3054,NCT02825550,Tumor Response (Efficacy),Serum Level of AFP,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
3055,NCT03685708,Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL),Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.,,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3056,NCT02575378,Progression-free survival,,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
3057,NCT03222895,Distribution of lymph node metastases,3- and 5-year overall and disease free survival,,2019-03-01,RECRUITING,OBSERVATIONAL,['NA']
3058,NCT01143545,Tabulation of toxicity type and grade,"To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.",,2010-12-07,TERMINATED,INTERVENTIONAL,['PHASE1']
3059,NCT03550625,Assessment of the computer- made optical diagnosis of each colorectal polyp,,,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA']
3060,NCT05185505,Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection,Immune Cell Biomarkers,,2023-01-30,RECRUITING,INTERVENTIONAL,['PHASE4']
3061,NCT01969591,solid diet time,"Complications:anastomotic leakage,intestinal obstruction,wound infection",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
3062,NCT00256269,To assess the overall response rate,Evaluation of Time to Death,,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2']
3063,NCT03950141,progression-free survival,overall survival,Safety and tolerability as measured by number and grade of toxicity events,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3064,NCT05944809,The highest grade of thrombocytopenia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.,"The highest grade of leukopenia, neutropenia,anemia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.",,2023-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3065,NCT04831814,Rate of accurate diagnosis of sessile serrated polyps/adenoma by the Endoscopists in the two groups.,Diagnostic Characteristics,,2019-04-04,COMPLETED,INTERVENTIONAL,['NA']
3066,NCT01151852,Progression-free Survival,Safety and Tolerability of Imatinib,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3067,NCT05961982,Efficacy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA),Safety of EUS-guided RFA of pancreatic cystic neoplasms at one year,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
3068,NCT04190498,The study will compare OSA prevalence in a group of patient curatively resected for NASH-related HCC with a group of HCV-related HCC.,The study will compare non-recurrence-free survival rate between groups.,,2020-01-21,WITHDRAWN,OBSERVATIONAL,['NA']
3069,NCT03811431,Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination.,,,2011-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3070,NCT00234429,Determine the progression free survival,Determine objective tumor response,,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3071,NCT02164149,CT scan after colon cancer surgery. The length of the tumour feeding artery will be measured on the images.,,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
3072,NCT01845753,Rate of Lynch Syndrome in a population of primary colorectal cancer,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
3073,NCT02085460,Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events (CTCAE) Version 3.0.,Number of Subjects Who Did Not Developed Grade ≥3 Mucositis,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3074,NCT03985072,Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study,Incidence of Andes-1537 anti-drug antibodies (ADAs) in the plasma,Evaluate the exploratory response of tumor markers,2019-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
3075,NCT04989855,ORR,Safety and Tolerability,,2021-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3076,NCT02314117,Progression-free Survival (PFS),PK: Minimum Concentration (Cmin) of Ramucirumab,,2015-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
3077,NCT01375569,Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).,Count of Participants With Adverse Events,,2011-06-22,COMPLETED,INTERVENTIONAL,['PHASE2']
3078,NCT01569282,Morbidity,"The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions",,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
3079,NCT03516695,Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting,TheraSphere® Dosimetry in the subgroup of HCC participants,,2018-02-23,TERMINATED,OBSERVATIONAL,['NA']
3080,NCT05342350,GALAD performance for liver cancer early detection,Establishment of a bio-repository of longitudinally collected from patients with cirrhosis to be used for future studies,,2022-04-15,RECRUITING,OBSERVATIONAL,['NA']
3081,NCT02145013,Mortality,Survival outcomes,Impact of PET CT on overall survival following liver resection,2013-11,UNKNOWN,OBSERVATIONAL,['NA']
3082,NCT02121366,Safety of EUS-guided ethanol ablation,Technical feasibility,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
3083,NCT05983419,Safety for full resection in BE,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3084,NCT05608200,Overall survival (OS),Adverse Events (AEs),,2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
3085,NCT05420415,5-year DFS,5-year OS,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
3086,NCT01010360,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
3087,NCT04359732,Imaging parameters as potential predictors of tumor response,Early regression model (ERI),,2020-05-08,RECRUITING,INTERVENTIONAL,['NA']
3088,NCT05257694,Recurrence-free survival (RFS),Recurrence,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
3089,NCT03269903,Through-the-scope stent placement (feasibility): incidence of device related adverse device events at moment of stent placement,"Retrosternal pain related to esophageal stent, measured with the Visual Analog Scale (functional outcome)",,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
3090,NCT00502671,"Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE",Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3091,NCT03121729,occurrence rate of severe complications,Procalcitonin,,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA']
3092,NCT01900002,Median Progression Free Survival (PFS),"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0",,2013-09-13,COMPLETED,INTERVENTIONAL,['PHASE2']
3093,NCT05956990,Fear of Progression Questionaire-Short Form (FoP-Q-SF),Platelet count,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3094,NCT04573088,Postoperative pain as measured by VAS score,Anxiety and depression measured by State-Trait Anxiety (STAI) questionnaire,,2020-06-22,UNKNOWN,INTERVENTIONAL,['NA']
3095,NCT02856815,Recurrence Free Survival (RFS),Hematological examination,,2018-05-28,COMPLETED,INTERVENTIONAL,['PHASE2']
3096,NCT03475004,Objective Response,Adverse Events,,2018-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3097,NCT05732623,Diet and the risk of eoCRC,,,2022-12-05,RECRUITING,OBSERVATIONAL,['NA']
3098,NCT01034358,Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]),,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3099,NCT00287859,Maximum tolerated dose,,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3100,NCT04229537,Rate of adverse events,Overall survival (OS),,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
3101,NCT01491217,Overall response rate(ORR) evaluation,,,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3102,NCT02057471,Hemoglobin levels,C Reactive Protein levels,Number of adverse events associated with intravenous iron infusion,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3103,NCT04235660,Feasibility of Recruitment (Recruitment Rate),Objective Response Rate,,2020-07-22,TERMINATED,INTERVENTIONAL,['NA']
3104,NCT05239741,Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants,Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE),,2022-04-02,RECRUITING,INTERVENTIONAL,['PHASE3']
3105,NCT02748798,Signal to Noise Ratio,Correlation with PFTs,,2020-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3106,NCT03382327,Comparison of the intra-operative modifications rates,Preoperative images independent analysis,,2017-10-16,COMPLETED,INTERVENTIONAL,['NA']
3107,NCT04013841,Intestinal microbiome composition,Intestinal microbiome composition,,2021-04-08,COMPLETED,INTERVENTIONAL,['NA']
3108,NCT01325649,Locoregional recurrence rate,Rate of involvement of circumferential resection margin (pCRM positive of resected specimens,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
3109,NCT04158349,"Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with unresectable peritoneal carcinomatosis of colorectal or appendiceal origin",The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured.,,2021-03-22,TERMINATED,INTERVENTIONAL,['PHASE1']
3110,NCT01552200,NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3111,NCT04444167,Objective response rate (ORR),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2020-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3112,NCT00838656,Percentage of patients completing 12 courses of chemotherapy,Rates of optimal and suboptimal interval debulking,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
3113,NCT02437656,The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).,Sphincter preservation rate and downstaging rate,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3114,NCT01461525,Quality of life outcome,Anal function,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
3115,NCT00991003,The primary endpoint was the number of cancerous lesions and polyps detected on CCE compared to conventional colonoscopy,"Secondary endpoints were completeness of the exam completeness, patient acceptance and adherence to preparation regimen",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
3116,NCT00215514,"To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.",,,2000-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3117,NCT03956940,Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.,Overall Survival,,2019-10-04,TERMINATED,INTERVENTIONAL,['NA']
3118,NCT00826410,number of surgical site infections according to CDC guidelines after laparotomy in general surgery,risk factors for surgical site infections,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3119,NCT01043484,Rate complete pathologic responses,Rate of sphincter preservation,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3120,NCT01572987,Complete histological eradication of Barrett's esophagus,Complication rates,,2011-09,TERMINATED,INTERVENTIONAL,['NA']
3121,NCT01905384,Rate of Long-term Stent Failure,Rates of Adverse Stent-related or Intervention-related Outcomes,,2017-11-08,COMPLETED,INTERVENTIONAL,['NA']
3122,NCT04838496,The main study parameter is the proportion of patients with a pathological complete response (pCR) and those patients who started a wait and see strategy and have sustained clinical complete response (cCR) at 1 year.,Costs,,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3123,NCT04771637,ASA status,internal environment,heart rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
3124,NCT02599324,Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6,Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4,,2015-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3125,NCT04850430,Mortality rate,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3126,NCT00140036,Correlation of genotype with safety and efficacy measures.,,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3127,NCT05307198,pCR rate,Concentration of DAMP,,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2']
3128,NCT05148494,Quality of bowel preparation,Post-operative complications,,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE4']
3129,NCT02890355,Overall Survival (OS),Duration of Response (DoR),Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay,2016-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3130,NCT03602885,Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks,Discussions About End-of-life Care Preferences With Healthcare Proxy and Care Team,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
3131,NCT06215651,Conversion success rate,Overall survival,,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2']
3132,NCT04218253,Incidence of complications at 30 days after surgery,Postoperative hospital stay,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3133,NCT00049400,dose defining,Symptomatic deterioration,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3134,NCT05900583,pathological complete response (pCR),Overall survival (OS),,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3135,NCT03685799,Influence of histological concordance on the risk of recurrence,Identification of histological factors of recurrence.,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
3136,NCT03097276,proportion of patients with total hospitalization of less than 15 days during the first postoperative month,,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
3137,NCT00005021,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3138,NCT04812808,Change in IL-6/GP-130/STAT3 pathway expression (%),Number of patients with adverse events,,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
3139,NCT02150317,the overall survival rate of each group,,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
3140,NCT02509143,Number of patients who experience moderate or severe level nausea or vomiting,Serious adverse events,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
3141,NCT04257526,Improvement in lifestyle score assessed via lifestyle questionnaires,,,2022-03-23,RECRUITING,INTERVENTIONAL,['NA']
3142,NCT00637091,Response rate,"Progression free survival, overall survival",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3143,NCT04066153,Unmet physical functioning needs,Physical activity level,,2019-08-20,COMPLETED,OBSERVATIONAL,['NA']
3144,NCT05366816,Number of Participants Achieving Overall Response,Incidence of Treatment-Related Toxicity and Adverse Events,,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3145,NCT05018208,Quantification of false alerts and downstream clinical actions (Arm 2),Point-in-time assessment of physiological signals from standard of care devices (Arm 1),,2021-12-15,RECRUITING,OBSERVATIONAL,['NA']
3146,NCT01774162,Sampling Adequacy,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3147,NCT01351220,Change from Baseline in receipt of CRC screening at 6 months and 24 months,Change from Baseline in frequency of patient provider communication at 6 months and 24 months,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
3148,NCT00212589,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3149,NCT02721576,Objective response rate,Progression free survival,,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3150,NCT06149481,Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC,Overall survival,,2024-03-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3151,NCT05531331,The change in the adaptation of the experimental group according to the Ostomy Adjustment Inventory-23 scores at the end of the second month,The change in the ability of individuals with stoma to care for their stoma at the end of the 2nd month,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
3152,NCT02589860,Melphalan exposure,,,2015-10-30,WITHDRAWN,OBSERVATIONAL,['NA']
3153,NCT00635323,Overall response rate,Laboratory tests,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3154,NCT03743883,Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use,Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA']
3155,NCT05643105,Anastomotic leak,Local recurrence,Intraoperative complications,2022-12-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3156,NCT05602935,Pathologic complete response (pCR) rate,Overall survival(OS),,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3157,NCT02882503,To evaluate pancreatic tumor ablation effect,Biochemical profile,,2016-06,WITHDRAWN,INTERVENTIONAL,['NA']
3158,NCT05726097,Adequate cleanliness rate,Assessment of patient tolerance of the bowel preparations,,2023-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3159,NCT04341909,any procedure related adverse outcome,,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
3160,NCT04637048,Evaluate the overall survival rate of all patients with hepatobiliary tumor,Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor,,2017-02-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3161,NCT04786600,Overall survival,Best overall response,,2021-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3162,NCT05872841,disease control rate (DCR),overall survival(OS),,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3163,NCT02780700,Progression Free Survival (PFS),Percentage of Patients With Grade 3 or Worse Adverse Events,,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3164,NCT01801930,Dose Limiting Toxicity (DLT),Tumor Response Rate in Cycle 1,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3165,NCT04892342,Objective Response Rate (ORR) by Independent Central Review (ICR),ADA,,2021-09-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3166,NCT00003522,,,,1997-08-13,TERMINATED,INTERVENTIONAL,['PHASE2']
3167,NCT05265663,Overall survival,Progression of disease (local and distant),,2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
3168,NCT01861873,volumetric uptake values of 18-FDGal will be measured and the 18-FDGal PET/CT one month after stereotactic body radioation therapy will be compared to the baseline status in sub-volumes receiving more than 15 Gy,evaluate toxicity to SBRT by toxicity scoring system that includes biochemical measures as well as symptomatic scores.,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3169,NCT00244348,overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.,cost,,2005-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3170,NCT05766748,Recommended Phase 2 Dose,Body Weight,,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3171,NCT05223036,Percentage change in duodenal polyp burden,Future candidate biomarkers measured by genomic and transcriptomic platforms in residual tissue biopsies of adenomas and normal mucosa,,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE2']
3172,NCT00183833,To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.,Toxicity.,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3173,NCT02465502,Percentage of participants without disease progression or death at the end of 8 weeks,"Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03",,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE2']
3174,NCT03024684,3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart,occurrence of clinical complications related to hepatic decompensation,,2017-01-03,RECRUITING,INTERVENTIONAL,['PHASE4']
3175,NCT04776655,Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.,Compliance,,2021-04-30,RECRUITING,INTERVENTIONAL,['PHASE3']
3176,NCT02644148,Quality of life,Complications,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
3177,NCT06178939,incidence of postoperative delirium,total score of QOR-40,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3178,NCT01636674,time to recurrence,,,2009-07,UNKNOWN,INTERVENTIONAL,['NA']
3179,NCT05579444,Identification of microbial determinants of gastrointestinal diseases.,Quantify change in microbial species over time post colonoscopy,,2022-11-11,TERMINATED,OBSERVATIONAL,['NA']
3180,NCT01384240,to determine whether tissue in nepoplastic or non-neoplastic,,,2010-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
3181,NCT05740995,Major pathological regression (MPR) rate,"The correlation between detection of genomic, immune, microbial and metabolite features and the rate of therapeutic responses.",,2020-12-01,RECRUITING,OBSERVATIONAL,['NA']
3182,NCT03076216,Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0,Pain Scores,Tumor Response,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
3183,NCT06267417,To measure grade of oral mucositis in patients receiving laser arm placebo arm.,,,2023-04-10,RECRUITING,INTERVENTIONAL,['NA']
3184,NCT01749332,ctDNA differences,collect preliminary data,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
3185,NCT01375738,Blood sugar stabilization after gastrectomy,,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
3186,NCT03242369,Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS),Detection of colorectal neoplasia,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
3187,NCT02128958,Number of Subjects With Overall Survival,"Pharmacokinetics (PK) Parameters of CF102 - AUC_0-12, Steady State (ng*h/mL)",,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3188,NCT05415475,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],Pharmacodynamics of CEA-CAR-T cells[Cell dynamics],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,2021-09-10,RECRUITING,INTERVENTIONAL,['PHASE1']
3189,NCT00000611,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3190,NCT04980443,Sensitivity of CELTiC,C-statistic of CELTiC,Association between CELTiC test score and FIT concentration,2021-08-03,COMPLETED,INTERVENTIONAL,['NA']
3191,NCT06202781,Single-cell profiling,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
3192,NCT00724503,Progression-Free Survival (PFS) at Any Site,Percentage of Participants With Overall Response,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
3193,NCT02615665,Overall survival,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
3194,NCT01941641,Objective tumour response rate,Number of response to neoadjuvant therapy,,2013-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3195,NCT05815303,pCR,OS,,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2']
3196,NCT03447691,score of QoR40 (Quality of Recovery 40),score of QoR40 (Quality of Recovery 40),,2017-08-27,UNKNOWN,INTERVENTIONAL,['NA']
3197,NCT01464593,Determine the Local Tumor Control at 1 Year Post Randomization,Overall Survival,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2']
3198,NCT05311319,Disease Free Survival (DFS),Safety: adverse events,,2022-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
3199,NCT01359397,Progression free survival,Overall survival,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
3200,NCT01078311,To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma,To correlate trough sorafenib level with side effects (rash and hypertension),,2010-02,UNKNOWN,OBSERVATIONAL,['NA']
3201,NCT00973440,To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.,,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
3202,NCT05881746,relapse-free survival,postoperative mortality,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3203,NCT05584540,Enrollment Rate,CSQ-I Score,The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3204,NCT04833387,Pathological complete response,Clinical complete response (CCR),,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3205,NCT02527577,consumption of morphine over the first 48 hours postoperative.,pharmacokinetic of ropivacaine (plasma concentrations),,2010-04,TERMINATED,INTERVENTIONAL,['NA']
3206,NCT04929015,Correlation of ctDNA clearance with activity of chemotherapy,Associations between CA125 levels and ctDNA levels,,2021-04-29,RECRUITING,INTERVENTIONAL,['NA']
3207,NCT02119026,Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination),Tumour Assessments (Based on RECIST Criteria) in 2nd-line,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3208,NCT03512756,Overall Survival,Progression Free Survival,,2018-03-27,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3209,NCT00103168,Overall survival,Adverse events,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3210,NCT04308837,Pathological Response,Peritoneal Disease-free Survival,,2018-12-03,RECRUITING,INTERVENTIONAL,['PHASE2']
3211,NCT03954548,Adenoma miss rate [AMR],Polyp Miss Rate [PMR],,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
3212,NCT04479527,PFS,Incidence of AE and SAE,,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3213,NCT02273362,Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining),Adverse Event Profile,Erlotinib Hydrochloride Plasma Level,2014-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3214,NCT01955096,food intake time,readmission,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
3215,NCT04522011,The incidence of postoperative complications,,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3216,NCT04847297,rate of serious complications,Mortality,,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3217,NCT02141295,"Progression-free Survival (PFS), Time to Event",Cmax Accumulation Ratio (AR) of Vanucizumab,,2014-06-30,TERMINATED,INTERVENTIONAL,['PHASE2']
3218,NCT04724226,Objective response rate (ORR) by RECIST 1.1 and mRECIST,Median overall survival time (mOS),Treatment-related adverse events,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3219,NCT04515615,The incidences and types of adverse events,Treatment completion rate,,2020-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3220,NCT05517811,Post-operative thrombotic and hemorrhagic complications,pre-operative distant metastasis,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
3221,NCT03435107,Objective response rates (RECIST 1.1),,,2018-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3222,NCT03068052,Colonoscopy participation,Risk assessment completion,,2017-05-08,COMPLETED,INTERVENTIONAL,['NA']
3223,NCT06065059,Measure anti-tumor activity using RECIST 1.1 (Phase 2 only),Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination,,2023-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3224,NCT04891900,Objective Response Rate (ORR),Duration of Overall Survival (OS),,2021-05,UNKNOWN,INTERVENTIONAL,['NA']
3225,NCT01432314,Time to tumor progression,Best tumor response by modified RECIST (mRECIST) and RECIST criteria,,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3226,NCT00084604,"Time to progression, evaluated using RECIST","Incidence of toxicity, evaluated using CTCAE version 3.0",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3227,NCT00077519,,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3228,NCT05846594,Median Time to Diagnosis,Incidence and Severity of Liquid Biopsy Sample Collection-Related Adverse Events,,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE4']
3229,NCT00727831,Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data,Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3230,NCT01126346,"Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population","Improve overall post-operative QOL ratings at 3 months, relative to discharge",,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3231,NCT04182386,Future liver remnant hypertrophy,Effect of sarcopenia on hypertrophy,,2012-08-01,UNKNOWN,OBSERVATIONAL,['NA']
3232,NCT00565708,Disease-free survival,Overall survival,,2008-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3233,NCT04536922,Treatment,,,2021-01-27,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3234,NCT06335147,pathologic complete response（pCR）,Incidence of Treatment-Emergent Adverse Events,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3235,NCT05620628,PFS (progression free survival),ORR (objective response rate),,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3236,NCT05291988,Demographic information,COVID-19 impact assessment,,2022-10-08,TERMINATED,INTERVENTIONAL,['NA']
3237,NCT00707681,To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients,"Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight",,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
3238,NCT06013774,Device Feasibility,Radioactivity distribution in 3D,,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
3239,NCT03563248,Proportion of participants with R0 resection,Number of participants with treatment related serious adverse events,,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3240,NCT00023634,toxicity,,,2001-06,TERMINATED,INTERVENTIONAL,['PHASE1']
3241,NCT04677244,Procedure impact,,,2021-11-11,RECRUITING,INTERVENTIONAL,['NA']
3242,NCT04334421,Comprehensive Complication index,Perineal hernia,,2020-04-03,COMPLETED,OBSERVATIONAL,['NA']
3243,NCT02887612,Positive Predictive Value,prognostic molecular markers,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
3244,NCT01694342,,,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
3245,NCT02630420,Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events,Progression free survival,"Changes in genetic aberrations over the course of the disease by comparing archival, baseline and progression samples.",2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3246,NCT00503776,Number of Patients With Each Degree of Swallowing Dysfunction,Changes in the Frequency and Types of Dietary Intakes,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3247,NCT04947826,Objective response rate,Overall survival rate at 12-month time point,Discontinuation rate due to any adverse events,2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3248,NCT02112747,Successfully following screening guidelines appropriate to the participant's risk profile,Cost effectiveness of the interventions,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
3249,NCT04682158,Progression Free Survival,Overall Survival,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3250,NCT02486497,Recurrence free survival,Toxicity,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
3251,NCT05531864,visual analogue scale,Intraoperative heart rate changes,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
3252,NCT00579579,"To prospectively evaluate bowel, sexual and bladder function in patients who undergo resection for stage I-III rectal cancer.","To evaluate the expectations, informational needs and satisfaction with the surgical consent process in patients undergoing resection for stage I-III rectal cancer.",,2006-11-28,COMPLETED,OBSERVATIONAL,['NA']
3253,NCT06061146,PFS,AE,,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3254,NCT06219096,Fluorescence imaging effect of the live,Postoperative hospital stay,Disease-free survival,2023-12-10,RECRUITING,INTERVENTIONAL,['NA']
3255,NCT03724071,Phase II part - Overall response rate,,,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3256,NCT01980810,response rate,number of adverse event,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2']
3257,NCT06017323,Proglumide Recommended Phase II dose and schedule (RP2D),Change in tumor marker (CA19-9),,2023-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3258,NCT02760537,self-reported status of the series of HBV vaccinations by follow-up calls in seven months after mailing the results verified by the medical records,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
3259,NCT03869892,Progression-free Survival (PFS),Time to treatment failure (TTF),,2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3260,NCT05319431,Progression-free survival (PFS),Number of participants with adverse events (AEs),,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2']
3261,NCT05727787,Maximum tolerated dose (MTD) of Single Fraction GRID SBRT,Molecular correlatives: TCR repertoire analysis.,,2023-02-23,RECRUITING,INTERVENTIONAL,['NA']
3262,NCT06141109,PFS,Area Under the Plasma Concentration Versus Time Curve (AUC) of MB07133,,2022-01-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3263,NCT02859753,Time to disease progression according to American Society of Interventional Radiology criteria,,,2014-01-15,COMPLETED,INTERVENTIONAL,['NA']
3264,NCT00321100,Objective Response Rate (ORR),Overall Survival,,2006-04-12,TERMINATED,INTERVENTIONAL,['PHASE2']
3265,NCT01065818,"Optimal Timepoint During the Course of Neoadjuvant Therapy [CRT, CT (Chemotherapy) or RT Radiotherapy)] That FLT-PET Imaging Can Predict Response",,,2009-08,TERMINATED,INTERVENTIONAL,['NA']
3266,NCT05646537,stoma compliance scores of the participants,comfort level of the participants,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
3267,NCT02515734,Best deepness of response,Number of adverse events,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3268,NCT00030498,Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3269,NCT03401814,"Quantify tissue mechanical properties of the liver and liver tumor using MRE in patients receiving radiation therapy + immunotherapy at baseline, mid-treatment and time of followup imaging determined by standard of care to assess response to therapy",,,2018-08-02,COMPLETED,OBSERVATIONAL,['NA']
3270,NCT05990569,Patient satisfaction assessed using the Likert scale after receiving Bupivacaine pudendal nerve block with or without Methylene Blue.,Complications,,2023-08-12,RECRUITING,INTERVENTIONAL,['NA']
3271,NCT02575339,Phase II: Time to Progression (TTP),Phase II: Radiographic Response Rate (RRR),,2016-07-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3272,NCT05544929,Dose intensity,Elimination half-life (T1/2) of KFA115 or pembrolizumab,,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE1']
3273,NCT05510895,Tumor regression grade (TRG),Translational research 3,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3274,NCT02517554,Completion of Surveys,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
3275,NCT03595904,Number of Participants Who Completed a Screening Colonoscopy,Number of Participants Who Were No-show Appointments,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
3276,NCT05958433,duration of hospital stay,assess the effects of preoperative education using stoma appliance on quality of life in colorectal cancer patients with a stoma,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3277,NCT05967533,Natural killer (NK) cell killing activity,Immunologic effects of FWG (Immune Correlates): serum cytokines analysis,,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
3278,NCT04132505,Maximum tolerated dose (MTD),Overall survival,Effect of this binimetinib/hydroxychloroquine treatment on changes in muscle and fat mass,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE1']
3279,NCT04779151,Overall Response Rate (ORR),,,2021-04-07,SUSPENDED,INTERVENTIONAL,['PHASE2']
3280,NCT04247256,Objective Response Rate,"Biomarkers ABCG2, ABCB1, SRPK1",,2020-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3281,NCT00610636,Both groups of patients were analyzed with intention-to-treat principle. The primary end-point was time-to-progression. The secondary points were overall survival and surgical morbidity.,"Surgical morbidity, Chemotherapeutic complications",,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3282,NCT02198898,incidence of adhesive intestinal obstruction,,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
3283,NCT01843049,Dose limiting toxicity(DLT),Late toxicity,Local recurrent rate within the >50% SUVmax region of the primary tumor,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3284,NCT03532204,Progression Free Survival,Quality of life EORTC QLQ CR29,,2019-04-15,WITHDRAWN,INTERVENTIONAL,['NA']
3285,NCT02792842,The discontinuation rate of oxaliplatin due to OIPN,,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3286,NCT00576940,The ratio of postoperative complications (infectious and surgical),assessment of visceral protein turnover,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3287,NCT04514484,Incidence of dose limiting toxicities (DLTs),Human immunodeficiency virus (HIV) viral loads,Change in infiltrating immune cell markers,2021-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3288,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,Cost-benefit analysis,,2019-10-09,RECRUITING,OBSERVATIONAL,['NA']
3289,NCT03400657,overall survival,Differences in overall survival after performing MDT at center,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
3290,NCT00081900,To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.,To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.,,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3291,NCT03506321,Compare chromoendoscopy predictions and HD-WL/NBI predictions of submucosal invasive cancer (SMIC) and residual or recurrent adenoma (RRA) to compare correlation with histological findings,Compare the difference between live endoscopic assessment and use of carefully selected endoscopic images to predict SMIC,,2018-02-07,COMPLETED,INTERVENTIONAL,['NA']
3292,NCT05955833,"89Zr-trastuzumab uptake (standard uptake values (SUVmean, %ID/kg) in normal organs/tissues and bloodpool in historical controls with HER2+ breast cancer (n = 20) who underwent 89Zr-trastuzumab PET imaging.",HER2 expression measured by IHC on tumor biopsies,,2023-06-26,RECRUITING,INTERVENTIONAL,['PHASE1']
3293,NCT03255811,Evaluation of apatinib mesylate tablets as first-line maintenance treatment for advanced gastric or gastroesophageal junction progression free survival site adenocarcinoma,,,2017-03-25,UNKNOWN,INTERVENTIONAL,['NA']
3294,NCT02665741,Adenoma Detection Rate,Withdrawal Time,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3295,NCT01126645,Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT,safety of SIR Spheres,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3296,NCT06001372,The rate of study completion by enrolled participants. Study completion is defined as participating in at least 2 of the 3 Ketamine-Assisted Psychotherapy (KAP) sessions.,The proportion of screened patients that meet criteria on the Existential Distress Scale (EDS: Single domain ≥ 3 or total score ≥ 6).,,2023-10-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3297,NCT01658878,ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort,Effective T-Half of nivolumab,,2012-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3298,NCT04861987,Maximum Plasma Concentration (Cmax) of capecitabine,Number of participants with Adverse Events of Special Interest (AESI),,2021-06-18,RECRUITING,INTERVENTIONAL,['PHASE1']
3299,NCT00976898,Median Overall Survival,Patterns of Failure,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
3300,NCT04873895,Serious adverse event (SAE) rate,axitinib treatment intensity,,2022-01-24,RECRUITING,INTERVENTIONAL,['PHASE1']
3301,NCT05158374,"Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel",Change in the proportions of bacterium the colorectal microbiome after aspirin and/or metformin medication,,2022-08,UNKNOWN,INTERVENTIONAL,['NA']
3302,NCT04267549,R0-surgery conversion rate,surgery-related complications,pathological response,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3303,NCT05914077,Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.,Proportion of patients with Serious Adverse Events,,2023-09-13,RECRUITING,INTERVENTIONAL,['PHASE3']
3304,NCT03041129,Hepatic fat fraction,Hepatic phosphate concentrations,,2017-04-14,COMPLETED,OBSERVATIONAL,['NA']
3305,NCT03084133,Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.,"Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale.",,2017-04-10,COMPLETED,INTERVENTIONAL,['NA']
3306,NCT00096070,1-year survival rate,Time to treatment failure,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3307,NCT04889404,Incidence of adverse events related to the safety specifications,,,2021-05-22,RECRUITING,OBSERVATIONAL,['NA']
3308,NCT05518903,Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDA,,,2022-11-15,RECRUITING,INTERVENTIONAL,['PHASE2']
3309,NCT00112918,Disease-free Survival in Stage III Cancer Patients - Number of Events,Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3310,NCT00199797,"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.","Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin.",,2005-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
3311,NCT04640103,Adverse event rate,Incidence of second tumor in patients with Lynch syndrome,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3312,NCT02062515,Number of Participants with Adverse Events,,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
3313,NCT02143401,Incidence of adverse events,Time to treatment failure,Change in cleaved and total CK18 levels in serum,2014-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3314,NCT05173246,Objective response rate (ORR),Severe toxicity,,2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3315,NCT04800549,Nurse Observation Chart of Child Mucositis Evaluation,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3316,NCT00280332,The prevalence of advanced colonic adenoma in the re-screening population,The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
3317,NCT02195011,The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety,Median Overall Survival,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3318,NCT05745558,Percentage of patients willing to participate in prehabilitation program,Work status,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
3319,NCT00443040,Time to Return of Upper and Lower GI Function,Laboratory Values,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3320,NCT00569309,Number of Participants Experiencing Immune Reconstitution,Collection of Baseline Immune Reconstitution and Quality of Life Pilot Data for Comparison in Future Post-transplant Immunotherapy Trials,,2007-12-12,COMPLETED,INTERVENTIONAL,['NA']
3321,NCT00683085,Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events,Number of Participants With Tumor Regression,,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3322,NCT04509492,The number of patients with occult hepatic metastasis missed by CT or MRI during staging of pancreatic and GI malignancy.,,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
3323,NCT04301557,Pathological Complete Response(pCR),3 year disease free survival,,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE2']
3324,NCT05443217,Long-term outcomes after treatment,Objective response rate,,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3325,NCT06067620,Time to first passage of faeces,Incidence of incisional hernia,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3326,NCT05162118,RP2D (phase 1),CEA,,2022-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3327,NCT05173909,"Serum LEVELS of IL-2, IL-4, IL-6, IL-10, TNF-ɑ, IFN-γ",,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
3328,NCT05682794,disease-free survival ratev,DRM status,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
3329,NCT01373021,total amount of administered fentanyl,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3330,NCT02366819,R0 (analysis will be performed evaluating the R0 rate),Progression free survival,Change in SUVmax for the primary esophageal tumor,2014-12-11,RECRUITING,INTERVENTIONAL,['PHASE4']
3331,NCT00756548,Efficacy - Preparation Quality Using a 4 Point Scale,Serum Chemistry Results (Osmolality),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3332,NCT01350167,Efficacy of screening measure to detect very early/early stage HCC (Barcelona Clinic Liver Cancer Staging System),Cost - Effectiveness of screening measure,,2001-11,UNKNOWN,INTERVENTIONAL,['NA']
3333,NCT00341276,Linkage of genetic markers,Gene environment interactions (case control),,1995-07-06,COMPLETED,OBSERVATIONAL,['NA']
3334,NCT00056355,,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3335,NCT01772407,Cost during the 2 postoperative years,"Mortality, morbidity and quality of life during the 2 postoperative years",,2009-09,COMPLETED,OBSERVATIONAL,['NA']
3336,NCT04010071,Progression-free Survival (PFS),Rate of 6-months and 1-year overall survival,Tumor mutation burden,2020-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3337,NCT05519319,Overall survival (OS),Progression-free survival(PFS),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
3338,NCT02243358,Frequency of R0 Resection,,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3339,NCT01341132,,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
3340,NCT00023946,Overall survival,,,2001-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3341,NCT04615013,Maximum tolerated dose and recommended phase 2 dose (RP2D),Overall survival,Concordance of cell free deoxyribonucleic acid (DNA),2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1']
3342,NCT04751773,Serious adverse events,Surgical stress: Noradrenaline,LPS-induced TNF-a production of whole blood,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3343,NCT00414570,correlate 18F-FLT uptake with hENT1 expression with biopsy samples where available,to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre,,2007-11,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
3344,NCT05890742,"Event Free Survival, EFS(EFS), defined as the time from randomization to the first determination using RECIST v1.1 of inoperable disease progression, local recurrence or distant metastasis after surgery, or death from any cause, whichever occurs first.","Overall-survival(OS), defined as the time from randomization to death from any cause",,2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE3']
3345,NCT03993743,Incidence and type of adverse events induced by CD147-CART hepatic artery infusions,CD147-CART detection in extrahepatic sites,,2019-05-27,UNKNOWN,INTERVENTIONAL,['PHASE1']
3346,NCT06246630,Objective Response Rate,Concordance between drug sensitivity test results and patients' treatment response,,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3347,NCT02965976,Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study,Quality of Life Score as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 OES18,,2016-12-30,COMPLETED,INTERVENTIONAL,['PHASE2']
3348,NCT02207959,Gastric neoplasia presence,Specificity for the detection of neoplasia,,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1']
3349,NCT04690972,Surgery for a hepato-bilio-pancreatic issue,,,2020-12-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3350,NCT05395780,Objective response rate (ORR),Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy,,2022-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3351,NCT02890511,Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD),PK parameters for DHP107 derived from determining their plasma concentrations using validated assays.,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3352,NCT02511522,Proportion of patients achieving improvement of liver cancer pain/discomfort,Proportion of patients reporting clinically significant improvement in QoL from baseline to day 30 and day 90,,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3353,NCT00769730,HBV viral load,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
3354,NCT03993873,Define the Recommended Phase 2 Dose,Overall survival (OS),,2019-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3355,NCT03702491,PFS,,,2018-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
3356,NCT00120172,"To evaluate the efficacy (measured by time to progression) of oxaliplatin, capecitabine, and bevacizumab as first-line therapy in elderly patients with metastatic colorectal cancer.",Vulnerable Elders Survey (VES-13) and Geriatric Depression Scale (GDS) scores,,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3357,NCT03423056,Peak oxygen comsumption,Peak oxygen comsumption - 3 weeks,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
3358,NCT03598166,Percentage of Participants Who Undergo Screening Within 6 Months of Outreach,Self-reported Most Common Reasons for Refusing Blood Test on Questionnaire in Intervention Group,,2018-10-11,COMPLETED,INTERVENTIONAL,['NA']
3359,NCT01908322,"Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).",Safety variables will be summarized using descriptive statistics based on adverse events collection.,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
3360,NCT05709197,Delayed gastric emptying (DGE),Functional outcome at 12 months,,2023-04-17,RECRUITING,INTERVENTIONAL,['NA']
3361,NCT01325883,The relative decrease in exercise capacity (LT) associated with NAC prior to upper gastrointestinal cancer resection will predict outcome (1 year mortality) following surgery.,Patients whose LT changes following NAC so that they move into a higher risk category will have a worse outcome (1 year mortality) when compared with those who do not increase risk category.,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
3362,NCT03082079,progression-free survival,patient satisfaction scores,,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
3363,NCT05687747,Sensitivity of FAPI-PET/MRI to detect intrahepatic HCC using contrasted multiphasic MRI liver as standard comparison,Sensitivity estimation of 68Gallium-FAPI-46 PET/MRI in per-lesion analysis for all lesions with available surgical resection samples for histopathology assessment,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3364,NCT02125929,Pancreatic fistula rate,Mortality rate,Hospital stay time,2014-04,COMPLETED,INTERVENTIONAL,['NA']
3365,NCT01222689,Survival at 24 Weeks,Number of Patients With Dose Modifications and Reason for Dose Modification.,Plasma Biomarkers Potentially Predictive of Dual MEK/EGFR Inhibition,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3366,NCT02510118,Quality of life,Progression-free Survival (PFS),,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3367,NCT06236464,Primary Endpoint,Secondary Endpoint,,2023-09-25,RECRUITING,OBSERVATIONAL,['NA']
3368,NCT02022033,Feasibility of Adjuvant FOLFOX-A,Disease-free Survival,,2014-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3369,NCT04454099,Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.,Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
3370,NCT05502198,MELD-score,Quality of life (Questionnaire),,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
3371,NCT06115837,Cancer specific survival,,,2023-09-01,COMPLETED,OBSERVATIONAL,['NA']
3372,NCT00980382,"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic",To investigate the time to progression and overall survival,,2004-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3373,NCT01879904,curative resection rate (3 month),Curative resection rate (1 year),,2010-02,COMPLETED,INTERVENTIONAL,['NA']
3374,NCT06032767,RTOG/EROTC Acute Radiation Reaction Scoring Standard,,,2023-08-14,RECRUITING,OBSERVATIONAL,['NA']
3375,NCT05448846,Change in functional capacity,Rate of mortality,Colorectal Surgery Procedure,2022-04-08,RECRUITING,INTERVENTIONAL,['NA']
3376,NCT00025415,Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug,Child-Pugh Classification,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3377,NCT00832637,Tumor Control Rate,Toxicity,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3378,NCT05170256,Progression free survival (PFS) .,Overall survival,Frequency of PD-L1 status by CPS score,2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2']
3379,NCT00559741,Improvement of hematologic and gastrointestinal tolerance to therapy,Time to progression,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3380,NCT00690677,To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer,Time to tumor progression and response rates,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3381,NCT05414461,Durable clinical benefit,,,2019-03-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3382,NCT06035471,cfDNA methylation markers,,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3383,NCT01176604,Overall survival,,,2010-08-04,COMPLETED,INTERVENTIONAL,['NA']
3384,NCT00001452,"Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.",,,1995-12-14,COMPLETED,OBSERVATIONAL,['NA']
3385,NCT05178576,Recurrence-free survival (RFS) at one year,Immunogenicity,,2022-06-24,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3386,NCT04004234,Progression-free survival (PFS) at 6 months,Number of participants with laboratory test abnormalities,,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3387,NCT00355212,Sustained complete response at one year after the treatment.,costs.,,2001-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3388,NCT03487523,Number of participants taking part in the Scottish national bowel cancer screening programme,,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA']
3389,NCT03542214,Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used),Tumorregression,,2018-04-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3390,NCT00419159,The Number of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST),Biomarkers Predictive of Clinical Benefit (Median PFS and OS by PTEN ) on Everolimus (RAD001) 10mg/Day,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3391,NCT04464967,Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.,Phase 2a - Impact of SNK01 in combination with cetuximab on quality of life in subjects with advanced EGFR cancers evaluated using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13).,,2021-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3392,NCT04327050,success rate,complications,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
3393,NCT02724358,Time to progression,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
3394,NCT02118077,Number of Participants with Serious and Non-Serious Adverse Events,Objective tumor response,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3395,NCT05127759,ORR,OS,,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3396,NCT03507998,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,CGX1321 half life,,2017-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1']
3397,NCT03766633,Accuracy of the LiverVision® software volumetric measurements,Comparison,,2018-04-29,UNKNOWN,OBSERVATIONAL,['NA']
3398,NCT05873621,Number of harvested extra-mesorectal lymph nodes,Time of surgery,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
3399,NCT02205307,Anastomotic Leak Rate,Incidence of Post-Operative Abscess Requiring Surgical Management,,2015-01,TERMINATED,INTERVENTIONAL,['NA']
3400,NCT03465202,Area under the curve (AUC) of capecitabine and metabolites,Time of maximum plasma concentration (Tmax) of capecitabine and metabolites,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
3401,NCT00075686,Overall survival comparison between treatment groups,"Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3402,NCT00220051,Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.,Bowel function and quality of life,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3403,NCT01192763,Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),"Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS",,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3404,NCT04476329,Overall Survival,FACIT FACT-Hep Quality of Life Measurements,,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2']
3405,NCT04615143,Disease-free survival,Major pathological response rate,,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3406,NCT02558868,Overall Survival,Progression Free Survival,,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3407,NCT05138159,Overall Survival,Incidence of Adverse Events,,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3408,NCT06184594,Colorectal Cancer (CRC) Screening completion,The Colorectal Cancer Screening Beliefs Instrument Score,,2024-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3409,NCT01993472,Progression free survival (PFS),Quality of Life,,2013-11,TERMINATED,INTERVENTIONAL,['PHASE2']
3410,NCT02948426,Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b),Time to Disease Progression,Number of Participants With a Grade 3 or Higher Dose-Limiting Toxicity (DLT),2017-02-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3411,NCT06225921,Feasibility of combination adebrelimab and dalpiciclib as assessed by number of participants who experience adverse events,Overall survival (OS),,2023-12-29,RECRUITING,INTERVENTIONAL,['PHASE1']
3412,NCT01334710,Comparison of MRI/CT Scans to Pre-treatment Scan,Toxicity Assessment,,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
3413,NCT01346839,Differences in Time to Documented Follow-up of a Red Flag Suggestive of Cancer,Trigger Positive Predictive Value,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3414,NCT05113459,"pathologic Complete Response, PCR","Overall survival , OS",,2021-12-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3415,NCT06114082,Objective response rate (ORR),Treatment-related serious adverse event,,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2']
3416,NCT05092750,To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.,,,2021-09-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3417,NCT01324856,abdominal complications,,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
3418,NCT06270017,Tumour growth,response evaluation,,2022-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3419,NCT06269978,Half-life,Overall response rate,,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE1']
3420,NCT05493358,5 year disease-free survival by Kaplan Mayer,The percentage of pattern of recurrence/metastasis,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
3421,NCT05101148,Proportion of patients who take each gastrointestinal medication,Time to last measurable concentration (tlast) of selumetinib and N-desmethyl selumetinib,,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3422,NCT06123455,Overall survival (OS),Safety profile,Changes in CD8+ T cell infiltration in tumor tissue,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3423,NCT05534841,Complete response MRI criterion,MRI accuracy,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
3424,NCT01038544,The primary outcome measure will be the accuracy of the combination of EUS and EBUS to correctly diagnose the presence or absence of mediastinal lymph node metastases compared to EUS alone.,Change in treatment plan based on EBUS,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
3425,NCT05679583,R0 rate,Tumor recurrence,,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
3426,NCT01134601,Maximum Tolerable Dose of Selumetinib (AZD6244) Hyd-Sulfate in Combination With Radiation Therapy (RT) and Capecitabine in Participants With Locally Advanced Adenocarcinoma of the Rectum.,"Changes in Phosphorylated ERK (pERK) in Peripheral Blood Mononuclear Cells and Tumor, and Transforming Growth Factor Alpha (TGFa) Levels",Dose-Limiting Toxicity (DLT),2010-05-24,TERMINATED,INTERVENTIONAL,['PHASE1']
3427,NCT01032291,Percentage of Participants With a Response to Treatment During the Proof of Concept Period,Participants With Treatment-Emergent Adverse Events (TEAE),,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2']
3428,NCT02550847,The tumor recurrence rate after operation at 6 months,The overall survival after operation at 6 months,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
3429,NCT00291473,adverse events,immune responses including HER2 and NY-ESO-1 specific IgG and T cells,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3430,NCT06118060,Heart rate variability,Abdominal pain,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3431,NCT02372162,Availability of comprehensive imaging and molecular fingerprint data of individual tumors,Biomarker analysis,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
3432,NCT04600466,To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes,,,2021-01-22,RECRUITING,OBSERVATIONAL,['NA']
3433,NCT03614546,Overall Survival(OS),Minimal volume of liver free from radiation,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
3434,NCT02182804,Accuracy,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
3435,NCT01265576,failure free survival,clinical benefit response,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
3436,NCT03889093,Change in concentrations of PBMC,Change in concentrations of PBMC,,2018-08-09,RECRUITING,INTERVENTIONAL,['NA']
3437,NCT02583815,Number of Participants Who Use PAM Device,Brief Fatigue Inventory (BFI),,2015-08,COMPLETED,OBSERVATIONAL,['NA']
3438,NCT06217094,Maximum tolerated dose,Overall survival,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3439,NCT06181318,Predicting the posthepatectomy hemorrhage after major liver resection,Correlation between remnant liver function after major liver resection and postoperative mortality,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3440,NCT04750772,finial clinical staging（TNM）,SUVmax,,2019-10-16,RECRUITING,INTERVENTIONAL,['NA']
3441,NCT02784652,Pain relief rate,Overall survival,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3442,NCT04727723,Progression Free Survival (PFS),Information about the patient's diagnosis-related group (DRG),,2021-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3443,NCT01929460,Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration,Median Cyst Fluid Amylase,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
3444,NCT01807325,Gene classifier that will classify lesions as benign or malignant with 95% certainty,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
3445,NCT03694431,Caregiver preparedness for caregiving using the Preparedness for Caregiving Scale,HBPC clinician perception of facilitators and barriers to implementation of HBPC services,,2019-01-07,TERMINATED,INTERVENTIONAL,['NA']
3446,NCT04986566,Intervention Acceptability as reported by participants,"Healthcare resource use (e.g., hospital readmission)",,2021-10-19,RECRUITING,INTERVENTIONAL,['NA']
3447,NCT00895388,Quality of LIfe (EQ 5D),ICIQ Urinary function Short form,,2009-05,WITHDRAWN,INTERVENTIONAL,['NA']
3448,NCT00107679,Time to high-grade anal dysplasia or anal cancer,time from low-grade anal dysplasia to normal,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
3449,NCT03254121,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR",,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
3450,NCT00251186,To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.,To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.,,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2']
3451,NCT04111029,Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment,Mortality,,2020-01-16,RECRUITING,OBSERVATIONAL,['NA']
3452,NCT01528878,Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT.,Overall Survival of Patients With Liver Cancer or Metastases to the Liver,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
3453,NCT02038114,Impact of Patient Pamphlets on knowledge,Impact of patient education pamphlets on health-related quality of life (HRQoL),Impact of patient education pamphlets on patient satisfaction with care,2013-09,COMPLETED,INTERVENTIONAL,['NA']
3454,NCT04118933,objective response rate,,,2019-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
3455,NCT03870607,Response rate (clinical and radiological),Variation of systemic immune parameters,,2019-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
3456,NCT01754636,Inclusion in at least one Clinical trial (amendment n°3 -02/2014),Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014),,2012-11,COMPLETED,OBSERVATIONAL,['NA']
3457,NCT03478488,Overall Survival (OS),Time to progression (TTP),,2018-04-16,RECRUITING,INTERVENTIONAL,['PHASE3']
3458,NCT05471596,Prospective Power/Time Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Sold Tumors Utilizing a Single Generator at a Single Surgical Center,90 day complication rate,,2022-02-14,COMPLETED,OBSERVATIONAL,['NA']
3459,NCT00515853,Cleveland Clinic Incontinence (CCI) Score,,,2006-11-27,COMPLETED,INTERVENTIONAL,['NA']
3460,NCT00867321,Time to Progression (TTP) (Phase II),Tumor Response at 6 Months,,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3461,NCT05359939,Hepatocellular carcinoma - sensitivity and specificity of two PET tracers,Hepatocellular carcinoma - sensitivity and specificity of MRI and CT,,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
3462,NCT00238394,Time to disease progression,Laboratory measures,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3463,NCT04757311,Progression Free Survival (PFS),Advers events,Percentage of use biologics in right side tumors.,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
3464,NCT04410887,Pathological response rate,Disease free survival (DFS),,2020-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3465,NCT00382811,The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death,The secondary efficacy end-point is overall survival (OS),,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3466,NCT03402477,Rate of regrowth,Diagnostic accuracy of MRI to detect regrowth during follow-up after complete response,,2018-01-10,RECRUITING,OBSERVATIONAL,['NA']
3467,NCT06111274,Objective Response Rate (ORR),The Minimum Concentration of ABSK021,,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3468,NCT01761266,Overall Survival (OS),Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib,Percent Change From Baseline in Serum Biomarker,2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3469,NCT03378128,Percentage of patients experiencing grade 3 or 4 post-operative complications,Score of Suidan preoperative predictive index parameters,,2018-01-12,COMPLETED,INTERVENTIONAL,['NA']
3470,NCT00899002,Identification of proteomic profiles and molecular pathways involved in tumor progression,Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features,,2007-07,WITHDRAWN,OBSERVATIONAL,['NA']
3471,NCT01077817,"Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)",,,2010-02-26,COMPLETED,OBSERVATIONAL,['NA']
3472,NCT01954732,"Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples",Percentage of pancreatic cancer stem cells in tissue samples,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3473,NCT04660812,Number of Participants With Treatment-emergent Adverse Events,Number of Participants With Anti-Drug Antibodies to the Biologic Component(s) of Combination Therapy,,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3474,NCT00028834,Objective response rate (complete or partial responses),Overall survival,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3475,NCT05982197,Change in severity of radiation induced mucositis,,,2023-01-03,COMPLETED,INTERVENTIONAL,['NA']
3476,NCT01215578,Predictive molecular markers of response to sunitinib,Residual concentration,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3477,NCT03077594,Mucosal Impedance as measured by an endoscopic probe,Volumetric Laser Endomicroscopy,,2016-09-26,COMPLETED,OBSERVATIONAL,['NA']
3478,NCT01916148,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
3479,NCT01664494,Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment,Median Dose of Capecitabine,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
3480,NCT05438420,Tumor response using RECIST version 1.1 throughout study,Change in the area under curve (AUC) of Q702 and its primary metabolites,,2023-01-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3481,NCT04394598,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,Number of the concurrent chemotherapy cycles that patients can receive during radiotherapy,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3482,NCT05980481,Safety(adverse event),Duration of relief (DOR),,2023-08-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3483,NCT01927497,30-day Uncomplicated Perineal Wound Healing,,,2013-03-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3484,NCT06220617,Sensitivity and specificity of the screening test with comparison to colonoscopy,,,2024-01-11,RECRUITING,OBSERVATIONAL,['NA']
3485,NCT00006037,,,,1999-11,TERMINATED,INTERVENTIONAL,['PHASE2']
3486,NCT02892305,Overall Survival,Intraoperative estimated blood loss,,2018-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3487,NCT00577889,Six Month Survival Rate,Confirmed Response Rate,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3488,NCT05720338,Composite endpoint comparison,Cost analysis for overall healthcare costs,,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE3']
3489,NCT00506571,Maximal overall response rate,"Progression-free survival, Overall survival, Toxicity assessment, & Pharmacokinetic characteristics and association with genetic polymorphism",,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
3490,NCT00853203,To collect information about factors affecting colon and rectal cancer patients' quality of life (QOL) in order to develop a QOL program.,"To look at acceptability of an Expressive Disclosure Group Program for colon and rectal cancer patients, and examine its effect on quality of life.",,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
3491,NCT00331422,Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy,Quality of Life Score of Patients Receiving Neoadjuvant Chemotherapy,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3492,NCT05178030,The negative predictive value of the ddPCR assay with regard to KIT exon 11 circulating tumour mutation,Determination of time between first detection of secondary mutations and progression,,2021-05-11,RECRUITING,OBSERVATIONAL,['NA']
3493,NCT04853017,Evaluate the safety of ELI-002,Determine the biomarker reduction and clearance rate,,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3494,NCT01731821,the postoperative pancreatic fistula(POPF) rate,morbidity and mortality,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3495,NCT00319683,,,,na,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3496,NCT02959151,Number of patients with adverse event,Detection of transferred T cells in the circulation using quantitative -PCR,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3497,NCT01764789,Quality of life(QoL),Inflammation,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3498,NCT01621919,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
3499,NCT01798173,Dosage of the vitamin B12 and the folates,,,2008-06-20,COMPLETED,INTERVENTIONAL,['NA']
3500,NCT04518449,incidence of diarrhea,,,2022-12-01,WITHDRAWN,OBSERVATIONAL,['NA']
3501,NCT00005944,,,,1999-07-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3502,NCT02929186,FIT Completion Rate,Mail/Electronic Message Engagement,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
3503,NCT04601272,Shared Decision Making Process Measure,Knowledge,,2020-09-29,COMPLETED,OBSERVATIONAL,['NA']
3504,NCT06078709,Pathologic complete response,Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy,,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2']
3505,NCT06277921,the type of complications and the incidence of it,,,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3506,NCT03149978,TRG,Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0,,2014-07-01,UNKNOWN,OBSERVATIONAL,['NA']
3507,NCT01576380,disease control rate (DCR),progression free survival (PFS) per independent central review,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3508,NCT05759923,Occurence of DLTs,PK parameter: AUCO-24,,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE1']
3509,NCT04166318,Change in FIQoL in the de-intensified CRT arm,Incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil or capecitabine,Overall survival,2020-01-02,RECRUITING,INTERVENTIONAL,['PHASE2']
3510,NCT05891028,Standardized uptake value,Adverse events collection,,2023-05-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3511,NCT05449483,R0 Surgical Resection Rate .,Overall survival (OS),,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2']
3512,NCT03433092,Gastrointestinal Tract Cancer Incident Measure,,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
3513,NCT03342417,Clinical Response,Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate,Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - QLQ-OV28,2018-02-14,TERMINATED,INTERVENTIONAL,['PHASE2']
3514,NCT05824403,Diagnostic tools,Clinical data access,,2023-11-28,RECRUITING,OBSERVATIONAL,['NA']
3515,NCT04641923,Incidence of peri-hepatic adhesions at the time of repeat liver surgery,30-day mortality and morbidity,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3516,NCT05716620,HCC detection rate of US vs AMRI in cirrhotic patients,Survival of patients,,2022-02-08,RECRUITING,OBSERVATIONAL,['NA']
3517,NCT02648386,Safety and Tolerability assessed by Adverse Events,Maximum Flow Rate (Qmax),,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3518,NCT02958566,Hospital stay cost,Patient satisfaction,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3519,NCT01744340,"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.",Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.,,2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3520,NCT04044651,Overall survival (OS),OS stratified according to degree of PVTT (Vp0-3 vs Vp4),AFP level change,2019-10-30,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3521,NCT05791136,Progression-free survival (PFS),Time to death or distant metastasis (TTDM),,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3522,NCT04812743,Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.,,,2020-01-10,TERMINATED,INTERVENTIONAL,['NA']
3523,NCT01806740,Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib,Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression,,2013-05-09,TERMINATED,INTERVENTIONAL,['PHASE4']
3524,NCT05916443,Identification of EO-CRC specific signatures and pathways,,,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3525,NCT02618447,Ability of the 4D PC MRA to measure flow direction of flow as compared to reference standards of the Doppler Flow Analysis,,,2014-08-05,TERMINATED,INTERVENTIONAL,['NA']
3526,NCT02736448,Progression free survival,toxicity,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3527,NCT00821990,Survival,,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3528,NCT04960072,Overall Survival (OS),Change in Quality of Life,,2021-06-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3529,NCT00209638,objective tumor response,"Response duration, time to progression, overall survival, and safety will also be assessed.",,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3530,NCT00003354,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3531,NCT05804799,Measurement of standard deviation of CT attenuation values at the liver,Sensitivity to detect malignant liver tumor,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
3532,NCT02494388,Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors,Number of participants with adverse events as a measure of safety,,2015-06,TERMINATED,OBSERVATIONAL,['NA']
3533,NCT01785212,transection speed,Perioperative T-cell subsets,Costs and health economics,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3534,NCT05508503,Accuracy,Combined specificity,,2022-10-21,COMPLETED,OBSERVATIONAL,['NA']
3535,NCT05802056,Incidence of adverse events,Overall survival,,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE1']
3536,NCT05028231,Pathologic Complete Response,Objective Response Rate,Intestinal flora,2021-06-05,RECRUITING,OBSERVATIONAL,['NA']
3537,NCT05160168,"Expansion (Phase 2): Expansion Cohorts 1, 2, 3 and 4: confirmed Objective Response Rate (ORR)",Overall Survival,,2022-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3538,NCT01839604,Number of Participants With Dose Limiting Toxicities During Cycle 1,"Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data.",,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3539,NCT02530983,Completion of the Mayo Clinic Upper Digestive Disease Survey by patients at varying time points following surgery,"Establishment of ""normal"" or expected scores from the Mayo Clinic Upper Digestive Disease Survey",,2015-08,RECRUITING,OBSERVATIONAL,['NA']
3540,NCT04212286,"The sensitivity, specificity and accuracy of CEUS and EOB-MRI","The sensitivity, specificity and accuracy of combined CEUS and EOB-MRI",,2019-10-23,COMPLETED,INTERVENTIONAL,['NA']
3541,NCT00686543,Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15,,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3542,NCT00688766,Compare the progression free survival (PFS) in both study arms,Evaluate the safety and tolerability of IPI-504 in this patient population,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE3']
3543,NCT02985944,Adenoma detection rate,Factors affecting the withdrawal time,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
3544,NCT04340193,Number of treated participants with laboratory abnormalities,,,2020-09-15,TERMINATED,INTERVENTIONAL,['PHASE3']
3545,NCT04593446,The rate of surgical site infection,The patient's tolerability for bowel preparation,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3546,NCT01497457,Determination of the distance between a rectal tumor and the pouch of Douglas,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
3547,NCT04309747,Effectiveness analysis,Secondary validity analysis,,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA']
3548,NCT03402607,Change in Quality of Life (QOL) Using EORTC C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30),The Total Healthcare System Costs Associated With PLA vs HIGRT,,2018-08-08,TERMINATED,INTERVENTIONAL,['NA']
3549,NCT04083053,High Resolution Anoscopy (HRA) discomfort scale,,,2019-09-17,COMPLETED,INTERVENTIONAL,['NA']
3550,NCT04145388,Number of patients identified at high risk of cancer,,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3551,NCT04656249,Progression free survival (PFS),The Rate of Treatment Related Adverse Events,Clinical benefit rate (CBR),2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3552,NCT05099549,Phase 2a/Expansion,Phase 2a/Expansion,,2021-11-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3553,NCT02377232,Colon Cancer Screening Intent,Colon Cancer Screening Completed,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
3554,NCT00258180,"Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month",,,2005-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3555,NCT02328365,Postoperative mortality at one year,Medical complications,Findings and interventions at medical visits,2014-03,COMPLETED,INTERVENTIONAL,['NA']
3556,NCT05635630,Relapse-free survival (RFS) time,The rate of achieving NED status when relapses happen.,,2022-06-24,RECRUITING,INTERVENTIONAL,['NA']
3557,NCT03847636,Complete eradication rate of DAs,Median number of CryoBalloon treatments to complete eradication.,,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3558,NCT02859155,Survival,Recurrence,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
3559,NCT05846971,The impact of methylation assay on physician confidence in clinical care decision-making.,,,2021-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3560,NCT02885727,Improvement in median Progression Free Survival using the combination of RT and durvalumab.,,,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3561,NCT03587818,The Longitudinal Preparedness for Colorectal Cancer Surgery Questionnaire (PCSQ),Behaviour pertaining when and how to seek health care for recovery support: Visits at outpatients clinics,,2012-11-01,COMPLETED,INTERVENTIONAL,['NA']
3562,NCT05051046,Rate of complete colonoscopies,Medico economic criteria,,2022-01-31,RECRUITING,INTERVENTIONAL,['NA']
3563,NCT01210911,Survival after 6 months,toxicity profile,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3564,NCT02076906,Toxicity,Immune Markers,,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3565,NCT05800080,The pathological complete response;,"major pathologic response, MPR",,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3566,NCT06276764,"The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods",Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention.,Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®,2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3567,NCT02420509,Progression-Free Survival,Quality of Life,,2015-08-27,TERMINATED,OBSERVATIONAL,['NA']
3568,NCT05802394,Resection rate,Major pathological response,The prognostic role of targeted therapy selected based on MRD,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
3569,NCT02133079,electrocardiogram,changes in antigen specific T cells,Change from baseline in subpopulation of CD8+ T cells at the end of vaccination,2012-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3570,NCT06314646,Rate of anastomotic leak,Cancer recurrence,,2024-05-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3571,NCT00002930,,,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3572,NCT03030404,Characterization of the natural and clinical histories of hereditary gastric cancer syndromes,,,2017-01-27,RECRUITING,OBSERVATIONAL,['NA']
3573,NCT03065855,Post-operative urinary retention requiring re-catheterisation,Urethrorrhagia,,2017-02,UNKNOWN,INTERVENTIONAL,['NA']
3574,NCT02849015,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Overall survival（OS）,,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3575,NCT03040453,Immunological response,"Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months.",,2017-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
3576,NCT03542799,Safety: Occurrence of study related adverse events,Effectiveness: duration of in vivo survival of EGFR CART,,2018-05-22,UNKNOWN,INTERVENTIONAL,['PHASE1']
3577,NCT05600335,incidence of various postoperative complications,radicality of surgery,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
3578,NCT02578888,"FAMCARE Survey will be administered, a 20 item scale measuring the degree to which family members are satisfied with the healthcare providers' behaviors. Comparison of family member scores between 2 arms, as well as at face value will be evaluated.",,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
3579,NCT04801459,Late postoperative recovery results,,Postoperative complications,2021-04-02,UNKNOWN,INTERVENTIONAL,['NA']
3580,NCT02970526,Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).,pain assessed by visual analog scale (VAS).,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
3581,NCT00096031,Overall Survival at 6 Months,Time to Progression,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3582,NCT03883919,Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities,Duration of stable disease,,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3583,NCT03957564,The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.,Types of tumor-associated DNA in tumor tissues after operation.,,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2']
3584,NCT02100254,Change in likelihood of CRC screening in previously unscreened subjects,"Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences",,2009-10-01,COMPLETED,INTERVENTIONAL,['NA']
3585,NCT00950144,"Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)",,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
3586,NCT00004873,,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3587,NCT02399995,changes in the quality of life (QoL),,,2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3588,NCT00544349,Efficacy: objective tumor response rate (RECIST criteria),Tumor progression rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3589,NCT03344289,polyp detection rates,"sensitivity, specificity, and accuracy of optical diagnosis on a per polyp basis",,2018-01-21,COMPLETED,INTERVENTIONAL,['NA']
3590,NCT00394615,To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.,,,2003-10,TERMINATED,INTERVENTIONAL,['NA']
3591,NCT03094351,Overall Survival Rate,Disease Free Survival Rate,,2017-07-29,RECRUITING,INTERVENTIONAL,['PHASE3']
3592,NCT01999478,Early cancer changes in the colon,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
3593,NCT05674097,Six pattens of blood flow and AMCA based on the preoperative observation,,,2020-06-08,COMPLETED,OBSERVATIONAL,['NA']
3594,NCT01480128,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
3595,NCT01231022,Protective effection of peripheral hematopoietic stem cell infusion for DILI,Change of cytokines,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
3596,NCT00109941,Survival,Opioid growth factor markers,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3597,NCT01991678,Pharmacokinetics (PK) of NKTR-102 and its metabolites,Safety and tolerability of NKTR-102,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3598,NCT04025437,Overall survival,Recurrence-free survival,,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3599,NCT03637569,Overall survival,,,2018-04-01,RECRUITING,OBSERVATIONAL,['NA']
3600,NCT00172861,,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
3601,NCT05604716,scores of digestive physiological and social psychological functions,progressive-free survival,,2001-01-01,RECRUITING,OBSERVATIONAL,['NA']
3602,NCT03930043,Metagenomic Linkage Groups (MLGs),,,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3603,NCT01479803,Diagnostic accuracy of fine needle aspiration Echo Tip® HD ProCore™ versus EchoTip® in the etiological cyto histological in pancreatic solid tumors explored under endoscopy ultrasonography.,ease of puncture between the 2 types of equipment.,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3604,NCT05199285,Confirmed objective response rate (ORR),Incidence of adverse events,,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2']
3605,NCT04522544,Objective response rate (ORR) [according to RECIST 1.1] at 6 months.,Quality of Life (QoL),Translational research,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
3606,NCT06208748,To estimate the median progression free survival (mPFS),To describe patient-reported quality of life outcome measures.,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3607,NCT02580929,mortality,,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
3608,NCT02413437,diagnostic accuracy,,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
3609,NCT02484833,Incidence of grade 3-4 AEs,Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3610,NCT00176761,To assess the antitumor response of this immunotherapy regimen.,To evaluate the toxicity of this treatment regimen.,,2000-03,TERMINATED,INTERVENTIONAL,['PHASE2']
3611,NCT01858649,the major pathological response rate,Post operative complication,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3612,NCT00988897,"Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.",Overall response rate of stage I and II,,2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3613,NCT02831179,Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level,,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3614,NCT04144907,13C Phenylalanine Oxidation,,,2021-04-26,RECRUITING,INTERVENTIONAL,['NA']
3615,NCT03634683,Safety based on Incidence of Treatment-Emergent Adverse Events (AEs) and Serious AEs,Quality of life of patients,,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3616,NCT02767986,causal attributions of breast cancer,,,2016-05-10,COMPLETED,OBSERVATIONAL,['NA']
3617,NCT03736720,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,Incidence of Grade 3+ Treatment Related Adverse Events (TRAE),,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3618,NCT01177631,Recurrence,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
3619,NCT02695628,Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue,Adverse Events Related to 18F-fluoromisonidazole (18F-FMISO),,2016-09-13,COMPLETED,INTERVENTIONAL,['PHASE2']
3620,NCT00539617,Progression Free Survival (PFS),Time to Progression (TTP),,2007-10-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3621,NCT00016198,,,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3622,NCT05031975,"To assess the activity in terms of seroreversion of TEMIRI consolidation regimen administered to patients with high-risk stage II (pT4) or III MSS, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.",Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),To assess the accuracy of ctDNA as disease recurrence biomarker,2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2']
3623,NCT01009593,Overall Survival,Overall Response Rate (ORR),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3624,NCT02305186,Safety: Incidence of Dose-Limiting Toxicities (DLTs),Response Rate (RR),,2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3625,NCT05095831,Clinical condition at one-year follow-up,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
3626,NCT04791293,MELD-Na score difference between the groups,,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
3627,NCT00514930,To estimate the local and remote intra-hepatic and extra-hepatic recurrence rates and their impact on survival.,Complications and unexpected adverse events (early and late) related to RFA aspirator treatment to be assessed. Data points to be collected as per proforma for trial.,,2007-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3628,NCT02273752,Incidence of Stomatitis,Response Rate Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2']
3629,NCT06192862,CRC screening uptake rate,qualitative factors checklist associated with CRC screening,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3630,NCT04417764,Incidence of Adverse Events,Overall Survival,,2019-06-20,RECRUITING,INTERVENTIONAL,['PHASE1']
3631,NCT01741038,Overall Survival,Health-Related Quality of Life (HRQoL),Longitudinal changes in tumor burden,2017-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3632,NCT03780946,Pancreatic fistula,Discharge of the magnets,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
3633,NCT01117428,Number of Participants With Adverse Events (AEs),Terminal Half-Life (T½),,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3634,NCT01927978,"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.",,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
3635,NCT02428270,"Percentage of patients who experience complete response, partial response, or stable disease",Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3636,NCT06196294,Number of Patients with Dose Limiting Toxicity,Median γδT cell persistence,,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3637,NCT02829788,Peritoneal carcinomatosis staging,,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
3638,NCT02388256,Recovery of physical function,Adverse events related to acupuncture,Adherence to enhanced recovery program after surgery,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3639,NCT00761345,To Determine the Dose Limiting Toxicities,To Measure Progression Free Survival and Overall Survival,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3640,NCT05652361,Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system,Assessment of oncological outcomes: Frequency of Loco-Regional Tumor Free Survival (LRFS),,2021-05-19,RECRUITING,INTERVENTIONAL,['NA']
3641,NCT04285008,rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure,,,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA']
3642,NCT00704600,phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission,,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3643,NCT05316103,Accuracy of pCLE-targeted optical biopsy,Complications of biopsy,,2021-11-04,RECRUITING,INTERVENTIONAL,['NA']
3644,NCT02333409,pain scores in numeric rating scale (NRS),Quality of Life scores,,2015-03,TERMINATED,INTERVENTIONAL,['NA']
3645,NCT05953662,DFS rate,3 years OS Rate,,2023-09-15,RECRUITING,INTERVENTIONAL,['NA']
3646,NCT05954871,Number of Participants with Dose-Limiting Toxicities (DLTs),Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1,,2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE1']
3647,NCT00064181,,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3648,NCT05662488,Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans,Progression-free survival after treatment,,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3649,NCT04140526,Rate of treatment related adverse events (TRAE) according to CTCAE v5.0,Overall Survival (OS),,2020-09-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3650,NCT02827786,"EMA (colour scale) images will be compared to baseline US grey-scale images for a specific target lesion, as determined by standard of care imaging (US, CT, MRI or PET) and/or histologically proven lesion in a given subject.",US grey-scale and EMA colour maps will be obtained from both target liver lesions and background liver tissue from the same subject and compared.,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
3651,NCT04613570,Carcinoma,Advanced gastric cancer,,2021-01-02,RECRUITING,INTERVENTIONAL,['NA']
3652,NCT00086762,Quality of life as measured by Functional Assessment of Cancer Therapy,"Immune suppression as measured by cytotoxicity, stimulated release of IL-12, -4, -10, intracellular cytokines and lymphocyte phenotype",,2004-06,COMPLETED,INTERVENTIONAL,['NA']
3653,NCT05136326,To evaluate the rate of complete pathologic response (pCR),"To assess the incidence, nature, and severity of adverse events",,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3654,NCT02353936,response rate,Progression free survival,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3655,NCT03261791,recurrence-free survival,safety: the potential side effects,,2017-07-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
3656,NCT01450696,Overall Survival - FAS,Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3']
3657,NCT03675243,Fecal incontinence quality of life scale,Sphinctrometry,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
3658,NCT02279719,Assessment of Disease Control Rate in the Intent to Treat Population- Phase II,Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors,,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3659,NCT06036563,specificity,,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3660,NCT02409199,Progression-free survival (PFS),Safety (incidence of adverse events),,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3661,NCT05775939,Change in mean standardized uptake value (SUV) changes in the heart,Cardiac related death,,2023-01-20,RECRUITING,INTERVENTIONAL,['NA']
3662,NCT01092689,"Quantify and characterize HCA-DNA adducts in resected human pancreatic tissue after a dietary relevant dose of PhIP, the most mass abundant HCA in charred meat.",Quantify [14C]PhIP and [14C]PhIP metabolites in urine and plasma.,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3663,NCT03745794,Number of Participants Discharged Opioid-Free,Patients and Family Free of Opioid Use,,2019-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3664,NCT03716063,Metastasis recurrence rate in 1 year,Metastasis recurrence rate in 3 years,,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
3665,NCT03440515,treatment success rate,,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3666,NCT03924466,Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma,Influence image-guide biopsy on patient management,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3667,NCT04854213,To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment.,Metabolic response (exploratory studies),,2021-10-06,RECRUITING,INTERVENTIONAL,['NA']
3668,NCT03693846,Number of Participants With Progression-Free Survival at 6 Months,Duration of Response,,2019-02-15,TERMINATED,INTERVENTIONAL,['PHASE2']
3669,NCT04981119,Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing,Percentage of enrolled participants who experience an adverse event (AE) related to apheresis,,2021-10-29,RECRUITING,OBSERVATIONAL,['NA']
3670,NCT05945797,Shortening of CBD cannulation time,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3671,NCT00878163,Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients,Time to treatment failure,,2009-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3672,NCT00587314,Response to treatment,,,2004-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3673,NCT05602792,"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.","In part III,Overall Survival (OS)","In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011",2020-04-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3674,NCT03093129,recurrence free survival 2 years after surgery,Predictive value of tumour biomarkers in terms of predicting response to artesunate therapy,,2018-01-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3675,NCT02561273,Overall Response Rate,Progression-free Survival,,2015-09-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3676,NCT00623883,"number, size, and location of ACF identified","complications of stain-enhanced, magnification colonoscopy",,1999-01,COMPLETED,INTERVENTIONAL,['NA']
3677,NCT03828799,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Determination of circulating free DNA concentration,,2019-05-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3678,NCT05518110,Patients free of disease progression,Safety and tolerability,Comparison of new methods of multi-omics data integration vs existing models using AUROC,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2']
3679,NCT02423720,"Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)","Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)","Sleep quality, as assessed by NCCN Distress Thermometer and NIH PROMIS instruments at the beginning, midpoint and end of the study",2015-04-28,COMPLETED,INTERVENTIONAL,['NA']
3680,NCT01210027,"Measure of Liver Function Before, During and After Radiation",Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes,,2007-03,RECRUITING,OBSERVATIONAL,['NA']
3681,NCT04918459,Death adjusted cumulative incidence of rebleeding at 30-day,Mortality rate at 6 months,,2021-08-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3682,NCT04988971,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,Overall incidence of grade 3/4 gastrointestinal adverse events,Changes of fecal flora and enteritis-associated inflammatory factors,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
3683,NCT00360971,Duration of Oral Mucositis as Measured in Terms of Days,Time to Second Primary Tumor,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3']
3684,NCT00305760,Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3685,NCT03399331,severity of OM,pain,,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
3686,NCT00889343,To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo,Safety,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2']
3687,NCT01339754,Progression-free survival (PFS) rate at 6 months,Impact of pharmacogenomic and pharmacokinetic profile on anti-tumor activity,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3688,NCT04264260,survival,serious adverse effect,,2019-12-24,RECRUITING,INTERVENTIONAL,['PHASE2']
3689,NCT00730158,Proportion of Participants With Grade 2-4 Toxicities,Circulating Tumor DNA - Percentage of Patients With DNA Mutations,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3690,NCT03708783,the incidence of postoperative complications within 30 days,3-year disease free survival,,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA']
3691,NCT03310892,Colonoscopy completion rate,Colonoscopy scheduling rate,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
3692,NCT04837508,Objective Response Rate (ORR) by Independent Review Committee (IRC),Incidence of anti-drug antibody (ADA),,2021-06-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
3693,NCT03215355,Improved image quality after injection as determined by contrast-to-background calculation and expert observation.,"Toxicity with ""off label"" dosing",,2017-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3694,NCT01795274,Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment,overall survival,,na,WITHDRAWN,INTERVENTIONAL,['NA']
3695,NCT01957852,Reoperation rate for intra-abdominal bleeding after CRS and HIPEC,Length of hospital stay,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
3696,NCT00507351,Pain and symptom data across multiple institutions,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
3697,NCT05543304,Objective response rate,Progression free survival,,2018-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3698,NCT00914537,High resolution anoscopy,,,2009-06-02,COMPLETED,OBSERVATIONAL,['NA']
3699,NCT06327386,Evaluation efficacy of tumor regression level,SUV,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
3700,NCT04742959,Dose limiting toxicity (DLT),Volume of Distribution (Vd),Genetic Alteration Status,2021-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3701,NCT05609253,Itraconazole drug and blood levels,Effects of itraconazole on angiogenesis,,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE1']
3702,NCT03435666,AUC0-t,AUC_%Extrap_obs,,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
3703,NCT00192712,time to treatment failure,"response rate, survival, toxicity",,2002-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3704,NCT01181609,Percentage of Participants Achieving Overall Disease Control (ODC),OS - Time to Event,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3705,NCT04883970,Standardized uptake value（SUV）,,,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3706,NCT05890339,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,Proportion of participants need to rehospitalized after surgery,,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3707,NCT06324032,Evaluation of EUS-E accuracy quantitative,"Complication rate (perforations, bleeding) of the procedure",,2020-12-17,RECRUITING,OBSERVATIONAL,['NA']
3708,NCT03126058,occurrence rate of severe complications,Procalcitonin,,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA']
3709,NCT01152437,Percentage of Participants With Disease Control (DC),"Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8)",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3710,NCT05052671,Progression free survival (PFS),Overall survival (OS) in ctDNA positive versus ctDNA negative.,,2022-05-25,RECRUITING,OBSERVATIONAL,['NA']
3711,NCT02179463,Pathological Response,downstage proportion,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
3712,NCT02166190,Clinical Success- composite,Mutational Profile of DNA post interventional procedure,Safety Profile and Quality of Life,2014-06,TERMINATED,INTERVENTIONAL,['NA']
3713,NCT03741517,Protocol adherence,,Safety of core needle biopsy: NCI Common Terminology Criteria,2019-01-30,RECRUITING,OBSERVATIONAL,['NA']
3714,NCT01675128,Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies,Number of Participants With a Decrease in elF4E mRNA Expression in Peripheral Blood,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3715,NCT03023436,2-year Median survival time,Morbidity and mortality,Molecular biomarker alteration,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3716,NCT04483284,Progression Free Survival,The incidence of AEs and SAEs by NCI-CTCAE v5.0,,2020-06-24,UNKNOWN,INTERVENTIONAL,['PHASE2']
3717,NCT00515216,Overall Response Rate (ORR),Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3718,NCT00003531,Number of Participants With Objective Response and Stable Disease,,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3719,NCT01552291,Morbidity,Perioperative immunocompetence,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
3720,NCT05821361,Overall response rate ( ORR) per RECIST 1.1,Disease Control Rate (DCR) per RECIST 1.1,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3721,NCT02565017,Acceptability of IBM Watson Oncology,,,2015-09-15,COMPLETED,OBSERVATIONAL,['NA']
3722,NCT02314052,Phase 2: Preliminary Antitumor Activity,AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8,,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3723,NCT00589563,Severity of Chronic GVHD,Incidence of Disease Relapse/Progression at 2 Years Post HSCT,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3724,NCT02233712,Diptheria Toxoid Antibody Levels,Adverse Events,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3725,NCT02173353,Evaluate the use of ultrasound to detect motion of pancrease and surrounding structures,Quality of ultrasound imaging for Pancreas,Assess organ motion and compare in conjunction with magnetic resonance imaging or CT,2014-02,COMPLETED,OBSERVATIONAL,['NA']
3726,NCT04863768,association between gene mutational status and disease-free survival,Descriptives,,2006-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3727,NCT00048126,Tumor measurements (RECIST criteria),"Time to progression, time to response, duration of response, time to treatment failure, survival.\n",,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3728,NCT03666442,tumor area in endoscopy,tumor thickness in TRUS,,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3729,NCT04948125,Objective response rate(ORR),Duration of response(DOR),,2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
3730,NCT01987726,Proportion of patients who have multiple options recommended,Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort,,2013-09-03,COMPLETED,OBSERVATIONAL,['NA']
3731,NCT01225523,Progression-free survival,Rate of local recurrences and metastasis,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3732,NCT00003769,,,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3733,NCT02238613,Tumor Response rate,Adverse events,,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
3734,NCT04237441,survival following pancreatic surgery,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
3735,NCT00063986,Peri-operative Mortality at 30 Days,Rate of Conversion to Open Operation After Neoadjuvant Therapy,,2004-06-24,COMPLETED,INTERVENTIONAL,['PHASE2']
3736,NCT04069949,Incidence of Treatment-Emergent Adverse Event,Duration of response,,2019-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3737,NCT02938481,Distribution of metastatic LNs,Prognostic outcomes according to the central radicality,,2013-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3738,NCT02882659,Safety of DKC as assessed by laboratory examinations,Efficacy of DKC as assessed by change in quality of life,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
3739,NCT00242788,Objective tumour response (CR and PR) at study closure based on the RECIST,"Incidence of controlled disease (CR, PR and SD) at study closure",,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3740,NCT01354795,"Compare the degree of cytologic quality in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.","Compare the diagnostic yield in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.",,2010-09,COMPLETED,INTERVENTIONAL,['NA']
3741,NCT02456285,Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO),,,2015-05-20,COMPLETED,OBSERVATIONAL,['NA']
3742,NCT05042336,MPR,ORR,,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3743,NCT01113736,If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.,Decrease in operative time and a promotion of peritoneal remodeling,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3744,NCT05151068,The change of sleep,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3745,NCT03700541,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,Pain assessment,,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3746,NCT00772083,self-reported seeking of medical care for diagnosis of anemia found at time of blood donation,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3747,NCT04443816,Loss of health related quality of life (HRQL),Disability,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3748,NCT04281511,progressive-free survival,,,2019-04-03,COMPLETED,OBSERVATIONAL,['NA']
3749,NCT01796782,overall survival (OS),Number of adverse events of QYHJ Formula,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3750,NCT03267173,Number of patients with tumor response,Number of patients with adverse event,,2017-06-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3751,NCT01384227,To determine whether tissue is neoplastic or non-neoplastic,,,2009-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3752,NCT06148298,Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction,,,2023-05-24,RECRUITING,OBSERVATIONAL,['NA']
3753,NCT05911217,Disease free survival (DFS),The immunogenicity in subjects receiving CT041 infusion in this study,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
3754,NCT00735917,Six Month Survival,Progression-Free Survival,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3755,NCT06208371,Five-year survival rate,Treatment-related Adverse Events,,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3756,NCT06172634,treatment related adeverse event,overall response rate,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3757,NCT01905969,Relapse free survival,,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
3758,NCT01421680,Postoperative complication rate,Patient compliance of oral nutritional supplements,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
3759,NCT01492127,Variation of plasma proteasome,Variation of plasma proteasome,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
3760,NCT01356628,Time to Disease Progression,Response Rate (RR),,2011-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3761,NCT03566056,"Hypotension, defined as mean arterial bloodpressure <65 mmHg, measured by invasive arterial blood-pressure, the first morning after surgery at 06.00 (AM)",,,2018-01-18,COMPLETED,OBSERVATIONAL,['NA']
3762,NCT03629691,PFS (progression-free survival),LRC (duration of locoregional control ),,2015-02-01,COMPLETED,OBSERVATIONAL,['NA']
3763,NCT00072787,,,,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3764,NCT04625543,Major Pathological Response (MPR) rate,The incidence of adverse events,,2020-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3765,NCT04552236,Predicting early HCC recurrence after treatment by Ultrasound elastography,,,2021-01,UNKNOWN,OBSERVATIONAL,['NA']
3766,NCT04928625,Recommended Phase II Dose (RP2D),Objective response rate (ORR),,2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
3767,NCT02607540,"overall survival, OS","disease control rate,DCR",,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
3768,NCT05740956,Efficacy of HS-10502: Objective response rate (ORR)（Stage 2）,[Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only),,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1']
3769,NCT01077739,Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression,Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3770,NCT05803382,Recommended phase 2 dose (RP2D),Molecular subpopulations particularly sensitized to BETi and capecitabine,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE1']
3771,NCT03380858,fistula incidence,infection,,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA']
3772,NCT05543863,platelet function testing at 5 days,postoperative complications,,2022-08-20,RECRUITING,OBSERVATIONAL,['NA']
3773,NCT03857815,PFS,ORR,,2019-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
3774,NCT00949182,Safety and tolerability as assessed by NCI CTCAE v3.0,"AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3775,NCT03117023,sleep time,side effects,,2017-04-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
3776,NCT00075647,Overall survival (OS),Expression and phosphorylation status of p70s6k,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3777,NCT00606385,Recurrence rate,Survival,,2007-12,UNKNOWN,INTERVENTIONAL,['NA']
3778,NCT02454790,Late toxicity,Loco-regional tumor control,Patient-rated symptoms and Quality-of-Life,2014-09,RECRUITING,OBSERVATIONAL,['NA']
3779,NCT01407107,The Number of Participants Experiencing Dose Limiting Toxicities (DLT),Number of Participants With a Pathological Complete Response (pCR),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3780,NCT05451862,confirmed Objective Response Rate (ORR) by localized mRECIST,Quality of Life using EQ-5D-5L questionnaire,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
3781,NCT00719641,Number of Participants Without Re-looping Among Those With Looping,,,2008-08-05,COMPLETED,OBSERVATIONAL,['NA']
3782,NCT05310565,Patient Retention,Patient-reported outcomes,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
3783,NCT03610100,"Number of participants that have survived throughout treatment and also into follow-up, as measured by the primary cause of death and date of death CRFs.","Number of patients with treatment-related adverse events as assessed by CTCAE v4.03. Toxicity is assessed by CTCAE v4.03 alongside Quality of Life Questionnaires, QLQ-C30 and QLQ-PAN26.","Discovery of possible biomarkers which may predict any additional benefit of Acelarin over gemcitabine. These will be assessed from plasma, cell pellet and serum samples collected from participants throughout the trial.",2015-12,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3784,NCT02624895,"average relative dose intensity of every drug""",Questionnaire score,,2015-12-30,COMPLETED,OBSERVATIONAL,['NA']
3785,NCT00588367,"A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis.",,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
3786,NCT05377034,Best Overall Response Rate (BORR) at 12-months post-randomization.,Quality-adjusted life years at 18 months.,Occurrence of adverse events leading to death.,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE2']
3787,NCT01004003,Time to Progression (TTP) in Phase II,Overall Survival,,2009-10-22,COMPLETED,INTERVENTIONAL,['PHASE2']
3788,NCT01287637,Postsurgical morbidity.,Socio-economic effect of early reversal of temporary ileostomy,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3789,NCT00644254,Overall cancer-specific survival,Disease-free survival (DFS)& Correlation of ECLNI with other pathological variables,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
3790,NCT03435536,Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.,Correlation between circulating tumor DNA rate and Ca19.9 dosage,,2018-02-26,COMPLETED,INTERVENTIONAL,['NA']
3791,NCT02628951,objective response rate,response rate according to molecular subtypes,,2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE2']
3792,NCT04316078,Feasibility of PEP (percent of patients using videos/complete questionnaires),Secondary clinical outcomes 4 (treatment intensity and continuity),,2020-03-15,COMPLETED,INTERVENTIONAL,['NA']
3793,NCT03285867,The change of LSM(kpa) measured by FibroScan(a kind of external harmless ultrasonoscope),,,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA']
3794,NCT01103128,BRCA1 vs. BRCA2 mutations,Interaction of other cancer genes with BRCA1 and BRCA2,,2009-03,TERMINATED,OBSERVATIONAL,['NA']
3795,NCT06208397,Radiological assessment of CRLM,,,2023-12-24,RECRUITING,OBSERVATIONAL,['NA']
3796,NCT01978808,the overall diagnostic accuracy rate of both needles,,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
3797,NCT06121700,Overall survival (OS),Surgical mortality,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3798,NCT03090139,Time-to-first Indicator of Sub-optimal Therapy,Physician Survey Questionnaire,,2017-03-28,COMPLETED,OBSERVATIONAL,['NA']
3799,NCT04500990,Objective Response Rate,Overall survival,,2020-09,UNKNOWN,OBSERVATIONAL,['NA']
3800,NCT06048367,Safety and Tolerability Assessment of CNSI-Fe(II),PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II),,2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE1']
3801,NCT04103372,Demonstrate a change in rectal preservation rates,Assess patient willingness to be randomised,,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3802,NCT05097911,Evaluable Non-Target Disease Response,Evaluation of Best Overall Response,,2021-08-02,RECRUITING,INTERVENTIONAL,['PHASE1']
3803,NCT05371197,Pathological complete response (pCR) rates,Drug feasibility,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3804,NCT00548626,Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.,Influence of different factors in obtaining a positive cytological result,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
3805,NCT01276795,Protein balance,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3806,NCT00801320,To gain experience in appropriate clinical processing of tumor samples and determining cell yield.,"Based on feasibility of collection of blood samples of subjects, quantification of T cell subsets, regulatory T cells, activated memory effector cells, and DC phenotype at pre-surgery and post-surgery time points.",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
3807,NCT06126406,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-11-06,RECRUITING,INTERVENTIONAL,['PHASE1']
3808,NCT02742935,The severity of adverse events (AEs) determined as per NCI CTCAE V4.03.,,,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3809,NCT03545711,ORR,PFS,,2018-05-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3810,NCT03137706,Young's modulus (stiffness) on fresh tissue,,,2016-11-14,TERMINATED,OBSERVATIONAL,['NA']
3811,NCT03599947,Sensitivity and specificity of the model in the diagnosis of colorectal cancer,,,2018-07-16,UNKNOWN,OBSERVATIONAL,['NA']
3812,NCT04687969,Diagnostic value of multimodal imaging in primary prostate cancer patients,Scan-rescan repeatability,,2022-10-23,RECRUITING,OBSERVATIONAL,['NA']
3813,NCT03473574,Objective response rate (ORR),Quality of Life,,2018-05-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3814,NCT05010863,Getting serum,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
3815,NCT01243619,Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis,,"Analyze Correlation Between FDG and FLT PET Scans, and the Correlation Between Both Types of PET Scan and the Response to Treatment.",2010-08,COMPLETED,INTERVENTIONAL,['NA']
3816,NCT02319187,progression free survival,quality of life,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
3817,NCT00582335,Evidence of mutations in selected candidate genes,,,1998-02-10,COMPLETED,OBSERVATIONAL,['NA']
3818,NCT06165380,Objective Response Rate,Safety,,2023-10-23,RECRUITING,INTERVENTIONAL,['PHASE2']
3819,NCT06120127,Progression free survival,Grade 3-4 adverse effect rate,,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2']
3820,NCT00034034,,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3821,NCT03971747,Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055],OS,DCR,2019-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
3822,NCT01555489,Safety of Ascorbic Acid in Combination With Gemcitabine and Erlotinib for Stage IV Pancreatic Cancer,Evaluate Quality of Life Using Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3823,NCT05989724,MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II),CL,SON-DP concentration in tumor biopsy tissue,2023-09-19,RECRUITING,INTERVENTIONAL,['PHASE1']
3824,NCT06221878,Short-term outcome,Long-term Oncologic outcome,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
3825,NCT04659148,Oncological outcome,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
3826,NCT05245968,Progression-free survival (PFS),Metabolite ratio,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
3827,NCT01096745,Time to progression,Response rate Overall survival Safety profile,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
3828,NCT00585221,Time to Progression (TTP).,,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
3829,NCT02913066,Complete Remission Rate (CR),Progression-Free-Survival (PFS),,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
3830,NCT02117479,Overall Survival (OS),Participants With Treatment-Emergent Adverse Events (TEAEs),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE3']
3831,NCT02604615,"overall survival, OS","disease control rate,DCR",,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
3832,NCT02246049,Progression-free survival (PFS) at 10 months,Treatment duration,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3833,NCT00602745,Overall Survival,Clinical Benefit assessed by Time to Symptoms Worsening (TTSW),,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3']
3834,NCT03796429,overall survival (OS) of GS regimen plus PD-1 antibody (Toripalimab),Incidence of adverse Events of GS regimen plus PD-1 antibody (Toripalimab),,2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2']
3835,NCT04087421,"Bowel function, change in symptom 1 score assessed using the Measure Yourself Medical Outcome Profile (MYMOP2) Score.",Health economics assessed using the ICEpop CAPability measure for Adults (ICECAP-A).,,2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE3']
3836,NCT01624285,"Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee",Time to first HCV viral recurrence,,2012-07-16,COMPLETED,INTERVENTIONAL,['PHASE2']
3837,NCT00660205,,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
3838,NCT05997459,PFS,,,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3839,NCT03385577,Program Acceptability - Plan to continue intervention exercises after completion of the study,Depressive Symptoms,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
3840,NCT00003704,overall survival,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3841,NCT03829969,OS,Patient-Reported Outcomes collected via the EORTC QLQ-OES18,,2019-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3842,NCT04985357,Best overall response (BOR),,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3843,NCT02385630,Post-prandial satiety gut hormone area under the curve,Fasting ghrelin concentration,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3844,NCT02233374,Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.,Impact of pCR rates on long term disease control,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
3845,NCT03274011,Progression Free Survival,Overall Response Rate,,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3846,NCT03221127,Death,Infectious disease,,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3847,NCT05394740,ORR in Phase II part,Incidence of adverse events,Biomarkers in the PhIb and PhII cohort,2022-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3848,NCT00077142,Maximum Tolerated Dose (MTD) of TAC-101,,,2001-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3849,NCT01927341,Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Local Radiology Assessment: Phase 2,Overall Survival (OS),,2013-11-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3850,NCT02722395,Planning target volume (PTV),,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
3851,NCT05998447,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator.,Overall Survival (OS),,2023-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
3852,NCT02178436,Overall Survival (Phase II),Progression Free Survival (Phase II),"Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)",2014-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3853,NCT03606928,Objective response rate,Safety: adverse events as assessed by CTCAE v4.0,,2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3854,NCT00891878,Comparison of Progression-free Survival,Duration of Response,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3855,NCT00789958,Stratum-specific (R0 and R1) 2-year Overall Survival,2-year Overall Local Relapse Rate,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3856,NCT00630084,"Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",Safety - adverse event rate and profile,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3857,NCT04362839,Recommended dose level of the combination,Objective response rate (ORR),Immune response,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3858,NCT05862792,Postoperative Dysphagia with Dysphagia Survey,Postoperative Pain Medication Usage,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
3859,NCT06123117,cumulative opioid consumption during the stay at the recovery,cumulative opioid consumption (emergency and inpatient surgery),pain-control failure & possible causes,2024-01-16,RECRUITING,INTERVENTIONAL,['NA']
3860,NCT00084643,"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0",Change in biochemical and molecular correlates,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3861,NCT05699655,Pathological complete response,Objective Response Rate (ORR),,2023-05-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3862,NCT04443036,PFS,Adverse events,,2020-06-11,UNKNOWN,INTERVENTIONAL,['NA']
3863,NCT04842916,Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders,Psychological status of patients in relation to therapy response,,2020-09-22,UNKNOWN,OBSERVATIONAL,['NA']
3864,NCT00617708,Progression-Free Survival,Toxicity,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3865,NCT05697198,The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period,,,2021-04-19,RECRUITING,OBSERVATIONAL,['NA']
3866,NCT03416322,Adenoma detection rate,Boston Intestinal Preparation Scale,,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA']
3867,NCT03223779,The Duration of Local Control,Serial ctDNA,,2017-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3868,NCT06335576,C-index,Sensitivity and specificity of model,,2024-03-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3869,NCT05595122,Stentdysfunction after technical successful EUS-CDS,Costs,,2022-12-02,RECRUITING,INTERVENTIONAL,['NA']
3870,NCT01783951,Progression free survival（PFS）,Quality of life,,2013-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3871,NCT05447715,Sequential treatment of PFS with furoquitinib in second-line (F-C group) versus third-line (C-F group),,,2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3872,NCT03114631,Number of Participants Who Survived at 1 Year,Number of Participants Who Survived at 3 Years or more,,2017-01-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3873,NCT04601961,HIF-1 gene expression,Number of Circulating tumour cells,,2020-03-04,RECRUITING,INTERVENTIONAL,['NA']
3874,NCT00718354,Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .,"Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3875,NCT02549456,Major postoperative complications,Functional outcome,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
3876,NCT03950609,Objective response rate,Incidence of adverse events,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3877,NCT00909103,Value of endoscopic ultrasound elastography for the differential diagnoses of pancreatic masses.,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
3878,NCT03477019,difference in measured response between treated and untreated lesions,Occurrence of adverse effects,,2018-11-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3879,NCT01172028,Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere,Antitumor activity,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3880,NCT01005199,Progression-free survival,Correlation between vitamin B12 and overall survival,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3881,NCT05176223,Time to progression,,,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE2']
3882,NCT00052689,Proportion of patients alive at 6 months (Arm II),Time to treatment failure,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3883,NCT01248637,correlation of intratumoral hypoxia with patient survival rate,to assess utility of circulating osteopontin and miR-210 for identifying hypoxia,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
3884,NCT00814242,tumor recurrence rate in one or two years; Disease-free survival;Overall survival.,"Overall survival rate in one, two，three or five years; Disease-free survival in one, two，three or five years; hepatic function of patients after surgery, the incidence rate of complications and the decline level of serum AFP concentration.",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3885,NCT05320029,Number of Participants With Anastomosis Success,,,2018-08-30,COMPLETED,INTERVENTIONAL,['NA']
3886,NCT05142033,Percent of patients referred for molecularly targeted clinical trials,Percent of patient participating in microbiome collection and analysis,,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
3887,NCT02586285,Time to tumor recurrence,Overall survival,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
3888,NCT04982276,Objective response rate (ORR),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2021-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3889,NCT00551421,"Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)",Overall Survival,,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3890,NCT00308516,"Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment","Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death",,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3891,NCT03142282,Progression free survival,Overall survival,,2019-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3892,NCT03946917,Objective response rate (ORR),Intestinal microorganism,,2019-03-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3893,NCT00089960,Objective response rate as defined using modified RECIST criteria.,"Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3894,NCT00118261,Number of patients that develop study drug related toxicity,Number of patients that can increase the erlotinib dose to 200mg,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3895,NCT00030511,,,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3896,NCT04971525,Cumulative Occurrence of Malignancies in CD Participants With PAF,Number of Participants With Comorbidities,,2023-04-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3897,NCT01038154,all cause mortality,free time of disease recurrence,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3898,NCT03170869,Local Recurrence Rate (LRR),Survival Time,,2017-04-12,TERMINATED,INTERVENTIONAL,['NA']
3899,NCT05755594,Rate of long-term Survival,Incidence of postoperative complications,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3900,NCT03073785,Local control,Tumor and organ motion,Pharmacokinetics parameters of zoledronic acid,2016-09-16,RECRUITING,INTERVENTIONAL,['PHASE2']
3901,NCT04749108,3-year Disease free survival (DFS) for Phase III,Evaluation of sexual function in women by Female Sexual Function Index (FSFI) questionnaire score,,2021-11-26,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3902,NCT06283303,Treatment Emergent Adverse Event（TEAE）,Progression-free survival (PFS),,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3903,NCT01836913,"Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based",Cost-effectivity analyses,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3904,NCT01774851,Progression Free Survival (PFS),,,2013-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3905,NCT05575986,Days required for platelet recovery to ≥75×10^9/ L,Safety of treatment,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE4']
3906,NCT02428907,patient perception of colonoscopy,Staff perception of teamwork,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
3907,NCT03491878,R0 rescetion rate,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
3908,NCT05138302,OS,,,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA']
3909,NCT02345746,Determine response rate,,,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3910,NCT04093141,2-year survival proportion from 1) diagnosis and 2) IRE,Nutritional status assessment (PG-SGA-SF),,2019-05-01,RECRUITING,INTERVENTIONAL,['NA']
3911,NCT05103020,curative-intent resection rate,Overall response rate (ORR),,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3912,NCT00988936,To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed.,To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3913,NCT00578396,Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression,Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.,,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3914,NCT04341012,Utility of breath profiles for disease diagnosis or prognosis,,,2019-09-10,COMPLETED,OBSERVATIONAL,['NA']
3915,NCT04317352,Mortality,,,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
3916,NCT02880306,the risk of developing hepatocellular carcinoma,,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
3917,NCT04329494,Incidence of adverse events,Cytoreductive surgery rate (Arm 3),,2020-08-21,RECRUITING,INTERVENTIONAL,['PHASE1']
3918,NCT06009705,Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events.,Assessment of progression-free survival (PFS) in elderly esophageal cancer patients treated with toripalimab in combination with S-1 and radiotherapy.,,2022-10-01,RECRUITING,OBSERVATIONAL,['NA']
3919,NCT05443841,number of patients who had positive pleural lavage cytology,Time period from date of surgery to the date of death,,2022-07-18,RECRUITING,OBSERVATIONAL,['NA']
3920,NCT02461979,number of HCC patients with abnormal (APAL) VDR polymorphism,,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
3921,NCT02148549,Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3922,NCT05593458,Major Pathological Response rate,pathological Complete Response rate,,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
3923,NCT04443543,clinical complete response rate,overall survival,,2020-06-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3924,NCT05916261,Disease control rate (DCR),overall survival (OS),,2023-04-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3925,NCT04029909,Dose limiting toxicity(DLT),Maximal tolerable dose(MTD),T1/2,2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
3926,NCT01133990,Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter,Phase 2: Overall Survival (OS),,2010-03-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3927,NCT05144698,Safety of RAPA-201 Cell Therapy,Quality of Life (QOL),T Cell Immune Reconstitution,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3928,NCT03088163,Response rate,Overall survival,,2016-08,UNKNOWN,INTERVENTIONAL,['NA']
3929,NCT04816045,Tumor stage,VAR2,,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3930,NCT04599777,Overall survival (OS),DOR assessed by investigators according to mRECIST.,,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3931,NCT06152263,"Microvascular density differences between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa",,,2023-09-30,RECRUITING,OBSERVATIONAL,['NA']
3932,NCT05621824,Number of Participants with no clear pancreas lesions,Number of Participants with other pancreas diseases,,2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3933,NCT00713128,frequency of delayed emesis (vomiting/retching),"Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction",,2008-04,COMPLETED,OBSERVATIONAL,['NA']
3934,NCT06072287,Illness-related distress,Cognitive and Behavioural Responses to Symptoms,,2023-06-28,RECRUITING,OBSERVATIONAL,['NA']
3935,NCT02845999,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3936,NCT03360695,Disruptions in Cancer Care,PHQ-9,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
3937,NCT04007744,Response rate of sonidegib in combination with pembrolizumab (Part B),Progression-free survival (PFS),Level of serum soluble PDL-1,2020-02-13,RECRUITING,INTERVENTIONAL,['PHASE1']
3938,NCT00842257,Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.,Disease Control Rate as Defined by RECIST Criteria,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3939,NCT03200821,Survival,Gastrin-17 Antibodies,,2000-08-14,COMPLETED,INTERVENTIONAL,['PHASE3']
3940,NCT04843215,Disease Free Survival(DFS),Overall Survival(OS),Postoperative morbidity,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
3941,NCT00111761,Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1),Time to Initial Objective Tumor Response (Part 1),,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3942,NCT00834236,Number of Participants With Accurate Diagnosis for Gastric Cancer,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
3943,NCT06078982,Objective response rate (ORR),Drug-related safety indicators,,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE1']
3944,NCT05823987,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2']
3945,NCT01642446,Overall survival,Quality of life(Qol),,2013-01,COMPLETED,INTERVENTIONAL,['NA']
3946,NCT03633539,Postoperative complications,5-year overall survival rate,,2020-08,WITHDRAWN,INTERVENTIONAL,['NA']
3947,NCT03082378,survival,complication,,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3948,NCT01912222,Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3949,NCT00789841,Gastrointestinal transit time in NET patients,Changes in carcinoid symptoms and biomarkers,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
3950,NCT03469375,Progression free survival,Histopathologic staging,,2014-04-01,COMPLETED,OBSERVATIONAL,['NA']
3951,NCT00262769,Overall Survival,Toxicity,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3952,NCT05854368,"Characterization and validation of a signature combining plasmatic proteins related to inflammation and carcinogenesis process, associated with the presence of gastric mucosal dysplasia lesions compared with an H. pylori negative control group.","Characterization of the plasma levels of the proteins biomarker composing these signatures specific for the different stages of gastric cancer cascade, between the different studied pathology groups",,2023-07-03,RECRUITING,INTERVENTIONAL,['NA']
3953,NCT03813381,Body weight change,Waist circumference reduction,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
3954,NCT02399228,"Patients Achieving Less Than or Equal to ""2"" RTOG Score At Visit 9",NRPS (Numerical Rating Pain Scale),Safety Will be Assessed Based on the Frequency and Severity of Adverse Events.,2015-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3955,NCT01257360,Rate of pathological complete remissions,Correlative biomarker analyses,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
3956,NCT02426450,Safety and Tolerability,Overall survival,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3957,NCT05427383,Overall Survival (OS) according to RECIST 1.1 by IRC,Incidence of neutralizing Antibody，Nab,Change from baseline in CA72-4 (carbohydrate antigen 724),2022-04-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3958,NCT01471132,Overall Survival,Safety,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
3959,NCT01924260,"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0",Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than 2 patients experience DLT graded according to NCI CTCAE version 4.0,,2013-08-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3960,NCT02503969,Individual attended colorectal cancer screening,Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
3961,NCT02784639,Area under ROC curve,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3962,NCT00047346,"Pharmacokinetic (PK) and pharmacodynamic profile, as measured by Cmax, Tmax, AUC0-24, AUC0-infinity, Cl/F, T1/2, accumulation ratio, and Cssmin","Objective response rates (partial, complete, stable disease), as measured by CT scans using RECIST criteria",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3963,NCT05677113,The primary outcome will be the 2-year Progression-Free Survival (PFS) rate,Five-year overall survival,,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
3964,NCT02112214,The incidence of gastric cancer between the intervention and placebo groups,Modification of atrophy score,,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3965,NCT03013712,Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0,Anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3966,NCT02672657,Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire,"Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale",,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
3967,NCT02450032,Change in Subject's World Health Organization Performance Status,Adverse Events,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3968,NCT04076761,Median progression-free survival (PFS),Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30,,2019-12-11,TERMINATED,INTERVENTIONAL,['PHASE2']
3969,NCT00477880,Response,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3970,NCT03728348,"Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49",,,2018-11-06,COMPLETED,OBSERVATIONAL,['NA']
3971,NCT03521765,WHOQOL-BREF(the World Health Organization Quality of Life-BREF),Barthel Index (BI),,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
3972,NCT00735241,Toxicity and safety,,,2008-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3973,NCT01542294,chemotherapy complete rate,overall survival(OS),,2011-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3974,NCT00902291,Survival rate at 6 months,Disease Control (Stable Disease or better per RECIST criteria),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3975,NCT05888623,Adenoma Detection Rate,Adenocarcinoma detection rate,Bowel preparation quality,2022-10-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3976,NCT05052099,Overall response rate (ORR),Incidence and severity of adverse events (AEs) (with severity determined according to NCI CTCAE v5.0),,2021-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3977,NCT03748134,OS in PD-L1 positive population,PFS - PD-L1 positive,,2018-12-24,COMPLETED,INTERVENTIONAL,['PHASE3']
3978,NCT03258450,The acceptability of the intervention will be assessed through the Client Satisfaction Questionnaire.,Psychological distress will be accessed through The Hospital Anxiety and Depression Scale (HADS),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
3979,NCT04338763,Determination of the maximum tolerated dose (MTD) and the recommended dose for phase II of RP72 monotherapy and RP72 in combination with Gemcitabine,,,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
3980,NCT05152147,Overall survival,Incidence of anti-drug antibodies (ADAs),,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3']
3981,NCT06203587,Establishment and optimization of imaging method for [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347 PET/CT.,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
3982,NCT03136406,Objective response rate by irRC,"Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03.",,2017-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3983,NCT01658917,"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.","To collect detailed history, demographic, treatment data, and perioperative findings.",,2012-07-24,COMPLETED,OBSERVATIONAL,['NA']
3984,NCT04589247,Proportion of participants with change in their physician-assessed burden score,,Management changes as assessed by a Clinician Feedback Form,2020-11-16,RECRUITING,OBSERVATIONAL,['NA']
3985,NCT02182778,Overall survival rate,Number of Participants with Adverse Events as a Measure of Safety,,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3986,NCT01325961,Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).,clinical response and safety of the treatment by radiotherapy,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
3987,NCT04352894,Best modality of ICG injection,Sensitivity of ICG fluorescence,,2020-09,UNKNOWN,INTERVENTIONAL,['NA']
3988,NCT02651987,Median Progression Free Survival (PFS),Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon,,2015-12-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3989,NCT05796700,Progession-free survival,,,2008-01-01,COMPLETED,INTERVENTIONAL,['NA']
3990,NCT04189809,Rate of therapeutic proposals correctly predicted by the BCLC international classification,Rates and causes of discrepancies,,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA']
3991,NCT00964080,To determine the dose of MBP-426 for use in the Phase II portion of this study of MBP-426 administered every 21 days in combination with leucovorin (folinic acid or FA) and fluorouracil (5-FU),To characterize the safety profile of the combination therapy,,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3992,NCT06047379,Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.,,,2023-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3993,NCT03151213,visual analogue pain scale (VAS Pain) post operatively,,,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3994,NCT04109573,Manometric indices,Patient reported outcomes,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
3995,NCT03998033,The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy,Assess the persistence of ET140202 T cells circulating in blood over time.,,2019-05-30,TERMINATED,INTERVENTIONAL,['PHASE1']
3996,NCT02078700,percentage of cancer patients that accept and attend the early palliative care programme,percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3997,NCT01552226,Post-operative pain control day 5,Patient use of supplemental narcotic analgesia day 5,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
3998,NCT04165018,Diagnostic yield between FNB samples placed in formalin for pathology evaluation from two different types of needle,"Rate of adverse events of utilizing the FNB technique, including pancreatitis, bleeding, or perforation",,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
3999,NCT06232759,Progression-free survival,Overall survival,,2022-04-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4000,NCT00984048,Changes in biomarkers in patients that have acquired clinical resistance.,Number of participants with adverse events relating to the liver biopsy procedure,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
4001,NCT00436774,Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires,,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
4002,NCT06276153,overall survival,progression-free survival,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4003,NCT00052910,Overall Survival,Disease Free Survival,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4004,NCT01926444,"Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)",Subject Satisfaction and Acceptability of the Colonic Analgesia - Patient's Global Impression of Abdominal Pain,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4005,NCT02551991,Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT),Median Duration of Response (DoR),,2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
4006,NCT02575859,Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.,Peritoneal progression-free survival,Progression-free survival,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4007,NCT04038736,Evaluation of the performance of the C-scan System in detecting polyps≥10 mm compared to FIT results,,,2019-12-26,COMPLETED,INTERVENTIONAL,['NA']
4008,NCT05640791,Incidence of adverse events,Overall survival (OS),,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4009,NCT01579812,Recurrence-Free Survival,Overall Survival,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4010,NCT03228667,Objective Response Rate,Progression Free Survival,,2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4011,NCT06076811,The prognostic value of ctDNA status,Molecular characterization,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
4012,NCT02902575,Morbidity,Adverse events,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
4013,NCT04721301,Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0,Tissue Response,,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
4014,NCT01794676,Modified genetic factors that exist and may influence the phenotypic presentation of disease in unrelated MEN 1 families.,,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
4015,NCT02215044,Occurence of dose limiting toxicity according to CTCAE,Tumor marker (CA19-9) response to treatment with BI 2536 and gemcitabine,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1']
4016,NCT05428553,Adverse events,Recurrence after 6 months,Number of clips,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4017,NCT01565811,complication rate,To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
4018,NCT01835223,"PFS, Assessed Using Standard RECIST Criteria",Overall Survival Rate,"Drug Exposure, as Assessed by Steady State PK",2013-07-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4019,NCT01943864,Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12,Number of Participants With Independent Radiologist Assessed Duration of Response,,2013-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
4020,NCT01658436,Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review,Stage 1 - Disease Control Rate,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4021,NCT05841706,Rate of Protocol adherence,Number of blood products received,,2023-08-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4022,NCT06041945,Non-inferiority in Adenoma Detection Rate,Change in the cost of polypectomy and histology in screening programs,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
4023,NCT03137628,metabolomics,,,2017-03-20,UNKNOWN,OBSERVATIONAL,['NA']
4024,NCT02856568,"MTD of ricolinostat or a dose up to 240 mg/day whichever is lower, of ACY-1215",Time to treatment failure,Laboratory correlates measured from tissue by immunofluorescence,2017-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
4025,NCT06133023,Clinical success within 180 days of randomisation,Incidence of new pancreatic cancer,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4026,NCT00586989,1. The number of patients and the number of lesions with HGD or early ACA detected with WLE and ETMI 2. The number of patients with HGD and early ACA detected with targeted biopsies only with ETMI and WLE,1. The positive predictive value (PPV) of HRE and AFI 2. The reduction of false-positive findings after NBI (both the initial in vivo NBI assessment as well as later assessment based on still images),,2007-12,COMPLETED,OBSERVATIONAL,['NA']
4027,NCT05812430,Objective Response Rate(ORR),Disease Control Rate(DCR),,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE2']
4028,NCT01193452,response rate,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
4029,NCT01910610,Duration of Disease Control (DDC),Safety profile of each treatment sequence,,2013-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4030,NCT03601351,Disease free survival.,Perioperative complications.,,2018-05-04,COMPLETED,OBSERVATIONAL,['NA']
4031,NCT03798769,Rates of completion,Cumulative dose of FOLFIRINOX received,Progression free survival,2019-01-31,COMPLETED,INTERVENTIONAL,['NA']
4032,NCT01026753,Fecal Occult Blood Test (FOBT) completion rate,"The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
4033,NCT00966667,Normative influences of family and friends,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
4034,NCT02681601,Anthropometric measurement: Body Composition,Quality of life: Appetite,,2016-07-19,TERMINATED,INTERVENTIONAL,['NA']
4035,NCT02047474,Progression free survival rate,Objective response rate,,2014-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4036,NCT02599103,The changs of metabolomics profile between before and after oil consumption,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
4037,NCT02503384,Annual caseload for pediatric liver transplantation,,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
4038,NCT02785523,"Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.",Vanillylmandelic acid (VMA) in urine.,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
4039,NCT06023147,Objective response rate (ORR),Disease control rate (DCR),,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4040,NCT02669914,Overall Response Rate of Intracranial Disease,Overall Survival (OS),,2016-09-12,TERMINATED,INTERVENTIONAL,['PHASE2']
4041,NCT05585554,Overall Survival (OS),Treatment-related toxicity,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4042,NCT05781581,All-cause mortality at 30 days after operation,Major Adverse Cardiovascular Events (MACE),,2023-03-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4043,NCT03311776,Predictive biomarkers,,,2008-07-03,RECRUITING,OBSERVATIONAL,['NA']
4044,NCT05420480,Overall survival(OS),Disease free survival (DFS),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4045,NCT04409990,SWE accuracy,SWE and ADC measurement,,2020-03-02,COMPLETED,INTERVENTIONAL,['NA']
4046,NCT05048017,Progression Free Survival (PFS),Mortality at 12 months,Adverse Drug Reaction (ADR),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4047,NCT02202928,Progress-free survival,Phenotypic analysis of T cells,,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
4048,NCT01766986,Overall Survival,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4049,NCT03850912,'Emergency Department - Treat and Release' (EDTR) Rate at 30-days,Sustainability of ePRO symptom management within a health system,,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4050,NCT04780477,Change in Ki-67+ Level,Change in CD68+ Lamina Propia Macrophages Count,,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
4051,NCT01248663,Delayed gastric emptying,Measurement of plasma intestinal peptides,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
4052,NCT01248403,overall survival,disease control rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4053,NCT05856864,Adverse Events（AEs）,,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE1']
4054,NCT03705013,The number of subjects with discordant results that can be attributed to intercurrent disease,,,2018-10-30,TERMINATED,OBSERVATIONAL,['NA']
4055,NCT05233098,Effective dose (Gy) for the whole body,,,2023-02-04,COMPLETED,OBSERVATIONAL,['NA']
4056,NCT00499850,"Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin",,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
4057,NCT01114035,gene identification,mutation identification,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
4058,NCT00040833,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4059,NCT01401309,Detecting,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
4060,NCT00375999,Overall Survival,,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4061,NCT04195828,major pathological response,R0 resection rate,,2020-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4062,NCT01251640,Tumor Response (Adjudicated Blinded Read Assessment): Phase II,Overall Survival (OS): Phase II,,2011-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4063,NCT05740111,Number of resectable cancers detected in patients diagnosed through the surveillance programme compared to the unscreened individuals as reported to the Cancer Registry of Norway.,The psychological well-being of participants undergoing surveillance as assessed by the Psychological Well-being Questionnaire,,2022-09-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4064,NCT05770739,postoperative length of stay,30-day readmission rate,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4065,NCT00427089,"Efficacy was measured as the degree of cleansing using a 5 grades scale for each of the predefined colon areas resulting into a final grading of the overall quality of gut preparation (A or B: ""success"" versus C or D: ""failure"").","Laboratory tests (such as blood chemistry and hematology) were conducted to support the safety data as well as measurement of body weight, blood pressure and pulse rate, but also tolerance.",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4066,NCT00102011,Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy,,,2000-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4067,NCT03902379,Examine feasibility of an online CCI as defined by participant's evaluation of the online intervention,Examine acceptability of an online CCI,,2016-07-27,WITHDRAWN,INTERVENTIONAL,['NA']
4068,NCT00215722,Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.,Evaluate the Quality of Life,,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
4069,NCT01693848,Effect of resection of metastasis on urinary excretion of modified nucleosides,Identification of modified nucleosides as biomarkers for colorectal cancer,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
4070,NCT04014478,Visual Analog Scale Changes over the time,Quality of Life Score Changes over the time,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
4071,NCT06018246,Patient-generated subjective nutrition assessment,Walking time,Adverse reaction,2021-07-20,COMPLETED,INTERVENTIONAL,['NA']
4072,NCT00716976,Incidence of Hearing Loss,Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT),,2008-06-23,COMPLETED,INTERVENTIONAL,['PHASE3']
4073,NCT02362048,Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4074,NCT02873741,Presence of Anal hr-HPV,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
4075,NCT00865527,Proportion of enrolled patients who attend for their assigned screening test,Proportion of patients found to have invasive colorectal carcinoma,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
4076,NCT02698137,procedure-related adverse events,technical failure of the procedure,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
4077,NCT04271813,Objecitve response rate,Disease control rate,,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4078,NCT04840264,60-day Obstruction Clearance Rate,Quality of Life assessed by EORTC QLQ-OG25,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2']
4079,NCT00827580,the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.,,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
4080,NCT05387876,Microbiome alterations,,,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4081,NCT01741636,"Satisfaction with the timing, content, and delivery of the intervention",,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4082,NCT01804621,Colorectal cancer screening,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
4083,NCT01580202,The cumulative probability of HBV reactivation,Incidence of hepatic decompensation and liver-related mortality,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4084,NCT02773524,Overall Survival,Rates of Adverse Events,Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts.,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
4085,NCT01916239,Gene expression profiling in colon tissues,microRNA expression profiling in colon tissues,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4086,NCT02445209,Overall Survival,Safety as assessed by adverse events according to CTCAE v4.0,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4087,NCT01446666,Detection Rate of Patients With HCC,Positive Predictive Value for HCC,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
4088,NCT00398398,Overall Response Rate,Toxicity Profile,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4089,NCT03524820,response to treatment,,,2017-10-17,TERMINATED,INTERVENTIONAL,['PHASE2']
4090,NCT05348187,therascreen® KRAS RGQ PCR Kit,,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
4091,NCT03588533,Adverse event,Overall survivals (OS),,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
4092,NCT01282658,,,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
4093,NCT06208046,5-year overall survival,,,2023-07-01,COMPLETED,OBSERVATIONAL,['NA']
4094,NCT00264446,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
4095,NCT05692284,Patient Identification Form,SELF CARE ABILITY SCALE,,2022-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4096,NCT00427375,"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after",Quality of life (QLQ C30 - CR38),,2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4097,NCT05698459,MTD (Maximum Tolerance dose),Immunogenicity,,2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1']
4098,NCT01129570,The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma,Tumor response as measured by RECIST criteria and AFP concentrations,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4099,NCT01340508,Pathological complete response rates,Sphincter Preservation rates,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4100,NCT01182116,Improved function and capacity of the neorectum.,,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
4101,NCT05723965,accuracy of artificial intelligence with experienced physician,real life survival outcome of diagnosis by artificial intelligence.,,2010-10-01,COMPLETED,OBSERVATIONAL,['NA']
4102,NCT00096733,Survival of the potential liver transplant recipient,Recipient survival from time of transplant (either living or deceased donor),Recipient complications,2004-10,COMPLETED,OBSERVATIONAL,['NA']
4103,NCT00022334,Dose limiting toxicity and maximum tolerable dose.,clinical response in patients with measurable disease.,,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4104,NCT04499833,hepatocellular carcinoma recurrence,hepatocellular carcinoma recurrence through liquid biopsy,,2021-03-25,RECRUITING,INTERVENTIONAL,['NA']
4105,NCT00513357,Change in Appetite as Measured by ESAS,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4106,NCT05922930,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-10-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4107,NCT06275204,Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program,Participation rate of subjects selected for the program,,2024-03-04,RECRUITING,OBSERVATIONAL,['NA']
4108,NCT02474537,Vz/F of INC280,Unbound fraction and Vz/F based on unbound concentration in plasma,,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4109,NCT04046887,Frequency of Dose Limiting Toxicities (DLTs),European Organization for Research and Treatment of Cancer quality of life questionnaire,,2019-09-11,TERMINATED,INTERVENTIONAL,['PHASE1']
4110,NCT00719303,Progression-free survival,Change in self-reported quality of life measured using RAND-36,Vitality measured using RAND-36 and GSRS-IBS,2012-06-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
4111,NCT03911167,Postoperative complication rate，%,"hospitalization expenses,yuan",,2017-09-01,COMPLETED,OBSERVATIONAL,['NA']
4112,NCT02284802,accuracy of confocal endomicroscopy,,,2014-09-10,COMPLETED,INTERVENTIONAL,['NA']
4113,NCT05759325,Progression-free survival,,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4114,NCT01971775,Amount of drain at postoperative period,4. Postoperative hospital stay Complications,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4115,NCT04245644,Overall survival,,,2019-03-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4116,NCT01832948,Objective Response Rate (ORR),Incidence of Adverse Events,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4117,NCT02227914,Time To Progression (TTP) - Phase 2,Overall Survival (OS) - Phase 2,,2014-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4118,NCT01039506,Progression free survival,Safety events,,2009-10-15,COMPLETED,OBSERVATIONAL,['NA']
4119,NCT00236249,"Readiness for discharge, checked twice a day",Clinical side effects twice a day,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4120,NCT01648465,15 month PFS (Progression-Free Survival) rate,Association of biologic markers with disease progression,,2012-08-06,TERMINATED,INTERVENTIONAL,['PHASE2']
4121,NCT04931381,6-month disease control rate,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
4122,NCT06060704,ORR（Objective response rate）,Quality of life: EORTC QLQ-C30,,2023-11,RECRUITING,INTERVENTIONAL,['PHASE2']
4123,NCT04789200,Marking and distension of the bowel lumen at CT of the abdomen,Delineation of bowel wall enhancement related to concurrent intravenous contrast at CT of the abdomen and pelvis,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4124,NCT06130826,Recommended phase 2 dose,Pharmacokinetics of M5A-IL2 (M5A-ICK blood clearance ),,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
4125,NCT00804817,Health Related Quality of Life (HRQoL),Symptom experience (Common Terminology Criteria for adverse events - CTCAE v. 3.0),,2007-12,COMPLETED,INTERVENTIONAL,['NA']
4126,NCT04646187,cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up,Identification of predictors of successful de-escalation.,Patients' attitudes towards deprescribing anti-TNF agents,2021-03-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
4127,NCT02928224,"(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm",Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment,(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis,2016-10-13,COMPLETED,INTERVENTIONAL,['PHASE3']
4128,NCT01929915,Perioperative immunoprofile,survival rate,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
4129,NCT03251417,Disease control rate,Median overall survival time,,2017-09-10,TERMINATED,INTERVENTIONAL,['PHASE2']
4130,NCT00210249,Number of Participant Deaths,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
4131,NCT03812770,Progression Free Survival (PFS),Adverse Events,,2018-08-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
4132,NCT05192018,Feasibility of early reversal of adefunctioning ileostomy,,,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA']
4133,NCT01994681,Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.,,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
4134,NCT00215644,Percentage of Participants With Objective Response Assessed by Independent Review Committee,Matuzumab Serum Concentration,,2005-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
4135,NCT05730192,Positive percent agreement (PPA),,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
4136,NCT00845884,response rate,"Safety, PFS, overall survival",,2009-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4137,NCT01569620,"Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.",,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
4138,NCT03830606,objective response rate（ORR）,safety profile: assessed by CTCAE v4.0,,2016-03-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4139,NCT03264716,Hepatic Progression free survival,An overall tumor response classification,,2017-08-31,COMPLETED,INTERVENTIONAL,['NA']
4140,NCT02869477,Survival of patients,Collection of patients characteristics,,2002-01,RECRUITING,OBSERVATIONAL,['NA']
4141,NCT03410641,"Incidence of the group of cancers related to smoking, diet or body mass index",Incidence of prostate cancer,,1972-01-15,COMPLETED,OBSERVATIONAL,['NA']
4142,NCT03039595,Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer,Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer,,2017-03-29,COMPLETED,OBSERVATIONAL,['NA']
4143,NCT05131815,Feasibility of BurnAlong,Measure of Experiential Aspects of Participation (MeEAP),,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
4144,NCT04699539,1-year Local Control Rate (1y-LCR),Overall Survival(OS),,2021-03-31,RECRUITING,INTERVENTIONAL,['NA']
4145,NCT04512209,Biophysical properties of the tumor tissue - measurement of hydraulic conductivity,Measurement of Pt penetration,,2019-10-11,RECRUITING,INTERVENTIONAL,['NA']
4146,NCT04062656,Rate of pathological complete responses,Patient-reported outcome (PRO),,2019-09-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4147,NCT04686942,sensitive of detection tumor,,,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA']
4148,NCT02130752,Surgical duration,Postoperative Mortality and Morbidity,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
4149,NCT03398122,PFS,QOL,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
4150,NCT00838578,Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0,,,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4151,NCT00903136,Comparison of participants' satisfaction with the TCE vs esophagogastroduodenoscopy (Phase II),Results of the histologic analysis of any biopsy specimens (Phase II),,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4152,NCT01715233,Response,Overall Survival,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4153,NCT01801904,number of patients alive and without disease progression,worst grade toxicity per patient,gene expression on tumor tissue,2012-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4154,NCT05809869,Rate of abscopal effect,Distant control rate,,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
4155,NCT01077986,phase II part: response rate,Pharmacodynamics: biomarkers in blood and tumor tissue,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4156,NCT05429203,Number of participants with procedure-related adverse events,Ability to perform interventions,,2022-10-25,RECRUITING,INTERVENTIONAL,['NA']
4157,NCT00405873,Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later,Safety and Tolerability,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
4158,NCT01443260,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)",Detection of Anti-tumor Activity,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4159,NCT06148402,Objective Response Rate,ctDNA and efficacy,,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4160,NCT05956847,Changes in ecDNA content in different gastric precancerous lesions,,,2023-08-10,RECRUITING,OBSERVATIONAL,['NA']
4161,NCT02529007,Number of polyps detected per patient,Patient comfort score,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
4162,NCT03915171,Sensitivity and specificity of blood MSI detected by NGS,Correlation between MMR gene and other gene mutations,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
4163,NCT03806218,Minimum diameter of ablation zone per unit time,Local tumor progression (LTP),Ablation time,2015-05-16,COMPLETED,INTERVENTIONAL,['NA']
4164,NCT00257426,Median survival,number of subjects with toxicities,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4165,NCT02898649,Safety (frequency of procedure-related complication and death),Change in CA 19-9,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
4166,NCT02806661,Recurrence rate,Inflammatory factors,,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
4167,NCT00352404,Histological proof of neoplastic tissue (Intraepithelial neoplasia or cancer),Prediction of extent and severity of inflamed mucosa,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4168,NCT01912131,assess the acceptability of this piloted P-COCC intervention,qualitative analyses,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
4169,NCT00790218,Maximum Plasma Concentration of CF102 (Cmax),Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4170,NCT03531632,Number of Participants With Adverse Events,The Number of Participants With Response Based on the Change in Tumor Volume,,2018-06-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4171,NCT05963724,Adenoma Detection Rate,Withdrawal Time,,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
4172,NCT04607668,Myelopreservation,Anti-tumor Efficacy,,2020-10-16,TERMINATED,INTERVENTIONAL,['PHASE3']
4173,NCT02897778,Change from Baseline in T-Cell Morphology,λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose,"Variability and Changes in Protein Lysine Acetylation in Peripheral Blood Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose and Examine the Underlying Biological Variation",2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
4174,NCT04172714,Tumor to Normal Liver Activity Ratio (TNR),Number of Participants With Tumor Response Using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) Post Y90 Embolization,,2019-12-16,COMPLETED,INTERVENTIONAL,['NA']
4175,NCT04684355,Quality of life degree,Anxiety and depression degree,,2020-12-22,UNKNOWN,INTERVENTIONAL,['NA']
4176,NCT00765869,Involvement in screening decision,Influence of doctor on screening decision,,2008-07,UNKNOWN,INTERVENTIONAL,['NA']
4177,NCT01013805,Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimen,Dose Intensity of the treatment drug,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4178,NCT04450758,Number of patients with 90 day mortality,colorectal surgeon performing resectional surgery,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
4179,NCT03337087,Best response rate (Phase II),Incidence of adverse events (Phase II),,2018-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4180,NCT04271657,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiopathomics artificial intelligence model,The sensitivity of the radiopathomics artificial intelligence model,,2020-01-10,COMPLETED,OBSERVATIONAL,['NA']
4181,NCT00743964,Failure-free survival,progression-free survival,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4182,NCT02324114,Hsp90α Concentration(ng/ml) of plasma,,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
4183,NCT01919151,Survival,,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
4184,NCT06154785,To assess the impact of the stable low-pressure approach (using Airseal Insufflator) and its associated parameters into the the early rehabilitation program after colorectal surgery on length of stay.,The Surgical and Medical morbidity at 30 days,,2023-12-15,RECRUITING,OBSERVATIONAL,['NA']
4185,NCT01350726,,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
4186,NCT03941184,Incidence Rate of SCAD,SCAD recurrence,Odds of validated rheumatoid arthritis in SCAD cases compared to controls,1995-01-01,COMPLETED,OBSERVATIONAL,['NA']
4187,NCT02446379,The location of PET imaging agent as measured by the LightPathTM Imaging System,Number of participants with adverse events,,na,WITHDRAWN,OBSERVATIONAL,['NA']
4188,NCT01551589,radiation pneumonitis and radiation esophagitis,Local control rate/ Inside irrational field recurrence rate,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
4189,NCT00423254,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,to describe any objective tumor responses to the treatment with MKC1106-PP,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4190,NCT00004066,,,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4191,NCT03313596,"Progression-free survival, PFS",Median overall survival time,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
4192,NCT03283761,Objective Response Rate,Safety and Toxicity Profile of the Combination of Nab-paclitaxel and FOLFOX,,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE2']
4193,NCT05329766,Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,Percentage of participants with anti-drug antibodies to zimberelimab,,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2']
4194,NCT01177007,Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria,Mean Radiation Dose Delivered to Total Liver,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4195,NCT01520259,gallbladder cancer/pre-cancer,,,2012-01-10,COMPLETED,OBSERVATIONAL,['NA']
4196,NCT06218420,To evaluate the efficacy of stereotactic body radiotherapy (SBRT) as bridging therapy for patients with hepatocellular carcinoma (HCC) enlisted for liver transplantation (LT).,To assess the occurrence of adverse events related to SBRT during waiting time period and after LT,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4197,NCT01695772,Percentage of Participants Achieving Complete Resection (R0 Resection),"Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12",,2012-10-16,COMPLETED,INTERVENTIONAL,['PHASE4']
4198,NCT00068575,Median Overall Survival (OS),,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4199,NCT00544011,Objective response (complete and partial) rate,Biomarkers predictive of efficacy,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
4200,NCT05138887,acute radiation-induced proctitis (ARP) incidence,cancer remission rate assessed by imaging,adverse events,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4201,NCT01982487,PFS (Phase IIb),"Toxicity rate, graded according to NCI CTCAE version 4.0",,2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4202,NCT03047603,PIVKA-II,"ALT, AST，γ-GT， AFU",,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
4203,NCT02205008,relapsed free survival,overall survival,surgery and intraperitoneal chemotherapy-related morbidity and mortality,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4204,NCT05225207,Number of Participants With Non-serious ADRs,Percentage of Participants With Overall Response,,2019-05-28,COMPLETED,OBSERVATIONAL,['NA']
4205,NCT05501379,Comparison of physical activity assessments within 1 week after initiation of cancer therapy,Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy,,2022-09-21,RECRUITING,OBSERVATIONAL,['NA']
4206,NCT02436018,Low pulse oximetry incidence,Other adverse events,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
4207,NCT04969835,Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.,Overall survival (OS),,2021-07-16,RECRUITING,INTERVENTIONAL,['PHASE1']
4208,NCT01761461,The primary endpoint of the study is disease-free survival (DFS).,,,2013-02-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
4209,NCT00879333,Overall Survival (OS),Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4210,NCT04111978,Progression-free survival (PFS) for each study group,Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group,,2020-11-05,RECRUITING,INTERVENTIONAL,['PHASE3']
4211,NCT01504997,The Incidence of Post-operative Intra-abdominal Infectious Complications,Incidence of Adverse Events,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
4212,NCT03851939,ORR,DCR,,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
4213,NCT04091295,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
4214,NCT05408169,Number of screening tests returned to the central laboratory and successfully processed providing an adequate result.,Acceptability of interventions (qualitative),,2022-06-20,COMPLETED,INTERVENTIONAL,['NA']
4215,NCT00063960,overall survival,time to hepatic recurrence or progression,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4216,NCT04605913,Determine safety of (m)-GCN+TTF,Overall Survival,,2022-04-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4217,NCT06296706,OS,Plasma concentration of docetaxel (free and total),,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
4218,NCT06094868,Progression-free survival (PFS),Security,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4219,NCT00511446,Progression-free survival rate,Median overall survival,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4220,NCT01033240,Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,Treatment-Emergent Adverse Events Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,,2010-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4221,NCT01057953,genetic variation assessment,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
4222,NCT06261047,Progression free survival,Duration of control,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
4223,NCT04305145,Proportion of patients with Steroid-Free Colitis,Overall Response Rate,,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE2']
4224,NCT02889276,"Change in Global Health Status/QoL (subscale of EORTC QLQ-C30, Version 3) scores in cancer survivors",Change in Self-efficacy to regulate exercise scale score,,2017-02-20,TERMINATED,INTERVENTIONAL,['NA']
4225,NCT05374122,Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up,Insufficient biopsy sample rate,,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4226,NCT05706025,Testing difference in Biomarkers between Control and BE/EAC patients,Testing difference in Multiple Biomarkers between Control and BE/EAC patients,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
4227,NCT03867084,Overall Survival (OS),"Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score",,2019-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4228,NCT05191667,Number of participants with Dose Limiting Toxicities (DLTs),Overall survival (OS),,2022-01-18,RECRUITING,INTERVENTIONAL,['PHASE1']
4229,NCT04408599,Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD),Half-life (t1/2) of NC410,,2020-06-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4230,NCT05012527,Completeness rate of the procedures,,,2021-06-11,COMPLETED,OBSERVATIONAL,['NA']
4231,NCT00122876,Safety,Survival,,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4232,NCT02483884,Sensitivity and specificity of [68Ga]RM2 PET to identify lesions in comparison to whole-mount histopathology (number of histologically verified cancer lesions identified),Evaluation of SUV threshold,Number of patients with adverse events,2015-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4233,NCT00387387,"Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1","Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging",,2006-10-20,COMPLETED,INTERVENTIONAL,['PHASE1']
4234,NCT01027221,Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity,"quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months",,2009-11,COMPLETED,INTERVENTIONAL,['NA']
4235,NCT03407001,Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres and B-mode non-contrast enhanced ultrasound,Assessment of CEUS and contrast enhanced magnetic resonance imaging (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads),,2018-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4236,NCT01754272,Primary colorectal cancer tumor blocks,Metastatic tumor blocks,Residual blood samples,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
4237,NCT01640860,Response rate,"progression free survival, overall survival and adverse events",,2007-12,COMPLETED,OBSERVATIONAL,['NA']
4238,NCT05517681,The number of positive lymph nodes,The incidence of postoperative complications,,2020-09-07,COMPLETED,INTERVENTIONAL,['NA']
4239,NCT03308552,Overall survival（OS）,Adverse events,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
4240,NCT04164017,Accuracy,,,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4241,NCT03770689,Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC),Apparent Terminal Half-life (t1/2) of Peposertib,,2019-03-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4242,NCT00025025,,,,2001-10,COMPLETED,OBSERVATIONAL,['NA']
4243,NCT01738633,"items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30",item EA (eating) of OES18,,2013-01,TERMINATED,INTERVENTIONAL,['NA']
4244,NCT00001805,,,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4245,NCT01167738,Progression-free survival at 6 months,Toxicity,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
4246,NCT03615599,Incident cases of breast cancer among subjects with documented dietary habits.,Incident cases of prostate cancer among subjects with documented dietary intakes.,Incident cases of colorectal cancer among subjects with documented dietary habits.,2002-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4247,NCT05462496,Achievement of overall immune response,Overall survival rate (OS),,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
4248,NCT02745197,Muscle fatty acid content,Plasma C-reactive protein,,2017-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4249,NCT02656524,Number of participants with treatment emergent adverse events as a measure of safety and tolerability,Resource utilization per patient,Time frame between the baseline computed tomography and the first drug delivery,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
4250,NCT01758965,Delayed bleeding rate after ESD,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
4251,NCT02367001,Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters,"Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)",,2014-02,COMPLETED,INTERVENTIONAL,['NA']
4252,NCT03536208,Determine change in AXL pathway,Antitumor effect,,2019-05-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
4253,NCT02252250,Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.,Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.,Quality of life outcomes evaluation,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4254,NCT03657914,Number of lymph nodes dissected,Postoperative drainage tube indwelling time,Local recurrence rate of tumor within 3 years,2017-07-12,UNKNOWN,INTERVENTIONAL,['NA']
4255,NCT04046575,Maximum tolerated dose (MTD) of hypofractionated IMRT with chemotherapy,Number and type of adverse events experienced by patient,,2019-11-07,RECRUITING,INTERVENTIONAL,['PHASE1']
4256,NCT03741088,Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors,Analgesic Requirements After the Ablation Procedure,,2018-03-21,COMPLETED,INTERVENTIONAL,['NA']
4257,NCT05124743,Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.,,,2021-09-24,SUSPENDED,OBSERVATIONAL,['NA']
4258,NCT03975465,Timing of Aspiration (category),,M.D. Anderson Dysphagia Inventory (MDADI) (number),2018-09-10,RECRUITING,INTERVENTIONAL,['NA']
4259,NCT01775280,Primary endpoint ist the percentage of patients that can be downstaged to resectability,Immunological response to radioembolization,,2012-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4260,NCT05163236,sensitivity of the fecal immunochemical test for the detection of colorectal cancers,Treatment,,2021-04-20,COMPLETED,OBSERVATIONAL,['NA']
4261,NCT03160924,Post-operative hospital stay,Direct hospital costs,,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
4262,NCT02618356,Median disease progression free survival (mPFS) of Raltitrexed combined with S-1,,,2015-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
4263,NCT01859858,Pharmacokinetics of SN-38,,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4264,NCT04644250,Pathologic complete response rate,R0 resection rate,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4265,NCT03355391,colorectal cancer rate,,,2018-01-30,UNKNOWN,OBSERVATIONAL,['NA']
4266,NCT01190462,Percentage of patients free from progression and alive after 12.5 weeks following the first dose of treatment,"Correlation between overall response rate, progression-free survival, overall survival, and safety with skin toxicity and efficacy",,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
4267,NCT03071094,Overall Response Rate (ORR) According to RECIST 1.1.,,,2017-07-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4268,NCT00299299,,,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
4269,NCT00792363,Response Rate,Progression free survival,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4270,NCT06041477,OS,Safety profiles of all participants,,2023-09,RECRUITING,INTERVENTIONAL,['PHASE3']
4271,NCT05319730,Objective Response Rate (ORR),Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase,,2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4272,NCT02706301,Change in Pain Severity assessed using the Brief Pain Inventory (BPI),Change in Self-Efficacy for Pain Control assessed using the subscale of the Chronic Pain Self-Efficacy Scale,Patient Satisfaction assessed using the Client Satisfaction Questionnaire 10-item version,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4273,NCT00010062,,,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
4274,NCT00450788,cancer incidence,Mortality,,2007-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4275,NCT03820544,Intraoperative Estimated Blood Loss,,,2017-09-01,TERMINATED,INTERVENTIONAL,['NA']
4276,NCT05583890,Health inequalities,,,2022-08-25,RECRUITING,OBSERVATIONAL,['NA']
4277,NCT03596411,Sleeve gastrectomy,Obesity related comorbidity,,2018-05-17,UNKNOWN,OBSERVATIONAL,['NA']
4278,NCT03144661,Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs),Analysis of biomarkers,,2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE1']
4279,NCT04629326,Standardized uptake value（SUV）,,,2021-07-20,RECRUITING,INTERVENTIONAL,['NA']
4280,NCT03160209,Risk factors for ESCC - Tobacco and alcohol consumption,The germline genetic and epigenetic alterations associated with susceptibility to ESCC.,,2017-07-26,COMPLETED,OBSERVATIONAL,['NA']
4281,NCT04950166,Clinically Significant Events (CSE),Pegsitacianine fluorescence and imaging performance,,2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE2']
4282,NCT02433639,progression-free survival at 4-months (PFS4mo),safety and tolerability as measured by number and grade of toxicity events,"protein/genomic biomarkers of efficacy from serum, plasma or tumor",2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4283,NCT05848739,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,ST316 Assessment Objective Response Rate (ORR),,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1']
4284,NCT04498520,Incidence of treatment-related adverse events (AE),Median progression-free survival (PFS),,2021-03-31,WITHDRAWN,INTERVENTIONAL,['PHASE1']
4285,NCT03686709,Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging,,,2018-06-19,RECRUITING,INTERVENTIONAL,['NA']
4286,NCT06006260,Self-report Questionnaire,,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
4287,NCT01863355,Pain score(VAS) within 48hrs after surgery,,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
4288,NCT00700102,Overall Survival: Time From Randomization to Death From Any Cause,Response Rate: Participants With Response Status Based on RECIST Criteria,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4289,NCT04970914,Progression-free survival (PFS),Overall Survival (OS),Number of TB cells count and interleukin-6/8/10,2021-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
4290,NCT06092242,Progression Free Survival,Quality of life score,,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4291,NCT03313700,3-year disease free survival rate,operation time,,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
4292,NCT05141617,24-week re-bleeding,24-week adverse events,,2021-11-03,UNKNOWN,INTERVENTIONAL,['NA']
4293,NCT01317069,duration of survival after operation,disease free survival,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
4294,NCT04306458,Total number of dissected lymph nodes,Quality of life after esophagectomy,,2021-01-18,RECRUITING,INTERVENTIONAL,['NA']
4295,NCT03082911,Participation,Help to decide about participation,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
4296,NCT04658589,Number of harvested lymph nodes in D2 lymph node dissection,Conversion to open surgery,,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4297,NCT03959696,Shared Decision Making Process (SDMP) Scale Score,Clinician satisfaction with the visit,Clinician attitude toward shared decision making,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4298,NCT00833131,The rate of patients with R0 resection,The rate of complete pathological response,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
4299,NCT00280761,Correlation of NF-kappa B pathway activation with therapeutic outcomes,Correlation of p53 pathway-mediated events with clinical outcomes,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
4300,NCT04371224,Progression-free survival,QOL: eortc qlq-c30,,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
4301,NCT00091195,Survival,,,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2']
4302,NCT01895530,Difference in gene expression of citokynes,Postoperative complications,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4303,NCT00188266,Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.,Survival and disease-specific survival,,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4304,NCT04789980,Overall Survival (OS),Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores,Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy,2021-01-29,RECRUITING,OBSERVATIONAL,['NA']
4305,NCT05999812,"Objective Response Rate of of ATRA, bevacizumab and atezolizumab combination",Frequency of adverse events,,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2']
4306,NCT05029102,Progression Free Survival,Overall Survival,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4307,NCT04926532,Objective response rate (ORR),Overall survival,,2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4308,NCT04358328,Mortality,Mortality,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
4309,NCT02079389,"A change in the stage of Tumor, lymph Node and metastases (TNM-stage)",A change in the postoperative treatment strategy,Does the use of contrast enhanced ultrasound examination during surgery for colon and rectum cancer provides more findings of liver metastases?,2013-05,COMPLETED,INTERVENTIONAL,['NA']
4310,NCT00087334,Response rate,Overall survival in (phase II),,2004-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4311,NCT06327269,Recurrence-free survival with adjuvant therapy,,,2021-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4312,NCT01092091,Tumor response,Plasma arginine levels,,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4313,NCT03076567,Relation of DNA methylation marakers to gastric cancer status,,,2017-03-09,COMPLETED,OBSERVATIONAL,['NA']
4314,NCT04390724,Patient Group 2: HCC Resection,,,2020-07-17,RECRUITING,OBSERVATIONAL,['NA']
4315,NCT04761783,Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy,Determine the impact of SIGNATERA on patient reported outcomes,,2021-05-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4316,NCT04048278,Upregulation or Downregulation of Gene Expression.,Specimen outcome measure,,2018-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4317,NCT01287585,Overall survival,Safety and tolerability - number of participants with adverse events.,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4318,NCT05565066,Diagnostic yields of EUS-FNA with EUS-FNB for solid masses,Quality of histologic specimen,,2014-12-01,COMPLETED,OBSERVATIONAL,['NA']
4319,NCT00024063,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
4320,NCT01712958,"identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics",,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
4321,NCT04552405,Evaluate changes in calprotectin levels,Evaluate changes in stool inflammatory markers,,2017-09-12,COMPLETED,INTERVENTIONAL,['NA']
4322,NCT04642664,Objective Response Rate (ORR),Incidence of Treatment-Emergent Adverse Event,Clinical benefit rate (CBR),2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4323,NCT06214533,Postoperative opioid use,Post-operative hospital time,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4324,NCT04440865,Adenoma Detection Rate (ADR),Morbidity: bleeding rate (%),,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
4325,NCT03121807,Overall survival,Cycles of salvage chemotherapy completed,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
4326,NCT01002287,"The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.",Mobilization Time,,2009-10,TERMINATED,INTERVENTIONAL,['NA']
4327,NCT01604798,Serum peptide mass fingerprinting (PMF),Expressed peptide peaks,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
4328,NCT04386057,Dose Limiting Toxicity-Lead In,Overall survival (OS),,2020-05-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4329,NCT01697449,Percentage of Participants With At Least One Adverse Event (AE),Progression Free Survival (PFS),,2009-03,COMPLETED,OBSERVATIONAL,['NA']
4330,NCT04123379,Significant Tumor Necrosis (STN),Overall Survival (OS),,2020-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4331,NCT01110941,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)",,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4332,NCT04380103,objective response rate (ORR),the surgical resection rate of patients with liver-only metastases,,2020-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4333,NCT03704077,Overall response rate (ORR),Overall survival (OS),,2019-10-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4334,NCT06003998,Overall survival,Peritoneum/plasma ratio of intraperitoneal irinotecan,,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2']
4335,NCT05845450,major pathological response rate,microbiota,Overall survival,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2']
4336,NCT01126463,Maximal tolerated dose,Bio-availability,,2010-05-26,COMPLETED,INTERVENTIONAL,['PHASE1']
4337,NCT04045496,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,Duration of response ( DOR ),,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE1']
4338,NCT03446157,Disease Control Rate,Toxicity of Treatment,,2018-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4339,NCT01349881,"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)",Cancer type (colorectal vs rectal),,2013-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4340,NCT01849588,Decline in HCV-RNA Level,Overall Survival,Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
4341,NCT04429542,Incidence of Dose Limiting Toxicities (DLTs),Immunogenicity of BCA101 and pembrolizumab,,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE1']
4342,NCT04466891,Confirmed objective response rate (ORR) by independent central review (ICR),Incidence of anti-drug antibodies (ADAs),,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4343,NCT05603572,To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration,To assess area under the curve (AUC) of KAT (oral and oral + IT),,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4344,NCT02331914,Secondary GIST mutations in circulating tumor DNA of patients with progressive disease on TKI treatment,Secondary mutations in circulating tumor DNA related to pharmacokinetics of TKI,,2014-12-08,RECRUITING,OBSERVATIONAL,['NA']
4345,NCT06059885,Tumor recurrence rate (DRR),,,2021-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
4346,NCT05402592,Shorter Length Of Hospitalization,Higher quality of life on the 30th day after surgery in patients given a carbohydrate-rich beverage before surgery,,2022-07-13,COMPLETED,INTERVENTIONAL,['NA']
4347,NCT06281379,Postoperative outcome,,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
4348,NCT04287218,Change of total score on Fear of Cancer Recurrence Inventory (FCRI) from baseline to 2nd follow-up,Comparison of changes in health care usage between intervention arm and aTAU,Perceived risk of recurrence measured by the visual analogue scale from 1-100,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
4349,NCT04253106,Number of subjects in whom somatic mutations or methylation profiles are detected.,Replicability of observations over successive endoscopies. Correlation between blood and gastric fluid.,,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4350,NCT04939103,the accuracy of predicting pCR after nCRT,,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
4351,NCT05043857,Local Recurrence Rate,Overall Survival,,2021-07-06,RECRUITING,INTERVENTIONAL,['NA']
4352,NCT03351647,Measurement of serum ustekinumab trough concentrations (expressed in microg/mL) at week 8.,Clinical evaluation at week 24,,2018-02-14,COMPLETED,OBSERVATIONAL,['NA']
4353,NCT00064051,Objective response rate (partial and complete response) as assessed by RECIST criteria,Safety and feasibility,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4354,NCT00681421,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),To evaluate immunological responses,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4355,NCT03465722,"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1",European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib,,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE3']
4356,NCT06221748,Overall Survival (OS)(Phase III),Incidence of echocardiograms abnormalities,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4357,NCT02696759,Number of Subjects Who Complete Fecal Collection,,,2016-07,TERMINATED,INTERVENTIONAL,['NA']
4358,NCT02536183,Feasibility of treatment,Determine the Changes in Pharmacodynamic Immune Markers in Participants,,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1']
4359,NCT05047510,HCC lesions,,,2021-09-10,RECRUITING,INTERVENTIONAL,['NA']
4360,NCT05542680,Reflux symptoms,Skin pressure injury,,2022-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4361,NCT05969847,Organ preservation,Anorectal function,,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4362,NCT04656782,Standardized imaging protocol consensus among panelists,Description of heterogeneity of mCRC imaging protocols,,2021-01-26,UNKNOWN,OBSERVATIONAL,['NA']
4363,NCT03555149,Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,Percentage of Participants With at Least One Adverse Event (AE),,2018-09-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4364,NCT02930902,Incidence of toxicities as defined by Common Terminology Criteria for Adverse Events version 4.0,Resection rate,Overall survival (OS),2017-02-20,COMPLETED,INTERVENTIONAL,['PHASE1']
4365,NCT05279612,Investigate patients ORR,R0 resection,,2021-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4366,NCT01744639,Nutritional Status,Minimal hepatic encephalopathy,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
4367,NCT01465802,Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III,"Mean Plasma Ctrough for PF-05199265 by Visit for Cohorts I, II and III",,2011-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
4368,NCT06255041,"Sensitivity of detection of any cancer (breast, lung, prostate or colorectal cancer) by the breath test.",Intra-observer variability among the detection dogs,The duration for which a breath sample collected on an alternative mask substrate remains effective for detection by a detection dog,2021-02-10,RECRUITING,OBSERVATIONAL,['NA']
4369,NCT01345175,To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.,efficacy of metronidazole,,2011-04-26,COMPLETED,INTERVENTIONAL,['PHASE3']
4370,NCT00961571,Progression-free Survival,,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2']
4371,NCT05453760,Area under the curve (AUC) of the Lung ultrasound score,Complications according to the Dindo-Clavien classification,,2022-08-21,RECRUITING,OBSERVATIONAL,['NA']
4372,NCT05034783,Metabolic parameters,Diagnostic value,GLP-1R expression and SUV,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4373,NCT02507414,"Relative changes in plasma-hormone concentrations (pro-ANP, PGF2, GLP-1, ACTH, cortisone, adrenaline, IL-1, IL-6, TNF-alfa and CRP (stress hormones)) from baseline.",Relative changes in systemic vascular resistance from baseline measured in dyn.s/cm5,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4374,NCT02682485,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),,2017-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4375,NCT01899976,Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL,total number of adverse events,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
4376,NCT02550613,The recurrence rate at 3 months after treatment,The overall survival after treatment,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
4377,NCT05667350,The sensitivity and specificity of the combined model in detection of biliary tract cancers.,The sensitivity and specificity of the combined model in detection of different stages of biliary tract cancers.,,2022-02-28,RECRUITING,OBSERVATIONAL,['NA']
4378,NCT03524300,3-year disease free survival rate,operation time,,2018-06-01,RECRUITING,INTERVENTIONAL,['NA']
4379,NCT02631499,Early recurrence rates,Overall Survival,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4380,NCT04826003,Percentage of Participants with Adverse Events,Change on 4-1BB tumor expression levels,,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4381,NCT02784470,Gastric Outlet Obstruction Scoring System (GOOSS) score,,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4382,NCT03028584,EHR-based SCPs and care planning,Impact of providing EHR-based care planning,,2017-09-11,COMPLETED,OBSERVATIONAL,['NA']
4383,NCT01494506,Overall Survival,Pharmacokinetic Measurements of Total Irinotecan,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4384,NCT00536874,Overall Survival at 18 Months,Specific Tumor Marker Response (Ca 19-9) to Neoadjuvant Therapy,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4385,NCT02599662,Maximum Tolerated Dose,QOL surveys,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
4386,NCT00822562,Overall survival rate,"non-tumor life span, intra-liver recurrence rate, metastasis rate",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
4387,NCT04652180,Respiratory postoperative complications.,Postoperative quality of life.,,2020-11-06,RECRUITING,INTERVENTIONAL,['NA']
4388,NCT00303771,Progression Free Survival (survie sans progression),Overall Survival (survie globale),,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4389,NCT06067438,"Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone","Serum amiodarone level, classified as therapeutic or subtherapeutic",,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4390,NCT04589234,Progression Free Survival,Radiologic response,,2020-10-20,RECRUITING,INTERVENTIONAL,['PHASE2']
4391,NCT04069468,QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment,"Determination of a correlation between Dose volume histogram (DVH) for total perfused tumour, Index lesion and whole normal liver tissue, using 99mTc-MAA (SPECT or SPECT/CT) and Y-90 (PET/CT or PET/MRI).",,2019-03-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4392,NCT05673148,Overall Survival (OS),Time to local recurrence (TLR),,2023-01-10,RECRUITING,INTERVENTIONAL,['PHASE3']
4393,NCT05185869,Adverse Events (AEs),Disease Control Rate (DCR),,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4394,NCT01518829,Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
4395,NCT01330823,TNF-alpha,hospital stay,,2006-06,SUSPENDED,INTERVENTIONAL,['PHASE3']
4396,NCT05939063,Lymph node positive rate,Overall survival (OS),,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
4397,NCT05737615,SUV mean measurement,,,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE1']
4398,NCT05411679,Overall Response Rate (ORR) as measured using RECIST v1.1,Incidence of treatment-emergent AEs leading to dose reduction of trial treatment,Magnitude of response to first-line chemotherapy,2023-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4399,NCT02909062,EAM Max Step-count On-Chemotherapy - EAM Max Step-count Pre-Chemotherapy,,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
4400,NCT03718650,Radiosensitivity Index and Degree of Pimonidazole Staining,Correlative Biomarkers,,2021-04-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
4401,NCT05768282,The proportion of patients with esophageal stenosis after RFA,The adverse events rate,,2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4402,NCT01786980,Overall survival,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
4403,NCT03219918,Adenoma detection rate,Malignancy detection,,2017-06-19,TERMINATED,INTERVENTIONAL,['NA']
4404,NCT02358070,Lifestyle factors,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
4405,NCT03333967,Progress free survival,Disease-free survival,adverse events,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
4406,NCT05898828,Phase II Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and niv...,Phase II Component: To determine progression free survival (PFS) in EsC participants receiving the investigational adjuvant vaccine regimen,,2024-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4407,NCT04752358,Efficacy: Overall Response Rate (ORR),Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs,,2021-09-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4408,NCT01572974,Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method,SF-36 general health (GH) subscale,,2010-01,TERMINATED,OBSERVATIONAL,['NA']
4409,NCT02494973,3-year RFS rate,,,2015-05-26,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4410,NCT00161460,Colorectal cancer screening test utilization,Cancer worry score,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
4411,NCT00845689,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4412,NCT00003753,,,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4413,NCT02682589,disease-free survival,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
4414,NCT00617981,Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause,Safety,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4415,NCT02296658,Distant metastasis free survival,Chemoradiotherapy-induced toxicities assessed by CTCAE 4.0,Comparison of dosimetric differences between radiation techniques,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4416,NCT01700283,"Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors",,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
4417,NCT00857805,Overall survival,Downstaging,,2009-01-07,COMPLETED,INTERVENTIONAL,['NA']
4418,NCT01717014,Distal Margins,Usability: Manueverability,,2013-05,TERMINATED,INTERVENTIONAL,['NA']
4419,NCT06151262,Incidence of CIM,Safety and Tolerability,,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
4420,NCT01016860,Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.,,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1']
4421,NCT02359058,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (TE-ADA),,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4422,NCT04637893,Colorectal Cancer prevention,,,2020-12-16,COMPLETED,OBSERVATIONAL,['NA']
4423,NCT04048317,Evaluate the effectiveness of drug-eluting bead trans-arterial chemo-embolization in patients of hepatocellular carcinoma,,,2019-09-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4424,NCT00445965,response rate,cumulative toxicities,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4425,NCT01977066,"Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30",Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26),Fatigue (Multidimensional Fatigue Inventory (MFI)),2013-11,COMPLETED,INTERVENTIONAL,['NA']
4426,NCT02255669,duration of stent patency,stent related complication,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
4427,NCT00851305,To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.,To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
4428,NCT00313755,with at least one adenoma after white light NBI in the right colon.,Number of hyperplastic polyps detected by white light vs NBI.,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
4429,NCT05478083,Liver growth,Symptoms of depression,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4430,NCT03562234,Change in liver function,Post-operative 30 day complications using the International Study Group for Liver Surgery (ISGLS) complications score,,2018-10-22,UNKNOWN,OBSERVATIONAL,['NA']
4431,NCT06196775,Progression-Free-Survival,Incidence of Adverse Events,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4432,NCT02965794,Length of stay,Time to return to normal diet,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
4433,NCT00002955,,,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4434,NCT04797884,Quality of Life Survey,Frequency of Adverse Events - PRO-CTCAE,,2023-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4435,NCT03397745,Change in Bispectral index score,The changes of BIS,,2018-01-15,COMPLETED,INTERVENTIONAL,['NA']
4436,NCT02389751,"MTD and recommended phase II dose of ganetespib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",pCR for patients who undergo surgical resection after neoadjuvant therapy,,2015-04-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4437,NCT00145769,Local recurrence,Quality of life,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4438,NCT03316872,Overall response rate,Overall survival rate,,2018-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
4439,NCT02595021,Postoperative complications,Hospitalization days,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
4440,NCT00354978,Median Progression-free Survival (PFS),,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4441,NCT05159479,Relationship of baseline cardiovascular risk with FIC,Cardiovascular symptom assessment,,2021-10-13,RECRUITING,OBSERVATIONAL,['NA']
4442,NCT05524012,Tumor regression grading (TRG),Surrogate marker: Carcinoembryonic Antigen (CEA),,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
4443,NCT03465982,pathologic complete response (pCR),OS,,2018-06-05,RECRUITING,INTERVENTIONAL,['NA']
4444,NCT03228147,A tea product with the highest total average nutrition supplement scores as assessed by questionnaires,,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
4445,NCT02842580,The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.,Progression free survival (PFS) at 2 years and at 3 years,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2']
4446,NCT05332821,Overall Survival(OS),Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0,,2022-12-28,RECRUITING,OBSERVATIONAL,['NA']
4447,NCT01538498,Devleopment for the peritoneal carcinomatosis index (PCI),,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
4448,NCT05246943,Compare the D-dimer results of DVT positive subjects to DVT negative subjects to identify a specific result range seen in the DVT positive subjects.,,,2022-05-25,WITHDRAWN,OBSERVATIONAL,['NA']
4449,NCT04017650,Incidence of treatment-related grade 3 adverse events,Duration of response,,2019-06-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4450,NCT01963429,local progression-free survival(LPES),disease-free survival (DFS),overall survival (OS),2013-09-30,COMPLETED,INTERVENTIONAL,['NA']
4451,NCT02513784,Difference in Esophageal F. Nucleatum Between Experimental Group and no Intervention Group,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
4452,NCT00964457,response rate,,,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
4453,NCT03604614,PFS,Median survival,,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4454,NCT04714086,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
4455,NCT05444491,To investigate the prediction and monitoring effect of plasma ctDNA methylation on postoperative recurrence of primary colorectal cancer patients after radical surgery,,,2022-06-20,RECRUITING,OBSERVATIONAL,['NA']
4456,NCT06115655,Specificity,,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
4457,NCT05803928,"Recurrence-free Survival, RFS",Biomarkers in tumors and peripheral blood,,2023-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
4458,NCT04324567,"Peak value of surgically induced C-reactive protein (CRP), expected to occur 1-3 days after surgery",Dehiscence of the perineal wound at 3 months follow-up,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor in up to 10 patients with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,2019-10-09,COMPLETED,OBSERVATIONAL,['NA']
4459,NCT03609359,"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST",Disease control rate (DCR),Tests of various biomarkers,2018-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
4460,NCT05689138,microbial features by 16s rRNA sequencing,,,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4461,NCT02233595,tumor volume,,,2014-10-15,TERMINATED,OBSERVATIONAL,['NA']
4462,NCT00851955,All cause mortality,"For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice.",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
4463,NCT00980889,confirmed stent failure,Survival,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4464,NCT04422730,comparaison of quality of life score between 4 groups,,,2020-06-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4465,NCT04508387,respiratory parameters: tidal volume,morphine consumption,,2019-04-22,COMPLETED,INTERVENTIONAL,['NA']
4466,NCT03223818,Length of post-operative hospital Stay,,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA']
4467,NCT03245736,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),Number of Participants With Increased Prostate Specific Antigen (PSA),,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4468,NCT00981110,The rate of patients with a Surgical site infection,,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4469,NCT02395523,local progression - free survival,overall survival,,2015-03-05,COMPLETED,INTERVENTIONAL,['NA']
4470,NCT02399137,Progression Free Survival,Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4471,NCT05935579,Objective response rate,overall survival rate,,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2']
4472,NCT00254137,Objective response rate (CR+PR),Grade 3/4- toxicities.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4473,NCT04131946,Characterize individual -level facilitators and barriers to engaging in CRC screening and related diagnostic tests and treatment when applicable,,,2019-11-12,COMPLETED,INTERVENTIONAL,['NA']
4474,NCT01885351,CRCS adherence provided by the electronic medical record,Feasibility of MyCRCS+ in target setting - patient survey,Development of MyCRCS+ intervention content,2013-03-01,COMPLETED,INTERVENTIONAL,['NA']
4475,NCT02734004,Second Stage Cohorts: DCR at Week 24,Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736,,2016-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4476,NCT01387880,Clinical benefit (SD+PR+CR),,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4477,NCT02021500,Overall Survival,Disease progression,,2014-01-02,COMPLETED,OBSERVATIONAL,['NA']
4478,NCT00305838,Number of patients required to detect a significant difference in CA 125 doubling time before and after starting tamoxifen,,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
4479,NCT03238885,Pathological complete response(pCR),,,2013-03-01,COMPLETED,OBSERVATIONAL,['NA']
4480,NCT02645864,Maximum tolerance dose,Overall survival,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4481,NCT04656041,Pathologic Complete Response Rate,Overall Survival,,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2']
4482,NCT05041153,Overall response rate,,,2022-02-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4483,NCT03209349,Full colon exam,Adenoma detection rates,,2017-06-14,COMPLETED,INTERVENTIONAL,['NA']
4484,NCT04631692,Colorectal cancer screening uptake,,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4485,NCT01180452,Frequency of dysplasia and adenocarcinoma,Success of endoscopic detection,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4486,NCT02861885,patients with sessile serrated lesions,Detection techniques diagnosis performance,,2016-02-24,UNKNOWN,OBSERVATIONAL,['NA']
4487,NCT01642186,Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6),Number of Participants With Tissue Biomarkers Collected,,2012-07-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4488,NCT00005036,Overall survival,Quality of life,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4489,NCT05559775,ORR,,,2022-08-10,RECRUITING,INTERVENTIONAL,['PHASE2']
4490,NCT04215471,Objective Response,Correlation between genetic profile and tumor response,,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4491,NCT03379844,"Safety, expressed as the rate of unacceptable toxicity.",Changes in hepatic function as determined by hepatobiliary scintigraphy,,2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2']
4492,NCT05739981,Minimal Residual Disease,OS,,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4493,NCT00087256,To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.,To monitor the toxicity and safety of celecoxib in this population.,,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
4494,NCT00943280,The primary outcome variable for this aim will be the number of subjects in each group that need to be contacted until 20 in each group agree to participate in this study.,"To access variables for prediction of non-participation: age, gender, education level, employment, marital status, esophageal symptoms",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4495,NCT06012318,Prevalence and severity of adverse symptoms,Trajectory of adverse symptoms,,2023-09-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4496,NCT00248053,polyp number and size,side effects and medication compliance,,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4497,NCT02024009,Progression free survival,Quality of life,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4498,NCT04899492,Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery,Evaluate the efficacy of interventions on patient quality of life,,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4499,NCT03718351,En-block resesction rate,Morbidity defined by the Clavien-Dindo classification,,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA']
4500,NCT05572528,The recurrence rate after LDLT in high risk patients,,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4501,NCT00116454,"to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan",Deterioration of the hepatocellular function,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4502,NCT03509428,Post-operative length of hospital stay,Nutrition -4,,2018-03-26,UNKNOWN,INTERVENTIONAL,['NA']
4503,NCT03006302,6 Month Survival,Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation,,2018-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4504,NCT00227773,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4505,NCT03177382,disease free survival,assessment of nutritional status,,2017-06-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
4506,NCT02599909,"To collect blood/urine/tumor samples, stool, and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut ...",Correlation between microbiome and patients' clinical outcome,,2015-11-06,WITHDRAWN,OBSERVATIONAL,['NA']
4507,NCT03278015,median overall survival time (mOS),Disease control rate(DCR),,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4508,NCT05371873,MRD monitor,,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4509,NCT00062426,,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4510,NCT01312389,Number of Participants With Adverse Events,Clinical Response,,2011-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4511,NCT01218841,,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4512,NCT00126633,Micrometastases for predicting time to progression and overall survival,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4513,NCT03124212,Establishing the CASCADE Cohort,Cancer Surveillance,,2017-04-01,RECRUITING,OBSERVATIONAL,['NA']
4514,NCT03958812,Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC),Comprehensive diagnostic model of VOCs and CTCs,,2019-06-15,UNKNOWN,OBSERVATIONAL,['NA']
4515,NCT04640480,"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)",Time to progression(TTP),,2024-06-21,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
4516,NCT03450889,Incidence of colorectal cancer during protocolled endoscopic surveillance,Incidence of post-colonoscopy complications,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
4517,NCT05718284,POST-OPERATIVE PULMONARY COMPLICATIONS,CARDIO-VASCULAR COMPLICATIONS,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
4518,NCT00636948,Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.,Reoperation within 30 days of initial surgery.,,1999-12,COMPLETED,OBSERVATIONAL,['NA']
4519,NCT02578368,Overall survival (OS),Toxicity - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4520,NCT05405530,The incidence of hypoxia,The incidence of other adverse events,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
4521,NCT01632722,2 years recurrence-free survival (2Y-RFS),,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4522,NCT01520779,Recurrence of hepatocellular carcinoma,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
4523,NCT03785496,To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors),To evaluate antitumor efficacy of PDR001,,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
4524,NCT00003530,,,,1977-03-21,TERMINATED,INTERVENTIONAL,['PHASE2']
4525,NCT00208936,,,,1996-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4526,NCT01607788,Post-transplant survival,,,2009-11,UNKNOWN,OBSERVATIONAL,['NA']
4527,NCT03812289,Proportion of participants who are transplanted or with localized disease control per Milan criteria,Incidence of liver toxicity assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0,Proportion of histopathologic changes in irradiated tumor sites relative to uninvolved liver tissue,2019-02-07,TERMINATED,INTERVENTIONAL,['NA']
4528,NCT04117087,Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks,Overall Survival (OS),,2020-05-28,RECRUITING,INTERVENTIONAL,['PHASE1']
4529,NCT06018896,Quality of life (QOL),Overall survival (OS),,2023-08-25,RECRUITING,INTERVENTIONAL,['PHASE3']
4530,NCT06212128,operative time required for primary resection of rectal tumour,duration of hospitalisation,,2016-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4531,NCT01411579,Apparent Diffusion Coefficient (ADC) value changes of the lesion during chemotherapy.,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
4532,NCT04973046,The tissue oxygen saturation score of gastric tube during esophagectomy,The rate of anastomotic leakage,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
4533,NCT02606396,Change in dysphagia severity according to validated symptom score,"Incidence of procedure related adverse events, classified according to the American Society of Gastrointestinal Endoscopy lexicon",,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
4534,NCT03415815,Numbers of lymph nodes and percentages of patients with surgeries,Impact factors of lymph metastases,Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries,2017-12-12,UNKNOWN,OBSERVATIONAL,['NA']
4535,NCT00653107,Dysphagia measured with the dysphagia grading scale at week +2 after start of treatment. Pain at rest measured with ESAS at week +2 after start of treatment.,Health related quality of life,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3']
4536,NCT04893408,long time survival in patients operated for pancreatic cancer,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
4537,NCT03682276,Incidence of treatment-emergent adverse events [Safety and Tolerability],Pathologic response rate,,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4538,NCT00040859,Objective tumor response rate,Quality of life,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4539,NCT01738620,items SL (sleep disorder) and QL2 of the QLQ C30,PSQI score,,2013-01,TERMINATED,INTERVENTIONAL,['NA']
4540,NCT02758951,Phase III (n=358): histological response of colorectal PM to neoadjuvant systemic therapy,,,2017-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4541,NCT03391232,Number of Participants With Treatment Related Adverse Events,Number of Predicted Antigen Specific T Cell Responses Per Patient,Number of Participants Having Induced Recruitment of TILs,2018-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4542,NCT05932836,Accuracy of Organoid drug sensitivity test in predicting the response to mFOLFOX6 infusion in HCC patients with successful Organoid culture,The predictive effect of Organoid drug sensitivity test on the survival of patients with HCC.,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
4543,NCT03061591,Size of polyps,Curcumin and curcuminoid levels in urine.,,2017-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
4544,NCT00020774,,,,1998-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4545,NCT04605042,diagnostic specificity of WS technique and SNP technique by EUS-FNB,Cell density of WS technique and SNP technique by EUS-FNB,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
4546,NCT00550563,"Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity",,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
4547,NCT04908176,area under the plasma concentration-time curve (AUC) of midazolam,"area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite",,2022-08-24,RECRUITING,INTERVENTIONAL,['PHASE1']
4548,NCT01469598,Response rate,Number of Adverse Events,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4549,NCT03350126,Disease Control Rate (DCR),"Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),",,2017-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4550,NCT01525550,Progression-Free Survival (PFS): Investigator Assessment,Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS),,2012-06-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4551,NCT03159585,treatment-related adverse events as assessed by CTCAE v4.03,assess the expression of tumor markers,,2017-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
4552,NCT06099821,Progression free survival,treatment-related adverse event,,2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
4553,NCT01344538,"Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.",,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4554,NCT02106806,oxidative stress markers,FACIT-F,CTCAE,2011-05,COMPLETED,INTERVENTIONAL,['NA']
4555,NCT04207918,Local control rate,ctDNA in predicting tumor response rate and prognosis,,2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
4556,NCT05212025,Overall Response Rate (ORR),Incidence of Grade 3 or Higher Treatment-Related Toxicity,,2022-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4557,NCT03223376,Progression free survival (PFS),The European Organization for Reasearch and Treatment of Cancer（EORTC ） Quality of Life Questionnaire-Core 30 V3.0 (QLQ-C30 v3.0),,2017-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4558,NCT02961296,The rate of exceeding the resistance criteria in Helicobacter pylori(H. pylori) antibiotic susceptibility test(Agar dilution method),The success rate of H. pylori strain separation,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
4559,NCT04594863,SIRT-6 expression,,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA']
4560,NCT05462717,Dose Limiting Toxicities,Progression-Free Survival (PFS),,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1']
4561,NCT01460745,Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux,"Percentage of liver resection outcomes R0, R1 and R2",,2011-11,COMPLETED,OBSERVATIONAL,['NA']
4562,NCT03278925,"Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression in cirrhotic liver",Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis,Incidence of hepatocellular carcinoma,2018-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
4563,NCT03488667,Number of Adverse Events related to toxicity.,Programmed cell death ligand 1 (PD-L1) expression in tumor cells,,2018-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4564,NCT01092078,Colon Cancer Screening Behavior,Social Influence relating to colon cancer screening,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
4565,NCT00978549,Overall survival,Health economic evaluation as assessed by EQ-5D,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4566,NCT00253383,Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceased,"Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
4567,NCT00019110,,,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4568,NCT02995850,II: Safety,RR (response rate),,2017-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4569,NCT03316599,The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel,The progression free survival in this population of patients.,,2018-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
4570,NCT03519074,Efficacy Evaluation: Timing,,,2016-07-22,RECRUITING,INTERVENTIONAL,['PHASE2']
4571,NCT01575340,change in inflammatory markers,assessing the risk of inflammatory and nutritional complications,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
4572,NCT01786850,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
4573,NCT01688336,Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer,Rate of Resectability (RR),"Correlation of Tumor Markers (Ca19-9, CEA) With Outcomes (RR, DCR, PFS, and OS).",2012-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4574,NCT04194268,survival,Quality of life EORTC QLQ Pan26,,2019-12-03,RECRUITING,INTERVENTIONAL,['NA']
4575,NCT04022746,Change in percent non-viable/necrotic tumor,Change in tumor size and enhancement,,2019-06-11,RECRUITING,INTERVENTIONAL,['NA']
4576,NCT03811652,Percentage of patients with changes in laboratory parameters from baseline,Overall Survival (OS),,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
4577,NCT04670718,Visualisation of gastrointestinal tract,Ability to asses depth of invasion of resected GI early tumor,,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
4578,NCT00825669,overall survival,the changes of the PVTT,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
4579,NCT00001693,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4580,NCT03168594,Overall response rate (ORR),Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）,,2017-04-29,TERMINATED,INTERVENTIONAL,['PHASE2']
4581,NCT00730353,Progression Free Survival Rate at 24 Weeks,Toxicity Profile,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4582,NCT04444921,Progression-free survival,Incidence of adverse events,,2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE3']
4583,NCT05278351,Progression free survival time (PFS),Overall survival (OS),,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2']
4584,NCT02526836,Lymph nodes harvest,Survival outcome,,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4585,NCT02869581,Survival of patients with pancreatic neoplasms,Collection of patients characteristics,,2000-01,RECRUITING,OBSERVATIONAL,['NA']
4586,NCT03120104,Change of The Wexner Score,Change of Functional assessment of Cancer Therapy - Colorectal (FACT-C),,2017-06,UNKNOWN,INTERVENTIONAL,['NA']
4587,NCT02491372,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire II,Change in Quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Oesophageal and Gastric Cancer,,2015-09,WITHDRAWN,INTERVENTIONAL,['NA']
4588,NCT03064308,Feasibility of a home based exercise programme following surgery in the older patient.,Hand Strength Test,Intervention Compliance Questionnaire,2017-06-26,COMPLETED,INTERVENTIONAL,['NA']
4589,NCT05551416,New strategies for gastric cancer (GC) early diagnosis,Characterization of the microbiome: 16S rRNA studies,,2021-09-09,RECRUITING,OBSERVATIONAL,['NA']
4590,NCT04444232,Alters' intent to become screened for CRC in the next six months,,,2014-09-09,COMPLETED,INTERVENTIONAL,['NA']
4591,NCT01079767,3-month disease-control rate according to RECIST criteria,3-month objective response rate according to RECIST criteria,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4592,NCT03522649,Overall Survival (OS),Disease Control Rate in biomarker positive patients,,2018-04-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
4593,NCT04072198,ORR,Quality of life with QLQ-C30 questionnaire,,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
4594,NCT00583271,,,,2002-06,COMPLETED,OBSERVATIONAL,['NA']
4595,NCT00622622,Safety(toxicities as assessed by NCI CTCAE version 3),survival,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4596,NCT03529669,Completion Rate,Number of Patients Who Would be Prepared to Repeat the Procedure,,2018-04-18,COMPLETED,INTERVENTIONAL,['NA']
4597,NCT05433402,Disease-free survival,Time occurrence of new primary colon cancer and new polyps,Biological Markers,2022-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4598,NCT04798612,T-cell infiltration in tumor,Immunological and inflammatory cytokines and interleukins,,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2']
4599,NCT01669356,postoperative body composition change compared to preoperation measurement,,complicatons incidence after surgery,2012-07,COMPLETED,INTERVENTIONAL,['NA']
4600,NCT00885066,Clinical or laboratory toxicities as assessed by CTC,,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4601,NCT01882933,Overall survival,Score QLQ-STO 22,,2013-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4602,NCT04213222,estimated ORR,estimated OS,,2020-10,UNKNOWN,OBSERVATIONAL,['NA']
4603,NCT02871999,"Pain degree change after surgery, Graded according to Numerical Rating Scale(NRS)",Testosterone(Male) in blood,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
4604,NCT02215070,Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide,Disease Free Survival Compared to Historical Controls,Evaluate GI Toxicity Assessment by Video Capsule Endoscopy.,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2']
4605,NCT04713891,Clinically significant abnormality in physical examinations,Progression free survival (PFS),,2021-03-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
4606,NCT02585687,Global survival,,,2012-07,TERMINATED,INTERVENTIONAL,['NA']
4607,NCT00378066,time to progression,"overall survival, safety, response",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4608,NCT04103697,3-year disease-free survival,Preoperative tumor-associated complications rate,,2019-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
4609,NCT01843829,Efficacy,Efficacy,,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
4610,NCT05914389,TRG0/1,Minimal Residual Disease (MRD),,2023-08,RECRUITING,INTERVENTIONAL,['PHASE2']
4611,NCT03030508,Disease-free survival,Three year disease free survival rate,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
4612,NCT04310839,30-day readmission rate,Ileus,,2020-11-03,COMPLETED,OBSERVATIONAL,['NA']
4613,NCT01008566,Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0,Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST),,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
4614,NCT02323906,Dose-Limiting Toxicity (DLT),Time to progression (TTP),,2015-01-16,TERMINATED,INTERVENTIONAL,['PHASE1']
4615,NCT03407040,Availability of stored specimens and/or data,,,2018-01-30,TERMINATED,OBSERVATIONAL,['NA']
4616,NCT01047111,Disease free survival,Locoreginal recurrence and recurrence pattern,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
4617,NCT06088459,All adverse events (AE),Immunogenicity,,2023-11,RECRUITING,INTERVENTIONAL,['PHASE1']
4618,NCT03874871,R0 resection rate,overall survival,,2019-03-20,RECRUITING,OBSERVATIONAL,['NA']
4619,NCT04083378,Impact of software use on the minimal margins of ablated lesions properly covered by ablation on a three-dimensional analysis,Liver function,,2020-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4620,NCT06168357,Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4621,NCT00023868,,,,2001-11-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4622,NCT02288195,Local-regional failure-free survival,Rate of receiving pre-operative or post-operative chemoradiation,,2014-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4623,NCT01819766,Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.,Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
4624,NCT00296114,,,,2004-02,COMPLETED,OBSERVATIONAL,['NA']
4625,NCT00630045,disease free survival rate,response rate and safety of XELOX as a neoadjuvant regimen,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
4626,NCT00107861,- Evaluate the safety of a single IV administration of Ad.hIFN-β.,Explore preliminary clinical activity.,,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4627,NCT02633098,Recurrence free survival at 2 years,Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins),,2017-04-26,RECRUITING,INTERVENTIONAL,['PHASE2']
4628,NCT05333809,Objective response rate (ORR),Overall survival (OS),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4629,NCT06178848,frontal spectral power,Riker sedation-agitation score,,2023-06-26,COMPLETED,INTERVENTIONAL,['NA']
4630,NCT02407392,"Feasibility as assessed by the ratio of patients approached to recruited, percentage of patients who complete both endoscopies",Number of adverse events,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
4631,NCT05577143,Area under the ROC curve (AUC) of the TFPI-1 biomarker,Extension of c-index to the 3-group case proposed by Van Calster B et al.,,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4632,NCT05993923,Change in functional status after colorectal cancer surgery between groups,The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4633,NCT04930991,Safety and Tolerability,Correlation,,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4634,NCT00622557,,,,2007-05-01,COMPLETED,OBSERVATIONAL,['NA']
4635,NCT01281943,Progression free survival (PFS),Polymoprhism assessment,,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4636,NCT00894725,short-term morbidity rate,long-term outcome,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4637,NCT05687552,comparison of pet -ct finding with ct finding,,,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4638,NCT06061744,recurrence,,,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4639,NCT00093379,2 Year Failure Free Survival,Number of Participants With Progression-Free Survival at 2-Year,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4640,NCT03766607,"Progression free survival, PFS",Adverse event,,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4641,NCT00899626,Development of new screening strategies based on substances found in tissue and biofluid samples,,,2002-06,RECRUITING,OBSERVATIONAL,['NA']
4642,NCT00842686,Pathological complete remission rate (pCR),Quality of life,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4643,NCT00884767,"Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity",,,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
4644,NCT05070156,Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability] after B010-A injection.,Disease control Time (DDC),,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4645,NCT00121914,time to tumour progression,causes of death,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4646,NCT03462992,AUC of the MonoMark test,,,2012-12-11,UNKNOWN,OBSERVATIONAL,['NA']
4647,NCT04278144,"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)",Incidence of potential-immune related toxicities,,2020-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4648,NCT02613156,Perioperative complications,relapse-free survival,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
4649,NCT00539253,Nodule Enhancement,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
4650,NCT02706184,Common toxicity criteria for diarrhea Version 4.0,ECM/BCM-Index,stool microbiome analyses,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4651,NCT05523778,Rate of POPF within 3 months after EN.,Total cost of hospitalization,,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
4652,NCT05464875,Duration Of Response,Vd（volume of distribution）,Assessment of dose effect of antineoplastic agents,2022-07-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4653,NCT03317119,"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities",Overall survival,,2018-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
4654,NCT05751265,Objective Response Rate (ORR),Progression-free survival,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4655,NCT05609396,Uptake,"Uptake by deprivation, sex and age",,2022-05-03,COMPLETED,INTERVENTIONAL,['NA']
4656,NCT02349412,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G),Concordance Between Patient and Family Caregiver Report of Prognosis/Curability,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4657,NCT04811898,The recommended phase II dose of LNA-i-miR-221 (RP2D),To assess the efficacy of LNA-i-miR-221,,2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1']
4658,NCT00786058,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
4659,NCT02328716,disease-free survival period,Study of Ex vivo correlation.,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
4660,NCT02818530,Changes in anterior chamber depth measured by ultrasound.,Time dependent changes in anterior chamber depth during prolonged trendelenberg position.,,2017-06-21,TERMINATED,INTERVENTIONAL,['NA']
4661,NCT01681446,disease free survival,Number of Participants with Adverse Events,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
4662,NCT00224692,Pain score,,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3']
4663,NCT02425683,Number of Patients Completing Full 6 Cycles,Disease-free survival (DFS),,2015-03-26,TERMINATED,INTERVENTIONAL,['PHASE2']
4664,NCT04121286,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,Duration of response ( DOR ),,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE1']
4665,NCT05785975,To assess if positive subjects are complying with follow-up screening,,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
4666,NCT05994456,Pathological complete remission (pCR) rates,Incidence of Treatment-Related Adverse Events,,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2']
4667,NCT00073138,Objective Response Rate in subjects with Recurrent Colorectal Cancer,Toxicities associated with treatment administration,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4668,NCT02587793,survival,cancer progression,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
4669,NCT02724202,Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.,Duration of Quality of Life,,2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4670,NCT01262417,abdominal and peri-hepatic adhesion during the second operation,tumour evolution in patients,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4671,NCT03085004,Incidence of serious and minor adverse events occurring within 30 days post ablation,,,2019-04-12,RECRUITING,INTERVENTIONAL,['PHASE3']
4672,NCT02816879,Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome,"Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer.",,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4673,NCT06135571,Metastatic rate of No.253 lymph node,5-year overall survival rate,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
4674,NCT03848182,Change in CD4 T cell responses after TT booster vaccine,Change in CD8 T cell responses after TT booster vaccine,Change in myeloid-derived suppressor cells,2017-07-21,TERMINATED,INTERVENTIONAL,['PHASE2']
4675,NCT00630240,"The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.",,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
4676,NCT02717923,Progression-Free Survival of maintaining treatment（mPFS）,,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4677,NCT00973193,Pathological Complete Response (pCR),"Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research",,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
4678,NCT01251458,• To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC),• To determine overall survival (OS),,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4679,NCT02210039,Number of Participants With Tolerability of the Procedure,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4680,NCT03278327,Suggest that there are significantly more than 60 % of patients with a relative decrease of at least 50 % between the total percentages of esophageal time crossed in pH4 (Ph metric dosage) before and after endoscopic treatment.,Use of Inhibitor of the pump with proton (PPI),,2017-06-27,UNKNOWN,INTERVENTIONAL,['NA']
4681,NCT02968810,Change in serum AFP-L3%,Change in Model for End-Stage Liver Disease score,Change in serum immune markers,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4682,NCT02404753,3-year progression-free survival,Postoperative quality of life,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
4683,NCT03231462,Pulmonary complications,The change of symptom,,2015-03-06,RECRUITING,OBSERVATIONAL,['NA']
4684,NCT00594113,CRC screening completion,"PAPM stage and perceived barriers among participants preferring various screening methods (iFOBT, Colonoscopy)",,2007-08,COMPLETED,INTERVENTIONAL,['NA']
4685,NCT01128387,MTD of Panitumumab in Combination With Cisplatin/Fluorouracil and Radiation for Locally Advanced Esophageal Cancer Determined by Number of Participants Experiencing DLT,Pathologic Response,,2010-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4686,NCT03039608,the time when stricture occurs,the frequency of complications,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
4687,NCT00598247,RECIST Response,Toxicity,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4688,NCT01023529,Effect on patient's target symptom.,Time to improvement in patient's symptoms and QoL.,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
4689,NCT01937104,ONSD and PaCO2,ONSD and PaCO2,ONSD and PaCO2,2013-09,COMPLETED,INTERVENTIONAL,['NA']
4690,NCT01624025,disease control rate according to the RECIST v1.1,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4691,NCT01962376,progression-free survival(PFS),Objective response rate (ORR),Adverse events,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
4692,NCT00201318,"We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.",,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4693,NCT01740375,2-year disease-free survival (DFS) rate,treatment-related mortality,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE3']
4694,NCT04653181,postoperative complications,Need for red blood cell transfusion,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
4695,NCT02175914,CT and MRI imaging for desmoids,,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
4696,NCT04885439,Patient and Caregiver Anxiety,Patient Symptom Burden,,2015-07-01,COMPLETED,INTERVENTIONAL,['NA']
4697,NCT05555888,complete response (CR) rate,10 year Quality of Life,,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE2']
4698,NCT04969107,disease-specific survival,recurrence-free survival,,2012-01-01,RECRUITING,INTERVENTIONAL,['NA']
4699,NCT00492193,Time to upper and lower GI recovery and post-operative hospital length of stay.,Postoperative ileus related mobidity.,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
4700,NCT05854394,6-minute-walking-distance (6MWD),Quality of Life Scale,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
4701,NCT02484404,Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors,Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.,,2015-06-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4702,NCT01418742,"Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)",Severity of panitumumab related adverse events,,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2']
4703,NCT00075595,Time to death from progression,Incidence of grade 3 or 4 toxicity,,2002-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
4704,NCT03253107,Discovery of predicting bio-markers for gastric cancer chemotherapy response,Combination prediction model for palliative chemotherapy response in gastric cancer,,2015-11-30,RECRUITING,OBSERVATIONAL,['NA']
4705,NCT05655494,Proportion of patients who self-refer to cancer clinical trials,Mediators of intervention effectiveness,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4706,NCT05113290,Objective response rate (ORR) according to mRECIST criteria,Number of participants with adverse events,,2021-12-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
4707,NCT03898895,"Progression-free survival, PFS","Disease control rate, DCR",,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
4708,NCT05830019,local progression-free survival,adverse events,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
4709,NCT04141566,Specific Quality of life of patients with PCPC and PLIC,90 day morbidity and mortality rate,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
4710,NCT03169842,Cyst fluid glucose level,,,2017-05-25,COMPLETED,INTERVENTIONAL,['NA']
4711,NCT02065037,Polyp Detection Rate,advanced lesion per patient detection rate,patient comfort by a validated nurse administered comfort score,2014-06,TERMINATED,INTERVENTIONAL,['NA']
4712,NCT00009893,survival at 6 months,tumor response rate,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4713,NCT05914987,Number of Subjects Receiving Targeted Therapy,,,2023-12-04,RECRUITING,OBSERVATIONAL,['NA']
4714,NCT04677088,Safety evaluation of the TCR-T treatment,Overall survival (OS),,2018-03-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
4715,NCT04980157,Colorectal Cancer Screening Status,,,2021-11-01,COMPLETED,OBSERVATIONAL,['NA']
4716,NCT01544452,Synchronous colon cancers and liver metastasis,sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver,,2010-08,TERMINATED,INTERVENTIONAL,['NA']
4717,NCT03006926,DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR,DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status,,2017-02-13,COMPLETED,INTERVENTIONAL,['PHASE1']
4718,NCT02191969,To measure the change in fatigue after three months between the intervention and control arm,To measure changes in Self-Efficacy at baseline between the intervention and control groups.,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4719,NCT00988741,Evaluate time to progression among all patients treated with ARQ 197 compared to placebo,Further evaluate pharmacokinetics of ARQ 197.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4720,NCT00651677,operative time,urinary and sexual function,,2011-04,WITHDRAWN,INTERVENTIONAL,['NA']
4721,NCT03544255,Number of organoids successfully generated from pancreatic cancer biopsies,Response of the pancreatic cancer organoids to the selected anti-cancer drugs,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
4722,NCT02298907,Oxygen uptake at lactate threshold,Number of patients with adverse post-operative outcome measures,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
4723,NCT03951337,Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment,64Cu-ATSM toxicity,,2019-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4724,NCT06307314,Different grades radiotherapy-induced oral mucositis,Tumor response,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
4725,NCT04336241,Recommended Phase 2 dose (RP2D) of RP2,Percentage of stable disease (SD),,2019-10-17,RECRUITING,INTERVENTIONAL,['PHASE1']
4726,NCT01897636,pancreatic tumor response rates,survival rates,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
4727,NCT01883336,Progress of pancreatic cyst,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
4728,NCT05752890,To distinguish the clonality of recurrent HCC as the original or a de novo one for post-radiotherapy patterns of failure,,,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4729,NCT06046846,To investigate the usability in terms of user satisfaction of the asensei app to deliver a mHealth prehabilitation programme.,To collect preliminary data and assess for change on a participants quality of life by using the EORTC QLQ-OG25 questionnaire in order to inform the sample size for a fully powered RCT as part of the feasibility study.,Semi structured interviews,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4730,NCT00088933,Number of patients experiencing each of the toxicities by grade for each treatment arm,Average quantity of circulating CEA cells determined by quantitative real time RT-PCR,,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1']
4731,NCT01821482,progression-free survival(PFS),quality of life (QOL),Laboratory findings,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
4732,NCT04160897,The 5-year cumulative incidence of hepatocellular carcinoma,The 5-year cumulative liver disease-related mortality,,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA']
4733,NCT03126071,PFS,AEs,,2017-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
4734,NCT00734890,Toxicity,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4735,NCT02549755,To Compare Changes in 11C-acetate Uptake at One and Three Months Following Radiotherapy With Pre-treatment Uptake of 11C-acetate,,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2']
4736,NCT05205187,Response of target organ,,,2022-02-28,RECRUITING,OBSERVATIONAL,['NA']
4737,NCT03319459,Incidence of dose-limiting toxicity (DLT),Pharmacokinetics (PK) of FATE-NK100,,2018-01-18,COMPLETED,INTERVENTIONAL,['PHASE1']
4738,NCT03496441,Evaluate the feasibility of fecal samples' analysis,Evaluation the presence of a correlation between fecal microbiota composition and the risk of anastomotic leak.,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA']
4739,NCT04192071,Information seeking behavior,,,2020-01-06,RECRUITING,INTERVENTIONAL,['NA']
4740,NCT05440708,Phase 2: Overall Response Rate (ORR) to TTI-101,Cohort A and Cohort B: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples,,2023-03-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4741,NCT03554434,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
4742,NCT06250075,The use of probiotics can modify the incidence of postoperative complications,Modulation of nutritional parameters using probiotics-phase angle,,2020-12-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4743,NCT04779554,Drug Half-Life (T1/2) - Pharmacokinetics,,,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2']
4744,NCT01946854,Tumor Growth Rate,,,2013-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4745,NCT04506983,Percentage of adverse events,Proliferation ratio of CAR-T cells,,2022-06-10,SUSPENDED,INTERVENTIONAL,['PHASE1']
4746,NCT01082224,Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC),Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal),,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4747,NCT05358249,PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1,Phase II: Dose intensity by treatment,,2022-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4748,NCT04302363,Diagnostic efficacy of colorectal cancer model in Chinese people,Effect of diet on intestinal flora and DNA methylation in Chinese people,Effects of intestinal microflora and DNA methylation under different stool characteristics,2018-02-01,UNKNOWN,OBSERVATIONAL,['NA']
4749,NCT01234246,,,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
4750,NCT00385203,"Tumour Metabolic Activity as Assessed by Change in Central Review of Standardised Uptake Value (SUVMax) at Day 29, in Patients With GIST Tumours. SUVmax at Day 29 Minus SUVmax at Baseline.",Anti-tumour Activity as Measured by Total Lesion Volume at Week 16 in GIST Patients by Central Review of CT Images.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4751,NCT00511576,To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.,,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1']
4752,NCT03500757,Standard System Usability Score on a Likert Scale,,,2018-04-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4753,NCT03472833,25(OH) vitamin D,Quality of Life questionnaire,,2018-04-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4754,NCT00006009,,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4755,NCT03429816,Aim 2: Correlation of molecular subtypes with histological response after neoadjuvant therapy in patients,Aim 2: Correlation of molecular subtypes with relapse-free survival,Aim 2: Correlation of molecular subtypes with overall survival,2018-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4756,NCT00988195,"Plasma arginase and arginine levels,as well as tumour response, i.e. an effect on growth in the milieu of arginine depletion.","Overall Survival, Time to Progression",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4757,NCT00164892,Recurrence free survival and the quality of life score within the two years of study period,Overall survival in long term,,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4758,NCT03963726,PFS,Quality of life score of tumor patients(0-60),,2019-06-03,UNKNOWN,INTERVENTIONAL,['NA']
4759,NCT05533892,Objective response rate (ORR) at 6 months,Duration of response (DOR),,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1']
4760,NCT02592603,Number of serrated lesions >=5mm,Proportion of minor adverse events,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
4761,NCT02106871,Skeletal Muscle Fatigue,,,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
4762,NCT02336724,Disease Control Rate,Incidence of adverse events,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
4763,NCT00507273,Current patterns of medical practice in management of patients with GIS,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
4764,NCT01227239,Phase II: pathological complete response rate,safety,,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4765,NCT05818267,duration of disease control(DDC),The incidence of adverse events,,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
4766,NCT03757754,The number of dose-limiting toxicity,Area under the concentration-time curve from zero extrapolated to infinity (AUC0-∞),,2015-06-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
4767,NCT01071824,Pouch function 4 month after closure of protective ileostomy.,Pouch function 2 and 12 month respectively after closure of protective ileostomy.,,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
4768,NCT05739110,Overall survival,Disease-free survival,,2022-07-15,COMPLETED,OBSERVATIONAL,['NA']
4769,NCT01211561,Reduction in ACF biomarkers,,,2010-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4770,NCT06189898,Progression free survival,loco-regional recurrence free survival,,2023-12-15,RECRUITING,OBSERVATIONAL,['NA']
4771,NCT00003431,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4772,NCT00795184,"Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.",,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
4773,NCT01938326,Maximum pain score using VAS at postoperative day#1,EORTC-C30 and STO22,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
4774,NCT03115957,Morbidity of infection,Laboratory examination,,2017-04-14,COMPLETED,INTERVENTIONAL,['NA']
4775,NCT04058236,Changes in serum heparan sulfate concentrations,Changes in levels of Inflammatory markers Interleukin-1 and CRP,,2019-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
4776,NCT03043313,Confirmed Objective Response Rate (cORR) Per RECIST 1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B,Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry),,2017-06-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4777,NCT01834014,To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS),Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
4778,NCT06164769,blood loss,,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
4779,NCT00867724,Ability to screen the entire length of the colon to the cecum.,"Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4780,NCT04372992,Percentage of participants with good compliance to adjuvant therapy,Costs analysis,,2020-09-01,TERMINATED,INTERVENTIONAL,['NA']
4781,NCT03404076,Progression free survival after a three year follow-up,,,2014-12-01,COMPLETED,OBSERVATIONAL,['NA']
4782,NCT03042416,Immediate safety evaluation,Perceived clinical benefit,,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE3']
4783,NCT00451022,To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols.,,,2004-09-13,RECRUITING,OBSERVATIONAL,['NA']
4784,NCT02800330,"As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related.",The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4785,NCT05817201,Overall survival,Progression-Free survival,,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4786,NCT00613743,difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.,the requirement of supplementary systemic analgesics,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
4787,NCT00131599,,,,2002-08,UNKNOWN,OBSERVATIONAL,['NA']
4788,NCT05280379,Levels of pro-inflammatory cytokines en chemokines,,Carcino-embryonal antigen,2022-09-19,RECRUITING,OBSERVATIONAL,['NA']
4789,NCT01246986,Time to Progression (TTP),Time to Worsening (TTW) of Symptoms (FACT-Hep),,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
4790,NCT05638048,Incidence of Peripheral central venous catheter-associated thrombosis in patients with PICC tube,Patients' satisfaction with health education after PICC catheterization,,2022-07-10,COMPLETED,INTERVENTIONAL,['NA']
4791,NCT00525785,Complete Pathologic Response Rate,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4792,NCT04622098,Estimating the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.,characterization of SEL in Egypt,,2020-11-18,UNKNOWN,OBSERVATIONAL,['NA']
4793,NCT02399943,"Percentage of patients who experience complete response, partial response, or stable disease",Date of first confirmed response to the first date in which progression is observed,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4794,NCT01129206,Overall Response,Correlation of FDG PET Response With Response Rate,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4795,NCT02325648,pulmonary vascular permeability index,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
4796,NCT03412994,Progression-free survival (PFS),Quality of life(QoL),,2018-02-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
4797,NCT01574027,Reduction in ACF biomarkers,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4798,NCT04555265,Early tumor recurrence,Other tutor recurrence,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
4799,NCT05303714,Secondary Resectability Rate (percent),Complication rate,,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
4800,NCT01838317,Glucose to Insulin Ratio,Changes in Serum and MRI End Points,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4801,NCT00974948,"Absolute and relative changes in 7-point Likert-score for abdominal pain at 1 and 3 months post-randomization. Secondary endpoints were change in morphine equivalent consumption (MEQ), quality of life (DDQ-15), and overall survival.",2. Quality of life 3. Survival,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4802,NCT04595838,The incidence of severe oral mucositis symptomatic events observed during the second cycle of chemotherapy.,Analgesic use to control mouth pain,,2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
4803,NCT02988635,Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure),Resource utilization at the end of life (EOL): emergency room admissions,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4804,NCT00449163,Overall Survival up to 2 Years,Rate of Toxicity in Study Participants,,2006-03-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4805,NCT02621658,Adenoma Detection Rate,Patient satisfaction,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
4806,NCT00758381,Progression Free Survival,- overall Response Rate (RECIST Criteria) - duration of response - overall survival time,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
4807,NCT03499626,Definition of MTD (maximum tolerable dose),Progression Free Survival,,2017-05-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4808,NCT02074202,The pathological diagnosis of the liver tumor will be compared with the test result of the PET/CT scan findings.,,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
4809,NCT02845986,overall postoperative morbidity rates,The variation of prealbumin,,2016-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4810,NCT02526043,Overall survival,Incidence of postoperative complications,,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4811,NCT01697072,Overall Survival,Immunogenicity,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3']
4812,NCT00983801,Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST),Number of Participants With Serum Chemistry Abnormalities,Number of Participants With Best Response as Assessed With Modified RECIST,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4813,NCT04695847,Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators,Part 2: Number of Participants with Corrected QT Interval (QTc),,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
4814,NCT06084234,Proportion of HCC detected at late stage,Number of participants who encountered screening related Psychological harm,,2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE4']
4815,NCT04514497,Occurrence of grade 4 hematologic AEs (Dose Expansion Phase),Changes in tumor expression patterns of pS343-NBS1,Tumor deoxyribonucleic acid damage response (DDR) gene mutations present,2021-10-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
4816,NCT02961998,Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome,Overall survival,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4817,NCT06252974,Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis,,,2024-02-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4818,NCT00062283,,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4819,NCT01442324,Effectiveness of IRE for the treatment of metastatic liver cancer or cholangiocarcinoma.,Time to in situ recurrence,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
4820,NCT05277675,1-year overall survival,immune-related adverse events,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA']
4821,NCT01601808,Overall survival,Patient pain assessment,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
4822,NCT03665714,Change of Serum Prealbumin level,Incidence of postoperative Infections,,2018-10-23,COMPLETED,INTERVENTIONAL,['NA']
4823,NCT03274427,Progression-free Survival,quality of life,,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
4824,NCT01984658,Safety and tolerability,Efficacy; Tumor change,Safety & efficacy; Quality of life,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4825,NCT02451384,the changes of CTCs countings between the pre and post-operation among the arms,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
4826,NCT02999217,Changes in haemoglobin level,Duration of hospital stay,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
4827,NCT00398333,"To assess the efficacy of a nutritional intervention with supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment, using the variation in quality of life changes as the tolerability index.",To assess the effect of a nutritional supplement over the nutritional status of the patient with disseminated neoplastic illness.,,2005-06,TERMINATED,INTERVENTIONAL,['PHASE4']
4828,NCT05708924,Determine Maximum Tolerated Dose (MTD) of FT538,Adverse Events,Tumor biopsies (if feasible) at the time of catheter placement and catheter removal for study related analysis,2023-04-28,SUSPENDED,INTERVENTIONAL,['PHASE1']
4829,NCT02157974,Hepatic glucose release,Hepatic de novo lipogenesis,Bile Acid Metabolomics: sphingosine-1-phospate,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4830,NCT00436514,,,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
4831,NCT05368051,pathologic complete response（pCR）,,,2021-10-01,RECRUITING,OBSERVATIONAL,['NA']
4832,NCT05612477,Feasibility -Accrual,Safety- HCC recurrence,,2023-01-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4833,NCT03925883,Rate of follow-up colonoscopy,,,2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
4834,NCT01624090,Number of Participants With an Objective Response (Complete Response + Partial Response),Number of Participants With Serious and Non-Serious Adverse Events,,2012-09-06,TERMINATED,INTERVENTIONAL,['PHASE2']
4835,NCT04692545,Length of hospital stay,Prolonged length of stay,,2016-12-01,COMPLETED,OBSERVATIONAL,['NA']
4836,NCT05022030,Progression free survival (PFS) rate at 9 months,Adverse event rate,,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
4837,NCT06181201,histological response according to Ryan classification,,,2024-01-19,RECRUITING,OBSERVATIONAL,['NA']
4838,NCT05983406,DEP accuracy,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
4839,NCT01583699,Qualitative MALT-features on Endomicroscopy,Sensitivity and Specificity of Endomicroscopy to diagnose GI-MALT-Lymphoma,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
4840,NCT05334069,Provision of blinded reference set of cancer versus non-cancer blood samples,Test performance at the time of initial cancer diagnosis by clinical stage,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
4841,NCT04292496,Anastomotic leakage,Postoperative surgical complications,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
4842,NCT04667403,Satisfaction of patients with advanced or metastatic pancreatic cancer of the impact of telemedicine in the management of their pain.,Number of unscheduled hospitalizations recorded of each patient.,,2022-02-07,UNKNOWN,INTERVENTIONAL,['NA']
4843,NCT00002655,,,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4844,NCT05617430,Progression free survival (PFS) per RECIST v1.1,Overall survival (OS),,2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE2']
4845,NCT00124163,,,,2005-07,UNKNOWN,OBSERVATIONAL,['NA']
4846,NCT04430985,Disease-free Survival at 3 years,Safety and tolerability of the treatment,"Explorative analysis of biomarkers predictive of response to the combination of nivolumab, ipilimumab in combination with FOLFOX",2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4847,NCT02230553,overall response rate,Overall survival,,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4848,NCT01347697,Performance in Timed-Stands Test,Local recurrence,,2011-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4849,NCT01196494,,,,na,TERMINATED,INTERVENTIONAL,['NA']
4850,NCT05797870,The objective response rate,,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4851,NCT03422601,disease-free survival (DFS),,,2017-07-13,UNKNOWN,OBSERVATIONAL,['NA']
4852,NCT01464918,Total time taken to complete the ESD procedure,Safety,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
4853,NCT02869503,Survival of patients with colorectal cancer,Collection of patients characteristics,,2001-01,RECRUITING,OBSERVATIONAL,['NA']
4854,NCT00077298,Time to tumor progression,Overall survival,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4855,NCT05030493,Progression-Free Survival (PFS),"Evaluation of Correlation between Change in Gene Expression Region in Tumor Tissue at Baseline and Discontinuation of Protocol Treatment of Main Study, and Efficacy Endpoints (OS and PFS)",,2021-08-31,RECRUITING,OBSERVATIONAL,['NA']
4856,NCT03890354,Post operative compliction,Surgical outcome,,2019-02-21,COMPLETED,OBSERVATIONAL,['NA']
4857,NCT02916199,Incidence rate of post-endoscopic retrograde cholangiopancreatography,Success rate of stone removal,,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
4858,NCT02460822,Patient Satisfaction and Usability of the MyChemoCare Application,Improved Quality of Life,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4859,NCT05969899,Objective Response Rate（ORR）,Disease Control Rate（DCR）,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2']
4860,NCT05175092,Overall Survival (OS),Quality of Life Survey Score: EORTC QLQ-LMC21,,2023-11,WITHDRAWN,INTERVENTIONAL,['NA']
4861,NCT06252545,The clinical trial education and communication needs,,,2024-02-02,RECRUITING,INTERVENTIONAL,['NA']
4862,NCT02119065,Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values,In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient,,2014-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4863,NCT04847063,To determine the correlation between ex vivo simulated HIPEC in the SMART system and in vivo HIPEC with respect to two measures of response to treatment: percent necrosis and Ki-67,To measure Quality of Life by FACT-C and EQ-5D-5L,,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE1']
4864,NCT00049296,"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.",,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4865,NCT00621036,Safety and tolerability,Kinetics of humoral immune response development,,2007-10-19,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4866,NCT02699606,Objective Response Rate (ORR),Plasma Concentration of Erdafitinib,,2016-07-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4867,NCT02380443,To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2),To assess change from baseline in Health-Related Quality of Life (HRQoL),"Immunological response 9whether immune response correlates with Overall Survival (OS), RECIST and histopathology)",2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4868,NCT05524844,Correlation between Enterobacteriaceae (from 16S) and NOTCH3 expression in BE tissue.,,,2021-02-09,RECRUITING,OBSERVATIONAL,['NA']
4869,NCT05512182,objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0,,2022-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4870,NCT04687631,Conversion resection rate of liver metastases,time interval from chemotherapy to hepatectomy,,2021-01-14,RECRUITING,INTERVENTIONAL,['PHASE3']
4871,NCT02239328,Patient Reported Outcomes Measurement Information System (PROMIS) Scores.,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
4872,NCT00940316,Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD),Effect on Downstream Targets of Epidermal Growth Factor Receptor (EGFR) in Skin Rash Associated With Pharmacologic EGFR Inhibition,,2010-01-18,COMPLETED,INTERVENTIONAL,['PHASE2']
4873,NCT01669668,"Local recurrence, defined as the recurrence at the size of original tumor",Ability of patients who develop recurrence to undergo salvage transplantation,,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4874,NCT03089268,Risk of developing metachronous advanced lesions or cancers,Prevalence of serrated lesions in FOBT screening population,,2017-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4875,NCT01422928,Changes in immune biomarker levels,Changes in Symptom Scores,,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4876,NCT00242502,Progression-free Survival (PFS) Rate,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4877,NCT05469061,pCR,Disease-free Survival，DFS,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
4878,NCT04217083,Test Sensitivity and specificity for colorectal cancer,Test Sensitivity and specificity for colorectal polyps,,2019-01-02,UNKNOWN,OBSERVATIONAL,['NA']
4879,NCT00159445,"To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas",To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4880,NCT01276379,Progression Free Survival,Tumoral Response,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4881,NCT02276300,Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4882,NCT03990532,Overall survival (phase II),1-year local progression-free survival,,2019-04-30,RECRUITING,INTERVENTIONAL,['NA']
4883,NCT02066233,Median Tolerability Score on 10-point Visual Analog Scale (VAS),"Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy",,2014-03,COMPLETED,INTERVENTIONAL,['NA']
4884,NCT01693861,Effect of chemotherapy on urinary excretion of modified nucleosides,,Identification of modified nucleosides as biomarkers for colorectal cancer,2012-10,COMPLETED,OBSERVATIONAL,['NA']
4885,NCT00003652,,,,1999-01-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4886,NCT05587387,Overall survival (OS 2),Adverse event,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
4887,NCT03828266,Abdominal Infection rate after colorectal surgery.,Outcome of Abdominal Infection Treatment,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4888,NCT02044224,Patient Satisfaction With Anaesthesia Technique,Description of patient characteristics,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4889,NCT02693847,Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up,All cause mortality,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
4890,NCT04201730,The time to first flatus,Incidence of postoperative complications,,2019-12-25,COMPLETED,INTERVENTIONAL,['NA']
4891,NCT01077869,Feasibility of FDG-PET in the evaluation of radiation-induced mucositis.,,,2010-01,TERMINATED,OBSERVATIONAL,['NA']
4892,NCT02638766,Disease Control Rate,Quality of life by EQ-ED-5L questionnaire,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4893,NCT00416793,Overall Survival Rate at 6 Months,Overall Response Rate,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2']
4894,NCT04915599,Change in Feasability Questionnaire (regarding Patient reported tolerance of cryotherapy with Cooral ®),Change in degree of acute OM up to 6 weeks after EOT,,2021-06-22,COMPLETED,INTERVENTIONAL,['NA']
4895,NCT05801666,Arts' Dumping Questionnaire,Medical charts and drug use.,,2023-02-10,RECRUITING,INTERVENTIONAL,['NA']
4896,NCT00004234,,,,1999-08-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4897,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4898,NCT03516448,OS （Overall Survival）,RFS(Recurrence Free Survival),,2016-03-24,UNKNOWN,INTERVENTIONAL,['PHASE3']
4899,NCT02205398,Incidence of Dose Limiting Toxicities (DLTs),Progression Free Survival,,2014-07-28,TERMINATED,INTERVENTIONAL,['PHASE1']
4900,NCT05822752,Best Overall Response (BOR) per Investigator,Overall Survival (OS),,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
4901,NCT04718038,Progression-free survival(PFS),Safety,,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
4902,NCT02570893,The overall survival,Scores of Quality of life,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
4903,NCT00225745,To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls,To generate hypotheses for future studies and treatment based on the findings,,2004-04,COMPLETED,OBSERVATIONAL,['NA']
4904,NCT03895359,Time to Intrahepatic Progression,Cost-benefit,,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE3']
4905,NCT03227926,Overall response rate (ORR) to panitumumab according to RECIST v1.1.,Toxicity according to CTCAE version 4.03.,,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4906,NCT00034502,,,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4907,NCT05174325,Pathologic complete remission (PCR),Radiographic response,,2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4908,NCT06325267,Clinical characteristics of overall cohort by liver disease etiology,Risk factors of prognosis in overall cohort and different etiologies,,2010-01-01,RECRUITING,OBSERVATIONAL,['NA']
4909,NCT00711412,Determine Pathologic Complete Response,Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy.,,2006-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
4910,NCT05174286,CRC Screening Uptake,Change in Life's Simple 7 Score (CVD Risk Screening Measure),,2023-03-19,RECRUITING,INTERVENTIONAL,['NA']
4911,NCT02164448,gas passing,sips of water time,soft diet time,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4912,NCT05179824,Create robust data set of health information,Evaluate longitudinal paired tissue and cell free molecular testing,Review medical information for standard of care decisions and health outcomes,2020-10-19,RECRUITING,OBSERVATIONAL,['NA']
4913,NCT04804956,Identification of mesorectal microbial biomarkers as prognostic factor for rectal cancer,Evaluation of mesorectal dysfunctionality and dysbiosis on tumor progression,,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
4914,NCT02192983,Response rate,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4915,NCT01514045,Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene,,,2011-04,RECRUITING,OBSERVATIONAL,['NA']
4916,NCT05829291,Safety - Adverse events,To evaluate the radiological response of liver metastases using the RECIST criteria .,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
4917,NCT04554771,Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria,Feasibility delay,Predictive biomarkers using oa RNA sequencing,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4918,NCT01595217,"EHCC performance on DWI, ADC map and MRCP","ADC, SNR, CNR and SIR for EHCC lesion under different b values",,2012-03,COMPLETED,INTERVENTIONAL,['NA']
4919,NCT05496270,3-year diseases free survival,Local recurrence rate,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
4920,NCT02192541,Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept,Number of Cycles on Treatment,Number of Participants Who Had a Dose Limiting Toxicity (DLT),2014-12-02,TERMINATED,INTERVENTIONAL,['PHASE1']
4921,NCT01492907,Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine,Quantify ambient adducts in the human pancreas,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4922,NCT06163365,Primary hypothesis,Secondary hypothesis,,2022-07-26,RECRUITING,OBSERVATIONAL,['NA']
4923,NCT05604950,Selection of treatment modalities for elderly patients with oesophageal cancer,,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
4924,NCT04981665,2-year Recurrence Free Survival Rate (2-year RFS rate),Adverse Events (AEs),,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
4925,NCT05190445,Overall response rate (ORR) as defined by RECIST v1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Compare levels of HER2 protein expression and/or gene amplification and HER2 gene amplification in ctDNA isolated before treatment initiation with clinical benefit derived from study treatment,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4926,NCT02157363,operating time,,,2014-06-16,TERMINATED,INTERVENTIONAL,['NA']
4927,NCT03132792,"Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).",Interval between the date of first T cell infusion and date of disease progression or death due to any cause,,2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
4928,NCT05788874,SUVmax,,,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4929,NCT01383707,Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS),Overall Survival (OS),,2011-08-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4930,NCT06147037,Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053,"To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053",,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE1']
4931,NCT00303745,Stable disease rate,Progression-free and overall survival,,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
4932,NCT05892354,The incidence of severe oral mucositis,Number of participants with adverse events,,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4933,NCT02382263,"PHASE II: Evaluate the effectiveness of two selected schemes of gemcitabine and nab-paclitaxel, vs. gemcitabine alone. (Six months overall survival)",Phase II: change in FAP and Cav-1 tumor markers as an inidicatior of treatment efficacy,,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4934,NCT02063230,"Dose Normalized Cmax, Unbound Selumetinib",,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4935,NCT05648955,Change in cross-sectional skeletal muscle mass area on the third vertebral level (L3) [cm2],Change in health-related quality of life as measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 global health score),Change in physical function,2023-03-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4936,NCT04102098,"Recurrence-Free Survival (RFS), as Determined by IRF",Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,,2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4937,NCT01349517,Health related quality of life,Morbidity Mortality Survival rate,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
4938,NCT01688908,Cost for saving 1 quality-adjusted life year (QALY),Change of life quality due to early diagnosis and treatment,,2012-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4939,NCT03922152,"Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]",Assessment of the Overall Survival,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
4940,NCT04751955,Progression free survival,Quality of life by FACT-C v4.0,,2022-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4941,NCT00868569,overall survival,resection rate of liver metastasis progression-free survival,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4942,NCT00682227,Safety (toxicities as assessed by NCI CTCAE version 3),Immunological and clinical response,,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
4943,NCT05194072,Number of participants with dose limiting toxicities (DLTs),Incidence of antidrug antibodies (ADAs),,2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE1']
4944,NCT06167421,Severe complication rate,Postoperative quality of life assessment,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4945,NCT05051475,Level of late post-procedural pain (at day 30 after treatment),The rate of complications,,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
4946,NCT03391934,Progression Free Survival (PFS),immunogenicity,,2018-01-20,RECRUITING,INTERVENTIONAL,['PHASE3']
4947,NCT00681876,Time To Progression,"Quality of life, Symptoms improvement",,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2']
4948,NCT01541709,progression-free survival (PFS),percentage of successful dose escalation,,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4949,NCT06233708,Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up,Multivariate Cox regression analysis of overall survival at 5-year follow-up,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
4950,NCT03802747,Dose-Limiting Toxicity of Y-90+SBRT in Combination with Dual Immune Checkpoint Blockade,Time to Tumor Progression (TTP),,2019-08,WITHDRAWN,INTERVENTIONAL,['PHASE1']
4951,NCT00094029,,,,2004-09,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
4952,NCT04751591,Early operative mortality rate,En bloc resection rate,,2021-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4953,NCT01369420,Safety,Efficacy,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4954,NCT03623984,Comparison of intraoperative findings to preoperative PET scan findings,Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement,,2019-06-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
4955,NCT05423886,Detection rate of colorectal cancer and advanced adenomas,Acceptability,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4956,NCT01339650,Pharmacokinetic profile,Safety (number of subjects with adverse events and/or dose limiting toxicities),,2011-05-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4957,NCT05461430,BOR,PFS,,2022-07-15,RECRUITING,OBSERVATIONAL,['NA']
4958,NCT01415089,Quality of life,Satisfaction with intervention,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
4959,NCT00965965,Comprehension of randomly assigned educational document,Readiness to undergo colorectal cancer screening,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
4960,NCT05613478,Recurrence-free survival (RFS),Safety and toleraty,,2022-11,RECRUITING,INTERVENTIONAL,['PHASE3']
4961,NCT04282980,Progression-Free Survival(PFS) based on independent imaging review,Disease Control Rate(DCR),,2020-04-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4962,NCT03389126,response rate,,,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4963,NCT06245356,Treatment specific safety,Quality of life questionnaire - Colorectal (QLQ-CR29),,2024-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4964,NCT01198145,Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT),Percentage of Patients in Each Arm That Experience Clinically Significant Deficits in Overall Quality of Life and Fatigue,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4965,NCT02797405,Validation of the correlation between the clinical tumor response and the results of A/MS bioassays using tumor samples,Validation of the correlation between the healthy tissue response (i.e. AE reported as per CTCAE v4) and the results of MS/A bioassays using skin biopsies,,2016-10,TERMINATED,INTERVENTIONAL,['NA']
4966,NCT03258541,Clinical performance,Comparative dosimetric studies,,2017-01-15,TERMINATED,INTERVENTIONAL,['NA']
4967,NCT06066931,The assessment of the frequency of early postoperative complications,The assessment of the frequency of late postoperative complications and quality of life,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4968,NCT05674123,Incidence of adverse events,,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
4969,NCT02356276,5-year overall survival,side effects,CEA mRNA expression of peritoneal lavage fluid,2015-05-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
4970,NCT05181488,3-year local recurrence rate,Overall survival,,2020-04-02,RECRUITING,INTERVENTIONAL,['NA']
4971,NCT04172571,Objective response rate (ORR),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2018-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4972,NCT04947020,Overall survival,Disease-free survival,Lymph node ratio,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4973,NCT06315101,Survival analysis,Adverse Events assessment,,2023-09-01,COMPLETED,OBSERVATIONAL,['NA']
4974,NCT04162535,Evaluation of patients serum on cell culture,Survival Comparison,,2018-11-26,UNKNOWN,INTERVENTIONAL,['PHASE1']
4975,NCT04869618,Diagnostic performance of SPECTRA IMDx for assessment of lower risk lesion (GIM/LGD/Gastritis/Normal) and higher risk lesions (HGD/EGC) against the gold standard of histopathology from gastric resection specimen,Evaluation of performance of HD-WLE combined with NBI in detection of HGD/EGD prior to ER.,,2021-05,UNKNOWN,INTERVENTIONAL,['NA']
4976,NCT05939687,hernia rate,Quality of life indicators by HerQLes scale,,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE3']
4977,NCT00101348,MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride determined by DLT graded according to the CTCAE version 3 (Part II),Progression-free survival,,2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4978,NCT06166589,ORR,OS,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4979,NCT01798134,Freedom From Tumor Progression at 6 Months,12 Month Survival,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
4980,NCT02009449,Pharmacokinetic (PK) parameters,Anti-Pegilodecakin antibody formation,,2013-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
4981,NCT00376987,Reversal of cadmium-induced inhibition of mismatch repair,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4982,NCT02087475,Progress Free Survival,Life Quality,,2011-01,RECRUITING,INTERVENTIONAL,['PHASE3']
4983,NCT01765673,Change in Swallowing Frequency 70 & 110 Hz,Change in Swallow Initiation Time,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
4984,NCT00062257,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4985,NCT03259035,Measurement of organ preservation rate,Cost effectiveness using the EQ-5D-5L questionnaire,,2018-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4986,NCT00477711,Tumor response rate,"Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4987,NCT05385549,PFS,,,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE2']
4988,NCT03033927,Progression Free Survival,,,2017-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4989,NCT01381822,To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib.,To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D.,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
4990,NCT01004159,12-week Progression Free Survival Rate Upon Escalation of Cetuximab Dose to 500mg/m2 in Combination With Irinotecan After Progression on Standard Dose Therapy in Patients With KRS Wild Type Colorectal Cancer,Response Rate of Cetuximab 500mg/m2/Week in Combination With Irinotecan in the Enrolled Patient Population,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
4991,NCT02748772,PFS,RR,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
4992,NCT01736904,Progression free survival which is calculated from the start of treatment to disease progression or death,Objective response rate which includes complete response(CR) and partial response(PR) participants,Overall survival which is calculated from the start to treatment to the death,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
4993,NCT03250637,Colorectal cancer,,,1993-12,COMPLETED,OBSERVATIONAL,['NA']
4994,NCT01845675,overall response rate,toxicities,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4995,NCT01465113,Arm 2 (high grade dysplasia): 15-Prostaglandin dehydrogenase expression,effects on insulin resistance,,2010-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4996,NCT05297955,Data analysis of relationship between CTC and pathological indicators of hepatocellular carcinoma,,,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
4997,NCT06205836,Complete Response Rate,Number of participants experiencing grade 3 or above drug-related toxicities requiring treatment discontinuation,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4998,NCT01493336,Relative bioavailability: Area under the concentration-time curve (AUC),Safety: Incidence of adverse events,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4999,NCT05171166,Progression-free survival,Number of paitents with treatment-related adverse events,,2021-12-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5000,NCT03708042,Overall survival,Comparison of pathological diagnosis between specimens of endoscopic biopsy and surgically resected in esophageal cancer,,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5001,NCT02715141,life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model,presence of previously identified progression biomarker on resected tissue samples of polyps,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
5002,NCT01267305,TEG values,inhospital mortality,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
5003,NCT02273141,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Polyp Detection Rate (Overall Colon),,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5004,NCT02788526,Overall survival,Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5005,NCT04549064,Diagnosis of Pancreatic Cancer,,,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5006,NCT06214988,textbook outcome; stoma-free survival at two years without major LARS,Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30),,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5007,NCT00522665,To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer,"To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001",,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5008,NCT03230318,Substudy 2: Progression Free Survival at 3 Months (PFS 3),Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs),,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
5009,NCT04846309,"frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment",Pathological complete response (pCR) rate,,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE1']
5010,NCT05985252,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,Total hospitalization costs,Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5011,NCT00786006,Progression-free survival,Safety,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5012,NCT05301842,Progression Free Survival (PFS) for Arm A vs Arm C,Overall Survival (OS) for Arm B vs Arm C,,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3']
5013,NCT02512172,Number of Patients Experiencing a DLT (dose-limiting toxicity) as defined by NCI CTCAE v4.0,Overall Survival (OS),,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1']
5014,NCT01393197,Time to progression,remission rate,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
5015,NCT02336087,"Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4)",Time to treatment failure,"Quality of life, assessed using the FACT-G questionnaire",2016-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5016,NCT01243372,Progression-free survival as measured by RECIST,tumor response as measured by RECIST,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
5017,NCT04451603,"Use of prediction software or tools to estimate volume and health of the future liver remnant (FLR), monitor changes in liver volume and health post treatment",,,2018-10-19,COMPLETED,OBSERVATIONAL,['NA']
5018,NCT04294953,morphine consumption,Postoperative patient satisfaction,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5019,NCT00845039,Progression-Free Survival (PFS) Rate at 18 Weeks,Serum Anti-IMC-A12 Antibody Assessment,The Number of Participants Who Died During 30-Day Follow-Up,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2']
5020,NCT00898378,Creation of an OMIC profile to predict the risk of colorectal cancer (CRC),Identification of interactive molecular pathways that underlie the development and progression of CRC,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5021,NCT03792932,Recurrence Free Survival,Detected lymph node number,,2019-02-02,RECRUITING,INTERVENTIONAL,['NA']
5022,NCT01646697,Local recurrence at the site of resection,,,2011-11-07,COMPLETED,INTERVENTIONAL,['NA']
5023,NCT01943500,The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.,,,2013-09-30,COMPLETED,OBSERVATIONAL,['NA']
5024,NCT06220058,Incidence of incisional hernia.,Morbidity and mortality rates,,2024-01-15,RECRUITING,INTERVENTIONAL,['NA']
5025,NCT04548947,Incomplete resection rate (IRR),Incomplete resection of colorectal polyps,,2021-01-12,COMPLETED,INTERVENTIONAL,['NA']
5026,NCT01075893,Number of stem cells in the colonic crypt,Stem cell position in colonic crypt,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
5027,NCT02354898,Pharmacokinetic profile of BBI503,Overall Survival,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5028,NCT01466569,"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination",Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5029,NCT03818997,Objective response rate,Duration of stable disease using RECIST 1.1 and iRECIST,,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5030,NCT01532427,Safety,usability,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
5031,NCT04916054,to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival,To evaluate the impact on overall survival,,2021-06-04,COMPLETED,OBSERVATIONAL,['NA']
5032,NCT01054911,Number of Participants With Adverse Events,Alteration in Diffusion and Vascularity Kinetics,,2009-10,TERMINATED,INTERVENTIONAL,['NA']
5033,NCT04145141,"To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression",To estimate 3 years progression-free survival following immunotherapy for PLC,,2021-07-28,RECRUITING,OBSERVATIONAL,['NA']
5034,NCT05264896,3 year disease free survival,Pathology - tumor regression grade,,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE3']
5035,NCT02683655,Progression free survival,,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5036,NCT03525067,Postoperative infectious complications at postoperative day 90,Mortality post operative day 90,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
5037,NCT02119663,Overall Survival (OS),Participants With Treatment-Emergent Adverse Events (TEAEs),,2014-06,TERMINATED,INTERVENTIONAL,['PHASE3']
5038,NCT01242605,"To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.",Response rate,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5039,NCT02646462,Ratio of malignant/total number of lymph nodes,Number of N1 patients,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
5040,NCT01766661,post-operative morbidity,local and/or distant recurrence of neoplasm,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
5041,NCT03246516,Time limit of first doctor consultation,Survival,,2017-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5042,NCT00049101,,,,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5043,NCT00601198,"Test Drug in 28 Patients and Assess PSN. If 5 or More Have Grade 3 & 4 PSN, Trial Will be Terminated.","Assess PSN in 69 Patients. If Total Number of Cumulative PSN is > or Equal to 14, Drug Will be Rejected.",,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
5044,NCT02395640,progression free survival,quality of life questionnaire,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5045,NCT00674973,Progression-Free Survival,Number of Participants With Adverse Events (AEs),,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5046,NCT02889679,Incomplete resection rate (histologic),,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
5047,NCT05432934,Total postoperative opioid consumption in the first 48 hours after surgery (hydromorphone equivalents.,Length of stay in hospital (days).,,2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5048,NCT04888403,Pathologic Complete Response(pCR),postoperative complications rate,,2021-12-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
5049,NCT05811546,Difference in DNMT1 and EZH2 expression.,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
5050,NCT04473625,Stool-based test for colorectal cancer,,,2020-07-21,COMPLETED,OBSERVATIONAL,['NA']
5051,NCT01286883,Primary endpoint: correlation of stem cell markers on CTCs with response to therapy,Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs,,2011-02,TERMINATED,OBSERVATIONAL,['NA']
5052,NCT02537340,Detection rate,Overall survival,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
5053,NCT02351219,Radical resection rate,Progression-free survival,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5054,NCT02407977,Dosimetric accuracy of the device with reference to a commercially available dosimeter,Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.,,2015-11-13,COMPLETED,OBSERVATIONAL,['NA']
5055,NCT00053222,Objective response,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5056,NCT03760822,Quality of life at 4 months as assessed by the following dimension of the EORTC QLQ-ELD14 questionnaire: illness burden,Progression-free survival,,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5057,NCT05221398,Recurrence-free survivial,Overall survival,,2019-03-03,COMPLETED,OBSERVATIONAL,['NA']
5058,NCT02585908,Reduced size of the tumor.,"Safety, as measured by the rate of adverse events and serious adverse events",,2019-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5059,NCT05955196,Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample,"To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS)",,2023-01-09,RECRUITING,OBSERVATIONAL,['NA']
5060,NCT06300489,MTD（maximum tolerable dose）,,,2024-03-03,RECRUITING,INTERVENTIONAL,['PHASE1']
5061,NCT01419483,Frequency of Adverse Events (Safety),Progression Free Survival (months),,2011-07,TERMINATED,INTERVENTIONAL,['NA']
5062,NCT03698253,Progression-free survival,Rate of treatment-associated adverse events.,,2013-10-01,COMPLETED,INTERVENTIONAL,['NA']
5063,NCT03692429,Occurence of Dose Limiting Toxicities,,,2018-11-28,RECRUITING,INTERVENTIONAL,['PHASE1']
5064,NCT05472753,Change in the alpha diversity index (Shannon),Change in stool calprotectin,,2022-11-16,UNKNOWN,INTERVENTIONAL,['NA']
5065,NCT02295774,Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy,To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5066,NCT04833036,PFS,ORR,,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5067,NCT03166553,Objective response rate and/or 1-year survival rate,the rate of incidence of adverse events,,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA']
5068,NCT00003157,Maximum tolerated dose,Survival,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5069,NCT05746962,proportion of colonoscope loop formation,evaluation of risk factors about loop formation,,2023-03-06,RECRUITING,INTERVENTIONAL,['NA']
5070,NCT04984096,Progression-Free Survival (PFS),Overall Survival (OS),,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
5071,NCT00534001,Prequit Change in Cigarettes Per Day,Abstinence,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5072,NCT04781270,conversion resection rate,Early tumor shrinkage,,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE3']
5073,NCT05147168,Quality of Life(SF-36),,,2021-11-22,RECRUITING,OBSERVATIONAL,['NA']
5074,NCT05934981,Number of patients with pain at 24 hours after the end of the intervention by VAS ≤ 3 without taking opioids (without step 2 and step 3 analgesics).,Evaluation of predictive factors of opioid intake,,2023-08-30,RECRUITING,INTERVENTIONAL,['NA']
5075,NCT02565641,Overall objective response rate,Incidence of adverse events,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5076,NCT04880148,Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments,Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire,,2021-11-03,RECRUITING,INTERVENTIONAL,['NA']
5077,NCT05571098,Psychosocial Adjustment to Illness Scale (PAIS-SR) scores should be lower in the NNP applied group than in the non-applied group.,,,2021-07-08,COMPLETED,INTERVENTIONAL,['NA']
5078,NCT04049461,Bone alkaline phosphatase,Incidence of distant metastasis and local recurrence,Overall survival,2019-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5079,NCT02216799,Achievement of target blood glucose (140 mg/dL to 200 mg/dL),Developement of hypoglycemia ( blood glucose < 70 mg/dL),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5080,NCT03294343,Occult cancer or precancerous lesion in histological specimen,Incidence of primary uterine cancer,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
5081,NCT00378716,Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival,Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5082,NCT00007826,,,,2000-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5083,NCT03579758,Overall survival,Incidence of residual disease after or at the time of re-resection,,2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5084,NCT03203525,Incidence of adverse events,Biomarker analysis,,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE1']
5085,NCT00004879,,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5086,NCT03601923,Progression Free Survival,Evaluation of the safety and tolerability of niraparib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE),,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5087,NCT01902953,Efficacy of Lymphoseek for Detection of Sentinel Nodes,Localization Rates,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5088,NCT05943444,Low Anterior Resection Syndrome (LARS) score 1 year after surgery,The incidence of postoperative anastomotic complications,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA']
5089,NCT05919095,Radical resection rate,The incidence of treatment-related adverse event,,2023-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5090,NCT01911988,Disease Free Survival,5 years overall survival,,2013-06,UNKNOWN,OBSERVATIONAL,['NA']
5091,NCT01209325,Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants,"Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level",,2011-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
5092,NCT01749956,Pathologic Complete Response Rate,The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5093,NCT04517643,Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT,,,2020-11-12,COMPLETED,INTERVENTIONAL,['NA']
5094,NCT00354705,Occurence of Recurrent Colon Cancer,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA']
5095,NCT00066716,Pathological response rate at time of surgical resection,Toxicities and safety,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5096,NCT01923987,R0 resection rate,Toxicity,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5097,NCT01907607,Number of Participants With Non Progression at 4 Months,Efficacy Assessment of PD-0332991 in Terms of Overall Survival Time,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5098,NCT03337841,One-year recurrence-free survival rate,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2017-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
5099,NCT03560817,Health utilities for SF-6Dv2 after the start of the chemotherapy,Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy,,2017-01-04,COMPLETED,OBSERVATIONAL,['NA']
5100,NCT01619475,Pain control in living donors following partial hepatectomy,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
5101,NCT02140723,Interaction between the status of the biomarker TP53 and response to treatment,overall survival,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
5102,NCT00003591,To determine the one-year and median survival rates after PXRT,To correlate p53 status with treatment response to PXRT,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5103,NCT01191814,Complications related to stent dysfunction,Procedural complications,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
5104,NCT05289726,incidence of grade 3 hand-foot skin reaction,tumor control rate,,2022-04-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
5105,NCT04919824,Procedure time,Delayed post-procedural adverse event,,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5106,NCT05170360,1. association between some risk factors and colorectal cancer,1. Estimation of KRAS and BRAF genes mutations associated with CRC. 3. Association between these risk factors and gene mutations on different types of CRC.,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
5107,NCT00677781,Postoperative morbidity,Mortality,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
5108,NCT02588443,Number of Adverse Events,,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5109,NCT04797923,Rate of R0 resection,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5110,NCT01882205,The difference in total number of neoplastic lesions detected by chromoendoscopy and virtual chromoendoscopy,The difference in the ratio number of neoplastic lesions/ total number of lesions between chromoendoscopy and virtual chromoendoscopy,Number of biopsies per colonoscopy taken in the different groups.,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
5111,NCT01789983,"To measure the feasibility of implementing the WWE program among cancer patients, age ≥60, as they undergo cytotoxic chemotherapy treatment.",To measure relationships between physical activity levels and p16 levels.,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
5112,NCT03392571,To evaluate 2 year survival from date of entry into study,Time to Recurrence,,2018-08-15,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5113,NCT02649361,Progress free survival (PFS),Disease Control Rate (DCR),,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5114,NCT05617352,The number of lymph nodes,,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
5115,NCT02574637,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8,Percentage of Participants With Abdominal Pain Remission,,2016-01-05,TERMINATED,INTERVENTIONAL,['PHASE2']
5116,NCT00427973,Progression-free Survival,Overall Survival,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2']
5117,NCT02425605,Overall survival,toxicity defined as NCI-CTC(version 4.02),,2014-12-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5118,NCT05253651,Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR),Time to meaningful change in EORTC QLQ30 score,,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE3']
5119,NCT06162143,Low Anterior Resection Syndrome (LARS) score,Diarrhea,,2023-11-15,RECRUITING,OBSERVATIONAL,['NA']
5120,NCT05718349,Microbial composition,,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
5121,NCT05632939,The recommended dose,Overall survival（OS）,,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5122,NCT04973098,Adverse Event of Special Interest,,,2021-08-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
5123,NCT00089024,Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment,,,2004-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
5124,NCT02508389,Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria,"Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths",,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5125,NCT02720601,Progression-free survival (PFS),Toxicity,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5126,NCT01750619,Technical success.,Endoscopic en bloc resection rate,,2011-07,RECRUITING,OBSERVATIONAL,['NA']
5127,NCT02446574,Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint),Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint),,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5128,NCT01447927,Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus,Overall Adverse Event Rates,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5129,NCT02765620,Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process,PFS,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
5130,NCT02425137,Disease control rate (DCR),"safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade)",,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5131,NCT01688232,relapse in relation with the immunoscore determined on a tumor section.,relapse in relation with the immunological events and psychological status of the patient during the monitoring,,2012-09-27,UNKNOWN,OBSERVATIONAL,['NA']
5132,NCT03910140,The response to treatment,Lifetime (months),,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5133,NCT02592902,Occurrence of EER (percentage),Presence of pepsin,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
5134,NCT06229197,Incidence of reflux gastritis assessed according to RGB classification,Long-term complications,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5135,NCT05785234,Total consumption of fentanyl in 24 hours after surgery,,,2023-04,RECRUITING,INTERVENTIONAL,['NA']
5136,NCT06267703,Chronic atrophic gastritis,,,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5137,NCT03217253,Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction,Best response,,2018-03-16,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5138,NCT04443049,Progressive disease requiring change of therapy in both groups,Decompensation of underlying cirrhosis in both groups,,2020-07-10,UNKNOWN,INTERVENTIONAL,['NA']
5139,NCT03989180,"Performance of the C-Scan system in terms of communication between the C-Scan Capsule and the System Track in different locations, positions and configurations.",,,2016-01-06,COMPLETED,OBSERVATIONAL,['NA']
5140,NCT00025142,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5141,NCT02169765,Overall survivals,Recurrence rates,morbidity,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5142,NCT00868998,Response Rate,Toxicity,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2']
5143,NCT05183295,Tolerability of the NEAAR medical food,Progression-free Survival,,2022-04-27,WITHDRAWN,INTERVENTIONAL,['NA']
5144,NCT05689775,Perineal wound healing,Abdominal wall strength,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
5145,NCT00190515,Disease-free survival,Rate of adverse event,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5146,NCT02860429,neural electrophysiological test,"stress hormone,in blood.",,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
5147,NCT04134832,The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.,,,2019-06-27,UNKNOWN,OBSERVATIONAL,['NA']
5148,NCT01056809,Overall survival,Complications and side effects,,2010-01,TERMINATED,INTERVENTIONAL,['NA']
5149,NCT04685395,Incidence of oral mucositis,The pain score,,2019-12-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
5150,NCT00339183,Overall Survival,Number of Participants With Adverse Events (AEs),,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
5151,NCT00423696,Progression-free survival at 6 months,Quality of life,,2006-03-23,COMPLETED,INTERVENTIONAL,['PHASE2']
5152,NCT05335460,TRG0/1,ORR,PCR rate,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5153,NCT05047146,Clinicopathological factors of Hepatocellular Carcinoma,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
5154,NCT03722056,rates of intraoperative tumour rupture,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
5155,NCT05164406,Transfusion,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5156,NCT05129774,5-year OS,Postoperative complications,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5157,NCT02270606,Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation,Postoperative mortality rates,,2014-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5158,NCT01401075,Quality of Life,Safety and tolerability,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5159,NCT00470353,Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining,"Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment",,2006-09,TERMINATED,INTERVENTIONAL,['NA']
5160,NCT06229080,Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver,Serious adverse event,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
5161,NCT04808791,Safety/Tolerability,Overall Survival,,2021-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5162,NCT00568646,Objective tumor response rate based on tumor measurements according to the RECIST,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5163,NCT02619942,Disease-free survival,Metastasis rate of central lymph node (3rd station),,2016-01-09,UNKNOWN,INTERVENTIONAL,['NA']
5164,NCT05029882,Objective Response Rate (ORR),Overall survival (OS),,2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE1']
5165,NCT04813523,Major pathologic response (MPR),Pathologic complete response (pCR),,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5166,NCT05737953,Types and concentrations of cfDNA and proteins contained in the vesicular fluid,Development of a progressive benign malignancy prediction model,,2022-07-13,RECRUITING,OBSERVATIONAL,['NA']
5167,NCT01170104,Time to progression,To evaluate the toxicity profiles,,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
5168,NCT05876026,Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.,,,2023-05-08,RECRUITING,OBSERVATIONAL,['NA']
5169,NCT01589328,Reduction in depression score,Overall survival,,2012-03-15,COMPLETED,INTERVENTIONAL,['NA']
5170,NCT03925870,Duration of response (DOR),Overall survival (OS) rates,,2019-06-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5171,NCT04064034,Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood,,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
5172,NCT00985192,Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.,Biomarker Correlations: Time to Progression,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5173,NCT02584985,R1 resection rate,Disease-free survival at 3 years,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5174,NCT01187901,Change in Duodenal Polyp Burden From Baseline to 6 Months,Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5175,NCT04493905,30-day postoperative morbidity assessed by Clavein-Dindo classification,"Cancer recurrence or cancer-related death at 90 days, 1, 3- and 5-years",,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
5176,NCT02205047,Near Complete Pathological Response Rate,Toxicity,,2015-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5177,NCT01439698,Number of Participants with Adverse Events,Number of overall stent occlusion-free days post intervention,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
5178,NCT02501603,compare progression free survival as measured by RECIST 1.1,safety as measured by CTCAE,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5179,NCT03215264,Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib,,,2017-10-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5180,NCT01815853,Disease-free Survival,Adverse effects,,2013-06,RECRUITING,INTERVENTIONAL,['PHASE3']
5181,NCT05527301,Change in Low Anterior Resection Syndrome score from Baseline to 8 weeks,Change of fecal metabolites assessed by fecal analysis,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5182,NCT03563274,Safety,"Percentage of patients downstaged to surgery, transplantation or any local ablative therapy (RFA/MWA…)",,2018-06-21,TERMINATED,OBSERVATIONAL,['NA']
5183,NCT00659867,The primary objective is to investigate whether chromoscopy-guided endomicroscopy has a higher sensitivity than standard endoscopy with respect to detection of IN and to compare the proportion of patients with at least one IN,Efficacy of chromoscopy-guided endomicroscopy in the detection of lesions and in the reduction of the number of biopsies. Time needed for the examination will be measured and compared between the two groups.,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
5184,NCT01558921,Disease related Treatment Failure (DrTF),Quality of life LARS,,2011-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5185,NCT00498407,• Objective response rate (RR),• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5186,NCT04572542,Objective response rate,Disease Control Rate（DCR）,,2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5187,NCT03014284,Expression of B7-H1,,,2017-01-20,WITHDRAWN,OBSERVATIONAL,['NA']
5188,NCT04928807,pathological complete response (pCR) rate,dverse events (AEs) were graded according to the NCI CTCAE version 5·0,,2021-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5189,NCT01116271,"Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.",Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5190,NCT04056260,sensitivity and specificity,,,2020-03-20,UNKNOWN,INTERVENTIONAL,['NA']
5191,NCT00176800,Median Recurrence Free Survival Time,Percentage of Patients That Require Dose Modification Due to Toxicity,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5192,NCT05194293,Objective response rate (ORR) (unconfirmed),Pathologic complete response,Immune biomarkers,2023-06-29,RECRUITING,INTERVENTIONAL,['PHASE2']
5193,NCT01514786,Number of Participants Reporting Preferred Screening Type as Reported by Chart Audits,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
5194,NCT06107413,Progression Free Survival (PFS),Percentage of Participants Achieving Best Overall Response (BOR),,2023-11-12,RECRUITING,INTERVENTIONAL,['PHASE2']
5195,NCT02400788,Phase 2 : Time To Progression (TTP),,,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5196,NCT00828620,PET response on day 7,To asses the correlations between biomarkers and PET changes after Cetuximab,,2009-01,TERMINATED,OBSERVATIONAL,['NA']
5197,NCT01282502,To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation,To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5198,NCT01657383,Surgical Outcome,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
5199,NCT03957096,Number of patients with dose-limiting toxicities (DLTs),Incidence of antidrug antibodies (ADA),,2019-07-17,TERMINATED,INTERVENTIONAL,['PHASE1']
5200,NCT03118349,Occurrence of graded adverse events (AEs) in each subject,Cl,Evaluate the relationship between circulating CA19-9 levels and MVT-1075 pharmacokinetics,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
5201,NCT04596384,Maximum CCI,Change in Sleep,,2021-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5202,NCT02730104,Time to disease progression,Patient satisfaction with treatment,,2015-11-23,COMPLETED,OBSERVATIONAL,['NA']
5203,NCT01320852,Overall Survival,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
5204,NCT01963182,severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan,"evaluation of treatment efficacy (progression-free survival, duration of response)",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5205,NCT03781934,Incidence of clinically significant changes in ECGs,Plasma levels of α fetoprotein (AFP),,2018-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5206,NCT01906021,To measure accuracy of temperature monitoring using non-invasive thermomap (temperature imaging profile) method compared to the currently accepted invasive thermocouples method,,,2013-09-23,COMPLETED,INTERVENTIONAL,['NA']
5207,NCT05173298,collected blood samples,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC,,2021-08-02,RECRUITING,OBSERVATIONAL,['NA']
5208,NCT00061815,"Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.",Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5209,NCT03803930,The diagnostic yields,the tissue integrity,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
5210,NCT00209612,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.,,2004-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5211,NCT05999019,ClassIntra grade,3-year disease-free survival,,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
5212,NCT05867303,Incidence of Adverse Events [Safety and tolerability],Progression Free Survival (PFS),,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1']
5213,NCT03520257,overall survival,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5214,NCT02830633,The postoperative voiding function assessed by IPSS questionnaire.,C-reactive protein,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
5215,NCT00928161,Frequency of acid reflux episode (during each 24 hour pH probe),,,2012-11,WITHDRAWN,INTERVENTIONAL,['NA']
5216,NCT05193292,Objective Response Rate,Duration of Response,,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5217,NCT03152435,Occurrence of study related adverse events as assessed by CTCAE v4.0,Determine duration of in vivo survival of EGFR CART .,,2017-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5218,NCT06310993,Primary Outcome Measure,Secondary Outcome 7,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5219,NCT00025337,Overall survival,Progression free survival,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5220,NCT00457327,Morbidity and mortality until day 30 postoperative,Ranking of factors influencing quality of life,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2']
5221,NCT02707796,"Evaluation of the correlation between partial oxygen pressure in arterial blood sample and oxygen reserve index calculated by pulse co-oximetry, and sensitivity and specificity of oxygen reserve index in patients undergoing hemicolectomy",Sensitivity and specificity of oxygen reserve index,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
5222,NCT03401229,Change From Baseline in NBS at Week 40,Change From Baseline in SF-36v2 Mental Health at Week 56,,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
5223,NCT02555813,Number of participants with adverse events,Best Overall Response,,2015-05-08,COMPLETED,OBSERVATIONAL,['NA']
5224,NCT03295006,Alternative two-compartment TheraSphere dosimetry methodology,Dose reproducibility,Normal tissue dose and tumor dose using post-procedural PET/CT Imaging,2016-10-31,COMPLETED,OBSERVATIONAL,['NA']
5225,NCT04594811,Phase 2: Objective response rate (ORR),Number of participants with anti-drug antibodies (ADA) to NT-I7,,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2']
5226,NCT00601692,Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy,Clinical and pathological complete response rate,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5227,NCT06001476,Incidence of complications in the application of cold snare polypectomy for 5-9mm small bowel polypectomy in patients with PJS,Incidence of complications within 28 days after enteroscopy,,2023-08-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5228,NCT05351931,"Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.",Disease free and overall survival at 3 and 6 months after stop of RCT.,Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.,2022-06,UNKNOWN,INTERVENTIONAL,['NA']
5229,NCT05587452,Specificity,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
5230,NCT00950417,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,To determine the complete response rate、partial rate、disease responserate、disease control rate in the patients subject to treatment,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5231,NCT03895255,Anastomotic Leakage Rate,The postoperative hospital stay,,2016-10-02,UNKNOWN,INTERVENTIONAL,['NA']
5232,NCT04380012,Objective Response Rate,The Incidence of Adverse Events,,2019-12-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
5233,NCT00011960,,,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5234,NCT05356117,Protein Supplementation (PS) Rate,Psychosocial function - Physical Function,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
5235,NCT00877071,The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM,The Local Effects of the LC BeadTM in the Explanted Liver of Those Patients Who go on to Receive Liver Transplantation,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5236,NCT02775695,Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response,,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5237,NCT00524069,Margin status after pancreatic resection,Toxicity,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA']
5238,NCT02402062,Objective Response Rate,Biomarkers in Serum and Tumor Tissue,,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5239,NCT05872334,Incisional hernia,Wound dehiscence,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
5240,NCT05875870,Sleep-wake rhythm,Survival rate,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
5241,NCT05195281,Evaluation of molecular subtype modification,,,2021-07-14,RECRUITING,INTERVENTIONAL,['NA']
5242,NCT03775707,overall survival (OS),Adverse Events,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5243,NCT04323917,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood,Prediction of prognosis of PC by EMT-TF mRNA levels in blood,,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA']
5244,NCT02177552,The proportion of participants alive one year after randomisation,Registration of further lines of therapy,Analysis of cmet by immunohistochemistry,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
5245,NCT00867477,Comparison Patient's PMRR + Mean Exhaled NO Measurement,,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5246,NCT04891874,Participants Without Recurrence (Disease-free).,Overall Survival (OS) Rate.,Number of Participants Occured Adverse Events(AE),2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
5247,NCT04478110,CRC screening rates,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
5248,NCT01781520,Treatment toxicity,Phenotypic analysis of peripheral blood immune cells,,2013-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5249,NCT00681798,Define Recommended Dose (RD),"Determine antitumour activity as determined by overall response rate (RR), progression free survival (PFS), disease control rate and duration of response",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5250,NCT00119912,1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.,2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.,,1999-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5251,NCT04584008,Objective response rate (ORR) of patients receiving targeted agent,Differences of OS between 2 groups,,2020-09-23,RECRUITING,INTERVENTIONAL,['NA']
5252,NCT01121848,Progression-Free Survival (PFS),Median Overall Survival (OS),,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5253,NCT05037461,Change in tumor size,overall survival,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
5254,NCT02289547,Progression free survival,Toxicity profile of each patients measured by NCI-CTCAE ver 4.0,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
5255,NCT00498134,"Changes in cell proliferation, apoptosis and oncogene expressions",The incidence of gastric cancer in a high risk area,,2004-03,UNKNOWN,INTERVENTIONAL,['NA']
5256,NCT03357757,Proportion of subjects who complete 4 doses of Avelumab in combination with VPA,Hsp90 concentration in serum,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5257,NCT00460681,disease-free survival,overall survival,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
5258,NCT00043004,Survival rate as measured by Kaplan Meier method at 30 months,Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2']
5259,NCT05111353,Safety of neoantigen SLP vaccine as measured by number of subjects experiencing each type of adverse event,Immunogenicity of neoantigen peptide vaccine as measured by the phenotype of neoantigen-specific T cells (only Arm 1 and Arm 2),,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5260,NCT00327119,,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5261,NCT01416714,create a database for the collected tissue,To create tissue microarrays for each gastrointestinal cancer subtype,,2008-07-02,SUSPENDED,OBSERVATIONAL,['NA']
5262,NCT00977717,neuropathy,,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
5263,NCT02466906,Disease-free survival（DFS）,Adverse effects (AE),,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
5264,NCT06296056,potential efficacy,,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5265,NCT04389086,Proportion of patients with a clear resection margin,Colorectal cancer specific quality of life,,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE3']
5266,NCT00196885,"muscle cross-sectional area, peak forces",muscle 31Phospho-magnetic-resonance spectroscopy,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5267,NCT05082948,Composite of stent migration or total stent dislodgement,Length of procedure,Dysphagia,2021-07-20,RECRUITING,INTERVENTIONAL,['NA']
5268,NCT02338778,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,immunology index,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5269,NCT01262482,Progression free survival,Toxicity,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5270,NCT06277518,admitted to ICU after surgery,,,2023-09-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5271,NCT04940442,Number of patients with screening completion,,,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA']
5272,NCT02965417,Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,,,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5273,NCT00540982,Number of Participants With Grade 3 and 4 Toxicities,,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5274,NCT03747068,"to determine whether preoperative exposure to anti-TNF therapy affects histological measures of fibrosis in the rectum, as increased rectal fibrosis may be a potential factor in adverse anastomosis complications following IPAA surgery",,,2009-10-09,COMPLETED,OBSERVATIONAL,['NA']
5275,NCT05041608,Safety of procedure,Quality of Life after procedure,,2021-02-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5276,NCT02998268,Disease free survival rate,Reduction of local immune infiltration.,Association of anti-PD1 therapy with increased intra-tumoral immune cell infiltration.,2017-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5277,NCT06294808,Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment.,,,2017-07-17,COMPLETED,OBSERVATIONAL,['NA']
5278,NCT05919030,Progression-Free Survival (PFS),Number of participants experiencing Adverse Events (AEs),,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
5279,NCT06022887,Acceptability of the study,Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region,,2023-10-18,RECRUITING,INTERVENTIONAL,['NA']
5280,NCT01833637,"Trend perceived symptom burden and quality of life in our female patients with advanced gynecologic, breast, thoracic, or gastrointestinal malignancies.",Assess level of understanding about advance care planning in both the control and intervention group.,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5281,NCT00291785,"Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity",,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5282,NCT01455831,Disease Free Survival,Other post-operative (day 0 - day 28) complications,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5283,NCT02772575,response,,,2016-04,WITHDRAWN,OBSERVATIONAL,['NA']
5284,NCT04489368,"Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy",,,2020-01-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5285,NCT05646511,Organ-preservation adapted DFS,Proportion of radical resection in salvage surgery cases in the NOM subgroup,Artificial Intelligence (AI) (deep learning) analysis,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3']
5286,NCT02321969,Recurrence/Number/Size of metachronous colorectal adenoma(s),Adverse effect(s) of GTE supplementation,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
5287,NCT06123338,Pathological Complete Response Rate (pCR),,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5288,NCT00058474,Loco-regional disease control as assessed by evidence of tumor at 3 years,Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis,,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
5289,NCT06259058,R0 resection rate,Incidence of adverse events,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5290,NCT04673448,Best objective response,Overall survival,,2021-10-18,RECRUITING,INTERVENTIONAL,['PHASE1']
5291,NCT03706326,Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0,Median CAR-T cell persistence,,2018-09-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5292,NCT02965248,peritoneal metastasis rate,Toxicity by NCI CTCAE v.4.0,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5293,NCT00085410,Objective Response Rate,Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5294,NCT00087503,To assess the antitumor activity of edotecarin by repeating radiographic assessments at 6-week intervals for all patients.,Blood samples for PK evaluation will be collected during Cycles 1 and 2 and limited to the patients included in the first stage of the study.,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5295,NCT00032344,"Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA",Phase III: Medical outcomes including mortality. Colonoscopy outcomes in subgroup of polyp free patient at baseline to determine long term risk.,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5296,NCT03956056,Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events,Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry,,2020-02-13,TERMINATED,INTERVENTIONAL,['PHASE1']
5297,NCT00789763,TO DETERMINE MTD,RESPONSE (ACCORDING TO RECIST),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5298,NCT04821778,Overall survival,Distant metastasis free survival,Radiomics analysis,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
5299,NCT02319356,maximal oxygen uptake (VO2Max),,,2015-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
5300,NCT02796820,Disease-free survival (DFS),Metastasis-free survival (MFS),The adverse events of Huaier Granule,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
5301,NCT00516165,Progression-free Survival Rate at 24 Weeks,Overall Survival,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5302,NCT03677050,Boston Bowel Preparation Score,Adenoma detection rate,,2018-09-14,COMPLETED,INTERVENTIONAL,['NA']
5303,NCT03254511,R staging (residual of tumor),heparin induced thrombocytopenia,,2016-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
5304,NCT03785210,Best Overall Response (BOR),Overall Survival (OS) of Nivolumab Combined With Oral Vancomycin and Tadalafil in Participants With Refractory Hepatocellular Carcinoma (HCC) or Liver Dominant Metastatic Cancer From Colorectal Cancer or Pancreatic Ductal Adenocarcinoma (PDAC),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5305,NCT05276791,Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.,Additional histopathologic evaluation may be performed to evaluate potential differences between the two techniques.,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5306,NCT04729283,LARS score,IIEF5,,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA']
5307,NCT04425122,Microbiological culture from biopsy specimens,Overall survival,,2020-07-01,RECRUITING,OBSERVATIONAL,['NA']
5308,NCT03419247,Number of participants with gene testing data available at 8 weeks from baseline tumor biopsy.,"Potential predictive biomarkers of response to treatment such as BRCA, PALB2 and ATM mutations.",,2020-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
5309,NCT02736500,toxicity rate,Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET,,2015-09-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5310,NCT00116935,Recurrence-free survival,GIST-specific survival,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5311,NCT00114946,"To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.",To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.,,2005-05,TERMINATED,INTERVENTIONAL,['PHASE4']
5312,NCT05622071,Objective Response Rate,Quality of life questionnaire - Hepatocellular Carcinoma (QLQ-HCC-18),,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE2']
5313,NCT05395910,Safety Profile of PIPAC/ePIPAC with Paclitaxel by monitoring adverse events,Area under the curve (AUC) of Paclitaxel administered via PIPAC/ePIPAC using blood drawn from patient.,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE1']
5314,NCT04985604,Phase 2: Evaluate the efficacy of tovorafenib monotherapy or in combination with other therapies,"Phase 2: Assess the safety and tolerability of tovorafenib as monotherapy, or in combination with other therapies",,2021-07-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5315,NCT04531228,progression-free survival,adverse effects,,2020-10-11,UNKNOWN,INTERVENTIONAL,['NA']
5316,NCT05375708,Progression-free survival,Depth of response,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5317,NCT02192333,"Mean of the two z scores of the two highest scores for the symptoms that determined the participant's eligibility as ""high need"" assessed using patient-reported outcomes (PRO) survey",Social support assessed using the patient-reported outcomes (PRO) survey,,2015-08-03,COMPLETED,INTERVENTIONAL,['NA']
5318,NCT00837135,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",,,2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5319,NCT03468244,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Overall Survival of Personalized mRNA Tumor Vaccine,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
5320,NCT04249622,"Reduction rate of >= grade 2 abdominal toxicities including abdominal distension, abdominal pain, diarrhea, dyspepsia, stomach pain, and typhlitis","Other pertuzumab induced gastrointestinal toxicities (PIGT) such as abdominal pain, bloating and flatulence","Difference in the fecal microbiome, hydrogen breath test, and permeability test",2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5321,NCT01570166,overall survival,disease-free survival,,2011-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5322,NCT03109938,Diagnostic Accuracies,,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
5323,NCT03125343,3-year disease free survival.,Health economic evaluation,,2017-01,RECRUITING,INTERVENTIONAL,['NA']
5324,NCT04848753,To compare IRC-assessed events-free survival (EFS) in 2 arms,5- year OS rate,,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5325,NCT03020342,vh-chimera DNA,recurrence-free survival time ----measurement in weeks,current HCC marker (AFP ng/ml),2016-05,UNKNOWN,OBSERVATIONAL,['NA']
5326,NCT06001658,Average minimum Euclidean distance from CD8+ T cells to immunosuppressive tumor-associated macrophages (TAMs) at the per-cell level in patients with a major pathologic response versus pathologic non-responders.,R0 resection rate,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5327,NCT04323722,Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment,IMRT (Intensity-Modulated Radiotherapy) dosimetric study in patients with filled or empty bladder,,2020-09-08,RECRUITING,INTERVENTIONAL,['NA']
5328,NCT02393703,successful isolation of exosomes,evaluation of the liver microenvironment,,2015-03,RECRUITING,OBSERVATIONAL,['NA']
5329,NCT04390945,Progression-free survival，PFS,"Objective Response Rate, ORR",,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5330,NCT01311050,,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
5331,NCT00628784,"Confirm the feasibility and safety of endoscopic cryotherapy in patients with Barrett's esophagus with LGD, HGD, intramucosal cancer and in patients with severe squamous dysplasia.","Assess the incidence of side effects, complications, adverse events and number of treatment sessions needed to reach primary endpoints.",,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5332,NCT05398822,Local recurrence of rectal cancer,,,2019-07-18,COMPLETED,OBSERVATIONAL,['NA']
5333,NCT00005076,Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.,Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5334,NCT01511146,"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.","Progression free survival, adverse events",,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
5335,NCT00242723,"permit evaluation of patients referred to the Thoracic Surgery Branch, NCI in order to identify individuals who will be suitable candidates for treatment/intervention protocols",,,2005-11-09,RECRUITING,OBSERVATIONAL,['NA']
5336,NCT00217568,Overall survival,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5337,NCT02561494,Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day,Change of the pain score from postoperative 6 h to postoperative 5 day,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5338,NCT06087718,Clinical feasibility of the Maastro boosting technique.,Complications within the first 30 days after completion of salvage total mesorectal excision (TME) surgery up to 3 years after treatment.,Collecting 3D ultrasound measurements of the gross tumor volume (GTV) and intestinal wall layers at every fraction of Maastro applicator brachytherapy.,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5339,NCT03570502,Postoperative pancreatic fistula according the 2016 update of the International Study Group (ISGPS),Diabetes,,2016-11,UNKNOWN,OBSERVATIONAL,['NA']
5340,NCT01813253,Overall Survival,Incidence of adverse events,,2013-05-13,TERMINATED,INTERVENTIONAL,['PHASE3']
5341,NCT02896803,Response rate,Toxicities according CTCAE v4.03,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5342,NCT04076631,Pathological stage of liver cirrhosis,The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF),,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
5343,NCT04188990,Mortality rate,Patient's functional status,,2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
5344,NCT03782428,"Level of circulating inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL17C &IL-22) pre and post intervention.",Number of patients with chemotherapy induced diarrhoea assessed by CTCAE v3.0,,2016-08-26,COMPLETED,INTERVENTIONAL,['NA']
5345,NCT04214990,The incidence of gastric cancer between the intervention and placebo groups,Improvement of atrophy and intestinal metaplasia,,2020-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
5346,NCT02862587,Progress-free survival,Quality of life,,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5347,NCT02657850,Change in rate of dysphagia symptoms,change in rate of secondary treatment side effect,,2016-06-09,WITHDRAWN,OBSERVATIONAL,['NA']
5348,NCT01164202,Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure,Disease-free Survival,,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5349,NCT05485077,Negative predictive value and positive predictive value of polygene methylation in colorectal cancer,,,2022-07-09,RECRUITING,OBSERVATIONAL,['NA']
5350,NCT01477866,All cause mortality,,,na,SUSPENDED,INTERVENTIONAL,['NA']
5351,NCT03204019,Objective Response Rate(ORR),Progression free survival(PFS),,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
5352,NCT02089763,Time to progression (TTP),Safety profile of PEG-BCT-100 treatment,"Biomarker study - to explore the predictive and prognostic functions of tissue biomarkers, ornithine transcarbamylase (OTC) and arginine succinate synthetase (ASS)",2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5353,NCT04868877,To evaluate the ORR of MCLA-129 alone or in combination with Osimertinib in molecularly defined populations of advanced/metastatic solid tumors.,Proportion of patient with treatment discontinuations,,2021-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5354,NCT02373020,"virulence genes: eaeA, bfpA and stx. PCR",Strains: OF E COLI,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
5355,NCT05673343,disease free-survival,overall survival (OS,,2023-01-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5356,NCT03567850,Healthcare Utilization of Patients,,,2018-10-19,COMPLETED,INTERVENTIONAL,['NA']
5357,NCT02648282,Distant Metastasis Free Survival (DMFS),Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities,,2016-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5358,NCT03418948,Adenoma miss rate (%),To compare patient reported outcomes e.g. pain,,2017-12-08,UNKNOWN,INTERVENTIONAL,['NA']
5359,NCT01294202,Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria,"Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5360,NCT04673955,Overall Survival,Duration of treatment interruptions,,2020-09-03,RECRUITING,OBSERVATIONAL,['NA']
5361,NCT05313906,ORR,DCR,,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5362,NCT01461057,Number of Participants With Adverse Events (AEs),,,2011-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5363,NCT02370498,Overall Survival (OS) in PD-L1 Positive Participants,Percentage of All Participants That Discontinued Study Treatment Due to AE,,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5364,NCT04695184,anastomotic leak,Length of post-operative hospital stay,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
5365,NCT00737802,Pressure at the gastric sling and clasp fibers,,,2013-04-12,TERMINATED,OBSERVATIONAL,['NA']
5366,NCT03079427,2-year disease-free survival,Overall survival,,2017-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
5367,NCT06322563,SAE-Safety and Tolerability,OS,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5368,NCT01717066,time to recurrence,overall survival,side effect,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5369,NCT04192734,Incidence of adverse events,Adverse events of special interest,,2019-12-18,COMPLETED,OBSERVATIONAL,['NA']
5370,NCT04514835,Progression-free survival（PFS）,Objective Response Rate，ORR,Exploratory analysis of biomarkers for predicting efficacy,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5371,NCT03289533,Number of Participants With Abnormal Laboratory Parameter Values (Chemistry) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version (v) 4.03,Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Positive Neutralizing Antibodies (nAbs),,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5372,NCT03030937,Adverse Event（AE）,Quality of Life (QoL),,2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5373,NCT00093782,Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria),Time to Progression,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5374,NCT01985958,Number of Participants With Adverse Events,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
5375,NCT01105650,Response Rate,Overall Survival,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5376,NCT00006366,,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5377,NCT03484000,Fatigue,,,2018-06-01,RECRUITING,INTERVENTIONAL,['NA']
5378,NCT00858858,Protection Against DNA Damage by UDCA,,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
5379,NCT04392479,Overall response rate (ORR).,Exploratory biomarkers,,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5380,NCT00826982,To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.,To determine the degree of RNA overexpression of pancreas cancer specific biomarkers in the pre-operative fine needle aspirate of lymph nodes and tumors of patients with pancreatic cancer using a set of pancreas cancer specific biomarkers,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
5381,NCT05768178,Durable Clinical Benefit (DCB),EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC),,2023-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5382,NCT03767517,Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]),Patient satisfaction with care (Feeling Heard and Understood),Exploratory Aim 1f. Caregiver bereavement (Caregiver Bereavement Items ([CBI]),2020-08-24,COMPLETED,INTERVENTIONAL,['NA']
5383,NCT00325078,Efficacy of Treatment With Study Drug,,Gut Immune Cell Types and Their Cytokine Profile,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5384,NCT03309917,Change in internal carotid artery blood flow when mean arterial pressure (MAP) is set to 80-85 and 60-65 mmHg,Comparison of the slope of linear regression of MAP and internal carotid artery blood flow for the evaluations when MAP is set to 80-85 and 70-75 mmHg and that of the evaluations when MAP is set to 70-75 and 60-65 mmHg,,2017-12-27,COMPLETED,INTERVENTIONAL,['NA']
5385,NCT04631731,"Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.","Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs.",,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5386,NCT02819869,relapse-free survival of hepatocellular carcinoma patients,,,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5387,NCT02912052,Disease free survival，DFS,Overall survival,number of lymph nodes retrieved,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5388,NCT02558205,Correlation of CT perfusion metrics to radiation dose deposition of Y-90 as measured by PET/CT,Correlation between CT perfusion metrics and post treatment response as measured by RECIST 1.0 criteria,,2015-07,WITHDRAWN,OBSERVATIONAL,['NA']
5389,NCT01683864,Disease Free Survival,,Kinetics of Mitomycin and Cisplatin,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5390,NCT03428074,Overall survivals in patients with esophageal cancer who received surgeries,Death rates within 30 days after surgeries,Extents of lymph metastases,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
5391,NCT04150874,Number of Participants with Early Tumor Response,Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD),,2020-02-19,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5392,NCT06287814,3-year disease-free survival (DFS),Time to molecular recurrence,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5393,NCT05512377,Objective response (OR),Change from baseline in EORTC QLQ-BIL21 tiredness domain score,,2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE2']
5394,NCT05765214,CRC-KPSS change and screening uptake,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
5395,NCT01061515,Overall survival,,,2011-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5396,NCT00021047,,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5397,NCT00290719,Pathological response (complete and partial) post-operatively,Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE1']
5398,NCT00012324,Overall survival,Response to treatment in patients with and without prior therapy,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5399,NCT02616926,overall survival,disease free survival,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
5400,NCT02813096,early recurrence,overall survival,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
5401,NCT05047991,Progression-Free Survival (PFS),UGT1A1,,2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5402,NCT03511963,PFSR9m,SAE,Ctrough,2018-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5403,NCT04821258,Rate of complications.,Quality of life assessment.,,2021-04,UNKNOWN,INTERVENTIONAL,['NA']
5404,NCT00962312,6-month survival rate,Tumour biomarker analysis,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5405,NCT01642797,number of participant with gastric IM/IN/CA,number of biopsies needed per patient,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
5406,NCT01438645,Sedation Score,Ancillary maneuvers to facilitate procedure,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
5407,NCT05942560,Change in anxiety symptoms at 12 months,Overall survival,,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5408,NCT05692024,Change in hepatic fat fraction.,Change in liver fibrosis assessment and plasma levels of liver enzymes,Change in stool metabolomics,2024-03-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5409,NCT04752930,Peritoneal Metastasis Free Survival (PMFS),The Overall Survival (OS) at 3 years after radical resection of colorectal cancer,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
5410,NCT04923932,Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria),incidence of various adverse events (AE),,2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
5411,NCT00086996,Pathological Complete Response,Progression-free Survival,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5412,NCT05155124,Incidence of DLT（Dose-limited toxicity）,Adverse Eevents,,2022-09,RECRUITING,INTERVENTIONAL,['PHASE1']
5413,NCT00261378,Objective response rate measured according to RECIST and EASL,Time To Progression,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5414,NCT05536102,Pathological complete remission rate,3-year PFS rate,Adverse events (AEs),2022-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
5415,NCT05520788,Progression-free survival (PFS),Quality of Life (QoL) after treatment,,2020-05-01,RECRUITING,OBSERVATIONAL,['NA']
5416,NCT03148093,Reasons for dose adjustments and/or discontinuation of treatments,Burden for caregivers providing support to patients enrolled in the registry per Modified Caregiver Strain Index (MCSI),Progression free survival,2017-06-30,TERMINATED,OBSERVATIONAL,['NA']
5417,NCT05465993,recurrence rate,Incremental cost-effectiveness ratios (ICERs),,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
5418,NCT04021277,Number of patients with adverse device effects,Best overall response (Part 1b only),,2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE1']
5419,NCT02226289,Response rate,Progression free survival,,2020-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
5420,NCT05020132,Change in the Bristol stool chart between baseline and 12 months,Multivariate analysis of risk factors for LARS,,2015-11-01,COMPLETED,OBSERVATIONAL,['NA']
5421,NCT03732768,Maximum Tolerated Dose (MTD),,,2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1']
5422,NCT04976439,Description of survival,,,2021-05-01,COMPLETED,OBSERVATIONAL,['NA']
5423,NCT04478175,Program faisability,Patient's satisfaction measured by VAS,,2021-04-29,COMPLETED,INTERVENTIONAL,['NA']
5424,NCT03007225,Number of Participants With Complete Response,,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5425,NCT02976909,R0 resection rate,Adverse envents,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5426,NCT02466009,Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability.,Subject's Quality of Life as Assessed by the Comprehensive Geriatric Assessment Form While Receiving Study Treatment.,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5427,NCT03762837,Gallbladder cancer,,,2019-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5428,NCT04923646,Return proportion,Return proportion,,2021-06-30,COMPLETED,INTERVENTIONAL,['NA']
5429,NCT06012734,The RP2D of LB-100 when given in combination with standard doses of atezolizumab,The incidence of dose-limiting toxicity,Concentration of LB-100 and endothall in tumor tissue,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5430,NCT03572400,Disease-free survival rate,Disease control rate,,2018-11-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
5431,NCT05828875,Quality of Life Assessment survey,,,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5432,NCT00003216,,,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5433,NCT04801511,PCR rate,2-year disease-free survival rate,,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
5434,NCT05907642,Low Anterior Resection Syndrome Questionnaire Score,The European Organization for Research and Treatment of Cancer quality of life questionnaire c-30,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
5435,NCT01290783,Progression Free Survival (PFS),Safety,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
5436,NCT03843957,Percent of Patients Who Complete the mPATH-CRC Program,mPATH-CheckIn Feasibility,,2019-10-31,COMPLETED,INTERVENTIONAL,['NA']
5437,NCT00207831,Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone,Compare overall survival,,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
5438,NCT00006115,,,,1999-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
5439,NCT04955730,Surgical Site Infection - Organ/Space Incisional,Time to Initiation of Planned Oncologic Therapy,,2021-08-05,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5440,NCT01063192,The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.,"The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy .",,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
5441,NCT00030797,,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5442,NCT04477343,Maximum tolerable dose [Safety and Tolerability],Overall Survival,,2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1']
5443,NCT00005586,All-cause mortality,Disease recurrence,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5444,NCT06281405,Complete response (CR) rate,Rate of surgical complications,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5445,NCT06218433,Sensitivity and specificity of positive utDNA for urothelial cancer within one year of follow-up,Urothelial cancer grade,Cost of utDNA screening,2023-04-10,RECRUITING,INTERVENTIONAL,['NA']
5446,NCT01555801,Diagnostic accuracy,,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
5447,NCT01339273,Morphine Consumption in the First 48hours After the Operation,Time to Hospital Discharge,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
5448,NCT00001240,,,,1989-01,COMPLETED,OBSERVATIONAL,['NA']
5449,NCT02611024,Response Rate,Overall Survival,,2016-05-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5450,NCT02979470,progression free survival,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
5451,NCT04728321,Objective response rate (ORR),Number of participants with adverse events (AEs),,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5452,NCT02156557,Validation of binding of peptide,,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5453,NCT05722288,Percentage of patients completing 4 weeks of time-restricted eating during RT,Oxidative DNA damage,,2023-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
5454,NCT06115629,All-cause mortality,Fear of cancer recurrence as determined by the cancer worry scale score,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5455,NCT00010166,,,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5456,NCT00129870,Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule,Reasons for treatment discontinuation,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4']
5457,NCT05270889,Overall Response,,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5458,NCT02945878,gradings of oral mucositis,,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
5459,NCT00003439,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5460,NCT00290316,To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.,2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.,,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
5461,NCT02567942,natural killer cell activity,helper T cell activity,change of percentage of CD39 and CD73,2016-02,COMPLETED,INTERVENTIONAL,['NA']
5462,NCT05051670,major complication,Hospital stay,,2021-12-16,COMPLETED,INTERVENTIONAL,['NA']
5463,NCT00059891,Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.,"Determine continence, bowel function, and quality of life of patients treated with this surgery.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
5464,NCT03719716,Health related quality of life: EuroQol EQ-5D-5L,Trial feasibility assessment: conversion rate,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
5465,NCT01202409,Response Rate (RR),Overall Progression-free Survival (PFS) for CAPOX and Panitumumab,,2010-11-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5466,NCT00557024,Overall survivals,Recurrence rates,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
5467,NCT02845258,Repeated drainage frequency,Long time complication rate,,2006-01,RECRUITING,OBSERVATIONAL,['NA']
5468,NCT00503867,Number of Participants With Adverse Events Grade 3 or Higher,Overall Survival,,2007-07-18,TERMINATED,INTERVENTIONAL,['NA']
5469,NCT05257863,Development of a preoperative score for morbidity/mortality in colorectal surgery,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
5470,NCT01233713,Overall post-operative complication rate defined according to the Clavien-Dindo Classification,In-hospital costs,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5471,NCT02723942,Radiological assessment,CAR-T cell testing,,2015-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5472,NCT00752063,Progression-free survival,"Tumor response rate, overall survival and safety of the regimen in HCC patients",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
5473,NCT01683357,feasibility on an intention-to-treat basis,safety of the procedure,reliability of the procedure from an oncological standpoint,2001-09,COMPLETED,OBSERVATIONAL,['NA']
5474,NCT04824053,"Change from baseline levels in pro-inflammatory circulating markers C-reactive protein (CRP), interleukin (IL)-6, macrophage inhibitory cytokine 1 (MIC-1) and tumour necrosis factor alpha (TNFα), as well as in fecal calprotectin.",To assess the effect of treatment on colorectal adenoma recurrence,,2022-02-28,RECRUITING,INTERVENTIONAL,['NA']
5475,NCT02632006,Overall survival,Quality of life,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5476,NCT05871164,Carcinological efficacy of pancreatic radiofrequency,,,2023-06-12,RECRUITING,OBSERVATIONAL,['NA']
5477,NCT01930435,Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.,Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
5478,NCT00940030,"Anastomotic leakage, wound infection (including deep abscess)",patient's symptoms (through questionaire),,2007-10,COMPLETED,INTERVENTIONAL,['NA']
5479,NCT03963544,Overall survival (OS),,,1990-01,RECRUITING,OBSERVATIONAL,['NA']
5480,NCT00227747,Rate of complete surgical resection,Acute and late toxicity,,2005-11-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5481,NCT01209013,Incidence of esophageal stenosis,Measure oligomer concentrations,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5482,NCT00372450,Change in health-related quality of life from baseline to 30 days and 3 months after self-expanding plastic stent or self-expanding metal stent placement,Overall rate of mortality,,2006-12,WITHDRAWN,INTERVENTIONAL,['NA']
5483,NCT04148378,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,Validation of Sequencing Methods,,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA']
5484,NCT06313970,Objective response rate (ORR),Adverse Events,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5485,NCT00087191,Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,,,2004-05,TERMINATED,INTERVENTIONAL,['NA']
5486,NCT05715255,Change in reported PRO-CTCAE Symptoms,Change in unscheduled health care visits,,2023-05-08,RECRUITING,INTERVENTIONAL,['NA']
5487,NCT01807117,Negative Predictive Values for PET-CT and PET-MRI,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
5488,NCT00566644,Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study,,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3']
5489,NCT03717402,Frequency of Symptom Survey Completion,Usability,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
5490,NCT03035006,Best objective response evaluation of portal vein tumor thrombosis,Overall survival of overall disease,,2017-04-14,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5491,NCT04098237,Feasibility of completing pancreatic enzyme replacement therapy during the first 8 weeks of the study: daily compliance diary,Mean change in daily active minutes from baseline,,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2']
5492,NCT05902533,Assess patient reported GI toxicity using PRO-CTCAE Diarrhea,Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed.,,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5493,NCT04857203,The Role of Vitamin D in response to neoadjuvant therapy for the patients with locally advanced rectal cancer,,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
5494,NCT02403050,Intra- and inter-observer variability of tumor target volume (cubic centimetres) estimation,local recurrence of tumor,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
5495,NCT06055166,PFS rate,AEs,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5496,NCT05773248,Perioperative morbidity,Readmission rate,,2023-03-13,COMPLETED,OBSERVATIONAL,['NA']
5497,NCT05235932,3-year disease free survival rate,inflammatory immune response,,2022-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5498,NCT03658837,Quantitative Assessment using EORTC QLQ-OES-24,Qualitative analysis,,2019-01-03,COMPLETED,OBSERVATIONAL,['NA']
5499,NCT00681577,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),To evaluate immunological responses,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5500,NCT02174549,Overall Response rate (ORR) by RECIST,Duration of Response,Progressive Free Survival,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5501,NCT04769414,Overall response rate (ORR),Overall survival (OS),,2021-02-20,COMPLETED,INTERVENTIONAL,['PHASE2']
5502,NCT03311789,The percentage of patients alive and without progression at 6 months,List of adverse event frequency and grade,,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5503,NCT00026234,Survival rate,Adverse events as assessed by NCI CTC version 2.0,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5504,NCT05673434,Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),CAR-T cell testing,,2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5505,NCT03535727,Progression-free Survival (PFS) Using RECIST 1.1 Criteria,"Safety of the Combination of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Patients With Untreated Metastatic PDA.",,2018-06-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5506,NCT00251355,To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.,to obtain a preliminary assessment of the efficacy of this regimen in this patient population.,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5507,NCT02076594,Progression Free Survival (PFS),"Tolerability of the treatments evaluated in term of occurrence of: side effects graded according to the NCI-CTCAE scale (version 4.0); serious adverse reactions, expected and unexpected",,2013-01,TERMINATED,INTERVENTIONAL,['PHASE3']
5508,NCT00445497,Incidence of serious adverse events (randomized and registered patients),Health service costs (randomized patients),,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
5509,NCT00852228,Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.,The per-operative and post-operative complications associated to liver surgery,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
5510,NCT01910974,SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE,,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
5511,NCT00955344,Colorectal Cancer Screening Rates,Content of practice improvement plan,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
5512,NCT05429866,Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.,,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5513,NCT05280665,30-day mortality,Hospital stay,Neoadjuvant treatment usage,2022-02-14,COMPLETED,OBSERVATIONAL,['NA']
5514,NCT01698710,Frequency of Pancreatitis,Size of Cystic Lesion,,2012-11,TERMINATED,INTERVENTIONAL,['NA']
5515,NCT00012363,6-month survival rate,Toxicities,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5516,NCT06117891,Overall survival (OS),Treatment sequences post first-line AB or other IO combinations,,2023-11-27,RECRUITING,OBSERVATIONAL,['NA']
5517,NCT01547845,PRO symptom measurement,,,2012-02-10,COMPLETED,OBSERVATIONAL,['NA']
5518,NCT03660449,Progression-Free Survival,rate of grade 3-4 radiation pneumonitis,,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5519,NCT05575622,"CTC-PD-L1, exosomal PD-L1, and exosomal LAG-3",,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
5520,NCT05254171,Overall Survival (OS),Progression Free Survival (PFS),Exploratory,2022-08-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5521,NCT00416767,,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5522,NCT05970666,Occurence of AE and SAE,Overall survival（OS）,,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE2']
5523,NCT03766659,Diagnostic yield,morbidity rate,,2019-06-19,RECRUITING,INTERVENTIONAL,['NA']
5524,NCT03331562,Progression- Free Survival at 6 Months From Initiation of Trial Treatment,Cellular VDR Targets in the Immune Microenvironment With PD1 Blockade,Exploratory: Monitor and Compare the Gut Microbial Communities in Both Arms of the Trial,2017-12-27,COMPLETED,INTERVENTIONAL,['PHASE2']
5525,NCT01519817,Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine,Changes in Soluble Cluster of Differentiation 40L (sCD40L),,2012-01-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5526,NCT04191421,Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab,Overall survival time,,2020-01-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5527,NCT06057831,Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.,A feasibility study done to evaluate the benefit of using PET/MRI with respect to improved identification of the target and hence target delineation,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5528,NCT00813605,Progression Free Survival,Incidence of antibody formation,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5529,NCT00364013,Progression-free Survival,Number of Participants With Adverse Events (AEs),,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5530,NCT02843802,Relief degree,Overall survival（OS）,,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5531,NCT05233436,Objective response rate (ORR) in Dose Expansion (Part 2),Time to event endpoints (OS) in Dose Expansion (Part 2),,2022-02-24,TERMINATED,INTERVENTIONAL,['PHASE1']
5532,NCT00797485,Time to failure of strategy,"Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment",,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
5533,NCT05500157,PLD-Q 4 weeks,Cost-effectiveness iMCQ,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
5534,NCT02217020,The ratio of tumor downstaging to stage 0 and stage I,Reported Adverse events,,2014-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
5535,NCT03113604,"Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib",,,2015-11-20,WITHDRAWN,OBSERVATIONAL,['NA']
5536,NCT00942461,Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5537,NCT02150746,Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells,,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5538,NCT01639443,Percentage of GI Clinic Capacity Filled,Cost Comparisons,,2013-07-08,COMPLETED,INTERVENTIONAL,['NA']
5539,NCT03743428,Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis,Overall Survival (OS),,2020-10-22,SUSPENDED,INTERVENTIONAL,['NA']
5540,NCT00870558,Tumor recurrence at 2 years,,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5541,NCT02355249,The incidence of respiratory complications,Health-related quality of life scores（HRQoL）,blood biomarker analysis,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
5542,NCT02956772,Progression free survival,Incidence of adverse events,Quality of life using EuroQol five dimensions five levels questionnaire,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
5543,NCT05850884,evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals,,,2023-11-30,RECRUITING,OBSERVATIONAL,['NA']
5544,NCT00997802,sensitivity in the detection of colorectal polyps and cancers in CTC,specificity and predictive values in the detection of colorectal polyps and cancers in CTC.,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5545,NCT01875549,Stent patency,survival period,complication,2013-05,WITHDRAWN,INTERVENTIONAL,['NA']
5546,NCT05238922,Number of Participants Discontinue study due to TEAE,Duration of Response (DOR),,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE1']
5547,NCT03210064,ORR,QoL,,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
5548,NCT06143579,Overall response rate (ORR),Overall survival (OS),,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5549,NCT02016274,progression free survival,overall survival,quality of life,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
5550,NCT02701088,Tolerance profile: Proportion of patients with no significant toxicities responsible for irradiation breaks,The acute and late toxicities assessed according the SOMA/LENT scale,,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5551,NCT03088423,tumor response assessments,,,2011-10-01,COMPLETED,OBSERVATIONAL,['NA']
5552,NCT05424432,Pathologic complete response,Health related quality of Life related to esophageal carcinoma,,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE2']
5553,NCT02191761,Determine the MTD,Total Clearance of SM04755 after oral administration,,2014-06-19,COMPLETED,INTERVENTIONAL,['PHASE1']
5554,NCT05929820,Rate of completion of a CRC screening test,Qualitative feedback on details of CRC screening test,,2023-09-15,RECRUITING,INTERVENTIONAL,['NA']
5555,NCT04744792,Disability of patients and spouses,,,2006-03-01,COMPLETED,OBSERVATIONAL,['NA']
5556,NCT01627808,Stroke volume variation,Stroke volume variation,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
5557,NCT06253520,Safety,Safety,,2024-04-07,RECRUITING,INTERVENTIONAL,['PHASE1']
5558,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,Number of Open Tests,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
5559,NCT04147481,Incidence of postoperative chronic pain,Gastrointestinal decompression,The numeric rating scale of postoperative pain,2019-10-21,UNKNOWN,INTERVENTIONAL,['NA']
5560,NCT03260179,AE,PFS,Exosomes,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE1']
5561,NCT03427814,Progression Free Survival (PFS) by Investigator Assessment,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5562,NCT00003260,,,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5563,NCT00620295,Maximum tolerated dose of bortezomib and gemcitabine,"Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5564,NCT05692596,Database creation,,,2022-10-06,RECRUITING,OBSERVATIONAL,['NA']
5565,NCT02475499,Incident pancreatic cancer,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
5566,NCT01543620,,,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
5567,NCT04235114,The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.,Lesion detection rate of FDG PET/CT compared with 89Zr-DFO-nimotuzumab in patients with EGFR-positive (by IHC) lung and colorectal cancers using PET/CT.,,2020-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5568,NCT04859582,Overall Survival (OS),Percentage of Participants Discontinuing Study Drug Due to AEs,,2018-11-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5569,NCT05584592,Changes in patient's comprehensive quality of life composite,"Skeletal muscle mass index (Skeletal muscle mass index, SMI) changes",,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
5570,NCT00532740,,,,2004-12,COMPLETED,OBSERVATIONAL,['NA']
5571,NCT00921869,Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT),"Best overall tumor response, duration of response and stable disease, assessed by Response Evaluation Criteria in Solid Tumors.",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5572,NCT02650661,Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal,Cost effectiveness analysis,,2015-11-23,COMPLETED,INTERVENTIONAL,['NA']
5573,NCT00728585,Incidence of WHO grade 3 or 4 oral mucositis,Incidence of febrile neutropenia and invasive bacterial infections,,2008-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5574,NCT06247956,ORR based on RECIST v1.1 assessment.,DCR based on RECIST v1.1 assessment,,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2']
5575,NCT05418387,Acceptability of the intervention,Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group,,2022-09-30,WITHDRAWN,INTERVENTIONAL,['NA']
5576,NCT03077685,Incidence of Treatment Emergent Adverse Events (safety and tolerability),Change in tumor markers,,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5577,NCT00112099,Overall survival,perioperative blood loss,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5578,NCT04798560,Development of Postoperative pancreatic fistula after pancreaticoduodenectomy,Overall survival,,2018-10-10,UNKNOWN,OBSERVATIONAL,['NA']
5579,NCT00876551,Closure of postsurgical leak,C reactive protein,,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
5580,NCT00851136,Incidence and nature of dose-limiting toxicities,Incidence of anti-PRO95780 antibodies,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5581,NCT05262491,Phase Ib: Recommended Phase II Dose (RP2D),Progression-free Survival (PFS),,2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE1']
5582,NCT05012007,Percentage of returned FIT Kits,Percentage of returned FIT Kits,Interim analysis,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
5583,NCT02756455,% of patients without leaks after gastric surgery correctly identified by PCT and CRP,PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD,,2015-01,UNKNOWN,OBSERVATIONAL,['NA']
5584,NCT05916001,Surgical site infection (SSI),Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT),,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5585,NCT02000999,"• Sensitivity accuracy of cytology, FISH and mutation profiling using histologic diagnosis in conjunction with clinical and/or imaging follow-up as the gold standard.",• Technical success and ease of procedure,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
5586,NCT01126450,"Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)","Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)",,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1']
5587,NCT02191878,Maximum tolerated dose (MTD),Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort,Assessment of Pharmacodynamic Effect,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5588,NCT05304234,Feasibility of screening protocol,,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5589,NCT03275987,screening mammography or colonoscopy,,,2014-04-23,COMPLETED,INTERVENTIONAL,['NA']
5590,NCT05549960,Feasibility of pre-planned laser setting in lesion ablation,Rate of resectability,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
5591,NCT02236884,Composite mesure of prioperative feasibility and safety,Composite mesure of oncological outcome,,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5592,NCT01668680,"Length of progression free survival (PFS), measured in months.","Quality of life, as expressed by FACT-C.",,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2']
5593,NCT00278876,2-year Relapse Free Survival Rate,Toxicity Profile,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5594,NCT01613950,Incidence rate of Dose Limiting Toxicities.,Severity of adverse events (AEs),,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5595,NCT02508532,"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1","KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT",,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5596,NCT04454762,Blood pressure [Safety and Tolerability],Health-related quality of life (HRQOL),,2020-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
5597,NCT00075868,"Prevention of the incidence of moderate, severe, or life-threatening diarrhea","Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5598,NCT01677468,Survival rate of the subjects,Complication rate of TACE,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
5599,NCT00151476,Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA,Rectal or Pouch Adenoma Burden Based on Polyp Counts,,2004-11,TERMINATED,OBSERVATIONAL,['NA']
5600,NCT05504265,Postoperative pain score,Rate of pulmonary infection,,2022-08-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5601,NCT05628545,Overall Survival,PFS（Progression-Free Survival ),,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5602,NCT03342937,Months of Progression-free Survival (PFS),Months of Overall Survival,,2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5603,NCT05709249,Two-year disease-free survival (DFS),Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM),,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
5604,NCT01689792,Polyp detection rate,Acceptability and tolerability of medication using patient questionnaires,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5605,NCT00718562,Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib,PK profile,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5606,NCT03467308,Measure TRIM59 in the study groups.,Targeting new prognostic and therapeutic markers for colorectal cancer.,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
5607,NCT03760614,Dose limiting toxicity (DLT),Overall response rate (ORR),,2021-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5608,NCT01165346,non-progression part,Medical costs,,2009-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
5609,NCT03707080,Time to HCC recurrence - Prospective Cohort,Number of events of early HCC recurrence - Prospective Cohort relative to Historical Cohort,,2018-03-09,COMPLETED,OBSERVATIONAL,['NA']
5610,NCT02439385,Progression-free survival,"Fatigue (FACIT-Fatigue scale (version 4, Korean version)",,2015-08-24,COMPLETED,INTERVENTIONAL,['PHASE2']
5611,NCT05627297,Good/Poor overall survival,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
5612,NCT04599140,Incidence of adverse events (AEs),Overall survival (OS),Biomarker analysis,2020-10-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5613,NCT00568529,Response Rate,time to progression and overall survival,,2007-10,SUSPENDED,INTERVENTIONAL,['PHASE2']
5614,NCT04319354,Ryan tumor regression grade system (number of patients with complete/partial/no response),Number of participants with 1 and 2-year disease free recurrence,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
5615,NCT02464215,Postoperative complication rate,3-year disease free survival rate,,2014-03-01,UNKNOWN,INTERVENTIONAL,['NA']
5616,NCT03822572,Primary Endpoint - disease free survival (DFS),Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study),,2019-02-14,RECRUITING,INTERVENTIONAL,['NA']
5617,NCT04999332,Curative resection rate,Treatment-emergent adverse event rate,,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
5618,NCT00084929,Number of Participants With Advanced Adenomas (>=5mm) Detected by CT Colonoscopy (Per Patient),Interobserver Sensitivity Variability,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
5619,NCT06033482,The lymph node metastasis rates in No.12aa and No.12av groups.,,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
5620,NCT04214418,Phase 1: Estimated maximum tolerated dose (MTD),Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability),,2020-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5621,NCT01293448,Treatment effect,Post procedure pain,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
5622,NCT05920980,Pain scores of movement-evoked pain at postoperative 24 hours,plasma lidocaine concentration,,2023-06-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5623,NCT05161624,"Receiver operating characteristic curve, ROC","Area under curve, AUC",,2021-12-15,UNKNOWN,OBSERVATIONAL,['NA']
5624,NCT03066557,PFS,QoL,,2017-03-15,UNKNOWN,INTERVENTIONAL,['NA']
5625,NCT03523312,The proportion of patients who undergo definitive surgery,,,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5626,NCT03309722,distant recurrence,,,2008-10-10,RECRUITING,OBSERVATIONAL,['NA']
5627,NCT03655002,Incidence of adverse events,Overall survival,Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA),2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5628,NCT00517920,Objective Response Rate,,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5629,NCT05626569,1-year progression-free survival,Treatment-related adverse events,,2022-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
5630,NCT00003835,Survival,,,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5631,NCT01738217,"Third step: assess the rate of patients in whom, among the 7 liver segments, the surgeon will be able to selectively target a predefined area.",Third step: assess the ability of the medical device to detect tumor lesions which were previously known.,,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5632,NCT00902733,"Quality of life, psychological distress, symptom relief, geriatric assessment outcome, and resource use at 3 months",Long-term impact at 6 months,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5633,NCT01263002,Proportion of patients with HBV DNA levels < 60 IU/mL,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
5634,NCT02633020,Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes,Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12,,2016-04-13,COMPLETED,INTERVENTIONAL,['PHASE2']
5635,NCT00004103,,,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5636,NCT06161909,disease-free survival (DFS),recurrent metastasis pattern,,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5637,NCT05625737,Objective Response Rate (ORR),Adverse Event (AEs),Exploratory endpoint,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5638,NCT03895723,disease-free survival (DFS),Sugical complications,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
5639,NCT04269941,number of patients operated for gastric GIST,,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
5640,NCT01444014,Visual assessment of the distribution of gastric carcinoids.,Plasma or serum concentrations of biomarkers such as gastrin and chromogranin A (CgA),,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
5641,NCT02737228,Overall Response Rate (ORR),Clinical laboratory tests,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5642,NCT05099211,Acceptability of the program in terms of the number of sessions attended,,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5643,NCT00216034,Time of recurrence (calculation of 3-year disease-free survival and overall survival rates),"Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5644,NCT02598414,Anastomotic leak rate,Mortality,,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5645,NCT04097444,Progression-free survival (PFS),Functional Assessment of Cancer Therapy (FACT) / Gynaecologic Oncology Group (GOG) Neurotoxicity 4,,2019-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
5646,NCT02454075,A Reduction of 25% in the Gastric ECL Cell Density.,"Acid Control Study 3, Control of Gastric Acid Secretion Assess by Changes in Drug-controlled Gastric Acid Analysis: Acid Output",,2011-04-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5647,NCT01828918,postoperative early recurrence,,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
5648,NCT00642733,Overall survival; time to progression,"AEs, lab parameters",,2007-08,TERMINATED,INTERVENTIONAL,['PHASE4']
5649,NCT04143191,Recurrence-free survival,Quality of life,,2019-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
5650,NCT01302613,The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.,The primary endpoint of the phase II portion of the study is complete pathologic response.,,2011-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5651,NCT05562297,2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel,"Correlation among ctDNA, serum tumor markers, and CT evaluations before and after neoadjuvant therapy, before and after curative resection, during and after adjuvant therapy, and during and after the maintenance treatment of immunotherapy.",,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5652,NCT01309256,Acute-inflammatory response after undergoing robotic and laparoscopic gastrectomy,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
5653,NCT04869956,Surgical site infection,Recurrences of CRC after surgery,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
5654,NCT05801965,Cancer-specific Quality of Life,User engagement,,2023-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5655,NCT03252808,Dose Limiting Toxicity (DLT),Progression-free survival (PFS) by irRECIST,1 year survival rate,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5656,NCT00699374,Overall Survival (OS),European Quality of Life (EQ-5D)- Health State Profile Utility Score,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
5657,NCT04304209,complete response rate,Tumor response,,2019-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5658,NCT00611858,Pathological Complete Response Rate,1-Year Overall Survival Rate,1-Year Disease-Free Survival Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
5659,NCT00245362,Overall survival,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5660,NCT03150615,Incident rate of delayed gastric emptying,Maximum Plasma Concentration fasting plasma GLP-1 level,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
5661,NCT04732494,Objective Response Rate (ORR) Assessed By The Investigator's Review Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1,Incidence of Adverse Events And Serious Adverse Events,,2021-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5662,NCT00165633,Relapse-free survival period.,,,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5663,NCT05951842,Postoperative immune function (NK cell count),,,2018-04-16,WITHDRAWN,INTERVENTIONAL,['NA']
5664,NCT04792892,Toxicity related to treatment,Sexual function,,2021-08-01,RECRUITING,OBSERVATIONAL,['NA']
5665,NCT01402687,Develop and validate a clinically applicable SNP-based screening platform for mucositis risk,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
5666,NCT03886753,Change in symptoms,Assess therapeutic range,,2019-05-15,TERMINATED,OBSERVATIONAL,['NA']
5667,NCT02606305,"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine,,2016-03-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5668,NCT00281788,,,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5669,NCT06165328,Diagnostic yield in diagnosis colorectal tumor,Procedure-related adverse events,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
5670,NCT04566133,Median Progression Free Survival (PFS),Overall Survival,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2022-02-15,TERMINATED,INTERVENTIONAL,['PHASE2']
5671,NCT03852290,Assessment of C677T and A1298C MTHFR polymorphisms and response rate,Assessment of C677T and A1298 MTHFR polymorphisms and toxicity,,2019-01-16,UNKNOWN,OBSERVATIONAL,['NA']
5672,NCT01425879,Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1,Progression-free Survival,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5673,NCT00911092,Initial complete clinical response,Prolonged clinical response at one year,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5674,NCT01472250,chemotherapy regimen,treatment expense,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
5675,NCT01891552,time to progression,number of adverse events,quality of life,2013-05,COMPLETED,OBSERVATIONAL,['NA']
5676,NCT04651504,Number of colonoscopy completions after positive fecal immunochemical test,Proportion of patients who complete a complete diagnostic evaluation within 60 days of positive fecal immunochemical test,,2020-12-02,RECRUITING,INTERVENTIONAL,['NA']
5677,NCT02542670,Number of cancer patients with abnormal genetic mutations .,,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
5678,NCT06190301,The cumulative occurrence rate of complications of grade ≥2 within 2 years after treatment commencement,overall survival,,2024-01-11,RECRUITING,INTERVENTIONAL,['NA']
5679,NCT04632199,Incidence of Treatment-emergent adverse events,Optimal injected radioactivity range,,2021-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5680,NCT00230451,To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.,To assess the qualitative and quantitative toxicities of this regimen.,,1997-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5681,NCT00518557,"Safety and tolerability, Mortality","Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival",,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
5682,NCT01330186,Tumor response,,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
5683,NCT00071994,Progression-free survival rate in patients treated with ZD 1839,EGFR expression,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5684,NCT05842187,PFS (Progressive free survival),DCR (Disease control rate),,2023-03-03,RECRUITING,INTERVENTIONAL,['NA']
5685,NCT06078657,1 year overall survival rate,adverse events,biomarker,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5686,NCT00447967,Objective Response Rates,Symptoms improvement,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5687,NCT02799251,Presence of post operative infection,Anesthetic and surgical parameters,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
5688,NCT05196334,Comparison between organoid's and patient's response,,,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5689,NCT02761408,Number of participants with treatment-related adverse events assessed by CTCAEv5.0,,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
5690,NCT04015804,Conversion rate for robotic surgery,Operating time,,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5691,NCT00152243,Overall survival and relapse-free survival,Adverse events,,1997-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5692,NCT00766142,Median Progression-free Survival (PFS) Time,Overall Survival (OS) Time,,2007-05-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5693,NCT01926236,Overall survival,Quality adjusted life years (QALYs),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5694,NCT03009253,translational resection rate,Local control rate,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
5695,NCT02532803,Measurement of the accuracy of a novel MRI assessment tool to accurately stage Early Rectal Cancers and Polyps,Measurement of the Sensitivity and specificity of MRI for lymph node metastasis,,2015-08-13,UNKNOWN,INTERVENTIONAL,['NA']
5696,NCT02175992,Health-related quality of life,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
5697,NCT02975141,MTD of afatinib in combination with gemcitabine/nab-paclitaxel,Incidence of Treatment-Emergent Adverse Events,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
5698,NCT03463876,Objective Response Rate (ORR),Progression-free survival(PFS),,2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5699,NCT00784446,Dose limiting toxicity.,Assessment of overall response rate and progression free survival.,,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5700,NCT01239355,Progression-free Survival,Overall Survival,,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2']
5701,NCT00207051,determination of maximum tolerated dose (MTD),Efficacy based on duration of response and time to progression based on assessment,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5702,NCT00759226,Primary endpoint rate of freedom of progression (PR+CR+SD).,"Secondary endpoint median survival, progression free survival and toxicity.",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5703,NCT01724775,Prognosis assessment of postoperative patients,Safety assessment of the patients in perioperation period,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
5704,NCT00381706,Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma,Time to Treatment Failure in Patients With Adenocarcinoma,,2006-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
5705,NCT04082364,Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A),Number of patients who have ADA to tebotelimab,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5706,NCT05290480,'Patient Mobility and Observer Mobility Scale,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
5707,NCT02254941,Overall survival,Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
5708,NCT04534309,Weight change at 6 months in Coach-Directed Program,Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs,Weight change at 12 months by program,2020-09-22,COMPLETED,INTERVENTIONAL,['NA']
5709,NCT03342677,Comparison of Gd-EOB-DTPA enhanced liver MRI and CT scan images in characterizing cirrhotic nodules and HCC in liver transplant candidates,Investigation of Gd-EOB-DTPA enhanced MRI efficacy in diagnosis and staging of HCC in cirrhotic patients and its potential impact on liver transplantation eligibility in patients who are liver transplant candidates,,2017-11-07,UNKNOWN,INTERVENTIONAL,['NA']
5710,NCT02877589,hepatitis B virus (HBV) serological status,hepatitis C virus (HCV) serological status,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
5711,NCT05511051,Overall Survival,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5712,NCT01523808,Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment,Summary of CA 19.9 Over Time,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5713,NCT02636738,Technique success,,,2016-06-06,TERMINATED,INTERVENTIONAL,['NA']
5714,NCT04715308,To assess the impact of urinary diversion/reconstruction subtypes on quality-of-life,To measure the rate of reintervention for complications associated with urinary diversion/reconstruction,,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA']
5715,NCT00210106,Complete Hepatic Response Rate at 3 Months,Event-free Survival,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
5716,NCT05536362,Measurement of Post-operative Pain,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5717,NCT02818907,"disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)",,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
5718,NCT00601705,Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate,Postoperative Adjuvant Chemoradiotherapy Feasibility,,2008-01-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5719,NCT01221324,postoperative inflammatory complications,Anastomotic leakage,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
5720,NCT01625351,Feasibility of haploidentical HSCT,event-free survival,,2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1']
5721,NCT01787864,Presence of dysplasia before and after ablation,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
5722,NCT04095364,Progression-free survival (PFS),Adherence to letrozole maintenance therapy,,2019-09-20,RECRUITING,INTERVENTIONAL,['PHASE3']
5723,NCT00164944,To find the prevalence of adenomas and advanced neoplasms of the first degree relatives,,,2004-04,COMPLETED,OBSERVATIONAL,['NA']
5724,NCT02975661,Disease free survival (DFS),Concomitant medication,,2017-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5725,NCT00012389,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5726,NCT01939665,Safety (number of adverse events),Tumor response,,2013-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5727,NCT03716596,overall survival,Related tumor markers,,2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE1']
5728,NCT01275664,Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis),Percentages of Patients With NIDL Based on FLIE,,2011-06,TERMINATED,INTERVENTIONAL,['NA']
5729,NCT03006705,Relapse-free survival (RFS),Safety will be analyzed through the incidence of laboratory abnormalities,,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE3']
5730,NCT01053104,"Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)",Dose intensity in mg/m2/week and toxicities as for stage 1,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
5731,NCT03447431,To develop biological tools to simplify screening in future clinical assays,,,2018-04-05,UNKNOWN,OBSERVATIONAL,['NA']
5732,NCT02591030,overall survival,quality of life (EORTC QLQ-C30 ),,2015-12-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5733,NCT00991952,Overall Response Rate,,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5734,NCT04791644,This study will compare fecal microbiota richness and composition differences between LS patients with no previous adenoma at inclusion in AAS-Lynch study and LS patients with history of adenoma or adenoma at inclusion in AAS-Lynch study.,Gut microbiota composition description,,2021-04-20,RECRUITING,OBSERVATIONAL,['NA']
5735,NCT03748927,"Characterize the natural history of Fibrolamellar hepatocellular carcinoma (FL- HCC), including clinical presentation, family history, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurre...",,,2019-04-08,WITHDRAWN,OBSERVATIONAL,['NA']
5736,NCT01471249,improvement of dysphagia post stenting,Quality of life post stenting,,2011-06,TERMINATED,OBSERVATIONAL,['NA']
5737,NCT06309485,Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.,Anti-tumor activity if WGI-0301 in combination with Sorafenib based on OS.,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5738,NCT05600309,Overall Survival (OS),TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,,2022-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5739,NCT03721653,Progression Free Survival (PFS),2nd-PFS,,2018-11-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5740,NCT05128123,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",Assessment of the relationship between social health determinants and the quality of life of patients at 6 and 18 months after inclusion in the CHIEF cohort study,,2022-01-21,RECRUITING,OBSERVATIONAL,['NA']
5741,NCT03751176,Progression-free survival at 6 months,Biomarkers analysis by liquid biopsies.,,2018-11-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5742,NCT00438906,To determine the diagnostic yield of screening high risk patients,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
5743,NCT00503321,progression-free survival,"Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors",,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5744,NCT00083122,Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR),Time to Progression,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5745,NCT01310972,"OS, PFS, DFS",,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5746,NCT03972956,Confirmation of diagnosis by pathologist,,,2020-12-23,RECRUITING,OBSERVATIONAL,['NA']
5747,NCT04027088,Surgical fistulas,Weight loss,,2019-08-10,UNKNOWN,INTERVENTIONAL,['NA']
5748,NCT05019794,Objective Response Rate (ORR),Accumulation ratio (Racc),,2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2']
5749,NCT03410914,Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF),Average Length of Stay in Hospital,,2018-08-13,COMPLETED,INTERVENTIONAL,['PHASE2']
5750,NCT00853684,Time to progression,Overall survival,,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5751,NCT04766502,Peritoneal Regression Grading Score (PRGS),Quality of life mesure,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
5752,NCT03837301,complete resection rate (%) of tumor,,,2018-09-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
5753,NCT02495896,Progression-free survival,,,2015-09-03,TERMINATED,INTERVENTIONAL,['PHASE1']
5754,NCT05674773,Metachronous (advanced) neoplasia,Associations with treatment choice,,2019-05-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5755,NCT00290615,Response Rate (Percentage of Participants With Partial or Complete Response),Overall Survival,Effect on Wound Angiogenesis,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5756,NCT02981498,progression-free survival rate,AE event,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5757,NCT02560623,DNA Yield,Specificity of Barrett's Dysplasia Detection,,2015-10-15,COMPLETED,INTERVENTIONAL,['NA']
5758,NCT04269499,Feasibility of MR imaged administration of holmium microspheres,Tumor response after 3 months based on CT imaging (according to RECIST 1.1 criteria),,2019-11-11,COMPLETED,INTERVENTIONAL,['NA']
5759,NCT03631641,Incidence rate of non-colonic cancers,,,2018-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5760,NCT02776683,Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment,Progression-Free Survival (PFS) Time as Assessed by Central Imaging Review,,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5761,NCT06251050,The incidence of Severe Oral mucositis (WHO grade ≥3),Taste function,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5762,NCT04574245,5-year overall survival,The prognostic predictive value for patients with different C-GCLM classification,,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5763,NCT04942665,Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio,"Qualitative Assessment of Overall Intraoperative Visualization of the Extrahepatic Biliary Tree (Common Hepatic Duct, Cystic Duct, Common Bile Duct, Aberrant Ducts)",,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
5764,NCT00402025,Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies,Change From Baseline in Pain Intensity,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5765,NCT04417699,Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59,Safety and Tolerability,,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5766,NCT02792023,The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value),The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy,,2016-06-30,UNKNOWN,INTERVENTIONAL,['NA']
5767,NCT01505205,,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
5768,NCT03528863,Acceptability as assessed by adherence to practice instructions,"Efficacy as assessed by a ""Are You at Peace?"" one-item spiritual probe",,2018-05-07,COMPLETED,INTERVENTIONAL,['NA']
5769,NCT00002689,Survival,Patterns of failure,,1995-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5770,NCT03547999,Overall Survival (OS),Progression Free Survival (PFS),,2018-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5771,NCT00660894,Disease-free survival,Identification of predictive markers,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5772,NCT01874938,Progression Free Survival (PFS) Rate,PFS,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
5773,NCT06223061,"Compliance to pre-, intra-, and post-operative audit standards",Rates of unsuspected gallbladder cancer.,,2023-07-31,RECRUITING,OBSERVATIONAL,['NA']
5774,NCT00047762,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5775,NCT02715089,Progression-free survival (PFS),Adverse Drug Reaction (ADR)/Adverse Event (AE),,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
5776,NCT00349076,"Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.","Resection rate, rate of sphincter preservation, tumor regression, cumulative incidence of local and distant recurrences, overall survival, toxicity, quality of life",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5777,NCT05523960,the rate of major complications,,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5778,NCT02632188,Progress-free survival,Quality of life,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5779,NCT03975049,Disease-free survival,Treatment related quality of life,Tumor regression grade after neoadjuvant therapy,2019-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5780,NCT00489697,evaluation of the response to bevacizumab based chemotherapy by RECIST criteria,survival time,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
5781,NCT04258137,Assessment of cancer outcome in terms of overall survival (2 distincts population),Proportion of patients treated with a targeted therapy (in 2 distincts populations),,2020-09-04,RECRUITING,INTERVENTIONAL,['NA']
5782,NCT00084591,Acute toxicity by CTCAE at 6 weeks following study completion,Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5783,NCT03564912,DFS,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2018-08-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5784,NCT00620607,response rate,effect of huC242-DM4 on tumor uptake of FDG,,2007-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5785,NCT00362102,Response according to the RECIST criteria accessed every 6 weeks,"Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements.",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5786,NCT06331988,Relapse free survival,Overall survival,,2022-07-21,RECRUITING,OBSERVATIONAL,['NA']
5787,NCT03479645,Colorectal screening rate,FIT kit return rate by insurance status,,2018-03-23,COMPLETED,INTERVENTIONAL,['NA']
5788,NCT01978444,3-year disease free survival,3-year overall survival,Postoperative intraperitoneal free cancer cell (IFCC),2014-09,UNKNOWN,INTERVENTIONAL,['NA']
5789,NCT04711473,Colorectal Cancer Screening Completion,Choice of Colorectal Cancer Screening Test,,2021-10-27,COMPLETED,INTERVENTIONAL,['NA']
5790,NCT03649321,Overall Response Rate (ORR),Number of Participants With an Adverse Event of Grade 3 or Higher,,2019-01-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5791,NCT00858871,To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment,To compare health-related quality of life,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5792,NCT06134765,The incidence of reduced absolute neutrophil count(ANC) of grade ≥3 in the first cycle of chemotherapy,,,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5793,NCT03124394,Overall Survival,Cost-effectiveness,,2015-06-01,UNKNOWN,OBSERVATIONAL,['NA']
5794,NCT03064828,Sensitivity and specificity of low-dose CTC for the polyp detection,Sensitivity and specificity of CTC for the detection of poly malignancy,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
5795,NCT03008343,Relief degree of tumors,Overall survival（OS）,,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5796,NCT02570399,Feasibility in terms of toxicity related to radiation therapy,Quality of life questionnaire of treated patients,,2015-02-26,UNKNOWN,INTERVENTIONAL,['NA']
5797,NCT02019199,Tumor Motion,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
5798,NCT02329106,Evaluate the safety of IRE for unresectable liver cancer close to diaphragmatic dome using Common terminology Criteria for Adverse Events (CTCAE).,Evaluate the efficacy of IRE for unresectable liver cancer close to diaphragmatic as measured by cell death of CRLM after IRE is demonstrated macroscopically by using vitality-staining with triphenyl-tetrazoliumchloride (TTC),,2014-12-01,COMPLETED,INTERVENTIONAL,['NA']
5799,NCT03302858,Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA,Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA,,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
5800,NCT03448731,Efficacy in the prevention of skin toxicity,Incidence of Treatment-Emergent Adverse Events,,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5801,NCT04843956,Quality of the sample in relation to the technique,Sample contamination relative to technique,,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA']
5802,NCT05239507,"To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years",To describe the demographic and clinical characteristics of patients with unresectable HCC,"To investigate the correlation between survival outcomes and clinical characteristics, liver function, and underlying disease in unresectable HCC",2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
5803,NCT01465451,disease-free survival,safety profiles,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
5804,NCT00033735,Survival of Irofulven vs. 5-FU,Objective Tumor Response of Irofulven vs. 5-FU and Clinical Benefit of Irofulven vs. 5-FU,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5805,NCT00784667,To determine the response rate (RECIST criteria). Responses will be evaluated for the whole patient group and separately for k-ras wild-type and k-ras mutant tumours,Overall survival,,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
5806,NCT02793479,Elimination Rate of Barrett's Esophagus in the study population,,,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA']
5807,NCT00874224,Time to functional Recovery,Reasons for delay of discharge after functional recovery,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5808,NCT00321594,Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II),,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5809,NCT05720598,The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.,Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy,,2022-11-04,RECRUITING,INTERVENTIONAL,['NA']
5810,NCT00597311,recurrence rate,Impact on quality of surgical resection,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5811,NCT03731819,Table time of Abbreviated PB MRI,Requirement for re-examination,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
5812,NCT01860846,Total Activity Impairment (TAI),Number of Participants With Serious Adverse Events,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
5813,NCT03516916,"Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy",,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
5814,NCT01977053,"emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)",relationship between psychosocial criteria and anxiety,intervention cost,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5815,NCT02513849,"A change in Ki67 expression following tamoxifen therapy, by comparing the pre- and post- tamoxifen biopsies",A change in ER-β expression,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
5816,NCT05566743,PFS,OS,,2022-09-11,RECRUITING,INTERVENTIONAL,['PHASE2']
5817,NCT02974556,Incidence of endoperitoneal recurrence at 36 months,EORTC QLQ-C30 Summary Score,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5818,NCT02253602,Ferumoxytol dose response,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
5819,NCT03671369,Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs,,,2018-10-02,COMPLETED,OBSERVATIONAL,['NA']
5820,NCT02210182,pharmacokinetics,Biomarker,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5821,NCT00004248,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5822,NCT05364489,Progression Free Survival (PFS),Drug-Related Safety Indicators,,2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5823,NCT00091026,Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST),Overall Survival,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5824,NCT00004884,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5825,NCT02309619,Mortality and complications.,Quality of life.,,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
5826,NCT00386984,Overall survival time,Prognostic relevance of the Somatostatin receptors,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5827,NCT00044967,overall survival,,,2002-05,COMPLETED,OBSERVATIONAL,['NA']
5828,NCT06236568,Survival,Graft survival,,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
5829,NCT05320692,PFS assessed by BIRC,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE3']
5830,NCT00539643,Response to Treatment by RECIST Criteria,Overall Survival,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5831,NCT05292443,PFS: Progression-free survival,TTD: Time to Treatment Discontinuation,,2021-12-20,WITHDRAWN,OBSERVATIONAL,['NA']
5832,NCT02546973,HRQL in patient's with anal cancer 3 years after diagnosis,"HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level",,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5833,NCT02745639,Pathological response rate,Acute Toxicity,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5834,NCT01075633,Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No],Complications rate,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5835,NCT03703063,Treatment safety as assessed by CTCAE v4.03,Response rate,,2018-09-17,UNKNOWN,INTERVENTIONAL,['PHASE1']
5836,NCT05002127,Phase 3,,,2022-01-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5837,NCT02482259,Time taken to complete assessments,Muscle mass and timed get up and go as predictors of outcome,Biomarker assessment of frailty and associated factors,2013-12-01,COMPLETED,OBSERVATIONAL,['NA']
5838,NCT05178745,Assessment of resection rate (R0/R1),Safety (serious and non-serious adverse events occurring during treatment,,2016-09-07,COMPLETED,OBSERVATIONAL,['NA']
5839,NCT02034110,Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort,Number of Participants With Adverse Events (AEs),,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5840,NCT02873845,Objective burden score in the dimensions of the COBQoL questionnaire with good psychometric properties,,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
5841,NCT00345696,Progression Free Survival,Resection rate of hepatic or pulmonary metastases,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5842,NCT00004904,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5843,NCT05991947,Differences in ctDNA gene and tumor-specific proteins expression,,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
5844,NCT00428285,High grade dysplasia (AIN 2/3),Tolerability and safety of the treatment,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5845,NCT02151019,Reduction in incidence of grade 2 or higher GI toxicity,"Differences in the toxicity profile between the two types of neoadjuvant concomitant chemotherapy, graded by the NCI-CTCAE Version 4",,2014-10-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5846,NCT01775449,Cold pain thresholds,QLQ-C30 (Quality of Life questionnaire C30)scores,,2013-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5847,NCT02612077,Progression-free Survival,Quality of Life - Global Health Status,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5848,NCT01415479,Intention to undergo CRC screening in the next six months,Completion of CRC screening,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
5849,NCT03832621,"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ",Assess quality of life,Evaluate the tumor mutational load,2019-03-25,COMPLETED,INTERVENTIONAL,['PHASE2']
5850,NCT04720131,Objective response rate,Safety,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5851,NCT00423306,Response Rate,toxicities,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5852,NCT05871099,5-years Recurrence-free survival,Toxic and side effects of the program,,2022-11-20,RECRUITING,INTERVENTIONAL,['PHASE3']
5853,NCT04383210,Objective Response Rate,,,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5854,NCT05231850,Primary End point: Disease Free survival [ Time Frame: 3 years ],Incidence of adverse events,,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5855,NCT01544413,Completement of performance of laparoscopic sentinel lymph node biopsy,"Detection rate of laparoscopic sentinel lymph node, learning curve",,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5856,NCT01666145,Successful Insertion of Ablation Antenna Into Target Lesion,Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM),,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5857,NCT04599790,Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST),DOR assessed by investigators according to mRECIST.,,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5858,NCT03807518,Change in Physical Fitness,Change in concentration of blood markers of Inflammation- White Cell Differential,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
5859,NCT01279291,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy.",,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1']
5860,NCT03219593,Progression-free survival (PFS),Adverse Events(AEs),Tumor biomarkers,2017-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
5861,NCT02394535,Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with at most 1 instance of dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,Changes in MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI),,2015-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5862,NCT02000089,Evaluate pancreatic juice for early cancer markers.,Compare pancreas juice with pancreas cyst fluid,Diagnostic performance of a tumor marker gene test for CA19-9 interpretation,2014-01-06,RECRUITING,INTERVENTIONAL,['PHASE3']
5863,NCT00677586,Severe complication rate after resection of primary and metastatic lesions,Postoperative hospital stay,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
5864,NCT04720716,Objective response rate (ORR),The incidence and severity of Treatment-Emergent Adverse Events,,2021-02-07,RECRUITING,INTERVENTIONAL,['PHASE3']
5865,NCT02780921,percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board,quality of life,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5866,NCT05887505,Ratio of liver failure,Complications after surgery,,2023-06-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5867,NCT04803318,Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.,Assessing overall survival,,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5868,NCT03839550,Recurrence-free survival(RFS),,,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
5869,NCT01673607,,,,2012-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
5870,NCT01466504,p63 expression levels,Tumor response,,2011-05,TERMINATED,OBSERVATIONAL,['NA']
5871,NCT05242991,Hyposalivation,,,2021-03-01,RECRUITING,INTERVENTIONAL,['NA']
5872,NCT00889187,Grade 3-5 Toxicity Rate [Phase II],Surgical Mortality Rate [Phase II],,2009-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5873,NCT01321450,Total operation time,postoperative intervention,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
5874,NCT04887805,Progression free survival,Incidence of adverse events,,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
5875,NCT03970694,5-year overall survival rate,3-year progression-free survival rate,,2019-05-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5876,NCT00554125,Disease-free survival,overall survival,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
5877,NCT04177875,Objective Response Rate (ORR),The incidence of adverse events and the incidence of severe adverse events（ grade 3-4),,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5878,NCT02842749,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Progression free survival,,2016-03-14,COMPLETED,INTERVENTIONAL,['PHASE4']
5879,NCT01395563,muscle mass and strength,quality of life,,2009-01,WITHDRAWN,INTERVENTIONAL,['NA']
5880,NCT01421940,Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week,Number of patients with adverse events during 24 weeks of the study,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5881,NCT06119867,Comparision of the incidence of stage III colon cancer between European and Japanese pathological investigation methods.,"Comparison of the extramural invasion (venous, lymphatic, perineural) between the European and Japanese pathological approaches",,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE3']
5882,NCT04752267,Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters,,,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
5883,NCT02837029,Phase IB: Objective Response Rate (ORR),Disease Control Rate (DCR),Circulating Free DNA (cfDNA) Mutation Analyses,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5884,NCT03187314,Objective response rate (ORR),Health-related quality of life (HRQoL),,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2']
5885,NCT05781568,Biomarker dosage,,,2023-02-24,RECRUITING,OBSERVATIONAL,['NA']
5886,NCT00235898,,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5887,NCT01946139,Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry,Acceptability of Anal Cancer Screening,,2013-12-04,COMPLETED,INTERVENTIONAL,['NA']
5888,NCT02909530,Correct histological diagnosis of the mass assessed by each needle,Adverse events,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
5889,NCT03529760,HBV-DNA positive,,,2018-05-08,UNKNOWN,OBSERVATIONAL,['NA']
5890,NCT00869258,Conversion Rate of Inoperable to Operable,,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5891,NCT05693519,Overall survival,Standardized incidence of second primary malignancies,,2022-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5892,NCT02703714,Overall Response Rate (ORR),Median Overall Survival (OS) Stratified by Sub-type of Biliary Cancer,,2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5893,NCT01488487,Time to Progression (TTP),Objective Response Rate (ORR),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5894,NCT02564146,Overall survival (OS),Neurotoxicity Assessment FACT taxane score,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5895,NCT06000553,"the aim is to search for immune and metabolic abnormalities in patients with at-risk TIPMP in the blood or by echo-endoscopic sampling, then compare and combine them with the criteria used in clinical practice.",,,2023-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5896,NCT05083780,Number of participants with treatment-related adverse events assessed by CTCAE v5.0,Objective Response Rate,,2021-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5897,NCT02523053,Time to tumor recurrence,Overall survival,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5898,NCT06230328,Epidemiological profile and pathological staging,Description of clinical condition,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5899,NCT06225011,Immune cell composition and microenvironment,,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5900,NCT01956812,overall survival,Clinical benefit,,2013-12,TERMINATED,INTERVENTIONAL,['PHASE3']
5901,NCT00899132,Characterization of TAB3 and its signaling networks that are involved in tumorigenesis,,,2007-02,TERMINATED,OBSERVATIONAL,['NA']
5902,NCT05133102,Intra-class correlation coefficients (ICC) by BE status,,,2021-03-19,RECRUITING,OBSERVATIONAL,['NA']
5903,NCT06179602,Safety as assessed by complications according to CTCAE v6.0.,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
5904,NCT05672316,Overall response rate (ORR) (Phase II),Incidence of toxicity (Phase II),,2023-05-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5905,NCT00300547,Feasibility of MR colonography to diagnose possible synchronous carcinomas and polyps,Altered operative strategy due to findings on MR colonography,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5906,NCT00189683,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
5907,NCT04406857,Incidence of Dose-limiting Toxicities (Part IB),Neoadjuvant Rectal Score at the Maximum-tolerated Dose,"Interactions of Capecitabine, IPdR and Their Metabolites",2021-03-17,TERMINATED,INTERVENTIONAL,['PHASE1']
5908,NCT02550743,Maximum Tolerated Dose of BYL719,Pathologic Complete Response for Patients With Rectal Cancer,,2016-06-03,TERMINATED,INTERVENTIONAL,['PHASE1']
5909,NCT06032338,Performance of colonoscopy in FIT positive patients,Cost-effectiveness analysis,,2023-09-14,RECRUITING,INTERVENTIONAL,['NA']
5910,NCT01774266,Early detection of gastric cancer,Monitoring progression of disease,Detection of H.pylori and gastric atrophy,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
5911,NCT01904968,"Mutational status evaluation of BRAF, KRAS and PI3KCA :",,,2011-12,WITHDRAWN,OBSERVATIONAL,['NA']
5912,NCT01558947,the relapse-free survival time/rate,,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5913,NCT02444897,VAS score,Bowel motility,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5914,NCT04611035,Efficacy of second-line therapy,Haematologic and non-haematologic toxicities,,2020-01-20,UNKNOWN,OBSERVATIONAL,['NA']
5915,NCT04204850,Disease control rate,Number of Side Effects Reported,,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2']
5916,NCT02578732,Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.,Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A,,2016-07-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5917,NCT01281683,,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
5918,NCT02850874,Peritoneal disease-free survival,Postoperative mortality,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5919,NCT05794048,Theranostic metabolic signatures of TNEP.,Comparison of metabolic profiles on surgical specimen,,2022-06-08,RECRUITING,INTERVENTIONAL,['NA']
5920,NCT05945082,Presence of F.nucleatum in a colon cancer biopsy,,,2017-11-29,RECRUITING,INTERVENTIONAL,['NA']
5921,NCT02291614,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Progression Free Survival (PFS) at 6 Months in Participants Treated at the MTD,,2014-11-27,TERMINATED,INTERVENTIONAL,['PHASE1']
5922,NCT05245877,"Venous thromboembolism, number of patients",Post-operative hemoglobin below 70 g/l,,2022-08-17,RECRUITING,INTERVENTIONAL,['PHASE4']
5923,NCT02325323,Incidence of gastric cancer or high grade dysplasia of the gastric mucosa,Percentage of development of gastric cancer or high grade dysplasia,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
5924,NCT00209625,objective tumor response,"Response duration, time to progression, median survival time, and safety",,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5925,NCT04435977,PFS,safety and tolerability,,2020-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
5926,NCT05914766,Self-Efficacy (CASE-Cancer),Quality of Life (FACT-C),,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
5927,NCT04911647,Re-intervention rate,"Procedure related complication, Postoperative complication",,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
5928,NCT04677673,Overall Survival,Disease-free survival (DFS),,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5929,NCT04119622,Major pathological response rate,Overall Survival (OS),,2019-10-08,RECRUITING,INTERVENTIONAL,['PHASE2']
5930,NCT05535569,(Phase II) PFS,PFS,,2017-07-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5931,NCT00106054,To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases,"oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment",,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5932,NCT04985136,Stage II：Overall survival （OS）,Proportion of neutralizing antibody (Nab),,2021-09-26,TERMINATED,INTERVENTIONAL,['PHASE3']
5933,NCT00844675,Frequency of bleeding after EMR is performed,Measurement of a change in the size of ulcer,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5934,NCT05791747,social representations,Intention to turn to hypnosis,,2023-03-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5935,NCT01832246,diagnostic accuracy between endoscopic ultrasonographic staging and conventional endoscopic staging,,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
5936,NCT01579591,The impact of the probiotic preparation on increasing the TRG1-2 rate.,Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
5937,NCT01395017,Overall Survival,Progression Free Survival (PFS),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5938,NCT00954525,"Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.",Progression-free survival,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5939,NCT04411589,detection rate of GIN and EGC,diagnostic accuracy in a per-biopsy analysis,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
5940,NCT05828446,To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population,To perform a cost-effectiveness analysis comparing US to different alternative screening strategies for HCC in Switzerland.,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
5941,NCT03574493,"Efficacy of surgical method (success determined by composite of Oncologic, morbidity and functional outcomes)",,,2018-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5942,NCT00644020,DFS(disease free survival),1.OS （Overall Survival） 2.QOL (quality of life),,2007-12,UNKNOWN,OBSERVATIONAL,['NA']
5943,NCT03140189,rate of major postoperative complications,disease-free survival,,2017-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5944,NCT04483076,pCR rate,Five-year overall survival,,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE3']
5945,NCT03993353,Overall Survival (OS),Adverse event rates,,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2']
5946,NCT01125865,Stent patency,Technical success,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
5947,NCT02489201,Number of participants with Adverse Events,Progression-free survival,,2015-07-21,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5948,NCT05346757,Sensitivity for advanced colorectal neoplasm,Cost-effectiveness for advanced colorectal neoplasm detection,,2022-03-23,RECRUITING,INTERVENTIONAL,['NA']
5949,NCT01453452,"Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day",DNA methylation patterns,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
5950,NCT00648102,"To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer",Investigate clinical activity,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5951,NCT05173610,Treatment efficacy (Disease free survival),Number of participants with treatment-related adverse events (acute and late toxicity) as assessed by CTCAE v4.0,,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2']
5952,NCT00002997,,,,1998-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5953,NCT04607291,Model Development for Prediction of Intent and Colorectal Cancer (CRC) Screening Behaviors,Prediction of Which CRC Screening Test is Most Acceptable,,2019-09-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5954,NCT04329429,Objective Response Rate (ORR),Adverse Events,,2020-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5955,NCT02602327,Maximum tolerated dose (MTD),Biomarker response,,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5956,NCT01132755,Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection,Safety of Peritoneal Lavage in Place of Laparoscopic Lavage.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5957,NCT06017141,Neutrophil extracellular traps (NET) formation,Changes in gene expression,,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2']
5958,NCT03809247,16sRNA and metagenomics,,,2019-02-01,RECRUITING,OBSERVATIONAL,['NA']
5959,NCT05349331,Progression-free survival,pCR rate in surgery group,Correlation of serum tumor molecular marker with survival,2022-05-05,RECRUITING,INTERVENTIONAL,['NA']
5960,NCT00296322,Relapse-free Survival,Overall Survival,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5961,NCT02422095,Natural history and disease progression in pancreatic cysts,Evaluate the role of plastic stents in patients undergoing EUS-guided drainage of pancreatic fluid collections.,,2015-02,WITHDRAWN,OBSERVATIONAL,['NA']
5962,NCT00607282,"Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)","Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5963,NCT04169399,Progression free survival (PFS),Adverse Events,,2019-11-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
5964,NCT03006263,overall postoperative morbidity rates,The variation of C-reactive protein,,2016-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5965,NCT05679050,Disease-free Survival(DFS),Treatment-Emergent Adverse Event Rate,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
5966,NCT06085755,ORR (Objective response rate),Progression free survival (PFS),,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5967,NCT03038984,cancer,"Disease course, Copenhagen IBD Disease course Type",,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5968,NCT02748551,"""Major"" Surgical Morbidity",Extent of lymph node dissection,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
5969,NCT01444521,Overall response rate,Time to event efficacy,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5970,NCT04607057,Body weight change for 2 months after surgery,Mortality rate,,2020-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
5971,NCT03665571,NK cell activity,Survival of participants,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
5972,NCT02321579,Oxidative stress marker (MDA concentation),Glutathione related enzyme activities,,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
5973,NCT03833661,Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC),Durable Response Rate (DRR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite Instability (MSI) Status,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
5974,NCT00002506,,,,1992-08,COMPLETED,INTERVENTIONAL,['PHASE2']
5975,NCT04342676,"LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).",LNR and K ras were evaluated and ASSOCIATION with PFS and OS.,,2017-03-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5976,NCT05757492,Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab,Overall survival (OS) using RECIST v1.1 assessed by the investigator,,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5977,NCT02043184,Medication Adherence using pill count and self report,Healthcare Utilization is the use of Emergency room and Hospital admissions,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
5978,NCT04701645,Number of implanted microdevices successfully retrieved,,Correlate extent of tumor response with genetic features of the tumor tissue,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE1']
5979,NCT01286987,Part 1: Recommended Part 2 Dose of Talazoparib,,Part 1: Apparent Volume of Distribution (Vz/F) of Talazoparib,2011-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5980,NCT04800991,Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators,The investigational device(application) usage compliance by underlying disease,Frequency of Adverse Events,2021-03-17,COMPLETED,INTERVENTIONAL,['NA']
5981,NCT02641925,HOMA-IR change,HOMA-IR change according to anastomosis type,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
5982,NCT05396560,Fecal Immunochemical Test Sensitivity and Specificity,,,2022-04-15,RECRUITING,OBSERVATIONAL,['NA']
5983,NCT00819559,Disease-free survival,Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
5984,NCT06328283,glutamine synthetase,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5985,NCT01742169,Completion of fecal occult blood test (FOBT),,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
5986,NCT00730483,Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE,Symptomatic Response by Assessing Symptom Severity in Patients,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
5987,NCT00613080,"The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively",Number of Patients Who Underwent Abdominoperineal Resection,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5988,NCT03579004,Disease free survival,Pathological complete response rate following chemoradiotherapy,,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
5989,NCT03475966,Change in functional walking capacity as measured by the six-minute walk test (6MWT),Heart rate - assessment of change over time,Lower extremity strength - assessment of change over time,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA']
5990,NCT02047513,Time to Disease free survival (DFS),Tumor recurrence,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5991,NCT04605419,Registration of treatment related pain through a Visual Analogue Score (VAS),The rate of patient's that have gained from the treatment,,2020-10-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
5992,NCT02064803,Change from baseline Gastric Outlet Obstruction Score System - GOOSS,Overall survival,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
5993,NCT03281447,Self evaluated Self Efficacy for Cancer,Health-related Quality of Life,,2016-02-26,COMPLETED,INTERVENTIONAL,['NA']
5994,NCT02070419,Difference in tumor grade,Survival rate,,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5995,NCT00310050,Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy,Number of Participants That Survived,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1']
5996,NCT03733197,Scale development,Pilot intervention,,2024-01,WITHDRAWN,INTERVENTIONAL,['NA']
5997,NCT03688555,Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally),Patient Global Impression of Change in Disease Severity,,2018-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
5998,NCT00126867,,,,2005-05,TERMINATED,OBSERVATIONAL,['NA']
5999,NCT01703910,gene expression profiles,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6000,NCT01104116,Positive and Negative Predictive Value of PET Imaging for Identifying Malignant IPMN,Change in Lesion Characteristics to Assess Benefit of PET Scans,,2009-09,TERMINATED,INTERVENTIONAL,['NA']
6001,NCT04927260,Survival,Quality of life in real-life according to FACT-G questionnaire,,2021-03-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6002,NCT00188331,,,,2003-11,COMPLETED,OBSERVATIONAL,['NA']
6003,NCT04310709,Response rate,Overall survival,,2020-06-16,COMPLETED,INTERVENTIONAL,['PHASE2']
6004,NCT01386697,,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
6005,NCT02050178,Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6006,NCT00791544,Dose-limiting toxicities (DLT) based on grade = or > 3 hematological or non-hematological toxicity and on fasting hyperglycemia,Anti tumoral activity,,2008-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6007,NCT00349024,"Symptoms, other than pain, considered important to the pediatric population",,,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
6008,NCT01066624,Incidence of Oral Mucositis,,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6009,NCT00911820,7-month Progression-Free Survival,Progression-Free Survival,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6010,NCT04705818,Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D,Blood kynurenin level,,2021-07-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6011,NCT01786122,Changes in Health Related Quality of Life (EORTC QLQ-C30),progression-free survival,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
6012,NCT00966706,Progression-free survival at 6-months,Toxicity,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6013,NCT01102335,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Overall survival,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
6014,NCT00474812,Median Overall Survival,Gait Speed,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6015,NCT00536614,Overall survival,"response to treatment, and toxicity",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6016,NCT01522677,Safety,Sustained immunity,,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6017,NCT01725321,Detection rate of proximal serrated polyp,Missed rate for proximal serrated polyps,Adenoma detection rate,2012-10,COMPLETED,OBSERVATIONAL,['NA']
6018,NCT02605265,Pathologic Complete Response,Surgical complications,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
6019,NCT04591379,Safety - Adverse reactions are classified according to CTCAE version 4.0,Efficacy - local immunological changes,Quality of recovery,2021-02-26,COMPLETED,INTERVENTIONAL,['PHASE2']
6020,NCT03546569,ctDNA/cfDNA levels in relation to colorectal stent placement,Metastatic ability of the cancer cells,,2018-05-01,COMPLETED,OBSERVATIONAL,['NA']
6021,NCT06331403,Acceptability of Intervention,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6022,NCT04494919,The technical success rate,The adverse events rate,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
6023,NCT02048943,Incidence of adverse events graded by NCI CTCAE version 4.0,Biomarker expression levels in tumor specimens,,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
6024,NCT03448874,Incidence of overall subject pre-specified* procedure related Adverse Events,"Incidence of ""deployment failure""",,2018-04,WITHDRAWN,INTERVENTIONAL,['NA']
6025,NCT02563002,Overall Survival (OS),Number of Participants Who Discontinued Study Treatment Due to an AE,,2015-11-30,COMPLETED,INTERVENTIONAL,['PHASE3']
6026,NCT01936233,recurrence free survival,adverse events,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
6027,NCT02784353,The incidence and severity of general complication,"Grasping power(dynamometer, kg)(Changes in the parameters of rehabilitation)",,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
6028,NCT02500147,Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%),"The association of percentage liver fat with M30, a hepatic apoptosis marker",,2011-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6029,NCT03711890,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.,,,2019-03-26,RECRUITING,INTERVENTIONAL,['NA']
6030,NCT05975645,Overall response rate (ORR),Incidence of Serious adverse events (SAEs),,2023-08-15,RECRUITING,INTERVENTIONAL,['PHASE1']
6031,NCT01130805,Response rate,Toxicities,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6032,NCT04937322,Adverse Events,stent occlusion-free duration,,2016-01-25,COMPLETED,OBSERVATIONAL,['NA']
6033,NCT00448838,Progression-free survival,Time to progression,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
6034,NCT02145559,Pharmacodynamic Biomarker p70S6K,Fasting Serum Glucose and Triglycerides,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6035,NCT06245798,overall survival rate,,,2023-01-01,COMPLETED,OBSERVATIONAL,['NA']
6036,NCT03139058,"Determine the prevalence, by registry data analysis, of cirrhosis in patients with VADS cancer",,,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA']
6037,NCT04072679,Incicende of Adverse Events (AEs),Anti-drug antibody (ADA),,2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6038,NCT03443921,Overall mortality at one year after randomization;,Performance status at 3 years after randomization,,2018-03,UNKNOWN,INTERVENTIONAL,['NA']
6039,NCT00003087,,,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6040,NCT00160836,Sensitivity and specificity for the diagnosis of malignancy with both devices,unusual findings at histopathological examination of surgical specimens.,,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
6041,NCT00689715,recurrence during follow up,predictive factors for complete resolution,,2006-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6042,NCT04297423,Adenoma detection rate,Tolerability and satisfaction with preparation,,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6043,NCT05593328,Overall Response Rate,Safety: Exposure Response Evaluation of Onvansertib,,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6044,NCT02910843,Pathological near complete or complete tumor response (npCR or pCR),Postoperative complications,,2017-02-22,TERMINATED,INTERVENTIONAL,['PHASE1']
6045,NCT04344158,Overall survival (OS),Duration of Response (DOR),,2020-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6046,NCT04062721,Incidence of treatment-emergent adverse events,Potential predictive biomarkers,,2021-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6047,NCT04046250,Mucositis,Incidence Adverse Events That Are Related to Treatment,,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6048,NCT03449914,Evaluate the prognostic value of baseline G8 screening tool for survival.,,,2017-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6049,NCT05787587,Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy in participants by measuring Duration of Response using RECIST criteria v1.1,Area Under the Plasma Concentration Versus Time Curve (AUC) of IDE161,,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1']
6050,NCT01630798,validate binding of the fluorescent-labeled peptide to esophageal neopla,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6051,NCT04401124,assorted surgical parameters,hospitals' protection measures and extent of implementation,,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
6052,NCT00683787,Overall Response Rate,Toxicity,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
6053,NCT05442138,Tumor Regression Grading,,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6054,NCT05001763,"Time to defaecation, measured in hours, from the time the surgery ends till the first observed",Incidence of adverse events related to drug usage,,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6055,NCT02131441,abdominal adhesion,time to disease recurrence,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
6056,NCT02488161,Mortality,Number of participants with Cancer recurrence,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
6057,NCT06280248,Complete resolution or a decrease in the sizes of pancreatic fluid collections (PFCs),,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6058,NCT02167087,Number of procedures with successful identification of sentinel nodes,"Localization of the identified sentinel nodes, and whether or not they are included within the normal resection lines",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6059,NCT00062023,"Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol",,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2']
6060,NCT04633122,PFS assessed by independent central review,"To compare the safety profile of DCC-2618 (ripretinib, ZL-2307) to the safety profile of sunitinib by using AE/SAE/AESI collection during study.",,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE2']
6061,NCT05408221,ORR,OS,,2022-11-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6062,NCT01928524,Median Overall Survival,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6063,NCT05761717,Overall survival (OS) after initial administration.,,,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6064,NCT00813540,Safety (Monitoring for Adverse Events),Feasibility (Adherence to the exercise training program),,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6065,NCT02988934,Incremental yield for dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,Outcomes of patients undergoing WATS sampling.,,2016-04,TERMINATED,OBSERVATIONAL,['NA']
6066,NCT04066543,PFS,,,2019-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
6067,NCT05078515,Specificity of PREDICT score,,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
6068,NCT04837118,Aerobic fitness,Feasibility of Automated Self Assisted 24-hour recall (ASA24) (24-hour dietary recall),,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6069,NCT03697044,Time to Hepatic Progression (TtHP),Quality of Life post DEBIRI delivery,,2019-01,UNKNOWN,OBSERVATIONAL,['NA']
6070,NCT04009811,Voice Handicap Index (VHI) overall score,Head and Neck quality of life EORTC QLQ-H&N35 questionnaire score,,2020-07-17,COMPLETED,INTERVENTIONAL,['NA']
6071,NCT01298401,Dose-limiting toxicity of ganitumab and capecitabine given concurrently with radiotherapy,Overall survival (for patients treated at maximum-tolerated dose of ganitumab),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6072,NCT01225757,Fluid administration decrease,Cardiac complications,,2010-11,WITHDRAWN,INTERVENTIONAL,['NA']
6073,NCT05076279,number of retrieved lymph nodes,3 year relapse-free survival,,2021-11-15,RECRUITING,INTERVENTIONAL,['NA']
6074,NCT03563144,Progression-Free Survival,Evaluation of safety as determined by incidence or treatment-emergent adverse events,,2018-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6075,NCT06159478,Overall response rate (centrally assessed),Adverse event rate,,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2']
6076,NCT03043508,Time to Pancreatic Neuroendocrine Tumors (PNET),Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET,,2015-04-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6077,NCT04040374,Per patient diagnosis of gastric cancer,Agreement on image and IOU based diagnosis of gastric cancer between AI and expert endoscopists,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
6078,NCT02256800,Progression-free survival,overall survival,,2014-08-13,COMPLETED,INTERVENTIONAL,['NA']
6079,NCT01022541,Overall response rates,Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6080,NCT02733809,Overall and disease-free survival genes.,Potential genetic targets for resistance.,,2014-01,RECRUITING,INTERVENTIONAL,['PHASE4']
6081,NCT05381753,"Dose adjustment of avapritinib in cohort 1, 2, and 3",,,2022-08-29,RECRUITING,OBSERVATIONAL,['NA']
6082,NCT03867370,Pathological response rate,Incidence of adverse events,,2019-04-26,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6083,NCT01911832,quality of life,short-term complication of the surgery,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6084,NCT02404935,Progression Free Survival at 6 months,,,2013-11-22,COMPLETED,INTERVENTIONAL,['PHASE2']
6085,NCT01591421,Recommended phase II dose of BKM120 (Phase I Component),Translational Research,,2012-09-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6086,NCT02919644,immunological efficacy,evaluation of the predictive role of immune cells in tumor microenvironment,,2016-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
6087,NCT00215995,Number of Participants With Desired Response,Number of Participants With Overall Survival,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6088,NCT06334458,Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool,,,2023-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6089,NCT02093104,Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period,,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
6090,NCT05962502,Objective response rate (ORR),Drug-related adverse reactions,,2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2']
6091,NCT03109457,Hep C cAg by Immunohistochemistry,,,2017-09-06,COMPLETED,OBSERVATIONAL,['NA']
6092,NCT01903395,utilization of preventive colonoscopy,time delay between signed informed consent and utilization of colonoscopy,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
6093,NCT00007813,,,,1997-05-31,COMPLETED,INTERVENTIONAL,['PHASE1']
6094,NCT00626158,To establish the maximum tolerated dose of fixed-dose rate gemcitabine plus capecitabine given by biweekly administration in patients with advanced pancreatic and biliary tract malignancies.,"Frequency, type, and grade of adverse events using this combination in this patient population",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6095,NCT03910387,Weight stability,Duration of response,,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6096,NCT01551641,Treatment efficacy,Safety,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6097,NCT00049699,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6098,NCT04400292,The number of lymph nodes visualized to be fluorescent and nonfluorescent.,,,2020-05-20,RECRUITING,INTERVENTIONAL,['NA']
6099,NCT02122185,Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria,"Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",,2015-02-25,SUSPENDED,INTERVENTIONAL,['PHASE2']
6100,NCT06070636,Objective response rate (ORR),Overall survival (OS),,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6101,NCT05123209,Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood),,2021-08-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
6102,NCT02324335,Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy,Time to Onset of Severe Oral Mucositis (WHO Grade ≥3),,2014-08-14,COMPLETED,INTERVENTIONAL,['PHASE2']
6103,NCT01508520,diagnosis accuracy of ME-NBI,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
6104,NCT04701476,Overall Response Rate (ORR) for the NSCLC cohort,TTP,,2021-05-20,RECRUITING,INTERVENTIONAL,['PHASE2']
6105,NCT00063947,Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,Overall survival,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6106,NCT04665362,Treatment related adverse events,Progression free survival,,2021-01-25,UNKNOWN,INTERVENTIONAL,['PHASE1']
6107,NCT05293158,HBsAg change from baseline to week 6,Change of Cellular response (IFN gamma),,2024-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6108,NCT03716518,Completion Rate of 8-cycle Adjuvant Chemotherapy,Incidence of SAEs,,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
6109,NCT01411072,Overall Survival,,,2011-09,UNKNOWN,INTERVENTIONAL,['NA']
6110,NCT02855944,Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population),Overall Survival (ITT Population),,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6111,NCT03785665,Measure the variability of the motility (Whole gut transit time from ingestion to excretion {hours}) of the MD1 (Motility dummy 1) capsules in the Gastrointestinal tract of human subjects with and w/out polyps in previous Colonoscopy.,,,2019-06-15,COMPLETED,INTERVENTIONAL,['NA']
6112,NCT00558155,"During the postoperative period, all patients were observed for both surgical and non-surgical complications","The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6113,NCT01507103,Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline,Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6114,NCT01179724,bleeding incidence after ESD,the size of healing ulcer after ESD,,2009-07,UNKNOWN,INTERVENTIONAL,['NA']
6115,NCT04668872,Correlation of tissue necrosis and radiation-induced cell injury levels with delivered dose at 14-21 days,,,2020-12-07,RECRUITING,OBSERVATIONAL,['NA']
6116,NCT03322280,Overall survival (OS),Duration of portal patency,,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6117,NCT05750030,"Safety of atezolizumab/bevacizumab in combination with FMT, measured by incidence and severity of treatment-related adverse events, determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.",Quality of life (QoL) as assessed by the patient-reported outcome EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level Version) questionnaire.,Differences in serum and stool metabolomic and lipidomic signatures in patients before and after FMT.,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2']
6118,NCT00836992,"Overall quality of life (QOL) scores at baseline, weeks 1, 3, 5, and end of treatment as assessed by LASA",Percentage of patients for which physician reports indicate that availability,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6119,NCT03487016,Progression-free survival,Quality of life as assessed by EORTC-QLQ-C30,Kinetics of circulating tumor DNA during first-line chemotherapy,2019-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6120,NCT02181140,Diagnostic Accuracy,Complication Rates,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6121,NCT03007212,changes in Radiological Response in the (CT/ MRI) after the intervention,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6122,NCT02038738,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT)",,2014-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6123,NCT02369757,Participation rates,Qualitative analysis,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
6124,NCT02242409,4 month progression free survival,Overall Survival,,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2']
6125,NCT00777192,Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients,Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients,,2008-08,TERMINATED,OBSERVATIONAL,['NA']
6126,NCT04127396,Time to progression,adverse events(AEs),,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6127,NCT05464030,Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators,Part 2A: Number of Participants with Symptomatic Adverse Events (AEs),,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE1']
6128,NCT02674373,Progression free survival (PFS),Overall survival (OS),,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
6129,NCT02833298,HCC screening rates,Incidence of liver transplant,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
6130,NCT00049348,Percentage of margin-free resections produced by each program,Effect of therapy and recurrence on CA19-9 values,,2003-10-13,COMPLETED,INTERVENTIONAL,['PHASE2']
6131,NCT03900910,The reinfection rate,,,2018-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6132,NCT01011010,Safety and toxicity as assessed by NCI CTCAE v3.0 criteria,Correlative studies,,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
6133,NCT03485196,Disease Free Survival,Overall survival(OS),,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
6134,NCT02575898,Feasibility of a creative writing intervention in an advanced cancer population,,,2016-01-14,COMPLETED,INTERVENTIONAL,['NA']
6135,NCT01813942,The number of patients correctly identified by recurrence predictive model,,,2013-03,UNKNOWN,OBSERVATIONAL,['NA']
6136,NCT05736705,Speed of Endoscopic Submucosal Dissection,Rate of esophageal stricturing post-procedure,,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6137,NCT01243047,To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate,To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6138,NCT01234272,,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6139,NCT01164722,Complete Response Through 1 Year,Incidence of Metachronous Lesions,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6140,NCT06050200,Successful resection,Overall morbidity,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6141,NCT02966483,Overall survival,The patient's Quality of life: EORTC QLQ-30 questionnaire,,2016-04,RECRUITING,INTERVENTIONAL,['NA']
6142,NCT04203160,Phase 2: Overall Response Rate (ORR),Incidence of Toxicities,,2020-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6143,NCT00549952,incidence and severity of oral mucositis,,,2007-10,UNKNOWN,OBSERVATIONAL,['NA']
6144,NCT04136002,Specificity of advanced neoplasia detection,Sensitivity and specificity of advanced adenoma detection,,2019-10-08,RECRUITING,OBSERVATIONAL,['NA']
6145,NCT06116019,Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities,Local Control,,2023-10-11,RECRUITING,OBSERVATIONAL,['NA']
6146,NCT01098422,PFS,60 Day All-cause Mortality Rate,,2010-01,TERMINATED,INTERVENTIONAL,['NA']
6147,NCT00601549,Oncologic Results,Functional recovery of patients,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6148,NCT04522752,Correlation between size and pathological type of benign epithelial gastric polyp and polyp development.,Correlation between helicobacter pylori infection and pathological type of benign epithelial gastric polyp.,,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA']
6149,NCT05411133,Incidence and severity of adverse events,Effect of Cabotamig (ARB202) on tumour as determined by changes in RECIST evaluation from baseline,,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE1']
6150,NCT01554059,Pathological complete response rate,Safety data of this regimen,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6151,NCT02118064,Number of Patients with Serious and Non-Serious Adverse Events,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6152,NCT00768001,,,,2008-06,TERMINATED,OBSERVATIONAL,['NA']
6153,NCT04230018,Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis,Mutation Consistency of tissue and blood sample,prediction accuracy of survival rate,2018-12-28,UNKNOWN,OBSERVATIONAL,['NA']
6154,NCT05200221,Incidence of adverse events and serious adverse events.,overall survival(OS),,2022-01-19,UNKNOWN,OBSERVATIONAL,['NA']
6155,NCT01899118,Pathology complete remission rate,Incidence of Adverse Events,,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
6156,NCT04124406,Enrollment of Subjects,National Rates Comparison,,2019-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6157,NCT05869474,Overall survival (OS),Visual analog scale (VAS),,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
6158,NCT03287843,Pathological Complete Response Rate,Overall Survival,,2006-01-01,COMPLETED,INTERVENTIONAL,['NA']
6159,NCT03933449,Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE),,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3']
6160,NCT01098760,For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment,For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6161,NCT05165602,the relationship between 68Ga SUVmax before treatment and the therapeutic effect will be assessed by SPSS26.0,the relationship between the dynamic change of 68Ga SUVmax and the therapeutic effect will be assessed by SPSS26.0,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
6162,NCT06091748,Specificity of 68Ga-DOTATOC PET-CT Imaging for Detection of Somatostatin Receptor Positive GEP-NET,Incidence and severity of AE and SAE,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6163,NCT05528783,The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.,3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.,,2022-04-25,RECRUITING,OBSERVATIONAL,['NA']
6164,NCT03722498,Progression-free survival,Objective response rate,,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6165,NCT03417765,Incidence of treatment-emergent adverse events,Assessment of quality of life,,2018-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6166,NCT04495387,change of taste chemotherapy-related alterations,Emotions elicited by foods,,2021-07,UNKNOWN,OBSERVATIONAL,['NA']
6167,NCT05336266,Feasibility determined by the number of patients that take the prescribed dose of ketorolac (4 times daily) for 5 consecutive days.,Mean change in calories consumed from baseline through the End-of-Treatment visit,,2022-07-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6168,NCT06035133,"tumor regression grading, TRG",,,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6169,NCT03888313,The patient's experience of participating in a pretreatment group consultation,,,2019-04-26,COMPLETED,OBSERVATIONAL,['NA']
6170,NCT00535041,safety,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
6171,NCT00512681,Maximal overall response rate,"Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6172,NCT04844112,Rate of complete ablation of the tumor after 1 month clinical follow up,Safety of the approach route before and after the fusion process,,2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
6173,NCT03314961,Lymph node metastases in rectal cancer,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6174,NCT05222971,6-month progression-free survival rate,Progression-free survival,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6175,NCT02475889,PD-L1 expression in primary tumor,,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
6176,NCT05755672,"Follow-up examination of tumour remission, progression or recurrence",Quality of life changes,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
6177,NCT03263429,Recommended phase 2 dose of CB-839 in combination with panitumumab and irinotecan hydrochloride (Phase I),Overall Survival,,2017-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6178,NCT01828762,Vital signs，physical examinations and adverse events,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
6179,NCT05495152,Disease-free Survival (DFS),,,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6180,NCT01100801,Response Rate (RR),,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
6181,NCT02581501,Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer,Progression Free Survival,Assess Safety and Toxicity based upon NCI Common toxicity criteria version 4.1.,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE1']
6182,NCT05376943,The occurrence of HCC after direct acting antiviral HCV treatment.,The difference in liver function tests among the population of patients treated with DAAs and those who were not receiving the therapy.,,2022-05-10,UNKNOWN,OBSERVATIONAL,['NA']
6183,NCT02693236,objective rate response (CR+PR) as measured by RECIST criteria,number of participants with adverse events,,2014-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6184,NCT04030260,The progression-free survival (PFS) rates at 6 months,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE2']
6185,NCT01461148,immune response against FSP peptides,safety,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6186,NCT06143644,2-year recurrence free survival rate of the cohort evaluated by ctDNA,Time point of ctDNA MRD test for recurrence monitoring,,2022-01-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6187,NCT02478892,"identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.",,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
6188,NCT05000294,Objective response rate (ORR),Disease control rate (DCR),,2021-12-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6189,NCT06201585,The rate of postoperative complications,,Intraoperative instrument operation error rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6190,NCT06246448,Time to functional recovery,Abdominal wall complaints,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
6191,NCT00164918,Bowel function and related symptoms early post-op,,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
6192,NCT06008925,Phase IIa:ORR,Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses,,2022-11-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6193,NCT03855904,To evaluate the efficacy of TC-325 in preventing 30-day rebleeding following the index malignant hemorrhage: Rebleeding rate,"1. To evaluate the efficacy of TC-325 in immediate hemostasis and rebleeding at 24 hours, 72 hours, 90 days and 180 days following presentation at initial bleeding episode as well as 6-month survival rate",,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6194,NCT03578445,Clinical impact of EUS-guided microbiopsies in patients with pancreatic cystic lesions,Diagnostic values of gene mutations (NGS analyses) in microbiopsy material in the surgical subcohort,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
6195,NCT00172627,,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
6196,NCT04456283,5 years Survival,,,2019-05-20,UNKNOWN,OBSERVATIONAL,['NA']
6197,NCT04786704,Detection of advanced colorectal neoplasia,Efficacy of sDNA in the detection of advanced colorectal neoplasia in low-risk asymptomatic subgroup.,,2021-03-22,COMPLETED,OBSERVATIONAL,['NA']
6198,NCT02649868,To determine the imaging characteristic of radiopaque beads including qualitatively comparing virtual and actual bead perfusion in evaluating tumor vascularity in the treatment of hepatic tumors using bead embolization.,,,2016-01-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
6199,NCT04642547,Progression free survival,Safety endpoint,,2020-12-02,COMPLETED,INTERVENTIONAL,['NA']
6200,NCT01899261,Severe Treatment-related Toxicity,Time to Local Progression (TTLP) of Treated Lesions,,2010-10-07,COMPLETED,INTERVENTIONAL,['NA']
6201,NCT05546879,Percentage Proportion of patients experiencing adverse events,Best overall objective response rate (ORR),PK-PD evaluation,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1']
6202,NCT04107623,perfusion assessment,Anastomotic leakage,,2020-06-16,COMPLETED,INTERVENTIONAL,['NA']
6203,NCT02973750,Association of Age With Changes,Impact of Inflammation on Toxicity and Relative Dose-Intensity (RDI),Overall Survival (OS),2016-10-20,COMPLETED,OBSERVATIONAL,['NA']
6204,NCT04917263,pathological complete response on the operative specimen,,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
6205,NCT02754661,Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy,Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
6206,NCT03057171,"Expression of THRIL, PACER",,,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
6207,NCT04520932,Treatment response,,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
6208,NCT05406024,Acceptability rate,European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30),,2022-09,UNKNOWN,OBSERVATIONAL,['NA']
6209,NCT00219557,Overall Survival (OS),Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study,,2005-07-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6210,NCT00005862,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6211,NCT01946711,Change of Inflammation of the Nasal Mucosa and Paranasal Sinus,Safety Assessment,Nasal Obstruction,2013-08-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6212,NCT05396781,Procedure time,Clinical impact,Performance Characteristics,2022-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
6213,NCT04107766,Target lesion recurrence (local recurrence) rate,Numeric Pain Rating Scale,,2020-01-15,RECRUITING,OBSERVATIONAL,['NA']
6214,NCT05769725,DFS,,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6215,NCT00201331,To compare the DFS and OS of HDFL vs. weekly bolus 5-FU plus high dose LV as adjuvant chemotherapy for N2 colon cancer,"3. To assess the disease-free survival of patients with high or low TS level of N2 colon cancer, when adjuvant chemotherapy of 5-FU was administered by bolus or continuous infusion .",,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
6216,NCT00003044,,,,1996-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
6217,NCT05296005,Incidence of adverse events,18F-FDG dPET/CT to evaluate and characterize residual primary tumor following neoadjuvant chemotherapy and initial chemoradiation therapy for subsequent adaptive boost radiation delivery.,Standard uptake value SUVmax Tumor-to-liver metrics,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6218,NCT05907824,Disease-free survival (DFS),Life quality satisfaction evaluated according to a scale.,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
6219,NCT04559451,Postoperative liver function failure,Postoperative morbidities and mortalities,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
6220,NCT04259398,five year survival,3 year survival,,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6221,NCT01850667,Treatment related toxicity-free survival,Local control rate,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6222,NCT03189030,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),,,2017-05-02,TERMINATED,INTERVENTIONAL,['PHASE1']
6223,NCT03417843,Incidence of adverse and serious adverse events,Technical efficiency of the method,,2018-02,UNKNOWN,INTERVENTIONAL,['NA']
6224,NCT00112632,"Overall tumor response (complete response, partial response, stable disease, and progression of disease)",Overall survival,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6225,NCT01366144,"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0",Time to progression,Change in gamma-H2AX levels,2011-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6226,NCT05084833,Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization,Cost and Cost-Effectiveness Analysis,,2022-02-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6227,NCT03421327,Qualitative analysis of how parents and children with either Huntington's Disease or hereditary cancer communicate about genetic risk information,,,2017-09-01,COMPLETED,OBSERVATIONAL,['NA']
6228,NCT01805622,Effectiveness (RE-AIM Framework),Implementation (RE-AIM Framework),Cost-effectiveness analysis,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
6229,NCT00017082,,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6230,NCT04929652,Objective response rate (ORR),Assess the anti-tumor activity:DCR,,2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6231,NCT01144195,Objective Response Rate,Incidence of adverse events,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
6232,NCT00041652,,,,2000-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6233,NCT00208546,toxicity,translational research,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6234,NCT03314649,prognostic molecular markers,DFS,,2017-12-21,COMPLETED,OBSERVATIONAL,['NA']
6235,NCT05961111,Systemic Immune Response,Quality of Life Assessment,,2023-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6236,NCT03654534,"body weight loss ratio at 1, 3, 6 months",severe side effects on digestive tract,,2019-04-16,UNKNOWN,INTERVENTIONAL,['PHASE3']
6237,NCT04196075,Symptomatic relief and quality of life after AP,AP side effects,,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6238,NCT00327093,"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment",Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up),,2006-05,TERMINATED,INTERVENTIONAL,['PHASE4']
6239,NCT00300027,Echocardiogram every 2 cycles (q 2 cycles),Fluorodeoxyglucose positron emission tomography (FDG-PET) (3 scans prior to C3),,2006-04,TERMINATED,INTERVENTIONAL,['PHASE1']
6240,NCT04357873,"Objective Response Rate (ORR), investigator assessment",Overall Survival (OS),,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6241,NCT02435433,Overall Survival (OS),Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS),,2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE3']
6242,NCT04683744,"Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",,,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA']
6243,NCT04634448,The Prevalence of Appendiceal Tumours in Periappendicular Abscess,Surgery after follow-up MRI,,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6244,NCT05738980,RFS,OS,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
6245,NCT03112668,Feasibility defined as survey follow ups,,,2017-12-06,COMPLETED,INTERVENTIONAL,['NA']
6246,NCT02318888,Surgery for small bowel obstruction,Postoperative complications,,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
6247,NCT05913895,"Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0,Change From Baseline in Pain Scores on the Brief Pain Inventory-Taiwan Scale at 2 Weeks",,,2023-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6248,NCT00003427,,,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6249,NCT05360745,Change in quality of life,Adverse events due to chemotherapy,,2022-06-29,WITHDRAWN,INTERVENTIONAL,['NA']
6250,NCT05845502,Overall survival (OS),,,2023-05-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6251,NCT04593615,3-year disease free survival rate,Inflammatory and immune response,,2020-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6252,NCT00426153,Percent Change in Liver Volume,Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6253,NCT03850769,R0 resection rate,,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6254,NCT02937506,Patient Satisfaction,,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6255,NCT00172159,Response rate and resectability after neoadjuvant therapy.,Survival of the patients.,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6256,NCT05442632,The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period,Incidence of liver failure,,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
6257,NCT05558436,Diagnostic sensitivity,"Diagnostic specificity, accuracy, positive predictive value and negative predictive value",,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
6258,NCT00471328,Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6259,NCT03807999,3-months deterioration-free rate,Overall Survival,,2015-02-19,COMPLETED,INTERVENTIONAL,['PHASE2']
6260,NCT04455282,Difference in CTC detection rate between peripheral and tumor draining veins.,Dynamic Biobank,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
6261,NCT03680508,Objective Response Rate,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0,,2019-12-19,RECRUITING,INTERVENTIONAL,['PHASE2']
6262,NCT04188535,Ability to measure disease control (for imaging registry expansion cohort),Dosimetric change,,2020-01-15,RECRUITING,INTERVENTIONAL,['NA']
6263,NCT04892810,To compare induced immunomodulation by RFA and MWA in HCC patients,To evaluate early induced immunomodulation after MWA in HCC patients,,2021-05-31,UNKNOWN,OBSERVATIONAL,['NA']
6264,NCT05438459,Progression Free Survival (PFS) rate at 6 months (Phase II),Biomarker of GAIA-102(Phase II),,2022-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6265,NCT00006062,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6266,NCT06245785,overall survival,,,2023-01-01,COMPLETED,OBSERVATIONAL,['NA']
6267,NCT03040986,Proportion of Participants With an Objective Response (Partial Response + Complete Response),"Overall Percent Change in Variant Allele Fraction (VAF, %) of KRAS in Participants With Detectable KRAS Mutant Circulating Tumor Deoxyribonucleic Acid (ctDNA) at Baseline and After Treatment",,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE2']
6268,NCT06028724,Real world prevalence of clinically useful mutations in solid tumors,To evaluate the association between somatic genetic alterations and the clinical characteristic of the enrolled patients,,2023-05-26,RECRUITING,OBSERVATIONAL,['NA']
6269,NCT01097304,Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining,"Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6270,NCT03303495,Overall survival,Incidence of Adverse Events (Adverse Reactions),,2011-11-14,UNKNOWN,INTERVENTIONAL,['PHASE3']
6271,NCT03356002,Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy,Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers,,2018-01-28,COMPLETED,INTERVENTIONAL,['NA']
6272,NCT05924997,Adverse events (AEs) and serious adverse events (SAEs),Overall Survival,,2023-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6273,NCT00958841,Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs),Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
6274,NCT05009953,Objective Response Rate (ORR),UGT1A1,,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6275,NCT02453490,Objective response rate,R0 resection rate of liver,The early tumor shrinkage （ETS）and depth of response(DPR),2015-10-11,TERMINATED,INTERVENTIONAL,['PHASE3']
6276,NCT02486198,The relief of neurotoxicity in patients with grade 2 or higher neurotoxicity by means of CTC 4.03 and EORTC QLQ-CIPN20,quality of life,,2015-05-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6277,NCT02672865,Post Operative Complications,,,2016-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6278,NCT00633607,"Establish a Hereditary Colorectal Tumor Registry to facilitate development and implementation of epidemiological, clinical and cancer control research.",,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
6279,NCT03360461,To investigate the ability of EMI-137 to produce visible fluorescence in regional lymph nodes draining the colon cancer.,Study of in vivo imaging compared against ex vivo fluorescent detection,,2018-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
6280,NCT02811497,Overall response rate (ORR),Incidence of treatment-emergent adverse events (AEs),,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6281,NCT01905202,Number of patients with adverse events,Number of participants who develop C. difficile induced diarrhea,48 hour gastroesophageal pH measurement,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
6282,NCT01345526,"PFS rate, toxicity, compliance",,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6283,NCT03482102,Best Overall Response rate,Time to Disease Progression,,2018-05-14,RECRUITING,INTERVENTIONAL,['PHASE2']
6284,NCT04256707,Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs),Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1,,2020-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6285,NCT05703750,Overall Survival(OS),Progression free survival(PFS) per mRECIST,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA']
6286,NCT04513119,The incidence of local tumor progression (LTP),Tumor-free survival,,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
6287,NCT00599833,Progression-free survival rate at 6 months,Clinical benefit response,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6288,NCT04066660,Disease Control Rate,Quality of Life (QoL),,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6289,NCT05187481,Overall survival,the United States Eastern Oncology Collaboration Group (ECOG) score scale,,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
6290,NCT00559351,"mean, median, 1-year, 3-year, 5-year overall survival",curative resection rate,,2001-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6291,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,,2016-04-22,COMPLETED,INTERVENTIONAL,['NA']
6292,NCT00706576,Number of participants with opioid growth factor toxicity,Change in plasma opioid growth factor levels,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6293,NCT05877573,pCR rate,SAE,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
6294,NCT03635489,Progression-Free Survival (PFS),Percentage of Participants With Adverse Events (AEs),,2018-08-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6295,NCT03388190,Primary - progression-free survival (PFS),Secondary 8 - Quality-of-life (QoL),Exploratory 5 - Histologic and molecular tumor biomarkers,2018-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6296,NCT03350945,Tumor localization time,Blood loss,,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6297,NCT02162758,Percentage of Participants With Recurrence of Intestinal Metaplasia (IM),Change From Baseline in the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Total Score,,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2']
6298,NCT02757859,Overall Survival,Site of first recurrence,Presence of cells in cytologic washing,2016-04-27,RECRUITING,INTERVENTIONAL,['NA']
6299,NCT05236972,Disease Free survival [ Time Frame: 3 years ],Overall Survival [ Time Frame: 5 years ],,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
6300,NCT04217954,Overall response rate,Progression-free survival,,2020-07-28,COMPLETED,INTERVENTIONAL,['PHASE2']
6301,NCT00059982,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6302,NCT03213314,Correlation between the pre-operative liver health assessment score and the post-operative liver function composite integer-based risk score.,• To evaluate LiverMultiScan image interpretations correlated with post-operative length of stay.,,2017-09-07,COMPLETED,INTERVENTIONAL,['NA']
6303,NCT01312857,to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases,to analyze tumor tissue for predictive biomarkers,,2011-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6304,NCT00072332,,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6305,NCT00051467,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6306,NCT00488332,Optical assessment of oral mucositis in patients undergoing radiation or chemoradiation for head and neck cancer treatment,,,2006-03,TERMINATED,OBSERVATIONAL,['NA']
6307,NCT04821895,genetic profiles in gastrointestinal stromal tumor (GIST) patients,To help for search the potential targeted agents for the treatment of these wild type GIST patients,,2021-08-28,RECRUITING,OBSERVATIONAL,['NA']
6308,NCT02983500,Rate of patients with loss of > 5 % body weight,Cachexia assessment,,2016-08-28,COMPLETED,OBSERVATIONAL,['NA']
6309,NCT02231203,Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood,Change in in vivo systemic inflammatory response parameters,Cognitive function,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6310,NCT01659632,,,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
6311,NCT05715632,pCR rate,Adverse reactions and perioperative complications (Security),,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
6312,NCT00075504,Response Rate According to RECIST Criteria,Overall Survival,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6313,NCT03914443,Rate of participants with dose limiting toxicities (DLTs),Overall survival (OS),,2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6314,NCT00137592,colorectal cancer screening,colorectal cancer screening knowledge,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
6315,NCT03214939,Сytotoxicity,Relapse-free period,,2016-09-27,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
6316,NCT04517019,Evaluation of the impact of an Activity tracker based Fitness programme on the Qualitiy of Life after oncological Therapy,,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
6317,NCT01080248,Response Rate by RECIST Criteria.,Overall Survival,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
6318,NCT05593393,"The termination of the follow-up of IPMN patients, including death termination and recommended surgery termination.",The new development of worrisome features or high-risk stigmata,,2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6319,NCT05497531,Comparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency,Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS),,2022-09-07,RECRUITING,INTERVENTIONAL,['NA']
6320,NCT06109961,Phase 1 recruitment rate,Phase 2 numbers of closure all external openings of fistula tracts,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6321,NCT02071862,Safety and tolerability of CB-839: Incidence of adverse events,Clinical activity: Change in tumor volume from baseline,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6322,NCT01338948,rate of conversion (to laparotomy or laparoscopy assisted),,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6323,NCT05322486,Overall survival,Progression free survival (PFS),,2020-10-29,UNKNOWN,OBSERVATIONAL,['NA']
6324,NCT05894837,Objective Response Rate,Overal survival,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6325,NCT03735511,Overall Survival,Progression-Free Survival,,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA']
6326,NCT02289183,3-year disease free survival rate,3-year recurrence pattern,,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6327,NCT02521129,Number of participants with complications,,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6328,NCT03528785,"Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)",assess surgical morbidity,,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
6329,NCT04083573,Consistency between the result from medical monitor and that from medical augmented reality glass,,,2019-09,UNKNOWN,OBSERVATIONAL,['NA']
6330,NCT00995358,Overall survival after the 1st vaccination,Time to progression after the 1st vaccination,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
6331,NCT02425930,Disease-Free Survival,Expenditure of hospitalization,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
6332,NCT01951521,Complete response rate,(disease-free) survival,,2014-09-01,UNKNOWN,INTERVENTIONAL,['NA']
6333,NCT00058201,Overall survival,Survival rate at 2 and 5 years,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6334,NCT05367284,Treatment acceptability questionnaire,,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
6335,NCT01471353,Sorafenib Activity,Correlative Tissue Analysis,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6336,NCT03914170,Median Progression free survival (PFS),Liver metastases resection rate,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
6337,NCT00165490,"To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.",To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6338,NCT02922049,Detection of persistent or recurrent intestinal metaplasia/dysplasia and esophageal and gastric lesions by confocal laser endomicroscopy and classic histopathology,Sensitivity and specificity of the procedure,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
6339,NCT02172651,VDR Binding Sites,Number of Participants with Serious and Non-Serious Adverse Events,,2014-07-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6340,NCT05033392,Pathological complete response rate,Incidence of Adverse Events,,2021-09-14,RECRUITING,INTERVENTIONAL,['PHASE2']
6341,NCT03614013,Survival,,,2018-07-04,UNKNOWN,OBSERVATIONAL,['NA']
6342,NCT03078361,Rate of Feedback from Community Advisory Board,Rate of Receipt of Assessments from Participants,,2014-04-28,COMPLETED,INTERVENTIONAL,['NA']
6343,NCT01198704,Predictive factors of HCC recurrence,Correlation of HCC differentiation between liver biopsy and explant liver,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6344,NCT00421824,Response rate,Overall survival,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6345,NCT01459614,Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months,Overall Survival (OS),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6346,NCT04357483,Incidence of POPF,Postoperative complication,,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6347,NCT05632328,Objective Response Rate,Grade 3-5 Treatment-related Toxicity Rate,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6348,NCT02358161,Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel,Progression free survival,,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6349,NCT04329000,Number of tablets consumed,,,2010-02-02,COMPLETED,INTERVENTIONAL,['NA']
6350,NCT05004831,PFS,Safety and tolerance,,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2']
6351,NCT05681949,The reproducibility of the therapy recommendations made by ADBoard (yes/no),Time between primary presentation and start of diagnostics/therapy as recommended,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6352,NCT00892424,Determine the MTD of sorafenib and RT in patients with liver metastases using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT in patients with liver metastases.,"Document any observed late toxicities of treatment. Determine 1) the in-field local control based on CT response at 3 months;2)the time to progression and overall survival of this cohort, 3)changes in quality of life in these patients",,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6353,NCT02300922,To determine the maximum tolerated dose for 90Y-IMP288.,,,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6354,NCT04269746,Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression,,,2020-12,UNKNOWN,OBSERVATIONAL,['NA']
6355,NCT06308445,Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis.,"Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis",,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6356,NCT01344330,Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites,Cruciferous vegetable intake correlated with HDAC activity (in PBMCs),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6357,NCT03097666,Efficacy: Percent Eradication by therapeutic dose,Efficacy: Treatment,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
6358,NCT04491942,Recommended phase 2 dose (RP2D) of BAY 1895344,Progression-free survival (PFS),,2021-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6359,NCT03359850,Apparent Total Body Clearance (CL/F) of Niraparib and M1 During PK Phase,Change From Baseline in Temperature During Extension Phase,Clearance of Unbound Niraparib and M1 (CLfu/F) During PK Phase,2018-02-20,COMPLETED,INTERVENTIONAL,['PHASE1']
6360,NCT01342705,Cumulative incidence of HepatoCellular Carcinoma during follow-up,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2011-05,TERMINATED,INTERVENTIONAL,['PHASE3']
6361,NCT03367247,Feasibility of the BOLSTER Intervention,Acceptability of the BOLSTER Intervention,,2018-04-24,COMPLETED,INTERVENTIONAL,['NA']
6362,NCT02751892,Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version,Change in minutes spent in moderate and vigorous intensity physical activity with accelerometry,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
6363,NCT01224392,reduction in metabolic tumor activity,cost evaluation,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6364,NCT03488537,sensitivity/specificity for CRC,Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation,,2018-02-28,COMPLETED,INTERVENTIONAL,['NA']
6365,NCT04660058,corelation between the bile acid profile and gastric microbiota in different groups,,,2020-12-20,COMPLETED,OBSERVATIONAL,['NA']
6366,NCT02812628,3-year local recurrence,3-year disease-free survival,Perforation rate,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
6367,NCT05608967,Usability,Complications,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
6368,NCT03642067,Cohort C: Objective response rate (ORR),Number of participants experiencing study drug-related toxicities,,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6369,NCT01621295,Frequency/duration/content of routine cancer consultations surrounding key topics in the clinical dialogue.,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
6370,NCT03426904,Relapse free survival after randomization,Pathological tumor stage,,2018-10-24,RECRUITING,INTERVENTIONAL,['PHASE3']
6371,NCT02407561,Gene expression profiling will be undertaken to determine if RNA is a superior biomarker to protein,,,2015-02,TERMINATED,OBSERVATIONAL,['NA']
6372,NCT00379743,Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.,Stage at diagnosis.,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
6373,NCT05415345,evaluate the concentration of IgG antibodies to HEV,Serious adverse events occurred throughout the study,,2021-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6374,NCT03619668,Changes in position and shape of the tumour during RT.,Change in functional imaging parameter: Ktrans.,,2018-06-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6375,NCT03727763,Objective Response Rate(ORR),adverse events,,2018-10-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
6376,NCT04670445,"Change in participant knowledge, using the Immunotherapy Knowledge Assessment",Patient questions asked in visit with oncologist,,2021-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6377,NCT03667911,Boston bowel preparation score,cecal intubation rate,,2018-09-15,UNKNOWN,INTERVENTIONAL,['NA']
6378,NCT00504257,Six Month Progression Free Survival (PFS),Overall Survival (OS),,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6379,NCT00003864,,,,1999-09-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6380,NCT03069664,Change in experienced quality of life,Change in need for pancreatic enzyme supplements,,2017-11-17,RECRUITING,INTERVENTIONAL,['NA']
6381,NCT04103567,"The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called ""exposed"" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)",Types of other bacteria forming the overall bacterial composition before neoadjuvant treatment,,2020-01-14,RECRUITING,INTERVENTIONAL,['NA']
6382,NCT01477814,colorectal cancer screening,cost-effectiveness of various strategies for screening,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
6383,NCT04406831,Analysis of miRNA profile,miRNA PCR expression,,2015-04,RECRUITING,OBSERVATIONAL,['NA']
6384,NCT04229004,Overall Survival,Duration of Clinical Benefit,,2020-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6385,NCT02375880,"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.",Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1),,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6386,NCT06294548,Phase II,Disease Control Rate (DCR),,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6387,NCT06152419,Patient questionnaire on radiotherapy-related anxiety,,,2023-10-17,RECRUITING,INTERVENTIONAL,['NA']
6388,NCT01012011,Adverse events collection,Performance status,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
6389,NCT05252078,DFS,3-year OS rate,,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2']
6390,NCT06109467,Objective Response Rate (ORR),Overall Survival (OS),,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
6391,NCT02863770,"The yield of EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",Quantitative Parameters of Pancreas Lesions,,2016-07,RECRUITING,INTERVENTIONAL,['NA']
6392,NCT01351103,Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated,Absorportion and plasma concentrations of PDR001,,2011-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6393,NCT03436563,Clearance of circulating tumor DNA (cohort D),Disease-Free Survival (DFS) - cohort D only,,2018-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6394,NCT02958683,Change in volume of each thoracoabdominal compartment during breathing,Synchrony of chest wall movement,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
6395,NCT00949273,postoperative complications,3-years overall survival,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
6396,NCT00586404,"To determine the prevalence and incidence of low grade dysplasia, high grade dysplasia and adenocarcinoma in a large cohort of patients with Barrett's esophagus","To determine the magnitude of the contribution of selected factors (e.g. age, gender, ethnicity, obesity, tobacco use, alcohol use, ASA/NSAID/PPI use, duration of GERD symptoms, length of BE, HH) to the risk of HGD and CA",,2007-11,TERMINATED,OBSERVATIONAL,['NA']
6397,NCT00780169,"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)",Time to Progression and Overall Survival,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6398,NCT01935778,disease-free survival,safety profile,,2013-10-02,RECRUITING,INTERVENTIONAL,['PHASE3']
6399,NCT02522520,Maximum oxygen uptake - ( VO2 peak),Pedometer Step Count,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
6400,NCT02987296,"NK cell killing as measured on peripheral blood mononuclear cells (PBMC) between the control (placebo) and experimental cohorts, using a standard NK cell killing assay.",Compliance with perioperative arginine supplementation,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
6401,NCT02614339,Disease free survival,recurrence rate of polyps after polypectomy,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
6402,NCT00389935,Blood Transfusion requirements,Hemoglobin overall complication rate Constipation Neuropathy,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6403,NCT03217643,Evaluate the 2-year progression-free survival,,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6404,NCT02017015,Overall Response Rate (ORR) Based on Independent Radiological Review (IRR),Kaplan-Meier Estimate of Overall Survival (OS),,2013-12-24,COMPLETED,INTERVENTIONAL,['PHASE2']
6405,NCT02433938,bowel function recovery (Time to first bowel movement or flatus),Use of NG Tubes (Nasogastric tube (re)insertions),,2015-07,COMPLETED,INTERVENTIONAL,['NA']
6406,NCT05605197,Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability],Pharmacodynamics of U87 CAR-T cells,,2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE1']
6407,NCT05030246,Overall Survival (OS),adverse events,,2021-07-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
6408,NCT03144765,Quality of Mesorectal Excision,3-year oncologic outcomes,,2018-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6409,NCT03800602,Overall response rate (ORR),Biological response: carcinoembryonic antigen (CEA),,2019-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6410,NCT05138094,Time to functional recovery,Three and five-year overall survival,,2021-08-06,RECRUITING,INTERVENTIONAL,['NA']
6411,NCT03448341,To assess the changes of deglutition function by means of Videofluoroscopy (VFS) from before to after radiochemotherapy,"To correlate radiation dose features received by the different swallowing related structures (SWOARs) to the changes of MDADI, FEES and VFS scores from before to after treatment by using a Machine Learning Methodology",,2016-07-16,COMPLETED,OBSERVATIONAL,['NA']
6412,NCT04229524,The incidence of anastomotic fistula,,,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA']
6413,NCT02422680,Patient Satisfaction,Patient Pain (own Perception),,2015-03-23,WITHDRAWN,OBSERVATIONAL,['NA']
6414,NCT06326437,the Kessler psychological distress scale-10,Locke-Wallace Marital Adjustment Scale,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6415,NCT02012231,Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394,Identification of Recommended Phase 2 dose (RP2D),,2014-02,TERMINATED,INTERVENTIONAL,['PHASE1']
6416,NCT02460198,Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor,Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor,,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2']
6417,NCT05732181,Pain severity,,,2017-05-09,COMPLETED,INTERVENTIONAL,['NA']
6418,NCT03581890,Postoperative 1-year mortality rate (study 2),Postoperative 90-day mortality (study 2),,2007-12-01,UNKNOWN,OBSERVATIONAL,['NA']
6419,NCT02010567,Pathological Complete Response (pCR) Rate,Overall Survival (OS) Based on Pathological Complete Response (pCR).,,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6420,NCT04227808,1-year RFS rate,Health-related quality of life,,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
6421,NCT04337879,Progression-free survival (PFS),Duration of response (DOR),,2020-07-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6422,NCT06233994,Progression Free Survival (PFS),,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6423,NCT00898768,"The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.",The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.,,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6424,NCT05257135,Number of biological risk factors for colorectal cancer,,,2021-12-23,RECRUITING,INTERVENTIONAL,['NA']
6425,NCT00686569,Early detection of postoperative complications,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
6426,NCT00390416,1-year Survival,Patients With Measurable Disease the Confirmed Response Rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6427,NCT02870010,Tolerance: toxicities will be defined according to the scale: National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTC AE v3.0) to determine the limiting dose,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6428,NCT01679756,Overall surgical morbidity,Readmission,,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
6429,NCT01938313,Recovering Rate,Quality of life,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6430,NCT06115174,Difference in overall survival 'OS' between the two groups.,,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6431,NCT05901519,Mitigation of liver inflammation as reflected by sTNFR1 levels,Assess tumor response,,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE2']
6432,NCT03310632,tumor assessment in millimeters,Eastern Cooperative Oncology Group (ECOG) status,,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6433,NCT03038100,Overall Survival - PD-L1-Positive Subpopulation,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6434,NCT02839954,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells,Phase II: Objective Response Rate,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6435,NCT06037343,Hypervascular capsule,Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI,,2023-02-23,RECRUITING,OBSERVATIONAL,['NA']
6436,NCT05168163,Progression-free survival (PFS),Incidence of adverse events (AEs),,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE2']
6437,NCT00696696,4-month Progression Free Survival (PFS) Rate,Median Overall Survival (mOS),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6438,NCT06206707,Clinical remission of immune-mediated diarrhea,Endoscopic remission,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
6439,NCT01130142,Overall survival comparison,"Comparison of PFS, TTP and ORR",,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6440,NCT03065868,Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%,,,2015-12-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6441,NCT04139135,EFS,5-year OS rate,,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE3']
6442,NCT05278078,"Expression analysis of slimming myokines, cachectic factors, cytokines genes by Real-Time PCR",,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6443,NCT00228189,Toxicity,,,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6444,NCT04559087,Postoperative complications,survival,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6445,NCT00582699,"The levels of specific cytokines (IL-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma), the diagnosis of Depression, depressive symptom severity, and the pattern of depressive symptoms.",,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
6446,NCT05655780,Molecular profile of the tumor,,,2023-01-09,RECRUITING,OBSERVATIONAL,['NA']
6447,NCT04547725,6-month disease control rate,Safety evaluation,,2020-09-16,RECRUITING,INTERVENTIONAL,['NA']
6448,NCT05053191,Frequency of nurses' use of family centered care practices,,,2021-09-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6449,NCT00028405,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6450,NCT01531712,Resectability rate after neoadjuvant treatment with chemotherapy plus chemoradiotherapy.,Adverse events,,2011-02-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6451,NCT05497726,Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW,Number of SLN identified,,2023-01-27,COMPLETED,INTERVENTIONAL,['NA']
6452,NCT02110082,"The primary safety endpoint is the incidence, potential significance, and clinical importance of adverse events",Trough observed concentration (Cmin) of BMS-663513 in combination with Cetuximab,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6453,NCT02012023,mortality,operation data,hospital costs,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6454,NCT00553332,Objective Response Rate (CR and PR),Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6455,NCT02691052,Global Health Status/Quality of Life Score at 3 months,Correlations of tumor response and survival with genetic alterations,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
6456,NCT00813696,overall survival,time to progression,,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
6457,NCT02198092,Septin9 Plasma Levels,Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers,Circulating Colonic Epithelial Cells at Blood Draws,2014-07,COMPLETED,OBSERVATIONAL,['NA']
6458,NCT03448549,3 year disease free survival,The accuracy of assessment of preoperative CT images on the stage,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6459,NCT02422433,Feasibility of the marking OFDI capsule for diagnosing BE by comparing OFDI images and biopsy diagnosis,Sensitivity of the marking OFDI Capsule to correctly detect and mark the region of interest in BE,,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6460,NCT04674228,Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms,Number of participants with evidence of progression of upper GI disease,,2021-05-07,COMPLETED,OBSERVATIONAL,['NA']
6461,NCT01094561,S-MRCP and S-EUS Concordance,The Positive Predictive Value of S-MRCP,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
6462,NCT03526952,Change in mutual identity from four different time points,Patients' change in adjustment to bladder cancer from four different time points,Therapeutic Alliance,2018-05-04,UNKNOWN,INTERVENTIONAL,['NA']
6463,NCT04224480,Number of CD8+ Ki67+ T cells found in resected tumour from subjects,,,2019-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6464,NCT02301091,Overall survival rates,Number of participants with adverse events,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
6465,NCT04599660,To evaluate the onset of other neoplasms in very-low and low risk GIST patients,Overall survival (OS).,,2020-11-25,COMPLETED,OBSERVATIONAL,['NA']
6466,NCT05006326,Sensitivity and specificity of 68Ga-PSMA PET/MR for diagnosis and staging in hepatocellular carcinoma.,Correlation of 68Ga-PSMA uptake in HCC patients with PSMA expression levels in tissues.,,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA']
6467,NCT03188432,Quality of life (QOL) assessed using Functional Assessment of Cancer Therapy-Ovarian questionnaire,Response rates evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6468,NCT03143140,completed tumor necrosis,tumor recurrence,,2014-05-22,UNKNOWN,INTERVENTIONAL,['NA']
6469,NCT02171286,Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report,Percent of cases in which a Oncopanel report is generated on a tumour specimen that has been received,Concordance between Oncopanel results and ctDNA sequencing,2014-10,COMPLETED,OBSERVATIONAL,['NA']
6470,NCT02347904,The percentage of patients completing the preplanned number of 6 cycles of SOX.,Overall survival,AUC of S-1,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6471,NCT05121571,Progression free survival,tumor response,,2016-04-21,COMPLETED,INTERVENTIONAL,['NA']
6472,NCT05375643,Genomic testing uptake,Acceptability of questionnaire modality,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
6473,NCT03502317,Global Health Score,Health care utilization,,2018-08-14,UNKNOWN,INTERVENTIONAL,['NA']
6474,NCT03936179,overall survival rate,acute and late toxicities,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
6475,NCT00647153,Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66,Safety of iodine I 123 anti-CEA recombinant diabody T84.66,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6476,NCT00473941,Depressive symptoms,,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
6477,NCT00149578,chemotherapy and concurrent chemoradiotherapy in locally advanced pancreatic cancer. .,"The secondary end points are to evaluate the distant metastasis rate and time to tumor progression, overall survival time and quality of life after induction",,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
6478,NCT01880918,The rate of anastomotic leakage.,Rate of other device related complications and measures during hospitalization and post procedure.,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
6479,NCT02832882,12 month local tumor progression (LTP) rate,Technical success rate,Technical efficacy 2,2016-10-21,COMPLETED,INTERVENTIONAL,['NA']
6480,NCT02164136,Sexual function,5-year recurrence pattern,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
6481,NCT03889626,Progression Free Survival (PFS),Overall Survival (OS),Adverse Events,2019-03-22,UNKNOWN,INTERVENTIONAL,['PHASE3']
6482,NCT00692211,Colorectal Cancer Screening,,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6483,NCT03564834,Postoperative complication rate,Postoperative pain,,2018-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
6484,NCT04668976,Percent frequency liver toxicity,Progression free survival,,2020-11-25,RECRUITING,INTERVENTIONAL,['PHASE2']
6485,NCT00061308,response rate,response duration time to response time to progression survival safety,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6486,NCT05180565,To measure the incidence of serious adverse events related to using the device,To measure the patient tolerability of the device using a patient questionnaire,,2019-12-18,COMPLETED,INTERVENTIONAL,['NA']
6487,NCT03653377,HPV vaccination,,,2018-12-17,COMPLETED,OBSERVATIONAL,['NA']
6488,NCT03951324,Frequency and type of criteria visually identified on malignant VLE clips,Number of procedures needed to view and conduct to use VLE for diagnostic confirmation,,2019-05-10,UNKNOWN,OBSERVATIONAL,['NA']
6489,NCT00966277,Number of Participants With Venous Thromboembolic Events (VTE),,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6490,NCT04696757,DFS,,,2018-02-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6491,NCT06168084,Helicobacter pylori eradication,adverse events,,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE4']
6492,NCT00268463,Progression-free Interval (PFI),"Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study",,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3']
6493,NCT00788957,Part 2: Percentage of Participants With an Objective Response,Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab,,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6494,NCT04956640,To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation,To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax),,2021-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6495,NCT04948034,Objective Response Rate,Acute Toxicity,,2021-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
6496,NCT03299946,Number of patients who complete pre-op treatment and proceed to surgery.,Disease free survival (DFS),,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE1']
6497,NCT06189547,overall survival (OS),cancer-specific survival (CSS),,2023-02-02,COMPLETED,OBSERVATIONAL,['NA']
6498,NCT04331184,Local tumor progression,technical success rate,,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA']
6499,NCT04080154,Progress free survival (PFS),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2']
6500,NCT05322499,Objective response rate (ORR),Overall survival (OS),,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6501,NCT01704703,Objective response rate (TRO),Adverse events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6502,NCT02848638,Degree and distribution of Y90 particle uptake,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
6503,NCT00568308,Disease-free Survival,Compliance,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6504,NCT04212026,The objective response rate (ORR) after the 5th dose of nivolumab of the reference liver metastasis that was not biopsied.,Adverse events,,2020-06-28,TERMINATED,INTERVENTIONAL,['PHASE2']
6505,NCT02337673,Change of regional ventilation partition (ROI analysis in 8 pulmonary ROIs) from preoperative to postoperative state.,Ventilator-obligatory-free days,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
6506,NCT03766776,PFS,,,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA']
6507,NCT05153304,Treatment-related Adverse Events,Duration of response,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6508,NCT01335074,Maximum Tolerated Dose,Overall response rate,,2011-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6509,NCT01471470,R0 resection rate,Angiogenetic biomarkers,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6510,NCT00002883,,,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6511,NCT05044676,Measurement of the phenotype of expression of CD226 3 weeks after the start of treatment,Correlation between pathology features (tumoral and non-tumoral liver) and the frequency and phenotype of expression of CD226,,2023-09-08,RECRUITING,OBSERVATIONAL,['NA']
6512,NCT00166465,Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.,,,2003-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6513,NCT05580445,Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine,Disease control rate (DCR) according to RECIST v1.1,"Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine",2022-08-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6514,NCT03316053,Cell Markers,,,2017-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6515,NCT02997956,Median Progression Free Survival,Number of patients alive at two years post treatment,,2017-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6516,NCT01203163,Proportion of patients experiencing Adverse Reactions of Special Interest,Overall safety in patients with renal insufficiency (disease),,na,WITHDRAWN,OBSERVATIONAL,['NA']
6517,NCT04112940,Amount of Residue in the Pharynx,Number of Participants Reporting Dislike of Thickened Liquid Stimuli,,2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
6518,NCT02688712,Evaluation of pathologic response,Immunologic monitoring parameters,,2016-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6519,NCT00209703,Incidence and severity of adverse event,"Determine the clinical response rate, disease-free survival(DFS), overall survival(OS)",,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2']
6520,NCT01747642,Number of patients who have prolonged survival,Reduction in serum alpha-fetoprotein level and decrease in tumor size,,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6521,NCT04609813,Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions,Diagnostic performance of abnormal cell count,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
6522,NCT01964534,Progression-free survival (PFS),Number of Adverse Events,,2013-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
6523,NCT02385578,The rates of EGC detection,,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
6524,NCT00769652,Change in Patient Generated Subjective Global Assessment (PG-SGA) Score at Time of Initial Presentation and Throughout Study,,,2006-10,TERMINATED,INTERVENTIONAL,['NA']
6525,NCT00084461,Objective response rate,Incidence of toxicity,,2004-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6526,NCT01982994,Percentage of patients with diagnosed gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.,Percentage of patients with a diagnosis of gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education.,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
6527,NCT00700570,Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases,Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6528,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6529,NCT00004909,,,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
6530,NCT00687843,Relapse-free survival,"Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers",,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6531,NCT02018107,"Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)",Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6532,NCT01032057,Progression-free survival at 39 weeks (from registration) according to RECIST criteria,Radiotherapy quality assurance (adherence to protocol),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6533,NCT01191632,Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity,"To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria",,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6534,NCT00730860,disease free survival,overall survival,,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
6535,NCT01313078,"Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.",,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6536,NCT00040183,,,,2001-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
6537,NCT06310473,Pathologic complete remission rate (pCR),Overall Survival (OS),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6538,NCT04675138,Concordance Rate,Reason for Discordance,,2020-08-20,UNKNOWN,OBSERVATIONAL,['NA']
6539,NCT01251237,Overall Acceptance on VAS (100mm) rating,Efficacy on five-grade scale for pre-defined colon areas,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6540,NCT04230187,Progression-free survival (PFS),"Toxicity assessed using the NCI common toxicity criteria, version 5.0.",,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
6541,NCT05438771,Oral Care Control Chart,Number of participants with abnormal laboratory test results,patient education,2021-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6542,NCT04152265,Completion of the assigned screening strategy,Determination of anthropometric data,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
6543,NCT05205330,Disease Control rate (DCR),Safety and Tolerability of CR6086 combined with AGEN2034,,2021-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6544,NCT04798898,Overall survival,Recurrence rate,Complications,2022-11-14,RECRUITING,INTERVENTIONAL,['NA']
6545,NCT03500471,Overall postoperative morbidity and mortality,cost,3-year Overall survival rate,2018-04-16,COMPLETED,OBSERVATIONAL,['NA']
6546,NCT05352204,overall survival,disease-free survival,,2020-04-30,COMPLETED,OBSERVATIONAL,['NA']
6547,NCT00227617,Best Objective Response,Biochemical Marker Response,,2005-06-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6548,NCT00875615,Number of Subjects Experiencing Adverse Events,Number of Patients Achieving Clinical Benefit,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6549,NCT00004102,,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6550,NCT04952753,Expansion: Progression-free survival (PFS) by investigator assessment per RECIST 1.1,ADA incidence on treatment,,2021-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6551,NCT02200315,Postoperative surgical site infection,Hospital stay,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6552,NCT03646591,Completion rate of preoperative FLOT regimen,Postoperative mortality,,2017-11-15,COMPLETED,OBSERVATIONAL,['NA']
6553,NCT03463616,Percentage of patients who needed additional radiology examination/s before treatment planning after routine MRI of abdominal organs compared with routine CT of abdominal organs.,Disease free survival after 3 years,,2018-03-15,COMPLETED,OBSERVATIONAL,['NA']
6554,NCT06061432,Rate of complications during endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),Rate of clinical success of endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6555,NCT04697303,Overall survival,FSFI-6,,2020-10-26,COMPLETED,OBSERVATIONAL,['NA']
6556,NCT04569331,Quality of life related to health (European Organization for the Research and treatment of Cancer Quality of Life Questionnaire (QLQ-CR29).,Low anterior resection syndrome (LARS),Percentatge of patients with postoperative paralytic ileus,2020-05-15,COMPLETED,INTERVENTIONAL,['NA']
6557,NCT00562640,Best Response,,,2007-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
6558,NCT04892927,Improved information sharing,,,2021-05-03,UNKNOWN,OBSERVATIONAL,['NA']
6559,NCT02857608,Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods),Incidence of Adverse Events,,2016-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6560,NCT00155558,To determine the maximum tolerated dose and dose limiting toxicity,response,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6561,NCT05638438,the objective response rate (ORR),Adverse events,,2022-12-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6562,NCT00080236,Peak absolute change in aspartate transaminase (AST) values measured from baseline to up to 3 days post-transplantation,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6563,NCT05448222,progression free survival,Hospital cost,,2022-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6564,NCT05088811,Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma,,,2021-08-21,UNKNOWN,OBSERVATIONAL,['NA']
6565,NCT04107077,The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency,Perioperative mortality at 30 days,,2019-11-11,RECRUITING,INTERVENTIONAL,['PHASE2']
6566,NCT04434989,Disease-free survival,Adverse events,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
6567,NCT00897494,Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
6568,NCT06196671,Overall survival，OS,disease control rate (DCR),,2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6569,NCT01528059,Glycemic control,Nutritional status assessment,,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6570,NCT01844375,Meters Walked During 2-Minute Walk Test,Nitrogen Balance,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
6571,NCT04024345,Multidimensional Scale of Perceived Social Support,,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6572,NCT00357474,overall survival rate,Disease free survival rate and recurrence rate,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6573,NCT03599362,Number of Participants Who Proceeded to Surgical Resection,,,2018-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
6574,NCT00732745,Progression-free survival (Phase II) at 5 months,Correlation of tumor characteristics and tumoral expression with response and outcome (Phase II),,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1']
6575,NCT01264952,"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)","Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology",,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6576,NCT02005419,Recurrence-free survival at one year after curative resection,Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6577,NCT05715905,Rate of patients who remain in a colon cancer clinical trial to trial completion,,,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6578,NCT06130644,MSI status,Tumor Mutation Burden (TMB),,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
6579,NCT02809287,Blood loss,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6580,NCT05314101,progression free survival,Objective Response Rate (ORR),Overall survival (OS),2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6581,NCT04493060,Disease control rate at 12 weeks (DCR12),Incidence of adverse events (AEs),Changes in the cytokine profile pre- and post-treatment,2020-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6582,NCT06065371,Primary Endpoint,Overall Survival (OS),Exploratory Endpoint,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6583,NCT01723969,Tumour markers assessment,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
6584,NCT02556281,Number of patient with a first relapse,Number of free tumoral DNA in blood of patient with colorectal cancer,,2012-10-15,UNKNOWN,INTERVENTIONAL,['NA']
6585,NCT00311272,,,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6586,NCT00107250,Dose limiting toxicity,Tumour Response,,2005-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
6587,NCT06091137,Appendectomy is associated with risk of subsequent CRC incidence,,,2022-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6588,NCT04755907,Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.,Response of the colorectal cancer patients to neoadjuvant chemotherapy.,Response of the colorectal cancer patients to adjuvant chemotherapy.,2021-03-01,RECRUITING,OBSERVATIONAL,['NA']
6589,NCT04111692,Change in Polycystic Liver Disease Quality of Life,,,2017-11-06,RECRUITING,OBSERVATIONAL,['NA']
6590,NCT01183780,Overall Survival (OS),Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab,,2010-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6591,NCT01203969,rate of 30 day morbidity and mortality,Duration of postoperative hospital stay,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6592,NCT05216653,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX,Quality of life of the patients in a neoadjuvant setting of short-course radiation then Envafolimab Plus CAPEOX as assessed by FACT-C questionnaire,,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6593,NCT04448652,Postoperative opioid-consumption,mortality,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
6594,NCT04609137,"Number of patients (n, %) developing a clinically-relevant pancreatic fistula (CR-POPF)","Number of patients (n, %) requiring an unplanned hospital readmission after discharge",,2020-10-13,COMPLETED,INTERVENTIONAL,['NA']
6595,NCT00486954,Overall Survival (OS) in the Randomized Part of the Study,Number of Participants With Mutations That May Correlate With Response and Toxicity to Lapatinib,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6596,NCT04484636,"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer",Number of patients receiving therapies in accordance to their genomic profiles,,2020-10-28,RECRUITING,INTERVENTIONAL,['NA']
6597,NCT05537129,3 year-DFS,morbidity and mortality rates,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
6598,NCT06121089,Disease-free survival.,Number of days of inpatient treatment.,Quality of life in patients after ICR and RHC using questionnaire.,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
6599,NCT06231524,Overall survival,Progression-free survival,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
6600,NCT02195180,Progression free survival (PFS),Quality of Life status,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6601,NCT01049620,To assess the maximum tolerated dose (MTD),Response rate,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6602,NCT03848962,Collection of Biospecimens for Novel Research Uses,,,2016-06-30,RECRUITING,OBSERVATIONAL,['NA']
6603,NCT04006301,Part 2: Overall Response Rate (ORR),Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method,,2019-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
6604,NCT03132025,Progression-free Survival of Patients with Apatinib and Capecitabine Combination That is prolonged,,,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
6605,NCT01704664,Phagocytic activity of blood platelets in gastric cancer patients.,,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
6606,NCT00066274,,,,2002-07-23,COMPLETED,INTERVENTIONAL,['PHASE2']
6607,NCT03673072,Primary efficacy endpoint is overall survival (OS),Number of patients with any serious perioperative morbidity or mortality,,2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
6608,NCT04749862,Participant Recruitment,Intervention implementation process measures: frequency of reported problems,Information systems,2021-03-22,RECRUITING,OBSERVATIONAL,['NA']
6609,NCT01008475,Randomized Part: Progression Free Survival (PFS),Time to Treatment Failure (TTF),,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6610,NCT02322593,Overall Survival,Disease Control Rate,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6611,NCT03109639,Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles,Qualification of the sample obtained using the two needles will be performed by spectroscopic analysis.The ratio of absorbance at 260 nm and 280nm; the ratio of absorbance at 260nm and 230nm will be measured,,2017-04-13,COMPLETED,INTERVENTIONAL,['NA']
6612,NCT04002778,Procedure duration,Diagnostic yield,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6613,NCT02908165,EASL criteria for tumor response,Overall survival (OS),,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6614,NCT01596790,Predictive value of the CTC on the Progression Free Survival,Comparison of the results with the CellSearch system vs EPISPOT,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6615,NCT00113360,Progression Free Survival (PFS),,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6616,NCT00047229,Rate of objective response (complete and partial),Safety and tolerability,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6617,NCT02013154,Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab),Progression Free Survival (PFS),,2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6618,NCT05648006,Progression-free survival,Toxicity by CTCAE v5.0,,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2']
6619,NCT03589131,Operative time of robotic-assisted rectal cancer surgery.,Accurate safety margin,,2015-04-29,COMPLETED,INTERVENTIONAL,['NA']
6620,NCT01042028,Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death,Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy,,2010-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6621,NCT00654342,Accuracy & sensitivity of sentinel lymph node mapping,,,2007-10,UNKNOWN,INTERVENTIONAL,['NA']
6622,NCT01130363,Number of patients with fundic gland polyps and PPI use that have a higher gastric pH,,,2006-10,TERMINATED,OBSERVATIONAL,['NA']
6623,NCT06075836,Reader speed with vs without AI assistance.,,,2023-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6624,NCT02199002,acid pocket position,number of reflux episodes,acid pocket contents,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6625,NCT00286130,the percentage of patients surviving without disease progression in each arm at 9 months,Safety,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6626,NCT01628640,Tumor necrosis,,,2012-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6627,NCT00898495,Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection),,,2007-05-11,COMPLETED,OBSERVATIONAL,['NA']
6628,NCT04110093,Progress Free Survival,Adverse Effect,,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6629,NCT04938986,Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision,"Actual survival (patient alive without recurrence, alive with recurrence, dead)",,2022-04-04,RECRUITING,INTERVENTIONAL,['NA']
6630,NCT00022698,Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0),"Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths",,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6631,NCT04030624,The Feasibility of Remote Electronic Patient Monitoring Intervention,Health Care Utilization,,2020-09,WITHDRAWN,INTERVENTIONAL,['NA']
6632,NCT01339169,Visual assessment of the distribution of gastric carcinoids.,Plasma or serum concentrations of biomarkers such as gastrin or chromogranin A (CgA).,,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6633,NCT02809846,Change in Daily Opioid Use Assessed as Recorded by the Subject in Their Analgesia Diary.,,,2016-07,TERMINATED,INTERVENTIONAL,['NA']
6634,NCT06242457,Complete resection of adenocarcinomas located in the jejunum or ileum is associated with 5-year survival rates of 20% to 30%.,,,2023-07-15,COMPLETED,OBSERVATIONAL,['NA']
6635,NCT04146441,Volume change of primary tumor,Rate of reported toxicity,,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6636,NCT04430738,Incidence of dose alterations (Cohort 1D),"Objective response rate (ORR) (Cohorts 1C, 1E, 1F, and 1G)",,2020-09-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6637,NCT00051987,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6638,NCT00039793,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6639,NCT00101998,"Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.","Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.",,2003-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6640,NCT01031784,Toxicity of Ho-166 poly lactic microspheres using CTC vs 3 criteria,tumor response according to RECIST criteria,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6641,NCT04348084,impact of clinically relevant (CR-) POPF,identifying positive and negative prognostic factors,,2009-01-30,COMPLETED,OBSERVATIONAL,['NA']
6642,NCT04490694,Objective remission rate（ORR）,Overall survival,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6643,NCT05628038,Local objective response rate,Safety and tolerability of the treatment,,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE2']
6644,NCT03831698,Retention rate of participants,Proportion of participants with treatment-related adverse events in each arm.,,2019-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6645,NCT01541683,measurement of Palatability of the PEG-electrolyte solution,Side effects,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
6646,NCT03298451,Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg,Summary of Tremelimumab Concentration Over Time,,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6647,NCT00209651,objective tumor response,"Response duration, time to progression, overall survival, and safety will also be assessed.",,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6648,NCT06172478,Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy,Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2']
6649,NCT01598077,Dose-limiting toxicities (DLTs),"Serum concentration of LJM716,",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6650,NCT01346917,Prevalence of postoperative nausea and vomiting.,Duration of postoperative hospital stay.,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
6651,NCT04144738,Specificity with the mt-sDNA 2.0 test,Specificity for no colorectal neoplastic findings,,2019-11-15,COMPLETED,OBSERVATIONAL,['NA']
6652,NCT06124729,cCR,Disease-free survival (DFS) and overall survival (OS),,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6653,NCT01099631,Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium,Peripheral Blood T Cells Count,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6654,NCT00177242,Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.,Determine the time course of serial CA19-9 measurements during treatment.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6655,NCT04295473,3-year survival rate,Quality of life in PGSAS-45 scale,,2020-03-02,RECRUITING,INTERVENTIONAL,['NA']
6656,NCT01363739,Progression-Free Survival,Overal survival,,2009-04,UNKNOWN,OBSERVATIONAL,['NA']
6657,NCT02525965,Overall survival rates of each group,Occurrence rate of recurrence of each group,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
6658,NCT05920863,Major pathological response,Recurrence-free survival (RFS),,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6659,NCT04436679,Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.,Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.,,2021-02-02,RECRUITING,OBSERVATIONAL,['NA']
6660,NCT03001726,overall survival,progression-free survival,adverse events,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
6661,NCT03944447,Treatment of Symptoms,Monitoring Adverse Events,,2018-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6662,NCT05350501,Response to treatment at 6 months,Immunogenicity and cross-reactivity,,2023-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6663,NCT04943419,Level of MDSC in patients with postoperative complications,Level of MDSC in patients with left and right sided tumours,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
6664,NCT02195141,• Pathological complete remission rate (pCR),Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE),• Disease-free survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6665,NCT04482257,λz,,,2020-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
6666,NCT01125020,tumor recurrence and metastasis,Postoperative survival,,2008-12,UNKNOWN,INTERVENTIONAL,['NA']
6667,NCT00356889,Number of Confirmed Tumor Responses.,Duration of Response,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6668,NCT02841800,survival benefit,repeated biliary interventions,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
6669,NCT00003225,To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.,"To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival.",,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6670,NCT06200363,Adverse event,Quality of life questionnaire (QLQ-C30),,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE1']
6671,NCT01090505,overall survival,response rate,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
6672,NCT02943837,"Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis",,,2016-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
6673,NCT00960427,Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy,,,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
6674,NCT03844620,"Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms",Proportion of patients referred to clinical trial,,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6675,NCT05212012,Disease control rate 12 weeks after randomization (ITT-population),Adverse events,,2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6676,NCT03298945,Population level adenoma detection rate (ADR),Adequate bowel prep quality,renal failure,2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6677,NCT04965597,Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS),Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT,,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2']
6678,NCT02290977,Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT,Radiologic response assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST) after scheduled TACE-RT for HCC with PVTT,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
6679,NCT00774839,Self-reported expenses associated with colon cancer treatment and living with this illness.,"Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs.",,2008-10,COMPLETED,OBSERVATIONAL,['NA']
6680,NCT04842812,Safety of TILs/CAR-TILs treatment in advanced solid cancers,Primary clinical efficacy of the TILs/CAR-TILs treatment in advanced solid cancers,,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
6681,NCT03023722,Response Rate as Measured Per RECIST 1.1 Criteria,Drug Toxicity,,2017-05-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6682,NCT02013492,Effect of beta-adrenergic blockade on the host immune system,Overall survival,,2014-01-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6683,NCT05836246,Quantitative ultrasound information,,,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6684,NCT05188573,Clinical performance of test: Specificity,Stage Shift,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6685,NCT00285701,,,,2006-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6686,NCT02806076,12 month local tumor progression (LTP) rate,Technical success rate,Technical efficacy 2,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6687,NCT01313026,changes in LARS score,Patient Satisfaction,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
6688,NCT00416507,,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6689,NCT00026364,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6690,NCT04993131,Overall survival,Survival in relation to biological markers,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
6691,NCT04947995,The sensitivity and specificity of blood-based multi-omics assay for early detection of gastric cancer with comparison to EGD and/or histological diagnosis.,,,2021-06-15,UNKNOWN,OBSERVATIONAL,['NA']
6692,NCT00902902,,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
6693,NCT02781155,Adherence to moxa regimen assessed by Daily Moxa Diary,Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts,,2016-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6694,NCT06278493,Maximum tolerated dose (MTD),,,2018-08-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6695,NCT03029611,Rate of Pathologic Complete Response (CR),Tumor Burden,Predictive Signature of CR Induction When Vaccinated With an IGFBP-2 Vaccine in Combination With Neoadjuvant Chemotherapy Assessed by Whole Exome Sequencing on Vaccinated Patients' Tumors,2017-04-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6696,NCT05250791,Clinicians' reasons for not recruiting patients.,Total hospital stays including readmission,Pro-inflammatory cytokine levels,2023-02-02,RECRUITING,INTERVENTIONAL,['NA']
6697,NCT00493428,"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization.",Document and compare the effects of the GABAb receptor agonist Baclofen on changes in serum tumor markers ( alpha-fetoprotein andd CA19-9 levels) in patients with no-metastatic HCC at diagnosis.,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6698,NCT03824899,pathological response rate,,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
6699,NCT00057980,Overall survival,Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response,,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6700,NCT04525989,Incidence of acute grade 2-5 gastrointestinal toxicity,Cost effectiveness analysis measured by QALY,Exploratory: Difference in concentrations of CEA (carcinoembryonic antigen) between treatment arms,2021-04-20,RECRUITING,INTERVENTIONAL,['NA']
6701,NCT02726243,Composition of fecal microbiota by 16S sequencing,Profile of fecal bile acids,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
6702,NCT01929122,Stool Microbiome Composition and Metabolome,"Navy Bean or Rice Bran metabolites in stool, urine and blood.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6703,NCT00507585,"To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver.",,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6704,NCT00492752,Overall Survival,Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6705,NCT04937738,Histopathological regression rate (Becker regression criteria),Median overall survival,,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6706,NCT01222208,Whole body protein balance,Synthesis rates of hepatic secretory proteins,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6707,NCT02299843,mortality during perioperation,,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
6708,NCT00908752,"To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy",To evaluate the safety of brivanib in combination with TACE,,2009-07-20,COMPLETED,INTERVENTIONAL,['PHASE3']
6709,NCT03164382,Overall survival,Time to Intrahepatic tumor Progression,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6710,NCT01257035,Response to chemoradiotherapy measured by TRG,Survival,,2010-11,TERMINATED,OBSERVATIONAL,['NA']
6711,NCT02557061,Number of alive patients,Rate of preoperative blood T-lymphocytes,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6712,NCT01768195,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,the incidence of hepatitis B virus relapse and relapse related hepatitis,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6713,NCT00766155,Disease-free survival,"Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6714,NCT05958550,Whether hypothermia occurs,,,2024-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6715,NCT06040099,Progression Free Survival (PFS),Duration of Response (DoR),,2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2']
6716,NCT04966195,overall survival,objective response rate,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
6717,NCT01598597,Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA),"Demographic distribution (age, sex) of subjects participating in this study",,2012-03,COMPLETED,OBSERVATIONAL,['NA']
6718,NCT04906174,Incidence of complications after liver resection,,,2021-04-10,RECRUITING,OBSERVATIONAL,['NA']
6719,NCT00646100,survival rates,quality of life,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6720,NCT01744054,Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization,,,2012-10-25,TERMINATED,INTERVENTIONAL,['PHASE1']
6721,NCT05196867,Change in FIB-4 score,,,2022-02-11,RECRUITING,INTERVENTIONAL,['NA']
6722,NCT05551247,ORR,SAE,,2022-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6723,NCT03126435,Overall Survival,Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate,"Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score",2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE3']
6724,NCT02290574,Adverse Event of Laparoscopic TME and Hyperthermia With CCRT,Pathologic Complete Response of Hyperthermia With CCRT,,2014-11,TERMINATED,INTERVENTIONAL,['NA']
6725,NCT05400031,Oral mucositis grading,,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA']
6726,NCT02368977,Device usability factors,Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability,,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA']
6727,NCT00288925,"Safety, Pharmacokinetics","Tumour shrinkage, Tumour objective response rate",,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6728,NCT02724436,Postoperative complication,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
6729,NCT04328948,Major progression-free survival,Long term toxicity,,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
6730,NCT05540951,objective response rate,,,2018-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
6731,NCT01043016,Maximum tolerated dose,Treatment efficacy as measured by computed tomography (CT) or magnetic resonance imaging (MRI) and endoscopy exam 3 weeks after the start of study treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) standard,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
6732,NCT04290806,Course of treatment (treatment reality),,,2019-12-04,RECRUITING,OBSERVATIONAL,['NA']
6733,NCT00004911,,,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6734,NCT05663450,Rate of R1-resection during oncologic surgery,Post-surgical survival,,1996-05-01,COMPLETED,OBSERVATIONAL,['NA']
6735,NCT01436721,the size of any subphrenic collection or pleural effusion,incidence of postoperative morbidity,,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6736,NCT04970498,Changes of ADC map of MRI,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
6737,NCT02013050,Duration of Severe Oral Mucositis (SOM),"Percent of Patients With RECIST 1.1 Classification of ""Complete Response""",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6738,NCT06205485,Quality of Life defined using the LARS score,Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1 and T2 rectal cancer,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6739,NCT03738111,Maximum Tolerated Dose,Overall Survival,Molecular Marker,2018-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
6740,NCT01456598,3 year relapse free survival,3 years overall survival,,2011-11-21,COMPLETED,INTERVENTIONAL,['NA']
6741,NCT03732235,time to progression,Number of adverse events,,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA']
6742,NCT00495625,Number of Participants With Progressive Disease (PD) at Interim Analysis,Number of Participants With Serious Adverse Events (SAEs),,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6743,NCT05397444,Hospital readmissions,prolonged length of stay,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
6744,NCT03352349,Change of Portal vein pressure,Adverse effect of Terlipressurinum,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6745,NCT01032590,Impact of an Internet-based intervention on weight loss,Potential moderators of weight loss,,2009-07,WITHDRAWN,INTERVENTIONAL,['NA']
6746,NCT05141656,OS,PFS,,2019-08-31,UNKNOWN,OBSERVATIONAL,['NA']
6747,NCT05451901,Time to clinical success from randomization,Morphological change of pancreas,,2022-07-29,RECRUITING,INTERVENTIONAL,['NA']
6748,NCT02841865,Response to treatment,Impact of Choi criteria and Progression of Disease,,2015-07-24,COMPLETED,OBSERVATIONAL,['NA']
6749,NCT01888965,Biomarker Discovery,Safety,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6750,NCT03856255,Mean Score Indicating Ease of Use in Taking a Picture That Included the Measuring Device and Polyp in Order to Photo-document the Measurement Reading,Mean Difference in Size of Polyp,,2019-06-24,TERMINATED,INTERVENTIONAL,['NA']
6751,NCT00588900,The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy,Overall Survival,,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6752,NCT04090554,Distribution of acceptability scores,Prevalence of other benign esophageal pathologies,,2019-09-24,COMPLETED,INTERVENTIONAL,['NA']
6753,NCT01676194,Survival,Efficacy of TACE,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3']
6754,NCT01618643,"Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer",To differentiate mucosal neoplasia from invasive cancer,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
6755,NCT05152472,Progression-Free Survival (PFS),Tolerability profile,,2022-01-14,RECRUITING,INTERVENTIONAL,['PHASE2']
6756,NCT00306137,Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period,Health related quality of life measurements,,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6757,NCT03838796,Disease free survival,Overall survival,,2019-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6758,NCT00023933,Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities,Immune response,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6759,NCT00139633,local control at 4 years,,,2000-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
6760,NCT03419663,the relationship between overall cereal consumption and gastric cancer occurance,the relationship between other grain and gastric cancer occurance,,2017-09-12,COMPLETED,OBSERVATIONAL,['NA']
6761,NCT01776346,Progression to esophageal adenocarcinoma,"Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases",,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
6762,NCT01498289,Overall Survival (OS),Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6763,NCT03093688,Objective Response Rate (ORR),Tumor Marker,Progression-Free Survival (PFS),2017-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6764,NCT04117945,Overall survival (OS),Incidence of adverse events,,2020-03-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6765,NCT00123825,To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers,To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6766,NCT04490551,Yield of Advanced Neoplasia,Yield of Proximally Located Advanced Neoplasia,,2019-12-05,COMPLETED,INTERVENTIONAL,['NA']
6767,NCT02466113,Disease free survival,Overall survival,,2016-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6768,NCT03082495,Change in Cardiorespiratory fitness,Safety: Adverse event rate,Number of positive lymph nodes,2017-06-26,COMPLETED,INTERVENTIONAL,['NA']
6769,NCT01639352,Disease Control Rate (DCR),Toxicity Profile of Protocol Therapy,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6770,NCT02394834,Overall survival (OS),"Evaluation of the Relationship between a Change in Each Biomarker in Tumor Tissue at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints",,2015-05-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6771,NCT04810585,Progression free survival,Prognostic or Predictive Biomarker for Aflibercept (plasma biomarker),,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4']
6772,NCT05334719,Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation,Incidence of Adverse Events (AEs),,2022-02-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6773,NCT00910676,To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began,To assess the patient quality of life with the DLQI questionnaire,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6774,NCT01684904,To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer,Number of participants with adverse events as a measure of safety and tolerability,,2013-02-20,RECRUITING,INTERVENTIONAL,['NA']
6775,NCT06278454,Adverse events (AE) and severe adverse events (SAE),Resection rate (R0 and R1),Distribution of NRT6008 injection in human body and radioactivity of biological samples,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6776,NCT03393182,Postoperative 30-day morbidity rate,QOL measurement : EORTC QLQ-C30/STO22,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
6777,NCT06198400,Evaluation of the blood flow in pancreatic remnant with use of ICG,Correlation between ICG perfusion and development of pancreatic fistula,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6778,NCT05243966,Proportion of participants with treatment emergent adverse events during the study,Percentage of split thickness skin graft take at 1 week post Matrix™ application,,2022-01-10,RECRUITING,OBSERVATIONAL,['NA']
6779,NCT04197310,Objective Response Rate (ORR),Number of Participants with Treatment Related Adverse Events,,2019-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
6780,NCT05653453,Overall survival (OS),Progression Free Survival rate at 6 months,,2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6781,NCT04640792,Comparison of the Adenoma Per Extraction (APE) between the two arms,Comparison of the Adenoma Detection Rate (ADR) between the two arms,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
6782,NCT00052364,Time to progression,Progression-free survival,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6783,NCT00469443,Time To Progression,Symptoms improvement,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6784,NCT01641887,Participant Satisfaction,Patient decisions,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
6785,NCT04355156,Overall survival,Monitoring dose reductions and the reasons behind them,,2012-09-17,COMPLETED,INTERVENTIONAL,['PHASE2']
6786,NCT02759601,Determine Maximum Tolerated Dose,Phase I & II: To determine pharmacokinetic parameters for tefinostat and CHR-2847 when administered orally at different dose levels and dose schedules.,Phase I & II: To determine the impact of HDACi on anti-tumour immune responses.,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6787,NCT00386399,6-month overall survival,To explore pharmacogenetic factors that may influence the toxicity and efficacy of MMC in this patient population.,,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6788,NCT01772706,To evaluate the efficacy of preventive and curative low energy laser induced mucositis in patients receiving concomitant chemotherapy and radiotherapy for squamous cell carcinoma of the head and neck with stage III-IV,To assess the quality of life using the QLQ-HN35 questionnaire.,To document the Overall survival calculated from the date of randomization to death from any cause or up to 5 years.,2008-10-30,UNKNOWN,INTERVENTIONAL,['NA']
6789,NCT02468726,Success of bowel cleansing,Stool weight,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6790,NCT06110598,Relapse-free survival (RFS),Overall survival (OS),,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6791,NCT05970705,PFS,DOR,AE,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6792,NCT01831310,neutrophil functions,Length of stay,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6793,NCT00095992,Response,Molecular correlates on archival tumor specimens and peripheral blood mononuclear cells (PBMCs),,2005-03-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6794,NCT01102556,Creation of a registry and blood/tissue bank,"Improvement in the diagnosis, prevention, detection, and treatment of pancreatic cancer.",,2004-07,RECRUITING,OBSERVATIONAL,['NA']
6795,NCT03721952,Hospital Anxiety and Depression Scale (HADS) - family,QUAL-E (Fam),Key Implementation Outcomes,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6796,NCT00335491,Patient perception and pattern of change,Structural and function changes,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
6797,NCT04637698,The objective response rate of patients with pancreatic cancer receiving OH2 injection.,To evaluate the impact of OH2 in patients with pancreatic cancer on the quality of life,,2021-02-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6798,NCT01568151,Number of participants who undergo colorectal screening because of interventions,Number of problems associated with intervention program,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6799,NCT03511703,overall survival,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6800,NCT02685631,Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease,Time to Progression,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
6801,NCT05476796,Progression free-survival,Quality of life questionnaire - Core 30 (QLQ-C30),,2023-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6802,NCT05652894,Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC),Adverse events,,2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6803,NCT06036745,Disease-free survival,Adverse Events,,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6804,NCT05540925,Overall survival (OS),Local recurrence,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
6805,NCT05441475,To evaluate the objective response rate of ABSK-011 combined with atezolizumab in subjects with advanced FGF19 overexpression or unresectable HCC,,,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2']
6806,NCT02173990,Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.,Safety and tolerance,,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2']
6807,NCT05901376,The different of MiR-223 level between gastric cancer and control group,,,2023-04-25,RECRUITING,OBSERVATIONAL,['NA']
6808,NCT02023541,Overall survival,Toxicity,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1']
6809,NCT05529940,2-year survival rate,Response rate in neoadjuvant setting,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6810,NCT02439580,Nutritional Status,Cytotoxicity,,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6811,NCT05211323,Progression free survival (PFS),Overall response rate,,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE2']
6812,NCT03144804,Overall Response Rate,Overall Disease Control Rate,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2']
6813,NCT00165464,"To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).",To assess the toxicity of this combination in esophageal or gastric carcinoma.,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6814,NCT05635279,Death,Censored,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
6815,NCT04753359,Exfoliated intestinal epithelial cell transcriptomics,Fasting insulin,Bowel habits,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
6816,NCT06229340,Objective response rate,Overall survival,,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE2']
6817,NCT02013986,Change from baseline in salivary cortisol at the first day after surgery,Days of stay in intensive care unit (ICU) after surgery,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
6818,NCT05211388,Conformity with planned ablation zone,,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
6819,NCT04180033,Diagnostic yield advanced colorectal neoplasia,Burden of colonoscopy,,2020-02-18,COMPLETED,INTERVENTIONAL,['NA']
6820,NCT06206096,ORR,"Safety and tolerability by incidence, severity and outcome of adverse events",,2021-05-26,RECRUITING,INTERVENTIONAL,['PHASE2']
6821,NCT03411707,"Sensitivity and Specificity of Multiple Screening Methods With Comparison to Colonoscopy, Both With Respect to Cancer.",,,2018-03-19,RECRUITING,OBSERVATIONAL,['NA']
6822,NCT00019006,,,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6823,NCT05062889,ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven),Overall survival TD1 (OS-TD1),,2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2']
6824,NCT02900664,Frequency of dose reductions,Presence and/or concentration of anti-CJM112 antibodies.,,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
6825,NCT02150135,ECOG score change,Progression free survival rate,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6826,NCT03995459,Evolution from baseline of liver volume and liver function values,Evolution from baseline of liver volume and liver function values,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
6827,NCT00202111,Five-year survival,Quality of Life outcomes,,1998-01,UNKNOWN,INTERVENTIONAL,['NA']
6828,NCT00506207,Blood level of irinotecan and S-1 and their metabolites,"Maximal response rate, progression-free survival, survival",,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
6829,NCT03246438,CRC screening completion,Choice of screening test,,2017-11-14,COMPLETED,INTERVENTIONAL,['NA']
6830,NCT02649569,Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course),,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
6831,NCT00004897,,,,1999-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6832,NCT00571740,Progression-free survival (PFS) rate at 6 months,Quality of life,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6833,NCT03704727,Intestinal permeability,Gastrointestinal adverse events,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
6834,NCT04796454,Progression-free survival (PFS),Jaundice scale,,2022-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6835,NCT01186705,Overall Objective Response Rate (ORR),,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
6836,NCT02624154,The survival rate,,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
6837,NCT01384253,Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of ²¹²Pb-TCMC-Trastuzumab.,Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by γ-camera imaging.,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6838,NCT00303758,Overall survival,Duration of hospitalization,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6839,NCT00602147,Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis,,,2007-07,TERMINATED,OBSERVATIONAL,['NA']
6840,NCT03428477,Progression Free Survival (PFS),New Primary Cancers,Change in lean body mass (exploratory endpoint),2018-05-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6841,NCT05737563,Overall survival (OS),Disease Control Rate (DCR),,2023-02-17,RECRUITING,INTERVENTIONAL,['PHASE3']
6842,NCT01893294,"MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0","Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6843,NCT02395705,Overall survival rate,predictive factors,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6844,NCT05225428,Video Education Acceptability (Qualitative Interview Study),,,2022-08-04,RECRUITING,INTERVENTIONAL,['NA']
6845,NCT01721954,Overall Survival (OS),Progression-free Survival,,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6846,NCT01333917,Apoptosis,Number of Participants with Adverse Events,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6847,NCT03096951,Change in cardiorespiratory fitness,Adherence,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
6848,NCT02720926,Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin),Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1']
6849,NCT02523911,Overall bowel cleansing,Number of patients completing the bowel preparation,Degree of haziness,2016-03,WITHDRAWN,INTERVENTIONAL,['NA']
6850,NCT05481476,objective response rate (ORR),adverse events (AE),,2023-09,RECRUITING,INTERVENTIONAL,['PHASE2']
6851,NCT01702116,measurement of circumferential resection margin,estimated blood loss,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
6852,NCT05232357,"Expression levels of PGP9.5, GFAP, VIP, nNOS, TH, ChAT and SOM of different gastrointestinal lesions",,,2022-03-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
6853,NCT00297791,locoregional recurrence rate,out-of-hospital postoperative costs,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6854,NCT00462553,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events,Overall survival,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6855,NCT03781193,Correlation between psychological predictors questionnaires outcome and quality of life,,,2018-03-06,UNKNOWN,OBSERVATIONAL,['NA']
6856,NCT03474861,The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.,Tumor Response of the treatment in patients with advanced gastrointestinal cancer.,,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
6857,NCT04838964,Objective Response Rate (ORR) by Independent Review Committee (IRC),Incidence of anti-drug antibody (ADA),,2021-04-28,RECRUITING,INTERVENTIONAL,['PHASE2']
6858,NCT05202236,objective response rate (ORR),,,2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE2']
6859,NCT06109207,Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events,Overall survival (OS),,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1']
6860,NCT02047305,Complete Response,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
6861,NCT02081469,To compare the HBV relapse rate during the follow-up period in HBV carriers with malignant tumor receiving tenofovir for 24 and 48 weeks after the end of chemotherapy.,"To estimate the efficacy of TDF during chemotherapy with after chemotherapy and post-chemotherapy,as measure by the HBV reactivation, clinical relapse and adverse events in all patients.",,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE4']
6862,NCT03779009,Tumor status of the sentinel lymph node (SLN) and other lymph nodes (LN's),Immunological markers,,2018-03-01,RECRUITING,INTERVENTIONAL,['NA']
6863,NCT03140007,Diagnostic accuracy of cholangioscopy or cholangiography,Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm,,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA']
6864,NCT01065441,The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.,The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6865,NCT00342004,All cancer incidence,All deaths,,1997-05-01,COMPLETED,OBSERVATIONAL,['NA']
6866,NCT03028155,Assessment of 3-month overall morbidity and mortality,Assessment of health related quality of life (HRQOL): SF-36,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
6867,NCT04046445,valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS),Evaluate anti-tumor effect of study treatment by measure of Relapse Free Survival (RFS),Assess shedding and viremia of VSV-GP128,2019-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6868,NCT00982592,Median Progression-free Survival (PFS),Incidence of Toxicities (grades1 and 2),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6869,NCT01836120,Progression-free survival (PFS),Overall Survival (OS),,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
6870,NCT05158907,Improvement in detection rate of adverse effects of patient reported adverse effect (AE) scale versus the standard CTCAE grading by a physician.,Reduction in cost of cancer care using patient reported AE scale.,,2021-11-23,SUSPENDED,INTERVENTIONAL,['NA']
6871,NCT02443948,Correlation of change in cf-DNA levels with disease status in GIST patients harboring specific DNA mutations,Correlation of the level of cf-DNA related to disease status in GIST patients harboring specific DNA mutations,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
6872,NCT01238666,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
6873,NCT05368805,PK parameter for dabigatran and rosuvastatin: Cmax:,PK parameters of fruquintinib and metabolite M11: Cmax:,,2022-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6874,NCT00229567,passage of stool.,time to readiness for discharge from hospital,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
6875,NCT06281925,Proportion of Participants with Peripheral Neuropathy at Visit 5,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6876,NCT05296681,Tumor Response by RECIST v1.1 Criteria,,,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE2']
6877,NCT00323011,,,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2']
6878,NCT01291420,Immunogenicity of intradermal DC vaccination,,,2010-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6879,NCT01031056,None: Biospecimen will be collected for future research.,,,2010-01,WITHDRAWN,OBSERVATIONAL,['NA']
6880,NCT02881554,Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging,Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging,,2016-12-21,RECRUITING,INTERVENTIONAL,['NA']
6881,NCT01677559,Dose-limiting toxicities (DLTs),Antitumor activity of MLN8237 and nab-paclitaxel combination therapy,,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6882,NCT00518349,Patient Assessment of Pain Experienced During Colonoscopy,,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
6883,NCT01668498,Percentage of patients developing no skin toxicity ≥ grade 2,Skin-toxicity related dose reductions of panitumumab,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6884,NCT03452501,Incidence of adverse events (AEs) to Remsima®,Proportion of switched patients with UC achieving disease control.,,2018-08-26,COMPLETED,OBSERVATIONAL,['NA']
6885,NCT00112697,Progression-free survival rate at 6 months,Overall survival,,2003-10-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6886,NCT03189719,PFS Per RECIST 1.1 As Assessed By Investigator in All Participants,Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10),,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
6887,NCT01941953,Disease Control Rate according to RECIST 1.1,Adverse Events,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6888,NCT04633382,Reduction of bed-days,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6889,NCT02351089,Change in incidence of loose/watery stools,,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
6890,NCT03146234,Safety and tolerance,Engraftment,Anti-tumor responses to CAR-GPC3 T cell infusions,2017-03-17,COMPLETED,INTERVENTIONAL,['NA']
6891,NCT04097028,Number of Patients With a Pathologic Complete Response,Number of Patients With Grade 3 or Higher Treatment Related Adverse Events,,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6892,NCT03807947,Pain and discomfort during and after procedures,Access-related adverse events,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
6893,NCT02228200,Change in quality of life,Health care utilization,Intervention nurses' experience,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6894,NCT04866290,Overall Survival,Time to Progression,,2016-09-22,COMPLETED,OBSERVATIONAL,['NA']
6895,NCT04659590,Stability of buffer transfer medium,Comparison between tumour surface imprint and rectal mucous imprint,,2020-11-06,COMPLETED,OBSERVATIONAL,['NA']
6896,NCT04449874,Percentage of Participants With Dose-Limiting Toxicities (DLTs),Relationship Between Tumor Pharmacodynamic Effects of GDC-6036,,2020-07-29,RECRUITING,INTERVENTIONAL,['PHASE1']
6897,NCT05647941,Detection of levels of circulating exosomal lncRNA-GC1,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
6898,NCT05063565,Objective Response Rate (ORR),Whole liver and remnant liver volumes at baseline and follow-up imaging assessments measured using Simplicit90Y software.,,2023-11-03,RECRUITING,INTERVENTIONAL,['PHASE2']
6899,NCT03515252,Incidence of Treatment-Emergent Adverse Events [Safety],Quality of Life (QOL),,2005-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
6900,NCT06282120,Progression Free Survival,EORTC-QLQ (European Organization for Research and Treatment of Cancer - Quality of life Questionnaire) C30 (version 3.0),,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
6901,NCT04957407,pepsinogen value for precanceous lesion and Gastric cancer,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
6902,NCT04272268,Rate of respiratory complications within 30 days after surgery,Recruitment rate,,2019-10-01,RECRUITING,OBSERVATIONAL,['NA']
6903,NCT04104672,Number of participants with clinically significant changes in vital signs and clinical laboratory parameters,Overall response rate,AB680 gene expression,2019-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6904,NCT05156307,Colorectal cancer,,,2021-05-20,RECRUITING,OBSERVATIONAL,['NA']
6905,NCT04000906,Determine the maximal tolerated dose (MTD) of Nab paclitaxel (Abraxane®) administered IP by PIPAC in concomitance with cisplatin.,The QoL,,2020-11-11,RECRUITING,INTERVENTIONAL,['PHASE1']
6906,NCT05301556,Serum Pre-Albumin,Nutritional Risk Screening (NRS) 2002,Adverse Events,2022-06-24,COMPLETED,INTERVENTIONAL,['NA']
6907,NCT06202417,DCR,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
6908,NCT03254498,Adenoma miss rate,Comfort score,comparison of surveillance intervals,2016-04,COMPLETED,INTERVENTIONAL,['NA']
6909,NCT00497107,Disease-free survival,"Overall survival, compliance, adverse events, QOL, tumor markers",,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
6910,NCT00048139,Tumor measurement (RECIST criteria),"Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival.",,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6911,NCT06066138,Feasibility of reducing drug exposure while maintaining plasma drug concentration,"Minimal frequency (median, range) of atezolizumab dosing to keep the trough concentration at or above 6 microgram/mL",,2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6912,NCT03924804,1. The change of bladder volume,,,2019-06-19,COMPLETED,INTERVENTIONAL,['NA']
6913,NCT02149914,gastroesophageal reflux disease questionnaire,Upper gastrointestinal endoscopy,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
6914,NCT05986890,Gastric emptying as per gastric emptying scintigraphy at 7 days post-operatively.,Improvement of quality of life as measured GIQLI,,2023-08-17,RECRUITING,INTERVENTIONAL,['NA']
6915,NCT02618811,Complications,Need for opioid analgesia postoperatively,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6916,NCT01533090,Evaluation of the overall quality of bowel preparation,compliance,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
6917,NCT01127698,"Fractures, hip fractures",,,1987-03,COMPLETED,OBSERVATIONAL,['NA']
6918,NCT06008119,Progression-free Survival (PFS),Disease control rate (DCR),,2023-11-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6919,NCT04510129,PD-L1/PD-1 inhibitor response,,,2020-02-05,RECRUITING,OBSERVATIONAL,['NA']
6920,NCT04114591,Life,,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
6921,NCT01690715,Prognosis (disease graduation),Relation established between survival and degree of underlying liver dysfunction,,2012-07,TERMINATED,OBSERVATIONAL,['NA']
6922,NCT06031285,"RFS, recurrence-free survival",,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6923,NCT04158908,Potential Improvements to the Oncolo-GIST Manual According to Structured Qualitative Surveys,,,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
6924,NCT03862768,Progression-free Survival,Overall Survival,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
6925,NCT00423345,findings compared across investigation modes,Delayed diagnosis of CRC,,2006-10,TERMINATED,OBSERVATIONAL,['NA']
6926,NCT00637728,Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase,Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
6927,NCT00461929,~ presence or absence of genetic abnormality as seen in CML patients on imatinib,,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6928,NCT00165048,Symptom-free susrvival and the quality of life score within the two years of study period.,Overall survival in long-term.,,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
6929,NCT05789485,proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%,,,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2']
6930,NCT01371942,,,,2010-05,UNKNOWN,OBSERVATIONAL,['NA']
6931,NCT01114087,Average difference of the concentration of spermatozoa in the ejaculate measured before treatment and after 6 months of treatment.,Plasmatic concentration of the inhibitors of tyrosine kinase,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
6932,NCT05339321,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),Efficacy: antiviral activity of SCG101,,2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
6933,NCT01579721,morbidity,oncology,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6934,NCT00664482,Treatment-emergent changes in localized injection site reactions following each dose,Feasibility,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
6935,NCT05200299,2-year Disease-free survival,Quality of Life assessed by SF-36,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6936,NCT00357682,Conversion of Barrett's esophagus to adenocarcinoma of the esophagus or high-grade dysplasia,All causes of mortality,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6937,NCT00924690,Elaboration using the Elaboration Likelihood Scale,Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6938,NCT04663789,Clinically relevant postoperative pancreatic fistula (CR-POPF),Length of postoperative hospital stay,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6939,NCT05186116,Disease free survival,Donor quality of life,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
6940,NCT03473587,Change in colorectal cancer screening rate,,,2014-11-07,UNKNOWN,INTERVENTIONAL,['NA']
6941,NCT02873455,Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.,Postoperative hospital stay,,2016-08,UNKNOWN,INTERVENTIONAL,['NA']
6942,NCT01325909,Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.,Activity levels before during and after neoadjuvant chemoradiotherapy,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6943,NCT01922492,Changes of insulin secretory function,Adverse effects,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
6944,NCT05170802,CT scan finding new lymph nodes,Data on adverse events and complications related to Irreversible Electroporations.,,2017-12-20,RECRUITING,OBSERVATIONAL,['NA']
6945,NCT02454673,Disease Free Survival,Estimate of TN Change From Baseline to Surgery,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
6946,NCT04341337,qualitative analysis of the interviews,,,2019-03-02,COMPLETED,OBSERVATIONAL,['NA']
6947,NCT02483832,CRC screening follow-up rate,Changes in attitudes towards CRC and CRC screening as measured by survey,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
6948,NCT05954702,Mortality,Drain use time,,2023-07-21,RECRUITING,INTERVENTIONAL,['NA']
6949,NCT03986502,Caregiver burden,,,2021-01-22,COMPLETED,INTERVENTIONAL,['NA']
6950,NCT00003326,,,,1997-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
6951,NCT04138212,overall survival,postoperative complications,,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE3']
6952,NCT06221657,Proportion of subjects maintained at HBV DNA <29 IU/mL,blood Phosphorus levels,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6953,NCT05113264,Patient Engagement with the Penny chatbot,Patient Satisfaction with the Penny chatbot interactions will be measured by the Promoter Score,,2021-08-02,RECRUITING,INTERVENTIONAL,['NA']
6954,NCT04370574,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,Identification of prognostically significant biomarkers,,2021-01-14,RECRUITING,OBSERVATIONAL,['NA']
6955,NCT01308645,Evaluating Tumor Response Rate,Determine duration of response rate by measuring time to progression,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
6956,NCT03770988,Objective Response Rate,Safety assessed by incidence of treatment-emergent adverse events,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6957,NCT05550701,cancer specific survival,,,2021-05-05,COMPLETED,OBSERVATIONAL,['NA']
6958,NCT03879811,response rate of TMZ followed by nivolumab in participants with MMR-proficient Colorectal Cancer,,,2019-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6959,NCT02614534,Locoregional Control (LC),Quality of life questionnaires QLQ-CR29,,2015-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6960,NCT01154335,To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.,Response Rate,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6961,NCT02215889,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.,Overall Survival,,2014-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6962,NCT05657210,5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation,Recurrence-related factor,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
6963,NCT01537107,MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.,Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II),,2012-03-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6964,NCT03946033,Modification rate of adjuvant therapeutic strategy,,,2019-05,WITHDRAWN,INTERVENTIONAL,['NA']
6965,NCT00478309,Factors that moderate the impact of GERA feedback on CRC screening utilization,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
6966,NCT06114420,Cancer-specific survival,Find a differentially expressed gene,,2023-01-30,RECRUITING,OBSERVATIONAL,['NA']
6967,NCT06236282,Operation time,TME quality (Operative outcome),,2012-05-01,COMPLETED,OBSERVATIONAL,['NA']
6968,NCT06048926,PFS evaluated by IRC,Progression-free survival evaluated by Researchers,,2022-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6969,NCT05891301,gastrointestinal dysfunction,Patient Mobility in the hospital,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
6970,NCT06316882,number of gastric adenocarcinoma,Socio-demographic characteristics of population in screening program,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
6971,NCT04418843,Complete resection of the lesion,Sub-analysis by center participating in the study,,2020-06-08,COMPLETED,INTERVENTIONAL,['NA']
6972,NCT02745847,The toxicities following SBRT will be determined.,The quality of life will be analyzed.,,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6973,NCT03614650,percentage of adverse effects after EIE cell injection,The anti-cancer effects,,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6974,NCT04291755,Checkpoint inhibitor response,,,2019-06-28,UNKNOWN,OBSERVATIONAL,['NA']
6975,NCT05468177,Objective response rate (ORR),R0 resection rate,,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6976,NCT03706157,Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution,"In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution",,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4']
6977,NCT06184867,Number of Participants with Genetic Testing Uptake,Acceptance and Usability of the Relational Agent,,2023-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6978,NCT02330497,Safety of the pancreatic radiofrequency ablation under EUS guidance,Safety of the pancreatic radiofrequency ablation under EUS guidance,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
6979,NCT04618809,"Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made)",Fitbit assessed functional status. Fitbit data: heart rate,,2020-09-22,RECRUITING,INTERVENTIONAL,['NA']
6980,NCT00602082,Objective response rate,Quality of life,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6981,NCT03288987,Progression Free Survival (PFS),Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity),,2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6982,NCT00336648,Number of Patients with Resection,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6983,NCT04737213,Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.,,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6984,NCT06311279,Anastomotic leak amount,,,2024-03-05,RECRUITING,INTERVENTIONAL,['NA']
6985,NCT02716207,The maximum tolerated dose will be determined,Pain intensity will be determined.,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
6986,NCT02289378,Progression-free survival,Response rate,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
6987,NCT05226572,Diagnostic yield (%) of repeated EUS-fine needle biopsy of pancreatic masses after previous non-diagnostic or inconclusive results,"Sensitivity (%), specificity(%), positive predictive value(%), negative predictive value(%), specimen adequacy(%), Bethesda classification, adverse events incidence (%) and factors that influenced repeated EUS-fine needle biopsy performance.",,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
6988,NCT01496521,occurrence of high grade dysplasia and invasive ESCC,occurrence of high grade dysplasia and invasive ESCC,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6989,NCT06275958,Progression-Free Survival,Cost-effectiveness,,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6990,NCT00002793,,,,1991-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6991,NCT00069095,PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6992,NCT05195970,Correlation of colonic lesion gene expression with urolithin production,Correlation of dietary behavior with urolithin production,,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
6993,NCT05056896,Change of ISC marker gene expression,Change in Microbiome,,2022-06-03,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6994,NCT02628067,Objective Response Rate (ORR),Percentage of Participants who Discontinue Study Intervention due to AEs,,2015-12-18,RECRUITING,INTERVENTIONAL,['PHASE2']
6995,NCT03813641,Progression-free Survival (PFS) Time,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate),,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
6996,NCT03681951,Percentage of Participants Achieving Complete Response or Partial Response Based on RECIST 1.1 Criteria-Part 4,Time Invariance Following Repeat Dose of Pembrolizumab-Part 3,,2018-11-16,TERMINATED,INTERVENTIONAL,['PHASE2']
6997,NCT01547260,Immunomodulatory effect (phase II).,Clinical efficacy,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6998,NCT00963612,To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.,To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
6999,NCT02234986,Overall Response Rate,Progression Free Survival (PFS6) rate,Frequency and severity of adverse events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7000,NCT03300609,Progression free survival 1,Treatment Response,,2018-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
7001,NCT04244552,"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters",For the PLD Combination Therapy Cohort: ATRC-101 immunoreactivity in tumor biopsies at baseline and during treatment,,2020-02-11,TERMINATED,INTERVENTIONAL,['PHASE1']
7002,NCT01167816,Toxicity,Determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1']
7003,NCT02981641,Overal survival,Local control rate,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
7004,NCT01998009,The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result,The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
7005,NCT03349762,Distant Metastasis-Free Survival rate,Immunity function,,2018-11-02,RECRUITING,OBSERVATIONAL,['NA']
7006,NCT05908643,"Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).",Disease-specific survival,Evaluation of the importance of neoantigen selection to clinical outcome.,2023-03-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7007,NCT01229839,overall survival,Time to progression,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7008,NCT03430843,Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set,Number of Participants Experiencing Adverse Events (AEs),,2018-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
7009,NCT03207594,Number of patient who self-report smoking cessation,Compliance with smoking cessation,,2016-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7010,NCT00986518,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)","Laboratory test: hepatic function, immune function, haematology",,2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7011,NCT04560751,Objective response rate（ORR）,Adverse events(AEs),,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA']
7012,NCT02976896,Disease control rate,Quality of life using esophageal special scale QLQ - OES18,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7013,NCT01433861,Rate of reflux esophagitis,,,2012-07,TERMINATED,INTERVENTIONAL,['PHASE3']
7014,NCT00280618,Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST,Adverse Events collections and evaluation,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7015,NCT04437212,Major Pathological Response Rate (MPR),Perioperative complication rate,,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7016,NCT03927898,1 year Progression-Free-Survival (PFS),Expression of PD-L1 on circulation tumor cell,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7017,NCT03695952,Objective response rate,Adverse events,,2018-07-01,RECRUITING,OBSERVATIONAL,['NA']
7018,NCT04738188,Downstaging success rate,Recurrence rate of Hepatocellular carcinoma,,2020-03-18,RECRUITING,INTERVENTIONAL,['NA']
7019,NCT01262560,Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS),Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7020,NCT01163812,Compliance of lymph node dissection,distance to resection margin and number of harvested lymph nodes,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7021,NCT01239056,Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail Plastic Stent Inserted Through the Metal Stent Lumen,Adverse Events,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
7022,NCT05623150,Primary outcome measure CHALNA2,7th outcome measure CHALNA2,,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7023,NCT02155088,Maximum Tolerated Dose (MTD),Progression-Free Survival (PFS),,2014-10-30,COMPLETED,INTERVENTIONAL,['PHASE1']
7024,NCT03145558,Progression Free Survival,Duration of CR,Time to local recurrence,2017-12-05,SUSPENDED,INTERVENTIONAL,['PHASE2']
7025,NCT04371198,Number of Participants With Biopsies That Form Spherical Organoids,,,2020-09-18,COMPLETED,INTERVENTIONAL,['NA']
7026,NCT01072981,The primary objective is to assess overall survival,The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7027,NCT02128100,Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability,Overall Response Rate for Participants as Assessed by Contrast-enhanced CT Scan of the Abdomen at 12 Months.,Quality of Life Assessment at 12 Months Post-treatment,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
7028,NCT05742750,Objective Response Rate (ORR),Overall Survival (OS),,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7029,NCT00923520,Determine the Maximum Tolerated Dose,Anti-tumor Effects,,2009-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
7030,NCT05027711,Treatment related Toxicity,Evaluation of potential prognostic biomarkers,,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2']
7031,NCT02689401,Assess the safety of intravenous ferumoxytol for the use in esophageal cancer patients,Determine the accuracy of MRI-ferumoxytol for the identification of positive metastatic nodes in patients with esophageal cancer,,2016-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7032,NCT05007912,Anastomosis complication,,,2021-06-21,UNKNOWN,OBSERVATIONAL,['NA']
7033,NCT02582034,"The primary endpoint is to compare the response rate of the treated lesion at the first radioembolization, evaluated using European Association for the Study of the Liver (EASL) criteria of yttrium-90 marked glass microspheres SIRT",Post-therapeutic dosimetry measured by Positron emission tomography-computed tomography PET / CT,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7034,NCT06326502,Dose-limiting Toxicity (DLT),,,2024-02-07,RECRUITING,INTERVENTIONAL,['PHASE1']
7035,NCT02941861,Recurrence rate of Liver Carcinoma after surgery,,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
7036,NCT02078804,Mortality from colorectal cancer in the Swedish population.,To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.,,2014-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7037,NCT04352023,Comparison of analgesic efficacy after major surgery in pancreatobiliary cancers: Intravenous patient-controlled analgesia versus patient-controlled epidural analgesia,"Investigation and comparison of pain and clinical progress during rest after surgery, side effects of drugs administered to IV-PCA and PCEA, and complications related to PCEA procedure",,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7038,NCT03694977,Identification of potential biomarkers of MCS110 in combination with PDR001,Safety as measured by number and grade of toxicity events,,2019-01-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
7039,NCT00006015,Overall toxicity,,,2000-05,TERMINATED,INTERVENTIONAL,['PHASE2']
7040,NCT02745509,Overall survival,Post-operative quality of life,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
7041,NCT04159363,Caregivers' quality of life,Caregivers' anxiety and depression,,2020-02-01,UNKNOWN,INTERVENTIONAL,['NA']
7042,NCT02347956,morbidity,mortality,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7043,NCT04968145,30-day re-admission,Patient reported outcomes,,2017-07-19,COMPLETED,INTERVENTIONAL,['NA']
7044,NCT04317599,First-line Systemic anticancer therapy (SACT) treatment patterns in BRAFV600E mutant mCRC patients,Time to treatment cessation,,2020-04-12,COMPLETED,OBSERVATIONAL,['NA']
7045,NCT04680598,HBV Reactivation rate,adverse event,,2020-12-25,RECRUITING,OBSERVATIONAL,['NA']
7046,NCT02364024,Time to Recurrence (TTR),Disease-Free Survival (DFS),,2005-11,COMPLETED,OBSERVATIONAL,['NA']
7047,NCT00559455,"Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan","Time to Progression (TTP), 6 month survival, overall survival, AFP",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7048,NCT01664169,Number and percentage of responder,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
7049,NCT02608229,Maximum Tolerated Dose (MTD) of BVD-523,Overall Survival (OS),,2016-06-06,TERMINATED,INTERVENTIONAL,['PHASE1']
7050,NCT00237172,To study the antineoplastic effect of the investigational drug.,To study the safety and pharmacokinetics of the investigational drug.,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7051,NCT02632448,Maximum Tolerated Dose(s),Overall survival,,2016-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7052,NCT02718729,Incidence of anastomotic leakage,30 days postoperative morbidity and mortality,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
7053,NCT02728167,Normalized blood loss (ml/cm2),Number of patients with postoperative complications assessed using Dindo-Clavien classification,,2016-04,TERMINATED,INTERVENTIONAL,['NA']
7054,NCT05679960,Accuracy of Urine PolypDx device in detecting colorectal cancer,Negative Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC),,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
7055,NCT01308190,Local recurrence,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7056,NCT01045200,Patient satisfaction,Resource utilisation,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
7057,NCT03330561,Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03,"Biomarkers (CD137, soluable HER2, cell surface antigens for immunotyping) in tumor tissues and blood samples",,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE1']
7058,NCT01791361,The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix,"To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds",,2012-09-19,COMPLETED,OBSERVATIONAL,['NA']
7059,NCT03937362,Accuracy of clinical response evaluations for detecting substantial residual locoregional disease,Accuracy of clinical response evaluations for detecting any residual locoregional disease,,2019-08-08,UNKNOWN,OBSERVATIONAL,['NA']
7060,NCT06205472,The 3-year Overall Survival,Local Control Rate,,2024-01-26,RECRUITING,INTERVENTIONAL,['PHASE2']
7061,NCT05238584,3y Disease Free Surveillance,Postoperative immunological changes (Interleukin monitoring),Duration of the hospital stay,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
7062,NCT04853043,Progression free survival (PFS),Overall survival (OS).,,2021-11-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7063,NCT03952442,Quality of Life (QOL),Knowledge-Attitude-Practice,,2019-02-21,UNKNOWN,INTERVENTIONAL,['NA']
7064,NCT00150670,Overall survival,"Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7065,NCT02017678,Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment,Time to progressive disease,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7066,NCT02821533,Tumor response,overall survival,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
7067,NCT03492671,Curative Intent Resection (R0) rate,Overall Survival Rate,,2019-07-17,RECRUITING,INTERVENTIONAL,['PHASE2']
7068,NCT01218880,Maximum tolerant dose,objective response rate,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7069,NCT04948398,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
7070,NCT00464919,To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.,To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7071,NCT00447330,Median Progression-Free Survival (PFS),Median Survival,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7072,NCT03847428,Recurrence-free survival (RFS) for Arm A vs Arm C,Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C,,2019-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7073,NCT02252913,safety and tolerability,PK parameters,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7074,NCT02088775,Local control,Change in dose measured by PET-CT scan,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
7075,NCT01310062,,,,2010-08,UNKNOWN,OBSERVATIONAL,['NA']
7076,NCT01660971,"Maximum tolerated dose of gemcitabine hydrochloride and dasatinib given together with erlotinib hydrochloride, determined by incidence of dose-limiting toxicity graded according to NCI CTCAE v 4.0","Serious and other significant adverse events (AEs), graded according to NCI CTCAE v 4.0",,2012-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
7077,NCT01693445,maximum tolerated dose,disease control rate,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7078,NCT00189657,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
7079,NCT04534075,Intensity of the urgency syndrome,Acute side-effects,Composition of microbiota,2020-09-02,RECRUITING,INTERVENTIONAL,['PHASE3']
7080,NCT05632744,Safety of the CG-100 Intraluminal Bypass Device,Safety of the CG-100 Intraluminal Bypass Device,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
7081,NCT06237582,Evaluate the incidence of IELN invasion by ovarian cancer,"In cases of IELN positivity, review thoroughly preoperative scans and MRIs in order to detect radiological features, usually overlooked, that could help identify the positivity of these LNs prior to pathological analysis.",,2022-06-16,COMPLETED,INTERVENTIONAL,['NA']
7082,NCT05592626,Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR),Phase 1 and 2 (Dose Escalation and Expansion): Anti-drug Antibody (ADA) formation,,2023-01-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7083,NCT05043987,Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.,CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA),,2022-11-16,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7084,NCT05219539,Change of general surgical skills score,Changes of clinical research possibilities score,,2021-11-11,COMPLETED,OBSERVATIONAL,['NA']
7085,NCT05370001,Carbon dioxide level from an arterial line (PaCO2) after 15 minutes of HFJV.,Injury of the airway following endotracheal intubation.,,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
7086,NCT05131919,"To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR)",To assess the date of relapse,,2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7087,NCT01343212,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
7088,NCT05773144,Chemotherapy Relative Dose Intensity,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
7089,NCT06293898,To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1,,,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1']
7090,NCT05778851,The impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral,The impact of EsoCheck/EsoGuard on health care provider's patient risk assessment for BE,,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
7091,NCT02617134,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells,Objective Response Rate,,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7092,NCT00002625,,,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7093,NCT01938716,To Quantifiably Assess Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue After a Single Intraoperative Infusion in Patients.,To Correlate Intratumoral Gemcitabine Levels and Its Tumoricidal Activity With Ki67 Index and Intratumoral Apoptosis.,,2012-03,TERMINATED,INTERVENTIONAL,['NA']
7094,NCT05142709,OS from start of 1st line treatment in metastatic ESCC,the role of radiotherapy for patients treated with 1st immunotherapy.,,2021-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7095,NCT02053805,"Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers","Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.",Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
7096,NCT00659022,Difference in response of liver metastases between control group and experimental groups determined by FDG-PET,Complications of surgery,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
7097,NCT04511039,Maximum tolerated dose/ recommended phase II dose,Number of subjects with DNA damage response,,2021-06-08,RECRUITING,INTERVENTIONAL,['PHASE1']
7098,NCT02893540,PFS1,QOL,,2016-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7099,NCT00471484,Objective tumor response rate as measured by RECIST criteria,Tissue VEGF expression,,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7100,NCT04999007,The morbidity of anastomotic leakage.,,,2021-09-02,RECRUITING,INTERVENTIONAL,['NA']
7101,NCT04473794,Clinical utility of Compcyst in pancreatic cysts as assessed by patient chart review,,,2022-07-20,RECRUITING,OBSERVATIONAL,['NA']
7102,NCT01743300,The feasibility of midazolam as a phenotyping probe for sunitinib exposure (area under concentration time curve)in cancer patients,The influence of sunitinib on CYP3A4 activity,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7103,NCT04851054,VEGF in serum on postop day 4,,,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
7104,NCT03688230,Progression Free Survival (PFS),Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).,,2019-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7105,NCT03336658,correlation of ITB based calculated N stage with real N stage in CRC - patients,correlation of ITB based calculated DFS with real DFS in CRC - patients,,2015-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7106,NCT04958720,Diagnostic and therapeutic approach,Create and validate a predictive model,,2020-04-27,RECRUITING,OBSERVATIONAL,['NA']
7107,NCT04297280,Objective Response Rate (ORR),Adverse Events,,2020-04-29,RECRUITING,INTERVENTIONAL,['PHASE2']
7108,NCT01390194,image quality outcome,,,2011-07-01,COMPLETED,OBSERVATIONAL,['NA']
7109,NCT01370928,Patients´ evaluation of pain and discomfort,Caecum intubation rate,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7110,NCT04259762,Completion of a Pap Smear test to screen for cervical cancer,Change in Self-Efficacy measured using the Health Behavior Survey,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7111,NCT05224882,The assessment of the prevalence of oral adverse events induced by chemotherapy in pediatric cancer patients .,Assessment of dental awareness among parents of pediatric cancer patients .,,2023-08-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7112,NCT05267275,incidence of complications related to rectal anastomosis,,,2021-11-30,RECRUITING,INTERVENTIONAL,['NA']
7113,NCT00728650,Survival,Efficacy,,2003-10,COMPLETED,OBSERVATIONAL,['NA']
7114,NCT01051167,Response rate (RECIST-Criteria),"Secondary objectives: Safety, Quality of life",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7115,NCT01516710,Perioperative morbidity,Incidence of incisional hernia,,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7116,NCT00265876,Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks,Toxicity,,2006-04-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7117,NCT04555135,Average Number of Adenomas Per Extraction,Procedure Time,,2020-09-28,TERMINATED,INTERVENTIONAL,['NA']
7118,NCT02318095,Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen,Number of Participants Who Received an R0 Resection,,2015-02-17,COMPLETED,INTERVENTIONAL,['NA']
7119,NCT00460837,Patient experience and compliance with reduced laxative tagging versus standard preparation,Comparison of per polyp specificity between the two preparation regimens,,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7120,NCT01897610,To assess progression-free survival (PFS),Number of participants with adverse events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7121,NCT02623621,Progression Free Survival,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
7122,NCT02786329,Incidence of recurrences:,Rate of postoperative complications after TIVA versus inhalation anaesthesia,Rate of local anaesthetics systemic toxicity incidence,2016-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7123,NCT00629863,Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized,"Health resource utilization, including the selection of treatments and subsequent use of health service resources",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
7124,NCT03917173,Disease free survival,patients performing the adjuvant chemotherapy.,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
7125,NCT06031779,serum bile acid profile before treatment,concentration of serum tumor markers before treatment,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
7126,NCT05911152,3-year overall survival,Postoperative pain score,,2016-01-01,RECRUITING,OBSERVATIONAL,['NA']
7127,NCT00943449,Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201,To investigate biomarkers,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7128,NCT06037980,median PFS,Perioperative morbidity and mortality,,2023-11-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7129,NCT04616534,Overall survival (expansion cohort),Increase in deoxyribonucleic acid (DNA) damage level (expansion cohort),"Pharmacodynamic (biological endpoints, toxicity and efficacy) parameters",2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
7130,NCT00290966,to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression,"Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months.",,1998-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7131,NCT00162526,To evaluate the tolerability and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,To evaluate the toxicity and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,,2005-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7132,NCT06321081,progression free survival,Overal survival,,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7133,NCT01245582,Overall Survival (OS),Response Rate (RR),,2011-07,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7134,NCT04548440,R0 resection rate of patients who underwent surgery following preoperative treatment,Number of patients with adverse events and severity according to NCI CTCAE v5.0,,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7135,NCT04028479,Progression-free survival (PFS) - 5th line of therapy,Overall survival (OS),,2021-05-05,RECRUITING,OBSERVATIONAL,['NA']
7136,NCT00084942,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7137,NCT00303888,Safety,,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE1']
7138,NCT06256315,30-day overall complication rate,The rehospitalization rate within 30 days after surgery,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
7139,NCT03610490,Objective response rate (ORR),Incidence of adverse events,Health-related quality of life,2018-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7140,NCT01403103,Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa,"Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3",,2012-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
7141,NCT00263354,To evaluate the progression-free survival in the ITT population,To investigate safety using NCI-CTC criteria version 2,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7142,NCT00385515,Duration of Ulcerative Oral Mucositis,Number of Participants With Ulcerative Oral Mucositis,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7143,NCT00003085,,,,1996-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7144,NCT05304741,Overall Survival,Diagnostic Indicators,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
7145,NCT01405183,Prevalence of hepatitis C in renal cell carcinoma patients,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
7146,NCT02940496,Incidence of dose limiting toxicity (DLT),Overall survival (OS),,2016-12-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7147,NCT05397171,All Substudies: Incidence of AEs leading to discontinuation of AZD8853,Substudy 1 - Part B: Change in CD8 tumor infiltration in paired biopsies,,2022-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7148,NCT04774679,Correlation of a macroscopically visible fragments in the 22g EUS-FNA needle specimens with final histologic diagnosis,Area Under the size of the macroscopically visible core size versus histologic core size,,2021-02-06,UNKNOWN,INTERVENTIONAL,['NA']
7149,NCT02314819,overall survival,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7150,NCT01015820,Mean Blood Vessel Radius (BVR),,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
7151,NCT03724435,Survival,,Impact on Quality of Life and Cost,2019-12-06,TERMINATED,OBSERVATIONAL,['NA']
7152,NCT00854854,Determine response rate,"Determine safety of combination,time to treatment failure, overall survival time",,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7153,NCT02465593,anti-tumor activity,,,2015-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7154,NCT05419479,Switch Maintenance-Progression Free Survival,Number of Participants With Treatment-Related Adverse Events,,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7155,NCT02201797,repeatability coefficient (RC),,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
7156,NCT05201872,The positive rate of bacterial contamination of peritoneal washings,Postoperative complications,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
7157,NCT01812876,Number of participants with adverse events; incidence of Shenqifuzheng'ADRs and identify factors that contributed to the occurrence of the adverse reaction,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
7158,NCT00611507,Response rate - RECIST criteria (unidimensional),Progression-free Survival (PFS),,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7159,NCT04795180,Length of hospital stay (number of days),Anorectal functional outcome assessed by Colorectal Functional Outcome Questionnaire (COREFO) questionnaire,,2013-12-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7160,NCT01156831,Locoregional control,Tumor regression grade,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
7161,NCT01964027,PFS and OS,,,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
7162,NCT00422773,"To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer","To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival",,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7163,NCT04783831,POPF,Position and degradation of biodegradable stents,,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
7164,NCT01659346,First Variceal Bleeding,Reappearance of Esophageal varices in presence of Portal Vein Thrombosis,,2016-02,WITHDRAWN,INTERVENTIONAL,['NA']
7165,NCT03427268,Progression-free Survival Rate at Three Months,Overall Response Rate (ORR),,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2']
7166,NCT03734068,Tumor response,number of treatment required to achieve objective response in HCC patients,,2018-06-13,UNKNOWN,OBSERVATIONAL,['NA']
7167,NCT02984566,Difference in accumulated patient dose distribution with and without KIM,Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18),,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7168,NCT02879721,"Change in expression of proteins associated with inflammation, proliferation and cancer development",Change in regulation of potential new biomarkers associated with esophageal cancer,,2009-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7169,NCT06265844,Serum prealbumin,Feeding amount,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
7170,NCT04601610,ORR,OS,,2021-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7171,NCT00004127,Clinical response rate,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7172,NCT01498757,Biomarkers predictive,,,2012-01,WITHDRAWN,OBSERVATIONAL,['NA']
7173,NCT05648084,Artificial intelligence's sensitivity and accuracy to predict the stage of the cancer,"to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients",,2022-12-15,RECRUITING,OBSERVATIONAL,['NA']
7174,NCT02308345,Length of visit (minutes),Participant-rated usefulness of video summary,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
7175,NCT02638051,Objective Response Rate (ORR),Quality of Life (QoL),,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7176,NCT06134011,The differences of the metabolism information,,,2023-09-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7177,NCT04677192,OS,Complete ablation rate,,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7178,NCT00387530,Evidence of Epstein-Barr virus (EBV) lytic phase activation (expression of EBV antigens BZLF1 and LMP2) as assessed by biopsy on day 3 of course 1,Tumor response in patients with measurable disease as assessed by RECIST criteria,,2006-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7179,NCT03771456,Anastomotic Leakage rate,Length of postoperative hospital stay,,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA']
7180,NCT00031616,,,,2001-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7181,NCT05128890,Hospital charges,,,2016-04-16,RECRUITING,OBSERVATIONAL,['NA']
7182,NCT02246725,"Quality of Life, such as pain, anxiety.",Survival,Numbers of chemotherapy cycles,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
7183,NCT04784520,progression-free survival,duration of response,HA121-28 plasma concentration,2021-06-22,TERMINATED,INTERVENTIONAL,['PHASE2']
7184,NCT05625932,Incidence of any VTE,Incidence of bleeding events according to genetic risk,,2023-03-02,RECRUITING,INTERVENTIONAL,['PHASE3']
7185,NCT06086457,Overall survival (OS),QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Score in Participants,Biomarkers for the predicting of efficacy,2024-02-04,RECRUITING,INTERVENTIONAL,['PHASE3']
7186,NCT05529667,PFS,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2019-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7187,NCT01913223,Safety outcome,Effectiveness of the procedure in terms of complete neoplasia resections,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7188,NCT00900432,Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1),,,2004-07,COMPLETED,OBSERVATIONAL,['NA']
7189,NCT00293436,Disease-free survival (phase II),Overall survival (phase II),,2005-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7190,NCT00128596,Safety and tolerability,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7191,NCT02575807,Phase 2: Progression Free Survival (PFS),Overall Survival (OS),,2016-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7192,NCT02124317,Objective response rate,Safety and tolerability,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7193,NCT01180088,OVERALL BLOOD LOSS,BLOOD TRANSFUSION RATE,,2010-08,UNKNOWN,INTERVENTIONAL,['NA']
7194,NCT02338518,3 year progression free survival,Adverse events of preoperative chemotherapy,Sensitivity analysis of primary outcome adjusted for stratification factors,2015-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7195,NCT05763927,pCR following neoadjuvant chemotherapy,1 year OS(overall survival) rate,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7196,NCT02069145,Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer,Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7197,NCT00680901,Overall Survival in All Randomized Participants,Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Hematology Parameters,,2008-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7198,NCT05727163,Objective Remission Rate (ORR),"Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.)",,2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2']
7199,NCT03982121,Recommanded phase 2 dose (RP2D),,,2019-06-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7200,NCT01745874,Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment,Tumoral regression after neoadjuvant treatment,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
7201,NCT01232829,Survival Rate,Time to Disease Progression,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7202,NCT04230772,Incidence of surgical complications,Number of retrieved lymph nodes,,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
7203,NCT00103311,Objective Response (CR or PR) as Determined by the RECIST Criteria,Overall Survival,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7204,NCT04973631,histologic type,,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
7205,NCT03853733,Genitourinary toxicity after the end of radiotherapy,palliative colostomy after the end of palliative radiotherapy,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
7206,NCT02853474,Overall survival (as intent-to treat analysis),Number of patients treated with chemotherapy,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7207,NCT05509751,Acceptability of the intervention and the study,Effect of the intervention on unplanned healthcare utilization,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
7208,NCT02005809,Post-ESD bleeding rate according to second look endoscopy,Post ESD bleeding rate according to bleeding degree during endoscopic submucosal dissection,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
7209,NCT00478140,Objective Response (Complete and Partial Response),Overall Survival,,2007-05,TERMINATED,INTERVENTIONAL,['PHASE2']
7210,NCT02261844,Improved metabolic profile of liver cells,Decreased hepatic inflammation,,2015-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7211,NCT00322712,Time to Death,,,2006-09,TERMINATED,OBSERVATIONAL,['NA']
7212,NCT04224415,Objective Response Rate,Adverse events(AE) and severe adverse events(SAE),,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7213,NCT04299880,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1']
7214,NCT06308510,Sensitivity mFast-SeqS,Concordance detection rates peritoneal dissemination,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7215,NCT00949949,"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin",Timed endpoints,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7216,NCT06298123,Recurrence-Free Survival (RFS),Overall Survival (OS),"Imaging data (enhanced CT and MRI） and histopathology data, if available.",2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
7217,NCT01963949,Biopsy of Liver Masses,,,2013-10,WITHDRAWN,OBSERVATIONAL,['NA']
7218,NCT00511264,,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
7219,NCT05016245,Safety assessed within 60 days post treatment using NCI-CTCAE v5.0,Procedure technical success,,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE3']
7220,NCT01949194,A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib,Objective Response Rate (RR),,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
7221,NCT00915382,progression-free survival,overall survival,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7222,NCT00623805,Progression-free Survival,Percentage of Participants With a R0 Resection,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7223,NCT04404595,Phase 2: Objective Response Rate (ORR) per independent central read,Phase 1b/2: Cytokine expression level in blood after CT041 infusion,,2020-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7224,NCT03099031,Venous thromboembolism recurrence,Heparin induced thrombocytopenia,Premature treatment discontinuation,2015-05,COMPLETED,OBSERVATIONAL,['NA']
7225,NCT02401971,time to progression(TTP),overall survival (OS),,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
7226,NCT04005365,ORR,,,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
7227,NCT05229874,Total Number of Retrieved Lymph Nodes,Postoperative lymph node anatomy duration,,2022-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7228,NCT02604979,Evaluate the heart-rate corrected QT (QTc) interval (msec) during robotic-assisted laparoscopic gastrectomy,,,2015-09-23,COMPLETED,OBSERVATIONAL,['NA']
7229,NCT01697891,Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline,Change in M. D. Anderson dysphagia inventory from baseline,,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7230,NCT03874026,Activity,Toxic effects,Type of cells infiltrating the tumor microenvironment.,2019-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
7231,NCT01569984,Tumor perfusion,Blood flow,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7232,NCT05822557,Health and feeding related quality of life,Adverse Events,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
7233,NCT05839002,Five-year survival of patients,,,2010-05-21,COMPLETED,OBSERVATIONAL,['NA']
7234,NCT00137852,"Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma",Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7235,NCT01158274,Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b),Overall response rate (Parts 2a and 2b),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7236,NCT01715441,Non-progression rate,Response rate,Cmax and Tmax of sorafenib and irinotecan,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7237,NCT02624726,Overall Response Rate,Toxicity profile (CTCAE v4.0),,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7238,NCT05961423,The time to recurrence of cancer after curative resection,Assessment of disability,,2020-06-19,RECRUITING,INTERVENTIONAL,['NA']
7239,NCT00426829,Toxicity (during and within 1 month after completion of radiotherapy),,,2007-05,TERMINATED,INTERVENTIONAL,['PHASE1']
7240,NCT01954745,Median Progression Free Survival (PFS),Median Overall Survival (OS),,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7241,NCT04007770,Cognitive difficulties as measured by the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog),,,2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7242,NCT05068531,Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent,Disease-specific survival after complete tumor resection,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
7243,NCT00642577,Progression-free survival.,"AEs, laboratory tests",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7244,NCT02365441,Objective tumour response (complete or partial response) as determined by RECIST v1.1,Overall survival,Macroscopically complete removal of all residual disease by surgery,2015-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7245,NCT00193167,overall response rate,toxicity,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7246,NCT01180153,objective response rate,overall survival,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
7247,NCT02959385,Overall survival,"Determination of internal target volume (ITV) of thoracic esophageal cancer by evaluating movement of ultrasonic endoscopically placed titanium clips, with or without swallowing, during radiotherapy simulation",,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
7248,NCT03966209,Acute Graft Rejection Rate,Over all survival Rate,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
7249,NCT00560365,Overall survival by intention-to-treat analysis,NHS cost per life-year saved,,2004-03,UNKNOWN,OBSERVATIONAL,['NA']
7250,NCT02978612,Functional decline in instrumental activities of daily living (IADL) and/or activities of daily living (ADL),Overall survival,,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7251,NCT06011473,feasibility of CGM system,SSI rate,,2023-08-27,RECRUITING,INTERVENTIONAL,['NA']
7252,NCT05338307,Determine whether oral BHB supplementation is safe and tolerable,Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa,,2022-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7253,NCT01632020,Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy,,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2']
7254,NCT04737187,Survival Probability at 18 Months,Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs),,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
7255,NCT03594422,Safety and tolerance,Anti-tumor activities of HQP1351,,2018-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
7256,NCT04718701,Progression-free survival (PFS),The incidence and severity of adverse events (AEs) and severe adverse events (SAEs),,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7257,NCT02830594,Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry,Overall Survival (OS),,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7258,NCT05937438,1-year disease-free survival,3-year overall survival,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7259,NCT01233505,Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0,Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST),,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
7260,NCT03200340,Duration of Severe Oral Mucositis (SOM) during the active treatment and short-term follow-up periods,Reduction in patient-reported mucositis-related mouth pain and analgesic use,"Healthcare resource use including reliance on gastrostomy feeding, unplanned office visits, emergency room visits, and hospitalizations",2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7261,NCT02921139,freedom form local progression,Grade of toxicity,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
7262,NCT03222635,"Overall survival (descriptive statistics in SPSS, percentages, survival analysis)",Quality of life during follow-up endoscopies (questionnaires),,2017-07-25,RECRUITING,INTERVENTIONAL,['NA']
7263,NCT04246125,Maximum absorbed skin dose and dose distribution,,,2020-10-13,COMPLETED,OBSERVATIONAL,['NA']
7264,NCT03346005,The ability of AeonoseTM to distinguish between patients with and without colorectal cancer in a FIT-positive population in terms of sensitivity and specificity.,Acceptance rate of AeonoseTM.,,2017-11-09,COMPLETED,INTERVENTIONAL,['NA']
7265,NCT01169558,Safety: Number of Participants With Serious and Specific Adverse Events,Efficacy: Progression-free Survival,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7266,NCT02100189,Specificity of Sponge Cytology Using FISH,Tolerability of FISH Spongy Cytology,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
7267,NCT04782557,"Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood",Adverse events of EUS-PVA and HVA,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
7268,NCT00145860,,,,2002-04,TERMINATED,OBSERVATIONAL,['NA']
7269,NCT00014456,Define dose limiting adverse events associated with the combination,Objective antitumor response,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7270,NCT04948762,Resection status,Return of bowel function,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
7271,NCT05201105,Recurrence-free survival after abdominal-perineal amputation in case of failure of radiochemotherapy,Overall survival after abdominal-perineal amputation,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
7272,NCT03365765,disease-free survival,incidence of adverse reactions after chemotherapy,,2018-02-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7273,NCT05240404,Disease-free survival,Predictive Biomarkers,,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7274,NCT05507632,Objective response rate (ORR),Overall survival rate,,2022-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7275,NCT00494299,Time to Progression (TTP),Overall Survival (OS),,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7276,NCT02061956,Efficacy,Safety,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
7277,NCT00363051,Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST),Effect of Octreotide Depot on the Trough Concentrations of Everolimus,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7278,NCT01658943,Overall Survival,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug,Objective Response Rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7279,NCT04767984,Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention,Banking of colorectal specimens,,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2']
7280,NCT05352802,The incidence and severity of postoperative complications,Oncological outcomes,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
7281,NCT04741490,1-year disease-free survival rate (1-year DFS),Overall survival (OS),,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
7282,NCT04141995,Number of patients able to undergo resection surgery,Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea,,2021-02-12,RECRUITING,INTERVENTIONAL,['PHASE2']
7283,NCT02334332,"Patient/informal caregiver satisfaction with timing, content, and delivery of the intervention",Change in mean survey scores,,2015-01,WITHDRAWN,INTERVENTIONAL,['NA']
7284,NCT06119906,Contrast of neoplastic vs non-neoplastic Barrett's,Image quality of Hyper-Spectral Endoscopy after post-hoc analysis,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7285,NCT00091117,MTD,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7286,NCT04972149,complication,number of use for each surgical instruments,,2021-05-18,UNKNOWN,OBSERVATIONAL,['NA']
7287,NCT03088150,Overall survival (OS),Time to progression,,2017-07-13,RECRUITING,INTERVENTIONAL,['NA']
7288,NCT04172194,overall survival,tolerance,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
7289,NCT05740852,Pneumonia,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
7290,NCT02687230,Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873,Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay,,2016-07-11,TERMINATED,INTERVENTIONAL,['PHASE1']
7291,NCT05424068,Measuring safety/practicality as assessed during one-on-one with the health coach (analyzed as qualitative data),Physiological measures of Performance,Measure of performance status,2022-12-02,RECRUITING,INTERVENTIONAL,['NA']
7292,NCT00474734,,,,2007-05,UNKNOWN,OBSERVATIONAL,['NA']
7293,NCT05100446,Helicobacter pylori eradication,,,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7294,NCT05411757,Adverse Events (AEs),Best of response (BOR),Lymphocyte subtype,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7295,NCT01694511,Incidence of detected dysplasia by each endoscopic technique.,The number of biopsies taken and the duration of the different endoscopic techniques.,The endoscopic prediction capability of present dysplasia compared to histopathology for HRME.,2009-11,COMPLETED,INTERVENTIONAL,['NA']
7296,NCT02036216,"To collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients with HCC.","Early diagnosis, treatment monitoring and prognosis evaluation.",,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
7297,NCT02677129,Short Physical Performance Battery,Activities of daily living,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
7298,NCT05514301,Sensitivity of polydeep vs high experienced endoscopist blinded to polydeep,To compare the diagnostic yield of the optical diagnosis,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
7299,NCT00459030,Comparison of traditional print versus simple electronic communication versus usual care in terms of increasing colorectal cancer (CRC) screening rates,Mediating effect of potential cognitive-affective factors related to CRC screening,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
7300,NCT05368688,"The molecular features of Fusobacterium (Fn) correlated with colorectal cancer (onset, recurrence, metastasis and survival)",,,2022-06-30,TERMINATED,OBSERVATIONAL,['NA']
7301,NCT02089919,The number of participants with adverse events,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,The dose of CSC vaccine,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7302,NCT00652132,Rate of Brock grade ≥ 1 hearing loss,Feasibility of central audiology review,,2007-12-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7303,NCT00732082,To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.,To evaluate the clinical response and time to disease progression with computed tomography examinations at two month intervals (current standard of care in gemcitabine-treated patients).,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE1']
7304,NCT03087071,Response rate,Overall survival (OS),,2017-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7305,NCT03830801,The number of subjects from which we will be able to collect biopsy samples using IVLCM technique,,,2017-12-06,RECRUITING,INTERVENTIONAL,['NA']
7306,NCT05646030,Feasibility of CEA assessments at home using (automated) capillary sampling,Clinical laboratory sample processing time:,,2022-03-25,RECRUITING,INTERVENTIONAL,['NA']
7307,NCT05938322,Adherence to the ketogenic diet,Investigate indices of quality of life,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7308,NCT05181865,Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1,Phase 1: PK parameters - Half-life (t1/2),Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301,2022-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7309,NCT05690451,Accuracy per patient,Sensitivity per patient,,2021-12-28,RECRUITING,OBSERVATIONAL,['NA']
7310,NCT00060567,"To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.","Safety, E7070 activity and Pharmacokinetics",,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7311,NCT02552121,Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events,Part 2: Duration of Response,,2015-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7312,NCT02529774,Liver Relapse-Free Survival Rate,Disease free survival,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7313,NCT00531245,"In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities","To investigate the time to progression(TTP), overall survival and toxicity",,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7314,NCT01539993,Assess efficacy of percutaneous and transarterial treatments for liver cancer.,long term follow up,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7315,NCT00017056,,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7316,NCT00438737,Safety (rate of perioperative safety findings),Overall survival,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7317,NCT06187961,Number of Patients Amendable to Curative Surgical Interventions,Quality of Life (QoL) after treatment,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7318,NCT02278653,Functional outcome,Early detection of local failure (standard surgery still possible),,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
7319,NCT02995096,Overall survival,Hepatocellular carcinoma specific survival,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
7320,NCT05805956,progression-free survival,,,2022-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7321,NCT05131243,ctDNA dynamic detection,Tumor Marker examination,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
7322,NCT01372735,Local recurrence rate,Overall Survival,,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7323,NCT04047173,2-year local progression-free survival rate,incidence of complications,Radiation-induced liver injury,2019-08-12,UNKNOWN,INTERVENTIONAL,['NA']
7324,NCT05833126,Objective Response Rate,Graft Rejection,,2023-12-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7325,NCT02539537,Progression-Free-Survival (PFS),Quality of life questionnaire - Core 30 (QLQ-C30),,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7326,NCT03859128,BICR-RFS,Incidence of AEs,,2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7327,NCT02478996,peak oxygen uptake (VO2peak),quality of life,feasibility of the online-based sports program,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
7328,NCT01786694,functional success of microdialysis,the quality of life after the surgery,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7329,NCT03235167,metastasis free survival time,,,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
7330,NCT01716546,Objective response rate,Maximum Tolerated Dose of the combination,,2011-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7331,NCT02209441,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
7332,NCT00578838,To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
7333,NCT05067374,Adherence to the hepatitis C screening,Care access and prospective care cascade : percentage of cured women,,2022-03-23,RECRUITING,OBSERVATIONAL,['NA']
7334,NCT03585062,R0 resection rate,The quality of life,,2017-11-20,TERMINATED,INTERVENTIONAL,['PHASE2']
7335,NCT00249301,The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.,,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1']
7336,NCT03182270,Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts,Feasibility data on nCLE during EUS-FNA procedure (rate of successful nCLE procedure),,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
7337,NCT00726037,T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer,Optimal Time for Future Dendritic Cell Vaccine Administration,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
7338,NCT05426811,Progression-free Survival (PFS),Incidence and severity of adverse events (AE) and serious adverse events (SAE),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7339,NCT02886104,Overall survival,Complete ablation rate in CRLM,,2016-08,RECRUITING,INTERVENTIONAL,['NA']
7340,NCT01555762,Progression-Free Survival,Percentage of Participants With Balducci Score,,2012-03-05,COMPLETED,OBSERVATIONAL,['NA']
7341,NCT01181245,To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib,Maximal tumor response as determined by RECIST criteria,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7342,NCT00513851,Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930,"Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7343,NCT04966819,Short Form-Survivor Unmet Needs Survey (Unmet needs) at 12 months,Short Form-Survivor Unmet Needs Survey (Unmet needs),,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
7344,NCT02860234,Organ preservation rate,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29),,2016-08,COMPLETED,OBSERVATIONAL,['NA']
7345,NCT00075465,Time to tumor progression,Tolerability,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7346,NCT01993784,Objective response rate,adverse events,,2013-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7347,NCT02148562,genetic variants of Hepatitis B,genetic variation in host-specific immune markers,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
7348,NCT05844371,The 1-year DFS rate,,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7349,NCT01362127,Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.,HRQOL and Swallowing Function,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7350,NCT03156036,Pathologic complete response rate(Pathologic staging and tumor regression grade.),,,2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE2']
7351,NCT01332669,tumor response,Number of treatment required to achieve objective response,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7352,NCT01013649,Overall survival (Phase III),Changes in fatigue,,2010-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7353,NCT06307327,Evaluation consistency,,,2024-03,RECRUITING,OBSERVATIONAL,['NA']
7354,NCT01423734,reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.,evaluate the reproducibility perfusion insensitive diffusion coefficients (ADC high) of liver metastases,,2011-08-23,COMPLETED,OBSERVATIONAL,['NA']
7355,NCT04924179,Progression-free survival (PFS),AEs,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7356,NCT04189393,"Compositional changes of the oral and gut microbiome, assessed by alpha-diversity using 16S rRNA (ribosomal ribonucleic acid) sequencing, described in a surgical patient journey from moment of diagnosis until full recovery","Compositional changes of the oral and gut microbiome, assessed by beta-diversity using 16S rRNA sequencing, correlated to the development of infectious complications (30-day)",,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
7357,NCT00025441,,,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7358,NCT04051450,Generation of candidate biomarkers PD-L1/PD1/GEP by laboratory assay qPCR for prognostication.,,,2020-05-01,RECRUITING,OBSERVATIONAL,['NA']
7359,NCT00936572,"Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function","Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7360,NCT00955097,identification of liver tumors,improved ablation of liver tumors,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1']
7361,NCT01429961,Time to progression (TTP),toxicity,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
7362,NCT05178303,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis (Arm 1),The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2),,2015-11-30,COMPLETED,INTERVENTIONAL,['NA']
7363,NCT02189421,Technical success of the direct peroral cholangioscopy,Adverse events associated with direct POC,,2014-04,UNKNOWN,INTERVENTIONAL,['NA']
7364,NCT03847532,Patients with germIine mutations in MutYH,,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
7365,NCT00004941,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7366,NCT04208958,Objective Response Rate (ORR),Duration of VE800 Bacterial Strain Colonization in Stool,,2020-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7367,NCT02213419,Rate of Subjects with Complete or Partial response of treatment,Incidence rate of adverse events after treatment,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
7368,NCT01462994,"Percentage of patients with histologically proven GIST, measurable lesion in imaging and activating CKIT and PDGFRA mutation, where detection of tumor specific DNA encoding for mutated CKIT or PDGFA is possible in the plasma at least at one timepoint",,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7369,NCT01364493,Objective response rate,adverse events,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7370,NCT05361668,Incidence of treatment-emergent adverse events (TEAEs),Pharmacokinetics (PK) of paltusotine,,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7371,NCT02494037,Survival,Qualitative Experience of Care (QEC),,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
7372,NCT03846726,PFS,OS,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
7373,NCT03775525,Dose-limiting toxicity,Apparent Volume of Distribution (Vd/F),,2019-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
7374,NCT05608044,Objective Response Rate,Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab,,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7375,NCT03151564,Metastasis Detection Accuracy,,,2017-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7376,NCT04152343,Rate of Local Occurrence,,,2019-12-07,COMPLETED,INTERVENTIONAL,['NA']
7377,NCT04941287,Progression free survival (PFS),Immunogenicity,Tumor microenvironment modulation and immunologic response,2021-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7378,NCT02664974,Maintenance of body weight,Improvement of tolerance to chemotherapy,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7379,NCT02928081,5-year overall survival rate,5-year disease-free survival rate,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
7380,NCT02963207,Accuracy measures in comparison to the final histopathology in regards to polyps' subtype (SSA/P versus non-SSA/P),Agreement in predicting post-colonoscopy surveillance interval with final histopathology,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7381,NCT04384575,Specificity,,,2020-02-22,COMPLETED,OBSERVATIONAL,['NA']
7382,NCT02726334,Maximum Tolerated Dose,,,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1']
7383,NCT00660140,To determine the response rate and time to failure for patients treated with this regimen,Survival times,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7384,NCT00215982,response rate,toxicity and tolerability,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7385,NCT04106024,PFS,,,2018-10-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
7386,NCT03244683,Postoperative complications,Length of stay and readmission,,2017-08-28,TERMINATED,INTERVENTIONAL,['NA']
7387,NCT05709899,postoperative analgesia,,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7388,NCT02028949,tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose,Evaluate the rate of objective response,,2012-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
7389,NCT05471401,"Percentage of participants who undergo successful inflation of the gastric balloon with oral contrast agent, with verification by MR or CT imaging",Translation movement of stomach between CBCT scans with and without balloon insufflation,,2023-04-25,RECRUITING,INTERVENTIONAL,['NA']
7390,NCT05199168,Incidence of the recurrent laryngeal nerve injury,Operation time (thoracic phase),,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
7391,NCT05159440,Recommended Phase 2 Dose (RP2D),Accumulation ratio (Rac) of TORL-2-307-MAB,,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE1']
7392,NCT05561699,safety（AE or SAE）,Disease free survival（DFS）,,2022-09-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7393,NCT04091165,Acceptability of Smart Phone Application,Adherence to Recommended Nutritional Plan,,2019-09-23,COMPLETED,OBSERVATIONAL,['NA']
7394,NCT05704985,"Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D","Serum concentrations of proinflammatory cytokines such as IL-6, IL-10, TNFa, IL-1b, and interferon (IFN)-g will be assessed at various time points",,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE1']
7395,NCT04392609,pTRG,,,2020-01-15,UNKNOWN,OBSERVATIONAL,['NA']
7396,NCT02486601,Complete pathological response rate,Assessment of genetic polymorphism involved in tumor-response when appropriate,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
7397,NCT01870791,Survival,Safety profile,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2']
7398,NCT01917617,Completion rate during the 12 weeks in the short hydration group,Overall survival,,2013-05-22,COMPLETED,INTERVENTIONAL,['PHASE2']
7399,NCT02823860,Presence of biological and tumoral factors related to resistance to oncological treatments,"behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities",,2016-02-12,COMPLETED,INTERVENTIONAL,['NA']
7400,NCT03914950,Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF,Lesion Size,,2014-02-07,COMPLETED,INTERVENTIONAL,['NA']
7401,NCT05044728,Immune Related Adverse Events (irAEs),2-year survival rate,,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7402,NCT06178445,ORR,"The incidence, nature, causality, seriousness, and severity of adverse events using NCI CTCAE 5.0",,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7403,NCT00508573,Number of Women Participating in Registry,,,2007-05,RECRUITING,OBSERVATIONAL,['NA']
7404,NCT06010862,Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability],Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Duration of Response (DOR) of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-09-30,RECRUITING,INTERVENTIONAL,['PHASE1']
7405,NCT04037787,Length of stay,Healthcare costs,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
7406,NCT05980403,Lymphatic metastases,,,2023-07-18,RECRUITING,OBSERVATIONAL,['NA']
7407,NCT01629524,Association between immune related cytokine and number of lymph nodes retrieved.,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
7408,NCT00698204,Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy,Evaluation of Pain Severity at 5000 cGy Radiation,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7409,NCT00835679,Patients With a Biologic Response,Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration,,2009-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
7410,NCT01929499,DFS (Disease free survival),QoL (quality of life),,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
7411,NCT05470452,AFROC-AUC,Cancer Identification Diagnosis Compliance Rate,,2021-07-28,RECRUITING,INTERVENTIONAL,['NA']
7412,NCT05281276,Pharmacokinetics profiles-(DF),Objective response,,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE1']
7413,NCT00830557,Collection of information regarding food preparation and intake by survey,,,2000-10,RECRUITING,OBSERVATIONAL,['NA']
7414,NCT01214512,Colonoscopy and CD24 assay correlation,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
7415,NCT04799431,Number of participants experiencing study drug-related toxicities,Overall Survival (OS),,2023-05-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7416,NCT05576571,Evaluate efficacy (methylation profiling results),,,2020-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7417,NCT00019084,,,,1996-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7418,NCT03731910,Treatment response mRECIST,Time to Progression,,2018-12-11,UNKNOWN,INTERVENTIONAL,['NA']
7419,NCT01307878,Progression-free survival,Toxicity of chemotherapy,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7420,NCT04644068,"The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.",Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.,,2020-11-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7421,NCT00566800,Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride,Toxicity,,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
7422,NCT04473677,The accuracy of the new qFIT to diagnose colorectal advanced adenoma.,Develop a predictive model of advanced colorectal neoplasms which includes the value of qFIT.,,2020-08-17,COMPLETED,OBSERVATIONAL,['NA']
7423,NCT02140034,Overall Survival,Peritoneal Recurrence Rate,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7424,NCT02269683,R1 resection rate,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
7425,NCT06123637,Remifentanil requirement,,,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7426,NCT00534664,,,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7427,NCT05487443,Progression free survival (PFS),Overall survival (OS),,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7428,NCT04722133,Objective response rate (ORR),Incidence of treatment related adverse events (TRAE),,2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE2']
7429,NCT00883454,The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.,,,na,COMPLETED,OBSERVATIONAL,['NA']
7430,NCT01289028,Percent of Patients Achieving Complete Response (CR),Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7431,NCT03977090,"Extended period recommended dose,RDE","Antidrug antibody, ADA",,2019-04-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
7432,NCT05744362,Overall survival,,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
7433,NCT05833971,pathologic complete response (pCR),Disease-free survival(DFS),,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7434,NCT01163396,Progression-free survival (PFS),Evaluation of potential surrogate markers predictive of bevacizumab activity,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7435,NCT05587972,Create data set,,,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
7436,NCT03010813,Perioperative complications,Voice function after TORS,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
7437,NCT01458509,feasibility of electronic PRO assessment,problems people experience,,2011-10-11,COMPLETED,OBSERVATIONAL,['NA']
7438,NCT04114006,Diagnostic yield of the WATS approach versus standard gastric biopsy mapping,,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
7439,NCT02491593,Number of patients with high fecal blood output in relation to colorectal cancer,Number of patients with low fecal blood output in relation to colorectal polyps,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
7440,NCT04270929,Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD),Serologic response rates (CA 19-9),,2019-12-23,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7441,NCT04334395,Complication rate,The survival time,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7442,NCT00006112,,,,1996-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7443,NCT00132067,Toxicity as assessed by CTCAE v 3.0,Duration of survival,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7444,NCT00116506,Evaluate 1 year progression-free survival,"Determination of the observed response rate, median duration of response and overall survival",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7445,NCT03281070,Anastomotic leakage,,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
7446,NCT03285230,Health outcomes,,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7447,NCT05893667,Overall survival Disease-free survival,Pathological response through Ryan Tumor Regression Grade,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
7448,NCT02829359,HBV reactivation on the recovery of liver function,,,2012-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7449,NCT01910909,To evaluate the SBRT effect on adverse events,To measure the progression free survival,RT response prediction probability evaluation by diffusion-weighted (DW) MRI and positron emission tomography,2013-08,COMPLETED,INTERVENTIONAL,['NA']
7450,NCT04519151,PFS of patients treated with pembrolizumab in combination with lenvatinib.,Impact of the treatment protocol on health-related quality of life using the QOL questionnaire (EORTC) QLQ-OV28.,,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2']
7451,NCT01137162,,,,2008-08,TERMINATED,OBSERVATIONAL,['NA']
7452,NCT04967482,Success rate of conversion to resection,Overall survival (OS),,2021-07-09,RECRUITING,INTERVENTIONAL,['NA']
7453,NCT00419627,,,,2007-02,UNKNOWN,OBSERVATIONAL,['NA']
7454,NCT02025036,OS-2 year,pathologic complete response rate,,2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7455,NCT03475953,Phase II (cohort A'): Assessment of the antitumor activity of regorafenib,Phase II (cohort B): assessment of the antitumor activity of regorafenib,,2018-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7456,NCT04813406,Overall survival(OS),Disease Control Rate (DCR),,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
7457,NCT01776307,Disease Control Rate,Number of Patients With Adverse Events and Serious Adverse Events,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7458,NCT02920944,single diagnostic yield of the histologic core,total diagnostic yield of the histologic core,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7459,NCT05400122,Persistence of donor NK cells,Clinical Response,,2022-09-09,SUSPENDED,INTERVENTIONAL,['PHASE1']
7460,NCT03516942,Change in level of self-reported financial burden,Change in level of self-reported financial burden,,2018-06-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7461,NCT02640924,Local control rate (treatment in-field control rate),Patient report outcome - quality of life as assessed by the EQ-5D-3L,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
7462,NCT00205322,"Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients",Is the oral drug an advantage in this patient population,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7463,NCT03717935,Change in Hepatic Fat Fraction,Change Bile Acid Metabolomics: sphingosine-1-phospate,,2018-10-08,COMPLETED,INTERVENTIONAL,['NA']
7464,NCT01216813,Patients' opinion of how to manage any of the issues that arise,Theories and a hypothesis from data collected for use in a future interventional study,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
7465,NCT01677884,Efficiency of treatment based on objective response rate,Hepatic metastasis resection rate,Total area under the curve of contrast-enhanced liver ultrasound,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7466,NCT03340974,Radiographic Stable Disease (SD) or Better Based on RECIST Criteria,,,2018-02-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7467,NCT04204577,Progression-Free-Survival(PFS),Quality of life score(QOL),,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7468,NCT02125409,Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.,"Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).",,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
7469,NCT03732105,"Recurrence Free Survival,RFS",health related quality of life,,2019-03-06,RECRUITING,INTERVENTIONAL,['NA']
7470,NCT05576506,AUC (95% CI),To record and evaluate any unknown risks and adverse events of hyperspectral imaging in specimen image acquisition,,2022-10-08,RECRUITING,OBSERVATIONAL,['NA']
7471,NCT02017002,Overall survival duration,Change of lung function after surgery,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
7472,NCT00353457,Pathologic complete response,Disease free survival,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2']
7473,NCT00320749,Maximum Tolerated Dose (MTD),Therapeutic Response,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7474,NCT02641873,AUC0-24h (Area under the plasma concentration versus time curve),Progression Free Survival (PFS),,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7475,NCT03975491,Interleukin-6,Circulating Tumor Cells,Tumor Fraction,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7476,NCT00357422,overall survival rate,disease free survival rate and recurrence rate,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
7477,NCT05704010,Small bowel adenoma,,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
7478,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,,2017-11-01,RECRUITING,OBSERVATIONAL,['NA']
7479,NCT04895709,Incidence of AEs leading to death,Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator,,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7480,NCT03671265,"Adverse events (AE), Serious Adverse Event(SAE) Adverse events",OS,,2018-09-17,UNKNOWN,INTERVENTIONAL,['NA']
7481,NCT02033538,response rate,Adverse events,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7482,NCT03184493,Number of participants with tumor recurrence,,,2017-06-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
7483,NCT05687617,Number of patients with peritoneal metastases detected only with ICG.,,,2022-12-15,TERMINATED,INTERVENTIONAL,['PHASE2']
7484,NCT01766349,"Changes of respiratory muscle performance (MIP/MEP, PFT)from baseline",Total length of hospital stay,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
7485,NCT01727908,The percentage of increasement of endoscopic detection of (pre)malignant for gastric cancer by staining of the gastric mucosa.,"To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale.",,2012-11,TERMINATED,INTERVENTIONAL,['NA']
7486,NCT05535894,Concomitant Analgesic/Narcotic Use,,,2022-08-10,RECRUITING,OBSERVATIONAL,['NA']
7487,NCT00444678,Response Rate for the Combination Treatment,Survival,,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7488,NCT01202136,Prevalence and incidence of malignant pancreatic cysts,Model for prediction of malignant pancreatic cysts,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
7489,NCT00522795,Complete Pathologic Response,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7490,NCT03620916,Severity of pain at rest,Postoperative complications,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
7491,NCT04911517,pathologic complete response（pCR）,3-year overall survival (OS),,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7492,NCT00384800,To assess the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.,To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.,,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
7493,NCT04541875,To use the MAR-Scale to identify the top patient-reported reasons for non-adherence to specific medications indicated to treat these rare diseases.,To perform psychometric analysis of the MAR-Scale questionnaire based on data collected from rare disease patients.,,2021-01,WITHDRAWN,OBSERVATIONAL,['NA']
7494,NCT04574050,Feasibility: the number of patients recruited into this study over a 12-month period,,,2021-01-11,COMPLETED,INTERVENTIONAL,['NA']
7495,NCT05257590,Objective Response Rate (ORR)_mRECIST,Pharmacodynamics analysis for the relationship of AUC and AE,,2022-05-23,RECRUITING,INTERVENTIONAL,['PHASE2']
7496,NCT05241574,Rate of patients with clinical complete response.,"Acute and late toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5.",,2021-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7497,NCT01155882,To determine range of morbidity and mortality,Effect of occlusion of the splenic vein at the confluence.,,2010-09-20,COMPLETED,OBSERVATIONAL,['NA']
7498,NCT04151719,Overall Survival,,,2020-02-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7499,NCT06041490,EFFICACY: One-year recurrence-free survival rate (1-year RFS rate),SAFETY: Incidence of adverse events and serious adverse events,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7500,NCT03050879,Total Number of Retrieved Lymph Nodes,3-year overall survival rate,,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
7501,NCT03611309,Patient quality of life,Caregiver prognostic awareness assessment,,2018-09-25,COMPLETED,INTERVENTIONAL,['NA']
7502,NCT00005591,,,,1999-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7503,NCT00662688,Thromboembolic events,Tolerance of regimens,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7504,NCT03274349,"Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis",Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters,,2017-03-17,UNKNOWN,INTERVENTIONAL,['NA']
7505,NCT05400915,(Phase II) Progression-free survival,Number of Participants With Adverse Events That Are Related to Treatment,,2019-07-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7506,NCT01814631,image quality,,,2013-03,WITHDRAWN,OBSERVATIONAL,['NA']
7507,NCT04595266,Objective response rate (ORR),Proportion of patients with liver surgery,,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2']
7508,NCT03554395,Objective response rate,Symptom remission rate,,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7509,NCT05775120,"To assess the state of the gastric mucosa according to endoscopic and morphological studies using the OLGA system, and their correlation with serological markers of atrophy",To determine the prevalence of H. pylori in the Moscow population according to the serological method - level of IgG antibodies to H.pylori.,Develop recommendations for GC prevention and early detection strategy.,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
7510,NCT03408665,SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis,Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.,,2019-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7511,NCT05759975,Oral Mucositis evaluation according NCI scale,Saliva analysis,,2023-01-13,RECRUITING,INTERVENTIONAL,['NA']
7512,NCT03738280,Lesion borders (smooth or irregular),,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
7513,NCT06314022,Compliance with the laxative intake with the use of the mobile application,Evaluate colonoscopy quality indicators,,2024-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7514,NCT05263219,Overall survival (OS),Adverse Events (AEs),,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3']
7515,NCT00183807,To assess the time to progression of CPT-11 and cisplatin in combination with celebrex in patients with metastatic or unresectable carcinoma of the esophagus,"To evaluate the effects of celebrex on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays on endothelial cell proliferation, migration and invasion.",,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2']
7516,NCT05331911,The presence of disease progression,Length of hospital stays,blood loss and blood transfusion,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE4']
7517,NCT02144727,overall survival,Finding biomarkers predicting lymph node metastasis and recurrence,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
7518,NCT04709510,The incidence of thromboembolic events by radiological assessment,Rate of predisposing factors of the patients,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
7519,NCT03940131,Overall response rate (ORR),Overall survival (OS),,2020-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
7520,NCT03881111,OS in PD-L1 biomarker-positive participants,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score,,2019-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7521,NCT03618758,Overall survival (Phase 2),Conversion surgery ratio,,2018-12-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7522,NCT05629442,Rate of successful pathologic complete response,Overall Survival (OS),,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7523,NCT03435770,To measure side effects and adverse event of EUS-guided RFA,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7524,NCT00002759,,,,1996-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7525,NCT01209962,Diffusion MRI,Apparent Diffusion Coefficient (ADC),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
7526,NCT02040142,Evaluate the technical parameters,Progression-free survival,Patient Reported Outcomes,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7527,NCT02162823,Survival,Factors influencing survival,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
7528,NCT04653818,HCC recurrence,changes in Child-Pugh scores over time,,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7529,NCT02307500,"activity of regorafenib screening, in terms of 2-months progression free survival rate",safety profile of regorafenib according to NCI-CTC v.3,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7530,NCT02610764,"Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery.","Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery.",Progression free survival,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7531,NCT00094861,Number of Participants With Grade 2 or Higher Dysphagia,Maximal Body Weight Loss,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7532,NCT05970900,Organ preservation,Anorectal function,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
7533,NCT04918992,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system in prediction radiation proctitis,The specificity of AI prediction system in prediction radiation proctitis,The sensitivity of AI prediction system in prediction the radiation proctitis candidates,2021-06-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7534,NCT04688242,Major LARS at 1 years after proctectomy,Other complications within 1 years after proctectomy,,2021-02-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
7535,NCT05278260,Number of participants who develop grade 3 oropharyngeal mucositis,,,2022-05-25,RECRUITING,INTERVENTIONAL,['NA']
7536,NCT02787954,Time to progression,1 year survival,,2016-01,TERMINATED,OBSERVATIONAL,['NA']
7537,NCT05592197,Overall Survival (OS),ncidence of Adverse Events (AE),,2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
7538,NCT02966054,Physical activity,Colorectal cancer-specific quality-of-life (FACT-C),,2014-08,COMPLETED,INTERVENTIONAL,['NA']
7539,NCT01570075,overall survival,disease-free survival,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
7540,NCT04559139,Difference in overall survival,Difference in progression-free survival,,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7541,NCT01096914,Tumor response,time to local recurrence,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
7542,NCT04050085,Incidence of adverse events,Overall survival,,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7543,NCT00501306,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
7544,NCT02512237,Maximum tolerated dose of ARX788,Number of subjects developed anti-ARX788 antibody,,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1']
7545,NCT00410579,"Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials",,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
7546,NCT06171321,Accuracy of postoperative ctDNA in monitoring recurrence and metastasis,ctDNA clearance rate,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7547,NCT04905082,Recall rates of personal genomic results,Operationalization of contextual guideline concordant care,HOPE-Genomics tool usage,2021-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7548,NCT01931644,Biospecimen & Clinical Data Collection,,,2013-07,RECRUITING,OBSERVATIONAL,['NA']
7549,NCT00002533,,,,1993-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7550,NCT00561522,The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.,The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.,,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7551,NCT06011772,Immunogencity of vaccine,Progression free survival,,2023-12-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7552,NCT04075305,Toxicity in common toxicity criteria for adverse events (CTCAE).,,,2019-02-01,RECRUITING,OBSERVATIONAL,['NA']
7553,NCT03356158,Incidence of Adverse Events [AEs],Cancer antigen [CA19-9],,2017-11-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
7554,NCT05867810,nutrition assessment,Biochemical data,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
7555,NCT02843945,Safety of CivaSheet Radiation Treatement,Length of Hospital Stay,,2017-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7556,NCT02837159,Body Mass Index,Lower-body flexibility,,2016-10,WITHDRAWN,INTERVENTIONAL,['NA']
7557,NCT05864105,Objective Response Rate,,,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2']
7558,NCT01673269,the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD,To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
7559,NCT01336985,To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan,To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads,,2011-03-28,TERMINATED,INTERVENTIONAL,['PHASE1']
7560,NCT01955629,Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy,Part 2: Aflibercept Biomarkers Evaluation,,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7561,NCT04792684,Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing,,,2020-12-30,RECRUITING,OBSERVATIONAL,['NA']
7562,NCT02840890,episode of nausea and / or vomiting,Quality of life questionnaire(QLQ-C30),,2015-11-05,COMPLETED,INTERVENTIONAL,['NA']
7563,NCT00758186,The primary endpoint was postoperative complication rates.,"Secondary outcomes evaluated included type of surgery performed, bowel preservation, presence of a stoma, postoperative bowel function, length of hospital stay, and hospitalization costs.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7564,NCT02799420,The percentage of cancer cells in biopsy samples,The expression ratio of tumor marker in biopsy samples,,2016-06-20,COMPLETED,INTERVENTIONAL,['NA']
7565,NCT04466592,general quality of life,Number of participants maintaining their social activities,,2019-12-13,COMPLETED,INTERVENTIONAL,['NA']
7566,NCT03929666,Objective response rate (ORR) (Part 2),Incidence of lab abnormalities (Part 2),,2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7567,NCT03033225,Tumor response,,,2016-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7568,NCT00501605,"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.","PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression",,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7569,NCT01120288,Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.,Assess the safety of EZN-2968 in patients with liver-predominant solid tumors. Determine the modulation of HIF-1 alpha protein levels in tumor biopsies pre- and post-administration of EZN-2968.,,2010-04-29,COMPLETED,INTERVENTIONAL,['PHASE1']
7570,NCT04966611,OS,PFS,,2021-07-15,RECRUITING,OBSERVATIONAL,['NA']
7571,NCT01335555,What is the effect of chemotherapy on the fitness of patients prior to cancer surgery?,Survival outcome at 1 year,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
7572,NCT05965921,Number of additional Barrett's neoplasia found on quadrantic biopsies,Impact of AI (WISE VISION) in real-life,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
7573,NCT03585530,Overall survival(OS),Quality of life(QOL),,2018-09-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
7574,NCT02082782,Efficacy,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7575,NCT05929885,The Grade 3-5 Toxicity Rate.,Overall survival (OS).,,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
7576,NCT00199277,Preoperative variations in hemoglobin.,Length of hospital stay,,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
7577,NCT04699188,Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only),Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM,,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7578,NCT02560779,Overall Response Rate (ORR),TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA),,2016-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7579,NCT04739072,Detection of recurrences post completion of curative therapies,Overall survival (OS),"Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations",2019-11-22,RECRUITING,OBSERVATIONAL,['NA']
7580,NCT04192929,Adenomas per colonoscopy,Inspection time,,2023-09,WITHDRAWN,INTERVENTIONAL,['NA']
7581,NCT01823471,"The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.",The difference in overall adenoma detection between HD-WLE and i-scan,The difference in advanced adenomas between HD-WLE and i-scan and between the first and second inspection round.,2010-11,COMPLETED,INTERVENTIONAL,['NA']
7582,NCT04810299,Nausea-vomiting,,,2021-04-16,COMPLETED,INTERVENTIONAL,['NA']
7583,NCT00258297,Effect on the signaling pathways by immunohistochemistry after 2-3 weeks of exposure to gefitinib,,,2004-04,TERMINATED,INTERVENTIONAL,['PHASE2']
7584,NCT02454140,Maximum Tolerated Dose,Overall Survival,,2014-06-20,COMPLETED,INTERVENTIONAL,['NA']
7585,NCT04730102,Existence of intraluminal malignant cells in fluid samples from rectal washout,Fluid volume needed to perform rectal washout during transanal total mesorectal excision to eliminate intraluminal malignant cells,,2020-02-13,COMPLETED,OBSERVATIONAL,['NA']
7586,NCT00100841,Progression Free Survival Rate,,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7587,NCT05064410,"Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening",,,2017-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7588,NCT05320328,Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.,Stent patency at 1 year,,2021-06-10,UNKNOWN,OBSERVATIONAL,['NA']
7589,NCT01521780,Expression Levels of Beta-catenin Protein From Core Needle Biopsy (CNB) Equivalents of Resected HCC.,Expression Levels of Low Density Lipoprotein Receptor (LDL-R) in Resected HCC and Adjacent Liver From Whole Tissue Sections.,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
7590,NCT00525200,Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype,Disease free and overall survival and relation to p53 genotype,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7591,NCT03559335,Postoperative inflammatory complications,,,2018-01-15,COMPLETED,OBSERVATIONAL,['NA']
7592,NCT03460080,PIVKA-II,Prothrombin Time (PT) (%),,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
7593,NCT03032224,Changes in Body composition after surgery for esophageal cancer with curative intent.,Mortality,,2015-03-23,COMPLETED,OBSERVATIONAL,['NA']
7594,NCT03593681,Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement,"Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis",,2018-08-27,COMPLETED,OBSERVATIONAL,['NA']
7595,NCT01726465,A decrease of 100 UI/L of AST and ALT compared with placebo.,Difference in blood transfusions.,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
7596,NCT00526110,Progression Free Survival,Median Overall Survival,,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7597,NCT01570452,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
7598,NCT01142713,Dose and irradiated volume of small bowel and urinary bladder,,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
7599,NCT06149741,Low anterior resection syndrome (LARS),Bowel ischaemia,,2023-11-20,RECRUITING,INTERVENTIONAL,['NA']
7600,NCT05909423,Pathological response,Analysis of perturbations in the immune activity with a focus on effector and memory CD8+ T cells,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7601,NCT05269381,Incidence of adverse events,Immunogenicity responders,Pre-existing Immunity,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
7602,NCT01696695,PFS by Therapeutic Regimens,Percentage of Participants With Dose Modification of Capecitabine,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
7603,NCT00661154,Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin,Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
7604,NCT00909558,Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?,"Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?",,2009-05,SUSPENDED,INTERVENTIONAL,['PHASE1']
7605,NCT00332943,Sensitivity of VAS score vs. ReCon score,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7606,NCT04910386,Progression-free survival (PFS),Disease control rate (DCR),,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7607,NCT02316535,disease free survival,quality of life,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
7608,NCT01116687,Number of Participants With Objective Radiographic Response (ORR),Number of Related Serious Adverse Events (SAEs),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7609,NCT00661167,Overall response rate,Disease control rate,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7610,NCT01034332,To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT,,,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
7611,NCT02308722,Maximum tolerated dose (MTD),Overall survival and progression free survival at 12 and 24 months post D1 SBRT,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7612,NCT01727388,realization of a full digital rectal examination,Evaluation of the position by the patient,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7613,NCT00270647,Major cardiovascular events,Colorectal cancer,,1997-07,COMPLETED,INTERVENTIONAL,['NA']
7614,NCT04031872,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,Progression free survival (phase II only),,2020-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7615,NCT02651415,Number of Participants That Have Any Grade HFSR Toxicity,Median Time to Progression Free Survival (PFS),,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7616,NCT04926376,Overall Response Rate (ORR) by mRECIST,,,2021-11-02,COMPLETED,INTERVENTIONAL,['NA']
7617,NCT02726854,ORR (Objective response rate),Number of participants with treatment-related adverse events as assessed by NCI-CTC（V3.0）,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7618,NCT04124601,Incidence of treatment-emergent adverse events (safety and tolerability),Pathologic therapy response to neoadjuvant treatment,,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7619,NCT01925274,Progression Free Survival (PFS) as Assessed by Investigators,Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C),,2013-11-15,TERMINATED,INTERVENTIONAL,['PHASE2']
7620,NCT01344902,Determine the carcinoma- and adenoma lesion true detection rate,,,2009-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7621,NCT02532478,Stoma closure rate,,5-year overall survival,2007-02,COMPLETED,OBSERVATIONAL,['NA']
7622,NCT00829465,OS of 1 years; TTP,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7623,NCT04188145,The Time-to-Treatment Failure (TTF),Quality of Life (QoL),,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE3']
7624,NCT05782465,Gastric Cancer,,,2019-08-23,RECRUITING,OBSERVATIONAL,['NA']
7625,NCT04418895,complete pathologic response (pCR) rate,Median Neoadjuvant Rectal Score (NAR),,2021-08-13,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7626,NCT06282016,Asthma,Area deprivation,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7627,NCT02785835,Overall survival,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7628,NCT04192539,serum taurine levels,,,2017-01-18,COMPLETED,INTERVENTIONAL,['NA']
7629,NCT05733611,Objective Response Rate (ORR),Complete Response Rate,,2023-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7630,NCT00461708,Overall Survival (OS) During the Study,Percentage of Participants With Disease Control According to RECIST,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7631,NCT03042000,3y-DFS,pCR,,2017-02,UNKNOWN,INTERVENTIONAL,['NA']
7632,NCT03648073,Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET,,,2019-01-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7633,NCT00942266,Disease Control Rate (Stable Disease or Objective Response),Fluorouracil Steady-state Pharmacokinetics,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7634,NCT03935763,Overall survival,Quality of life using Patients Reported Outcomes,,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7635,NCT00005648,Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777.,The incidence of adverse events with respect to severity and relationship to the study medication as a measure of safety,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7636,NCT00623077,Maximum tolerated dose of tomotherapy up to 12 Gy,Disease-Free Survival,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1']
7637,NCT04749381,Postoperative complications,Length of hospital stay,,2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
7638,NCT02016534,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).,"Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens",2014-02,TERMINATED,INTERVENTIONAL,['PHASE2']
7639,NCT00319007,"Pouch mucosal apoptosis index at 0, 1 and 2 months","Faecal cytotoxicity at 0, 1 and 2 months",,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7640,NCT02951273,Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension,Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.,,2016-12-08,COMPLETED,OBSERVATIONAL,['NA']
7641,NCT02292173,Maximum Tolerated Dose (MTD),Overall Survival (OS),,2015-02-18,COMPLETED,INTERVENTIONAL,['PHASE1']
7642,NCT00652587,overall survival rates,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7643,NCT06129812,Overall survival,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
7644,NCT00975897,Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors,Attitudes of patients about tests and treatment,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7645,NCT00935779,,,,2002-10,COMPLETED,OBSERVATIONAL,['NA']
7646,NCT01164215,Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy,Toxicity differences between PK-guided therapy versus non-PK-guided therapy,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7647,NCT02964468,Gastrointestinal toxicity,Quality of Life during the treatment,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
7648,NCT05126290,Number of CTNNA1 genotypes associated with a cancer phenotype,,,2021-03-16,RECRUITING,OBSERVATIONAL,['NA']
7649,NCT00005871,,,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
7650,NCT01497392,"Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment",Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens,,2012-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
7651,NCT03451773,Duration of Treatment-related Adverse Events (AEs),Overall Progression Free Survival,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2018-05-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7652,NCT02735057,maximum tolerated dose (MTD),overall survival,,2016-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7653,NCT02862704,Number of patients with adverse event,Detection of transferred T cells in the circulation using quantitative -PCR,,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7654,NCT02777801,Incidence of hepatitis B virus associated hepatitis,Interruption of chemotherapy due to hepatitis,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
7655,NCT01534923,describe doctor-patient communication about CRC screening,examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes,,2012-02-07,COMPLETED,OBSERVATIONAL,['NA']
7656,NCT01989000,"Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on overall survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.",Immunohistochemically determined parameters of the tumor microenvironment assessed in a pretreatment tumor biopsy to predict overall and recurrence-free survival,Immunohistochemically determined parameters of the tumor microenvironment assessed in pretreatment tumor biopsies and post-surgery resection material correlate,2013-11,COMPLETED,INTERVENTIONAL,['NA']
7657,NCT02291211,PFS: Progression Free Survival,Safety as measured by recording the subjects' Adverse Events from randomization to termination,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
7658,NCT04524442,Mean change from baseline in serum potassium levels over 24 hours,Number of Participants with Notable Changes in Electrolyte and Blood Gas parameters,,2021-01-27,COMPLETED,INTERVENTIONAL,['PHASE4']
7659,NCT00290524,Hospitalisation stay measured in days,Post-surgery complications,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
7660,NCT02114359,comparison of overall survival,comparison of quality of life,comprehensive geriatric assessment,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7661,NCT01517009,"The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.",The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7662,NCT01842971,number of complete surgical procedure,quality of life,,2013-06-07,TERMINATED,INTERVENTIONAL,['PHASE3']
7663,NCT05233332,ORR（by ICR）,Number of Adverse Events,,2022-02-24,RECRUITING,INTERVENTIONAL,['PHASE2']
7664,NCT01089595,Progression Free Survival,"Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging",,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
7665,NCT04736485,Pathologic response after pre-operative treatment,Treatment-Related Adverse Events,,2021-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7666,NCT00045175,,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7667,NCT04603586,1-year Disease Progression-Free-Survival (DPFS),Overall Survival,,2020-10-20,UNKNOWN,INTERVENTIONAL,['NA']
7668,NCT03935282,Proportion of patients reporting at least one non-ideal or missing CVH topic,Measure of tool acceptability with Tool Assessment,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7669,NCT02192034,Navigation role in colorectal cancer screening,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
7670,NCT05637567,Hematogenous metastases-free survival,Number of resected lymph nodes,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7671,NCT04411524,Pathologic Complete Response Rate,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7672,NCT02245217,RECIST 1.1 Therapeutic Responses to 1 Cycle,,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA']
7673,NCT04759794,The usefulness of new staining method,,,2021-02-04,RECRUITING,INTERVENTIONAL,['NA']
7674,NCT04759846,Encorafenib AUC(0-inf),MRAUC,,2021-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7675,NCT05464706,Quality of life after liver surgery,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7676,NCT02687009,Dose limiting toxicity,Niclosamide blood levels,,2017-11-07,TERMINATED,INTERVENTIONAL,['PHASE1']
7677,NCT00003873,Overall survival,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7678,NCT05117047,Disease free Survival,Textbook Outcome in liver surgery (TOLS),,2015-02-14,COMPLETED,OBSERVATIONAL,['NA']
7679,NCT03698643,Patient effective radiation dose per TACE,Tumor response,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
7680,NCT01863303,incidence of CRC,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
7681,NCT01305980,Evaluating Tumor Response Rate,Determine duration of response rate by measuring time to progression,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
7682,NCT01834963,Two-year overall survival rate,toxicity,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7683,NCT06084897,EFFICACY:1-year overall survival probability,QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants,Biomarkers for the predicting of efficacy,2023-10-16,RECRUITING,INTERVENTIONAL,['PHASE2']
7684,NCT00024375,,,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
7685,NCT02052557,PCA (Patient Controlled Analgesia) Usage,Home Oral Narcotic Use,NG (Nasogastric) Placement,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7686,NCT06162520,Area under the Receiver Operating Characteristic curve (AUROC) of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,Accuracy of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,,2021-12-17,COMPLETED,OBSERVATIONAL,['NA']
7687,NCT00397878,Median Progression Free Survival (PFS),Time to Progression,Pre- and Post-treatment Expression Values for Each Biological Correlate,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
7688,NCT00783172,progression measured with CT scan,,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
7689,NCT02570529,Gastrointestinal ulcer incidence,Adverse event of gastrointestinal hemorrhage,,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7690,NCT05536713,Blood-based test compliant rates,Patient satisfaction with the blood-based test,,2023-02-09,RECRUITING,OBSERVATIONAL,['NA']
7691,NCT02712112,disease control rate,,,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE2']
7692,NCT01288833,Rate of Accurate High Confidence Polyp Histology Predictions by the Endoscopist in the Two Groups.,Learning Curve,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
7693,NCT00487552,Success Rate Associated With the Creation of a Gastro-jejunal Anastomosis Using the Cook Magnetic Anastomosis Device With Trans-anastomotic Deployment of a Gastro-jejunal or Duodenal Stent,,,2008-01,TERMINATED,INTERVENTIONAL,['NA']
7694,NCT02882269,disease-free survival,number of lymph nodes retrieved,,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7695,NCT02380131,progression-free survival(PFS),Objective response rate (ORR),The number of Participants with adverse events,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
7696,NCT00443196,"Complete Response, No Response",,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7697,NCT00598117,To prospectively evaluate the quality of life of patients before and after esophageal cancer resection.,To describe a cohort of long term survivors of esophageal cancer in order to identify significant features in patients more than 18 months post surgery.,,2003-08,COMPLETED,OBSERVATIONAL,['NA']
7698,NCT04002128,Number of the patients with hoarseness,One year survival and complications,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
7699,NCT00501176,Intra-operative measurement of the Culture from the bile.,"Intraoperative measurements of inflammatory reaction in the liver, hepatoduodenal ligament and around the bile ducts with biopsies. Stent dysfunction and cholangitis after ERCP and pre-operative bile flow relief. Postoperative analysis.",,2006-12,COMPLETED,INTERVENTIONAL,['NA']
7700,NCT03357978,Infections in A-T,Cancer risk,,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7701,NCT00440167,TTF2,Toxicity,,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
7702,NCT04993378,EV-Score,Survival significance of EV-Score,,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
7703,NCT02866383,Clinical benefit rate (CBR),QoL,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7704,NCT02405585,Progression Free Survival,Resection Rate,,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2']
7705,NCT02947165,"Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001",Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE1']
7706,NCT05953337,Incidence of serious adverse events (SAEs),,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
7707,NCT03322995,Completion of all intended neoadjuvant therapy and surgical therapy,Progression-free survival,,2018-06-21,RECRUITING,INTERVENTIONAL,['PHASE2']
7708,NCT03893695,Dose-limiting Toxicity(DLT),Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA),,2019-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7709,NCT02484079,Complete resection rate,Factors explaining the primary outcome,,2015-05-18,COMPLETED,INTERVENTIONAL,['NA']
7710,NCT00149565,134 patients for each of the two treatment arms are needed.,,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7711,NCT05970159,Postoperative complications,Mortality,Days of ICU stay,2023-08,RECRUITING,OBSERVATIONAL,['NA']
7712,NCT03981497,Time to Local Progression,Organ specific Progression Free Survival (PFS),,2018-02-28,RECRUITING,OBSERVATIONAL,['NA']
7713,NCT05498194,The neoantigen landscape of patients with gastric cancer,The ratio of predicted neoantigens being immunogenic.,,2022-08-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7714,NCT02542215,Overall mean Area Under the Curve (AUC) of oral mucositis severity over time,Mean cumulative radiation dose at time of severe (WHO grade 3 or 4) oral mucositis onset,,2015-06,TERMINATED,INTERVENTIONAL,['PHASE2']
7715,NCT04268290,Postoperative hospital stays,Morbidity and mortality rates,,2020-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
7716,NCT02961374,Number of Participants With Grade 2/3 Adverse Event (AE),Absolute and Percent Change in Desmoid Tumor Size,Change in Differentially Expressed Genes of Duodenal Polyps and Uninvolved Tissue,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE2']
7717,NCT05396326,The incidence of treatment related adverse events (TRAE).,Progressive free survival (PFS),,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
7718,NCT03331055,visal analogue scale (VAS) score,times of breakthrough pain (BTP),complications,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
7719,NCT02872831,Diagnostic Accuracy of the 22G SharkCore™ and the 22G BNX EUS-FNA needle,Specificity of the 22G SharkCore™ needle and the 22G BNX EUS-FNA Needle for the diagnosis malignancy in solid lesions of the pancreas and gastrointestinal tract.,,2016-07,TERMINATED,INTERVENTIONAL,['NA']
7720,NCT01386931,Compare the percent of patients with inadequate samples (defined by an absence of cellular elements to account for a mass/lesion) between the two groups,Compare the percent of patients requiring repeat procedures between the groups,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
7721,NCT05251233,Incidence of delayed gastric emptying as measured by Modified Accordion Grading System (MAGS),Marginal ulcer-free survival (MUFS),,2022-04-21,RECRUITING,INTERVENTIONAL,['PHASE2']
7722,NCT00273247,Recurrence Free Survival,Overall Patient Survival,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7723,NCT03561948,Positive peritoneal lavage,,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
7724,NCT01276002,Recurrence of pancreatic pseudocyst,,,2011-01,WITHDRAWN,INTERVENTIONAL,['NA']
7725,NCT05836064,Re-scheduled colonoscopy,GastroBot functionality,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7726,NCT00006357,,,,2000-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7727,NCT00065117,,,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7728,NCT04410302,Establish and characterize at least 200 patient-derived cancer xenografts (PDXs),,,2019-11-12,RECRUITING,OBSERVATIONAL,['NA']
7729,NCT01116804,"To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer",,,2010-06-16,COMPLETED,INTERVENTIONAL,['PHASE1']
7730,NCT03154190,Hospitalization Visits (Chart Review),Palliative Care Consult (Chart Review),,2017-08-08,UNKNOWN,INTERVENTIONAL,['NA']
7731,NCT03246321,Major toxicity,Procedure-related characteristics: blood loss,,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7732,NCT02243007,Survival Rate at 18 Month,Local Control Rate,,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7733,NCT01383538,The maximum tolerated dose (MTD) for FOLFIRINOX plus IPI-926 in patients with advanced pancreatic cancer.,Objective response rate (ORR) by RECIST criteria,,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7734,NCT05476978,The model's ability to differentiate pancreatic cancer from other pancreatic solid lesion,"The model's ability to specify the pancreatic solid lesions such as pancreatic cancer, CP, AIP and NET",,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7735,NCT01598194,Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.,Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis,,2012-01-30,COMPLETED,INTERVENTIONAL,['NA']
7736,NCT00673673,Progression Free Survival,Overall Survival,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7737,NCT03591705,progression-free survival,Downstage hepatectomy rate,,2018-07-06,RECRUITING,INTERVENTIONAL,['NA']
7738,NCT03189576,ctDNA level,,,2015-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7739,NCT00059826,Overall survival at 18 months,Distant disease control,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7740,NCT06332079,Progression-free survival (PFS) Rate,Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire,,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
7741,NCT02692365,Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
7742,NCT04136522,2 years recurrence free survival,Recurrence pattern,,2020-01-10,RECRUITING,INTERVENTIONAL,['NA']
7743,NCT04708951,Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
7744,NCT02676791,Local carcinoma recurrence,,,2016-02-16,COMPLETED,INTERVENTIONAL,['NA']
7745,NCT02082691,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
7746,NCT03916510,MRI tumour regression grade,Neoadjuvant Rectal (NAR) score,Analyse the immune microenvironment as evidenced by immune cell infiltrates,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7747,NCT03578224,Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification,Number of nodes identified,,2018-09-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7748,NCT03806426,Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period,Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months,,2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE3']
7749,NCT02848443,Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin,"PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumab",Peripheral blood mononuclear cells,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7750,NCT01387373,Response rate,Toxicity,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7751,NCT05162352,Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).,DCR assessed by investigators according to RECIST 1.1.,,2021-12-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7752,NCT01861678,Anastomotic leakage rate,Amount of blood loss,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
7753,NCT00275210,Every 3 years colonoscopy for polyp free patient,"Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS",,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7754,NCT02184910,the change of pepsinogen level before and after H. pylori eradication,,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
7755,NCT00428220,Number of Participants With Treatment-emergent AEs (Treatment-Related),,Summary of Duration of Clinical Benefit,2007-07,COMPLETED,INTERVENTIONAL,['NA']
7756,NCT05995821,Biological specimens obtained from cancer patients,,,2016-08-25,RECRUITING,OBSERVATIONAL,['NA']
7757,NCT02488746,Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved,Number of participants with needs of surgical therapy or endoscopic re-resection,,2015-03,TERMINATED,OBSERVATIONAL,['NA']
7758,NCT02167321,Disease free survival (DFS),Evaluation for rate of various events after surgery,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
7759,NCT03248661,Primary endpoint is a received completed FIT kit within 15 months after the participant received results from the original FIT test,,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7760,NCT04776837,Treatment Response at 1st Scan,Skeletal Muscle Analyses,,2019-05-15,COMPLETED,OBSERVATIONAL,['NA']
7761,NCT01609504,oncological result in term of local and/or systematic recurrence,cancer-related mortality,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7762,NCT01396707,Overall response rate,Overall survival,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7763,NCT05498766,3-year DFS rate,"Incidence and severity of adverse reactions, serious adverse reactions, suspicious and unexpected serious adverse reactions",,2023-10-12,RECRUITING,OBSERVATIONAL,['NA']
7764,NCT04595058,Recurrent biliary obstruction (RBO),Survival,,2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7765,NCT04047771,Occurrence of adverse events (AEs) and serious adverse events (SAEs),Pharmacokinetics (AUC 0-inf),,2019-09-10,TERMINATED,INTERVENTIONAL,['PHASE1']
7766,NCT01750918,Part 3: Progression Free Survival (PFS),Part 3: Number of Participants With Treatment Emergent Adverse Events,,2012-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7767,NCT04359498,Surgical complications,,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
7768,NCT03468634,Device safety testing (no detectable damage in biopsy samples when reviewed by histopathology),Diagnostic model developed (algorithm able to discriminate disease with >50% specificity and >50% sensitivity),,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
7769,NCT04939051,Mean change Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR) 5+ cells,,Safety profile of treatment with OCA,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
7770,NCT03644459,AUC(0-∞) of T1h after Each Subsequent Introduction (multiple dose),PGA after Each Subsequent Introduction (multiple dose),Half time (t1/2) of T1h after Each Subsequent Introduction (multiple dose),2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7771,NCT06233864,"Object Response Rate, ORR",Adverse Events (AE),,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7772,NCT06284226,To evaluate the safety and the efficacy,To assess the modulation in tumor markers,,2022-03-25,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7773,NCT00016952,tumor response rate,quality of life,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7774,NCT05547828,Objective Response Rate (ORR),Drug-Related Safety Indicators,,2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7775,NCT06324409,First round screening participation,Overall screening participation,,2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7776,NCT00358683,"For ethical reasons, provide the opportunity for patients > 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum",Incidence of adverse events reported by the patients during the long-term treatment period of the study.,,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7777,NCT05171335,Percent Tumor Necrosis,Explant Biomarkers,,2022-06-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
7778,NCT01651949,Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event,Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine,,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE3']
7779,NCT00039611,,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
7780,NCT01963117,Time to Local Tumor Progression After Combined Hyperthermia and RT,Overall Survival Rate After Combined Hyperthermia and RT,,2013-10,TERMINATED,INTERVENTIONAL,['NA']
7781,NCT04487067,Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage,Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire,,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7782,NCT00004604,Safety,Immune response,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7783,NCT01830621,Overall Survival,Change of Global Quality of Life at 8 Weeks From Baseline,,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7784,NCT00662246,all cause mortality,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7785,NCT05171517,Microflora analysis accomplished,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
7786,NCT05986383,Postoperative liver failure rate (50-50 criteria),Clavien-Dindo grade of postoperative complications,,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7787,NCT01946282,FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year,"FIT Completion for Groups Offered $5 vs. Outreach Alone, $10 vs. Outreach Alone, and $5 vs. $10 Incentive",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
7788,NCT00176774,Toxicity,To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7789,NCT00172640,,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
7790,NCT06211933,Survival rate at 12 months after HIFU intervention,Clinical benefice rate regarding performance status,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7791,NCT01529164,response rate,Number of participants with adverse events,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
7792,NCT00222898,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
7793,NCT04547881,Total time for lesion removal,,,2016-12-12,COMPLETED,OBSERVATIONAL,['NA']
7794,NCT05838391,Time to plan and deliver treatment fractions.,Complete Clinical Response Rate,,2023-05-18,RECRUITING,INTERVENTIONAL,['NA']
7795,NCT00410774,Disease-free survival rate at 1 year,Median overall survival rate at 1 and 2 years,,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7796,NCT04358341,Disease control rate (DCR),EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores,,2020-06-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
7797,NCT00510627,To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.,To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.,,2007-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7798,NCT04258566,ICG Fluorescene,Exvivo fluorescence,,2022-01-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
7799,NCT00588549,To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.,To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.,,1998-07,COMPLETED,OBSERVATIONAL,['NA']
7800,NCT05738421,To provide objective data on the bolus transit during swallowing in tracheostomized patients with tracheal tube and without tracheal tube,To evaluate the features of swallowing,,2021-12-06,RECRUITING,OBSERVATIONAL,['NA']
7801,NCT01939275,"Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings",,,2014-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7802,NCT04379999,Genome-wide expression analyses using RNA-Seq,Acceptability of the pilot study intervention and the willingness of the subject to participate in a similar larger study.,,2018-09-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7803,NCT00002773,,,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7804,NCT02253511,Overall survival,Recurrence-free survival,Number of participants with adverse events,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
7805,NCT02310477,Overall survival (OS),Progression-free survival (PFS),,2014-02,COMPLETED,OBSERVATIONAL,['NA']
7806,NCT03177681,Percentage Change in Firmicutes in Stool from Baseline to Day 12,Adherence Rate of Dannon® Oikos® Yogurt Intake,,2022-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
7807,NCT04161781,Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer,,,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
7808,NCT02149771,Median survival time,Time to Disease Progression,,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7809,NCT04486378,Disease-free survival (DFS),Occurrence of dose reduction and discontinuation of IMP due to a TEAE.,,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
7810,NCT01628211,overall survival,list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery,,2012-04,RECRUITING,INTERVENTIONAL,['PHASE2']
7811,NCT04694183,R0 resection rate,Serious adverse events(≥grade 3）,,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE2']
7812,NCT04775056,Immunogenicity index-seroconversion rates of neutralizing antibody,Immunogenicity index-seropositive rates of neutralizing antibody,,2022-08,WITHDRAWN,OBSERVATIONAL,['NA']
7813,NCT00633295,To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum,To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7814,NCT04827732,Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT,Frequency of late adverse events as measured by CTCAE v 5.0,,2021-05-04,RECRUITING,INTERVENTIONAL,['NA']
7815,NCT00190554,Disease free survival,Operative morbidity,,2000-05,TERMINATED,INTERVENTIONAL,['PHASE3']
7816,NCT05187312,Diagnostic yield,,,2022-01-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7817,NCT04855448,learning curve of surgicla failure,Disease free survival,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
7818,NCT05449860,Local tumor progression rate,Technical success rate,,2020-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7819,NCT01378013,Sepsis,Mortality,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
7820,NCT02732483,Rebleeding rate,Mortalities,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7821,NCT02457624,Detection rate for gastric premalignant lesion,Detection rate for gastric dysplasia,,2008-03,UNKNOWN,OBSERVATIONAL,['NA']
7822,NCT00972465,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,"To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment",,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
7823,NCT05768503,Progression-Free Survival (PFS),Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29),,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7824,NCT03191487,"The rate of prescriptions for chemotherapy in the outpatient clinic prepared at the latest the day before a session (except for predefined, limited stability products) and administered in full, per patient, during a follow-up period of 6 months",Overall costs,,2018-04,WITHDRAWN,INTERVENTIONAL,['NA']
7825,NCT04673526,Quality of life associated to incontinence as assessed by Faecal incontinence quality of life scale (FIQL),Post-operative complications,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
7826,NCT00220168,Time to disease progression (TTP),"Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements).",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7827,NCT06061263,recurrence-free survival,,,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7828,NCT01763489,feeling able to judge the applicability of the trial,,,2014-01,WITHDRAWN,INTERVENTIONAL,['NA']
7829,NCT03949907,Combined endpoint - overall survival and weight maintenance,Abnormal values in safety laboratory variables,Serum levels of immunologic profiles,2020-04-14,RECRUITING,INTERVENTIONAL,['NA']
7830,NCT05673772,5-year disease-free survival,Distant metastasis,,2020-10-23,RECRUITING,INTERVENTIONAL,['PHASE2']
7831,NCT01751919,Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate,Terminal Elimination Half-life (t1/2) of Imatinib mesylate,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7832,NCT01919879,Non progression rate at 6 months,Tolerance of the treatment,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7833,NCT04414306,Change in non-screening cancer prevention behaviors,Uptake of tobacco quitting behaviors,,2020-10-08,COMPLETED,INTERVENTIONAL,['NA']
7834,NCT05341622,FIT Completion,FIT Positive Follow-up Completion,,2022-05-27,COMPLETED,INTERVENTIONAL,['NA']
7835,NCT04825834,"Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.","Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy",,2021-03-22,RECRUITING,OBSERVATIONAL,['NA']
7836,NCT02142322,response rate,resection rate,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7837,NCT03949777,Aer-O-Scope Validation of Cecal Intubation,,,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
7838,NCT05780736,Disease-free Survival (DFS),Participant Treatment History,,2023-08-04,RECRUITING,OBSERVATIONAL,['NA']
7839,NCT01029418,To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of AZD6244 and sorafenib in patients with advanced hepatocellular cancer.,To investigate if the combination sorafenib and AZD6244 increases Time To Progression (TTP) over sorafenib alone in patients with advanced hepatocellular carcinoma patients.,,2009-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7840,NCT02934958,Colonoscopy Completion,,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
7841,NCT01522209,Detection of Liver Metastasis during Operation,Comparison of Specicivity of all imaging modalities,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
7842,NCT03662412,overall survival,Response rate,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7843,NCT04456218,Image quality evaluation: the light brightness and the imaging sharpness in Likert scale,In biliary stricture arm: Number of the lesions with or without presenting of the specific features for DDx of the benign or malignant stricture,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
7844,NCT04411537,Pathologic Complete Response Rate,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7845,NCT05046756,"Change of body composition (weight, kg)",The Wexner score,,2021-05-11,RECRUITING,INTERVENTIONAL,['NA']
7846,NCT00114842,Sensitivity/specificity for water versus air for distension of colon in MR colonography,Sensitivity/specificity of MR colonography versus colonoscopy,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7847,NCT03927495,Objective response rate assessed by investigator based on RECIST 1.1,,,2019-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
7848,NCT00019786,Overall survival,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7849,NCT01140347,Overall Survival (OS),Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)],,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7850,NCT04330716,Rate of patients who have germline genetic tests,Cascade testing in positives,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
7851,NCT02165215,"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)",Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),,2014-08-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7852,NCT03234465,Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4),,,2017-07-18,TERMINATED,INTERVENTIONAL,['PHASE2']
7853,NCT01366833,To investigate the change in dysphagia score (0-4 Likert scale) measured at baseline and at 10 weeks,,,2011-06,TERMINATED,INTERVENTIONAL,['NA']
7854,NCT03274882,Progression free survival (PFS) rate,Abnormalities in 12-leads ECG parameters [safety and tolerability],,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7855,NCT03432676,Best objective response rate,,,2019-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7856,NCT02287168,elimination,dissemination,,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7857,NCT05419531,rate of young endurance athletes that have colorectal cancer on screening colonoscopies.,Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).,,2022-10-18,RECRUITING,OBSERVATIONAL,['NA']
7858,NCT05163873,Assessing the feasibility of the trial based on overall QoL reported in intervention group compared with standard care group,,,2021-12-09,RECRUITING,INTERVENTIONAL,['NA']
7859,NCT00464620,6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST),Number of Participants With Tumors With Mutations in Kinases,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7860,NCT02415829,The tumor regression grade of all the patients enrolled,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
7861,NCT03321630,Progression-Free Survival (PFS),,,2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE2']
7862,NCT01381211,Time to Progression (TTP).,Toxicities and adverse events (recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3.0),,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7863,NCT05950503,Surgery conversion rates,Overall survival,,2023-07-10,RECRUITING,OBSERVATIONAL,['NA']
7864,NCT02269631,Change in Weight,Satiety,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
7865,NCT00354601,Objective Tumor Response,Quality of Life,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2']
7866,NCT03333265,Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis,,,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7867,NCT06157996,Progression-free Survival (PFS),Duration of response (DoR),,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7868,NCT05316480,Overall response rate (ORR),Overall survival (OS),,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7869,NCT05318404,Percentage of body weight loss,Postoperative daily protein intake,,2020-12-08,COMPLETED,INTERVENTIONAL,['NA']
7870,NCT01130701,"To estimate the 3 year progression-free survival of patients with localized, resectable pancreatic cancer",To estimate resection rate,,2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7871,NCT05108428,Feasibility of MRI guided dose adaptive chemoradiation therapy,Number of Participants with Pathological Complete Response (pCR),Number of Participants with Disease-Free Survival (DFS),2021-12-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7872,NCT01839630,Summarized patient characteristics,Treatment pattern of Sorafenib,,2013-05-30,COMPLETED,OBSERVATIONAL,['NA']
7873,NCT02436564,Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.,Proportion of tumour-derived organoids that are genetically identical to the source tumour.,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
7874,NCT05498506,the number of linear stapler cartridges,,,2022-12-01,COMPLETED,OBSERVATIONAL,['NA']
7875,NCT00355238,The Number of Participants Experiencing Adverse Events (AEs),Change From Baseline to End of Treatment in FHSI-8 Total Score,,2006-12-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7876,NCT04919577,Roux stasis syndrome,Gender,,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
7877,NCT05670561,Pain Intensity at 12hours after the beginning of TACE operation,Analgesic Consumption,Quality-of-Life Assessment at 24hours after the beginning of TACE operation,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE4']
7878,NCT06203613,To assess the sensitivity and specificity of using [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for the diagnosis of metastatic gastric and pancreatic cancer,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
7879,NCT00478374,To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.,changes in the blood concentration of tumor marker AFP,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7880,NCT03797625,Progression Free Survival,,,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7881,NCT05043363,Clinician experience of LumenEye examination,"Diagnostic accuracy of the LumenEye for the detection of rectal pathology including tumour, polyps and inflammation",,2020-11-14,COMPLETED,OBSERVATIONAL,['NA']
7882,NCT04696055,Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment,Number of Participants With Dose Modification,,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7883,NCT04516174,The prognosis of aged patients,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
7884,NCT02885376,"Incidence of severe oral mucositis, defined as grade 3 or 4 on the World Health Organization (WHO) scale","Use of opioid analgesics for oral mucositis pain, as expressed in morphine equivalents.",,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7885,NCT00267046,Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7886,NCT06157463,Change of FAPI SUV,Correlation of FAPI SUV,,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7887,NCT06085976,Incidence on intraoperative bleeding.,Rate of postoperative complications,,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2']
7888,NCT05507411,1-year DFS of CCR-Watch and Wait group,EORTC QLQ-30,,2022-08-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7889,NCT05936931,CRC screeningintentions,,,2024-02,WITHDRAWN,INTERVENTIONAL,['NA']
7890,NCT02703545,Proportion of patients and resected lesions with pancreatic cancer in situ (high grade dysplasia) or invasive malignancy,Calculate survival time from point of diagnosis and treatment,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
7891,NCT04923672,Steps per day,Fitness level,,2023-02-20,RECRUITING,INTERVENTIONAL,['NA']
7892,NCT00757640,Reduced biliary complications,Improved quality of life,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
7893,NCT03523546,Utilization of acute and specialty care,Survival,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7894,NCT00685763,"Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)",Collect and Analyze Tumor Control Measures,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
7895,NCT03649945,3 year disease-free survival rate,overall survival,,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
7896,NCT03110328,overall survival,,,2018-02-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7897,NCT01083537,Time to Resolution of Bowel Obstruction,Evaluation of Toxicity,,2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7898,NCT02782949,Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa,Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage,"Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)",2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7899,NCT01824953,Newly developed gastric neoplasm,Degree of gastric atrophy,Helicobacter pylori,2010-01,COMPLETED,OBSERVATIONAL,['NA']
7900,NCT04246177,Overall Survival (OS),TTP per RECIST 1.1,,2020-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7901,NCT00918827,Relapse-free survival,,,2009-04-01,COMPLETED,OBSERVATIONAL,['NA']
7902,NCT00002650,,,,1995-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7903,NCT02403024,Change in VO2peak,Change in VO2peak (secondary comparisons),,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7904,NCT03238404,Postoperative length of stay,Prealbumin,,2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
7905,NCT03824366,Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First On-table Attempt for Each Respective Fraction.,,,2019-04-23,COMPLETED,INTERVENTIONAL,['NA']
7906,NCT00339560,Gallbladder Cancer,,,1997-05-16,COMPLETED,OBSERVATIONAL,['NA']
7907,NCT06040177,Objective response rate(ORR),Overall Survival (OS),,2023-02-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7908,NCT05497869,pectoralis minor length through Rigid standard plastic transparent right angle,,,2022-08-10,COMPLETED,INTERVENTIONAL,['NA']
7909,NCT06318234,Evaluation efficacy of tumor regression level,SUV,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
7910,NCT05070598,ORR (Objective control rate),OS(Overall survival),,2021-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
7911,NCT05412706,Progression-Free Survival 1,Incidence of Treatment-Emergent Adverse Events,Translational objectives 3 for evaluated association between in vitro drug screening sensitivity on Patient-derived organoids and clinical outcome,2023-09-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7912,NCT02587247,Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68,"To evaluate the clinical impact (new lecture of imaging, new examens)",,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7913,NCT04340401,pathologic complete response rate(pCR rate),Major adverse events,,2020-05-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
7914,NCT04923620,Pathological response rate,disease-free survival,,2021-10-20,RECRUITING,OBSERVATIONAL,['NA']
7915,NCT02649348,The proportion of postoperative complications,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
7916,NCT02186886,Clinical response,Calprotectin stool levels,molecular spectral range,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
7917,NCT04232891,relapse rate in MRD- patients,minimal residual disease detection rate,,2019-11-18,UNKNOWN,OBSERVATIONAL,['NA']
7918,NCT01074996,Progression Free Survival(PFS),safety and tolerance,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
7919,NCT04662346,correlation to post-operative complication,,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
7920,NCT03912857,Objective Response Rates (ORR),Disease Control Rate (DCR),,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7921,NCT01490203,Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results,Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
7922,NCT04639284,Objective response,"Time to deterioration in patient-reported quality of life, physical functioning, and role functioning",,2020-12-23,UNKNOWN,OBSERVATIONAL,['NA']
7923,NCT00002935,,,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7924,NCT03941626,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",Clinical response,,2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7925,NCT05794750,Pathologic complete response rate (pCR),Incidence and severity of adverse events (AEs) and clinically meaningful abnormal laboratory test results,"Relationship between the expression of immune markers in tumor tissues and blood,the distribution of immune cells, and the efficacy and prognosis of patients",2023-04-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7926,NCT04707365,overall survival,,,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7927,NCT00875771,Progression free survival (PFS),Rate of hepatic metastases resection,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7928,NCT05618821,Total Number of Retrieved Lymph Nodes,Intraoperative situation,,2022-06-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7929,NCT05634590,Progression-Free Survival (PFS),Overall survival (OS),,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7930,NCT05362344,Sensitivity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,Specificity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,Ease of stool testing,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
7931,NCT04212221,Objective response rate (ORR),Overall survival (OS),,2020-04-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7932,NCT01972737,Antibody responses,Persistent immunological responses,Time to recurrence and disease-free survival and immune responses,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7933,NCT02138617,Progression Free Survival,Overall Survival,,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7934,NCT03884868,Grade of distress experienced by patients,Grade of understanding of the information reported by patients,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
7935,NCT03792048,Incidence of anastomotic fistula,Incidence of pancreaticojejunostomic stricture,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
7936,NCT00561470,Overall Survival (OS),Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7937,NCT01707758,,,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA']
7938,NCT05463328,"Rate of postoperative anastomosis leakage(pancreatic,billary and intestinal).",Postoperative 30 days mortality rate.,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7939,NCT04183218,Cardiac event rate at 12 months,Overall survival,Imaging changes,2019-09-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7940,NCT01472770,Rate of patients progression free at 3 months,Overall survival,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7941,NCT02156700,Tumor stiffness,tumor to parenchyma stiffness ratio,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
7942,NCT03754192,Pefusion parameters,Pathological examination,,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA']
7943,NCT00266097,Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride (Part 2),,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7944,NCT00006001,,,,2000-08,TERMINATED,INTERVENTIONAL,['PHASE2']
7945,NCT00958386,Objective response rate,Evaluation of molecular predictive markers,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7946,NCT03986541,Progression free survival,Disease control rate,,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA']
7947,NCT02630108,Overall Survival,Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
7948,NCT01423604,Overall Survival,Summary of Clinical Benefit,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7949,NCT04852679,Clinical Benefit Rate (CBR) of tumour response assessed using RECIST (Version 1.1) and confirmed by Blinded independent central review (BICR),Incidence of Adverse Events (AEs),,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE3']
7950,NCT03142516,Progression-free survival at one year,Combined analysis of prognostic factors in metastatic disease,RAS/BRAF mutations' detection proportion,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7951,NCT05055726,Number of responders,Frequency of adverse events,,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7952,NCT02519140,Lift Efficacy,Dissection Adequacy,,2014-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7953,NCT00003867,,,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7954,NCT05234450,Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
7955,NCT00304135,Overall survival,Biliary complication rate,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7956,NCT00588263,determine the prevalence of recurring BRCA1 and BRCA2 mutations,,,2000-07,WITHDRAWN,OBSERVATIONAL,['NA']
7957,NCT01787500,Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0,,,2013-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
7958,NCT00950820,Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours,safety-endpoints,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7959,NCT00148226,,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7960,NCT00288275,Progression Free Survival,Tumor Response,,2004-07,TERMINATED,OBSERVATIONAL,['NA']
7961,NCT01703026,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
7962,NCT01290523,Number of Participants With Adverse Events,Radiographic Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,,2010-05,TERMINATED,INTERVENTIONAL,['NA']
7963,NCT04819958,3-year disease free survival rate,Duration of postoperative hospital stay,,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA']
7964,NCT03816358,Maximum tolerated dose (MTD),Biomarker analysis,,2019-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
7965,NCT04842968,At least 12 lymph nodes harvested,Overall survival,,2021-04-15,UNKNOWN,INTERVENTIONAL,['NA']
7966,NCT03597581,RGX-202-01 treatment-emergent adverse events,RGX-202-01 area under the curve,,2018-06-05,RECRUITING,INTERVENTIONAL,['PHASE1']
7967,NCT03460925,Clinical response to the treatment in terms of resectability,Quality of life,,2018-05-02,UNKNOWN,INTERVENTIONAL,['NA']
7968,NCT01313377,Quality of life,Toxicity of adjuvant chemotherapy,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7969,NCT03205501,"Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137.",Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy.,,2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7970,NCT06018714,2-year recurrence and metastasis rate,2-year disease-free survival rate,completion rate of maintenance therapy,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7971,NCT06217016,secondary catheterization owing to urinary retention,Postoperative complications,,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7972,NCT02311803,Sexual function,5-year recurrence pattern,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
7973,NCT04487002,recurrence rate,post-operative complications,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
7974,NCT03632746,The specificity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients,The sensitivity of the Nomogram alone in predicting lymph node metastasis in early gastric cancer patients,,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7975,NCT01303393,,Information needs - patients' and next of kins',,2007-01,COMPLETED,OBSERVATIONAL,['NA']
7976,NCT04365946,Analysis of microbiome in subtypes of intestinal metaplasia and gastric cancer,,,2020-04-18,UNKNOWN,OBSERVATIONAL,['NA']
7977,NCT03168152,Time to local tumor progression,Incidence of intrahepatic failure,,2017-05-11,WITHDRAWN,INTERVENTIONAL,['NA']
7978,NCT02047500,Number of Subjects Experiencing Dose Limiting Toxicity (DLT),Number of Subjects With Treatment-emergent Adverse Events (TEAEs),,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1']
7979,NCT01824004,Disease free survival,Number of participants with adverse events as a measure of safety and tolerability,Health -related quality of life,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7980,NCT03150992,Change in incidence of pain,Nutritional intake,,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA']
7981,NCT01373320,Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected),"Retention (i.e., number of participants who complete all planned assessment timepoints)",,2010-03,COMPLETED,INTERVENTIONAL,['NA']
7982,NCT00677144,overall response rate,"Safety, time to progression, and overall survival",,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7983,NCT06007846,Patients Progression Free Survival at 6 months,,Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment,2023-07-31,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7984,NCT04367025,Major pathologic response (MPR),OSR,,2020-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
7985,NCT02024841,Maximum tolerated dose and recommended dose,Overall survival,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7986,NCT01458717,2-year survival rate,efficacy of imaging study after neoadjuvant chemoradiation,,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7987,NCT04465734,tumor assessment,,,2022-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE3']
7988,NCT00628186,the length of hospital stay after pancreaticoduodenectomy,early and late complications after pancreaticoduodenectomy,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
7989,NCT05476432,Overall survival,the predictive power of thymidylate synthase (TYMS),,2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE3']
7990,NCT01336452,characteristic of Perfusion MR,,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
7991,NCT05593419,TIIC signature,,,2022-10-31,RECRUITING,OBSERVATIONAL,['NA']
7992,NCT00609310,Recurrence rate of neoplasia,"Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients",,2015-05,SUSPENDED,INTERVENTIONAL,['PHASE2']
7993,NCT06037655,Objective response rate (ORR),overall survival (OS),Major Pathological Response Rate (MPR),2023-09-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7994,NCT05830097,Incidence and severity of Adverse Events (AEs),MTD/RP2D of CBP-1019.,,2023-03-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7995,NCT04648020,To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2021-02-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7996,NCT01402401,efficacy of AUY922 in combination with trastuzumab as assessed by RECIST,,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
7997,NCT05468944,Complication rate,Overall survival rate,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7998,NCT01094600,Primary outcome: correlation between S-MRCP with ePFT,,,2012-06,WITHDRAWN,INTERVENTIONAL,['NA']
7999,NCT05690958,Intended uptake of EAC screening,Views on the organization of EAC screening,Acceptability of screening test accuracy,2023-02-13,RECRUITING,OBSERVATIONAL,['NA']
8000,NCT03156582,Number of participants whose tumoral characteristics on the liver explant were under the criteria of the AFP score,Progression free survival after LT for HCC,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
8001,NCT04943653,6-month progression free survival (6-month PFS),Ascites response,,2021-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8002,NCT00059865,Survival after 6 months of treatment,Toxicity as assessed by CTC v3 every 4 weeks,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8003,NCT03909997,Number of patients with severe 30-day or in-hospital morbidity,Median and percentage of patients with long-term survival,,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA']
8004,NCT05178095,ADR,Procedural time,,2020-09-30,COMPLETED,INTERVENTIONAL,['NA']
8005,NCT03364621,Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumor recurrence in clinical environments,Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples,,2017-08-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8006,NCT03869151,increased over all survival,,,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA']
8007,NCT04310111,Tumor size,Adverse events,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
8008,NCT01598584,quality of life,chemotherapy induced nausea and vomiting,,2012-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8009,NCT00497497,Incidence and nature of dose-limiting toxicities,Incidence and severity of infusion reactions,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8010,NCT03792269,Progression-free Survival (PFS),Adverse Events (AE),,2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8011,NCT00042900,,,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8012,NCT03398512,radical resection rate,complication rate,,2018-02-01,TERMINATED,INTERVENTIONAL,['NA']
8013,NCT02170090,Disease free survival (DFS),locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence),,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8014,NCT02530593,QoL in colon cancer patients,Analyse health economy aspects of QoL and morbidity in the patient population,,2015-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8015,NCT04068896,Number of Patients with Clinically Significant Laboratory Abnormalities:,Skeletal muscle index during therapy with NGM120,,2019-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8016,NCT03307941,Phase II: pCR rate,Phase II: Number of the tumour-infiltrating lymphocytes (TILs),,2017-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8017,NCT01941992,"Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.",Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0),Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8018,NCT04952272,Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors,,,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE1']
8019,NCT00479817,Progression Free Survival,Incidence of the occurence of AMG 386 Antibody formation,,2007-07-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8020,NCT05076591,Number of patients with Adverse Events（AEs）,,,2022-06-20,RECRUITING,INTERVENTIONAL,['PHASE1']
8021,NCT02542436,Overall Survival (OS),Percentage of Participants with Adverse Events of Special Interest,,2015-09-01,WITHDRAWN,OBSERVATIONAL,['NA']
8022,NCT02024412,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,quality of life,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
8023,NCT03458975,Objective response for liver metastases,Dosage of cytokines,,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8024,NCT03567629,"Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first.",The incidence of treatment related emergent adverse events（Safety and Tolerance）,,2018-05-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
8025,NCT03698461,Serial changes in Cluster of Differentiation(CD) 8+ T cell densities,Microbiome profile,,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8026,NCT02581215,Progression Free Survival (PFS),Characterize Adverse Events (AE),,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8027,NCT00419614,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
8028,NCT01711450,Dose of intravenous sedation required during and after the procedure,Complication rate of paravertebral block,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
8029,NCT02543762,"Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain",Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
8030,NCT06044142,Assess the impact of photo-bio-modulation low level (LL) laser treatment in managing mucositis,,,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1']
8031,NCT06160557,"Disease Free Survival, DFS",,,2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8032,NCT05221320,"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.,,2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE2']
8033,NCT01442649,Progression-free survival (PFS) at 4 months,Quality of life,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8034,NCT02774187,Overall survival,Number of of Patients developed Adverse Events,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8035,NCT04854668,Progression Free Survival (PFS) assessed by IRC,Duration of Response (DOR),,2020-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8036,NCT05980182,Colorectal Screening Status,Determine the feasibility of the mHealth Application - Sharing Content,,2023-08-05,RECRUITING,INTERVENTIONAL,['NA']
8037,NCT04484909,Recommended phase II dose (RP2D),Overall survival (OS),Resection status,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
8038,NCT01157039,To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.,To compare the toxicity profile of glutamine and FOLFOX to historical data.,,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8039,NCT00910494,surgical complication rate,local control,,2010-01,TERMINATED,INTERVENTIONAL,['NA']
8040,NCT05552729,Cognitive function,Asthenia,,2022-09-22,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8041,NCT05040438,Objective Response Rate (ORR) of administering VAX-NK/HCC combined with HAIC,The serum cytokine levels,,2019-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
8042,NCT05383976,Adenoma Detection Rate,,,2023-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8043,NCT01956864,Number of participants on high dose Vitamin D with adverse events,Changes in the expression of serum and imaging biomarkers,,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8044,NCT00253526,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8045,NCT03602417,Clinical success rate,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
8046,NCT03249727,"Test performance of NK Vue (ability of NK Vue to detect CRC in those subjects in risk categories P2, P3 or P4)",Test performance of NK Vue in combination with FIT,,2017-07-05,TERMINATED,INTERVENTIONAL,['NA']
8047,NCT06304597,Temperature,Evaluate targeted detection with nivolumab-800CW and durvalumab-680LT of the tumor by ex vivo visualization of the resection specimen with PEARL Trilogy,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
8048,NCT04654494,disease free survival,,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
8049,NCT00238381,Composite evacuation score after total mesorectal excision,Morbidity,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8050,NCT05002686,1 year Progression Free Survival (PFS),Percentage of pathologic complete response(pCR),Potential biomarker to predict prognosis,2021-08-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8051,NCT01818973,The pathologic tumor regression grade (TRG),5-y local relapse free survival,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
8052,NCT04621474,Inter-observer agreement,Preferred imaging modality,,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA']
8053,NCT02241499,Improvement of dysphagia.,Endoscopic response of the primary tumor.,Metabolic response,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8054,NCT03722628,The level of Matrix metalloprotinease-1 genotypes polymorphism in the study population,,,2018-12-15,UNKNOWN,OBSERVATIONAL,['NA']
8055,NCT06044311,Metabolic Response,Ability to take vactosertib before and after standard of care chemoradiation,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8056,NCT06210971,Pathologic Complete Response,Incidence of adverse events,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8057,NCT01224990,The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.,,,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
8058,NCT05694559,genetic risk screening tool (GRST) questionnaire,,,2022-11-23,RECRUITING,INTERVENTIONAL,['NA']
8059,NCT04161092,Five-year overall survival,Health economic evaluation,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
8060,NCT06333769,complete response (CR) rate,3y-DFS,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8061,NCT04252456,"Overall survival (OS) according to VEGFR2 levels, evaluating the difference in terms of median OS among patients with high VEGFR2 activity and patients with low VEGFR2 activity",Angiogenetic factors levels concentration before and during treatment.,,2018-04-23,UNKNOWN,INTERVENTIONAL,['NA']
8062,NCT05702385,CPV-measured differences in cost of care between control and intervention arms,,,2023-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
8063,NCT05155475,Evaluation of the common bile duct size,,,2019-06-04,COMPLETED,OBSERVATIONAL,['NA']
8064,NCT02660671,Colonoscopy participation,Scheduling of colonoscopy,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
8065,NCT04695470,PFS(progression free survival) rate at 6 months,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8066,NCT04705363,Credibility score,,,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
8067,NCT03133286,Obtain pre- and post-irradiation participant-collect blood samples,,,2017-04-06,UNKNOWN,OBSERVATIONAL,['NA']
8068,NCT03461341,Utilisation of routine surveillance imaging across European Centers,Health-related quality of life (HR-QL) as assessed by EORTC QLQ-C30 questionnaire,,2009-06-01,COMPLETED,OBSERVATIONAL,['NA']
8069,NCT05894824,PFS rate at 24 weeks,adverse events categorized in accordance with CTCAE 5.0 Criteria.,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8070,NCT01722162,Progression Free Survival (Arm B),Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8071,NCT02222753,Disease-specific survival,Overall survival,Disease-free survival,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
8072,NCT03245190,16 weeks progression-free rate (16W-PFR),12 months overall survival rate,Screening characteristics of ctDNA measurement (multi-gene analysis).,2018-04-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8073,NCT03432624,Fourfold Table Analysis Indexes,Statistical Analysis Indexes,,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA']
8074,NCT03713229,Incidence of anal cancer,,,2010-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8075,NCT00936689,survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events.,Radiological tumor response; TTSP; TTP; Overall duration of response; Quality of life; ECOG score; Impact on liver function; No.of treatments administered.,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8076,NCT04348838,Variation of overall survival time (OS) after pharmaceutical treatment,Variation of serious adverse event rate of HCC treatments in clinical practice,,2019-08-26,RECRUITING,OBSERVATIONAL,['NA']
8077,NCT02857270,Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs),Overall Survival (OS) (Dose Expansion Arms Only),,2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
8078,NCT02743221,Progression Free Survival (PFS),Overall Survival (OS),,2016-04-29,COMPLETED,INTERVENTIONAL,['PHASE2']
8079,NCT00004190,overall response rate,objective tumor response,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8080,NCT02317471,Number of participants with adverse events related to gp96 immunotherapy,Overall survival,,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8081,NCT02421432,TME quality & circumferential resection margin (CRM),Number of harvested Lymph Nodes,5-year overall survival,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
8082,NCT02008422,progression-free survival (PFS),overall survival (OS),,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
8083,NCT06301672,Body Mass Index,Feeding amount,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8084,NCT04018872,Percentage of pathological complete response with itraconazole,Levels of itraconazole and metabolites in esophageal tissue,,2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2']
8085,NCT05040425,Mucositis pain,Body mass index (BMI),Electrical body conductivity,2021-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
8086,NCT04980950,The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients.,The impact of immunonutrition on intestines in gastric and colorectal cancer patients.,,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8087,NCT03646409,VTE- and bleeding incidence,Arterial thromboembolism (ATE) incidence,,2018-06-11,COMPLETED,OBSERVATIONAL,['NA']
8088,NCT00003360,,,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8089,NCT03037385,(Phase 2) Number of Participants with AEs and SAEs,(Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC,,2017-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8090,NCT05957016,Pathologic complete response (pCR),overall survival (OS),,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
8091,NCT02246634,Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.,To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.,,2014-08,RECRUITING,INTERVENTIONAL,['NA']
8092,NCT06129604,EP2 and EP4 receptor subtypes tumor biomarker expression within the PGE2 signaling pathway.,Incidences of TPST-1495 drug therapy based potential adverse events,,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE2']
8093,NCT04832776,ORR,PFS,,2021-04-17,RECRUITING,INTERVENTIONAL,['PHASE2']
8094,NCT01269255,maximum tolerated dose,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8095,NCT02458573,soft diet intake after surgery,postoperative pain,,2015-06-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8096,NCT01833286,overall survival,disease-free survival,Morbidity,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
8097,NCT03067792,response rate,progression free survival,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8098,NCT01196000,Rate of conversion to open surgery as an indicator of surgical technical difficulty,Health economics,,2011-12,WITHDRAWN,INTERVENTIONAL,['NA']
8099,NCT02638857,Overall survival,Quality of life,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8100,NCT04604158,Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.,Participant's experience with Elly app at Day 180-360.,,2020-12-02,UNKNOWN,INTERVENTIONAL,['NA']
8101,NCT02613221,Progression Free Survival (PFS) Rate at 6 Months,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs),,2015-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8102,NCT01545063,Number of catheter related infections,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
8103,NCT02161029,Amount of submucous tissue in gastrointestinal submucosal tumors harvested with a new drill biopsy instrument used with flexible endoscopes.,,,2014-07-02,COMPLETED,INTERVENTIONAL,['NA']
8104,NCT05053386,"Objective Response Rate, ORR","Overall survival, OS",,2021-10,UNKNOWN,INTERVENTIONAL,['NA']
8105,NCT02556762,Overall survival,Biomarkers,,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8106,NCT02046174,Overall Survival,Pain Assessment,Necrosis Comparison of Tumors Using PET-CT Scan,2014-04-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8107,NCT00005053,,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8108,NCT04762953,Incidence of Treatment-Emergent Adverse Events [Safety],Patient Reported Quality of Life Outcomes,Correlation of Plasma and Ascite Exosomal Gene Signature (EXOSIG) to Treatment Response,2021-02-18,RECRUITING,INTERVENTIONAL,['PHASE2']
8109,NCT00788125,Maximum Administered Dose of Dasatinib (Phase I),,,2008-09-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8110,NCT03252821,Change in fatigue,Adherence,,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
8111,NCT00576654,Recommended phase II dose (RP2D) of study drugs,Tumor response,Excision repair cross-complementation group 1 (ERCC1) expression levels,2007-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8112,NCT02767752,Disease-free survival (DFS),Quality of Life,Determination of plasma IL-6,2016-11,TERMINATED,INTERVENTIONAL,['PHASE2']
8113,NCT03731130,QoL (EORTC QLQCR29) absolute values and change over time,Overall survival,,2018-10-05,RECRUITING,OBSERVATIONAL,['NA']
8114,NCT05500027,Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
8115,NCT05816902,lung metastasis,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8116,NCT00514761,Progression event count,safety and tolerability,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8117,NCT03968406,Maximum tolerated dose (MTD),Overall survival,Overall quality of life as assessed by the FACT questionnaire,2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE1']
8118,NCT00004867,Proportion of these patients with FDG-PET findings that contraindicate surgery,The proportion of false positive lesions found by FDG-PET.,,1999-11,COMPLETED,INTERVENTIONAL,['NA']
8119,NCT00848094,"Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.","1,2 and 3 years survival",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8120,NCT02369939,Improvement of complete remission,Quality of life,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
8121,NCT06324357,Dose optimization (Phase II): Objective response (OR),Dose optimization (Phase II): Patient-reported outcome (PRO) - EORTC IL19,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8122,NCT03775850,Evidence of anti-tumor activity of EDP1503 based on ORR,Overall Survival,,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE1']
8123,NCT01933789,Occurrence of Discussion About Goals of Care at Target Visit,Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit,Group Differences - Stable Treatment Preference (Filter for Subgroup Analysis of Goal-concordant Care),2013-09,COMPLETED,INTERVENTIONAL,['NA']
8124,NCT04999306,patient adherent to the program.,Quality of life questionnaire-Core 30 (QLQ-C30),,2023-05-17,RECRUITING,INTERVENTIONAL,['NA']
8125,NCT00471146,Overall Survival (OS),Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8126,NCT05594927,Overall survival (OS),Mean area under the concentration-time curve during the dosing interval (AUC0-t),,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE3']
8127,NCT02539225,Progression Free Survival (PFS),Number of Participants With Anti-Ramucirumab Antibodies,,2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8128,NCT01312467,"Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)",Safety and Tolerability of Metformin Hydrochloride Treatment,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8129,NCT03102229,Number of patients hospitalized during treatment or within 4 weeks after completing radiotherapy.,Modified Glasgow Prognostic Score,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
8130,NCT02394769,Change in Urinary Prostaglandin Metabolites (PGE-M),Spectral Biomarkers of Colorectal Cancer,,2015-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8131,NCT05996458,Cancer or precancerous lesions detected,,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
8132,NCT02781532,Evaluation of ingesta,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
8133,NCT04054908,Acceptability of specimens for analysis,Change in relative abundance of following gut bacteria that occur with oral fluoropyrimidine therapy,,2018-04-13,COMPLETED,OBSERVATIONAL,['NA']
8134,NCT04069702,Number of Participants With VR Side Effects,Change in Pain Self-efficacy as Measured Using Items Adapted From the Self-efficacy for Pain Management Subscale of the Chronic Pain Self-Efficacy Scale,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
8135,NCT00310882,,,,2006-05,WITHDRAWN,OBSERVATIONAL,['NA']
8136,NCT06027242,Change of area of psoas muscle,Change of serum pre-albumin value,,2023-02-21,RECRUITING,INTERVENTIONAL,['NA']
8137,NCT03793725,R0 (resection rate),RFS,,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
8138,NCT03980288,Dose limited toxicity and Maximum Tolerated Dose,Antitumor efficacy-Disease control rate (DCR),,2019-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8139,NCT00617071,Screening utilization over the 6-month observation period,Identification of predictors of CRC screening use and screening preference,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8140,NCT00612586,Progression Free Survival (PFS),PFS From Start of First Line Therapy,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8141,NCT02960282,"Best tumor response, defined as a complete response or a clear decrease in tumor burden",,,2016-10-20,TERMINATED,OBSERVATIONAL,['NA']
8142,NCT03353311,Adherance to ERAS protocol,Number of items of the ERAS protol correlated wih adverse events as described by the Clavien Dindo Classification and with a longer hospital stay,,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
8143,NCT01044511,"HRQoL, EORTC C-30, EOS-18",,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
8144,NCT00006994,Effectiveness of L-glutamine for mucositis,Compliance (dose taken) in patients treated with L-glutamine when given with radiation treatment,,2001-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8145,NCT03253289,Change in mRNA levels,A panel of CAR downstream target genes,,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8146,NCT02332499,Overall Survival (OS),Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8147,NCT03762590,"Change of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients","Uptake of surveillance for pancreatic, other associated cancers and health behaviors",,2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8148,NCT03237130,pathological local lymph node status,,,2017-02-15,COMPLETED,OBSERVATIONAL,['NA']
8149,NCT01483144,Number of Subjects With Any FAP-related Event.,Improvement in Investigator Lower GI Assessment,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8150,NCT02530398,the grade of adverse events,,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
8151,NCT03945799,Disease free survival,Overall survival,,2019-04-22,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8152,NCT05908838,Overall survival,Immune function,,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8153,NCT05397548,Detection of levels of circulating exosomal lncRNA-GC1,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
8154,NCT00665197,Dysphagia relief,Treatment Toxicity,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8155,NCT02305459,Description of the clinical context in which SIR-Spheres are applied,Hepatic PFS,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
8156,NCT02724397,Number of Proximal Serrated lesions and colorectal adenomas in proximal colon,Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy,,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8157,NCT02548780,Area under the Curve (AUC),Progression Free Survival,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
8158,NCT01608841,disease control rate,progression-free survival,,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
8159,NCT04984369,ORR,OS,,2021-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8160,NCT03776435,Age and sex-standardized incidence rate ratio (IRR) for malignancies of hematologic system,Age and sex-standardized incidence rate ratio (IRR) for all cancers,Subgroup analysis,2018-01-15,UNKNOWN,OBSERVATIONAL,['NA']
8161,NCT04006041,Pathologic complete response rate,Perioperative mortality,,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
8162,NCT05369234,Management of Oral Mucositis and Esophagitis,,,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE3']
8163,NCT06333561,Overall survival,Progression-Free-Survival,Objective response rate,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
8164,NCT04150081,Validation of molecular signatures,Sensitivity and specificity of follow-up tests,,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA']
8165,NCT01522820,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0",NY-ESO-1 specific humoral immunity,Time to disease progression,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8166,NCT03422120,Natural Killer Cell Activity (NKA) at baseline compared to POD1 in CRC surgery patients,Natural Killer Cell Activity (NKA) in healthy donors (HD) as compared to colorectal cancer (CRC) patients (at baseline),,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
8167,NCT06040021,OS,,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
8168,NCT04327986,Best Overall Response (BOR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) of Bintrafusp Alfa (M7824) & NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy in Participants With Locally Advanced Pancreas Cancer,Complete Pathological Response Rate(s) For Participants Who Underwent Surgical Resection After Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment,Number of Participants With a Dose-limiting Toxicity (DLT),2021-06-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8169,NCT03662659,BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants,Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests,,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
8170,NCT01182831,immediate pain relief,,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
8171,NCT00595972,time to progression,toxicity,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8172,NCT05961709,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2025-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8173,NCT02852915,Disease free survival,Adverse events (mortality and morbidity),,2016-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8174,NCT01212510,Prediction of tumor progression,Prediction of tumor response,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
8175,NCT05166577,Phase 2: Overall response rate (ORR),Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC],,2021-10-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8176,NCT04774757,3-year DFS,1-year DFS,,2021-03-10,RECRUITING,INTERVENTIONAL,['NA']
8177,NCT04538677,Attitude and satisfaction with video consultation,Satisfaction of surgeons: Questionnaire,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
8178,NCT02801500,Bilioenteric anastomotic leakage,Bilioenteric anastomotic stricture,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
8179,NCT01816607,Presence of metastatic disease 5 years after rectal cancer treatment,Histomorphological response to preoperative chemoradiotherapy,Detection of regional malignant lymph nodes at time of diagnosis,2013-10,COMPLETED,OBSERVATIONAL,['NA']
8180,NCT00004002,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8181,NCT02576548,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).",Area under the plasma concentration versus time curve (AUC),,2015-09-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8182,NCT00033371,Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher,Percent Change in the Area of Plaque-like Duodenal Polyps,Percent Change in Polyp Size in Focal Area(s) of the Colorectum,2001-12-13,COMPLETED,INTERVENTIONAL,['PHASE2']
8183,NCT00155805,,,,2004-02,UNKNOWN,OBSERVATIONAL,['NA']
8184,NCT00508690,Incidence and classification of surgical site infection (SSI),"Incidence of colitis, other infectious diseases and other postoperative complications.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8185,NCT00568425,Evaluate the late effects of radiation treatment,,,2005-09,TERMINATED,OBSERVATIONAL,['NA']
8186,NCT03358095,Emerged complications related to surgery or preoperative endoscopy within 120 days of surgery,,,2017-11-26,WITHDRAWN,INTERVENTIONAL,['NA']
8187,NCT00508846,Patient Responses to Questionnaire,,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
8188,NCT03590275,Overall survival,Toxicity rate,,2017-10-02,COMPLETED,OBSERVATIONAL,['NA']
8189,NCT02194829,Progression-free Survival,Disease Control Rate,,2014-08-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8190,NCT05171426,incidental cancer,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
8191,NCT00155415,Cleansing level of colon and detected lesion number during colonoscopy,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
8192,NCT04286711,Dose-Limiting Toxicity [DLT],Overall Survival [OS],,2020-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8193,NCT00204373,"Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.",The Median Survival From the Time of Diagnosis.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8194,NCT01570010,Overall survival,Health related quality of life and fatigue,,2012-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8195,NCT04222530,Diagnostic accuracy,Operating time,,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA']
8196,NCT01901692,Progression-free survival (PFS) rate,Exploratory analysis for overall patient survival rate,,2013-07-29,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8197,NCT03874559,Exosomal Biomarkers Assessment,Exosomal Functionality Assessment,,2018-02-13,UNKNOWN,OBSERVATIONAL,['NA']
8198,NCT02725125,Disease control rates,Duration of remission,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
8199,NCT06194877,Part 2: ORR as Assessed by Initial Investigator Review,Part 2: Number of Participants with Reductions in Dosing with BGB-3245,,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1']
8200,NCT03079778,Intrahepatic progression,QoL-quality of life,Extrahepatic failure,2019-07-31,WITHDRAWN,INTERVENTIONAL,['NA']
8201,NCT02999893,Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.,Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.,Number of patients who will benefit from APR-246 therapy as assessed by quantitation of ctDNA levels in patient serum and plasma samples.,2017-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8202,NCT05934331,PFS,OS,,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
8203,NCT04776590,Pathologic complete response rate,overall survival,,2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2']
8204,NCT01833832,Intraperitoneal Progression Free Survival (PFS),Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),,2013-04-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8205,NCT00006981,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8206,NCT01978717,The changes of peripheral immune cells and cytokines,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8207,NCT04392050,Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention,,,2020-01-31,RECRUITING,OBSERVATIONAL,['NA']
8208,NCT04104230,Knowledge and Tissue Bank,,,2012-03-12,RECRUITING,OBSERVATIONAL,['NA']
8209,NCT01260168,The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.,To collect samples from patients diagnosed with colorectal cancers.,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
8210,NCT01903694,determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8211,NCT03297710,Maximum tolerated dose (MTD),,Time until treatment related grade 3+ toxicity,2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8212,NCT04595864,OS,PFS,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8213,NCT05129787,Local tumor progression,Inflammatory response,,2021-12-16,RECRUITING,INTERVENTIONAL,['NA']
8214,NCT00005864,,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8215,NCT01129700,To evaluate the pathologic response,Acute/ late toxicities,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8216,NCT01781403,Recommended Dose (RD),Pathological Complete Response,Disease-free Survival,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8217,NCT03415451,The success rates of fiberscope-guided NG tube insertion,,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
8218,NCT05215899,Mindfulness-based yoga and meditation intervention may reduce fatigue level of colorectal cancer patients,,,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA']
8219,NCT04411706,Objective Response Rate (ORR),Safety as measured by the rate of AEs,,2020-06-21,UNKNOWN,INTERVENTIONAL,['PHASE2']
8220,NCT02779608,response rate of ascites,side effects of chemotherapy,,2017-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
8221,NCT01306630,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors","To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria.",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8222,NCT05882370,Objective response rate (ORR) by RECIST 1.1 and mRECIST,Median overall survival time (mOS),Treatment-related adverse events,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8223,NCT06203327,early gastric neoplasm,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
8224,NCT01082315,Safety,Clinical efficacy,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
8225,NCT04063683,Progress free survival (PFS),Duration of Response(DOR),,2019-10-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
8226,NCT06143748,Progression-free survival,Treatment-related adverse events,Correlation between genetic biomarkers and survival,2024-03-02,RECRUITING,INTERVENTIONAL,['PHASE2']
8227,NCT01327521,Freedom from local progression at 6 months and 12 months,Serum AFP levels,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
8228,NCT00952003,To determine efficacy in terms of response rate according to RECIST criteria,To determine overall survival time following treatment with a chemoimmune therapy,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8229,NCT03892681,Specificity,Inter-reader agreement between two radiologists,,2019-04,UNKNOWN,INTERVENTIONAL,['NA']
8230,NCT03645655,Change of PIVKA-II,Change of AFP,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
8231,NCT00745134,Number of Participants With Pathologic Complete Response (pCR) Rate,Number of Participants With Tumor Downstaging,,2008-08-11,TERMINATED,INTERVENTIONAL,['PHASE2']
8232,NCT02403544,Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin,Tumor response rate including complete response and partial response rates,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
8233,NCT00335959,Pathologic Complete Response,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2']
8234,NCT06283134,MTD,Serum neutralizing antibody level,,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
8235,NCT05898789,Disability,Physiological measures of performance,,2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
8236,NCT01719549,Progression-free survival,FGFR2 copy number,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8237,NCT00392470,Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score,,,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
8238,NCT02057562,Adenoma detection rate,Frequency of colon diverticulosis,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
8239,NCT03416478,Disease Free Survival,Overall survival,,2018-01,UNKNOWN,OBSERVATIONAL,['NA']
8240,NCT04572633,Primary Safety: Procedure-Related Major Complications,Secondary Safety: All Adverse Events,,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8241,NCT05408897,recurrence,,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
8242,NCT05637268,3-year DFS rate,5 years OS rate,,2020-11-26,RECRUITING,INTERVENTIONAL,['PHASE2']
8243,NCT05194371,Overall survival,Proportion of using chemotherapy or target therapy concurrently with radiotherapy,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
8244,NCT06208436,Recurrence-free survival,Overall survival,,2023-10-07,RECRUITING,OBSERVATIONAL,['NA']
8245,NCT00862524,Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.,"Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.",,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8246,NCT02786602,"Clinical characteristics (age, sex, tumor location) compared between LRP1 high and low methylation groups.",,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
8247,NCT04143048,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8248,NCT03161925,Overall survival,,,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA']
8249,NCT04440735,DSP107 Serum Concentration,Preliminary Efficacy (Part 2 only),,2020-10-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8250,NCT05834543,ORR,Incidence of serious adverse events (SAEs),,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8251,NCT01074333,Safety and toxicity of Erbitux treatment,Clinical efficacy of Erbitux treatment,,2008-09,TERMINATED,OBSERVATIONAL,['NA']
8252,NCT02250053,"1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.",Circulating tumor cells measured at baseline and six-months.,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
8253,NCT00590278,"This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate",,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8254,NCT04704960,correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer,mutations related to target drug,,2021-02,UNKNOWN,OBSERVATIONAL,['NA']
8255,NCT01816256,Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs),Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN,Identify any genetic markers or biomarkers associated with asymptomatic PVT and PHTN,2013-05,COMPLETED,INTERVENTIONAL,['NA']
8256,NCT05498779,Recurrence after ablation,Overall survival related to HCV virus,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
8257,NCT04293458,Primary Efficacy,Secondary Efficacy,Safety of EsoCheck device administration,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
8258,NCT06313190,Progression-free survival (PFS) rate,Treatment-related adverse events,Correlation between ctDNA and overall survival,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8259,NCT02624115,FAZA PET uptake in locally advanced rectal cancers prior to and after chemoradiotherapy,Correlation of FAZA-PET and blood oxygen level-dependent MRI to Pimonidazole staining in locally advanced rectal cancer,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
8260,NCT03495674,Retention,,,2018-04-04,COMPLETED,INTERVENTIONAL,['NA']
8261,NCT00088816,Overall survival,Adverse events,,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
8262,NCT02919969,Overall Response Rate,Incidence of Adverse Events to Evaluate the Safety and Tolerability of Pembrolizumab,,2016-10-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8263,NCT05354817,Assess response rate after 4 cycles of FOLFIRINOX,Overall Survival,,2021-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
8264,NCT02584244,"Correlate LUM015 fluorescence in gastrointestinal cancers (pancreatic, esophageal, and colorectal) with pathology results","Number of safety events in humans with colorectal, pancreatic, and esophageal cancer.",,2016-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8265,NCT03974594,Bioequivalence based on Peak Plasma Concentration (Cmax),Adverse Event,,2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
8266,NCT01486251,Echography measure,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8267,NCT03332576,Safety as measured by adverse event reporting (CTCAE),Impact on residual tumour,,2013-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8268,NCT04422002,Survival,Surgical complications,,2019-12-01,COMPLETED,OBSERVATIONAL,['NA']
8269,NCT04295109,effective bolus times,postoperative hospitalization days,,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA']
8270,NCT01157598,the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESD,the dose of midazolam and meperidine during ESD with BIS monitoring,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
8271,NCT00640081,Failure-free survival at 10 months,Toxicity of each treatment regimen by NCI CTCAE v3.0,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8272,NCT03592550,Difference in liver position after set-up,Number of available imaging positions,,2018-09,UNKNOWN,OBSERVATIONAL,['NA']
8273,NCT00500292,Number of Patients With an Objective Disease Progression Event,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8274,NCT02293954,Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2,The Average Increase of Tumor-to-blood (T:B) Ratio From Day 1 to Day 2,,2015-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8275,NCT00426127,Tumor Response Measured by CT Scans After Each Set of 3 Cycles of Chemotherapy,Safety and Effect of Chemo Regimen on D-Dimer Measured by Drawing D-Dimer Levels Every Cycle,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
8276,NCT01831726,Clinical Benefit Rate (CBR),Overall Survival (OS),,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8277,NCT05080907,Collection of Biospecimens for Novel Research Uses,Number of subjects enrolled,,2016-07-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8278,NCT02520453,Disease-free survival,,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8279,NCT02077881,Overall Survival,Time to Progression of Disease,,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8280,NCT02007876,Muscle Mass,Effects of Individual MAT Program Segment,Effect of MAT of Hospital Length of Stay,2013-06,WITHDRAWN,INTERVENTIONAL,['NA']
8281,NCT04274868,Establish a national bank of rare biological material,,,2015-09-10,RECRUITING,OBSERVATIONAL,['NA']
8282,NCT02470559,Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0,Progression free survival,,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8283,NCT00558051,The primary endpoint of this study is to evaluate the feasibility and safety of semi-continuous intralymphatic vaccination dendritic cells.,"The secondary objective of this study is to evaluate the immunity results from either single injections or semi-continuous infusion, intradermal or intranodal, administered immunization with the DC vaccine for colorectal cancer (CRC) patients.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8284,NCT05536427,Tolerance(DLT/ MTD/ OBD),Overall Survival (OS),,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE1']
8285,NCT06061445,ORR,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8286,NCT04520737,Physical Fitness- 6MWT,Nutritional status- UMA,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8287,NCT05576480,Pathological complete remission rate (pCR),Number and severity of adverse events,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8288,NCT00149266,overall survival,quality of life,,1995-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8289,NCT03844750,Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.,Median Relapse-free survival (RFS) per RECIST 1.1,,2019-07-22,RECRUITING,INTERVENTIONAL,['PHASE2']
8290,NCT01264822,Transition rate to secondary therapy for eradication of Helicobacter pylori,,,2011-01-13,COMPLETED,OBSERVATIONAL,['NA']
8291,NCT01336062,Objective response rate,biomarkers,,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8292,NCT06263088,Biomarker testing rate of Black participants diagnosed with GI cancer,Change in Health literacy score among black participants diagnosed with GI cancer,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8293,NCT04032119,Overall procedural time,Lymphovascular invasion,,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8294,NCT03396705,Gene expression,,,2017-09-12,TERMINATED,OBSERVATIONAL,['NA']
8295,NCT03391843,Pelvic complete resection rate,The incidence of >=3 grade adverse events,,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8296,NCT00948337,Screening behavior for second primary cancer,Knowledge and attitudes of Secondary cancer screening and dietary supplement,,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
8297,NCT05203627,Objective measures of patient nutrition - Skeletal mass Index,,,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8298,NCT04775862,Progression-free survival (PFS),Determine the prevalence of RAS G12C mutation via using cfDNA,,2021-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2']
8299,NCT03652077,Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only),Immunogenicity of INCAGN02390,,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
8300,NCT02966223,Primary,Secondary,,2017-08-17,TERMINATED,INTERVENTIONAL,['NA']
8301,NCT00037804,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
8302,NCT03959839,local recurrence rate,Short-term local recurrence rate,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
8303,NCT00972036,"To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).",To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8304,NCT02679495,gastric caner occurrence,gastric tissue DNA methylation change of selected genes,,2015-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8305,NCT05323929,scar area,,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
8306,NCT05993702,Progression-free Survival (PFS),Incidence and severity of adverse events (AE) and serious adverse events (SAE),,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8307,NCT01393249,Risk of pancreatitis,Course of pancreatitis,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
8308,NCT02851784,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.","disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test","Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test",2009-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8309,NCT04678011,Advanced neoplasia,Complications,,2020-11-24,RECRUITING,OBSERVATIONAL,['NA']
8310,NCT01640522,Depression,Fatigue,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
8311,NCT02792881,Morbidity,The Surgery Task Load Index (SURG-TLX),,2016-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8312,NCT04596865,Patterns of disease recurrence,"Determine if/how specific patterns of recurrence (local only, distant only, synchronous local and distant) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:",,2020-10-12,COMPLETED,OBSERVATIONAL,['NA']
8313,NCT00897832,Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
8314,NCT00580281,"This pilot study will collect longitudinal data on bone metabolism for patients treated with imatinib. Sixty patients will be followed over a two-year period on this protocol, with bone marker assessments ascertained every 3 months (+2 weeks).",,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
8315,NCT02311907,"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).",Times to Onset of CTCAE Grade 3+ PN,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8316,NCT05711823,Complete response rate,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8317,NCT05181605,Overall Survival,Adverse events,,2022-04-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8318,NCT00663741,Safety and pharmacokinetics,Duration of response,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8319,NCT02008539,Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute,,,2013-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8320,NCT03775863,Incidence of recurrent hepatocellular carcinoma after liver transplantation.,Survival in patients with hepatocellular carcinoma after liver transplantation.,,2017-11-11,COMPLETED,OBSERVATIONAL,['NA']
8321,NCT00534053,Our primary outcome is FOBT card return rate,Predictors of Non-compliance to fecal occult blood testing,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8322,NCT00075439,Proportion of patients progression-free at 6 months,Time to treatment failure,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8323,NCT01673334,Diagnostic Yield,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8324,NCT01198743,local recidivism or metastasis reappearance,specificity and global safety,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
8325,NCT00920023,To Determine the Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable Lymph Node Metastases.,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8326,NCT01945879,Incidence of NCI CTC Toxicity III°/IV° and severe bleedings,overall survival,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8327,NCT01956149,Disease Control Rate (DCR),Correlation of circulating tumor cells with the clinical response,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8328,NCT00482586,"Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter",,,2003-10,COMPLETED,OBSERVATIONAL,['NA']
8329,NCT03257280,Hospital stay,Impedancemetry,,2017-10-20,UNKNOWN,INTERVENTIONAL,['NA']
8330,NCT02815150,preoperative gastric residual volume of gastric fluid,Reoperation rate within 30 days post operation,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
8331,NCT01068769,"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control",Progression-free Survival (PFS),,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8332,NCT06218810,1-year Progression Free Survival rate,irORR,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
8333,NCT06010888,Objective Response Rate（ORR）,Overall Survival（OS）,,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE2']
8334,NCT03301805,Part II: Overall response rate (PR + CR),Part II: Incidence of grade 3/4 hematological toxicity,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8335,NCT04331743,Recommended Phase II Dose (RP2D),Duration of Response (DoR),,2021-06-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
8336,NCT03498885,Anastomotic leakage,5-years disease free survival rate,,2018-01-01,RECRUITING,INTERVENTIONAL,['NA']
8337,NCT05250843,Recurrence-free Survival,Adverse effects,,2022-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8338,NCT02163759,"Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population","Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28948 Population",,2014-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8339,NCT06249321,"progression-free survival, PFS",disease control rate (DCR),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8340,NCT02502474,Number of patient with Staphylococcus aureus colonic carriage,Number of patient with Staphylococcus aureus carriage in the groin,,2015-02-02,COMPLETED,INTERVENTIONAL,['NA']
8341,NCT04340141,Overall survival (OS),Computed tomography (CT)-based radiomics as non-invasive predictors of overall survival,,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8342,NCT01746771,Safety evaluation(phase I),Efficacy evaluation(Phase II),,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8343,NCT03252938,Feasibility rate,Immune response in whole blood and tumor tissue,,2017-08-15,RECRUITING,INTERVENTIONAL,['PHASE1']
8344,NCT01966289,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Progression Free Survival (PFS),,2014-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
8345,NCT01477229,"To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients",QoL in an unselected population of rectal cancer patients,,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8346,NCT02892721,Difference in sensitivity between arms,Characteristics of radiologists performing well versus those that do not.,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
8347,NCT01189929,To determine the maximum tolerated dose of demcizumab (OMP-21M18) when combined with gemcitabine +/- Abraxane®,To determine the exploratory biomarker changes of gemcitabine plus demcizumab (OMP-21M18),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8348,NCT01549327,Empowerment,Cost-effectiveness,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
8349,NCT00656838,"To determine the effectiveness and maintenance of a colon-rectal cancer screening patient reminder program.Identify patient, primary care team, and system factors important to implementation success.","Create, refine, and disseminate an implementation guide for colon-rectal cancer screening reminder programs by combining the findings from the primary aim.",,2008-04,COMPLETED,INTERVENTIONAL,['NA']
8350,NCT03693170,Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments,PGIC Scores Over Time,,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE2']
8351,NCT05736731,Phase 2: The Overall Response Rate (ORR) for patients,Cytokine analysis,,2023-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8352,NCT02632682,Probe-based confocal laser endomicroscopy (pCLE) will be compared to standard histologic analysis in the evaluation of Barrett's esophagus.,,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
8353,NCT06138223,Quality of life (EORTC-QLQ-30) summary score,Health-related quality of life: fatigue,(Serious) Adverse Events potentially related to the exercise intervention,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8354,NCT03043183,complication,,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
8355,NCT00321685,Pathologic Complete Response Rate,5-year Recurrence-free Survival Rate,,2006-07-25,COMPLETED,INTERVENTIONAL,['PHASE2']
8356,NCT05789433,Whole-Body Intermuscular Adipose Tissue,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
8357,NCT03445585,Number of participants in the study.,Number of clinical phenotypes and/or endpoints observed (per category),,2017-01,RECRUITING,OBSERVATIONAL,['NA']
8358,NCT00504998,"Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.",To identify an objective tumor response to Rexin-G,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8359,NCT04699994,"Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)",Incidence rate of all adverse event,,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
8360,NCT00003939,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
8361,NCT04605237,Survival,Number of histologically confirmed recurrences,,2014-01-01,RECRUITING,OBSERVATIONAL,['NA']
8362,NCT00764595,Progression-free survival,Types and severities of adverse events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8363,NCT05775159,Progression free survival (PFS),Objective response rate (ORR),,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2']
8364,NCT01252498,Salivary levels of PGE2 and PGI2 during and after radiotherapy,Patient reports of oral pain during and after radiation therapy,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
8365,NCT00838968,5-years survival rate,,,2008-01,WITHDRAWN,INTERVENTIONAL,['NA']
8366,NCT05495776,Frequency of microsatellite instability and Lynch syndrome,Impact of the presence of microsatellite instability/deficiency,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
8367,NCT01082757,Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene,Subject and tumour characteristics and their association with KRAS mutational status,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
8368,NCT02139605,primary endpoint:Overall Survival,Disease-free survival,,2013-07-05,RECRUITING,INTERVENTIONAL,['NA']
8369,NCT00960284,1-year progression-free survival (Phase II),Pattern of relapse,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8370,NCT05854498,Progression Free Survival (PFS),Efficacy of irinotecan measured by PFS for patients with and without irinotecan containing regimens,,2023-10-13,RECRUITING,INTERVENTIONAL,['PHASE2']
8371,NCT04120935,Number of patients longitudinally monitored,Number of patients triaged in proof-of-concept (POC) clinical trials,Correlation of new prognostic and predictive biomarkers with clinical outcomes,2019-10-15,RECRUITING,OBSERVATIONAL,['NA']
8372,NCT02137343,Overall Survival,"Incidence of subject adverse events, laboratory abnormalities and immunogenicity",,2014-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8373,NCT01034683,objective response rate(ORR) time to progression (TTP) toxicities,1-year survival rate KPS score,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
8374,NCT00003063,,,,1991-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
8375,NCT01897584,arterial oxygenation (PaO2),cerebral perfusion pressure,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
8376,NCT06271109,complete resection of the neoplasm,recurrence rate,,2021-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8377,NCT06026618,Change in Hemoglobin,number of complications related to IVI administration,,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8378,NCT03659357,the size in centimeters,intensity of the neoplasms measured in the CTE in Hu,,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8379,NCT01186081,Disease-free survival,Treatment related toxicities,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8380,NCT00960609,First outcome was the rate of CVs detectable with e-flow IOUS along clamping of the HV for which resection could be needed.,"Secondary outcome was safety (morbidity, mortality, blood loss, blood transfusions) of the procedure.",,2008-01,COMPLETED,OBSERVATIONAL,['NA']
8381,NCT04810156,Time to response or downgrading of liver injury in days,Overall survival rates at 6 months,Description of changes in the fecal microbiome,2021-04-07,RECRUITING,INTERVENTIONAL,['PHASE2']
8382,NCT02005614,Rate of Local Control Over time (RECIST Criteria),,,2013-11,TERMINATED,INTERVENTIONAL,['NA']
8383,NCT04984733,Tumour Response to nivolumab,The percentage of patients who have achieved response,,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2']
8384,NCT03781050,Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps,Adverse events,,2018-09-16,UNKNOWN,INTERVENTIONAL,['PHASE4']
8385,NCT01867697,Response rate (RR),Frequency of secondary micro-radical surgical resection (R0 resection),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8386,NCT00920868,To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.,"To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8387,NCT01911273,Overall Survival (OS),Observed Serum Concentration of Circulating Protein,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2']
8388,NCT00010023,,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8389,NCT02279134,Disease-free survival (DFS),Overall survival (OS),Adverse events,2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8390,NCT00257322,Participants Exhibiting Immune Response,Response Rates and Overall Survival.,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8391,NCT05978193,PFS,Incidence of Grade III and higher treatment-related adverse events,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
8392,NCT04582981,progression free survival (PFS),disease control rate (DCR),quality of life score (QOL),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
8393,NCT00184834,,,,1999-06,COMPLETED,OBSERVATIONAL,['NA']
8394,NCT02675738,Number of cases with confirmed preoperative diagnosis,,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
8395,NCT05239169,Recurrence free survival at 12 months (RFS@12).,QoL EQ-5D-5L,,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8396,NCT00009737,Disease-free Survival,Number of Participants With Any Adverse Events and Serious Adverse Events,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8397,NCT04276909,Assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery,Correlate resected tissue with LUM Imaging System to identify imaging threshold,,2026-01,WITHDRAWN,INTERVENTIONAL,['NA']
8398,NCT02960620,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
8399,NCT00576134,Respiratory evaluation,Nasofibroscopy,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8400,NCT00356161,Safety of device and regional therapy,quality of life,,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
8401,NCT02726399,Progression Free Survival,,,2016-03-18,TERMINATED,INTERVENTIONAL,['PHASE2']
8402,NCT00885469,"Accuracy parameters (sensitivity, specificity, NPV, PPV) of PillCam ESO 2 in detecting suspected Barrett's Esophagus (BE) as compared to standard EGD, using unblinded EGD as the reference standard.",Subjects' satisfaction will be assessed by a post procedure questionnaire,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
8403,NCT05645198,Ratio of (patient who suffers from) pancreatic fistula,,,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8404,NCT05440864,Number of greater than grade 3 adverse events (AEs) or immune related adverse events that leads to treatment cessation,Rates of R0 resection,Taxonomic profiling of gut microbiome,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2']
8405,NCT05018182,Pathological response,Number of patients with 30-day post-operative mortality,,2021-08-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8406,NCT03519997,Overall Response Rate,Safety and Tolerability: rates of adverse events according to the CTCAE,Treatment response,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8407,NCT04343456,Disease free survival,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
8408,NCT03452774,Proportion of patients Eligible for CTE versus Actual CTE,Time from Intervention to Actual CTE (months),,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
8409,NCT01622569,Change in Total Polyp Grade,Nasal Polyp Surgery Eligilbilty,,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3']
8410,NCT00740753,"Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.",,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8411,NCT04166240,EPRP Outcome,,,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8412,NCT03925428,Maximum tolerated dose,Duration of response,Effect of GSK525762C and entinostat combination therapy on gene expression patterns,2020-09-18,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8413,NCT00296335,Relapse-free Survival Rate,Number of Patients With Adverse Events,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8414,NCT04104139,Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD),Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment,Rate of pathologic complete response after standard total mesorectal excision (TME),2019-12-11,RECRUITING,INTERVENTIONAL,['PHASE1']
8415,NCT00159471,"To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.","To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival.",,2005-02,TERMINATED,INTERVENTIONAL,['NA']
8416,NCT00976768,Progression-free survival,Response rate,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8417,NCT03216174,Complete resection,,,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA']
8418,NCT05012540,The overall survival,,,2013-08-01,COMPLETED,OBSERVATIONAL,['NA']
8419,NCT03442569,Overall Response Rate,Toxicity of Treatment,,2018-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8420,NCT01152645,Antitumor effect,Adverse events,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8421,NCT01305993,Evaluating Tumor Response Rate,Determine duration of response rate by measuring time to progression,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
8422,NCT02930291,3-year disease free survival rate,Visual Analog Score for pain,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
8423,NCT01171755,Response rate,,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE2']
8424,NCT01766765,The time to the first adjuvant chemotherapy,Rehospitalization rate,,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
8425,NCT04656392,Specificity of the eNose for detecting confirmed BE,Safety of eNose based on reported Adverse Events.,,2021-04-20,RECRUITING,INTERVENTIONAL,['NA']
8426,NCT00837031,"Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment","Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8427,NCT00905710,"The primary endpoints of the study are the number of adenomas, advanced adenomas, carcinomas at baseline and the number of the number of adenomas, advanced adenomas, carcinomas and the number of patients requiring colectomy at 2-year follow-up.",The secondary endpoints of the study are the number of complications from colonoscopy at baseline and at 2-year follow-up.,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
8428,NCT04719988,Clinical complete response (cCR) at 10 months,,,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8429,NCT00042939,Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria),Proportion of Patients With Thromboembolic Events,,2003-12-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8430,NCT02562963,"Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy",Tumor Marker,,2015-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8431,NCT03499808,Overall confirmed hematologic response rate,Progression free survival,,2018-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8432,NCT05101382,Number of retrospectively recruited CRC cases,,Biomarkers correlation with OS,2020-10-28,RECRUITING,OBSERVATIONAL,['NA']
8433,NCT00466856,Tumor response,Patient report of Health-related quality of life (HRQOL),,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8434,NCT01449864,Acute Toxicity,,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
8435,NCT04160416,Incidence of adverse events,,,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8436,NCT02095678,Mean Transit Time (MTT),Minimal Breathhold Time,,2013-12-01,COMPLETED,INTERVENTIONAL,['NA']
8437,NCT04751448,Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
8438,NCT03581773,CTCAE Mucositis,QOL MDASI,,2017-12-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
8439,NCT05832372,Prevalence or occurrence of upper gastrointestinal diseases,,,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8440,NCT00224601,Number of pre-cancer lesions or early cancer detected.,"Anatomopathologic criteria (size of lesions, …).",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8441,NCT03447951,Objective Response Rate (ORR),EQ-5D-5L quality of life score,,2018-06-19,RECRUITING,INTERVENTIONAL,['PHASE2']
8442,NCT04406974,Patient experiences after local recurrence,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
8443,NCT02650271,overall survival,Recurrence rate,Perioperative reactivation of hepatitis B virus replication,2021-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8444,NCT05699746,Recurrence-free survival,Clearance of circulating tumor DNA (ctDNA),,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8445,NCT01774344,Overall Survival (OS),Disease Control Rate (DCR),Overall Survival (OS),2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
8446,NCT02766842,Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method,Procedure time,,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8447,NCT02656134,Genetic profile in FAP patients,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
8448,NCT01185483,,,,2009-11,UNKNOWN,OBSERVATIONAL,['NA']
8449,NCT03043950,Overall Survival (OS) of pre-defined risk groups low vs. high,Antineoplastic treatment in later lines,Adverse Drug Reactions,2017-01-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8450,NCT01763450,To assess the objective response rate(ORR),To assess the R0 resection rate of liver metastases,To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
8451,NCT02858206,Adverse events,Recurrence rate,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
8452,NCT01792934,Overall survival,Safety and efficacy of the additional local treatment measured by number of serious adverse events.,,2013-05,RECRUITING,INTERVENTIONAL,['NA']
8453,NCT02200250,Reviewing patients symptoms following resection,,,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
8454,NCT03682744,Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events,Serologic response rates,,2018-09-13,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8455,NCT05076305,Assessment of resectability,Assessment of staging,,2021-10-15,UNKNOWN,OBSERVATIONAL,['NA']
8456,NCT03921684,Incidence of Treatment-Emergent Adverse Events (Safety),Overall Survival (OS),,2019-04,RECRUITING,INTERVENTIONAL,['PHASE2']
8457,NCT05990257,pain control,,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA']
8458,NCT01427647,Plasma levels of several cytokines after colorectal cancer surgery,Incidence of adverse clinical outcomes between groups,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8459,NCT02178644,pCR Rate,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8460,NCT05547568,Major postoperative complications (Dindo-Clavien ≥ 3 grade),,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
8461,NCT00210184,2-month Response Rate,Progression-free Survival,,2004-07-21,COMPLETED,INTERVENTIONAL,['PHASE2']
8462,NCT00972881,Histologically confirmed R0 resection rate,Local failure-free survival,,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8463,NCT04241887,Effectiveness of PVB on pain intensity,Surgeon's satisfaction,,2017-09-09,COMPLETED,INTERVENTIONAL,['NA']
8464,NCT05004350,Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR),Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data,Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening,2021-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8465,NCT05183425,The consistency of drug sensitivity,The establishment of PDO,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
8466,NCT01521702,progression-free survival,complication,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8467,NCT00352833,safety and efficacy data,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8468,NCT04179773,"Frequency of patients with ENT, upper digestive-tract or colorectal cancer with a diagnosis of cirrhosis",Frequency of chemotherapy side effects according to CTCAE version 5.0 classification in cirrhotic patients who have received chemotherapy,,2019-01-24,RECRUITING,OBSERVATIONAL,['NA']
8469,NCT03843905,Overall survival (OS),Microbiota composition,,2018-11-15,UNKNOWN,OBSERVATIONAL,['NA']
8470,NCT00524186,"Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)",Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival,,2007-05,TERMINATED,INTERVENTIONAL,['PHASE1']
8471,NCT01593475,feasibility and compliance,disease-free survival.,,2011-09-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8472,NCT02054598,Colorectal cancer screening completion,Colorectal cancer screening related intent,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8473,NCT05665322,Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups,Reason for for failure of technique requiring switch to different guidance technique,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
8474,NCT02600481,Troponin T level is set as the marker of myocardial injuries after robot-assisted surgeries,Chest CT scan is used to determine pulmonary complications,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
8475,NCT03993327,Percent of known liver lesions per standard staging scans identified on iodine I-124 (I-124) M5A imaging,Incidence of adverse events,,2020-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8476,NCT03165721,Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST),Change in Distress From Baseline,,2017-08-16,TERMINATED,INTERVENTIONAL,['PHASE2']
8477,NCT05257408,Progression-free Survival as Assessed by BICR,Combined Response According to RECIST v1.1 and GCIG Criteria,,2022-06-29,RECRUITING,INTERVENTIONAL,['PHASE3']
8478,NCT00036790,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8479,NCT03093116,Overall Response Rate (ORR) Phase 2,Intracranial objective response rate (Phase 2),,2017-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8480,NCT03650517,Clavien Dindo Complication,C-Reactive Protein value (CRP) days 1 & 3 postoperative,Pain evaluation,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
8481,NCT04716062,Clavien Dindo score (post-operative complications),Lenght of specimen,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
8482,NCT01243398,Overall survival,Progression-free survival,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8483,NCT01607255,Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate,,,2013-05-16,COMPLETED,INTERVENTIONAL,['PHASE4']
8484,NCT01657175,Quality of Life,Contacts with the health care system,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8485,NCT01876069,The rates of diagnostic sufficiency,The presence of histologic core,Procedure related complications,2013-07,COMPLETED,INTERVENTIONAL,['NA']
8486,NCT06326736,Incidence of Treatment Emergent Adverse Events (TEAEs),Disease control rate (DCR),,2024-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8487,NCT05940740,Nightingale Symptom Evaluation Scale,Self-Care Needs Evaluation Form,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
8488,NCT05495048,disease-free survival rate,,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
8489,NCT06178211,pCR rate,Potential biomarkers such as ctDNA or PD-L1 expression,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8490,NCT02031536,Disease Free Survival (DFS),Overall Survival (OS),,2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2']
8491,NCT04177797,Complete pathologic response rate,Incidence of adverse events,,2020-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
8492,NCT01686880,Peri-operative morbidity,Contra-lateral Lobe Hypertrophy,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8493,NCT05643989,Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale,Late complications rate during resectional surgery,,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
8494,NCT06199115,Neuropathic Pain Synptom Inventory : pain,Evaluation of sensitive and motor symptoms,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
8495,NCT03205176,Incidence of dose-limiting toxicity (DLT).,Clearance (CL).,,2017-06-30,COMPLETED,INTERVENTIONAL,['PHASE1']
8496,NCT05002452,Tumor Response,Distant control,,2021-12-20,RECRUITING,OBSERVATIONAL,['NA']
8497,NCT00969657,Pathological complete response (ypT0N0),"Several extra outcomes are registered for research: Local relapse at 2 years, metastases free survival, survival and relapse free survival",,2009-08,COMPLETED,OBSERVATIONAL,['NA']
8498,NCT06006390,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-09-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8499,NCT05771025,Overall survival time,Unplanned reoperation rate,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
8500,NCT05519202,Pathological complete response(pCR),tumor regression grade(TRG),,2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8501,NCT02943265,Patient Perception of Care (Scale),,,2017-09-18,COMPLETED,INTERVENTIONAL,['NA']
8502,NCT02473094,Pathological Complete Response,Quality of Life,,2015-07,TERMINATED,INTERVENTIONAL,['PHASE2']
8503,NCT06228599,Adverse Events,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8504,NCT01399684,Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator,Change From Baseline in ATAs Levels of MEGF0444A,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8505,NCT04680104,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,economical impact,,2015-11-03,COMPLETED,OBSERVATIONAL,['NA']
8506,NCT02002195,progression-free survival,time to treatment failure,,2013-11,UNKNOWN,OBSERVATIONAL,['NA']
8507,NCT02427841,R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment,Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Percent of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT),,2016-01-21,COMPLETED,INTERVENTIONAL,['PHASE2']
8508,NCT05253846,complete pathologic response (pCR),Rectal Continence,Correlation of FFS and pCR with ctDNA status,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8509,NCT05793554,Validation of tissue classification through fluorescence perfusion,Usability of video sharing and annotation technology in multiple sites,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8510,NCT01637805,Objective response rate,,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
8511,NCT04874259,1 year patient survival,Recurrence,,2022-08-22,RECRUITING,INTERVENTIONAL,['NA']
8512,NCT05103904,Overall response rate (ORR),Duration of response (DR),,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2']
8513,NCT04464668,Change in Colorectal Cancer Screening Rates - Repeat FIT,Differences in Screening Rates,,2020-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8514,NCT02843217,"Colorectal Cancer Screening, beginning age 50",,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
8515,NCT02560376,Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis,Adverse events collection,,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
8516,NCT05448157,"To evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery",,,2022-05-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8517,NCT04038619,Clinical response/remission of immune-related diarrhea/colitis,Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response,"Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples",2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
8518,NCT00780117,Annual lumbar-sacral MRI is performed,Annual serum alpha-foeto protein level monitoring,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
8519,NCT03602079,Phase I: Maximum Tolerated Dose,Phase I Volume of distribution at steady state (Vss).,,2018-07-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8520,NCT03357991,Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.,Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.,,2015-01-11,UNKNOWN,OBSERVATIONAL,['NA']
8521,NCT00578721,Rectal Tissue Putrescine Reduction,Safety/Toxicity,,2008-09-24,COMPLETED,INTERVENTIONAL,['PHASE2']
8522,NCT06141031,Phase 2: To assess pathologic response rate (R0 resection) for those who revert to resectable status,Phase 2: Assess quality of life associated with treatment protocol using EORTC QLQ-C30,,2024-01-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8523,NCT02728193,Death,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
8524,NCT06080204,Disease-free survival time,Overall survival time,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
8525,NCT02307539,Qualitative interview data,"Patient/family out of pocket expenses, as measured by the Finances and Out of Pocket Costs Tool",,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8526,NCT00002455,Survival rate,,,1971-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
8527,NCT05845294,Anxiety of patients was assessed by Hospital Anxiety and Depression Scale,,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
8528,NCT01538680,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
8529,NCT05769959,Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs),"Part 1, 2, 3: Overall survival (OS)",,2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8530,NCT04466267,The molecular mechanism of patients primary or secondary resistance to cetuximab,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
8531,NCT02017600,the R0 resection rate of participants,1-year overall survival rate of participants,,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2']
8532,NCT02674100,Adverse Events,Overall Survival,,2016-01,RECRUITING,OBSERVATIONAL,['NA']
8533,NCT04821843,Overall survival,Distant metastasis free survival,Radiomics analysis,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8534,NCT04161560,relative adverse drug reaction,,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
8535,NCT05286814,Determine overall response rates,Determine hepatic progression-free survival (PFS),,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE2']
8536,NCT03334708,Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer,,,2017-10-30,RECRUITING,OBSERVATIONAL,['NA']
8537,NCT01722175,Liver free of tumors,Liver synthetic and transport function,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8538,NCT02229058,Progression-free survival,Disease control rate,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8539,NCT04652440,Measure Tolerability,Median Disease-free survival (mDFS),,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8540,NCT04917289,Overall Survival,Adverse event,,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8541,NCT01895504,Cecal intubation rate,Pain,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
8542,NCT00578279,The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8543,NCT05372198,Progression-Free Survival (PFS),adverse events (AE),,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2']
8544,NCT03721744,Overall survival (OS),Quality of Life (QoL),,2018-10-25,UNKNOWN,INTERVENTIONAL,['PHASE3']
8545,NCT01473940,Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the Maximum Tolerated Dose (MTD),Recovery of Tumor Immune Surveillance: T-cell Response to Defined Pancreatic Cancer Tumor Antigens,,2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8546,NCT01845337,The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.,,,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8547,NCT04391049,Dose Limiting Toxicity,Overall Survival,,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE1']
8548,NCT00154778,To evaluate the response rate,To determine time to progression and safety,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8549,NCT03563157,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1","QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component",,2018-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8550,NCT06218914,Adverse events and Serious adverse events,"Preliminary anti-tumor activity of NT-112 in subjects with unresectable, advanced, and/or metastatic solid tumors",,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE1']
8551,NCT02027948,feasibility of a nutritional management algorithm,treatment toxicity of chemoradiotherapy,,2013-12-23,COMPLETED,INTERVENTIONAL,['NA']
8552,NCT05582109,Objective response rate,Adverse Events,,2022-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8553,NCT03417570,Number of Participants Who Had a Diagnostic Yield Obtained,Safety as Measured by Number of Participants With Procedure-related Adverse Events,,2017-12-22,TERMINATED,INTERVENTIONAL,['NA']
8554,NCT03048123,Disease control rate,Adverse Events,,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8555,NCT02861690,Response rate,Number of Participants With Adverse Events (Toxicity),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8556,NCT04516083,Number of patients who have a somatic mutation at the same time as a germline mutation,,,2019-12-21,UNKNOWN,OBSERVATIONAL,['NA']
8557,NCT05250895,To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry,Treatment response,,2022-04-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8558,NCT02767375,Recurrence Free Survival,Adverse Events That Are Related to Treatment,,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8559,NCT00779688,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious lesions.,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
8560,NCT00486460,,,,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
8561,NCT02887599,Difference of the severity of the pancreatic cancer,Correlation of the cytotoxic immune status,,2016-08-08,COMPLETED,INTERVENTIONAL,['NA']
8562,NCT01052922,Adherence to FOBT test kit,,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
8563,NCT05036486,To perform large-scale NGS analysis for specific populations,"To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan.",,2021-10-25,RECRUITING,OBSERVATIONAL,['NA']
8564,NCT03856658,Hepatic progression-free survival,EORTC Quality of Life Questionnaire,,2019-02-05,RECRUITING,INTERVENTIONAL,['PHASE2']
8565,NCT03471403,Number of serious and non-serious adverse events,Change in Spigelman stage,,2017-10-10,RECRUITING,OBSERVATIONAL,['NA']
8566,NCT02589483,"Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.",,,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
8567,NCT01850654,Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients,,,2012-12-26,COMPLETED,INTERVENTIONAL,['NA']
8568,NCT02789371,the overall diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the solid occupying lesions,Blood contamination and cellularity in specimens obtained by modified wet suction technique and 5ml dry suction technique,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
8569,NCT03231722,Overall response rate,R0 Resection Rate,,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE3']
8570,NCT05691491,Dose limiting toxicity and the maximum tolerated dose,Rate of >= grade 3 adverse events (AE),,2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8571,NCT01138904,Response rate by RECIST,overall survival,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8572,NCT00004095,,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8573,NCT00647530,Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab,Adverse events,,2008-05-15,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8574,NCT00425841,Clinical response rate as assessed by RECIST criteria,Histologic response rate,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8575,NCT03171389,clinical benefit rate (CBR),Fatigue assessment,,2017-03-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
8576,NCT01923233,Safety,Anti-Tumor Response,,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8577,NCT05591534,Tolerance,Surgical morbidity for recurrence,,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2']
8578,NCT00533078,efficacy of an omega-3 PUFA containing lipid emulsion in reducing the incidence of °3-4 colitis (CTC AE v3.0),,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8579,NCT00777478,Maximum Tolerated Dose,determine the safety and toxicity profile using the CTCAE criteria.,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
8580,NCT03914352,Disease-free survival,,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
8581,NCT00497263,functioning anastomosis & no occurrence of adverse events related to device use,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
8582,NCT00639327,"In phase II part, progressive disease rate will be measured for the safety. In phase III part, overall survival will be measured for the benefit of doublet.","Adverse events, response rates, progression free survival, time to treatment failure, change over rates to 3rd line",,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8583,NCT05734300,Change in patient-reported postoperative recovery - Quality of Recovery 15,Rate of secondary standard resection,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
8584,NCT05706558,. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery),"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).",,2016-12-13,RECRUITING,OBSERVATIONAL,['NA']
8585,NCT00004136,Efficacy of Radiofrequency Ablation in Patients with Primary or Metastatic Liver Cancer,,,1998-03-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8586,NCT02117557,Early morbidity rate,Inflammatory and immune response,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
8587,NCT05384184,Build the next generation biobank of liver-derived organoids,Evaluate the clinical relevance of the generated organoids,,2019-06-06,RECRUITING,OBSERVATIONAL,['NA']
8588,NCT01754623,Margin-negative (R0) Resection Rate,Overall Survival (OS) Rate,,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2']
8589,NCT02192671,Hospital mortality,Recurrence rate,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
8590,NCT06290505,Progression free survival rate is the proportion of patients alive and progression free (the cancer has not worsened) assessed by CT Scan and clinical review.,Overall survival.,,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2']
8591,NCT03920202,Bowel function assessment using Low anterior resection syndrome questionnaire,Risk factors: preoperative chemoradiotherapy,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
8592,NCT04903548,SPECT CT,,,2021-04-20,RECRUITING,OBSERVATIONAL,['NA']
8593,NCT01341197,Important Lower and Upper GI tract Lesions,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
8594,NCT03215017,"Bowel function, Low anterior resection syndrome (LARS)",Quality of Life (QoL),,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
8595,NCT03086993,Overall Survival,Objective response rate (CR + PR) as determined by the Investigator,Incidence of Treatment-Emergent Adverse Events (Safety),2018-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8596,NCT01621243,Part B: Overall Survival,Part B: Duration of progression-free survival,,2012-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8597,NCT03974984,Changes in neutrophil to lymphocyte ratio from preoperatively to day 1 postoperatively,Changes in quality of recovery-15 score from preoperatively to day 1 postoperatively.,,2020-06-04,WITHDRAWN,OBSERVATIONAL,['NA']
8598,NCT00006094,Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0,,,2000-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8599,NCT00381862,Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.,Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8600,NCT03550482,Quality of life improvement,Nutritional level,,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8601,NCT01428141,Determination of the maximum tolerated dose (MTD),,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
8602,NCT03827044,Primary End point: Disease Free survival,Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.,,2018-08-31,TERMINATED,INTERVENTIONAL,['PHASE3']
8603,NCT05265169,Local tumor progression free survival at 24 months,Proportion of subjects with CTCAE grade 3 events or greater within 90 days after MWA,,2023-01-13,RECRUITING,INTERVENTIONAL,['NA']
8604,NCT03083613,Objective Response Rate,Progression-free survival,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8605,NCT05074966,median PFS,Overall Survival OS,,2021-09-06,RECRUITING,INTERVENTIONAL,['PHASE3']
8606,NCT01291823,Tumor response rate,The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.),,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
8607,NCT05977764,to identify D-CEUS quantitative parameters useful for characterizing FLLs.,,,2020-03-13,RECRUITING,INTERVENTIONAL,['NA']
8608,NCT04230759,Disease-free survival (DFS),Quality of life questionnaires,,2020-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8609,NCT04770207,Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors,,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
8610,NCT04164797,progression-free survival(PFS),overall survival (OS),,2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
8611,NCT00002485,Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.,,,1992-02,COMPLETED,OBSERVATIONAL,['NA']
8612,NCT04662853,Gut-microbiota-based color-rectal cancer diagnosis.,Dietary habits,,2017-01-17,UNKNOWN,OBSERVATIONAL,['NA']
8613,NCT01791374,Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested,"Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.",,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8614,NCT01686412,Autonomic response monitoring (blood pressure digital and manual monitoring),Baroreflex sensitivity (by the method of sequence),,2012-07,COMPLETED,INTERVENTIONAL,['NA']
8615,NCT04777708,Objective response rate (ORR),Incidence of adverse events,,2021-10-13,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
8616,NCT02254889,A 10-cm VAS was used to evaluate pain after ESD.,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
8617,NCT05875558,ORR,OS,,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8618,NCT06271629,Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29),,2022-02-26,COMPLETED,OBSERVATIONAL,['NA']
8619,NCT05751733,Progression-Free survival (PFS),Disease Control Rate (DCR),,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
8620,NCT01681368,Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months,Total Clearance of Birinapant After Administration,,2012-08-15,TERMINATED,INTERVENTIONAL,['PHASE2']
8621,NCT05001321,Texture of nuclei,Recurrence/metastasis,,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8622,NCT01657695,Survival,Response to therapy,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
8623,NCT04164069,Incidence of adverse events,,Dasatinib on pharmacokinetics (PK) of oxaliplatin,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8624,NCT00069953,Overall Survival (1-year Rate Reported),Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8625,NCT06016725,Physical function,Anthropometry measuring waist circumference in centimeters,,2023-08-28,RECRUITING,INTERVENTIONAL,['NA']
8626,NCT03129607,Pancreatic fistula,Mortality,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
8627,NCT05412628,To analyze the similarity of microbiota distribution between the buccal field and the esophageal area in the same patient,To analyze the distribution difference of microbiota among the patients with esophageal cancer/oropharyngeal cancer and non-cancer control,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
8628,NCT05217446,Progression-free Survival (PFS),Objective Response (OR),,2022-07-11,RECRUITING,INTERVENTIONAL,['PHASE2']
8629,NCT04098081,response rate,overall survival,,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE2']
8630,NCT01358812,Response Rate,Analyses of Potential Predictive Factors,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8631,NCT00226811,Objective Response (Complete Response (CR) or Partial Response (PR)),Overall Survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8632,NCT01566474,Oxidative stress,The presence of DNA anomalies (tetraploidy and aneuploidy.,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8633,NCT01996306,Overall survival,Correlation between UGT1A1 genotype and safety,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8634,NCT04461275,Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.,• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.,• Groningen Frailty Index (GFI),2020-06-19,COMPLETED,INTERVENTIONAL,['NA']
8635,NCT04588051,Median Progression-free survival (PFS),Rate of adverse events according to CTCAE v5.0,,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8636,NCT00828672,"Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.",Death Rates and Overall Survival,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8637,NCT05568095,Overall survival,Incidence and severity of adverse events (AEs) and serious adverse events (SAEs),,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3']
8638,NCT05303740,PFS,OS,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
8639,NCT04669951,Tumor-to-background ratio,uPAR in patient groups,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
8640,NCT00609622,Progression-free Survival (PFS),Change From Baseline in Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity (FACT&GOG-Ntx) Score,,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2']
8641,NCT00004099,,,,1999-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8642,NCT04454151,Evaluation of changes in size of adenomas measured by upper endoscopy,Evaluation of changes in size of adenomas measured by lower endoscopy,Evaluation of changes in size of desmoid tumors,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8643,NCT05081024,Complete clinical response (cCR),Overall survival,Specificity,2021-09-03,RECRUITING,OBSERVATIONAL,['NA']
8644,NCT02359968,Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification,Evaluation of the efficacy of both regimen in term of quality of life,Prognostic factor and treatment effect controlling for possible confounding factors,2015-02-26,COMPLETED,INTERVENTIONAL,['PHASE2']
8645,NCT01392352,Change in endothelial dependent function,Change in endothelial independent function,,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2']
8646,NCT01631539,Feasibility of chemoembolization with DC Bead loaded with Irinotecan,progression-free survival,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA']
8647,NCT03195699,Pharmacokinetics - AUC(0-t),Best Overall Response,Assess the bioavailability between different formulations of TTI-101,2017-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8648,NCT04929392,Clinical complete response (CR),Overall survival (OS),,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8649,NCT06109779,Recurrence free survival (RFS) for Arm A vs. Arm B,Overall Survival (OS) for Arm A vs. Arm B,Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.,2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE3']
8650,NCT06008522,Number of Adverse Device-related Events (ADEs) and Serious Adverse Device-related Events (SADEs) using immuno-OCT,validation of OCT system: immunohistochemistry,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8651,NCT05975593,Changes in tumor microenvironment,,,2023-12-19,RECRUITING,OBSERVATIONAL,['NA']
8652,NCT00573404,Maximum tolerated dose of imatinib mesylate in combination with sunitinib malate,Preliminary data on anti-tumor activity of these drugs as assessed by RECIST,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE1']
8653,NCT05141643,Tumor drug uptake within PDAC tumors prior at pre-treatment baseline,changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.,,2021-11-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8654,NCT04602013,PFS,HRQoL,,2020-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
8655,NCT02721550,pathologic Complete Response,Disease-Free Survival,,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE4']
8656,NCT00394602,Longitudinal Quality of Life + Symptom Assessment Data,,,2004-04-07,TERMINATED,OBSERVATIONAL,['NA']
8657,NCT00491140,Association of different biomarkers with Cetuximab sensitivity,Association of different biomarkers with time to progression and survival,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
8658,NCT01970722,Incidence of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) guidelines,Progression-free survival (PFS),,2014-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8659,NCT00440817,Occurrence of lymphoma,Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
8660,NCT03936530,metastasis rate,3-year DFS,,2019-10-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8661,NCT04144751,Blood-based biomarkers associated with genetic and epigenetic alterations.,,,2019-11-15,COMPLETED,OBSERVATIONAL,['NA']
8662,NCT01587872,Cecal intubation rate,Detection of additional colonic pathology,,2011-10,TERMINATED,INTERVENTIONAL,['NA']
8663,NCT00867113,Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months,Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months,,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE2']
8664,NCT01364454,Patient's participation to colorectal cancer screening program,,,2010-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8665,NCT04373928,OS,DFS,,2017-11-10,RECRUITING,INTERVENTIONAL,['NA']
8666,NCT01211132,The primary outcome is the prevalence of adenomas in the two groups.,"The secondary outcomes are the number of adenomas detected per subject, cecal intubation rate, insertion times, withdrawal times and complication rates in the two arms.",,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
8667,NCT04408105,"To characterize the association between patient-level knowledge, attitudes, and barriers regarding BE screening.",,,2020-02-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8668,NCT01739608,Participation rate to FS and CT Colonography,Type of false positive detections of Computer-aided detection for CTC in a CRC screening program,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
8669,NCT02512224,Mortality Calculated From Outcome Section From DPC Database at 90 Days,Mortality Calculated From Outcome Section From DPC Database at 30 Days,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
8670,NCT03487939,The ratio of tumor downstaging to stage 0 and stage I,Quality of life (QLQ C30),,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8671,NCT01821196,Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer,,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
8672,NCT00643682,Boston Bowel Preparation Scale Score,Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
8673,NCT05879172,success rate of anastomosis,time period of recovery,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
8674,NCT04820179,Overall Response Rate or Stable Disease,T2 Signal,,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE2']
8675,NCT02328677,Recurrence,Treatment toxicities,,2007-03,RECRUITING,OBSERVATIONAL,['NA']
8676,NCT02165800,Sexual function,5-year overall survival rate,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
8677,NCT04313114,CRC Screening,,,2021-09-20,RECRUITING,INTERVENTIONAL,['NA']
8678,NCT00970138,Progression free survival,Toxicity,,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8679,NCT05867966,Change in emotional distress,Change in perception about their fatigue,,2024-01-16,RECRUITING,INTERVENTIONAL,['NA']
8680,NCT02376543,Total Time Comparison,Complication Comparison,,2015-03-06,WITHDRAWN,INTERVENTIONAL,['NA']
8681,NCT04683783,Percentage of patients who complete the entire cycle,Morbidity rate,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
8682,NCT00006155,,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8683,NCT06112704,Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,Assess the incidence of anti-drug antibodies (ADAs),,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE2']
8684,NCT02905578,Overall survival,Adverse event frequency and categorization,,2018-11-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8685,NCT00039078,Adverse experiences,,,2000-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8686,NCT02332551,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,Progress free survival(PFS),2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
8687,NCT03727126,Lymph node yield,Conversion rate,,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8688,NCT05863052,Treatment related Adverse Events,Difference in cancer related mortality,Demographic differences,2022-01-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8689,NCT00035087,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),Overall survival,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8690,NCT02711969,Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer,"Duration of Response(Stable disease, partial response or Complete response)",,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8691,NCT04090164,Prevalence of HCV Seropositivity in Breast Cancer Patients.,Disease-related Events,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
8692,NCT05493930,diagnosis of lymph node metastasis,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
8693,NCT04163627,Technical procedures evolutiveness,Regional disparities,,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA']
8694,NCT05014737,postoperative nausea and vomiting,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8695,NCT06079554,Metabolomics results of lesions and atrophic gastritis.,microbiomics of lesions and atrophic gastritis.,endoscopic observation,2023-10-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8696,NCT02482909,The patient survival,The disease-free survival,,2005-07,TERMINATED,INTERVENTIONAL,['NA']
8697,NCT05732493,pCR,Surgical complications,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8698,NCT00101894,"Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen",Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8699,NCT01895790,Complications (Safety),Survival,,2014-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8700,NCT05760391,OS from start of 1st line treatment in metastatic ESCC,Disease control rate,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
8701,NCT05671822,Phase II: Objective Response Rate (ORR)[,"Occurrence of adverse events (AEs), and serious adverse events (SAEs) （Phase II）",,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2']
8702,NCT05877352,Availability of potential primary outcome data,Resource use and cost,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA']
8703,NCT04420013,Plasma CD154 level dosage,Clinical evolution parameters,,2020-09,UNKNOWN,OBSERVATIONAL,['NA']
8704,NCT02945267,TTP,Adverse Events,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8705,NCT05629845,90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy,procedure related adverse events within 30 days of secondary prevention,,2022-11-22,RECRUITING,INTERVENTIONAL,['NA']
8706,NCT01175733,Phase II: safety and tolerability,Time-to-progression (TTP) and overall survival,,2010-07-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8707,NCT03815461,PFS,Adverse reaction rate,,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8708,NCT00096083,To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies,To determine the progression free and overall survival in patients with hepatic malignancies following this therapy,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8709,NCT04273451,The prediction accuracy of the radiopathomics artificial intelligence model,The F1 score of the radiopathomics artificial intelligence model,,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA']
8710,NCT03355495,Decrease in Cecal Intubation Time,Increase in Adenoma Detection Rate,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
8711,NCT01171300,Pathologic complete response (ypT0N0) rate,Quality of mesorectal excision.,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
8712,NCT00582829,Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.,,,2003-06,COMPLETED,OBSERVATIONAL,['NA']
8713,NCT02032368,Change of circulating tumor cell(CTC) count at different timepoints,,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
8714,NCT01623206,"Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.",Number of patients with partial or complete response in clinical endpoints,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8715,NCT01262183,1-year overall survival,CTCs and CECs,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
8716,NCT00233935,Toxicity defined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (Version 3.0),Dose-related biologic effects and pharmacodynamic properties of Poly E,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8717,NCT00807313,Metabolic complete remission rate,Late toxicity,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
8718,NCT01186263,Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy,Adverse events as elicited upon indirect questioning.,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8719,NCT00093652,Response (phase II),Immunohistochemistry,,2003-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8720,NCT01665937,Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma,Overall Survival,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8721,NCT04654247,Gastric precancerous detection rate,Adcanced ADR,,2019-04-20,COMPLETED,INTERVENTIONAL,['NA']
8722,NCT01605318,Percentage of Participants With Laboratory Abnormalities,Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels,,2013-02-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8723,NCT04296630,Screening intention,Post comments,,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8724,NCT02992340,Phase 2B: Progression Free Survival (PFS),"Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)",,2016-12-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8725,NCT00585637,"Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.",Change in CRP From 0 to 3 Months.,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8726,NCT02633436,optical density (ODs) of each slice by immunohistochemistry assay,SLC1A5 expression detected by WesternBlot,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
8727,NCT03143270,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8728,NCT00979680,Sphincter preservation rate,Overall Survival,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8729,NCT05461235,Progression-free Survival (PFS),Overall Survival (OS),,2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8730,NCT04296240,pathologic complete response rate,Toxicity of neoadjuvant chemotherapy,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8731,NCT00385970,3-Year recurrence-free survival rate,"5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP.",,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8732,NCT03335813,Percent Volume of the Tumor Receiving the Prescription Dose (V100),Number of Participants With the Need for Dilation,,2018-03-06,COMPLETED,INTERVENTIONAL,['NA']
8733,NCT00866957,HIF-1alpha bio-marker,Understand biological behavior of the tumors,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
8734,NCT00294827,Survival,Time to progression side-effects,,2006-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8735,NCT01454180,Overall survival,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8736,NCT05143619,Teaching rates of the hepatocellular carcinoma diagnosis guidelines,,,2019-05-10,RECRUITING,OBSERVATIONAL,['NA']
8737,NCT00295035,,,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8738,NCT03387098,Objective response rate by RECIST,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.",,2018-01-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8739,NCT02942238,Disease-free survival,The accuracy of preoperative staging with CT,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
8740,NCT02514551,Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ,Number of Participants With Anti-Ramucirumab Antibodies,,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8741,NCT05313282,The progression-free survival (PFS) by RECIST 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2022-06-15,RECRUITING,INTERVENTIONAL,['PHASE3']
8742,NCT03603756,objective response rate,treatment-related adverse events,,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
8743,NCT01477190,postoperative pain,opioid side effects,,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8744,NCT00025532,,,,2001-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8745,NCT05356897,Progression-free survival rate,Incidence of adverse events,,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8746,NCT02773459,Progression-free survival (PFS),Overall survival (OS),,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8747,NCT02894775,Number of participants included in a clinical trial,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
8748,NCT00500968,Drain fluid content analyses,"Co-variables measured in the form of: operation time, complications in relation to diagnosis, duration of hospitalization and cost. Patients receiving a pancreas stent are followed in order to evaluate the natural course of the pancreas stent",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
8749,NCT01306058,Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC),Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI),,2011-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8750,NCT05177068,Surgical complete resection rate (R0),adverse event (AEs),,2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE2']
8751,NCT03791918,Overall survival,Progression free survival,,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
8752,NCT05740189,Safety: Incidence of Dose-related SAEs,BE regression,,2023-02-19,RECRUITING,INTERVENTIONAL,['NA']
8753,NCT04733521,preliminary antitumor activity of SC-43,overall survival(OS) according to RECIST criteria version 1.1,phosphorylated signal transducer and activator of transcription 3(p-STAT3) status in peripheral blood mononuclear cells (PBMCs) of subjects,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8754,NCT00568438,,,,2000-10,COMPLETED,OBSERVATIONAL,['NA']
8755,NCT04517032,Catastrophic Expenditure at 6 months,Colorectal cancer stage at the time of diagnosis,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8756,NCT01485744,Toxicity,Response Rate,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8757,NCT00363584,Survival at 2 years,Health economics,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8758,NCT05129046,DFS,Surgical Outcomes,,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA']
8759,NCT05307835,Relapse Free Survival Rate,EORTC QLQ-C30 (version 3),,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE1']
8760,NCT00296608,,,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8761,NCT05471674,Pathological tumour response rate,Safety and tolerability of nivolumab,Exploratory analyses,2020-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8762,NCT00254683,PET/CT specificity and sensitivity for tumor response,Correlation between PET/CT and complete clinical Response,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
8763,NCT03634982,Number of participants with dose limiting toxicities (DLTs),Duration of Response (DOR),,2018-09-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
8764,NCT01557101,Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8765,NCT05463796,"Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.",,,2023-04-25,RECRUITING,OBSERVATIONAL,['NA']
8766,NCT05425472,Objective response rate,ECOG Score for performance status,,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
8767,NCT05491616,Disease Free survival 18 months,overall survival at 2 years,,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
8768,NCT02520154,Progression-free survival,Overall survival,Change in biomarker expression level,2016-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8769,NCT01747707,overall survival time (OS),safety profile,,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
8770,NCT02352935,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,Over Survival (OS),2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
8771,NCT05300269,Percentage of participants with Pathological complete response ( pCR ),Disease-free survival ( DFS ),,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2']
8772,NCT03821545,Concentration of inflammatory markers,Length of hospital stay,,2019-01-28,COMPLETED,INTERVENTIONAL,['NA']
8773,NCT01035398,Analyses of dietary factors and Helicobacter pylori infection (previous vs current),,,2000-04,UNKNOWN,OBSERVATIONAL,['NA']
8774,NCT02243384,Survival rate,postoperative complications,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
8775,NCT01121939,Objective Response Rate (ORR),Disease Control Rate,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8776,NCT05723562,Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR),Number of Participants with Anti-Drug Antibodies against Dostarlimab,,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE2']
8777,NCT05971199,Progression-free survival(PFS),Time to progression(TTP),,2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE2']
8778,NCT06207981,Disease-related event free survival (DREFS) at 2 years,,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3']
8779,NCT00468455,Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
8780,NCT01234051,Response rate,Overall survival,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
8781,NCT02365662,Recommended Phase 2 dose of ABBV-221,Objective Response Rate (ORR),,2015-01-09,TERMINATED,INTERVENTIONAL,['PHASE1']
8782,NCT04014465,progression free survival,Adverse Events,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
8783,NCT02297607,Quality of Life after surgery,Jejunostomy tube-specific complications,Length of hospital stay,2014-11,TERMINATED,INTERVENTIONAL,['NA']
8784,NCT03960008,To compare the duration of disease control in treated lesions when utilizing SBRT versus TACE as a bridging strategy for patients with HCC eligible for liver transplantation,To assess 90 day Post-transplant mortality,,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8785,NCT03219723,Percentage of Participants Who Had One or More Adverse Drug Reactions,H. Pylori Eradication Rate,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
8786,NCT00839111,"Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause","Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated.",,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
8787,NCT03527784,Incidence of parastomal hernia,Quality of Life measured by RAND 36,,2018-05-03,TERMINATED,INTERVENTIONAL,['NA']
8788,NCT04413526,The survival rates for one-year to five-year,The Child-Pugh score after therapy,,2020-05-25,COMPLETED,OBSERVATIONAL,['NA']
8789,NCT00576056,Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality,Determine the Overall Survival in Patients Treated With This Combination Regimen,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
8790,NCT02571374,Number of participants with colorectal cancer on symbiotic to prevent postoperative infection,,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
8791,NCT04890015,Anastomotic leakage rate between treatment arms,Definitive and / or temporary stoma rate after anastomotic leakage,,2017-07-10,UNKNOWN,INTERVENTIONAL,['NA']
8792,NCT04795063,Morbidity rates,Time of digestive tract reconstruction,,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8793,NCT03881332,Glomerular filtration rate,,,2019-12-26,COMPLETED,OBSERVATIONAL,['NA']
8794,NCT00806663,"reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.",drug treatment safety,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8795,NCT00723996,The primary outcome will be determined through review of medical records or a telephone follow-up 6 months after enrollment,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
8796,NCT04883775,Biodistribution of MVT-2163,,,2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE1']
8797,NCT06195254,progression-free survival (PFS),Pain relief rate (PRR）,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
8798,NCT03884400,Distribution of Biospecimens From Biorepositories/Biobanks for Research Use,,,2021-01-01,WITHDRAWN,OBSERVATIONAL,['NA']
8799,NCT05494658,The proportion of postoperative blood glucose>8mmol/L,Postoperative hospital stay,,2022-08-26,RECRUITING,INTERVENTIONAL,['NA']
8800,NCT03520283,Retention Rate,Qualitative Assessment of Changes in Outcomes With Semi-structured Interviews,,2018-05-29,COMPLETED,INTERVENTIONAL,['NA']
8801,NCT04229849,Overall Survival (OS),Assessment of Health-related quality of life,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8802,NCT04036643,Tumor response assessed by modified the Ryan tumor regression grading system obtained by quantification of the residual cancer cells compared to fibrosis on the surgical specimen,Calculation of the Net Reclassification Index (NRI) by comparing the sensitivity of [18F] -FDG-PET / MRI and the sensitivity of MRI alone for TRG1,,2019-11-27,UNKNOWN,INTERVENTIONAL,['NA']
8803,NCT04878783,Predictive performance of radiomics analysis on the pre-treatment CT scan.,Association between radiomics and molecular expression in regards to long-term outcomes,,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA']
8804,NCT05595473,Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE,To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST,,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8805,NCT06326879,Incidence rate ratio of colorectal cancer recurrence,Correlation between socioeconomic characteristics and incidence rate of colorectal cancer recurrence,,2023-11-30,RECRUITING,OBSERVATIONAL,['NA']
8806,NCT00926536,"Cumulative Dose (CD), a Measure of Radiation Dose",,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
8807,NCT00868816,disease-free survival,overall survival liver metastasis-free survival,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8808,NCT02221245,"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).",,,2013-04-05,TERMINATED,OBSERVATIONAL,['NA']
8809,NCT06153368,Objective response rate (ORR),Adverse events (safety),,2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8810,NCT01056796,"To evaluate for the occurrence of adverse events related to the use of the CAR™ 27 device, include anastomotic leak, bleeding, ring evacuation and strictures at 6 months.",Evaluation of the creation of a functioning CAR™ 27 anastomosis in radiated patients,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8811,NCT04057365,Overall Response Rate,Median Overall Survival,,2019-10-07,RECRUITING,INTERVENTIONAL,['PHASE2']
8812,NCT06205862,CRA recurrence rate,Changes in intestinal mucosal microbiota Pre- and Post-FMT,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8813,NCT04006600,Persistence of a stomy 2 years after rectal surgery when stoma was primarily intended to be temporary,,,2018-03-16,COMPLETED,OBSERVATIONAL,['NA']
8814,NCT02351765,Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin,Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8815,NCT01950442,Safety of gentle dilation,impact on staging,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
8816,NCT02648880,Change in 400-meter Walk Time,Determination of Hospital Readmission,,2016-05-10,COMPLETED,INTERVENTIONAL,['NA']
8817,NCT00027638,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8818,NCT02747862,Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
8819,NCT05753748,Neoplastic Progression,Patient-Reported Gastroesophageal Reflux,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
8820,NCT02110329,Recurence rate according to molecular results,Survival rate according to molecular results,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
8821,NCT02713386,Progression-free survival (PFS) (Phase II),Overall survival (OS) (Phase II),Change in serum C-reactive protein (CRP),2016-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8822,NCT01777594,Time to progression,Overall survival,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8823,NCT02226380,The 3-year overall survival rate in patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,The 3-year disease-free survival rate in the patients who will receive mFOLFOX6 regimen neoadjuvant chemotherapy regimen,The R0 resection rate in the patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
8824,NCT03203005,Immunogenicity (T-cell response in peripheral blood),Overall survival (OS),,2017-09-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8825,NCT03775980,Local Tumor Control,Treatment specific quality of life,,2019-09-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8826,NCT02559024,Immune Score,,,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE1']
8827,NCT00856115,Factors that influence appraisal and diagnostic delay,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
8828,NCT04792515,pathologic complete response (PCR),Percentage of Progression-free survival (1-PFSR),,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8829,NCT00109954,Toxicity as measured by NCI CTCAE version 3.0,,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8830,NCT04080414,Feasibility of home-based high-intensity interval training among colorectal cancer survivors,,,2019-08-02,COMPLETED,INTERVENTIONAL,['NA']
8831,NCT02723604,Number of Participants With Severe World Health Organization [WHO] (Grade 3-4) Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy,Time to Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis Following the Initiation of Radiotherapy,Time to Reach Planned Dose of Radiation Therapy,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8832,NCT01150045,Disease-free Survival,Overall Survival,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
8833,NCT01484444,Analyzed of DNA mutations,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
8834,NCT02216110,Patient's death,Development of metachronous cancers,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
8835,NCT00845611,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),evaluate immunological responses,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
8836,NCT02101099,Peak push force is increased in patients receiving propofol as compared to conscious sedation.,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
8837,NCT01024504,Overall response rate,Overall survival,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8838,NCT03557216,Presence of ACN,Fecal calprotectin test predictive value for ANC detection,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
8839,NCT00479752,"The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria",• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8840,NCT04478929,gastroscopy image data set,,,2020-08,UNKNOWN,OBSERVATIONAL,['NA']
8841,NCT01053923,Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI,Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI,,2009-12,WITHDRAWN,OBSERVATIONAL,['NA']
8842,NCT05787535,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",Duration of TCR T cells in-vivo persistence,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1']
8843,NCT01258868,Tabulation of patient toxicities and their grades,Number of patients of first 20 lung CA patients with cell line development greater than or equal to 5.,,2010-12-01,TERMINATED,INTERVENTIONAL,['PHASE1']
8844,NCT03129139,Anti-tumor activity,,,2017-10-10,RECRUITING,INTERVENTIONAL,['PHASE1']
8845,NCT05990231,Objective response rate,Adverse events,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
8846,NCT03035136,Adenoma detection rate,Polyp detection rate,,2017-01-15,COMPLETED,OBSERVATIONAL,['NA']
8847,NCT02409186,Over Survival,,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8848,NCT02570516,Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine),Number of subject with adverse events as mesure of safety.,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
8849,NCT05146297,Change in Clinical Trial Accrual,Physician Post -intervention survey,,2022-12-24,RECRUITING,INTERVENTIONAL,['NA']
8850,NCT02293850,"Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base.",Dose-Limiting Toxicity (DLT) for patients using OBP-301.,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
8851,NCT03428529,Clinical downstaging,Pathological downstaging,,2011-01-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8852,NCT01561014,Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride,Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8853,NCT02823691,incidence of SAEs and AEs,biochemical responses to Lanreotide ATG 120 mg in combination with Metformin,,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
8854,NCT04770623,Overall response rate (ORR),Overall survival (OS),,2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8855,NCT04843397,Define the prevalence of pre-malignant upper GI tract lesions as measured by standardised endoscopy and biopsy protocol,Correlation between life-style factors and pathological outcomes,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8856,NCT00536770,Overall survival rate at 6 months,Duration of overall survival,,2007-09,SUSPENDED,INTERVENTIONAL,['PHASE2']
8857,NCT00057876,Overall Survival Time,Overall Response,,2003-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
8858,NCT05555901,Progression-Free Survival (PFS),Overall survival (OS),,2023-06-18,RECRUITING,INTERVENTIONAL,['PHASE2']
8859,NCT04232748,Overall survival,Chemotherapy interruption,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8860,NCT05013125,Adenoma missed rate,Number of CAD assisted abnormality,,2021-08-09,UNKNOWN,INTERVENTIONAL,['NA']
8861,NCT05928897,ORR,OS,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8862,NCT01051596,Percent of Patients With Disease Control,Percent of Patients With an Objective Response,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8863,NCT01348256,Progression Free survival,Overall survival,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
8864,NCT04677998,Advanced neoplasia,Surgery,,2020-11-24,RECRUITING,OBSERVATIONAL,['NA']
8865,NCT00954655,response,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
8866,NCT06334926,overall survival,,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
8867,NCT00521404,Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer,Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term,,2007-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8868,NCT01023984,Incidence of recurrence at 12 months,Number of days not spent in hospital from initial treatment until 2 years afterwards,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8869,NCT03732508,Duration of Progression-Free Survival (PFS),Adverse Events(AE),,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
8870,NCT01869725,Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan,,,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8871,NCT01356030,Direct comparison of tissue sampling techniques for patients with suspected pancreaticobiliary cancers.,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
8872,NCT02560298,Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1,Sensitivity analysis of ORR,Changes in expression of tumor biomarkers,2016-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8873,NCT05379907,Impact of SIGNATERA™ on treatment decisions,Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations,,2022-08-23,WITHDRAWN,OBSERVATIONAL,['NA']
8874,NCT04545957,Proportion of patients with QOL decline exceeding 2 x MID,Performance of the synthetic CT in RT planning,,2020-10-14,RECRUITING,INTERVENTIONAL,['NA']
8875,NCT03644511,"Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditions",Incidence of treatment-emergent adverse events (TEAE),,2019-01-24,TERMINATED,OBSERVATIONAL,['NA']
8876,NCT02688023,3-year disease-free survival,Number of participants with surgery complications,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
8877,NCT01815463,Correlation of Adnab-9 stool result with outcome of colonoscopy,Define the origin of the Adnab-9 bound antigen,,2006-08,TERMINATED,OBSERVATIONAL,['NA']
8878,NCT04095468,Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.,Anorectal function assessed by low anterior resection syndrome (LARS) score,,2017-09-18,RECRUITING,OBSERVATIONAL,['NA']
8879,NCT02215837,Progress-free survival,Severity of adverse events,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
8880,NCT02092298,Overall Survival (OS) From the First Laparoscopic HIPEC,,,2014-05-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8881,NCT01806272,The incidence of grade II and less oral mucositis at the end of treatment,Tumor response to chemoradiotherapy,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
8882,NCT05889806,Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations.,,,2023-05-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8883,NCT02699073,Tumor response rate at 2 months according Choi Criteria,Correlation between Baseline cell free DNA and survival outcomes (PFS and OS),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8884,NCT05832892,Objective response rate (RECIST 1.1),Predictive biomarkers,,2023-10-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8885,NCT04115254,Rate of Improvement in Tumor Control-Phase II,Overall Survival Rate-Phase II,,2019-10-22,SUSPENDED,INTERVENTIONAL,['NA']
8886,NCT05336643,Lymph node detection with technetium 99m colloid and SENSEI gamma probe,Concordance of nodes seen on PET MRI/CT and SPECTCT,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8887,NCT03605706,Overall Survival,Overall Survival (OS) rate at 9 months and 12 months,,2019-05-31,UNKNOWN,INTERVENTIONAL,['PHASE3']
8888,NCT05589675,Participation rates to the screening program,Participation rates to the screening program,,2023-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8889,NCT02480361,Remnant sitz markers in small intestine at postoperative day 7,hospital stay,serum albumin level in postoperative day 7,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8890,NCT01365910,Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%,Number of Patients With Each Worst-Grade Toxicity,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
8891,NCT03904121,Postoperative mortality,Functional performance,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
8892,NCT00328887,"Since this is a dose escalation, phase I design to evaluate toxicity, the analysis for this section will be purely descriptive. Adverse events will be considered on an individual basis.",,,2004-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8893,NCT00849264,overall survival,disease-free survival,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8894,NCT02604784,Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.,The Peritoneal Carcinomatosis Index (PCI) before and after therapy,,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8895,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
8896,NCT01778595,"Participation rate, data quality",,,2013-01-08,COMPLETED,OBSERVATIONAL,['NA']
8897,NCT01469611,Determine the maximum-feasible dose,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8898,NCT02149108,Overall Survival (OS),Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment,,2014-09-25,COMPLETED,INTERVENTIONAL,['PHASE3']
8899,NCT00403052,Occurrence of adverse events,Overall survival time,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1']
8900,NCT05835947,The incidence of anal HSIL and cancer in women with genital HSIL and/cancer in England,The amount of time in years and months between the diagnosis of genital HSIL/SCC and anal HSIL/SCC,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
8901,NCT02850991,Overall Survival,Progression-free survival,"local control rate, recurrence pattern",2016-04,COMPLETED,INTERVENTIONAL,['NA']
8902,NCT05172713,Retrospective study of the patient outcomes who had an incomplete colonoscopy after a positive immunological fecal test,,,2021-01-16,UNKNOWN,OBSERVATIONAL,['NA']
8903,NCT01219543,To investigate the safety and tolerability of AZD1480,To obtain a preliminary assessment of the anti-tumour activity of AZD1480,,2010-11,TERMINATED,INTERVENTIONAL,['PHASE1']
8904,NCT02347618,Incidence of grade 2 or greater toxicity,Time to death,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
8905,NCT00259402,"Efficacy endpoints include tumor response, progression free and overall survival.","Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations.",,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8906,NCT02943031,Overall Survival (OS),Progression-Free Survival (PFS),,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
8907,NCT00990860,"Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))",No. of TACE cycles,,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8908,NCT03705442,Incidence of grade III/IV diarrhoea between the two groups of patients,Difference in quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) between the two groups of patients,,2018-02-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
8909,NCT01379482,Overall survival,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8910,NCT02366286,Rate of HBV vaccination in subjects with negative HBV serology,Incidence of HCC over the period of the study,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
8911,NCT02955901,Score of mucosal visualization,Withdrawal time,Patients characteristics questionnaire,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
8912,NCT01572324,Response rates,Overall survival,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8913,NCT01362361,progression free survival,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8914,NCT01609660,Mucosal cytokine,Short chain fatty acids,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8915,NCT00226941,Dose-limiting Toxicity (DLT) - Number of Participants Affected,Survival at 5 Years,,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8916,NCT06060847,Comprehensive Complication Index,Control of obesity-induced comorbidities,,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8917,NCT01268943,Dose Related Toxicity,,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8918,NCT01967823,Percentage of Participants With a Response,Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells,Number of Participants With Serious and Non-serious Treatment Related Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),2013-10-24,COMPLETED,INTERVENTIONAL,['PHASE2']
8919,NCT05147389,Neoplastic bile duct diagnosis confirmation after one year follow-up,,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
8920,NCT03329950,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0,Pharmacokinetic evaluation,,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8921,NCT01180959,Progression Free Survival (PFS),Overall Survival (OS),,2011-04-14,COMPLETED,INTERVENTIONAL,['PHASE2']
8922,NCT02136069,"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)",Number of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab,,2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3']
8923,NCT02355262,Total number of months uninsured (total gap months),,,2014-07-01,COMPLETED,OBSERVATIONAL,['NA']
8924,NCT03304210,Maximally Tolerated Dose (MTD) of Abraxane,Decreased Platelets - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,,2017-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
8925,NCT03248375,Number of Participants With Local Tumor Response According to mRECIST,Number of Participants With Treatment-related Laboratory Adverse Events,,2016-08-03,COMPLETED,INTERVENTIONAL,['NA']
8926,NCT03161522,Overall survival (OS),Time to local or regional disease recurrence,Time to disease progression,2018-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
8927,NCT06227871,Complication occurrence,Associated intra-abdominal injuries,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
8928,NCT04723004,Overall survival (OS),ADA,,2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8929,NCT00026338,Overall survival,Pharmacokinetics,,2001-10-29,COMPLETED,INTERVENTIONAL,['PHASE3']
8930,NCT01009801,Time to progression (Phase II),Time to treatment failure (Phase II),,2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8931,NCT02468362,Disease Free survival,5 year survival,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
8932,NCT04608786,Recommended phase II dose (RP2D),the number of subjects presenting detectable anti drug antibodies (ADAs),,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
8933,NCT04177407,postoperative complications,Overall complication rate within 30 days after surgery.,,2017-03-23,UNKNOWN,INTERVENTIONAL,['NA']
8934,NCT00410618,Nature and long-term ramifications of CNS injury as a result of cancer treatment,Relationship between MRI measures and cognitive performance,,2003-04,COMPLETED,OBSERVATIONAL,['NA']
8935,NCT02043821,DDC:Duration of Disease Control,DCR:Disease Control Rate,Safety,na,UNKNOWN,INTERVENTIONAL,['NA']
8936,NCT00470951,Disease free survival,Quality of life,Immunologic response,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
8937,NCT04681274,Specific tumor phenotypes,Small lesion detection and characterization,,2020-08-31,COMPLETED,OBSERVATIONAL,['NA']
8938,NCT02375997,Overall survival,Adverse event,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
8939,NCT02564224,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
8940,NCT03038568,assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans,,,2017-01-27,RECRUITING,OBSERVATIONAL,['NA']
8941,NCT03267641,Time to recurrence,Overall Survival,,2016-05-16,COMPLETED,OBSERVATIONAL,['NA']
8942,NCT03344172,Proportion of Grade IIb or Higher Histolopathologic Responses,Change in Coagulation Index (CI),,2017-12-13,TERMINATED,INTERVENTIONAL,['PHASE2']
8943,NCT04888663,"Phase 2: Progression-free survival in patients with HER2-positive gastric cancer receiving trastuzumab, ramucirumab, and paclitaxel combination treatment",Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE v4.02,,2018-02-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8944,NCT01748851,Progression free survival,performance status (quality of life),,2012-12,TERMINATED,INTERVENTIONAL,['PHASE3']
8945,NCT05732129,"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response",The Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8946,NCT01930864,Non-Progression at week 12th of treatment,Safety,,2015-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8947,NCT02778308,Disease Free Survival,Gastrointestinal system Adverse events,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
8948,NCT04601727,16s rRNA pyrosequencing analysis of microbial flora of rectal cancer patients,Categorisation of microbial flora against response to neoadjuvant chemoradiotherapy,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
8949,NCT04787523,Immun cell infiltrate in pathology sections from the tumour,,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
8950,NCT05441163,HRQoL deterioration free survival (QFS),,,2023-04-08,RECRUITING,INTERVENTIONAL,['NA']
8951,NCT03983057,Progression-free survival,Carbohydrate antigen 19-9,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8952,NCT02363647,Overall response rate (ORR),Overall survival (OS),,2015-01,TERMINATED,INTERVENTIONAL,['NA']
8953,NCT02577588,Safety,evaluation of p53 specific T cell Responses by analysing data from EliSpot assay,,2016-05-01,TERMINATED,INTERVENTIONAL,['PHASE1']
8954,NCT00956436,To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC.,To assess the anti-tumor response in this study population,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8955,NCT04748744,Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases,,,2019-11-06,COMPLETED,OBSERVATIONAL,['NA']
8956,NCT04296851,Mean percentage change of the number and size of polyps in colon and/or duodenum.,A qualitative assessment of the total extent of colorectal polyposis,,2020-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
8957,NCT00280709,"Clinical follow-up every month, starting one month after stent insertion. Clinical and/or laboratory signs of stent dysfunction?",,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8958,NCT06216834,psychosocial status,,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
8959,NCT01368094,Surgical Site Infection at D30,,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
8960,NCT00112086,proportion of clinical complete remission,overall survival among all enrolled patients.,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8961,NCT03267524,Geriatric assessment,,,2017-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8962,NCT05951127,2-year OS,3 years PFS,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8963,NCT05289895,Proteomic analysis of blood and urine,,,2022-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8964,NCT02437071,response rate,Toxicity,,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8965,NCT02296736,Review pre-operative imaging to distinguish the organ of origin of pancreatic head tumours,Resectabilty of the pancreatic tumour,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
8966,NCT04368182,Safety of C-TCR055,DOR,,2020-04-13,UNKNOWN,INTERVENTIONAL,['PHASE1']
8967,NCT05130073,Overall survival (OS),,,2019-07-31,COMPLETED,OBSERVATIONAL,['NA']
8968,NCT02327481,Operating time,Recurrence patterns,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
8969,NCT05981066,Clinically significant abnormal changes in laboratory tests,"Overall Survival, OS",,2023-07-10,RECRUITING,INTERVENTIONAL,['NA']
8970,NCT04564898,activity,survival,Clearance,2022-01-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8971,NCT04935853,Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months,The complications and postoperative mortality rates in patients who underwent surgery,,2022-05-23,RECRUITING,OBSERVATIONAL,['NA']
8972,NCT05185739,"Major pathological response rate, defined as the proportion of patients with less than 10% viable tumour at resection.",Determine the toxicity of pre-operative therapy according to Common Terminology Criteria for Adverse Events (CTCAE) V5.,,2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2']
8973,NCT02050659,tumorload in the greater omentum,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
8974,NCT02299648,molecular screening ( biopsy of their tumor and will be analyzed using cancer panel/nanostring CNV and immunohistochemistry),OS/PFS,,2014-07-25,COMPLETED,INTERVENTIONAL,['NA']
8975,NCT03019588,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),Number of Participants Who Discontinue Study Treatment Due to an AE,,2017-02-16,TERMINATED,INTERVENTIONAL,['PHASE3']
8976,NCT01134666,Safety and tolerability evaluated based on the incidence and severity of AEs.,Response rate,,2009-11-30,TERMINATED,OBSERVATIONAL,['NA']
8977,NCT03602677,Anastomosis leakage rate,Hospital costs,,2018-09-24,RECRUITING,INTERVENTIONAL,['NA']
8978,NCT04624282,Metabonomic difference in patients with chronic gastritis and gastric carcinoma,Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA']
8979,NCT00868114,Overall Survival,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2']
8980,NCT05657249,Comparison of alternative surveillance program (alternating focused MRI + US in 6 month interval) and conventional surveillance (biannual US) for HCC detection,comparison between false referral rates of biannual US and annual focused MRI,comparison between incidental findings between biannual US and annual focused MRI,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8981,NCT02376478,"Number of anogenital warts, anogenital HPV DNA positivity and mucosal HPV seropositivity",,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
8982,NCT05878977,response prediction in first line immune checkpoint inhibitors treatment in metastatic melanoma assessed by human gastrointestinal microbiome (bacterial and viral) and exosomal mRNA expression of PD-L1 and IFNγ,,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
8983,NCT06101836,Patient comfort during colonoscopy - Sedation,,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8984,NCT03793322,The accuracy of positive margins of resection detected by ICG fluorescence.,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
8985,NCT04430231,Disease-free overall survival,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
8986,NCT01103492,Number of Participants With Adverse Events,,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
8987,NCT02260440,Objective Response Rate (ORR),Overall Survival (OS),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8988,NCT05163028,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.",Pharmacokinetic variables including volume of distribution,,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE1']
8989,NCT00222469,"To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin",To determine the tolerability and toxicity profile of this regimen in this patient population,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8990,NCT03908255,Overall Survival,Quality of life using FACT-Hep,International normalized ratio (INR),2021-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8991,NCT00314353,One-year Progression-free Survival (PFS),Duration of Response,,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8992,NCT05243862,Administration safety,Measured Memory T Cell Immune Response,,2022-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8993,NCT03245203,R0 resection rate,overall response rate (ORR),,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
8994,NCT04829032,Number of Hartmann's procedure vs colic resection with primary anastomosis performed in 3-months in urgent or emergency setting for left-sided acute colonic diseases.,The number of patients treated with Hartmann's procedure with a permanent stoma after one year.,,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA']
8995,NCT02927626,Survival rate,quality of life(QOL),,2016-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8996,NCT01318200,Freedom from local progression,Freedom from local progression,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
8997,NCT05887531,Post-surgical readmisions,Strength,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
8998,NCT01255007,To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.,To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
8999,NCT04896879,Needs and experiences of healthcare professionals caring for patients with LARS through focus groups,,,2016-11-22,COMPLETED,OBSERVATIONAL,['NA']
9000,NCT06085560,Anticipatory Racism,,,2023-07-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9001,NCT01809756,severity of esophagitis (NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0 score),weight loss (NCI CTCAE 4.0 score),,2014-02-25,TERMINATED,INTERVENTIONAL,['NA']
9002,NCT00351572,,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
9003,NCT00899093,YKL-40 measurements,,Variability of YKL-40 measurements,2007-09,TERMINATED,OBSERVATIONAL,['NA']
9004,NCT05565417,Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohort,Phase 2a Cohort(s)- Number of participants with adverse events following administration of IMT-009,,2022-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9005,NCT06195904,Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing,Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing,,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9006,NCT03189992,Complete patient recruitment,,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9007,NCT01887717,Overall Survival (OS) From Time of Randomization,Number of Participants With Treatment Emergent Adverse Events (TEAE),,2014-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
9008,NCT03444194,Tissue biopsy,RECIST,,2017-05-12,UNKNOWN,INTERVENTIONAL,['NA']
9009,NCT05264688,diagnose accordance rate,Total Glycolysis (TLG),,2022-01-20,UNKNOWN,OBSERVATIONAL,['NA']
9010,NCT04833699,time to the first passage of flatus after surgery,The time to the first bowel movement,,2021-04-05,COMPLETED,INTERVENTIONAL,['NA']
9011,NCT04655807,Change from Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12,Change in PD Biomarker Levels of Fecal Lactoferrin from Baseline Compared with Placebo,,2021-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9012,NCT05984342,disease-free survival rate,Rate of adverse events,,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE1']
9013,NCT02931981,Overall Survival,Relapse-free Survival,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
9014,NCT03951389,"The correlation between wild type PIK3CA, PIK3CA exon 9 and PIK3CA exon 20 mutations and developing of metastatic disease and overall colorectal patient survival",,,2012-05-22,COMPLETED,OBSERVATIONAL,['NA']
9015,NCT02347852,Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire,"Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')",,2015-01-20,COMPLETED,OBSERVATIONAL,['NA']
9016,NCT00191607,"- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments",Quality of life,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9017,NCT01290536,Number of Participants With Adverse Events,Radiographic Response,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9018,NCT01934179,"Incidence of chemotherapy related grade 3 or higher adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",Change in TL after chemotherapy,"Association of each geriatric scale, and pro-inflammatory markers to the incidence of chemotherapy related adverse events and TL",2013-10,TERMINATED,OBSERVATIONAL,['NA']
9019,NCT03814369,Adenoma detection rate,caecal intubation time,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9020,NCT05811195,Oral mucositis Children's International Mucositis Evaluation Scale (CHIMES),Analysis NET and TSE,,2023-03-10,RECRUITING,INTERVENTIONAL,['NA']
9021,NCT01328223,Response rate,Overall survival,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
9022,NCT02649153,Time to first peristalsis,,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9023,NCT00019474,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9024,NCT02421185,Number of participants with Objective Response,Duration of Objective Response (DOR),,2015-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9025,NCT03144856,Progression-free survival (PFS),Safety (incidence of adverse events),,2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
9026,NCT03491709,Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion,Immunogenicity indicators: neutralizing antibodies,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9027,NCT00006479,,,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
9028,NCT05550974,complication,number of use for each surgical instruments,,2022-09,RECRUITING,OBSERVATIONAL,['NA']
9029,NCT01237132,Overall survival of resected patients for HCC,Disease-free survival of resected patients for HCC,,na,COMPLETED,OBSERVATIONAL,['NA']
9030,NCT03003078,Safety / Tolerability of Device according to CTCAE V4.0,Pain Scores,tumour response,2017-03-27,COMPLETED,INTERVENTIONAL,['NA']
9031,NCT05995990,Raman spectroscopy is able to discriminate between healthy liver tissue and colorectal liver metastases.,Tissue sections can be analysed by Raman spectroscopy more time effectively than normal clinical practice.,,2020-11-25,COMPLETED,INTERVENTIONAL,['NA']
9032,NCT04563975,disease control rate,overall survival rate,,2020-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
9033,NCT04257448,Recommended dose for expansion (RDE),Progression free survival (PFS),,2020-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9034,NCT05365412,"Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors","Disease-free survival according to sex, molecular profiles and sex hormone receptors",,2019-01-01,RECRUITING,OBSERVATIONAL,['NA']
9035,NCT00262808,Proportion of patients with a change in tumor-associated macrophage VEGF expression,Disease-free and overall survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9036,NCT05601609,Overall survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),Cancer-specific survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),,2020-11-11,COMPLETED,OBSERVATIONAL,['NA']
9037,NCT00985777,Maximum Tolerated Dose (MTD),Number of Participants With Adverse Events (AEs),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9038,NCT02619435,the rate of evaluable patients alive and not progressed at 6 months,overall survival,,2015-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9039,NCT00095927,"Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment",Swallowing function,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9040,NCT05957822,CRT maximal amplitude,re-operation,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
9041,NCT04716166,FEV1/FVC ratio,,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9042,NCT00081354,Case Control,,,2004-04-06,COMPLETED,OBSERVATIONAL,['NA']
9043,NCT00222664,,,,1983-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9044,NCT00606788,weaning duration,reintubation rate,,2005-11,SUSPENDED,INTERVENTIONAL,['NA']
9045,NCT00823290,Maximum tolerated dose of LBH589,Laboratory abnormalities (CTC grade 3 or grade 4 toxicities),,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9046,NCT06052202,Receipt of Colorectal Cancer Screening Test at Month 6,Change from Baseline in Colorectal Cancer Knowledge at Month 6,,2023-12-08,RECRUITING,INTERVENTIONAL,['NA']
9047,NCT02066363,Changes in body composition,Time to to exacerbate Quality of Life,Survival in study,2014-03-01,TERMINATED,INTERVENTIONAL,['NA']
9048,NCT01111292,The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.,,,2010-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9049,NCT04248569,Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 4 (CD4) T cells at 10 weeks,Overall survival (OS),,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE1']
9050,NCT02511756,CTP as predictive marker for efficacy measured by progression-free survival,Local and distant recurrences,,2015-07,TERMINATED,INTERVENTIONAL,['NA']
9051,NCT00292279,Systemic inflammatory response syndrome (SIRS),Post operative nutritional cost & total treatment cost,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9052,NCT02090101,Response rate after 2 months in patients with colorectal cancer with liver metastases treated with anakinra and LV5FU2/bevacizumab,Rate and safety profile according to NCI-CTCAE v4,,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9053,NCT06133439,Implementation outcomes,,Maintenance,2023-01-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9054,NCT02807844,Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment,Phase Ib and Phase II: All Collected Deaths,,2016-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9055,NCT05394129,Diagnostic accuracy,Cytomorphologic feature,,2019-04-09,RECRUITING,OBSERVATIONAL,['NA']
9056,NCT05345678,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
9057,NCT05682898,Incidence of surgical complications,,,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9058,NCT06333392,Proximal sessile serrated lesion detection rate,Single use accessories for the procedure,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9059,NCT04850716,Progression-Free Survival (PFS),Disease Control Rate (DCR),,2021-04-27,RECRUITING,OBSERVATIONAL,['NA']
9060,NCT02718235,The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC,The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
9061,NCT02015169,complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor).,Exploratory biomarker analysis,,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9062,NCT01736813,"safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent",Overall survival,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
9063,NCT00904813,Time to Local Recurrence.,Tumour Regression Based on the Dworak Grading Scoring System,,1998-11,COMPLETED,INTERVENTIONAL,['NA']
9064,NCT04563897,Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
9065,NCT05190042,The rates of complete closure of mucosal/submucosal defects,Post polypectomy syndrome,,2022-01-18,COMPLETED,INTERVENTIONAL,['NA']
9066,NCT02073435,Complications,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9067,NCT04871321,collected blood samples,Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer,,2021-04-14,RECRUITING,OBSERVATIONAL,['NA']
9068,NCT02758977,1 Year Disease-free Survival,Incidence of posthepatectomy renal failure,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
9069,NCT03680183,Average plasma concentration of the drugs (TKIs),Incidence of adverse reaction caused by TKIs,,2018-05-22,UNKNOWN,OBSERVATIONAL,['NA']
9070,NCT05014776,Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST),Number of participants experiencing grade 3 or above drug-related toxicities,,2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2']
9071,NCT02043288,Overall survival (OS),Quality of life (QoL) using EORTC QLQ-C30,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9072,NCT06136845,To characterize the microbiota of esophageal cancer patients differentiating it by: - demographic criteria - tumor characteristics,,,2020-01-13,RECRUITING,OBSERVATIONAL,['NA']
9073,NCT03411200,Lower body strength measured with the 30-second chair stand test,Survival,,2018-04-04,COMPLETED,INTERVENTIONAL,['NA']
9074,NCT05292417,Progression-free survival (PFS),Safety:Percentage of Participants With Adverse Events (AEs),,2022-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
9075,NCT04972994,early recurrence of the cancer,,,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA']
9076,NCT03053544,Pathological Complete Response (pCR) rate,Tumor Hypoxia,,2016-12-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9077,NCT00955240,Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment,Duration of objective response,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2']
9078,NCT05159050,Determine the maximum tolerated dose (MTD) of intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM),Assess whether intra-abdominal pressure is location-dependent,,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE1']
9079,NCT04389151,effectiveness of neoadjuvant therapy,,,2020-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9080,NCT02870036,Adverse events (AE),accumulative excretion rate,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
9081,NCT06261814,False discovery rate,Ability of the model to predict binary treatment response,,2024-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9082,NCT02785783,Number of polyps per patient,,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
9083,NCT03852693,Frequency of distant metastases in aNET measuring 1-2 cm,Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
9084,NCT03311750,Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy,Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 20 of PIK3CA gene mutations,,2018-03-26,TERMINATED,INTERVENTIONAL,['PHASE2']
9085,NCT03694600,Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs Ultrasound,To compare the performance (sensitivity and specificity) of ultrasound alone to the multi-analyte Test alone for the detection of liver cancer lesions that are ≤ 2cm in diameter.,,2019-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9086,NCT01959087,Length of postoperative hospital stay,Post-operative quality of life,,2014-01-27,COMPLETED,INTERVENTIONAL,['NA']
9087,NCT03257033,Overall Survival,"Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation",,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
9088,NCT00881504,Progression-free Survival,Safety and Toxicity,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2']
9089,NCT00890305,The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.,Tumor and immunological markers.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9090,NCT03400280,Composite primary endpoint,Cost-effectiveness,,2018-01-08,UNKNOWN,INTERVENTIONAL,['NA']
9091,NCT03471052,Change in surface area of residual inlet patch post ablation,"Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)",,2018-03-06,UNKNOWN,INTERVENTIONAL,['NA']
9092,NCT01926743,To compare the number of retrieved lymph node in each nodal station after additional application of near infra-red fluorescence imaging,,,2013-08-01,COMPLETED,INTERVENTIONAL,['NA']
9093,NCT05654896,Liver abscess and intervention,,,2022-11-26,RECRUITING,INTERVENTIONAL,['PHASE3']
9094,NCT02325739,Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only),T1/2 of FGF401: Phase I,,2014-12-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9095,NCT03171428,Short-term outcome: Occurrence of postoperative complications or death after surgery,,,2007-01-01,COMPLETED,OBSERVATIONAL,['NA']
9096,NCT04331041,Progression-free survival (PFS),Local control,,2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2']
9097,NCT05030870,The incidence of hypoxia,The incidence of other adverse events,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
9098,NCT01456923,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
9099,NCT00213486,clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan,overall survival rate at one and two years,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9100,NCT02247336,Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening,Number of Patients Who Received Referral for Genetic Consultation,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
9101,NCT00003544,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9102,NCT03640572,Overall survival (OS),Systemic recurrence,,2007-06-01,COMPLETED,OBSERVATIONAL,['NA']
9103,NCT00881621,Overall Survival,Adverse Events,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2']
9104,NCT03723304,Tumour-specific liver transplant failure rate,,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
9105,NCT05859945,Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9106,NCT05248048,Maximal Tolerable Dose#MTD#,Antitumor efficacy-Overall survival (OS),,2021-09-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9107,NCT05267080,Local Tumour Control,Economic aspects,,2023-01-25,RECRUITING,OBSERVATIONAL,['NA']
9108,NCT00265824,Progression-free survival during maintenance therapy,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9109,NCT05927584,Success rate,Radical rescue surgery specimen quality,,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9110,NCT02866019,Proportion of participants without stenosis until 8 weeks after endoscopic submucosal dissection (ESD),QOL assessed by the EORTC QLQ-OG 25,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9111,NCT03198975,Presence of microvascular invasion,,,2017-06-23,UNKNOWN,OBSERVATIONAL,['NA']
9112,NCT03716089,3-year disease free survival rate,The variation of C-reactive protein,,2018-10-11,RECRUITING,OBSERVATIONAL,['NA']
9113,NCT04224402,Regression Free Survival,Overall Survival,EORTC Quality of Life Questionnaire(QLQ)-C30,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
9114,NCT00485316,Overall survival and disease-free survival,Direct cost,,1993-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9115,NCT05084456,The hematological and non-hematological toxicity profile of oral docetaxel in combination with ritonavir,,,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
9116,NCT01046864,"Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests","Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9117,NCT01585428,Number of Participants With an Objective Clinical Response,Number of Patients With Serious and Non-serious Adverse Events,,2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2']
9118,NCT05616403,Textbook outcome,,,2010-01-18,COMPLETED,OBSERVATIONAL,['NA']
9119,NCT01005875,Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma,The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
9120,NCT01640405,Progression free survival (PFS),"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9121,NCT00037180,Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy,Health resource utilization (collected data to be evaluated separately from this protocol),,2002-04,TERMINATED,INTERVENTIONAL,['PHASE2']
9122,NCT00081549,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9123,NCT02806648,Activity of palbociclib (PD0332991) considering objective response rate,"Positive expression of tumor biomarkers (Cdk4, Cdk6, fosfo-Rb1, D1 cyclin, p53, Ki67)",,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9124,NCT00054873,,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9125,NCT03330964,Levi sensory nerve toxicity classification standard,The quality of life questionnaire(QLQ)-C30,National Cancer Institute(NCI)Common Toxicity Criteria,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
9126,NCT05916846,Assess the efficacy of EUS-RFA post-procedure after one year,Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
9127,NCT06280508,1-year EFS rate,OS,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9128,NCT03172884,Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.,,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9129,NCT03823144,"4. Tumor blood flow (velocity, mm/sec)",Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
9130,NCT01494012,The rate of grade 3 or greater non-hematologic acute toxicity as graded by the CTCAE v. 4.0,Overall survival,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
9131,NCT02016391,Patient Satisfaction With Sedation Technique,Maximal pain intensity,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9132,NCT03770559,Posteroperative length of stay,R0 resection,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
9133,NCT05657418,RP2D,ORR,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
9134,NCT02312284,Distant metastasis free survival,Surgery complication,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9135,NCT03475615,overall survival,,,2018-03-16,UNKNOWN,INTERVENTIONAL,['PHASE3']
9136,NCT06126419,Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry,,,2023-11-08,RECRUITING,INTERVENTIONAL,['NA']
9137,NCT00052962,Progression Free Survival,Number of Participants With an Adverse Event,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9138,NCT00496678,"To develop, implement, and evaluate a primary care-based, patient navigation program using specially-trained community health workers. We will investigate the effect of this intervention on timing and quality of cancer-related care.","Secondary aims examine the impact of navigation on disparities in care, improvement in patient activation and total costs.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9139,NCT03009747,Risk factors of bowel dysfunction after sphincter-preserving surgery,Incidence of bowel dysfunction after sphincter-preserving surgery,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
9140,NCT00287976,Best overall response (complete response and partial response),Surgical resection (complete or incomplete),,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9141,NCT05409482,Progression-free survival（PFS）,Occurence of AE and SAE,,2022-08-20,RECRUITING,OBSERVATIONAL,['NA']
9142,NCT02023593,Disease control rate,Progression free survival,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9143,NCT00810719,Progression Free Survival,Overall Survival,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9144,NCT03612726,Overall survival,Frequency and Severity of Adverse Events,,2018-07-16,RECRUITING,OBSERVATIONAL,['NA']
9145,NCT02665299,Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.,Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
9146,NCT03242187,Number of lymph nodes retrieved,Functional outcome,,2017-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9147,NCT03619317,• Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA']
9148,NCT01650766,,,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
9149,NCT03370198,The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43),The overall survival (OS).,,2017-10-11,TERMINATED,INTERVENTIONAL,['PHASE1']
9150,NCT04862260,Characterization of dose-limiting toxicities,CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo,To explore the feasibility of a larger multicenter trial,2021-10-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9151,NCT05160740,3-year disease free survival rate,Mortality rates,,2021-09-23,RECRUITING,INTERVENTIONAL,['NA']
9152,NCT06152276,Overall major complications,,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
9153,NCT01462890,Progression Free Survival (PFS),Translational Research - Complementary and Alternative Treatment Questionnaires,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9154,NCT03971201,overall survival,progression free survival,,2019-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
9155,NCT04725994,Dose Limiting Toxicities (DLTs),,,2021-06-28,RECRUITING,INTERVENTIONAL,['PHASE1']
9156,NCT01065688,the postoperative quality of life (QOL),"the incidence of postoperative complications, nutritional status, and the incidence of the remnant gastritis and the reflux esophagitis",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9157,NCT00653484,Physical activity-energy expenditure,Body weight and composition,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
9158,NCT01904656,Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).,Effect Modification,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
9159,NCT00877045,,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
9160,NCT04451343,"Assess how the patients, their relatives and their family members, face the disease.",,,2018-07-06,COMPLETED,OBSERVATIONAL,['NA']
9161,NCT04959448,Baseline Disease Characteristics,Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment),,2021-08-12,RECRUITING,OBSERVATIONAL,['NA']
9162,NCT00602329,"Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value","Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival",,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2']
9163,NCT00189566,Progression-free survival of patients in the three groups,Quality of life,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9164,NCT01635595,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9165,NCT00671996,Neutropenia,Quality of Life,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9166,NCT04653701,Technical success,,,2020-11-14,UNKNOWN,OBSERVATIONAL,['NA']
9167,NCT06220045,Incidence of surgical wound infection,Morbidity and mortality rates,,2024-01-15,RECRUITING,INTERVENTIONAL,['NA']
9168,NCT00335816,Effect of different chemoradiation-to-surgery intervals on postoperative complications,,,2008-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9169,NCT05407272,"the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care",,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
9170,NCT00967291,Progression-free survival at 6 months,Overall survival,,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2']
9171,NCT05281159,Opening link within SMS Text message,Overall completion of any CRC screening test,,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
9172,NCT00088894,Grade 3-4 neutropenia in terms of specific single-nucleotide polymorphisms (SNPs) and/or copy number variations that are associated with the prevalence of these events (Clinical endpoint),OS (Clinical endpoint),,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9173,NCT00901732,The primary objective is to estimate ht incidence of OM in H&N cancer patients undergoing radiation therapy with or without chemotherapy and/or sensitizer who receive Caphosol.,"The secondary objective of this study is to correlate components of OM data with clinical outcomes (pain, narcotic use, oral intake)",,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9174,NCT02727309,Progression free survival,Objective response rates,,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9175,NCT02903498,Progression Free Survival (PFS),Number of Participants with Adverse Events,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9176,NCT04837833,measurement differences between ultrasound tumor volumes,,,2021-04-06,RECRUITING,INTERVENTIONAL,['NA']
9177,NCT02545751,The proportion of patients with tumor responses after the initiation of treatment.,"The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
9178,NCT05497778,"National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0",,,2022-10-21,RECRUITING,INTERVENTIONAL,['PHASE1']
9179,NCT01590719,Progression-free survival (PFS) in patients with Met-positive tumors,Duration of response (DOR),,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9180,NCT00195572,Survival time,"Response rate, duration of response, time to progression, safety, quality of life",,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9181,NCT04034355,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),Patients With Disease Free Survival,,2019-01-07,TERMINATED,INTERVENTIONAL,['PHASE3']
9182,NCT02413476,Five-year disease free survival rate,"Intraoperative situation (The number of lymph node dissection,the number of positive lymph nodes,extra-cavity anastomosis time,intraoperative blood loss,the rate of conversion)",,2015-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9183,NCT03767764,Yliver,AAb AFP,,2018-12-27,COMPLETED,OBSERVATIONAL,['NA']
9184,NCT05963087,Objective response rate (ORR),Overall survival time,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9185,NCT04216251,Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment.,Change in Stool Metabolite Profile,,2020-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9186,NCT00575640,The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.,"Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme.",,2004-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9187,NCT00003926,,,,1998-11,TERMINATED,INTERVENTIONAL,['PHASE1']
9188,NCT04491929,Feasibility and translational analysis,Overall Survival,,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
9189,NCT00851045,Progression free survival based on tumor assessments (CT/MRI),"Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9190,NCT00606619,Days of hospital stay after operation,Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9191,NCT00825110,the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.,Secondary outcome measure is the survival and response to treatment of the identified cases.,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
9192,NCT02155140,Fatigue,Health economic analysis,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
9193,NCT04190589,Lymph node count,Readmissions,Conversion rate,2020-05-18,RECRUITING,INTERVENTIONAL,['NA']
9194,NCT04160962,EORTC Questionnaire QLQ-C30,,,2020-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9195,NCT01640808,Recurrence-free Survival,Time to Recurrence,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9196,NCT03148119,Incidence of QRH-882260 Heptapeptide administration-related adverse events,Efficacy of QRH-882260 Heptapeptide administration for detection of polypoid and non-polypoid colonic neoplasia,Efficacy of QRH-882260 Heptapeptide administration for detection of dysplasia in the setting of IBD,2017-03-31,TERMINATED,INTERVENTIONAL,['PHASE1']
9197,NCT00467116,Maximum Tolerated Dose,Tumor response rate,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9198,NCT01375972,Progression-free survival rate at 6 months,overall survival,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9199,NCT00855348,Clinical/surgical diagnosis of invasive colorectal adenocarcinoma detected by optical colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification.,"Detection of adenomatous polyp(s) equal to or greater than 10 mm, flat lesion (s) or non-invasive adenocarcinoma by colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification will also be described.",,2008-06,COMPLETED,OBSERVATIONAL,['NA']
9200,NCT06328868,Concentration of Serum prealbumin,Feeding amount,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9201,NCT02912559,Disease free survival (DFS),Incidence of adverse events,,2017-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9202,NCT03621644,Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5,Patient-reported quality of life (QOL),,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9203,NCT05288205,Number of participants with dose limiting toxicities,Progression-free survival (PFS),,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9204,NCT00793455,Colorectal Cancer Screening Completion.,Colorectal Cancer Screening Completion,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
9205,NCT02803515,Changes in serum levels of HSP90 and 70 on peripheral venous samples.,,,2017-01-16,TERMINATED,INTERVENTIONAL,['NA']
9206,NCT00335010,differences in microvascular hemoglobinsaturation,differences in anastomotic stenosis,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
9207,NCT03193710,Cancer free survival,Colorectal cancer antibodies,Days of hospitalization,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9208,NCT02048540,R0 resection rate,safety of peroperative treatment and surgery,circulating tumor cell number change,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9209,NCT01582750,Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values,,,2010-10,UNKNOWN,OBSERVATIONAL,['NA']
9210,NCT02510911,Time to first bowel movement,Consumption of sleep inducing drugs,preoperative caffeine consumption,2015-08,TERMINATED,INTERVENTIONAL,['NA']
9211,NCT05287672,Weight gain by BMI by kg/m2,,,2022-06,UNKNOWN,OBSERVATIONAL,['NA']
9212,NCT03479814,complete pathological response (pCR),Evaluation of PET-response as predictive factor,,2016-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9213,NCT05064618,Phase II study; response rate (based on RECIST ver1.1),Response rate （Phase I）,,2021-08-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9214,NCT00318604,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
9215,NCT03917017,Postoperative survival,Disease-free survival,Intraoperative blood loss,2019-01-01,RECRUITING,INTERVENTIONAL,['NA']
9216,NCT01301495,Palliation assessment based on Dysphagia Scores,Assessment of Complications and MD Anderson Dysphagia Score,,2010-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9217,NCT03486678,Incidence of Treatment-Emergent Adverse Events,OS,,2018-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9218,NCT05237921,Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI),Number of participants that meet estimated dietary intake and exercise goals,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
9219,NCT06031480,"Objective response rate (ORR, RECIST v1.1)",,,2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9220,NCT05898854,Patient management,Prognostic value,,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
9221,NCT05520866,Proportion of days before surgery engaged in prehabilitation,Change in Mean score on the SF-36,Median Satisfaction Scores,2023-03-14,RECRUITING,INTERVENTIONAL,['NA']
9222,NCT05056714,Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI),,,2022-01-27,RECRUITING,OBSERVATIONAL,['NA']
9223,NCT04842565,Progression-free survival time (mPFS) (mRECIST),Time to Progression (TTP),,2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
9224,NCT05982301,"Progression-Free survival 2, PFS2",After Effects,,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2']
9225,NCT04506138,Major Pathologic Response (MPR),Event Free Survival（EFS）,FACT-E questionnaire,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9226,NCT03257332,Global health status/quality of life: EORTC QLQ-C30,Low anterior resection syndrome,Physical performance,2019-11-12,WITHDRAWN,OBSERVATIONAL,['NA']
9227,NCT00525005,overall response rate,"safety, progression-free survival, and overall survival",,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9228,NCT00969046,To identifymaximum tolerated dose (MTD),"To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration",,2003-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9229,NCT01286818,Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events,Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)],,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9230,NCT02460991,Overall Survival,Frequency of Treatment Emergent Adverse Events,FACT-Hep Quality of Life,2015-11,TERMINATED,INTERVENTIONAL,['PHASE3']
9231,NCT00288119,Assay of DNA and RNA markers,Score of tolerability and acceptability,,2005-10-01,RECRUITING,OBSERVATIONAL,['NA']
9232,NCT04744688,The difference between changes in concentration of prothrombin fragment 1+2.,Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC,,2021-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9233,NCT01837446,Mucositis severity,Patient's satisfaction,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9234,NCT00920192,Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs,PK profile of foretinib,,2009-08-12,COMPLETED,INTERVENTIONAL,['PHASE1']
9235,NCT00381173,"Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.","Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9236,NCT01273805,2-month Progression-Free Survival Rate,Grade 4-5 Treatment-Related Toxicity,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9237,NCT02649491,Change in Olfactory Signatures in patient sample,"Changes in the scores of Inflammatory Bowel Questionnaire,",,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
9238,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,the total amount of insulin required for glycemic control after pancreatic resection,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
9239,NCT04409223,Progression-free survival (PFS),Adverse Events and Serious Adverse Events,,2020-09-12,TERMINATED,INTERVENTIONAL,['PHASE3']
9240,NCT04524676,1-year rebleeding rate,Complications of portal hypertension,,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
9241,NCT01506115,Complications associated with the procedure,Survival time,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
9242,NCT03559543,Nutritional status,,,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2']
9243,NCT05731726,Pathological complete response rates,single cell sequence,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
9244,NCT05353582,Progression free survival,Hospitalization time,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9245,NCT05557656,Overall survival (OS),Adverse events (AEs),,2023-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9246,NCT02272699,Disease-free survival,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9247,NCT02585362,Change in physical performance,Overall survival,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
9248,NCT01395537,PHASE II: To Assess the Response Rate to This Regimen.,To Determine the Overall Survival,,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9249,NCT03383159,Differences In Microbiota,Predictive model validation,,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA']
9250,NCT00860691,"Fe, transferrin, ferritin","loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery",,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
9251,NCT01282333,Maximum-tolerated dose of veliparib in combination with cisplatin and gemcitabine,Recommended phase II dose,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9252,NCT05249114,Establish the maximal tolerated dose of cabozantinib in combination with Lu-177 dotatae at a standard dose of 7.4 GBg in four 8-week cycles followed by continuation of cabozantinib.,Establish objective response rate as measured by RECIST 1.1,,2022-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9253,NCT02841046,Number of Days Needed for Anal Exsufflation After Surgery,Number of Days in Hospital,Complication After Surgery,2016-07-27,COMPLETED,INTERVENTIONAL,['NA']
9254,NCT02555358,The pathological complete response rate,Adverse events,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9255,NCT00027521,,,,2000-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
9256,NCT03061370,Survival,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
9257,NCT03747588,Intra-abdominal infection,Length of hospital stay (day),progression-free survival,2018-12-01,RECRUITING,INTERVENTIONAL,['NA']
9258,NCT03891654,DCE-CT Perfusion Metrics: Blood Flow,Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease,,2019-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9259,NCT00133913,,,,2004-03,UNKNOWN,OBSERVATIONAL,['NA']
9260,NCT05357196,To obtain best disease control rate (DCR) data(Phase II),Area under the plasma concentration versus time curve (AUC),,2020-04-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9261,NCT03576872,80% or higher rate of completing at least 3 of 4 nurse-led encounters with participants,80% or higher on the index of rates for follow-up phone calls and binder review prior to cycle 2 of chemotherapy,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
9262,NCT05404347,Overall Survival,RFS,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
9263,NCT05184803,Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.,,,2022-03-23,RECRUITING,INTERVENTIONAL,['PHASE2']
9264,NCT04416490,Overall Survival (OS),Quality of Life Assessment (FACT/GOG-NTX-12),Results on blood pressure,2020-03-25,RECRUITING,OBSERVATIONAL,['NA']
9265,NCT03568669,Neurocognitive Outcomes,Neourcognitive Outcomes,,2016-01,RECRUITING,OBSERVATIONAL,['NA']
9266,NCT00131586,,,,2003-04,TERMINATED,OBSERVATIONAL,['NA']
9267,NCT04645251,Map the natural course of PLD,Determine whether rate of liver growth can be used to predict disease progression,,2021-01-21,RECRUITING,OBSERVATIONAL,['NA']
9268,NCT00963092,"Creation of repository of blood, saliva, and tumor samples",,,2002-08,UNKNOWN,OBSERVATIONAL,['NA']
9269,NCT02969122,Overall survival,morbidity and mortality of HIPEC and EIPL,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
9270,NCT05379972,Objective Response Rate (ORR) of unirradiated tumors,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 during concurrent SBRT/olaparib,,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
9271,NCT02026583,Progression free survival,,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9272,NCT01853618,Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution,Overall Survival,,2013-05-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9273,NCT00720668,The Rate of Exacerbation of chronic hepatitis B after RFA,mortality,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
9274,NCT00001276,Treatment Outcomes,,,1991-05-21,RECRUITING,OBSERVATIONAL,['NA']
9275,NCT06301828,ORR,Incidence of Treatment-Emergent Adverse Events,,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE2']
9276,NCT05664139,Objective tumor response rate (ORR),Adverse event collection,"Changes of CD4+ cells count, CD8+ cells count, Th1 cells count, Th2 cells count, Treg cells count in peripheral blood",2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9277,NCT03382886,Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D),Overall Survival,,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE1']
9278,NCT04739722,Colosense specificity for subjects with negative findings,,,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9279,NCT00137449,Number of Participants With Clinical Benefit Response (CBR) According to RECIST,Score of EQ-5D (Euro Quality of Life-5 Dimension) Weighted Health Index,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9280,NCT00419978,,,,2004-06,TERMINATED,INTERVENTIONAL,['NA']
9281,NCT05839951,Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS),Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment,,2023-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9282,NCT06241066,DFS,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
9283,NCT00609505,Patient satisfaction,Cost-effectiveness,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
9284,NCT01856322,Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.,,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
9285,NCT02274376,Safety and tolerability: incidence and nature of adverse drug reactions,Incidence and nature of dose interruptions,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
9286,NCT04700410,Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.,Number of adverse events after study intervention,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
9287,NCT04810663,Efficacy of Radiotherapy in operated gastric cancer,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9288,NCT00831181,Pathologic Response and Complete Response,Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9289,NCT01434485,Number of Adverse Drug Reactions,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
9290,NCT06262581,pathological complete regression rate,Disease free survival,,2023-09-23,RECRUITING,INTERVENTIONAL,['PHASE2']
9291,NCT03930888,Progression of the self sufficiency,Effect of tumor localization,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
9292,NCT05051423,"Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.",,,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA']
9293,NCT01066741,Rate of occurrence of grade ≥ 3 (RTOG classification) mucositis during irradiation (only the first occurrence will be reported),Evaluation of the cost of severe mucositis treatment,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3']
9294,NCT02967094,"""Visibility score"" evaluated by blinded performing endoscopist",Duration of endoscopy,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
9295,NCT04641637,The completeness of coverage of the tumor vasculature by therapeutic agent at the completion of the treatment as evaluated on non-contrast CT scan,Tumor response,,2022-06-30,COMPLETED,INTERVENTIONAL,['NA']
9296,NCT02375672,Median Progression Free Survival (mPFS),Number of Patients With Grade 3 or Higher Treatment Related Adverse Event,,2015-05-28,COMPLETED,INTERVENTIONAL,['PHASE2']
9297,NCT02646241,diagnostic accuracy,accuracy of malignant potential on contrast enhanced EUS,,2016-01-02,COMPLETED,INTERVENTIONAL,['NA']
9298,NCT00003834,response rate,overall survival,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9299,NCT05208372,Expression of ctDNA,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
9300,NCT04224896,SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES,,,2011-03-01,COMPLETED,OBSERVATIONAL,['NA']
9301,NCT06187610,Symptom self-management knowledge,Patients engagement while learning,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
9302,NCT05981235,"Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG.",PFS,,2023-12-14,RECRUITING,INTERVENTIONAL,['PHASE1']
9303,NCT01304602,Maximum tolerated dose,Biological half life of BKM120,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9304,NCT01927328,Hemoglobin differences between groups,Differences in hematinic markers.,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
9305,NCT06172647,Proportion and abundance of bacterial taxa (defined as total percentage of bacterial DNA sequences),,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
9306,NCT00355004,Rate of colorectal cancer screening,Number and dates of sigmoidoscopies and colonoscopies scheduled and performed,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
9307,NCT00598156,progression-free survival,overall survival,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9308,NCT02572050,Number of retrieved lymph nodes in the topographical N2 area,Quality of life,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
9309,NCT02745561,response rate,Overall survival,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
9310,NCT00717990,Objective Response Rate,Overall Survival,,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2']
9311,NCT02488577,Overall percent of postoperative complications.,Recurrence.,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
9312,NCT01582841,Implementation effectiveness,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9313,NCT05007015,EORTC-QLQ-C30,Bowel diaries,,2022-01-15,RECRUITING,INTERVENTIONAL,['NA']
9314,NCT03836131,The percentage of cancer in patients with GM-LSTs treated with endoscopic resection.,,,2018-12-31,COMPLETED,OBSERVATIONAL,['NA']
9315,NCT02650427,Safety (Number of adverse events. Toxicity grade > 3),Infiltration of leucocytes in tumor tissue,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9316,NCT02967289,Disease Free Survival (DFS),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2017-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9317,NCT01218854,The difference between MD-NASS and standard method,,,2012-03-20,COMPLETED,INTERVENTIONAL,['PHASE1']
9318,NCT01315548,Contrast enhanced harmonic endoscopic ultrasound,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
9319,NCT03780439,diagnostic accuracy of procalcitonin to detect post-operative infection,diagnostic accuracy of procalcitonin to detect overall post-operative complications,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
9320,NCT03620461,Assess adverse events (per CTCAE v4.0 criteria),,,2013-12-01,COMPLETED,OBSERVATIONAL,['NA']
9321,NCT00747136,"Determine sensitivity/specificity to identify dysplasia/cancer in the esophagus WavSTAT System alone, endoscopist alone/combination of WavSTAT and endoscopist. Sensitivity of the endoscopist will be compared to combination of endoscopist and WavSTAT.",,,2008-08,TERMINATED,OBSERVATIONAL,['NA']
9322,NCT01475331,Number of Participants With the Changing in Cyst Volume,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9323,NCT02325999,DFS,,,2013-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9324,NCT02465736,Toxicities of neo-adjuvant chemoradiotherapy,Health Related Quality of Life,,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9325,NCT04198337,Complete resection of GIST,technical success in complete resection,,2014-08-01,RECRUITING,INTERVENTIONAL,['NA']
9326,NCT00002828,,,,1995-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9327,NCT06275165,Change from Baseline in gastrointestinal symptom distress Scale at study day 5(end day),,,2024-03-27,RECRUITING,INTERVENTIONAL,['NA']
9328,NCT04515082,"Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.","To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm.",,2020-08,UNKNOWN,OBSERVATIONAL,['NA']
9329,NCT01306799,Volumetric bone mineral density as measured by pQCT,measure vitamin B12 levels at each study visit,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
9330,NCT02347735,Anastomotic leakage,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
9331,NCT05894694,PFS,1-year PFS rate,,2023-06-11,RECRUITING,INTERVENTIONAL,['PHASE4']
9332,NCT04865601,Correlation of DNA adduct and DNA repair products,Correlation of DNA adducts with CRC causes,,2021-02-15,RECRUITING,OBSERVATIONAL,['NA']
9333,NCT00193882,Relief of dysphagia,Time to achieving a complete response i.e. dysphagia score of 0.,,2003-07-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9334,NCT05861336,Resectability rate,Quality of life questionnaire (QLQ),,2023-06-14,RECRUITING,INTERVENTIONAL,['PHASE2']
9335,NCT04203459,Animal model experiment: to verify the ability of intestinal bacteria to control anti msln car-t targeted killing pancreatic cancer cells.,,,2019-10-20,UNKNOWN,OBSERVATIONAL,['NA']
9336,NCT01921673,Progression-free survival,Biomarker,,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9337,NCT01596582,Concordance Between Patient Preference and Test Ordered,Provider Satisfaction,Concordance Between Patient Preferences for a Screening Tests Other Than Colonoscopy and Test Ordered for High Versus Low Risk Patients,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9338,NCT00841282,Increments of medications used for sedation,willingness to repeat colonoscopy,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
9339,NCT05857631,3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity,C-MOSES scoring,,2023-05-29,RECRUITING,INTERVENTIONAL,['NA']
9340,NCT03817489,"Change of Week 1 Practice Compliance at Week 2 to 7 of intervention, and 6-month post-intervention",,,2017-01-04,UNKNOWN,INTERVENTIONAL,['NA']
9341,NCT03053999,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review,,2012-10-09,UNKNOWN,OBSERVATIONAL,['NA']
9342,NCT00259922,To compare alvimopan with placebo for efficacy in the treatment of OBD,"Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9343,NCT03330028,Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC),,,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
9344,NCT00001165,,,,1978-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9345,NCT00835133,Collection of familial data and biospecimens in a data and tissue repository for familial pancreas research,,,2002-08,RECRUITING,OBSERVATIONAL,['NA']
9346,NCT05053971,Objective response rate (ORR) (Phase II),Progression free survival,Non-sequencing biomarker analysis,2022-11-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9347,NCT02021604,Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism,Ratio of Standard Uptake Value max to sub max,,2013-10-09,RECRUITING,INTERVENTIONAL,['PHASE1']
9348,NCT02300727,Number of Participants With Serious and Non-Serious Adverse Events,Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS),,2015-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9349,NCT00282100,To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.,To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.,,2005-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9350,NCT00812942,Participation to colorectal cancer screening,,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
9351,NCT00019591,Response rate every 3 months for up to a year after completion of study treatment,,,1999-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9352,NCT00064207,"Overall survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter in phase III",Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) v3.0 and EORTC QLQ PAN-26 every 3 months in years 1-2 and every 6 months thereafter,,2003-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9353,NCT03984578,Immune T-cell infiltration before and after treatment,Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours),,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
9354,NCT00149396,Clinical Laboratory Safety - Coagulation,Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha),,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9355,NCT02662478,Success rate,Accuracy of classification system,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
9356,NCT04241523,Resection rate,Exploratory serum biomarker research,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
9357,NCT03516708,Phase II Treatment Cohort only: Neoadjuvant Rectal (NAR) Score,Phase I and Phase II Treatment Cohort only: Complete clinical response rate (cCR),,2019-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9358,NCT02292758,6-month and 12-month Progression-free Survival (PFS) Rates,Relative Dose Intensity (RDI),Dynamic Change in Mutation Concentration While the Patient is Receiving Cetuximab Treatment,2014-12-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9359,NCT05229900,Number of participants with DLTs by dose level,Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only),,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE1']
9360,NCT00101036,Response Rate,Disease Control Rate.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9361,NCT00785785,Time to Progression Free Survival (PFS),,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9362,NCT00324428,"Pain (visual analog scale, CGI,PGA); Medication use (medication diary)",Safety (cognitive assessment - neuropsychological battery),,2006-05,COMPLETED,INTERVENTIONAL,['NA']
9363,NCT06289712,Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up,Develop software solutions potentially usable in real-time and tailored for clinical use.,,2023-11-23,RECRUITING,OBSERVATIONAL,['NA']
9364,NCT06096896,5-years overall survival (OS) after MWA for early HCC,Rate of completed ablation after MWA,,2023-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9365,NCT02500004,Brown adipose tissue (BAT) activity measured by PET(-MRI),"Lean tissue mass measured by MRI, DXA, and doubly labeled water",,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9366,NCT01643460,Cyst resolution,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
9367,NCT06205732,Progression-Free-Survival,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
9368,NCT02135419,Anal Cancer Incidence,Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization,Quality of Life Assessment Measured by the A-HRSI (Validated Tool),2014-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9369,NCT05954078,ctDNA clearance rate,Treatment Completion Rate,,2023-07,RECRUITING,INTERVENTIONAL,['PHASE3']
9370,NCT05355155,"Objective Response Rate (ORR) ,Based on RECIST 1.1",Safety as measured by number and grade of adverse events,,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9371,NCT04389957,Provider Screening Adenoma detection rate (Sceening colonoscopies only),Bowel Preparation Quality (provider level),,2020-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9372,NCT02595086,"Incidence of Dumping syndrome, assessed by Sigstad score (≥7)",Gross and microscopic changes measured by gastroscopy (composite),,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
9373,NCT05657145,Visualization of papilla,,,2023-01-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9374,NCT05910970,Recurrene-free survival,Adverse events,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
9375,NCT05421689,Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI),Patient-reported dysphagia symptoms based on Eating Assessment Tool EAT10 score,Patient-reported Quality of Life based on FACT-HN score,2022-05-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9376,NCT00710710,Best Objective Response Evaluated According to the RECIST Criteria by Independent Review,Number of Participants With Incidence and Intensity of Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE),,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9377,NCT04684095,Changes of quality of life (QoL) at 1 year after randomization compared with baseline,Patient satisfaction,Economic assessment for ePRO compared to regular follow-up,2021-05-26,RECRUITING,INTERVENTIONAL,['NA']
9378,NCT06131840,Number of participants with DLTs by dose level,Overall survival (OS),,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE1']
9379,NCT01389986,Time to first flatus,Patients' satisfaction,,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9380,NCT03854799,The primary objective of this trial is to evaluate the rate of complete pathologic response (pCR),Sphincter preservation rate,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9381,NCT02406508,Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib,,Quality of life questionnaires,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9382,NCT00614601,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,We will use overall survival and adverse events rates as secondary endpoints.,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
9383,NCT05233540,Overall survival according to circulating tumour DNA status,Overall survival according to circulating tumour DNA and immune markers.,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
9384,NCT03007407,Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1,"Frequency of Adverse Events Assessed by CTCAE 4.0, From Beginning of Treatment to 90 Days After Last Dose",,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
9385,NCT04823416,Risk Factors for Mortality in cases of obstructed left colonic Carcinoma,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
9386,NCT00756951,Efficacy of Oral Mucositis assessment will be completed by trained site personnel. The WHO score will be the primary measure and NCI CTCAE will be a secondary measure for assessing Oral Mucositis.,,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9387,NCT04457193,Percentage of participants with normal esophageal acid exposure time,Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI),,2018-06-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9388,NCT00605800,To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).,To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.,,2006-03,WITHDRAWN,OBSERVATIONAL,['NA']
9389,NCT00021268,,,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
9390,NCT06134388,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).,"Evaluating the safety and tolerability of sulfasalazine through investigating Renal function test (serum creatinine (mg/dL), blood urea nitrogen (mg/dL) and creatinine clearance (mL/min)).",,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
9391,NCT01550510,Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.,Number of Participants That Are Alive After 11 Weeks.,,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9392,NCT01149434,Tumor Response in the Ovarian Cancer Cohort,Tumor Response,,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9393,NCT03774589,Bilioenteric anastomotic leakage,Bilioenteric anastomotic stricture,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
9394,NCT00182130,Hospital rate of local recurrence,Quality of life,,2002-05,UNKNOWN,INTERVENTIONAL,['NA']
9395,NCT00779311,Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab,Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1']
9396,NCT03188991,Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability),Cyst Volume Response,,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE2']
9397,NCT05061017,Objective Response Rate (ORR) - (Cohorts 2 & 3),2-year Overall Survival (OS),,2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9398,NCT05254847,1 year DFS rate,AE,,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2']
9399,NCT00508872,Complete Gross Resection Rate,,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9400,NCT04896931,Establishment of BTC population,establishment of sample collection (tumorblocks and blood),,2022-07-12,RECRUITING,OBSERVATIONAL,['NA']
9401,NCT03350490,Relief degree of tumors,Overall survival（OS）,,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9402,NCT00003368,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9403,NCT05424159,2-year cumulative local regional progression rate (LRP),Late toxicity,,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
9404,NCT01758679,Progression-free survival,,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9405,NCT00033306,"Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.","Determine the response duration, time to progression, and survival in patients treated with this drug.",,2002-02,TERMINATED,INTERVENTIONAL,['PHASE2']
9406,NCT05057845,Objective Response Rate (ORR),Adverse Events,,2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
9407,NCT05242757,The size (tumor diameter) and number (tumor recurrence lesions) of PHC tumors were examined by enhanced abdominal CT,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9408,NCT02571946,one-year overall survival,Hepatobiliary phase signal change after proton beam therapy,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9409,NCT04147494,To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies,evaluate the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution,Additional correlation of biodistribution of standard of care tracer,2019-11-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9410,NCT00646139,Maximum tolerated dose,Biological effects,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9411,NCT03705754,Number of tumors visualised from peritoneal cavity/number of tattoos visualised form peritoneal cavity,,,2019-02-06,RECRUITING,INTERVENTIONAL,['NA']
9412,NCT05363722,Objective response rate (ORR),Immune Best Overall Response（iBOR）according to iRECIST criteria,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
9413,NCT06022978,Diagnostic accuracy for T1a and T1b staging,,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
9414,NCT03853473,6 Minute Walk Test Distance (Pre Surgery),Intraoperative Blood Pressure Variability,Length of Hospital Stay,2019-02-22,COMPLETED,INTERVENTIONAL,['NA']
9415,NCT03123432,immunomodulating effects,length of hospital stay after surgery,,2011-06-01,COMPLETED,INTERVENTIONAL,['NA']
9416,NCT00900419,Genetic mutations or altered growth factor expression,Establishment of a tissue repository of normal and dysplastic respiratory epithelium,,2001-05-03,RECRUITING,OBSERVATIONAL,['NA']
9417,NCT04825470,Graft Survival,Disease free survival,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9418,NCT03636607,Calculating the overall diagnostic sensitivity and specificity and ROC,Calculating the overall diagnostic sensitivity and specificity and summarizing the intrinsic correlations,,2018-06-13,RECRUITING,INTERVENTIONAL,['NA']
9419,NCT04312360,Change in bacterial composition (Exploratory primary outcome 2),Assessment of any adverse events or side effects regarding the spraying of the right hemicolon with fosfomycin/metronidazole gel in track 2.,,2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2']
9420,NCT03167125,Increased colorectal cancer screening rates,,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
9421,NCT02252926,Reduction of oral and pharyngeal pain measured on Visual Analogue Scale (VAS),Safety: Peak plasma concentrations of bupivacaine,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9422,NCT04400136,Percentage of post-operative GERD based on the trial protocol. Clinical evaluation,evaluate in each group of the study (arm type) the endoscopic finding of peptic lesions of the esophagus-gastro-duodenal mucosa at 24 months of follow-up,,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9423,NCT03065257,Number of participants with reduction in clinical symptoms,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Number of participants with successful completion of treatment,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA']
9424,NCT02961283,Part B: evaluates the preliminary efficacy of ASN003 in subjects with selected BRAF and PI3 kinase mutated cancers,Appearance of new tumor lesions,Change in tumor mutational status,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1']
9425,NCT00001587,,,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9426,NCT02700555,Incidence of newly developed diabetes mellitus,3-year recurrence-free survival & 5-year recurrence-free survival,,2016-02,TERMINATED,OBSERVATIONAL,['NA']
9427,NCT00005981,Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9428,NCT01105806,To document advance directive (AD)completion,To longitudinally follow discussions about ADs and nature of hospitalizations,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
9429,NCT04177316,disease free survival (DFS),Overall survival,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
9430,NCT05040360,Recurrence-free survival (RFS),Incidence of adverse events,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2']
9431,NCT03070262,overall survival (OS),progression-free survival (PFS),,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
9432,NCT04516681,Objective Response Rate,Overall Survival,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
9433,NCT04894643,Perioperative Mortality and Complications,Quality of Life questionnaire: Brief Pain Inventory,,2020-09-14,RECRUITING,INTERVENTIONAL,['NA']
9434,NCT02743065,Progress-free-survival (PFS),Objective Response Rates,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
9435,NCT00006812,,,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE2']
9436,NCT01540435,Failure-free survival (FFS@18),Pathologic response rate,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9437,NCT01020006,Number of Participants With Treatment Emergent Adverse Events (AEs),,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9438,NCT04488549,Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,,,2020-05-20,COMPLETED,OBSERVATIONAL,['NA']
9439,NCT00585312,Time to Disease Progression,Colorectal Polyp Burden,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
9440,NCT00910819,Course of Antineoplastic Treatment,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
9441,NCT03322592,EUS-FNB diagnostic accuracy,Macroscopic on-site evaluation [MOSE],,2018-03-29,COMPLETED,INTERVENTIONAL,['NA']
9442,NCT03367611,Colonic lesion.,,,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
9443,NCT00565682,To measure the amount of rescue medication (opioid) needed to relief,To determine the overall analgesic effect using the visual analog scale (VAS),,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9444,NCT05279677,ORR,Adverse events,,2022-08-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9445,NCT06253611,Objective response rate (ORR) at 4 months,1-year and 2-year PFS,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9446,NCT00327457,Medical record verified flexible sigmoidoscopy or colonoscopy,,,2002-06,COMPLETED,INTERVENTIONAL,['NA']
9447,NCT00978107,Maximal tolerated dose,Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9448,NCT05943041,Incidence of Adverse Events from baseline to 8 weeks,,Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE1']
9449,NCT05346536,CTC-AXL measurement concordance rate,Evaluation of circulating immune system: platelets,,2022-06-16,RECRUITING,INTERVENTIONAL,['NA']
9450,NCT00957424,Number of Participants Willing to Continue With Preferred HRP,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9451,NCT05028725,Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases & controls only),Median Acceptability Scores,,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
9452,NCT03028831,colonic mucosal proliferation,colonic secondary bile acids,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
9453,NCT00262171,,,,2002-05,UNKNOWN,OBSERVATIONAL,['NA']
9454,NCT02723253,Number of patients defined as good responders (G1 or G2) according to the Mandard regression grading system.,The number of patients still alive at the end of follow-up,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9455,NCT01669109,Health-related quality of life,Spiritual well-being,Qualitative Interviews,2012-09,COMPLETED,INTERVENTIONAL,['NA']
9456,NCT05889325,Progression-Free Survival (PFS),Duration of Response (DoR),,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9457,NCT04369053,Specificity of the Freenome test,,,2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9458,NCT03894384,Diagnostic value of trefoil factor family 3 (TFF3) in serum of gastric cancer as non invasive marker,,,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA']
9459,NCT05677490,Overall survival (OS),Patient reported outcomes,Feasibility and compliance of intervention,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE3']
9460,NCT00320320,Response rate after FOLFIRI reintroduction,Overall survival,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2']
9461,NCT02887313,Pathological complete response rate,Disease free survival,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
9462,NCT05846035,the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.,,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA']
9463,NCT04547153,hematological response rate (HeRR),quality of life assessed by EORTC QOL C-30 and STO-22 (QoL),,2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE2']
9464,NCT00002515,,,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9465,NCT02353858,Pathological complete response rate,post operative morbidity,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9466,NCT00265356,proportion of patients who have a change in management resulting from PET,prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9467,NCT00882973,The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine,Safety profiles,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9468,NCT00436072,"To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.","Determine response rate, progression-free survival and overall survival of adding ZD6474 to cetuximab and irinotecan in this patient population.",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9469,NCT01653496,Overall compliance to the ERAS program,Mortality,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9470,NCT05189730,Incidence of adverse events,Overall Survival,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
9471,NCT02137356,Number of patients with adverse events,Number of patients whose tumors demonstrate pathological complete response at resection,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
9472,NCT00611000,"DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells",Differential gene expression in colonic and PBMCs by microarray analysis,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9473,NCT03183219,Overall survival（OS）,,,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9474,NCT04787341,Overall survival,Objective Response Rate,,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
9475,NCT03259009,Progression-free survival (PFS),Overall survival (OS),,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
9476,NCT00487409,this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.,Will evaluate the surgical approach using electrocautery with surgical clips and staples,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
9477,NCT00748215,Number of Participants With Grade 3/4 Diarrhea,,,2009-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9478,NCT04619342,Progression Free Survival（PFS）,Adverse Events,,2020-10-30,UNKNOWN,INTERVENTIONAL,['NA']
9479,NCT02077868,Overall survival,Quality of life (QoL),,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
9480,NCT01292369,System performance,,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
9481,NCT00608595,Change of gene and protein expression pattern from pre- to post-treatment levels,,,2002-07,TERMINATED,INTERVENTIONAL,['NA']
9482,NCT02997241,patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis,Overall survival at 5 years,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
9483,NCT01744353,"Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.","Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer.",,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9484,NCT02127541,Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.,Comparison of the angiogenesis markers with the those of breast carcinoma patients,,2014-01-06,COMPLETED,INTERVENTIONAL,['NA']
9485,NCT05387681,pathological complete response (pCR),pathological partial response(MPR),,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9486,NCT06109805,Plasma metabolite content,,,2023-10-20,RECRUITING,OBSERVATIONAL,['NA']
9487,NCT02506803,Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
9488,NCT04985981,Occurrence of Anastomotic leak,Time to diagnosis of anastomotic leak,Additive curative surgery (no/yes: liver; lung; locoragional relapse),2021-04-01,SUSPENDED,OBSERVATIONAL,['NA']
9489,NCT01740947,anastomotic leakage and/or abscess,Disease free survival,In hospital and out-of-hospital costs,2013-01,TERMINATED,INTERVENTIONAL,['PHASE4']
9490,NCT05630794,Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201,Proportion and severity of treatment emergent adverse events,Adenoma-derived organoid take rates between samples obtained prior to and following treatment,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
9491,NCT04357171,The rate of readmissions due to severe dehydratation,The rate of early postoperative complications after stoma closure operation,,2012-01-14,COMPLETED,INTERVENTIONAL,['NA']
9492,NCT00628368,Role of predictive factors in the EGFR signaling pathway in response to treatment,Establishment of a tissue bank,,2005-11,UNKNOWN,INTERVENTIONAL,['NA']
9493,NCT06202183,Gut Microbiome Genomes,Change in Chemotherapy Toxicity,,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9494,NCT05095519,True Negative Rate per lesion.,GLUT-1 expression,,2021-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
9495,NCT02511821,Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively,"Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool",,2015-07-22,COMPLETED,INTERVENTIONAL,['NA']
9496,NCT06121622,Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours,,,2024-01-16,RECRUITING,OBSERVATIONAL,['NA']
9497,NCT01523353,Anaerobic threshold prior to liver resection,Recovery of fitness,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9498,NCT00187109,To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.,,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9499,NCT04345770,overall survival,complication rate,,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9500,NCT04620473,Objective Response Rate（ORR）,Postoperative complications,,2023-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9501,NCT05149807,Phase III : Event-free Survival (EFS),30-day postoperative mortality.,,2022-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9502,NCT00147147,Overall survival,the site of recurrence,,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9503,NCT02056691,Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells,Irisin levels,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9504,NCT04207463,Overall response rate (ORR),Overall survival (OS),,2020-06-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
9505,NCT04163237,Disease-free Survival,Overall Survival,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
9506,NCT06117241,Stool,,,2023-10-17,RECRUITING,INTERVENTIONAL,['NA']
9507,NCT01697462,Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs),Number of Participants With Hand-Foot Syndrome (HFS),,2009-07,COMPLETED,OBSERVATIONAL,['NA']
9508,NCT00003571,disease free survival,determine the prognostic and predictive values for response to this therapy,,1998-08,COMPLETED,OBSERVATIONAL,['NA']
9509,NCT01187641,"The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.","We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images",,2010-08-18,COMPLETED,OBSERVATIONAL,['NA']
9510,NCT04683939,Occurrence of dose-limiting toxicities (DLTs) within a patient during the DLT evaluation period,BNT141 - Duration of response (DOR),,2022-01-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9511,NCT06144827,Feasibility of Quantitative Multiparametric MRI,Change in Total Liver Volume and Volume of non-irradiated and irradiated lobes,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9512,NCT03904043,Clinical complete response rate,Organ preservation rate,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
9513,NCT05720559,Overall Survival (OS),,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9514,NCT02572687,Number of Participants with Dose Limiting Toxicities (DLTs),Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies,,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1']
9515,NCT00394992,"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.","Overall survival, defined as the percentage of patients alive 5 year after randomisation.",,2006-12,TERMINATED,INTERVENTIONAL,['PHASE3']
9516,NCT05021172,Responses to Qualitative Acceptability survey,,Proportion of patients screened for colorectal cancer,2021-08-24,COMPLETED,INTERVENTIONAL,['NA']
9517,NCT00797732,Treatment Compliance Rate,MDADI Scores,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
9518,NCT05571644,Pathological complete response (pCR) rates,Local recurrence rate,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2']
9519,NCT02601079,Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue.,Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment.,,2016-09,TERMINATED,INTERVENTIONAL,['NA']
9520,NCT04807972,Phase 2: Overall Survival,Phase 2: Percentage of Participants Experiencing Adverse Events,,2021-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9521,NCT05837065,the Harrell concordance index (C-index),the time-dependent area under the receiver operating characteristic curve(tdAUROC),,2022-09-15,RECRUITING,OBSERVATIONAL,['NA']
9522,NCT01959061,Progression-free survivial,,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9523,NCT01807390,Change in pain perceptions,Change in general health related quality of life,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
9524,NCT05477836,Length of colon explored,Perception of difficulty,,2022-10-18,COMPLETED,INTERVENTIONAL,['NA']
9525,NCT02710812,Rate of organ preservation,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
9526,NCT02451956,Object response rate (ORR),Number of subjects with Adverse Events as a Measure of safety and tolerability,,2015-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9527,NCT01269567,Pelvic sepsis,Rate of closure of stoma,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9528,NCT01932385,progression free survival and overall survival,response rate,,2013-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9529,NCT05347745,therascreen® KRAS RGQ PCR Kit,,,2022-01-07,UNKNOWN,INTERVENTIONAL,['NA']
9530,NCT00184782,Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection,,,2003-09,UNKNOWN,INTERVENTIONAL,['NA']
9531,NCT01525056,"efficacy of PET, CT-perfusion and MRI to stage patients with rectal cancer",,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9532,NCT05163483,Objective Response Rate（ORR）,Overall survival(OS),,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9533,NCT05609695,Overall Survival,Progress Free Survival,,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9534,NCT04093648,Dose Limiting Toxicity (DLT) Rate,Response Rate according,,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
9535,NCT06287671,Correlation between biomarker in plasma and tissue,,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9536,NCT00154700,Response rate,Toxicity,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9537,NCT05027425,Cellular rejection rates,Recurrence-free survival and overall survival outcomes based on survival follow up reporting,,2021-12-07,RECRUITING,INTERVENTIONAL,['PHASE2']
9538,NCT05923255,3-year disease free survival,5-year overall survival rate (OS),,2023-05-14,RECRUITING,INTERVENTIONAL,['NA']
9539,NCT03453164,Disease control rate,Peak antigen-specific cytotoxic T lymphocyte population,,2018-03-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9540,NCT04166604,Rate of patients free of trifluridine/tipiracil dose reduction or postponement of cycles of > 7 days at 6 months or at progression or death or stop of treatment for another cause than neutropenia if observed in 6 months.,Clinical or biological factors at baseline associated with the occurrence of grade 3-4 neutropenia,,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9541,NCT00837239,Progression Free Survival at 4 Months,Median Overall Survival,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9542,NCT05444088,Objective Response Rate,Progression-Free-Survival assessed by investigator,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9543,NCT00357942,Use of supplemental analgesics,Oral intake of food,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9544,NCT00137761,To determine the response rate of Iressa and docetaxel in patients with advanced pancreatic cancer following failure of gemcitabine-based therapy,"To determine the safety, radiologic response rate, progression-free survival and overall survival of patients treated with Iressa and docetaxel",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9545,NCT03507140,"Comparison of the relative abundance of pathobionts and symbionts before and 6 months after liver transplantation, in the bile of recipients.","Biobanking of blood, saliva, bile, feces and urine for further analyses such as metabolomic studies on blood, urine and feces metagenomic studies on saliva, and immunomonitoring on blood.",,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA']
9546,NCT04508764,Number of primary barriers to genetic testing for family members,,,2021-04-09,RECRUITING,INTERVENTIONAL,['NA']
9547,NCT05412082,Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART,Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI),,2022-10-05,RECRUITING,INTERVENTIONAL,['PHASE1']
9548,NCT00003446,,,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9549,NCT00895323,Tissue distribution,,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
9550,NCT03766295,Overall Survival (median),Progression Free Survival,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9551,NCT02824835,percentage of cells in G2/M arrest after dose-dependent exposure,,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
9552,NCT01666756,"Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906,Change in levels of soluble biomarkers,2014-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9553,NCT03022734,complete resection (R0) rate for rectal and liver lesions,Response rate (RECIST V1.1),,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
9554,NCT02552745,Pain scores,Hospital Stay,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
9555,NCT00642603,Progression-free Survival (PFS) in U.S. Patients Only,,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
9556,NCT03638206,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",CAR-T cells testing,,2018-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9557,NCT01271192,5-year disease free survival,"Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience",,2010-12,UNKNOWN,INTERVENTIONAL,['NA']
9558,NCT02094105,incidence and mortality of ESCC,"Cumulative incidence and mortality of total cancer, and gastric cardia cancer",,1999-11,COMPLETED,INTERVENTIONAL,['NA']
9559,NCT00031837,Quality of life as measured by FACT-Hep version 4 every 4 weeks,Safety as measured by the occurrence of bleeding complications,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE3']
9560,NCT03300544,Incidence of dose limiting toxicities of TVEC,Overall survival,,2017-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9561,NCT00526786,The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.,1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.,,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4']
9562,NCT03421288,Comparison of Event free survival (EFS) between arms,Overall survival (OS) and EFS in the subgroup of patients with PD-L1 CPS score ≥ 5 and ≥ 10 and patients with MSI,ctDNA clearance on treatment,2018-09-14,RECRUITING,INTERVENTIONAL,['PHASE2']
9563,NCT02855788,response rate,overall survival,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
9564,NCT03803267,Postoperative pain score,Serum C-reactive protein (CRP),,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
9565,NCT03622229,"EUS-FNB procurement yield of tissue ""core"" using two different FNB needles.",Macroscopic on-site evaluation (MOSE),,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
9566,NCT06231680,RCCEP response rate at 3 weeks,Thalidomide treatment-related adverse events,,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2']
9567,NCT03760003,Modified Mayo Score,Number of clinically-significant laboratory abnormalities,,2019-09-23,COMPLETED,INTERVENTIONAL,['PHASE2']
9568,NCT02106858,Percentage of patients with adverse drug reactions (ADRs),Overall survival (OS),,2014-06-25,COMPLETED,OBSERVATIONAL,['NA']
9569,NCT05546892,Anastomotic leak rate,Bowel preparation compliance,,2023-02-10,RECRUITING,INTERVENTIONAL,['NA']
9570,NCT03536793,"Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.",,,2018-10-24,RECRUITING,OBSERVATIONAL,['NA']
9571,NCT01247506,,,,2010-02,UNKNOWN,OBSERVATIONAL,['NA']
9572,NCT05872295,Objective Response Rate (Part 2),Evaluation of the immunogenicity of IKS014 (Part 1 and 2),,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE1']
9573,NCT04727307,Recurrence-free survival,,,2021-01-26,RECRUITING,INTERVENTIONAL,['PHASE2']
9574,NCT03755921,M. D. Anderson Dysphagia Inventory (MDADI),Deglutition evaluation,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
9575,NCT01875198,Bleeding amount,postoperative complication,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
9576,NCT02579278,To determine if there is a link between EMVI status and ctDNA,To investigate the effect of ctDNA status on patient survival outcomes,,2015-11,RECRUITING,OBSERVATIONAL,['NA']
9577,NCT01116791,Overall survival time (OS) following CRS+HIPC (from surgery to cancer-related death),In-hospital perioperative complications,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
9578,NCT00006245,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9579,NCT04082455,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,progression-free survivals,,2018-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9580,NCT02915393,Detection of helicobacter pylori by Urea Breath Test(UBT),TCM syndrome type diagnosed by two professional TCM doctors,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
9581,NCT06057350,CRC recurrence or sign of lymph nodes or distant metastases,Health related quality of life and functional outcomes after 30 days and one year,Cost-effectiveness,2023-10-27,RECRUITING,INTERVENTIONAL,['NA']
9582,NCT03209765,Compliance rate,Compliance rate of second round,,2017-06-16,COMPLETED,INTERVENTIONAL,['NA']
9583,NCT05101265,Total plasma dose-normalized AUC0-∞,Pharmacogenetics,,2021-03-09,RECRUITING,INTERVENTIONAL,['PHASE1']
9584,NCT04628780,Objective response rate (ORR) in the Expansion cohorts (Part 2),Overall survival (OS) in the Expansion Cohorts (Part 2),,2020-12-16,TERMINATED,INTERVENTIONAL,['PHASE1']
9585,NCT01151007,Frequency of KRAS mutation,The incidence of the colorectal carcinoma,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
9586,NCT05355662,Recurrence of the primary disease after surgery,Post-operative complications in patients who underwent liver transplantation,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
9587,NCT03499795,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL or no Evidence of HPV-16/18 at Week 36,"Percent Change From Baseline in the Size of Peri-Anal Lesions as Determined by the Investigator at Weeks 36, 64, and 88",2018-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
9588,NCT03630393,Postoperative Pain Medication Use,Discharge Day (Post-operative Day 0 or 1),,2019-05-09,TERMINATED,INTERVENTIONAL,['NA']
9589,NCT02547610,The imaging biomarkers determined by MR-PET,,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
9590,NCT00603460,"Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.",,,2012-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9591,NCT04221555,Pathologic complete regression (pCR) rate,Disease free survival (DFS),,2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2']
9592,NCT00443573,"Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)","Tumor response rate, as assessed by RECIST criteria",,2006-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9593,NCT05086250,Feasibility of enrolling subjects which will be measured by the proportion of patients dropping out of study for any reason prior to the end of treatment visit.,"To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores.",,2022-10-20,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9594,NCT00629759,"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver","Secondary objectives include determination of JX-594 pharmacokinetics, replication and shedding, immune response, and injection site tumor responses.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9595,NCT05319054,Adherence of participants to the treatment programme,LARS treatment history,,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9596,NCT06166147,Performance of cfDNA methylation-based model for discriminating pancreatic cancer versus non-cancer,Performance of pre-defined model in clinical sub-groups of interest,,2023-12-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9597,NCT05707338,early postoperative complications,,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9598,NCT02573974,Measurement of muscle mitochondrial bioenergetics,Determining the isotopic composition of nitrogen hair,,2016-01-19,COMPLETED,INTERVENTIONAL,['NA']
9599,NCT02677389,Feasibility as defined by recruitment rate,Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II),,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
9600,NCT05118451,Main evaluation indicators,Secondary evaluation index,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
9601,NCT01409499,Overall survival (OS),cost of treatments,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9602,NCT04904042,Pathological evaluation,Global mortality.,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
9603,NCT02661971,Phase III: Overall Survival (OS): time from randomization to death of any cause,Phase II/III: Subgroup analyses: PFS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric),,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9604,NCT04560270,Correlation of the ctDNA level to the response to chemotherapy,Progression free survival,,2016-04-25,COMPLETED,INTERVENTIONAL,['NA']
9605,NCT02606916,Clinical response rate,grade 3 or 4 toxicities according to CTCAE4.0,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9606,NCT06199466,Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel,,,2024-01-22,RECRUITING,INTERVENTIONAL,['PHASE1']
9607,NCT01622543,Progression Free Survival,Overall Survival,,2012-10-26,COMPLETED,INTERVENTIONAL,['PHASE2']
9608,NCT04420130,6-month PFS rate,Incidence of Treatment-Emergent Adverse Events,,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
9609,NCT01846650,Area Under Curve (AUC),,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
9610,NCT00165061,Overall survival,4.Recurrence of the disease,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9611,NCT06204835,HCC lesions,,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
9612,NCT03875235,Overall Survival (OS) Rate at 24 Months,Disease Control Rate (DCR) - 48 Weeks,,2019-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9613,NCT05990543,Progression free survival,Overall survival,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9614,NCT01248962,Number of Participants With and Without Hypersensitivity Reaction,The Odds Ratio for the Relationship of Baseline Variables to the Carboplatin Hypersensitivity Rate,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9615,NCT02211443,Number of participants with SCT200-related adverse events,Area Under the plasma concentration versus time curve (AUC) of SCT200,Time to Disease Progression (TTP) of SCT200,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9616,NCT02651974,Percentage of individuals who complete FIT screening measured by return FIT kit,"Pre-post analysis of current results reporting strategy (which will utilize a white envelope for normal results, and a red envelope for abnormal results) to prior generic envelope for FIT result reporting for both normal and abnormal results.",,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9617,NCT03586869,Overall Response Rate by RECIST Version 1.1,ORR by RECIST Version 1.1,Quality of Life by patient-reported outcomes (PROs),2018-07-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9618,NCT05319145,Short Physical Performance Battery (SPPB),Days spent at home (number of days),,2022-05-01,UNKNOWN,INTERVENTIONAL,['NA']
9619,NCT06050707,Change in locoregional failure (LRF) at Year 2,Quality of life (QOL),,2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
9620,NCT03072641,Changes in microbiota composition after probiotics use,Epigenetic changes after probiotics use,,2010-06-03,COMPLETED,INTERVENTIONAL,['NA']
9621,NCT00307736,"Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy","Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy.",Pathologic Complete Response,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9622,NCT04975516,Progression free survival,Incidence of adverse events,,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2']
9623,NCT05831488,"Assess the relationship between Seismofit®-estimated VO2 peak and CPET-measured VO2 peak in HPB, gastro-oesophageal or colorectal cancer patients undergoing preoperative assessment for major surgery.",Assess patient experience of the Seismofit® test using a brief measure that has been used previously in CPET research,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
9624,NCT01794793,Incidence of adverse events to evaluate long term safety data,Percentage of patients with clinical benefit as assessed by the investigator,,2013-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9625,NCT05754229,False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system,,,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9626,NCT05978882,Detection rate of Sentinel lymph nodes,5 year recurrence free survival rate,,2023-08-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9627,NCT01890213,Number of participants with adverse events,,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9628,NCT00171912,To assess the efficacy and the safety of imatinib mesylate therapy,To evaluate the effects of imatinib on quality of life and healthcare resource use,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9629,NCT02197351,Detection of Intestinal Metaplasia or Dysplasia,Helicobacter pyrlori detection,,2014-07,RECRUITING,INTERVENTIONAL,['NA']
9630,NCT04906343,Advanced neoplasia and colorectal cancer incidence at 3 years,,,2021-06-05,UNKNOWN,INTERVENTIONAL,['NA']
9631,NCT03473327,Oxidative and immunological gene-expression before and after laparoscopic surgery for colon cancer using whole blood gene expression profiling from blood samples,Assessement of inflammatory tumor invasion using immunohistochemestry on tumor tissue samples,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
9632,NCT02697058,Progression Free Survival (PFS) in Part 2 of Study,"Volume of Distribution at Steady-State (Vss)-Total Irinotecan, SN-38, and SN-38-Glucuronide (SN-38G)",,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9633,NCT02164240,Number of Participants With Serious and Non-Serious Adverse Events,Median Progression Free Survival (mPFS),,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9634,NCT00547612,Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography,,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9635,NCT06316466,OS,PFS,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
9636,NCT03114085,time to progression,,,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
9637,NCT03031171,Colonoscopy completion,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
9638,NCT05427669,3-year Disease-free Survival (DFS),3-year distant metastatic-free survival （DMFS）,,2022-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
9639,NCT05352542,CAR transgene levels in peripheral blood,Incidence of anti-LCAR-H93T antibody,,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE1']
9640,NCT01273090,Toxicities of imetelstat sodium,,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1']
9641,NCT02402842,Progression-free survival rate,HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9642,NCT06022692,disease control rate (DCR),overall survival (OS),,2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9643,NCT00265850,Overall Survival,Duration of Tumor Response,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9644,NCT04011969,Fecal immunochemical test (FIT),,,2019-07,UNKNOWN,OBSERVATIONAL,['NA']
9645,NCT01253161,Progression-free Survival (PFS) at One Year,Adverse Events Possibly Related to Study Treatment,,2011-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9646,NCT01052376,"Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.",,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
9647,NCT03708952,Numbers of participants with polyps,Numbers of participants with cardiometabolic diseases,Numbers of participants died,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9648,NCT00769483,Progression Free Survival,Treatment Toxicity,Correlation Between Plasma IGF-I Expression in Patients Treated With MK-0646 and OS,2008-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9649,NCT02490111,Proportion of patient developing gallstone at 12 month after gastrectomy,Time to gallstone formation,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9650,NCT02868151,World Health Organization criteria of grading oral mucositis.for head and neck cancer patients,,,2016-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9651,NCT05205629,Progression Free Survival,Conversion rate,,2022-01-30,UNKNOWN,OBSERVATIONAL,['NA']
9652,NCT02194387,Change in waist circumference (Pilot II),,,2014-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9653,NCT06043466,To obtain the maximum tolerable dose of C-13-60 cells [Safety and Tolerability],The content of CEA in peripheral blood after infusion of C-13-60 cell [Cell dynamics],Overall survival(OS) of C-13-60 cell treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-08-11,RECRUITING,INTERVENTIONAL,['PHASE1']
9654,NCT02985801,Change in Body Weight,Change in Body Weight Composition,,2016-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9655,NCT00812175,The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions,Reports of adverse events,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
9656,NCT02404909,to investigate the influence of the liver resection on hemodynamic status in terms of hemodynamic indexes changes,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
9657,NCT05802407,Disease-free survival,Overall survival,The prognostic role of targeted therapy selected based on MRD,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
9658,NCT06186609,Progression-free survival,Overall Survival,,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9659,NCT01091428,Phase 2: Progression-Free Survival (PFS),Phase 2: Number of Participants With Clinically Significant Vital Sign Findings,Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes,2010-04-16,COMPLETED,INTERVENTIONAL,['PHASE2']
9660,NCT06013657,Mortality,Length of stay,,2021-12-01,COMPLETED,OBSERVATIONAL,['NA']
9661,NCT04582500,Patient Satisfaction,Assessing Workflow of incomplete colonoscopies,,2021-02-15,RECRUITING,OBSERVATIONAL,['NA']
9662,NCT03289273,"Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)",Duration of regorafenib treatment,,2017-09-13,COMPLETED,OBSERVATIONAL,['NA']
9663,NCT01484925,,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
9664,NCT04852653,Positivity of the liquid biopsy,Genetic profile of the primary tumor predictive of the response to nCRT,,2021-09-21,RECRUITING,OBSERVATIONAL,['NA']
9665,NCT02246322,Clinical performance of 22G and 25G needles,Major complications,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
9666,NCT04823754,Evaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician.,Evaluate the association between individual prognosis expectation (patient and physician) and data from the available literature.,,2021-07-12,COMPLETED,OBSERVATIONAL,['NA']
9667,NCT06124131,Difference in proportion of participants completing colorectal cancer screening between study arms,"Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot",Number of patients who receive intended treatment,2023-11-11,RECRUITING,INTERVENTIONAL,['NA']
9668,NCT00007618,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
9669,NCT03948763,Number of Participants Who Discontinued Study Treatment Due to an AE,Mutant KRAS Specific T cells,T-cell receptor (TCR),2019-06-26,COMPLETED,INTERVENTIONAL,['PHASE1']
9670,NCT03794193,3-year Disease-free Survival,Distant organ metastasis rate,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
9671,NCT05823584,Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.),Sensitivity (TERT C228T vs AFP/AFP-L3/PIVKA-II),,2019-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9672,NCT00482222,Progression-free survival,Safety,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
9673,NCT03398291,Real overall survival,Postoperative mortality,,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
9674,NCT01323400,Progression-free survival,"Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9675,NCT04231929,Tumor response,Best overall response,,2020-05,WITHDRAWN,INTERVENTIONAL,['NA']
9676,NCT00383266,Overall Response Rate (ORR),Overall Survival (OS),,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9677,NCT00628147,Neoplasm Miss Rate,Procedure Complications,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9678,NCT00655499,Objective Response Rate (ORR) During the Combination Therapy Phase,Overall Survival (OS),,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9679,NCT05861947,Pharmacokinetics: Terminal elimination half life,Laboratory abnormalities,Exploratory endpoint (PD biomarker): IFN-γ level,2023-08-26,RECRUITING,INTERVENTIONAL,['PHASE1']
9680,NCT05127096,Specificity of the FirstSight test,,,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA']
9681,NCT05419362,"To assess the anti-tumor activity of GEN-001, when administered as combined with avelumab",Overall Survival (OS),Microbiota,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9682,NCT00496509,Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.,Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9683,NCT03647527,the highest grade of oral mucositis,,,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9684,NCT01360411,Malignant or benign lesion,Value of a Visual Analog Scale for strain image categorisation,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9685,NCT06314958,Recurrence-Free Survival,Overall Survival,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
9686,NCT01451658,Rebleeding,complication survival,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
9687,NCT03868215,Sensitivity,,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
9688,NCT03819088,Quality of life scores,Serum albumin level,,2019-04-17,COMPLETED,INTERVENTIONAL,['NA']
9689,NCT01921699,proliferation and migration of PANC1 cell line in the tested groups.,To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
9690,NCT03668431,"Number of participants with grade 3, 4 and 5 adverse events","Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001",,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
9691,NCT02204150,Feasibility of OFDI Imaging in Subjects Swallowing the OFDI Capsule,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9692,NCT00278889,Progression Free Survival,QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI),,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9693,NCT00922181,Variability of ablation diameters,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
9694,NCT00677612,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),To evaluate immunological responses,,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9695,NCT01519999,Change in colorectal cancer screening adherence,Providers'/staff shared decision-making experience,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
9696,NCT03601156,Pathological Complete Response (pCR),Number of Postoperative Complication,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
9697,NCT02726997,"Pharmacodynamic Changes Induced by Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Using a 2-Sample T-Test","Feasibility of Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Determined by Methods of Thall et all",,2016-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9698,NCT03556384,Overall Response Rate,Adverse events related to TMZ,,2018-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9699,NCT05256381,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),Number of Participants with Anti-drug Antibodies (ADAs),,2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9700,NCT03706248,"Sensitivity, specificity, positive predictive value and negative predictive value",,,2018-07-28,COMPLETED,OBSERVATIONAL,['NA']
9701,NCT03228043,Number of Participants overall survival,Number of Participants overall survival,Number of Participants overall survival,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
9702,NCT02204332,"The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.",Progression-free survival (PFS),"Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0).",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2']
9703,NCT00579163,To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.,A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.,,1994-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9704,NCT04943406,Prognostic impact of ctDNA positivity,Prognostic impact of ctDNA positivity in peritoneal lavage and peripheral blood on the risk of peritoneal and distant metastases,,2020-05-08,RECRUITING,OBSERVATIONAL,['NA']
9705,NCT02869152,2nd Phase: Detection rate of refined protocol in identifying SLN,Ergonomic optimization of the protocol as measured by surgeon satisfaction,,2016-08,UNKNOWN,INTERVENTIONAL,['NA']
9706,NCT00867126,"Changes in symptoms and quality of life as measured by the validated FACT-Hep scale version 4 questionnaire at baseline, every 4 weeks during therapy, and then at the completion of therapy",Time to disease progression,,2009-03-02,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9707,NCT05279287,Number of errors in an operation using validated methodology- Objective Clinical Human Reliability Analysis (OCHRA),Application of Machine learning and Artificial Intelligence to video analysis,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
9708,NCT04223401,Postoperative morbidity rate by Clavien-Dindo,Psychological status by Hospital Anxiety and Depression Scale (HADS).,,2020-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9709,NCT02196935,Successful ERCP or EUS,Definitive Diagnosis,,2010-09,RECRUITING,OBSERVATIONAL,['NA']
9710,NCT00354679,Evaluation of Safety and Toxicity,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9711,NCT05038098,Safety of endoscopic peritumoral gastric injection of FerroTrace,,,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
9712,NCT03636893,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,Overall Survival (OS) Disease Free Survival (DFS),,2018-08-24,COMPLETED,INTERVENTIONAL,['PHASE2']
9713,NCT00177853,"Determine efficacy of combination of irinotecan, celecoxib and concurrent radiotherapy on pancreatic cancer; determine highest/safest doses of these drugs",Tumor diminishment for safe excision,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE1']
9714,NCT00483080,Progression Free Survival (PFS),Safety according to NCI-CTCAE criteria (version 3),,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9715,NCT03316677,the predictive value of intraoperative anastomosis testing on anastomotic leak.,The sensitivity of the 2 methods of intraoperative anastomosis testing.,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
9716,NCT00225784,Objective Response of Tumor by RECIST 1.0 Criteria,Pattern of Failure After Therapy,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9717,NCT06022861,Objective Response Rate(ORR) as assessed by IRC,Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab),,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE3']
9718,NCT01596634,Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses,Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
9719,NCT05001009,Percent of patients with a goals of care conversation note documented in Stage 2,Percent of patients with a goals of care conversation note documented in Stage 1,,2022-09-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9720,NCT06124001,Phase IIa:ORR,Phase Ib and Phase IIa: herpes simplex virus type I antibodies,,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9721,NCT04753879,Progression-free Survival (PFS) after 6 months according to IRECIST criteria.,Number of participants experiencing grade 3 or above drug-related toxicities,,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
9722,NCT01764802,"Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version",Body change stress graded according to the Impact of Treatment Scale (ITS),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9723,NCT03718221,Patient-level Colorectal Cancer (CRC) Screening,Neighborhood-level Screening,,2018-08-30,COMPLETED,INTERVENTIONAL,['NA']
9724,NCT04927897,Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen,Evaluation of risk factors for the presence and/or the extent of microscopic tumor spread identified by the meta-analysis we performed,Analysis of (re)biopsy material,2022-08-16,RECRUITING,OBSERVATIONAL,['NA']
9725,NCT03768531,Number of participants experiencing study drug-related toxicities,Disease free survival (DFS),,2019-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9726,NCT00132041,Proportion of Participants With Successful Control of Disease at 18 Months,Remote Tumor Occurrence Rates,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
9727,NCT03189914,Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2),Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15,Quality of Life (QOL) (Phase 1 and 2),2017-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9728,NCT02762448,HCV clearance and complete regression of NHL by ASV+ DCV,,,2016-07,WITHDRAWN,OBSERVATIONAL,['NA']
9729,NCT04694794,Utility of Educational Brochure assessment,Baseline Educational Assessment,Feasibility Assessment,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
9730,NCT02611661,Safety and tolerability of administering hepatic locoregional therapy following radioembolization as measured by occurrences of grade 3 or higher toxicities of interest,Response rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy,,2016-01-19,TERMINATED,INTERVENTIONAL,['PHASE1']
9731,NCT05722223,To explore the feasibility of a trimodal prehabilitation program in the hospital setting,Anxiety and depression,Circulating tumor DNA and mutational variations,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
9732,NCT03426514,Early morbidity rate,5-year overall survival rate,,2018-03-25,RECRUITING,INTERVENTIONAL,['NA']
9733,NCT00775073,Time to Progression,Overall Survival,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9734,NCT05850559,Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt,,,2023-10-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9735,NCT05616533,The coincidence rate of tumor response obtained from 50 PDX models with clinical real tumor response acquired from corresponding patients received neoadjuvant therapy.,,,2023-09-12,RECRUITING,OBSERVATIONAL,['NA']
9736,NCT00798746,Reflux Symptoms: Open Esophagectomy versus Minimally Invasive,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9737,NCT02069041,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]),,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9738,NCT04825574,Safety as assessed by the number of serious adverse events and adverse events of special interest,,,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9739,NCT06255379,Progression Free Survival (PFS),adverse events (AE),,2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9740,NCT05952947,Adverse events and serious adverse events,Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ),T cell subgroup in peripheral blood,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1']
9741,NCT01559844,Number of Participants Who Died,Proportion of Participants With Virologic Failure Prior to Transplant,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9742,NCT03153332,The primary outcomes was the precise allocation of hepatic disease,Time spent to judge tumor location,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
9743,NCT03814005,"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose","Part B, Percentage of Solid Tumors Participants with CR or PR",,2019-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9744,NCT05124704,Predicted effect-site concentration of propofol (Ceprop) at certain time points,Postoperative exhaust time,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
9745,NCT01542177,Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).,Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
9746,NCT04616950,Hospital course of patients with cancer of the digestive system,Modeling of the hospital journey based on observations made during the period preceding the COVID-19 epidemic,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
9747,NCT05640609,the objective Response Rate (ORR) of the experimental group.,disease control rate (DCR),,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9748,NCT03944252,Primary endpoint is Objective Response Rate (ORR).,,,2018-09-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
9749,NCT04633512,"Support personnel satisfaction with ActivSightTM, as quantified by Likert scale.",Ability of ActivSightTM to display biliary tree.,,2020-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9750,NCT01581840,Response to treatment,Overall survival,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9751,NCT05615818,Progression-free survival (PFS),Percentage change in tumour size,Incidence of Adverse Events,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
9752,NCT02530437,Pathologic Complete Response Rate (Phase II),Overall Survival,,2017-03-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9753,NCT01271712,Progression-free Survival,Duration of Response (DOR),,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9754,NCT00484211,Antitumour activity defined as progression free survival (PFS),Experimental imaging study (DCE-MRI),,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9755,NCT06097078,Rate of patients with anastomotic leakage,Rate of intraluminal hemorrhage,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9756,NCT01703585,Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.,Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%,,2012-10-04,COMPLETED,OBSERVATIONAL,['NA']
9757,NCT04635488,metastasis rate of lateral lymph node,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
9758,NCT02051868,Best overall response rate by 24 weeks post treatment,Identification of potential tumour biomarker,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9759,NCT04544852,The proportion of participants that completed the FIT test within three months post enrollment.,,,2017-12-04,RECRUITING,INTERVENTIONAL,['NA']
9760,NCT04843189,Number of lymph nodes harvested,5-year overall survival,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
9761,NCT03120195,Feasibility of EndoRotor® for the ablation of Barrett's mucosa,Ease of performing the EndoRotor® procedure,,2017-01-27,COMPLETED,INTERVENTIONAL,['NA']
9762,NCT02282722,Number of Patients With Accurate Understanding of Chemotherapy Benefits,Patient-Reported Prognostic Understanding in Median Years,,2015-06-10,COMPLETED,INTERVENTIONAL,['NA']
9763,NCT06242067,progression-free survival(PFS),Duration of Response (DOR),,2023-04-23,RECRUITING,INTERVENTIONAL,['PHASE2']
9764,NCT01735799,,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
9765,NCT02781935,Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI),Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
9766,NCT03044743,Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients,Th1/Th2 change in the peripheral blood,,2017-04-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9767,NCT00437502,Date of first objective finding will be used to define the date of relapse,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
9768,NCT03516071,Time to Progress (TTP),Overall survival (OS),,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE2']
9769,NCT00449995,diagnostic accuracy of confocal laser scanning microscopy for detection of metaplasia or neoplasia in Barrett´s esophagus,inter- and intra observer variability for confocal laser scanning microscopy,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
9770,NCT04344847,Excision of GIST during LSG,,,2016-12-12,UNKNOWN,INTERVENTIONAL,['NA']
9771,NCT00398086,Number of Participants With Dose-limiting Toxicities,Maximal Degree of Anemia,,2006-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9772,NCT00407186,overall survival,health-related quality of life,,2007-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9773,NCT04312633,Primary Outcome Measure:,Secondary Outcome Measure:,,2020-04-01,RECRUITING,OBSERVATIONAL,['NA']
9774,NCT02972541,Rate of stoma formation,Chemotherapy related complication,,2016-09-30,UNKNOWN,INTERVENTIONAL,['NA']
9775,NCT06230471,Objective response rate,overall survival rate,,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE2']
9776,NCT03829852,"Effectiveness of regorafenib use in routine clinical practice setting, assessed by tumor response","Eligibility of subsequent therapies and the outcome, assessed by PFS","Exploratory outcome: Image pattern as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in image patterns",2019-02-11,COMPLETED,OBSERVATIONAL,['NA']
9777,NCT01868971,The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.,7. Patient satisfactory.,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
9778,NCT00824785,Overall survival,"response rate, toxicity, quality of life and PFS",,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
9779,NCT00238212,Response probability (confirmed complete and confirmed partial responses),Time to progression,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9780,NCT02746432,The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.,The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.,Thirty days post-operative mortality,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9781,NCT03138720,CA19-9 value,Overall Survival,,2017-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9782,NCT01460888,Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer,Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
9783,NCT02349958,measure treatment response to HIPEC and tumor debulking,Toxicity Monitoring,QOL,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
9784,NCT03621982,Part 1 Combination Therapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT),Part 2 Combination Therapy: Number of Patients with Confirmed Positive Anti-drug Antibody (ADA) Responses,,2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE1']
9785,NCT05055648,Pulmonary complications,Overall survival (OS),Concordance of observed cardiac complications with predicted,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
9786,NCT03162510,MTD of Oxaliplatin,Overall survival,,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE1']
9787,NCT00260559,Change from baseline in SF36 Quality of Life Questionnaire at 36 month,,,1999-05,RECRUITING,OBSERVATIONAL,['NA']
9788,NCT03187951,Change in 6 Minute Walk Test (6MWT),,,2017-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9789,NCT04174079,Disease-free survival,overall survival,,2019-12-11,RECRUITING,INTERVENTIONAL,['NA']
9790,NCT00382720,Time to Progression,Overall Survival (OS),,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9791,NCT03368859,Progression Free Survival (PFS),Overall Survival (OS),,2018-03-20,TERMINATED,INTERVENTIONAL,['PHASE2']
9792,NCT04923529,16-week progression-free survival (PFS) rate,Safety outcome measures,,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9793,NCT03031691,Percentage of patients with anti-brontictuzumab antibodies,Overall survival,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9794,NCT02465060,Objective response rate,Progression free survival,,2015-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9795,NCT00220064,Disease stabilization rate or tumour marker response,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9796,NCT02276768,Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID,"Standard laboratory measures (biochemistry, hematology, urinalysis)",,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9797,NCT00003186,,,,1997-04,COMPLETED,INTERVENTIONAL,['NA']
9798,NCT04315311,Change In Coefficient Of Fat Absorption (CFA) From Baseline,Change In Gastrointestinal Quality Of Life Index (GIQLI) From Baseline,,2020-05-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9799,NCT06039280,Prevention of post-embolization syndrome,Adverse events of Dexamethasone and NAC in patients undergoing transarterial chemoembolisation for HCC,,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9800,NCT00305877,Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy,Two-year Disease-free Survival (DFS),,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9801,NCT04740346,3-year overall survival,Incidence of vitamin B12 deficiency,,2021-07-05,RECRUITING,INTERVENTIONAL,['NA']
9802,NCT01868347,evaluation of arterial oxygenation,evaluation of difference between arterial end-tidal partial pressure of carbon dioxide,variation of gas exchange in post operative period,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
9803,NCT06178926,Sedation efficacy,Injection pain,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
9804,NCT00006006,,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9805,NCT00297128,feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma,"collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9806,NCT01186731,Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level,SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9807,NCT04168944,Tumor free survival rate,Overall survival rate,the side effects,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9808,NCT04375930,means of quality of life change,,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
9809,NCT02694562,Local Tumor Control,Time To Tumor Progression,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
9810,NCT02381561,Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity,Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements,,2016-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9811,NCT01213004,To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.,To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT),,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9812,NCT03606317,Prognosis and practice patterns in the management of cachexia and its associated symptoms.,,,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9813,NCT03258398,Part 2: Overall Response Rate,,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
9814,NCT02024607,The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9815,NCT01133132,Change in level of physical activity,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
9816,NCT00114179,Overall survival rate,Response rate,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9817,NCT05025826,Demonstrate a 50% decrease of the grade> or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm,Comparison between the two arms of Neurological toxicities,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
9818,NCT05425940,Overall Survival,Overall Survival,Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE3']
9819,NCT01472029,"Rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference pathologist.",Overall survival,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9820,NCT03347630,diagnostic performance for staging,Diagnostic performance to assess tumor response,,2017-10-02,UNKNOWN,INTERVENTIONAL,['NA']
9821,NCT00364364,"For patients who undergo surgery after the 111In-hPAM4 study, targeting will be correlated against surgical findings.","Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and nuclear (FDG-PET; optional)findings.",,2007-05,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9822,NCT04638959,differences in abundance of gut microbiota,evidence of gastric carcinoma,Basic information of patients with different clinical outcomes,2019-09-30,UNKNOWN,OBSERVATIONAL,['NA']
9823,NCT00031694,Response Rate of at Least 30%,Overall Survival,Bryostatin 1 Pharmacokinetics,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9824,NCT03866525,The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008,The immunogenicity of OH2,,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9825,NCT03300570,"Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After 7 Days of Intervention",Percentage of Participants With Grade 3 or Higher Diarrhea Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0,,2018-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
9826,NCT00892593,"rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of ""usual care"" patients in the same patient population.",the pathology found at repeat colonoscopy in each group.,,2009-05,UNKNOWN,INTERVENTIONAL,['NA']
9827,NCT00994903,Total complications,Change in functional recovery,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9828,NCT01605734,Time to Progression,AFP,,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
9829,NCT04316000,Initial Fear of Cancer degree,Long-term Fear of Cancer degree,,2019-11-22,SUSPENDED,OBSERVATIONAL,['NA']
9830,NCT00590239,Pathologic and Clinical Outcomes,Efficacy of endoscopic detection of early esophageal lesions,,2007-05-15,RECRUITING,OBSERVATIONAL,['NA']
9831,NCT05732662,ORR,Treatment Related Severe Adverse Effects,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9832,NCT06104241,Dose-limiting toxicity (DLT）,PFS,,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9833,NCT04293497,The comparison of sensitivity between conventional staining method and new staining method,The evaluation of correlation index of staining at three type slides,,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
9834,NCT04984980,objective response rate,overall survival,,2020-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9835,NCT01712347,Overall survival from the time of starting first-line therapy,Number of participants with adverse events,,2012-10-11,COMPLETED,OBSERVATIONAL,['NA']
9836,NCT05226169,Maximum change of Hb concentration,OS,,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE3']
9837,NCT05512520,1-year progression-free survival,Treatment-related adverse events,,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2']
9838,NCT02997293,Hospital length of stay,,,2017-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9839,NCT03474354,CORRELATION OF LUMI DISTRIBUTION WITH NECROSIS,Distribution of radiopaque beads and correlation with necrosis,,2018-05-02,COMPLETED,OBSERVATIONAL,['NA']
9840,NCT00415155,Phase 2: Time to progression,Phase 2: Safety,,2008-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9841,NCT06323382,Progression-Free-Survival (PFS),Adverse events,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
9842,NCT06051695,Phase 2: The Overall Response Rate (ORR) for patients,Cytokine analysis,,2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9843,NCT04186117,Isolation of circulating tumoral cells,,,2016-09-09,RECRUITING,INTERVENTIONAL,['NA']
9844,NCT00353262,AUC0-inf for Free Platinum,Marked Laboratory Abnormalities,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9845,NCT00003381,Evaluate the quality of life of patients,,,1998-07,TERMINATED,OBSERVATIONAL,['NA']
9846,NCT04203641,Adverse events (as per CTCAE v. 5.0),Proportion of patients expressing anti-L-DOS47 antibodies,,2019-12-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9847,NCT01528501,objective response rate within the first six treatment cycles,Safety and tolerability of LBH 589,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2']
9848,NCT04446793,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
9849,NCT03401827,survival rate,adverse event,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9850,NCT02489214,Number of Participants with Adverse Events,Progression-free survival time,,2016-05-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9851,NCT04689347,"To evaluate the safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease",Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),OS of FLIRT bevacizumab,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9852,NCT05718115,Predict response to anti-HER2 directed therapy using DLR,,,2023-02-15,RECRUITING,OBSERVATIONAL,['NA']
9853,NCT00878657,Disease-free survival (Phase II),,,2009-04,TERMINATED,INTERVENTIONAL,['PHASE1']
9854,NCT04161287,Local control rates,Adverse reaction,,2019-10-11,RECRUITING,OBSERVATIONAL,['NA']
9855,NCT02069704,AUC at Steady State (AUCss) of BEVZ92 and Avastin®,Volume of Distribution (Vd) of BEVZ92 and Avastin®,,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9856,NCT02256514,Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance,Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
9857,NCT03437200,12-Month Progression-free survival using RECIST 1.1,Relative dose intensity of 5FU,,2019-01-17,TERMINATED,INTERVENTIONAL,['PHASE2']
9858,NCT01364805,Determine safety of combined gemcitabine chemotherapy with IV ascorbate.,Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9859,NCT02586701,Six Minute Walk Test (6MWT),,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
9860,NCT00297648,Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments,Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9861,NCT03042169,Overall survival,Number of interventional palliative procedures per patient,,2021-08-25,UNKNOWN,INTERVENTIONAL,['PHASE3']
9862,NCT05829057,Number of participants with physical examinations,changes of cytokines relative to the baseline,,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE1']
9863,NCT02664077,"Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.",Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),,2016-06,TERMINATED,INTERVENTIONAL,['PHASE3']
9864,NCT04866381,Objective Response Rate,Subject safety,,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9865,NCT03777475,OS,PFS,,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA']
9866,NCT05059717,Magnetic Resonance Displacement Encoding with Stimulated Echo (MR DENSE) imaging data of patients treated with chemotherapy prior to resection of metastases to explore its utility in detecting sinusoidal liver injury.,,,2018-07-12,WITHDRAWN,INTERVENTIONAL,['NA']
9867,NCT02352337,Rate of patients alive and without radiological and/or clinical progression,Progression survival,,2014-12-23,COMPLETED,INTERVENTIONAL,['PHASE2']
9868,NCT01770405,performance evaluation,Safety and feasibility evaluation,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
9869,NCT02965209,Diagnostic yield of NMSE in patients with suspected small bowel diseases,Adverse events,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
9870,NCT04152889,DFS,,,2020-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
9871,NCT04525313,response rate,progression free survival,,2020-08,UNKNOWN,OBSERVATIONAL,['NA']
9872,NCT02600143,Genetic predisposition for immunotherapy-induced colitis,Analysis of the gut microbiome in stool samples,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
9873,NCT05530746,Detection of advanced colorectal adenoma,Detection of non-advanced colorectal adenoma,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
9874,NCT01659424,Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance,4) Quality of Life,,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9875,NCT05594914,AE,OS,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9876,NCT00002615,,,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9877,NCT01605305,TPP,OS,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9878,NCT05856305,Acute Toxicity,Tumor Volume reduction kinetics,,2023-07-05,RECRUITING,INTERVENTIONAL,['PHASE2']
9879,NCT01725490,the mean percentage change of the number and size of polyps in colon and/or duodenum.,,,2013-02-15,COMPLETED,INTERVENTIONAL,['PHASE2']
9880,NCT02837263,Recurrence rate at 1 year,Overall survival estimated using the Kaplan-Meier method,Expression levels of PDL1,2016-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9881,NCT05432193,Treatment emergent adverse events,Uptake of [Ga-68]-PNT6555 in tumor lesions,Uptake of the [Ga-68]-PNT6555 imaging agent and optimal scanning specifications for future studies,2022-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9882,NCT02176746,The number of participants with adverse events,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,The dose of CSC vaccine,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9883,NCT00971126,"Terms of efficacy assessment: objective tumor response, overall survival, progression-free survival. Terms of safety assessment: adverse effects, laboratory values.",,,2009-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9884,NCT01853319,Progression-Free Survival (PFS),,,2013-07-24,COMPLETED,INTERVENTIONAL,['PHASE3']
9885,NCT04469556,Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.,Cluster Tendency analysis using artificial neural networks and radiomic methods combined,,2020-10-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
9886,NCT05520385,"an association between occurrence of CRC and blood group A+ , O + .",an association between occurrence of CRC and overweight and class І obesity patients,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
9887,NCT04704934,Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel,Percentage of Participants Who Have Treatment-emergent ADAs,,2021-05-21,RECRUITING,INTERVENTIONAL,['PHASE3']
9888,NCT05694338,Percent of patients considered frail assessed by Clinical Risk Analysis Index (RAI-C) Scores of 21 or higher,Adverse outcomes after major surgery,,2023-03-13,RECRUITING,OBSERVATIONAL,['NA']
9889,NCT01269216,pathologic complete response rate,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9890,NCT06311396,Omics studies and functional morphological studies,,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
9891,NCT04131192,Rate of dose limiting toxicities of each subject,Overall Survival (OS),,2019-11-11,TERMINATED,INTERVENTIONAL,['PHASE1']
9892,NCT04177602,Rate of pathological complete remissions (pCR)/Phase 2 part,Rate of perioperative complications,,2019-11-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9893,NCT02954913,Comprehensive Complication Index,Cost Analysis,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
9894,NCT05605600,Development of LARS Severity tool,Commence initial psychometric evaluation of the New LARS score,,2022-10-03,COMPLETED,OBSERVATIONAL,['NA']
9895,NCT04625803,Tumor regression rate of MSS/pMMR patients,mortality rate,,2021-01-04,RECRUITING,INTERVENTIONAL,['PHASE2']
9896,NCT05323409,Instrument to measure Self-Management (IMSM),Supportive Care Needs Survey (SCNS),,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
9897,NCT02665026,Postoperative complication,Disease-free survival,,2016-01-04,COMPLETED,INTERVENTIONAL,['NA']
9898,NCT00274209,Prevalence of dysplastic lesions by white light vs. chromoendoscopy,,,2005-12,COMPLETED,OBSERVATIONAL,['NA']
9899,NCT05480306,Progression Free Survival (PFS),Incidence of ≥Grade 3 related treatment-related adverse events (TRAEs).,Exposure-response relationships for DKN-01 as data permit.,2022-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
9900,NCT02140463,feasibility,response rate,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
9901,NCT02714374,Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue,,2016-03-25,TERMINATED,INTERVENTIONAL,['PHASE1']
9902,NCT00267020,Overall Survival (OS),Number of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) (Toxicity),,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9903,NCT04361162,Overall response rate (ORR),Overall survival (OS) in patients,,2020-05-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9904,NCT03609268,progression free survival,overall survival,,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA']
9905,NCT06210724,Colorectal Cancer,Microscopic colitis,Blood tests,2023-10-09,RECRUITING,OBSERVATIONAL,['NA']
9906,NCT01521104,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
9907,NCT01802203,Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.,Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
9908,NCT02070822,tumor response,change of baseline MRI parameters,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
9909,NCT01505972,Participation rate,Response rate in FOUR&TWO group,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
9910,NCT05613621,clinical outcomes of MAFLD vs. non-MAFLD.,,,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9911,NCT02191566,"3-year recurrence-free survival, RFS","5-year overall survival, OS",compliance for chemotherapy,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2']
9912,NCT06111326,Phase II: Dose Expansion Part-objective response rate (ORR),,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9913,NCT04793958,Progression-free Survival (PFS),Quality of Life Assessment,,2021-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9914,NCT05641896,Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.,Further characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5),,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2']
9915,NCT01662609,Number of Abnormalities Detected by EUS,,,2007-08-23,COMPLETED,OBSERVATIONAL,['NA']
9916,NCT06260293,Shorts Physical Performance Battery(SPPB),,,2023-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9917,NCT03841799,Characterization of colorectal tissue microenvironment of patients with locally colorectal neoplasia.,Identification of potential molecular abnormalities in cancer cells from colorectal tissue and from blood samples.,,2019-05-02,RECRUITING,OBSERVATIONAL,['NA']
9918,NCT05181306,Recurrence,Cost,,2010-10-01,COMPLETED,OBSERVATIONAL,['NA']
9919,NCT01876407,Evaluate the effectiveness of using low-intensity laser compared with placebo as preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy.,Assess the intervention tolerance and side effects of it.,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9920,NCT00176735,,,,2001-12,TERMINATED,INTERVENTIONAL,['NA']
9921,NCT01262040,"Determine the feasibility of Narrow Band Imaging (NBI) at the time of thorascopic, laparoscopic or robotic surgery.",Determine what percentage of patients have surface metastasis identified with NBI that were not seen on white light imaging.,,2010-12-14,COMPLETED,INTERVENTIONAL,['NA']
9922,NCT00625573,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy","To evaluate overall survival, time to progression, response duration, time to response and safety of this combination",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9923,NCT06148636,Determine recommended therapeutic dose of [212Pb] VMT-α-NET,Maximum tolerated radiation dose for kidneys,,2023-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9924,NCT01214681,Faecal calprotectin concentration,Plasma short chain fatty acid concentration,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
9925,NCT01456455,HER2 Status,Outcome according to HER2 Status,Outcome according to ethnicity of patients,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
9926,NCT06054308,pathologic response,Disease free and overall survival,,2024-02-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9927,NCT04454476,Safety of Trametinib treatment: adverse events,,,2022-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9928,NCT05013697,Progression free survival (PFS， RECIST assessment),Incidence of Treatment-related adverse Events,,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
9929,NCT03111823,Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed,Change in QOL,Change in endothelial function,2016-07-07,TERMINATED,INTERVENTIONAL,['NA']
9930,NCT04486651,Overall Survival (OS) in Participants With PD-L1 CPS≥1,Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),,2020-09-16,UNKNOWN,INTERVENTIONAL,['PHASE3']
9931,NCT02789891,3-year disease overall survival rate,EORTC QLQ-C30 and QLQ - STO22,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
9932,NCT01284504,"Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.","Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.",,2011-01,TERMINATED,INTERVENTIONAL,['NA']
9933,NCT05145647,To estimate the local control rate at primary tumor site,Treatment toxicity grading according to the CTCAE,Overall survival (OS),2022-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9934,NCT04195373,Determine MTD and dose for phase II,Efficacy of therapy assessed by changes in tumor marker level,,2020-11-23,WITHDRAWN,INTERVENTIONAL,['PHASE1']
9935,NCT01998152,Change in skeletal muscle area (cm2) between individualized nutritional counselling versus usual nutritional care,"Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA).",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
9936,NCT00005030,,,,1999-09-29,WITHDRAWN,INTERVENTIONAL,['PHASE1']
9937,NCT01915225,"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets","Collection of detailed history, demographic, treatment data, and perioperative outcomes data related to surgical quality and safety in order to categorize and track the specific procedures.",,2013-07-21,RECRUITING,OBSERVATIONAL,['NA']
9938,NCT01032967,Overall survival and disease-free survival,Quality of life and function outcomes,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9939,NCT00997685,To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer,To evaluate the safety profile of XELOX peri-operative treatment,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
9940,NCT01198548,Rate of Sufficient Cholecalciferol,PFS of Patients Receiving Study Treatment,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
9941,NCT05091346,Phase 2 Part: Objective Response Rate (ORR),Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab,,2021-10-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9942,NCT03542877,12-Week Progression Free Survival,Overall Survival (OS) by PIK3CA Mutation Status,,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9943,NCT04868227,GENE EXPRESSION CHANGE,VITAMIN D STATUS CHANGE,,2014-03-28,COMPLETED,INTERVENTIONAL,['NA']
9944,NCT05382364,Percentage of participants discontinuing from study therapy due to AE,Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1),,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9945,NCT02958163,Objective response rate at 6 months,Overall response rate based on the MRI evaluation in Child Pugh B7 patients,MRI description of tumors at the hepatobiliary phase at 6 months after treatment,2017-02-20,TERMINATED,INTERVENTIONAL,['PHASE2']
9946,NCT05440552,Detection rate,,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9947,NCT03348241,The effect of Gum Arabic to prevent Chemotherapy-induced Oral Mucositis was the primary outcome that assessed using World Health Organization Mucositis Scoring.,,,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE2']
9948,NCT00353015,Participant Response Rate of Irinotecan and Cisplatin,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9949,NCT04833959,Incidence of treatment emergent adverse events assessed by CTCAE v5,,,2021-03-26,SUSPENDED,INTERVENTIONAL,['PHASE1']
9950,NCT05156788,R0 resection rate,RFS,,2021-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9951,NCT06207656,Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases,Incidence and severity of AEs CTCAE v5 criteria,To determine the presence/expression level/levels of serum and tumour tissue biomarkers associated with cell and tumour growth and/or involved in the mechanisms of action of EBC,2024-01-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9952,NCT02231723,Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs),Assess pharmacodynamic activity of BBI608 when administered in combination with standard chemotherapies,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9953,NCT02705651,Growth rate of the tumor in mm,Documentation of lymph node and/or distant metastases,,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
9954,NCT00408122,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9955,NCT00361231,Median Progression Free Survival,Overall Response Rate,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9956,NCT01691664,Disease free survival,quality of life,Immunological assessment,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
9957,NCT01099527,To assess response rate in phase II,,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9958,NCT02350166,30-day complications,C-reactive protein,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
9959,NCT01188109,Recurrence-free Survival as Measured by CT Scan,Immunohistochemistry to Determine Status of Excision Repair Cross Complementation Gene-1 (ERCC1) Expression,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
9960,NCT05718882,Progression free survival,Safety endpoint,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
9961,NCT02235324,Progression-free survival during the second phase of the study,Incidence of adverse events graded according to NCI CTCAE version 4.0,"mRNA level of VEGFR1, VEGFR2, and VEGF-A",2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9962,NCT03757455,Days until discharge from university hospital,Readmission frequency,,2020-09-01,TERMINATED,INTERVENTIONAL,['NA']
9963,NCT05049317,Incidence of urinary dysfunction,Incidence of urinary dysfunction,,2021-11-24,RECRUITING,INTERVENTIONAL,['NA']
9964,NCT04186156,Proportion of patients alive and progression free at 4 months,To determine the pharmacodynamic response to KA2507,,2020-03-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9965,NCT00695227,The primary aim of the study is to establish that patients with symptoms of LPR who are referred to an otolaryngology clinic have a prevalence of Barrett's metaplasia equivalent to that of a population with GERD symptoms.,,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
9966,NCT05449847,Relation between MicroRNA and HCV,,,2021-05-13,COMPLETED,OBSERVATIONAL,['NA']
9967,NCT01409005,8-weeks progression free survival rate (PFS rate),Percentage of Patients with Adverse Events,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9968,NCT03963206,survival of the patient after start of treatment,Number of patients with each dose of Cabozantinib,,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9969,NCT03579199,Histological analysis of explanted liver parts,bilirubin and prothrombin levels,,2019-03-18,UNKNOWN,INTERVENTIONAL,['NA']
9970,NCT01721941,Maximum tolerated dose of TH-302 use in TACE,Objective response rate,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
9971,NCT03490461,A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.,,,2017-11-22,COMPLETED,OBSERVATIONAL,['NA']
9972,NCT06275997,Miss rate reduction,patient satisfaction,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9973,NCT05314946,Feasibility of the trial,Post-operative mortality,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9974,NCT04727151,Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP),Phase 1 and Phase 2: Cytokine level detection,,2021-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9975,NCT00342472,PAH exposure,,,1998-02-12,COMPLETED,OBSERVATIONAL,['NA']
9976,NCT04397601,Overall Survival (OS).,Progression-free survival (PFS).,Serum level of PlGF (Placental Growth Factor).,2020-05-11,RECRUITING,OBSERVATIONAL,['NA']
9977,NCT02012699,Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC),Procurement and banking of excess biological material for future analysis,"Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future studies",2013-11-01,RECRUITING,OBSERVATIONAL,['NA']
9978,NCT04294160,Dose intensity,Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments,,2020-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9979,NCT01047293,"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)",,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9980,NCT00822991,Size of HCC which is detected first,The improvement of prognosis of patients who are diagnosed in this study,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
9981,NCT05116085,Major pathological response (MPR) rate,Number of Participants with Treatment-emergent Adverse Events (TEAEs),,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9982,NCT06079229,Evolution in the ADL questionnaire score between pre-operative and post-operative 3 to 30 months after surgery.,,,2023-11-06,RECRUITING,OBSERVATIONAL,['NA']
9983,NCT06091930,Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1),Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations,,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE1']
9984,NCT02384759,Radiological progression-free survival according to the investigator,progression-free survival,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9985,NCT01608022,Overall Response Rate,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9986,NCT03959774,demonstrate that the adherence rate of digital follow-up is greater than 70% in a population of elderly patients.,,,2020-12-30,UNKNOWN,INTERVENTIONAL,['NA']
9987,NCT04798781,Progression-free survival,Incidence and severity of adverse events,,2021-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9988,NCT06050447,Mortality rate,Recurrence-free survival,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
9989,NCT03797326,Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE),Plasma Concentration of Lenvatinib,,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9990,NCT03099564,Progression free survival (PFS),Estimate overall survival (OS),,2017-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9991,NCT06269341,Overall Survival,,,2010-02-01,RECRUITING,OBSERVATIONAL,['NA']
9992,NCT04692454,The number of CD8+ T,,,2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
9993,NCT00108953,Time to Progression (TTP),Percentage of Participants for Whom Disease Control Was Achieved,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9994,NCT05158621,Primary,,,2021-12-14,COMPLETED,OBSERVATIONAL,['NA']
9995,NCT00626639,Pharmacokinetics of Palifermin,Overall Survival,,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9996,NCT05038813,Objective Response Rate(ORR),Overall Survival(OS),,2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9997,NCT04151394,Overall survival,,,2019-01-31,COMPLETED,OBSERVATIONAL,['NA']
9998,NCT01314027,Progression-free survival,feasibility of adjuvant chemotherapy,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
9999,NCT05975749,Disease-free survival,Side effects,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10000,NCT01402089,Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol,"Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)",,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10001,NCT02836977,Disease free survival,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10002,NCT05579353,expressional quantity,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
10003,NCT02274753,Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients,Relapse in relation with the immunoscore on biopsies,,2015-03-11,UNKNOWN,OBSERVATIONAL,['NA']
10004,NCT06168812,Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide,,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE2']
10005,NCT03131102,Acute Fatigue Score (AFS),Hospital length of stay,Quality of life,2017-08-29,COMPLETED,OBSERVATIONAL,['NA']
10006,NCT05640830,Progression-free survival,,,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10007,NCT01611506,Dose limiting toxicity,"Toxicity (according to NCI-CTCAE, Version 4.0)",,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10008,NCT02909114,local control assessed by RECIST,overall survival,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10009,NCT02836535,Number of complications,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
10010,NCT00911196,Expression of c-MET in the same hepatocellular carcinoma tumor samples,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
10011,NCT02243267,Response to Treatment,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
10012,NCT02326948,Number of participants with alcohol consumption,,Number of participants with polypoid lesions of gallbladder,2014-08,COMPLETED,OBSERVATIONAL,['NA']
10013,NCT00507598,"•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.","Correlate changes of serum & urine biomarkers /p trt to predict response or toxicity,& correlate w/other treatment outcomes. Compare the metabolic profile between pts w/various stages of colorectal cancer.",,2007-07,COMPLETED,OBSERVATIONAL,['NA']
10014,NCT02399735,GVHD,Acute rejection,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
10015,NCT00033319,,,,1997-05,UNKNOWN,INTERVENTIONAL,['NA']
10016,NCT03819387,Number of patients with treatment-related adverse events as assessed by CTCAE v5.0,Additional pharmacokinetic parameters for siRNA,To evaluate correlation between KRAS mutations and clinical outcome,2019-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10017,NCT02274012,Change of tumor burden (in centimeters) for participants during protocol therapy,ErbB2 levels benefit during therapy.,,2014-05-29,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10018,NCT02958059,Rate of complication that related with infection.,Grade of post-ERCP infectious complication,,2016-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10019,NCT03797443,Disease control rate (CR+PR+SD x18 weeks),Changes in patient's self-reported pain levels,,2019-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10020,NCT00966251,To assess the safety and tolerability of CT-011 in patients with Primary Hepatocellular Carcinoma,,,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10021,NCT02630004,Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale),Pharmacokinetics evaluation [Clearance],Number (percentage) of patients with progression disease using the RECIST 1.1 criteria,2015-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10022,NCT00134758,SPIGELMAN severity score of duodenal lesion after 2 years of follow-up,Compliance to the treatment,,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10023,NCT05732389,Complete clinical response,Change in Quality of life (EORCT QLQ-CR29),,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10024,NCT03722875,Overall survival(OS),,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10025,NCT00047333,Progression-free survival,Overall survival,,2002-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10026,NCT01933958,Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib,Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.,,2013-09-04,COMPLETED,OBSERVATIONAL,['NA']
10027,NCT03872908,Cohort 2: Efficacy of compression induced by surgical gloves vs peripheral neuropathies development in patients treated by oxaliplatine after a cumulative dose of 595 mg/m2,Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand,,2019-09-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10028,NCT04233151,Progression-free Survival（PFS）,,,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE3']
10029,NCT06194734,Overall survival (OS),Quality of Life (QOL) scores,,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE3']
10030,NCT04222413,To determine the Objective Response Rate (ORR) according to Evaluation Criteria (RECIST 1.1) in patients treated with metarrestin at the MTD,To assess safety and tolerability of metarrestin in subjects with metastatic solid tumors,,2020-10-27,RECRUITING,INTERVENTIONAL,['PHASE1']
10031,NCT03928678,length of hospital stay in days,,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
10032,NCT04171141,Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2),Change from baseline of immune cells from tumor biopsies,,2019-11-19,TERMINATED,INTERVENTIONAL,['PHASE1']
10033,NCT06329869,Overall objective response rates (ORR),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Biomarkers-related endpoints,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10034,NCT00465023,"To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.","to evaluate tumor response, local control and survival in this patient population.",,2003-06,COMPLETED,INTERVENTIONAL,['NA']
10035,NCT02953743,Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ)),Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs),,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10036,NCT03488953,Overall survival three years after 2nd-stage of hepatectomy,Morbidity of the donor,,2018-04-10,UNKNOWN,INTERVENTIONAL,['NA']
10037,NCT02364154,metabolic phenotype of colorectal cancer,tumor stage,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
10038,NCT03630068,Recurrence-free survival,Clinical and radiological complications,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
10039,NCT05908916,Progression-free survival,,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10040,NCT05026905,Best objective response rate (ORR),Incidence of Treatment-related Adverse Events [Safety and Tolerability],,2021-12-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10041,NCT00672828,Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion,Self-reported stage of CRC screening test adoption,Clinic variables as CRC screening predictors,2008-01,COMPLETED,INTERVENTIONAL,['NA']
10042,NCT05228743,R0 resection rate,1 year overall survival,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10043,NCT04734249,Objective response rate (ORR),Assess the anti-tumor activity:DCR,,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
10044,NCT05989789,Procedure-Safety (No residual source of radiation),Number of patients without side effects,,2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
10045,NCT05759741,Wexner incontinence score,Rate of postoperative complications,,2023-01-17,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10046,NCT00003486,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10047,NCT00168155,disease free survival,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10048,NCT02020928,Incidence of Oral Mucositis,Degree of mucositis,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10049,NCT00958737,Disease-free survival (DFS),Treatment compliance,,2009-05-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10050,NCT02561546,glycosylated hemoglobin (A1C),postprandial glucose (PPG),,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
10051,NCT05293041,Blood loss,I-FABP (change in organ damage markers),,2022-03-27,RECRUITING,INTERVENTIONAL,['PHASE4']
10052,NCT01388101,The performance of e- Ab sensor,,,2010-09,UNKNOWN,INTERVENTIONAL,['NA']
10053,NCT02592304,"DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.",,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
10054,NCT03693677,The progression free survival at 6 months according to the RECIST 1.1 criteria,Treatment safety,,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10055,NCT01574677,Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result,Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA']
10056,NCT00031941,,,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10057,NCT02587689,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells,,,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10058,NCT03003065,Safety (will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0),"Quality of life (in every visit, European Organization for Research and Treatment of Cancer core questionnaire [EORTC QLQ-C30] will be filled and specific symptom enquiry is made; itchiness, fever and general well-being over a Likert 0-4 scale.",,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE2']
10059,NCT00613665,Safety measures: injection site and systemic reactions,Immunogencity measures: antigen-specific antibodies and cellular immune response,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10060,NCT05528952,objective response rate (ORR),disease control rate (DCR),,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2']
10061,NCT03962478,6-month survival rate,Stent dysfunction free survival,,2019-05-31,COMPLETED,INTERVENTIONAL,['NA']
10062,NCT00845819,Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0),OMDQ (oral mucositis daily questionnaire) score during treatment,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10063,NCT04242199,Number of treatment-emergent adverse events,Vz/F of INCB099280,,2020-09-04,RECRUITING,INTERVENTIONAL,['PHASE1']
10064,NCT00427713,Disease-free survival at 3 years,Toxicity,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10065,NCT00230399,"To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.","To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan.",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10066,NCT02620865,Median Overall Survival (OS),TTP,,2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10067,NCT02768428,knowledge about TACE (A 40-item exam is performed to test the patients' knowledge),,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
10068,NCT00043199,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
10069,NCT06261008,adherence rate,qualitative factors associated with repeat FIT adherence,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10070,NCT03039322,Golgi protein correlated with presence of HCC,,,2014-12-22,COMPLETED,OBSERVATIONAL,['NA']
10071,NCT04034459,Overall Response Rate (ORR),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2016-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10072,NCT06101277,Number of participants with controlled disease,Time to treatment failure,,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
10073,NCT02459652,R0 resection rate,R0 resection rate in borderline resectable pancreatic cancer,,2012-12-28,COMPLETED,INTERVENTIONAL,['PHASE2']
10074,NCT05635929,"Quality of life evaluation of radiotherapy, with or without chemotherapy, long-term symptoms (6 months) after 1 month of use of the tested composition in head & neck cancer patients.",Comparison between oral mucositis severity in patients receiving radiotherapy with patients receiving radiotherapy plus chemotherapy.,,2022-10-11,COMPLETED,INTERVENTIONAL,['NA']
10075,NCT01099085,Progression free survival of XP ± simvastatin,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10076,NCT00753675,Progression Free Survival,Overall Survival,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10077,NCT00160030,Percentage of patients having completed the full treatment and Endoscopic complete response rate,Toxicity profile (NCI-CTC).,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10078,NCT01748773,Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score,Overall Survival,,2013-01-29,COMPLETED,INTERVENTIONAL,['PHASE2']
10079,NCT03903185,Measurement of the pharmacokinetics of LDV\SOF,"Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF).",,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10080,NCT05644249,Objective tumor response according to RECIST v 1.1 after second PIPAC,Adverse events of chemotherapy drugs,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
10081,NCT03027401,Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records.,Assessment of effects of the informed consent process,,2017-01-10,WITHDRAWN,OBSERVATIONAL,['NA']
10082,NCT05875402,Adverse Events (AE),,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
10083,NCT05340569,Unexpected abortion,Early distant recurrence,,2022-03-28,RECRUITING,INTERVENTIONAL,['NA']
10084,NCT02582918,Patient satisfaction and acceptability,Repeat Screening,,2018-03-26,COMPLETED,INTERVENTIONAL,['NA']
10085,NCT02489916,Number of participants with Adverse Events,Progression Free Survival,Area under the plasma concentration versus time curve (AUC),2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10086,NCT04913233,Colorectal cancer screening sensitivity,,,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10087,NCT00041262,Survival,Quality of life,,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
10088,NCT03368131,The pathological complete response rate(pCR),Adverse events,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10089,NCT04484311,Residual neoplasia,,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
10090,NCT04265417,Disease-free survival,Postoperative C-reactive protein,,2015-01-06,COMPLETED,OBSERVATIONAL,['NA']
10091,NCT02301962,Number of subjects with adverse event.,Duration of response.,,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
10092,NCT03413254,Proportion of peritoneal metastases detected after a negative second look DLS,Quality of life assessed with the EQ-5D-5L questionnaire,,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10093,NCT03029793,Pathologic Response,Overall Survival,,2016-05,UNKNOWN,OBSERVATIONAL,['NA']
10094,NCT04798820,Change from preoperative weight change at postoperaive 18 months in SE and IE groups.,Quality of life of the patients,,2021-03-09,RECRUITING,INTERVENTIONAL,['NA']
10095,NCT05427227,Tumor associated proteins expression level of exosomes,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
10096,NCT00002711,,,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10097,NCT00077545,Objective response rate (CR + PR),Duration of improvement of dysphagia,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10098,NCT05125094,Overall Survival,tumor response,,2021-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10099,NCT03457844,Progression Free Survival(PFS),Disease Control Rate(DCR),,2018-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
10100,NCT05132244,Frequency of glucose levels maintained within range in Arm 1 compared to Arm 2,Overall survival (OS) in each study arm from the initiation of FOLFIRINOX,"Amount of circulating biomarkers, measured in molar, for participants in each study arm from screening until the end of study visit",2024-02,RECRUITING,INTERVENTIONAL,['NA']
10101,NCT02330913,Anastomosis related complication rate,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10102,NCT00882310,Number of Subjects Who Experience Dose Limiting Toxicities (DLTs),Score on FACT-Hep (Version 4),,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10103,NCT01087268,Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire,Health economics data,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10104,NCT00910143,"Local recurrence, recurrence-free survival, overall survival",Percentage of patients undergoing transcatheter arterial embolisation,,1993-01,COMPLETED,OBSERVATIONAL,['NA']
10105,NCT05953961,Disease Progression,Duration of Response,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA']
10106,NCT05569668,OS(overall survival),DFS(disease-free survival),,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
10107,NCT05110573,Major complication rate,Oncological outcomes,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
10108,NCT04157322,clinically detectable recurrence at 1 year after surgery.,,,2019-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10109,NCT01858805,overall survival,recurrence-free survival,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
10110,NCT01476592,Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels,Describe the effect of resveratrol on tumor growth as demonstrated by standard cross sectional imaging and tumor markers.,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10111,NCT03046745,Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval,Reservation of frozen serum for novel gastric cancer serologic marker analysis,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
10112,NCT00004547,Number of Participants With Adverse Events,Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10113,NCT04807673,Event Free Survival (EFS),Quality of life differences (EORTC QLQ-OES18),,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10114,NCT01423799,"Quality of Life (QOL), measured with the EORTC QLQ-C30",QOL assessed by the EORTC QLQ-OG 25,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10115,NCT03548948,Change in colonic inflammation,Change in serum hepcidin,,2015-07-15,COMPLETED,INTERVENTIONAL,['NA']
10116,NCT00819754,"Phase II: Using the RD established in phase I, assess efficacy of the IXO with bevacizumab combination as measured by progression-free survival",Qualitative and quantitative toxicity,,2003-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10117,NCT06231017,Objective response rate (ORR),Adverse events (Safety）,,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2']
10118,NCT04638010,Number of participants who complete needed cancer screening and prevention services,,,2011-02-16,COMPLETED,INTERVENTIONAL,['NA']
10119,NCT02169388,Frequency and severity of Adverse effects during Chemotherapy,The observed changes in nutritional status after chemotherapy,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
10120,NCT02659241,Change in level of protein expression in p53-related pathways,,,2016-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10121,NCT03550885,Change in the mucosal abundance of bacterial genes associated with sulfur and bile acid metabolism,Change in colonocyte proliferation,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10122,NCT01182922,Percentage of invitees attending screening colonoscopy in each invitation letter group,"Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation.",,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10123,NCT01822613,Phase II primary outcome measure: Progression free survival (PFS),Progression free survival (PFS) per RECIST 1.1 (Ph 1b ),,2013-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10124,NCT00942383,Comparison of transverse ablation diameter between intraoperative ultrasound elasticity imaging (USEI) and postoperative cross-sectional imaging (CT or MRI).,Feasibility of image processing and image segmentation using this clinical free-hand system.,,2007-09,TERMINATED,OBSERVATIONAL,['NA']
10125,NCT05845268,cCR rate,immune-related adverse event rate,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10126,NCT05775146,Progression free survival (PFS),Toxicity Assessment,Exploratory endpoints/outcomes. To identify blood biomarkers that can correlate with disease events,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10127,NCT00375024,Questionnaire Results Regarding Time to Diagnosis,Questionnaire Results Regarding Patient Navigators,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
10128,NCT02682394,Blood levels of free DNA,,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
10129,NCT01329809,Delivery to and replication within tumors,Toxicity: Grade I-IV Adverse Events (according to CTCAE),,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2']
10130,NCT04936581,Vaizey score,Postoperative complications,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
10131,NCT03361150,Oxygen consumption (VO2),Hospital Anxiety and Depression Scale (HADS) score,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10132,NCT00553813,Survival,Evaluate the gene expression profile in relation to clinical outcomes,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
10133,NCT01658813,Progression Free Survival,Median Survival,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10134,NCT02106650,Grade 2 Oral Mucositis Prevention,Objective Response Rate,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10135,NCT05095636,PFS,AEs,,2021-03-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
10136,NCT01198392,Time to progression,Response rate,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
10137,NCT01735968,Characteristics of dose limiting toxicities (DLTs),Effect of basic PK parameter: CL/F,,2013-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
10138,NCT00373347,Identify new blood markers of liver cancer,,,2004-11,RECRUITING,OBSERVATIONAL,['NA']
10139,NCT05417230,ORR,AEs,ctDNA,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10140,NCT05541445,Major pathologic response,Overall survival (OS),,2022-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10141,NCT01067053,Time to progression,Safety of treatment according to the number of adverse events reported,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10142,NCT03981679,AUC,Intplex parameters,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
10143,NCT04130399,Local control rate among PDAC patients treated with neoadjuvant chemotherapy followed by SBRT,Rate of grade 3-4 non hematological toxicity rates,,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10144,NCT01478373,Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease,DCR (CR+PR+SD) at the End of Treatment,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10145,NCT00173277,,,,2003-06,UNKNOWN,OBSERVATIONAL,['NA']
10146,NCT02591082,Survival,Tumor response,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
10147,NCT05541601,Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.,To better understand the incidence of HCC in a UK population stratified by underlying cirrhosis aetiology,,2022-02-23,RECRUITING,OBSERVATIONAL,['NA']
10148,NCT04198051,The change of concentration of P-hydroxyphenylalanine metabolites in urine during chemotherapy,The change of the number of tumor necrosis factor(TNF)-α in blood during chemotherapy,,2019-12-20,UNKNOWN,INTERVENTIONAL,['NA']
10149,NCT05280444,Objective Response Rate(ORR),Adverse Events(AEs),,2022-05-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10150,NCT05620706,AE/SAE,ORR,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
10151,NCT04899739,Rate of lymph nodes wrongly categorised by ultrasound endoscopy. (Specificity),Development of an algorithm capable of characterizing lymph nodes metastases by the mean of artificial intelligence,,2021-12-05,RECRUITING,INTERVENTIONAL,['NA']
10152,NCT05202314,Pathological complete remission,Overall Survival,,2021-12-12,RECRUITING,INTERVENTIONAL,['NA']
10153,NCT00004258,To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10154,NCT00798447,reduction of pro inflammatory activity,,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10155,NCT05971108,Stage of hepatocellular carcinoma at diagnosis,Survival rates,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
10156,NCT00327132,Hp eradication rate and complete histological rate,overall survival (OS)Relapse-free survival (RFS),,2006-07,COMPLETED,INTERVENTIONAL,['NA']
10157,NCT05325528,Objective Response Rate (ORR),progression-free survival,,2022-04-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10158,NCT01655693,Overall Survival (OS),Objective Response Rate (ORR),Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10159,NCT01896531,Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis,Serum Concentration of Ipatasertib,,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE2']
10160,NCT04707560,Quantification of tissue quality,Diagnostic performance between different suction method,Complication,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
10161,NCT00858338,toxicity of IP FUDR after surgery prior to chemoradiation,"Time to relapse, disease specific survival",,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10162,NCT00503035,13-HODE Colonic Tissue Levels,PGE2 Colonic Tissue Levels,,2003-08-20,COMPLETED,INTERVENTIONAL,['PHASE2']
10163,NCT02694536,Percentage of Participants With Adverse Events (AEs),Progression-Free Survival (PFS) According to RECIST,,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10164,NCT05130710,presence of peritoneal seeding,presence of peri-gastric lymph node involvement,,2020-02-25,COMPLETED,OBSERVATIONAL,['NA']
10165,NCT01490866,Progression-free Survival,Frequency of Adverse Events as a Measure of Safety,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10166,NCT00310076,Time to Progression,Number of Events of Toxicity Graded 3 and 4,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10167,NCT01671683,,,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
10168,NCT01688700,Pathology complete remission rate,Quality of life,,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10169,NCT02951091,progression free survival,,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10170,NCT03974672,Measuring severity of complications with the Dindo Clavien complications scale,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
10171,NCT01863862,The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.,Multivariable analysis of prognostic factors associated with clinical complete response.,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
10172,NCT03350412,Thoroughness to report molecular profiling,Percentage of complete data capture for treatment-related check-point events,,2015-10,UNKNOWN,OBSERVATIONAL,['NA']
10173,NCT00230646,Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).,"Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months.",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10174,NCT02278133,Overall response rate in phase II,Number of participants with dose interruptions and dose reductions (phase Ib/II),,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10175,NCT03583528,Sensitivity of 68Ga-DOTATOC PET/CT in the diagnosis of SSTR positive tumors.,Total number of lesions per anatomic location identified by 68Ga-DOTATOC PET/CT,,2018-07-11,RECRUITING,OBSERVATIONAL,['NA']
10176,NCT02788669,LRP1 molecular expression,,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
10177,NCT01333475,pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced Colorectal Cancer,Number of Participants With Adverse Events,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10178,NCT06316401,Safety of ESD under SA,Median ESD duration,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
10179,NCT05193604,Overall response rate (ORR),Overall survival (OS),,2022-03-24,TERMINATED,INTERVENTIONAL,['PHASE1']
10180,NCT00427492,Time to defecation after colonic resection,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10181,NCT02117466,Clinical Benefit Rate,Quality of life (QoL) and health related QoL,,2014-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10182,NCT03412773,Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,,2017-12-28,COMPLETED,INTERVENTIONAL,['PHASE3']
10183,NCT04230603,Inflammatory classification with HSI,Tissue perfusion,,2019-06-06,UNKNOWN,INTERVENTIONAL,['NA']
10184,NCT04194775,Overall survival (OS),"Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale",,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10185,NCT03558048,Relationship between IBD and PSA,Location of disease,,2019-08-01,RECRUITING,OBSERVATIONAL,['NA']
10186,NCT02468076,Feasibility (ratio of technically successful RFA-applications to all examinations in which RFA-use was intended),safety (number and type of adverse events),,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10187,NCT04573881,Primary Safety: Procedure-Related Major Complications,Secondary Safety: All Adverse Events,,2021-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10188,NCT01728480,"The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)",,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10189,NCT05970302,Objective Response Rate (ORR),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2023-07-07,RECRUITING,INTERVENTIONAL,['PHASE2']
10190,NCT05227014,Transfusion rate,Postoperative hemoglobin values,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
10191,NCT04813627,Occurrence of ctDNA positivity in the first post-AdCTx blood sample,Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial,,2021-07-02,RECRUITING,OBSERVATIONAL,['NA']
10192,NCT00385177,Pharmacokinetic parameters for SN2310 and SN-38,,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10193,NCT05721300,Incidence of early liver cancer,,,2023-02-10,RECRUITING,INTERVENTIONAL,['NA']
10194,NCT02730533,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure,The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10195,NCT02864043,Performance of manually identified VLE features in predicting biopsy defined dysplasia,Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
10196,NCT05692037,Progression Free Survival Rate of Liver Target Lesions,Disease control rate (DCR),,2022-12-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10197,NCT00823810,Survival,Time to progression,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
10198,NCT03113955,Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging),Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread,,2017-10-24,COMPLETED,INTERVENTIONAL,['NA']
10199,NCT01898741,Safety,,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
10200,NCT02911363,Histological quality of the EMR specimen obtained during the procedure will be analyzed and compared to cassette vs. no cassette for pathology review.,Ease of use of the Captivator tissue cassette will be comparable to Standard of Care.,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10201,NCT02511223,Objective Response Rate (ORR) by using RECIST 1.1,,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10202,NCT01629004,Uptake of appropriate CRC screening,Uptake of lower gastrointestinal investigations,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
10203,NCT04291976,detection rate of neoplasia for each technique,Size of the lesion in mm,,2020-03-13,COMPLETED,INTERVENTIONAL,['NA']
10204,NCT00627042,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab,Number of Participants With Drug-Related Treatment-Emergent Adverse Events,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10205,NCT05663788,Pooled sensitivity of endoscopic optical diagnosis for predicting deep submucosal invasion in routine colonoscopies,Pooled LR- of endoscopic optical diagnosis for predicting deep submucosal invasion in a 20-image test before and after the learning module in the intervention group,,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
10206,NCT04831632,diagnostic performance,qualitative iFOBT positivity rate,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
10207,NCT06278701,Albumin rising,Improved quality of life,,2023-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10208,NCT04518579,anti tumour immunity,change in pain intensity,,2018-04-15,COMPLETED,INTERVENTIONAL,['NA']
10209,NCT00225641,Overall and cancer-specific mortality,Quality of life. Cost-effectiveness of follow-up,,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
10210,NCT02835924,Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.,Overall survival (OS),,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10211,NCT00502502,Patient Symptom Assessment (Questionnaire),,,2002-11,COMPLETED,OBSERVATIONAL,['NA']
10212,NCT03315195,Postoperative complications,,,2017-11-25,UNKNOWN,INTERVENTIONAL,['NA']
10213,NCT00471965,Overall survival,"Response rate, secondary resection rate, quality of life",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10214,NCT03291951,Number of moderate and severe chemotherapy-associated toxicities,,,2018-02-23,COMPLETED,INTERVENTIONAL,['NA']
10215,NCT00014079,Determine the clinical and pathologic significance of unstable DNA elements,Determine the clinical and pathologic significance of loss of heterozygosity,,1997-09,COMPLETED,OBSERVATIONAL,['NA']
10216,NCT06310902,Bioinformatics analysis of single-cell sequencing results,,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
10217,NCT00499395,Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease,Findings on day 7 after RFA using FDG-PET imaging,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
10218,NCT03740360,Mutations in pancreatic cystic neoplasm,Relation between pancreatic fluid and serum molecular analysis,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
10219,NCT03182179,Change in LARS score,Irritable Bowel Syndrome-Quality of Life,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
10220,NCT02215447,Response rate,Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
10221,NCT01383746,Progression -free survival at 6 months (from date of inclusion),Safety of RADIOEMBOLIZATION using the NCI-CTCAE V3.0 classification.,,2011-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10222,NCT03116945,"Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.",,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
10223,NCT01385956,Number of Participants With Serious Adverse Events,Number of Participants With Overall Survival (OS),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10224,NCT05592925,Postoperative pathological results of tumor N stage.,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
10225,NCT03601988,DFS,OS,,2018-07-28,UNKNOWN,INTERVENTIONAL,['PHASE3']
10226,NCT00540579,"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0",,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10227,NCT00355862,Recurrence free survival,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10228,NCT00136669,To determine the duration of acupuncture effects,,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10229,NCT05088889,"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1","Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0",Assessment of disease biomarkers as a surrogates or predictors to response following administration of SBRT and immunotherapy: Exploratory,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE1']
10230,NCT02527772,Progression-Free-Survival,Time-to-Progression,,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10231,NCT00917384,Overall Survival (OS),Number of Participants Who Developed Antibodies Against IMC-1121B,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10232,NCT05770635,Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation,,,2022-12-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10233,NCT02764801,Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization,,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10234,NCT02756468,Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery,PCT and CRP cuts-off in 5th POD with a good NPV for AL,,2015-01,UNKNOWN,OBSERVATIONAL,['NA']
10235,NCT06133062,Progression free survival (PFS),Incidence and severity of adverse events,,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2']
10236,NCT04380506,Validate the ability of the diameter (in cm) of abdominal collection detected during the contrast-free abdomen CT in POD3 to predict risk of biliary fistula,,,2020-03-15,UNKNOWN,INTERVENTIONAL,['NA']
10237,NCT04466254,Best of Response (BOR),Deepness of Response (DpR),,2020-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
10238,NCT03287375,"Number of patients with major/complete histologic response (PRGS 1+2) peritoneal biopsies, within a series of three PIPAC procedures.",Number of patients where MRI is accurate in describing PM distribution and progressive/regressive disease,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10239,NCT01434199,caecal intubation rate,Caecal intubation time,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
10240,NCT06223230,Median progression-free survival time,Duration of Response,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
10241,NCT03546998,Detection of epidermoid carcinoma of the esophagus,Result of achalasia treatment by investigating dysphagia and gastro-esophageal reflux,,1973-01-01,RECRUITING,OBSERVATIONAL,['NA']
10242,NCT04408859,Quality of life index,,,2018-04-17,UNKNOWN,OBSERVATIONAL,['NA']
10243,NCT00973609,Time to failure of maintenance and reinduction treatment strategy measured from randomization,"TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research.",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10244,NCT04021056,Evaluate the recurrence free survival rate of HCC patients after curative treatments,,,2011-01-01,UNKNOWN,OBSERVATIONAL,['NA']
10245,NCT04074538,Adenoma or advanced adenoma incidence,Second primary cancer incidence,,2013-01-01,RECRUITING,OBSERVATIONAL,['NA']
10246,NCT02595931,"Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride","Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride",Change in biomarker levels,2016-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10247,NCT04130971,Tumour response to treatment,Normal tissue response to treatment,,2019-02-01,RECRUITING,OBSERVATIONAL,['NA']
10248,NCT05163977,Post-Operative Pancreatic Fistula,primary or reactionary hemorrhage,,2021-06-12,UNKNOWN,INTERVENTIONAL,['NA']
10249,NCT02817308,correlation of CA19-9 levels in urine and saliva with those in the serum,Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum.,,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
10250,NCT00005874,,,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10251,NCT04592211,dose limiting toxicity,overall response rate,,2021-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10252,NCT04752215,Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period,Objective response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in patients with measurable disease,,2021-05-06,RECRUITING,INTERVENTIONAL,['PHASE1']
10253,NCT00844077,Conversion from Barrett's intestinal metaplasia to dysplasia or esophageal adenocarcinoma.,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
10254,NCT00619541,"N° of non progressive disease (complete and partial responses, stable disease)","Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10255,NCT04817813,Survival and disease-free survival at 5th year.,Follow up- Date of death,,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA']
10256,NCT01006577,Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score),cancer related deaths,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
10257,NCT00183872,"Objective Response (Complete, Partial, Stable and Progression)",Progression Free Survival,,2005-04-14,COMPLETED,INTERVENTIONAL,['PHASE2']
10258,NCT01953406,Time-to-progression(TTP)of lung metastasis,Disease control rates (CR + PR + SD)of lung metastasis,Adverse Events,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10259,NCT03961373,Overall survival analysis,Percentage of completion of protocol treatment,,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3']
10260,NCT00016042,,,,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10261,NCT03071237,Distribution of IPA origin,Reconstruction rate of IPA by CT scan,,2017-03-04,COMPLETED,OBSERVATIONAL,['NA']
10262,NCT04523389,Association between the number and size of exosomes and their content on cancer stage and progression,,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
10263,NCT05210322,Tube free survival,Complication rate,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
10264,NCT03801876,"Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment",Cost-benefit economic analysis of treatment,,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE3']
10265,NCT01238055,time to progression,Progression free survival,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10266,NCT03375320,Progression-free survival (PFS),Radiographic response rate,,2018-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10267,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),,2006-08,COMPLETED,OBSERVATIONAL,['NA']
10268,NCT04028375,MSCT and MRI staging in Gastric Cancer.,MSCT and MRI prediction of prognosis in gastric cancer,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
10269,NCT05515185,Maximum tolerable dose,,,2022-09-09,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10270,NCT00769106,Time to recurrence (TTR),AEs and SAEs,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10271,NCT05004441,objective response rate (ORR),adverse events (AE),,2021-07-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10272,NCT02831842,Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice,OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice,,2016-06-09,COMPLETED,OBSERVATIONAL,['NA']
10273,NCT02862613,Progress-free survival,Quality of life,,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10274,NCT05274945,pathological assessment of response to treatment,adverse events of chemotherapy,,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10275,NCT05307926,Disease-free survival,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
10276,NCT00271011,Percentage of Patients With an Objective Response,Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events,,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2']
10277,NCT03199144,patient overall survival,CEA level post operatively at one month,,2017-04-20,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10278,NCT00318903,The determination of pathologic response in patients who undergo surgical resection.,To assess the toxicities associated with this treatment and any impact on surgery.,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10279,NCT05959226,3-year overall survival rate,QLQ-C30 assessment,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10280,NCT01254617,"Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",Natural killer cell activation,Immune cell activation,2011-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10281,NCT01822444,Identification of biomarkers,Validation of identified biomarkers,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
10282,NCT00152230,Relapse-free survival and overall survival,Adverse events,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10283,NCT02751606,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.,Comparison of 7 Tesla and 3 Tesla MRI,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
10284,NCT01198522,Maximum tolerated dose and the preliminary tolerability profile.,Antitumor activity,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10285,NCT01822210,Change of tumor volume in the stomach.,performance status,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10286,NCT03628651,Biomarker Identification,,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA']
10287,NCT03801915,Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug,Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2019-11-13,COMPLETED,INTERVENTIONAL,['PHASE2']
10288,NCT02623153,response rate,adverse events,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10289,NCT00033462,Proportion of patients who are progression-free at 24 weeks,Overall response rate in EGFR positive patients,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10290,NCT01796145,Overall survival,Liver stiffness (kPa),,2013-02-27,RECRUITING,INTERVENTIONAL,['NA']
10291,NCT00034216,"Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.",,,2002-07-16,RECRUITING,OBSERVATIONAL,['NA']
10292,NCT03656627,Dose-Limiting Toxicity (DLT),Overall Survival,,2019-06-27,TERMINATED,INTERVENTIONAL,['PHASE1']
10293,NCT02861430,Concordance between immunochemistry and molecular biology,Disease-free survival,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
10294,NCT02078726,Adenoma Detection Rate (ADR) During Colonoscopy Procedure,,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10295,NCT05192460,Objective Response Rate (ORR),The concentration of Lymphocyte,,2022-03-28,RECRUITING,INTERVENTIONAL,['NA']
10296,NCT06096493,Disease free survival.,,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
10297,NCT02558504,complete histological eradication of the high grade glandular epithelial neoplasia,"Percentage of patients with severe adverse reaction and minor adverse reactions linked to the procedure used, described by anatomical site",,2013-01-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10298,NCT03567863,cumulative length of tissue core biopsies per needle pass,intra-observer evaluation of the anatomopathological criteria used,,2018-06-24,COMPLETED,INTERVENTIONAL,['NA']
10299,NCT01483638,progression-free survival,Adverse events,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
10300,NCT01419769,Safety - Freedom From Major Complications: SAE's,Clinical Success,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
10301,NCT01801163,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Time from start of treatment until death from any cause or date of last patient contact.,"3.2.4 To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms as well as serum VEGF and soluble VEGFR2 levels and correlate with efficacy outcomes.",2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10302,NCT06139042,"The sensitivity and specificity of the cfDNA methylation model in detection of liver, biliary tract and pancreatic cancers.","The sensitivity and specificity of the combined model in detection of different stages of liver, biliary tract and pancreatic cancers.",,2023-11-01,RECRUITING,OBSERVATIONAL,['NA']
10303,NCT05241899,Progression free survival (PFS),"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10304,NCT02166255,Overall survival,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10305,NCT03349255,Toxicity profile of ET1402L1-CART-cell treatment,AUC of serum cytokine levels,,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10306,NCT03720678,Incidence of dose-limiting toxicities (DLTs) during dose escalation phase,Immunomodulatory activity in subsets for AB928 in combination with mFOLFOX,,2018-11-18,COMPLETED,INTERVENTIONAL,['PHASE1']
10307,NCT01914692,fistula of pancreas,infection of incisional wound,postoperative pancreatitis,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10308,NCT03602703,Pattern of immunity in patients with de novo HCC develped after treatment with DAAs,,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
10309,NCT03519308,Number of Adverse Events,Proportion of Margin Negative Surgical Resections,,2020-07-29,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
10310,NCT03819920,Screening Behavior: Differences in colorectal cancer screening completion rates between usual care (UC) and CCRAT,Colorectal cancer screening rates at 12 months as a function of CCRAT score,Fear: Health Belief Model Likert Scale,2015-10-06,COMPLETED,INTERVENTIONAL,['NA']
10311,NCT05815082,5-year progression-free survival,Complications,,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3']
10312,NCT06232395,The performance of the new biomarkers in the post-operative monitoring of gastric cancer,The performance of the new biomarkers as prognostic biomarkers,,2024-02-18,RECRUITING,OBSERVATIONAL,['NA']
10313,NCT00290485,Patient response rate according to RECIST criteria,Evaluate whether the response rate can predict survival,,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
10314,NCT00885950,Histologically proven hepatic sinusoidal injury,90-day morbidity and mortality,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
10315,NCT04015245,Series changes of Prothrombin Time-Intemrnational Normalized Ratio,Series changes of blood pressure levels before and after TACE,,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10316,NCT05718232,Overall Survival (OS),Time to Progression （TTP）,,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10317,NCT01666444,Overall Survival,Frequency and Severity of Adverse Events (AEs),,2012-10-31,COMPLETED,INTERVENTIONAL,['PHASE2']
10318,NCT04607421,Cohort 3: Objective response rate by blinded independent review,Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746,,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE3']
10319,NCT04272034,Number of treatment-emergent adverse events,Vz/F of INCB099318,,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10320,NCT05628194,MSM awareness of strategies to decrease anal cancer risk,,,2023-06-08,RECRUITING,OBSERVATIONAL,['NA']
10321,NCT00303927,Toxicity,Response rate,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10322,NCT01188876,Best Overall Response,Area Under the Plasma Drug Concentration-Time Curve (AUC),,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10323,NCT05620537,postoperative overall survival,,,2022-11-10,COMPLETED,OBSERVATIONAL,['NA']
10324,NCT02135757,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
10325,NCT03243916,overall survival(OS),Quality of life (QOL),,2017-08-15,UNKNOWN,INTERVENTIONAL,['NA']
10326,NCT06185556,Local control,Cost-effectiveness ratio (ICER) per patient,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10327,NCT01908478,Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I),Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells,,2013-10-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10328,NCT01710215,Cost: Cost per-patient effectively screened.,Cost: Incremental costs for the FIT and Colo strategies relative to the Usual Care strategy.,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10329,NCT01877096,Screening colonoscopy completion,Psychological mediators,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
10330,NCT02269904,DFS (Disease Free Survival),adverse event,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
10331,NCT00418938,Progression-free Survival (PFS),Duration of Response,,2006-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10332,NCT01396668,Time to progression,clinical benefit rate,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10333,NCT04747600,the incidence of the pancreatic fistula,recurrence rate in percentage,,2014-06-01,COMPLETED,OBSERVATIONAL,['NA']
10334,NCT05169528,6-minute-walk-test,Patient Satisfaction Survey,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
10335,NCT02809898,Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）,Tumor status （worse/ maintain/ better）,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
10336,NCT01130337,Percentage of Participants With Disease-free Survival (DFS) at Month 18,Percentage of Participants With Objective Response,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10337,NCT00887822,Overall Survival,Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10338,NCT01995396,Rates ot postoperative surgical complications within 30 days.,Other postop complications,Late complications after surgery,2014-02,TERMINATED,INTERVENTIONAL,['NA']
10339,NCT06260943,Proportion of Participants Enrolled in Clinical Research,,,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10340,NCT01843400,Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.,Tumor response assessed by RECIST or physicians own evaluation,,2013-04-22,COMPLETED,OBSERVATIONAL,['NA']
10341,NCT01705002,Pharmacokinetic (PK) profile of PROMITIL,Toxicity profile of PROMITIL,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10342,NCT05176860,CBCT Image Quality,Patient Experience,,2022-12-20,COMPLETED,INTERVENTIONAL,['NA']
10343,NCT04568330,Scale,Scale,Scale,2014-03-21,COMPLETED,INTERVENTIONAL,['NA']
10344,NCT04999072,Relapse free survival,,,2020-04-19,UNKNOWN,OBSERVATIONAL,['NA']
10345,NCT00610389,Response rate,Immunological response,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
10346,NCT04140552,Overall Survival,,,2008-01-01,RECRUITING,OBSERVATIONAL,['NA']
10347,NCT01719926,Number of dose limiting toxicities at each dosage cohort,Efficacy,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10348,NCT03565029,Distant Relapse-Free Survival (DRFS),Patient reported outcomes,,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10349,NCT04713618,Change in sexual function,Change in vaginal microbiome,,2021-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10350,NCT02702401,Overall Survival (OS),Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE),,2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
10351,NCT04589975,Conversion to open rate: predictive factors oncological outcomes,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
10352,NCT05967910,Effect of Chronic stress on efficacy of immune checkpoint inhibitors,Effect of chronic stress on quality of life,The correlation between peripheral immune cells signature and chronic stress and the efficacy of ICIs,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
10353,NCT03174574,"Genomic and risk factor differences among family members who share identical predisposing CDKN2A gene mutations, with different phenotypes; will discover patterns of tumorigenesis, tissue specificity, gene-gene, and gene-environment interactions.",,,2016-08-17,COMPLETED,OBSERVATIONAL,['NA']
10354,NCT02250209,3-year disease-free survival (DFS),Prognostic value of biomarkers,,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
10355,NCT05701553,Incidence of adverse events,12-month survival rate,,2023-01-26,RECRUITING,OBSERVATIONAL,['NA']
10356,NCT05849571,Children's International Mucositis Evaluation Scale (ChIMES),,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
10357,NCT05920928,Clinical complete response,,,2023-09-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10358,NCT03627728,PFS1,biomarker evaluation,,2018-06-13,RECRUITING,INTERVENTIONAL,['PHASE2']
10359,NCT05458388,Early gastric cancer detection rate,,,2022-07-12,RECRUITING,INTERVENTIONAL,['NA']
10360,NCT00562380,Pharmacokinetic profile,Circulating levels of IGF-1R and IGF-BP3,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10361,NCT01395667,Maximally tolerated dose,Improved rate,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10362,NCT03244787,Percentage of patients in intervention and control groups who completed any colorectal cancer screening during the six-month study period,Number of polys found in intervention polyps (histology),,2017-01,COMPLETED,INTERVENTIONAL,['NA']
10363,NCT02510378,percentage of patients undergo R0 surgery during the follow-up,The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0),,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10364,NCT01783171,MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients,Progression-free survival,Protein expression in serum as measured by fluorescence activated cell sorting (FACS),2013-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
10365,NCT03071458,Genetic and transcriptomic landscape,Validation of the molecular classification by integrative analysis,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
10366,NCT06228963,6-months CR rate,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Exploratory biomarkers,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
10367,NCT02871245,Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.,Immune cell number ratio in blood.,,2016-09-21,UNKNOWN,INTERVENTIONAL,['NA']
10368,NCT00003677,Number of Patients with Toxicity,,,1999-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10369,NCT00869570,Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II),Adverse events as assessed by NCI CTCAE v3.0,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10370,NCT05840263,Extract key themes to integrate into preliminary drafts,,,2023-05-31,RECRUITING,OBSERVATIONAL,['NA']
10371,NCT00741676,2 year survival,efficacy and clinical out come,,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
10372,NCT05162755,Assessment of antitumor activity using RECIST v1.1 (Dose expansion part),Overall Survival (OS) (Dose escalation and dose expansion parts),,2021-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10373,NCT02889328,Disease control rate,Toxicity profile by the NCI-CTCAE v4.03,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10374,NCT02437916,AMG 228 half-life (t1/2),Changes in numbers of cytotoxic T lymphocytes (CTL),,2015-04-21,TERMINATED,INTERVENTIONAL,['PHASE1']
10375,NCT04970056,Development of PDAC,,,2020-09-18,RECRUITING,OBSERVATIONAL,['NA']
10376,NCT01992406,Transanal specimen extraction possible or not,quality of life,,2013-11,UNKNOWN,OBSERVATIONAL,['NA']
10377,NCT04692987,Number of participants with colorectal cancer screening completion,Barriers towards the colorectal cancer screening uptake,,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
10378,NCT01266187,Disease free survival,Secondary objectives,,2011-07,TERMINATED,INTERVENTIONAL,['NA']
10379,NCT00310115,Number of Patients with Smoking Abstinence,Number of Cigarettes Smoked Daily,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
10380,NCT04117100,Assess the number of patients with intraprocedural bleeding,,,2018-06-01,RECRUITING,OBSERVATIONAL,['NA']
10381,NCT04228614,prediction accuracy of recurrent rate,Mutation Consistency of tissue and blood sample,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
10382,NCT01473303,Convergent validity of each selected PRO-CTCAE item (phase II),Responsiveness (sensitivity to change) of PRO-CTCAE (phase II),,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10383,NCT03955224,Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline,Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0,,2021-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10384,NCT06185907,Duration of stay,,,2021-04-15,COMPLETED,OBSERVATIONAL,['NA']
10385,NCT02455648,Post-operative stenosis,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
10386,NCT00114244,Objective Response (OR = CR or PR) as Determined by the RECIST Criteria,Progression-free Survival,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10387,NCT02386397,Limiting toxicity,,,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10388,NCT06034860,Proportion of participants with objective response,Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1']
10389,NCT00006046,Number of Patients With Dose-limiting Toxicities (DLTs),Number of Patients With Tumor Responses,,2000-07-12,TERMINATED,INTERVENTIONAL,['PHASE1']
10390,NCT03719924,survival at 9 months,Quality of life (questionnaires),,2019-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10391,NCT01145404,Objective response rate (ORR),Biomarker analysis,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE2']
10392,NCT02652663,Disease free survival,,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
10393,NCT01953419,ORR,,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10394,NCT00867334,Number of Patients With Adverse Events,Number of Participants With Stabilization or Reduction in Tumor Size,,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10395,NCT01326065,Long term outcome,Quality of the surgical specimen,,2011-02,TERMINATED,OBSERVATIONAL,['NA']
10396,NCT02485834,Overall Survival,Number of Participants Who Reported Grade 3 or Higher Adverse Events,Change in FDG-PET SUV Measures,2015-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10397,NCT06016400,Within two months from the start of chemotherapy,Length of hospital stay of patients in vitamin D treatment group and placebo group,,2021-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10398,NCT01483014,Objective response using the RECIST criteria,Overall survival,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10399,NCT02789709,Disease-free survival,Postoperative mortality,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
10400,NCT04281290,Evaluation of feasibility and safety,Overall Survival,,2020-07-13,TERMINATED,INTERVENTIONAL,['PHASE1']
10401,NCT04292366,Number of residents participating in colorectal cancer screening,,,2020-10-02,COMPLETED,INTERVENTIONAL,['NA']
10402,NCT02218801,Number of post-operative complications,Number of post-operative complications in the first 50 patients compared to the second 50 patients,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
10403,NCT02475772,Adverse events according to CTCAE criteria,Clinical benefit according to RECIST criteria,Plasma concentrations of cisplatin and doxorubicin,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10404,NCT03598998,Overall response rate (ORR) according to Lugano classification (Phase II),Incidence of unacceptable toxicity assessed by NCI CTCAE version 5.0,,2019-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10405,NCT04889742,Local tumor recurrence,Patient reported quality of Life,,2024-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10406,NCT00022139,Proportion of successes,Quality of life,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10407,NCT06256705,"Clinical response defined by the PFS as the time measured from the day of first administration of PRRT to first progression or death at 18 months, whichever occurs first",,,2024-03-25,RECRUITING,INTERVENTIONAL,['NA']
10408,NCT06241079,Overall survival,,,2003-03-31,COMPLETED,OBSERVATIONAL,['NA']
10409,NCT01428752,prevalence of colorectal adenoma(any size),prevalence of advanced adenoma,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
10410,NCT03388047,Level of confidence in delineating the area of interest by multispectral imaging,Correlation with molecular biomarkers,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
10411,NCT01650428,Pathological Complete Response (PCR),Tumour Cell Density,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10412,NCT00107341,Confirmed tumor response rate,Duration of response,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10413,NCT00733746,Overall Survival at 2 Years,Response Rate,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10414,NCT05003700,Objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10415,NCT05195502,Evaluation of metabolic profile,Colonic biofilm,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10416,NCT01653327,Change in Pain Score,Duration of Analgesic Effect,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10417,NCT03476057,cfDNA,Tumor mutation burden,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
10418,NCT06048458,Change in myocardial blood flow from baseline with adenosine stress assessed by quantitative perfusion cardiac MRI,Change in retinal vessel density,,2022-05-18,RECRUITING,OBSERVATIONAL,['NA']
10419,NCT04354662,Pathological complete response rate (pCR),5-year Survival Rate,,2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
10420,NCT04044313,Progression free survival rate at 6 months,Adverse events,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10421,NCT03459235,assessment of quality of life of patients operated for a rectal cancer (rectal resection) - Sexual sequelae (for men),,,2018-03-20,UNKNOWN,INTERVENTIONAL,['NA']
10422,NCT06320301,the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC,To evaluate the overall survival (OS).,The DoR based on an immunomodified RECIST (imRECIST）,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10423,NCT05319314,Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study,Tmax: The time to reach maximum(peak) in peripheral blood or other body fluid drug concentration after single dose administration (days),,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
10424,NCT01933945,Overall survival (OS),TTP from initiation of sorafenib,Duration of treatment of sorafenib after TACE,2013-10-28,COMPLETED,OBSERVATIONAL,['NA']
10425,NCT00856375,Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population,PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10426,NCT05007548,Correlation of the ICGR15 with the conventional liver function tests,Comparison of CTV and Ga68-Dolacga PET parameters in patients with PHLF,,2021-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
10427,NCT03181334,Increase in colorectal cancer screening rate of the 5 tested invitation approaches.,,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
10428,NCT05278195,Overall Survival(OS),Accuracy,,2022-04-01,UNKNOWN,OBSERVATIONAL,['NA']
10429,NCT03334890,mSEPT9 level,"CR,PR,SD,PD",,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
10430,NCT04466124,Establish a cohort of liver cancer patients treadted with proton beam therapy.,,,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10431,NCT03470883,Complete long-term remission (> 12 months),Endoscopic description and anatomopathological results,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
10432,NCT03392103,The ratio of patients occured Grade 3 or higher adverse events,3-year overall survival probability,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10433,NCT06038578,Progression free Survival (PFS),Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores,,2023-10-04,RECRUITING,INTERVENTIONAL,['PHASE2']
10434,NCT03969784,percentage of microparticule,,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10435,NCT00601510,Overall tumor response as assessed by RECIST,Quality of life,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10436,NCT01230697,Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration,Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival),,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
10437,NCT00016250,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10438,NCT01838109,Body weight decrease rate 8weeks after discharge compared with preoperative body weight,serum albumin,ONS related gastrointestinal adverse event,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10439,NCT06014944,cCR rate,,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10440,NCT02556619,Change in Health-Related Quality of Life (HRQoL),Cost Utilization,,2019-04-02,UNKNOWN,INTERVENTIONAL,['NA']
10441,NCT01853813,Response Rate,"evaluation of serum IL-8, bFGF, HGF, PlGF, SDF-1, MCP-3",RECIST criteria and those defined by Chun,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
10442,NCT05526846,Effect of the intervention on participant's Healthy Plant-Based Diet Index,Secondary health gains associated with adopting a plant-based diet,,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10443,NCT00625625,Disease-free survival,,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
10444,NCT00999882,Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing,To collect and store DNA for future exploratory research that may influence response to AZD8055,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10445,NCT05179837,Proportion of participants that have a lesion that can be adequately evaluated with OCT,Weighted kappa,,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
10446,NCT03419481,Response rate (RR) according to RECIST1.1,Overall survival (OS),,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10447,NCT05083247,R0 Resection rate,Technical and quality success rate of EUS-delivered fiducials.,,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2']
10448,NCT00006038,,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10449,NCT00504322,Expression of CD40L and cytokines,,,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10450,NCT05716594,Disappearance rate of pseudocyst（PDR） after stent implantation,Time of disappearance of pseudocyst after stent implantation,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10451,NCT06151223,Collection of radiology images and videos,,,2021-07-13,RECRUITING,OBSERVATIONAL,['NA']
10452,NCT00265798,Objective Response Rate,Overall Survival,,2005-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10453,NCT06328101,Standardized incidence ratio (SIR) of first invasive cancer,Risk factor associated with cancer diagnosis.,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10454,NCT02025842,risk for hepatocellular carcinoma,survival,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
10455,NCT04039607,Overall Survival (OS),Time to Symptom Deterioration (TTSD),,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10456,NCT01236300,NPV (Negative Predictive Value),Overall Complication Rate,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
10457,NCT04241835,"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma",To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0,,2020-01-28,RECRUITING,INTERVENTIONAL,['PHASE1']
10458,NCT00122720,"The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life",Postoperative complications,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10459,NCT03885219,6-month progression-free survival (PFS),Objective Response Rate (ORR),,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10460,NCT00079066,Overall survival,Safety profile,,2003-12-30,COMPLETED,INTERVENTIONAL,['PHASE3']
10461,NCT04499924,Incidence of dose modifications (Phase 2 only),Utility index values as assessed by the EQ-5D-5L,,2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10462,NCT00575523,Occurrence of dysrhythmias,Clinical complications,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10463,NCT01275222,Progression-free Survival (PFS) - Phase II,"Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.",,2002-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10464,NCT02066272,The frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
10465,NCT06024980,Swallowing ability to four different textures,The time in weeks of nasogastric feeding,,2023-01-03,RECRUITING,INTERVENTIONAL,['NA']
10466,NCT04562727,DFS,Tumor reactivity assessment,,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10467,NCT05568017,objective response evaluation,analysis of tumor specific circulating NET transcripts,,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
10468,NCT01596283,Postoperative Complications,Postoperative Length of Stay,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10469,NCT00056537,Maximum Tolerated Dose (MTD) as a function of pre-treatment anti-SEA/E-120 levels,Time to progression and Survival,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10470,NCT03834701,Incidence of adverse events (AEs) after EUS-guided radiofrequency ablation (RFA),Rates of secondary surgery,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10471,NCT01718873,Objective Response Rate,Toxic Effects,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10472,NCT01375088,NCI.CTC Scale,hyposalivation scale,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10473,NCT05229003,ORR,AEs,,2022-03-09,RECRUITING,INTERVENTIONAL,['PHASE2']
10474,NCT00981162,Maximum tolerated dose of everolimus (Phase I),Toxicity and adverse events as assessed by NCI CTCAE v3.0,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10475,NCT05010434,ORR (objective response rate),Adverse effects,,2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10476,NCT00449137,Thymidylate synthase expression,,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10477,NCT01556815,Effectiveness of sorafenib in increasing the effectiveness of transarterial chemoembolization (TACE),Survival in the two treatment groups,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
10478,NCT02029157,Progression-free survival (PFS),Overall survival,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10479,NCT04003181,Serum concentration of FGF19,Quality of life after treatment with antibiotics or bile acid binder,,2017-09-28,COMPLETED,INTERVENTIONAL,['NA']
10480,NCT03749083,One year local recurrence rate in participants that test positive for ctDNA compared to participants that tested negative for ctDNA,Median Fecal Incontinence Severity Index (FISI) score,,2019-12-31,WITHDRAWN,OBSERVATIONAL,['NA']
10481,NCT00084773,Safety profile,Activity in terms of pathological complete response rate,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
10482,NCT05364918,Acute radiotherapy-induced oral mucositis,Oral pain,,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE3']
10483,NCT04503967,Objective response rate,Overall survival,,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10484,NCT00055250,6-month survival,PK,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10485,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
10486,NCT00817895,disease free survival,overall survival,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
10487,NCT05135364,Progression-free survival (according to mRECIST),Disease control rate (according to mRECIST and RECIST 1.1),,2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2']
10488,NCT01927016,To identify predictors of recurrence after esophageal cancer surgery,"Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes",,2012-07,COMPLETED,OBSERVATIONAL,['NA']
10489,NCT03045497,Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads,Changes in contrast fill time,,2012-12-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10490,NCT00541125,Toxicities by NCI-CTC v. 2.0,Time to treatment failure,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10491,NCT00891332,Overall Response Rate (ORR),Pharmacokinetics,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10492,NCT00570713,Overall Survival (OS),Best Overall Response Rate,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10493,NCT01789229,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,,,2003-09,RECRUITING,OBSERVATIONAL,['NA']
10494,NCT05985798,Overall survival (OS),Adverse Events (AEs),,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10495,NCT06313268,Adverse events,,,2022-04-21,RECRUITING,OBSERVATIONAL,['NA']
10496,NCT03239158,Relief degree of tumors,Overall survival（OS）,,2017-09-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10497,NCT00003298,Grade 3 or Higher Toxicity Incidence on Step 1,Progression Free Survival,,1999-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10498,NCT00828984,Difference (After Treatment Minus Before Treatment) of EGFR Expression,Change in E-cadherin Expression as Measured in Endoscopically Normal (Non-ACF) Mucosal Biopsies,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10499,NCT01150916,diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
10500,NCT00134589,Completion of colorectal cancer screening,Patient's intention to ask/patient asking medical provider for colorectal cancer screening,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10501,NCT03449030,Recommended Phase 2 Dose (RP2D) of TAK-164,Number of Participants With Positive Antidrug Antibody (ADA) Levels in Serum,,2018-04-23,TERMINATED,INTERVENTIONAL,['PHASE1']
10502,NCT01048580,"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)",Pharmacokinetic (PK) data for the combination of perifosine and capecitabine,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10503,NCT02534142,Variables related to non-completion of colonoscopy following a positive fecal occult blood test,,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
10504,NCT01377220,,,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
10505,NCT02081547,IPC status,Survival,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
10506,NCT02117674,polyp detection rate,patients' satisfaction,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10507,NCT05874726,Tissue sample repository,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
10508,NCT01372527,Cancer completion for all eligible cancers,TopCare system measures (intervention practices),,2011-06,COMPLETED,INTERVENTIONAL,['NA']
10509,NCT01549795,Time to recurrence after liver transplant,Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis),,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
10510,NCT06321913,vital signs,Overall Survival (OS),CLDN18.2 expression level,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10511,NCT05374369,Tumor detection rate in the positive screening results,,,2022-03-29,COMPLETED,OBSERVATIONAL,['NA']
10512,NCT01895257,Time to progression (TTP1 overall),Overall Survival (OS),SIR-spheres treatment,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
10513,NCT02537171,Progression-free survival (PFS),Adverse Events(AEs),,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
10514,NCT05935384,Sensitivity of ctDNA to Detect Disease Progression,Lead Time,,2023-10-25,RECRUITING,OBSERVATIONAL,['NA']
10515,NCT05415709,Incidence of chemotherapy-related adverse events,Quality of life (QOL) assessment EORTC QLQ-C30,,2022-06-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10516,NCT05642338,HGD/EAC,The rate of progression to HGD/EAC after a WATS-positive-biopsy-negative diagnosis for HGD/EAC,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
10517,NCT02287597,"Effectiveness: Second-line time to progression, in months","Safety (composite outcome measure): Incidence, nature and severity of all serious adverse events reported in second line mCRC treatment with Avastin plus chemotherapy and information on outcome and action taken with the drug",,2014-11-13,COMPLETED,OBSERVATIONAL,['NA']
10518,NCT02867592,Objective Response (Osteosarcoma Stratum),Overall Survival (OS),Change in Immune Biomarkers,2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10519,NCT04239261,Development of Oral Mucositis during ChemoRadiation Treatment,Change in Bowel Movements,,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE2']
10520,NCT00001332,,,,1992-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10521,NCT03403296,overall survival(OS),,,2016-07-13,COMPLETED,OBSERVATIONAL,['NA']
10522,NCT04616495,five year overall survival (OS),Quality of life using EORTC questionnaires: QLQ-C30,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
10523,NCT06138769,Progression-free survival,Adverse events,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10524,NCT02799212,presence of postoperative ascites during the postoperative course,Postoperative morbidity on Renal failure,,2018-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10525,NCT03135652,Disease free survival,Toxicities,,2017-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10526,NCT03503630,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269,Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire,,2018-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10527,NCT04314349,Correlation of radiogenomics,Treatment response and survival,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
10528,NCT05458791,Quantification of Parameters for Intra-arterial Perfusion,Impact of low dose radiation technique on intra-arterial perfusion parameters,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
10529,NCT01197664,"Toxicity and tolerability of the paricalcitol regimen, as measured by calcium levels",Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
10530,NCT04485286,Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.,,,2020-07-19,RECRUITING,INTERVENTIONAL,['PHASE2']
10531,NCT01539824,Disease stabilisation rate,Tumour Markers,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10532,NCT02981719,Safety (number of adverse effects),Technical success of ablation,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
10533,NCT02677597,PFS,,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10534,NCT00956241,Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.,Quality of life,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
10535,NCT01991379,Best Response Rate (phase II portion),RR by EORTC criteria,,2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10536,NCT04054713,Comparing the incidence of dysplasia by directed biopsies with acetic acid chromoendoscopy against taking non-directed protocolized biopsies( Seattle protocol) in patients with Barrett's esophagus.,,,2019-07-03,RECRUITING,INTERVENTIONAL,['NA']
10537,NCT05924282,5-year overall survival,Readmission,,2010-07-01,COMPLETED,OBSERVATIONAL,['NA']
10538,NCT04178642,The survival rate without hepatic recurrence at 1 year,Overall survival,,2020-09-22,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10539,NCT02937519,Number of Participants with Adverse Events as a Measure of Safety,Overall survival,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
10540,NCT04722055,Kappa coefficient,,,2021-01-26,COMPLETED,OBSERVATIONAL,['NA']
10541,NCT04721470,AFP variation rate,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
10542,NCT00955149,To examine the safety and tolerability of Tarceva (Erlotinib) in patients with primary sclerosing cholangitis and trisomy 7 on biliary cytology.,To assess among patients with primary sclerosing cholangitis and trisomy 7 the resolution of this cytologic abnormality following treatment with Tarceva (Erlotinib).,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10543,NCT00162110,Evaluate the efficacy of Erbitux in the treatment of mucinous gastrointestinal adenocarcinoma involving the peritoneal surfaces based on clinical response rate.,"To evaulate surgically resected tumor specimens of the EGF receptor, mucins 1-6, and anglogenic indices such as vessel counts, VEGF expression, and Ki-67 expression. To evaluate the safety of Erbitux monotherapy in this patient population.",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10544,NCT03899415,Safety evaluation based in Incidences of adverse events/serious adverse events,Overall survival rate,,2019-04-20,RECRUITING,INTERVENTIONAL,['PHASE1']
10545,NCT00594529,Curative resection rates of liver metastases,Completion rates of neoadjuvant chemotherapy,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10546,NCT05964361,Safety of IL15/IL15Ra/WT1 DC vaccine administration: total (S)AEs (grade),Evaluation of changes in quality of life: How patient-reported quality of life evolves over time,,2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10547,NCT04597970,Progression free overall survival，PFS,Overall survival， OS,,2020-10-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
10548,NCT01493206,clinical outcomes,toxicities,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10549,NCT02066064,G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.,"polyp and adenoma detection, procedure times and safety",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
10550,NCT04008511,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Overall response rate (ORR),,2019-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10551,NCT03817866,Disease Progression,,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
10552,NCT04245683,patient preferences for operative vs. non-operative management of rectal cancer,Patient adherence to surveillance protocols,,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
10553,NCT03206151,Progression-free Survival (PFS),Incidence of anti-CMAB009 antibody,,2017-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10554,NCT05869097,Overall Survival (OS),Treatment-Related Adverse Events (TRAE),,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
10555,NCT00763425,Complete removal rate of colorectal polyps,Complication rate,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
10556,NCT00434161,Incidence of Cataract Development or Progression at Month 12.,Incidence of Second Primary Malignancies or Other Malignancies,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10557,NCT05856500,Appendicular skeletal muscle mass index(kg/㎡),Survival rate(%),,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10558,NCT00574353,"the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.","determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent",,2007-12,WITHDRAWN,INTERVENTIONAL,['NA']
10559,NCT04072224,Description of volume of in vivo ablation,liver response,,2018-10-23,COMPLETED,OBSERVATIONAL,['NA']
10560,NCT01161316,progression-free survival,Adverse events,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10561,NCT04149613,microRNA expression Level,Dietary pattern,,2018-05-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10562,NCT00885885,Objective response rate,Evaluation of molecular predictive markers for response.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
10563,NCT02987699,Tumor response,Number of of Patients developed Adverse Events,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10564,NCT01106066,MTD/pathologic CR,,,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10565,NCT05028933,Adverse Event(AE),Number of circulating tumor cells (CTC) in peripheral blood,,2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE1']
10566,NCT03172377,Cumulative incidence of persistent disease flares.,The decremental cost effectiveness ratio of this interval lengthening strategy,,2017-05-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10567,NCT03700398,detect rate,,,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA']
10568,NCT01457976,"Survey respondents are presented with scenarios that seek to elicit views and attitudes on the concepts of personal responsibility, and the acceptability of financial incentives. The analysis will present these views and attitudes in aggregate form.",,,2011-09,WITHDRAWN,OBSERVATIONAL,['NA']
10569,NCT05088733,Survival rate,quality of life (QOL) questionnaire,,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10570,NCT02273167,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Polyp Detection Rate (Overall Colon),,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10571,NCT04845490,overall survival,The positive rate of cancer cells of participants by exfoliative cytology examination,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10572,NCT00379639,Best Overall Response,,,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10573,NCT04123574,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,Genomic analysis before and after treatment.,,2019-10-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
10574,NCT00263055,Occurrence of dose-limiting toxicity,Long term toxicity,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4']
10575,NCT05847855,Sensitivity and specificity,Sensitivity and specificity in distinguishing different AJCC stages,,2023-04-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10576,NCT00591045,5 year overall survival,R0 resection rate,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10577,NCT04771520,Overall response rate (ORR),Incidence of adverse events,,2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10578,NCT03985891,ORR,OS,,2020-12-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10579,NCT05517239,Progression free survival,Overall survival,,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10580,NCT00962494,Health Behaviors,Satisfaction with intervention,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10581,NCT05643677,Progression-free survival (PFS),Overall survival（OS）,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10582,NCT00530010,Patient Completion,,,2004-12,COMPLETED,OBSERVATIONAL,['NA']
10583,NCT05025371,Overall survival,,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
10584,NCT05589480,Recurrence-free survival,,,2022-08-01,COMPLETED,OBSERVATIONAL,['NA']
10585,NCT00441311,Colorectal cancer screening recommendations,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10586,NCT02264665,Number of Participants With Adverse Events Leading to Death - Based on Treatment Received At-least Once During the Study,Number of Participants With Types of Main Lines of Treatment Received During the Follow-up - Based on Targeted Therapy Group and Other Treatments Group at Inclusion,,2015-05-12,COMPLETED,OBSERVATIONAL,['NA']
10587,NCT05408182,Postoperative pain score,Readmission rate,,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10588,NCT04912258,liver relapse-free survival,response rate,,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10589,NCT00030342,Safety as measured by NCI common toxicity table at study completion,,,2001-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10590,NCT05493332,Conversion therapy success rate,Patient reported outcome（PRO）,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10591,NCT00792350,"Efficacy: status of tumor, patients performance status",Reports of adverse events,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
10592,NCT02124148,Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414,"B2, E2, E3 Dose Expansion: Duration of Response",,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE1']
10593,NCT04104633,Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV),Identification of patient's tumor genomic profile with blood sample,,2018-06-14,UNKNOWN,INTERVENTIONAL,['NA']
10594,NCT04712604,Acceptability of the intervention,Change in quality of life,,2021-03-14,COMPLETED,INTERVENTIONAL,['NA']
10595,NCT01505166,Percent of Patients Who Survived After Treatment (Part 2),,Number of Alive Subjects (Part 1),2012-03,TERMINATED,INTERVENTIONAL,['PHASE2']
10596,NCT03387982,Difference in pain quality 4 weeks post-procedure for subjects receiving Balloon Cryotherapy or Radiofrequency Ablation via the Pain Quality Assessment Scale (PQAS),,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
10597,NCT01285557,Overall Survival (OS),Time to Tumor Response (TTR),,2011-04-14,TERMINATED,INTERVENTIONAL,['PHASE3']
10598,NCT05355168,Major pathological remission rate,"1-, 2-, 3-year Disease-free survival rate (DFS).",,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10599,NCT02383797,Number and severity of adverse events to vaccination,,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
10600,NCT00153998,"Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population",Molecular predictive markers for response and toxicity,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10601,NCT00807911,disease-free survival,"overall survival, pattern of failure,safety, quality of life",,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10602,NCT01324882,Intubation of Cecum,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
10603,NCT01825603,"Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",Survival,,2013-04-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10604,NCT02671357,The incidence of severe complications,"Postoperative in-hospital, 30-day and 90-day mortality",Delayed gastric emptying (DGE) rate,2016-03,COMPLETED,OBSERVATIONAL,['NA']
10605,NCT03058289,Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5),"Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6.",Exploratory: Overall Subject Outcome,2017-02-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10606,NCT02751736,Low Anterior Resection Syndrome score,Postoperative complication,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
10607,NCT02238847,"Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms","For Participants Not Undergoing Curative Intent Surgery, Sustained Biliary Drainage to One Year After Stent Placement",,2015-03-24,COMPLETED,INTERVENTIONAL,['NA']
10608,NCT06278883,Uptake of genetic testing recommendations by the provider,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10609,NCT00462501,Complete Pathologic Response,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10610,NCT00117299,Response rate,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10611,NCT02844075,complete pathologic response rate,Incidence of adverse event based on CTCAE 4.0.,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10612,NCT00054262,,,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10613,NCT05178628,The number of VTE events during the trial,Change from baseline in QoL,,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3']
10614,NCT06199895,Objective Response Rate,Incidence of adverse events,,2023-11-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10615,NCT03292991,"Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.",Liver transplantation rate,,2015-06-09,UNKNOWN,OBSERVATIONAL,['NA']
10616,NCT00849979,Validation of M. D. Anderson Symptom Inventory - Gastrointestinal (MDASI-GI) Questionnaire (Response),,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
10617,NCT01473121,Descriptive analysis of clinical profile of newly diagnosed HCC patients,Descriptive analysis of tumor properties,,2012-08-13,COMPLETED,OBSERVATIONAL,['NA']
10618,NCT00020761,To determine the antitumor activity of irinotecan and paclitaxel in patients with unresectable adenocarcinoma of the esophagus and gastric cardia.,To evaluate the toxicities of irinotecan and paclitaxel in this patient population.,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10619,NCT03257163,Recurrence-free survival (RFS) rate,,,2017-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
10620,NCT02006030,Determine time to tumor progression (TTP),Tumor response rates,,2014-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10621,NCT00677924,Number of Participants With Adverse Events (AEs),Number of Participants With Best Overall Tumour Response (BOR),,2008-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10622,NCT05760430,Conversion rate,Overall survival,,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2']
10623,NCT01508000,Progression free survival,Safety,,2013-06,TERMINATED,INTERVENTIONAL,['PHASE2']
10624,NCT01260194,Median Progression Free Survival (PFS),Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4']
10625,NCT05316818,Rate of adverse events,Overall survival time (OS),,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2']
10626,NCT02418988,overall survival,progression-free survival,,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
10627,NCT00130689,Overall Response Rate,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10628,NCT05561907,Time to initiation of solid oral intake without symptoms of GOO,Chemotherapeutic regimen tolerance,,2022-10-28,RECRUITING,INTERVENTIONAL,['NA']
10629,NCT00746317,Determine the safety and tolerability of escalating doses of GC33,Perform a preliminary assessment of anti-tumor activity of GC33,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10630,NCT04975620,Comparison of EUS-FNB sensitivity using two types of FNB needles,Comparing the score of blood content n for each pass in two types of FNB needles.,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
10631,NCT04053985,PFS,DCR,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10632,NCT00019344,,,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10633,NCT04152356,Disease-free Survival,Overall Survival,,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA']
10634,NCT00072553,Response rate,Quality of life,,2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10635,NCT02910960,Total area of procured tissue between the two FNB needles,Diagnostic adequacy between the two FNB needles,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
10636,NCT04603040,Objective response rate (ORR),OS rates at 9 months and 12 months,JS001 anti-drug antibody assessment,2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
10637,NCT00420394,Feasibility of the study regimen.,Overall and progression free survival following the study treatment plan,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
10638,NCT00080002,,,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2']
10639,NCT04673968,Body composition,Mitochondria functionality,,2020-02-25,RECRUITING,INTERVENTIONAL,['NA']
10640,NCT04597294,Peritoneal recurrence rate,Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22),,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10641,NCT04535414,Determine if Bethesda protocol provides improved sensitivity for detection of early stage gastric cancer in CDH1 germline mutation carriers compared to the Cambridge method,To estimate and compare the difference in crude cancer detection rates between endoscopy using the Bethesda protocol and the Cambridge method,,2023-06-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10642,NCT01482442,Median overall survival time,Health care costs,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10643,NCT01196130,Rate of Successful Biomarker Determination,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
10644,NCT05722275,The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system,The accuray of intelligent analysis system in predicting peritoneal metastasis,Overall survival,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
10645,NCT02045368,Maximum Tolerated Dose (MTD),Disease Response based on RECIST Criteria,,2014-01-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10646,NCT02902484,Maximum Tolerated Dose (MTD),,,2017-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10647,NCT05625893,Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0),Local tumor progression rate,,2022-09-16,RECRUITING,INTERVENTIONAL,['PHASE2']
10648,NCT03069950,Resection rate assessed using RECIST (version 1.1),,,2017-02-28,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10649,NCT05545046,Visual Analogue Scale (VAS),,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
10650,NCT06086002,Technique efficacy,,,2023-09-18,RECRUITING,INTERVENTIONAL,['NA']
10651,NCT01440855,Reported uptake of behavioral actions recommended in Facing Forward,Usability of Facing Forward,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
10652,NCT01982227,Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo,Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
10653,NCT03693807,% frequency liver toxicity,progression free survival,,2018-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10654,NCT01348503,Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.,,,2011-05,TERMINATED,INTERVENTIONAL,['PHASE1']
10655,NCT05505370,Intubation of terminal ileum and cecum,User feedback for operating characteristics of the device,,2022-04-21,COMPLETED,INTERVENTIONAL,['NA']
10656,NCT04763824,Percent change in evidence based cancer screening,,Participation rates in the Telementoring and Practice Facilitation Sessions,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10657,NCT01526200,new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography,new colorectal liver metastases detected during 6-month postoperative follow-up,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
10658,NCT05291338,Interleukin 28 B (IL28B) rs12979860.,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
10659,NCT02056548,Cumulative incidence rate of hepatitis B viral reactivation,Severity of reactivation of hepatitis B,,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
10660,NCT05858736,Incidence of treatment emergent adverse events (TEAE),"Overall survival (OS),",,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
10661,NCT02217891,qualitive data,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
10662,NCT02103322,AUC0-tau,Fluctuation Rate,,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10663,NCT05965817,To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.,,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10664,NCT04058600,Hospital Anxiety and Depression Scale (HAD),,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA']
10665,NCT01472419,Overall Survival,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
10666,NCT03100409,Changes in food intake,Change in quality of life for cervical cancer patients: (European Organization for Research and Treatment of Cancer Cervical cancer module- EORTC QLQ-CX 24),,2017-02-01,TERMINATED,INTERVENTIONAL,['NA']
10667,NCT05424692,The difference of 3-year disease-free survival rate of patients in both group,The difference of OS of patients in both group,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
10668,NCT03806244,"Accuracy of Surgical stereotactic navigation defined as the distance, in millimetres, between the position of the surgical landmark and the position determined by the navigation system",Number of intra and/or postoperative complication,,2019-07-17,TERMINATED,INTERVENTIONAL,['NA']
10669,NCT05948449,Pathological complete response rate (pCR),Safety and Tolerability,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10670,NCT03095209,Serum inflammation markers,Quality of life and pain,,2017-02-24,COMPLETED,OBSERVATIONAL,['NA']
10671,NCT05988645,Number of mural injuries.,Perception of difficulty.,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
10672,NCT02930278,3-year disease overall survival rate,Visual Analog Score for pain,,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA']
10673,NCT00019019,,,,1994-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10674,NCT00660426,"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.",To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10675,NCT01843218,assess erectile dysfunction,Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer,,2008-03,TERMINATED,INTERVENTIONAL,['NA']
10676,NCT00952497,The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.,"Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response.",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10677,NCT05225038,"Change in participants physical capacity, as represented by hand grip strength",Physical capacity as represented by 6-Minute Walk Test,,2022-06-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10678,NCT03533920,Objective Response Rate by independent evaluator,,,2017-10-25,COMPLETED,INTERVENTIONAL,['NA']
10679,NCT03500068,Developing organoids from advanced pancreatic cancer patients that predict non response or response,Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.,,2017-09-04,UNKNOWN,INTERVENTIONAL,['NA']
10680,NCT01076517,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
10681,NCT03520790,Overall survival,Progression free survival,,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10682,NCT01134276,Incidence of Infectious Complications After Biliary Drainage,Total Hospital Cost During Admission After Biliary Drainage,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
10683,NCT00334984,,,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA']
10684,NCT02933307,Expectations & experiences of care givers,System usability Scale,Performed surgical procedure,2015-04,COMPLETED,INTERVENTIONAL,['NA']
10685,NCT00333099,Frequency and grade of mucositis,Cost,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10686,NCT05628857,Objective Response Rate (ORR),Terminal elimination half life,,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE2']
10687,NCT00033540,Response,Median Survival Time for Participants With Relevant Biologic Markers,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10688,NCT00004910,,,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10689,NCT01437618,Progression-Free Survival,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
10690,NCT02728596,Incidence of Febrile Neutropenia Among Intermediate Risk Participants,Overall Survival (OS),Differences Among Cohort Components and Intervention and Usual Care Components,2016-10-07,COMPLETED,INTERVENTIONAL,['NA']
10691,NCT04361682,Predictive value of PIBs and drains amylase values for Pancreatic Fistula (PF),,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
10692,NCT00995202,Overall survival rate,Disease-free survival rate,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10693,NCT01887158,quality of bowel preparation rated according to a modified Ottawa bowel preparation scale,Lesion detection (type and lesion detection rate/patient),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10694,NCT05148572,Metabolome profiling for recurrence prediction.,,,2021-11-10,RECRUITING,OBSERVATIONAL,['NA']
10695,NCT03291054,Overall Response Rate,Overall Survival,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE2']
10696,NCT00504153,Progression-free Survival Rate,Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10697,NCT05361161,OS,,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10698,NCT05806931,Disease control rate (DCR):,Duration of Response,,2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2']
10699,NCT04965454,Lack of Objective Response,Disease Control,,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10700,NCT02453464,Maximum Tolerated Dose (MTD),Overall Survival (OS),,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
10701,NCT02268825,Safety of combination mFOLFOX and MK-3475,,,2015-01-23,TERMINATED,INTERVENTIONAL,['PHASE1']
10702,NCT04223141,Mortality,Medical complications,,2020-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10703,NCT03759548,Impact in Quality of Life during pharmacological treatments,Pharmacological treatment-related adverse events,,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
10704,NCT03528876,Progression free survival,Decline in quality of life,,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE2']
10705,NCT03277716,Overall survival (OS),Distant metastasis-free survival,,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10706,NCT00239200,"Primary Objective: To determine the response rate of metastatic or recurrent squamous cell carcinoma of the esophagus, when treated with lapatinib (GW572016)",Secondary Objective: To determine the toxicity of this regimen,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2']
10707,NCT04622423,Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS,Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors,,2019-11-06,RECRUITING,OBSERVATIONAL,['NA']
10708,NCT05359042,Change in overall score of EQ-5D,Predictive value of ED Visit and/or hospital admission,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10709,NCT03374293,Local control,Overall survival,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10710,NCT02198274,Anti-tumour response,Mean residence time (MRT),,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10711,NCT00019760,,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10712,NCT05969171,PFS,DCR,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10713,NCT05621629,Pena's questionnaires score before treatment,,,2022-09-01,COMPLETED,OBSERVATIONAL,['NA']
10714,NCT01798251,Progression Free Survival (PFS),adverse events (AE),K-ras gene type,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
10715,NCT02301286,5 year overall survival,Time to Treatment Failure,,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10716,NCT02184663,Health-related quality of life (HRQoL) at 16 weeks,anxiolytic / antidepressant consumption,,2014-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10717,NCT00737373,response (WHO criteria),,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10718,NCT05743426,Disease-free survival,Quality of life Toronto Extremity Salvage Score (TESS),,2023-03-17,RECRUITING,OBSERVATIONAL,['NA']
10719,NCT00002984,Number of subjects experiencing adverse events,Efficacy of treatment,,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10720,NCT04875793,The enrollment rate of individuals who underwent CRC screening in the intervention group vs. control group,The percentage of individuals who screened positive and enrolled in colonoscopy for follow-up in the intervention group vs. control group.,,2021-06-10,COMPLETED,INTERVENTIONAL,['NA']
10721,NCT02495051,presence of gastric and / or intestinal metaplasia diagnosed at histology,"evaluation of actual other symptoms (respiratory, dysphagia)",,2010-02,COMPLETED,OBSERVATIONAL,['NA']
10722,NCT00386594,Elimination of high-grade dysplasia in Barrett's esophagus,,,2006-10,TERMINATED,INTERVENTIONAL,['NA']
10723,NCT01659619,degree of food stasis,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10724,NCT03314532,disease-progression-free period,overall survival period,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
10725,NCT00939666,Local recurrence,Percentage of patients that chooses the minimal invasive strategies over standard surgery,,2009-07-01,COMPLETED,INTERVENTIONAL,['NA']
10726,NCT00041691,,,,na,TERMINATED,INTERVENTIONAL,['PHASE1']
10727,NCT02879227,Feasibility of treatment: Number of patients with completed treatment,Quality of life,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10728,NCT06060899,Intraoperative blood loss,Length of hospital stay,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
10729,NCT01269229,complete resection (R0) rate for rectal and liver lesions.,Toxicity profile,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10730,NCT03223142,Local control rate,Complication rate,,2017-07,UNKNOWN,INTERVENTIONAL,['NA']
10731,NCT01319890,Return to normal activity/work,Cancer free survival,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
10732,NCT02295930,10 months-progression free rate (10m-PFR),Overall toxicity rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10733,NCT03469258,Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer,Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer,,2018-04-13,TERMINATED,INTERVENTIONAL,['PHASE2']
10734,NCT00083226,Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST),Progression Free Survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10735,NCT01710293,Median Time from Initial Follow-up Delay to Follow-up Action,,,2017-01-27,WITHDRAWN,INTERVENTIONAL,['NA']
10736,NCT04943679,Incidence of adverse events,12-month survival rate,,2021-06-15,RECRUITING,OBSERVATIONAL,['NA']
10737,NCT04954521,OS,PFS,,2021-06-30,RECRUITING,OBSERVATIONAL,['NA']
10738,NCT02541149,"serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects",,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
10739,NCT00605722,Percentage of Participants With Progression-free Survival (PFS),Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10740,NCT01671488,"To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.","To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT.",,2013-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10741,NCT01400620,Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups,Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10742,NCT05068206,Disease Control Rate (DCR),Duration of disease remission (DOR),,2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE2']
10743,NCT03844347,Manifestations of Psychological Well-being Measurement,Physical activity evaluation,,2019-10-21,RECRUITING,INTERVENTIONAL,['NA']
10744,NCT02775461,Number of individuals with pancreatic diseases,,,2013-03-01,RECRUITING,OBSERVATIONAL,['NA']
10745,NCT03654950,Patient reported experiences in themes,Patient reported experiences divided into themes,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
10746,NCT02441998,"ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals","Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value",,2013-10,COMPLETED,OBSERVATIONAL,['NA']
10747,NCT00324987,Progression Free Survival,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug,,2008-04,TERMINATED,INTERVENTIONAL,['PHASE3']
10748,NCT04882423,Hydroxylated PhlP profile with both cruciferous and apiaceous vegetables,,,2013-09-19,TERMINATED,INTERVENTIONAL,['NA']
10749,NCT00576563,"The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63","Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10750,NCT04179084,Objective Response Rate (ORR),Progression-free survival (PFS),,2019-08-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
10751,NCT05978349,Follow-up and record DFS of patients,Follow-up and record OS of patients,,2022-02-14,RECRUITING,INTERVENTIONAL,['NA']
10752,NCT01047475,The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response),,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10753,NCT05725473,Clinical efficacy,,,2023-01-12,RECRUITING,INTERVENTIONAL,['NA']
10754,NCT00541112,Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI,Predictive biomarkers of response to cetuximab,,2007-10-29,TERMINATED,INTERVENTIONAL,['PHASE2']
10755,NCT03172559,Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).,Difference between the two arms in disease-free survival,,2020-09,WITHDRAWN,INTERVENTIONAL,['NA']
10756,NCT06241352,Decrease rate of CA19-9,Disease control rate,,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10757,NCT02834169,Incidence of rare peritoneal surface malignancies,Impact of specific treatment strategies,,2010-10,UNKNOWN,OBSERVATIONAL,['NA']
10758,NCT04105062,Phase II only: Ability of LS301 to predict presence of positive margins,,,2021-12-31,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10759,NCT05498051,Safety of SLN identification,number of SLNs identified,,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
10760,NCT00123318,The percentage of major radiotherapy protocol violations,Median survival and overall survival at 3 years,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10761,NCT02924714,Progression free survival (PFS),Quality of Life (QoL),,2017-01,SUSPENDED,INTERVENTIONAL,['NA']
10762,NCT01625702,circulating tumor cells in blood,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
10763,NCT01189903,,,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10764,NCT03336216,Progression free survival (PFS) by Blinded Independent Central Review (BICR),Number of clinically significant changes in lab assessment: Urine,,2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2']
10765,NCT00316914,Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event,Change From Baseline in Quality of Life (QOL) at One Month,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10766,NCT00844688,RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC,Toxicity evaluation in accordance with CTCAE v3.0,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10767,NCT02702323,Progress Free Survival,Toxicity as measured by CTCAE V4.0,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10768,NCT01727921,Diagnostic accuracy,Technical success,Complications,2013-01,COMPLETED,INTERVENTIONAL,['NA']
10769,NCT05257057,Lynch Syndrome Screen Positive Rate,,,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10770,NCT06314971,Recurrence-free Survival,,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
10771,NCT01160367,family decision-making self-efficacy,"family psychological outcomes (depression, caregiver burden, decision making distress)",,2010-08-26,COMPLETED,INTERVENTIONAL,['NA']
10772,NCT05828381,The pathological complete response rate,The disease free survival rate,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10773,NCT05983315,Correlation between endoscopic CONECCT's classification,,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
10774,NCT04142203,Analgesic consumption postoperatively,Analgesic use after 23 h surgery,Adverse events after 23 h surgery,2017-05-16,COMPLETED,OBSERVATIONAL,['NA']
10775,NCT03792347,Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events),Radiographic Response,,2019-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10776,NCT05034627,Incidence of dose-limiting toxicities (DLTs),Mean plasma asparaginase activity,Therapy induced changes in the tumor and tumor ecosystem,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
10777,NCT00573911,The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10778,NCT05587088,Safety and efficacy,Survival,,2022-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10779,NCT02919553,Rate of core tissue acquisition adequate for histologic analysis.,"Cell block will be assessed of presence of any core tissue with intact architecture with this scale: graded 0 = none, 1 = present but marginal adequacy, 2 = present and adequate. Dimensions of the largest core will be noted if possible.",,2018-01,WITHDRAWN,INTERVENTIONAL,['NA']
10780,NCT00414492,,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
10781,NCT04237740,3 years recurrence-free survival rate,5 years overall survival rate,,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10782,NCT05305820,Change in Cardiorespiratory Fitness,Change in Nutritional Status- Blood Screening,Change in Smoking Status,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10783,NCT02185443,Local Progression Free Survival,Toxicity,,2014-05,RECRUITING,INTERVENTIONAL,['PHASE2']
10784,NCT00902759,FACIT (Facit Fatigue Scale) and Medical Outcomes Study Short Form-36 (MOS-SF-36) questionnaires,,,2009-01-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10785,NCT01991873,Progression-free survival,Health and skin related Quality of life,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10786,NCT05714553,Number of patients achieving a reduction in tumour volume (Objective response rate; ORR),,,2023-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10787,NCT00428597,Progression Free Survival (PFS),EORTC QLQ-C30 - Pain Subscale,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3']
10788,NCT06315855,oral health related quality of life,comorbidities,,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10789,NCT01871545,SubStudy 2: Perfusion Fraction (PF),Tumor Response,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
10790,NCT05174156,Objective Response Rate (ORR),Adverse events (AEs),,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10791,NCT02261714,Patients' Immune Response,Clinical Efficacy,Relationship Between (KRAS) Status and Clinical Efficacy,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10792,NCT01293942,conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer,"R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A",,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10793,NCT01807936,Overall survival,Disease free survival,locoregional recurrence and recurrence pattern,2013-03-20,COMPLETED,INTERVENTIONAL,['NA']
10794,NCT02320123,Intent to Discuss Hospice Care (Based on the Transtheoretical Stages of Change Model),Health Care Utilization: Mean Number of Hospitalizations in Six Months by Group,,2016-05-23,COMPLETED,INTERVENTIONAL,['NA']
10795,NCT02148731,Occurrence of Adverse Events,Performance of the brief screening tool,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
10796,NCT05261113,Outcome relevance of CE-IOUS,Sensitivity and Specificity of CE-IOUS compared to other imaging methods,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
10797,NCT00905047,patients preference after randomization and cross-over,safety of each treatment,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10798,NCT02371304,Recurrence free at 3 year follow-up,Treatment related morbidity,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
10799,NCT05263336,Anastomotic leak,Postsurgical Ileus,,2021-01-03,RECRUITING,INTERVENTIONAL,['NA']
10800,NCT05641129,Primary outcome,Secondary outcome 9,,2023-01-16,COMPLETED,OBSERVATIONAL,['NA']
10801,NCT04389632,Number of participants with dose-limiting toxicities (DLTs),Number of participants with antidrug antibodies (ADAs),,2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1']
10802,NCT04618692,Biliary complications after living donor liver transplantation,Time to biliary complications,,2020-12-02,COMPLETED,INTERVENTIONAL,['NA']
10803,NCT00083616,Duration of Response,Overall Survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10804,NCT04643366,Three-year disease free survival (DFS),Number of patients who do not require an ostomy at time of surgery,,2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10805,NCT04097795,Costs,Care-related burden among informal caregivers,,2019-07-01,TERMINATED,OBSERVATIONAL,['NA']
10806,NCT04813861,Lesion Response,Delayed Lesion Response,,2010-01-04,COMPLETED,OBSERVATIONAL,['NA']
10807,NCT02340975,Progression Free Survival at 6 (PFS-6) Month in Phase 2,Percentage of Participants With Objective Response in Phase 2 by Programmed Death-ligand (PD-L1) Status,,2015-03-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10808,NCT04823715,Disease-free survival of the patient after start of treatment,,,2020-10-15,COMPLETED,OBSERVATIONAL,['NA']
10809,NCT00003237,,,,1998-06-22,COMPLETED,INTERVENTIONAL,['PHASE2']
10810,NCT05810714,Number of Participants to Return Fecal Immunochemical Test (FIT),,,2021-11-20,COMPLETED,INTERVENTIONAL,['NA']
10811,NCT03801083,Objective Response Rate (ORR),EuroQol 5 dimensions 5 levels (EQ-5D-5L),,2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
10812,NCT01188980,determine if early increase blood supply (EIBS)can predict presence of Dysplasia,determine if EIBS can predict presence of BE in patients undergoing upper endoscopy,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
10813,NCT05616494,Overall response rate (ORR) by Independent Review Committee (IRC),Disease control rate (DCR) by IRC and investigator,Plasma concentration of docetaxel (free and total),2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE2']
10814,NCT01540344,Progression-free survival (PFS),Pathohistological regression,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2']
10815,NCT04242342,local control at 2 years,,,2020-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10816,NCT00675012,To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.,Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10817,NCT03650348,Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab,Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs]),,2018-08-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
10818,NCT01862562,Early complication rate,Health-related QOL score,,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
10819,NCT05975463,Objective response rate (ORR),Disease Control Rate (DCR),,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10820,NCT01924741,Morbidity and mortality (peripoerative),Liver Growth as assessed by imaging-based volumetry,Inclusion criteria by registry participants,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
10821,NCT00516230,,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA']
10822,NCT02209415,Number of patients eligible for treatment,,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
10823,NCT04583488,Maximum Tolerated Dose (MTD),Progression-Free Survival,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE1']
10824,NCT05329597,Genotyping,,,2020-06-24,UNKNOWN,OBSERVATIONAL,['NA']
10825,NCT01360255,"comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE",progression- free - time,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
10826,NCT04089657,Disease control rate(DCR),Adverse events（AE）,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10827,NCT06184555,postoperative complication,,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
10828,NCT02120911,% of patients completing trastuzumab and pertuzumab treatment.,Pharmacokinetics of pertuzumab and trastuzumab,SUV of pre-treatment trastuzumab-PET,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10829,NCT01079780,Progression-free Survival,Overall Survival,,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE2']
10830,NCT05545436,"Pathological complete response rate (pCR, Becker criteria, TRG 1A)","R0 resection rate and objective response rate (ORR, RECIST 1.1)",,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10831,NCT00338988,Number of Participants With Objective Response,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10832,NCT03334591,progress free survival(PFS),adverse events,,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10833,NCT02942706,Progression Free Survival 1 (PFS1),Quality of life (QoL),,2021-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10834,NCT02824185,Specificity of FCH-PET/MRI for the detection of preoperative lesions,Costs avoided and induced by performing FCH-PET/MRI,,2017-06-14,COMPLETED,INTERVENTIONAL,['NA']
10835,NCT05402124,Measurement of Adverse Events,"Factors related to uptake, in-study adherence and post-study maintenance using measurement of chemoprevention knowledge",,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10836,NCT04402424,Colorectal Cancer,Other Significant Colorectal Disease,,2019-07-16,COMPLETED,OBSERVATIONAL,['NA']
10837,NCT06202001,Objective Response Rate (ORR),"Safety and tolerability by incidence, severity and outcome of adverse events",,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10838,NCT01946061,3-year disease-free survival,,,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2']
10839,NCT01733147,Change in Esophageal Tissue PGE2 Levels,Change in Esophageal Macrophage Markers,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10840,NCT04381130,Overall survival,Change in quality of life assessed with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3.0,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10841,NCT00503932,Maximum Tolerated Dose (MTD),,,2007-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10842,NCT00006103,overall survival,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10843,NCT02141906,Response,Progression,,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2']
10844,NCT03548844,DFS,Quality of life,,2018-05-24,UNKNOWN,INTERVENTIONAL,['NA']
10845,NCT00190385,Incidence of small hepatocellular carcinoma (HCC),Clinical value of serum alfa-fetoprotein assay,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10846,NCT00003344,,,,1998-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10847,NCT01924533,Overall Survival,Duration of Response,,2013-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10848,NCT04258956,"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria",,,2019-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
10849,NCT02552017,Adenoma detection rate,Adenoma detection rate of individual endoscopist before and after trial commencement,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
10850,NCT05795595,Phase 2 (Cohort Expansion): Objective response rate (ORR),,,2023-03-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10851,NCT05430841,Diagnostic accuracy,Number of lesions,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
10852,NCT01148056,Bowel Quality of Life,Accuracy,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2']
10853,NCT01836926,Early Complications number,Clinical functional outcome,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10854,NCT06193733,Disease-free survival,Overall survival,,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10855,NCT00414271,Number of Participants With Pathological Response,Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10856,NCT04874519,Build a Fibrolamellar Cancer/FLC registry,,,2021-11-24,RECRUITING,OBSERVATIONAL,['NA']
10857,NCT02503696,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
10858,NCT00711243,Response Rate in Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (Phase II),Toxicity Profile,,2005-04-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10859,NCT06200259,"Test the hypothesis that ""Spot Delete"" technique in proton therapy reduces late toxicity in low- and intermediate-risk prostate cancer patients",,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
10860,NCT04210115,Overall Survival (OS),Number of participants discontinuing study treatment due to an adverse event (AE),,2020-02-28,RECRUITING,INTERVENTIONAL,['PHASE3']
10861,NCT01236690,"The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.",,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10862,NCT00162669,"The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.",Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent,,2005-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
10863,NCT06006650,Pathologic complete response rate (pCR),Overall survival(OS),,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10864,NCT04120701,3-year Disease-Free Survival in ctDNA positive patients,,,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE3']
10865,NCT01703390,Response,Number of adverse events during study treatment,,2012-12-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10866,NCT04152018,Duration of Response (DR) for Dose Expansion,Overall Survival,,2019-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10867,NCT00349336,Weekly Steady-state Exposure of Bevacizumab,Terminal Half-life of Bevacizumab,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10868,NCT03478449,Migration of pN stage in gastric cancer patients,,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
10869,NCT04005339,"The efficacy of fluorouracil, leucovorin, and nanoliposomal irinotecan in advanced biliary tract cancers following progression on or intolerance of gemcitabine and platinum chemotherapy.","Maximum change in tumor marker, CA19-9.","Archived tumor tissue using next-generation sequencing (NGS) and immunohistochemistry (IHC) in order to elucidate potential mutational biomarkers predictive of response to fluorouracil, leucovorin, and nanoliposomal irinotecan.",2019-07-29,RECRUITING,INTERVENTIONAL,['PHASE2']
10870,NCT03779035,Disease free survival (DFS) rate,The rate of patients with hepatic or locoregional recurrence,,2018-12-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
10871,NCT00573131,Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT,,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
10872,NCT02424838,Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.,Rate of complications,,2014-07-28,COMPLETED,INTERVENTIONAL,['NA']
10873,NCT05575765,"Tumor images of multimodal digestive endoscopy, combination of high-definition white light endoscopy, endoscopic cerenkov luminescence imaging (ECLI) and probe-based confocal laser endomicroscopy (pCLE)",,,2023-08-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10874,NCT03173729,Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps,Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.,,2017-02-11,RECRUITING,OBSERVATIONAL,['NA']
10875,NCT05572684,Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab,Progression-free Survival (PFS) per RECIST,,2022-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10876,NCT06236321,To assess if subsets of Rectal Cancers can be correlated with FFC scan hydrogen ion dissociation curves,To determine correlation between faecal microbial composition and response to neoadjuvant chemoradiotherapy,,2022-11-04,RECRUITING,INTERVENTIONAL,['NA']
10877,NCT02414009,Progression-free survival of FOLFIRI versus CAPTEM,Quality of life measured by EORTC FACT-C,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10878,NCT02849717,The primary outcome measure for this study is fatigue assessed by the FACIT-F fatigue subscale..,Quality of Life (QOL) on self reported psychological distress questionnaires: Spielberg State/Trait Anxiety Inventory (STAI Form Y-1).,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10879,NCT04540159,Immune Checkpoint levels,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
10880,NCT00531115,Confirmed objective response rate,Treatment safety,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
10881,NCT00587067,Number of Patients With Treatment Related Toxicity,Median Survival,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10882,NCT03646110,Overall survival rate,Postoperative pulmonary complication,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
10883,NCT05340231,PFS,Pathological response rate (PCR+MPR),,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10884,NCT00049322,Neovessel Formation as Measured by Angiogram at 14 Weeks,Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10885,NCT05916040,Response to therapy,Anxiety and depression state via HADS,,2023-10-03,RECRUITING,OBSERVATIONAL,['NA']
10886,NCT02847429,Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.,Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
10887,NCT06328361,Disease-free survival,Complication rates,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10888,NCT05794841,Diagnostic performance of positive predictive value (PPV) and negative predictive value (NPV).,,,2023-04-01,RECRUITING,OBSERVATIONAL,['NA']
10889,NCT03131921,Resting energy expenditure,Total energy expenditure,,2016-04-05,COMPLETED,OBSERVATIONAL,['NA']
10890,NCT06235164,pathological complete response,major pathological response,,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10891,NCT04683731,"Decision Quality assessed using the multi-dimensional measure of informed consent (MMIC) which incorporates knowledge, intent, and behavior.",Number of providers who open their provider notification,,2021-01-19,COMPLETED,INTERVENTIONAL,['NA']
10892,NCT01362790,Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01,Duration of Response,Count of Participants SS1P Cycles Received Following Onstudy,2011-05-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10893,NCT05563922,Organ preservation rate at 3 years,5-year overall survival（OS） rates,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10894,NCT04891016,pathological complete response rate,disease-free survival,,2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
10895,NCT02185937,imatinib area under the curve,number of adverse events,,2014-08,TERMINATED,INTERVENTIONAL,['PHASE1']
10896,NCT00177307,Progression Free Survival (PFS),"1-, 2-, and 3-year Overall Survival",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10897,NCT02905188,Number of Patients with Dose Limiting Toxicity,Median T cell persistence,,2019-03-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10898,NCT05359861,"Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)",Serum concentrations of atezolizumab,,2022-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10899,NCT03612674,Adenoma Detection Rate (ADR),Colonoscopists' ADR in the previous year,,2018-04-04,UNKNOWN,INTERVENTIONAL,['NA']
10900,NCT03009227,Overall survival,Quality of life in patients after D2 and D3 lymph node dissection using questionnaire,,2017-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10901,NCT05585814,Tumor regression grade (TRG),Quality of life score (QoL score),,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10902,NCT06248879,Body Mass Index,Feeding amount,,2024-02-28,WITHDRAWN,INTERVENTIONAL,['NA']
10903,NCT05786716,Durable Clinical Benefit (DCB),Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants,,2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10904,NCT05200611,The efficacy of fecal immunochemical test to detect advanced adenoma,The efficacy of fecal immunochemical test to detect colorectal neoplasms,,2022-01-04,UNKNOWN,OBSERVATIONAL,['NA']
10905,NCT04783844,Accuracy,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
10906,NCT01674907,Clinical/demographic patient characteristics at baseline,Relationship between termination of Avastin treatment and time point of progression,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
10907,NCT03191604,Altered chosen treatment modality due to NBI,Differences in pathology identification between subgroups,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
10908,NCT04447092,Objective Response Rate,Immune-related response,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10909,NCT05877599,Adverse events and serious adverse events,"Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors",,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE1']
10910,NCT06210360,2-year Overall Survival Rate,Incidence of adverse events,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10911,NCT01267695,Rate of disease recurrence at 2 years,Determine the safety and tolerability of this drug in these patients.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
10912,NCT06293014,Time to treatment failure (TTF),European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30),,2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE2']
10913,NCT02647177,Detection of early progression to Tumor,,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
10914,NCT03263663,Progression-free-survival,,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
10915,NCT02138422,Response Rate,,,2014-07-31,COMPLETED,INTERVENTIONAL,['PHASE3']
10916,NCT00834028,tumor progression,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
10917,NCT01251666,Ratio of sensitivities (RSN) for detection of advanced neoplasias,Positivity rate,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10918,NCT03649035,Number of participants with feasible EUS-guided Cryothermal Ablation,Number of participants with treatment-related adverse events,,2018-07-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10919,NCT06071507,Clinical Success,Nutritional status,Overall Survival,2023-11-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10920,NCT03577808,Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.,Response of the rectal cancer patients to neoadjuvant chemoradiation.,,2018-08-17,UNKNOWN,OBSERVATIONAL,['NA']
10921,NCT03206866,serum regucalcin in HCC patients,,,2016-12-30,UNKNOWN,OBSERVATIONAL,['NA']
10922,NCT02790333,Pancreatic fibrosis accessed by histopathology and pancreatic stellate cell,Readmission rate,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
10923,NCT01101906,Time to progression (TTP),"Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events",,2011-01-10,TERMINATED,INTERVENTIONAL,['PHASE2']
10924,NCT04985071,Pancreatic fistula,Bleeding complication,,2021-08-18,RECRUITING,OBSERVATIONAL,['NA']
10925,NCT02112162,Radiosensitivity index,,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10926,NCT02374931,Standard uptake value (SUV) measured as percent injected dose per cc,IHC staining intensity in tissue samples,,2015-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
10927,NCT04466189,Establish a cohort of Pancreatic cancer patients treadted with proton beam therapy.,,,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10928,NCT00005910,,,,2000-06,COMPLETED,INTERVENTIONAL,['NA']
10929,NCT01747096,Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence.,Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process,Tolerance of 68-Ga-DOTANOC,2012-11,COMPLETED,INTERVENTIONAL,['NA']
10930,NCT04969029,3-year relapse-free survival,,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10931,NCT00469963,Tumor response,Survival,,2003-12,TERMINATED,INTERVENTIONAL,['NA']
10932,NCT03606863,morbi-mortality,,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
10933,NCT00241722,To compare alvimopan with placebo for long-term safety and tolerability,"Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)",,2005-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10934,NCT02089373,The percentage of cancer cells in biopsy samples,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
10935,NCT06125262,Overall survival and disease-free survival.,Event-free survival,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
10936,NCT00790569,CO-confirmed 7-day Abstinence,Change in Cigarettes Per Day,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
10937,NCT04011982,Determination of the correlation between clinical characterizations and biological characterizations of patients suffering from exocrine pancreatic cancer,Comparison of healthy tissu and tumor stroma from primitive tumor versus from metastases,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
10938,NCT00457691,Progression-free Survival (PFS),Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10939,NCT04518800,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,The proportion of patients receiving antibiotics during the entire chemotherapy period.,,2020-08-18,UNKNOWN,INTERVENTIONAL,['NA']
10940,NCT03458949,variation of the rate of participation in colorectal cancer screening,,,2018-06-18,UNKNOWN,INTERVENTIONAL,['NA']
10941,NCT00006468,,,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10942,NCT01966081,Measure of polyunsaturated fatty acids in adipose tissue lipids.,,,na,UNKNOWN,INTERVENTIONAL,['NA']
10943,NCT03474341,Histopathologic response,Overall survival.,,2018-04-09,UNKNOWN,OBSERVATIONAL,['NA']
10944,NCT02476045,Efficacy,overall survival,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
10945,NCT05016869,progression-free survival (PFS),Adverse events (AEs),,2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10946,NCT02581059,Subject Fatigue Assessment,Evaluate Overall Survival (OS),,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2']
10947,NCT05363007,12W-PFS,,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10948,NCT02899325,Sensitivity of 18F-FDGal in the diagnosis of HCC on per-patient basis,Specificity of 18F-FDGal in the diagnosis of HCC,,2019-10,WITHDRAWN,OBSERVATIONAL,['NA']
10949,NCT00873756,Incidence and nature of dose-limiting toxicities,Incidence of anti-dulanermin antibodies,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10950,NCT04812912,"Change in testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH in young male patients (<50y) undergoing therapy for colorectal cancer",,,2021-03-18,RECRUITING,OBSERVATIONAL,['NA']
10951,NCT06258824,Diagnostic Value as measured by Area under the Curve (AUC) for candidate miRNAs,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
10952,NCT01762813,Cancer-specific survival,Recurrence-free survival,,2013-01-01,RECRUITING,OBSERVATIONAL,['NA']
10953,NCT04185779,Occurrence of colorectal neoplasia,Number of participants who consent for future contact,,2019-12-13,RECRUITING,OBSERVATIONAL,['NA']
10954,NCT00555620,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),Progression-Free Survival (PFS),,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10955,NCT05018156,Genetics referrals,Genetic testing,,2021-11-10,COMPLETED,INTERVENTIONAL,['NA']
10956,NCT04716010,Percentage of Red Meat Containing Products,Intention to Reduce,Ease of Store Use,2021-10-18,COMPLETED,INTERVENTIONAL,['NA']
10957,NCT05245474,pCR rate,quality of life score,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10958,NCT01831531,3-yr local control rate,Overall survival,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10959,NCT01462513,Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).,Overall survival time in a subgroup of MUC1 positive cancers,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10960,NCT06026800,Number of Participants with Adverse Events (AEs) [safety and tolerability],Cytokines Level [immunogenicity],,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1']
10961,NCT00044863,"Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma",,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10962,NCT00516945,incidence of chemotherapy interruptions,chemotherapy dose intensity reduction due to hepatitis B reactivation,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
10963,NCT06049511,World Health Organization Oral Mucositis Toxicity Scale,Oral assessment guide,,2021-08-15,COMPLETED,INTERVENTIONAL,['NA']
10964,NCT00003487,"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable",,,1996-05-30,TERMINATED,INTERVENTIONAL,['PHASE2']
10965,NCT02870582,Overall Survival (OS),Safety variables will be summarized using descriptive statistics based on adverse events collection,,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE3']
10966,NCT03355612,Disease Free Survival(DFS),Percentage of Participants With Adverse Events,,2017-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10967,NCT04736472,Penetrance: proportion of pharmacogenetic tests ordered by providers,Grade 3 or higher toxicity,,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10968,NCT00483834,Objective Response Rate,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10969,NCT00444782,Response rate (Partial and Complete Response) according to modified RECIST.,Immune Response,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10970,NCT03899636,Overall Survival,,,2021-02-23,RECRUITING,INTERVENTIONAL,['PHASE3']
10971,NCT05450484,2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE,,,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1']
10972,NCT04278274,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response,The sensitivity of AI prediction system and expert radiologists in prediction tumor response,,2020-02-08,RECRUITING,OBSERVATIONAL,['NA']
10973,NCT05544812,AE,OS,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
10974,NCT02173756,change in pain of mucositis before and after meal,Evaluation of the local tolerance and other topical treatment taken throughout the mucositis,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
10975,NCT04225364,Pathologic complete remission (PCR),Overall survival (OS),perioperative adverse events,2020-01-17,COMPLETED,INTERVENTIONAL,['PHASE2']
10976,NCT02861300,PHASE 2: Number of patients with response to treatment,PHASE 1: proportion of patient who respond to treatment,,2016-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10977,NCT04835402,Serious adverse reaction (SAR) rate according to CTCAE v5,"Adverse event rate (CTCAEv5, all grades)",,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10978,NCT05497739,The incidence of peritoneal metastasis,The safety,,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10979,NCT01806649,disease control rate,overall survival,,2013-07-01,TERMINATED,INTERVENTIONAL,['PHASE2']
10980,NCT00272051,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W,Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10981,NCT03151759,Matrilysin levels,,,2002-11-06,COMPLETED,OBSERVATIONAL,['NA']
10982,NCT03069833,"Sensitivity, Specificity, False Positive, False Negative",,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
10983,NCT02806037,localization rate of liver tumor,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
10984,NCT03958032,Postoperative complications,Major complication,,2016-12-03,COMPLETED,OBSERVATIONAL,['NA']
10985,NCT01488045,Patient Satisfaction Scores (Absolute Value),Physician Perceptions (Absolute Value),,2011-06,COMPLETED,INTERVENTIONAL,['NA']
10986,NCT02497157,Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1),Incidence of adverse events,Deepness of response (DoR),2015-05-21,COMPLETED,INTERVENTIONAL,['PHASE2']
10987,NCT03517176,Optimal Biological Dose (OBD) of CEND-1 when given in combination,Preliminary evidence of anti-tumor activity of CEND-1 when given in combination with nabpaclitaxel bound and gemcitabine by objective radiographic assessment according to RECIST 1.1,Immunohistochemical assessment of tumor biopsies for the expression of Neuropilin-1 in order to study if the response to CEND-1 therapy can be predicted based on the Neuropilin-1 expression level,2018-07-31,COMPLETED,INTERVENTIONAL,['PHASE1']
10988,NCT00171977,To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy,Safety,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10989,NCT00135005,To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle,patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle),,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10990,NCT00022373,,,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
10991,NCT02965521,Adherence,Change in fasting glucose,,2017-04-10,COMPLETED,INTERVENTIONAL,['NA']
10992,NCT05036265,Prognostic factors,,,2011-09-01,COMPLETED,OBSERVATIONAL,['NA']
10993,NCT00937456,To decrease postoperative major 30-days morbidity from 45% in the open arm to 25% in the laparoscopically-assisted arm.,economical interest of the surgical technique apprehended through a hospital point of view,,2009-10-07,COMPLETED,INTERVENTIONAL,['NA']
10994,NCT06178809,The advance time of ctDNA dynamic detection compared with AFP+ imaging in monitoring of primary hepatocellular carcinoma recurrence or progression,,,2023-12-25,RECRUITING,OBSERVATIONAL,['NA']
10995,NCT02460432,Cumulative stent patency during 6months after stent placement,Adverse events,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
10996,NCT05785325,Objective Response Rate,Overal survival,,2023-08-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10997,NCT01442506,diagnostic yield of targeted biopsies with high definition endoscopy using i scan virtual chromoendoscopy and acetic acid guided biopsies,,,2009-04,UNKNOWN,OBSERVATIONAL,['NA']
10998,NCT04609592,Measure Complication free Surgery,Overall Survival (OS),,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE1']
10999,NCT05414448,ADR,False positive rate,,2023-03-07,RECRUITING,INTERVENTIONAL,['NA']
11000,NCT04616183,Best overall response (complete response [CR] + partial response [PR]),Incidence of adverse events,,2020-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11001,NCT03880877,Progression-free survival,Duration of treatment,,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
11002,NCT06048133,"Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.",Evaluate safety of the proposed drug combination.,,2024-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
11003,NCT00670553,Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD),Safety profile of oral LBH589 when given in combination with standard Radiotherapy,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11004,NCT03191110,Quality of life (EORTC QLQ-C30),Co-morbidities,,2010-08-03,RECRUITING,OBSERVATIONAL,['NA']
11005,NCT04364373,5-year overall survival,Late postoperative complications rate,,2020-03-31,RECRUITING,INTERVENTIONAL,['NA']
11006,NCT01874665,Clinical Benefit Rate (CBR) in Cohort A,"Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib",,2013-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11007,NCT02238769,SUVratio of FECH PET,Patients' lifespan,Data analysis,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
11008,NCT04768686,Overall response rate in subjects treated with FLX475 in combination with pembrolizumab,,,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
11009,NCT04115163,Overall response rate (ORR),Overall survival (OS),,2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2']
11010,NCT03781960,Objective Response Rate,Overall Survival,,2019-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
11011,NCT00352755,Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events,Overall Survival,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2']
11012,NCT03652896,prognosis,hospital stay,volume of transfusion,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
11013,NCT01334112,Response rate,Number of Participants with Adverse Events as a Measure of Safety,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11014,NCT05870969,Early diagnosis rate of HCC patients,The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis,The compliance rate of each risk group defined at the initial risk stratification,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
11015,NCT05366881,Detection of cancer,Clinical outcomes,,2022-05-03,RECRUITING,OBSERVATIONAL,['NA']
11016,NCT01292356,Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies,,,2010-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
11017,NCT03320317,Length of stay,Complication rate,,2018-03-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11018,NCT02800005,postoperative complications,Change of the postoperative AFA,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
11019,NCT03099629,Changes of forced vital capacity (FVC),Changes of dyspnea using Modified Borg Dyspnea score,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
11020,NCT05111860,Peri-operative complications,Overall survival,,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11021,NCT04756648,Adverse Event of Special Interest （ AESI）,Antitumor efficacy-Duration of disease control (DDC),,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE1']
11022,NCT00692770,Recurrence Free Survival (RFS) by Independent Assessment,Overall Survival (OS),The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET,2008-08-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11023,NCT02360605,Repeat Screening,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11024,NCT05700656,Objective response rate (ORR),"RNA sequencing, THG-b signaling, other",,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11025,NCT04066894,Sacral Nerve Stimulation (SNS) Success,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29,,2019-04-12,TERMINATED,INTERVENTIONAL,['PHASE2']
11026,NCT01507545,Progression-Free Survival (PFS),"Biomarkers Based OS, Within Treatment Group",,2012-03-27,TERMINATED,INTERVENTIONAL,['PHASE2']
11027,NCT03708705,relapse rate of tumor,,,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA']
11028,NCT00025129,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11029,NCT02425657,MCSAT (Mayo Clinical Skills Assessment Tool),Endoscopy training computer generated data - Total score,,2016-09-14,UNKNOWN,OBSERVATIONAL,['NA']
11030,NCT04890171,3-year disease-free survival in the ITT population,Cost-effectiveness measured with Incremental cost effective ratio (ICER),,2021-06-11,RECRUITING,INTERVENTIONAL,['NA']
11031,NCT04219332,Total Number of Retrieved Lymph Nodes,3-year overall survival rate,,2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11032,NCT02852161,Diagnostic accuarcy,comfort,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
11033,NCT04086888,OS (overall survival),progression-free survival (PFS),,2016-12-12,UNKNOWN,OBSERVATIONAL,['NA']
11034,NCT01527409,"Changes from Baseline in Exercise, Diet, and Posttraumatic Growth Inventory(PTGI)",Cancer Belief System(CBS),,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
11035,NCT03849352,"To evaluate whether patients who have undergone CRC treatment are able to comply with remote follow-ups using telephone reviews and digital technology to help promote and track individual healthy lifestyle, diet and PA changes.",To ascertain whether there was any change in diet and lifestyle factors from baseline to end of intervention (2 months),,2019-03-18,UNKNOWN,INTERVENTIONAL,['NA']
11036,NCT03253822,CRC screening participation,Ethnicity,,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
11037,NCT00091286,Number of patients with an immune response to the peptides,Immunogenicity of the peptide mixture measured in the peripheral blood,,2003-03-24,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
11038,NCT03645148,Number of participants experiencing clinical and laboratory adverse events (AEs),Progression Free Survival,Peripheral blood T cell receptor sequencing analysis,2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE1']
11039,NCT00698451,The Primary Efficacy End Point is the Number of Patients With an Objective Response.,The Secondary Efficacy Endpoints is Duration of Objective Response.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11040,NCT01520324,Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings),Bowel Cleansing Quality Evaluated by Boston Bowel Preparation Scale After Intake of Bowel Cleansing Formulation and of a Total Dose of 200 mg of Methylene Blue MMX Tablets Administered During and at the End of the Intake of the Bowel Cleansing Formulation,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11041,NCT02828865,Tumor response,Assess for presence of adverse events,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11042,NCT00309517,Overall survival,,,1997-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11043,NCT00893295,Intervention impact on colorectal cancer (CRC) screening utilization over the 6-month observation period,"Intervention impact on population health-management representations related to CRC screening, as assessed by perceived salience and coherence and self-efficacy-related CRC screening measured with 6 to 10 Likert-type items on both the baseline and end ...",,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
11044,NCT02980146,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
11045,NCT03260842,Pancreas Cancer,,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
11046,NCT01270360,"To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers",To create biological collections for screening purposes (asymptomatic subjects),,2010-09,COMPLETED,OBSERVATIONAL,['NA']
11047,NCT04497038,Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D),Pharmacokinetic (PK) profile: Elimination clearance (L/hr),,2021-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11048,NCT04062058,PCR rate,R0 resection rate,,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
11049,NCT00207298,Change in management based on PET procedure,Safety of 18F-FDG,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
11050,NCT04008407,Rate of surgical referral,Adenoma recurrence rate,,2017-08-14,RECRUITING,INTERVENTIONAL,['NA']
11051,NCT02867865,Overall Survival,Deterioration free rate of quality of life (QOL) scores at baseline and three monthly,,2016-09-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11052,NCT02544737,"The proportion of patients with response (CR, PR, SD and PD based on RECIST version 1.0) assessed at 5-6 weeks after the initiation of treatment.","The proportion of patients alive (overall survival rate) from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
11053,NCT05648318,Bowel preparation,withdrawal time,,2022-01-08,COMPLETED,INTERVENTIONAL,['NA']
11054,NCT02243735,Normalization of Hb-level.,Difference in Morbidity score,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
11055,NCT01453894,Completion of a Fecal Occult Blood Test (FOBT),,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
11056,NCT06302400,"The incidence of adverse and serious adverse events in patients receiving individualized treatment with 166Ho- microspheres, using National Cancer Institute CTCAE v5.0.","The rate of efficacy as defined as overall response rate (ORR) in patients receiving individualized treatment with 166Ho- microspheres, using modified RECIST (mRECIST) response evaluation criteria.",,2024-02-22,RECRUITING,INTERVENTIONAL,['NA']
11057,NCT02534246,Direct Comparison of pancreatic mass histologic tissue adequacy using two EUS guided fine needle biopsy needles,,,2016-08,WITHDRAWN,INTERVENTIONAL,['NA']
11058,NCT01099111,Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms,,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
11059,NCT03448757,non-invasive hemodynamic parameter measurements during exposure AM RF EMF,Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls,Searching for cancer-specific frequency modulation,2018-02-15,RECRUITING,INTERVENTIONAL,['NA']
11060,NCT00331786,Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months,Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11061,NCT02753465,disease-free survival rate,30-day mortality rate,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
11062,NCT01555450,Reduction of social inequalities,Evaluation of psychological mechanisms,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
11063,NCT04318756,Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa,Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
11064,NCT06162650,Complete response (CR) rate,Safety profiles,,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2']
11065,NCT05420064,Comparison of participant perceived quality of care,,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
11066,NCT05621499,1-year DFS rate,Adverse Events (AEs),,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11067,NCT04116073,Disease Control Rate (DCR) at 4 months using RECIST 1.1,Number of participants experiencing study drug-related toxicities,,2020-04-09,RECRUITING,INTERVENTIONAL,['PHASE2']
11068,NCT00767377,Time to progression,Toxicity,PET Scan response,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11069,NCT01686971,,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
11070,NCT00658801,all cause mortality,,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1']
11071,NCT02075385,Swallowing function,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11072,NCT03790475,Completion of the assigned screening strategy within 18 weeks of enrollment,Diagnostic yield for CRC and advanced adenomas,,2018-08-25,UNKNOWN,INTERVENTIONAL,['NA']
11073,NCT02606292,Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy,,,2014-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11074,NCT04948697,Objective Response Rate (ORR) as assessed by the investigator,Immunogenic Response to BAT1706,,2021-08-20,COMPLETED,INTERVENTIONAL,['PHASE2']
11075,NCT03040180,Histopathologic tumor regression following electrochemotherapy,Tumor Immunologic response following electrochemotherapy,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11076,NCT00196105,Time to Death,,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
11077,NCT00622804,Bile reflux by Dual scintigraphy,Morbidity and Mortality,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE3']
11078,NCT00919061,Median PFS,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11079,NCT00955019,,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
11080,NCT01025570,To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination,To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination,,2010-05,TERMINATED,INTERVENTIONAL,['PHASE1']
11081,NCT02374255,Number of Patients Perception of Improved Goals of Care Discussions,Communication Skills Training,,2016-03-15,COMPLETED,INTERVENTIONAL,['NA']
11082,NCT00494221,Progression Free Survival,Overall Survival,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11083,NCT01392131,Number of patients who have prolonged survival after receiving Oncoxin,Reduction in serum alpha-fetoprotein level and decrease in tumor size,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11084,NCT03834272,Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology,Number of patients with reported adverse events,,2019-03-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11085,NCT02681796,Total consumption of morphine or morphine-equivalent in patients undergoing pancreatic resections in the control group compared with the study group,Effect of epidural analgesia during the initial post-operative period as measured by relative ratios of blood level inflammatory markers,,2016-06-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11086,NCT01539681,Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.,Time to Progression,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
11087,NCT00742729,Receipt of a colorectal cancer screening test,Knowledge and attitudes regarding CRC screening.,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
11088,NCT00776399,Primary Outcome Measures:3-year survival,"Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11089,NCT01301417,Rate of anastomotic leakage,Rate of other device related complications and measures during hospitalization and post procedure:,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
11090,NCT05638698,Molecular disease control rate,Correlation between molecular response and disease free survival,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11091,NCT02528175,Acute toxicities,Assessment of radiologic response following treatment.,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
11092,NCT03380689,Maximum tolerance dose,Overall survival,,2018-01-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11093,NCT04879953,Overall survival at 6 months,overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
11094,NCT01721174,Stent patency rate,Unscheduled readmission rates,,2012-11,TERMINATED,INTERVENTIONAL,['NA']
11095,NCT03265418,Positional stability of BioXmark liquid fiducial markers during the treatment course,Potential BioXmark induced alterations in the surgical specimen,,2018-01-02,COMPLETED,INTERVENTIONAL,['NA']
11096,NCT01258192,response to induction therapy,safety and tolerability,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11097,NCT05332496,Overall Survival(OS),Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0,,2022-12-28,RECRUITING,OBSERVATIONAL,['NA']
11098,NCT02168608,survival rate,complications,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
11099,NCT06238167,1-year Disease-free survival rate,"Safety will be analyzed through the incidence of adverse events, serious adverse events",,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11100,NCT02015754,"Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer",One-year Survival Percentage,Exploratory Endpoint - Angiogenesis,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11101,NCT01609231,Assessment of Progression-free Survival (PFS),Percentage of Participants With Objective Response Rate (ORR),,2012-07-06,TERMINATED,INTERVENTIONAL,['PHASE2']
11102,NCT00897819,Correlation of MSI and LOH to outcome and response,,,2007-01-03,COMPLETED,OBSERVATIONAL,['NA']
11103,NCT01232296,Overall Survival - Overall Survival,Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11104,NCT00003798,,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11105,NCT00824707,time-to-progression(TTP),The overall response rate,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
11106,NCT05009550,Numeric Pain Scale assesment,Incidences of adverse effects (like nausea and vomiting),,2021-05-15,UNKNOWN,INTERVENTIONAL,['NA']
11107,NCT02087878,Collection of Samples,,,2014-03-31,WITHDRAWN,OBSERVATIONAL,['NA']
11108,NCT05808712,Rate of supportive care needs in cancer,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
11109,NCT05682768,Post operative Pancreatic Fistula,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
11110,NCT01497444,Overall response rate (Phase II),AFP response rate (Phase II),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11111,NCT02728804,Cumulative Incidence Rate of Treatment-related Major Financial Hardship,"Financial Stress (Patient, Caregiver, or Bereaved Caregiver)",,2016-06-22,COMPLETED,OBSERVATIONAL,['NA']
11112,NCT05918094,Progression-Free Survival (PFS),Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-STO22 (EORTC QLQ- STO22),,2023-04-30,RECRUITING,INTERVENTIONAL,['PHASE3']
11113,NCT05465512,AUC for BNCISS,disease free survival,,2022-01-04,COMPLETED,OBSERVATIONAL,['NA']
11114,NCT03107416,estimate the local tumor progression (LTP) rates (phase II),,,2017-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11115,NCT00320515,Objective Best Tumor Response,Overall Survival,,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11116,NCT02558959,Progression Free Survival,Overall Survival,,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11117,NCT01687673,Median Time to Progression (TTP),Number of Participants Whom Discontinued Treatment Due to Intolerable Toxicity,,2012-10-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11118,NCT02696408,prevalence of grade 3 mucositis and more,Safety,,2016-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
11119,NCT06134089,Number of messages generated by participants,,,2023-12-05,COMPLETED,OBSERVATIONAL,['NA']
11120,NCT02027545,Number of Participants With CRC Screening Ordered,Number of Participants With CRC Screening Utilized,,2015-11-20,COMPLETED,INTERVENTIONAL,['NA']
11121,NCT06307080,Safety and efficacy assessment,Survival benefit,The application of medical-mechanical combination therapy mode,2023-10-08,RECRUITING,INTERVENTIONAL,['NA']
11122,NCT01308840,The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.,The Number of Participants Who Experience an Adverse Event,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11123,NCT04835324,overall survival,Incidence of Adverse Events (AEs),,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
11124,NCT03962088,Change in expression levels of plasma miRNA,miRNA expression and surveillance,,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA']
11125,NCT03218345,Severe adverse events,Survival,,2016-08,RECRUITING,INTERVENTIONAL,['NA']
11126,NCT00892658,Determine the MTD of sorafenib and RT in patients with hepatocellular carcinoma using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT.,"Determine late toxicities, in-field local control at 3 months, overall survival, progression time, and progression free survival. Quantify alteration in perfusion parameters.Assess serum and tissue biomarkers. Assess quality of life in these patients.",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11127,NCT00552149,Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months,Evaluation of PFS and over,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11128,NCT04391348,Demonstrate that the identification of new tumour lesions by an experimental procedure combining PET-TDMs with 18F-FDG and 18F-Fluorocholine in patients with HCC modifies the initially planned therapeutic strategy,Number of patients who had an additional examination proposed by the MCM (multidisciplinary consultation meeting) following the PET-TDMs performed,,2020-07-17,COMPLETED,INTERVENTIONAL,['NA']
11129,NCT05720910,Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 ),GERONTE patient-centered system implementation and usage,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11130,NCT03163186,To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.,To identify potential risk factors for complications in transradial approach.,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
11131,NCT02562976,Number of patients with severe gastric atrophy and/or intestinal metaplasia in early gastric cancer and non-early gastric cancer,"correlations between Helicobacter pylori infection and moderate-to-severe EGA classification, OLGA stage III-IV, OLGIM stage III-IV",,2013-05,COMPLETED,OBSERVATIONAL,['NA']
11132,NCT04581473,"Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's Choice","Phase II: Disease control rate (DCR), as assessed by IRC and by Investigators",,2020-10-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11133,NCT01927965,To establish the dose of Minnelide™ recommended for future phase 2 protocol,To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11134,NCT00001576,,,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11135,NCT00004108,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11136,NCT04547166,PFS,DCR,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11137,NCT03950102,Rate of transplant complication,Rate of dropout from transplant waitlist,,2015-07-01,UNKNOWN,INTERVENTIONAL,['NA']
11138,NCT03996681,Disease control rate (DCR),Adverse Events,,2019-07-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
11139,NCT04929912,Incidence of Treatment-Emergent Adverse Events (CTCAE),Modified FACE-Q evaluation for Skin Cancers,,2021-06-24,RECRUITING,OBSERVATIONAL,['NA']
11140,NCT01704651,Postoperative Length of Hospital Stay,Postoperative Ileus Incidence,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11141,NCT00006467,overall survival at 6 months,response rate,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11142,NCT04230499,Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.,Clinical effect of eRapa on duodenal polyp number and burden.,Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11143,NCT03676478,Functional recovery (6mWD - 6-minute Walked Distance),Global Health status score,Levels of Haemoglobin A1c (HbA1c),2019-03-25,RECRUITING,INTERVENTIONAL,['NA']
11144,NCT05743504,Pathological complete response rate,Number of participants with delay in planned radical esophagectomy,,2023-09-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11145,NCT00003485,,,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2']
11146,NCT06311851,Objective response rate,Adverse event,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11147,NCT01512589,Total Toxicity Burden (TTB),,,2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11148,NCT05518201,Number of subjects with Severe adverse events (SAE),The immunogenicity of subjects receiving 3 doses of vaccination was assessed by IgG antibodies and neutralizing antibodies,,2022-09-23,RECRUITING,INTERVENTIONAL,['PHASE1']
11149,NCT01489332,Pathological complete remission rate (pCR),Quality of life,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
11150,NCT00281736,Efficacy,Response,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11151,NCT05529615,3-year disease-free survival rate,,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
11152,NCT00668161,Proliferation rate in the upper part of colon and rectal mucosa crypts.,quality of life (measured by standardized self-report instruments) and sleep quality,,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11153,NCT01238042,Optimal Light Dose,Resolve Barrett's mucosa,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11154,NCT05795296,Objective response rate (ORR),Adverse Events,,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11155,NCT03034473,Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.,Wexner-Score-Questionnaire,,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11156,NCT00155883,tumor response rate,"clinical benefit response, toxicities, quality of life, time to disease progression, overall survival",,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2']
11157,NCT01155258,To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST),Progression-free and overall survival,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11158,NCT06043999,Three years disease-free survival rate,Urinary function,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
11159,NCT02188927,Participation rate,Response rate,Cost of including Advance Notification Letter,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
11160,NCT00293124,Time to Disease Progression,Overall Survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11161,NCT05966246,Quantitative intestinal motility measurement using radio-opaque markers,"Measurement of the amount of food intake, first flatus time and first defecation time",,2022-01-25,COMPLETED,INTERVENTIONAL,['NA']
11162,NCT00392366,Accuracy of predicted lesion geometry to histologically measured dimensions,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
11163,NCT00417976,Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy,Response Rates Defined by RECIST 1.0,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11164,NCT00709826,Progression Free Survival,Overall Survival,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11165,NCT04160650,"The rate of self care activation (Patient Activation Measure PAM, Insignia Health; Hibbard et al. 2004)","The rate of quality of life (The Functional Assessment of Cancer Therapy Scale - Colorectal, FACT-C, Cella et al. 1993)",Incidence of morbidity,2019-10-21,COMPLETED,INTERVENTIONAL,['NA']
11166,NCT05690035,Objective Response Rate (ORR),Incidence of Treatment-Emergent Adverse Events,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11167,NCT04592861,Overall survival duration,"Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire",,2020-11-01,TERMINATED,INTERVENTIONAL,['PHASE3']
11168,NCT00176813,"To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.",To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11169,NCT04995354,WHO grade of mucositis,,,2022-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11170,NCT00335543,Median survival,"Quality of life before, during, and after therapy",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11171,NCT01098344,Adverse event and severity according to NCI CTCAE Version 4.02,Plasma concentrations of MK0752,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11172,NCT02837679,Change in Quality of life,Length of hospital stay,Health costs per patient,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
11173,NCT01533740,Impact of Tregs frequency on overall survival,Impact of Tregs frequency radiologic response rate,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
11174,NCT01591798,Quality of mesorectal excision,Long-term outcome,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11175,NCT01784900,Progression Free Survival,Progression Free Survival,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11176,NCT03836352,Safety as measured by the rate of adverse events,Overall survival,Changes in immune cell infiltration,2018-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11177,NCT02305615,Progression-Free Survival (PFS),Percentage of Participants with Adverse Events (AEs) and Serious AEs,,2015-01-13,COMPLETED,OBSERVATIONAL,['NA']
11178,NCT04069455,CR29 scores,Overall survival,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
11179,NCT02409849,PFS,OS,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
11180,NCT04734691,Progression free survival,Quality of life C30,,2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11181,NCT01379612,Tumor regression grade,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
11182,NCT04724291,Comparison to EGD in Identifying Lesions.,Safety of MCC Compared to EGD. Documentation of Any Adverse Event Patient Encounters up to the 30 Day Follow-up.,,2021-02-10,COMPLETED,INTERVENTIONAL,['NA']
11183,NCT02385617,Ad libitum calorie intake,Subjective symptom scores,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
11184,NCT00035035,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
11185,NCT00003610,severity of mouth pain,,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11186,NCT04929223,Objective Response Rate,Plasma Concentrations of Divarasib,,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE1']
11187,NCT03039309,Curative resection rate,Mortality rates,,2016-08-05,RECRUITING,OBSERVATIONAL,['NA']
11188,NCT00655655,"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)",,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11189,NCT04361227,Closure time after ESD,Clips used post-ESD,,2020-07-02,COMPLETED,OBSERVATIONAL,['NA']
11190,NCT02220062,percentage of participants with 50% decrease or less than 3 points in Pain Visual Analogue Scale (VAS),,,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
11191,NCT03741166,Blood-based biomarkers associated with genetic and epigenetic alterations.,,,2018-11-08,COMPLETED,OBSERVATIONAL,['NA']
11192,NCT00040820,,,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
11193,NCT00678535,Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments,Safety - Number of Participants With Adverse Events (AEs),,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11194,NCT06243393,Progression Free Survival (PFS),Overall Survival (OS),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11195,NCT04337333,Cumulative patency of inner covered stent and Two-in-one stent,Stent dysfunction-free patient survival,,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA']
11196,NCT00075712,Quality of life by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-ovarian cancer (QLQ-OV28),,,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11197,NCT00655785,toxicities as assessed by NCI-CACAE ver3),Survival,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11198,NCT01054924,,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
11199,NCT03072095,FIT completion within 3 months,Response to text-based CRC screening outreach,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
11200,NCT05447611,"The main objective of the EMPACOL project is to investigate, in non-metastatic CRC patients, a possible correlation, between perceived HCP's empathy and survival (OS and DFS).","The relationship between caregiver empathy, as perceived by the patient, and quality of life (QoL) will be studied.",,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11201,NCT03816345,Clinical measures of interest,,,2019-07-16,RECRUITING,INTERVENTIONAL,['PHASE1']
11202,NCT03175679,Incidence of Treatment-Emergent Adverse Events [Safety],Biological activity of infused iNKT cells,Disease Control Rate (DCR),2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
11203,NCT03092518,Overall survival,morbidity,,2017-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11204,NCT05228431,Rate of pCR,OS,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11205,NCT05052086,"Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI",,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
11206,NCT00714077,3-year disease free survival rate,safety,,2008-04,UNKNOWN,OBSERVATIONAL,['NA']
11207,NCT05726188,Recurrence,Cancer-related survival,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
11208,NCT00109070,,,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11209,NCT02127645,incidence of local and distant recurrence,anorectal function,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11210,NCT04264962,Recurrance rate,quality of life (QOL) questionnaire,,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11211,NCT05313191,To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.,To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.,,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
11212,NCT02153398,Aggravation of Regurgitation at Week 8 by Investigators,Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11213,NCT00009906,"Toxicity defined as any grade 3 or greater organ toxicity, or any grade 4 or greater hematological toxicity as assessed by CTCAE version 2.0",,,2000-12,TERMINATED,INTERVENTIONAL,['PHASE3']
11214,NCT04037319,"Incidence of atrial fibrillation within 90 days of colorectal cancer surgery, defined as ≥30 seconds of atrial fibrillation identified on a 24-hour cardiac monitor OR absence of p waves and irregularly irregular rhythm on an electrocardiogram",Number of events of use of health services for atrial fibrillation or sequelae of atrial fibrillation,,2020-01-16,UNKNOWN,OBSERVATIONAL,['NA']
11215,NCT03220711,"Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein",,,2017-07-28,TERMINATED,INTERVENTIONAL,['NA']
11216,NCT05276037,Survival,FDG PET-CT value in Milan-in patients,,2019-01-01,RECRUITING,OBSERVATIONAL,['NA']
11217,NCT04081831,Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed),Case-fatality and survival rate,,2019-07-31,COMPLETED,OBSERVATIONAL,['NA']
11218,NCT04188002,Metabolic Equivalent Task Hours (METs) for Physical Activity,Number of Times Visiting the Site,,2017-03-25,COMPLETED,INTERVENTIONAL,['NA']
11219,NCT03101475,Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation),Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.,,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11220,NCT04495088,disease-free survival,Patient reported outcome: Functional outcome according to Wexner score,,2020-09-30,RECRUITING,INTERVENTIONAL,['PHASE3']
11221,NCT01522612,Progression free survival,"Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire",,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
11222,NCT00654160,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy,Response rate of genotype-based dosing in the subset of patients that has colorectal cancer,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11223,NCT05382741,Disease Free Survival,Incidence of adverse events,,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2']
11224,NCT06069778,Phase 2 - Disease-free survival (DFS),Phase 2 - Occurrence of abnormal laboratory parameters,,2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11225,NCT00570531,Disease Free Survival Time,The Proportion of Toxicities Experienced by Participants,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2']
11226,NCT02969096,Rate of complete tumor ablation,Adverse Events,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
11227,NCT05892289,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,Proportion of participants need to rehospitalized after surgery,,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11228,NCT00064259,Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU,Microarray Data,,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11229,NCT03551951,Quantity of cfDNA in bone marrow,,,2016-07-01,RECRUITING,OBSERVATIONAL,['NA']
11230,NCT01512745,Overall Survival(OS),Percentage of Participants With Adverse Events,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11231,NCT01375816,Tumor response,Correlation of UGT1A family polymorphism and the toxicity of liposome-encapsulated irinotecan hydrochloride PEP02 or irinotecan hydrochloride,,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2']
11232,NCT01612325,Target lesions tumour response,Toxicity according CTC v 4 criteria,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11233,NCT03237325,Duration of Severe Oral Mucositis (SOM),,,2017-12-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11234,NCT02717949,Number Subjects Who Experience Adverse Events on HCV Treatment as Assessed by Division of AIDS (DAIDS) Adverse Event (AE) Grading Table Version 2.0.,Number of Subjects Who Have a Change in Lymph Node Size From Baseline After HCV Treatment,,2016-02-25,TERMINATED,INTERVENTIONAL,['PHASE4']
11235,NCT04678349,ileostomy stoma output,dietary intake,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
11236,NCT04512508,Percentage of positive results for Anal Test system versus anal liquid cytology and anoscopy for the presence of high-risk human papillomaviruses,Number and percentage of patients to have a positive opinion to use Self-Test system.,,2020-08-30,UNKNOWN,INTERVENTIONAL,['NA']
11237,NCT06090643,Return rate of completed FIT kits,,,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
11238,NCT02582970,Percentage of Participants With Adverse Events,Mean Direct Medical Cost for Cancer Related Medical Care Utilization,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11239,NCT05969444,High grade dysplasia/Gastric adenocarcinoma,,,2015-06-01,COMPLETED,OBSERVATIONAL,['NA']
11240,NCT01378143,Overall survival (OS),Duration of response (DR),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11241,NCT02203409,Safety of the procedure defined as the incidence of postoperative complications and mortality,survival rate,,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
11242,NCT00217555,Quality of life,Overall survival,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11243,NCT01668017,Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT),Percentage of Subjects With Disease Control,,2012-09-30,TERMINATED,INTERVENTIONAL,['PHASE1']
11244,NCT05601505,"Disease-related treatment failure, DrTF","overall survival, 2yOS",,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
11245,NCT04054518,Six-month progression-free survival,Incidence of distant progression,Six-month progression-free survival according to immune biomarkers,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11246,NCT05055323,Incidence of dose limited toxicity (DLT),Fatty tissue accumulation of PP,,2021-07-29,RECRUITING,INTERVENTIONAL,['PHASE1']
11247,NCT00012246,Frequency and severity of toxic effects,,,2002-07,TERMINATED,INTERVENTIONAL,['PHASE2']
11248,NCT05714111,Local progression free survival,Overall Survival,,2022-03-04,RECRUITING,OBSERVATIONAL,['NA']
11249,NCT01187212,Progression-free survival,Biomarker for sorafenib,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11250,NCT03813784,Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participants,Number of Subjects with treatment-related adverse events (AEs),,2019-03-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
11251,NCT02392637,Median Progression Free Survival (PFS),Number of Participants With Treatment Response Rate,,2015-04-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11252,NCT02288728,postoperative mortality and morbidity,reflux esophagitis,,2014-12,TERMINATED,INTERVENTIONAL,['NA']
11253,NCT02146703,Objective reponse rate,"Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11254,NCT05000697,Decision to Watch and Wait due to clinical complete response,Colostomy-free survival at 3 years,,2021-07-14,RECRUITING,INTERVENTIONAL,['NA']
11255,NCT04232735,SOURCE observational scale,Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention),SOURCE evaluation questionnaire (tailor made evaluation questionnaire),2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
11256,NCT01876511,Progression Free Survival (PFS) at 20 Weeks in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1),Does MSI as a Marker Predict Treatment Response,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11257,NCT03295500,Overall survival rate,the value of ICG R15,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
11258,NCT03954756,Overall survival rate,Overall survival,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11259,NCT06177522,pCR rate,,,2023-12,RECRUITING,INTERVENTIONAL,['PHASE2']
11260,NCT00919282,overall survival,safety of treatment,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11261,NCT04196816,Overall survival,Progression-free survival,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11262,NCT05378919,disease-free survival,Overall survival,,2015-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
11263,NCT02632201,Overall survival,Quality of life,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11264,NCT03503162,The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System,,,2018-05-17,COMPLETED,INTERVENTIONAL,['NA']
11265,NCT04643041,1 year DFS rate,3 years OS rate,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
11266,NCT02186574,Rate of reverse seroconversion,All-cause mortality,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
11267,NCT03500380,Progression-free Survival (PFS) as Assessed by an IRC,Overall Survival,,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11268,NCT05203549,Establishment of patient-derived organoids,Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
11269,NCT00026299,Recommended dose of ZD1839 in combination with oxaliplatin,,,2001-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11270,NCT02779465,Change in serum levels of 25-hydroxy vitamin D,Number of participants on Vitamin D treatment with adverse events,,2016-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11271,NCT04753203,Progression Free Survival,Duration of response,,2021-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11272,NCT04005118,Rate of prolonged postoperative ileuss,Expression intensity in cytoplasm of protein ligase HACE1 in tumoral and non-tumoral tissues,,2019-05-28,UNKNOWN,OBSERVATIONAL,['NA']
11273,NCT01319877,Percentage of Participants With Bevacizumab-related Serious Adverse Events,Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
11274,NCT06173726,Dose-Limiting Toxicity,,,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
11275,NCT03740503,Genomic Characterization of Tumor Samples,,,2013-11-01,RECRUITING,OBSERVATIONAL,['NA']
11276,NCT03678883,Part 3 Arm B,,,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11277,NCT03818165,Assess preliminary efficacy by overall survival,Assess preliminary efficacy by in-liver progression free survival (PFS),Assess if circulating tumor cells (CTC) correlate with response,2019-07-29,TERMINATED,INTERVENTIONAL,['PHASE1']
11278,NCT04382079,oral mucositis,"IL-1, IL-6, IL-10,TNF",,2020-04-08,UNKNOWN,INTERVENTIONAL,['NA']
11279,NCT05013216,Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells,Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.,,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1']
11280,NCT01139242,"Higher incidence of CRC screening, if needed, among experimental participants.",,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
11281,NCT03914820,Local recurrence free survival (LRFS),mortality at 30 and 90 days from surgery,,2020-06-19,RECRUITING,INTERVENTIONAL,['NA']
11282,NCT02401802,Inadequate bowel preparation.,"Acceptability of the preparation (interference with work, leisure activities or sleep",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11283,NCT00003786,Clinical Response Rate,,,1999-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11284,NCT04293419,Pathological complete response (pCR) rate,Calculation of the neoadjuvant rectal (NAR) score,,2019-12-18,RECRUITING,INTERVENTIONAL,['PHASE2']
11285,NCT05760599,DCR per RECIST 1.1,Biomarkers such as PD-L1 expression,,2023-02-27,RECRUITING,INTERVENTIONAL,['PHASE2']
11286,NCT03320733,Negative predicative value,Parameters optimization keV,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
11287,NCT00016900,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11288,NCT00111904,Safety,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11289,NCT03941093,Overall Survival (OS),"Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",,2019-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11290,NCT02948309,Overall survival (OS),Incidence of treatment-emergent adverse events (AE),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11291,NCT01239082,The primary outcome is colorectal cancer mortality.,FIT Positive - If Colonoscopy is Warranted,,2012-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11292,NCT03028311,Incidence of adverse event assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,,,2017-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11293,NCT03764137,Image Quality,,,2019-03-14,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11294,NCT06002425,Influence Rate of ChatGPT on Treatment Plans,3-year Progression-Free Survival (PFS) Rate,5-year Overall Survival (OS) Rate,2023-08-29,RECRUITING,INTERVENTIONAL,['NA']
11295,NCT04836741,Disease free survival,,,2015-07-01,COMPLETED,INTERVENTIONAL,['NA']
11296,NCT01587534,the change in body weight at eight weeks after the randomisation,Frequency of bowel movements per day,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11297,NCT03274804,Feasibility Rate of a Combined Therapy,Overall Survival,,2018-04-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11298,NCT01231347,To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas,Number of subjects with adverse events,,2011-04,TERMINATED,INTERVENTIONAL,['PHASE3']
11299,NCT00147550,"Objective Response Rate, Safety.","Time to progression, overall survival, patient reported outcomes.",,2004-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11300,NCT04403022,Adverse Events Rates,,,2021-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11301,NCT03395938,The proportion of siblings that contacted the study team within 4 weeks from point of engagement by the index colorectal cancer patient.,,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
11302,NCT01093755,Change in Esophageal Inflammation Biomarker COX-2 Gene Expression,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11303,NCT01550055,Overall response rate,Progression-free Survival,,2009-05-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11304,NCT00475293,objective response rate,adverse events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11305,NCT04667351,overall survival,Adverse Events,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11306,NCT00787787,Median Progression-free Survival,Median Overall Survival,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2']
11307,NCT01782573,"the positive rate of the baseline culture , the preoperative culture , and the postoperative culture",the post - operative surgical site infection,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11308,NCT04560712,Retention,Satisfaction of pain control,Postoperative length of stay,2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11309,NCT05801211,Stoma rate at 1 year after tumor resection,type of chemotherapy regimen,,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11310,NCT04034953,Breast cancer detection rate,,,2018-08-06,UNKNOWN,INTERVENTIONAL,['NA']
11311,NCT02864381,Objective Response Rate (ORR),Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities,,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11312,NCT01701310,To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related anaemia,To determine differences in anemia symptomatology response between groups.,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11313,NCT03281382,Toxicity of the gene therapy,PET imaging,,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11314,NCT00486356,Toxicities of combined chemotherapy regimen,Antitumor activity,,2004-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11315,NCT03027895,clinical success,technical success,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
11316,NCT05711433,incidence of postoperative pancreatic fistula,,,2014-07-01,COMPLETED,OBSERVATIONAL,['NA']
11317,NCT03122548,Objective Response Rate (ORR),Overall Survival (OS),,2017-08-14,TERMINATED,INTERVENTIONAL,['PHASE2']
11318,NCT04652271,Mortality,Morbidity,,2021-09,UNKNOWN,OBSERVATIONAL,['NA']
11319,NCT00467194,Maximum tolerated dose,Change in DCE-CT scan assessment of angiogenesis,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11320,NCT00554905,Overall Survival,Recurrence rates,,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
11321,NCT05596630,Local control rate（LC）,Progression-free survival (PFS),,2023-05-08,RECRUITING,INTERVENTIONAL,['NA']
11322,NCT03687853,Death,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
11323,NCT05375370,Change in tcDNA dosage between baseline and 3 Months,Survival at 2 years,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11324,NCT06132087,R0 resection rate,Time to distant metastases,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
11325,NCT04899908,Local Recurrence,Neurocognitive function: cognitive impairment,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11326,NCT04526483,The success rate of laparoscopic gastric surgery,Lymph node dissection rate,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
11327,NCT03295591,Cutoff value of CTC counts,Overall survival,,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA']
11328,NCT00509561,Overall survival,Health economics,,2008-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11329,NCT03944304,Disease control rate,,,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE2']
11330,NCT03788226,3-year disease-free survival,safety (The incidence of chemotherapy related adverse events),,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11331,NCT02333721,3-year disease free survival rate,Technical performance,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
11332,NCT01103323,Overall Survival,Tumor Response,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11333,NCT02686372,To Evaluate safety of the TCR-T treatment,To evaluate objective response rate,,2018-05-16,COMPLETED,INTERVENTIONAL,['PHASE1']
11334,NCT01132469,5-year disease(gastric cancer)-free survival rate after ESD procedure,The safety of ESD procedure,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
11335,NCT04287335,Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy,"Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC",,2018-09-18,COMPLETED,OBSERVATIONAL,['NA']
11336,NCT00001241,,,,1989-01-27,COMPLETED,OBSERVATIONAL,['NA']
11337,NCT03853772,Demographic and clinical data obtained via chart review and questionnaires,,,2019-04-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11338,NCT02237157,Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas,CA19-9 Tumor Reduction,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11339,NCT04254939,Phase II: ORR based on mRESIST 1.1,,,2019-08-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11340,NCT05603039,Objective remission rate (ORR),Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR),Overall survival (OS),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11341,NCT03990974,30-day postoperative infection rate,Distant infection rate,,2020-09,SUSPENDED,INTERVENTIONAL,['PHASE3']
11342,NCT05022511,Participation,Rate of compliance to follow-up with colonoscopy after a positive FIT,Survey evaluation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
11343,NCT01768988,Pain intensity (Visual Analogue Scale; VAS Score),Neuropathic Pain,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE4']
11344,NCT03957486,difference between SpHb value and SaHb value (SpHb - SaHb) in g/dL,,,2019-05-14,COMPLETED,INTERVENTIONAL,['NA']
11345,NCT00947206,ever had a CRC screening test,up-to-date for CRC screening,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11346,NCT00906997,Colorectal cancer-related mortality,Advanced colorectal neoplasm detection rate,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
11347,NCT05215535,Cost effectiveness,Survival,,2022-04-12,RECRUITING,INTERVENTIONAL,['NA']
11348,NCT05104567,Objective Response Rate (ORR),Cend of infusion of cetuximab,,2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11349,NCT00126542,Response rate of patients treated with the combination of bevacizumab and OSI-774,Overall survival,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11350,NCT02304978,TNM primary colorectal tumor stage,Interaction plate / tumor cell,,2009-06-22,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
11351,NCT04404647,90-day complication rate and severity,Longitudinal changes in nutritional status assessment,,2020-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
11352,NCT01661270,Progression-free Survival (PFS),Percentage of Participants With Objective Response,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11353,NCT01273493,Pharmacokinetics of trabectedin,Evaluate survival data,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11354,NCT04988191,"Pathological complete response rate based on blinded, independent, central review",Incidence of Treatment-Related Adverse Events,,2020-12-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11355,NCT00165854,"to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.",measure duration of response and stable disease; to measure median and one year survival.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11356,NCT03787537,Change in nutritional status,length of hospital stay,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
11357,NCT05727007,Diagnostic accuracy in T stage,Diagnostic accuracy in peritoneal or nearby organ infiltration,,2019-01-23,COMPLETED,INTERVENTIONAL,['NA']
11358,NCT02525380,The rate of Time to progression of hepatocellular carcinoma 30 patients.,,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11359,NCT02688114,Change in the Percent of Mucosa Healed by Neosquamous Epithelium,Change in inflammatory cell infiltrate,,2017-10-18,COMPLETED,INTERVENTIONAL,['NA']
11360,NCT02738606,Overall survival,Patients who abandon treatment,,2016-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11361,NCT04112836,Percent of planned chemotherapy delivered,Factors associated with the percent of chemotherapy received,,2019-03-15,UNKNOWN,OBSERVATIONAL,['NA']
11362,NCT01333631,Number of the patients with side effects,Number of the patients survived,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
11363,NCT03260712,Detection of progression-free survival (PFS) rate at 6 months defined according to RECIST 1.1.,Progression free survival rate at 6 months according to iRECIST,"Biomarkers predictive of response and toxicity (protein profiling, HLA typing)",2020-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11364,NCT06266091,"Puncture-free survival, PuFS",Peak serum concentration (Cmax),,2021-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11365,NCT06251726,Lymph node invasion rate,Molecular profile of the tumor,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11366,NCT01662752,Subjects in Which the SLN(s) Are Identified,Sensitivity and Specificity of Tumour-bearing Status of SLN(s) as a Measure of Lymph Node Status When Assessed by Standard Techniques,Frequency and Tumour-bearing Status of Aberrant SLN(s,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11367,NCT00544193,Measurement of biochemical parameters in tumors that may correlate with the effectiveness of therapy,,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11368,NCT02602067,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),Adverse Events,Tumor response,2015-11,TERMINATED,INTERVENTIONAL,['PHASE1']
11369,NCT03552744,"Number of PCPs who have at least one patient ever tested with FOBT, or who prescribe at least one FOBT to eligible patients (patients not already tested within recommended intervals, with no contra-indication for screening).",Change in PCPs' future intentions to prescribe colonoscopy vs. FOBT over the next 6 months,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
11370,NCT01124994,Accuracy of CLE-EMR,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
11371,NCT00754468,Depth of Injury,Side Effects of Subjects Receiving Cryospray Therapy.,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11372,NCT05058846,Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings,Proportion of participants who have additional medical procedures,Change in scores on the Disease Specified Perceived Risk Survey,2022-01-20,RECRUITING,OBSERVATIONAL,['NA']
11373,NCT01700062,biochemistry data; Various inflammation-related cytokines ;,clinical outcome(hospital stay..),,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11374,NCT02707328,Maximum tolerable dose,quality of life,,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1']
11375,NCT05070247,Dose Expansion: Overall Response Rate (ORR),Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations,,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11376,NCT05177484,"the feasibility of running the study, to see if it could be run as a large multi-centre study",postoperative allogenic red blood cell transfusion rates,,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
11377,NCT02752698,complication,change of blood and biochemiacl,,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA']
11378,NCT01366586,,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
11379,NCT00209677,Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.,,2004-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11380,NCT05139082,Overall response rate (ORR),Overall survival (OS),,2021-11-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11381,NCT03899649,Overall Survival,,,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11382,NCT03919383,6 months progression free survival rates,Adverse Events,,2019-04-15,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11383,NCT00003543,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11384,NCT01441336,3 year recurrence free survival,,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11385,NCT02867280,Recurrence free survival,Incidence of dose modification of sorafenib due to adverse events.,,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE3']
11386,NCT00373737,,,,1999-05,COMPLETED,OBSERVATIONAL,['NA']
11387,NCT00561275,Toxicity of multiple peptide vaccinations,"Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11388,NCT00066677,Progression-free Survival,Number of Participants With Thromboembolic Events,,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2']
11389,NCT01584544,Number of Participants Experienced Dose Limited Toxicity,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11390,NCT03450512,the arisen of EC in the CT scan,,,2019-01-14,RECRUITING,OBSERVATIONAL,['NA']
11391,NCT01053013,Overall Survival - Based on Most Recent Scan,Overall Survival - Based on Stage IV Disease Diagnosis,Pain Assessment of Pancreatic Cancer Participants,2010-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11392,NCT05203978,Complete colonoscopy defined by caecum intubation (binary criterion : yes or no),Polyp removal (binary criterion : yes or no),,2022-03,UNKNOWN,OBSERVATIONAL,['NA']
11393,NCT01266707,Toxicities as assessed by NCI-CACAE ver3,Survival,,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
11394,NCT05704413,"Relation between biological parameters and outcomes of digestive disease (IBD, CRC)",Brain-microbiota interaction,,2021-06-17,RECRUITING,OBSERVATIONAL,['NA']
11395,NCT01386242,Overall survival (OS),Disease Control Rate,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11396,NCT02632019,Overall survival,Quality of life,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11397,NCT05619016,Percentage of HER2-positive lesions,Safety aspects of ABY-025,Dynamic PET parameters,2022-11-23,RECRUITING,INTERVENTIONAL,['PHASE2']
11398,NCT03416244,Overall survival,Incidence of Treatment-Emergent Adverse Events,,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE2']
11399,NCT04417010,local tumor progression,,,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA']
11400,NCT02776878,"Progression-free survive, calculated from registration until progression or death","Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria",,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
11401,NCT04047004,Surgical complications,Adjuvant chemotherapy,,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11402,NCT05886465,Progression free survival rate at 6 months,Adverse events,,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE2']
11403,NCT03221400,"Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate",Phase 2a: Overall survival,,2017-08-29,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11404,NCT05801783,Systemic immune response,Quality of Life Assessment,,2022-12-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
11405,NCT05171530,Maximum tolerated dose of lenvatinib,Overall survival (OS),Exploratory Outcome,2022-01-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
11406,NCT01626001,Patient Percentage with 4DCT Acquisition Artifacts,Artifact Reproducibility Reducing 4DCT Acquisition,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11407,NCT01416662,capability of CDA to predict the occurrence of early severe hematological toxicity upon gemcitabine,Overall Survival,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11408,NCT05916014,Specificity of AI model to diagnose the Kimura-Takemoto classification,The MIOU value of AI model in semantic segmentation of endoscopic atrophy picture,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
11409,NCT00036517,,,,2002-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11410,NCT02862015,European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change,Adverse effect,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
11411,NCT00559858,Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity,Measurement of biomarkers that might predict the occurrence of HFS,,2004-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
11412,NCT05738772,Serum level of Soluble PDGFRβ,,,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11413,NCT01844908,Incidence of prolonged ileus,30-day mortality rate,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
11414,NCT04851106,The negative predictive value (NPV) determined from shear wave elastography,,,2021-09-21,UNKNOWN,OBSERVATIONAL,['NA']
11415,NCT06310564,Progression-free survival (PFS).,questionnaire QLQ-C30,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11416,NCT00989651,Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase),"Incidence of toxicity, graded according to National Cancer Institute CTCAE version 4.0",Genomic BRCA mutation status,2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11417,NCT05496491,Disease Free Survival,Treatment Compliance,,2022-08-30,RECRUITING,INTERVENTIONAL,['NA']
11418,NCT00006389,Observed Response Rate.,Progression-free Survival,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11419,NCT05223673,"Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)",Adverse Events (Phase III Part),,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE3']
11420,NCT05497271,diagnostic accuracy by cystic fluid analysis,DNA mutation profile of cystic fluid,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
11421,NCT05439993,Progression-free survival rate (PFSR) at 4 months,,,2022-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11422,NCT03550001,lymph node yield,Local recurrence rate,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
11423,NCT03075553,Response Rate for Participants Who Achieve a CR or PR [CT-based Response],Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events,,2017-05-17,TERMINATED,INTERVENTIONAL,['PHASE2']
11424,NCT01017822,Overall survival (Phase II),Response rate (Phase II),,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11425,NCT02399813,Progression Free Survival,Number of Participants With Adverse Events,,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11426,NCT03225560,Quality of Bowel Preparation,Patient reported adherence to bowel preparation instructions,,2018-11-21,COMPLETED,INTERVENTIONAL,['NA']
11427,NCT04967183,Adverse effects,Preferences of the subjects,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
11428,NCT00474994,Overall Objective Response,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11429,NCT03780049,Overall survival (OS),Conversion rate to resection,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11430,NCT03259763,Rate of gastric outlet obstruction recurrence,Duration of stent patency,,2020-10-26,RECRUITING,INTERVENTIONAL,['NA']
11431,NCT01373047,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,Designer T cell survival and phenotype following infusion,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11432,NCT04216901,Accuracy of Vision location,Consistent of vision positioning between diagnostic system and endoscopists,,2019-12-24,UNKNOWN,OBSERVATIONAL,['NA']
11433,NCT00644618,Survival,"response rate, clinical benefit response, and safety",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11434,NCT00669136,Immunological response rate in PBMC as indicated by the ELISPOT assay,Immunological response rate in lymph nodes as indicated by the ELISPOT assay,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1']
11435,NCT04185454,Osteocalcin ratio,Lipid profil 2,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
11436,NCT03370432,Incidence of colorectal cancer in the DCH cohort,,,1993-12,COMPLETED,OBSERVATIONAL,['NA']
11437,NCT01149304,HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.,Safety of the study drugs.,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11438,NCT03524287,overall postoperative morbidity rates,Lymph node noncompliance rate,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
11439,NCT04647045,Serum cytokine level,Constipation related symptoms,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
11440,NCT02563548,"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",Dose-Expansion Phase: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG),,2015-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
11441,NCT01315522,The stent patency,adverse events,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11442,NCT02325453,Compare the three treatment arms in terms of tumor recurrence after treatment. (Disease-free survival),"Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress. (Granulocyte-to-lymphocyte ratio.)",,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
11443,NCT00606944,Recovery,Postoperative Complication,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11444,NCT00267787,"Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.",,,2004-09,TERMINATED,OBSERVATIONAL,['NA']
11445,NCT01843725,To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept,"The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1",,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11446,NCT03064490,Number of Participants With Pathologic Complete Response (pCR),Safety of the Combined Drug Therapy With Radiation Therapy.,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
11447,NCT00925769,Part 1: PRD of Bevacizumab for Part 2,Part 2: Overall Survival,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11448,NCT05257122,progression free survival (PFS),safety: the potential side effects,,2022-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
11449,NCT04747951,The rate of complete responses,rate of intraoperative and postoperative complications,,2020-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
11450,NCT00004042,,,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11451,NCT05545293,Postoperative nutritional status and quality of life,Postoperative intestinal function recovery time,,2022-09-14,RECRUITING,OBSERVATIONAL,['NA']
11452,NCT03384511,Tumor response defined by RECIST criteria,Treatment-Related Adverse Events as Assessed by CTCAE,,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
11453,NCT06265285,Change in patient-reported rating of Cancer CARE Cancer Connected Access and Remote Expertise (CARE) after 8 weeks,Overall survival (OS),,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
11454,NCT02129257,Progression-Free Survival (PFS) rate at 1 year,"Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS.",,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE2']
11455,NCT05997147,Recurrence-free survival,Overall survival,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
11456,NCT03549338,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.",,,2018-11-29,TERMINATED,INTERVENTIONAL,['PHASE2']
11457,NCT06070376,Reinterventions,Patency time of the prostheses.,,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
11458,NCT05383066,Progression-Free Survival,disease control rate,,2022-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11459,NCT05648487,R0 resection,Relapse-Free Survival,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11460,NCT01471756,Efficacy of Two Devices used in EMR,Compare the Use of Two Injectates,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11461,NCT05259488,LOS,Time of tolerated food intake,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
11462,NCT02919878,Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer.,R0 resection rate,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
11463,NCT05442502,The rate of early postoperative complications.,Time of esophagojejunostomy,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
11464,NCT05382442,Number of participants with adverse events (AEs),Overall survival (OS),,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
11465,NCT00816777,Progression Free Survival,Overall Survival,,2008-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11466,NCT06301464,The level of serum pepsinogens,,,2003-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11467,NCT05906615,Pain score,Dose reduction of opioids,,2021-01-14,COMPLETED,INTERVENTIONAL,['PHASE2']
11468,NCT05098197,Overall Survival (OS),Change in Quality of Life,,2021-09-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
11469,NCT03127111,Time to recurrence (TTR),Overall survival (OS),,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11470,NCT05178043,The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1,Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline,,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11471,NCT04154124,"Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT",,,2019-11-23,UNKNOWN,INTERVENTIONAL,['NA']
11472,NCT00041275,Survival measured weekly,Quality of life as measured by EORTC quality of life instrument monthly,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11473,NCT02864485,disease-free survival,disease-free survival,,2016-08-03,RECRUITING,INTERVENTIONAL,['NA']
11474,NCT04558684,Clinical complete response rate (cCR),Incidence of adverse events (AEs),,2019-11-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11475,NCT02841436,Tumor response,Assess for presence of adverse event,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11476,NCT04535024,Objective Response Rate,Acute Toxicity,,2021-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
11477,NCT04357587,Treatment response as measured by Carcinoembryonic antigen (CEA) blood test,,,2020-08-06,RECRUITING,INTERVENTIONAL,['PHASE1']
11478,NCT04856046,Multi-target hepatocellular carcinoma panel (MHP) score,,,2021-11-06,RECRUITING,OBSERVATIONAL,['NA']
11479,NCT03029988,Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging.,,,2017-07-26,TERMINATED,INTERVENTIONAL,['PHASE1']
11480,NCT03191123,3-year overall survival,Recurrence rates,mortality,2016-07-05,UNKNOWN,INTERVENTIONAL,['NA']
11481,NCT00768937,Safety of Sorafenib in combination with TACE,,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11482,NCT00324753,Communication Content,,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
11483,NCT02069561,Changes of apoptosis,Change of Microbiota composition from baseline,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
11484,NCT05299840,progression-free survival,Quality of life of patients,,2023-06-07,RECRUITING,INTERVENTIONAL,['NA']
11485,NCT02748304,Overall survival,Number of patients with treatment-related bleedings who use aspirin,,2016-04,TERMINATED,INTERVENTIONAL,['NA']
11486,NCT01348412,progression-free survival,Estimate the quality of life (QLQ C30) and the fatigue MFI20,,2010-12-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11487,NCT03619681,The proportion of patients experiencing dose limiting toxicities.,Progression free survival according to RECIST 1.1 criteria.,,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
11488,NCT03563586,Surgical Site Infections,Time to beginning of adjuvant treatment for colorectal cancer,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
11489,NCT03087864,feasibility defined as percentage completion of treatment with atezolizumab.,Overall survival,"Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.",2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
11490,NCT05520840,Number of patient with presence of best isolated serum biomarkers selected from different candidates,Number of patient with presence of other isolated serum biomarkers selected from different candidates,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11491,NCT04024358,PNI and VI correlation with DFS,Correlation of neurotoxicity with PNI,,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11492,NCT05764720,Acute Grade 3+ treatment related GI toxicities,Progression Free Survival,,2023-05-14,RECRUITING,INTERVENTIONAL,['NA']
11493,NCT02416609,Progression-free survival,Overall survival,,2014-01,RECRUITING,INTERVENTIONAL,['NA']
11494,NCT02332213,VOCs differentiating the study groups,Groups of gastrointestinal microbiota correlating to VOCs,Gastrointestinal microbiome in cancer patients,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11495,NCT05201352,Overall survival,,,2022-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11496,NCT04163900,Overall Survival (OS),,,2019-12-24,TERMINATED,INTERVENTIONAL,['PHASE3']
11497,NCT02880020,Overall response rate defined as the number of subjects with a best objective response of confirmed CR or PR divided by the number of subjects,Response rate by Choi criteria,,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
11498,NCT00685828,Progression-free survival,Toxicity as assessed by NCI CTC v2.0,,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11499,NCT05719480,Achieve the expected number of enrolled cases,,,2022-11-20,RECRUITING,OBSERVATIONAL,['NA']
11500,NCT05646043,Individual patient compliance,Laboratory examinations - coagulation factors (fibrinogen),,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
11501,NCT01697943,Change in QOL (Quality of Life),Nutritional status of patients,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
11502,NCT02291289,Progression-Free Survival (PFS),Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score,,2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2']
11503,NCT06248554,Disease-free survival,Adverse effects,,2019-12-01,RECRUITING,INTERVENTIONAL,['NA']
11504,NCT01308723,Part II: Safety/tolerability: Incidence of adverse events,Safety: additional anti-drug antibodies sampling after termination of study drug treatment,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11505,NCT03192735,Radical surgical resection rate,adverse event,,2017-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11506,NCT06173037,Overall Response Rate (ORR) by Independent Review Committee (IRC),Expression of MSLN using IHC,,2023-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11507,NCT03905967,Overall survival,Time to progression,,2019-06-16,UNKNOWN,INTERVENTIONAL,['PHASE3']
11508,NCT00865189,Percentage of Participants With Tumor Sterilization Defined by ypT0-N0,Percentage of Participants With Surgery,,2007-10-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11509,NCT02415036,Objective response rate in percentage of Melphalan/HDS treatment,Progression free survival in months of patients receiving Melphalan/HDS treatment.,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2']
11510,NCT00094003,,,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11511,NCT00286000,Response rate,TTP,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11512,NCT03691090,OS,AE,Antidrug Antibodies (ADAs),2018-12-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11513,NCT03631407,Number of Participants Who Discontinued Study Treatment Due to an AE,Trough Plasma Concentration (Ctrough) of Vicriviroc,,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE2']
11514,NCT01880554,Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.,Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
11515,NCT00142428,Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma,Objective Response Rate,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11516,NCT02966821,Progression-free survival (PFS) rate at Week 16,Overall survival (OS),,2017-01-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11517,NCT04724551,Incidence of clinically relevant pancreatic fistula,Biological markers,,2012-06-01,COMPLETED,OBSERVATIONAL,['NA']
11518,NCT02697084,time of disease-free survival,best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
11519,NCT00691054,Overall Survival Rate at 6 Months,Median Overall Survival of Participants,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11520,NCT02608203,level of changes (%) between care management before DOTANOC PET and care management after DOTANOC PET,number of patients for whom PET allowed the detection of lesions not described by standard imaging,,2016-05-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11521,NCT00526331,Length of Hospital Stay (LOS) by Participant,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11522,NCT06054906,Percentage of participants with ≤10% tumor cell survival in resection specimens,Number of participants with treatment-related adverse events as assessed by NCI-CTC,Distribution of immune cells in tumor tissue,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2']
11523,NCT03475680,Postoperative 30-day surgical site infection (SSI).,Date of adjuvant chemotherapy beginning,,2018-08-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11524,NCT05336539,Application value of polygene methylation detection in colorectal cancer in community population,,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
11525,NCT00006348,response,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11526,NCT06244446,"Objective response rate (ORR), which is defined as the proportion of patients with complete response (CR) and partial response (PR) at 6 months . CR or PR is assessed in accordance with mRECIST.","Number of Participants with biomarkers change ( AFP , PIVKA II) in both groups.",,2024-02-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11527,NCT04735198,To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.,To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.,,2021-01-20,RECRUITING,INTERVENTIONAL,['NA']
11528,NCT01511653,Measure the sensitivity of a blood based panel of biomarkers relative to fecal immunochemical testing,To measure the sensitivity and specificity of a combined panel of blood and stool based biomarkers for the detection of colorectal cancer,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
11529,NCT06001567,Proportion of patients with PLT >75×10^9/L or doubling from baseline,Adverse events (AEs),,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2']
11530,NCT02037399,present pain intensity (PPI),,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
11531,NCT02075086,Progression Free Survival,Feasibility,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
11532,NCT02232490,changes in plasma AFP,CT scan,adverse effects,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11533,NCT02406170,Toxicity graded according to NCI Common Terminology Criteria for Adverse Events Version 4.0,Overall survival,,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11534,NCT05287165,Incidence of Treatment Related adverse events (AEs),Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood),,2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
11535,NCT03430635,Identification of PET/CT parameters that can be predictors of survival,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
11536,NCT05006131,Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment,Proportion of screening patients who experience complications/adverse events of screen-related procedures,,2020-07-10,RECRUITING,OBSERVATIONAL,['NA']
11537,NCT04907864,Median change (kg) in handgrip strength,"Rate of toxicity with clinical significance, and possible relationship to either study intervention",,2020-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
11538,NCT00268398,disease-free survival,Pharmacogenetics,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11539,NCT05901779,postoperative infectious complications,total bilirubin,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
11540,NCT01572428,Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient,Patients With 1 or More Conventional Adenomas,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11541,NCT00002570,Survival,response duration,,1994-07-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11542,NCT05125614,Overall survival,,,2020-05-01,COMPLETED,OBSERVATIONAL,['NA']
11543,NCT04709055,Percentage of patients with postoperative complications of grade II or higher in the Clavien-Dindo,Patient and professionals experience (ancillary study using semi-directive interviews),,2021-01-14,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11544,NCT05220046,Retention Rate,Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose,,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE1']
11545,NCT05855291,Overall survival,,,2018-01-22,COMPLETED,INTERVENTIONAL,['NA']
11546,NCT03359187,Change of mucositis grading,Patient satisfaction with the mouth wash,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
11547,NCT00433576,Concentrations of biomarkers,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11548,NCT05385250,Rate of PIFs,Quality of Life measures (EORTC),,2021-08-23,RECRUITING,INTERVENTIONAL,['NA']
11549,NCT04527861,3-year disease free survival rate,5-year overall survival rate,,2021-04-08,RECRUITING,INTERVENTIONAL,['NA']
11550,NCT05685602,Dose limiting toxicity rate,Overall survival (OS),Pharmacokinetics (PK) of both CA-4948 and nab-paclitaxel,2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE1']
11551,NCT05913674,Feasibility of mEPIC,Satisfaction of care team,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11552,NCT03130634,GI associated adverse events,,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11553,NCT00323583,Quality of life,Tolerance and Safety NCI-CTC version 2,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
11554,NCT04880811,Objective response rate,Overall survival,,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
11555,NCT05606848,Change in serum prealbumin,Energy intake in kcal / kg BW,,2022-11-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11556,NCT05444686,SUV of primary and metastases lesions,,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11557,NCT02311465,Functional Assessment of Cancer Therapy: General (FACT-G) Health Related Quality of Life Questionnaire,Hospitalizations,,2015-12,WITHDRAWN,INTERVENTIONAL,['NA']
11558,NCT01678664,Rate of hepatic progression free survival at 24 months,Toxicities treatment,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11559,NCT02027363,progression-free survival (PFS),Safety,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11560,NCT01216189,Change in Sexual Function (Total FSFI Scores) Between Baseline and 2 Years Follow-up.,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
11561,NCT02795104,Percentage of Participants Who Received All Needed Screening and Any Needed Screening Across the Three Randomized Arms,Cost of the Interventions,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
11562,NCT04815746,The Gastrointestinal Symptom Rating Scale (GSRS),,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11563,NCT03251612,Progression free survival 8 weeks after start of treatment,Quality of life as measured by questionnaire EQ-5D-5L,,2017-09-22,COMPLETED,INTERVENTIONAL,['PHASE2']
11564,NCT05350384,funduscopic examination,abdominal CT-scan,Therapy,2021-06-18,COMPLETED,OBSERVATIONAL,['NA']
11565,NCT01661088,The Percentage of Patients That Underwent an R0 Resection,Median Overall Survival Time,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11566,NCT04227886,Toxicities,pCR,,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA']
11567,NCT04657848,Rate of reflux esophagitis after operation,Postoperative nutrition status,,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA']
11568,NCT06013098,the occurrence of atelectasis,oxygenation index,,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE4']
11569,NCT06247293,Intra-abdominal recurrence-free survival (RFS),survival rate,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11570,NCT06192719,Gallbladder Cancer/Dysplasia development,,,2019-12-01,RECRUITING,OBSERVATIONAL,['NA']
11571,NCT00539318,there is no primary outcome measures in this study,,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
11572,NCT00054457,Proportion of successes,"Quality of life as measured by the LASA, FACT-E and Patient Uniscale Swallowing questionnaires",,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11573,NCT04717765,"Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy",Pain assessed by EVA - score 0 to 10 - all patients,,2021-02-10,COMPLETED,INTERVENTIONAL,['NA']
11574,NCT03717298,Quality of Life: EORTC QLQ-C30,Compliance with the treatment with chemotherapy (CT) and Immunotherapy (IT) test,,2018-10-30,COMPLETED,INTERVENTIONAL,['PHASE2']
11575,NCT03278626,Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response),,,2017-06-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11576,NCT04977739,signal intensity of the probes,,,2021-08-03,COMPLETED,OBSERVATIONAL,['NA']
11577,NCT05606549,Fear of Progression Questionnaire-Short form (FoP-Q-SF) for Partners,Dyadic Coping Inventory(DCI),,2022-10-19,RECRUITING,INTERVENTIONAL,['NA']
11578,NCT01356264,six minute walk test,Fatigue,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11579,NCT05726864,Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival),Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST,,2023-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11580,NCT03364582,Colorectal cancer risk,Mortality,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
11581,NCT03486418,Optical diagnosis of each colorectal polyp,,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
11582,NCT04844970,Weight change,AEs,Chemotherapy Dose change,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
11583,NCT00655876,Overall Survival (24-month Rate Reported),"Quality-adjusted Survival (Using EQ-5D), Only if Primary Hypothesis is Supported",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11584,NCT03303833,Overall cancer diagnoses,,,2006-07-01,RECRUITING,OBSERVATIONAL,['NA']
11585,NCT02292745,overall survival,predictive value of a set of biological markers for treatment response,,2014-12-02,COMPLETED,INTERVENTIONAL,['NA']
11586,NCT00114231,3-Year Disease-free Survival,Local Recurrence Rate,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11587,NCT05789797,"Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines).","Proportion of patients with detected toxic damage to at least one system or organ (by selected parameters), according to the criteria of common toxicity grade III of the CTCAE scale, from the baseline (Visit 1) to Visit 4, measured in both groups.",,2022-05-12,RECRUITING,OBSERVATIONAL,['NA']
11588,NCT01693523,Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms,"Relationship Between Dynamic Changes in Inflammation Biomarkers and Symptom Outcomes, Controlling for the Grouping Variables (Tumor Markers, Weight Loss), Evidence of Infection, ECOG PS, Age and Gender Examined",,2013-01-28,COMPLETED,INTERVENTIONAL,['PHASE2']
11589,NCT04897854,Quality adjusted overall survival,Number of patients with adverse events,Level of CA 19.9,2021-04-22,RECRUITING,INTERVENTIONAL,['PHASE3']
11590,NCT04191551,Progression of intestinal metaplasia,,,2018-07-30,RECRUITING,OBSERVATIONAL,['NA']
11591,NCT00509964,response rate,safety,,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
11592,NCT05627414,R0 resection rate,safety profile,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11593,NCT00844883,Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.,Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE,Median Overall Survival OS Stratified by BCLC Criteria,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11594,NCT00952029,Disease-control duration,Geriatric evaluation,,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11595,NCT04976634,Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR),Arm 2: Number of Participants Who Discontinued Study Treatment Due to an AE,,2021-08-18,RECRUITING,INTERVENTIONAL,['PHASE2']
11596,NCT04618367,Progression free survival rate at 6 months,Adverse events,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
11597,NCT00841607,pancreatic leak/fistula,overall morbidity,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
11598,NCT06099951,Complete tumor response rate.,Sphincter preservation rate,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11599,NCT02616692,"Preference weight scores for 13 selected HCC treatment attributes associated with Sorafenib, repeated TACE, and HAIC",Maximum acceptable risk of life-threatening side effect willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time,,2016-05-09,COMPLETED,OBSERVATIONAL,['NA']
11600,NCT04513808,Recurrence-free survival,QoR-15,,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE3']
11601,NCT02223078,Antibody Levels,Number of Participants with Serious and Non-Serious Adverse Events,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11602,NCT04592289,Incisional surgical site infection (SSI) rate,Bowel preparation compliance,,2020-10-30,RECRUITING,INTERVENTIONAL,['NA']
11603,NCT00561418,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation,Time to Progression,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11604,NCT02658214,Tumor assessment based on RECIST 1.1 (for cohort 6 only),,,2016-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11605,NCT02425059,Number of participants with Adverse events,Percentage of lesions that show no sign of recurrence 12 months after IRE,Overall survival (OS),2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
11606,NCT05025033,Progression Free Survival,adverse events,biomolecular markers,2019-05-30,COMPLETED,INTERVENTIONAL,['PHASE2']
11607,NCT06300463,"Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm",Number of Participants Per Arm with ctDNA Clearance,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
11608,NCT00941655,Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II,Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications,,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE3']
11609,NCT06190847,pCR,the surgical conversion rate,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
11610,NCT04025567,To evaluate the effect of oral vancomycin therapy in the relative CXCR6 gene expression levels in the liver,,,2020-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11611,NCT05184283,Change in mean muscle fat,Delta HOMA-IR,,2022-06-16,TERMINATED,OBSERVATIONAL,['NA']
11612,NCT03214835,Efficacy of EndoCDx brush,Assessment of pain,,2018-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
11613,NCT00587652,Any dysplasia or adenocarcinoma detected over all biopsies using each method.,The association between staining patterns and histologic grade of the biopsies obtained using methylene blue will be assessed.,,2002-12,COMPLETED,OBSERVATIONAL,['NA']
11614,NCT02412683,Oxaliplatin-Specific Neurotoxicity Scale,Sense of Coherence scale (SOC-scale),,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11615,NCT03210948,Diagnostic accuracy,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2019-01-23,UNKNOWN,INTERVENTIONAL,['NA']
11616,NCT00939848,Progression free survival,"• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life",,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11617,NCT05870800,"Determine the rate of complete histopathologic response to neoadjuvant immunotherapy with neoadjuvant chemotherapy in pMMR resectable, non-metastatic colon cancer.",Assess short and long-term quality of life through Patient-Reported Outcomes (PROs),,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11618,NCT06311565,Healthy lifestyle behaviors scale II,,,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11619,NCT04071964,Number of participants with an anastomotic leak,Number of participants with cancer reoccurence,,2019-07-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11620,NCT00020150,,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11621,NCT00026403,overall survival,quality of life,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11622,NCT05546619,RFS,OS,,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11623,NCT01918683,Progression Free Survival,,,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11624,NCT00317772,Maximum Tolerated Dose (MTD) of Topotecan,Response Rate,,2004-09-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11625,NCT01249521,Disease control (ie non progression) at 6 months,Response rate,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
11626,NCT04395352,Adenoma detection rate (ADR),Number of patients with delayed adverse events,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
11627,NCT06071052,"Time to progression, TTP",Safety evaluation,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11628,NCT00825474,overall survival,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
11629,NCT04264676,"Disease Free Survival, DFS","Recurrence Rate, RR",,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE2']
11630,NCT01032044,"Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of ""Optimally Treated""",,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
11631,NCT02005484,Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category,Time to Progression,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2']
11632,NCT00368329,Patients' responses to therapy will be evaluated clinically after completion of their neoadjuvant chemoradiation.,Patterns of failure and the 2-year progression-free survival (PFS) rate.,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE1']
11633,NCT01815307,1 year recurrent free survival rate,Duration of overall survival,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11634,NCT03279601,Overall response rate (ORR),Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11635,NCT05586061,objective response rate (ORR),duration of response (DOR),,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11636,NCT06084884,"1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase",12. Pharmacokinetics - Exposure of AZD5851,,2023-11-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11637,NCT03175705,Incidence of Treatment-Emergent Adverse Events [Safety],Biological activity of infused T cells,Disease Control Rate (DCR),2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
11638,NCT01775644,Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST),Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST,,2012-12-14,COMPLETED,OBSERVATIONAL,['NA']
11639,NCT02534389,Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).,Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11640,NCT04308174,Ro resection rate,Response rate,,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11641,NCT03638193,Safety of CART-meso infusion: number of adverse events,CAR-T cell detection,,2018-07-11,UNKNOWN,INTERVENTIONAL,['NA']
11642,NCT04443985,Lymph node,,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
11643,NCT03322267,1-year relapse-free survival (RFS) rate.,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),Blood-based biomarkers,2018-10-27,RECRUITING,INTERVENTIONAL,['PHASE2']
11644,NCT02646137,Number of patients with successful ablation,,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11645,NCT05308446,Progression-free survival (PFS),Incidence of adverse events,,2022-07-19,RECRUITING,INTERVENTIONAL,['PHASE2']
11646,NCT04276090,Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy,Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.,,2020-05-01,TERMINATED,INTERVENTIONAL,['NA']
11647,NCT03858855,Effects of essential oils on nausea and anxiety,Acceptability of using a personal inhalation bottle for inhalation of essential oils - perception of benefit of essential oil for symptoms,,2019-02-18,COMPLETED,INTERVENTIONAL,['NA']
11648,NCT02385604,Disease-free survival,Histopathologic response,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11649,NCT05390398,Change in cancer-related fatigue,Cost-effectiveness evaluation,Clinical parameters,2022-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11650,NCT03422432,Time to adjuvant systemic chemotherapy,,,2017-09-28,UNKNOWN,INTERVENTIONAL,['NA']
11651,NCT04920214,Specificity,,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11652,NCT03958747,Tibial Nerve Cross-Sectional Area Comparison,Reduction of Intraepidermal Nerve Fiber Density,,2019-12-17,RECRUITING,INTERVENTIONAL,['NA']
11653,NCT03146520,Clinical performance of EarlyTect Colon Cancer to detect colorectal cancer,Positive ratio of SDC2 methylation in other cancers,,2016-12-13,COMPLETED,OBSERVATIONAL,['NA']
11654,NCT00079261,Complete response as assessed by Cheson criteria,Freedom from treatment failure as assessed by Cheson criteria,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11655,NCT04300959,12 months OS rate,Incidence of Treatment-Emergent 3/4 Adverse Events,,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11656,NCT03291106,Distribution of Lynch syndromes in endometrial cancer,Reliability of clinical criteria for screening Lynch syndromes,,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
11657,NCT03236649,Overall survival (OS),Assessment on Quality of life 2,"Genome level (DNA, mRNA, miRNA) biomarker analysis",2017-09-20,TERMINATED,INTERVENTIONAL,['PHASE3']
11658,NCT05793593,number of people beyond the index participants who complete FIT screening,,,2023-03-17,RECRUITING,INTERVENTIONAL,['NA']
11659,NCT06118762,Progression free survival (PFS),Security,,2023-10-20,RECRUITING,INTERVENTIONAL,['PHASE4']
11660,NCT05472896,Progression-free survival (PFS) by Independent Review Committee,2 year survival rate,Adverse event/ serious adverse event,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE3']
11661,NCT06017297,Incidence of related treatment emergent adverse events,Event Free Survival (EFS),,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
11662,NCT05810805,Concentrations of different gas in digestive tract,The correlation between the severity of gastrointestinal symptoms and gas concentrations in various parts of the digestive tract.,,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11663,NCT01088204,noncompliance rate,3-year disease free survival,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
11664,NCT02551237,IADL (Instrumental Activities of Daily Living) Score,EORTC QLQ-C30 + EDL14,,2016-01-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11665,NCT02686424,overall survival,,,2010-03,SUSPENDED,OBSERVATIONAL,['NA']
11666,NCT06103890,pCR,OS,,2023-05-22,RECRUITING,OBSERVATIONAL,['NA']
11667,NCT02002806,Pain Control,"Disease-specific, recurrence-free survival",,2012-01,COMPLETED,INTERVENTIONAL,['NA']
11668,NCT06315361,Prevalence of significant fibrosis by non invasive tests,Identification of MACE,,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11669,NCT01433146,Temperament in non-metastatic colorectal cancer patients,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
11670,NCT00924092,To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.,"To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, &amp; decreases in circulating tumor cells &amp; tumor markers.",,2009-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
11671,NCT06146946,3-year disease free survival rate,3-year overall survival rate,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11672,NCT03451643,POSTOPERATIVE MORBIDITY,QUALITY OF LIFE,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
11673,NCT05366829,Safety as assessed by number of participants experiencing adverse events,Response and progression will be evaluated in this trial using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (v1.1).,,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
11674,NCT02374411,Collect questionnaire data from 150 HIPEC surgeons,HIPEC surgeon attitudes toward patient nutritional support self-assessed by questionnaire,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
11675,NCT05009927,Progression-free-rate at 6 months (PFR 6m),Duration of response (DOR),,2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE2']
11676,NCT01998347,median overall survival,median progression free survival,time to progression,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
11677,NCT01755767,Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,,2012-12-27,COMPLETED,INTERVENTIONAL,['PHASE3']
11678,NCT05518643,Rate of Postoperative Pancreatic Haemorrhage (PPH),Cancer recurrence rate,,2022-07-15,RECRUITING,OBSERVATIONAL,['NA']
11679,NCT02340065,number and rate of missed adenomas,mean number of adenomas per procedure,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11680,NCT02510469,Disease free survival,,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11681,NCT06161233,Change in health-related QoL outcomes in RCC patients,User experience of the CAPABLE system in other cancer types patients,,2023-05-16,COMPLETED,INTERVENTIONAL,['NA']
11682,NCT04158635,Compliance,Time to treatment failure (TTF),Quality of life assessment,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11683,NCT01528683,Safety and Efficacy,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
11684,NCT05482516,Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse,Reasons for failure of enrollment,,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3']
11685,NCT04000529,"Dose interruptions, reductions and dose intensity, by treatment",Overall Survival,,2019-07-30,TERMINATED,INTERVENTIONAL,['PHASE1']
11686,NCT05482477,Clock Drawing Task(CDT),The time of get out of bed for the first time after operation,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11687,NCT00410956,"Antitumor efficacy (complete and partial response, stable and progressive disease)",Toxicity as measured by NCI Common Toxicity Criteria,,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11688,NCT06134193,Progress free survival (PFS) per RECIST v1.1,Incidence rate of adverse events,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11689,NCT02688699,effectiveness of EndoClotTM in preventing post-procedural bleeding,,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11690,NCT02206360,Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.,Non-Pancreatic cancers diagnosed while on this protocol,,2014-04,RECRUITING,OBSERVATIONAL,['NA']
11691,NCT05303298,Objective gastro-oesophageal reflux (GOR),Survival,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
11692,NCT00790322,Compare the proportion of patients in the two arms who develop severe oral mucositis,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11693,NCT06280495,3-year Progression-Free Survival Rate,Treatment-related adverse events,,2024-02-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11694,NCT00867750,Health-related quality of life (HRQL),Pharmaco-economic assessment,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11695,NCT06313567,Disease-free survival,Side effects,,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE3']
11696,NCT03133650,Maximum tolerated laser fluence rate,,,2017-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11697,NCT02024087,Number of Participants With Adverse Events as a Measure of Safety and Tolerability.,Disease Control Rate (DCR),,2014-08-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11698,NCT00241020,Overall Survival,· Safety,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11699,NCT00743678,To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis,"Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11700,NCT04755036,Measurement of consensus in therapeutical decisions in pancreatic cancer between low/mid vs high volume hospitals,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11701,NCT01397747,"Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.",,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
11702,NCT01613469,To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.,The proportion of subjects with complete pathological response at surgical resection,,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11703,NCT03457454,Assess the care coordination and communication with primary care providers by colonoscopy clinics/practitioners,,,2017-09-08,COMPLETED,OBSERVATIONAL,['NA']
11704,NCT05908747,Surgical complete resection rate (R0),Adverse events (AEs),,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2']
11705,NCT04996459,overall response rate,Safety (the incidence of adverse events and serious adverse events),,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA']
11706,NCT00020267,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11707,NCT02949947,Complete Response Rate in Hemoglobin (HGB),,,2017-12-18,TERMINATED,INTERVENTIONAL,['PHASE2']
11708,NCT03890198,Systemic Cytokine Concentrations,Overall Survival (OS) after administration,,2019-04-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
11709,NCT04328740,Determine recommended Ph2 dose (RP2D) of TP-1454,Determine antitumor activity of TP-1454.,,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE1']
11710,NCT05322577,Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),Part 2: OS,,2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE1']
11711,NCT03857737,5-year DSS,Complication,,2019-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11712,NCT02342847,Change from baseline of the Karnofsky index,Physical examinations,,2014-12-10,COMPLETED,OBSERVATIONAL,['NA']
11713,NCT01595256,Exploration the Effect of Walking Program in Patients With Colorectal Cancer.,,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
11714,NCT04479436,Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer,Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer,,2020-09-14,TERMINATED,INTERVENTIONAL,['PHASE2']
11715,NCT05514561,The diagnostic performance of fecal calprotectin in diagnosis of significant ileocolonic lesions,The diagnostic performance of fecal immunochemical test in diagnosis of significant ileocolonic lesions,,2020-03-22,COMPLETED,OBSERVATIONAL,['NA']
11716,NCT01567930,Disease Progression,Circulating tumor cells levels,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
11717,NCT02424955,Changes in Blood Perfusion (Relative Blood Flow),,,2014-11-18,COMPLETED,INTERVENTIONAL,['NA']
11718,NCT05301465,PFS,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
11719,NCT00898846,mRNA levels,Histopathological examination,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
11720,NCT00041639,,,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11721,NCT03016026,Rehabilitative rate,Mortality rates,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
11722,NCT04749303,Adenoma Detection Rate (ADR),Severe adverse events,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
11723,NCT02329860,Overall Survival,Disease Control Rate,,2014-03-26,COMPLETED,INTERVENTIONAL,['PHASE3']
11724,NCT04389892,Differentiation between murale nodules and mucus clots or debris,Guiding EUS-FNA by the enhancement pattern,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
11725,NCT00085163,"Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter","Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11726,NCT03957135,2 year survival,,,2019-05-20,RECRUITING,INTERVENTIONAL,['NA']
11727,NCT01032928,Optimal Respiratory - Swallow Phase,Percentage of Impairment According to the Penetration-Aspiration Scale,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11728,NCT04084158,PFS,TTDM,,2019-09-07,SUSPENDED,INTERVENTIONAL,['PHASE2']
11729,NCT02952859,Time from diagnosis to death for any reason,,,2017-01,TERMINATED,OBSERVATIONAL,['NA']
11730,NCT06047015,Abscopal effect: percent change in non-treated colorectal liver metastasis.,Quality of life questionnaire,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11731,NCT04508140,Safety: Adverse Events,Survival Rate,,2020-06-17,TERMINATED,INTERVENTIONAL,['PHASE2']
11732,NCT00247338,Infectious complications,Post-operative nutritional cost & total treatment cost,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11733,NCT00436215,Clinical Response Rate.,Number of Participants With Adverse Events,,2006-12-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11734,NCT04227041,Progression-free survival (PFS),Incidence of Treatment-Emergent Adverse Events [Safety],,2020-01-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11735,NCT03384940,Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer,Treatment-Emergent Adverse Events (TEAEs) Reported By ≥20% Of Participants Following Treatment With DS-8201a in Participants With HER2-expressing Advanced Colorectal Cancer,,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11736,NCT04666727,Somatic mutation burden,,,2020-09-29,RECRUITING,OBSERVATIONAL,['NA']
11737,NCT04196062,Complete (R0) resection,Technical Success,,2020-05-01,COMPLETED,INTERVENTIONAL,['NA']
11738,NCT03829748,Increase in diagnostic yield of pancreatic solid lesions,Number of passes to reach diagnosis,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
11739,NCT06311929,Disease-free survival,Overall survival,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11740,NCT05723978,Disease-free survival (DFS),,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
11741,NCT02591784,The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.),Overall survival (OS),,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11742,NCT04248452,Overall survival,Progression-free survival,,2020-05-26,RECRUITING,INTERVENTIONAL,['PHASE3']
11743,NCT03978702,"Measurement of immune effectors (Tcells, NK) levels after pancreatectomy",,,2021-02-24,UNKNOWN,INTERVENTIONAL,['NA']
11744,NCT01872104,Survival rate,Progression-free survival,Quality of life,2013-08,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11745,NCT03697239,Disease Control Rate,Changes in patient's self-reported pain levels,,2019-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11746,NCT05907772,Overall survival,,,2022-08-27,COMPLETED,OBSERVATIONAL,['NA']
11747,NCT04319484,3 years recurrence-free survival rate,5 years overall survival rate,,2020-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11748,NCT03579784,Disease control rate,Safety and tolerability as measured by number and grade of toxicity events,,2018-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11749,NCT00516269,Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement,,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11750,NCT02288611,Change from baseline in large intestinal microbiota composition verses control intervention (0-3 months),Change from baseline in Bowel function verses the control intervention (0-3 months,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
11751,NCT05722327,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",,,2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE1']
11752,NCT01764087,Tumor Overall Response Rates (ORRs) in Phase II Portion,Pharmacokinetic (PK) Evaluation in Phase II Portion,Exploratory Biomarker Evaluation in Phase II Portion,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11753,NCT03478943,Disease-free surviva,Disease Control Rate,,2016-01-30,UNKNOWN,OBSERVATIONAL,['NA']
11754,NCT04010227,Short-form of Zarit Burden Interview,Value Progress Subscale of the Valuing Questionnaire.,,2019-09-16,COMPLETED,INTERVENTIONAL,['NA']
11755,NCT05959564,Intentions toward HPV vaccination,Ratings of the Chatbot,,2023-07-26,COMPLETED,INTERVENTIONAL,['NA']
11756,NCT05105828,Shear wave elastography score,,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
11757,NCT01812577,Intensity of postoperative pain after radiofrequency ablation of liver lesion,Consumption of post-operative opioid,Satisfaction of patient and of the operator,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
11758,NCT05068193,Cmax,,,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11759,NCT02981862,Assessement of CaptHPV method,,,2016-12-19,COMPLETED,INTERVENTIONAL,['NA']
11760,NCT03390517,Anastomotic Leak Rate,,,2017-11-09,COMPLETED,INTERVENTIONAL,['NA']
11761,NCT05025631,PFS,Correlation between geriatric assessment and efficacy and safety,,2020-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11762,NCT01127711,"Fractures, hip fractures",,,1997-09,COMPLETED,OBSERVATIONAL,['NA']
11763,NCT03480971,Mucositis,Mucositis,,2019-05-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
11764,NCT04903340,Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.,,,2021-04-12,COMPLETED,OBSERVATIONAL,['NA']
11765,NCT01621217,To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11766,NCT02624271,Sensitivity of GastroPanel blood test,,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA']
11767,NCT00693290,Clarity of the mucosa evaluated by the Ottawa Scale.,Concordance with the bowel preparation.,,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
11768,NCT03907579,Number of Participants With Varying Levels of Behavioral Intentions Related to Colorectal Cancer Screening and Prevention,,,2017-03-11,COMPLETED,INTERVENTIONAL,['NA']
11769,NCT01150877,"The metabolic consequences, including tolerability and toxicity, of prolonged, high-dose physiological vitamin D in patients with colorectal cancer.",Patient survival with regards to high-dose vitamin D supplementation.,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11770,NCT03539822,Phase II- Overall Response Rate (ORR),Overall Survival (OS),,2018-10-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11771,NCT04665687,Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.,"Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence.",,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA']
11772,NCT02338297,APS improvement,Response Rate,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
11773,NCT03491540,Postoperative 30-day surgical site infection (SSI).,Temporary stoma closure rate,,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11774,NCT05242237,Time to progression or death (months),,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
11775,NCT05647122,Proportion of patients with radiological response (ORR),Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA),,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE1']
11776,NCT01504126,Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride,Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D,"Changes in immune response, measured by serum levels of VEGF",2012-03-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11777,NCT01685632,heat shock protein expression (blood/cell ratio)compared to baseline values,,,2012-09,TERMINATED,INTERVENTIONAL,['NA']
11778,NCT00435097,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
11779,NCT00393822,Incidence of Grade ≥ 2 (WHO scale) oral mucositis,Incidence of grade ≥ 2 (WHO scale) oral mucositis,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11780,NCT05994859,Success rate of conversion to resection,Adverse Events (AEs),,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
11781,NCT02025244,To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.,Detection of mitotic activity in case of Gastrointestinal Stromal Tumors,,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
11782,NCT04612504,The response rate of patients with HCC receiving SynOV1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE1']
11783,NCT05438836,"Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)",Treatment Related Hospitalization,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
11784,NCT03676517,pathologic complete response (pCR) rate,Cost effectiveness,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
11785,NCT03946852,Ischemic Cholangiopathy,Graft survival,Re-operation rate,2019-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11786,NCT03340558,Change in CD8 T cell immune infiltrates,Overall Survival,,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11787,NCT02021110,Effect of UDCA on total liver volume,Effect of UDCA on absolute total kidney volume,Adverse events as a measure of tolerability and safety of UDCA,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11788,NCT05233787,Quality of life over the 12 months after surgery,Changes in microbiome composition and diversity from baseline to 1 month,,2022-03-24,RECRUITING,INTERVENTIONAL,['NA']
11789,NCT03863236,Postoperative complications,Hospital stay,,2019-04-01,RECRUITING,INTERVENTIONAL,['NA']
11790,NCT06172049,Survival,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
11791,NCT04866108,Objective Response Rate (ORR),Quality of Life (QoL),,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2']
11792,NCT00557102,Tumor response rate,Tolerability,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11793,NCT05731336,"Overall Survival, OS","Adverse events, AEs",,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
11794,NCT02454647,R0 resection rate,Adverse events are assessed according to CTC criteria v 4.0,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
11795,NCT00577902,"To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.","To assess antioxidant capacity, nutritional biomarkers and nutritional risk of patients during and after concurrent radiation and chemotherapy.",,2005-06,COMPLETED,OBSERVATIONAL,['NA']
11796,NCT04868747,serum concentration of NET(neutrophil extracellular trapping)-related biomarker,survival of patients,,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA']
11797,NCT04085211,"Sensitivity, specificity, positive predictive value of specific endoscopic image enhancement findings to diagnose or stage the severity of different gastrointestinal conditions",median duration for image enhanced endoscopy procedures,,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA']
11798,NCT02584556,recurrence free survival,Time of tumor distant metastasis,,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11799,NCT05714475,Disease free survival,Disease free survival (12),,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
11800,NCT02901301,The overall response rate using RECIST 1.1,Time to response,,2017-02-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11801,NCT02324556,Number of specimens with grade I specimen according to Quirke,Postoperative complications scored according to Clavien-Dindo within the first 12 months,,2015-01,TERMINATED,OBSERVATIONAL,['NA']
11802,NCT02301143,Kaplan-Meier Estimates for Time to Treatment Failure (TTF),Participants With Treatment Emergent Adverse Events (TEAEs),,2015-04-21,COMPLETED,INTERVENTIONAL,['PHASE2']
11803,NCT05835778,Incidence of ADRs,,,2023-06-07,RECRUITING,OBSERVATIONAL,['NA']
11804,NCT04907591,"Change of body composition (weight, kg)","Muscle mass (lumbar 2,㎠)",,2021-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11805,NCT00411151,Objective Response Rate (ORR),Safety and Tolerability: Adverse Events in ≥10% of Patients,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11806,NCT04717648,Early predictive factors of anastomotic leakege,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
11807,NCT00932724,Tumor assessment by using CT scans and/or MRIs,"Assessment of survival by ""physical exam""",,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2']
11808,NCT03443661,pCR,Safety,,2016-02-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11809,NCT00447746,5 year overall survival,: Postoperative morbidity and mortality rates,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
11810,NCT06083974,OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy,Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
11811,NCT04982939,Pathological complete response (pCR) rate,Disease Control Rate (DCR),,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2']
11812,NCT03699761,Grade III-IV complications,Treatment cost,,2020-09-01,RECRUITING,INTERVENTIONAL,['NA']
11813,NCT05165446,Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer,Studies on liver injury and glycemic control.,,2022-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11814,NCT05170282,The diagnostic accuracy of infantile liver tumors with deep learning algorithm,The diagnostic negative predictive value of infantile liver tumors with deep learning algorithm,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11815,NCT03615170,Disease free survival,,,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA']
11816,NCT00422864,Tolerability rate,Distant response rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11817,NCT04561791,Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.,,,2019-01-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11818,NCT05277766,Maximally tolerated dose (MTD) of Nal-IRI,Overall treatment response,Exploratory outcome: Expression of human carboxylesterase 2 (hCE2),2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE1']
11819,NCT05849480,Phase II: Overall response rate (ORR),5-year overall survival,,2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11820,NCT03668158,recurrence rate,,,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA']
11821,NCT06126575,AUC from time zero to infinity (AUC0-∞),,,2024-01-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
11822,NCT02814864,Decrease of one grade on the LENT SOMA,Frequency of diarrhea,,2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
11823,NCT06035731,Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive care,Anxiety,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11824,NCT03513198,Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment,Tumor response to treatment,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
11825,NCT02193594,The patient's survival time and recurrence time,The number of patients with complications,The pathologic profiles and the pathologic response rates,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11826,NCT01205828,Clinical Benefit Rate,Biomarker Analysis,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11827,NCT00906373,Progression Free Survival (PFS),The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity),,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11828,NCT02226224,the consistency between EUS and pathologic determination of tumor depth,,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
11829,NCT04889495,Safety profile,Efficacy profile,,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11830,NCT05779553,Tumor endothelial marker 1 in colorectal cancer,,,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11831,NCT04460066,major pathologic response rate,adverse events rate,,2020-11-18,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11832,NCT04699487,Percentage of patients with at least one OM grade >2 at any time during radiotherapy.,Evolution of body weight over time,"For each neck dermatitis lesion: date of onset, location and CTCAE v5 grade",2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
11833,NCT04069975,Detection rate of precancerous lesions and cancer of upper digestive system improvement,,,2019-06-02,UNKNOWN,OBSERVATIONAL,['NA']
11834,NCT02791503,Overall survival,Tumor marker CA 19.9,,2016-05-30,COMPLETED,INTERVENTIONAL,['NA']
11835,NCT03979547,Acceptability-scientifically adequate,visceral adipose tissue (VAT),,2019-01-03,TERMINATED,INTERVENTIONAL,['NA']
11836,NCT02248805,Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule,Describe any evidence of anti-tumor activity,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11837,NCT01570582,24month progression free survival,Toxicity Profile,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11838,NCT03473925,Number of Participants Who Discontinue Study Treatment Due to an AE,Navarixin Trough Plasma Concentration (Ctrough),,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11839,NCT04859400,QoL,Success of recruitment rate in comparison to former studies,,2021-06-07,RECRUITING,INTERVENTIONAL,['NA']
11840,NCT05079503,Immune modulation in tissue,Identify predictive biomarkers for pathologic responders,,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA']
11841,NCT01175447,Maximum tolerated dose (MTD) of s-1 in combination with thoracic radiotherapy in elderly patients (> 70 years old) with esophageal Cancer,"Objective response rate (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]).",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11842,NCT06321055,Time to Next Therapy (TTNT) therapy after regorafenib,Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC).,,2024-03-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11843,NCT03013972,Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T),Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7),,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
11844,NCT03561350,MSI status in blood sample,,,2017-09-28,UNKNOWN,OBSERVATIONAL,['NA']
11845,NCT02651701,the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI,concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up,Transient dyspnea,2016-01,COMPLETED,OBSERVATIONAL,['NA']
11846,NCT05286099,Effective detection of early hepatocellular carcinoma,,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
11847,NCT05571956,simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts,,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
11848,NCT03381352,Response rate,Adverse events,,2015-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
11849,NCT03867799,Disease Control Rate (DCR),Overall survival,,2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11850,NCT04660760,Progression-free survival,Incidence of adverse events,,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2']
11851,NCT05880667,To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.,,,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11852,NCT03211598,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,FACT Hep4 Questionnaire,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
11853,NCT00232453,Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11854,NCT03123042,detection rate (%),False negative rate,,2017-03-20,RECRUITING,INTERVENTIONAL,['NA']
11855,NCT04789486,Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2,Quality of Life (QoL)-Completion of Daily Activities utilizing PROMIS Physical and Mental Health batteries,,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11856,NCT04937673,biomarkers related to pCR,Safety,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11857,NCT03027427,Clinical and laboratory evaluation and molecular profiling of tumor tissue,,,2017-02-01,RECRUITING,OBSERVATIONAL,['NA']
11858,NCT02090153,Overall Response Rate (ORR),Adverse Events (AEs),,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11859,NCT03753399,Average trajectory of C-ESAS over time,Number of Circulating tumor cells detected using microfluidic chip,,2019-01-04,COMPLETED,INTERVENTIONAL,['NA']
11860,NCT05800054,Body weight and body mass index (BMI),ORR,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
11861,NCT01335945,Abdominal pain reduction following cryoablation of the celiac plexus,Safety assessment,,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1']
11862,NCT00433550,Confirmed Tumor Response Rate (Proportion of Participants With Complete Response),Time to Treatment Failure,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11863,NCT05189171,MOS generation,,,2022-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11864,NCT01525940,To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level).,To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
11865,NCT05039177,Adverse Events,Duration of Response (DOR),,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11866,NCT03042780,Objective Radiographic Response Rate (ORR),Progression Free Survival (PFS),Treatment Related Morbidity,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2']
11867,NCT00514228,Progression-free survival,Serum alpha fetoprotein level,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11868,NCT01830582,determine the best MR imaging schedule,Determine if the best imaging schedule for DCE is the same as for DWI,,2013-04-09,COMPLETED,INTERVENTIONAL,['NA']
11869,NCT02405416,Normalized transection-related blood loss,Postoperative mortality,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
11870,NCT04517227,Discontinue rate caused by any AEs,Overall survival,,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11871,NCT03553004,Objective Response Rate (ORR),Proportion of participants with adverse events (AEs),,2019-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11872,NCT04566614,PREVAIL ctDNA Part 2 Study,PREVAIL ctDNA Part 2 Study secondary end point 6d,,2020-06-18,RECRUITING,OBSERVATIONAL,['NA']
11873,NCT03837782,overall survival,,,2019-02-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11874,NCT04280666,"sensitivity, specificity, positive predictive value, and negative predictive value",Characteristics of the gene map and the correlations with clinical characteristics,,2019-06-20,UNKNOWN,OBSERVATIONAL,['NA']
11875,NCT00930410,The principal outcome is the percentage of successful in vivo examination according to the localisation of the stenosis. A successful examination is defined by the obtention of exploitable image for the anatomopathology.,Frequency and grade of adverse effects induced by the confocal endomicroscopy,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
11876,NCT00036959,,,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11877,NCT00875147,Overall complications,"specific complications such as liver insufficiency, length of hospital stay",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
11878,NCT03447106,cost of treatment,the operation time,"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）",2018-02-28,UNKNOWN,INTERVENTIONAL,['NA']
11879,NCT05179889,Disease free survival (DFS),Incidence of treatment-related adverse events,,2021-07-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11880,NCT06206603,Traceability of microRNA/mRNA expression of polyps and cancer in blood,Correlation of Intestinal microbiota and microRNA/mRNA expression,,2024-01,RECRUITING,OBSERVATIONAL,['NA']
11881,NCT01280825,Feasibility of incorporating pharmacogenomic testing into routine medical care,Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting,To determine whether access to pharmacogenomic information improves satisfaction with care.,2011-01-14,RECRUITING,OBSERVATIONAL,['NA']
11882,NCT01259024,Monitor Safety After Treatment of DEB by Measuring Liver Function Tests and Assessing Performance Status.,To Track Survival Following Treatment With DEB to Confirm That Any Gains in Response Are Associated With an Increase in Survival.,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
11883,NCT00820053,Overall survival,Time to recurrence,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11884,NCT06202014,ORR,Incidence of grade 3 and above adverse events,,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2']
11885,NCT01092481,disease-free survival,safety profiles,,2010-01-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
11886,NCT03565354,Preoperative change in serum ferritin (mcg/L),Days (alive and) at home within 30 days of surgery (DAH30),Median waiting time to surgery (days),2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11887,NCT05914610,Surgical conversion rate,Quality of life (QOL),,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11888,NCT00825240,Colorectal Cancer Patients' Concerns + Behavior Changes Post Treatment,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
11889,NCT04720430,"Incidence of ""Wait List Drop Off""",Clinical Status of the subset of patients successfully reaching liver transplant,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
11890,NCT05101889,Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria,overall survival (OS),,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11891,NCT00253617,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
11892,NCT05514171,Disease free survival,,,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11893,NCT03508570,Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab,,,2018-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11894,NCT05871567,survival rate,recurrence rate,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
11895,NCT03278444,Overall Survival,Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score,,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
11896,NCT04831528,Objective response rate,duration of response,,2021-04-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11897,NCT01340755,Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens.,Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
11898,NCT00578201,"objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation)",Progression free survival Quality of life Dysphagia score Overall survival toxicity of this regimen,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11899,NCT00922688,"The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.",The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.,,2010-12,UNKNOWN,INTERVENTIONAL,['NA']
11900,NCT02008383,Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer,To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11901,NCT01676922,Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice,Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
11902,NCT04227951,30 day reoperation AND/OR additional drain placement,Drain related complications,,2019-12-17,COMPLETED,INTERVENTIONAL,['NA']
11903,NCT00002893,,,,1995-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
11904,NCT04678492,Helicobacter pylori eradication,adverse events,,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
11905,NCT03847753,Risk of Cancers,,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
11906,NCT01839981,Overall Survival,Safety profile assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11907,NCT01481545,Percentage of Patients With Complete Tumor Regression Rate (TRG1),Patients With Metastatic Lymphnodes at Pathology Exam After Surgery,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11908,NCT02504411,Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy,Cecal Intubation Rate (CIR),,2015-08,WITHDRAWN,INTERVENTIONAL,['NA']
11909,NCT05029453,Progression Free Survival [PFS],Adverse Events [AEs],,2021-08-26,UNKNOWN,INTERVENTIONAL,['PHASE4']
11910,NCT04591821,QoL,Correlation LARS score QoL,,2018-02-15,COMPLETED,OBSERVATIONAL,['NA']
11911,NCT01801852,Occurrence of study related adverse events,Anti-tumor responses to NKT cells infusions,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
11912,NCT02852096,The positive rate of cohort using dual or multiple tumor tissue paraffin blocks,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
11913,NCT05039333,Complication rate,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
11914,NCT04894370,Progression-Free Survival (PFS) rate at 1 year.,Progression-Free Survival (PFS) median.,,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE2']
11915,NCT04246970,Progression in the activities of daily life (ADL),Change in Quality of life,,2021-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11916,NCT00848237,Adverse Event Incidence,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
11917,NCT00005638,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11918,NCT02675946,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,CGX1321 half-life,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
11919,NCT02429622,Disease-free survival (DFS),Overall survival (OS),Adverse events,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11920,NCT05887661,The proportion of allogeneic red blood cell products transfusion,Number of Participants with postoperative complications (overall),,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
11921,NCT01609309,3-year disease free survival rate,Inflammatory and immune response,,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
11922,NCT01841294,Dosage of NKs activity after surgery,Major adverses events,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11923,NCT06152471,Occurrence of Abemaciclib induced diarrhea - STIDAT,Breast cancer recurrence,,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11924,NCT03497819,The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward],Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion],,2017-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
11925,NCT03858712,ePRO Oral Response Rate,ePRO oral ease of use,,2019-03-13,COMPLETED,INTERVENTIONAL,['NA']
11926,NCT00396487,Response according to RECIST criteria.,Toxicity,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
11927,NCT04228601,Objective Response Rate,Time to maximum concentration (Tmax),,2020-01-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11928,NCT00001823,Results of screening tests,,,1999-07-11,RECRUITING,OBSERVATIONAL,['NA']
11929,NCT03439891,Overall response rate (ORR) (Part 2),Proportion of participants with Child Pugh B Liver Function reporting immune-related adverse event (irAE),,2018-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11930,NCT05678257,Number of patients achieving progress-free survival (PFS),Number of patients reporting treatment-emergent adverse events (TEAEs),,2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE2']
11931,NCT01599052,Social cognitive performance,Influence of Biographical/Medical characteristics,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
11932,NCT06135649,Metastatic involvement of second nodal echelon,Recurrence-free survival,,2013-01,RECRUITING,OBSERVATIONAL,['NA']
11933,NCT00587236,Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC.,Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC.,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
11934,NCT05927857,To evaluate disease objective response rate (ORR),•To study the blood biomarkers,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11935,NCT05786924,Dose Expansion: Progression-free survival (PFS),Dose Escalation/Expansion: Overall survival,,2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE1']
11936,NCT04348058,Participation rate to screening colonoscopy within PCSP per recruitment strategy,Response rate to invitation to screening colonoscopy,,2020-08-20,UNKNOWN,INTERVENTIONAL,['NA']
11937,NCT05176665,Clinical benefit rate(CBR) as assess by RECIST v1.1,Clinical benefit rate(CBR) as assess by RECIST v1.1,,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11938,NCT00005594,The primary outcome measure of this study is to estimate the response rate and observe the time to tumor progression of the patients treated on this study.,Determine the duration of response in responding patients. Further characterize the safety profile of ISIS 2503 at the recommended dose and schedule.,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11939,NCT06282575,Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors,"TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)",,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
11940,NCT04790695,Overall survival,,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE2']
11941,NCT03510416,Time To Progression,Overall Survival,,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11942,NCT01651026,"list of diagnostic procedures used in clinical practice, according to participating Institute",,predictive factors for response to treatment,2011-01,RECRUITING,OBSERVATIONAL,['NA']
11943,NCT03781778,Feasibility: Retention,Variability in Gut Microbial Communities From Human Stool Samples -- BETA DIVERSITY,,2019-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
11944,NCT06173986,Treatment completion rate,Incidence of Adverse events (AE) or severe adverse events (SAE),,2023-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11945,NCT04305730,Rate of return of bowel function,Length of time under general anesthesia,,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
11946,NCT03011268,Proportion of patients in sustained clinical remission,Adverse events and serious adverse events frequency and severity,,2017-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11947,NCT01972919,Overall Survival,Efficacy of dose escalation,,2015-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11948,NCT03934606,baseline to post-results change in distress levels,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
11949,NCT05045911,The technical success rate,Clips used post-ESD,,2021-09-20,UNKNOWN,INTERVENTIONAL,['NA']
11950,NCT05606523,Body weight changes in mice after fecal material transplantation.,GALT function and systemic inflammation,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
11951,NCT02311595,Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping),,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
11952,NCT01983878,Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks),PK: Area Under the Curve Time Zero to Infinity (AUC[0-∞]) of Ramucirumab,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11953,NCT01478685,Number of participants with adverse events,Duration of Response,,2011-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
11954,NCT05655949,Incidence of Grade 3 or Higher Treatment-Related Toxicity,Disease Control Rate (DCR),,2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2']
11955,NCT03838029,Biomarkers in blood samples,Fatigue,,2019-11-20,RECRUITING,INTERVENTIONAL,['PHASE2']
11956,NCT00584363,To diagnose Pancreatic Cancer,Preventing patient form being misdiagnosed,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
11957,NCT02935309,Maximum Tolerated Dose (MTD),Occurrence of Treatment Related Adverse Events,Radiosensitivity Index (RSI),2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11958,NCT02977702,overall survival,,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
11959,NCT04442984,Progression-Free Survival,Treatment associated toxicities,,2019-11-03,RECRUITING,INTERVENTIONAL,['PHASE2']
11960,NCT00032123,,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11961,NCT06192030,Peritoneal-free survival,Rates of key gene mutation,,2022-08-27,RECRUITING,OBSERVATIONAL,['NA']
11962,NCT01463605,Safety of Nimotuzumab combined with Radiotherapy for older patients,Efficacy of Nimotuzumab combined with Radiotherapy for older esophageal cancer patients,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11963,NCT06021015,Disease control rate (DCR) of target lesions 1 month after the last TACE treatment,Equipment performance evaluation,,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11964,NCT03291379,Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814,"Assessment of Changes in Blood Flow on Dynamic Contrast-Enhanced (DCE) MRI Following Treatment With BTG-002814. The Following Parameters Will be Derived From DCE-MRI Images: Ktrans, Kep and Ve.","Study Tissue Biomarkers to Explore Key Immune, Inflammatory and Drug Related Mechanisms",2017-05-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11965,NCT03281369,For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs,Percentage of Participants With ADA to BL-8040,,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11966,NCT05411926,4) the dose and drug concentration of tacrolimus after liver transplantation in patients with hepatocellular carcinoma;,5) the overall survival (OS) and relapse-free survival(RFS) after liver transplantation in patients with hepatocellular carcinoma.,,2021-03-17,UNKNOWN,OBSERVATIONAL,['NA']
11967,NCT00901901,Overall Survival,Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS,Tumor Response,2009-05-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11968,NCT02354560,Evaluation of changes in size of desmoid tumors,,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
11969,NCT01398306,"Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.",Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
11970,NCT05564403,Overall survival (OS),Incidence of adverse events,Detection of mutations as well as prediction of outcomes,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE2']
11971,NCT06068257,"To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls.",,,2023-06-06,RECRUITING,OBSERVATIONAL,['NA']
11972,NCT00777504,"Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan",Effect on Quality of life as record by questionaires,,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
11973,NCT05482451,Overall response,Progression-free survival,Overall survival,2021-03-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
11974,NCT06089330,Incidence and severity of adverse events (AE) and serious adverse events (SAE),Overall Survival (OS),,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11975,NCT02847468,Vital status,Questionnaire of quality of life (EORTC QLQ-C30),,2017-03-27,TERMINATED,INTERVENTIONAL,['NA']
11976,NCT03976284,Stool weight,Sugary beverage intake,,2019-03-17,UNKNOWN,INTERVENTIONAL,['NA']
11977,NCT00002968,Survival,Disease-free survival,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11978,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11979,NCT04632459,Objective Response Rate (ORR),Best Overall Response Rate (ORR),,2021-06-16,UNKNOWN,INTERVENTIONAL,['PHASE2']
11980,NCT02028442,Phase 1b - Selection of suitable schedule for repeat cycle IV administration,,,2012-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11981,NCT05972655,Pathological complete response (pCR) rate,Validation of the Wexner score,,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE2']
11982,NCT05174169,Disease-Free Survival (DFS),Compliance with adjuvant chemotherapy,,2022-03-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11983,NCT04393220,OS,,,2020-05-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11984,NCT04977401,Increase the dissection speed of the ESD procedure,Total procedure duration,Adverse events,2021-09-21,TERMINATED,INTERVENTIONAL,['NA']
11985,NCT00820157,the overall survival rate of each group,the disease-free survival rate of each group,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
11986,NCT00372840,Number of sections of the Facing Forward manual read with satisfaction and comprehension,Changes in psychological outcomes from baseline to 8-week follow-up,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
11987,NCT00843934,response rate,,,2009-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11988,NCT00459901,To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer,To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration,,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2']
11989,NCT05518929,Incidence of hypoxia and severe hypoxia,Proportion of corrective hypoxic measures,,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE4']
11990,NCT01996540,Quality of Life (QoL),Overall survival (OS),,2012-08,COMPLETED,INTERVENTIONAL,['NA']
11991,NCT04901741,Go/no-go decision for a randomized expansion study,Time-to-next-anticancer-treatment (TTNT),,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11992,NCT05996666,Performance of liver cancer early detection model based on selected cfDNA methylation markers using qPCR,Comparison of currently used biomarkers for liver cancer detection,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
11993,NCT03049215,Decrease in Pancreatic Fluid Collection (PFC),Incidence of Early (<30 Days) Endoscopic Reintervention,,2017-11-06,TERMINATED,INTERVENTIONAL,['NA']
11994,NCT00042510,To evaluate the effects of G17DT in combination with cisplatin and 5-FU chemotherapy on tumor response assessed by radiographic means.,"To evaluate the clinical efficacy of G17DT in combination with cisplatin and 5-FU chemotherapy as measured by time to disease progression, best overall response and survival.",,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11995,NCT00242190,Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.,"Characterize pattern of responses, progression free survival, and survival after treatment",,2004-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11996,NCT03426371,Progression Free Survival (PFS) Time,quality of life score,,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
11997,NCT03167268,Skin toxicity reduction,,,2016-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11998,NCT01412294,Progression-free survival,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
11999,NCT04427761,Extent of the change experienced by patients with pancreatic cancer,,,2020-06-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12000,NCT00289003,"To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo.",To assess the safety of the investigational product,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12001,NCT00897741,Gene expression profiles,,,2004-12,COMPLETED,OBSERVATIONAL,['NA']
12002,NCT04358185,To assess efficacy of Itacitinib by overall response rate: objective response rate (ORR),Efficacy of Itacitinib by overall survival,Correlation of JAK1 mutations with treatment,2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12003,NCT03225781,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Immunomonitoring,,2017-07-01,TERMINATED,INTERVENTIONAL,['NA']
12004,NCT01802684,Progression free survival at 6 months,Curative salvage surgery,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12005,NCT00556023,Dose Limiting Toxicities: assessed through adverse event data collected weekly,Progression-Free Survival:,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12006,NCT05939661,Pathological complete response (pCR),,,2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE2']
12007,NCT05584137,Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage),Duration of Response (DOR) per RECIST 1.1 assessed by Investigator,,2023-06-15,SUSPENDED,INTERVENTIONAL,['PHASE2']
12008,NCT00004861,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12009,NCT06165094,Overall survival,,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
12010,NCT00583934,"Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease.",,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
12011,NCT00606398,two-year disease free survival (DFS),"Overall survival rate (OS), patterns of treatment failure, treatment efficacy (R0 resection rate), peri-operative morbidity and mortality rates, health related quality of life, hospital length of stay",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12012,NCT05085548,Determine Recommended Phase 2 Dose (RP2D),Assess serum tumor marker CA19-9 or appropriate tumor specific marker.,,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE1']
12013,NCT02639403,Change of the obstructive symptoms,Obstruction/colostomy-free survival,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12014,NCT03784326,Pathological complete response (PathCR),Tumor regression determined by CT or MRI,,2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
12015,NCT05022654,Optimal combination dose (only IIa),ADA,,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE2']
12016,NCT04707547,Analysis of the number of CD8+ T,,,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE4']
12017,NCT01280643,"Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects",Progression-free Survival,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
12018,NCT03634202,"maximum tolerated radiation dose (MTD) delivered by IMRT with SIB, in combination with oral capecitabine, for initially metastatic, low and middle rectal cancer after 4 induction cycles of mFolfox6 regimen.",The prognostic value of PET,,2015-05-05,TERMINATED,INTERVENTIONAL,['NA']
12019,NCT01652976,Progression Free Survival (PFS),"Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12020,NCT00520013,Consolidation Treatment-related Toxicity Rate,Consolidation Objective Response Rate,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12021,NCT04096417,Overall Response Rate (ORR),Incidence of Adverse Events,,2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12022,NCT02967107,Number of participants with residual or recurrent adenoma as assessed at surveillance endoscopy,Number of participants with pain after EMR as assessed by VAS score and telephone interview at 2 weeks,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12023,NCT04274972,Microbiome evaluation,Microbiome long-term evaluation,,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
12024,NCT04593277,Proportion of HCA-cancer surveillance (SM),Proportion of healthcare adherence (HCA)-all,,2022-10-23,RECRUITING,INTERVENTIONAL,['NA']
12025,NCT01846611,Overall Survival (OS),Objective Response Rate (ORR),,2013-10-16,COMPLETED,INTERVENTIONAL,['PHASE3']
12026,NCT05788744,Sub-study 2 eccDNA,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
12027,NCT03581344,TRG (Tumor Regression Grade),Impact of therapy on quality of life (QoL),,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
12028,NCT06253897,Qualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe;,Qualitative interview: experiences that are unique to patients between disease indications,,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12029,NCT01628328,Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer,,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
12030,NCT06256328,Progression-free survival (PFS) (site investigator assessment),Adverse event (AE),,2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2']
12031,NCT02727179,Overall survival,Morbidity,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
12032,NCT05494866,occurrence of DLTs,,,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
12033,NCT00608361,Pharmacokinetic parameters of dasatinib,,Liver dysfunction data,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12034,NCT03602092,To establish the database for GIST,,,2018-10-16,RECRUITING,OBSERVATIONAL,['NA']
12035,NCT03257761,Tumor response (dose expansion),Progression-free survival,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12036,NCT00103545,The primary endpoint is drop-out due to toxicity as the overall measure of feasibility,Duration and strength of the immune response induced by ACA 125 vaccination,,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12037,NCT00003950,Reduction in occurrences of severe diarrhea due to CPT-11 administration,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12038,NCT03582618,Objective Response Rate (ORR),Pharmacodynamics analysis for the relationship of AUC and Adverse Event (AE),,2018-07-12,TERMINATED,INTERVENTIONAL,['PHASE2']
12039,NCT03256201,Adherence,Assessment of Symptoms,,2016-02-01,RECRUITING,INTERVENTIONAL,['NA']
12040,NCT03798132,peritoneal carcinomatosis,surgical decision making.,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12041,NCT02402972,disease-free survival,adverse events of Chemotherapy and IPC,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
12042,NCT04283994,EHR documentation of Goals of Care discussions,Goal concordance,Key Implementation Factors,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12043,NCT00344552,Safety,Time to progression (TTP),,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12044,NCT03524274,Objective response rate,Symptom remission rate,,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12045,NCT01193517,"Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)","Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)",,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12046,NCT04179305,Change in Prognostic Understanding,Patient Performance Status,,2020-10-25,COMPLETED,INTERVENTIONAL,['NA']
12047,NCT02115542,Overall Survival (OS) at 6 Months,Progression Free Survival (PFS),,2014-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12048,NCT05396300,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],Pharmacodynamics of CEA-CAR-T cells[Cell dynamics],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1']
12049,NCT04503902,Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1,Progression free survival (PFS),,2020-10-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12050,NCT01964001,Antioxidant capacity,Inflammation markers,,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12051,NCT03774134,Risk of recurrence,Mesocolic lymph nodes yield,,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA']
12052,NCT03608540,Incidence of all Adverse Device Effects,R0 resection,,2018-07-09,TERMINATED,INTERVENTIONAL,['NA']
12053,NCT00290693,Rate of Participants Achieving Complete Response or Partial Response to Therapy.,Number of Study Participants Experiencing Toxicity After Receiving Protocol Therapy,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12054,NCT01640444,progression free survival (PFS),"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12055,NCT00373906,to induce objective/histologic responses in patients with MALT-Lymphoma,to evaluate the impact of bortezomib on progression free survival,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
12056,NCT05087992,Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients,Phase 1b: AUC0-t2: Area under the concentration-time curve of BI 9057 after multiple cycles,,2021-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
12057,NCT03044977,absolute neutrophil count decreased,Overall survival (OS),,2017-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12058,NCT05683470,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12059,NCT01444547,Overall response rate (ORR),Time to event efficay,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12060,NCT03992599,3 year disease-free survival (DFS),Distribution of metastatic LNs,,2019-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12061,NCT05489419,Efficacy of a multimodal prehabilitation,Evaluation of complications severity,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
12062,NCT02074124,Change in arterial flow during adenosine vasodilation test (CT perfusion parameter),Change in Permeability (CT perfusion parameter) during adenosine vasodilation test.,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
12063,NCT01286064,Colorectal cancer detection by means of optical fluoroscopy,,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
12064,NCT00524316,Progression-free Survival,Tumor Marker Response (AFP),,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2']
12065,NCT04729205,Evaluate Disease Control Rate,Plasma MLP level after Promitil infusion,,2021-01-13,TERMINATED,INTERVENTIONAL,['PHASE1']
12066,NCT05150691,Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.,Phase 2 Cohort b only: Overall Survival,,2022-01-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12067,NCT00019773,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12068,NCT01939210,Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction,"Change in patients' self-reported levels of psychological distress, physical pain and discomfort, and post-traumatic stress associated with cancer diagnosis and radiation treatment",,2010-02,TERMINATED,INTERVENTIONAL,['NA']
12069,NCT01409733,Proportion of patients completing scheduled treatment plan,,,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12070,NCT06265272,Assessment of LI-RADS with Ga-PSMA-PET/MRI,PET/MR protocol in liver cirrhosis,,2023-12-10,RECRUITING,OBSERVATIONAL,['NA']
12071,NCT02967770,4 month progression free survival rate,Change in tumor marker levels,,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12072,NCT01851174,Overall Survival Based on Toxicity Profile of Adverse Events.,Progression Free Survival Time,,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2']
12073,NCT02834546,Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication,Overall survival,,2017-07-25,COMPLETED,OBSERVATIONAL,['NA']
12074,NCT04109755,Tumour regression grade,EORTC QLQ-CR29,,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2']
12075,NCT00369109,Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors,Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
12076,NCT06181656,Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination,,,2024-02-05,RECRUITING,OBSERVATIONAL,['NA']
12077,NCT00172757,,,,2002-01,UNKNOWN,OBSERVATIONAL,['NA']
12078,NCT01051284,To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves,The feasibility of measuring pancreatic cancer stem cell populations by analysis of fine needle aspirate specimens,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12079,NCT06044506,Optimal treatment dosage,Progression-free survival,,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE1']
12080,NCT02915432,Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1),Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb,Correlation of the changes of TBNK lymphocytes subgroup in patients receiving chemotherapy combined with JS001 and its correlation with the anti-tumor activity,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12081,NCT03283527,Response prediction by EC-PDO,Overall survival (OS) in months,,2017-12-01,RECRUITING,OBSERVATIONAL,['NA']
12082,NCT03502343,Disease control rate,Adverse event,,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12083,NCT02734680,Overal survival,Local control rate,,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
12084,NCT03350763,"Stent failure rate, and need for re-procedure before pancreaticoduodenectomy.","Other complications related to preoperative biliary decompression, and post-surgical complications",,2017-11-18,WITHDRAWN,INTERVENTIONAL,['NA']
12085,NCT04431076,Pancreatic fistula,Return to preoperative exercise capacity,,2020-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12086,NCT05848843,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-04-25,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12087,NCT00431925,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
12088,NCT00312000,Overall survival,Toxicity profile,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12089,NCT00898482,Test new hypotheses as they emerge,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
12090,NCT01441388,Dose Limiting Toxicities (DLTs).,Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor,,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12091,NCT05750329,Three-year overall survival rate after surgery,Postoperative tumor-free survival period,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12092,NCT00494806,Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.,,,2005-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12093,NCT00841035,Epidermal Growth Factor Receptor Signaling(EGFR) in the Presence of Pancreatic Tumor Related to the Mechanism to Erlotinib.,The Secondary Objectives Include Analysis of Recurrence-free and Overall Survival and the Development of a Predictive Assay for Response to Erlotinib Based on Selected Bio-markers in Endoscopic Ultrasound-Fine-needle Aspiration Specimens.,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
12094,NCT01075113,Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).,Anti-tumor effects of the combination of sorafenib tosylate and vorinostat,,2010-08-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12095,NCT01777477,Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12096,NCT01152853,progression-free survival at 4-months (PFS4mo),toxicity,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12097,NCT05877001,Safety profiles by NCI-CTCAE version 5 .0,Progression free survival (PFS),,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12098,NCT04969874,patient attendance at monthly remote monitoring,felt swallowing,,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12099,NCT02936193,Progression-free Survival,3 years overall survival,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
12100,NCT01424293,Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.,,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
12101,NCT00961129,supportive cancer care needs,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
12102,NCT04434508,the number of lymph nodes (LNs) harvested among both groups,post-operative complications,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
12103,NCT01670409,Toxicities,Complete blood count,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12104,NCT00671463,Pancreatic leak,Clinical outcomes,,2008-04,WITHDRAWN,INTERVENTIONAL,['NA']
12105,NCT02085005,Progression Free Survival rate at 10 months (PFS@10m),Number of participants with adverse events,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12106,NCT06091683,Safety of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC),Peritoneal disease-free survival,,2021-04-30,RECRUITING,INTERVENTIONAL,['NA']
12107,NCT03185429,Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.,Quality score of life improvement,,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
12108,NCT04515394,Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators,Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab,,2021-01-28,TERMINATED,INTERVENTIONAL,['PHASE2']
12109,NCT02156505,The patency rate at 8 weeks after placement.,migration rate,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12110,NCT03323489,Change in Pain level from baseline - as measured using BPI,hand grip strength,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
12111,NCT03098108,local control rate at 3-year,Colonrectum Quality of life (QOL-CR) assessment,,2017-02-09,UNKNOWN,INTERVENTIONAL,['NA']
12112,NCT00591981,"Morbidity (Cardiac, pulmonary, infectous, etc.) and Mortality in Cohort",,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
12113,NCT03940001,"major pahological response, MPR",,,2019-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12114,NCT04831944,Pharmacokinetics Parameter : AUC(0-t) of parsaclisib,Pharmacokinetics Parameter : Vz/F of parsaclisib,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
12115,NCT03328234,Overall survival (OS),Adverse events,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12116,NCT03698825,Maximum Tolerated Dose (MTD),pharmacokinetics of TEW-7197,pSMAD as a pharmacodynamic marker,2018-08-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12117,NCT02309788,overall survival,,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
12118,NCT06008288,Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.,Number of participants with adverse events,,2023-10-27,RECRUITING,INTERVENTIONAL,['PHASE2']
12119,NCT03798626,Part 2 (Expansion) and Part 1b (Safety run-in): Progression free survival (PFS) rate [Cohort C subjects at RDE level],Number of patients with anti-drug antibodies for ramucirumab in the combination regimens,,2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12120,NCT00004233,Six month survival,evaluate quantitative and qualitative toxicities,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12121,NCT02271464,progression-free survival (PFS),Overall toxicity rate,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12122,NCT00137878,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
12123,NCT06018142,Perfusion ratio,,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
12124,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",,,2010-07,RECRUITING,OBSERVATIONAL,['NA']
12125,NCT02997553,Non-inferiority of indocyanine green guided sentinel lymph node biopsy,fluorescence imaging,,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
12126,NCT01952951,downstaging rate,quality of life,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
12127,NCT04627363,Progression free survival rate at 6 months,Adverse events,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12128,NCT03025152,Changes from baseline in total scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale),Incidence of withdrawn due to adverse events,,2016-11-11,TERMINATED,INTERVENTIONAL,['NA']
12129,NCT04607590,The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU),Patient and partner short form survey (SF-36) domains,Treatment efficacy,2019-05-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12130,NCT01703650,Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy,comparison of perfusion parameters among the pancreas tumors and parenchyma,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
12131,NCT03176082,Polypectomies,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
12132,NCT04631445,Progression-free survival per RECIST 1.1,To compare quality of life between arms via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLC-C30 (EORTC QLQ-C30) assessment.,,2020-12-02,RECRUITING,INTERVENTIONAL,['NA']
12133,NCT02319304,Primary Outcome Measure (Overall Survival Rate),Secondary Outcome Measure (Number of Adverse Events),,2015-03,TERMINATED,INTERVENTIONAL,['PHASE2']
12134,NCT04949256,Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants,Part 2 (Main Study): TTD in HRQoL Score Using EORTC QLQ-OES18,,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE3']
12135,NCT03269526,Overall survival,"Examine tumor tissue for immune system cells, cytokines and proteins to estimate whether the type and number of immune cells correlates with clinical responses",,2017-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12136,NCT02413853,Progression free survival (PFS),Survivin mRNA expression levels,Intratumoral gene expression of Wnt related biomarkers,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12137,NCT04324476,Progression Free Survival 1 (PFS 1),The occurrence of adverse reactions (AEs),,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12138,NCT00154752,oncologic results,functional results,,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12139,NCT00569387,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,We will use overall survival and adverse events rates as secondary endpoints.,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12140,NCT05269056,Area under curve of the model for detecting stage I/II gastric cancer,Area under curve of the early detection model at sequencing depth downsampling,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
12141,NCT05100082,Number of Participants with Grade 3 or higher Adverse Events,Overall Survival (OS),,2021-11-17,RECRUITING,OBSERVATIONAL,['NA']
12142,NCT04443478,The number of lower mediastinal lymph nodes retrieved,Overall survival in 3 years,Number of patients that can be screened and successfully recruited,2020-08-01,RECRUITING,OBSERVATIONAL,['NA']
12143,NCT01697917,Change in QOL (Quality of Life),Nutritional status of patients,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
12144,NCT01079533,Colorectal Cancer Screening,,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
12145,NCT01959269,Overall survival,Incidence of treatment emergent adverse events (TEAE),,2013-10-31,COMPLETED,OBSERVATIONAL,['NA']
12146,NCT05304572,feeding vessels detectability,inter-observer agreement,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
12147,NCT02628665,Partial remission rate,The recent incidence of adverse reactions,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
12148,NCT01247298,Local Recurrence Rate,Percentage of Participants With Local Failure Patterns,,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12149,NCT04896073,disease control rate,Overall Survival (OS),,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE2']
12150,NCT01232101,The primary aim of the present study was to compare and stent patency between covered and uncovered bileduct SEMS,"Secondary objectives were to study difference in technical success, efficacy of drainage and complication rate between covered and uncovered metal stents",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12151,NCT01590732,Incidence of adverse events,Complete response,,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
12152,NCT02781012,Berg's Interrogative Biology® Platform,,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
12153,NCT04435197,Pathologic complete response,Overall Survival (OS),,2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2']
12154,NCT01862198,The stent patency rate,Complication rate related to the hybrid stents,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12155,NCT05281003,Major hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,Cell lineage-specific hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,"EFS in eligible participants with locally advanced ESCC, stratified by PD-L1 biomarker expression (CPS ≥10, ≥1 and <1)",2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE2']
12156,NCT02973672,Number of patients with treatment-related adverse events,Serum SGM-101 concentrations,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12157,NCT04809870,Long-term survival,Pulmonary complications,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
12158,NCT00489359,Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate),Phase 2 - Progression-Free Survival,,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12159,NCT03087591,Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0,Survival as assessed by RECIST,,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12160,NCT00453661,Screening Rates,Compliance Rate Across 5 Cancer Types,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
12161,NCT02991092,recovery time of intestinal function,hospitalization time after operation（day）,body weight（Kg）,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12162,NCT02285660,Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas),,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
12163,NCT02815436,Rate of completion of FOBT in the year of receiving the interventions/control,Rate of return of FOBT tubes in the year of receiving the interventions/control,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
12164,NCT04459468,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for Progression free survival in Hepatocellular carcinoma patients.,,2022-11-04,RECRUITING,OBSERVATIONAL,['NA']
12165,NCT01157013,Response to sorafenib therapy shown in PET Scans,Tumor response evaluated by CT and MRI,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12166,NCT02057874,"Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).","Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)",,2014-02,TERMINATED,INTERVENTIONAL,['NA']
12167,NCT01988493,Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC),Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by Investigator According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria,,2014-01-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12168,NCT00498225,Over all survival(OS),"progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12169,NCT02481635,Type and the severity of side effects,Time to Progression,,2016-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12170,NCT00725400,Objective tumor response rate,Quality of life,,2010-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12171,NCT01744509,Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps,to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
12172,NCT05484024,Disease-free survival rate,Quality of life (QoL),,2022-08-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12173,NCT03551444,Recurrence rate,Identifications of predictive factors of HCC recurrence,,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12174,NCT04752384,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in VAS pain score calculated from BPI questionnaire.,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in average daily pain score calculated by OM pain app.,,2021-07-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12175,NCT05476380,pCR,DFS,,2021-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
12176,NCT04867525,Course of treatment (treatment reality).,"Carcinoma Health-related quality of life (Patient-reported outcome, PRO).",,2021-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12177,NCT01056601,Progression-Free Survival,Duration of Response,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12178,NCT00551213,Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion,Change From Baseline in Tumor Growth Rate,,2007-11-21,COMPLETED,INTERVENTIONAL,['PHASE2']
12179,NCT04746469,Overall colorectal cancer screening uptake (any modality),Colorectal cancer screening uptake by modality,,2020-09-02,COMPLETED,INTERVENTIONAL,['NA']
12180,NCT03586050,Number of Patients Whose Ablation Resulted in Technical Success,Number of Patients Whose Ablation Resulted in Technique Efficacy,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
12181,NCT01387932,Median Overall Survival,Objective Response Rates (ORR),Number of TACE-Related Adverse Events in Subjects Treated With HepaSphere/QuadraSphere vs Subjects Treated With Conventional TACE.,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12182,NCT01924819,Overall survival,Surgical complete resection rate (R0),,2009-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12183,NCT04645160,Phase I: Determine safety and establish the recommended Phase II dose (RP2D) of tivozanib in patients with cholangiocarcinoma who were previously treated with first-line chemotherapy.,Evaluate disease control response (DCR- complete response [CR] plus partial response [PR] plus stable disease [SD]) in patients with cholangiocarcinoma treated with tivozanib,,2022-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12184,NCT00893503,"Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.",Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
12185,NCT00458809,Maximum tolerated dose,Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12186,NCT01908504,The number of subjects with benefit from an intra-treatment PET-CT,Measure late toxicities,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
12187,NCT05542030,Lesions recurrence in a three-month follow-up after EMR,Recurrence risk after EMR,,2022-09-12,RECRUITING,INTERVENTIONAL,['NA']
12188,NCT02725996,Overall Survival(OS) :Overall survival was measured from the date of randomization until death from any cause.,,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12189,NCT02000050,Complete pathological response (pCR),Intention-to-treat (ITT) population,,2013-10-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12190,NCT00019513,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12191,NCT05610332,Objective response rate,"The prediction performance of Exosome contents (including proteins, nucleic acids)",,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
12192,NCT00873275,Pharmacokinetics of ursodiol,,,2009-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12193,NCT04108936,Overall survival,Quality of life (Questionnaire-WHOQOL-BREF),,2016-10,RECRUITING,OBSERVATIONAL,['NA']
12194,NCT03835663,Difference in the amount of bacteria of the gastric mucosa between the three previously described groups.,,,2018-06-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12195,NCT06243757,Appetite level score according to the MDASI-GI,,,2024-01-08,RECRUITING,OBSERVATIONAL,['NA']
12196,NCT03608878,time-to-ITTVP,,,2019-04-26,TERMINATED,INTERVENTIONAL,['PHASE2']
12197,NCT00023972,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12198,NCT04060342,"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)","Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275",,2019-08-13,TERMINATED,INTERVENTIONAL,['PHASE1']
12199,NCT01237665,Pathological complete response (pCR),OS,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
12200,NCT00848952,Report of proportion of the positives truths and the positive wrong for an examination,,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
12201,NCT01035437,Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer,Evaluate the efficacy of PDT in palliation of dysphagia,,2009-12,WITHDRAWN,INTERVENTIONAL,['NA']
12202,NCT01973725,Disease control rate,EORTC QLQ-C30 and QLQ-OES18,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12203,NCT02982694,Overall Response Rate,Safety and tolerability (adverse event assessment according to CTCAE v 4.0),,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2']
12204,NCT05489458,The evolution of the degree of vascular involvement in 64-MDCT scans,The Resection Rate at the end of the observation period.,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12205,NCT04194801,Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1,Pharmacokinetic Parameters of Time to Maximum Serum Concentration (Tmax) of Sugemalimab (CS1001),,2019-12-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12206,NCT01991522,Transfer of Skills to Clinical Colonoscopy,Retention of Clinical Skills,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
12207,NCT03097848,Disease free survival,mortality,,2017-05-04,UNKNOWN,INTERVENTIONAL,['NA']
12208,NCT02431078,three-year disease free survival rate,baseline detection of ZEB1 expression,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
12209,NCT00666978,Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months,Number of Slow and Fast Metabolizers by Genotype,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12210,NCT05557838,≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1,Duration of response (DoR) per RECIST 1.1/mRECIST,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE3']
12211,NCT04191655,Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy,Appropriateness of reported follow up recommendations per standard guideline recommendations,,2019-04-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12212,NCT03460197,The classification of Papanicolaou was used for the terminology in pancreatobiliary cytological evaluation of biopsy samples.,,,2018-04-20,COMPLETED,OBSERVATIONAL,['NA']
12213,NCT00224562,,,,2004-02,UNKNOWN,OBSERVATIONAL,['NA']
12214,NCT00110721,frequency of stable disease,safety of GM-CT-01 plus 5-FU,,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2']
12215,NCT05200442,Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with Cetuximab,Phase II Objective: Stable Disease,,2022-08-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12216,NCT06204523,"Investigate pathways of interest at a deeper level, as well as identify other potential pathways/functions impacting clinical outcomes.",,,2018-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12217,NCT03790553,Overall survival in ITT population,Questionnaire EORTC-QLQ-OES18,,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE3']
12218,NCT01461915,Number of Patients who Achieved Progression-Free Survival,Proportion of Patients who Achieved Overall Survival,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
12219,NCT03102047,Median modified Neoadjuvant Rectal (mNAR) Score,Frequency of adverse events assessed by CTCAE 4.0,,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE2']
12220,NCT05065801,Progression-free survival,Collection of circulating tumor DNA (ctDNA),,2022-01-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12221,NCT02761356,Visual assesment of Tc-99m-MAA in liver lesions compared to visual assesment of Y-90 sirtex.,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12222,NCT05856188,Change in the level of salivary transforming growth factor beta 1 during radiotherapy.,Change in Pain visual analog scale during radiotherapy.,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
12223,NCT05865756,acoustic cough features in HNC patients as biomarkers for dysphagia/aspiration.,,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
12224,NCT03772132,Progression Free Survival,percentage of patients with Clinical Benefit Response,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12225,NCT01969292,%Clear,Ottawa Stool Score,,2013-09,TERMINATED,INTERVENTIONAL,['NA']
12226,NCT01483443,Overall survival,Disease free survival,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12227,NCT04785820,"Overall Survival, Defined as the Time from Randomization to Death from Any Cause","Baseline PDL1, CD8+PD1+, CD8+TIM3+, and CD8+LAG3+ Expression in the Tumor Microenvironment",,2021-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12228,NCT03300414,Associate viral sequences and host gene expression signatures with established HCC risk factors in Asian Americans.,,,2017-03-20,COMPLETED,OBSERVATIONAL,['NA']
12229,NCT05238831,Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation.,Overall survival,,2023-01-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
12230,NCT02305810,"Circulating angiogenic factors, molecular imaging and tumor tissue factors changes during treatment with RAD001 at baseline, week 4, week 12 and at disease progression.","TTP, time to progression",,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12231,NCT01814501,Progression free survival(PFS),Overall survival,,2013-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12232,NCT05488587,Serum level of Zinc in cirrhotic patients and HCC,serum level of Zinc and the Barcelona clinic classification,,2022-08,RECRUITING,OBSERVATIONAL,['NA']
12233,NCT06152978,Event-free survival (EFS),adverse events,,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12234,NCT05497453,Duration of Response (DOR) (for Part 1 and Part 2 expansion),,,2022-08-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12235,NCT01465425,"Rates of Follow Up Imaging, Hospitalization, Intervention",Estimate Differences in Cost,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
12236,NCT02140021,Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia,,,2014-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12237,NCT02106910,Mean Procedure Preference Rating,Cytosponge™ Operating Characteristics,,2014-10-27,COMPLETED,INTERVENTIONAL,['NA']
12238,NCT03779464,PFS,Safety profile :Adverse events of nab-Paclitaxel plus S-1,,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12239,NCT00087360,Colorectal cancer (CRC) screening rates by chart review at 4 months,CRC risk perception by questionnaires at 4 and 12 months,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
12240,NCT03255070,Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.,Immunogenicity profile of ARX788,,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE1']
12241,NCT01277653,the difference of curative treatments & survival rates,the difference of early detection rates of HCC between both groups,,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
12242,NCT00577109,Progression-free survival,"AEs, laboratory parameters.",,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12243,NCT00576199,Progression-free Survival,Tumor Necrosis,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12244,NCT01411189,The proportion of patients had no or mild peristalsis during the therapeutic procedures,Adverse events and adverse drug reactions,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12245,NCT06030934,Objective Response Rate (ORR),Adverse Events (AEs),,2022-10-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
12246,NCT02777710,part 2 (extension part) : objective response rate (ORR),Peak Pexidartinib plasma concentration (Cmax),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12247,NCT00003276,objective tumor response rate,time to progression,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12248,NCT02282059,Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs),Progression-free survival by clinical judgment,,2014-12-12,COMPLETED,OBSERVATIONAL,['NA']
12249,NCT05904665,Secondary resection rate,ctDNA clearance rate,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
12250,NCT00294359,Phase III: - progression free survival,- cost of therapy and assessment of gain in quality-adjusted progression free survival,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12251,NCT02540850,Ct Value (Ct Values From PCR Reaction),Consistency (the Overall Ratio of True Positive and True Negative),,2014-02,COMPLETED,OBSERVATIONAL,['NA']
12252,NCT05262335,Objective response rate (ORR),Radical Resection Rate of Liver Metastases,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12253,NCT03295084,Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events,Objective tumor response to treatment based on RECIST 1.1 criteria,,2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12254,NCT00599378,"Follow up survey to assess participant compliance with CRC screening. For those non compliant participants, randomized to either Control group or CPI2 group - active intervention with implementation intentions-based communication concepts",120 day followup survey to assess perceived barriers and screening decisional stage,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12255,NCT05554744,Imaging response,Safety of EUS-FNI,,2015-06-18,RECRUITING,INTERVENTIONAL,['NA']
12256,NCT01661049,,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
12257,NCT01123811,objective response rate,Progression-free survival,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12258,NCT01260701,Overall Survival (OS),Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12259,NCT03253250,Recurrence-free Survival Rate (RFS）,Overall Survival Rate (OS）,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12260,NCT01519232,Changes in hepatobiliary single photon emission tomography (SPECT) after radiation therapy,"measuring values between regional radiation dose and local hepatic function as measured by hepatobiliary SPECT, in normal liver parenchyma",,2008-08,COMPLETED,OBSERVATIONAL,['NA']
12261,NCT04183478,overall survival,QOL,Hematology Index,2017-09-26,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12262,NCT04753996,Number of participants in study.,Number of clinical phenotypes and/or observations.,,2021-03-08,RECRUITING,OBSERVATIONAL,['NA']
12263,NCT02163187,Change in Bowel Function,Quality of Life,,2014-06-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12264,NCT01259193,numbers of adverse events,"Overall survival (OS), time to progression (TTP)",,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
12265,NCT04652947,"compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules",,,2016-12-07,COMPLETED,OBSERVATIONAL,['NA']
12266,NCT03021135,Local recurrence.,Sydney resection ratio (characterized by the following equation - lesion size in millimeters,,2018-06-07,COMPLETED,INTERVENTIONAL,['NA']
12267,NCT02533271,Disease-free survival rate,Quality of life (QoL),,2015-08,RECRUITING,INTERVENTIONAL,['PHASE3']
12268,NCT00303628,5-year Overall Survival Rate,Proportion of Patients Who Completed 12 Cycles of Treatment,Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months,2006-05-11,TERMINATED,INTERVENTIONAL,['PHASE3']
12269,NCT04584996,circRNAs for diagnosis,Bioinformatics,,2020-10-04,UNKNOWN,OBSERVATIONAL,['NA']
12270,NCT02009176,Survival rate,postoperative complications,,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
12271,NCT06231160,overall survival,Pain relief rate,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12272,NCT01128803,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Analysis of T lymphocytes,,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12273,NCT03599752,Overall survival (High risk),,,2018-07-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12274,NCT01751880,"changes of result of blood sample test, cardio pulmonary function test and vital signs reflecting of inflammation level and nutrition condition in patients with minimally invasive gastrectomy",,,2012-08-08,COMPLETED,INTERVENTIONAL,['NA']
12275,NCT01530503,Progression Free Survival (PFS),Overall Survival (OS),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12276,NCT00203411,Number of Subjects Requiring Dose Modifications,Quality of Life of Patients,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12277,NCT04053972,RFS,recurrence rate,,2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE3']
12278,NCT01963702,objective response,progression free survival (PFS),overall survival(OS),2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
12279,NCT05978141,Number of participants populating the T-cell Lymphoma Master Repository/TCLMR,,,2023-07-27,RECRUITING,OBSERVATIONAL,['NA']
12280,NCT01348009,Progression-free survival rate (in Phase 2 portion of study),Percentage of patients with adverse events (in Phase 1 and Phase 2 portions),,2011-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12281,NCT03674294,Complete response rate during the overall phase,Effects of CINV on daily life,,2015-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12282,NCT01575730,Area under the plasma concentration versus time curve (AUC) of platinum,Tissue Concentration (Cmax) of Platinum,,2012-05-21,COMPLETED,INTERVENTIONAL,['PHASE2']
12283,NCT05495308,The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.,"To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.",,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
12284,NCT03359681,Expression of Ki67 on tumor samples,microbiota,,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12285,NCT03699410,Negative Prognostic Value (NPV),,,2018-08-28,TERMINATED,OBSERVATIONAL,['NA']
12286,NCT01305200,Duration of Severe Oral Mucositis (WHO Grade 3 or 4),Severity of Mucositis,Ancillary Validation Study of ChIMES,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12287,NCT05187182,Expansion dose of CA-4948 in combination with FOLFOX/PD-1 inhibitor with/without trastuzumab,Overall survival (OS),,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
12288,NCT04027543,Overall survival (OS),30-day postoperative or in-hospital mortality,,2018-11-14,COMPLETED,OBSERVATIONAL,['NA']
12289,NCT01322633,Incidence Rate of Gastric Cancer,Incidence Rate of Overall Cancer,,2004-07,COMPLETED,OBSERVATIONAL,['NA']
12290,NCT05199649,Species and abundance of gut microbiota,Explore the changes of intestinal flora and metabolomics before and after medication,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
12291,NCT01472198,Progression free survival,Objective response,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12292,NCT04363983,Overall survival (OS),Survival without progression (SWP),,2021-01-13,RECRUITING,INTERVENTIONAL,['NA']
12293,NCT04174781,Progression Free Survival (PFS) per mRECIST,Adverse events (AEs),,2019-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12294,NCT01181557,"Questionnaire number 1, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma","Questionnaire number 3, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma",,2008-09,COMPLETED,OBSERVATIONAL,['NA']
12295,NCT04084249,FCI,CE,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
12296,NCT03895008,Disease Free Survival（DFS）,Overall survival(OS),,2019-07-08,RECRUITING,OBSERVATIONAL,['NA']
12297,NCT00008294,,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12298,NCT01646853,Objective Tumor Response,adverse events,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
12299,NCT00754494,Change in ACF pERK Levels,Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12300,NCT01622803,The time taken to insert bilateral stent,,,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12301,NCT00439608,Reponse Rate at Time of Surgery by Tissue,"Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12302,NCT00873002,Assessment of Safety and Tolerability,Adverse events and abnormal laboratory value severity as assessed by NCI CTCAE version 3.0,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1']
12303,NCT01632306,Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],,2013-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12304,NCT05453383,Objective response rate,Progression-free survival,,2022-07-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12305,NCT00686166,Pathologic Complete Response Rate,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to This Regimen.,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12306,NCT04157985,Progression-free Survival (PFS),Best Objective Response (BOR),,2019-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
12307,NCT06301399,ORR,DCR,,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12308,NCT00271986,anastomotic leakage,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
12309,NCT05730361,Objective Response Rate (ORR),Detection of Lentivirus Copy Number,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
12310,NCT05007132,Objective response rate,Progression-free survival,,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2']
12311,NCT01839500,"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria",Cohort II: Percentage of Participants Who Decline to the Recommendation Categorized by Reasons,,2013-04-25,COMPLETED,OBSERVATIONAL,['NA']
12312,NCT06096623,Electronic patient-reported outcome (ePRO) confirming treatment initiation,Time to treatment in days,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
12313,NCT04642924,Resection status,,,2019-10-22,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12314,NCT06236633,Safety of endovascular inferior mesenteric artery embolisation prior to surgical resection of the rectum in patients with tumours of the lower and middle rectum.,Markers of epithelial-mesenchymal transition : transcription factors,Operative data,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12315,NCT04710758,Overall survival,Postoperative recovery course,,2021-01-20,RECRUITING,INTERVENTIONAL,['NA']
12316,NCT06225843,Treatment-Emergent Adverse Events,Presence of ADA,,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
12317,NCT03212625,Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group,"Incidence of HFSR on 2, 4, 8, and 12 weeks on each group",,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4']
12318,NCT03900871,disease free survival,,,2019-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12319,NCT01159171,Percentage of Participants by Best Overall Response,Overall Survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12320,NCT03042611,Overall Survival (OS),Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire,,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE3']
12321,NCT00999843,The safety and tolerability of maintenance Sorafenib.,"Time to progression (TTP), progression-free survival (PFS) and overall survival (OS)",,2009-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12322,NCT04170530,MFS,Reported Adverse events,,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12323,NCT00833625,Pathologic Response,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12324,NCT01226979,Number of Participants With Pathologic Complete Response,Number of Participants With Acute Gastrointestinal Toxicity Associated With High-Dose-Rate Endorectal Brachytherapy (HDRBT) as Assessed by CTCAE v4.0,,2010-10-26,COMPLETED,INTERVENTIONAL,['NA']
12325,NCT01061840,To determine safety following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil™) vaccine in advanced solid tumor patients who have no acceptable form of standard therapy with curative intent.,To determine time to progression. To evaluate the effect of Vigil™ vaccine on immune stimulation. To evaluate whether lower cell doses would activate ELISPOT responses and to compare durability of dose elicited responses.,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12326,NCT05772546,Response Rate of CIT Treatment in Placebo Group,Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12327,NCT05692323,PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.,PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.,,2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
12328,NCT02731313,Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments,Weighted Kappa Coefficient Between Immunohistochemistry (IHC) 4B5 and Silver in Situ Hybridization (SISH) Techniques for HER-2 Testing in Centralized Laboratories,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
12329,NCT05374044,pathological tumor regression grade(pTRG),local recurrence,,2020-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12330,NCT00757172,Number of Participants With Pathologic Complete Response Following Surgery,Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12331,NCT02452853,Number of Complications reported using the National Cancer Institute Common Toxicity Criteria grading version 4.0,Overall survival,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
12332,NCT01563484,"Change from Baseline in serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase.",,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
12333,NCT01651624,Costs of the three different screening strategies proposed,Number and type of complications in all groups,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
12334,NCT05675059,Malnutrition: Low Skeletal Muscle Mass,,,2022-12-21,RECRUITING,INTERVENTIONAL,['NA']
12335,NCT03086642,Maximum Tolerated Dose (MTD),Overall survival (OS),,2017-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12336,NCT04996355,"The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening",,,2021-05-31,RECRUITING,OBSERVATIONAL,['NA']
12337,NCT02249650,Dose limiting toxicities (DLTs),,,2017-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12338,NCT01834742,Primary Variable,Safety profile,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12339,NCT00003422,"Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result",Economic implications,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12340,NCT06326619,Survival,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
12341,NCT00388206,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
12342,NCT02254486,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Polyp Detection Rate (Overall Colon),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12343,NCT03411915,Identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087,,,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE1']
12344,NCT05101772,The acquisition rate of the core tissue sample,the incidence of adverse events and the incidence of device defects,,2021-09-24,UNKNOWN,OBSERVATIONAL,['NA']
12345,NCT00202969,Response rate,"Safety profile, time to treatment failure",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12346,NCT01567917,The incidence of symptomatic or asymptomatic VTE,Risk factors for the development of VTE,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
12347,NCT05721872,Response to D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO),Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 hours,,2023-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12348,NCT01199250,"Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)",,,2100-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12349,NCT00624546,gene expression,,,2009-01,TERMINATED,OBSERVATIONAL,['NA']
12350,NCT02295956,Feasibility of Prehabilitation Program Among Pancreatic Patients,,,2015-02-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12351,NCT03300401,Local tumor response to therapy,,,2017-11-07,WITHDRAWN,INTERVENTIONAL,['NA']
12352,NCT04017845,Performance Indicators of Colonoscopic Examination,,safety and tolerance of colonoscopy.,2015-04-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12353,NCT01476553,Peritoneal Conversion Rate (PCR),Perioperative in-hospital morbidity,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
12354,NCT02161822,pathologic complete response rate,lipid lowering effect of simvastatin,,2014-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12355,NCT04965714,Necrosis of tumors,Overall survival (OS),Immune biomarker analysis,2022-04-13,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12356,NCT04177810,Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria,Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities,,2020-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
12357,NCT05023720,Regorafenib in combination with other drugs,Survival differences among the patients with different clinical phenotypes and genotypes,,2021-07-20,UNKNOWN,OBSERVATIONAL,['NA']
12358,NCT00159484,Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.,"To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen.",,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12359,NCT05850130,2-point improvement in the global NRS,Peripheral sensory neuropathy grading scale,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
12360,NCT03291574,Gastrointestinal function score,Physical fitness index,,2017-07-29,UNKNOWN,INTERVENTIONAL,['NA']
12361,NCT02299596,Recovery measured as physical recovery measured in questionnaire,Health economic analysis,,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12362,NCT02583659,Overall survival(OS) . overall survival Overall survival(OS),Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
12363,NCT05694936,Progression free survival,Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0,Quantification of total circulating tumour DNA (ctDNA),2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
12364,NCT00714701,This clinical study will assess the diagnostic yield of a clinical screening program for early pancreatic neoplasia in high risk individuals.,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
12365,NCT03314896,Overall survival,Adverse events (mortality and morbidity),,2016-10,RECRUITING,INTERVENTIONAL,['NA']
12366,NCT01670851,Perineal wound healing,Incidence of parastomal hernia,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12367,NCT00026130,Overall Survival,Toxicity,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12368,NCT02014116,Maximum Tolerated Dose (MTD) of LY3009120,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the End of Dosing Interval at Steady State (AUC[0-τ]) of LY3009120 Cycle 1 Day 28,,2013-11-26,TERMINATED,INTERVENTIONAL,['PHASE1']
12369,NCT04594655,MPI and major morbidity,Prediction of complication,,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
12370,NCT00305188,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment,Other: progression free survival and survival,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12371,NCT05033522,overall survival,Time to Symptomatic Progression,,2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12372,NCT06076837,Safety and Tolerability,"CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)",Baseline neutrophil lymphocyte ratio (NLR),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
12373,NCT00621556,"MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.",Laboratory,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE1']
12374,NCT03630978,Morbidity,Readmission rate,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
12375,NCT04187352,Overall survival (OS),Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1,,2019-12-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12376,NCT05973266,quality of bowel preparation,Anxiety,,2021-06-03,RECRUITING,INTERVENTIONAL,['NA']
12377,NCT02519348,Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events,Overall Survival (OS),,2015-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12378,NCT02031952,Recurrence-free survival,Post-operation complication,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
12379,NCT04871399,Disease-free survival at 3 years,Other Oncologic outcomes.,,2020-07-13,RECRUITING,INTERVENTIONAL,['NA']
12380,NCT01615653,Pain assessed using a numerical rating scale (NRS) from 0 to 10.,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12381,NCT03222557,GI-2 recovery,Adverse events related to EA/SA,,2017-11,UNKNOWN,INTERVENTIONAL,['NA']
12382,NCT01813994,Proportion of the patients with high-risk (III/IV) OLGA stages,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
12383,NCT03766178,Objective Response Rate (ORR),12-month survival rate,,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
12384,NCT03094884,Rate of severe acute esophagitis in patients with lung cancer and esophageal cancer treated with concurrent CRT using PLDR technique.,Response rate based,,2017-02-24,RECRUITING,INTERVENTIONAL,['PHASE1']
12385,NCT03895970,Progression-free Survival (PFS),Stable Disease,Incidence of Treatment-Emergent Adverse Event,2019-04-20,COMPLETED,INTERVENTIONAL,['PHASE2']
12386,NCT02387203,Overall survival,"Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease",Analyze number of live bacteria in PMP tumor and mucin,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12387,NCT03984214,Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.,Overall survival (OS),,2019-12-16,RECRUITING,INTERVENTIONAL,['PHASE3']
12388,NCT00159432,Median Time for Progression Free Survival,Number of Participants With Grade 3 or Higher Toxicity,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12389,NCT04674956,Progress free survival,Duration of Response,CA19-9 in serum,2021-03-04,RECRUITING,INTERVENTIONAL,['PHASE3']
12390,NCT06147180,score of Quality of life,Recurrence or metastasis,,2023-11-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12391,NCT02521649,Measurable Antibody Titer,Injection Site Reaction,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12392,NCT04740307,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),TTP per mRECIST as assessed by BICR,,2021-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12393,NCT05776524,Overall Survival,Disease Control Rate,,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE2']
12394,NCT00756509,"To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the",population pharmacokinetics of Nilotinib,,2008-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
12395,NCT05328908,OS in all randomized participants,DoR by investigator per RECIST v1.1 in all randomized participants,,2022-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12396,NCT05311176,Objective Response Rate of HER-Vaxx in combination with chemotherapy or pembrolizumab,Duration of Response,"Exploratory Outcome: Associations between clinical outcome and HER2/neu, PD-L1 expression",2022-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12397,NCT00209729,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the OS(Overall Survival) and DFS(Disease Free Survival).,,2005-04,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12398,NCT01382407,Relationship between acne and skin rash,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
12399,NCT02005315,Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12400,NCT01314105,Dose Limiting Toxicities During Treatment Course 1,Change From Baseline in Safety Laboratory Parameters,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12401,NCT01073384,Preliminary Efficacy,,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12402,NCT02200055,Bioimpedance Assessment,Amount of Intraoperative Fluids,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12403,NCT04299919,Three-year recurrence,Progression-free survival,,2007-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12404,NCT04905329,Relative dose-intensity (RDI) of the myelosupressive therapy course,Serious adverse events frequency,,2020-04-28,UNKNOWN,OBSERVATIONAL,['NA']
12405,NCT02385552,Adenoma detection rate,Colonoscopy quality indicators,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
12406,NCT04996095,Analysis of Predictive Markers,,,2021-10-01,RECRUITING,OBSERVATIONAL,['NA']
12407,NCT01994213,Objective Response Rate,Percent of Participants with OS of one year,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12408,NCT01387061,Overall survival plus multivariate analysis,Disease-free survival,,2001-06,COMPLETED,INTERVENTIONAL,['NA']
12409,NCT01383252,Success of colonoscopy,Polyp detection,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
12410,NCT02281266,Recurrence-free Survival,"number of patients with abnormal laboratory value, vital signs and ECG result",,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12411,NCT01804790,disease-free survival,Overall survival,,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12412,NCT05516641,Gut Flora modulation,Immune Profile,,2022-07-25,RECRUITING,INTERVENTIONAL,['NA']
12413,NCT03725254,Progression-free survival,local control rate,,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2']
12414,NCT01264705,Number of Patients With Dose Limiting Toxicity,Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12415,NCT01824875,Progression-free Survival,Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response,,2013-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12416,NCT00359476,"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]",The evaluation of the safety profile of vinflunine,,2007-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12417,NCT04085055,Degree of cellularity in biopsy sample,Diagnostic operating characteristics,,2019-09-09,UNKNOWN,INTERVENTIONAL,['NA']
12418,NCT00185874,To determine the toxicity of this regimen,To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE1']
12419,NCT04351009,Upstaging rate,Aberrant lymph node drainage,,2020-06-08,COMPLETED,INTERVENTIONAL,['NA']
12420,NCT03284879,Change from baseline activity for arthritis,,,2017-09-05,COMPLETED,OBSERVATIONAL,['NA']
12421,NCT05402891,Change in clone size distribution positive for NOTUM.,"Safety outcomes by analysing reported adverse events, physical examination and laboratory findings.","History of smoking, if yes number of pack years",2022-06-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
12422,NCT02772965,Percent of Participants Experiencing Treatment Failure,Percent of Patients With Positive Anti-TNF Antibody,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12423,NCT02041312,Cholesterol level in paitents with and withoutgastric neoplasm,Degree of decresed serum cholesterol levels in paitents with gastric neoplasm,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
12424,NCT05635149,Progression-Free Survival (PFS),Gut microbiome analysis,Exploratory endpoint,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
12425,NCT04220944,Progression Free Survival (PFS),Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V5.0 (Safety and Tolerability),,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12426,NCT00003687,,,,1998-06-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12427,NCT00442637,Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2),Translational research,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12428,NCT00636610,Progression-free Survival (PFS),Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12429,NCT03839277,"Adenoma detection rate, ADR","Polyp detection rate, PDR",,2019-06-12,SUSPENDED,INTERVENTIONAL,['NA']
12430,NCT03347162,Cohort 2: Medical treatment complications,Change in physical activity level,,2017-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12431,NCT04314401,Percentage of minority and underserved study participants accrued,Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository,,2020-11-11,RECRUITING,OBSERVATIONAL,['NA']
12432,NCT00028496,"Maximum tolerated dose of recombinant fowlpox-CEA(6D)/TRICOM vaccine determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria, version 2.0",,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12433,NCT02378389,The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer,preliminary antitumor activity for the regimen,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
12434,NCT03196232,Progression-free Survival (PFS),Treatment Delay or Reduction,,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE2']
12435,NCT01554969,Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12436,NCT02833363,Difference of Gastric Microbiota in the Process of Correa's Model.,Difference of Gastric Microbiota in the Process of Correa's Model.,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
12437,NCT03888638,Survival,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
12438,NCT02865811,Clinical Benefit Rate [CBR],Overall Survival,,2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
12439,NCT04587739,Drop-out rate,Actuarial overall survival and disease-free survival.,,2021-01-31,RECRUITING,INTERVENTIONAL,['PHASE1']
12440,NCT00657371,Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER),Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
12441,NCT03320629,Progression free survival,Side effects,,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12442,NCT05034887,Major pathological response [MPR] rate: by central assessment,AE rate,AE rate in the Exploration Part,2022-01-31,RECRUITING,INTERVENTIONAL,['PHASE2']
12443,NCT02249975,Presence of residual Barrett's Esophagus,Device Performance,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12444,NCT06195111,PFS (Progression-free survival),Quality of life: EORTC QLQ-C30,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12445,NCT02128425,Progression-free survival after induction and maintenance chemotherapy (PFS1),Translational research,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12446,NCT00709462,"To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.","To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)",,2004-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12447,NCT01889680,The time to disease progression,The severity of adverse events,,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12448,NCT00997022,Maximum tolerated dose of daily sorafenib,Duration of progression free survival,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12449,NCT02138383,Maximum Tolerated Dose (MTD),,,2014-05-22,COMPLETED,INTERVENTIONAL,['PHASE1']
12450,NCT04368702,Rate of Pathologic complete response-Gastric,Characterizing MRI-based tumor alterations/changes following MR-image guided radiation,,2021-05-01,SUSPENDED,INTERVENTIONAL,['NA']
12451,NCT04200027,oncological outcomes RLAR vs TaTMe,,,2021-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12452,NCT04585516,Presence of upper GI pathology,patient characteristics of colorectal cancer 7,Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12453,NCT00102752,Overall objective response rate,Serum CA-19-9,,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12454,NCT00718055,,,,2006-11,WITHDRAWN,OBSERVATIONAL,['NA']
12455,NCT04068194,Objective response rate (ORR) (Phase 2),Differential response to therapy (Phase 2),T cell receptor (TCR) clonality,2020-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12456,NCT04430842,Determination of maximum tolerated dose (MTD),Time to maximum concentration of QBS10072S in plasma (Tmax),,2020-07-20,COMPLETED,INTERVENTIONAL,['PHASE1']
12457,NCT02529878,radical resection rate,reaction rate,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
12458,NCT02004782,Rate of symptomatic stricture formation,Recurrence,Cost,2022-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12459,NCT00616941,Overview of Treatment-emergent Adverse Events (TEAEs),Tumor Measurement Results According to the Response Evaluation Criteria for Solid Tumors (RECIST) Up to 16 Weeks Post-Baseline,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12460,NCT02123407,the number of harvested lymph nodes,the diameter of harvested lymph nodes,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
12461,NCT03101566,The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment,Overall Response Rate (ORR),,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12462,NCT05785780,Up-to-date CRC screening,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,Implementation Fidelity,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
12463,NCT01975454,Progression-free survival(PFS),Adverse events,,2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12464,NCT06212700,Acceptability of the virtual multimodal hub.,Implementation Outcome: Maintenance,,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12465,NCT05171439,Bioinformatics analysis of single-cell sequencing in hepatocellular carcinoma,adverse events(AE),,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12466,NCT00307723,to determine the survival of patients treated with this regimen.,to evaluate the toxicities.,,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12467,NCT02052908,Incidence of toxicity,Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa,,2014-01-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12468,NCT05961969,Completion of transabdominal ISR,Fecal incontinence,,2022-02-21,RECRUITING,OBSERVATIONAL,['NA']
12469,NCT05992220,progression-free survival rate,"Tumor marker response (AFP, PIVKA-II)",,2022-10-22,RECRUITING,INTERVENTIONAL,['PHASE2']
12470,NCT04782791,Adverse events,R0 rate,,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12471,NCT05669482,To determine the efficacy of the RP2D identified in Part A,Number of abnormal laboratory values,,2023-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12472,NCT02083653,Overall Survival (OS) Time,Quality of Life Assessed by FACT-EGFRI-18 for Skin Rash,,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12473,NCT03007550,Early operative morbidity and mortality rate,Postoperative hospital stay,,2017-01-04,COMPLETED,INTERVENTIONAL,['NA']
12474,NCT04231175,Number of preventable unnecessary laparoscopies and explorative laparotomies defined as,Quality of Life between diagnostic arms by EQ5D5L,,2019-10-28,UNKNOWN,INTERVENTIONAL,['NA']
12475,NCT03255434,Evaluation of neurotoxicity associated with Oxaliplatin,,,2017-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12476,NCT05188586,Specificity,Stage Shift,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
12477,NCT01147965,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).",The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12478,NCT03161574,The rate of R0 resection,Reported Adverse events,,2017-08-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12479,NCT00716209,,,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
12480,NCT01105377,Confirmed Tumor Response,Time to Progression,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12481,NCT06263205,Rate of Postoperative Wound Healing Complications,Medical Costs Associated with Wound Care,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12482,NCT02037048,Recurrence Free Survival (RFS) compared to historical averages,Loco-regional control (LRC),"Prognostic effect of CTCs, Ki-67, and HER2 overexpression on pathologic response",2014-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12483,NCT02054923,Change in screening centre adenoma detection rate before and after intervention,Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
12484,NCT05354674,progression free survival,overall survival,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12485,NCT00476970,Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening,Number of Polyps and Cancers per 100 Patients in the Study vs Control Group,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12486,NCT00352261,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12487,NCT03010722,"disease control rate (DCR), measured in months",Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
12488,NCT02159339,Metastasis and/ or recurrence of gastric carcinoma,Disease-free (Recurrence/metastasis-free) survival (DFS) and overall survival (OS) of patients with gastric carcinoma after surgical resection,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
12489,NCT02946138,Progression-free survival of all patients,Objective responses rate,,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12490,NCT02762266,Number of Participants With a Local Progression Event,The Impact of Elevated Serum Alpha-Fetoprotein Level (AFP) on Overall Survival (OS),,2016-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
12491,NCT01471743,Number of participants with post-op Infections,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12492,NCT02092948,Assess the safety of [124I] PSCA-Minibody,Compare the sensitivity and specificity of [124I] PSCA-Minibody with conventional imaging,,2013-08-22,COMPLETED,INTERVENTIONAL,['PHASE1']
12493,NCT00905918,"Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels",,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12494,NCT02181075,Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound,Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12495,NCT04855331,Postoperative complications,The 90 days mortality rate after operation,Postoperative quality of life,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
12496,NCT05831150,Number of study participants who remain in clinical research until completion.,,,2024-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12497,NCT05864755,Overall response rate ( ORR) per RECIST 1.1,Time To Progress(TTP) per RECIST 1.1,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
12498,NCT04523467,Progression-free survival (PFS),Adverse events,Conversion rate,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
12499,NCT01064375,To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.,To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12500,NCT03015389,Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.,Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.,,2017-09-27,COMPLETED,OBSERVATIONAL,['NA']
12501,NCT06329102,Surgical complications defined by Calvien Dindo II to V,Quality of life after surgery measured with the 15D instrument,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
12502,NCT00583674,Progression Free Survival (PFS),Patient Reported Outcomes,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12503,NCT00033384,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12504,NCT04415385,ORR,Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with apatinib,,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12505,NCT02260505,Disease Free Survival (DFS),Patient's Quality of Life (QoL),,2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3']
12506,NCT02277834,"Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process",Compare the proteomic profile between pancreatic cancer and pancreatitis,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
12507,NCT01276483,Radiologic-pathologic correlation,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
12508,NCT05922358,Completion rate of 3 cycles of re-chemotherapy with oxaliplatin,Concordance rate between oxaliplatin skin test results and clinicians' judgment,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12509,NCT02813928,The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
12510,NCT00480298,endoscopic evaluation of the nasal polyp size compared to baseline,"Nasal Polyp score: endoscopic evaluation of the nasal polyp size compared to baseline. Nasal polyposis signs and symptoms including nasal discharge, nasal congestion, postnasal drip, sense of smell,olfactory test (sites Gent, Stockholm and Huddinge) and",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12511,NCT00681252,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),To evaluate immunological responses,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12512,NCT02266056,intra-abdominal pressure,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
12513,NCT00003287,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12514,NCT01821963,Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant,Sustained Virological Response (SVR),,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
12515,NCT04342910,Overall Survival (OS) in PD-L1 Positive Participants.,Plasma concentration of apatinib,,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE3']
12516,NCT05389527,Major pathological response (MPR),Adverse event (AE),,2022-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12517,NCT05039736,To evaluate overall response rate,,,2023-02-24,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12518,NCT00725335,Disease free survival,"overall survival,morbidity,postoperative mortality;blood loss,Liver function test,etc",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
12519,NCT06325410,type of resected tumor,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
12520,NCT01285778,Three-year disease-free survival rate,Predictive potential of different biomarkers,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12521,NCT05064553,To demonstrate that Oncoguard™ Liver HCC specificity exceeds 82%,To determine a point estimate and 95% confidence interval for Oncoguard™ Liver overall HCC sensitivity,,2021-07-26,RECRUITING,OBSERVATIONAL,['NA']
12522,NCT01343901,Percentage of Participants Without Detectable Metastatic Disease After a Complete Response Without Surgery,Percentage of Participants With Unresectability Criteria,,2010-09-30,COMPLETED,OBSERVATIONAL,['NA']
12523,NCT04222114,Overall survival (OS),Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab,,2020-10-06,RECRUITING,INTERVENTIONAL,['PHASE3']
12524,NCT06123494,Overall survival (OS),Serum concentrations of SHR-A1811 toxin-binding antibodies and free toxin SHR169265,,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE3']
12525,NCT00003254,Confirmed Response Rate,Toxicities,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12526,NCT03109301,Efficacy,,,2017-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12527,NCT03520088,Changes in sexual dysfunction pre- and post-Total Mesorectal Excision,,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
12528,NCT02272244,Overall Screening Adherence,Screening Knowledge and Perceptions,,2014-10-01,COMPLETED,INTERVENTIONAL,['NA']
12529,NCT04137679,Disease-free survival,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12530,NCT05141747,Adverse Events (AEs),Immunogenicity (ADA),,2022-01-19,UNKNOWN,INTERVENTIONAL,['PHASE2']
12531,NCT02970916,FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.,Number of participants with adverse events as assessed by CTCAE v4.0.,"Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)",2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12532,NCT02935634,Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks,Number of Participants With Laboratory Abnormalities in Specific Liver Tests,,2016-11-29,COMPLETED,INTERVENTIONAL,['PHASE2']
12533,NCT01628913,Progression Free Survival (PFS),Time to Treatment Failure (TTF),,2012-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12534,NCT00005869,,,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
12535,NCT01430052,Two year survival rate,Response rate,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12536,NCT05996484,Pathologic complete remission (PCR),Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18),,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12537,NCT02724267,Overall Survival,Time to Progression,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12538,NCT01219985,Number of Detected Uptakes on PET Images,Lesions Uptake Measurement (SUVmax),,2008-04,COMPLETED,INTERVENTIONAL,['NA']
12539,NCT05412355,long-term survival,Postoperative complications,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
12540,NCT02588248,Adenoma Detection Rates,Patient Comfort Level Recorded on Post-procedure Survey,,2017-04-27,TERMINATED,INTERVENTIONAL,['PHASE3']
12541,NCT00276861,Response Rate as Measured by RECIST Criteria,Time to Progression as Measured by the Kaplan Meyer Curve at Completion of Study Treatment,,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12542,NCT05883800,Incidence of acute gastro-intestinal toxicity equal or higher than grade 2,Incidence of late gastro-intestinal toxicity equal or higher than grade 2,Patient reported bowel-related outcome measures,2023-06-22,RECRUITING,INTERVENTIONAL,['NA']
12543,NCT05631873,Implement a new process using a structured result letter template to set the electronic health record follow-up interval after a screening colonoscopy.,,,2022-11-18,COMPLETED,INTERVENTIONAL,['NA']
12544,NCT01764477,The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur.,Gene expressions in hair follicle epithelial cells,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12545,NCT06040801,Assess the level of quality of life in frail and non-frail patient groups before and after treatment using EORTC QLQ-C30 v3 and EORTC QLQ-ELD14.,,,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
12546,NCT06305364,Primary Efficacy Endpoint - Gixam's diagnostic accuracy,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
12547,NCT03456206,CID diagnosis,,,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA']
12548,NCT00641147,Polyp Number,Change in Apoptosis Index Levels,Change in Akt Phosphorylation Levels,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12549,NCT02826837,Maximum tolerated dose,Changes in global health/QoL standardized score at post-treatment visits compared to baseline,,2022-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12550,NCT05128825,Overall Response Rate defined by the revised RECIST v1 .1. and assessed by ICR.,Time To Response as defined by the revised RECIST v1 .1. and assessed by ICR and the Investigator.,,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE2']
12551,NCT01201655,,,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
12552,NCT02021253,Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
12553,NCT06116864,Adenoma detection rate,Procedure complication (bleeding or perforation) by the end of the procedure. (Following lexicon for endoscopic adverse events methods),,2023-10-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12554,NCT02053324,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),Adverse Events,tumor response,2013-11-11,TERMINATED,INTERVENTIONAL,['PHASE1']
12555,NCT03638297,Response rate,duration of response,,2018-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
12556,NCT05350917,Objective Response Rate (ORR),Study on the mechanism of drug resistance after progression,,2022-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12557,NCT04566367,Detection rate of a second cancer or precancerous lesions,,,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12558,NCT03287947,Disease Control Rate,"Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib.",,2017-11-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12559,NCT04676633,Limited Dose Toxicity (LTD),,,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12560,NCT00254436,Patient Iron Levels,,,2001-10-31,TERMINATED,INTERVENTIONAL,['PHASE3']
12561,NCT00005832,Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777,Assess confirmed response (complete & partial) in patients with measurable advanced adenocarcinoma of the pancreas,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12562,NCT00003862,,,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12563,NCT05390112,Radiological response at 1 month according to mRECIST and ctDNA detection,Progression-free survival and overall survival,,2021-05-20,RECRUITING,OBSERVATIONAL,['NA']
12564,NCT01831037,Hepatocellular carcinoma,Profile with lowest risk for hepatocellular carcinoma,Regression of liver fibrosis,2015-07,WITHDRAWN,OBSERVATIONAL,['NA']
12565,NCT00260884,We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.,,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12566,NCT02729298,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events,Objective response rate using RECIST v1.1 and iRECIST,,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12567,NCT04298008,disease control rate (DCR) of AZD6738 and Durvalumab combination,quality of life measurement,,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
12568,NCT05345054,A database linking socioecological determinants of health with nationally validated surgical outcomes.,,,2022-08-01,COMPLETED,OBSERVATIONAL,['NA']
12569,NCT02131493,DFS,OS,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12570,NCT02446925,Y-90 distribution and concentration as determined by post embolization PET-CT,Secondary outcome (time to death from first treatment),,2015-05-01,TERMINATED,INTERVENTIONAL,['NA']
12571,NCT01319942,Response rate,Time-to radiological progression interval,,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
12572,NCT05194995,Dose Expansion phase: Overall response rate (ORR),Dose Expansion phase: Progression-free survival (PFS),,2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12573,NCT03047837,NFκB,Metformin concentration,,2017-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12574,NCT02898077,Overall Survival (OS),Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score,,2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12575,NCT03307408,Dosage of the inflammatory cells in liver,Dosage of the glucose,,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA']
12576,NCT00384878,"The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).","The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.",,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
12577,NCT00098982,Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0,Time to progression as measured by Kaplan Meier and RECIST every 8 weeks,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12578,NCT01001377,Overall Survival,Number of Participants With Adverse Events (AEs),,2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12579,NCT00844623,Adverse Events,Tumor response by WHO criteria,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12580,NCT04843644,oral mucositis,Microbiota,,2021-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12581,NCT00024427,Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer Patients,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12582,NCT05086627,Pathological complete response rate,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2022-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
12583,NCT00482625,Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment,Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2']
12584,NCT02830620,chimiokine MCP1 expression,,,2012-08-01,COMPLETED,INTERVENTIONAL,['NA']
12585,NCT03204994,Number & location of lymph nodes identified with and without fluorescent probe during rectal cancer surgery,Number of lymph nodes lying outside the CRM identified by fluorescence,,2017-08-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12586,NCT05265221,Resection speed,Complication rate,,2022-03-01,COMPLETED,OBSERVATIONAL,['NA']
12587,NCT03568110,90-day mortality,Health-related Quality of life at 12 months (EORTC-QLQ-STO22),,2019-03-05,COMPLETED,OBSERVATIONAL,['NA']
12588,NCT05162898,RFS,2-year OS%,,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12589,NCT03042091,"Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak",Incidence of mortality,,2016-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12590,NCT00006039,,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12591,NCT00906984,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
12592,NCT01580410,"The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments",Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G),,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12593,NCT00020826,psychometric validity of the STO22 module,debriefing questionnaire information,correlation between QLQ-C30 and STO22 scores,2001-04,COMPLETED,OBSERVATIONAL,['NA']
12594,NCT02620228,Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue,,,2016-06-09,COMPLETED,INTERVENTIONAL,['NA']
12595,NCT05245565,Postoperative anal function assessed by Vaizey scale,Overall survival,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
12596,NCT04977882,Tolerance to solid diet,C-Reactive Proteine,,2020-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12597,NCT04323618,Improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for liver cancer patients treated with the AV biofeedback respiratory guidance system.,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
12598,NCT04133324,CRP_D4/CRP_D2 Colorectal,CRP_D2 colorectal,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
12599,NCT04457284,Response,,,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12600,NCT05982899,frailty trajectories,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
12601,NCT00321828,Major Morbidity Related to the Intact Primary Tumor,Overall Survival as Measured by Death From Any Cause,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12602,NCT04166383,Best Overall Response (BOR),6-month Progression-free Survival (PFS),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2020-08-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12603,NCT03563352,The way patients with cancer choose and obtain nutritional supplements to support medical management,Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies,,2018-08-30,WITHDRAWN,OBSERVATIONAL,['NA']
12604,NCT02066688,"The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.",differences in Histological types of CRA OR CRC,"Changes in routine blood count, urine and stool routine test, liver and kidney functions",2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12605,NCT04600154,Change in cachexia staging score from baseline,QLQ-C30 Global health status/QoL,Progression free survival,2021-08-10,RECRUITING,INTERVENTIONAL,['NA']
12606,NCT01850316,One year local progression-free rate,Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
12607,NCT02631564,number of adverse events,Time to progression,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
12608,NCT01525953,Identification of prognostic factors for overall survival,Disease-free survival,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
12609,NCT00066404,,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12610,NCT00103103,Response rate as measured by RECIST every 8 weeks,Molecular correlates on and off study treatment,,2005-03,TERMINATED,INTERVENTIONAL,['PHASE2']
12611,NCT06134024,Rate of safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,Rate of long-term success of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12612,NCT00660153,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) in combination with FOLFOX6 chemotherapy.","To characterize the pharmacokinetic profile of tivozanib (AV-951) and FOLFOX6 chemotherapy when administered together, and to assess the antineoplastic activity of the combination of tivozanib (AV-951) and FOLFOX6 chemotherapy.",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12613,NCT01767675,determine the proportion of patients who are without evidence of disease progression,pharmacokinetics,,2013-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12614,NCT03902899,Proximal serrated polyp detection rate (PSPDR),Adenoma detection rate (ADR),,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
12615,NCT02000180,Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS),"Colonoscopy Specific Performance, Communication Skills, and Global Performance on an Integrated Scenario",,2013-06,COMPLETED,INTERVENTIONAL,['NA']
12616,NCT01420874,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.",Overall Survival,,2011-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
12617,NCT00275119,Progression-free survival,Locoregional and metastatic progression-free survival,,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
12618,NCT00433602,"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)",,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
12619,NCT04397783,parastomal hernia rate by imaging,Ease / difficulty in the management of stomatherapy devices,,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA']
12620,NCT02606097,Overall clinical benefit rate,Overall survival (OS),Changes in vital signs by body temperature,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12621,NCT05552651,Rate of pCR,Rate of MPR,Rate of SAE,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12622,NCT00675636,Identification of patients at high risk of developing hereditary colorectal cancer,Establishment of a tissue and data repository,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
12623,NCT03104439,Disease Control Rate,Median Overall Survival,,2017-05-10,RECRUITING,INTERVENTIONAL,['PHASE2']
12624,NCT02486094,"Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour",Overall Survival (OS),,2015-06,COMPLETED,OBSERVATIONAL,['NA']
12625,NCT00590031,Pathologic Complete Response,Evaluate Toxicity and Tolerability Including Surgical Morbidity and Mortality,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12626,NCT00004142,Patient Tumor Response Rate,,,1998-08-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12627,NCT00952926,Frequency of local recurrence,Overall survival,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
12628,NCT04653389,Event Free Survival（EFS）,Tumor biomarker,,2020-12-26,TERMINATED,INTERVENTIONAL,['PHASE2']
12629,NCT05827796,To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.,Incidence of Treatment-Related AEs,,2022-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12630,NCT01051479,To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).,Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis.,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12631,NCT03519412,Overall response rate (ORR),Safety and Tolerability,,2019-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12632,NCT03634332,Progression Free Survival,Overall Survival,Evaluate Blood Translational Biomarkers--T cell receptor (TCR) sequencing,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12633,NCT01839877,Progression-free survival rate at 9 months,Overall survival,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12634,NCT00294476,"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle",Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle,,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12635,NCT02849106,Number of interpretable chemogram,time to obtain chemogram,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12636,NCT02834052,Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC,Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC,,2018-01-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12637,NCT01060501,overall survival,Toxicity (WHO),,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12638,NCT05841134,Percentage of Participants With Pathological Complete Response (pCR),Incidence of adverse events during the treatment and follow-up (safety),,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12639,NCT02703142,"Number of participants with the major complications of gastric conduit (strictures, leakage, necrosis)",Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
12640,NCT02755311,Overall survival,Mortality,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
12641,NCT04500171,ColoCARE Completion Efficacy,,,2020-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12642,NCT04771988,Response to radioembolization,Progression-free survival,,2013-05-08,COMPLETED,OBSERVATIONAL,['NA']
12643,NCT03043664,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),ORR as Measured by Immune-related Response Criteria (irRC),,2017-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12644,NCT06055387,"Utilize CTCAE v5.0 to assess the grade and frequency of adverse events and treatment-related toxicity in frail and non-frail patient groups, and compare the differences between the two.",To compare overall survival between two distinct groups: frail and non-frail patients.,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
12645,NCT04986085,Risk of malnutrition in GEP NET,Subjective Global Assessment (SGA) rates,,2021-02-24,RECRUITING,OBSERVATIONAL,['NA']
12646,NCT00636298,Progression-free survival,Response rate,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12647,NCT05468138,3 year Disease Free Survival,5 year Overall Survival,,2022-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12648,NCT02304289,"Pharmacokinetic analysis of Cmax, Cmin, Tmax, and AUC.","Quality of life based on the ""Functional Assessment of Cancer Therapy Hep-30 scale"" (FACT-Hep-30)",,2014-11,TERMINATED,INTERVENTIONAL,['PHASE1']
12649,NCT05984602,Number of patients who proceeded to surgical resection,Number of changes in outcome of surgery that is attributed to study drug,,2023-07-14,RECRUITING,INTERVENTIONAL,['PHASE1']
12650,NCT05318794,Feasibility and safety of combined neoadjuvant systemic chemotherapy and pressurised intraperitoneal aerosol chemotherapy (PIPAC),Disease recurrence and survival,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12651,NCT05261542,Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.,,,2017-01-26,COMPLETED,OBSERVATIONAL,['NA']
12652,NCT02539212,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and RFA was done by the log-rank test.",Wilcoxon test was used for comparing liver function between MWA and RFA.,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
12653,NCT03759756,the diagnosis efficiency of the AI model,,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
12654,NCT04734821,Evaluation of the usefulness of ICG fluorescence to guide lymphadenectomy in oncological esogastric resections,Evaluation of the impact of fluorescence guidance in intraoperative evaluation of pre-anastomotic tissue perfusion,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
12655,NCT04486131,Lateral local recurrence,Quality of life as assessed by the QLQ-C30,,2020-10-06,RECRUITING,OBSERVATIONAL,['NA']
12656,NCT01786538,Progression-free survival,Number of participants with adverse events,,2013-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12657,NCT06063941,Visual analogue scale scores at 30 minutes after chromoendoscopy,Associated factors for visual analogue scale scores,,2023-10-10,RECRUITING,INTERVENTIONAL,['NA']
12658,NCT01804166,Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL),,,2013-03-21,COMPLETED,INTERVENTIONAL,['PHASE4']
12659,NCT05056337,Tumor response: Objective response rate (assessed based on mRECIST criteria),Adverse Events as assessed by CTCAE 5.0 criteria,,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12660,NCT06335420,Number and size of polyps found at the one-year follow up colonoscopy,Acceptability of treatment,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12661,NCT02625623,Overall Survival (OS),Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Questionnaire Scores at End of Treatment (EOT),,2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE3']
12662,NCT00280176,Dose-limiting toxicity,Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12663,NCT00149279,overall survival,quality of life,,1995-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12664,NCT00060268,,,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12665,NCT02041819,response rate,Adverse events,,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12666,NCT02199223,Safety of regorafenib + panitumumab,,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
12667,NCT05770102,Durable Clinical Benefit (DCB),Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants.,,2023-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12668,NCT01729923,"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",Relapse Free Survival in Patients Achieving CR,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2']
12669,NCT00778830,Percentage of Subjects With Best Overall Confirmed Response Rate (BORR),"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death",,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12670,NCT06224738,Adverse effects,Overall Survival (OS),,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12671,NCT02018367,The diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRME with directed biopsy,"The diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of HRME for the in-vivo diagnosis of neoplasia.",The clinical impact of HRME on the diagnosis and endoscopic surveillance of BE- associated neoplasia,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
12672,NCT04310553,Overall survival,"clinical benefit rate, CBR",,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
12673,NCT03471468,"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA©Procoag-PPL (Diagnostica Stago, Asnière, France)","Khorana score does assess the risk of thrombosis uner chemotherapy according to 3 levels :Score 0, 1, 2 or 3",,2018-07-23,TERMINATED,INTERVENTIONAL,['NA']
12674,NCT05599347,Anti-drug antibody development,Endoscopic remission,,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2']
12675,NCT03345563,Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale,Consensus Sleep Diary,,2019-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12676,NCT01930630,Number of participants with adverse events,Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI,,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
12677,NCT01423214,Surgical quality based on pathological examination,5-year disease-free survival rate,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
12678,NCT00760604,"Disease free survival defined as the time from surgical resection to the time of recurrent disease, death from esophageal cancer, or death from any cause.",To determine mortality and morbidity in arm A vs. arm B,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE3']
12679,NCT05575635,pCR,TRAEs,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12680,NCT04509635,disease control rate,overall survival,,2020-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
12681,NCT02469480,Rise or normalization of hemoglobin,Overall survival,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12682,NCT04135664,5-year overall survival rate,Quality of life differences (EORTC QLQ-OES18),,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
12683,NCT02732860,Rate of pPDX engraftment,Correlation between pPDX and organoid drug sensitivities,,2015-12,RECRUITING,OBSERVATIONAL,['NA']
12684,NCT00325494,"Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs",Objective Tumor Response Rate Assessed by Investigator,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12685,NCT06305169,Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer,Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12686,NCT04739046,Objective Response Rate,Overall survival,,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12687,NCT00606983,Re-insertion rate of urinary catheter after removal,Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12688,NCT04584775,Change from baseline in FACT-G at week 4,Change from baseline in FAMCARE-2 at week 4 and 8,Overall survival,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
12689,NCT05875584,"Evaluating the sensitivity, specificity, and accuracy of rbcDNA in colorectal cancer screening","Sensitivity of the rbcDNA screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC",,2023-05-18,COMPLETED,OBSERVATIONAL,['NA']
12690,NCT02022852,Disease free survival,Pathologic complete response,Compliance,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12691,NCT03340636,occurrence of severe adverse effects (grades 3-5),,,2018-01,UNKNOWN,OBSERVATIONAL,['NA']
12692,NCT03511183,Time to failure of strategy（TFS）,Time to failure of strategy（TFS）,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12693,NCT02109341,Dose finding safety and activity,Safety profile,,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12694,NCT03702998,Incidence of HCC,Mortality due to HCC or liver-related conditions,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
12695,NCT00160875,pathological complete response,PET scan parameters (radiological),,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12696,NCT04099641,Objective Response Rate (ORR),,,2019-09-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12697,NCT04431791,Time To Treatment Failure,Incidence of adverse events（AEs）,,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
12698,NCT02384811,Local control rate,Safety: Frequencies of treatment-related adverse event categories by NCI-CTC,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
12699,NCT05410197,Objective Response Rate (ORR),Incidence of Adverse Events (AE),,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
12700,NCT01733004,Severity and number of adverse events related to escalating doses of MM-141,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12701,NCT05625529,Clinical performance of ExoVerita™ assay,Stage Shift,,2022-12-19,RECRUITING,OBSERVATIONAL,['NA']
12702,NCT04906044,The incidence of serious adverse events,Wexner score,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12703,NCT01980238,"anastomotic leakage, reoperation and mortality rate",ileus rate,hospital stays and costs,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
12704,NCT01814345,Incidence of Her2 testing in Gastric cancer,,,2013-06,TERMINATED,OBSERVATIONAL,['NA']
12705,NCT04856787,Phase 3:PFS,Duration of response,,2021-06-22,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12706,NCT03323866,Disease specific quality of life questionnaire,Endoscopic evaluation of the nasal cavities,,2017-05-01,TERMINATED,INTERVENTIONAL,['PHASE3']
12707,NCT00341523,esophageal squamous dysplasia and cancer,Death from any cause,,2016-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12708,NCT01126866,surgically complete resectability; S-CR,Survival rate (OS) and progression free survival (PFS),,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2']
12709,NCT05915637,Fatigue Assessment,,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
12710,NCT00712855,"Type, frequency, and severity of adverse events.",,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12711,NCT05649969,Efficacy of STRONG Program on Treatment Outcomes,,,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12712,NCT04913662,Recommended dose,,,2021-04-26,UNKNOWN,INTERVENTIONAL,['PHASE1']
12713,NCT01662869,OS in the Intent-To-Treat (ITT) Population,European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12714,NCT03358849,Maximum Tolerated Dose,,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
12715,NCT00601627,One Year Survival Rate,Time to Treatment Failure,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12716,NCT03068403,Area under the echo-power curve (AUC),mrTNM staging,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA']
12717,NCT03763526,postoperative complications,operative nutrition status,Length of hospital stay,2018-12-20,COMPLETED,OBSERVATIONAL,['NA']
12718,NCT02665702,Progression Free Survival,,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12719,NCT01964235,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,Tolerability of study drug,,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12720,NCT00766220,Progression Free Survival,,,2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12721,NCT02435758,Sexual function,Urinary function,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
12722,NCT00019435,,,,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12723,NCT04741165,Objective Response Rate (ORR),Number of participants with adverse events (AEs),,2021-01-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12724,NCT01308086,Relapse Free Survival,Safety Profil according to NCI-CTAE v 3.0,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
12725,NCT04401800,Overall Response Rate (ORR) as assessed by Central Imaging Facility based on RECIST v1.1,Progression-Free Survival (PFS),,2020-09-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12726,NCT00407407,Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities,"Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug",,2006-11-01,TERMINATED,INTERVENTIONAL,['PHASE1']
12727,NCT02980861,Number of group Splenic Hilum (No.10) lymph nodes harvested,Quality of life,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12728,NCT01531621,Resectability,Radiological assessment,,2012-02,RECRUITING,OBSERVATIONAL,['NA']
12729,NCT00238407,Proportion of patients without local failure measured 6 months after completion of study treatment,Dysphagia as measured 6 months after completion of study treatment,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12730,NCT03686254,"Overall survival (OS), Month","Time to progression (TTP), Month",,2018-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12731,NCT00027768,Recurrence-free survival,Overall survival,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
12732,NCT01857726,Overall survival,Progression-free survival,,2013-07,WITHDRAWN,INTERVENTIONAL,['NA']
12733,NCT03210298,Overall survival,Quality of life according to QLQ-30 of EORTC,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
12734,NCT04229459,Incidence of Treatment-Emergent Adverse Events (Safety),Overall survival (OS),,2019-12-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12735,NCT05984511,Overall survival (OS),Adverse events (AEs),,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12736,NCT00372567,Progression-Free Survival (PFS),Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS) - Imatinib Treatment Arm,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12737,NCT04416685,peri-operative or postoperative complication,hospital stay,in hospital mortality,2014-05-01,COMPLETED,INTERVENTIONAL,['NA']
12738,NCT03694080,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),Cell proliferation as a marker for metastatic ability,,2018-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12739,NCT03484949,Diagnostic rate of patients with early gastric cancer,Characterization of the high-rik individual for gastric cancer,,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
12740,NCT03488446,Pathological lymph node status of every station,Lymph node stage (N stage),,2017-08-30,UNKNOWN,OBSERVATIONAL,['NA']
12741,NCT02188615,Overall survival rate,Mortality of perioperation,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
12742,NCT01898104,number of patients with complete pathological tumor regression,changes in quality of life from baseline,predictive and prognostic factors of tumor and circulating cells,2012-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12743,NCT06276686,withdrawal rate,Physical activity levels,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12744,NCT02607826,Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.,,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12745,NCT01641783,progression free survival,biomarkers,,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12746,NCT05357846,Overall survival,Perioperative mortality,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
12747,NCT04910789,3-year disease-free survival,The incidence of perioperative mortality,,2019-12-11,RECRUITING,INTERVENTIONAL,['NA']
12748,NCT05102110,Correlation of SNP allele frequency in genes associated with known aero-digestive cancers in paired samples of tumour type and rectal mucus.,,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
12749,NCT06034197,Feasibility of VGT-309,,,2023-09-27,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12750,NCT04139070,Incidence of Treatment-Emergent Adverse Events (CTCAE),Tumor volume,,2020-06-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
12751,NCT04428905,Quality of life: survey,,Outcome Measure for facilitators,2020-07-11,RECRUITING,INTERVENTIONAL,['NA']
12752,NCT04890054,Likelihood of any colorectal cancer (CRC) screening (for study-eligible patients),Colonoscopy referral,,2021-05-14,RECRUITING,INTERVENTIONAL,['NA']
12753,NCT03800693,Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale,Frequency of dose holds or reductions,,2019-03-14,RECRUITING,INTERVENTIONAL,['PHASE2']
12754,NCT03981146,Durable Clinical Benefit,Overall Survival Time,,2019-08-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12755,NCT00400114,"To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.",To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy,,2006-09-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12756,NCT04070898,Development of acute urine retention after removal of the bladder catheter after colon surgery.,Morbidity changes,,2019-09-15,UNKNOWN,INTERVENTIONAL,['NA']
12757,NCT00726622,Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on Pathological Evaluation.,Bowel and Stoma Function,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12758,NCT04853784,Incidence of postoperative complications,5-year overall survival OS,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
12759,NCT05059821,Assessment of immunological response,Progression free survival and overall survival time,,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
12760,NCT05620004,"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0.""",Change in tumor volume before and after treatment,,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12761,NCT03648632,Resection rate for all patients starting SBRT,Mortality,,2018-08-22,COMPLETED,INTERVENTIONAL,['NA']
12762,NCT04722341,Patient-reported outcomes (PROs),Sleep,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
12763,NCT03533582,Response rate for Group F patients,,Percentage of participants with adherence to surgical guidelines,2018-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12764,NCT06163729,Pathologic complete response (PCR),R0 resection rate,,2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2']
12765,NCT03485105,overall survival,,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
12766,NCT03592407,Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0,Overall survival (OS),,2018-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12767,NCT05275530,Overall completion of any Colorectal Cancer Screening test,Colorectal cancer screening uptake by modality,,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
12768,NCT04348188,Changes in Health Related Quality of Life: EORTC QLQ-30,Valuation of the measured force,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
12769,NCT02226107,Colonoscopy Completion,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12770,NCT06264921,Objective Response Rate (ORR),Accumulation ratio (AR),,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
12771,NCT00770991,Change in Burden of Rectal Polyps,Apoptosis and Cell Proliferation Measured by Percent Difference in Staining.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12772,NCT04937647,neoplasia detection rate,Endoscopist neoplasia detection rate,,2021-06-16,RECRUITING,OBSERVATIONAL,['NA']
12773,NCT03931044,Accuracy (%; 95% CI),Mean difference of total number of LNs retrieved during the lymphadenectomy of the D2 anatomical plane (mean±DS).,,2019-04,UNKNOWN,INTERVENTIONAL,['NA']
12774,NCT05507112,Pathological complete response (pCR) rates,Patient reported outcome: Functional outcome according to Wexner score,,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12775,NCT01827553,Overall survival,Changes in Quality of life,,2013-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12776,NCT05866172,overall survival,Adverse Events,,2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3']
12777,NCT05497336,Objective response rate (ORR),Number of participants with abnormality in ECG parameters,,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE1']
12778,NCT00717756,Response Rate by Recist Criteria,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12779,NCT00495924,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
12780,NCT01840436,Incidence of grade 2 or higher oral mucositis,Weight curve,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
12781,NCT03484221,The ratio of tumor downstaging to stage 0 and stage I,Quality of life (QLQ C30),,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12782,NCT00022477,Response rate of BMS-247550 in colon cancer,,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12783,NCT06084481,Objective Response Rate (ORR),Neutralizing Antidrug Antibody (nADA),,2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE1']
12784,NCT01938300,Change of MCF of EXTEM,Change of Fibrinogen,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
12785,NCT02945566,Phase III Primary Outcome: Organ Preservation,Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret,,2017-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12786,NCT02084524,Perioperative nutritional management,Evolution of the activities of daily living,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
12787,NCT03572283,Change in cell proliferation by Ki-67 expression in tumor cells,Number of Adverse Events,,2018-04-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12788,NCT01195415,Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS,Percentage of Treated Patients Experiencing Grade 3+ Toxicity Per National Cancer Institute Common Toxicity Criteria (CTC) Version 3.0,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12789,NCT03351959,Overall Survival,Molecular Profile of N+,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12790,NCT03465501,Evaluation of the tolerance of interstitial brachytherapy of the anal canal,Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups,,2007-08-17,COMPLETED,OBSERVATIONAL,['NA']
12791,NCT04651634,Incidence of severe OM,Analgesic use for OM,,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2']
12792,NCT04763707,serum Visfatin & serum Vaspin levels,,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
12793,NCT00220142,,,,2003-11,COMPLETED,OBSERVATIONAL,['NA']
12794,NCT04773626,Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.,,,2021-06,UNKNOWN,OBSERVATIONAL,['NA']
12795,NCT02988440,Dose intensity,Area Under the Plasma Concentration-time Profile (AUCtau) of sorafenib,,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
12796,NCT00002947,,,,1996-10,TERMINATED,INTERVENTIONAL,['PHASE1']
12797,NCT00003548,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12798,NCT04598984,The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer,,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
12799,NCT00247676,Objective Response (CR or PR),Plasma Concentration of Soluble KIT (sKIT),,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12800,NCT00493883,Survival time,,,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12801,NCT00581724,Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
12802,NCT05475301,Overall survival of patients with locally recurrent rectal cancer,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
12803,NCT02596256,Progression free survival,,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12804,NCT01847495,Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan,Overall survival,,2013-10,WITHDRAWN,INTERVENTIONAL,['NA']
12805,NCT02608879,Oral Mucositis Severity - NCI Scale,Change in Quality of Life as Measured by the Composite Score of the EORTC,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
12806,NCT01718626,Progression-free survival(PFS),Overall survival(OS),,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
12807,NCT03948100,Patient 6-minute walk test (6MWT),Patient and caregiver quality of life (QOL),,2018-12-20,RECRUITING,INTERVENTIONAL,['NA']
12808,NCT02280694,The median progression free survival (mPFS),,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12809,NCT00405587,Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation,"Tumor Levels of Phosphorylated Extracellular Signal-Regulated Kinapse (ERK), Cyclin D1, and Ki-67",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12810,NCT01967875,Progression-Free Survival (PFS),Quality of Life(QOL),,2013-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12811,NCT02443324,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE1']
12812,NCT05225116,Number of patients who complete pre-op treatment and proceed to surgery,Recurrence free survival(RFS),,2023-01-08,RECRUITING,INTERVENTIONAL,['PHASE1']
12813,NCT01350648,Progression of liver disease in patients with HBV,,,2011-08-23,COMPLETED,OBSERVATIONAL,['NA']
12814,NCT02683824,Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq),,,2016-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12815,NCT02298010,Topographic pattern of metastasis to regional lymph node stations,recurrence pattern,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
12816,NCT04997850,Conversion resection rate,OS,,2020-05-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12817,NCT03749005,Impact on operation strategy of three dimensional visualization technique,1-year disease free survival rate,,2017-04-18,UNKNOWN,OBSERVATIONAL,['NA']
12818,NCT00646022,Study the natural history of familial carcinoid tumors,Screen for occult disease and determine whether early detection affects the natural history of the disease,,2008-08-25,RECRUITING,OBSERVATIONAL,['NA']
12819,NCT00623831,"Number of Participants With Pyrogenicity at Each Dose Level Tested in the Intrasubject Dose Escalation Performed Over a Dose Range of 250 to 547,000 EU",Number of Participants With Best Overall Tumor Response,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12820,NCT05456165,Incidence and Severity of Adverse Events,T-cell response using Peripheral Blood Mononuclear Cells (PBMCs),,2022-05-19,TERMINATED,INTERVENTIONAL,['PHASE2']
12821,NCT04115618,Toxicity Effect,OS,,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12822,NCT00003057,,,,1997-03-26,COMPLETED,INTERVENTIONAL,['PHASE3']
12823,NCT04658147,Number of patients who complete pre-op treatment and proceed to surgery,Disease free survival (DFS) at 5 years,,2021-05-28,RECRUITING,INTERVENTIONAL,['PHASE1']
12824,NCT05506696,25OHD level,,,2012-09-24,COMPLETED,INTERVENTIONAL,['NA']
12825,NCT06152289,Develop an artificial intelligence solution to help with diagnosis in VCE,Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract,,2023-02-10,RECRUITING,OBSERVATIONAL,['NA']
12826,NCT04907539,RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1,Number of patients with adverse events (AEs),,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12827,NCT05498168,The ratio of predicted neoantigens being immunogenic,,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12828,NCT01065805,Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.,"Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course",,2009-03-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12829,NCT05035108,The incidence of adverse events (safety and tolerability).,Electrolyte level,,2020-11-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12830,NCT04615312,To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy,ORR,,2020-11-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
12831,NCT00209716,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.,,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12832,NCT05115916,Overall Colorectal Cancer Screening Uptake,Effect of electronic primer message on CRC uptake among participants who opened,,2019-08-28,COMPLETED,INTERVENTIONAL,['NA']
12833,NCT04338685,Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0,Overall Survival (OS),,2020-07-16,COMPLETED,INTERVENTIONAL,['PHASE1']
12834,NCT05664906,Comparison of the proportion of the most severe modified WHO Mucositis Grades,Number of analgesic and antibiotics use daily,,2023-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12835,NCT02647047,Assessment of postoperative pain control by mean of the visual analog scale at hospital discharge,Ready to discharge status,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
12836,NCT01952353,overall survival time,Number of Adverse Events,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12837,NCT05579340,Change in peak oxygen consumption (VO2peak),Postoperative complications,,2023-04,RECRUITING,INTERVENTIONAL,['NA']
12838,NCT05703555,intratumoral DM4 concentration,features in tumor micro-environment,,2024-02-16,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12839,NCT03238820,Complications,Body composition,,2014-01-10,COMPLETED,INTERVENTIONAL,['NA']
12840,NCT00044343,Tumor response rate (complete or partial).,Time to response duration of response time to progression 4-month progression-free survival 6-month progression-free survival overall survival safety data biomarkers,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12841,NCT05631015,The accuracy of recommentions for different disease with deep learning algorithm,The F-score of gastric diseases with deep learning algorithm,,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12842,NCT01608464,Pathological Complete Response ( regression score 1a- see response assessment) in each treatment group,Rate of conversion from PET non responder to responder with each type of salvage therapy,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2']
12843,NCT04439812,evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC,The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
12844,NCT01417494,"Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy",Survival with no deterioration of autonomy,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12845,NCT00752570,To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.,"To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12846,NCT03286920,Percentage of 5% body weight loss on Day 30,Re-hospitalization ratio,,2017-09-20,UNKNOWN,OBSERVATIONAL,['NA']
12847,NCT03455595,Evaluation of the CONECCT endoscopic score so as to improve colon therapeutic treatment polyps,,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
12848,NCT04889456,30-day morbidity with Clavien-Dindo grading,"Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions",,2021-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12849,NCT05051592,Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA,Adverse reactions experience by patient,,2021-03-26,UNKNOWN,OBSERVATIONAL,['NA']
12850,NCT00335595,Determine the free time to disease progression,Prognostic factor of the K-Ras gene mutation,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12851,NCT02929082,Tumoral environment invasion assessed by the presence of microvascular invasion of the tumor capsule after pathological examination of the surgical pieces,Interstitial force and traction force at the cell/tumor interface assessed by FRM,,2018-01-23,COMPLETED,INTERVENTIONAL,['NA']
12852,NCT02576080,Rate of metastatic relapse in GIST patient,Patients' quality of life,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
12853,NCT03674073,Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.,Progression-free survival at 2 years,,2018-10-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
12854,NCT01586117,Acute radiation-induced toxicity: daily diarrhea frequency,,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
12855,NCT03992456,Overall survival (OS),Patient-reported quality of life,Tumor tissue studies,2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12856,NCT03867916,Rate of Participation,Patient Acceptability,,2018-12-13,COMPLETED,INTERVENTIONAL,['NA']
12857,NCT00243633,Medical and economic interest of CEUS,Harmony inter-readers,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
12858,NCT03051464,TME-free survival,Overall Quality of life,,2017-04-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12859,NCT01510561,Safety (change in hematology and chemistry laboratory values from baseline),Efficacy,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12860,NCT00338039,Median Overall Survival,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12861,NCT02117895,Overall survival,"Disease-specific, recurrence-free survival",Pain Control,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12862,NCT01041404,Overall Survival - Time to Event,Trastuzumab Maximum Serum Concentration (Cmax),,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12863,NCT04190121,infective complications,length of stay in the ICU,patient's serum albumin changes,2019-03-26,UNKNOWN,INTERVENTIONAL,['NA']
12864,NCT05573217,Evaluate efficacy,,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
12865,NCT01918852,Incidence of HFS in first line treatment,Response rate,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12866,NCT00068068,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12867,NCT02339116,Progression Free Survival 2 (PFS2),Toxicity Rate,,2015-02-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
12868,NCT01626963,Operative Time,CRP,,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12869,NCT01655641,Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.,Secondary outcome measure,,2012-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12870,NCT01789723,Optimal dose and schedule of Fusilev to prevent or reduce mucositis,Relationship between Fusilev use and oral mucositis,Overall Response Rate (ORR),2013-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12871,NCT04617067,Overall survival (OS),Tumour response rate Duration of response,Incidence of hypercalcaemia,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
12872,NCT04913896,Predictive value of CT and MRI after the neoadjuvant treatment for developing a pCR at surgery,Prediction model based on CT and MRI of response in AGC,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
12873,NCT03078348,Rate of Fecal Immunochemical Test (FIT) Kit Return Per Study Arm,Rate of Diagnostic Colonoscopy,,2011-12-05,COMPLETED,INTERVENTIONAL,['NA']
12874,NCT04936399,Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS,,,2020-06-25,COMPLETED,OBSERVATIONAL,['NA']
12875,NCT00178698,Survival,Quality of Life,,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12876,NCT04391426,Composition of the biliary microbiota,,,2021-06-03,UNKNOWN,OBSERVATIONAL,['NA']
12877,NCT03556345,Objective Response Rate （ORR）,Overall Survival(OS),,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12878,NCT05883644,Objective response rate (ORR),Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18,,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE3']
12879,NCT05481463,Progression-Free Survival (PFS),adverse events (AE),,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2']
12880,NCT01859442,Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.,Alterations in mitochondrial energetics post-chemoradiotherapy and exercise,,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12881,NCT05356039,Resection,Quality of Life at 24 months after inclusion,,2022-04-19,RECRUITING,OBSERVATIONAL,['NA']
12882,NCT04415567,Disease-free survival (DFS),Overall survival (OS),3-year Recurrence rate (RR),2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
12883,NCT06078787,To evaluate the ORR according to RECIST 1.1 following Olaparib administration,To evaluate the OS according to RECIST 1.1 following Olaparib,,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12884,NCT04423354,Perioperative mortality,5-year disease-free survival rate,,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA']
12885,NCT04743479,Hazard ratio (HR),Diagnostic yield,,2020-12-01,RECRUITING,OBSERVATIONAL,['NA']
12886,NCT03219372,Time to Recurrence,Levels of Liver Tissue Markers Related to HCC,,2018-09-27,TERMINATED,INTERVENTIONAL,['PHASE2']
12887,NCT04400383,Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period,Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1),,2020-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12888,NCT05078866,Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II),Mismatch repair and/or microsatellite instability status of polyps (and adjacent normal mucosa as control),,2022-11-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12889,NCT01443377,Histopathological complete response rate (pCR),overall survival,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12890,NCT00025090,Recurrence-free survival,Cause-specific and overall survival,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12891,NCT05379205,Post-surgery complications.,Fecal microbiota analysis,,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12892,NCT03273231,natural killer cell cytotoxicity,metastasis,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
12893,NCT00030563,,,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12894,NCT05470738,"The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.","The secondary objective of the study is to know, in patients operated for pancreatic adenocarcinoma, the rate of postoperative complications, the rate of the postoperative morbidity and mortality, and the quality of the resection.",,2022-09-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12895,NCT03150628,Mortality,Readmissions,,2017-08-01,TERMINATED,INTERVENTIONAL,['PHASE2']
12896,NCT01300858,Tumor Growth Assessment by X-ray/CT,Number of study subjects with adverse events,,2011-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12897,NCT00004150,,,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12898,NCT01375699,The difference in left ventricular ejection fraction (LVEF) between arms,Comparison of candidate early markers of cardiac injury,,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12899,NCT02652702,colostomy associated complications,,,2016-12,TERMINATED,INTERVENTIONAL,['PHASE2']
12900,NCT06190730,SASSI,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12901,NCT03943173,Feasibility of olaparib,Symptom burden and health status,,2019-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12902,NCT03041662,death,biliary dysplasia,,2011-10-31,COMPLETED,OBSERVATIONAL,['NA']
12903,NCT00054951,,,,2001-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12904,NCT04526886,Unplanned chemotherapy treatment delay,Out of pocket costs associated with chemotherapy treatment visits,,2020-10-15,COMPLETED,INTERVENTIONAL,['NA']
12905,NCT02146313,Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs),Progression-free Survival (PFS) as Assessed by RECIST v1.1,,2014-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
12906,NCT00792285,colorectal cancer screening,colonoscopy screening,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
12907,NCT01719380,Phase 2: Progression Free Survival (PFS),Phase 2: Number of Participants With Any Variant in Gene Status at Baseline,,2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
12908,NCT03413605,Colorectal Cancer Screening Rate,,,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
12909,NCT06092112,The objective response rate based on mRECIST,Overall Survival,The impact of CD-801 treatment on immune cell profiling in serum after treatment.,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
12910,NCT04714983,Maximum tolerated dose (MTD) achieved during dose-escalation phase,Measure Immune response with ELISPOT,,2021-02-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
12911,NCT02906943,Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions,Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables,,2016-08,RECRUITING,OBSERVATIONAL,['NA']
12912,NCT04566848,Immune Checkpoints,,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
12913,NCT03008512,Progression-free survival rate at 6 months,Adverse events,,2016-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12914,NCT01075399,Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12915,NCT04094688,Progression-free survival (PFS),Prognostic effect of highest achieved 25(OH)D,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12916,NCT02457299,The number of participants with gastric conduit failures as a measure of safety and tolerability in the one-stage esophagectomy as compared with the two-stage esophagectomy.,Quality of Life (QOL) scores of patients in both arms,,2015-05,TERMINATED,INTERVENTIONAL,['NA']
12917,NCT02644408,Quality of Life (QoF),adverse events,,2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12918,NCT00526669,Percentage of Participants (Par.) With 5-month Progression-free Survival (PFS),"Number of Participants With Change From Baseline (Measured as AGI, ItoG3, and ItoG4) in Toxicity Grades for White Blood Cell (WBC) Count at the Indicated Time Points",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12919,NCT03120572,Change of forced vital capacity (FVC),Change of dyspnea,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
12920,NCT00691691,Response rate to SBRT,Treatment Related Toxicity,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
12921,NCT00874406,progression free survival,overall survival,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12922,NCT03487484,Change in quality of life specific for the gastrointestinal tract,Change in faecal Incontinence,,2018-03-22,TERMINATED,OBSERVATIONAL,['NA']
12923,NCT05513144,The sensitivity and specificity of ctDNA detection. Profiling of the most frequently detected gene mutations and level of mutations in ctDNA,Relative frequency of targetable mutations (incl. TMB and MSI status).,,2021-12-24,RECRUITING,OBSERVATIONAL,['NA']
12924,NCT03777657,Overall Survival (OS),time to response (TTR),,2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12925,NCT00593866,The Maximum Tolerated Radiation Dose,The Percentage of Participants Free From Local Progression at 2 Years,,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12926,NCT04161755,Drug related toxicity,,,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12927,NCT00059618,Maximum Tolerated Dose (MTD) of Bortezomib with Carboplatin Chemotherapy,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12928,NCT06159634,Dissection speed,Abdominal pain,,2023-12-05,RECRUITING,INTERVENTIONAL,['NA']
12929,NCT05909410,Perception about the impact of CHCs on favoring/contrasting specific symptoms onset,,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12930,NCT01238094,Progression free survival,,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12931,NCT05686226,Tumor response,Adverse Events,,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2']
12932,NCT06028516,ctDNA positive patients are detedcted before PET-CT,,,2021-01-06,RECRUITING,OBSERVATIONAL,['NA']
12933,NCT02843750,Postoperative Pneumonia,Postoperative Pulmonary Complications,Quality of Life,2016-06,WITHDRAWN,INTERVENTIONAL,['NA']
12934,NCT03563651,"Detection rates of Kras, Braf, or PI3K tumor DNA extracted from urine in patients without pre-existing mutations",,,2014-02-06,COMPLETED,OBSERVATIONAL,['NA']
12935,NCT03841201,"Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)",Translational research,,2019-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12936,NCT03458689,"Use of analgesics - ""change"" is being assessed","Sedation scores - ""change"" is being assessed",,2018-02-28,UNKNOWN,INTERVENTIONAL,['NA']
12937,NCT06056908,"Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.",,,2016-01-19,RECRUITING,OBSERVATIONAL,['NA']
12938,NCT00185588,Time-to-Treatment Failure (Intent-To-Treat Analysis),"Time-to-Progression, Evaluable Patients",,2004-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12939,NCT01486329,Safety and tolerability,Tumor perfusion,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12940,NCT02513199,Number of Participants With Objective Response Rate,Change in Child-Turcotte-Pugh (CTP) Score,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12941,NCT01642953,Drop rate from critical pathway,Recovery after surgery,,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
12942,NCT03015038,Immune cells trafficking,"Safety (Number of adverse events, ECOG status)",,2017-02-05,UNKNOWN,OBSERVATIONAL,['NA']
12943,NCT02509507,Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE),,,2016-02-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12944,NCT02952989,Incidence of dose-limiting toxicities (DLTs),Overall survival,,2017-02-23,TERMINATED,INTERVENTIONAL,['PHASE1']
12945,NCT04456933,Percentage of anastomotic leak (AL),Rate of Re-interventions,,2020-06-29,UNKNOWN,OBSERVATIONAL,['NA']
12946,NCT04587128,Cohort B Progression Free Survival (PFS),Overall Survival (OS),Circulating Tumor DNA (ctDNA) at time of Progression,2020-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
12947,NCT02730546,Pathological Complete Response (PathCR) Rate,Incidence of Dose-limiting Toxicities (DLTs) Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0,,2016-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12948,NCT03476122,Detection of circulating tumor cells,,,2018-03-15,UNKNOWN,OBSERVATIONAL,['NA']
12949,NCT01860742,Progression Free Survival (PFS),"Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment",,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12950,NCT00190801,Response rate according to RECIST criteria,The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12951,NCT03074461,Stool frequency,Antimotility drug usage,,2017-04-05,UNKNOWN,INTERVENTIONAL,['NA']
12952,NCT02541461,Change in body composition (changes in lean tissue mass and fatty tissue mass Using DEXA machine produced by Hologic),Changes in lipid profile,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12953,NCT05964530,Overall disease-free survival,Overall survival,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
12954,NCT02085031,Anastomosis-related early complication rate,Postoperative quality of life,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12955,NCT03291938,Maximum tolerated dose,Duration of response,Pharmacodynamic and predictive biomarkers of activity of IACS-010759,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
12956,NCT04665921,Incidence of dose limiting toxicities,Incidence of antidrug antibodies (ADA),,2021-01-18,TERMINATED,INTERVENTIONAL,['PHASE1']
12957,NCT00827723,concordance rate between ICGR-15 and Portal Pressure values in patients with resectable HCC and cirrhosis Child A from alcoholic and non-alcoholic origin.,postoperative liver failure.,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12958,NCT04520906,Complete tumor ablation rate,Complete ablation rate of lesions,,2020-12-17,UNKNOWN,INTERVENTIONAL,['NA']
12959,NCT05933980,ORR,DoR,,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2']
12960,NCT06102772,Progression Free Survival,Overall survival,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
12961,NCT05664607,Harris Benedict Equation,,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12962,NCT04492215,Rate of organised colorectal cancer screening at 24 months,Identification of denial of the colorectal cancer screening,,2021-05-31,RECRUITING,INTERVENTIONAL,['NA']
12963,NCT05947201,pathologic complete response (pCR) of the patients' resected tumors,R0 resection rate,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12964,NCT02291744,"TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)",,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
12965,NCT03247231,Removal of the subepithelial tumour (initial clinical success).,Long-term recurrence.,,2017-03-31,TERMINATED,OBSERVATIONAL,['NA']
12966,NCT02988921,Evaluation of tumor heterogeneity with IBEX software,Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation,,2016-10,RECRUITING,INTERVENTIONAL,['NA']
12967,NCT02403531,overall response rate (clinical complete response and partial response),Progression-free survival,,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12968,NCT02240771,Survival rate-,Tumor response,,2006-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12969,NCT02545556,Number of participants with Adverse events,Overall survival (OS),,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12970,NCT03250091,Risk stratification,"Gastric, faecal microbiome in cancer patients and patients with precancerous lesions",,2017-06-19,RECRUITING,OBSERVATIONAL,['NA']
12971,NCT06065891,Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection,To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?,,2023-09-05,RECRUITING,INTERVENTIONAL,['NA']
12972,NCT01681472,Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue,Number of AEs Per Severity,,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12973,NCT04984174,"age, sex, types of institutions and chemotherapy regimens",,,2021-08-04,RECRUITING,OBSERVATIONAL,['NA']
12974,NCT05485974,"adverse events (AEs), and serious adverse events (SAEs) overall",Pharmacokinetic variables including volume of distribution,,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
12975,NCT05596435,Area under curve of the model for detecting stage I/II/III pancreatic cancer,Specificity of the early detection model,,2022-10-10,RECRUITING,OBSERVATIONAL,['NA']
12976,NCT03699657,Minimum diameter of ablative zone,2-year LTP,Maximal diameter of ablative zone,2014-12-15,COMPLETED,INTERVENTIONAL,['NA']
12977,NCT05707598,Hospital stay after surgery,Disease-free survival,,2023-01-01,COMPLETED,OBSERVATIONAL,['NA']
12978,NCT02038283,Direct Health Care Costs for each CRC screening strategy,Factors Associated with HRQOL,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
12979,NCT00470340,Survival without recurrence at 2 years,Morbidity and mortality following adjuvant treatment,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12980,NCT02583087,Rate of histologically complete (R0) resection of esophageal adenocarcinoma or high grade dysplasia,rate of buried glands,,2016-01-02,UNKNOWN,OBSERVATIONAL,['NA']
12981,NCT00316862,Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery,Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12982,NCT03176680,Postoperative complications,Inflammatory markers,,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA']
12983,NCT05107661,: Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,,2021-09-26,TERMINATED,OBSERVATIONAL,['NA']
12984,NCT05963776,pulmonary complications of liver cirrhosior or HCC,,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12985,NCT00273312,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),Overall survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12986,NCT04053725,the proportions of patients with positive serum ctDNA that have postoperative relapse,The proportion of ctDNA content decreased in patients with good therapeutic effect,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
12987,NCT05551039,Proportion of patients with reasons for discontinuation,Descriptive summary of Pre-existing comorbidities,,2022-08-15,COMPLETED,OBSERVATIONAL,['NA']
12988,NCT05759858,Disease-free survival,"The incidence and mortality of postoperative hemorrhage, bile leakage and other complications.",,2022-12-14,RECRUITING,OBSERVATIONAL,['NA']
12989,NCT04617457,Overall survival after R0/R1 resection (OS-res),QoL-adjusted OS,,2021-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
12990,NCT00577031,PFS: Time to Event,European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12991,NCT03997162,Rate and type of post-operative complications,QoL after stomach cancer surgery,Overall survival of enrolled patients,2018-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12992,NCT05547529,Disease-free survival,R0 resection rate,,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE3']
12993,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
12994,NCT00562666,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction","Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria.",,2008-02,TERMINATED,INTERVENTIONAL,['PHASE1']
12995,NCT05170438,Overall response rate,Progression-free survival (PFS),,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12996,NCT02798224,CRC Screening use,,,2017-06-14,COMPLETED,INTERVENTIONAL,['NA']
12997,NCT03637647,Fitness,Sarcopenia defined by skeletal muscle radiation attenuation,,2012-06-01,COMPLETED,OBSERVATIONAL,['NA']
12998,NCT01919242,the type of complications and the incidence of it,,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
12999,NCT01361061,development of HCC,"comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between different etiologies",,2010-06,COMPLETED,OBSERVATIONAL,['NA']
13000,NCT04751149,to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.,Incidence of postoperative complications,,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
13001,NCT05836870,Safety and adverse events (AEs),,,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE3']
13002,NCT01883297,Number of occurrences and severity of side effects,Number of patients with an immunity and no immunity to the study treatment,,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13003,NCT02240433,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),"The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)",,2014-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13004,NCT05573035,Determine recommended Phase 2 Dose Range (RP2DR),Overall survival (OS),,2022-12-19,RECRUITING,INTERVENTIONAL,['PHASE1']
13005,NCT00826579,To assess the extent of upstaging due to the SLN procedure for colon cancer.,To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.,,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13006,NCT03265743,Realization of human papillomavirus vaccination,Reasons for non-vaccination,,2017-09-25,COMPLETED,OBSERVATIONAL,['NA']
13007,NCT03947840,Rate of immunological response,Rate of recovery in physical activity,,2019-01-30,COMPLETED,OBSERVATIONAL,['NA']
13008,NCT02725424,major Pathological response rate,,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13009,NCT04639180,"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)",The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13010,NCT02858778,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,Time to consultation in Ig vs. Cg groups,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
13011,NCT05910099,Rate of patients who remain in a rectal cancer clinical study to completion,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13012,NCT05802420,Progression-free survival,Overall survival,The prognostic role of targeted therapy selected based on MRD,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
13013,NCT00098527,Radiographic response rate (complete response & partial response),Change in plasma and urine TGFB levels,,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2']
13014,NCT05380557,Overall survival,,,2021-08-23,TERMINATED,OBSERVATIONAL,['NA']
13015,NCT00003365,,,,1996-08,TERMINATED,INTERVENTIONAL,['NA']
13016,NCT03052478,Objective response rate (ORR) by RECIST 1.1,,,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13017,NCT03851133,Presence of Visceral Adiposity,Progression Free Survival,,2019-03-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13018,NCT05066048,Species composition of fecal microbial,age in year,,2021-04-30,UNKNOWN,OBSERVATIONAL,['NA']
13019,NCT01628458,Safety,Chemotherapy,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13020,NCT03605186,"Change in ""patient-reported oral mucositis"".","Change in ""Clinical assessment of oral mucositis"".",,2019-02,UNKNOWN,INTERVENTIONAL,['NA']
13021,NCT02391662,Efficacy of treatment through 3-months deterioration free rate,CA 19.9 biomarker response,,2015-06-23,COMPLETED,INTERVENTIONAL,['PHASE2']
13022,NCT04181333,The incidence of adverse drug reactions in this surveillance,Assessment of tumor response: Assess the tumor response according to RECIST Ver. 1.1.,,2023-08-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13023,NCT02350400,Establish safety and toxicity profile of the irinotecan loaded DEBIRI beads (number of patients with adverse events according to Health Science Authority's Safety Reporting for Clinical Trials),Tumour response (measured by mRECIST),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13024,NCT05853172,R0 surgical conversion rate,Adverse event (AE),,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2']
13025,NCT03418922,Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event,Part 1 and Part 2: Serum Concentration of Nivolumab,,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13026,NCT04316013,Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine,Health utility with intravenous lidocaine versus no lidocaine,MINS Substudy,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE3']
13027,NCT01170754,Boston Prep Scale,Phosphorus Level in mg/dl,Boston Prep Scale (Per Protocol Analysis),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13028,NCT00055822,,,,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13029,NCT01320241,Overall Mean Survival and Median Survival,"Number of Participants with Adverse Events as a Measure of Technical Success, Clinical Success, Safety (including WBC and Immunological changes of lab, Leakage of the radioactive seeds and Complications related to the procedure.",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13030,NCT05865132,ORR,OS,,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2']
13031,NCT01008657,2 years global (local+distant) recurrence rate,Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly),,2010-02-09,COMPLETED,INTERVENTIONAL,['NA']
13032,NCT03047226,Pathogenic germline mutation,Variant of uncertain significance of germline mutation,,2017-02-28,COMPLETED,OBSERVATIONAL,['NA']
13033,NCT04847167,Enteroscopy success rate,Therapeutic success rate,,2020-02-24,COMPLETED,INTERVENTIONAL,['NA']
13034,NCT04960943,Objective Response Rate (ORR),Progression Free Survival (PFS),Safety and Tolerability,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13035,NCT03336229,Change in cardiorespiratory fitness,Survival,Feasibility of home-based exercise,2018-04,UNKNOWN,INTERVENTIONAL,['NA']
13036,NCT04025840,2-year overall survival,2-year progression-free survival,Time to oral intake after surgery.,2019-09-11,RECRUITING,INTERVENTIONAL,['PHASE4']
13037,NCT02931825,Comparison of the performed colonoscopy rate within 12 months following randomization / send letter in the 2 arms,,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
13038,NCT01924897,postoperative morbidity,Admission to HDU/ITU,Feasibility outcomes for exercise training,na,UNKNOWN,INTERVENTIONAL,['NA']
13039,NCT04838327,Feasibility and translational analysis,Quality of Life by EORTC QLQ-C30,,2021-08-16,RECRUITING,OBSERVATIONAL,['NA']
13040,NCT01254591,"Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)",,,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
13041,NCT00687830,"Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a Better Outcome.","Patient Satisfaction in the Two Groups, All Morning Prep vs. All Evening Bowel Prep.",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13042,NCT03742596,The Level of C-reactive protein (CRP),The gastrointestinal toxicity,The level of neutrophils,2018-11-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13043,NCT02685046,Effects of treatment on the mesenchymal gene expression profile,Number of participants with treatment-related adverse events as assessed by CTCAEv4.02,,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2']
13044,NCT02395471,Number of Participants With Adequate Cytosponge™ Sample,Ongoing Safety Measures,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
13045,NCT02419586,Time to first flatus,Length of stay,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
13046,NCT00005833,Confirmed complete and partial response rate to R115777,Frequency & severity of toxicities,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13047,NCT02072356,Adverse experiences,,,2010-10-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13048,NCT03507699,Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0,Progression free survival,,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE1']
13049,NCT00098787,Objective Response Rate,Overall Survival (OS),,2005-09-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13050,NCT00024362,,,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
13051,NCT02355119,Disease free survival (DFS),Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
13052,NCT03236636,Overall survival (OS),Assessment on Quality of life 2,"Genome level (DNA, mRNA, miRNA) biomarker analysis",2017-09-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
13053,NCT06016855,Gene mutations,,,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE4']
13054,NCT02277548,Average/Cumulative Opioid Dose,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
13055,NCT02909452,Changes from baseline in ECG results,Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab,Best overall tumor response,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE1']
13056,NCT06055439,Objective Response Rate (ORR),Overall survival (OS),,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13057,NCT02210364,Recommended dose of PM01183 in combination with capecitabine,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13058,NCT05589597,Safety and tolerability of EO4010 in combination with nivolumab,Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up,,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13059,NCT00278694,Number of patients obtaining pCR,"Clinical, radiological and molecular response to treatment",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13060,NCT02817685,The incidence of Hepatocellular carcinoma,,,2016-05,UNKNOWN,OBSERVATIONAL,['NA']
13061,NCT00537823,All-cause Mortality,Change in Tumor Size From Pretreatment to Preoperative CT Scan,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2']
13062,NCT02416635,The number of Circulating Tumor Cells (CTCs),,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
13063,NCT04188158,Disease-free survival (SLE) at 2 years,To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment,,2017-03-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13064,NCT01340105,Complete ablation rate,Hospital stay,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13065,NCT02967523,Objective tumor response,Changes in alpha-fetoprotein (AFP) blood levels,,2016-05,TERMINATED,OBSERVATIONAL,['NA']
13066,NCT01294358,MTD (Maximum Tolerated Dose),Number of Participants With Serious and Non-Serious Adverse Events,,2011-01-26,COMPLETED,INTERVENTIONAL,['PHASE1']
13067,NCT03253133,Maximum tolerated dose,Area Under the Curve (AUC),,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13068,NCT01387503,For Phase III - Overall Survival,Validation of the Metroticket model for the prognosis of survival after liver transplantation in patients exceeding Milan Criteria,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
13069,NCT02827565,"Technical Optimization of KRAS, BRAF and NRAS mutations detection","KRAS, NRAS et BRAF mutational status",,2016-02-03,COMPLETED,INTERVENTIONAL,['NA']
13070,NCT05855278,Overall survival,,,2019-08-13,COMPLETED,INTERVENTIONAL,['NA']
13071,NCT04879927,Rate of Treatment Interruption,,,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
13072,NCT03329690,Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set),Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set),,2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13073,NCT01668134,Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.,Measure the response rates associated with using SBRT in patients with resectable HCC and IHC,,2009-12-16,COMPLETED,INTERVENTIONAL,['PHASE1']
13074,NCT04430725,Time to local recurrence per treated nodule,Changes in patient reported outcomes per patient,,2019-08-07,RECRUITING,OBSERVATIONAL,['NA']
13075,NCT00216424,Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).,,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4']
13076,NCT02649647,Incidence of major bowel dysfunction,Quality of life impairment,Postoperative hospital stay by days,2016-02,RECRUITING,INTERVENTIONAL,['NA']
13077,NCT02705118,Registration accuracy,Registration time,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
13078,NCT03598231,Proportion of Responders of Low Anterior Resection Syndrome,Urinary function,,2018-05-25,COMPLETED,INTERVENTIONAL,['NA']
13079,NCT05075421,5-year survival rates,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
13080,NCT00178243,,,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13081,NCT03256084,Evaluation of CTC features,,,2017-07-17,RECRUITING,INTERVENTIONAL,['NA']
13082,NCT05859750,The number of subjects experiencing adverse events (AEs),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13083,NCT04848311,number of harvested station 253 lymph nodes,number of total lymph nodes harvested,complications,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
13084,NCT05385809,Surgical conversion rate,adverse event (AEs),,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
13085,NCT05007587,Objective Response Rate and Disease Control Rate of the HCC Participants,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,Hepatitis B infection,2021-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13086,NCT02441153,Disease-free survival,,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
13087,NCT05878405,Change in oral pain,Change in the amount of daily requirements of oral morphine equivalents,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
13088,NCT03908840,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial,Determination of Maximum Tolerated Dose,,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
13089,NCT00265720,"Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.","Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:",,2003-03,COMPLETED,INTERVENTIONAL,['NA']
13090,NCT00113776,Incidence of HAHA formation,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
13091,NCT00003600,Quality of life,Response rate,,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13092,NCT03396926,Overall response rate (ORR) (Expansion Cohort),Progression-free survival (PFS) (Expansion Cohort),,2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE2']
13093,NCT03054987,Rates of death attributable to the procedure.,Reintervention,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
13094,NCT00911391,Post-operative functional recovery,Perioperative Complications,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13095,NCT02447263,Number of participants with Adverse events,Overall survival (OS),,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13096,NCT06269445,Progression-free survival(PFS),Quality of life of the patients,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13097,NCT03814629,Clinical symptom score is assessing a change,kidney function test,,2015-08-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13098,NCT02338752,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,immunology index,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13099,NCT00154726,Response rate,overall survival,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13100,NCT01322815,Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients),,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2']
13101,NCT02788955,Change/maintenance in muscle mass,Change in physical function,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
13102,NCT04106167,Overall Survival (OS) post-Infusion,,,2019-06-11,TERMINATED,OBSERVATIONAL,['NA']
13103,NCT03340844,Patient survival,Morbidity,,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA']
13104,NCT05837598,Patient satisfaction assessed by patient feedback questionnaire.,Tumor board participant satisfaction assessed by in-session feedback questionnaire.,Patient receipt of mental health care assess by electronic medical record review.,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
13105,NCT01316679,,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
13106,NCT02488707,Hospital stay,,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
13107,NCT05489237,Phase 1b - Objective Response Rate (ORR) mRESIST v1.1,Phase 1b - Overall survival,,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
13108,NCT04661150,Pathological Complete Regression (pCR) Rate,Percentage of Participants With Adverse Events,,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13109,NCT03873532,Overall survival (OS),Duration of response (DOR),Detection of biomarkers,2018-07-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13110,NCT03271047,Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,Concentration Versus Time Summary of Plasma Concentration of Binimetinib,,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE2']
13111,NCT03468231,Overall survival,Tumor response,,2018-03-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
13112,NCT00968604,Dose-Limiting Toxicity (DLT),,,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13113,NCT05804331,Long term outcomes: recurrent and residual disease,Patient interviews/questionnaires,,2023-03-14,RECRUITING,OBSERVATIONAL,['NA']
13114,NCT04708470,Determine RP2D of entinostat,Duration of Response (DoR),,2021-10-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13115,NCT00826800,To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.,,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
13116,NCT04440943,Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0,Pharmacokinetic Evaluation,,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13117,NCT03333785,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,Patient experience of the care process,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
13118,NCT05832398,1. Progression-free survival,Overall survival,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
13119,NCT00024401,,,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
13120,NCT05394259,Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.,,,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE1']
13121,NCT04671862,Rate of occurence of radiation mucositis,Radiation dermatitis,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
13122,NCT03436719,Rate of Surgical Site Infection,,,2017-11-06,UNKNOWN,INTERVENTIONAL,['NA']
13123,NCT01394120,Overall Survival,,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
13124,NCT01624220,Assess Use of Implanted Fiducial Markers in Treatment Planning and Delivery Workflow for Frame-Based Spinal Stereotactic Body Radiation Therapy (Spinal SBRT),Esophageal Tolerance to Hyperfractionation,,2012-06-18,COMPLETED,INTERVENTIONAL,['NA']
13125,NCT01494155,Progression-free survival,Measure utilization of health services,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
13126,NCT00574275,Overall Survival (OS),Number of Participants With Anti-drug Antibodies,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
13127,NCT03435289,The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel,The number of participants with complete or partial response,,2017-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
13128,NCT04695964,anastomotic leak,Length of post-operative hospital stay,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
13129,NCT01030263,Whether specialized columnar epithelium was detected.,,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE4']
13130,NCT05524428,Primary Outcome 3: Appropriateness of Implementation Strategies,Secondary Outcome: CRC Screening Rates,,2023-03-24,RECRUITING,INTERVENTIONAL,['NA']
13131,NCT05117957,Safety (Adverse events),Disease control rate (DCR),,2022-02-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
13132,NCT02498041,Endoscopic Diagnostic Accuracy for Barrett's esophagus,Adverse events,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
13133,NCT01916447,"Safety monitoring including adverse events, vital signs, and laboratory assessments",Document any preliminary antitumor activity of TAS-102 administered in combination with CPT-11 and in combination with CPT-11 and Bevacizumab.,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13134,NCT00753844,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),evaluate immunological responses,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13135,NCT04250948,TRG0/1,Overall survival (OS),,2019-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13136,NCT01012804,,,,2000-01,WITHDRAWN,OBSERVATIONAL,['NA']
13137,NCT01811108,Number of Participants with AE,Patients Overall Survival,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
13138,NCT05312372,Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2),"Changes in vital signs : SBP, DBP, respiratory rate and temperature (Phase 2)",,2025-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13139,NCT05994521,Rate of gastric outlet obstruction (GOO),Nutritional status,,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13140,NCT02735941,Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer,Assessment of malignancy of colon cancer by tumor staging,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA']
13141,NCT00102700,Document progression free survival after treatment with ARQ 501 and gemcitabine,Document safety and efficacy of ARQ 501 in combination with gemcitabine,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13142,NCT04810910,Relapse Free Survival(RFS),Overall Survival(OS),Peripheral blood T cell receptor sequencing analysis,2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE1']
13143,NCT03162198,Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC),Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.,,2017-05-15,COMPLETED,OBSERVATIONAL,['NA']
13144,NCT06024343,Incidence of Clinically Relevant Postoperative Pancreatic Fistula,Recurrence-free survival (RFS),,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13145,NCT05816187,Changes in Health Related Quality of Life: EORTC QLQ-30,The five Times Sit to Stand Test (5x Sit-To-Stand Test),,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13146,NCT00061932,True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST),Change in Patterns of Gene Expression Pre- and Post-treatment Performed by GeneChip Analysis,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13147,NCT00252889,"Subjective parameters including ECOG performance status, specific symptoms, and side effects are graded according to standard Common Terminology Criteria for Adverse Events (CTCAE) v.30 criteria.",,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13148,NCT05493033,Anastomotic leak,Incision herniation,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13149,NCT03785873,Phase II: Median Progression-Free Survival (PFS),Median Overall Survival (OS),,2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13150,NCT03005002,Incidence of adverse events assessed by NCI CTCAE version 4.03,Overall response rate (both hepatic and extrahepatic disease) assessed by RECIST 1.1,Tumor immune profiling,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13151,NCT01249859,To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract,"Overall 3 year survival according to tumor stage, node invasion, and tumor localization",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
13152,NCT00019331,,,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13153,NCT04248816,HCC Screening Completion,HCC Screening Method,,2020-11-19,COMPLETED,INTERVENTIONAL,['NA']
13154,NCT00003514,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13155,NCT01228045,Overall Response Rate (ORR),Safety Evaluations,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
13156,NCT01667198,Screening centre leader's adenoma detection rate,Screening centre leader's withdrawal technique,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
13157,NCT00430027,Overall Toxicity,,,2006-11,TERMINATED,INTERVENTIONAL,['NA']
13158,NCT03683004,Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III),Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks,,2018-01-22,COMPLETED,OBSERVATIONAL,['NA']
13159,NCT04450836,To evaluate the feasibility of treatment sequence (R-TT or TT-R),To evaluate the safety (Treatment-Emergent Adverse Events) during treatment,,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13160,NCT03787667,Sensitivity,,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
13161,NCT01264432,Maximum tolerable dose defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,Proportion of toxicities of the combination of veliparib and LDRWAR as graded by the NCI CTCAE version 4.0,,2011-01-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13162,NCT01135849,Development of cardiomyopathy,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
13163,NCT02151123,False negative rate of test for colon cancer,,,2019-03,UNKNOWN,OBSERVATIONAL,['NA']
13164,NCT00118339,,,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
13165,NCT00252161,overall survival,adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13166,NCT00701857,The maximum tolerated dose (MTD) of pemetrexed,"Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13167,NCT05112016,"Quality of life, including functional and symptom scales, incontinence scores, sexual function",Costs,,2007-01-01,RECRUITING,OBSERVATIONAL,['NA']
13168,NCT04452357,"Acute grade 3+ gastrointestinal toxicity possibly, probably or definitely related to radiation.",,,2020-01-13,SUSPENDED,INTERVENTIONAL,['NA']
13169,NCT03482609,The incidence of postoperative referred pain in the left shoulder within 1 month,inflammatory and immune response,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
13170,NCT05328765,Overall survival,,,2023-06-09,RECRUITING,OBSERVATIONAL,['NA']
13171,NCT06206733,Progression Free Survival (PFS),Overall Survival (OS),Number of anti-drug antibody (ADA) Positive Participants,2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE3']
13172,NCT03976960,Number of biological risk factors for colorectal cancer,,,2018-09-19,RECRUITING,INTERVENTIONAL,['NA']
13173,NCT00039208,Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy,Overall survival,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13174,NCT05098847,Objective Response Rate,Adverse Events,,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2']
13175,NCT00658840,all cause mortality,,,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
13176,NCT01877135,at least one anal cancer,patient's feelings about his therapeutic care and impact on his emotional life,,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
13177,NCT03392584,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,Measure intermediate metabolites and inflammatory mediators after neoadjuvant CRT and subsequent APR for LARC with reconstruction of the perineum with VRAM.,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
13178,NCT03008980,Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
13179,NCT00711997,Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819,Tumor Resectability,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13180,NCT00609336,Median Overall Survival of Patients With Adenocarcinoma of the Pancreas,Percent of Patients Surviving at Annual Intervals,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13181,NCT02250638,A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
13182,NCT02635087,DFS,OS,,2015-12,RECRUITING,OBSERVATIONAL,['NA']
13183,NCT01344304,"Patient diary recording nausea, emesis, food ingestion, and rescue therapy",,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13184,NCT03043729,Pathologic complete response (pCR),ECOG,,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13185,NCT01267578,overall survival,Progression free survival,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
13186,NCT03606785,reduction in blood loss,,,2018-08-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13187,NCT04715581,Recurrence-free survival after surgery.,Physical activity at 30 days after surgery (sub-study).,"Physical activity at 3 months, 6 months and 1 year after surgery.",2021-11-25,RECRUITING,INTERVENTIONAL,['NA']
13188,NCT03350477,Relief degree of tumors,Overall survival,,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13189,NCT03109262,Image Quality for 90-Y PET/CT Scans,Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans,,2017-02-15,COMPLETED,INTERVENTIONAL,['NA']
13190,NCT02449109,Number of participants with Adverse events,Overall survival (OS),,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13191,NCT00193219,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment",Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13192,NCT03977077,Progression free survival (PFS),Overall survival,,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA']
13193,NCT02391207,the safety of HV-sparing surgery in terms of operative mortality and morbidity,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
13194,NCT03303469,Measure Changes in Treated HCC Tumor Hypoxia Following TACE and Radiotherapy,,,2017-10-30,TERMINATED,INTERVENTIONAL,['PHASE2']
13195,NCT01733719,Recruitment rate and retention,Quality of life,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
13196,NCT00422409,Change/improvement i Quality of life,Death,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13197,NCT05617469,Tumor regression grade,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
13198,NCT03765736,Companion Trial Enrollment,,,2020-04-20,TERMINATED,OBSERVATIONAL,['NA']
13199,NCT02188264,Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0,Progression-free survival (PFS),Change in expression of phosphorylated-mitogen-activated protein kinase 1,2014-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13200,NCT03104582,Acute cholangitis,Overall procedure related complication rate,,2011-11-01,COMPLETED,INTERVENTIONAL,['NA']
13201,NCT02158988,The primary outcome measure is overall survival,quality of life,frequency of necessary secondary surgical procedures and the length of hospitalisation,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13202,NCT02716012,Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib,Part 2 - Safety and tolerability of co-administering MTL-CEBPA with sorafenib assessed using frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system,,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13203,NCT05438667,The duration of efficacy,Adverse events,,2022-06-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13204,NCT00072098,toxicity grading,tumor response compared at four weeks to baseline,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE1']
13205,NCT05901194,The proportion of patients with lenvatinib who have a Liver transplantation (LT),Incidence of Treatment-Emergent Adverse Events,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13206,NCT04443309,Objective Response Rate (ORR),Adverse Events (AE),Biomarker,2020-09-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13207,NCT00911170,Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy,Number of Participants With Adverse Events (AEs),,2009-11-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13208,NCT02113384,Overall survival,Overall survival,,2012-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13209,NCT02685553,Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR,,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13210,NCT05043532,Rate of ability to perform successful molecular profiling in core tissue obtained during EUS-guided fine needle biopsy,Type of actionable mutations detected on molecular profiling,,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13211,NCT00826488,"It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.",,,2009-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13212,NCT00215462,To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.,To evaluate the toxicities of vinorelbine in this patient population.,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13213,NCT05942807,Overall survival,,,2021-05-15,RECRUITING,OBSERVATIONAL,['NA']
13214,NCT03149679,Objective response rate (ORR),Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2017-05-09,TERMINATED,INTERVENTIONAL,['PHASE2']
13215,NCT04268121,Relapse-free survival (RFS) - prospective cohort,Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort,,2021-01-05,RECRUITING,INTERVENTIONAL,['PHASE2']
13216,NCT02291198,NK cell activity,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13217,NCT04199832,Body Weight Change from baseline to the end of treatment,Overall Survival,,2019-12-20,COMPLETED,OBSERVATIONAL,['NA']
13218,NCT00541047,Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT),Freedom from biochemical progression (RADICALS-RT),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13219,NCT00049023,"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)",,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13220,NCT02573220,Maximum Tolerated Dose (MTD),metastectomy (with curative intent) rate,,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13221,NCT05844514,Validation and further discovery of VOC biomarkers for CRC.,Exploratory comparison between the breath test and FIT.,,2022-09-23,RECRUITING,OBSERVATIONAL,['NA']
13222,NCT01473290,Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT,Disease-free survival,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
13223,NCT05035446,Rate of complications,pain intensity,,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
13224,NCT01436617,Validate the utility of an IgE anti-cetuximab test in the treatment strategy,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
13225,NCT06077591,tumor response,rate of grade III/IV toxicities.,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13226,NCT02546596,"T stage (0 - 4), N (0 - 3) stage, tumor regression grade (0 - 4)",Treatment toxicity (grade 0 - 5),,2014-03-25,UNKNOWN,INTERVENTIONAL,['NA']
13227,NCT05780684,Proportion of patients that receive dose intensified infusional 5-FU in Cycle 6 of the FOX regimen,5-FU drug exposure,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
13228,NCT02075905,Risk Stratification,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
13229,NCT01010945,Maximum Tolerated Dose,Overall Survival,,2010-02-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13230,NCT02607332,Disease control rate,,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13231,NCT04616196,Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion,The development of anti-drug antibodies (ADA) against NKTR-255 and cetuximab,,2020-10-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13232,NCT03383458,Recurrence-free Survival (RFS),Time to recurrence (TTR),,2018-04-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13233,NCT05213741,Safety of magnetic-assisted colonoscope system,,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13234,NCT05137782,Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms,Acceptability as measured by willingness to recommend study participation to others.,,2023-01-03,COMPLETED,INTERVENTIONAL,['NA']
13235,NCT00955188,Adherence to colorectal cancer screening at 12 months post-intervention,Intention to get screened,,2004-08,COMPLETED,OBSERVATIONAL,['NA']
13236,NCT03161535,Quality of life (EORTC QLQ-OES 18 ),Circadian rhythms,,2017-09-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13237,NCT05841420,PFS (Progression Free Survival),Cumulative worst toxicity during treatment,,2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
13238,NCT02047994,Gastric cancer mortality,Incidence of- and mortality from other medical conditions,,2013-03,RECRUITING,INTERVENTIONAL,['PHASE4']
13239,NCT04340440,Operative mortality rate,2 years Overall survival rate,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13240,NCT02350686,Progression-free survival,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2015-05-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
13241,NCT01072851,Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools,Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13242,NCT01157806,percentage of patients not requiring palliative surgery during the follow-up,Determination of prognostic factors indicating the need for immediate palliative surgery.,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13243,NCT04519905,overall survival difference of definitive radiotherapy and chemoradiotherapy groups,cancer specific survival,,2020-01-06,RECRUITING,INTERVENTIONAL,['NA']
13244,NCT03607643,Response rate,Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.,,2019-01-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13245,NCT00789633,Overall Survival (OS),Progression Free Survival (PFS),,2008-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
13246,NCT00828048,Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
13247,NCT03745170,Overall survival (OS),Number of participants experiencing clinical and laboratory adverse events (AEs),,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE3']
13248,NCT05635266,Biospecimen & Clinical Data Collection,,,2021-10-26,RECRUITING,OBSERVATIONAL,['NA']
13249,NCT01321658,Postoperative complications,Living at home or in institution,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
13250,NCT05047926,Adherence to each prehabilitation component based on patient reported adherence (Cohorts 2 & 3),Acceptability of remote setting in Cohort 3,,2021-10-01,RECRUITING,INTERVENTIONAL,['NA']
13251,NCT06260150,Incidence rate of DVT,Amount of bleeding during surgery,,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13252,NCT05356156,The incidence of internal hernia within 3 years after surgery,Overall survival at 3 years after surgery,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13253,NCT04000737,Progression free survival (PFS),Effects of YIV-906 on mean t½ (Hr) of sorafenib in blood,,2020-01-10,RECRUITING,INTERVENTIONAL,['PHASE2']
13254,NCT06202105,3 year relapse-free survival by Kaplan Mayer,hospital stay,,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13255,NCT04616131,Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.,"Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response.",,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13256,NCT05883345,Validity of blood tests for gastric cancer screening and gastritis type,,,2023-04-24,RECRUITING,OBSERVATIONAL,['NA']
13257,NCT01220063,tumor response accoording to recist criteria,,,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
13258,NCT01872988,overall survival,time to liver decompensation,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE3']
13259,NCT04040842,LARS score change comparing before surgery and 1 year after the surgery.,,,2019-09-01,RECRUITING,OBSERVATIONAL,['NA']
13260,NCT01891344,Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study),Steady State Trough (Cmin) Level Rucaparib Concentrations,,2013-10-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13261,NCT02999672,Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).,Plasma/Serum Concentrations of Trastuzumab Emtansine,,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE2']
13262,NCT03534843,Overall survival of all patients,Short-term mortality of non-surgical subgroup,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
13263,NCT05866783,Disease-free survival,Overall survival,,2023-04-28,RECRUITING,OBSERVATIONAL,['NA']
13264,NCT02333279,Number of solid cancers,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
13265,NCT06164691,Clinical Complete Response,Prealbumin Level,,2022-08-14,TERMINATED,INTERVENTIONAL,['NA']
13266,NCT02063529,"the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.",Quality of life (QLQ C30),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13267,NCT00603577,"Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)","AE graded with NCI-CTCAE (Version 3.0) and coded using Medical Dictionary for Regulatory Activities (MedDRA, version 9.1)",,2008-01,TERMINATED,INTERVENTIONAL,['PHASE3']
13268,NCT01545804,disease stabilization,,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13269,NCT00441155,Safety and tolerability of nilotinib either as single agent or in combination with Imatinib,To assess any clinical responses in Imatinib-resistant GIST patients. Assessment of tumor response will be made based on modified RECIST criteria - to be assessed at the end of every cycle of treatment,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13270,NCT03076957,Maximum Tolerated Dose(MTD),"Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year",,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13271,NCT05235490,The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.,Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.,To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.,2021-01-28,COMPLETED,OBSERVATIONAL,['NA']
13272,NCT02810418,Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).,Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2,2016-08-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13273,NCT03635021,Progression-free survival rate at 35 months,Incidence and severity of AEs CTCAE v4.03 criteria,clinical impact of clonal dynamics by longitudinal analysis of circulating tumour deoxyribonucleic acid (ctDNA) in plasma,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13274,NCT00123760,To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility,To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values,,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13275,NCT04848051,Total number of participants who completed their colorectal cancer screening,Screening outcomes: diagnostic results,,2021-10-12,COMPLETED,INTERVENTIONAL,['NA']
13276,NCT01397019,2 year survival rate,,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13277,NCT00238199,Time to progression,Change in pancreatic cancer-induced pain,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13278,NCT05369117,Three-year disease-free survival rate,operative mortality,,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13279,NCT03896399,Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning,Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography,,2019-04-09,UNKNOWN,INTERVENTIONAL,['NA']
13280,NCT00842348,Adverse Events,Progression Free Survival (PFS): Kaplan-Meier Estimate,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13281,NCT01820091,Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis,Impact of Fusilev on number of Folotyn doses delivered,,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13282,NCT03600623,Number of participants with adverse events as a measure of safety and tolerability,Proportion of participants undergoing surgery after preoperative chemoradiation therapy,,2017-09-25,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
13283,NCT06055543,Improvement in nutritional status,ONS Satisfaction,,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE4']
13284,NCT00112580,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR),,,2005-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13285,NCT02042443,Overall Survival,Progression-free Survival,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13286,NCT05743842,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-03-14,RECRUITING,INTERVENTIONAL,['NA']
13287,NCT01501903,Diagnostic accuracy,Number of passes for diagnosis,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
13288,NCT01286155,The primary outcome from the survey will be the proportion of patients willing to undergo an esophageal capsule study compared to those willing to undergo an endoscopic procedure (Esophagogastroduodenoscopy or transnasal endoscopy),"Study established (age, gender, ethnicity, reflux) and potential risk factors (sleep apnea, visceral adiposity, Helicobacter pylori infection, Metabolic Syndrome)to develop a clinical risk factor model for diagnosis of Barrett's esophagus(BE).",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
13289,NCT02325986,overall response rate,overall survival,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
13290,NCT01675999,Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan,•Evaluation of another histopathological grade,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
13291,NCT04072445,Progression-free Survival (PFS),Number of Participants With Adverse Events,Prediction of Clinical Benefit by Thymidine Kinase 1 (TK1),2019-10-18,COMPLETED,INTERVENTIONAL,['PHASE2']
13292,NCT00006050,,,,1999-04-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13293,NCT03981614,Progression Free Survival (PFS),Number of Participants With Adverse Events,,2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13294,NCT01505400,Molecular profiling data to be made available in patient's electronic medical records.,Clinical trial accrual rates among patients with available molecular profiling data,,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13295,NCT01521091,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
13296,NCT00303940,,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13297,NCT06219031,CR、PR、SD、PD,,,2023-12-01,COMPLETED,OBSERVATIONAL,['NA']
13298,NCT05460403,Overall survival (OS),Distant metastasis (DM),Adverse events,2022-04-23,RECRUITING,OBSERVATIONAL,['NA']
13299,NCT04674696,Evaluate MRI good response rate after the total neoadjuvant treatment,Describe the safety and tolerability of total neoadjuvant treatment.,,2020-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13300,NCT06199297,progression free survival，PFS,"overall survival, OS",,2021-03-02,COMPLETED,OBSERVATIONAL,['NA']
13301,NCT03763214,Stent migration,Survival rate,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
13302,NCT04109495,EORTC Questionnaires - Quality of Life,Skeletal muscle index change,,2017-02-22,COMPLETED,INTERVENTIONAL,['NA']
13303,NCT05223088,Total/moderate tumor regression rate under pathology,Overall survival (OS),,2021-10-31,RECRUITING,INTERVENTIONAL,['PHASE2']
13304,NCT03587480,3-year disease-free survival,the score of quality of life,,2018-12-17,RECRUITING,INTERVENTIONAL,['NA']
13305,NCT06251973,Overall Response Rate,,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13306,NCT04959617,Specificity of quantitative FIT,,,2019-01-06,UNKNOWN,OBSERVATIONAL,['NA']
13307,NCT03591965,ORR,"6, 9 and 12 month of survival rate",Additional metabolites of ATG-008 in plasma and urine,2018-08-07,TERMINATED,INTERVENTIONAL,['PHASE2']
13308,NCT05653427,Objective Response Rate (ORR),Number of Participants with Anti-amivantamab Antibodies,,2022-12-08,TERMINATED,INTERVENTIONAL,['PHASE2']
13309,NCT04905030,(Long Term) Posterior beliefs about false risks of the HPV vaccine,Subjective vs Objective vaccination measure (binary indicators),,2021-04-28,UNKNOWN,INTERVENTIONAL,['NA']
13310,NCT05613465,Cancer-related fatigue,Immunologic function,,2022-10-25,RECRUITING,INTERVENTIONAL,['NA']
13311,NCT02518373,Change in plasma gastrin level.,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13312,NCT03015298,The results of the PET/MRI and PET/CT examination,Follow-up data,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
13313,NCT02833506,Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03,Time to disease progression as documented by Response Evaluation Criteria in Solid Tumors version 1.1,,2017-12-08,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13314,NCT00152906,Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.,To determine whether serum cytokines and P-III-P can help predict RILD.,,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13315,NCT05745415,Progression free survival,Overall survival,,2018-03-29,COMPLETED,OBSERVATIONAL,['NA']
13316,NCT02234180,Disease Free Survival (DFS),Overall Survival (OS),,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2']
13317,NCT05429190,Increased sensitivity for HCC detection,Cost-effectiveness analysis of SMS protocol,Patients acceptance of the SMS protocol (through a questionnaire),2023-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13318,NCT01139229,the incidence of anastomotic stricture,the clinicopathological parameters in relation to postoperative complications,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
13319,NCT01179750,amount of blood loss,drainage from peritoneal cavity during hospital,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
13320,NCT00390182,Overall Response,,Time of Advanced/Recurrent Disease Without Distant Metastases.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13321,NCT02594696,Feasibility of implementing the intervention in patients with SMI and cancer,Change in alliance with the oncology clinician,,2015-11-09,COMPLETED,INTERVENTIONAL,['NA']
13322,NCT00005597,"Assess response (confirmed & unconfirmed, complete & partial response)",Toxicities,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13323,NCT02043730,Progression Rate,Overall Survival,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13324,NCT00118755,Progression-free Survival (PFS),Duration of Overall Clinical Response (CR or PR),,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13325,NCT06314750,OS,,,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13326,NCT00094445,Six-Month Participant Survival,,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13327,NCT00828607,"Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.","Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
13328,NCT04134104,Sexual Dysfunction,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
13329,NCT05091528,Number of Participants With an Objective Response Rate,Proportion of Participants With Clinical Benefit Rate,,2022-02-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13330,NCT01704820,Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).,Evaluate endoscopist comfort with performing retroflexion in the proximal colon.,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
13331,NCT02520141,Progression Free Survival of Ramucirumab in Advanced Biliary Cancers,Percentage of Disease Control Rate,,2015-12-29,COMPLETED,INTERVENTIONAL,['PHASE2']
13332,NCT04567459,5)Sarcopenia assessment,,,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA']
13333,NCT04600518,Prognostic equivalence,Multivariate analysis,,2020-10-07,COMPLETED,OBSERVATIONAL,['NA']
13334,NCT03086538,Overall Response Rate,,,2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13335,NCT05610592,5-year event-free survival rate,Local recurrence,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
13336,NCT06071598,To define the functional role of MFSD2A in CRC through Polyunsaturated fatty acid (PUFA) ad genes analysis.,,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
13337,NCT04619329,Median Overall Survival (mOS),Adverse Events,,2020-10-30,UNKNOWN,INTERVENTIONAL,['NA']
13338,NCT02859064,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability,Overall Survival,,2017-07-28,TERMINATED,INTERVENTIONAL,['PHASE2']
13339,NCT02279771,anastomotic leak,Number of overall postoperative complications,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
13340,NCT00113256,survival,,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13341,NCT01434459,The maximum tolerated dose of gemcitabine when given in combination with therasphere,The progression free of patients treated on the trial,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1']
13342,NCT04406311,Lars score,Single question on QoL,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
13343,NCT05387005,Detection rates of H. pylori infection,The compliance(/adherence) of screening tests for H. pylori infection in the two randomized groups,,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13344,NCT06159049,SUVmaxFAPI and SUVmaxFDG for each target (Standardized Uptake Value),,,2022-07-21,COMPLETED,OBSERVATIONAL,['NA']
13345,NCT00483405,Disease Response Rate,Time to Progression,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13346,NCT06046963,Ascites objective response rate (ORR),Changes of ascite cell subsets in patients,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13347,NCT05964621,VTE incidence in primary pancreatic cancer resection,,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
13348,NCT03081988,Prediction model for CCRT response based on clinical and genetic molecular factors,in-vitro prediction of CCRT using primary esophageal cancer organoid,Clinical prediction factors for CCRT response (retrospective study),2015-10-19,RECRUITING,OBSERVATIONAL,['NA']
13349,NCT00154713,evaluate the clinical responses of vaccinated patients 6 weeks after the first injection,evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection,,2005-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13350,NCT05411432,SUV of organs,radioactivity of blood sample,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13351,NCT03662841,Time to progression,Tumor response,,2018-07-13,TERMINATED,INTERVENTIONAL,['NA']
13352,NCT04622176,Accuracy of lymph node diagnosis compared to MRI,,,2021-06-17,RECRUITING,OBSERVATIONAL,['NA']
13353,NCT04523818,Incidence of adverse events,Overall survival (OS),,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13354,NCT02277093,Progression-free Survival (PFS),Overall Survival (OS),,2015-09-22,TERMINATED,INTERVENTIONAL,['PHASE2']
13355,NCT04202848,The change of concentration of P-hydroxyphenylalanine metabolites in urine,The change of the number of Gastrin in blood during the therapy,,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA']
13356,NCT06094140,The proportion of patients receiving at least 80% of planned neoadjuvant treatment.,Objective response rate.,Analysis of tumour tissue (baseline and surgical resection) for molecular changes and gene expression profile.,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE2']
13357,NCT02033551,Number of subjects with adverse events,Tumor Assessment,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13358,NCT00646607,disease free survival (DFS),"overall Survival (OS), Toxicity and incidence of adverse events",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13359,NCT02221700,"Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy",Baseline treatment expectations,,2015-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13360,NCT05866510,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,Incidence of Treatment-Related Adverse Events,,2023-05-15,RECRUITING,INTERVENTIONAL,['PHASE2']
13361,NCT01760070,Procedure time for ESD,Bleeding Rate,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
13362,NCT04008797,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Duration of Response (DOR),,2019-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
13363,NCT03427346,Eradication rate of neoplastic Barrett's Esophagus,Intervention time,,2016-12,RECRUITING,INTERVENTIONAL,['NA']
13364,NCT03663114,Number of Participants With Hepatic Encephalopathy Risk Factors,Number of Participants with Hepatic Encephalopathy,,2018-07-02,COMPLETED,OBSERVATIONAL,['NA']
13365,NCT00004189,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13366,NCT04220151,Percentages of methylation of DNA in patients with HCC,,,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA']
13367,NCT00087282,,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13368,NCT00963794,"Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.",,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
13369,NCT02749513,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.,Inhibition of VEGFR2 pathway signaling as measured by Western blot,,2016-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13370,NCT04934618,Overall Suvival time（OS）,Disease control rate（DCR）,Safety and tolerability,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE2']
13371,NCT05010850,Safety Major Complications,,,2022-01-17,SUSPENDED,INTERVENTIONAL,['NA']
13372,NCT05606094,Percentage of Participants Receiving Locoregional Treatment for Localized Disease and Metastasis (Radiotherapy and/or Surgery),Number of Participants with Adverse Events of Special Interest (AESI) In Each Line of Treatment,,2023-03-09,COMPLETED,OBSERVATIONAL,['NA']
13373,NCT04524702,Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks),Overall survival,Changes in selected biomarkers in tumor microenvironment and circulation,2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13374,NCT03752398,Treatment-related adverse events as assessed by CTCAE v4.03,,,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13375,NCT02151864,Rate of dose limiting toxicities,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13376,NCT06217042,Disease-free survival (DFS),5-year overall survival rate,,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13377,NCT05417386,R0 Resection Rate,Resection rate,,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
13378,NCT02079220,anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC),Progression-free survival (PFS),,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13379,NCT04102436,Response rate,Immune monitoring,,2024-03-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13380,NCT00035334,,,,2001-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13381,NCT04044326,the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria,safety and local tumor recurrences,,2019-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
13382,NCT06222255,The LARS (Low Anterior Resection Syndrome) Score with Night symptoms,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29,,2023-12-06,RECRUITING,INTERVENTIONAL,['NA']
13383,NCT01882972,Retention feasibility,Self-reported Exercise-related Injury,,2013-06,WITHDRAWN,INTERVENTIONAL,['NA']
13384,NCT06013943,6-month progression-free survival rate (PFS),Objective response rate (ORR) per RECIST 1.1,Adverse events,2023-03-17,RECRUITING,INTERVENTIONAL,['PHASE2']
13385,NCT00003321,,,,1998-02,COMPLETED,OBSERVATIONAL,['NA']
13386,NCT01401907,Functional Assessment of Cancer Therapy (Quality of Life Measure),Coping (Brief Cope),,2011-05,COMPLETED,INTERVENTIONAL,['NA']
13387,NCT04153721,"Change, during the preoperative phase, of the psychological condition of the patients, assessed by GAD7 questionnaire scoring.",Evaluation of the number of postoperative critical values,,2020-03-11,COMPLETED,INTERVENTIONAL,['NA']
13388,NCT04455945,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) Symptom scales,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
13389,NCT00260364,Part B (Phase II): Overall response rate (complete response and partial response),and Assessment of pain,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13390,NCT04482608,Progression-Free Survival (PFS),Overall survival,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
13391,NCT00078468,To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.,"To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13392,NCT02868255,evaluation of the SIRP/CD47 expression,,,2016-01-03,COMPLETED,OBSERVATIONAL,['NA']
13393,NCT00697047,Long-term adherence to CRC screening,Impact of SOS interventions on outcomes and CRC-related costs,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13394,NCT04538313,Progression-Free Survival,EQ-5D score,,2020-08-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13395,NCT03158103,Recommended phase II dose (RP2D),Number of participants with partial response,,2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE1']
13396,NCT01149642,The rate of grade 3 and 4 acute mucosal toxicity,overall survival rates,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
13397,NCT02078362,Percentage of cell lysis,,,2013-09,UNKNOWN,OBSERVATIONAL,['NA']
13398,NCT01373346,Operation Related Mortality,Albumin : Good Response Group,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
13399,NCT05433467,The position of the needle,Intraoperative bleeding,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
13400,NCT02462564,Incidence for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,Risk factor for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
13401,NCT04248647,"Functional capacity: Six-minute walk test (Enright, 2003)","Nutritional status: body weight loss, serum albumin, hand grip strength, body mass index, lean body mass and percentage of body fat",,2016-10-26,COMPLETED,INTERVENTIONAL,['NA']
13402,NCT02332863,Procedure Duration Required for Placing the Fiducial Markers,Number of Fiducials Placed,,2016-08-03,COMPLETED,INTERVENTIONAL,['NA']
13403,NCT06196554,Predictive specificity of drug sensitivity,Concordance between organoids and source tumor tissue,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
13404,NCT00197470,,,,2000-01,UNKNOWN,INTERVENTIONAL,['NA']
13405,NCT06191120,Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.,10-120 minutes post-injection dynamic [18F]-ALF-FAPI-74 uptake levels in tumor lesions and reference organs,RNA-sequencing derived gene-expression levels per tumor lesion,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13406,NCT00756977,Efficacy - Preparation Quality Using a 4 Point Scale,Serum Chemistry Results (Osmolality),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13407,NCT01270178,The survival rate and recurrence rate between patients receiving ETV therapy and those in historical control,"HBV reactivation, incidence of ALT normalization, reduction of serum HBV DNA level, HBsAg loss and HBsAg seroconversion to anti-HBsAb, emergence of resistance.",,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
13408,NCT05007106,PFS per RECIST 1.1 as Assessed by Investigator at 12 months,Number of Participants Who Discontinued Study Intervention Due to an AE,,2021-09-16,RECRUITING,INTERVENTIONAL,['PHASE2']
13409,NCT05677048,Measure response rate to baseline and follow-up surveys by probands and at-risk relatives,,,2023-04-14,RECRUITING,INTERVENTIONAL,['NA']
13410,NCT02820077,mortality,Hospital length of stay,,2016-08-06,TERMINATED,INTERVENTIONAL,['NA']
13411,NCT01894269,overall survival,HBV reactivation,HBV resistance to lamivudine or entecavir,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
13412,NCT00563095,regression of tumour size,side effects,,2004-03,UNKNOWN,INTERVENTIONAL,['NA']
13413,NCT04646772,Postoperative mortality,Disease Free Survival,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13414,NCT03941561,DFS,OS,Side effects,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13415,NCT02687113,RFA feasibility rates on planning USG with/without fusion CT/MR and US,Number of patients with safety access route on planning USG with/without fusion technique,Anticipated number of overlapping of RFA electrodes on planning USG with/without fusion technique,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13416,NCT03864640,Content validity of Mediterranean Colorectal Cancer Registry: answering multiple-choice items,Face validity of Mediterranean Colorectal Cancer Registry: the major reason behind the negative response,,2019-02-27,COMPLETED,OBSERVATIONAL,['NA']
13417,NCT03494946,Overall Survival,,,2016-12-05,RECRUITING,INTERVENTIONAL,['NA']
13418,NCT05021029,Pre-malignant progression,Recruitment response rates,,2021-07-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13419,NCT00558207,Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine.,Further characterize the safety profile of ARQ 197,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13420,NCT06157892,Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment,Incidence of anti-drug antibodies (ADAs) against disitamab vedotin,,2024-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13421,NCT02678832,Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB),Physical activity as assessed with SQUASH,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
13422,NCT00402961,To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture,Number of emetic episodes during hospital stay,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13423,NCT03997435,Rate of pathologic complete response,Number of response to neoadjuvant therapy,,2019-09-10,RECRUITING,INTERVENTIONAL,['PHASE2']
13424,NCT01972503,3 years disease-free survival,3 years overall survival and metastasis-free survival,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
13425,NCT00677287,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),To evaluate immunological responses,,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13426,NCT04412161,overall and disease free survivals,,,2006-04-19,COMPLETED,OBSERVATIONAL,['NA']
13427,NCT04971304,Number of patients who develop febrile neutropenia,Number of patients who develop G-CSF associated adverse events,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
13428,NCT03228095,Performance of nanoarray sensor testing to detect target lesions and diseases,Groups of gastrointestinal microbiota correlating to VOCs,,2017-07-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13429,NCT04766736,Netrin-1 expression patterns in HCC samples,,,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA']
13430,NCT01861483,R0 resection rate,,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
13431,NCT02102646,Change in hepatic fat content,Correlation between Hepatic fat content and baseline androgen status,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13432,NCT05080621,Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST,Evaluate the time to response (TTR) of ripretinib in combination with binimetinib,,2021-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13433,NCT01964430,Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee,The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4),,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE3']
13434,NCT06277908,the type of complications and the incidence of it,,,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13435,NCT01084330,Progression Free Survival,"Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13436,NCT04755543,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Serum concentration of the antibody against LP002 within 1 hour prior to each administration,,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1']
13437,NCT00365391,Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).,Time to Treatment Failure,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13438,NCT03329248,Objective response rate by RECIST,Patient-reported outcomes of pancreatic cancer symptoms,,2017-11-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13439,NCT03366961,3-year overall survival,Response rate of chemotherapy,,2017-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
13440,NCT00899158,Urinary 3-methylhistidine levels,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
13441,NCT06282445,Progression-free survival,TRAEs,,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13442,NCT02312167,"The number of participants with adverse events, their type and severity",The ease of manipulation of the robotized probe (grade 1 to 5),"number of interpretable images per organ, per contrast agent and per pathology",2014-10,COMPLETED,INTERVENTIONAL,['NA']
13443,NCT01206218,Progression-free Survival,Response Rate,,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13444,NCT05352646,dose-limiting toxicity (DLT),recurrence-free survival(RFS) rate,,2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE1']
13445,NCT02777437,Disease free survival,The proportion of completion of laparoscopic surgery,,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13446,NCT02716688,response rate,Overall survival,Dysphagia score,2016-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13447,NCT05475288,Overall survival of patients with locoregionally recurrent colon cancer;,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
13448,NCT01959906,overall survival,,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
13449,NCT03118882,screening-related indicators,Circulating biomarkers association with breast and colorectal cancer,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
13450,NCT02521285,Differences in the Activation Status of NF-kB by Assessing Levels of Total and Phospho-p65 and Cytoplasmic to Nuclear Translocation of Phospho-p65 at 12 Months (Location C),Differences in the Change of a13pge2 at 12 Months (Location C),Incidence of Barrett's Esophagus (BE) Recurrence,2016-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13451,NCT04392700,Recurrence of HCC,The number of overall patients,,2019-07-25,RECRUITING,INTERVENTIONAL,['PHASE3']
13452,NCT00671372,The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab),,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13453,NCT00842647,,,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
13454,NCT02039635,Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks,adverse events,"Change in blood cytokine(IL-2, IL-8, IL-10) level after 16 weeks of trial drug intake",2013-12,COMPLETED,INTERVENTIONAL,['NA']
13455,NCT01786200,Klintrup-Makinen immune score,Local inflammatory response,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
13456,NCT00598975,Number of Patients With Dose Limiting Toxicities,Number of Patients With Overall Response,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13457,NCT00862784,Progression-Free Survival (PFS),Serum Anti-IMC-1121B (Immunogenicity) at Day 1,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13458,NCT00764140,mortality,distant metastasis,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
13459,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",Remission rates of co-morbidities,,2015-09-01,COMPLETED,INTERVENTIONAL,['NA']
13460,NCT00380588,Percentage of Patients Alive at 1 Year (1-Year Survival Rate),Progression Free Survival,Survival Time,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13461,NCT01132534,"To compare the detection rate of premalignant lesions(intestinal metaplasia, gastric atrophy, dysplasia) and early neoplasia of stomach between combined AFI/NBI endoscopy versus standard endoscopy",To assess the diagnostic accuracy AFI and NBI imaging,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
13462,NCT03208335,progress-free survival(PFS),Quality of life (QOL),,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13463,NCT02783261,liver hypertrophy,,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
13464,NCT05494359,"The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen",The stage of the cancer,,2023-04-04,RECRUITING,OBSERVATIONAL,['NA']
13465,NCT00339742,Esophageal Cancer,,,2003-03-25,COMPLETED,OBSERVATIONAL,['NA']
13466,NCT05884255,Progression-free survival (PFS) assessed by BICR,Incidence and severity of AE and SAE,,2023-07-06,RECRUITING,INTERVENTIONAL,['PHASE3']
13467,NCT04682847,Develop a platform to maintain liver functionality during treatment for liver cancer,Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT,,2020-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13468,NCT02307812,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
13469,NCT05486572,Hepatocellular Carcinoma Mortality,Overall Survival,,2023-11-03,RECRUITING,INTERVENTIONAL,['NA']
13470,NCT05578430,Major Pathological Response Rate (MPR rate),Incidence of Adverse Events (AE),,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13471,NCT05701436,The one-year DFS rate,Adverse events,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13472,NCT05030090,Evaluate nutritional status indicators change,Evaluate quality of life indicators change,,2021-06-25,COMPLETED,INTERVENTIONAL,['NA']
13473,NCT05487924,postoperative complication,time to first flatus,,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13474,NCT03026803,Response Rate,,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13475,NCT01361035,"Change in cervical, breast and colorectal cancer screening rates",Change in standardized patient ratings of physician communication behaviors,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
13476,NCT02399059,Global survival,Disease free survival,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13477,NCT05394415,Treatment safety,Overall survival (OS),,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13478,NCT00638612,Incidence of treatment emergent adverse events,Functional Assessment of Cancer Therapy - Pancreas (FACT-Hep),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13479,NCT03380052,The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
13480,NCT01656746,"Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins","Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar""",,2010-05,COMPLETED,INTERVENTIONAL,['NA']
13481,NCT03622437,Health-related quality of life and symptom burden,Cost-benefit - QALY's,,2016-02-26,COMPLETED,INTERVENTIONAL,['NA']
13482,NCT04032353,"the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.",tthe focal lesions of upper gastrointestinal tract,adverse events,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA']
13483,NCT00077389,Rate of complete remission after completion of study therapy,Event-free survival,,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13484,NCT02352831,Progression-free Survival (PFS) Rate,Number of Participants With a CA19-9 Response,,2015-08-31,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13485,NCT00030082,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13486,NCT01383343,"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)","Time until hematologic nadirs (ANC, platelets, hemoglobin)",,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13487,NCT05688176,Identification of biomarkers (messenger RNAs) for therapy response prediction,Development of a quantitative Polymerase Chain Reaction (qPCR) test for clinical use,,2016-06,RECRUITING,OBSERVATIONAL,['NA']
13488,NCT05214222,Objective Response Rate (ORR),The 3-year OS rate,,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE2']
13489,NCT04151030,Technical success of endoscopic vs radiographic Push-PEG placement in patients who are not candidates for a Pull-PEG placement,Procedure duration between endoscopic push PEG placement and IR guided push PEG placement,,2019-06-28,COMPLETED,INTERVENTIONAL,['NA']
13490,NCT01769534,To validate the Sendai criteria prospectively in patients with pancreatic cysts.,,,2012-06,TERMINATED,OBSERVATIONAL,['NA']
13491,NCT06038552,Overall survival,,,2002-01-01,COMPLETED,OBSERVATIONAL,['NA']
13492,NCT00493857,The primary goal is to assess the Objective Response Rate (ORR) that the combination of irinotecan and nimotuzumab will produce in patients with irinotecan-refractory metastatic colorectal cancer,"Assess the incidence of acneiform rash,drug reaction,adverse events, the assessment of progression-free survival,stable disease,time to disease progression, overall survival, objective response rates, safety and trough levels in the serum of patients.",,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2']
13493,NCT03985670,Pathological complete response rate,disease-free survival rate,,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13494,NCT05830890,Accuracy,Sensitivity,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13495,NCT02972034,Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT),Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by the Investigator,,2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
13496,NCT03112837,the incidence of Radiation Therapy Oncology Group grade 3 mucositis,,,2017-03-10,UNKNOWN,INTERVENTIONAL,['NA']
13497,NCT04712643,Overall Survival (OS),Percentage of Participants With Adverse Events,,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13498,NCT00912327,Objective response rate (ORR),Overall survival,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13499,NCT04602117,Overall response rate (ORR),Duration of response (DOR) of patients treated with the weekly paclitaxel with tri-weekly trastuzumab duocarmazine (SYD985) combination,,2021-07-28,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13500,NCT05093920,Tumor size,Serum Alpha-fetoprotein level ng/ml.,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13501,NCT01274143,Colonoscopy,Decisional Conflict,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
13502,NCT00003594,time to progression,quality of life,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13503,NCT00903565,To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.,• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.,,2008-09,UNKNOWN,OBSERVATIONAL,['NA']
13504,NCT04307654,Postoperative complications,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
13505,NCT02954094,"Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice",Establish a Biorepository Specimen Bank (BSB),,2016-12,RECRUITING,OBSERVATIONAL,['NA']
13506,NCT02021422,The Number of Participants with SAEs and AEs.,Gather preliminary information on the immune modulation and clinical activity of this therapy,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
13507,NCT03659903,median OS,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
13508,NCT02739698,"The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci, Cells Tumour Reduction up to >90% That Includes MP G3-G4) and G5 (no Residual Tumour)",,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13509,NCT03852251,Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2019-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13510,NCT05440565,Detection rate,,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13511,NCT03877601,Fluorescence signal in patients with Barrett's Esophagus,Interrogate potential new EC biomarkers,,2019-07-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
13512,NCT00505024,"To study the effectiveness of the interactive voice response system (IVRS), which is designed to send a report to a patient's doctor about severe symptoms they are experiencing.","To study if systematic symptom assessment (by the use of IVRS) is another way to report symptoms rather than the usual method, which is calling the doctor when there is a problem.",,2006-07,COMPLETED,INTERVENTIONAL,['NA']
13513,NCT00720512,Progression-free survival,Safety,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3']
13514,NCT02272036,Bowel cleanness measured by Boston Bowel preparation Scale,Patient satisfaction and compliance,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
13515,NCT03941080,Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,,2020-09-09,RECRUITING,OBSERVATIONAL,['NA']
13516,NCT04728750,Complete enucleation of a tumor in the pancreas,,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
13517,NCT04248634,Perineal complications,Quality of life assessement: EORTC QLQ30 score,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
13518,NCT06189846,The rate of complete and/or nearly complete response,Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management).,,2024-01-04,RECRUITING,OBSERVATIONAL,['NA']
13519,NCT05729230,Perception of prognosis and treatment side effects,Evaluation of patient satisfaction with the information received during the consultation,,2021-04-05,COMPLETED,OBSERVATIONAL,['NA']
13520,NCT03937440,Difference of stress responses between deep block and moderate block,,,2019-07-03,COMPLETED,INTERVENTIONAL,['NA']
13521,NCT02215642,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
13522,NCT05228587,To identify IGT PDR cut-off level below which the liver graft is not to be used for solid organ transplantation,To identify IGT PDR cut-off level(s) below which post-LT organ recovery is impaired (early allograft dysfunction).,,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
13523,NCT02528526,Safety and tolerability as measured by collection of adverse effects information,Efficacy as measured by MRI,,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13524,NCT03117556,Daily Narcotic Requirements,Use of Anti-emetics,,2017-08-31,WITHDRAWN,INTERVENTIONAL,['NA']
13525,NCT01883908,Number of Patients Completing Acupuncture Treatment,,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
13526,NCT03851887,ORR,DCR,,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13527,NCT02557932,H. pylori eradication rate,Factors associated with H. pylori reinfection,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13528,NCT00684801,Caregiver's satisfaction with end-of-life care,,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
13529,NCT04913376,Time until Grade 2 or higher patient-reported peripheral neuropathy after start of treatment in the first 12 weeks,Secondary Outcome Measures regarding comfort hilotherapy,,2021-05-17,UNKNOWN,INTERVENTIONAL,['NA']
13530,NCT05667064,Incidence of ADRs,,,2023-05-10,RECRUITING,OBSERVATIONAL,['NA']
13531,NCT05311189,Progression-free survival,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE,,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13532,NCT06300879,Postoperative TNM staging by Pathological findings .,Quality of Life at 3 Months Postoperatively will be assessed by EORTC QLQ-STO22 scale,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
13533,NCT03277144,incidence of duodenal stump leak,Frequency of DSF by surgical volume,,2017-09-11,UNKNOWN,INTERVENTIONAL,['NA']
13534,NCT03825861,Pathologic Complete Response (pCR),Rate of Disease Progression,,2017-02-23,RECRUITING,INTERVENTIONAL,['PHASE2']
13535,NCT05937919,Standardized uptake value,Number of participants with drug-related adverse events,,2023-05-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13536,NCT04514822,SUVmax 60/30 comparison between MLNs and BLNs,SUVmax 60/30 comparison from PTs between N0 and non-N0 stage,Accuracy,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
13537,NCT02041793,Resolution of Pseudocyst,Recurrence rate of pseudocyst,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
13538,NCT03713593,Overall Survival (OS),Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,2018-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13539,NCT01504477,Maximum Tolerated Dose,Duration of Disease Control,,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13540,NCT03374254,Percentage of participants with a dose limiting toxicity (DLT),Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),,2018-02-16,COMPLETED,INTERVENTIONAL,['PHASE1']
13541,NCT00705731,"Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).",Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
13542,NCT04850157,Relapse-free survival( RFS),Adverse Events (AEs),,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
13543,NCT01494363,Response rate,Overall survival,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13544,NCT04841616,False negative rate,the need to repeat procedure,,2021-07-01,RECRUITING,INTERVENTIONAL,['NA']
13545,NCT04763642,Intra-abdominal infection,Length of hospital stay (day),progression-free survival,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13546,NCT05844046,ORR,ORR-BICR,QOL,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2']
13547,NCT01637194,Number of patients with dose limiting toxicity,Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13548,NCT05842525,Objective response rate (ORR),Progression-Free Survival (PFS),Disease Control Rate (DCR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13549,NCT05198856,progression-free survival (PFS),Percentage of Participants With Adverse Events (AEs),,2022-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13550,NCT04643405,Overall Response Rate (Applicable for: phase II stage) .,Adverse events,,2021-03-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13551,NCT03942328,Progression-free survival rate at 2 years (Phase II),Progression-free survival,Change in immunologic correlates before and after vaccination treatment,2019-09-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13552,NCT04931654,Preliminary anti-tumour activity of AZD7789,Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA),,2021-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13553,NCT02072720,Change of VEGFR2 phosphorylation with IHC,Changes in vascular parameters in the tumor tissue to asses ongoing angiogenesis,,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13554,NCT05848947,Effective dose (Gy) for the whole body,,,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
13555,NCT02190071,positive malignancy rate of cover slides set and base slides set.,"positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy",,2014-06,COMPLETED,OBSERVATIONAL,['NA']
13556,NCT02705196,Number of patient with dose-limiting toxicities (DLTs) as evaluated accordingly to CTCAE 4.0,Overall Survival,,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13557,NCT03052335,Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm),Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
13558,NCT02205463,Maximum Tolerated Dose (MTD),Pharmacokinetics of KD019,,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13559,NCT00767273,Evaluate the performance of the novel imaging methods,Correlate FLT activity with clinical outcomes,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13560,NCT01594125,Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib,Number of Participants With Response by Alpha Fetoprotein (AFP),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13561,NCT02130427,Tumor Volume,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
13562,NCT02210260,Neuroendocrine response to surgery,Inflammatory pathway,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
13563,NCT01091207,Disease-control rate,Response rate,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13564,NCT02066974,Response rate,"Overall survival, relapse-free survival",,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
13565,NCT01151839,operative mortality,Treatment toxicity,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
13566,NCT04529850,Incidence of Treatment Emergent AE's,Cumulative Incidence of Severe OM,,2020-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13567,NCT04291651,Indolency,,,2019-10-08,RECRUITING,OBSERVATIONAL,['NA']
13568,NCT00615420,Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13569,NCT03127774,Progression Free Survival,Overall Survival,,2017-09-22,RECRUITING,INTERVENTIONAL,['PHASE2']
13570,NCT05103007,FLR,Progression-free survival (PFS),,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
13571,NCT04008082,Presence or absence of factors with a possible influence on OS,,,2019-05-14,COMPLETED,OBSERVATIONAL,['NA']
13572,NCT00077441,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart",Time to treatment failure,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13573,NCT02549053,Research of HPV DNA in esophagus biopsies using real time polymerase chain reaction (PCR),,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
13574,NCT01898091,Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.,,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13575,NCT00478010,Decision satisfaction,,,2007-01-19,COMPLETED,INTERVENTIONAL,['NA']
13576,NCT01759901,Post-operative surgical complications,Recurrence rate of hepatocellular carcinoma,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13577,NCT05396807,Progression Free Survival (PFS),Quality of Life (QoL),,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
13578,NCT00078975,Prolonged stable disease rate,Safety and tolerability,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13579,NCT05544253,recurrence-free-survival,,,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13580,NCT00514163,response rate,clinical benefit response,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13581,NCT04326296,"Safety, Tolerability",,,2020-05-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
13582,NCT03349957,tumeur response,,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
13583,NCT06210334,Overall Survival (OS),Adverse Events (AE),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13584,NCT04304131,sensitivity and specificity of EarlyTect,,,2020-06-07,COMPLETED,INTERVENTIONAL,['NA']
13585,NCT05224518,Quality of life of cancer patients(EORTC QLQ-CR29),Exercise Counseling and Programming Preferences,,2022-02-21,RECRUITING,INTERVENTIONAL,['NA']
13586,NCT03988712,Diagnostic yield of colorectal cancer,,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
13587,NCT02730611,Blood bile acids (micromols per liter),Hepatic FXR expression,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
13588,NCT02843581,Relief degree,Overall survival（OS）,,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13589,NCT00258232,Response rate by RECIST criteria at every other course,Time to treatment failure,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13590,NCT00654212,successful one-stage operation,"cumulative operative time, cumulative blood loss, conversion rate, post-operative pain, cumulative length of hospital stay, operative mortality, post-operative complications, ates of permanent stoma creation,disease recurrence, survival",,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13591,NCT01952847,Severity of Oral Mucositis for mTOR Inhibitor Patients,Summary of Adverse Events by Grade and Relationship - mTOR Inhibitor Cohort,,2014-07-10,TERMINATED,INTERVENTIONAL,['PHASE3']
13592,NCT03111732,Progression Free Survival (PFS),"Number of Participants With Grade 1-4 Adverse Events Unrelated, Unlikely, Possibly, and Probably Related to Capecitabine",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2']
13593,NCT05927142,Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.,Determine the clinical effect of combination therapy on quality of life using questionnaires,,2024-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13594,NCT04589884,To collect human tissue spectral features to build a spectral tissue library and build successively machine learning algorithm to enable real-time automated tissue recognition,To correlate HSI values with pathological data obtained as standard of care,,2020-09-22,TERMINATED,OBSERVATIONAL,['NA']
13595,NCT04407247,Treatment-related adverse events,Recurrent immune-related diarrhea/colitis,Change in frequencies of immune cells in tissue/blood/stool samples,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13596,NCT04588805,ncidence Rate of Perioperiative VTE,,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA']
13597,NCT04700527,The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.,Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.,,2023-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13598,NCT00634725,Overall survival,tolerance to erlotinib,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13599,NCT03430440,Postoperative pain (numerical rating scale: 0 ~ 10),Side effects of PCA (area and vomiting / hypotension / muscle weakness,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
13600,NCT06047158,Immune related index,Hospitalization related,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
13601,NCT00077337,,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13602,NCT05187416,Elastic modulus measured by Ultrasonic shear wave and tumor stromal component assessed by pathological analysis in pancreatic cancer,,,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA']
13603,NCT04247503,Incidence of cancer in the risk cohort,Measurement of test accuracy of biomarkers to detect pancreatic cancer,,2019-12-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13604,NCT00002593,"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival",Disease free survival,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13605,NCT05963191,to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.,Time of Colonoscopies,,2023-10-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13606,NCT00820339,Overall survival,"Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications",,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13607,NCT00867464,Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination,,,2009-03-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13608,NCT00618384,determination of time to progression (TTP),adverse events,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
13609,NCT02735317,EORTC QLQ-C30,The change of body weight from baseline.,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
13610,NCT05239546,Major Clinical Response (MCR) Rate,Overall Response Rate (ORR),,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2']
13611,NCT03787056,ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls,"Comparison of the initial values and of the kinetics of other serum tumor markers (CA15-3, CA 19-9, CA125, CEA, PSA, AFP) with those of progastrin",,2018-12-04,RECRUITING,INTERVENTIONAL,['NA']
13612,NCT05526339,The incidence of hypoxia,The incidence of other adverse events,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13613,NCT00122187,Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
13614,NCT01909830,Objective Response Rate (ORR),Overall Survival (OS),,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13615,NCT05447234,Overall Survival,AEs,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13616,NCT05287880,Comparison of BP between MLN and BLN.,,,2022-03-10,UNKNOWN,OBSERVATIONAL,['NA']
13617,NCT03708328,"Expansion: Progression Free Survival, Assessed According to RECIST v1.1","Dose Escalation: Progression Free Survival, Assessed According to RECIST v1.1",,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13618,NCT01286662,mortality,Incidence of desmoid tumors,,1978-01,COMPLETED,OBSERVATIONAL,['NA']
13619,NCT05792735,Pathological Complete Response Rate,Number of participants with treatment-related adverse events (TRAE) as assessed by CTCAE v5.0,Quality of life (QoL),2023-04-11,RECRUITING,INTERVENTIONAL,['PHASE2']
13620,NCT05388513,Survival,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
13621,NCT03998644,"Gut microbiota structure and function difference between colorectal cancer, precancer and healthy controls","Metabolic difference of blood samples between colorectal cancer, precancer and healthy controls",,2015-12,RECRUITING,OBSERVATIONAL,['NA']
13622,NCT04097067,Response rate,Acute and chronic toxicities,,2019-09-01,RECRUITING,INTERVENTIONAL,['NA']
13623,NCT01919463,Mean Intubation Time (MIT),Polyp Detection Rate (PDR),,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
13624,NCT03480152,Number of Non-Serious Adverse Events Probably Related to Treatment,Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells,Maximum Tolerated Dose (MTD,2018-05-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13625,NCT00766480,Complete histological response,,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
13626,NCT05884723,Perioperative blood transfusion,Cancer-related mortality,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13627,NCT02521727,number of participants having advanced neoplasms.,number of participants having advanced neoplasms based on age of the proband,,2015-11-26,COMPLETED,OBSERVATIONAL,['NA']
13628,NCT02046356,Technical success,IDR-free survival,RFA complications,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
13629,NCT01643278,Maximum tolerated dose defined as the highest dose studied for which the observed incidence of dose-limiting toxicity is less than 33% according to the National Cancer Institute Common Toxicity Criteria,"RR as measured by RECIST 1.1, Choi and immune-related response criteria",Genotype (v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT] and platelet-derived growth factor receptor-alpha [PDGFR-a]) mutation status,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13630,NCT02775227,Comprehensive Complication Index,Readmissions,Disease specific survival,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
13631,NCT01586416,Number of participants who withdraw from study after enrollment,Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
13632,NCT05381038,CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.,Clinically significant dose changes,ctDNA Analysis,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13633,NCT02657330,Maximum tolerated dose of SBP-101,Plasma drug half-life,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13634,NCT02907086,Number of blood samples collected,,,2017-07-07,COMPLETED,OBSERVATIONAL,['NA']
13635,NCT01695863,Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS),Renal Function Pre and Post Bowel Prep - Continued (mmol/L),Non-Serious Adverse Events on Self Report Scale,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13636,NCT05177393,Median Overall Survival,,,2019-02-28,RECRUITING,OBSERVATIONAL,['NA']
13637,NCT03129685,Short term mortality rate,Tumor response rate according to mRECIST criteria.,,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA']
13638,NCT05628441,Combined performance of endoscopist + CADe system in terms of per-patient sensitivity and specificity,Stand-alone performance of CADe system in terms of per-patient sensitivity and specificity,,2022-05-16,COMPLETED,OBSERVATIONAL,['NA']
13639,NCT02973490,postoperative complications,,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
13640,NCT05738616,Overall survival at 2 years,Quality of life assessment,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13641,NCT02041325,Positive for Hepatitis B Surface Antigen,Phenotypic Changes,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13642,NCT01755585,all cause mortality,,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
13643,NCT00267696,Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding.,Overall Survival for Patients Treated With the Regimen.,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13644,NCT04310540,Association between prostate specific membrane antigen (PSMA) uptake in hepatocellular carcinoma at PET with tissue PSMA expression,,,2020-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13645,NCT01835925,Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.,Tumor tissue results with clinical outcome post standard treatment. .,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
13646,NCT04166721,Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteria,Overall survival,,2020-02-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13647,NCT04949737,Estimation of the prevalence of Helicobacter pylori,,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13648,NCT00100815,Progression-free Survival,Overall Survival,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13649,NCT00192114,Percentage of Participants With Progression Free Survival (PFS) at 6 Months,Change From Baseline in Carcinoembryonic Antigen (CEA) Response at Each Cycle,Change From Baseline in Vascular Endothelial Growth Factor (VEGF) to Cycle 2 and Cycle 3,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13650,NCT01216527,Overall survival rate,Disease free survival rate,,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
13651,NCT04149015,Pathological complete and subtotal regression (TRG1a/b by Becker),,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
13652,NCT04697186,Helicobacter pylori eradication,adverse events,,2021-01-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13653,NCT05450029,Pathological complete response,Correlation between minimal residual disease (MRD) and survival,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13654,NCT01832116,The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A,Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13655,NCT05817994,"Number of endoscopic, endosonographic, and radiologic interventions undergone to reach a diagnostic liver biopsy [Phase 2]",Number of diagnostic liver biopsies,,2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13656,NCT03569761,CRC screening intentions,CRC screening completion,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13657,NCT04175756,Total operative time,Quality of excision: M.E.R.C.U.R.Y. criteria,,2020-01-02,COMPLETED,OBSERVATIONAL,['NA']
13658,NCT00081627,,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13659,NCT02653313,Shedding of viral genomes [Vg],Clinical outcome,,2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13660,NCT00268411,Objective response rate,Progression-free and overall survival,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
13661,NCT00793871,Progression-free Survival (PFS),Eastern Cooperative Oncology Group (ECOG) Performance Status,Time to Tumor Response (TTR),2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13662,NCT00088868,,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13663,NCT01292330,postoperative complications,hospitalization expenses and length of stay,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
13664,NCT04239001,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,The proportion of patients receiving antibiotics during the entire chemotherapy period.,,2020-02,UNKNOWN,INTERVENTIONAL,['NA']
13665,NCT00932438,Tumor Response,Number of Serious Adverse Events,,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13666,NCT04380545,Incidence of adverse events,Progression-free survival (PFS),Tissue and blood immunohistochemistry,2021-01-13,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13667,NCT04902872,Phase 2: Overall response rate (ORR),Phase 2: Incidence of TEAEs,,2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13668,NCT03603366,Patients' benefit/risk trade-offs,Preferences of aspirin using in different subgroups,,2019-08-14,COMPLETED,OBSERVATIONAL,['NA']
13669,NCT02023021,Recurrence-free survival at one year after curative resection,CA199 level after curative resection,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13670,NCT05002855,Evaluate the effect of the implementation of this protocol on 3-year overall survival.,,,2021-01-20,COMPLETED,OBSERVATIONAL,['NA']
13671,NCT01739439,MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1']
13672,NCT03599895,operation time,hospitalization expenses,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
13673,NCT04207489,The imaging effect of indocyanine green,,,2020-04-15,UNKNOWN,OBSERVATIONAL,['NA']
13674,NCT01150630,Event-free survival at 1 year (phase II),Lymph node status,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13675,NCT03595345,Tumour-specific death,Drop-out,,2016-12-15,COMPLETED,OBSERVATIONAL,['NA']
13676,NCT00006010,six-month overall survival,time to progression,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13677,NCT06143605,DFS,,,2013-01-30,COMPLETED,OBSERVATIONAL,['NA']
13678,NCT05326152,Immediate adverse effects,Recurrence,,2020-11-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13679,NCT02430636,Number of participants with Adverse events,Overall survival (OS),,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
13680,NCT00738790,The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.,"The rate of local control, overall survival and disease-free survival and toxicity.",,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
13681,NCT03667495,Colorectal cancer or adenoma recurred,,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
13682,NCT00946153,Phase 2: Time to Progression (TTP) by Independent Review Assessment,Phase 2: Overall Survival (OS),,2009-07-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13683,NCT01962168,Freedom from symptomatic recurrent biliary obstruction requiring reintervention,Ease of use,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
13684,NCT03946969,Safety and feasibility,Overall Survival (OS),Exploratory Outcomes,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13685,NCT05434026,the rate of postoperative complications,,,2022-08-03,RECRUITING,OBSERVATIONAL,['NA']
13686,NCT03420443,Action of synbiotics on irradiated GI mucosa in rectal cancer treatment,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
13687,NCT04856761,"RFS, recurrence-free survival","OS, overall survival",,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
13688,NCT00216086,Pathological Complete Response (pCR) Rate,Disease-Free Survival,,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2']
13689,NCT01415609,Ease of use of the overall procedure and Time of procedure.,Complications and Rate of Completion,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
13690,NCT01839487,Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study,Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20,,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE2']
13691,NCT00005860,,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13692,NCT05919264,During dose expansion describe the Overall Response Rate using RECIST v1.1,During dose expansion describe Progression Free Survival,,2023-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13693,NCT00746655,To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.,To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.,,2009-07,WITHDRAWN,INTERVENTIONAL,['NA']
13694,NCT04080024,Number of treatment related adverse events (AEs),Pharmacokinetics as measured by apparent volume of distribution at steady state (Vss) for Mn (L) the terminal phase half-life (T½) for manganese (Mn),Visualization of the pancreatic duct,2019-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
13695,NCT02103062,Progression Free Survival (PFS) Rate as Measured at Week 8,Number of Participants With Adverse Events,Kaplan Meier Estimate of PFS by Investigator Assessment,2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13696,NCT05331131,Assessing Pain Response,Adverse events,,2022-09-19,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13697,NCT02777463,The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.,The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
13698,NCT03619538,Estimate morphine consumption,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
13699,NCT00351195,Response,Survival,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2']
13700,NCT01929421,Response rate,number of participants with adverse events,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13701,NCT06028737,Histopathological tumor response rate (Becker regression criteria).,Correlation between the pathohistological response and overall and disease-free survival.,,2023-08-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13702,NCT00574860,NCI v3 to measure severity of OM,WHO criteria for measuring severity of OM,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
13703,NCT01097083,,,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2']
13704,NCT06033976,Rate of curative resection,Rate of R0 resection,Rate of delayed bleeding,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
13705,NCT00915850,Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST),median survival time (Phase II),,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13706,NCT00005599,,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13707,NCT00268437,Pathologic Complete Response Rate,Overall Survival,,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2']
13708,NCT05568433,Role of the cyst fluid concentrations of the specific biomarkers for differentiation the pancreatic cystic lesions,The Correlation between cyst fluid concentration and serum level of the specific biomarkers,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA']
13709,NCT05797077,5-years Progression Free Survival,Complication,,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3']
13710,NCT00786747,Up to date colorectal cancer screening status,Readiness to undergo colorectal cancer screening,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
13711,NCT03368651,Overall survival (OS),recurrence rate,,2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13712,NCT04713007,Perception of Care Coordination Caregiver,,,2021-06-03,RECRUITING,INTERVENTIONAL,['NA']
13713,NCT01596361,Verify the differences observed in the frequency of germline pharmacogenetic variants related to chemotherapy between Asian and Caucasian CRC patients,Characterise the deletion status of heat shock protein molecules and determine the association between heat shock protein deletion status and clinico-pathological outcomes in Asian and Caucasian patients with CRC,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
13714,NCT03875144,overall survival,Quality of life evaluation,,2020-08-14,RECRUITING,INTERVENTIONAL,['PHASE2']
13715,NCT04990895,Assessment of the Quality of Life of Colorectal Cancer Patients Using EORTC-QLQ CR29 Questionnaire,Patient self-efficacy,,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE3']
13716,NCT05976568,Overall Survival (OS) (Phase III),Time to progression (TTP),,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13717,NCT00985556,Progression-free survival,Time to progression,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13718,NCT04792801,Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline,Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout.,,2021-06-22,RECRUITING,OBSERVATIONAL,['NA']
13719,NCT00397540,"1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)",Overall Survival,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
13720,NCT03575637,time to treatment failure,"Progression free survival time (PFS), overall survival time (OS).",,2018-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
13721,NCT00967603,6-month progression-free survival,pharmacodynamics,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13722,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,Evaluation of Intervention Effectiveness - Change in Demographics,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
13723,NCT01291615,frequency in adverse events,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13724,NCT06293625,DFS (disease Free Survival),,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13725,NCT02720666,The maximum-tolerated dose (MTD) of K-001,Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13726,NCT01803009,Preferred CRC screening test,Uptake of CRC screening,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
13727,NCT03894618,Maximum Tolerated Dose (MTD) of SL-279252,Volume of distribution,,2019-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13728,NCT03311152,Presence of hepatocellular carcinoma.,Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013;2:69-72).,,2018-02-12,RECRUITING,INTERVENTIONAL,['NA']
13729,NCT01560260,Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1,"Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response.",Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical Benefit.,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13730,NCT01426074,Pathologic Complete Response (pCR),,,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13731,NCT02414100,"Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors",,,2013-12-12,WITHDRAWN,OBSERVATIONAL,['NA']
13732,NCT00987857,Overall survival,Frequency of endoscopy,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
13733,NCT02007954,Collection of Adverse Events Related to Study Device as a Measure of Safety,AFP Tumor Marker Pre- and Post-treatment,Exploratory Endpoint - Tmax of Doxorubicin and Doxorubicinol Post DEBDOX-M1 TACE,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13734,NCT05813028,"Change of Beck Anxiety Inventory score at baseline and one week later fisrt,second,third and forth chemothraphy.",,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
13735,NCT05489211,PSA50 response (Substudy 3 only),CA-125 response (Substudy 4),,2022-09-06,RECRUITING,INTERVENTIONAL,['PHASE2']
13736,NCT05323058,Severity of mucositis,Pain and burning sensation,Patient-Reported Oral Mucositis( PROMS scale),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13737,NCT05483075,Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention,Minutes Spent in Rapid Eye Movement (REM) Sleep,,2022-11-15,RECRUITING,INTERVENTIONAL,['NA']
13738,NCT01403727,Radiation Dose,Accuracy of needle targeting,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
13739,NCT01412957,Overall Survival,Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13740,NCT03626922,Objective Response Rate to pembrolizumab and pemetrexed plus oxaliplatin,Overall Survival,,2019-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13741,NCT06074536,"The Measurement of the achievement oh the shared decision shared decision making in CRC screening using the patient shared a self-decision-making questionnaire (SDM-Q9), validated in French",Explore understanding of the shared decision process among general practitioners and patients,,2024-03-06,RECRUITING,INTERVENTIONAL,['NA']
13742,NCT03924349,Success rate of localization,Number of Participants with Complication,,2019-07-08,COMPLETED,INTERVENTIONAL,['NA']
13743,NCT05415917,Safety as assessed by number of participants experiencing adverse events,,To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST),2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2']
13744,NCT01710592,"Determine in a randomised study if the response rate to docetaxel and oxaliplatin (ElTax) is comparable to epirubicin, oxaliplatin and capecitabine (EOX) and warrants further evaluation in advanced gastro-oesophageal cancer",To examine the effect of treatment on Quality of life.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13745,NCT00274872,Pharmaco-economic evaluation,,,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13746,NCT00460174,Response rate,Toxicity profile of bevacizumab and gemcitabine with radiation therapy,,2005-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13747,NCT04345978,Disease-free Survival,"IL-1β，IL-2,IL-4,IL-5,IL-6,IL-8,IL-10,IL-17A,IL-17F,TNF-α，TNF-β，",,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
13748,NCT02877056,Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer,,,2005-08,UNKNOWN,OBSERVATIONAL,['NA']
13749,NCT04527068,Progression-free survival (PFS),Duration of Response (DOR),,2020-09-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
13750,NCT02508467,"Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings",Preliminary evidence of fisogatinib (BLU-554) antineoplastic activity,,2015-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13751,NCT06011330,overall survival (OS),progress-free survival (PFS),Treatment-Related Adverse Events (TRAE),2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
13752,NCT01591590,Mortality,Tumour Progression,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
13753,NCT03711058,6-month Objective Response Rate (ORR) of Patients Treated With Copanlisib and Nivolumab,Number of Participants Experiencing Study Drug-related Toxicities,,2019-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13754,NCT02812641,Pathological complete response rate (randomized phase),Overall survival,Serum biomarker (VEGF-A),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
13755,NCT04644315,"Confirmed Objective Response Rate (ORR) as Determined by the Investigator Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",OS in Participants With Primary CNS Tumors,,2021-05-24,TERMINATED,INTERVENTIONAL,['PHASE2']
13756,NCT05400018,Ct Value (Ct Values From PCR Reaction),Kappa coefficient,,2020-11-20,COMPLETED,OBSERVATIONAL,['NA']
13757,NCT05479240,Pathological complete response rate,,overall survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13758,NCT00417209,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause,Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13759,NCT00499369,Progression-free Survival (PFS),Toxicity,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3']
13760,NCT05815290,complete response rate,pCR rate,,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2']
13761,NCT02625272,the content RNA of CEA and CK20 in circulating tumor cells and ascites,3-year local recurrence,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
13762,NCT01619696,acceptation rate of the entire sequence by eligible patients,"radiological changes while on chimiotherapy, to tumour regression, and prognosis",,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
13763,NCT01824459,Overall Survival,Adverse events (AE),,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13764,NCT03205735,progression free survival,toxicities evaluation,,2017-06-29,UNKNOWN,OBSERVATIONAL,['NA']
13765,NCT04525833,The incidence of a new diagnosis of any event of liver cirrhosis complications,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13766,NCT05933785,anal preservation rate,incidence of positive distal resection margin,,2018-01-02,COMPLETED,OBSERVATIONAL,['NA']
13767,NCT00718913,The proportion of patients completing protocol therapy (feasibility),Overall survival,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13768,NCT01328171,overall response rate,translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13769,NCT05952661,Correlations of minimal residual disease (MRD) and efficacy,The timing of MRD advance warning of recurrence in patients ahead of imaging cues,ctDNA mutation profiles in ESCC patients undergoing adjuvant immunotherapy.,2023-02-22,RECRUITING,OBSERVATIONAL,['NA']
13770,NCT01070290,Compare the progression-free survival (PFS) of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with advanced gastric cancer who have failed first-line treatment.,Further characterize the safety profile of ARQ 197,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13771,NCT00114829,Sensitivity in determining malignant or benign diagnose,Sensitivity/specificity of MR colonography,,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
13772,NCT00865982,R0-resection rate,Event free survival rate,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
13773,NCT02757391,Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0,Overall survival,,2019-08-09,TERMINATED,INTERVENTIONAL,['PHASE1']
13774,NCT02960061,Number of survival participants will be assessed according to the data collected by the followed up office.,Progression Free Survival,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
13775,NCT00086931,Complete pathological response rate at time of surgery,"Disease-free survival, safety, and overall survival at 5 years",,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13776,NCT05396846,Weight Loss,,Skin Carotenoids,2023-04-29,RECRUITING,INTERVENTIONAL,['NA']
13777,NCT04902261,1-Year Survival Rates,Adverse Events (AEs),,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2']
13778,NCT04384757,3 year relapse-free survival by Kaplan Mayer,Resected lymph nodes,,2020-07-29,RECRUITING,INTERVENTIONAL,['NA']
13779,NCT04891146,investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value,,,2020-03-05,COMPLETED,OBSERVATIONAL,['NA']
13780,NCT02058849,Endurance,Muscle Strength,Total Body Mass,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13781,NCT01853774,Primary Outcome is Clinic Attendance,The Secondary Outcome is Participant Completion of a CRC Screening Test.,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13782,NCT06335966,Patient acceptability: Number of patients interested in being screened via SECD at other care centers,Access: time to full diagnostic work up for patients with positive SECD results,,2024-01-25,RECRUITING,OBSERVATIONAL,['NA']
13783,NCT05803746,MPR,PFS,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
13784,NCT05873699,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE1']
13785,NCT05682157,Change in LARS score,,,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
13786,NCT04801719,Overall survival,Complications of endoluminal RFA of biliary tract,,2010-01-04,COMPLETED,INTERVENTIONAL,['NA']
13787,NCT05171660,Progression free survival time,Adverse Events,,2022-02-08,RECRUITING,INTERVENTIONAL,['PHASE3']
13788,NCT06272656,"comparison of liver cancer markers AKR1B10, AFP, AFP-L3% and DCP before and after TACE",progression- free - time,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13789,NCT03269994,Compare the effectiveness of cefoxitin with piperacillin-tazobactam as surgical antibiotic prophylaxis in decreasing the overall rate of postoperative surgical site infections in participants undergoing pancreatoduodenectomy,,,2017-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13790,NCT02694718,Percentage of Participants With Pathological Complete Tumor Response,Number of Participants With Any Adverse Events and Serious Adverse Events,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13791,NCT05233007,Predicting treatment resistance to anti-cancer therapy,,,2022-01-25,SUSPENDED,OBSERVATIONAL,['NA']
13792,NCT06152757,"AE, SAE, AESI, CRS, ICANS, TEAE",,,2023-10-09,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13793,NCT05811481,Overall survival,Progression-free survival for the first subsequent treatment PFS 2,,2022-12-27,RECRUITING,OBSERVATIONAL,['NA']
13794,NCT03851913,OS,PFS,,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13795,NCT02028806,Disease control rate,EORTC QLQ-C30,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13796,NCT04524260,Change of Anxiety,Change of Health related quality of life - SF-12,Socio-economic: ability to return to work,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
13797,NCT05911633,Technical success,Best overall response,,2024-02-29,RECRUITING,INTERVENTIONAL,['NA']
13798,NCT01161186,"to establish the maximal tolerated dose (MTD) of the AGX combination in patients with previously untreated, metastatic pancreatic adenocarcinoma.","To obtain a preliminary assessment of the clinical efficacy of AGX as measured by time to tumor progression, overall survival, objective radiographic response (ORR), and CA 19-9 biomarker response",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13799,NCT05147545,Change in circulating DNA induced by moderate effort in subjects free of malignacy,Change in circulating DNA induced by hyperlipidic meal in patients with colon cancer,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13800,NCT03679429,Accuracy optical biopsy,Adenoma detection rate,,2018-11,UNKNOWN,OBSERVATIONAL,['NA']
13801,NCT05639413,Overall Survival (OS),Correlation between predictive biomarkers and response to treatment,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
13802,NCT03851471,Overall Survival,10cm-VAS of the pain,,2019-04-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13803,NCT03307603,Phase II: Response rate,Phase II: Overall survival,,2018-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13804,NCT05886257,ORR per RECIST 1.1,PD-L1 Biomarker,,2022-12-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13805,NCT01638533,Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method,Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria,,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13806,NCT05420922,The treatment-related adverse events (TRAEs),The progression-free survival (PFS),,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
13807,NCT02543411,Fentanyl consumption during sedation,Incidence of nausea and vomiting,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
13808,NCT03947775,The proportion of participants in each arm with biopsy-proven HGAIN (AIN-2/3).,"The geometric mean titres (GMT) of antibody to each vaccine type above a pre-specified, validated cut-off. F",Change in anal carriage of vaccine HPV types. Repeated detection of anal HPV will indicate the duration of carriage. This will be compared between the early and delayed vaccine groups.,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13809,NCT00765180,Colorectal adenoma detection rate,"Procedure time, complication",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
13810,NCT01455311,Rank The Diagnostic Accuracy of Specimen,Cataloging Proteins,,2010-09,TERMINATED,OBSERVATIONAL,['NA']
13811,NCT00732836,Maximum Tolerated Dose (MTD) of HAI Abraxane,,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13812,NCT02595424,PFS,Response rate (complete response or partial response) by RECIST 1.1,Prognostic significance of well differentiated non-small cell gastroenteropancreatic neuroendocrine tumors,2016-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13813,NCT00005085,,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13814,NCT00440310,Overall Survival,,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13815,NCT04591431,OVERALL RESPONSE RATE (ORR),Overall survival (OS),,2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13816,NCT02132468,"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline","Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1",,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13817,NCT01057017,Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab,,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2']
13818,NCT05609149,3-year event-free survival rate,Local recurrence,,2016-10-30,COMPLETED,OBSERVATIONAL,['NA']
13819,NCT05615103,Pathologic complete response rate (pCR),Safety as measured by number of participants with Grade 3 and 4 adverse events,,2022-11-08,RECRUITING,OBSERVATIONAL,['NA']
13820,NCT02409524,To evaluate survival compared to historical controls,To evaluate safety in advanced HCC (adverse events),Tumor-Specific Immunity,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13821,NCT03504293,Diagnostic accuracy,Adverse event rate,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
13822,NCT02196688,Progression Free Survival (PFS),Over Survival (OS),,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13823,NCT05591053,Usability of the device by surgeon and support personnel satisfaction;,Ability of ActivSightTM to display blood vessels.,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
13824,NCT06192680,Progression free Survival,Incidence of adverse events,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13825,NCT06265350,Objective response rate (ORR),Overall survival (OS),,2024-02-02,RECRUITING,INTERVENTIONAL,['NA']
13826,NCT05053750,To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab,,,2021-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13827,NCT04195438,Measure the extent of HO-1 induction by measuring endogenous CO production in relationship to the extent of hepatic resection,Measure the relationship between HO-1 induction and the quality of post-hepatectomy liver regeneration,,2014-05-07,RECRUITING,INTERVENTIONAL,['NA']
13828,NCT06274190,Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome.,,,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13829,NCT00470535,Progression-free Survival,"Correlation of Response, QOL, and Survival With EGFR, E-cadherin, P-cadherin, Vimentin, Cytokeratin, ki67, and Fibronectin and With Other Prognostic Variables, Such as Age and Tumor Grade",,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
13830,NCT02518529,Measurable Gastrin-17 Antibody Titer,Overall Survival from date of randomization to death or end of study,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13831,NCT01619423,Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia),,,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13832,NCT04645797,Primary Outcome Measure,Secondary Outcome,,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
13833,NCT00482846,Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis,Reduction in incidence and duration of mucositis,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13834,NCT06031818,Clinical effectiveness of the explanation framework,Usability of the explanation framework,,2023-12-10,RECRUITING,OBSERVATIONAL,['NA']
13835,NCT03718078,malignant pCLE criteria,pCLE criteria diagnostic performance,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
13836,NCT06035250,Accuracy of TRG prediction by the AI model,Overall Survival (OS) at 5 years,,2023-09-10,RECRUITING,OBSERVATIONAL,['NA']
13837,NCT01584336,The incidence of postoperative morbidity and mortality,the surgical outcomes according to the method of reconstruction,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13838,NCT02575391,Measurement of Tolerability,Treatment Break Measurement,,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13839,NCT01908426,Overall Survival (OS),Objective Response Rate (ORR),,2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
13840,NCT03978481,Overall survival,Metachronous cancer (remnant stomach cancer),,2019-01-30,COMPLETED,OBSERVATIONAL,['NA']
13841,NCT05524090,In-hospital major morbidity,Shared decision-making: patients' healthcare satisfaction,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
13842,NCT02275403,Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN,Uptake of the offer of acupuncture at 10 weeks,,2015-04-13,COMPLETED,INTERVENTIONAL,['PHASE2']
13843,NCT02594150,Increase in return rate of completed FIT,,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
13844,NCT04513431,Adverse events that related to treatment,Maximum tolerated dose (MTD) of CEA targeted CAR T cells,,2020-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13845,NCT04174339,Objective response rate(ORR),Disease control rate(DCR),,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA']
13846,NCT00265811,Disease-free survival,Overall survival,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13847,NCT01393093,Time to progression,remission rate,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
13848,NCT06241326,Adverse events,Overall survival,,2024-02-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13849,NCT03377400,Progression-free survival,,,2017-12-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
13850,NCT05461248,Incidence of low anterior resection syndrome,Quality of life score,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13851,NCT06019455,Incidence of >=Grade 3 toxicities,Progression-free survival,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
13852,NCT00314678,Recurrence-Free Interval,Examine the toxicity of therapy and to develop suitable strategies for dose modification.,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13853,NCT03141437,Patients' decisional conflict (Part 2),Patients' decision-making process (Part 2),Feasibility of the multicomponent DS intervention and research methods (Part 2),2017-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13854,NCT01580540,Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13855,NCT03245892,number of patients with dose limiting toxicities weekly paclitaxel/carboplatin plus nivolumab and ipilimumab,,,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13856,NCT04455737,retrieved lymph nodes,survival,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
13857,NCT01299493,Practice-level colon cancer screening rate,,,2012-06-19,COMPLETED,INTERVENTIONAL,['NA']
13858,NCT00001532,evaluating the role of hereditary factor,"low dose radiation CT scan, and Zoom Scan",,1996-09-13,RECRUITING,OBSERVATIONAL,['NA']
13859,NCT00631410,Number of Participants With Adverse Events,Sunitinib Relative Dose Intensity in the Treatment Arm B,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13860,NCT04162665,Complete pathologic response (pCR - primary and nodal) rate,Proportion of patients able to complete a full course of total neoadjuvant chemotherapy,Average percent difference in coverage of planning target volume (PTV) by 95% isodose line,2020-02-14,RECRUITING,INTERVENTIONAL,['PHASE2']
13861,NCT02973204,Concordance between specific DNA mutations found in patient biopsies and plasma circulating tumor DNA,Correlations between mutations fund in circulating DNA and circulating tumor cells,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
13862,NCT01034670,Detection of neoplasia,,,2009-06,RECRUITING,INTERVENTIONAL,['NA']
13863,NCT00564720,Overall Survival,Symptoms improvement,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13864,NCT05164315,Overall Survival (OS),defecation function,,2022-01-03,RECRUITING,INTERVENTIONAL,['NA']
13865,NCT04543019,Progression free survival (PFS) and overall survival (OS),response to systemic therapy,,2020-12,UNKNOWN,OBSERVATIONAL,['NA']
13866,NCT04294264,Overall response rate,Incidence of adverse events,,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13867,NCT00135577,"Incidence of reported adverse events, including serious adverse events","Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13868,NCT00782834,Response Rate,,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2']
13869,NCT05031949,Progression-free survival based on RECIST v1.1,Number of Subjects with one or more adverse events as assessed by CTCAE 5.0,,2021-10-30,RECRUITING,INTERVENTIONAL,['PHASE1']
13870,NCT00409292,To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.,to Assess Overall Survival Associated With RAD001 in This Patient Population.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13871,NCT03098589,Adverse Events (AEs),,,2017-05-30,RECRUITING,OBSERVATIONAL,['NA']
13872,NCT00093444,"Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion",Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13873,NCT01773980,Number of participants with improved cancer screening,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
13874,NCT04318834,Number of participants with tumour whole genome sequencing returned within 8 weeks,Number of patients who received a targeted therapy (after first-line treatment),,2020-04-01,RECRUITING,INTERVENTIONAL,['NA']
13875,NCT05677724,single cell RNA sequencing,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
13876,NCT01451632,To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan,Immunogenicity,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13877,NCT01023633,DDC: Duration of Disease Control,"OS, RR, PFS, DCR, safety,",,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13878,NCT03215290,Cutting surface related complications,Interventions for cutting surface related complications,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13879,NCT00820456,To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.,To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.,,2008-04,TERMINATED,OBSERVATIONAL,['NA']
13880,NCT05746182,Rate of overall pathogenic germline mutations,Rate of completion of testing,,2023-04-07,RECRUITING,OBSERVATIONAL,['NA']
13881,NCT01547130,Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy,Total Preparation Time,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13882,NCT01858207,The rate of complete necrosis (CN),Major complication,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13883,NCT05197504,collected blood samples,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC,,2021-12-20,RECRUITING,OBSERVATIONAL,['NA']
13884,NCT03264807,Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancer,,,2015-08-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
13885,NCT04276415,Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Expansion),Number of Participants With Anti-drug Antibodies Against DS-6157a Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST),,2020-05-08,TERMINATED,INTERVENTIONAL,['PHASE1']
13886,NCT03060720,"We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool",Number of patients who disclose genetic testing results to relatives,,2017-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13887,NCT00745927,Degree of abdominal discomfort during and after colonoscopy,Number of neoplasm detected,,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
13888,NCT03064646,Percentage of organ preservative strategies after neoadjuvant treatment in locally advanced rectal cancer,Quality of Life in patient with rectal cancer,Colostomy free survival,2017-03-10,RECRUITING,INTERVENTIONAL,['NA']
13889,NCT01524575,6 month overall survival,Duration of overall response,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13890,NCT05077839,ORR,OS,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13891,NCT04212273,"The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI",The detection rate of the additionally found HCC,,2019-12-21,RECRUITING,INTERVENTIONAL,['NA']
13892,NCT01074216,To Achieve Target Vitamin D Level,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13893,NCT01191138,Gastric Emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide,Correlation of pancreatic duct leak with gastric emptying,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13894,NCT02259647,Overall Survival,Safety,,2014-10-01,COMPLETED,INTERVENTIONAL,['NA']
13895,NCT04543695,The rate of tumor down-staging,Incidence of surgical complications,,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13896,NCT01507064,Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA),Survival in the two treatment groups,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13897,NCT00003995,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13898,NCT05248581,percentage overall survival,,,2019-08-16,RECRUITING,OBSERVATIONAL,['NA']
13899,NCT00510796,Feasibility to perform both colon and endometrial cancer screening at the time of colonoscopy in women at high risk for colon and endometrial cancer.,,,2002-03,COMPLETED,OBSERVATIONAL,['NA']
13900,NCT05065957,To assess disease control rate (DCR),To assess overall survival (OS),,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13901,NCT00940758,To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy,To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13902,NCT04522687,Overall Survival,Progression Free Survival,,2012-01-01,RECRUITING,OBSERVATIONAL,['NA']
13903,NCT00640913,Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment,Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.,,2008-02,UNKNOWN,OBSERVATIONAL,['NA']
13904,NCT00154817,"The primary objective is to evaluate response rate, tolerability and failure pattern of local radiotherapy for the treatment of locally advanced HCC.",The second objective is to correlate parameters of tumor perfusion assessed by dynamic contrast enhanced MRI (DCEMRI) and serum cytokine levels with clinical outcomes.,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13905,NCT05795920,progression free survival progression free survival,Duration of response Duration of Response,,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
13906,NCT02432963,"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3","T cell reactivity to p53, assessed by flow cytometry",,2016-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13907,NCT05059444,Distant Recurrence Free Interval (D-RFi),Lead Time,Rate of ctDNA clearance with adjuvant chemotherapy,2021-09-07,RECRUITING,OBSERVATIONAL,['NA']
13908,NCT01385579,Completion of a Colorectal Cancer Screening,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13909,NCT04929028,Incidence of adverse events (High-risk stratum),Change in combination antiretroviral therapy (cART) adherence,Impact of reduced intensity CRT on quality of life,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE2']
13910,NCT01595243,12-Item Short Form Survey,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
13911,NCT00764621,Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.,"Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13912,NCT01906008,Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months,Average Area Under the Curve (AUC) for Fatigue Over 4 Months,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13913,NCT05846295,"Participant entered rate of accurate polyp size classification into diminutive (1-5 mm), small (6-9 mm), or large (≥10 mm) category on 40 question polyp sizing test.",Proportion of participant responses that underestimate actual polyp size category versus overestimate actual polyp size category on the 40-question polyp sizing test.,,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13914,NCT01210313,feasibility of physical activity,gen- and metabolic signs,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
13915,NCT04513223,DLT and the recommended Phase 2 dose (RP2D),,,2021-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
13916,NCT02567331,"Response rate, ie, percentage of participants with complete, partial, and overall response",Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13917,NCT03113942,Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy,effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy,,2017-06-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
13918,NCT04089631,Disease free Survival (DFS),Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy,,2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE3']
13919,NCT01359410,Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System,Number of Non-pancreatic Adverse Events,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
13920,NCT00813137,Time to progression,,,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
13921,NCT03481920,To assess the safety of this combination in patients with PDAC.,"Changes in CA 19,9 leves",Immune infiltrate.,2018-01-10,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
13922,NCT01979029,The Blood Pressure of the Arterial Arcade,Distal Colon Length,Systemic Blood Pressure,2013-02,COMPLETED,INTERVENTIONAL,['NA']
13923,NCT03532711,Objective Response Rate (ORR),Progression Free Survival (PFS),,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
13924,NCT06192212,perioperative 90-day mortality.,Albumin loss rate,,2023-12-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13925,NCT00052585,Response rate,,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2']
13926,NCT01078415,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
13927,NCT00639925,"Adverse effect, toxicities as assessed by NCI CTCAE version3.0",feasibility,,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
13928,NCT02088333,Completion of CRC Screening,Usability of the mCRC system,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13929,NCT04847726,Diagnostic accuracy for HCC: non-inferiority test,Diagnostic performance of perfulorobutane enhanced USG using different definition of washout,Role of perfluorobutane enhanced USG in EASL diagnostic algorithm of HCC,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
13930,NCT01607957,Overall Survival,"Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths",,2012-06-17,COMPLETED,INTERVENTIONAL,['PHASE3']
13931,NCT05027347,The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients,The concordance rate of mutation results between plasma and tissue biopsy assay,,2021-10-10,UNKNOWN,OBSERVATIONAL,['NA']
13932,NCT00243854,"To determine if giving chemotherapy, radiation, and Tarceva,(EGFR-tyrosine kinase inhibitor)will have side effects that will prevent surgery following this therapy",,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13933,NCT02485015,Overall Survival(OS),Disease-free survival,Adverse events,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13934,NCT00990535,Tumor stabilization,Decrease of chromogranin-A,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13935,NCT04837742,Drug spread level of erector spinae plane block,Postoperative recovery quality,,2021-04-14,COMPLETED,INTERVENTIONAL,['NA']
13936,NCT00199862,Toxicity defined by NCI Common Toxicity Criteria,HAHA levels - measured by plasmon resonance surface (Biacore®) assay,,2004-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13937,NCT00569790,Safety,"Progression-free survival, Response rate, Overall survival, Treatment situation",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13938,NCT03821025,Number of patients without stent failure,Cost,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
13939,NCT05689918,Level of awareness of esophageal cancer risk factors and alarm symptoms,Beliefs about esophageal cancer,,2022-12-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13940,NCT06148155,Complete PET imaging,,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
13941,NCT06128785,Time of first postoperative exhaust,Biochemical indexes 3,Adverse Event Assessment,2023-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13942,NCT01039519,Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0,Count of Participants With Treatment-Emergent Adverse Events (AEs),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13943,NCT00501813,Overall survival rate,Quality of live,,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
13944,NCT04022109,Specific chemistry identification in the exhaled breath,Gut microbiota analysis in relation to breath VOCs,Confounding factor analysis,2019-11-01,RECRUITING,OBSERVATIONAL,['NA']
13945,NCT00806611,The primary endpoint is cancer related pain control.,,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13946,NCT04764227,Local control rate,Overall survival,,2020-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13947,NCT04435652,Overall survival（OS）（stage 2）,Immunogenicity（stage 1 and 2）,,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13948,NCT04149093,Long-term outcomes (Quality of life questionnaire),Functional outcomes,,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA']
13949,NCT05006092,adenoma detection rate,Boston Bowl Preparation Score,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
13950,NCT03826446,Recurrence rate in open and laparoscopic complete mesocolic excision groups in right cancer colon,,,2016-01-13,COMPLETED,INTERVENTIONAL,['NA']
13951,NCT00484939,Progression-free Survival,"AEs, Laboratory Parameters, Vital Signs",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13952,NCT02504099,Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12),Percentage of Participants With Recurrent HCV Infection Post Liver Transplant,,2015-07,TERMINATED,INTERVENTIONAL,['PHASE3']
13953,NCT02707315,percentage of subjects who successfully undergo pancreaticoduodenectomy,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2013-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13954,NCT01380600,Determine the safety of JX-594 administered by biweekly IV infusion,Determine the anti-tumoral response of JX-594,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13955,NCT00826813,Overall survival,Dysphagia relief,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
13956,NCT03864211,Progression free survival,The general health status,,2019-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13957,NCT04636099,Intraoperative blood loss,3 years DFS,,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA']
13958,NCT04553458,"PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions",DEATH (Number of patients died from the disease),,2015-06,COMPLETED,OBSERVATIONAL,['NA']
13959,NCT01220934,Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST),Safety (incidence of adverse events),,2010-04-16,COMPLETED,OBSERVATIONAL,['NA']
13960,NCT01279681,Progression-Free Survival,Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment,Prognostic Single-nucleotide Polymorphisms (SNPs) for Grade 3+ Hypertension,2011-01,TERMINATED,INTERVENTIONAL,['PHASE3']
13961,NCT00519688,To evaluate the overall response rate of UFUR and thalidomide in the treatment of advanced HCC by RECIST criteria,To establish the safety profile.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13962,NCT02042378,Overall Response Rate (ORR) per RECIST v1.1 as assessed by the investigator,Trough (Cmin) level rucaparib concentrations,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13963,NCT01798160,Overall-Survival,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13964,NCT02724345,Overall survival,Time to recurrence,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
13965,NCT03169777,ORR by Immune-related response criteria (irRC ),"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03",,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13966,NCT03939845,OS,,,2019-04-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
13967,NCT01503411,Primary Effectiveness Endpoint,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
13968,NCT05130684,rate of completion of protocol treatment,,,2021-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
13969,NCT05875753,Adverse events after injection of 68Ga-FAPI-FS,SUVmax of tumor lesions on 68Ga-FAPI-FS,,2022-06-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13970,NCT01384695,to determine whether tissue is neoplastic or non-neoplastic,,,2009-06,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
13971,NCT05971628,Tolerance of the RAPID procedure,Comparison of the graft survival at 2 years after LT between RAPID group and control group,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13972,NCT04922853,pathological Tumor Regression Grade evaluation,cumulative local recurrence rate,,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3']
13973,NCT03601611,Rate of at least one grade improvement using the NCI CTCAE v5.0,Rate of sustained glucocorticoid-free remission,Biomarkers,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
13974,NCT02232620,Disease Control Rate (DCR),Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible,,2017-03-13,TERMINATED,INTERVENTIONAL,['PHASE2']
13975,NCT02337946,Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization,Percentage of Participants With Grade 3 or Higher Skin Toxicity,,2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
13976,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,PCP-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
13977,NCT04429841,Operative mortality rate,5 years Overall survival rate,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
13978,NCT05091775,"Acute anal fissure after diarrhea. Standard management of acute fissure (Diltiazem Jelly, supportive care, placebo suppository, sitz bath)","Acute anal fissure after diarrhea. Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)",,2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13979,NCT00373022,Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire,"Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels",,2004-01,COMPLETED,INTERVENTIONAL,['NA']
13980,NCT06013228,Fatigue,,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA']
13981,NCT00910741,Incidence of DLT and Response rate,Overall survival,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13982,NCT03483922,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC,,,2018-08-20,COMPLETED,OBSERVATIONAL,['NA']
13983,NCT01413022,Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX,Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13984,NCT03076372,Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.,Progression Free Survival,,2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE1']
13985,NCT06200831,"Comprehensive Complication Index, CCI",Quality of Life: EORTC QLQ-30,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
13986,NCT06026774,Number of Participants with Adverse Events (AEs) [safety and tolerability],Cytokines Level [immunogenicity],,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1']
13987,NCT02228889,Overall complication rate at 1 year,Quality of life postoperatively,,2015-01,RECRUITING,INTERVENTIONAL,['NA']
13988,NCT00217737,Disease-free survival,Impact of tumor biologic characteristics and their relationship to overall survival,,2005-09-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13989,NCT04735107,Defunction ileostomy rate,Postoperative morbidity,,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
13990,NCT01410760,Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis,Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.,,2011-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13991,NCT05686122,Feasibility of PainPac,Change in PROMIS - Emotional Distress (Depression) Short Form,,2023-09-28,RECRUITING,INTERVENTIONAL,['NA']
13992,NCT03268499,Time to progression (TTP),,,2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13993,NCT03310008,The objective response rate (ORR) before resection as measured by RECIST (version 1.1),The overall survival (OS),,2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
13994,NCT05172310,Diagnostic accuracy of FAPI-PET/CT in primary tumors,Safety of 68Ga-FAPI-46,,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
13995,NCT05209295,Cmax: Observed maximum concentration,Number of participants with a recording of concomitant procedures,,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1']
13996,NCT04257955,Patient's Compliance,,,2020-09-15,COMPLETED,OBSERVATIONAL,['NA']
13997,NCT02277392,Number of Adverse Events,,,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13998,NCT05513742,Overall Response Rate,Exposure Response by Pharmacokinetic (PK) Sampling,,2022-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13999,NCT00323518,the incidence of grade 3/4 oral mucositis using WHO grading system,,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14000,NCT05812287,Early gastric cancer detection rate,,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14001,NCT06279351,ETS,PFS,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14002,NCT01840592,overall survival,toxicity,,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14003,NCT05235607,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,Number of participants with Overall survival as assessed by RECIST1.1,,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14004,NCT06108310,Identification of radiogenomics signature (ATTRACT AI-model) of stage II-III colon tumors,Correlation of radiogenomics signature (ATTRACT AI-model) of colon cancer with clinical outcomes (DFS and RFS),,2021-01-02,RECRUITING,OBSERVATIONAL,['NA']
14005,NCT05143099,Objective response rate (ORR),Overall survival (OS）,biomarker analysis,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14006,NCT04575935,Disease free survival (DFS),Cost of the procedure,,2020-08-05,RECRUITING,INTERVENTIONAL,['PHASE3']
14007,NCT03290209,3-year disease specific survival rate,operation time,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14008,NCT04456140,Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families,Differences in survey responses between patient groups,,2020-06-29,COMPLETED,INTERVENTIONAL,['PHASE1']
14009,NCT04288284,early postoperative morbidity after curative resection of colorectal cancer,Overall survival,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
14010,NCT02554448,The number of Circulating Tumor Cells (CTCs),,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
14011,NCT05500248,Positive Predictive Value (PPV),Adenoma Detection Rate (ADR) in the rectosigmoid tract.,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
14012,NCT01384864,to determine whether tissue is neoplastic or non-neoplastic,,,2011-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14013,NCT00287222,Number of Participants Who Remained Free of Progression at the 27th Week.,,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14014,NCT04911959,Recurrence-free survival (RFS) evaluation,Overall survival ( OS) evaluation,,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14015,NCT05079438,≥Grade 2 proctitis,,,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3']
14016,NCT06334965,Clinical response,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14017,NCT02721056,Determination of the early Dose Limiting Toxicities,Local Progression Free Survival,,2016-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14018,NCT04183712,3-year DFS,3-year OS,sensitivity and specificity of ctDNA,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14019,NCT05014399,The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b),,,2021-09-20,RECRUITING,OBSERVATIONAL,['NA']
14020,NCT03554356,Incidence of CryoBalloon-related serious adverse events,Proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium,,2018-09-04,RECRUITING,INTERVENTIONAL,['NA']
14021,NCT03492827,infection rate 8 hours after ESD,infection rate 72 hours after ESD,complications of ESD,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
14022,NCT00900003,Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy,Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
14023,NCT01315990,Progression-free survival,Development of acneiforme follicular exanthema >= grade2,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14024,NCT01319084,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
14025,NCT01434264,Changes in personal concerns identified by the patient in the MYCaW questionnaire.,Changes in Daily physical performance,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
14026,NCT04777851,Progression-free Survival (PFS) Assessed by the Investigator as per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC,Change from Baseline in Health-Related Quality of Life as Assessed by the EuroQol's 5-level EQ-5D Health Questionnaire (EQ-5D-5L),,2023-10-11,RECRUITING,INTERVENTIONAL,['PHASE3']
14027,NCT01259414,overall survival,Time to progression,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14028,NCT04493125,The number of radiopaque markers transferred to the large intestine 3 days after surgery,,,2020-07-27,UNKNOWN,INTERVENTIONAL,['NA']
14029,NCT00800969,Diagnostic Accuracy of PET-CT,,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14030,NCT05636150,Progression free survival (PFS),Disease control rate (DCR),,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2']
14031,NCT05723107,Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0,Percentage of Participants who Report Post-Procedural Complications,,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
14032,NCT06042816,analgesic efficacy of free-opioid anesthesia,Adverse effects of free-opioid anesthesia,,2019-12-30,COMPLETED,INTERVENTIONAL,['NA']
14033,NCT06269744,Proportion of Participants who Complete FIT Test by Month 6,Proportion of Participants with Positive FIT who Complete Colonoscopy by Month 6,,2024-03-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14034,NCT03957590,Progression-free survival (PFS),The incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events'.,,2019-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14035,NCT02854072,Overall Survival,Toxicity according to the NCI CTCAE v4.03,,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
14036,NCT01088815,Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events,Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation,,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE2']
14037,NCT05572151,lymph node number,,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
14038,NCT01480817,Time to Progression (Efficacy),Alpha feto protein (AFP) responsiveness,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2']
14039,NCT05171309,Objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14040,NCT02217865,Effectiveness of Colorectal Cancer (CRC) Surveillance,,,2014-07-16,COMPLETED,OBSERVATIONAL,['NA']
14041,NCT05406206,Progression-Free Survival (PFS),Overall Survival (OS),,2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2']
14042,NCT06171854,Progression free survival (PFS),Safety as the description of adverse events,,2019-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14043,NCT05196087,Change from Baseline in ctDNA collected from biospecimens,Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms,,2022-07-20,RECRUITING,OBSERVATIONAL,['NA']
14044,NCT03705897,Proportion of patients achieving appropriate screening regimen.,,,2013-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14045,NCT00569673,Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0,Duration of Progression-free Survival and Overall Survival,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14046,NCT02867839,disease-free survival,Incidence of Treatment-Emergent Adverse Events [Safety],,2017-04-24,UNKNOWN,INTERVENTIONAL,['PHASE3']
14047,NCT01702558,Phase 1 (LA/mGC): MTD of Capecitabine When Combined With Trastuzumab Emtansine (2.4 mg/kg QW),Phase 1 (LA/mGC): t1/2 of 5-Fluorouracil (Metabolite of Capecitabine),,2012-12-03,TERMINATED,INTERVENTIONAL,['PHASE2']
14048,NCT01887509,Concordance in identification of lower pole of tumor,Assessment of predictive value of interpretation criteria,,2013-11-07,TERMINATED,INTERVENTIONAL,['NA']
14049,NCT05036109,To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease,,,2021-10-12,RECRUITING,INTERVENTIONAL,['NA']
14050,NCT00287768,overall survival,safety,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14051,NCT02527057,Pathologic response,Progression free survival,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
14052,NCT00003760,,,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14053,NCT00490685,,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14054,NCT03100461,CRC screening completion rate,Cost analysis of each intervention pathway,,2018-01-22,UNKNOWN,INTERVENTIONAL,['NA']
14055,NCT03413930,Circumferential resection margin (CRM),5-year overall survival rate,,2019-06,WITHDRAWN,INTERVENTIONAL,['NA']
14056,NCT03940027,the incidence of serious complications,Improvement of quality of life,,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA']
14057,NCT02500797,Number of Participants Who Achieved a Confirmed Response,Overall Survival (OS),OS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression,2015-08-13,COMPLETED,INTERVENTIONAL,['PHASE2']
14058,NCT00138177,"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0",DPD activity,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14059,NCT00259844,"To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.",To monitor and collect data on clinical outcomes (time to progression/relapse/death).,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14060,NCT01033682,"The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans",The correlation between bladder volume and small bowel volume planning target volume,,2009-05,UNKNOWN,OBSERVATIONAL,['NA']
14061,NCT02863367,Objective Response Rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
14062,NCT05155878,Overall survival,Radical resection,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
14063,NCT02568267,Objective Response Rate,Bone Biomarkers,,2015-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14064,NCT03817658,OS,The incidence and severity of adverse events (AEs),,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14065,NCT01747551,6-month Progression-free Survival (PFS),Duration of Objective Response,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14066,NCT05307367,Muscle mass,Patient-reported Quality-of-Life (QoL),,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
14067,NCT05229588,Evaluate the antitumor activity,Treatment safety,,2022-06-14,RECRUITING,INTERVENTIONAL,['PHASE2']
14068,NCT04221165,Average Pain Rating measured on the 11 Numeric Rating Scale,Death,,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14069,NCT03173001,Prevalence of intestinal protozoa (commensals) in patients with colorectal cancer and association with cancerogenesis,,,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14070,NCT05739045,pathological complete response rate (pCR),3-year DFS,,2022-11-03,RECRUITING,INTERVENTIONAL,['PHASE2']
14071,NCT05899985,Surgical quality,SLN Ultra-staging Overall Survival,FerroTrace enhanced MRI Response,2024-03-21,RECRUITING,INTERVENTIONAL,['NA']
14072,NCT03737591,Specificity,,,2010-05-01,COMPLETED,OBSERVATIONAL,['NA']
14073,NCT04790448,"Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.",Number of patients with adverse events and severity according to NCI CTCAE v5.0,,2020-07-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14074,NCT02759718,"Diagnostic accuracy of th CgA in the patient with PNET, change from preoperative levels of CgA at 3 months","Disease progression of PNET using CT imaging, change from preoperative imaging of CT at 3, 6,12, and 24 months",,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
14075,NCT06194708,1-year non-reversal rate of temporary stoma,,,2023-05-15,RECRUITING,OBSERVATIONAL,['NA']
14076,NCT03050268,Identification of novel cancer predisposing genes,,,2017-04-06,RECRUITING,OBSERVATIONAL,['NA']
14077,NCT02399410,surgical morbidity and mortality,pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab,,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14078,NCT04279080,functional bowel outcome after low anterior resection,,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
14079,NCT05806333,Diagnostic performance of FAPI PET,,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
14080,NCT05809661,stoma compliance,life quality,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
14081,NCT00055705,,,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14082,NCT00019604,Response,Evaluate the Ability of Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) to Monitor Response Following Radiofrequency Ablation (RFA),,1998-08,TERMINATED,INTERVENTIONAL,['PHASE2']
14083,NCT00375310,To evaluate the safety and tolerability of the combined treatment with Gemcitabine with Sorafenib and radiotherapy in patients with localized unresectable pancreatic cancer.,To evaluate the maximum tolerated dose (MTD) for Sorafenib during Chemo-radiation.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14084,NCT00247728,Tumour Non-recurrence Rate,Survival Rate,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14085,NCT04638751,Determine whether the microbiome composition can predict risk for colorectal cancer,Build a library of samples and data for future research,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
14086,NCT05173077,Specific chemistry identification in the exhaled breath,Gut microbiota analysis in relation to breath VOCs,Confounding factor analysis,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14087,NCT04274790,5-FU in ribosome,Specific molecular signature,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA']
14088,NCT05349110,"The Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).",The agreement in surveillance interval based on optical diagnosis and histopathology.,,2021-08-20,UNKNOWN,OBSERVATIONAL,['NA']
14089,NCT03211715,Quality of life in association to the severity of bowel dysfunction,,,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA']
14090,NCT02603302,Pathologic complete response,Overall survival,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14091,NCT02095236,Three-dimensional intra- and interfractional measurement of fiducial marker or transponder motion,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
14092,NCT05184751,"incidence of early onset colorectal neoplasias, risk factors",,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
14093,NCT02372747,Length of the incision,Postoperative complication,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14094,NCT03304860,Change in CRC screening rate of eligible parents of internal medicine residents at NYU from before to after the intervention,,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
14095,NCT00874263,Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.,"Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal.",,2008-03,COMPLETED,OBSERVATIONAL,['NA']
14096,NCT02403271,Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.,Phase 2: Pharmacodynamics,,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14097,NCT06308354,DFS,,,2011-01-01,RECRUITING,OBSERVATIONAL,['NA']
14098,NCT01101672,Post-operative pain on coughing,Recurrence and survival for cancer patient,,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14099,NCT05490719,PFS assessed by investigators,"The rates and severity of Adverse Events, Serious Adverse Events",,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14100,NCT00607594,Prolonged Stable Disease Rate (Defined as Stable Disease for ≥ 16 Weeks),Association Between Correlative Markers and Clinical Outcomes,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14101,NCT02713763,6 months progression free survival,Incidence of Adverse Events,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2']
14102,NCT02970513,Hamilton anxiety and depression score comparison,personality traits comparison,,2017-03-27,COMPLETED,INTERVENTIONAL,['NA']
14103,NCT05827055,Safety of oral proglumide therapy at 1200mg daily dose with chemotherapy,Effects of proglumide on Pain,,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2']
14104,NCT06059924,Cancer-specific survival,Recurrence-free survival,,1991-02-01,COMPLETED,OBSERVATIONAL,['NA']
14105,NCT01260415,"To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.","To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy.",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14106,NCT02559674,Overall Survival; Phase II,Correlation between the level of tumor DNA in patient plasma and response to study treatment,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14107,NCT02548169,Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03,Average of all changes in Quality of Life (QoL) Score,,2015-08,TERMINATED,INTERVENTIONAL,['PHASE1']
14108,NCT04525768,History of variceal bleeding,Complications of portal hypertension,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
14109,NCT05596890,Pathologic complete response rate,Dysphagia relief score,,2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2']
14110,NCT03776591,Complications,Prognostic significance of CTCs,Hospitalization,2016-09-01,RECRUITING,INTERVENTIONAL,['NA']
14111,NCT00857246,"Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab",Median Overall Survival (Adjuvant Therpary),,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14112,NCT04160832,Prevalence of germline pathogenic/likely pathogenic variants in cancer predisposition genes in patients with advanced colorectal polyps,Risk factors for germline pathogenic/likely pathogenic variants in patients with advanced colorectal polyps,,2019-10-24,RECRUITING,OBSERVATIONAL,['NA']
14113,NCT00600613,"Number of Participants Eligible for Cone Beam Tumor Localization""",,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
14114,NCT04336202,Workload,Local control,,2024-08,RECRUITING,INTERVENTIONAL,['NA']
14115,NCT04989153,Risk factors for GC,,,2016-03-05,UNKNOWN,OBSERVATIONAL,['NA']
14116,NCT00864513,Progression-free Survival,Number of Participants With Adverse Events,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
14117,NCT01577511,Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.,Number of circulating cancer cells per ml blood,,2012-06-12,COMPLETED,OBSERVATIONAL,['NA']
14118,NCT00112463,Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3,Survival,,2005-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14119,NCT01807546,Overall response rate,Number of Adverse Events,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14120,NCT02320448,Number of Patients with Adverse Events.,Feasibility: Completion of procedure in 28:35,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14121,NCT02626195,postoperative complication,postoperative cost( + nutritional support cost),immunologic change(CD4/CD8) after nutritional support,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14122,NCT01910948,blood immune factors,,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
14123,NCT00051441,The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy,Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
14124,NCT04970212,Effectiveness - DICE,Difference between T=0 and T=24hrs CECT tissue damage,,2021-09-24,COMPLETED,OBSERVATIONAL,['NA']
14125,NCT02942563,Pelvic complete resection rate,The incidence of >=3 grade adverse events,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14126,NCT00862342,Progression free survival,Toxicity profiles,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14127,NCT00004236,,,,1998-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
14128,NCT02638584,The Ulcer healing rate after endoscopic submucosal dissection,The evaluation of symptom score as assessed by the Korean Gastrointestinal Symptom Rating Scale questionnaire.,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14129,NCT05229809,2-year disease-free survival rate,Percentage of Participants With Adverse Events,,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14130,NCT03778710,The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients,The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients,,2018-12-18,COMPLETED,OBSERVATIONAL,['NA']
14131,NCT02121405,Disease-free survival,Overall survival,,2015-10,SUSPENDED,INTERVENTIONAL,['PHASE3']
14132,NCT04842006,Postoperative ctDNA,Treatment response by patient-derived organoid (PDO) therapy response,,2021-12-20,RECRUITING,INTERVENTIONAL,['NA']
14133,NCT03178929,Time to tumor recurrence,Overall survival,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14134,NCT05345613,Postprocedural bleeding,Intraprocedural bleeding,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14135,NCT01444755,Survival,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14136,NCT03541486,Overall survival (OS),Pathologic characteristics,Exploration of patient reported outcomes during combined therapy [qualitative string],2025-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14137,NCT00813293,Coagulation Zone Volume,Number of Treatment-Related Grade 1-4 Adverse Events (AEs) One Month After Radiofrequency Ablation (RFA),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14138,NCT06080854,R0 resection rate,Adverse Events,,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14139,NCT04796948,RP2D,CL,,2021-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14140,NCT03654729,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),Overall Survival (OS),,2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE3']
14141,NCT00969124,Detection Rates for All Polyps,Time Spent During Withdrawal Phase and Total Procedure,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14142,NCT04723030,Objective remission rate(ORR),Subject safety,,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14143,NCT00070122,Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab,Whether gene expression variables are predictive of survival and progression-free survival,,2004-04,TERMINATED,INTERVENTIONAL,['PHASE3']
14144,NCT00229554,colorectal cancer screening compliance,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14145,NCT00809796,"Any severe events, tumor marker CEA, and tumor size (CT scan)",,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14146,NCT01670721,Percentage of Participants With Adverse Events (AEs),Change From Baseline in HRQL EQ-5D-3L VAS Score,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
14147,NCT02758587,Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)),Change in immune cell infiltrate,,2017-07-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14148,NCT03422835,Positive rate of circumferential resection margin (CRM) of the specimens,the rate of postoperative complications,Quality of life outcomes evaluation,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
14149,NCT03061058,Progression-free Survival (PFS),Adverse Events,,2013-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
14150,NCT04213118,Disease free survival,Incidence of Treatment-Emergent Adverse Events Safety and Tolerability,,2020-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14151,NCT02128243,Overall Survival (OS),Quality of Life,Adverse Events,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14152,NCT02179489,Disease-free survival,QOL,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
14153,NCT05160896,ORR,AEs,,2021-11-12,RECRUITING,INTERVENTIONAL,['PHASE2']
14154,NCT02577263,Quality of life deterioration > 10% (dichotomic),Significant chemotherapy induced neurotoxicity > 10%,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
14155,NCT00819650,Overall survival,Time to recurrence,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14156,NCT04543617,Arm B vs Arm C: OS,Percentage of Participants With ADAs to Atezolizumab,,2020-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14157,NCT02366039,distinguishing between normal esophageal squamous mucosa and Barrett's dysplasia,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
14158,NCT00337389,Progression Free Survival,Incidence and Severity of Adverse Events,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
14159,NCT02430948,Effect of educational intervention on providers' recommendations,Patient compliance,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14160,NCT00587964,Local Control,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14161,NCT06175845,"Time to first event, ie stent dysfunction",Total days of overnight-hospital-stays,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14162,NCT01060007,Preoperative Gastrointestinal Morbidity,Determine Quality of Anorectal Function,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14163,NCT00821912,Response rate,Quality of life,,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14164,NCT03990025,Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging,Sensitivity and Specificity of detection of duodenal lesions,,2019-03-27,COMPLETED,INTERVENTIONAL,['NA']
14165,NCT03153280,Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.,Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).,,2022-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14166,NCT01760616,Time to significant progression after surgery and postoperative survival period.,Alpha-fetoprotein quantitation and related biochemical indicators,,2011-11-07,TERMINATED,INTERVENTIONAL,['PHASE4']
14167,NCT03592706,Progression-Free Survival (PFS),Improvement of immune responses,,2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14168,NCT05218889,ORR,"Safety and tolerability by incidence, severity and outcome of adverse events",,2021-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14169,NCT03051802,Optimize the clinical protocol using this technology,,,2017-01-27,TERMINATED,INTERVENTIONAL,['NA']
14170,NCT00004860,,,,2000-10-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14171,NCT02650635,Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide,PFS as measured by serial imaging studies and assessed by irRECIST,Changes in immunomodulation,2016-02-05,TERMINATED,INTERVENTIONAL,['PHASE1']
14172,NCT01522937,The Percentage of Patients With Local Control at 1 Year Post Treatment,The Number of Patients That Experience Grade 4+ Gastrointestinal Bleeding,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14173,NCT05528614,Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio,,,2022-01-13,COMPLETED,OBSERVATIONAL,['NA']
14174,NCT05420259,Mean Change in interleukin 6 (IL6),Change in skeletal muscle,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
14175,NCT01210495,"Overall Survival (OS) - Stratified Analysis, Randomized Portion",Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion,,2010-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14176,NCT02445014,Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule.,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
14177,NCT00832299,Pathologic Complete Response,"Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival",,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2']
14178,NCT05361252,The incidence of postoperative complications in the two groups.,The pain scale,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
14179,NCT00276744,6-month Overall Survival,,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2']
14180,NCT01404650,Progression-free Survival (PFS),Number of Patients With Adverse Events as a Measure of Safety and Tolerability,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14181,NCT01858662,Major Pathological Response Rate,Chemotherapy-associated hepatotoxicity:,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2']
14182,NCT04774198,Number of patients with persistent postoperative hypotension (<65 mmHg) after surgery,Number of patients with development of delirium after surgery,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
14183,NCT05738447,Overall Survival,,,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE1']
14184,NCT01621451,delayed ulcer bleeding,ulcer healing rate,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
14185,NCT03082586,Number of Dose Limiting Toxicities (DLTs) Occurring in Participants,Local Failure,,2016-11-20,COMPLETED,INTERVENTIONAL,['NA']
14186,NCT05914597,Feasibility of home delivery of CCE service,assessing the patient's acceptability of home delivery of CCE service,,2022-12-12,RECRUITING,INTERVENTIONAL,['NA']
14187,NCT02704143,One-year Overall Survival Rate,Median Overall Survival Will be Determined.,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14188,NCT02920554,Survival rates,,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
14189,NCT05129605,Diagnosis of prostate cancer,Positive predictive value of multiparametric MRI for detection of prostate cancer,,2020-02-12,RECRUITING,OBSERVATIONAL,['NA']
14190,NCT00399035,Overall Survival,Time to Wound Healing Complications,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14191,NCT01793207,"Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects","Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects",,2012-12,COMPLETED,OBSERVATIONAL,['NA']
14192,NCT04505553,Severity of chemotherapy-induced peripheral neuropathy (CIPN),"Incidence of pain, fatigue, nausea, and anxiety",,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14193,NCT00576992,"Determine the prevalence of gastric and esophageal disease in patients presenting with the complaints of dyspepsia, GERD, or extraesophageal symptoms","Determine whether the presence of any factors (hiatal hernia, NSAID use, age, race, gender, etc.) contribute to the above endoscopic diagnoses",,2003-01,TERMINATED,OBSERVATIONAL,['NA']
14194,NCT01227018,Disease Control Rate,Number of Patients With Each Worst Grade Toxicity,Biomarker Evaluation,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2']
14195,NCT04529135,postoperative recovery time,opioid related side effect.,,2020-08-26,COMPLETED,INTERVENTIONAL,['NA']
14196,NCT04778566,Evaluate the feasibility of the Cologuard test for Lynch Syndrome,Evaluate bowel preparation tolerability,,2021-11,WITHDRAWN,OBSERVATIONAL,['NA']
14197,NCT05356520,Disease-free survival time,Tumor recurrence,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
14198,NCT05327400,High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.,,,2022-05-01,UNKNOWN,OBSERVATIONAL,['NA']
14199,NCT05069571,Adenoma detection rate,Proportion of withdrawal overspeed,,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA']
14200,NCT03086096,"Number of indications that the device is being used for, as assessed by stage and previous treatment(s)","The quality of participants' lives, as assessed by the QLQ-C30 questionnaire (developed by EORTC)",,2018-02-02,COMPLETED,OBSERVATIONAL,['NA']
14201,NCT02015065,Number of Participants With a Clinical Activity-radiographic Response,Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET),,2013-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
14202,NCT01582178,Cecal Intubation Time,Patient Comfort During Insertion Phase of the Colonoscopy,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
14203,NCT02415101,"Complete histological response proportion, using the Chirieac grading system.",Nutritional status of patients in each study arm.,,2015-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14204,NCT05681390,MedianProgression free survival(mPFS),disease control rate(DCR),,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14205,NCT05327751,The change in HFS-specific QOL questionnaire (HFS-14).,The change in serum levels of malondialdehyde (MDA).,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
14206,NCT00034619,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
14207,NCT04864067,Quality of Life and Funcional Outcomes,Adverse events,,2021-06-09,RECRUITING,INTERVENTIONAL,['PHASE2']
14208,NCT05913141,Objective response rate (ORR),12-month survival rate,,2023-06,RECRUITING,OBSERVATIONAL,['NA']
14209,NCT02304445,Tumor response rate,Number of patients eligibility for liver transplantation,Overall survival,2015-11,WITHDRAWN,INTERVENTIONAL,['NA']
14210,NCT03380130,"Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.",Pattern of progression according to RECIST 1.1 criteria.,,2017-09-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14211,NCT04611997,3-year disease free survival rate,Total number of retrieved lymph nodes,,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14212,NCT02635503,Early morbidity rate,Plasma levels of several cytokines after colorectal cancer surgery,,2015-11,RECRUITING,INTERVENTIONAL,['PHASE3']
14213,NCT01754987,Number of Participants That Experience Serious Adverse Events.,Number of Participants That Are Alive After 15 Weeks of Treatment.,,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14214,NCT01808638,"Maximum concentration (Cmax), area under the curve (AUC), time to maximum concentration (tmax), and half life (t½) of the Atu027 siRNA single strand (A-strand), and of AtuFect01 and the helper lipid DPyPE",Quality of life,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14215,NCT04425239,Progression-free Survival,Overall Survival (OS),Metabolomic profiling,2018-05-21,COMPLETED,INTERVENTIONAL,['PHASE2']
14216,NCT02173119,Imaging response,Survival,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
14217,NCT03892252,"According to the 16s rDNA sequencing results, analyze the differences in intestinal flora of colon cancer patients with different TCM syndromes and TCM constitutions before and after surgery and their correlations",,,2019-03-10,COMPLETED,OBSERVATIONAL,['NA']
14218,NCT05195294,Objective response rate (ORR),Overall survival (OS),,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14219,NCT00926757,The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy,The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
14220,NCT05966194,Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan,Narcotic use through resolution of SOM,,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14221,NCT01365130,Number of Patients Without Progression at 3 Months,Number of Patients Experienced a Toxicity Associated With Cabazitaxel for Patients With Metastatic Gastroesophageal Adenocarcinomas That Have Progressed After at Least One Line of Therapy for Metastatic Disease.,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
14222,NCT06134700,To compare the efficacy of low pressure versus standard pressure pneumoperitoneum in laparoscopic nephrectomy,,,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14223,NCT04196803,Plasma methionine cycle metabolites,,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
14224,NCT04969887,Determine the proportion of participants with progression free survival at 6 months,Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0,,2021-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14225,NCT01791140,Median progression-free survival,Median progression-free survival according to age group (65-74 years; >/= 75 years),,2011-03,COMPLETED,OBSERVATIONAL,['NA']
14226,NCT02096666,Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1),Phase 1- Overall Survival,,2014-04-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14227,NCT02809716,"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles","HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles",,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
14228,NCT02329821,changes of lactate level,changes of acid-base status,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14229,NCT04185272,"evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry",,,2020-06-30,RECRUITING,INTERVENTIONAL,['NA']
14230,NCT05198934,Progression-free Survival (PFS),AUC of Panitumumab,,2022-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14231,NCT01717391,Percent Difference From Baseline IMRT Plan (%),Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.,,2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14232,NCT03713749,Rate of unsuccessful LND along the left RLN,"European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30 , QLQ-OES18",,2018-10-22,UNKNOWN,INTERVENTIONAL,['NA']
14233,NCT01579357,Influence of Cetuximab on metabolic activation of Capecitabine,,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14234,NCT04394572,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases",,,2021-01-07,COMPLETED,OBSERVATIONAL,['NA']
14235,NCT05355298,Part B: efficacy of AMP945,AMP945 levels in plasma,Effects on biomarkers,2022-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14236,NCT02549911,R0 resection,Overall survival time,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
14237,NCT05818072,The yield rate of intestinal metaplasia,Procedure time,,2023-03-13,RECRUITING,INTERVENTIONAL,['NA']
14238,NCT02194959,Colonoscopy completion,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
14239,NCT03216395,Bleeding free probability in 30 days after randomization,cost analysis (Based on the cost data from the Hospital,,2018-01-02,COMPLETED,INTERVENTIONAL,['NA']
14240,NCT03679039,The sensitivity and specificity of the model to predict the drug resistance,,,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA']
14241,NCT05759728,To determine the overall best response to CNA3103.,To determine progression-free survival,,2023-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14242,NCT02495337,"Effectively culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers for research purposes",,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
14243,NCT05569343,postoperative complications,Readmission,,2020-05-08,COMPLETED,OBSERVATIONAL,['NA']
14244,NCT01525706,Efficacy: Degree of Ablation,Efficacy: Cyst Resolution,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
14245,NCT01755013,Efficacy Profile,Safety Profile,,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14246,NCT04527666,Changes of portal vein thrombosis,Overall survival,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
14247,NCT03018418,Rates of Acute Toxicity,Quality of Life Changes,,2017-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14248,NCT05039983,Recommended phase 2 dose (RP2D),change in blood biochemical indicators,,2021-08-20,UNKNOWN,INTERVENTIONAL,['NA']
14249,NCT02156739,Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI),,,2014-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14250,NCT00399750,To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2),Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14251,NCT01996059,Body Mass Index,Onodera Prognosis Nutritional Index,Visick rates,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
14252,NCT04659018,The ability to predict the presence of adenomas and colorectal cancers.,,,2020-08-24,COMPLETED,OBSERVATIONAL,['NA']
14253,NCT03546127,Delay time to send a validated exome sequencing report from sample receipt,The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
14254,NCT03530267,Progression-free survival (PFS),PRO: Overall treatment utility,,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
14255,NCT04248582,Dose limiting toxicity (DLT),,,2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14256,NCT02497820,cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer,Overall cumulative of of new adenomas at five years,,2016-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14257,NCT01711242,disease free survival,5 year Overall Survival,Number of participants with adverse events as a measure of safety and tolerability,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14258,NCT05757336,Safety：the incidence of adverse events and serious adverse events,Proportion of acceptable radical resection of primary lesions,,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
14259,NCT01764438,"incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.","Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI",,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
14260,NCT04186234,Best objective response,Overall survival,Changes in Child-Pugh status,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA']
14261,NCT04835896,Phase 2: Progression-free survival in subjects with M7824 and paclitaxel combination treatment,"Safety and Tolerability, in terms of the number, severity, and duration of treatment-emergent adverse events as assessed by CTCAE v5.0",,2021-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14262,NCT02567045,Proportion of patients who participate in each screening arm,Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions,,2016-02-25,COMPLETED,INTERVENTIONAL,['NA']
14263,NCT00619242,Ki-67,,,2006-06,TERMINATED,INTERVENTIONAL,['NA']
14264,NCT00976170,Dose limiting toxicity and maximum tolerated dose,Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14265,NCT04163887,Rate of overall complications using the comprehensive complication Index (CCI),Disease-free and overall survival at 3 years.,,2021-01-27,RECRUITING,INTERVENTIONAL,['NA']
14266,NCT00030667,Toxicity reported using the CTC version 2.0,Time to disease progression,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14267,NCT00882765,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,"To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8",,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14268,NCT03884751,Maximum tolerated dose (MTD),Antitumor efficacy-Disease control rate (DCR),,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14269,NCT05667181,Incidence of anastomotic complications,,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
14270,NCT02216955,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14271,NCT01741363,Detection rate of upper gastrointestinal tract diseases,Helicobacter pylori eradication rate,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
14272,NCT03890926,Local control time,Incidence of adverse events,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
14273,NCT02935478,Weight,Eligibility for liver transplant,,2017-10-18,SUSPENDED,INTERVENTIONAL,['NA']
14274,NCT00909987,"Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria",Complete Phatologic Response (pCR),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14275,NCT04715061,"Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)",Heart rate variability,,2020-11-04,COMPLETED,INTERVENTIONAL,['NA']
14276,NCT01545687,The AUC of the MTS score,DFS at 12 months after treatment,,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3']
14277,NCT04915326,Nodal metastasis in early rectalò cancer,,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
14278,NCT01713387,Maximum tolerated dose,Number of Participants with dose limiting toxicity,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14279,NCT03484299,Incidence of Adverse and Serious Adverse events will be captured (safety and tolerability),Progression free survival,,2018-05-30,RECRUITING,INTERVENTIONAL,['PHASE1']
14280,NCT02527785,overall response rate,Toxicity profiles - The number of participants and grade of intensity of treatment related adverse events,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14281,NCT04514341,Time to completion of diagnostic colonoscopy,Navigation Services Provided,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
14282,NCT01238653,The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures,,,2010-11,TERMINATED,OBSERVATIONAL,['NA']
14283,NCT00113230,Pathologic Local Tumor Response,,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14284,NCT02967887,Objective tumor response,Progression-free-survival,Exploratory endpoint: Diagnostic performance of biomarkers,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
14285,NCT03637491,Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,"Phase 2: Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression, DNA Damage Repair (DDR) Gene Alterations, and Tumor Mutational Burden (TMB) in Baseline Tumor Tissue.",,2018-08-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14286,NCT06157060,2-year recurrence-free survival rate,Correlation between ctDNA-MRD status dynamic changes and relapse,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
14287,NCT06102902,Recommended phase 2 dose (dose escalation cohort),MAPK inhibition,Presence or absence of a given gene mutation,2024-11-12,RECRUITING,INTERVENTIONAL,['PHASE1']
14288,NCT01937208,Progression-free survival,Overall survival,radiation-related advent events,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
14289,NCT06254521,Pathological complete response (pCR) rate,3-year local recurrence rate,Molecular pathological analysis of tumor tissue,2024-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
14290,NCT05240625,Adenoma detection rate,Withdrawal time,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
14291,NCT01742065,FIT Completion,Any CRC Screening,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
14292,NCT05643391,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,Evaluation of efficacy of 166Ho radioembolization in unresectable hepatocellular using metabolic assessments (FDG and choline PET/CT),"Comparison between ""pre-scout"" HBS and HBS just after ""scout dose""",2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
14293,NCT00250796,"Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.",,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14294,NCT01952730,Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity,Two Year Survival,,2013-11-08,TERMINATED,INTERVENTIONAL,['PHASE1']
14295,NCT02114411,Sensitivity and Specificity of the GastroPanel test for the detection of AG,,,2017-01-31,UNKNOWN,OBSERVATIONAL,['NA']
14296,NCT00005956,Safety,,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
14297,NCT00549835,Frequency of any adverse effects,Total amount of conventional analgesics used and Total days on Analgesic,,2007-08,WITHDRAWN,INTERVENTIONAL,['NA']
14298,NCT05176002,Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.,Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant,,2021-09-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14299,NCT00217087,Change in Quality of Life,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14300,NCT00555334,Overall survivals,Recurrence rates,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14301,NCT05411718,To establish the effect of naproxen or aspirin on the abundance of T cells and other immune,,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2']
14302,NCT05508126,Diagnostic performance of DECT and mpMRI in tumor restaging assessment,Contrast-to-noise Ratio (CNR),,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
14303,NCT05281328,Height-adjusted total liver volume (htTLV),Adverse events (AEs),,2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14304,NCT03985644,Overall survival,Recurrence rate,,2019-07,UNKNOWN,OBSERVATIONAL,['NA']
14305,NCT05582031,Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment,Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities,,2023-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14306,NCT01453153,Recommended Phase 2 Dose (RP2D),Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders,,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14307,NCT01257711,The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for gastric cancer in terms of postoperative outcomes.,Grading of gastritis and/or esophagitis on endoscopy,,2008-10-09,COMPLETED,INTERVENTIONAL,['NA']
14308,NCT03311451,Safety: Incidence of Dose-related SAEs,Efficacy: Treatment,,2023-01-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14309,NCT01339832,Progression-free Survival,Incidence of Adverse Event (AE) and Serious Adverse Event (SAE),,2010-08,COMPLETED,OBSERVATIONAL,['NA']
14310,NCT05132738,No Evidence of Disease Rate (NED Rate),Objective response rate (ORR),Overall survival (OS),2021-08-01,UNKNOWN,INTERVENTIONAL,['NA']
14311,NCT00220077,To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.,Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.,,2002-06,UNKNOWN,INTERVENTIONAL,['NA']
14312,NCT05059119,Rate of associated comorbidity or intervention,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
14313,NCT01294085,One year survival rate,Progression free survival,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
14314,NCT00313859,overall response rate,duration of response,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14315,NCT01698190,Number of needle passes needed to obtain a pathologic diagnosis.,Frequency of adverse side effects.,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
14316,NCT00446290,Number of Participants With DLTs,,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14317,NCT00300950,Recurrence free time and survival,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14318,NCT06077981,Volume of solution,Number of additional injections,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA']
14319,NCT00985400,Effect size of the exercise intervention on physical function,Effect size of the exercise intervention on symptoms and quality of life,,2010-11-05,UNKNOWN,INTERVENTIONAL,['NA']
14320,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation",,2012-04,COMPLETED,OBSERVATIONAL,['NA']
14321,NCT03784677,Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events,Predictive biomarkers,,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE1']
14322,NCT05230329,we will assess the Number of harvested lymph nodes after colonic resectio,Health related quality of life,,2022-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14323,NCT04223102,16s rRNA gene sequencing to study bacterial phylogeny and taxonomy,rectal microbiota to study bacteria strains,,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14324,NCT05089266,Dose-limiting toxicity （DLT）,Objective response rate (ORR),,2021-11-30,RECRUITING,INTERVENTIONAL,['PHASE1']
14325,NCT04634539,"Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.",Describe any preliminary evidence of antitumor activity of the combination by assessment of overall survival as determined by RECIST 1.1 criteria in patients with measurable disease.,,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14326,NCT00986440,Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,,2009-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
14327,NCT02607982,response rate,Toxicity,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14328,NCT00291486,Number of Patients With Dose-Limiting Toxicities (DLT),Number of Patients With Human Anti-human Antibodies (HAHA) to 131I-huA33,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14329,NCT01074385,Impact of Dignity Therapy,Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care.,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
14330,NCT01960023,Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study,The frequency and severity of adverse events to evaluate the overall toxicity in the Phase II portion of the study.,,2013-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14331,NCT04851119,Area under the drug concentration curve of tegavivint,Antitumor effects of tegavivint in patients with solid tumors,,2021-11-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14332,NCT03193424,Progression-free survival (PFS),Total Survival (OS),,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14333,NCT06015971,Functionality,C-RP,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
14334,NCT05131776,Adverse events,Progression Free Survival,,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14335,NCT04677413,To determine the maximal tolerated dose (MTD) of dose-escalated hypofractionated RT.,"To evaluate the rate of distant failure, defined as development of disease outside of the pelvis.",,2021-06-03,RECRUITING,INTERVENTIONAL,['PHASE1']
14336,NCT02001623,Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events,Dose Expansion Part: Duration of Response (DOR),,2013-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14337,NCT02886247,pancreatic cancer,,,1994-06,RECRUITING,OBSERVATIONAL,['NA']
14338,NCT01580241,,,,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14339,NCT04368507,"2a cohort: Safety, Tolerability of YYB101 by ORR",2a cohort,,2019-08-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14340,NCT06192771,Study feasibility as measured by data fidelity for patient-reported outcomes,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
14341,NCT02944006,T-staging,mean diffusivity,transient dyspnea,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA']
14342,NCT00007943,,,,2000-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14343,NCT00434109,Percentage of Participants With Progression Free Survival (PFS) at 12 Months,Percentage of Participants With Overall Survival (OS) at 4 Years,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14344,NCT01151761,Progression-free Survival at 12 Months,Median Time to Overall Survival,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
14345,NCT01608711,Incidence of anti-AGS-1C4D4 antibody formation,,,2012-08-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14346,NCT03019016,Chart review on PeriOperative Information,Chart review on Postoperative Information,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
14347,NCT05100329,Objective response rate (ORR),Treatment-emergent adverse events (TEAEs),,2021-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14348,NCT00834860,"Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",Safety: adverse event rate and profile.,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14349,NCT02022995,evaluate the overall survival of patients with PRMT (arginine methyltransferase),evaluate the disease-free survival of patients with PRMT (arginine methyltransferase),,2014-01,COMPLETED,OBSERVATIONAL,['NA']
14350,NCT00862680,Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients,,,2009-03-12,COMPLETED,OBSERVATIONAL,['NA']
14351,NCT00003907,Time to Progression,Overall Survival,,1999-12-15,COMPLETED,INTERVENTIONAL,['PHASE2']
14352,NCT04731441,Feasibility of doing exercises,Quality of Life after CRS-HIPEC,,2021-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14353,NCT00016380,,,,2001-02-28,COMPLETED,INTERVENTIONAL,['PHASE3']
14354,NCT04534218,objective response rate,,,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
14355,NCT06293612,Heterochronous distant metastasis,Distant metastasis-free survival,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
14356,NCT01906216,Overall survival,Adverse events,AFP response,2013-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14357,NCT04193553,Progression-Free Survival (PFS),Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group,Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE2']
14358,NCT03590119,The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.,The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls,,2018-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14359,NCT01593098,Prevalence of adenoma and CRC,Differences in genetic profile between siblings of patients with advanced neoplasm and controls,,2010-06-08,RECRUITING,OBSERVATIONAL,['NA']
14360,NCT05935189,Creation of a registry,,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
14361,NCT01653301,Pathological major downstaging,survival,,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
14362,NCT00048529,,,,2002-09,SUSPENDED,INTERVENTIONAL,['PHASE2']
14363,NCT03965546,Frequency of ARTEMIS T cell treatment-related adverse events,IFN-γ serum levels,,2019-05-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14364,NCT05728710,Surgery,30-days mortality rate,,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14365,NCT04232176,Precision in polyps sizing the pathologist,Rate of polyps' recurrence at the end of the follow-up.,,2019-12-22,COMPLETED,OBSERVATIONAL,['NA']
14366,NCT03784040,Response Rate,Overall Survival,,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
14367,NCT03785938,Cost-benefit evaluation of the study,Evaluate responsible guardian/participants experience of the MaCROS study,,2019-01-20,UNKNOWN,INTERVENTIONAL,['NA']
14368,NCT01349075,Response to Treatment,Survival Time,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
14369,NCT01618253,Maximum Tolerated Dose,Health Related Quality of Life,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14370,NCT05552755,Percent change from baseline in polyp burden,"Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome",,2023-07-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14371,NCT00965172,"Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4",,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14372,NCT02528643,Overall Survival (OS),Progression Free Survival (PFS),,2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14373,NCT03751761,response rate,,,2018-06-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14374,NCT04273061,"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1",Duration of response (DoR) in each tumour-defined cohort,Compare the utility of iRECIST for response assessment to RECIST 1.1 in each tumour-defined cohort,2020-06-17,RECRUITING,INTERVENTIONAL,['PHASE2']
14375,NCT00003951,,,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14376,NCT03849469,"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.",,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1']
14377,NCT04962958,2-year cumulative recurrence-free survival rate,Adverse Events,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14378,NCT03645876,Objective response rate,12month and 24 month OS rate,Biomarkers and ADA,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2']
14379,NCT00154544,,,,2004-08,UNKNOWN,OBSERVATIONAL,['NA']
14380,NCT02694081,the amount of blood loss during operations of Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction,the number of patients with the complication of Reflux esophagitis,the number of patients with the complication of gastroesophageal reflux disease(GERD),2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
14381,NCT03175016,Tumor Response of six months,Quality of life,,2017-06-20,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14382,NCT00047307,Maximum tolerated dose of flavopiridol when administered biweekly in conjunction with radiation for patients with locally advanced pancreatic or extrahepatic bile duct cancer,"Molecular correlates of apoptosis including PARP cleavage and caspase-3 activation, as well as changes in expression of p21, phosphorylation status of pRb and cyclin D1",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14383,NCT02896907,Number of Participants With Adverse Events as Determined by CTCAE Version 4.03,Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30,,2016-10-18,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14384,NCT01450319,Overall Survival (OS) Time,Beta 2-microglobulin,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14385,NCT05262452,Percentage of subjects that were subject to surgical resection,Survival time,,2021-08-09,RECRUITING,INTERVENTIONAL,['NA']
14386,NCT02715804,Overall Survival,Number of Participants With Clinically Significant Abnormalities in Vital Signs,,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE3']
14387,NCT03910634,Overall objective response rate,Incidence of toxic and side effects above 3 degrees,,2019-04-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
14388,NCT01959672,"Number of Participants With Progressive Disease,","Tumor Response Rate, Evaluated on the Pathology Specimen",Number of Participants With CA-125-Specific T-cell Signal.,2013-09-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14389,NCT02978313,PFS,QoL,,2016-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14390,NCT00370513,Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).,Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans,,2006-12-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14391,NCT03038256,Pathological complete response rate,quality of surgery,,2018-01-31,RECRUITING,INTERVENTIONAL,['PHASE2']
14392,NCT00999921,Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).,Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia),,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14393,NCT05743036,Dose Expansion Phase - Objective response rate (ORR),Tumor tissue BRAF V600E mutational status,,2023-02-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14394,NCT06304974,Overall survival (OS),Anti-drug antibody (ADA),,2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
14395,NCT05416073,Pain intensity at 3 hours after HAIC treatment,Pain intensity on the 21st after HAIC treatment,Degree of satisfaction,2022-06-22,RECRUITING,INTERVENTIONAL,['PHASE4']
14396,NCT05310643,Objective response rate (ORR) by RECIST 1.1,MSI/MMR status,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2']
14397,NCT05592873,Lateral nodal recurrence,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
14398,NCT04031963,Early cancer changes in the colon,,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
14399,NCT01902849,measurement of interleukins IL6 and IL 10 plasmatic level,total opioid analgesic dose (mg),total opioid dose of remifentanil (mg ) used during surgery,2012-02,COMPLETED,OBSERVATIONAL,['NA']
14400,NCT03530969,Participants satisfaction with Health Care Provider (HCP) training,,,2018-05-07,COMPLETED,INTERVENTIONAL,['NA']
14401,NCT04862949,Organ-specific response rate,,,2021-05-01,COMPLETED,OBSERVATIONAL,['NA']
14402,NCT04068103,"Recurrence-free survival (RFS) the ""baseline ctDNA detected"" patient subset (Phase III)",Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer,Cost effectiveness of the use of ctDNA versus standard of care,2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14403,NCT04518774,Safety evaluation: Maximum-tolerated dose (MTD),Efficacy evaluation: γδT cells in peripheral blood,,2020-08-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14404,NCT04632303,Adjusted mean change in global health status/QoL score at 12 weeks,Chemotherapy dose intensity.,,2021-06-23,RECRUITING,INTERVENTIONAL,['NA']
14405,NCT05438927,Participant Rating on Ease of Use for the Mobile Application - Usability,Participant Compliance with Dietary Log - Intervention Adherence,,2022-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14406,NCT03823846,pain at rest (Numerical rating scale),adverse events during rehabilitation,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
14407,NCT05090215,Anaerobic threshold change,Change to the values inflammatory markers using venous blood samples after the application of a 12 week postoperative exercise programme,,2022-05-13,RECRUITING,INTERVENTIONAL,['NA']
14408,NCT00005818,Time to disease progression (TTP),Toxicity graded using the NCI CTC version 2.0,,2000-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14409,NCT04579380,Confirmed objective response rate (cORR) per investigator assessment,Trough concentration (Ctrough),,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14410,NCT02578602,"Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring ""size"" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability",Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14411,NCT02838836,"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome",ctDNA characteristics will be correlated with survival data,,2016-07-01,RECRUITING,OBSERVATIONAL,['NA']
14412,NCT04300114,PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1,Number of participants with treatment-emergent adverse events,,2020-08-19,TERMINATED,INTERVENTIONAL,['PHASE3']
14413,NCT01234935,Disease-free survival,Disease-free survival,,2011-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
14414,NCT00293397,Efficacy - Overall Survival,,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
14415,NCT03661047,The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.,The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period,,2019-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14416,NCT02553031,The recurrence rate at 1 year after surgery,The overall survival at 1 year after surgery,,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
14417,NCT05788484,Tumor-specific expansion cohorts: To further evaluate the safety of CDX-585 by tumor type.,Immunogenicity Evaluation,,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE1']
14418,NCT02887365,3-year disease-free survival Safety profile of tegafur-uracil,5-year overall survival,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
14419,NCT03403049,Dose-limiting toxicity,The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire,,2016-04-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14420,NCT01801059,Completion rate of CRC screening,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
14421,NCT04726800,Frequency of positive ctDNA preoperative converted to negative postoperatively.,,,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14422,NCT00259363,Phase II : Response and resectability rate.,,,2002-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14423,NCT06194461,Incidence of specific AEs,"Kinetics parameters that indicate persistence (eg, Clast and Tlast)",,2024-06-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14424,NCT04767295,pathologic complete response (pCR),,,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14425,NCT04035096,"Change from baseline by computerized tomography of Chest, abdomen and pelvis",Number of participants with changes of tumor markers,,2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14426,NCT00544908,Progression-free Survival (PFS) Rate at 4 Months,Response Rate,,2007-09,TERMINATED,INTERVENTIONAL,['PHASE2']
14427,NCT04681248,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
14428,NCT03997617,"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP",Number of patients for which the treatment recommendation issued by PFP were followed by the investigator,,2019-03-11,RECRUITING,INTERVENTIONAL,['NA']
14429,NCT04301986,7 Days Post-EGD Impact of Events Score (IES),Factors Influencing the Preferred Screening Modality,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
14430,NCT06019312,gut microbiota composition,Clostridioides difficile infection,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
14431,NCT04281667,Comprehensive Complication Index,Adjuvant therapy,Bowel microbiota,2020-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
14432,NCT02947971,Assessment of quality and performance of Compact Imaging System (CIS),,,2016-04-15,RECRUITING,INTERVENTIONAL,['NA']
14433,NCT02751177,"KRAS, NRAS et BRAF mutational status",,,2016-03-25,COMPLETED,INTERVENTIONAL,['NA']
14434,NCT05336617,percentage of complete colonoscopies,Quality of colonic preparation (Boston score),,2022-05-13,COMPLETED,OBSERVATIONAL,['NA']
14435,NCT00814359,The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks.,Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14436,NCT04101747,Number of intestinal flora,,,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA']
14437,NCT03546257,the accuracy in predicting the invasion depth of EGC.,The NBI findings that affect the accuracy for predicting of depth.,,2019-03,UNKNOWN,OBSERVATIONAL,['NA']
14438,NCT01978184,Age-Adjusted Charlson Comorbidity Index,Rate of R0 Resection,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14439,NCT05160753,Disease-free survival (DFS) at three years,,,2022-01-10,RECRUITING,INTERVENTIONAL,['NA']
14440,NCT00222079,,,,2004-11,TERMINATED,INTERVENTIONAL,['NA']
14441,NCT05954897,Objective Response Rate,Adverse Events,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14442,NCT03958240,Percentage of CD4 and CD8 T cells expressing PD-1,Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples,,2020-01-17,RECRUITING,INTERVENTIONAL,['NA']
14443,NCT03981848,tumor recurrent status,,,2019-07,UNKNOWN,OBSERVATIONAL,['NA']
14444,NCT02479984,Probability of diagnosis of metastasis (frequency),,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
14445,NCT01707641,incidence of grade III/IV mucositis,percentage of patients able to complete the chemo-radiotherapy treatment,percentage of patients who need enteral nutrition,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14446,NCT00323830,disease free survival,,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14447,NCT01588990,Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio,FACT-C Score: Phase B,,2012-06-26,COMPLETED,INTERVENTIONAL,['PHASE4']
14448,NCT04234568,Dose limiting toxicity (DLT),Overall survival,Change in deoxyribonucleoside concentrations,2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14449,NCT00100321,,,,2004-12-21,TERMINATED,OBSERVATIONAL,['NA']
14450,NCT00212615,Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event),Tumor assesment: after every 3rd treatment (each 9th weeks),,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14451,NCT02727894,Colorectal Cancer Stage (pTNM),Colorectal Cancer and Palliative Therapy,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
14452,NCT02381847,overall survival,time to distant metastasis,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
14453,NCT01351714,Number of additional lymph nodes removed through radical D3 resection,Disease free survival 2 and 5 years after initial surgery,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
14454,NCT02202096,Number of post-operative ER visits and readmissions,,,2015-02,WITHDRAWN,INTERVENTIONAL,['NA']
14455,NCT05945901,Progression-Free Survival (PFS) Assessed by IRC（Phase III）,Serious Adverse Events (SAE)（Phase III）,,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14456,NCT04259944,Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection,Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free,,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14457,NCT00586872,Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
14458,NCT06044961,Use of radiomics,,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
14459,NCT03609424,Disease control rate,Mutational analysis,,2019-02-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14460,NCT02384850,Numbers of Patients With Dose Limiting Toxicities,Number of Patients Experiencing Adverse Events,,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1']
14461,NCT06204497,Incidence of severe complications within 90-day,Quality of life evaluation,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
14462,NCT03594448,Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens,,,2018-09-05,RECRUITING,OBSERVATIONAL,['NA']
14463,NCT02705300,Time to first serious adverse event,Resection rate,,2016-05-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14464,NCT04817826,Primary outcome of Cohort 2: 2-year complete response rate,Post gastrectomy complications,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14465,NCT04895137,PCR rate,3 years OS Rate,,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14466,NCT01403064,Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy,Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE2']
14467,NCT02012829,participation rate of patients for CRC screening,GPs participation rate over 45%,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
14468,NCT03518632,Change of Oxgen consumption at anaerobic threshold :,Changes in Fatigue :,,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
14469,NCT00003993,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14470,NCT02004769,PFS(Progression-free survival ),Safety,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14471,NCT04239573,"Occurrence of an ""unfavorable"" outcome",Biomarker analysis from collected samples to compare the predictive performance of known and future biomarkers for dysplasia or cancer,Predictive accuracy of radiomic markers for dysplasia and pancreatic cancer,2020-06-16,RECRUITING,INTERVENTIONAL,['NA']
14472,NCT04032704,Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Cohort 7 only),Incidence of antitherapeutic antibodies (ATAs) to LV,,2019-10-09,TERMINATED,INTERVENTIONAL,['PHASE2']
14473,NCT04035876,Recurrence-free survival,Adverse effect,,2019-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14474,NCT03876106,"Safety and tolerability (maximum tolerated dose, MTD) of LUT014 topically applied qd for 4 weeks in metastatic colorectal cancer (mCRC) patients with epidermal growth factor receptor inhibitor (EGFRI) induced acneiform lesions.",Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI-18) on health-related quality of life (HRQoL) questionnaire,,2019-08-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14475,NCT03302403,Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03,Engraftment,Changes of cell subsets for CAR T cells against T cells,2017-12-29,UNKNOWN,INTERVENTIONAL,['NA']
14476,NCT02642913,Progression-free survival,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14477,NCT03773367,To determine the rate of histopathological response according to Becker criteria.,,,2018-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14478,NCT00425152,,,,1989-07,COMPLETED,INTERVENTIONAL,['PHASE3']
14479,NCT02640898,overall survival rate,progression free survival rate,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
14480,NCT04078828,The rate of general complications,"White blood cells(WBC) ,C-reactive protein (CRP) and procalcitonin (PCT) count in the blood sample",,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
14481,NCT02163291,Pathological complete response rate,"R0 rate, surgical morbidity and mortality",,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
14482,NCT04020276,Number of Participants with Acute Dose Limiting Toxicity (DLT),Local Control Rates,,2019-11-04,SUSPENDED,INTERVENTIONAL,['PHASE1']
14483,NCT04134559,Immune-related best overall response (irBOR),DNA sequencing of specimens,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14484,NCT00975247,"Bowel preparation quality, as measured by the Ottawa scale.",Withdrawal Time,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14485,NCT02682082,Difference in pain scores at 1 month and end of the trial,Difference in survival,,2016-05-27,TERMINATED,INTERVENTIONAL,['NA']
14486,NCT00892242,Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.,Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1']
14487,NCT02830737,Recurrence Rate,Overall Survival Rate,Number of Participants with Adverse Events,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
14488,NCT02745600,Comparison of the spatial coordiantes of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.,"Does the follow - up (3, 6 ,12months) imaging support the assumptions regarding local tumor control",,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
14489,NCT02856126,Overall survival,Number of of Patients developed Adverse Events,,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14490,NCT01935700,Overall Survival,Grade III Severe Adverse Events,,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14491,NCT04379232,Symptoms of Covid after surgery,,,2020-03-19,COMPLETED,OBSERVATIONAL,['NA']
14492,NCT05052723,Progression-free survival,Overall participant survival rate,,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14493,NCT02481219,Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE),Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
14494,NCT00546468,5 year disease free survival,Overall survival,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14495,NCT01448668,Overall survival time (OS).,"Number of patients with adverse events (AE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).",,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
14496,NCT01465659,Overall Response Rate (ORR) in Patients With Advanced Neuroendocrine Tumors (PNET) Treated With Temozolomide and Pazopanib Combination Treatment at the RP2D in Phase II,Number of Months That Patients Maintain a Response to Treatment Until Disease Progression or Death (Duration of Response),Amount of a Particular Tumor Biomarker in Blood as Correlated With Progression Free Survival,2011-12-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14497,NCT01329458,evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
14498,NCT06203821,Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]),,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
14499,NCT01896778,"Changes in tumor vascular (blood flow, blood volume)",Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,,2013-10-04,COMPLETED,INTERVENTIONAL,['NA']
14500,NCT05596188,Independent risk factors of preoperative anxiety and establishment of prediction model,Incidence of preoperative anxiety,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
14501,NCT05781074,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,,2023-03-23,RECRUITING,INTERVENTIONAL,['PHASE2']
14502,NCT01086059,Major malformations,Infant follow-up,,2003-11,COMPLETED,OBSERVATIONAL,['NA']
14503,NCT04729738,"correlation between the development of a postoperative complication within 30 days from surgery and patient-related characteristics (comorbidity, frailty, malnutrition and sarcopenia)","relatedness between the average density sarcopenia indices, HUAC, PI, TPA and the distance between the anterior-superior iliac spines and the size of the psoas muscles (RPSI)",,2012-06-01,COMPLETED,OBSERVATIONAL,['NA']
14504,NCT01219829,Number of subjects with histological features of PanIN lesions assessed,Evaluation of Recurrence Mechanism in PDC,,2009-03-18,COMPLETED,OBSERVATIONAL,['NA']
14505,NCT01814969,• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins,The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0),,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
14506,NCT03846882,Can FDG-PET / MR in combination with blood and tumor tissue biomarkers provide additional prognostic information for intermediate and high-risk rectal cancer?,How does the accumulation of FDG change in rectal cancer tissue when examined after 60 minutes vs examination after 90 minutes?,,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA']
14507,NCT03961646,Diagnostic accuracy,Image quality,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
14508,NCT01075555,Overall survival,Time to progression,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14509,NCT05253430,Disease-free survival,Postoperative mortality,,1990-04,COMPLETED,OBSERVATIONAL,['NA']
14510,NCT00179348,Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form,spiritual well-being,,2001-02-08,COMPLETED,INTERVENTIONAL,['NA']
14511,NCT01706822,The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met,Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
14512,NCT03426722,Proportion of patients who have occurrence of muscle cramps ( numeric rating scale score > 4),recurrence rate,,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14513,NCT05072041,Incidence of liver function impairment,Hepatic artery damage,,2021-10-31,RECRUITING,INTERVENTIONAL,['NA']
14514,NCT00002796,"Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)",,,1997-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14515,NCT05044065,Skeletal muscle cross sectional area,Prognostic markers,,2021-05-01,RECRUITING,INTERVENTIONAL,['NA']
14516,NCT00937079,"Detection of insulinomas, cure rate",,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
14517,NCT00140894,Safety and tolerability,Proportions of patients with improved overall colon rating,,2002-08-06,TERMINATED,INTERVENTIONAL,['PHASE4']
14518,NCT01280058,Progression-free Survival Using RECIST v. 1.1,Overall Survival,Percentage of Patients With Ras Pathway Activation,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14519,NCT02776527,disease free survival,overall survival,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14520,NCT03161379,CD8 count (cells/mm^3) in the tumor microenvironment,Pathologic complete response (pCR) rate at surgical resection,,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14521,NCT03403452,PFS（progress free survival）,DCR（disease control rate),,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14522,NCT01556490,Overall Survival (OS) Per Protocol (PP) Population,Tumor Response,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
14523,NCT00858000,Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
14524,NCT02282839,Oral mucositis,Quality of life,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
14525,NCT01288339,Progression-free survival time according to the MMP7 status (PFS),Molecular predictive markers for response.,,2010-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14526,NCT02834780,Number of Participants With Clinically Significant Change From Baseline in Vital Sign Parameters,"Part 2, Dose Expansion Phase: Time to Response (TTR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1",,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE1']
14527,NCT05432492,Objective Response Rate (ORR) Per mRECIST,Overall survival (OS),Percentage of participants who obtain a pathologic complete response (pCR),2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14528,NCT02321813,proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension),rates of patients with diseased quality of life in each dimension of the profile,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14529,NCT02287727,Disease free survival (DFS),Overall survival,,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14530,NCT06137248,Change in the hydrogen sulfide-metabolizing species of bacteria,Microbiome changes and tolerance,,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2']
14531,NCT03636620,overall survival,objective response rate,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14532,NCT02599116,"Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort",Compare the gut microbiome of appendiceal tumors by histopathology,Identify alterations in the gut microbiome post-CRS/HIPEC,2015-12,RECRUITING,INTERVENTIONAL,['NA']
14533,NCT00493025,Pathologic Complete Response Rate to the Neoadjuvant Regimen,Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14534,NCT03264274,Overall survival,Progression-free survival,,2017-02-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14535,NCT03228407,Correlation between the time from intravenous injection of fluorescein to visualization of fluorescein on probe based confocal endomicroscopy (pCLE) with esophageal permeability (i.e. - epithelial barrier function).,Correlation between the Ussing's chamber findings (esophageal permeability) and Mucosal impedance findings of patients with symptoms of refractory GERD and controls,,2017-04-28,UNKNOWN,INTERVENTIONAL,['NA']
14536,NCT03700411,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,Pain assessment,,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14537,NCT04491565,Adequacy of bowel prep,,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
14538,NCT02894801,death due to recurrence,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
14539,NCT04225026,Number of Subjects With of Acute Radiation Esophagitis (Defined as Grade >/= 2; NCI CTCAE Version 5) Through the End of Chemoradiotherapy for Non-Small Cell Lung (NSCLC) or Small Cell Lung Cancer (SCLC) When Avasopasem Was Added.,Number of Subjects With Acute Severe Radiation Esophagitis (Defined as Grade 3-4; NCI CTCAE Version 5) Through Completion of Chemoradiotherapy.,,2019-12-19,TERMINATED,INTERVENTIONAL,['PHASE2']
14540,NCT03214991,Overall survival rate,"Overall survival rate (K-ras mutation type, EUS-FNA)",,2017-05-12,UNKNOWN,OBSERVATIONAL,['NA']
14541,NCT04973475,False negative rate,The variation of C-reactive protein,,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14542,NCT04122937,P2X7R-inflammasome activity,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
14543,NCT01227707,Percentage of Participants With Pathological Complete Response (pCR),TTP - Time to Event,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14544,NCT01232374,3-yr overall survival,Quality of life,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
14545,NCT04909671,Mean number of adenomas per colonoscopy,Subjective endoscopist measures,,2021-09-13,UNKNOWN,INTERVENTIONAL,['NA']
14546,NCT01974661,Registration of adverse events as a measure of safety and tolerability,To study overall survival (OS),"Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI",2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14547,NCT03663712,Non-dose limiting toxicities for talimogene laherparepvec,,,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14548,NCT03435588,Final diagnosis of benign pancreatic mass,Rate of procedure-related adverse events,,2018-02-14,COMPLETED,INTERVENTIONAL,['NA']
14549,NCT02146508,Complete resolution of advanced esophageal squamous dysplasia,Safety of endoscopic interventions,,2013-06,SUSPENDED,INTERVENTIONAL,['NA']
14550,NCT00258323,Distant metastatic control at 1 year,Toxicity of maintenance gefitinib as measured by CTC version 2.0 every 8 weeks after the completion of radiotherapy,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14551,NCT01402908,Disease-Free Survival (DFS),Tumor Recurrence Rate (TR Rate),,2011-08,TERMINATED,INTERVENTIONAL,['PHASE3']
14552,NCT03737539,ctDNA methylation markers versus CT/MRI,,,2018-09-01,RECRUITING,OBSERVATIONAL,['NA']
14553,NCT00374036,Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line,"The tolerance, the quality of life, duration of hospitalization",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14554,NCT03947762,Progression-free survival (PFS) rate at 24 months,Patient satisfaction,,2019-07-03,TERMINATED,OBSERVATIONAL,['NA']
14555,NCT04393116,Development of patients' Distress,Patient's global health status,,2017-07-11,COMPLETED,OBSERVATIONAL,['NA']
14556,NCT03220984,the disease control rate (DCR),,,2017-03-16,UNKNOWN,INTERVENTIONAL,['PHASE2']
14557,NCT00093548,,,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14558,NCT04920149,Change in the occurrence of any colorectal neoplasia in LS patients,Significant findings & illnesses - adverse events,,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE2']
14559,NCT05792254,1-year progression-free survival rate,the Rates of AE and SAE,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14560,NCT02971696,Event free survival,Sorafenib induced side effects,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14561,NCT04759235,change of metabolites,Overall survival,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
14562,NCT01320267,Successful completion of the right hemicolectomy,Postoperative Measure of Pain,,2011-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14563,NCT00284817,The recommended Phase II dose will be based on acceptable dose-limiting toxicity,Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14564,NCT00582660,Subjects With Positive Response 72 Hours After Administration of Study Treatment as Measured by Immunoblot,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14565,NCT02726360,study-specific coding structure,,,2015-12-14,COMPLETED,OBSERVATIONAL,['NA']
14566,NCT02786342,PFS,OS,,2016-02-15,UNKNOWN,OBSERVATIONAL,['NA']
14567,NCT04444544,Health-related Quality of Life,Health-related Quality of Life,,2020-09-05,RECRUITING,OBSERVATIONAL,['NA']
14568,NCT04637061,Rate of 30 day-anastomotic failure (AF),Procalcitonin (PCT) measurement,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
14569,NCT01854749,Progression Free Survival,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14570,NCT00004870,,,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14571,NCT05891730,Number of colorectal cancer patients who remain in clinical trial until completion.,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14572,NCT05300789,Metachronous peritoneal carcinomatosis,Time to metachronous peritoneal carcinomatosis diagnosis,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
14573,NCT01787539,cancer free and overall survival,the rate of chemotherapy cessation,quality of life,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14574,NCT01474694,"TRE, measuring the error in the prediction of a surgical target location when using the navigation system.",1.Identification of suitable landmarks for registration,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14575,NCT02478476,"Occurrence of chemotherapy related toxicities including Anemia, Nephrotoxicity, Neutropenia, Neuropathy, and Thrombocytopenia associated with genotype.",,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
14576,NCT05557955,overall survival.,recurrence.,,2022-09-27,COMPLETED,OBSERVATIONAL,['NA']
14577,NCT05638243,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,,,2022-08-20,RECRUITING,OBSERVATIONAL,['NA']
14578,NCT04733794,Sexual function,,,2016-02-19,COMPLETED,INTERVENTIONAL,['NA']
14579,NCT01123473,Progression-free survival,Concordance of diagnostic tests,,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2']
14580,NCT00005997,Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue.,Assess the toxicity associated with this drug in this patient population.,,1999-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14581,NCT05932719,Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019),,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
14582,NCT04605185,Dose limiting toxicity(DLT),Duration of response (DOR),,2021-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14583,NCT01961791,Prognostic performance,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
14584,NCT04843176,Diagnostic accuracy for HCC,Occurrence of technical failures,,2021-03-19,RECRUITING,INTERVENTIONAL,['NA']
14585,NCT01727570,Six-Minute Walk Test (6MWT),,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14586,NCT06059001,"Number of AEs, SAEs to evaluate the safety and tolerability of OMO-103 plus gemcitabine/nab-paclitaxel",To evaluate quality of life (QoL) in patients with metastatic pancreatic cancer,,2023-08-31,RECRUITING,INTERVENTIONAL,['PHASE1']
14587,NCT05411094,Dose-limiting toxicities (DLTs) for olaparib in combination with durvalumab and radiation,Number and diversity of T cells,Correlation of efficacy endpoints with clinicopathologic variables,2023-05-22,SUSPENDED,INTERVENTIONAL,['PHASE1']
14588,NCT01447238,"Assess the yield of combination modalities in the diagnosis of pancreatic cysts using EUS/FNA, Fiber optics (direct visualization probe), and prototype needle based confocal laser-induced endomicroscopy miniprobe (nCLE)",,,2010-09-15,COMPLETED,OBSERVATIONAL,['NA']
14589,NCT03623737,pathological complete response,Number of participants with treatment-related adverse events as assessed by the NCI Common Toxicity Criteria (CTC),,2017-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14590,NCT04264754,To develop a molecular blood test that will be able to detect HCC based on change in methylation patterns between HCC and normal hepatic tissue,Liver EpiCheck Performance,,2018-02-13,TERMINATED,OBSERVATIONAL,['NA']
14591,NCT02101580,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer,,,2014-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14592,NCT03385148,diagnosis effecacy,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14593,NCT00336141,Toxicity,Response,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14594,NCT05023863,Incidence and severity of radiation induced oral mucositis,Time to develop grade III or IV radiation induced oral mucositis:,,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14595,NCT04692051,PFS,AEs,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14596,NCT01900691,Number of Patients With Successful Removal of Study Stent,Number of Patients With Benign Indications That Achieved Clinical Success,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
14597,NCT03416777,DNA damage,Oxidative stress,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
14598,NCT02458664,Recurrence free survival and Recurrence free survival after resection of the colon cancer,Overall survival,,2013-11,UNKNOWN,OBSERVATIONAL,['NA']
14599,NCT04230642,Evaluation of the feasibility of the Quantum Surgical device: Number of targets reached,Evaluation of the safety not related to the procedure,,2020-05-25,COMPLETED,INTERVENTIONAL,['NA']
14600,NCT00436137,Performance of colonoscopy,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
14601,NCT02972372,2-year disease-free survival rate,2 year overall survival,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
14602,NCT04015466,"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape",Daily routines as assessed by a new study-specific questionnaire,,2019-06-12,UNKNOWN,OBSERVATIONAL,['NA']
14603,NCT01507168,Progression-free survival (tumor assessments according to RECIST criteria),GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay,,2012-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14604,NCT04217096,Progression free survival,Adverse events,,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14605,NCT00773097,Number of Participants With Anti Muc-1 Antibody,Number of Participants With Adverse Events Associated With the Study Agent,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14606,NCT00058149,,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14607,NCT01533324,DCR,safety,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
14608,NCT06102278,overall survival,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
14609,NCT03856437,Intention to Vaccinate Free of Cost,Intention to Vaccinate With Cost,,2021-01-22,COMPLETED,INTERVENTIONAL,['NA']
14610,NCT00006198,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
14611,NCT00511862,Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST),Overall Survival,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14612,NCT03852836,Global quality of the images evaluated with a Likert score,"Performance of each sequence in the visualization of the pathology and / or an anatomical variant in the 1.5T magnetic field group, evaluated in percentage",,2019-02-26,TERMINATED,INTERVENTIONAL,['NA']
14613,NCT02586610,Pathological Complete Response (pCR) Rate,Overall Survival (OS),,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14614,NCT00019630,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14615,NCT03337347,CEA mRNA positive circulating tumor cells in colorectal cancer patients,Cancer specific survival in CTC positive CRC patients,,2004-01-01,COMPLETED,INTERVENTIONAL,['NA']
14616,NCT01937780,Disease-free survival,Pain relief of palliative radiotherapy,Overall survival,2013-10-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14617,NCT00016133,,,,2001-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14618,NCT00233415,Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14619,NCT03066167,Translation of scores to the Swedish language,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
14620,NCT03418298,Recruitment rate,Change in anxiety and depression,,2018-02-27,COMPLETED,INTERVENTIONAL,['NA']
14621,NCT04327700,Progression-Free Survival,Change in Alpha-fetoprotein Levels,,2021-01-26,SUSPENDED,INTERVENTIONAL,['PHASE2']
14622,NCT01239381,Local Control Rate,Median Survival Among Participants With Colorectal Cancer,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14623,NCT05563441,perioperative complications,disease free survival,,2015-01-20,COMPLETED,OBSERVATIONAL,['NA']
14624,NCT03814824,Time for Image Interpretation (Median - Scaled),Subjects With Dysplasia on Biopsies,,2019-01-23,COMPLETED,INTERVENTIONAL,['NA']
14625,NCT05994482,colorectal cancer incidence,perspectives on surveillance in older adults,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
14626,NCT04131803,objective response rate,,,2021-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14627,NCT02016326,Adenoma Detection Rate (ADR) in the right colon using High Definition White Light Colonoscopy Versus I-Scan enhanced Colonoscopy.,Adenoma Detection Rate (ADR) of High Definition White Light Colonoscopy Versus I-Scan colonoscopy through out the entire colon.,Presence or absence of learning effect while using this technology,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
14628,NCT03265483,"Blood 1,25-dihydroxyvitamin D2",,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14629,NCT01152164,To prospectively evaluate the quality of life of patients one year after rectal cancer resection,To prospectively evaluate the quality of life of patients two years after rectal cancer resection,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
14630,NCT00220155,Proportion of patients obtaining disease control in the form of tumour response or stabilisation,Progression free survival,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14631,NCT02220088,Progression free survival,overall survival,,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14632,NCT05808790,Local recurrence-free survival,Multiparameter flow cytometric analyses (FACS),,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14633,NCT00409864,Quality of life,Stent patency time will be defined by time to stent occlusion,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
14634,NCT05501353,the correlation between ctDNA mutations with methylation status and recurrence,Compare the difference of DNA with ctDNA in predicting postoperative recurrence through statistical method,,2022-07-22,RECRUITING,OBSERVATIONAL,['NA']
14635,NCT02222844,Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.,To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.,,2014-08,RECRUITING,INTERVENTIONAL,['NA']
14636,NCT03149523,Sequencing of the exome and tumor RNA,Transcriptomic profile of urinary RNAs,,2017-05,UNKNOWN,OBSERVATIONAL,['NA']
14637,NCT05684211,Progression-free survival (PFS),incidence of adverse events,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14638,NCT02582541,Stent patency rate,Change from Baseline in Bile Duct Stricture Diameter,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
14639,NCT00960349,"Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.","Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined.",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14640,NCT04799080,Semmens Weinstein Monofilament Test (SWMT),Functional Assessment of Cancer Therapy-Breast (FACT-B+),,2021-03-06,COMPLETED,OBSERVATIONAL,['NA']
14641,NCT01985698,postoperative complications,locoregional recurrence rate,self reported sexual function for female patients,2013-12,COMPLETED,INTERVENTIONAL,['NA']
14642,NCT00755118,Objective Response Rate,Overall Survival,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
14643,NCT06317103,Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%),"Accuracy in classifying the depth of invasion categories (""Mucosa"" or ""Submucosa"") for early gastric cancer (%)",,2023-08-22,COMPLETED,OBSERVATIONAL,['NA']
14644,NCT00847119,Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece),To determine the angiogenic profile changes in tumour.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14645,NCT00180960,To study overall survival,To study mortality-morbidity,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2']
14646,NCT05928312,Objective response rate (ORR),Assess the anti-tumor activity:DCR,,2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14647,NCT01848015,CTCs,Recurrence of gastric cancer after radical resection,,2013-06,UNKNOWN,OBSERVATIONAL,['NA']
14648,NCT02848079,Overall Response Rate,Overall Survival,,2016-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14649,NCT01923337,"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0",Time to failure,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14650,NCT05160727,Objective response rate,,,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14651,NCT03878550,AUROC,Sensitivity,,2019-05-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14652,NCT02748811,Number of patients completing planned treatment without dose reductions,Quality of Life prior,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
14653,NCT00002527,Disease free survival,,,1993-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14654,NCT05062720,Progression free survival,Patient reported outcomes (PROs),,2021-07-29,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14655,NCT00006340,,,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14656,NCT02738294,Specificity in distinguishing HGN from non-HGN,Negative predictive value (NPV) in distinguishing HGN from non-HGN,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14657,NCT06122896,"Number of Imaging-Negative, Assay-Positive Pancreatic Cancers or High-Grade Neoplasms",Clinical Predictors of Neoplastic Development,,2023-11-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14658,NCT03130790,Overall Survival (OS) - Phase 3 part,European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part,,2017-08-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14659,NCT05468827,proportion of pN+ patients in which affected lymph nodes are detected only within margins of ICG distribution,feasibility of ICG mapping for colon flexure tumours,,2022-07-26,RECRUITING,INTERVENTIONAL,['NA']
14660,NCT02713373,"Number of Participants With a Response, Evaluated According to RECIST 1.1",Progression Free Survival (PFS),,2016-08-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14661,NCT03797209,Removal success,,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
14662,NCT02991677,Sensory pain,Nerve fiber density,,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14663,NCT04814030,overall response rate,,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
14664,NCT04785287,Incidence of adverse events,Tumor response,,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14665,NCT02670122,Safety and Tolerability,OS,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
14666,NCT00637247,To Evaluate and Compare the Tolerability and Toxicity of the Two Treatment Arms by Comparing Adverse Events,Progression Free Survival,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14667,NCT03833466,Tumor microenvironment,Rate of pathologic complete response（pCR）,,2019-02-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
14668,NCT01937286,Recurrence of Hepatocellular carcinoma after LDLT,,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
14669,NCT02794337,In-field Progression Free Survival,Toxicity Assessment,,2014-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14670,NCT02439008,"Analyse of immunological parameters, decription of secreted markers and nanovesicles production",Number of Participants with Adverse Events related to radiotherapy,,2015-09-16,TERMINATED,INTERVENTIONAL,['NA']
14671,NCT05357508,Self-reported appropriate screening uptake,Linkage to Vaud tumor registry,,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14672,NCT03950154,Progression-free survival,,,2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
14673,NCT00630552,Safety,Time to Response,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14674,NCT04449679,Post-intervention evaluation,,,2020-04-15,COMPLETED,INTERVENTIONAL,['NA']
14675,NCT03190265,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs),,2017-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
14676,NCT00540332,"Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time",Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4,,2007-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14677,NCT01656265,"Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability",Antitumor effects according to RECIST 1.1.,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14678,NCT06158516,2-year disease-free survival (2y-DFS),2-year Overall survival,,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14679,NCT06113718,Length of hospital,Postoperative gastrointestinal symptoms,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
14680,NCT02949596,Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men,Evaluate quality of life among patients who are HIV positive in this cohort with the use of questionnaire HAT-QoL,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
14681,NCT03498326,disease free survival,Common Toxicity Criteria for Adverse Effects,,2018-04-02,RECRUITING,INTERVENTIONAL,['PHASE2']
14682,NCT00079274,Disease-free Survival (Arms A and D: Wild-type KRAS Patients),"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14683,NCT05809999,Proportion of persons with ≥ 1 neoplastic lesion detected,CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion),,2022-09-23,RECRUITING,INTERVENTIONAL,['NA']
14684,NCT02060188,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator,ORR by RECIST v1.1 by Independent Radiology Review Committee (IRRC),,2014-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14685,NCT00004065,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14686,NCT02820389,3-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient),Cost per correctly diagnosed medium to large polyps (≥6mm) and colorectal cancer using CTC as the initial investigation (measured in £ per patient),,2016-06-14,UNKNOWN,OBSERVATIONAL,['NA']
14687,NCT00600496,Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.,Tumor response.,,2007-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14688,NCT00026468,,,,1999-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14689,NCT05674422,ctDNA from liquid biopsy,TNT compliance,,2023-05-26,RECRUITING,OBSERVATIONAL,['NA']
14690,NCT02870153,Response Rate,Overall Survival,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14691,NCT01661686,Number of Participants With Recurrent Dysphagia.,Median Survival After SEMS Placement,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
14692,NCT00174564,To evaluate response rate according to RECIST criteria,To investigate safety using NCI-CTC criteria version 2,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14693,NCT02416466,Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events,"CAR-T detection in liver tumors, normal liver, and extrahepatic sites",,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14694,NCT01216202,Sexual Function,,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
14695,NCT00068432,Overall Survival at 6 months,Overall response rate,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14696,NCT00509444,"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.","The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14697,NCT00796718,Percentage of Participants With Pathological Complete Response,Percentage of Participants With Adverse Events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14698,NCT00632268,To evaluate the confirmed objective response rates (complete and partial responses),"To assess the overall survival(OS), progression-free survival(PFS), treatment-related toxicities, and pharmacokinetic profile of RAD001 used in combination with 5-FU and cisplatin",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14699,NCT01974869,changes in inflammatory cytokines,30 postoperative day complications.,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
14700,NCT00408551,Hepatic toxicity,Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients,,2005-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
14701,NCT04898842,"Symptoms of sub-acute bowel obstruction: abdominal pain, feeling bloated, feeling full-up quickly, nausea and / or vomiting",Weight,,2021-03-02,UNKNOWN,INTERVENTIONAL,['NA']
14702,NCT00027729,,,,2001-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14703,NCT01045538,"Phase 1 - maximum tolerated dose, Phase 2 - response rate",Overall survival,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14704,NCT00192075,Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST),Duration of Response,Duration of Response - A+FOLFOX4 - Avastin Subgroup,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14705,NCT04426955,PFS assessed by IRC,AE,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
14706,NCT01468623,Overall response rate (ORR),Progression-free survival (PFS),,2011-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14707,NCT00034281,Optimal Dosing for Phase II Studies.,Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response.,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14708,NCT03182894,Phase ll: Objective Response Rate (ORR),Overall survival (OS),,2018-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14709,NCT03307811,Diagnostic adequacy of the liver biopsy specimen,Complications/Infection,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
14710,NCT06319924,Assess the quality of the bowel preparation assessed by Boston Bowel Preparation Scale (BBPS),Caecal intubation rate,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
14711,NCT05773105,Desease control rate (DCR),Adverse Events (AEs),,2023-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14712,NCT00687349,"Patient and family ratings on the ""End-of-Life domain"" of the Quality of Communication Questionaire (QOC)","Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clinicians using Quality of End-of-Life Care questionaire",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14713,NCT05417932,Tumor response of SCG101 (Phase 2),Persistence of viral vector copy number (VCN) after SCG101 infusion,,2022-10-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14714,NCT02487017,Overall survival,Phenotypic analysis of T cells,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
14715,NCT05652920,Maximum tolerated dose of Ori-C101,Objective Response Rate,,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14716,NCT04338542,Change of RAS mutant clones in the metastatic lesion,Molecular patterns other than RAS,,2020-04-08,COMPLETED,OBSERVATIONAL,['NA']
14717,NCT01073358,rate of disease recurrence,,,2010-03-09,UNKNOWN,INTERVENTIONAL,['NA']
14718,NCT00559598,Gather information about clinical factors surrounding the date of blood extraction that may influence the proteomic patterns of the blood samples by reviewing clinical records of participants,,,2004-08,COMPLETED,OBSERVATIONAL,['NA']
14719,NCT02514031,Maximum Tolerated Dose,Tolerability,,2016-03-24,TERMINATED,INTERVENTIONAL,['PHASE1']
14720,NCT01219192,MDT,PFS,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
14721,NCT05660915,Rate of mortality after surgery,Incidence of postoperative complications,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
14722,NCT01549522,,,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
14723,NCT03519295,Progression free survival rate (PFS),Tolerance graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03,,2018-07-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14724,NCT06168825,Acceptability of the MOM intervention,Number of participants who reported MOM intervention as linguistically appropriate,,2024-01-17,RECRUITING,OBSERVATIONAL,['NA']
14725,NCT01296763,Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD),"Number of Years From Cycle 1, Day 1 On-Study to Date of Death",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14726,NCT03081637,Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
14727,NCT05214495,Oral Mucositis Severity,,,2022-02-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14728,NCT00075556,Objective tumor response rate,Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation,,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14729,NCT00031681,Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II),In vivo mechanistic basis for 7-hydroxystaurosporine activity,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14730,NCT04627012,Overall survival (OS),Adverse events,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
14731,NCT02186236,To validate the Trovagene urine assay,EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA),,2014-07,COMPLETED,OBSERVATIONAL,['NA']
14732,NCT05130060,Incidence of adverse events (AE),Progression free survival (PFS),,2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14733,NCT02727062,The number of subjects who comply with the compulsory four-time daily pain entries.,,,2018-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14734,NCT02477553,Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention,Number of Patients With High and Low Subjective Numeracy,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
14735,NCT03133273,Occurrence of the progression or death of the patient.,Grade 3 and higher adverse events related to chemotherapy,,2017-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14736,NCT06314516,Longitudinal variation in body composition,Patient and disease-specific factors,,2017-12-27,COMPLETED,OBSERVATIONAL,['NA']
14737,NCT01088789,Disease free overall survival.,,,2010-04-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14738,NCT02379520,Number of patients with dose limiting toxicity (DLT),Overall response rate,,2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14739,NCT04483349,"Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)","Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)",,2020-06-11,COMPLETED,OBSERVATIONAL,['NA']
14740,NCT02833753,Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin,,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14741,NCT05083338,Chronic postsurgical pain,,,2021-08-10,COMPLETED,OBSERVATIONAL,['NA']
14742,NCT05368636,Accuracy,,,2022-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14743,NCT03449966,The percentage of remnant cancer cells in biopsy samples,pCLE findings of residual cancer cells after chemotherapy,,2018-02-20,UNKNOWN,INTERVENTIONAL,['NA']
14744,NCT03365882,Progression-free Survival(PFS),Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.,,2017-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14745,NCT00769535,Clinical relevance,Clinical relevance,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
14746,NCT04067778,Adverse Events occurrence,Rate of Missed 2-Week Post-Procedural Assessment for Complications,,2020-11-06,COMPLETED,INTERVENTIONAL,['NA']
14747,NCT02322736,To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.,"To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®.","Frequency of primary tumor resection, of metastatic lesion resection, of BRAF testing in the entire number of the study participants and frequency of BRAF mutation in the unselected Greek patient population with WT RAS mCRC included in the study.",2014-11-21,COMPLETED,OBSERVATIONAL,['NA']
14748,NCT05013944,Measuring and/or Improving Quality of Care,,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
14749,NCT02451124,Average Methylation of Zinc Finger Protein 793 Assay,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
14750,NCT04359199,"Swallowing function 12-24 months after concurrent radiation and systemic therapy for HNC, as measured by the PCR",Correlation between radiation dose and location of swallowing function and quantitative swallowing function,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
14751,NCT04588246,Time to Neurologic Death,Incidence of Adverse Events associated with the interventions,,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE3']
14752,NCT05462613,overall survival (OS) (phase III),,,2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14753,NCT01770431,Incidence of Recurrence and Metastasis After Hepatectomy,Postoperative Survival Period,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14754,NCT03588442,Liver-related disease progression,Non-hepatocellular carcinoma malignant neoplasm,,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA']
14755,NCT03007446,reaction rate,adverse events,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
14756,NCT00885248,Staging of pancreatic cancer,Diagnosis of pancreatic cancer,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14757,NCT02365896,postoperative early anastomotic morbidity,Nutrition,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
14758,NCT00342641,,,,2005-06-08,COMPLETED,OBSERVATIONAL,['NA']
14759,NCT00099346,,,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE1']
14760,NCT06167967,Recurrence-free survival at 3 years,The proportion of patients in the low-risk cohort who did not receive adjuvant chemotherapy,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14761,NCT04211168,Rate of adverse events (AE),6-months and 1-year mortality rate,Biomarkers,2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2']
14762,NCT05894369,Tumor diameter,Overall survival,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA']
14763,NCT04803851,Disease control rate (DCR) based on RECIST v. 1 1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-05-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14764,NCT02850536,Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events,Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS),,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14765,NCT05433701,"Local progression-free survival rate, per-protocol (PP)","Local progression-free survival rate according to the tumor location, ITT",,2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14766,NCT05970133,The surgical efficiency of both NOSE procedures,CD4+ to CD8+ ratio,,2023-04-07,RECRUITING,INTERVENTIONAL,['NA']
14767,NCT04066816,Urolithin Phenotype and Colonic Health,Identify Changes in Microbiota and Microbes Responsible for Urolithin Formation Followed by Walnuts Consumption using Metagenomics Sequencing,,2019-05-20,COMPLETED,INTERVENTIONAL,['NA']
14768,NCT01392274,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
14769,NCT03245554,Tumor size will be measured.,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14770,NCT04629677,Bleeding risk (Cohort A and B),,,2019-04-02,RECRUITING,OBSERVATIONAL,['NA']
14771,NCT00002608,,,,1994-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14772,NCT05931068,Change in energy expenditure using indirect calorimetry,Hospital anxiety and depression scale,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
14773,NCT00537901,Effectiveness,Quality of life,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
14774,NCT02821754,6 Month Progression Free Survival (PFS),Number of Grades 1-5 Adverse Events Related to Tremelimumab and Durvalumab,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14775,NCT05526443,Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy,To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome,,2023-01-13,RECRUITING,OBSERVATIONAL,['NA']
14776,NCT02346032,Response rate,Overall survival,,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
14777,NCT06217224,Evaluate the best photobiomodulation protocol for preventing oral mucositis,Hospital internment,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
14778,NCT02894944,Number of participants with treatment-related adverse events assessed by CTCAE v4.03,Detection of adenoviral DNA in blood by PCR,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14779,NCT04680260,Recurrence Free Rate,Cost-effectiveness analysis,,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
14780,NCT01270984,To evaluate the pharmacokinetics of Luckyvec 400mg tablet and Glivec 100mg tablet in healthy subjects,"To evaluate the safety of Luckyvec 400mg tablet and Glivec 100mg tablet from vital signs, physical exam, ECG, laboratory test, adverse event and so on.",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14781,NCT04392167,Percentage of Correctly Identified Negative (Non-Dysplastic) Biopsies,Percentage of Participants With Adequate Tissue Contact to Acquire a High Quality Image,,2020-11-24,COMPLETED,INTERVENTIONAL,['NA']
14782,NCT03765411,In-hospital Complications,Costs and Charges,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
14783,NCT05657080,Sensitivity of Cytosponge for GIM,Number of participants with device-related adverse events as assessed by CTCAE v4.0,,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14784,NCT04764084,Dose limiting toxicity (DLT) and maximum tolerated dose (MTD),Progression-free survival (PFS),,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14785,NCT05130021,progress free survival(PFS)[Part 2],Safety and tolerability assessed by incidence and severity of adverse events,,2022-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
14786,NCT01273402,Determine the number of adverse events,Efficacy will be evaluating using CT scans and possibly PET imaging.,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14787,NCT00465725,Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14788,NCT03787251,PFS,ORR,,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14789,NCT04006951,Proportion of patients who gave their consent to participate in the study,,,2014-10-08,RECRUITING,INTERVENTIONAL,['NA']
14790,NCT05551832,Marginal ulcer incidence,QOL,,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE3']
14791,NCT04526470,Progression-free survival rate at 4 months,Time to response,Exploratory biomarker analysis for efficacy and resistance of alpelisib plus paclitaxel combination (using collected clinical samples) including mutations and RNA/protein expression levels of PI3K pathway genes,2020-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14792,NCT01198821,Establish the safety and tolerability of oral sodium bicarbonate in patients with advanced pancreatic carcinoma treated with gemcitabine,"Determine if oral bicarbonate improves overall survival, progression free-survival and response rate in patients with advanced pancreatic cancer",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14793,NCT04648917,overall survival (OS),progression-free survival (PFS),,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
14794,NCT01791309,objective response rate (ORR),efficacy,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14795,NCT03222089,Progression-free survival (PFS) rate at 10 months,Quality of life (QLQ C30),,2017-07-20,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14796,NCT04494022,Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.,Comparing image characters between two types of ultrasound contrast media,,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA']
14797,NCT06145230,Pathological characteristics,Risk factors,,2023-12-12,RECRUITING,OBSERVATIONAL,['NA']
14798,NCT01010126,Tumor Response Rate,Time to Treatment Failure,,2009-09-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14799,NCT02562924,Change in Lund-Kennedy Endoscopic Scores,Change in SNOT-22 Nasal Symptom Scores,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
14800,NCT04401813,Evaluation of the objective response rate of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma,Evaluate the ORR of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma (researched by the investigator according to RECIST V1.1).,,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14801,NCT03480256,Maximum Tolerated Dose (MTD),Area Under the Curve,,2018-07-27,UNKNOWN,INTERVENTIONAL,['PHASE1']
14802,NCT00569335,Safety,"Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14803,NCT00191984,Best Overall Tumor Response,Overall Survival,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14804,NCT03224221,One-year survival rate,Quality of life using EORTC QLQ C30 - scale,,2017-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
14805,NCT03200366,Participants Completing CRC Screening Per Electronic Medical Record Documentation,Change in Perceived Self-Efficacy for CRC Screening by FIT,,2017-07-26,COMPLETED,INTERVENTIONAL,['NA']
14806,NCT04985084,Acceptability outcome: participants' satisfaction and perspectives of the intervention,Dietary behavior self-efficacy,,2021-07-12,UNKNOWN,INTERVENTIONAL,['NA']
14807,NCT05496777,Therapist appreciation,Quality of life measurement,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
14808,NCT05653180,Objective response rate (ORR),"Overall Survival,OS",,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14809,NCT04652986,Disease-free survival at five years,Five years overall survival,Operative morbidity,2004-01,UNKNOWN,OBSERVATIONAL,['NA']
14810,NCT04526080,Overall Survival,Response Rates,,2021-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14811,NCT06106568,Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group,Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group,,2023-11-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14812,NCT05215964,Total psoas muscle change,Total kidney volume change,,2020-09-29,UNKNOWN,OBSERVATIONAL,['NA']
14813,NCT05740137,Adenoma detection rate (ADR),Polyps per positive patient (PPP),,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14814,NCT05040646,Consensus in / No important outcome,,,2021-11-01,COMPLETED,OBSERVATIONAL,['NA']
14815,NCT01694589,Changes in mean Gli-1 levels before and after drug,Complications from surgery by time of hospital discharge up to 30 days post-operatively,,2012-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
14816,NCT02228668,Overall Survival (OS) up to 8 and 10 years median follow-up of the stage III population randomized in the AVANT study.,Cancer Specific Survival (CSS) in patients with stage II and stage III colon cancer.,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
14817,NCT05116891,To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.,To assess PK of CAN04 after a single dose and at steady state,To assess ADA formation against CAN04.,2021-09-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14818,NCT01920113,A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,"A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil",2012-10,COMPLETED,INTERVENTIONAL,['NA']
14819,NCT02774161,Spectral slope,,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
14820,NCT01573468,Overall survival,Incidence of adverse events,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
14821,NCT00671645,"feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma","collection of response rate (T- and M-downstaging, pathological complete remission)",,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2']
14822,NCT04712032,90-days Anastomotic Leakage (AL) rate,days in hospital stay,,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
14823,NCT02406547,Number of polyps detected with both techniques (NBI versus WLE),Number of accurate detection of adenomas with morphologic features with both groups (NBI and WLE) compared to histopathology,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14824,NCT00998751,Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST),Progression Free Survival,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14825,NCT04859595,Maintenance of functional capacities,,,2021-07-29,COMPLETED,INTERVENTIONAL,['NA']
14826,NCT04572711,Number of adverse events,Healthcare Utilization,,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14827,NCT00739167,Quality of life differences between treatment groups,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
14828,NCT00339469,Biomarkers of insulin resistance and inflammation,Weight loss,,2005-08-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14829,NCT01215539,Objective Response,Economic evaluation,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14830,NCT00919659,nutritional status presented by phase angle,"quantity of port infections, quantity of oedema, quantity of diarrhea",,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14831,NCT04945733,Objective Response Rate (ORR),Number of Participants with Anti-Amivantamab Antibodies,,2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE2']
14832,NCT02463877,Rate of postoperative complications,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14833,NCT04993261,Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors,,,2015-09-23,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14834,NCT03996031,Patient activation,Patient satisfaction,,2019-08-19,COMPLETED,OBSERVATIONAL,['NA']
14835,NCT04773080,Incidence of postoperative acute kidney injury,Increase in length of hospital stay,,2021-01-21,COMPLETED,OBSERVATIONAL,['NA']
14836,NCT00618319,Changes in FDG-PET imaging,Characterize the safety profile of BIIB021,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14837,NCT04653480,Overall Response Rate,Progression Free Survival,,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14838,NCT06176885,PFS（Disease-free Survival）,DCR（Disease control rate）,,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
14839,NCT03452553,Efficacy: Time to progression (TTP),Physician rating of the handling and visibility of LC Bead LUMI™.,,2018-07-01,WITHDRAWN,INTERVENTIONAL,['NA']
14840,NCT00562068,"Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)",Epstein-Barr virus copy number (measured retrospectively),,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
14841,NCT05601323,Overall Survival,Adverse Events,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
14842,NCT00805896,Time to tumor progression(TTP),Overall survival (OS),,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
14843,NCT02865135,Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue,Time to Progression (TTP),,2017-03-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14844,NCT06115733,PFS,DCR,,2023-12-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14845,NCT00028002,Rate of Disease Progression at 2 Years,"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy",,2002-03-31,COMPLETED,INTERVENTIONAL,['PHASE2']
14846,NCT02289300,Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit,"Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results",,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14847,NCT01333332,To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.,,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
14848,NCT03788655,Technical feasibility of intrahepatic stenting,Survival rate,,2018-12-31,UNKNOWN,OBSERVATIONAL,['NA']
14849,NCT03615326,Overall Survival (OS),Treatment Discontinuations Due to AEs,,2018-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14850,NCT04143230,Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST),Clinical characteristics and outcomes of palliative care patients referred to an acute palliative care unit,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
14851,NCT03454035,Overall Survival,Cancer Antigen 19-9 (CA19-9) response,,2018-01-30,RECRUITING,INTERVENTIONAL,['PHASE1']
14852,NCT05322590,Objective Response Rate (ORR),Post Oxaliplatin Assessment,,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14853,NCT03434379,PFS-IRF Per RECIST v1.1 in the China Population,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population,,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
14854,NCT00487695,Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia),Mean Number of Biopsies Taken in Barrett's Surveillance Patients,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14855,NCT03803891,Technical Success,Histologically confirmed full-thickness resection,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
14856,NCT00902343,To determine if nomogram-based allocation of ANH is superior to allocation using extent of resection alone (planned resection of 3 or more liver segments) in patients undergoing partial hepatectomy.,To assess the impact of nomogram-based allocation of ANH compared to standard allocation on the need for fresh frozen plasma (FFP) transfusions.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14857,NCT03300843,Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) to Treatment,Number of Participants With Serious and Non-serious Adverse Events,,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE2']
14858,NCT03667612,correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes,The RER phenotype (the replication error phenotype),,2018-01-31,UNKNOWN,OBSERVATIONAL,['NA']
14859,NCT01099826,completing CRC screening test,,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
14860,NCT01784081,Feasibility of the patients with metastatic pancreas cancer to meet with the palliative care team and to complete symptom assessments.,"Changes in hospice referral, use, acceptance, and length of stay, compared to similar patients in the prior 12 months (from retrospective review)",,2014-04,WITHDRAWN,OBSERVATIONAL,['NA']
14861,NCT03767660,Total venous malformation lesion load,Concentration of D-dimer in blood,,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
14862,NCT01294072,Concentration of curcumin in normal and cancerous tissue,measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors,,2011-01,RECRUITING,INTERVENTIONAL,['NA']
14863,NCT01204476,"Safety profile of cixutumumab and everolimus with octreotide acetate among patients with advanced neuroendocrine tumors, defined by the incidence of adverse events",Anti-tumor activity as determined by RECIST,Changes in molecular markers,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14864,NCT04430452,Objective response rate (ORR),Overall survival (OS),,2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2']
14865,NCT00744640,Response rate,Progression-free survival and overall survival,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14866,NCT01642875,Frequency of delayed gastric emptying,Rehospitalization rate,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14867,NCT04635423,Percentage of participants with ≥1 serious adverse events (SAEs),Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58,,2020-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14868,NCT02138370,Time to disease recurrence,overall survival,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
14869,NCT02172690,Peritoneal Metastasis or Positive Cytology,Safety,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
14870,NCT04531930,3yCR,3yOSR,,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14871,NCT06130280,Local control rate CRC liver metastasis,,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
14872,NCT05543057,"1-, 2-, 3-year overall survival",Quality of life of patients with oesophageal cancer,Biomarkers to predict radiotherapy efficacy,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
14873,NCT01281618,activated myofibroblasts,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
14874,NCT05626985,GAMAD,circulating tumor DNA methylation,,2022-10-19,RECRUITING,OBSERVATIONAL,['NA']
14875,NCT05515705,Evaluation of the EUS navigation system's procedure duration compared to standard procedure times,Assessment of technological maturity and ergonomics,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
14876,NCT05239338,Disease-free survival,Physical activity (Accelerometer),,2021-12-06,RECRUITING,OBSERVATIONAL,['NA']
14877,NCT04727541,Major Pathologic Response (MPR) measured in the surgically resected tumor,Adverse Events of Special Interest,,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE2']
14878,NCT06139926,Changes in perioperative HADS scale scores.,,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
14879,NCT05161585,Secondary resection rate,ctDNA clearance rate,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
14880,NCT00535652,Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue,Safety Assessment,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14881,NCT01339000,Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy,Number of Participants With Adverse Events,,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14882,NCT05957289,Fear of Progression Questionaire-Short Form (FoP-Q-SF),Semi-structured interviews,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14883,NCT06283238,Number of participants with Progressive Disease,,,2024-04-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14884,NCT03712566,"Characterization of Genomic, epigenetic and Immune Profiling Features",Enable Data-Sharing,,2018-11-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14885,NCT01045941,To determine if it is safe to administer gemcitabine to patients with pancreatic cancer one week after laparoscopic distal pancreatectomy.,To determine the if the 1-year survival in patients with pancreatic cancer is improved with administration of gemcitabine one week following laparoscopic distal pancreatectomy,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14886,NCT04101292,Evaluation of the sensitivity of Bevacizumab-IRDye800 to visualize tumour tissue compared to anti-VEGF antibodies by the means of fluorescence intensity measurements,Level of accuracy of Full-field optical coherence tomography (FF-OCT) by the means of a qualitative analysis,,2021-04,WITHDRAWN,INTERVENTIONAL,['NA']
14887,NCT03578874,Resectability,Overall survival,,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE2']
14888,NCT00614393,Percentage of Participants Who Experience an AE of Infusion Site Reaction,Overall Response Rate (ORR) of Dalotuzumab in Combination With Cetuximab + Irinotecan Versus ORR of Cetuximab + Irinotecan Alone in Participants With Wild Type of Colorectal Cancer,,2007-12-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14889,NCT03234842,Compare the rate of a clinically significant reduction of DLCO (defined as a decrease of ≥ 10% from baseline) between protons and photons after preoperative or definitive chemoradiation,Compare overall survival rates,,2017-10-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14890,NCT05167409,"Objective response rate (ORR, per RECIST v1.1) (%)",Safety and tolerability according to the NCI CTCAE v5.0,,2022-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14891,NCT02008929,"Disease free survival, DFS","Overall survival, OS",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14892,NCT00994721,The primary end-point is recurrence-free survival.,"The secondary end-points are overall survival; local and distant control rate, and the quality of life.",,2009-02,COMPLETED,OBSERVATIONAL,['NA']
14893,NCT02843412,compare the positive rate,,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
14894,NCT00568971,"Response rate, overall survival",Side effects,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14895,NCT03799380,ED visits,Missed days of radiation +/- chemotherapy/immunotherapy treatment,,2019-11-05,COMPLETED,INTERVENTIONAL,['NA']
14896,NCT00805688,Patient Reported Symptom Severity and Interference,,,2008-11-12,COMPLETED,OBSERVATIONAL,['NA']
14897,NCT02836847,Progression Free Survival,percentage of patients with Clinical Benefit Response,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
14898,NCT04805788,3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC),Value of volumetric imaging analysis,Blood bank patient specimens for future analysis,2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14899,NCT02264496,Length of stay,Quality of Life Questionnaires,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
14900,NCT04767568,correlation between the biological signature of the test and the stage of the disease in patients whose diagnosis of adenocarcinoma was identified by pathology prior to surgery.,,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
14901,NCT00493441,Pharmacokinetics,,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2']
14902,NCT03702985,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,the morbidity of late radiation proctitis,,2018-05-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
14903,NCT05475041,Major complications,Intraoperative incidents,,2022-06-30,COMPLETED,OBSERVATIONAL,['NA']
14904,NCT05723705,Textbook Outcome in Liver Surgery (TOLS),Intra-operative ICG-margin assessment,,2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14905,NCT01086332,Dose limiting toxicities,Surgical resection rate,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE1']
14906,NCT00019825,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14907,NCT00141466,Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.,Cost efficacy of the implementation procedures.,,2005-09,UNKNOWN,INTERVENTIONAL,['NA']
14908,NCT02963831,Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method,,2017-09-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14909,NCT03949933,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,progression-free survivals,,2015-05-01,COMPLETED,INTERVENTIONAL,['NA']
14910,NCT03001596,Overall survival(OS),Recurrence-free survival (RFS),,2017-01,COMPLETED,INTERVENTIONAL,['NA']
14911,NCT06071845,Accuracy of the Oncoguard Esophagus (OGE) test,Trauma to the esophagus from the passage of the Cytosponge device,,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
14912,NCT00012220,Overall Survival,Toxicity,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14913,NCT01707511,,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
14914,NCT01853241,Comparison of the depth of insertion into the small bowel of SBE compared with SE from the pylorus.,A comparison of the mean adjusted diagnostic procedure time,,2010-05,TERMINATED,OBSERVATIONAL,['NA']
14915,NCT01634685,dose-limiting toxicities (DLT),maximally tolerated dose (MTD),,2012-08-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14916,NCT04316507,Days from decision to test to receiving genetic test results,,,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA']
14917,NCT03200171,Behavior of hepatocellular carcinoma,Progression-free survival (PFS),,2018-02-10,COMPLETED,OBSERVATIONAL,['NA']
14918,NCT04641455,"Visibility score"" evaluated by blinded performing endoscopist","Visibility score"" evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy",Duration of endoscopy,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
14919,NCT04814485,ORR (Objective Response Rate),Adverse events (per CTCAE v5.0 criteria),,2021-04-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
14920,NCT01927393,Symptom burden using the FACT-Trial Outcome Index (TOI),"Health care resource use including presence of advanced care planning, chemotherapy in the last 14 days of life, and length of time between hospice referral and death",,2014-12,WITHDRAWN,INTERVENTIONAL,['NA']
14921,NCT02820194,Control of local disease,Incidence of acute and late complications,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
14922,NCT00079027,Overall survival,Proteomic and immunological analysis,,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
14923,NCT01172548,Recurrence Free Survival Rate,Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14924,NCT01486992,adverse events,disease control rate,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
14925,NCT01313442,Collected samples,,,2011-03-02,RECRUITING,OBSERVATIONAL,['NA']
14926,NCT00643877,5 years disease-free survival,5 years overall survival and liver metastasis-free survival,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
14927,NCT05627635,Overall response (phase II),Surgical resection (phase II),,2023-05-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14928,NCT04106453,time to complete ablation,ablation completeness,,2019-09-14,COMPLETED,INTERVENTIONAL,['NA']
14929,NCT02903771,Pharmacokinetic (PK) profile of Cantrixil after intra-peritoneal (IP) administration,CA-125 level,Expression of Stem Cell Markers,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14930,NCT01485679,"Specificity of TEP-CT to point out malignant lesions in pancreas, the gold standard being the anatomopathological analysis of the piece of pancreas removed during the surgery.",Number of patients for which metastasis will be detected through TEP-CT and confirmed by biopsy and/or conventional specific device,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14931,NCT05911425,ORR,OS,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14932,NCT06106308,Objective Response Rate (ORR),Safety: Exposure Response Evaluation of Onvansertib,,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2']
14933,NCT04297202,Major pathologic response,Safety as measured by the rate of AEs,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14934,NCT05743959,Relapse-free survival,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
14935,NCT02709070,recurrence free survival,overall survival,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
14936,NCT02288377,Proportion of Patients Alive and Progression-free at 6 Months,Overall Survival,,2015-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14937,NCT01186237,urinary retention,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14938,NCT00640978,Number of Participants Surviving at 6 Months,,,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2']
14939,NCT01647828,Phase 2: Median OS by Notch 3 Percentile (ITT Population),,,2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14940,NCT04953962,Three-month progression free survival rate (3M PFSR),Overall survival (OS),,2021-12-18,COMPLETED,INTERVENTIONAL,['PHASE2']
14941,NCT02031939,overall survival,Respond rate,,2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14942,NCT03520946,Overall survival,Quality of life II (QoL),Explorative: Progression-free survival (PFS),2019-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14943,NCT02101593,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with sorafenib in advanced HCC,,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14944,NCT01766219,Overall Survival,Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria,,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14945,NCT00541593,Mortality,,,2007-09,TERMINATED,INTERVENTIONAL,['NA']
14946,NCT03410732,progression-free survival,Adverse event rate,,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14947,NCT03730545,Change from baseline serum concentration of immune markers to postoperative day 5,"Change among baseline, postoperative day 3 and 5 serum nutritional markers",,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
14948,NCT04242901,Number of participants who yield sequential FIT results in divergent strata used for clinical decision making,"Calculation of Odds Ratios for age, gender, family history of CRC, hypertension, obesity, smoking status, excessive alcohol intake, right sided tumour, stage 1 cancer",,2020-10-20,COMPLETED,OBSERVATIONAL,['NA']
14949,NCT03922230,Hydroxymethylation level,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
14950,NCT01326364,"Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)",,,2010-03,TERMINATED,OBSERVATIONAL,['NA']
14951,NCT03247296,HCC,,,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA']
14952,NCT01613430,"Completing at least one recommended cancer screenings (colorectal, breast, cervical)","Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening",,2012-06,COMPLETED,INTERVENTIONAL,['NA']
14953,NCT02939807,To assess objective response rate (per modified RECIST) of single agent ABC294640 in treatment of HCC,To assess the relationship between changes in immune cell subsets in peripheral blood from subjects being given ABC294640,,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14954,NCT04866862,Objective response rate(ORR),Tumor Mutation Burden (TMB),immunocytes and cell factor,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2']
14955,NCT00938210,Fatigue,Social support,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
14956,NCT02746796,Overall survival (only Part 2),Safety will be analyzed through the incidence of laboratory abnormalities,,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14957,NCT02878109,Hepatic and tumor blood flow before HCC treatment,,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
14958,NCT01950403,Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA),PD effect on cGMP levels (Stage II),"PD effect of linaclotide acetate on GCC signaling (i.e., VASP phosphorylation) and general proliferation (Ki67 expression)",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14959,NCT03923036,Difference in rates of cardiovascular adverse events leading to hospitalization between chemotherapy treated patients and chemotherapy-free patients.,Dose-effect relation ship between individual anticancer drugs combination/protocol and cardiovascular adverse events,,2019-04,UNKNOWN,OBSERVATIONAL,['NA']
14960,NCT03941457,Occurrence of treatment related adverse events as assessed by CTCAE v4.03,,,2019-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14961,NCT00016172,,,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14962,NCT01290926,Overall survival at 6 months fixed endpoint,"To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14963,NCT04471480,overall survival (OS),progression-free survival(PFS),,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
14964,NCT00881751,Overall Survival,Response Rate,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14965,NCT00096330,•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14966,NCT02204124,Post-op Morbidity,Number of Participants Who Experienced Postoperative Complications,,2015-01-01,TERMINATED,INTERVENTIONAL,['NA']
14967,NCT05717400,Overall Response Rate,,,2023-02-07,RECRUITING,INTERVENTIONAL,['PHASE4']
14968,NCT01490996,Completion of dose escalation over 2 cycles of therapy,Efficacy in terms of disease response and survival,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14969,NCT04581005,Oxygen consumption (VO2),,,2019-08-19,UNKNOWN,INTERVENTIONAL,['NA']
14970,NCT01279837,Clinical swallowing Ability,Swallowing Quality of Life,,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14971,NCT05475054,Major complications,Red blood cell transfusion,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
14972,NCT03049345,Specificity of Sentinel Lymph Node Sampling Method,Adverse surgical events,,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14973,NCT01833299,Effectiveness of sorafenib combined with TACE,Time to progression,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14974,NCT00005607,,,,2000-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
14975,NCT03575117,Change in physical active level,Change in colorectal cancer risk and physical activity coherence,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
14976,NCT02297217,Proportion of patients who achieve relief of dysphagia,Dysphagia progression free survival,,2019-11-21,RECRUITING,INTERVENTIONAL,['PHASE2']
14977,NCT05390684,anastomotic leak,infection,,2022-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14978,NCT06037902,absolute mean heart radiation dose,movement of tumor in cm,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
14979,NCT00043433,,,,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
14980,NCT03329664,Time to progression (TTP),Patient quality of life,,2020-02-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14981,NCT01877018,Patient's status participation to colorectal cancer screening program,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
14982,NCT05293054,The rate of successful use and application of Obsidian as a supplemental procedure in the creation of rectal anastomosis with minimal invasive technique,2-year mortality,,2021-12-15,COMPLETED,OBSERVATIONAL,['NA']
14983,NCT05959213,Quantitative data - Preoperatory levels of CA 19.9 (U/ml),,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
14984,NCT04370418,Incidence of treatment adverse events as assessed by National Cancer Institute Common Terminology Criteria for adverse events version 4.0,assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery.,,2020-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14985,NCT04791982,The effects of education provided to family members caring for colorectal cancer patients receiving chemotherapy on Caregiver Reaction Assessment Scala.,,,2018-08-18,COMPLETED,INTERVENTIONAL,['NA']
14986,NCT01553019,Radiation Toxicity,Response rate via CA 19-9,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14987,NCT05609448,Feasibility of performing intraprocedural treatment planning,Dosimetry optimization,,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14988,NCT00006332,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
14989,NCT00888888,Short-term survival,Long-term survival,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
14990,NCT03445260,The number of patients randomized to the study,Length of Hospital Stay,,2018-10-17,COMPLETED,INTERVENTIONAL,['NA']
14991,NCT05152498,Time to Progression,complete response,,2021-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14992,NCT06118047,Remission rate of EGFR inhibitor-related acneiform eruption,Quality of life（EORTC QLQ-C30),,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
14993,NCT00888407,Obtain HBV Screening Test,"Knowledge and Attitudes Regarding Hepatitis B, Health and Nutrition",,2006-09,COMPLETED,INTERVENTIONAL,['NA']
14994,NCT03269955,Incidence of clinically relevant pancreatic fistula,Period of hospitalization after surgery,,2017-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
14995,NCT02371655,"overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).",compliance of patients,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
14996,NCT02020707,Maximum tolerated dose,Incidence of adverse events (soft tissue expansion cohort),,2014-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14997,NCT06023004,ctDNA analysis,Cost-effectiveness of treatment,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
14998,NCT05517408,Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.,Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.,,2022-09-19,RECRUITING,INTERVENTIONAL,['NA']
14999,NCT00040391,,,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE2']
15000,NCT03005314,progression- free survival,overall survival,,2016-08,UNKNOWN,INTERVENTIONAL,['NA']
15001,NCT05109052,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,,2022-09-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15002,NCT04889859,diabetes remission rate (%),changes in gut microbiota,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
15003,NCT02923934,To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.,To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.,,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15004,NCT04241731,The time from the beginning of maintenance treatment until the disease progresses.,Quality of life score,,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
15005,NCT01366118,ypTN,Feasibility,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
15006,NCT06312982,CR,immune-related adverse event rate,,2024-02-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15007,NCT00860249,Completion of CRC Screening,The Secondary Outcome for the Study is the Time to Screening Completion.,,2009-03,TERMINATED,INTERVENTIONAL,['NA']
15008,NCT01486472,The incidence of LDO,Correlation between the concentration of S-1-related chemical compounds and the developement of LDO,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
15009,NCT02464930,Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia,"Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer",,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
15010,NCT05671315,Change of HBsAg level compared to baseline,Incidence of liver cirrhosis and hepatocellular carcinoma,,2019-07-03,RECRUITING,INTERVENTIONAL,['NA']
15011,NCT00023751,disease-free survival,colostomy-free survival,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15012,NCT01337492,Adverse events associated with technical aspects of the operation,Waiting Time,,2010-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
15013,NCT05344339,Reflux esophagistis,6th month reflux esophagistis,,2022-10-08,RECRUITING,INTERVENTIONAL,['NA']
15014,NCT05039762,Overall complication rate,Hernia rate,,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15015,NCT06327568,Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.,,,2022-06-17,RECRUITING,OBSERVATIONAL,['NA']
15016,NCT00642239,tumour local control rate,survival rate,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15017,NCT00499265,"Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events",,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15018,NCT01299688,To survey the frequency of HER2(+) CTC in gastric cancer,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
15019,NCT05410847,Conversion to negative rate,Adverse events,,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15020,NCT02082210,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies,,2014-03-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15021,NCT06141564,HCC recurrence diagnosed by dynamic contrast enhanced CT,,,2023-10-16,RECRUITING,OBSERVATIONAL,['NA']
15022,NCT02690350,Number of Patients with Dose-Limiting Toxicities (DLTs),Area Under the Curve to the Last Quantifiable Measure (AUClast)[,,2016-02-29,TERMINATED,INTERVENTIONAL,['PHASE1']
15023,NCT00003441,Antitumor Activity of MGI-114,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15024,NCT05588297,Tumor regression grade (TRG）,Quality of life score (QoL score）,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15025,NCT03366883,Overall Survival,Rate of R0 resection,,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
15026,NCT04351867,disease free survival,Assessment of life quality,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
15027,NCT01614522,The percentage of patients demonstrating clear evidence of inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients on Day 29.,Objective Response Rate,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15028,NCT01815879,Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.,"Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans.",,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
15029,NCT04398446,Change in sleep quality,Rate of side effects using medical-grade CBD concentrates,,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15030,NCT02016287,progression free survival,overall survival,quality of life,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
15031,NCT00046995,Disease-free survival,Quality of life,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
15032,NCT05553080,Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
15033,NCT06149923,assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15034,NCT05457075,Soluble immune checkpoints,,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
15035,NCT04020614,The awareness of patients about colorectal cancer,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
15036,NCT03859869,Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer,Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer,,2020-02-25,TERMINATED,INTERVENTIONAL,['PHASE4']
15037,NCT04536220,Status of survival,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
15038,NCT02509806,Progression free survival,,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15039,NCT04874207,Time from inclusion to death,Body composition,,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE4']
15040,NCT04012645,Anastomotic leakage,the change of surgical precedure,,2023-11-16,RECRUITING,INTERVENTIONAL,['NA']
15041,NCT02305914,Change in the Levels of fecal elastase-1,outpatient clinic and phone questionnaire,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
15042,NCT04589468,Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.,,,2020-10-02,RECRUITING,INTERVENTIONAL,['NA']
15043,NCT04947956,The incidence of treatment-emergent adverse events (TEAE),Time to progression,,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15044,NCT01374100,Change in Quality of Life (QoL),Program Satisfaction,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
15045,NCT03138239,Measure the absorption of PET-CT F-18-FDG and of PET -CT Ga-68-PSMA,,,2017-07-02,UNKNOWN,INTERVENTIONAL,['NA']
15046,NCT02435602,Positive predictive value,Evaluation of endoscopy ( NBI versus Lugol staining) tolerance using Visual Analogue Scale (VAS),,2013-12,COMPLETED,INTERVENTIONAL,['NA']
15047,NCT00621725,"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).",Safety/tolerability of Cediranib (single and multiple dose PK),,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15048,NCT01926197,Progression-free Survival (PFS),Grade 2 or Greater Gastrointestinal (GI) Toxicity,,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15049,NCT05462314,Levels of gene expression of the identified species in Gastrointestinal Malignancy,Relationship between treatment efficacy and microbiome diversity,,2022-03-29,RECRUITING,OBSERVATIONAL,['NA']
15050,NCT03289988,Diagnostic Power for prediction of advanced colorectal neoplasms,,,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA']
15051,NCT01498952,Phase 2: Time to Progression,Phase 1b and Phase 2: Area Under Serum Concentration-time Curve From Time Zero to Day 22 (AUC0-Day22) of MEDI-573 for Cycle 1,,2012-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15052,NCT00510107,response rate,safety,,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
15053,NCT00833859,Number of Participants With Resectability,Number of Participants With Overall Survival,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2']
15054,NCT01986738,Distance traveled by the pancreatic tumor between radiation treatments using Computed Tomography (CT) Scans and an Active Breathing Control (ABC) Device,Assess the impact of the determined treatment margins on the radiation dose to normal tissues and the ability to escalate dose to the tumor using Intensity-Modulated Radiation Therapy (IMRT),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
15055,NCT03129074,Biomarker,Incidence of Adverse Events and changes from baseline in safety parameters,,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15056,NCT03859557,Yield of WATS biopsies compared to Forceps biopsies,,,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
15057,NCT03576963,Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab,Incidence and severity of adverse events,,2020-01-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15058,NCT05003895,"To determine the safety and feasibility of T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor, in patients with advanced HCC, expressing GPC3","To determine the best overall response (BOR) rate according to Response Evaluation Criteria (by RECIST v 1.1) of treatment with T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor in participants with advanced HCC, expressi...",,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE1']
15059,NCT02273713,Progression Free survival,Overall survival,,2014-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15060,NCT04974281,Resection rate,Progression free survival (PFS),,2021-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15061,NCT04027790,Test Positivity,,,2019-05-03,COMPLETED,OBSERVATIONAL,['NA']
15062,NCT02683200,"Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI",Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained,,2015-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15063,NCT00004003,,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15064,NCT03808766,arterial flow through the tumor,The degree of tumor necrosis,,2018-08-13,TERMINATED,INTERVENTIONAL,['NA']
15065,NCT01016002,Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT,Toxicity using WHO criteria and criteria for local toxicity in the biliary system,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
15066,NCT05256459,Time the patients were diagnosed.,,,2022-05-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15067,NCT05794737,Detection of INHBA in Colorectal Carcinoma.,Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
15068,NCT02311712,Death from all causes,Change in Quality of life,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
15069,NCT01732380,Progression-Free-Survival,Response Rate,Overall survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
15070,NCT05487248,Optimal timepoint and cut-off value for early on-treatment ctDNA changes,CGP changes during treatment,prognostic value of ctDNA.,2023-10-12,RECRUITING,INTERVENTIONAL,['NA']
15071,NCT05729737,Evaluate if the time to peak (TP) is predictive of response to chemotherapy therapy measured by comparison of TP at CEUS imaging prior to the start of first-line chemotherapy and TP at imaging performed after 2 cycles chemotherapy,Assessment of overall survival,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
15072,NCT04687280,arterial enhancement,,,2009-04-22,COMPLETED,OBSERVATIONAL,['NA']
15073,NCT05680077,validity,reliability,,2022-10-28,COMPLETED,OBSERVATIONAL,['NA']
15074,NCT03326791,Disease Free Survival (DFS) after three years treatment,ASA in CRC and Cost-Effectiveness Analyses III,,2017-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15075,NCT02482701,"Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.",Histopathology,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
15076,NCT03566355,3-year local control ratio of the treated lung area,3-year disease-free survival rate of treated patients,,2018-05-23,RECRUITING,INTERVENTIONAL,['NA']
15077,NCT02928510,The Mechanism of Action (MOA) of idelalisib will be assessed with a number of tests in order to provide variability in comparisons for the units of measure.,,,2016-02-01,TERMINATED,OBSERVATIONAL,['NA']
15078,NCT05061199,length of the resection margin,,,2022-08-01,COMPLETED,OBSERVATIONAL,['NA']
15079,NCT02461836,disease-free survival (DFS),safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
15080,NCT03989115,Number of Participants With Dose Limiting Toxicities (DLTs),Overall Response Rate (ORR),,2019-07-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15081,NCT00183794,"Tumor Response Type: CR, PR, SD or PD",Median Time to Progression (Months),,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15082,NCT00178867,,,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
15083,NCT00582257,"Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer",To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.,,2005-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15084,NCT00352703,The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15085,NCT02467582,Disease-free survival (DFS),Adverse events (AEs),,2016-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15086,NCT02650375,incidence of adverse events,CL for Metatinib,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
15087,NCT06169163,To develop a breath test for detection of OSCC,To evaluate the effects of known confounding variables on the target VOCs in OSCC,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15088,NCT03213444,cardiac function evaluation,Proinflammatory cytokines,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
15089,NCT05717998,Changes in myocardial metabolism,Blood-based biomarkers,,2021-04-02,RECRUITING,OBSERVATIONAL,['NA']
15090,NCT05823272,incidence of sarcopenia 6-month after discharge,Changes in BMI (weight and height will be combined to report BMI in kg/m^2),,2024-03-22,RECRUITING,INTERVENTIONAL,['NA']
15091,NCT02654639,Length of Progression-Free Survival,,,2016-02,TERMINATED,INTERVENTIONAL,['PHASE2']
15092,NCT00325871,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
15093,NCT02501980,5-year HCC specific mortality rate,Identification of early diagnosis markers of HCC,,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15094,NCT02335619,Total symptom distress score,"Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)",,2015-02,COMPLETED,INTERVENTIONAL,['NA']
15095,NCT05384496,best objective response,,,2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE2']
15096,NCT00543842,Maximal tolerated dose (MTD),,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15097,NCT03879109,Proportion of curative surgery,Tolerance to treatment,,2019-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15098,NCT00506168,Maximal response rate and toxicities,Progression-free survival and overall survival,,2001-11,TERMINATED,INTERVENTIONAL,['PHASE2']
15099,NCT01844817,Overall Survival,Objective Response Rate,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
15100,NCT04185350,Standardized uptake value,Incidence of Adverse Events,,2019-05-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
15101,NCT01836237,Surgical Site Infection (SSI) Rate,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15102,NCT00992199,Metastasis in Peritoneum and peritoneal cavity,Overall survival,,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
15103,NCT02372500,Bowel function (as assessed by questionnaire),Morbidity,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
15104,NCT02343601,Incidence of patients presenting at least one complication after colorectal surgery,Perioperative mortality,Medico economic evaluation of cost of treatment,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15105,NCT05960955,Pathological complete response (pCR) rates,ADA,,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2']
15106,NCT00387842,Primary endpoint is cancer free survival at three years.,"Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen.",,1997-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
15107,NCT01900327,3-Year Survival Rate,First site of tumor recurrence,,2014-02,TERMINATED,INTERVENTIONAL,['PHASE3']
15108,NCT00149201,overall survival,toxicity,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15109,NCT05035147,Progression-free Survival (PFS),Overall survival(OS),,2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE4']
15110,NCT02962219,Change in Quality of Life,,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
15111,NCT03427242,PFS,OS,,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
15112,NCT05346874,Pathological complete response (pCR) rate,Progressive free survival,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15113,NCT01775501,Time to Progression,Duration of Response,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15114,NCT02650804,Overall Response Rate (ORR),Progression Free Survival (PFS),,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15115,NCT06242197,The effectiveness of written advice VS. standard verbal advice in transferring knowledge to first degree relatives of colorectal cancer patients,Determining the knowledge level about colorectal cancer in first degree relatives of CRC patients,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15116,NCT02026362,Time of tumor recurrence or metastasis,overall survival,,2013-07,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15117,NCT05067413,Rate of anastomotic leakage,3-year disease-free survival,,2020-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15118,NCT06285591,The duration of Severe Oral mucositis (WHO grade ≥3),Mouth and throat soreness (MTS) scores,,2023-11-10,RECRUITING,INTERVENTIONAL,['NA']
15119,NCT04564482,Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT,Pathological therapy response,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
15120,NCT05062837,Overall survival,Objective response rate of extrahepatic target lesions,,2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15121,NCT05062317,To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy,,,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE2']
15122,NCT00532987,,,,2003-12,TERMINATED,OBSERVATIONAL,['NA']
15123,NCT00251485,"To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.",To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15124,NCT03880617,"Change in Background, Disease and Treatment Information Form (BDTIF)",,,2015-03-25,COMPLETED,OBSERVATIONAL,['NA']
15125,NCT02056015,Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance,"Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients",,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15126,NCT04745754,Preventive care services,Cancer recurrence,Self-reported patient demographics,2021-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15127,NCT01391572,Survival,Failure pattern,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
15128,NCT04943484,Surgical conduct,Clinical variables associated with change of the surgical conduct,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
15129,NCT04407611,Participant uncertainty from cancer risk assessment at 12 months,,,2023-03-06,RECRUITING,INTERVENTIONAL,['NA']
15130,NCT00579748,The OCT images will be correlated to the specific biopsy site and biopsy number.,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
15131,NCT02130648,Analysis circulating free fetal DNA,,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
15132,NCT00668863,Progression-Free Survival (PFS),"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15133,NCT02512328,Feasibility,patient´s satification,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
15134,NCT04803890,Local tumor progression (LTP) rate,Complication rate,,2019-04-01,TERMINATED,INTERVENTIONAL,['NA']
15135,NCT04758195,Number of participants with major low anterior resection syndrome score (LARS score),Fecal continence impairment,Anorectal function impairment,2021-03-01,RECRUITING,INTERVENTIONAL,['NA']
15136,NCT00866944,Disease free survival rate (DFS),Quality of Life,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15137,NCT00441376,To determine the Pharmacokinetics (PK) of ThermoDox,To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15138,NCT02041936,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Quality of Life on the EORTC QLQ-PAN26 and EORTC QLQ-C30,,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15139,NCT01679327,Overall response rate,Number of Participants with Adverse Events,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
15140,NCT01517152,Perceptions of the clarity and ease of response to a series of questions,,,2012-01-04,COMPLETED,OBSERVATIONAL,['NA']
15141,NCT03532347,The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.,Duration of sampling procedures,,2017-05-22,COMPLETED,INTERVENTIONAL,['NA']
15142,NCT05706779,To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010),,,2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2']
15143,NCT05662527,Pathological complete response (pCR),Gene expression by mRNA,Endoscopic tumour assessment,2023-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15144,NCT03552458,Quality of Life post Radiation,Oral Bacteria Analysis and Gene Expression Analysis,,2018-06-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
15145,NCT04763174,Change in psychological distress,Change in Self-Efficacy for Symptom Management,Change in Parenting Concerns,2021-09-15,RECRUITING,INTERVENTIONAL,['NA']
15146,NCT03604926,immunological features of metastasis,,,2017-10-05,COMPLETED,OBSERVATIONAL,['NA']
15147,NCT01093222,Progression-free Survival,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15148,NCT01542281,Change in six minute walk test,Nutritional status,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
15149,NCT03923400,Location,,,2016-11-01,COMPLETED,OBSERVATIONAL,['NA']
15150,NCT05406089,Recurrence of the hepatocellular carcinoma after hepatectomy,Surgery information,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
15151,NCT02715362,Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events,Serum cytokine levels,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15152,NCT00268346,"The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15153,NCT02171429,"Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population","Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28949 Population",,2014-11-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15154,NCT04933227,Objective Response Rate (ORR) in the Full Analysis Set (FAS) Population,Number of Participants With Adverse Events,,2021-08-06,TERMINATED,INTERVENTIONAL,['PHASE2']
15155,NCT00872755,Laparoscopic Nissen fundoplication combined with posterior gastropexy may prevent postoperative paraesophageal or sliding herniation in surgical treatment of GERD,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15156,NCT02788565,Proportion of subjects with injection problems according to the subject,"Proportion of nurses who reported ""moderately"" or ""very"" or ""very much"" confidence in giving injections",,2016-03,COMPLETED,OBSERVATIONAL,['NA']
15157,NCT02611453,Technical success of CO2 cholangiography vs. iodinated contrast,Radiation usage/exposure of CO2 cholangiography using conventional fluoroscopy or digital subtraction fluoroscopy vs. iodinated contrast,,2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15158,NCT02642809,Tolerability of localized esophageal hypofractionated brachytherapy administered in two fractions when combined with pembrolizumab as measured by treatment related adverse events,Overall survival (OS),,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15159,NCT00425906,"Determination of whether ≥ 50% of patients utilize nicotine for treating ""hunger pain"" ≥ 2 times over a 48-hour period",Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only),,2003-12,WITHDRAWN,INTERVENTIONAL,['NA']
15160,NCT03428425,Conversion to negative rate,Adverse events,,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
15161,NCT06158139,Neurotoxicity,Objective response rate- no bridging therapy,,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
15162,NCT04616040,Adverse events of Camrelizumab,Objective Response Rate (ORR),Correlations between biomarkers and clinical activity,2020-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15163,NCT02324868,Self-reported autonomy score regarding bathing activities,Laboratory-Confirmed Bloodstream Infection,Catheter/Huber needle status,2016-01,TERMINATED,INTERVENTIONAL,['NA']
15164,NCT00515190,Overall survial in the two treatment arms,"Response rate, toxicity, duration of response, time to progression, Quality of life in the two treatment arms,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics, treatment efficacy and toxicity",,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
15165,NCT05740267,C-reactive protein (CRP) level,Postoperative Recovery course:,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15166,NCT04053998,Morbidity assessed according to the Comprehensive Complications Index® (CCI®),Disease free survival rate,,2019-08-09,COMPLETED,OBSERVATIONAL,['NA']
15167,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,Health status and quality of life,2020-07-17,RECRUITING,INTERVENTIONAL,['NA']
15168,NCT03397199,Progression-free Survival (PFS),Overall survival(OS),,2018-01-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
15169,NCT00763516,"Cumulative incidence of grade 3+ bowel perforation, grade 3+ bleeding and grade 4+ nonhematologic acute adverse events (occuring within 90 days of treatment start)",Collect and analyze tumor control outcomes,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
15170,NCT02162563,Progression-free survival (PFS),Correlation of evaluation by the panel with outcome,,2014-07,RECRUITING,INTERVENTIONAL,['PHASE3']
15171,NCT01024387,Objective Response Rate,1-Year Overall Survival,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15172,NCT00900094,Potential markers for early detection of cancer,,,2000-06,COMPLETED,OBSERVATIONAL,['NA']
15173,NCT04994548,technical success of early esophageal cancer resection,preemptive methods to the risk of bleeding,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
15174,NCT02594943,Highest proportion (number) of representative biopsies from tumors of diffuse gastric cancer,Amount of (mm2 and %) submucosal tissue within the biopsies.,,2018-08,WITHDRAWN,INTERVENTIONAL,['NA']
15175,NCT03762564,Overall survival (OS) at 6 months,Incidence and severity of adverse events,,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15176,NCT02241720,Number of Participants With Stable Disease at Eight Weeks Post-Treatment,,,2014-05,TERMINATED,INTERVENTIONAL,['PHASE2']
15177,NCT05985707,Overall response rate,Frequency of adverse events,,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15178,NCT04989764,The disease-free survival,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15179,NCT03515824,Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE),Minimum Serum Concentration (Cmin) of MK-1697,,2018-08-13,TERMINATED,INTERVENTIONAL,['PHASE1']
15180,NCT01040000,Efficacy OS,Pharmacokinetics and select immune responses to the antibody will be assessed.,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15181,NCT01968629,Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases,,,2013-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
15182,NCT01331928,objective tumor response rate,"the progression-free survival, overall survival, toxicity profiles",,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
15183,NCT02848066,AUC(Area Under the Curve),Relative abundance of glycosylations,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
15184,NCT03170180,response rate,,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15185,NCT04270890,To measure change in treatment volume between freebreathing and abdominal compression scans,Reported patient feedback regarding device comfort and compliance of use.,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA']
15186,NCT00735345,Percentage of complete remissions and resection rate,Evaluation of Quality of Life,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
15187,NCT05071755,Overall survival,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
15188,NCT02202564,Recurrence-free survival rate,,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15189,NCT05625841,oral mucositis severity,microbiota level,,2022-11-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15190,NCT02823678,Percent resected volume of pancreas and diabetes development,Blood glucose control,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
15191,NCT00201838,Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation,Serial Levels of TNF (Tumor Necrosis Factor) and Other Inflammatory Cytokines,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15192,NCT05125393,Operation time,Incidence of at least one serious complication within 30 days after resection,,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15193,NCT03828396,Assay sensitivity and specificity for colorectal cancer and advanced adenoma,,,2018-10-26,UNKNOWN,OBSERVATIONAL,['NA']
15194,NCT00085371,Survival in patients receiving triapine as second-line therapy,"Confirmed tumor response, defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15195,NCT01406574,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),Best Overall Response,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15196,NCT05140746,Target-to-background ratio(TBR),Overall survival,,2020-09-10,RECRUITING,INTERVENTIONAL,['NA']
15197,NCT03780634,Progression Free Survival (PFS),Adverse Events,,2019-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15198,NCT06169410,pCR,total response time,,2023-12-30,RECRUITING,INTERVENTIONAL,['PHASE4']
15199,NCT02666976,Changes of symptoms,changes of inflammatory biomarkers,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15200,NCT06204094,Complete response,Validation of the Wexner score,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15201,NCT04619082,The rate of HBV reactivation during TAF prophylaxis,The dynamic change of eGFR during TAF prophylaxis,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15202,NCT04252560,Microbiome,,,2020-01-31,RECRUITING,OBSERVATIONAL,['NA']
15203,NCT05155189,AESIs,progression-free survival by mRECIST 1.1,,2021-12-09,RECRUITING,INTERVENTIONAL,['PHASE1']
15204,NCT04180371,Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment,Part B: The association between EphA2 expression level and overall survival (OS) at 1 year by RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment,,2019-11-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15205,NCT00693173,The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.,Dosimetry comparison details.,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
15206,NCT01287286,Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy.,Life quality estimates of 10% improvement than control group.,,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15207,NCT04586491,development of oral mucositis,recovery time of oral mucositis,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
15208,NCT03746392,Documentation of goals of care,,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
15209,NCT01547923,Number and nature of grade IV toxicity.,Medical-financial study of pre-therapeutic screening.,,2008-06-16,TERMINATED,INTERVENTIONAL,['NA']
15210,NCT05924789,Describe the treatment patterns,,,2023-08-11,RECRUITING,OBSERVATIONAL,['NA']
15211,NCT05457244,Success rate (%),Postoperative Parameters:Readmission and reoperation rate,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
15212,NCT04696848,Maximum tolerated dose,Overall survival,Translational biomarker assessments obtained from blood,2021-02-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15213,NCT00454363,Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST),Percent Change in Tumor Blood Flow Assessed by Functional CT,Plasma Trough Level of GW786034,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
